UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF NEW YORK

-----X

CITY OF LIVONIA EMPLOYEES' RETIREMENT SYSTEM, On Behalf of Itself and All Others Similarly Situated,

> Plaintiffs, : Civil Action No. 07 CV 10329 (RJS)

WYETH, ROBERT ESSNER, JOSEPH MAHADY, KENNETH MARTIN, BERNARD POUSSOT, ROBERT RUFFOLO, JR. and GINGER CONSTANTINE,

VS.

Defendants.

DECLARATION OF MICHAEL J. CHEPIGA, ESQ.

- I, Michael J. Chepiga, Esq., make this declaration based on my personal knowledge and pursuant to 28 U.S.C. § 1746. I hereby state as follows:
- 1. I am a partner with the law firm of Simpson Thacher & Bartlett LLP, attorneys for Defendants Wyeth, Robert Essner, Joseph Mahady, Kenneth Martin, Bernard Poussot, Robert Ruffolo Jr., and Ginger Constantine. I respectfully submit this declaration in connection with the Reply Memorandum of Law in Support of All Defendants' Motion to Dismiss the Consolidated Class Action Complaint. I am fully familiar with the facts and circumstances stated herein, based on personal knowledge, the attached documents, and review of the files maintained by my firm.
- Attached hereto as Exhibit 1 is a true and correct copy of the following article: 2. Walter Armstrong, FDA's Approvable Problem, Pharmaceutical Executive, Nov. 1, 2007, available at http://pharmexec.findpharma.com/pharmexec/PE+Features/FDAs-Approvable-Problem/ArticleStandard/Article/detail/469652.

- 3. Attached hereto as Exhibit 2 is a true and correct copy of the following article: John Simons, FDA Damned If It Does, Damned If It Doesn't, Fortune, Nov. 9, 2007, available at http://money.cnn.com/2007/11/08/magazines/fortune/simons_fda.fortune/?postversion=2007110 905.
- 4. Attached hereto as Exhibit 3 is a true and correct copy of the following article: Alicia Mundy, Grassley, Dingell Lead Calls for Overhauling FDA, Wall St. J., July 30, 2008, at A4.
- 5. Attached hereto as Exhibit 4 is a true and correct copy of an excerpt from the slide presentation at Wyeth's October 5, 2006 annual conference for analysts and investors (cited in the Complaint \P 69).
- Attached hereto as Exhibit 5 is a true and correct copy of the Clinical Study 6. Report for Study 315 dated January 18, 2006 titled "Final Report: A Double-Blind, Randomized, Placebo Controlled Efficacy and Safety Study of DVS SR for the Relief of Vasomotor Symptoms Associated with Menopause."

I declare under penalty of perjury that the foregoing is true and correct. Executed on August 25, 2008

/s/ Michael J. Chepiga_

Michael J. Chepiga, Esq.



Pharmaceutical Executive

November 1, 2007

FDA's Approvable Problem

By Walter Armstrong

They scuttle product launches and send company stocks through the floor. They steal precious years from patents and require pricey new trials. They have the entire drug industry on edge, from struggling one-hit biotechs to struggling large-cap pharmas. They're FDA approvable letters—that odd regulatory response that isn't quite an approval and isn't quite a rejection—and in the past three or four years, they've become a major part of the FDA's arsenal for dealing with (or, as many say, not dealing with) new drug applications (NDAs).

As of October 1, the agency had already issued 23 approvable letters this year, including second letters for four drugs and a third for one. After hearing industry insiders grumble that a scared-safe FDA was upping the letter's use, Chris Milne of the Tufts Center for Drug Development looked into the issue in 2005 and counted 35 approvable letters for NDAs between 2001 and 2004, causing an average delay until approval of 20 months. FDA has issued 36 such letters since January 2006 alone.

So Approvability Gulch is a real place. The question is, what does the trend mean? Has FDA quietly raised its safety standards, as many people argue? Or is it using the letters to simply avoid approving drugs—waiting for the current political storms to settle? And if there is a new safety order, what are the potential risks for both the industry and the agency?

The Regulatory Creep of 'Basically Approvable'

Here's how the Code of Federal Regulations defines approvable letters: "In selected circumstances, it is useful at the end of the review period for the Food and Drug Administration to indicate to the applicant that the application or abbreviated application is basically approvable, providing certain issues are resolved. An approvable letter may be issued in such circumstances.... As a practical matter, the approvable letter will serve in most instances as a mechanism for resolving outstanding issues on drugs that are about to be approved and marketed."

That may sound benign, but in the post-Vioxx real world, "resolving" an "issue" can lead a drugmaker off a cliff. Some "approvable" drugs are hardly on the verge of approval:

- In 2005, Bristol-Myers Squibb killed its diabetes drug, Pargluva (muraglitazar), saying that it would take five
 years to gather data about cardio risks flagged by FDA. (The company may also have believed that additional
 data would sink Pargluva, a PPAR-antagonist like GlaxoSmithKline's Avandia, which was almost withdrawn this
 year because of its heart-attack risk.)
- Sanofi-Aventis' novel obesity treatment, Acomplia (rimonabant), marketed in Europe, received an approvable letter from FDA in 2006. After submitting the FDA-requested data, the French firm got an unfavorable review from an FDA advisory committee in June and withdrew its NDA. Unlike BMS, Sanofi is standing by its muchvaunted drug and plans to submit a new NDA for diabetes. But the ETA is 2010, at best.
- Novartis' Galvus (vildagliptin), its diabetes blockbuster-to-be, which was already on the market in Europe, received an approvable letter in February. The additional clinical trials are expected to postpone Galvus' launch

until 2009, putting the DPP4-inhibitor hopelessly behind Merck's first-in-class Januvia, which started the race with a mere three months' advantage. This has cost Novartis at least \$500 million in unmet projections and left its new U.S. rep army with little to sell.

Novartis CEO Dan Vasella, virtually the only pharma CEO willing to speak openly on the subject, has his take on the trend. "The FDA has become subject to politics," he told the *Financial Times* in September.

Analyst Steve Brozak, president of WBB Securities, agrees. "It's to the point where it's by exception—not the rule—that drugs are approved," he said, and then raised another red flag: "Innovation and safety are contraindicated. Pharma can't have blockbusters in very large populations at the same time FDA has no safety signals."

In a study released in August, James Kumpel, an analyst at Friedman, Billings, Ramsey, reported that FDA OK'd 38 new drugs between January and July, down 31 percent from 55 approvals for the same period in 2006. Meantime, the number of new molecular entities (NMEs) is at a 10-year low, seven through July, compared with an average of 12 over the same period every year since 1998. "They've raised the bar," said Kumpel, whose study helped spark a recent media flap about the drug-approval slowdown. "They've made it more difficult for drugs to get through the system."

It doesn't take a scientist or analyst, however, to detect that different drugs are being treated differently in FDA's decisions:

Gretchen Dieck, Pfizer

Big-market drugs Innovative drugs for common chronic conditions that will be used by millions of people are getting scrupulous scrutiny—particularly for heart and liver toxicity—and are routinely found wanting. The message seems clear: No more Vioxxs! As a result, pharma has had to sit on its hands as one after another potential top-seller gets jettisoned.

Me-too drugs These seem to be hit hardest of all. In 2005, only one of 14 me-too drugs won approval on the first try—another 10-year low. The poster child for these drugs is Merck's Vioxx spinoff, Arcoxia (etoricoxib), which didn't even earn an approvable letter. To many observers, FDA's new unofficial policy seems to be that me-too drugs don't just have to prove safety and efficacy—they have to prove superiority to existing drugs. "The discussion on what this [drug] brings over and above what's on the market is a question that's being asked," Vasella told the *Financial Times*. "FDA doesn't seem to trust the physicians any more."

Second indications Given that these drugs are already in wide use, their safety profile should present fewer uncertainties. But the agency asked to see more data for Wyeth's Pristiq (desvenlafaxine) and Endo's Frova (frovatriptan succinate), both for menopause; Encysive's Thelin (sitaxsentan), for hypertension; and Trexima (naproxen and sumatriptan), a new combination being codeveloped for migraine by Glaxo and little biotech Pozen, whose stock value dove by half at the news. The NASDAQ Biotechnology Index is down about 14 percent since last winter, a drop some analysts attribute to investor skittishness about the FDA's abundance of caution.

Priority NDAs FDA has seemed careful not to put the brakes on approvals for important drugs for life-threatening diseases; each gets not only a speedy six-month review but its own risk/benefit ratio. In oncology, for example, Pfizer's TKE inhibitor, Sutent, became the first drug ever approved for two indications at its first time at bat. First-inclass cancer drugs that sailed through include Vyyeth's mTOR (mammalian target of rapamycin) inhibitor, Torisel, and Glaxo's first small-molecule ERB1/2 inhibitor, Tykerb. Yet with oncology pipelines exploding, the gate may be closing. According to Tuft's Chris Milne, the agency has delayed (or rejected) five promising cancer therapies since January, including Genetech's Avastin (bevacizumab) for its third indication, breast cancer. Another NDA was blocked on dubious grounds, Milne says: "FDA told the company it doubted the postmarketing studies were going to be done on time and demanded the firm do them before approval. But, in fact, 89 percent of postmarketing studies in oncology meet their deadlines." And since such studies can take five to 10 years, the drug was DOA.

Still, not everyone inside pharma sees a conspiracy, or even a controversy, in the new wave of approvable letters. Gretchen Dieck, vice president of safety and risk management at Pfizer, said that to make a fair assessment, you'd have to examine each NDA on its own terms. "The drug development process is long—and not a straight line," Dieck said. "Something can come up, such as new side effects with a class of drugs or new surrogate markers, and the agency will say, 'You need to address this in your clinical trial.' It's not necessarily a matter of negligence on the part of the drugmaker."

Safety, Politics, or Both?

The explanation most often heard for the spike in approvable letters is the Mark Senak, Blogger obvious one: that FDA has raised the bar for drug safety. This takes account of both the scientific and the political aspects of the issue. Most letters ask for additional data either about a specific "safety signal" or about more general heart and liver toxicity. At the same time, the agency is seen as desperate to rehabilitate its image as a guardian of public health—and, ironically, "above" politics.

"Vioxx and other episodes shook confidence in the agency, and took it from being a gold standard to having a very tarnished image," said Mark Senak, senior vice president at Fleishman-Hillard and EyeonFDA.com blogger. But Senak also points to other factors that likely play a role. "Coinciding with that was the fact that for the past six years, FDA has been rudderless at the top," with a series of short-lived or interim heads until Andrew von Eschenbach's confirmation last spring.

Nor has drug-safety been the only area in which politics has appeared to intervene, Senak point out. The typically hush-hush process of drug approval burst wide open in 2004 during the machinations around the review of Plan B as an over-the-counter "morning after" pill. The acting director of the Center for Drug Evaluation and Review (CDER) sent it back, asking for more safety data related to its use by teenage girls—a decision widely viewed as a sop to President Bush's abstinence-only fundamentalist base. The ensuing protests from scientists both inside and outside FDA raised still-unanswered questions about the degree to which the agency is influenced by the administration's own political agenda.

"Congress began scrutinizing the internal process at FDA," said Senak, "and it saw a lot of things it did not like. Enforcement of regulations was down. People who were not experts but political appointees were inserted into advisory committees. There was a wave of whistle-blowers and a general degradation of morale."

There has been a prolonged and unprecedented public airing of internal disagreements about drug approval, with the drug-safety camp in open strife with the drug-review camp. "The agency has been called out on this by Congress. There have been specific charges that it suppresses safety information, or at least dissent," said attorney Daniel Kracov, head of Arnold & Porter's pharmaceutical practice. "It is a very difficult atmosphere to make tough decisions about drug safety, and this may induce too much caution on FDA's part."

Still, neither Senak nor Kracov believes that there has been a single order from on high to turn the ship around on safety. Speaking for FDA, Dr. John Jenkins, who has headed the Office of New Drugs at CDER since 2002, says there has not been. He emphasizes that each NDA is evaluated individually, and the agency doesn't set a target for how many drugs will be approved each year. Yet he acknowledged that public concerns over drug safety have had an effect. "The calls for having more certainty about safety than may have been required in the past are in the minds of decision makers when reviewing drugs," he said.

To Jenkins, the conventional wisdom on approvable letters gets the story backward. "It's probably true that we have been issuing more approvable letters recently, but in most cases that is a shift from what would have gotten a nonapprovable letter before," he said. If anything, "approvable" status means the drugmaker doesn't have to submit a whole new application, a bonus for pharma.

"In some cases, companies are looking for convenient explanations for not getting their applications approved," Jenkins added.

Jenkins can be forgiven for sounding a little gruff. The controversy over approvable letters has emerged on the heels of months of public excoriation of FDA's safety-monitoring failures and debate on how to "reform" the agency. Suddenly the media were painting FDA as an agency too browbeaten to approve drugs. Needless to say, these articles didn't carry headlines like "Newly Safety-Conscious FDA Stands Up to Industry Ire." Interestingly, of the 12 or so NDAs approved since late August, as the "slowdown" controversy gain traction, only one got an approvable letter.

A New Fulcrum for the Seesaw

But what about the accusation that FDA is basing decisions on politics not science? Jenkins Steve Brozak, Analyst framed his answer carefully. "We at FDA reflect the approval standards that we hear from Congress and the public. We can set the bar wherever they tell us to, though the pros and cons of any change must be carefully weighed," he said. "And some people would say that to do otherwise would be irresponsible of us."

In other words, it's true—a new, more cautious mind-set has taken hold at FDA, and given the chances of a

Democratic presidential victory in '08, it's no temporary trend. "I would not be surprised if the decisions we make now are different from decisions we would make in the past when looking at the same set of data," Jenkins said.

Jenkins may not be surprised, but drugmakers are—or claim to be. A recent First Albany Capital report notes that "the FDA's tolerance of [safety signals] appears to have declined," resulting in "unsettling surprises."

"I can't believe they weren't anticipating that things were going to get tougher," said Chris Milne. "But knowing things were going to get tougher and dealing with it are two different things."

In the first place, it's common knowledge that the speed with which FDA approves drugs goes in cycles. The regulatory barriers to approval move like a pendulum, rising and falling based on pressure from Congress, advocates, and, yes, even industry. "There is no constant, quantifiable bar for either safety or efficacy," said Ken Kaitlin, who heads the Tufts Center for the Study of Drug Development. "Where FDA puts the balance between the two is really a public decision."

That's why Kaitlin believes that this is a "he said, she said" in which both pharma and FDA are right. "FDA's standpoint is that it's doing the same thing it has always done—but just using a new fulcrum for the seesaw," said Kaitlin. "But from pharma's side, FDA has indeed raised the bar because now a drug needs to show a lot more weight in efficacy to offset the risks."

Chris Milne dates the swing toward safety to the agency's recall of Warner-Lambert diabetes drug Rezulin in 2000 due to liver fatalities—a debacle that featured both incompetence (three label changes) and intrigue (studies that the safety office kept secret from the rest of the agency). "After that, FDA did a self-analysis and instituted some changes to the way they review submission packages," said Milne. "So drugmakers may have been able to predict that this was all going to happen."

And far from being caught unawares, said Russ Somma, president of SommaTech, some companies may even be angling for an approvable letter—rather than withdrawing what they know is a flawed NDA. "It certainly looks better to stockholders," he said. And at certain large-cap pharmas, he explained, there's an unwritten policy not to yield to any FDA demand, turning the approval process into a game of Uncle.

The Carrot-and-Stick Approach

Let's not overlook the possibility that FDA is using approvable letters to push pharma to get with the program. Although Jenkins did not mention it, FDA officials have complained that the quality of recent NDAs has fallen off. "There's probably some truth to that," said APCO Worldwide's Wayne Pines. "Drugmakers feel enormous pressure to get applications to FDA as fast as possible. Some are submitting packages that don't have sufficient pivotal data, even at the risk of having FDA reject it and ask for more."

There are plentiful signs that the frustration pharma feels about FDA is returned by the agency. According to Somma, it's less the NDAs than the high number of postapproval fillings that are clogging the system and causing the approvable letters. "Companies are not always being up front about their business plan for a new drug," he said. "They come in a month after approval with a shopping list of changes they want to make rather than building this into the NDA. And FDA has to manage all of this, too, so the approvable letters are a way to deal with this increasing workload." In fact, the agency's chronically understaffed, overcommitted condition is a cause for considerable alarm inside FDA and pharma alike.

The agency may be drawing a line in the sand about the quality not only of safety and other data but of its relationship with pharma. "FDA has been sending a few important messages," said Somma. "It wants industry to sign onto its Quality by Design and 21st-Century initiatives. But it also wants transparency and honesty. More and more, FDA looks at NDAs and says, 'Is that all there is? You guys have spent 12 years and a billion dollars to make this drug and this is all the data you have?"

The heart of the drug-review process is, after all, a power struggle over access to information. "Legally, FDA can demand to look at every single piece of data," said Somma. "If they trust a company, they won't do that, but if you try to pull the wool over their eyes with the magic of your technology, say, or simply by hiding data, they're going to give you a hard time"-in the form of an unapprovable letter.

Ultimately, the message FDA is sending to industry is "work with us, not against us." An agency-funded study in 2005 by Booz Allen found that the more meetings a firm has with FDA about an NDA, the better its chances of getting its application approved. And Chris Milne points out that not a single fast-track or orphan drug, which are developed with maximum pharma—FDA teaming up, has ever been withdrawn from market. Yet for pharma, such close collaboration too often adds time and cost to the process without increasing the quality of the data. Certain safety signals will materialize only when a drug is on the market and in wide use—no matter how many Phase III trials are run.

In addition to costs of one kind of another, it may also come down to a question of trust, or the lack thereof. Both Big Pharma and FDA have, fairly or not, suffered a serious loss in public trust in recent years, and both remain under enormous stress. Given the current political climate, it's not clear what option FDA has other than to push back against pharma on issues like safety and transparency. It will be up to each drugmaker to decide how to respond. Yet the fact remains that the fortunes of Big Pharma and FDA are tied to each other, and rise and fall together.

Fortunately, there's cause for optimism. "FDA is reaching out to pharma on a regular basis, asking for more open interactions," Russ Somma said. "And a number of companies have gotten together to work with the agency on different issues," such as the consortia for biomarker R&D in cancer, cardiovascular disease.

Unrealistic Hopes, Unintended Consequences

Yet whether the new safety regime will—or even can—produce safer drugs remains to be seen. Many people inside pharma, including scientists, argue that the status quo doesn't need fixing. "In the vast majority of cases, when we find adverse events after approval, the benefit/risk ratio of the drug doesn't change. That means the system is working," Pfizer's Gretchen Dieck said. "In a very few cases, like Vioxx, it does change—but then everyone throws up their hands and says, FDA is broken!"

Tuft's Chris Milne marshals statistics to back Dieck up. "Withdrawals of drugs happen in a cluster—every three to five years," he said. "But the actual rate of withdrawals is consistent over time at 3 percent." In other words, faster drug approvals seem not to result in riskier drugs.

Likewise, there's considerable skepticism over whether the safety profile of drugs can be significantly improved—pending the advent of disease markers and personalized medicine. What needs fixing, from this point of view, is the uninformed—and, therefore, unrealistic—expectations of us consumers, not to mention our politicians.

"We need to do a better job as a society in communicating that just because a drug is FDA approved doesn't mean it is totally safe," said FDA's Jenkins. "What people really have to be thinking about is, What is an acceptable risk for the real benefits?" In that light, it's ironic that the prolonged post-Vioxx public drubbing of pharma and FDA may have only further raised false hopes about drug safety.

"You had congressmen who know little about safety or the drug approval process second-guessing FDA and proposing legislation for FDA," Dieck said.

The main thrust of PDUFA IV, of course, is to beef up safety monitoring without slowing down approvals. The legislation gives FDA more muscle to hold drugmakers accountable for better—or, at least, more extensive—data collection and reporting before and after approval. To the extent that it formalizes the demands for increased detection of safety signals that are currently resulting in approvable letters, PDUFA will, at the very least, likely remove the element of surprise from the process, limiting the disruption of launches, and, projections.

It may be too much to hope for that the PDUFA safety reforms will serve to restore public trust in FDA—and, by extension, Big Pharma, which strongly and visibly supported the legislation. Recent polls suggest that the tide has turned and public opinion is growing more favorable. But many people interviewed for this article voiced fears about how the agency will fare when—not if—the next Vioxx happens.

"The increased burdens on FDA require much greater resources to implement properly," said APCO Worldwide's Wayne Pines. "Congress holds the agency responsible, and if it doesn't get more money, it may not be able to meet expectations—and that could have very troubling consequences." Pines is president of the new nonprofit FDA Alliance, which is lobbying Congress to adequately fund the agency to the tune of \$2 billion. (For more information, see http://www.strengthenfda.org/ [http://www.strengthenfda.org/].)

Given that several influential congressmen are advocating something very much like tearing FDA down and starting over, the troubling consequences aren't hard to imagine. But even without another Vioxx, politics will always intrude. Next year's presidential election escalates the sense of uncertainty about the agency's agenda—and whether the pendulum will keep moving toward drug safety or begin tacking in the direction of speedier approvals.

There are other kinds of politics at play too. "At the same time that people are criticizing us about approving drugs too fast," FDA's Jenkins said, "we have a lawsuit being filed against the agency saying that patients should have access to drugs sooner."

In July, after FDA issued an approvable letter to Dendreon for its prostate cancer drug, Provenge (sipuleucel-Tg), asking for more data, the cancer activist group Care to Live went to court. By September, 200 men age 50 and older were marching, with their wives and other supporters, on the agency's headquarters in Rockville, MD. They chanted, waved placards, and acted, most uncharacteristically, like angry young protestors. Their signs read: "Approve Lifesaving Drugs Now" and "FDA: Federal Dinosaur Agency."



© 2007 Advanstar Communications Inc., Permission granted for up to 5 copies. All rights reserved.

You may forward this article or get additional permissions by typing http://license.icopyright.net/3.7456?icx_id=469652 into any web browser. Advanstar Communications Inc. and Pharmaceutical Executive logos are registered trademarks of Advanstar Communications Inc., The iCopyright logo is a registered trademark of iCopyright, Inc.







FORTUNE

FDA damned if it does, damned if it doesn't

Stung by criticism that it was too cozy with the industry, the agency got tougher after Vioxx. Now who's upset? Big Pharma. Fortune's John Simons examines an embattled regulator.

By John Simons, Fortune writer November 9 2007: 8:37 AM EST

(Fortune) - The FDA just can't win. After years of public ridicule and congressional scrutiny, the Food and Drug Administration is taking a

americanexpress.com/travel

> Explore. Plan. Book.

tougher stance against drugmakers in its review of new medicines. That new cautiousness, however, rankles its most powerful constituents: Big Pharma CEOs who charge that the agency is standing in the way of new medicines - and progress.

So is the FDA really to blame?

The agency's critics are vexed about recent reports that show FDA regulators have approved only 15 novel medicines so far this year - a pace that will likely match a 10-year low reached in 2002. Big Pharma CEOs contend that the FDA has become too anxious and hyper-vigilant about safety, requiring reams of additional data before it can make a decision.

"These developments have a negative impact on us," Novartis CEO Dan Vasella told Fortune recently. "Congress has been pressuring FDA reviewers - and it's extremely stressful for them. So, not making a decision becomes beneficial." Schering-Plough (Charts, Fortune 500) Chief Executive Fred Hassan echoed Vasella's sentiments in a recent interview with the Wall Street Journal. "When bureaucrats come under pressure, they tend to choose the path of asking for more data, as opposed to approving the drug."

Wyeth CEO Bob Essner lodged a more scandalous charge. He told the Financial Times earlier this week that the FDA's new safety-first attitude is "essentially establishing monopolies" to companies that are first to get a drug approved in a particular therapeutic class. Essner believes the FDA is now using the efficacy of existing drugs as a benchmark for whether a new drug gets approved in the same class. "If you're the first company to get approved in a certain area and competitors can't get on the market, the FDA is now establishing monopolies. And that's certainly not its mandate," noted Essner.

Wyeth has had three drugs delayed or rejected this year: bifeprunox, a treatment for schizophrenia, Pristiq, for depression and menopausal symptoms, and Viviant for osteoporosis. For its part, Novartis recently had its potential blockbuster diabetes treatment, Galvus, delayed by FDA for more testing, too.

Even so, FDA officials deny that there are new criteria in place for assessing new medicines. Some of the shift may be institutional. Until recently, the agency has lacked clear leadership for most of the decade. The commissioner's post was empty for nearly the first two years of the Bush Administration. Mark McClellan ran the FDA for 16 months starting in late 2002. After McClellan left to run Medicare and Medicaid in 2004, the FDA's top slot remained unfilled again until 2005, when Lester Crawford

took the helm - for just two months before resigning. Bush named Andrew Von Eschenbach acting commissioner in September 2005. Von Eschenbach didn't get the official title of commissioner until December 2006.

Ultimately, though, FDA Deputy Commissioner Janet Woodcock blames the industry for the dearth of new drugs coming through the agency. "I know the CEOs think we have become extremely conservative, but the standard for getting a drug approved has not changed," says Woodcock. "The number of new drug approvals is directly proportional to the number of applications we receive." The reason, then, for the downturn in new drugs approved in recent years? "It's because we're getting fewer submissions," says Woodcock.

The numbers support Woodcock's claim. It's no secret that Big Pharma has hit a research dry spell. Industry labs are churning out fewer novel discoveries and pipelines are virtually empty. The drop in new discoveries is reflected in the number of submissions sent to the FDA. Between 1996 and 2000, when the industry was still riding the wave of new lab finds, companies submitted an average of 38 new drug applications - technically "new molecular entity filings" - per year to the FDA. In turn, during the same period, the FDA granted an average of 36 approvals per year (see chart).

Beginning in 2001, new drug applications began to decline markedly. Between 2001 and 2006, the industry's annual average dropped to 29 applications per year, as the FDA averaged roughly 23 new drug approvals. Says Woodcock: "The percentage of drugs we reject has remained constant for years. But suddenly those empty pipelines make companies extremely conscious of drugs that don't get through."

To be fair, the FDA's new take on safety in recent years is not merely an industry hallucination. The agency says it doesn't keep a count of the number of times it asks companies to conduct additional studies or the frequency with which they order clinical tests with larger patient populations. But anecdotally, companies say this happens more than they would like. "There's no question that the FDA has shifted the risk/benefit ratio and is putting more demands on companies as they submit their applications," says Kenneth Kaitin, director of the Tufts Center for the Study of Drug Development.

Again, Woodcock blames the drugmakers. She says the research drought puts pressure on company researchers to push harder to get less efficacious drugs through the system. "Sometimes rather than tell their bosses that a drug isn't going to make it, researchers will submit it to the FDA and have us deliver the bad news," Woodcock notes.

If Big Pharma is feeling more put upon, there is one big change to which the FDA will admit. FDA has two main duties as it relates to medicines: pre-marketing evaluation and post-marketing observation, which includes, for instance, monitoring advertising practices and collecting ongoing safety data. FDA officials contend that in the wake of 2004's Vioxx recall, when Merck withdrew its wildly popular painkiller over concerns that it caused heart attacks, the FDA has become more vigilant in its post-marketing oversight of drugs.

After the recall, Congress and consumer advocates questioned whether Merck had strong-armed the FDA into approving a questionable drug. Since 2004, the FDA has dramatically increased the number of public warnings it issues with regard to drug safety. Between 1997 and 2004, FDA released an average of 43 drug safety warnings each year, alerting patients to possible hazards (see chart). Since 2004, the annual average has more than doubled to 93 (which includes 92 warnings issued through October of this year).

Similarly, the FDA has become more aggressive about placing so-called "boxed warnings" on drug labels. In 2003, the year before Merck's Vioxx recall, the FDA slapped 20 warnings on drug packages. In 2006, that number jumped to 66. Label warnings through September of this year: 62 (see chart).

Even with its new stance, the FDA hasn't gained any new fans. A 2007 poll conducted by the Consumer Reports National Research Center found that 84 percent of consumers believe drug companies have too much influence over the government officials who regulate them. "Whatever action we take, someone's going to be unhappy. That's why it takes a special kind of person to work here," says FDA's Woodcock. "A masochist."

Find this article at: http://money.cnn.com/2007/11/08/magazines/fortune/simons_fda.fortune/?postversion=2007110905	
Check the box to include the list of links referenced in the article.	

More

Enter Symbol(s) or Keyword(s)

SEARCH

WELCOME LNST_11378 | Log Out

My Account Messages Preferences

As of Wednesday, July 30, 2008

News Today's Newspaper

My Online Journal

Multimedia & Online Extras

The FDA's Steven Solomon testifies during a House hearing in April

Drugs

Heparin

₩ Vytorin

₩ Vioxx

Paxif

Avandia

≝ Ketek

Markets Data & Tools

Regulatory Issues

FDA foreign

inspections

Post-marketing

drug studies

Off-label use of

M Clinical trials

Set My Home Page | Customer Service

Classifieds



TODAY'S NEWSPAPER
MY ONLINE JOURNAL

Special Offer Subscribe to the print Journal today! Click Here!



Advertiser Links

A WSJ Monthly Fund Analysis, presented by Janus Weigh in on the Retirement Debate! Presented by WSJ & Allistate

AT&T's World Roaming

Grassley, Dingell Lead Calls For Overhauling FDA

By ALICIA MUNDY July 30, 2008; Page A4

THE WALL STREET JOURNAL

WASHINGTON -- Powerful members of Congress want to remake the Food and Drug Administration by giving it broad powers to levy fines, order drug recalls and restrict drug-industry advertising.

Leading the drive are Rep. John Dingell (D., Mich.) and his longtime friend in Congress, Sen. Chuck Grassley (R., Iowa). A series of crises during the past year, including deaths linked to tainted Chinese-made blood thinners and cases of salmonella linked to jalapeño peppers, have given ammunition to the lawmakers, both longtime critics of the FDA.

A House subcommittee led by Mr. Dingell plans a Thursday hearing on the FDA's response to the salmonella outbreak. Mr. Dingell called it a "disaster." Among those hurt were tomato growers, who lost millions of dollars during the month that their products were thought to be the culprit.

Congress isn't likely to enact major changes to the agency this year because it has only a brief fall session before the November elections, but 2009 may bring the most significant overhaul at the FDA in a generation if Messrs. Dingell and Grassley get their way.

Billy Tauzin, president of the drug industry's lobby, Pharmaceutical

Research and Manufacturers of America, said he has warned members about what may lie ahead. "It's an accumulation of things some companies did over the years. Now it's death by a thousand cuts," he said in an interview. "We gotta stop the bleeding."

Cracking Down

A string of drugsafety controversies

spurred congressional

regulatory procedure.

issues investigations

hearings on FDA

Some drugs and

have focused on:

Controversies over the popular prescription drugs Chantix, an antismoking pill, and cholesterol treatment Vytorin have added to pressure on the FDA, as critics suggest the agency was too lax in pursuing safety or efficacy concerns.

The lawmakers say an FDA restructuring should build a much taller wall between the agency and the industry it regulates. The FDA would gain authority to recall drugs, which it can't do today, and to impose significant fines on drug companies for safety violations. The lawmakers also want the FDA to inspect generic-drug makers before approving a new product. Perhaps most importantly, they want the next president to appoint a tough FDA commissioner completely independent from the industry.

FDA officials "are too cozy with the companies they regulate," Mr. Grassley said, adding that new leadership must "fix the culture."

The current FDA commissioner, Andrew von Eschenbach, said the agency is independent of industry influence. In an interview, he said he has been moving to get the agency to act faster on information that a drug may have problems. The heparin crisis demonstrated the challenge to the agency from globalized food and drug supplies, which he described as the biggest issue the FDA faces, but he said the agency's resources are limited.

The pharmaceutical industry is digging in against changes it believes would make it harder to bring innovative drugs to market. Speaking of stricter rules proposed by Mr. Dingell, an industry lobbyist testified this spring: "The FDA currently regulates virtually every stage in the life of a prescription medicine sold in the U.S."

However, drug companies can't afford to appear too aggressive in protecting sales or deflecting





TODAY'S MOST POPULAR

- Old Scam Casts Doubt on Citizenship
- 2. Opinion: The War in Georgia is a War for the West
- Georgia Routed as Peace Bid Fails
 IPhone Software Downloads Take
 Off
- 5. Mortgage Woes Hit Credit Unions
 MORE

PEOPLE WHO READ THIS...

Also read these stories:

FDA's Handling of Outbreak Riles

South Korea Poised to Raise Rates Treasury Prices Rise as Stocks Fall Drug Industry€™s €€ad-Dream€™

Team: Grassley and Dingeli Fatal Drug Errors At Home Rise Sharply

NEW! Are you on Facebook? See what content on this site is popular with your friends! Learn more »

Your Facebook Friends Are Reading stronger safety standards, because that might backfire and prompt embarrassing hearings in Congress.

Leading Democrats would like to see fewer Madison Avenue-style television commercials for prescription drugs. PhRMA earlier this month sent lawyers to meet with staffers for Mr, Dingell's committee and discussed how the industry could preserve its right to advertise medicines directly to consumers. The industry says TV ads help people learn more about diseases and treatments.

To lay the groundwork for their FDA overhaul, Messrs. Dingell and Grassley and their allies have ordered about 20 investigations of drugs and issues involving the FDA. Agency officials have spent hundreds of hours testifying before Congress.

Congressional leaders have directed their frustration at Dr. von Eschenbach, who has led the FDA since December 2006.

After the heparin scandal broke in February, Dr. von Eschenbach at first balked at asking for more money to fund overseas inspections, at one point causing Mr. Dingell to erupt: "You are not the first fellow I've skinned for not doing his job." Finally, on June 9, the commissioner joined the health and human-services secretary in a surprise, night-time news conference. They announced they would formally ask Congress for \$275 million for FDA overseas inspections — for the next fiscal year, ending Sept. 30, 2009.

The move prompted anger from lawmakers who said Dr. von Eschenbach should be seeking the money right away. Sen. Arlen Specter (R., Pa.), usually sympathetic to the agency, called the FDA "a joke." Senate Appropriations Chair Herb Kohl (D., Wis.) privately upbraided Dr. von Eschenbach for undercutting congressional allies, according to Senate staffers.

Mr. Grassley began his campaign to overhaul the FDA in 2004 during an uproar about the agency's slow reaction to potential links between popular antidepressants and teen suicides. Now, he has four staffers and a parade of FDA whistleblowers helping him investigate a plethora of FDA controversies, such as its approval of the antibiotic Ketek. The FDA has cited "serious protocol violations" in clinical trials of Ketek but didn't pursue a criminal case.

Mr. Grassley wants to give safety reviewers complete autonomy from the FDA Office of New Drugs, which he said has been compromised by its relations with industry lobbyists, among them former top FDA officials. Some current and former FDA safety reviewers have opened a whistleblower Web site to air their concerns that FDA leaders are pushing them to approve some drugs. An FDA spokeswoman said, "It is not unexpected that at times people will not be unanimous in their views,"

Mr. Dingell has a pending bill to add new drug-import registration fees and mandate certification of purity for incoming drug ingredients, among other measures.

"There's a total inability of the FDA to carry out" its mission," said Mr. Dingell, citing the heparin crisis and salmonella outbreak among other issues.

Write to Alicia Mundy at alicia.mundy@wsj.com

Hugh Downs Reports
Little known heart attack symptom many people tragically ignore. www.bottomlinesecrets.com What's Your Credit Score? The U.S. average is 693. See your 2008 report and score now for \$0, www.freegreditreport.com 32 Yr Old Quits 9 to 5 Learn how to make real money from home & get out of Rat Race! GrowthAndProspenty.net RELATED ARTICLES FROM ACROSS THE WEB Related Articles from WSJ.com Drug Makers Say FDA Safety Focus Is Slowing New-Medicine Pipeline Jul. 01, 2008
 Why Secrecy Still Shrouds FDA Drug Rejections Aug. 07, 2008
 Should Drugs Be Studied in More Patients Before Approval? Aug. 05, 2008
 Which Drugmaker Will Be Biggest in 2014? Hint: Not Pfizer Aug. 05, 2008 Related Web News FDA rejects Schering drug to reverse anesthesia wug. 01, 2008 pienews.com Powered by Sphere More related content EMAIL THIS ENGINEE FORMAT FOR PRINTING MOST POPULAR (R) ORDER REPRINTS 🚂 YAHOO! BLZZ 🥳 DIGG THIS 👺 MY SPACE x Get RSS GET RSS FEEDS

Return To Top

WSJ Digital Network:

Seen by 9 friends | 3 groups |

Work at Home? Employers Watch

Seen by 4 friends | 2 groups | New York

Provided by Seen This

► E-MAIL SIGN-UP

NEW: Sign up now for Keyword or Symbol Alerts. Click here

Don't miss the latest health news and analysis. Sign up to receive our daily newsletter. Check the box, then click below to subscribe.

in Today's Paper

The Health Edition

Save Settings

To view all or change any of your e-mail settings, click to the E-Mail Setup Center

RELATED INDUSTRIES

Health

Personalized Home Page Setup Put headlines on your homepage about the companies, industries and topics that interest you most.





PristiqTM

Proven SNRI Pharmacological Impact for Management of Depression

- Similar to Effexor XR® in terms of efficacy, safety and tolerability
- Very low potential for drug-drug interaction
- Well-established QTc safety profile

Wyeth






Comparative Studies in MDD Pristig™ and Effexor XR®

- Two Effexor XR trials of identical design
- ► Low dose Effexor XR (Study 309)
- Titration with Effexor XR (not Pristiq)
- ► High dose Effexor XR (Study 317)
- Titration with Effexor XR and Pristiq
- Flexible dose Pristiq, 200/400mg, placebo
- Study design: Comparisons vs placebo
- Post-hoc analysis: Allows Pristiq/ Effexor XR comparison

Wyeth



Pristiq™/Effexor XR® Comparator Studies Combined Data, Adverse Events >5%

Adverse Event (%)	Placebo (n=245)	Pristiq 200-400mg	75-150mg	Effexor XR 150-225mg
		(n=231)	(n=127)	(n=117)
Asthenia	4%	%6	%8	%9
Hypertension	3%	2%	3%	%9
Tachycardia	<1%	%9	%0	4%
Insomnia	%6	13%	11%	13%
Anorexia	1%	70%	2%	15%
Somnolence	7%	13%	%6	19%
Dry Mouth	4%	70%	13%	76%
Nausea	12%	38%	21%	29%
Vomiting	1%	2%	2%	3%
Sweating	4%	19%	%6	18%
Impotence [†]	<1%	%6	%9	11%

Wyeth

Wveth

Major Regulatory Submissions Planned For 2008

- Pristiq™ (Neuropathic Pain)
- Pristiq (Fibromyalgia)
- Methylnaltrexone Oral (Opioid-Induced Constipation)
- Rapamune[®] (Liver Conversion)
- Lybrel™ (Premenstrual Dysphoric Disorder)

WYETH RESEARCH P.O. BOX 42528 PHILADELPHIA, PA 19101 CSR-60178 Version No.: 1.0 Project No.: 3151A2 Compound No.: WAY-45233 Drug Name: DVS SR

TITLE: FINAL REPORT: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF DVS SR FOR THE RELIEF OF VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE

Protocol No.: 3151A2-315-US

Trial Phase (Check box): 1 2 3 X 4 Other

Study Dates: December 2003 through May 2005

Name and Affiliation of Principal Investigators: Multicenter study. The list of investigators and of the number of subjects enrolled at each site is provided in the List and Description of Investigators and Sites.

This study was designed and performed according to the guidelines for Good Clinical Practice.

Internal Reports Referenced: None

Related Reports: None

Date of Report: 18 January 2006

Date of Current Version: 18 January 2006

Document Location: CLINICAL R&D/CLINICAL STUDY REPORTS/3151A2

DVS SR/3151A2-315-US CSR-60178

CONFIDENTIAL 1 Wyeth

DVS SR

Protocol 3151A2-315-US

CSR-60178

TABLE OF CONTENTS

	_		_		
CI	ZΝ	J.)P	C	C

TITI	LE PA	GE		
TAB	LE O	F CONTI	ENTS	2
			BLES	
			URES	
1.0	LICT	OE A DI	DREVIATIONS AND DESINITIONS OF TERMS	1 :
1.0	LIST	OF ABI	BREVIATIONS AND DEFINITIONS OF TERMS	Ι.
2.0	ETH			
	2.1	Instituti	onal Review Board/Independent Ethics Committee	12
	2.2	Ethical	Conduct of Study	12
	2.3	Subject	Information and Consent	12
3.0	INV	ESTIGAT	FORS AND STUDY ADMINISTRATIVE STRUCTURE	12
4.0	INTI	RODUCT	ION	13
5.0	OBJ	ECTIVES	S	13
6.0	INV	ESTIGAT	ΓΙΟΝAL PLAN	14
	6.1	Overall	Study Design and Plan Description	14
		6.1.1	Protocol Amendments	1′
		6.1.2	Prestudy Period	1′
		6.1.3	Study Period	1′
		6.1.4	Posttherapy Period.	1′
	6.2	Discuss	ion of Design, Including Choice of Control Groups	1′
	6.3	Selectio	n of Study Population	1′
		6.3.1	Inclusion Criteria	1′
		6.3.2	Exclusion Criteria	18
		6.3.3	Removal of Subjects From Therapy or Assessment	18
	6.4	Treatme	ents	18
		6.4.1	Treatments Administered	18
		6.4.2	Identity of Investigational Product	18

DVS	SSR		Protocol 3151A2-315-US CS	R-60178
			TABLE OF CONTENTS	
		6.4.3	Method of Assigning Subjects to Treatment Groups	19
		6.4.4	Selection of Doses in the Study	19
		6.4.5	Selection of Timing of Dose for Each Subject	19
		6.4.6	Blinding	19
		6.4.7	Prior and Concomitant Therapy	20
		6.4.8	Treatment Compliance	20
	6.5	Efficacy	and Safety Variables	20
		6.5.1	Efficacy Measurements	20
		6.5.2	Safety Measurements	24
		6.5.3	Appropriateness of Measurements	26
	6.6	Data Qu	ality Assurance	26
	6.7	Statistic	al Methods Planned in the Protocol and Determination of Sample Si	ze26
		6.7.1	Statistical and Analytical Plans	26
		6.7.2	Determination of Sample Size	
	6.8	Changes	s in the Conduct of the Study or Planned Analyses	
		6.8.1	Twelve-Week Analysis	30
		6.8.2	Sequential Testing Strategy for Efficacy Variables	30
7.0	OTH	IER ANA	LYSIS METHODS: HEALTH OUTCOMES ASSESSMENTS	31
	7.1	Subject	Satisfaction	31
	7.2	Sexual F	Function Questionnaire	31
	7.3	EuroQua	ality of Life Visual Analogue Scale	32
3.0	STU	DY SUB.	JECTS	32
	8.1	Disposit	tion of Subjects	32
		8.1.1	Discontinuations	33
		8.1.2	Protocol Deviations	35
	8.2	Demogr	raphic and Other Baseline Characteristics	36
	8.3	Concom	nitant Therapy	38
9.0	EFF	ICACY E	VALUATION	39

CONFIDENTIAL 3 Wyeth

DVS S	SR		Protocol 3151A2-315-US C	SR-60178
			TABLE OF CONTENTS	
9	9.1	Populati	ions Analyzed	39
9	9.2	Demogr	raphic and Other Baseline Characteristics	39
9	9.3	Measure	ements of Treatment Compliance	42
9	9.4	Efficacy	y Results for the ITT Population	43
		9.4.1	Primary Efficacy Endpoint.	43
		9.4.2	Key Secondary Efficacy Endpoints	47
		9.4.3	Other Secondary Efficacy Endpoints	49
9	9.5	Efficacy	Results for the Per-Protocol Population	57
		9.5.1	Primary Efficacy Endpoints	57
		9.5.2	Secondary Efficacy Endpoints	58
9	9.6	Efficacy	Results for the Follow-up Population	59
9	9.7	Examin	ation of Subgroups	60
9	9.8	Statistic	al and Analytical Issues	65
		9.8.1	Statistical Power	65
		9.8.2	Handling of Dropouts or Missing Data	65
		9.8.3	Multicenter Studies	66
		9.8.4	Normality Testing	66
		9.8.5	Multiple Comparisons/Multiplicity	66
9	9.9	Efficacy	y Conclusions	67
10.0	SAFI	ETY EV	ALUATION	69
1	10.1	Extent o	of Exposure	69
1	10.2	Adverse	e Events	69
		10.2.1	Brief Summary of Adverse Events	69
		10.2.2	Treatment-Emergent Adverse Event Data	69
		10.2.3	Posttherapy-Emergent Adverse Events	73
		10.2.4	Analysis of Adverse Events	75
1	10.3		Serious Adverse Events, Safety-Related Discontinuations, and Othly Important Adverse Events of Clinical Interest	
		10.3.1	Deaths	

DVS SR Protocol 3151A2-315-US CSR-60178 TABLE OF CONTENTS 10 3 2 10.3.3 Other Events of Clinical Interest 81 Safety-Related Discontinuations 82 10.3.4 Analysis and Discussion of Deaths, Serious Adverse Events, Safety-10.3.5 Related Discontinuations, and Other Adverse Events of Clinical Interest 87 10.3.6 Narratives of Deaths, Serious Adverse Events, Safety-Related Discontinuations, and Other Adverse Events of Clinical Interest......94 Criteria for Determining Values of Potential Clinical Importance97 10.4.1 10.4.2 Summary of Subjects With Values of Potential Clinical Importance.......98 10.4.3 1044 10.5.1 10.5.2 Electrocardiograms. 126 10.5.3 10.6 Safety Conclusions 136 11.0 RESULTS OF OTHER ANALYSES: HEALTH OUTCOMES ASSESSMENTS138 11.2 Sexual Function Questionnaire 141 11.3 EuroQuality of Life Visual Analogue Scale......141 12.0 DISCUSSION AND OVERALL CONCLUSIONS.......141 14.0 CLINICAL DATA REPORT ERRATA......144

DVS SR

Protocol 3151A2-315-US

CSR-60178

LIST OF TABLES

Table 6.1-1: Basic Study Flowchart	15
Table 6.4.1-1: Test Article Administration	18
Table 6.4.2-1: Test Article Batch Numbers	19
Table 8.1-1: Summary of Subject Status: Number (%) of Subjects by Population Subset	33
Table 8.1.1-1: Number (%) of Subjects Who Withdrew From Study by Primary Reason for Withdrawal	34
Table 8.1.1-2: Number (%) of Subjects Who Withdrew During the Study by Time Interval	35
Table 8.2-1: Demographic and Other Baseline Characteristics, Safety Population	37
Table 8.3-1: Most Commonly Used Concomitant Medications: Number (%) of Subjects	39
Table 9.2-1: Demographic and Other Baseline Characteristics, ITT Population for VMS Data	40
Table 9.2-2: Baseline Values for Primary and Key Secondary Endpoints, ITT Population	42
Table 9.4.1.1-1: Changes in Average Daily Number of Moderate and Severe Hot Flushes at Weeks 4 and 12 for the ITT LOCF Population	43
Table 9.4.1.2-1: Changes in the Average Daily Severity Score at Weeks 4 and 12 for the ITT LOCF Population	46
Table 9.4.2.1-1: Summary of Mean Daily Change in Number of Awakenings at Week 12 for the ITT Observed Data Population	47
Table 9.4.2.2-1: Total Mood Disturbance Score at Week 12 for the ITT Observed Data Population	48
Table 9.4.3.1.3.1-1: Number (%) of Subjects With ≥75% Decrease in Average Daily Number of Moderate and Severe Hot Flushes for the ITT LOCF Population	53
Table 9.4.3.1.4-1: Median Time to First Day of 3 Consecutive Days of at Least 50% Reduction in Moderate and Severe Hot Flushes for the ITT Population	55
Table 9.5.1-1: Changes in Average Daily Number of Moderate and Severe Hot Flushes at Weeks 4 and 12 for the Per-Protocol Population	57
Table 9.5.1-2: Changes in the Average Daily Severity Score at Weeks 4 and 12 for the Per-Protocol Population	58

DVS SR

Protocol 3151A2-315-US

CSR-60178

LIST OF TABLES

Table 9.5.2-1: Comparison of Changes From Baseline to Week 12 Evaluation for Secondary Efficacy Variables, Per-Protocol Population, Observed-Cases Analyses	59
Table 9.6-1: Average Daily Number of Moderate and Severe Hot Flushes After Discontinuation of Test Article, Follow-up Population	60
Table 9.6-2: Average Daily Severity Score of Mild, Moderate, and Severe Hot Flushes After Discontinuation of Test Article, Follow-up Population	60
Table 9.7-1: Average Daily Number of Moderate and Severe Hot Flushes at Weeks 4 and 12 for the ITT LOCF Population, by Age Group	61
Table 9.7-2: Average Daily Severity Score for Mild, Moderate, and Severe Hot Flushes at Weeks 4 and 12 for the ITT LOCF Population, by Age Group	63
Table 9.8.1-1: Power for the Actual Sample Size	65
Table 9.8.5-1: Comparison in p-Values for Different Adjustment Methods for the Primary Endpoints at Week 4 and Week 12	67
Table 9.9-1: Summary of Efficacy Results at Week 12, ITT Population	68
Table 10.2.2-1: Number (%) of Subjects With Treatment-Emergent Adverse Events (Reported by at Least 5% of Subjects in Any Treatment Group)	70
Table 10.2.3-1: Number (%) of Subjects Who Discontinued During Weeks 1 to 12 With Posttherapy-Emergent Adverse Events (Reported by at Least 5% of Subjects in Any Treatment Group)	74
Table 10.2.3-2: Number (%) of Subjects in Study at Start of Week 13 With Posttherapy-Emergent Adverse Events (Reported by at Least 5% of Subjects in Any Treatment Group)	75
Table 10.3.2-1: Subjects With Serious Adverse Events	78
Table 10.3.3-1: Subjects With Adverse Events of Clinical Interest	82
Table 10.3.4-1: Number (%) of Subjects Reporting Adverse Events Resulting in Withdrawal From Study	84
Table 10.3.4-2: Subjects Who Withdrew Because of Selected Adverse Events	87
Table 10.3.6-1: Summary of Subjects With Narratives by Primary Reason for the Narrative	95
Table 10.4.1-1: Criteria for Determining Potentially Clinically Important Laboratory Test Results	98
Table 10.4.2-1: Number (%) of Subjects With Potentially Clinically Important Laboratory Test Results/Number of Subjects Tested, On-Therapy Period	100

7 Wyeth **CONFIDENTIAL**

CSR-60178

LIST OF TABLES

Table	10.4.3-1: Subjects Who Had Clinically Important Changes in Laboratory Test Results.	.101
Table	10.4.4-1: Baseline Mean and Mean Changes From Baseline for Selected Laboratory Tests	.103
Table	10.5.1.1-1: Criteria for Determining Potentially Clinically Important Vital Signs and Weight Results	.116
Table	10.5.1.2-1: Number (%) of Subjects With Vital Signs of Potential Clinical Importance/Number of Subjects Tested, On-Therapy Period	.117
Table	10.5.1.3-1: Subjects Who Had Clinically Important Changes in Vital Signs or Weight Results	.118
Table	10.5.1.4-1: Baseline Mean and Mean Changes From Baseline in Selected Vital Signs and Weight Results	.120
Table	10.5.3.1-1: Criteria for Determining Potentially Clinically Important Values in Adult Electrocardiogram Results	.126
Table	10.5.3.2-1: Number (%) of Subjects With ECG Results of Potential Clinical Importance/Number of Subjects Tested, On-Therapy Period	.128
Table	10.5.3.3-1: Subjects With Clinically Important Electrocardiogram Changes	.128
Table	10.5.3.4-1: Baseline Mean and Mean Changes From Baseline in Selected ECG Results	.130
Table	11.1-1: Satisfaction Survey: Number (%) of Subjects Reporting Being Satisfied or Extremely Satisfied	.139
Table	14.0-1: Summary of Errata	.144

8 Wyeth **CONFIDENTIAL**

CSR-60178

LIST OF FIGURES

Figure 9.4.1.1-1: Average Daily Number of Moderate and Severe Hot Flushes for the ITT LOCF Population Through Week 12	44
Figure 9.4.1.1-2: Average Daily Number of Moderate and Severe Hot Flushes for the ITT Observed Data Population Through Week 52	45
Figure 9.4.3.1.1-1: Average Daily Number of Mild, Moderate, and Severe Hot Flushes for the ITT LOCF Population Through Week 12	50
Figure 9.4.3.1.1-2: Average Daily Number of Mild, Moderate, and Severe Hot Flushes for the ITT Observed Data Population Through Week 52	51
Figure 9.4.3.1.3.1-1: Percentage of Subjects With a 75% Reduction in the Number of Moderate and Severe Hot Flushes From Baseline	53
Figure 9.4.3.1.4-1: Median Time to the First Day of at Least 3 Consecutive Days of a 50% Reduction From Baseline in the Daily Number of Moderate and Severe Hot Flushes for the ITT Population	56

9 Wyeth **CONFIDENTIAL**

DVS SR

Protocol 3151A2-315-US

CSR-60178

In addition, the following materials are available and are included in the submission if required by government regulations.

APPENDICES

Protocol and/or Amendments [16.1.1]

Sample Case Report Forms [16.1.2]

List of Institutional Review Boards and Independent Ethics Committees [16.1.3]

Sample Informed Consent Form [16.1.3]

List and Description of Investigators and Sites [16.1.4]

Investigator CVs or Equivalent Summary of Training and Experience Relevant to the Trial [16.1.4]

Signature of Responsible Party or Principal Investigator [16.1.5]

Listing of Patients Receiving Product From Specific Batches, When More Than One Batch Was Used [16.1.6]—Available on request

Randomization Scheme and Codes [16.1.7]

Audit Certificates [16.1.8]

Documentation of Statistical Methods [16.1.9]

Documentation of Inter-Laboratory Standardization Methods and Quality Assurance Procedures [16.1.10]

Publications Based on the Study [16.1.11] - Not Applicable

Important Publications Referenced in the CSR [16.1.12] - Not Applicable

1.0 LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS

Abbreviations	Definition
AE	adverse event
ALT	alanine transaminase
ANCOVA	analysis of covariance
AST	aspartate transaminase
BMI	body mass index
BP	blood pressure
CDR	clinical data report
COSTART	Coding Symbols Thesaurus for Adverse Reaction Terms
CSR	clinical study report
DVS SR	desvenlafaxine succinate sustained-release formulation
ECG	electrocardiogram
EE	evaluable for efficacy
EMEA	European Agency for the Evaluation of Medicinal Products
EQ VAS	EuroQuality of Life Visual Analogue Scale
FDA	Food and Drug Administration
FSH	follicle-stimulating hormone
HDL-C	high-density-lipoprotein cholesterol
IRB	institutional review board
ITT	intent to treat
LDL-C	low-density-lipoprotein cholesterol
LOCF	last observation carried forward
PCI	potentially clinically important
POMS	Profile of Mood States
PP	per protocol
RTI-HS	RTI Health Solutions
SD	standard deviation
SFQ	Sexual Function Questionnaire
SGOT	serum glutamic oxaloacetic transaminase (aspartate transaminase)
SGPT	serum glutamic pyruvic transaminase (alanine transaminase)
SNRI	serotonin and norepinephrine reuptake inhibitor
SR	sustained release
SS	Satisfaction Survey
TEAE	treatment-emergent adverse event
VMS	vasomotor symptoms
WBC	white blood cell
WLQ	Work Limitations Questionnaire

CONFIDENTIAL 11 Wyeth

CSR-60178

2.0 ETHICS

2.1 Institutional Review Board/Independent Ethics Committee

The protocol and amendments received institutional review board (IRB)/independent ethics committee approval before the study began.

2.2 Ethical Conduct of Study

The study was conducted according to the Declaration of Helsinki and its amendments that were in place at the time of the study.

2.3 Subject Information and Consent

Written informed consent was obtained from all subjects before their enrollment. The identity of the subjects was kept confidential. Each subject was assigned a subject number, which was used on the case report form instead of the subject's name.

3.0 INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE

This study was conducted at 42 sites. The principal investigators and the number of subjects enrolled at each site are listed in alphabetical order in Appendix 16.1.4 of this report, which is a separate document (List and Description of Investigators and Sites). The following contract research organizations participated in this investigation:

Charles River Laboratories Clinical Services (formerly Inveresk Research North Carolina, Inc.)
Amy Stroud, Project Manager

11000 Weston Parkway, Suite 100

Cary, NC 27513

This contract research organization conducted site qualification visits, site initiation visits, interim monitoring visits, and site closeout visits; selected monitors; and engaged in record keeping and record retention, disposition of unused supply of investigational drug, and in-house site management.

CONFIDENTIAL 12 Wyeth

CSR-60178

DVS SR Protocol 3151A2-315-US

LBR Regulatory & Clinical Consulting Services Lois Rosenberger, Project Director 25 Crestview Hills Mall Road, Suite 101

This contract research organization assisted with the processing, review, and tracking of documents, including regulatory documents, informed consent forms, IRB approvals, protocol and protocol amendments, investigators' brochure and safety attachment, and site advertising materials; developed and issued periodic newsletters to study sites; administered investigator payments; tracked subject enrollment; and conducted site qualification/site initiation visits.

ACE/Mr. Seth Levine c/o Wyeth Pharmaceuticals 500 Arcola Rd. Collegeville, PA 19426

Crestview Hills, KY 41017

This contract research organization provided database-building, data-entry, data-editing, and database-finalization services.

4.0 INTRODUCTION

The background information and rationale for the study can be found in the protocol, section 10, Introduction.

5.0 OBJECTIVES

The primary objective of the study was to compare the efficacy and safety of 4 doses of sustained-release desvenlafaxine succinate (DVS SR) and of placebo for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. The secondary objectives were to compare the effects of DVS SR and of placebo on sleep and health outcomes indicators.

CONFIDENTIAL 13 Wyeth

6.0 INVESTIGATIONAL PLAN

6.1 Overall Study Design and Plan Description

This study was an outpatient, multicenter, randomized, double-blind, and placebo-controlled trial. Although the primary efficacy evaluations were measured at 4 and 12 weeks, the trial duration was 12 months to provide safety data in a postmenopausal population. Subject enrollment was planned to be completed in approximately 6 months and the study in approximately 20 months.

A flowchart of the basic study assessments is shown in Table 6.1-1, Basic Study Flowchart.

CONFIDENTIAL 14 Wyeth

Table 6.1-1: Basic Study Flowchart

Visit	1A Washout ^a	1B Screening ^a	2 Week 0	3 Week 4	4 Week 8	5 Week 12	6 Week 26	7 Week 39	8 Week 52	Follow-up Visit ^b
Informed consent c	X									
Medical history		X								
Initial physical exam d		X								
Follow-up physical exam ^d						X	X		X	
Vital signs/weight (kg)		X	X	X	X	X	X	X	X	
Electrocardiogram		X				X			X	
Laboratory safety testing ^e		X		X		X	X	X	X	
FSH		X								
Dispense diary f	X	X	X	X	X	X	X	X	X	
Review diary		X^{g}	X	X	X	X	X	X	X	X
Randomization h			X							
Health outcomes questionnaires i			X	X		X			X	
Review adverse events		X	X	X	X	X	X	X	X	X
Review medications		X	X	X	X	X	X	X	X	X
Dispense test article			X			X	X	X		
Collect unused test article				X	X	X	X	X	X	
Complete dose record				X	X	X	X	X	X	

Abbreviation: FSH=follicle-stimulating hormone.

a. Visits 1A and 1B may have been combined.

b. Follow-up visit occurred approximately 15 days after the last day of test article intake to obtain information regarding number and severity of hot flushes, any new or persistent adverse events, and related concomitant medications and treatments.

c. An informed consent form approved by an institutional review board must have been signed and dated before any screening procedures, including washout, were performed.

d. The initial physical examination included complete physical examination, breast and gynecologic examinations, and height measurement (cm). The follow-up examination included physical examination at visits 5 and 6 and physical, breast, and gynecologic examinations at visit 8.

Table 6.1-1: Basic Study Flowchart--Continued

- e. Laboratory safety testing included hematology, blood chemistry, and urine assessment by dipstick.
- f. Diaries dispensed at visit 1A, for subjects requiring washout, collected medications taken and symptoms/complaints. Diaries dispensed at visits 1B, 2, 3, and 4 collected number/severity of hot flushes, sleep characteristics, medications taken, and symptoms/complaints. Diaries dispensed at visits 5, 6, and 7 collected number/severity of hot flushes, medications taken, and symptoms/complaints. Diaries dispensed at visit 8 collected number/severity of hot flushes, medications taken, and symptoms/complaints.
- g. Only subjects who required washout would have a diary to review at visit 1B.
- h. Randomization followed confirmation that all inclusion and no exclusion criteria had been met.
- i. See protocol, Attachments, for health outcomes questionnaires. Questionnaires were self-administered: Work Limitations Questionnaire at visits 2, 3 and 5; Profile of Mood States at visits 2 and 5; Satisfaction Survey at visits 5 and 8; Sexual Function Questionnaire at visits 2 and 5; and EuroQuality of Life Visual Analogue Scale at visits 2, 3, and 5.

CONFIDENTIAL 16 Wyeth

Protocol 3151A2-315-US

CSR-60178

6.1.1 Protocol Amendments

The protocol was amended once, on 28 February 2005, to add collection of VMS during the 15 days after discontinuation of test article.

6.1.2 Prestudy Period

Details of procedures performed during the prestudy period are given in the protocol, sections 16.1.1, Prestudy Screening and Baseline Evaluation; 16.1.1.1, visit 1A; and 16.1.1.2, visit 1B, and are summarized in the study flowchart, Table 6.1-1.

6.1.3 Study Period

Details of procedures performed during the study period are given in the protocol, sections 16.1.2, visit 2, through 16.1.8, visit 8, and are summarized in the study flowchart, Table 6.1-1.

6.1.4 Posttherapy Period

Details of procedures performed during the posttherapy period are given in the protocol, section 16.1.9, Follow Up, and are summarized in the study flowchart, Table 6.1-1.

6.2 Discussion of Design, Including Choice of Control Groups

A placebo control group was necessary to provide scientific evidence of efficacy and to ensure a reliable evaluation of the balance of benefits and risks of the test articles.

6.3 Selection of Study Population

6.3.1 Inclusion Criteria

Subjects must have met all of the inclusion criteria listed in the protocol, section 13.1, Inclusion Criteria, to be enrolled in the study.

CONFIDENTIAL 17 Wyeth

Protocol 3151A2-315-US

CSR-60178

6.3.2 Exclusion Criteria

Subjects must have met none of the exclusion criteria listed in the protocol, section 13.2, Exclusion Criteria, to be enrolled in the study.

6.3.3 Removal of Subjects From Therapy or Assessment

Information on the discontinuation and withdrawal of subjects is given in the protocol, section 16.2, Discontinuation and Withdrawal of Subjects.

6.4 Treatments

6.4.1 Treatments Administered

Test articles included 50-mg or 100-mg DVS SR pyramid-shaped tablets and matching placebo tablets in 2 sizes (Table 6.4.1-1). On study day 0, each subject was randomly assigned to 1 of 4 doses of DVS SR (50 mg, 100 mg, 150 mg, or 200 mg) or placebo. Each subject received her assigned treatment in an individualized package containing 15 blister packs. Each blister pack contained tablets for 7 days of treatment (21 tablets; 3 tablets per day).

Table 6.4.1-1: Test Article Administration

Treatment Group	Tablet A	Tablet B	Tablet C
DVS SR 50 mg	DVS SR 50 mg	Placebo for	Placebo for
		DVS SR 100 mg	DVS SR 100 mg
DVS SR 100 mg	Placebo for	DVS SR 100 mg	Placebo for
	DVS SR 50 mg		DVS SR 100 mg
DVS SR 150 mg	DVS SR 50 mg	DVS SR 100 mg	Placebo for
_	_	_	DVS SR 100 mg
DVS SR 200 mg	Placebo for	DVS SR 100 mg	DVS SR 100 mg
_	DVS SR 50 mg	_	_
Placebo	Placebo for	Placebo for	Placebo for
	DVS SR 50 mg	DVS SR 100 mg	DVS SR 100 mg

Source: protocol, section 17.1.

6.4.2 Identity of Investigational Product

DVS SR and placebo were supplied by the manufacturers, as shown in Table 6.4.2-1.

CONFIDENTIAL 18 Wyeth

Protocol 3151A2-315-US

CSR-60178

Table 6.4.2-1: Test Article Batch Numbers

Drug Name/Strength/	Formulation		
Dosage Form	Number	Batch Number	Source
DVS SR 50-mg tablet	0931717C	A35065	Wyeth Guayama, Puerto Rico
DVS SR 100-mg tablet	0931719C	A43076	Wyeth Guayama, Puerto Rico
Placebo for DVS SR tablet	0931807C	2003B0250	Wyeth Montreal, Canada
Placebo for DVS SR tablet	0931803C	2003B0034	Wyeth Montreal, Canada
Placebo for DVS SR tablet	0931803C	2003B0249	Wyeth Montreal, Canada
DVS SR 50-mg tablet	053151304AD	2003P1310	Wyeth Montreal, Canada
DVS SR 100-mg tablet	053151304AF	2003P0640	Wyeth Montreal, Canada
DVS SR 100-mg tablet	053151304AH	2003P1312	Wyeth Montreal, Canada
Placebo for DVS SR tablet	053151304AB	2003P1313	Wyeth Montreal, Canada
DVS SR 100-mg tablet	0931719C	A43076/ 94895A	Wyeth Guayama, Puerto Rico
DVS SR 50-mg tablet	0931717C	A35065/ 93324A	Wyeth Guayama, Puerto Rico

Source: Clinical Pharmacology.

6.4.3 Method of Assigning Subjects to Treatment Groups

Details on the measures adopted to minimize bias, including subject identification, randomization, and blinding procedures, are given in the protocol, section 18, Measures to Minimize/Avoid Bias.

6.4.4 Selection of Doses in the Study

The doses selected for DVS SR in this study were based on preclinical data with DVS SR and clinical data with venlafaxine, its precursor.

6.4.5 Selection of Timing of Dose for Each Subject

Subjects were instructed to take the 3 tablets at the same time orally with food, to swallow the tablets whole, and never to chew, divide, or crush tablets. Subjects could have taken the treatment at any time of the day but were instructed to take it at the same time each day throughout the study. The choice of once-daily administration was based on preclinical data with DVS SR.

6.4.6 Blinding

Test article for each subject was packaged individually and code-labeled by Wyeth Research, according to regulations. The labels contained the study number, subject randomization number, study days, and space to write the subject's number and initials and the subject instructions.

CSR-60178

The content of the subject's package depended on the double-blind schedule to which the subject was assigned. Each subject's package consisted of a 3-month supply of DVS SR or placebo plus an extra 2-week supply to allow for damage, loss, and variation in the day of a subject's visit (15 blister cards, each containing a 7-day supply of test article [21 tablets]).

6.4.7 Prior and Concomitant Therapy

6.4.7.1 Prior Therapy

All medications, treatments, and procedures beginning 8 weeks before test article administration were recorded according to procedures detailed in the protocol, section 14, Prior Treatment, and section 15, Concomitant Treatment.

6.4.7.2 Permitted Therapy

Permitted therapies are detailed in the protocol, section 15.1, Permitted Treatment.

6.4.7.3 Prohibited Therapy

Prohibited therapies are detailed in the protocol, section 15.2, Prohibited Treatment.

6.4.8 Treatment Compliance

Subject compliance was monitored by study site personnel and documented by returned pill counts. Compliance and any unresolved discrepancies in tablet count were recorded in the source document and on the drug inventory record. A subject must have taken at least 80% of the test article to be considered compliant. Lack of compliance over a 2-week period required discussion with the medical monitor to decide if the subject was to continue or withdraw.

6.5 Efficacy and Safety Variables

6.5.1 Efficacy Measurements

The efficacy variables included the daily collection of the number and severity of hot flushes, the proportion of subjects who had a decrease of 50% or 75% or more from baseline in the mean

CONFIDENTIAL 20 Wyeth

daily number of hot flushes, the time to onset of action, the daily collection of sleep assessments, the Profile of Mood States (POMS), and the Work Limitations Questionnaire (WLQ). For the primary efficacy variables, the evaluations at weeks 4 and 12 were the primary endpoints. For the secondary efficacy variables, the evaluations at week 12 were the primary time points.

CSR-60178

6.5.1.1 Primary Efficacy Variables

The primary efficacy variables were the change from baseline (1) in the number of moderate and severe hot flushes and (2) in the severity of hot flushes at week 4 and week 12. The calculation for the average daily number of hot flushes for each time period was

Sum of the number of hot flushes on each day Number of days with data

where the number of hot flushes was computed in 2 ways:

- (1) including moderate and severe hot flushes only, and this result was the primary endpoint for the number of hot flushes, and
 - (2) including mild, moderate, and severe hot flushes.

The average daily severity of hot flushes for each time period was calculated as

Sum of the daily severity scores
Number of days with data

where the daily severity score was calculated as

(# Mild hot flushes) x 1 + (# moderate hot flushes) x 2 + (# severe hot flushes) x 3

Total number of hot flushes on that day

Hot flushes were recorded daily during screening and throughout the study on diary cards (see protocol, section 16.1.1.2, and statistical analysis plan). A sequential testing procedure was applied to the primary efficacy variables to adjust for multiplicity.

CONFIDENTIAL 21 Wyeth

CSR-60178

DVS SR Protocol 3151A2-315-US

6.5.1.2 Key Secondary Efficacy Variables

Secondary efficacy variables were divided into key secondary efficacy variables and other secondary efficacy variables. A sequential testing procedure was applied to the key secondary efficacy variables as well.

The key secondary efficacy variables were the change from baseline in the number of awakenings because of hot flushes, the change from baseline in the total mood disturbance score from POMS, and the change from baseline in the WLQ total index score. A sequential testing procedure was applied to the number of awakenings, total mood disturbance score, and WLQ total index score (see section 6.7.1.3 for details).

6.5.1.2.1 Number of Awakenings Because of VMS

The number of awakenings from hot flushes was considered the first key secondary endpoint (see statistical analysis plan, section 7.0). The sleep diary selected in this study was to be completed during screening and throughout the initial 12 weeks of therapy to measure number of awakenings, time to fall asleep, time slept, and quality of sleep (see protocol, section 16.1.1.2). Sleep diaries are an accepted and validated method for assessing sleep disorders. Diaries have been found to accurately reflect sleep/wake cycles in several previous studies with good agreement between available methods for measuring changes in sleep patterns over time. ¹

6.5.1.2.2 Profile of Mood States

Total mood disturbance score is considered the second key secondary endpoint (see statistical analysis plan, section 7.0). Mood changes were assessed by POMS (see protocol, Attachment 6). The POMS was developed in 1971 as a measure of mood state and change of mood state.² It has been well validated in a number of populations and has been widely used in a number of studies involving menopausal women. The POMS asks respondents to rate 65 adjectives (eg, tense, energetic, carefree, discouraged) on a 5-point intensity scale with a recall period of 1 week. From these ratings, 6 individual factor scores (tension, depression, anger, vigor, fatigue, and confusion) and a total mood disturbance score are generated.

CONFIDENTIAL 22 Wyeth

Protocol 3151A2-315-US

CSR-60178

6.5.1.2.3 Work Limitations Questionnaire

The WLQ total index score is considered the third key secondary endpoint (see statistical analysis plan, section 7.0). Work efficiency was assessed by the WLQ (see protocol, Attachment 5), which is used for measuring the on-the-job impact of chronic health problems and/or treatment and has demonstrated high reliability and validity.³ The final version of the WLQ contains 25 items, 4 dimensions (limitations handling time, physical, mental, interpersonal, and output demands), with a 2-week recall period.

6.5.1.3 Other Secondary Efficacy Variables

The other secondary efficacy variables included

- Reduction in the number of mild, moderate, and severe hot flushes.
- Reduction in the weekly weighted severity score for moderate and severe hot flushes only, calculated for each week as follows:

(number of moderate flushes) x 2 + (number of severe flushes) x 3

- Responder analysis, with responders defined as subjects who reached at least a 50% or a 75% decrease in the number of hot flushes from baseline.
- Time to reach a 50% decrease in number of hot flushes from baseline for at least 3 consecutive days.
- Other sleep measurements (time to fall asleep, time slept, overall quality of sleep).
- POMS individual factor scores (tension, depression, anger, vigor, fatigue, and confusion).
- WLQ scores for 4 scales: time management, physical demands, mental-interpersonal demands, and output demands.

The statistical methods used to analyze these secondary efficacy variables and the various scores obtained from the diaries and questionnaires are detailed in the statistical analysis plan, sections 6.4 and 7.0.

CONFIDENTIAL 23 Wyeth

CSR-60178

6.5.2 Safety Measurements

Safety was monitored by means of scheduled physical examinations and vital signs measurements, clinical laboratory determinations, and electrocardiograms (ECGs) as described in the protocol, section 19, Safety.

6.5.2.1 Adverse Events

An adverse event was any untoward, undesired, or unplanned clinical event in the form of signs, symptoms, disease, or laboratory or physiological observations occurring in a human being participating in a clinical study, regardless of causal relationship, as detailed in the protocol, section 23.1, Definitions.

An adverse event was considered to be treatment emergent if (1) it was not present when the active phase of the study began and was not a chronic condition that was part of the subject's medical history, or (2) it was present at the start of the active phase of the study or as part of the subject's medical history but the severity or frequency increased during the active phase. For the purposes of this study, the active phase of the study was considered to begin at the time of the first dose of test article and end on the day of the last dose of test article.

Posttherapy-emergent adverse events were defined as adverse events that were not present during the last 7 days of the double-blind treatment period (ie, before the posttherapy period) and began during day 1 to day 15 posttherapy, or events that were present during the last 7 days of treatment and became more severe during the 15-day posttherapy period.

Any serious adverse event, including death from any cause, was to be reported to Wyeth Research immediately (within 24 hours) by telephone and fax or directly by fax so that, if required, a report could be prepared for submission to regulatory agencies. A serious adverse event was an adverse event that met any of the following criteria:

- Resulted in death.
- Was life-threatening (subject was at immediate risk of death from the event).
- Required inpatient hospitalization or prolongation of an existing hospitalization.
- Resulted in a persistent or significant disability/incapacity.
- Resulted in a congenital anomaly or birth defect.
- Resulted in cancer.

CONFIDENTIAL 24 Wyeth

CSR-60178

• Was medically important or required intervention (ie, based on medical judgment, the event could have seriously jeopardized the subject's health or required medical or surgical intervention to prevent a serious outcome).

While not meeting the definition of an serious adverse event, the following events were also to be reported to Wyeth Research in the same time frame and following the same process as for serious adverse events: pregnancy, test article overdose or abuse (with or without adverse event), and accidental exposure to test article.

6.5.2.2 Clinical Laboratory Evaluations

Laboratory determinations were analyzed by the central laboratory, located at the following address:

Quest Diagnostic Clinical Trials 7600 Tyrone Avenue Van Nuys, CA 91405

Quest Diagnostics was used by each investigator for all laboratory determinations unless a special test was required. In such cases, an additional laboratory was designated by the investigator for the special test only. Specimens for the laboratory determinations were obtained at visits 1B, 3, 5, 6, 7, and 8, unless otherwise specified. Values for laboratory test results considered potentially clinical important are listed in the statistical analysis plan, section 8.2.2, Analysis Method.

6.5.2.3 Vital Signs and Body Weight Measurements

Vital signs and body weight measurements were performed at visits 1B through 8 and evaluated according to the criteria for findings of potential clinical importance in vital signs and body weight found in the statistical analysis plan, section 8.1.2, Analysis Method.

6.5.2.4 Electrocardiograms

The procedures for central reading of ECGs are detailed in the protocol, section 19.2, Safety Assessment Methods. A 12-lead ECG was performed at visits 1B, 5, and 8. Readings and

CONFIDENTIAL 25 Wyeth

CSR-60178

interpretations of ECG tracings were performed centrally by e-Research Technology, Inc., located at the following address:

e-Research Technology, Inc. 30 S. 17th Street, 8th Floor Philadelphia, PA 19103

Values for ECG results considered potentially clinically important are listed in the statistical analysis plan, section 8.3.2, Analysis Method.

6.5.2.5 Other Safety Evaluations

Physical examinations and review of diaries are detailed in the protocol, section 19.2, Safety Assessment Methods.

6.5.3 Appropriateness of Measurements

A daily diary card is a well-accepted standard for the collection of information regarding hot flushes in pivotal studies. This primary efficacy endpoint was agreed upon in discussions with regulatory agencies in the planning stages of the study. The appropriateness of the sleep diaries, POMS, and WLQ was discussed in sections 6.5.1.2.1, 6.5.1.2.2, and 6.5.1.2.3.

6.6 Data Quality Assurance

Steps were taken to ensure that the data collected were accurate, consistent, complete, and reliable. These procedures are detailed in the protocol, section 24, Data Quality Assurance.

6.7 Statistical Methods Planned in the Protocol and Determination of Sample Size

6.7.1 Statistical and Analytical Plans

The Biostatistics Section of Wyeth Research performed statistical analyses. Statistical and analytical plans are detailed in the protocol, section 21, Statistical Analysis, and in the statistical analysis plan.

CONFIDENTIAL 26 Wyeth

CSR-60178

6.7.1.1 Populations Analyzed

The safety population included all subjects who were randomly assigned to a treatment group and received at least 1 dose of test article.

Three (3) populations were defined for the primary efficacy endpoints:

- 1. The intent-to-treat (ITT) population for analysis of hot flushes included all subjects who
- Were randomly assigned to a treatment group,
- Received at least 1 dose of test article,
- Recorded data for at least 5 days at the baseline week, and
- Had data for at least 5 days during at least 1 week in the first 12 on-therapy weeks after the baseline week.
- 2. The per-protocol (PP) population (termed efficacy evaluable [EE] in the statistical analysis plan) for analysis of hot flushes (for the first 12 weeks only) included those subjects with the same requirements as the ITT population and who
- Had 7 moderate to severe flushes per day or 50 per week for the baseline week,
- Had data for at least 5 on-therapy days for that week to be evaluable,
- Were compliant with the study medication schedule, defined as taking at least 80% of assigned doses, ie, at least 17 tablets per week, for the week to be evaluable, and
- Were not taking unacceptable concomitant medications.
- 3. The follow-up population included all subjects who
- Were randomly assigned to a treatment group,
- Received at least 1 dose of test article,
- Recorded data for at least 20 days during the last 28 days while on therapy, and
- Recorded data for at least 10 days during the 15 days after the last dose of test article.

All efficacy analyses were based on the ITT population, with or without last observation carried forward (LOCF), and on the PP population, and all safety analyses were based on the safety population.

CONFIDENTIAL 27 Wyeth

Protocol 3151A2-315-US

CSR-60178

6.7.1.2 Interim Analysis

Interim data analyses were conducted during the study as described in the protocol, section 21.3, Interim Analysis.

A 4-week interim analysis to choose doses for a future study and to determine if 1 or more doses could be dropped from the study was performed when half the subjects had completed 4 weeks of therapy or dropped out before 4 weeks. The interim analysis p-value adjustment procedure described by O'Brien-Fleming⁴ was used. The significance level for the interim analysis of number of hot flushes at week 4 was 0.005. As a result, the significance level was to be 0.048 for the final analysis of hot flushes at weeks 4 and 12. The subject treatment assignment was partially unblinded, and treatment groups were designated by randomly assigned letters. The summary report without individual subject treatment information was provided to a limited number of Wyeth Research personnel, not directly involved with subject care or conduct of the study, who used it for decisions about the dose groups in this and subsequent studies. Enrollment was completed at the time of the 4-week analysis. The results of this analysis did not affect the conduct of the study nor the final results.

A second analysis was to be done when all subjects had either completed 12 weeks of treatment or dropped out before 12 weeks. Results from that analysis were used to support or modify the dose selection decisions for subsequent studies. No statistical adjustment of p-values for analysis of hot flush data beyond 12 weeks was necessary because these were supplemental analyses to evaluate long-term therapy independent of the primary time points of interest, and these endpoints had not been evaluated as part of either analysis that preceded the final analysis. The subject treatment assignment was partially unblinded as described above. The results of this analysis did not affect the conduct of the study nor the final results.

6.7.1.3 Sequential Testing Strategy for Efficacy Variables

A sequential testing strategy with a specified order of testing was used to control for multiplicity in the primary and secondary efficacy variables.

To control the type I error rate, the significance level for primary efficacy results was to be examined in a stepwise manner: if either the 150-mg or 200-mg DVS SR groups showed significance at the p=0.024 level, then the 100-mg group was to be examined at the p=0.048

CONFIDENTIAL 28 Wyeth

level. If the 100-mg group was found to be significant at p=0.048, then the 50-mg group was also examined at the p=0.048 level.

The stepwise approach described for the primary efficacy analyses was also used for the analysis of additional efficacy variables derived from the VMS data (proportion of subjects with 50% and 75% reduction in symptoms, time to 50% reduction). These variables were tested sequentially for each dose, contingent on the statistical significance of the primary efficacy variables (number and severity of hot flushes at weeks 4 and 12).

Similarly, the analysis of key secondary variables was to be examined in a stepwise manner. For treatment groups that achieved statistical significance at week 12 for the primary efficacy variables, the subsequent pairwise comparison of the key secondary efficacy variables at week 12 was made at the 0.048 significance level in the following order:

- 1. Daily mean number of awakenings at night (question 3 of sleep diary).
- 2. Total mood disturbance score (POMS).
- 3. Work Limitations Questionnaire (WLQ): total index score.

All other pairwise comparisons on other secondary variables were considered exploratory.

6.7.2 Determination of Sample Size

It was expected that the differences between active treatment groups and the placebo group in the daily mean number of hot flushes would be at least 2 and that the standard deviation would be 3.0. A sample size of 100 subjects per group for the DVS SR dose groups and 50 for the placebo group would have greater than 90% power to detect a difference of 2 between a DVS SR group and the placebo group by using a 2-groups t-test with a 0.024 2-sided significance level (adjusted for interim analysis and multiple comparisons). These same patient totals would also provide greater than 90% power to detect a difference in mean severity score of 0.6 between a DVS SR group and placebo (assuming a standard deviation of 0.9) by using a 2-group t-test with 0.024 significance level. A total enrollment of 120 subjects in each DVS SR group and 60 in the placebo group was planned to ensure a sufficient number in the primary analysis population.

CONFIDENTIAL 29 Wyeth

Protocol 3151A2-315-US

CSR-60178

6.8 Changes in the Conduct of the Study or Planned Analyses

6.8.1 Twelve-Week Analysis

As defined in the protocol, section 21.3, the 12-week analysis (performed when all subjects had completed 12 weeks of therapy) had been planned as the final analysis through 12 weeks for the primary efficacy endpoints. However, additional data for the first 12 weeks were received for several subjects after that analysis was performed. When the final analysis through 52 weeks was done at the completion of the study, the results for the data through 12 weeks differed slightly from those previously done. The results from the final analysis are presented in section 9.4.1 because they are based on the most complete data.

Results of the original 12-week analysis for the primary efficacy endpoints are available in Supportive Table ST 6-1. Supportive Table ST 6-2 summarizes the results of the initial analysis of data through 12 weeks (labeled as Initial 12) and the final analysis for the primary efficacy endpoints at weeks 4 and 12.

6.8.2 Sequential Testing Strategy for Efficacy Variables

To control for multiplicity with regard to the 4 DVS SR dose groups versus placebo, a sequential testing strategy was specified (see section 6.7.1.3). A strict dose response with the highest dose of DVS SR having greatest efficacy was thought to be unlikely because it was hypothesized that higher doses of DVS SR could engage an excess of norepinephrine, actually causing sweating and vasodilatation. Therefore rather than performing a classical stepwise approach (highest to lowest dose) to control for multiplicity, the approach taken was to look at 150 mg and 200 mg DVS SR dose groups simultaneously.

For further perspective on the results of the main analysis, 2 other commonly used approaches to adjust for multiple comparisons were applied: the Bonferroni approach using the 3 highest doses and declaring statistical significance at the 0.016 level for each dose regardless of the results for the other doses, and the Dunnett's test, declaring statistical significance at the 0.048 level for each dose. These results are presented as supportive information and are discussed in section 9.8.5.

CONFIDENTIAL 30 Wyeth

CSR-60178

7.0 OTHER ANALYSIS METHODS: HEALTH OUTCOMES ASSESSMENTS

Health outcomes assessments included the Satisfaction Survey (SS) individual score, the Sexual Function Questionnaire (SFQ), and the EuroQuality of Life Visual Analogue Scale (EQ VAS).

7.1 Subject Satisfaction

Overall satisfaction with regard to test article was assessed by the SS at visits 5 and 8 (see protocol, Attachment 2), which assesses 8 items: control of hot flushes during the day, control of hot flushes and sweats at night, sleep, mood, libido, ability to concentrate, medication tolerability, and overall satisfaction.

The SS was developed by RTI Health Solutions (RTI-HS) and Wyeth Research to measure satisfaction and to be used in several clinical trials of DVS SR to evaluate the ability of DVS SR to control symptoms associated with menopause. Relevant constructs for the questionnaire were identified through focus groups conducted with women going through menopause. During the questionnaire-development process, a draft questionnaire and a cognitive pretest were used to guide revisions.

7.2 Sexual Function Questionnaire

At visits 2 and 5, subjects completed the SFQ, which, although developed to evaluate sexual dysfunction among depressed patients, has also been used to describe normative ranges for sexual function across age and sex (see protocol, Attachment 4). Items were selected that represent the major components of sexual functioning, based on the clinical literature and clinical experience. The scale also evaluates overall satisfaction of sexual functioning and enjoyment of sexual romantic life. Five (5) scores can be derived from the SFQ:

- Drive/desire score (sum of items 1 through 4),
- Arousal score (sum of items 5 through 8),
- Orgasm score (sum of items 9 through 11),
- Overall satisfaction of sexual functioning and enjoyment of sexual romantic life (sum of items 12 and 13), and
- Total severity score (sum of all 13 items with reverse scoring of the last 2 items).

CONFIDENTIAL 31 Wyeth

CSR-60178

DVS SR Protocol 3151A2-315-US

Subjects were asked to rate items 1 through 11 on a scale of 0 to 4. Items 12 and 13, which assess overall satisfaction with sexual functioning and enjoyment of sexual romantic life, were rated from 0 to 10. Total scores range from 0 to 64, with higher scores indicating more sexual dysfunction.

7.3 EuroQuality of Life Visual Analogue Scale

At visits 2, 3, and 5, subjects completed the EQ VAS to assess the respondents' self-rated health status on a graduated (0 through 100) vertical visual analogue scale (see protocol, Attachment 3). EQ VAS is a standardized instrument for use as a measure of health outcome. Applicable to a wide range of health conditions and treatments, it provides a simple descriptive profile and a single index value for health status. It is cognitively simple and takes only a few minutes to complete. Differences in this scale can be used as a measure of health outcome, as judged by the individual respondents. Below are some of the more specific ways in which EQ VAS is being used:

- Monitoring the health status of groups at different times, such as referral, admission, discharge, and follow-up of outpatients.
- Evaluating and auditing health care, by measuring changes in health status in individuals and in groups.
- Assessing the seriousness of conditions at different times.
- Assisting in providing evidence about medical effectiveness in processes where drugs or procedures have to be approved.
- Establishing levels of population health status both locally and nationally.

8.0 STUDY SUBJECTS

8.1 Disposition of Subjects

Of the 1169 subjects screened, 462 subjects were screen failures and 707 were randomly assigned to treatment in the study:

- 154 to DVS SR 50 mg.
- 157 to DVS SR 100 mg.
- 163 to DVS SR 150 mg.
- 155 to DVS SR 200 mg.

CONFIDENTIAL 32 Wyeth

Protocol 3151A2-315-US

CSR-60178

78 to placebo.

The most common reasons for screen failures were that the subject did not have enough hot flushes (24%), the subject withdrew consent during the washout/screening period (12%), enrollment closed during the washout period (12%), and there were laboratory test result abnormalities (10%) (Supportive Table ST 8-1).

The disposition of all subjects in the study is shown in Table 8.1-1. Eighteen (18) subjects did not use test article. The remaining 689 subjects who completed the prestudy period and took at least 1 dose of test article under double-blind conditions were included in all safety analyses. Sixty-nine (69) subjects had less than 5 days of on-therapy VMS data during the first 12 weeks of the double-blind period and were excluded from the ITT population for the primary efficacy variables. Overall, 368 subjects completed the study.

Table 8.1-1: Summary of Subject Status: Number (%) of Subjects by Population Subset

	DVS SR 50 mg	DVS SR 100 mg	DVS SR 150 mg	DVS SR 200 mg	Placebo	Total
Population Subset	(n=154)	(n=157)	(n=163)	(n=155)	(n=78)	(n=707)
Randomly assigned	154 (100)	157 (100)	163 (100)	155 (100)	78 (100)	707 (100)
Did not use test article	5 (3.2)	2 (1.3)	6 (3.7)	4 (2.6)	1 (1.3)	18 (2.5)
Safety population ^a	149 (96.7)	155 (98.7)	157 (96.3)	151 (97.4)	77 (98.7)	689 (97.4)
Excluded from ITT for VMS b	8 (5.2)	10 (6.4)	20 (12.3)	31 (20.0)	0	69 (9.7)
ITT population for VMS b	141 (91.6)	145 (92.4)	137 (84.0)	120 (77.4)	77 (98.7)	620 (87.7)
Completed 12 weeks	125 (81.2)	121 (77.1)	109 (66.9)	97 (62.6)	67 (85.9)	519 (73.4)
Completed study ^c	88 (57.1)	87 (55.4)	76 (46.6)	69 (44.5)	48 (61.5)	368 (52.0)

Abbreviations: ITT=intent to treat and VMS=vasomotor symptoms.

Source: Clinical, from DEMO1, DEMO5, DEMO5 ITT SYM, CPP1 D, and CPP5 D

8.1.1 **Discontinuations**

Overall, 321 subjects withdrew from the study during the double-blind period: 29 (38%) subjects treated with placebo and 292 (48%) subjects treated with DVS SR. Table 8.1.1-1 summarizes the number of subjects who withdrew by the primary reasons for withdrawal in each treatment

a. Safety population included all randomly assigned subjects who received at least 1 dose of test article.

b. ITT population for VMS included all randomly assigned subjects who took at least 1 dose of test article, had at least 5 days of VMS data at baseline, and had at least 5 on-therapy days of VMS data during the first 12 weeks.

c. Defined in the clinical data report (CDR) package as subjects who had a duration of therapy of 50 weeks or

Protocol 3151A2-315-US

CSR-60178

group. Significantly more subjects in the 150-mg and 200-mg DVS SR groups withdrew from the study because of adverse events (p<0.001 versus placebo), whereas for the 100-mg and 50-mg DVS SR groups the differences from placebo were not statistically significant. Subjects who withdrew from the study because of adverse events are discussed in section 10.3.4. The 150-mg DVS SR dose group was associated with a significantly (p=0.007) lower incidence of discontinuation for unsatisfactory response.

Table 8.1.1-1: Number (%) of Subjects Who Withdrew From Study by Primary Reason for Withdrawal

		DVS SR	DVS SR	DVS SR	DVS SR	
	Overall	50 mg	100 mg	150 mg	200 mg	Placebo
Reason	p-Value ^a	(n=149)	(n=155)	(n=157)	(n=151)	(n=77)
Discontinued b	0.040*	61 (40.9)	68 (43.9)	81 (51.6)	82 (54.3)	29 (37.7)
Adverse event	<0.001***	27 (18.1)	33 (21.3)	58 (36.9)	63 (41.7)	12 (15.6)
Failed to return	0.321	9 (6.0)	11 (7.1)	10 (6.4)	5 (3.3)	8 (10.4)
Other event	0.614	3 (2.0)	2 (1.3)	2 (1.3)	4 (2.6)	0
Protocol violation	0.578	2 (1.3)	0	1 (0.6)	1 (0.7)	0
Subject request unrelated to study	0.118	5 (3.4)	10 (6.5)	7 (4.5)	2 (1.3)	1 (1.3)
Unsatisfactory response - efficacy	0.020*	15 (10.1)	12 (7.7)	3 (1.9)	7 (4.6)	8 (10.4)

a. Statistical significance at the 0.05 and 0.001 levels is denoted by * and ***, respectively

Source: CPP5_D 21JUL05 13:50

The disposition over time of the 689 subjects included in the safety population is presented in Table 8.1.1-2. A subject who took at least 1 dose of test article during the specified time period was considered to be in the time period.

CONFIDENTIAL 34 Wyeth

b. Total discontinued is the sum of individual reasons because they are mutually exclusive by subject.

Protocol 3151A2-315-US

CSR-60178

Table 8.1.1-2: Number (%) of Subjects Who Withdrew During the Study by Time Interval

	DVS SR	DVS SR	DVS SR	DVS SR	
Time Period	50 mg	100 mg	150 mg	200 mg	Placebo
Week 1	10/149 (7)	12/155 (8)	24/157 (15)	36/151 (24)	0/77
Week 2	1/139 (<1)	3/143 (2)	5/133 (4)	3/115 (3)	0/77
Week 3	0/138	4/140 (3)	3/128 (2)	2/112 (2)	0/77
Week 4	7/138 (5)	5/136 (4)	4/125 (3)	7/110 (6)	1/77 (1)
Week 5-8	4/131 (3)	3/131 (2)	8/121 (7)	3/103 (3)	5/76 (7)
Weeks 9-12	10/127 (8)	9/128 (7)	9/113 (8)	6/100 (6)	5/71 (7)
Weeks 13-24	14/117 (12)	8/119 (7)	14/104 (13)	12/94 (13)	7/66 (11)
Weeks 25-36	9/103 (9)	15/111 (14)	8/90 (9)	10/82 (12)	9/59 (15)
Weeks 37-52	6/94 (6)	9/96 (9)	6/82 (7)	3/72 (4)	2/50 (4)
Total	61/149 (41)	68/155 (44)	81/157 (52)	82/151 (54)	29/77 (38)

Source: CPP4_D_DAI 28OCT05 15:48

More subjects in the DVS SR groups than in the placebo group withdrew during the first week of therapy. The primary reason for discontinuation during the first week was adverse event. After the first week, there was no difference among groups regarding the number of subjects who discontinued by time interval.

8.1.2 Protocol Deviations

Protocol deviations were identified by the sponsor before unblinding, based on exclusion/inclusion criteria, use of prohibited treatments, and compliance with test article. There were no systematic deviations from the protocol.

As specified in section 6.7.1.1, a PP population was defined for each week through the first 12 weeks of therapy. Depending on her compliance, a subject could have been excluded for only 1 evaluable week but included in others. Overall, 278 (45%) subjects were excluded from the PP population because of protocol deviations for at least 1 evaluable week during the initial 12 weeks of therapy (subjects could have been excluded for more than one reason): 2 did not have 50 moderate to severe hot flushes during the baseline week, 156 did not have at least 5 days of hot flush data for at least 1 week, 27 used prohibited medications that could have compromised efficacy evaluations, and 241 were not compliant with test article for at least 1 week. Supportive Table ST 8-2 provides a summary of subjects excluded from the PP population for primary endpoints by week and reason for exclusion.

CSR-60178

8.2 Demographic and Other Baseline Characteristics

The demographic and baseline characteristics for 689 subjects who took at least 1 dose of test article are summarized by treatment group in Table 8.2-1. Most subjects in each treatment group were white and had natural menopause with an intact uterus. Subjects were generally healthy postmenopausal women. However, the mean body mass index (BMI) was 27 kg/m², with 408 (59%) subjects being overweight (BMI>25 kg/m²) and 164 (24%) being obese (BMI>30 kg/m²). Before the start of the study, 128 subjects (19%) were receiving antihypertensive medications and 103 subjects (15%) were receiving lipid-lowering drugs. The total cholesterol level was greater than 6.465 mmol/L (250 mg/dL) in 179 (26%) subjects, and the triglyceride level was greater than 2.242 mmol/L (199 mg/dL) in 81 (12%) subjects. There were no significant differences between treatment groups for demographic or baseline characteristics. Statistical comparisons between treatment groups for demographics are shown in Supportive Table ST 8-3.

CONFIDENTIAL 36 Wyeth

Protocol 3151A2-315-US

CSR-60178

Table 8.2-1: Demographic and Other Baseline Characteristics, Safety Population

	DVS SR	DVS SR	DVS SR	DVS SR	
	50 mg	100 mg	150 mg	200 mg	Placebo
Characteristic	(n=149)	(n=155)	(n=157)	(n=151)	(n=77)
Age, year					
Mean	53.07	53.34	53.46	53.46	54.22
Standard deviation	4.48	5.61	4.66	4.40	5.44
Minimum-maximum	41.00-71.00	29.00-78.00	37.00-70.00	37.00-67.00	41.00-73.00
Race, n (%)					
White	127 (85.23)	135 (87.10)	134 (85.35)	133 (88.08)	59 (76.62)
Black	15 (10.07)	14 (9.03)	15 (9.55)	12 (7.95)	10 (12.99)
Other	7 (4.70)	6 (3.87)	8 (5.10)	6 (3.97)	8 (10.39)
Ethnicity, n (%)					
Hispanic or Latino	14 (9.40)	13 (8.39)	12 (7.64)	9 (5.96)	7 (9.09)
Non-Hispanic and non-Latino	135 (90.60)	142 (91.61)	145 (92.36)	142 (94.04)	70 (90.91)
Height, cm					
Mean	163.00	162.97	163.95	163.92	163.23
Standard deviation	6.56	6.49	6.95	5.94	7.09
Minimum-maximum	151.2-180.6	147.3-180.4	146.0-185.0	145.7-175.3	142.2-182.8
Weight, kg					
Mean	72.42	71.81	71.64	72.49	71.59
Standard deviation	13.65	12.60	13.03	12.03	13.15
Minimum-maximum	50.0-112.5	43.40-105.9	45.90-108.6	48.60-113.2	48.10-104.5
BMI, kg/m ²					
Mean	27.21	27.06	26.65	27.02	26.87
Standard deviation	4.56	4.67	4.47	4.57	4.75
Minimum-maximum	18.23-37.22	17.83-39.14	14.75-39.23	17.26-40.88	19.79-40.22
Type of menopause, n (%)					
Natural	118 (79.19)	121 (78.06)	123 (78.34)	118 (78.15)	59 (76.62)
Surgical (bilateral oophorectomy)	31 (20.81)	34 (21.94)	34 (21.66)	33 (21.85)	18 (23.38)
Years since natural menopause ^a					
Mean	4.39	4.44	4.68	4.87	6.43
Standard deviation	4.38	3.81	4.64	4.34	6.95
Minimum-maximum	0.55-23.70	0.49-16.92	0.59-24.41	0.49-21.71	0.54-35.13
Years since surgical menopause					
Mean	7.99	11.02	10.50	12.38	11.20
Standard deviation	5.89	7.82	9.55	10.67	9.54
Minimum-maximum	0.72-23.19	0.21-29.05	0.75-36.90	1.21-44.14	1.03-28.06

a. Years since natural menopause refers only to women with uterus.

Source: DEMO5 05AUG05 16:19

Protocol 3151A2-315-US

CSR-60178

8.3 Concomitant Therapy

A total of 73 (94.8%) subjects in the placebo group and 585 (95.6%) in the DVS SR groups received some type of concomitant therapy during the on-therapy phase of the study.

Table 8.3-1 shows the most common concomitant therapies (used by at least 10% in any therapeutic group) alphabetically by Anatomical Therapeutic Chemical (ATC) classification that were used during the period of test article administration.

Supportive Table ST 8-4 provides a summary of all nonstudy therapies taken at any time during the course of the study. Use of individual concomitant medications was comparable among DVS SR groups and the placebo group.

CONFIDENTIAL 38 Wyeth

Protocol 3151A2-315-US

CSR-60178

Table 8.3-1: Most Commonly Used Concomitant Medications: Number (%) of Subjects

	DVS SR	DVS SR	DVS SR	DVS SR	
	50 mg	100 mg	150 mg	200 mg	Placebo
ATC Classification	(n=149)	(n=155)	(n=157)	(n=151)	(n=77)
Time period: concomitant					
Any nonstudy medication	143 (96.0)	146 (94.2)	150 (95.5)	146 (96.7)	73 (94.8)
All other therapeutic products	15 (10.1)	11 (7.1)	9 (5.7)	17 (11.3)	7 (9.1)
Antihistamines for systemic use	36 (24.2)	46 (29.7)	34 (21.7)	33 (21.9)	21 (27.3)
Anti-inflammatory/antirheumatic products,					
nonsteroids	92 (61.7)	71 (45.8)	73 (46.5)	77 (51.0)	42 (54.5)
Antitussives, excluding combinations with	15 (10.1)	10 (7.7)	5 (4.5)	5 (4.6)	7 (0.1)
expectorants	15 (10.1)	12 (7.7)	7 (4.5)	7 (4.6)	7 (9.1)
Ascorbic acid (vitamin C), including combinations	19 (12.8)	26 (16.8)	19 (12.1)	23 (15.2)	15 (19.5)
	` /	` '	` '		9 (11.7)
Beta blocking agents, plain	7 (4.7)	14 (9.0)	10 (6.4)	7 (4.6)	` ′
Beta-lactam antibacterials, penicillins	16 (10.7)	9 (5.8)	11 (7.0)	12 (7.9)	4 (5.2)
Calcium	47 (31.5)	54 (34.8)	49 (31.2)	54 (35.8)	33 (42.9)
Cholesterol and triglyceride reducers	28 (18.8)	36 (23.2)	33 (21.0)	50 (33.1)	14 (18.2)
Corticosteroids for systemic use, plain	7 (4.7)	13 (8.4)	16 (10.2)	7 (4.6)	9 (11.7)
Drugs for treatment of peptic ulcer	25 (16.8)	31 (20.0)	22 (14.0)	23 (15.2)	7 (9.1)
Laxatives	21 (14.1)	26 (16.8)	15 (9.6)	23 (15.2)	6 (7.8)
Multivitamins, combinations	50 (33.6)	69 (44.5)	70 (44.6)	74 (49.0)	34 (44.2)
Nasal decongestants for systemic use	17 (11.4)	20 (12.9)	13 (8.3)	19 (12.6)	13 (16.9)
Opioids	12 (8.1)	10 (6.5)	16 (10.2)	10 (6.6)	9 (11.7)
Other analgesics and antipyretics	83 (55.7)	85 (54.8)	81 (51.6)	67 (44.4)	49 (63.6)
Other plain vitamin preparations	27 (18.1)	39 (25.2)	37 (23.6)	42 (27.8)	13 (16.9)
Renin-angiotensin system, agents acting on	6 (4.0)	9 (5.8)	11 (7.0)	10 (6.6)	8 (10.4)
Thyroid preparations	17 (11.4)	20 (12.9)	19 (12.1)	21 (13.9)	11 (14.3)

Abbreviation: ATC= Anatomical Therapeutic Chemical.

Source: NMED4_ATC3_5% 19OCT05 16:36

9.0 EFFICACY EVALUATION

9.1 Populations Analyzed

The ITT population for VMS data (primary efficacy endpoints) was detailed in section 6.7.1.1.

9.2 Demographic and Other Baseline Characteristics

Demographic and baseline characteristics for the 620 subjects who were in the ITT population for VMS data are summarized by treatment group in Table 9.2-1. There were no significant differences between groups for demographic or baseline characteristics. Statistical comparisons

CSR-60178

between groups for demographic characteristics are shown in Supportive Table ST 9-1. The ITT population had demographic and baseline characteristics similar to those of the safety population.

Table 9.2-1: Demographic and Other Baseline Characteristics, ITT Population for VMS
Data

	DVS SR	DVS SR	DVS SR	DVS SR	
	50 mg	100 mg	150 mg	200 mg	Placebo
Characteristic	(n=141)	(n=145)	(n=137)	(n=120)	(n=77)
Age, year					
Mean	53.21	53.48	53.29	53.51	54.22
Standard deviation	4.44	5.33	4.59	4.51	5.44
Minimum-maximum	42.00-71.00	39.00-78.00	37.00-70.00	37.00-67.00	41.00-73.00
Race, n (%)					
White	122 (86.52)	125 (86.21)	117 (85.40)	105 (87.50)	59 (76.62)
Black	14 (9.93)	14 (9.66)	12 (8.76)	10 (8.33)	10 (12.99)
Other	5 (3.55)	6 (4.14)	8 (5.84)	5 (4.17)	8 (10.39)
Ethnicity, n (%)					
Hispanic or Latino	12 (8.51)	13 (8.97)	10 (7.30)	8 (6.67)	7 (9.09)
Non-Hispanic and Non-Latino	129 (91.49)	132 (91.03)	127 (92.70)	112 (93.33)	70 (90.91)
Height, cm					
Mean	163.32	162.94	164.19	164.12	163.23
Standard deviation	6.55	6.44	6.94	5.98	7.09
Minimum-maximum	151.2-180.6	147.3-180.4	149.9-185.0	145.7-175.3	142.2-182.8
Weight, kg					
Mean	72.82	72.05	72.10	73.63	71.59
Standard deviation	13.65	12.30	13.12	11.94	13.15
Minimum-maximum	50.00-112.50	43.40-105.90	45.90-108.60	49.50-113.20	48.10-104.50
BMI, kg/m^2					
Mean	27.11	27.06	26.63	27.33	26.72
Standard deviation	4.51	4.64	4.47	4.57	4.72
Minimum-maximum	17.90-37.80	17.80-39.10	14.90-39.10	19.10-41.00	19.40-39.60
Type of menopause, n (%)					
Natural	111 (78.72)	115 (79.31)	106 (77.37)	94 (78.33)	59 (76.62)
Surgical (bilateral oophorectomy)	30 (21.28)	30 (20.69)	31 (22.63)	26 (21.67)	18 (23.38)
Years since natural menopause ^a					
Mean	4.35	4.19	4.37	4.92	6.43
Standard deviation	4.38	3.46	4.16	4.47	6.95
Minimum-maximum	0.55-23.70	0.49-16.92	0.59-19.16	0.49-21.71	0.54-21.71
Years since surgical menopause					
Mean	8.01	10.80	11.02	13.07	11.20
Standard deviation	5.98	7.42	9.82	11.61	9.54
Minimum-maximum	0.72-23.19	0.21-26.15	0.75-36.90	1.21-44.14	1.03-28.06

a. Years since natural menopause refers only to women with uterus.

Source: DEMO5_ITT_SYM 26OCT05 17:26

Table 9.2-2 provides the baseline values for subjects with at least 1 on-therapy evaluation for the primary efficacy endpoints (number and severity of hot flushes) and selected secondary efficacy endpoints (mild, moderate, and severe VMS, weekly weighted score, number of awakenings owing to VMS, total mood disturbance score, and total WLQ index score).

Overall, the baseline values for primary endpoints were similar across groups.

CONFIDENTIAL 41 Wyeth

Protocol 3151A2-315-US

CSR-60178

Table 9.2-2: Baseline Values for Primary and Key Secondary Endpoints, ITT **Population**

	DVS SR	DVS SR	DVS SR	DVS SR	
Endpoint	50 mg	100 mg	150 mg	200 mg	Placebo
Daily number of moderate and seven	re HF				
Number of subjects in ITT	141	145	137	120	77
Mean	10.8	10.5	11.2	11.1	11.0
Standard deviation	4.1	4.1	6.4	4.3	4.6
Daily severity score of HF					
Number of subjects in ITT	141	145	137	120	77
Mean	2.4	2.4	2.4	2.4	2.5
Standard deviation	0.3	0.3	0.3	0.3	0.3
Daily number of mild, moderate, an	d severe HF				
Number of subjects in ITT	141	145	137	120	77
Mean	12.4	11.9	12.7	13.1	11.9
Standard deviation	4.3	4.6	6.5	6.7	4.6
Weekly weighted score					
Number of subjects in ITT	141	145	137	120	77
Mean	193.3	189.9	200.9	199.4	198.3
Standard deviation	76.9	79.7	111.5	82.7	84.6
Number of awakenings due to HF					
Number of subjects in ITT	138	145	136	120	77
Mean	3.7	3.6	3.9	3.8	3.5
Standard deviation	1.7	1.9	2.7	2.4	2.1
Total mood disturbance score					
Number of subjects in ITT	95	111	91	79	59
Mean	38.6	34.3	30.2	41.3	34.0
Standard deviation	34.8	37.8	34.4	37.1	35.6
Total WLQ index score					
Number of subjects in ITT	105	94	96	82	52
Mean	6.3	6.6	6.6	6.2	6.5
Standard deviation	4.5	5.3	5.5	4.2	5.6

Abbreviations: HF=hot flushes and ITT=intent to treat.

Sources: hf itt locf ancova final 05.html, sleep itt ancova final 05.html, poms itt anova final 05.html, and wlq itt anova final 05.html.

9.3 **Measurements of Treatment Compliance**

To be considered compliant, subjects had to take at least 80% of test article a week (17 tablets per week) for the first 12 weeks of therapy. After the initial 12 weeks, compliance was measured by 4-week time intervals. Supportive Table ST 9-2 provides data on treatment compliance by time interval. Except for the first week of therapy, generally at least 90% of subjects were compliant with test article at each time interval with no difference among groups. During the first

Protocol 3151A2-315-US

CSR-60178

week, compliance was 82% for the 150-mg DVS SR group and 73% for the 200-mg DVS SR group.

Efficacy Results for the ITT Population 9.4

The results of the statistical analyses in the ITT population are discussed in this section. The results of the statistical analyses in the PP population are discussed in section 9.5.

9.4.1 **Primary Efficacy Endpoint**

9.4.1.1 **Changes in Average Daily Number of Moderate to Severe Hot Flushes**

The reduction in the average daily number of moderate and severe hot flushes at weeks 4 and 12 for the ITT LOCF population is shown in Table 9.4.1.1-1. Data for the ITT LOCF population at all time points through week 12 are shown in Supportive Table ST 9-3 and are graphed in Figure 9.4.1.1-1.

Table 9.4.1.1-1: Changes in Average Daily Number of Moderate and Severe Hot Flushes at Weeks 4 and 12 for the ITT LOCF Population

			Adjusted	d Change-	
Treatment Groups	Interval	Pairs, n	Mean	SE	p-Value vs Placebo
DVS SR 50 mg	Week 4	141	-5.77	0.35	0.331
	Week 12	141	-6.10	0.38	0.326
DVS SR 100 mg	Week 4	145	-6.62	0.34	0.013
	Week 12	145	-7.23	0.37	0.005
DVS SR 150 mg	Week 4	137	-6.48	0.35	0.027
-	Week 12	137	-6.94	0.38	0.020
DVS SR 200 mg	Week 4	120	-6.42	0.38	0.040
-	Week 12	120	-6.46	0.41	0.130
Placebo	Week 4	77	-5.22	0.46	
	Week 12	77	-5.50	0.50	

Abbreviations: ITT=intent to treat; LOCF=last observation carried forward; and SE=standard error.

Analysis of covariance: change=treat+site+baseline.

Source: hf itt locf ancova final 05.html


All treatment groups had a significant decrease from baseline in the adjusted mean daily number of moderate and severe hot flushes at all time points, reaching a 64% and 60% reduction from baseline in the 100-mg and 150-mg DVS SR groups, respectively, at week 12. When the 2 time points of primary interest (week 4 and week 12) are considered, the 200-mg DVS SR group results were not statistically different from the placebo group results at the p=0.024 level at either

CONFIDENTIAL 43 Wyeth

CSR-60178

time point, and the 150-mg DVS SR group results were different from the placebo group results at the p=0.024 level at week 12. The 100-mg DVS SR group results were different from the placebo group results both at week 4 (p=0.013) and at week 12 (p=0.005). The 50-mg DVS SR group results were not different from the placebo group results at the p=0.048 level at either time point.

Figure 9.4.1.1-1: Average Daily Number of Moderate and Severe Hot Flushes for the ITT LOCF Population Through Week 12



The efficacy of the 100-mg DVS SR group results was consistent, with data across all 12 weeks similar to the time points of primary interest (week 4 and week 12), and with differences from the placebo group results at all time points. There was an observed statistical difference in the 50-mg DVS SR group for week 1 and week 2; however, the difference was not maintained over time. The results for the 150-mg DVS SR group were significant at p=0.024 at weeks 1-3 and 5-9. The 150-mg and 200-mg DVS SR results yielded a reduction in the number of moderate and severe hot flushes that was of lower magnitude than the reduction produced by the 100-mg DVS SR dose.


CONFIDENTIAL 44 Wyeth

Protocol 3151A2-315-US

CSR-60178

The reduction in the average daily number of moderate and severe hot flushes over 52 weeks was examined for the ITT observed data population; the results are given in Supportive Table ST 9-4 and are graphed in Figure 9.4.1.1-2.

Figure 9.4.1.1-2: Average Daily Number of Moderate and Severe Hot Flushes for the ITT Observed Data Population Through Week 52



Note: The number of subjects varied at each time point. Over time, the percentage of subjects who withdrew for unsatisfactory response or failed to return was 20.8% in the placebo group compared with 11.7% in DVS SR groups.

For the first 12 weeks, the results of the ITT observed data population were similar to those obtained in the ITT LOCF population. For time points beyond week 12, the decrease in the average daily number of moderate and severe hot flushes obtained at 12 weeks was maintained over the 52 weeks in all DVS SR groups. The 100-mg DVS SR group results were different from the placebo group results at the p=0.048 level at all time points. The response in the placebo

CONFIDENTIAL 45 Wyeth

Protocol 3151A2-315-US

CSR-60178

group may be partly explained by the differences in the discontinuation rate over time between the active treatment groups and the placebo group (see Tables 8.1.1-1 and 8.1.1-2).

9.4.1.2 **Changes in Hot Flush Average Daily Severity Scores**

The reduction in the average daily severity score for the ITT LOCF population is given for weeks 4 and 12 in Table 9.4.1.2-1; full data are provided in Supportive Table ST 9-5.

Table 9.4.1.2-1: Changes in the Average Daily Severity Score at Weeks 4 and 12 for the ITT LOCF Population

		Adjusted Change					
Treatment	Time Point	Pairs, n	Mean	SE	p-Value vs Placebo		
DVS SR 50 mg	Week 4	141	-0.37	0.06	0.913		
	Week 12	141	-0.43	0.07	0.754		
DVS SR 100 mg	Week 4	145	-0.57	0.06	0.054		
	Week 12	145	-0.80	0.06	0.002		
DVS SR 150 mg	Week 4	137	-0.53	0.06	0.138		
_	Week 12	137	-0.59	0.07	0.235		
DVS SR 200 mg	Week 4	120	-0.57	0.07	0.072		
_	Week 12	120	-0.74	0.07	0.013		
Placebo	Week 4	77	-0.39	0.08			
	Week 12	77	-0.47	0.09			

Abbreviations: ITT=intent to treat; LOCF=last observation carried forward; and SE=standard error. Analysis of covariance: change=treat+site+baseline.

Source: hf itt locf ancova final 05.html

All treatment groups had a significant decrease from baseline in the adjusted mean daily severity score at all time points. When the 2 time points of primary interest (week 4 and week 12) are considered, the 200-mg DVS SR group results were different from the placebo group results at the p=0.024 level at week 12; the 150-mg DVS SR group results were not different from the placebo group results at the p=0.024 level at either time point; the 100-mg DVS SR group results were different from the placebo group results at week 12 (p=0.002), and at week 4 the p-value versus placebo was 0.054; and the 50-mg DVS SR group results were not different from the placebo group results at the p=0.048 level at either time point.

At other time points within the first 12 weeks, the 100-mg DVS SR results were statistically different from the placebo group results at all time points.

CONFIDENTIAL 46 Wyeth

CSR-60178

The reduction in the average daily severity score for the ITT observed data population is given in Supportive Table ST 9-6, and results are summarized thereafter. For the first 12 weeks, the results in the ITT observed data population were similar to those obtained in the ITT LOCF. For the time points beyond week 12, the decrease in daily severity score obtained at week 12 was maintained over the 52 weeks in all treatment groups.

9.4.2 **Key Secondary Efficacy Endpoints**

The key secondary efficacy variables were the average daily number of awakenings because of hot flushes, the total mood disturbance score (POMS), and the WLQ total index score, measured at week 12. Sequential testing procedure was applied to these key secondary efficacy endpoints to adjust for multiplicity (see section 6.7.1.3 and statistical analysis plan for details).

9.4.2.1 **Number of Awakenings Because of Vasomotor Symptoms**

The average daily number of times subjects were awakened because of VMS in the ITT observed data population is presented in Supportive Table ST 9-7. A summary of these data for the time point of primary interest, week 12, is shown in Table 9.4.2.1-1.

Table 9.4.2.1-1: Summary of Mean Daily Change in Number of Awakenings at Week 12 for the ITT Observed Data Population

	Adjusted Change					
Treatment	Pairs, n	Mean	SE	p-Value vs Placebo		
DVS SR 50 mg	111	-2.30	0.14	0.672		
DVS SR 100 mg	105	-2.77	0.14	0.013		
DVS SR 150 mg	97	-2.69	0.15	0.034		
DVS SR 200 mg	91	-2.68	0.15	0.043		
Placebo	63	-2.21	0.18			

Abbreviations: ITT=intent to treat and SE=standard error.

Source: sleep itt ancova final 05.html

There was a significant decrease from baseline in the number of awakenings because of VMS in all treatment groups. At week 12, the decrease in the mean daily number of awakenings in the 200-mg, 150-mg, and 100-mg DVS SR group results was different from that in the placebo group at the p=0.048 level.

CONFIDENTIAL 47 Wyeth

Protocol 3151A2-315-US

CSR-60178

9.4.2.2 Profile of Mood States

The total mood disturbance score at week 12 was examined in the ITT observed data population, and the result is shown in Table 9.4.2.2-1. Results for the subcategories (tension, depression, anger, vigor, fatigue, and confusion) are presented in Supportive Table ST 9-8.

Table 9.4.2.2-1: Total Mood Disturbance Score at Week 12 for the ITT Observed Data Population

	Adjusted Change			
Treatment	Pairs, n	Mean	SE	p-Value vs Placebo
DVS SR 50 mg	95	-33.12	3.50	0.015
DVS SR 100 mg	111	-30.32	3.20	0.047
DVS SR 150 mg	91	-25.90	3.58	0.272
DVS SR 200 mg	79	-31.55	3.85	0.040
Placebo	59	-19.84	4.37	

Abbreviation: SE=standard error. Analysis of variance: change=treat+site. Source: poms_itt_anova_final_05.html

The mean total mood disturbance scores observed in all DVS SR groups and in the placebo group decreased significantly from baseline at week 12. The 200-mg, 100-mg, and 50-mg DVS SR groups were different at the p=0.048 level from the placebo group in the total mood disturbance score at week 12. Subcategory results are summarized as follows:

- For the anger/hostility scale, results in the 200-mg DVS SR (p=0.020) and 100-mg DVS SR (p=0.047) groups were different from those in the placebo group.
- For the tension/anxiety scale, results in the 100-mg DVS SR group (p=0.034) were different from those in the placebo group.
- For the confusion/bewilderment, depression/dejection, and fatigue/inertia scales, results in the DVS SR groups were not different from those in the placebo group.

9.4.2.3 Work Limitations Questionnaire

Per protocol, the WLQ was to be completed only by subjects with regular work activity. At baseline, 541 (78%) subjects completed a WLQ. There was a significant decrease from baseline in all groups in the WLQ total index score and in the subscales (mental-interpersonal scale, time scale, or output scale) at weeks 4 and 12. None of the DVS SR groups achieved significant improvement in the WLQ total index score or in any of the subscores as compared with that in the placebo group at week 12.

9.4.3 Other Secondary Efficacy Endpoints

Other secondary analyses included the reduction in number of mild, moderate, and severe hot flushes, reduction in the weekly weighted severity score, response rate based on the percentage of reduction in hot flushes, time to reach a 50% reduction in the number of hot flushes, and other sleep parameters (time to fall asleep, time slept, and overall quality of sleep).


9.4.3.1 Vasomotor Symptoms Endpoints

9.4.3.1.1 Average Daily Number of Mild, Moderate, and Severe Hot Flushes

The reduction in the average daily number of mild, moderate, and severe hot flushes was determined over the initial 12 weeks of therapy for the ITT LOCF population (Figure 9.4.3.1.1-1 and Supportive Table ST 9-9).

CONFIDENTIAL 49 Wyeth

Figure 9.4.3.1.1-1: Average Daily Number of Mild, Moderate, and Severe Hot Flushes for the ITT LOCF Population Through Week 12




For the ITT LOCF population, the 200-mg DVS SR group results were different from the placebo group results at the p=0.024 level at weeks 1 through 4; the 150-mg DVS SR group results were different from the placebo group results at the p=0.024 level at all time points but week 11; the 100-mg DVS SR group results were different from the placebo group results at the p=0.048 level at all weeks; and the 50-mg DVS SR group results were different from the placebo group results at the p=0.048 level at week 1 only.

The reduction in the average daily number of mild, moderate, and severe hot flushes was also determined over 52 weeks for the ITT observed data (Figure 9.4.3.1.1-2 and Supportive Table ST 9-10) populations. For the first 12 weeks of therapy, the results in the ITT observed data population were similar to those obtained in the ITT LOCF. For time points beyond week 12, the

decrease in the average daily number of mild, moderate, and severe hot flushes obtained at 12 weeks was maintained over the 52 weeks in all DVS SR groups.

Figure 9.4.3.1.1-2: Average Daily Number of Mild, Moderate, and Severe Hot Flushes for the ITT Observed Data Population Through Week 52



Note: The number of subjects varied at each time point. Over time, the percentage of subjects who withdrew for unsatisfactory response or failed to return was 20.8% in the placebo group compared with 11.7% in DVS SR groups.

9.4.3.1.2 Reduction in Weekly Weighted Severity Score

A weighted score was defined to allow the calculation of a severity score based on moderate and severe hot flushes only.

For the ITT LOCF population (Supportive Table ST 9-11), the reduction in the weekly weighted score for moderate and severe hot flushes yielded results consistent with the daily severity score. The 100-mg DVS SR group reached a 70% reduction from baseline in the weekly weighted

CONFIDENTIAL 51 Wyeth

CSR-60178

score at week 12 (p=0.012 versus placebo for change from baseline in adjusted mean). The magnitude of the effect in the 200-mg and 150-mg DVS SR groups was similar to that in the 100-mg DVS SR group at early time points, but it did not reach statistical significance at the p=0.024 level versus placebo after weeks 4 and 6, respectively.

The reduction in the weekly weighted score for moderate and severe hot flushes was also determined for the ITT observed data (Supportive Table ST 9-12) population. The results were similar to those obtained in the ITT LOCF population. The 100-mg DVS SR group results were different from the placebo group results at the p=0.048 level at all time points.

9.4.3.1.3 Responder Analysis

A responder was defined as a subject with a 75% or greater reduction from baseline in the number of moderate to severe hot flushes. A 50% responder rate was also defined. The same definitions were applied for the number of mild, moderate, and severe hot flushes. The 2 time points of primary interest were weeks 4 and 12.

9.4.3.1.3.1 Subjects With at Least a 75% Decrease

The number and percentage of subjects with a decrease of at least 75% in the average daily number of moderate and severe hot flushes are given in Table 9.4.3.1.3.1-1 and in Figure 9.4.3.1.3.1-1 for the ITT LOCF population and in Supportive Table ST 9-13 for the ITT observed data population.

CONFIDENTIAL 52 Wyeth

Protocol 3151A2-315-US


CSR-60178

Table 9.4.3.1.3.1-1: Number (%) of Subjects With ≥75% Decrease in Average Daily Number of Moderate and Severe Hot Flushes for the ITT LOCF Population

			Decrea	ıse ≥75%	Relative Ratio	95%	6 CI	p-Value vs
Treatment	Time Period	Pairs, n	n	%	vs Placebo	Lower	Upper	Placebo
DVS SR 50 mg	Week 4	141	34	24.11	1.44	0.72	2.88	0.309
	Week 12	141	47	33.33	1.25	0.68	2.29	0.473
DVS SR 100 mg	Week 4	145	53	36.55	2.60	1.33	5.09	0.005
	Week 12	145	72	49.66	2.46	1.36	4.46	0.003
DVS SR 150 mg	Week 4	137	52	37.96	2.76	1.41	5.42	0.003
_	Week 12	137	56	40.88	1.72	0.94	3.13	0.078
DVS SR 200 mg	Week 4	120	40	33.33	2.26	1.13	4.52	0.021
	Week 12	120	54	45.00	2.05	1.11	3.78	0.022
Placebo	Week 4	77	14	18.18				
	Week 12	77	22	28.57				

Abbreviations: CI=confidence interval; ITT=intent to treat; and LOCF=last observation carried forward. Logistic: decrease 75%=treat+site. This relative ratio is the ratio of having 75% reduction compared with placebo. Source: hf itt locf reduction final 05 csr v24.rtf October 17, 2005 03:54

Figure 9.4.3.1.3.1-1: Percentage of Subjects With a 75% Reduction in the Number of **Moderate and Severe Hot Flushes From Baseline**



For the ITT LOCF population, the percentage of subjects with a 75% decrease from baseline in the number of moderate and severe VMS was significantly higher at both time points in the 200-mg and 100-mg DVS SR dose groups than in the placebo group; the 75% responder rate in

CSR-60178

the 150-mg DVS SR dose group was significantly higher than that in the placebo group at week 4 only.

For the ITT observed data population, the results were similar with a significantly higher percentage of responders in the 100-mg DVS SR dose group than in the placebo group at both time points (Supportive Table ST 9-13).

For the ITT LOCF and ITT observed data, the 75% responder rate in mild, moderate, and severe hot flushes in the 100-mg DVS SR group was higher than that in the placebo group at both time points (week 4 and week 12).

9.4.3.1.3.2 Subjects With at Least a 50% Decrease

The number and percentage of subjects with a decrease of at least 50% in the average daily number of moderate and severe hot flushes at weeks 4 and 12 are given in Supportive Table ST 9-14 for the ITT LOCF population and in Supportive Table ST 9-15 for the ITT observed data population. For both populations, results were similar: the percentage of subjects with at least a 50% decrease in the average daily number of moderate and severe hot flushes in the 200-mg DVS SR group was higher than that in the placebo group (p<0.024) at week 4, and the responder rate in the 100-mg DVS SR group was higher than that in the placebo group (p<0.048) at week 4.

The percentage of subjects with a reduction from baseline of at least 50% in the average daily number of mild, moderate, and severe hot flushes at weeks 4 and 12 was determined for the ITT LOCF population and the ITT observed data populations. Results are presented in Supportive Tables ST 9-16 and ST 9-17. Overall, results were consistent with those obtained from the responder analysis for reduction in the number of moderate and severe hot flushes.

9.4.3.1.4 Time to Consecutive Days of 50% Decrease

Results of survival analysis of the time to the first day that a subject had at least 3 consecutive days of 50% or more reduction from baseline in the daily number of moderate and severe hot flushes for the ITT observed data population are given in Table 9.4.3.1.4-1. The cumulative percentage of subjects who achieved a 50% decrease in hot flushes over the first 12 weeks (84 days) is shown in Figure 9.4.3.1.4-1.

CONFIDENTIAL 54 Wyeth

Protocol 3151A2-315-US

CSR-60178

Table 9.4.3.1.4-1: Median Time to First Day of 3 Consecutive Days of at Least 50% Reduction in Moderate and Severe Hot Flushes for the ITT Population


	Median Time to 50%			Log-rank p-Value vs
Treatment	Reduction, days	Lower Limit	Upper Limit	Placebo
DVS SR 50 mg	12.0	7.0	16.0	0.027
DVS SR 100 mg	7.0	4.0	9.0	0.001
DVS SR 150 mg	6.0	4.0	8.0	< 0.001
DVS SR 200 mg	5.0	4.0	8.0	< 0.001
Placebo	24.0	18.0	29.0	

Source: hf_itt_km_final_05.html

The median time to achieve a 50% reduction in hot flushes for at least 3 consecutive days was 12 days with the 50-mg DVS SR group, 7 days with the 100-mg DVS SR group, and less than 7 days with the 150-mg and 200-mg DVS SR groups. With all DVS SR doses, the time to reach a 50% reduction in the number of severe and moderate hot flushes was significantly shorter than that with placebo.

CONFIDENTIAL 55 Wyeth

Figure 9.4.3.1.4-1: Median Time to the First Day of at Least 3 Consecutive Days of a 50% Reduction From Baseline in the Daily Number of Moderate and Severe Hot Flushes for the ITT Population



9.4.3.2 Other Sleep Parameters for the ITT Population

The results for quality of sleep are shown in Supportive Table ST 9-18 for the ITT observed data population. None of the DVS SR groups achieved results different from those in the placebo group at the p=0.048 level.

The results for the measure of how long it took subjects to fall asleep are given in Supportive Table ST 9-19 for the ITT observed data population. None of the DVS SR groups achieved results different from those in the placebo group at the p=0.048 level.

The results for the measure of how long the subject slept are given in Supportive Table ST 9-20 for the ITT observed data population. The results for the 100-mg DVS SR dose were different from those for placebo at week 12 (p=0.026). Results for all other doses were not different from those for placebo.

Protocol 3151A2-315-US

CSR-60178

9.5 Efficacy Results for the Per-Protocol Population

9.5.1 Primary Efficacy Endpoints

Results for the changes in the average daily number of moderate and severe hot flushes in the PP population for weeks 4 and 12 are given in Table 9.5.1-1; full data are in Supportive Table ST 9-21.

Table 9.5.1-1: Changes in Average Daily Number of Moderate and Severe Hot Flushes at Weeks 4 and 12 for the Per-Protocol Population

			Adjusted	Change	
Treatment	Time Point	Pairs, n	Mean	SE	p-Value vs Placebo
DVS SR 50 mg	Week 4	126	-6.07	0.36	0.132
	Week 12	107	-6.59	0.37	0.218
DVS SR 100 mg	Week 4	124	-7.12	0.36	0.001
	Week 12	115	-7.96	0.35	< 0.001
DVS SR 150 mg	Week 4	117	-6.73	0.37	0.009
	Week 12	100	-7.06	0.38	0.045
DVS SR 200 mg	Week 4	93	-7.11	0.42	0.002
	Week 12	93	-7.09	0.40	0.043
Placebo	Week 4	73	-5.21	0.46	
	Week 12	62	-5.87	0.47	

Abbreviation: SE=standard error.

Analysis of covariance: change=treat+site+baseline.

Source: hf ee ancova final 05.html

The results for the average daily severity score in the PP population are given for weeks 4 and 12 in Table 9.5.1-2; full data are in Supportive Table ST 9-22.

Protocol 3151A2-315-US

CSR-60178

Table 9.5.1-2: Changes in the Average Daily Severity Score at Weeks 4 and 12 for the Per-Protocol Population

			Adjusted	Change	_
Treatment	Time Point	Pairs, n	Mean	SE	p-Value vs Placebo
DVS SR 50 mg	Week 4	126	-0.37	0.07	0.940
	Week 12	107	-0.43	0.08	0.439
DVS SR 100 mg	Week 4	124	-0.62	0.07	0.022
_	Week 12	115	-0.90	0.08	0.003
DVS SR 150 mg	Week 4	117	-0.56	0.07	0.078
_	Week 12	100	-0.66	0.08	0.298
DVS SR 200 mg	Week 4	93	-0.60	0.08	0.042
	Week 12	93	-0.81	0.09	0.028
Placebo	Week 4	73	-0.37	0.09	
	Week 12	62	-0.52	0.10	

Abbreviation: SE=standard error.

Analysis of covariance: change=treat+site+baseline.

Source: hf ee ancova final 05.html

Overall, the results for the primary efficacy endpoints from the PP population were consistent with the results obtained in the ITT LOCF and ITT observed data populations.

9.5.2 **Secondary Efficacy Endpoints**

Analyses in the PP population were made for the following secondary efficacy variables:

- Changes in the number of mild, moderate, and severe hot flushes.
- Changes in the number of awakenings due to hot flushes.
- Changes in the weekly weighted severity score.
- Responder analysis.
- Other sleep parameters.

The results of selected secondary efficacy variables at week 12 are shown in Table 9.5.2-1. The results of the secondary efficacy variables for the PP population at all other time points can be found in Supportive Tables ST 9-23, ST 9-24, and ST 9-25. The results of the efficacy analysis of the secondary efficacy variables for the PP population were similar to those obtained for the ITT populations.

Protocol 3151A2-315-US

CSR-60178

Table 9.5.2-1: Comparison of Changes From Baseline to Week 12 Evaluation for Secondary Efficacy Variables, Per-Protocol Population, Observed-Cases Analyses

n (%)	Adjusted Change From Baseline, Mean	•	
C N 4"1 1 N 4 1	r rom Dasenne, Mean	From Baseline, SE	SR vs Placebo
' of Mila, Moaer	ate, Severe VMS		_
	-6.26	0.51	
1	-7.06	0.39	0.201
,	-8.21	0.37	0.002
)	-7.55	0.41	0.043
	-7.49	0.43	0.057
of Awakenings	Because of VMS		
	-2.00	0.21	
	-2.16	0.17	0.553
	-2.76	0.17	0.003
	-2.63	0.17	0.016
	-2.58	0.18	0.027
rity Score			
	-108.0	8.48	
1	-119.7	6.59	0.262
;	-146.9	6.29	< 0.001
	-131.0	6.83	0.030
	-130.6	7.15	0.037
er of Moderate a	nd Severe VMS)		
19 (30.6%)			
			0.344
67 (58.3%)			< 0.001
			0.061
47 (50.5%)			0.012
	rity Score 19 (30.6%) 40 (37.4%) 67 (58.3%) 45 (45.0%)	-6.26 -7.06 -7.06 -8.21 -7.55 -7.49 • of Awakenings Because of VMS -2.00 -2.16 -2.76 -2.63 -2.58 • rity Score -108.0 -119.7 -146.9 -131.0 -130.6 • of Moderate and Severe VMS) -19 (30.6%) -19 (30.6%) -10 (37.4%)	-6.26

Abbreviations: SE=standard error and VMS=vasomotor symptoms.

Sources: hf ee ancova final 05 csr.rtf, sleep ee ancova final 05 csr.rtf, hf_ee_reduction_final_05_csr_v22.rtf, hf_ee_reduction_final_05_csr_v24.rtf

9.6 **Efficacy Results for the Follow-up Population**

Amendment 1 of the protocol planned for the collection of number and severity of hot flushes during the 15-day follow-up period after discontinuation of test article. However, the amendment was implemented at the end of the study, and only a limited number of subjects were included in the analysis. Tables 9.6-1 and 9.6-2 summarize the results for the mean daily number of moderate and severe hot flushes and the mean daily severity score between the last 28 days on therapy and the 15-day follow-up period.

CONFIDENTIAL 59 Wyeth

Protocol 3151A2-315-US

CSR-60178

Table 9.6-1: Average Daily Number of Moderate and Severe Hot Flushes After Discontinuation of Test Article, Follow-up Population

		Last 28	•	Follov	v-Up	AdjustedCha		p-Value
Treatment	Pairs, n	Mean	SD	Mean	SD	Mean	SE	vs Placebo
DVS SR 50 mg	44	3.9	5.3	5.1	5.5	1.63	0.45	0.786
DVS SR 100 mg	40	2.7	3.2	5.8	4.5	2.86	0.45	0.054
DVS SR 150 mg	24	2.5	2.2	5.5	3.9	3.00	0.61	0.061
DVS SR 200 mg	24	3.0	4.2	5.8	5.0	2.84	0.60	0.081
Placebo	24	3.3	3.3	4.8	3.2	1.44	0.59	

Abbreviations: SD=standard deviation and SE=standard error.

Source: hf fu ancova final 05.html

Table 9.6-2: Average Daily Severity Score of Mild, Moderate, and Severe Hot Flushes After Discontinuation of Test Article, Follow-up Population

		Last 28	•	Follov	v-Up	Adjusted		p-Value
Treatment	Pairs, n	Mean	SD	Mean	SD	Mean	SE	vs Placebo
DVS SR 50 mg	44	1.7	1.0	1.9	0.8	0.2	0.6	0.463
DVS SR 100 mg	40	1.7	0.7	2.0	0.7	0.3	0.6	0.543
DVS SR 150 mg	24	1.6	0.8	2.0	0.5	0.4	0.6	0.614
DVS SR 200 mg	24	1.5	0.8	2.1	0.6	0.6	0.5	0.172
Placebo	24	1.8	1.0	2.1	0.6	0.3	0.6	

Abbreviations: SD=standard deviation and SE=standard error.

Source: hf fu ancova final 05.html

After treatment discontinuation, there was a rapid increase in the mean daily number of moderate to severe hot flushes from that in the on-therapy period. In DVS SR dose groups of 100 mg or greater, the number was approximately twice that in the placebo group.

9.7 **Examination of Subgroups**

The changes from baseline in the average daily number of moderate and severe hot flushes and in the average daily severity score, sorted by age group, are shown in Table 9.7-1 and Table 9.7-2 for weeks 4 and 12 for the ITT LOCF population. Only descriptive results are shown. No statistical analysis was made because the number of subjects was small, especially in the age group above 60. Most subjects (81%) were 50 to 60 years old, and among them, 78% were 50 to 55 years old. Overall, the magnitude of effect observed in the different age subgroups was similar to that in the whole population.

Table 9.7-1: Average Daily Number of Moderate and Severe Hot Flushes at Weeks 4 and 12 for the ITT LOCF Population, by Age Group

-	Time	Ba	seline	Obs	erved		ge From seline		% Chango rom Baseli	
Treatment	Point	Pairs, n	Mean	SD	Mean	SD	Mean	SD	Mean	SD
110000000	1 01111	1 411 5, 11	1,10411		<50 Years	S.B.	1/1/411		1,10411	O.D
DVS SR 50 mg	Week 4	17	13.8	8.2	7.8	9.4	-6.0	5.5	-49.0	32.1
8	Week 12	17	13.8	8.2	7.0	8.5	-6.8	7.3	-51.4	38.2
DVS SR 100 mg	Week 4	19	11.7	5.3	5.1	5.1	-6.6	3.5	-60.2	30.1
C	Week 12	19	11.7	5.3	3.7	5.0	-8.0	4.0	-73.1	29.3
DVS SR 150 mg	Week 4	19	11.8	5.5	6.0	5.7	-5.8	4.4	-52.5	34.1
-	Week 12	19	11.8	5.5	4.0	3.7	-7.8	4.0	-67.5	22.6
DVS SR 200 mg	Week 4	12	8.8	1.4	4.0	3.1	-4.8	3.2	-54.4	35.9
	Week 12	12	8.8	1.4	5.3	5.7	-3.5	5.8	-39.2	69.1
Placebo	Week 4	6	9.5	1.3	5.5	4.3	-4.0	4.0	-43.3	44.0
	Week 12	6	9.5	1.3	3.6	2.2	-5.9	2.5	-61.0	24.7
					0-60 Years					
DVS SR 50 mg	Week 4	115	10.3	2.9	4.8	3.2	-5.6	3.6	-52.8	31.2
	Week 12	115	10.3	2.9	4.7	4.1	-5.7	4.3	-54.1	37.3
DVS SR 100 mg	Week 4	116	10.2	3.7	4.1	3.2	-6.1	4.5	-57.8	33.3
	Week 12	116	10.2	3.7	3.7	3.6	-6.6	4.7	-63.1	36.8
DVS SR 150 mg	Week 4	110	11.3	6.7	4.5	4.4	-6.8	7.6	-58.7	33.5
	Week 12	110	11.3	6.7	4.3	4.1	-7.0	7.7	-59.4	36.7
DVS SR 200 mg	Week 4	103	11.5	4.5	4.9	5.4	-6.6	3.9	-59.9	29.3
	Week 12	103	11.5	4.5	4.7	5.7	-6.8	4.4	-61.9	34.2
Placebo	Week 4	63	11.2	4.7	5.9	4.8	-5.3	4.4	-46.9	33.2
	Week 12	63	11.2	4.7	5.8	5.5	-5.4	4.7	-49.4	38.7
					>60 Years					
DVS SR 50 mg	Week 4	9	11.4	3.2	5.2	3.7	-6.2	3.8	-55.4	30.3
	Week 12	9	11.4	3.2	3.6	3.0	-7.8	4.5	-66.3	29.6
DVS SR 100 mg	Week 4	10	11.3	5.2	3.1	3.0	-8.3	6.7	-69.1	28.0
	Week 12	10	11.3	5.2	3.8	3.6	-7.5	7.3	-60.6	36.4

Table 9.7-1: Average Daily Number of Moderate and Severe Hot Flushes at Weeks 4 and 12 for the ITT LOCF Population, by Age Group

	an:	Ba	seline	Obs	erved		ge From seline		% Change rom Baseli	
Treatment	Time Point	Pairs, n	Mean	SD	Mean	SD	Mean	SD	Mean	SD
DVS SR 150 mg	Week 4	8	9.2	2.0	3.3	3.2	-5.9	3.9	-62.6	34.3
	Week 12	8	9.2	2.0	3.9	3.2	-5.2	3.7	-56.0	33.9
DVS SR 200 mg	Week 4	5	8.6	1.6	1.7	2.2	-7.0	2.1	-81.7	24.5
	Week 12	5	8.6	1.6	3.1	2.5	-5.5	2.4	-65.0	29.2
Placebo	Week 4	8	10.9	5.8	6.0	5.2	-4.9	3.3	-47.6	24.7
	Week 12	8	10.9	5.8	5.7	6.5	-5.3	3.7	-53.6	35.5

Abbreviations: ITT=intent to treat; LOCF=last observation carried forward; and SD=standard deviation. Source: hf_itt_locf_summary_age_final_02_ and final_06 and final_10_csr.rtf_Oct 3, 2005 9:29:17 AM

Table 9.7-2: Average Daily Severity Score for Mild, Moderate, and Severe Hot Flushes at Weeks 4 and 12 for the ITT LOCF Population, by Age Group

							Chang	e From	% Cł	nange
			Base	line	Obse	rved	Base	eline	From B	Baseline
Treatment	Time Point 1	Pairs, n	Mean	SD	Mean	SD	Mean	SD	Mean	SD
				A	ge <50 Yea	rs				
DVS SR 50 mg	Week 4	16	2.4	0.2	1.8	0.8	-0.6	0.8	-23.2	33.2
•	Week 12	13	2.4	0.2	1.8	0.9	-0.6	0.9	-26.0	38.4
DVS SR 100 mg	Week 4	17	2.5	0.3	1.8	0.9	-0.7	0.8	-28.5	32.9
	Week 12	16	2.5	0.3	1.3	0.8	-1.1	0.7	-46.6	28.7
DVS SR 150 mg	Week 4	17	2.4	0.3	2.1	0.6	-0.2	0.6	-10.2	24.1
_	Week 12	13	2.3	0.3	1.9	0.8	-0.4	0.7	-17.1	32.8
DVS SR 200 mg	Week 4	10	2.3	0.5	1.7	1.0	-0.6	1.0	-24.3	40.9
_	Week 12	10	2.3	0.5	1.7	1.0	-0.6	1.2	-21.7	44.3
Placebo	Week 4	6	2.3	0.3	2.0	0.7	-0.3	0.7	-12.7	31.4
	Week 12	5	2.4	0.3	1.6	0.9	-0.7	0.8	-32.7	37.6
				Ag	ge 50-60 Ye	ars				
DVS SR 50 mg	Week 4	113	2.4	0.3	2.0	0.6	-0.3	0.5	-14.4	22.7
-	Week 12	104	2.4	0.3	2.0	0.6	-0.3	0.6	-13.0	27.1
DVS SR 100 mg	Week 4	109	2.4	0.3	1.8	0.7	-0.6	0.8	-22.7	31.4
	Week 12	97	2.4	0.3	1.6	0.9	-0.8	0.9	-32.1	35.8
DVS SR 150 mg	Week 4	101	2.4	0.3	1.8	0.7	-0.5	0.7	-22.1	30.6
	Week 12	89	2.4	0.3	1.7	0.7	-0.6	0.7	-26.0	29.9
DVS SR 200 mg	Week 4	94	2.4	0.3	1.8	0.8	-0.6	0.8	-22.7	31.5
_	Week 12	83	2.4	0.3	1.6	0.9	-0.8	0.9	-32.0	37.8
Placebo	Week 4	63	2.5	0.3	2.0	0.7	-0.4	0.8	-16.3	29.5
	Week 12	55	2.5	0.3	2.0	0.7	-0.5	0.8	-19.7	30.9
				A	ge >60 Yea	rs				
DVS SR 50 mg	Week 4	8	2.4	0.4	2.0	1.0	-0.4	0.8	-21.2	36.7
C	Week 12	8	2.4	0.4	2.0	1.1	-0.4	0.8	-19.6	38.3
DVS SR 100 mg	Week 4	9	2.3	0.3	1.4	0.6	-0.9	0.7	-37.2	28.9
C	Week 12	8	2.3	0.3	1.3	0.9	-1.0	1.1	-40.1	47.3
DVS SR 150 mg	Week 4	7	2.3	0.2	1.6	0.8	-0.7	0.9	-27.7	34.9
S	Week 12	7	2.3	0.2	1.8	0.5	-0.5	0.5	-20.6	21.6

Table 9.7-2: Average Daily Severity Score for Mild, Moderate, and Severe Hot Flushes at Weeks 4 and 12 for the ITT LOCF Population, by Age Group

			Base	line	Obsei	rved	Change		% Cl From B	0
Treatment	Time Point		2000	SD	Mean	SD	Mean	SD	Mean	SD
DVS SR 200 mg	Week 4	4	2.4	0.2	1.4	0.8	-0.9	0.6	-41.1	29.4
	Week 12	4	2.4	0.2	2.2	0.5	-0.2	0.4	-9.4	17.0
Placebo	Week 4	8	2.4	0.2	2.1	0.5	-0.3	0.5	-13.2	19.4
	Week 12	7	2.4	0.2	1.7	1.2	-0.7	1.1	-29.8	47.3

Abbreviations: ITT=intent to treat; LOCF=last observation carried forward; and SD=standard deviation.

Source: hf_itt_ancova_age_final_05_csr.rtf Oct 3, 2005 9:29:17 AM

Protocol 3151A2-315-US

CSR-60178

9.8 Statistical and Analytical Issues

9.8.1 Statistical Power

As discussed in section 6.7.2, the planned sample size for this study was calculated based on 90% power to detect a difference of 2 hot flushes per day between the placebo group and the active treatment groups at the 0.024 significance level. The calculations were based on a standard deviation of 3.0. The sample size calculated also provided greater than 90% power to detect a difference of 0.6 in the mean severity score of hot flushes (SD=0.9).

The estimates of variability used in these calculations were based on the most relevant available data from previous Wyeth studies of VMS. However, these studies were for a different compound in a different subject population. In this study, the variability for the number of moderate-to-severe flushes was considerably greater (SD=4.5) than originally estimated (SD=3.0).

Because the number of subjects randomly assigned to a treatment group in the study (n=707) was approximately 30% larger than originally planned (n=540), retrospective power calculations have been done to estimate the power in light of the actual number of subjects included in the ITT population for VMS data (n=620) and the actual variability observed (SD=4.5). Table 9.8.1-1 shows the power for the actual sample size included in the ITT population (approximately 140 for the DVS SR dose groups and 77 for the placebo group) for several different significance levels because the appropriate level depends on the comparison being made and the multiple comparison procedure being followed.

Table 9.8.1-1: Power for the Actual Sample Size

	Power (%) for Number of Hot	Power (%) for Severity of Hot
Significance Level	Flushes (Diff=2, SD=4.5)	Flushes (Diff=0.6, SD=0.9)
0.048	87	>99
0.024	81	>99
0.016	76	98

Abbreviations: Diff=difference and SD=standard deviation.

Source: statistical software nQuery Advisor 5.0.

9.8.2 Handling of Dropouts or Missing Data

All analyses were based on available data at each time point, unless specifically noted otherwise.

CONFIDENTIAL 65 Wyeth

CSR-60178

9.8.3 Multicenter Studies

Analyses were based on the pooled data from the multiple study sites, and "site" was included as a factor in the model for many analyses. Details are provided in the statistical analysis plan.

9.8.4 Normality Testing

Normality testing for the number and severity of hot flushes was done at weeks 4 and 12. Deviations from normality were found. Because of this, the number and severity of hot flushes were also analyzed nonparametrically by using the Kruskal-Wallis test for overall comparison among groups and the signed-rank test for pairwise comparisons. The results of these analyses can be found in module 16.1.9, Statistical/Clinical Pharmacokinetics Documentation.

9.8.5 Multiple Comparisons/Multiplicity

To control for multiplicity with regard to the 4 DVS SR dose groups, a sequential testing strategy was specified in the protocol, section 21.2, Statistical and Analytical Plans. The results in the 200-mg and 150-mg DVS SR groups met some of the statistical criteria to allow progression to the evaluation of data for the 100-mg DVS SR group. These results are supported by 2 other commonly used approaches to adjust for multiple comparisons, as noted in section 6.8.2.

One is a Bonferroni approach, which uses the first 3 highest doses and declares statistical significance at the 0.016 level for each dose. It would be appropriate to use the 3 highest doses of DVS SR and not all 4 doses because statistical adjustment should not be required for a dose (50 mg) that was included in the study for the purpose of demonstrating an ineffective dose.

The second is the Dunnett's test, which would declare statistical significance at the 0.048 levels after appropriate adjustment of the p-values. Table 9.8.5-1 also provides a comparison in p-values when the Dunnett's test is used at weeks 4 and 12. Full results are provided in Supportive Table ST 9-26. In the discussion of those results, it is appropriate to use 0.048 as the significance level for all treatment groups.

CONFIDENTIAL 66 Wyeth

DVS SR Pr

Protocol 3151A2-315-US

CSR-60178

Table 9.8.5-1: Comparison in p-Values for Different Adjustment Methods for the Primary Endpoints at Week 4 and Week 12

			n Average Number of o Severe Hot Flushes	Reduction in Average Daily Severity Score			
Treatment	Interval	p-Value vs Placebo	Dunnett's Adjusted p-Value vs Placebo	p-Value vs Placebo	Dunnett's Adjusted p-Value vs Placebo		
DVS SR 50 mg	Week 4	0.331	0.680	0.913	1.000		
	Week 12	0.326	0.673	0.754	0.991		
DVS SR 100 mg	Week 4	0.013	0.042	0.054	0.150		
_	Week 12	0.005	0.016	0.002	0.007		
DVS SR 150 mg	Week 4	0.027	0.079	0.138	0.337		
_	Week 12	0.020	0.060	0.235	0.525		
DVS SR 200 mg	Week 4	0.040	0.115	0.072	0.193		
C	Week 12	0.130	0.322	0.013	0.040		
Placebo	Week 4						
	Week 12						

Source: hf_itt_locf_ancova_dunnett_csr_2.rtf and hf_itt_locf_ancova_dunnett_csr_3.rtf

With both approaches, the 100-mg DVS SR dose significantly decreased the number of moderate and severe hot flushes at weeks 4 and 12 and the severity of hot flushes at week 12.

9.9 Efficacy Conclusions

The results of the primary, key secondary, and other secondary efficacy variables at week 12 in the ITT population are summarized in Table 9.9-1. The results of these analyses demonstrate the efficacy of the 100-mg DVS SR dose for the treatment of VMS associated with menopause.

CONFIDENTIAL 67 Wyeth

Protocol 3151A2-315-US

CSR-60178

Table 9.9-1: Summary of Efficacy Results at Week 12, ITT Population

	p-Value vs Placebo				
	DVS SR	DVS SR	DVS SR	DVS SR	
Efficacy Variables	50 mg	100 mg	150 mg	200 mg	
Primary variables ^a					
Number of moderate and severe hot flushes	0.326	0.005	0.020	0.130	
Daily severity score	0.754	0.002	0.235	0.013	
Key secondary variables ^b					
Number of awakenings due to hot flushes	0.672	0.013	0.034	0.043	
Total mood disturbance score	0.015	0.047	0.272	0.040	
WLQ total index score	0.808	0.127	0.537	0.691	
Other secondary variables					
Number of mild, moderate, and severe hot flushes ^a	0.365	0.016	0.020	0.175	
Weekly weighted severity score ^a	0.593	0.012	0.066	0.357	
75% responder rate ^a	0.473	0.003	0.078	0.022	
50% responder rate ^a	0.326	0.123	0.116	0.484	
Time to reach 50% reduction in number of hot flushes b	0.027	0.001	< 0.001	< 0.001	

Abbreviations: ITT=intent to treat and WLQ=Work Limitations Questionnaire.

Sources: hf_itt_locf_ancova_final_05_csr.rtf; sleep_itt_ancova_final_05_csr.rtf;

poms_itt_anova_final_05_csr.rtf; wlq_itt_anova_final_05_csr.rtf; hf_itt_locf_reduction_final_05_csr_v24.rtf;

The 100-mg DVS SR dose was more effective at the p=0.048 level than placebo according to the primary efficacy variables, the number of moderate and severe hot flushes at weeks 4 and 12 and the severity score at week 12; the 2 key secondary efficacy variables, the number of awakenings due to hot flushes and the total mood disturbance score at week 12; and several other secondary efficacy variables, the number of mild, moderate, and severe hot flushes, the weighted severity score for moderate and severe hot flushes, the number of subjects with at least a 75% decrease from baseline in the number of hot flushes at week 12, and the time to reach a 50% reduction in the number of hot flushes. Results for the 100-mg DVS SR dose were consistent across the different populations (ITT LOCF, ITT observed cases, or PP populations) and across the scheduled time points over the 52 weeks of therapy.

The 150-mg DVS SR dose significantly decreased the number of moderate and severe hot flushes at week 12, but not the severity of hot flushes. The 200-mg DVS SR dose had a significant effect on the severity of hot flushes at week 12 but did not significantly decrease the number of moderate and severe hot flushes. Both doses also yielded positive results at week 12

a. For the ITT last-observation-carried-forward (LOCF) population.

b. For the ITT observed data population.

hf_itt_locf_reduction_final_05_csr_v21.rtf; hf_itt_locf_reduction_final_05_csr_v22.rtf;

hf_itt_km_final_05_csr.rtf

CSR-60178

in the number of awakenings due to hot flushes. The 50-mg DVS SR dose separated from placebo only at the initial 2 weeks of therapy for the primary efficacy variables.

Overall, in this study, the placebo effect was high, reaching 47% and 50% decreases from baseline in the number of moderate and severe hot flushes at weeks 4 and 12, respectively. The same magnitude of response has been observed in other VMS studies with similar inclusion criteria. ^{10,11,12}

10.0 SAFETY EVALUATION

10.1 Extent of Exposure

A total of 689 subjects took at least 1 dose of test article and were included in all safety evaluations: 149 subjects in the 50-mg DVS SR group, 155 subjects in the 100-mg DVS SR group, 157 subjects in the 150-mg DVS SR group, 151 subjects in the 200-mg DVS SR group, and 77 subjects in the placebo group.

10.2 Adverse Events

10.2.1 Brief Summary of Adverse Events

All adverse events reported during the study are summarized by body system according to the Coding Symbols for Thesaurus of Adverse Reaction Terms (COSTART) in Supportive Table ST 10-1. Supportive Table ST 10-2 summarizes all adverse events by body system and severity and includes the investigator's opinion of drug relationship for each treatment group. If a subject had more than 1 of the same adverse event but of different severities, the subject was listed under the maximum severity reported. Supportive Table ST 10-3 summarizes all adverse events that reported during the 15-day follow-up period, grouped by body system and treatment group.

10.2.2 Treatment-Emergent Adverse Event Data

The presentations and analyses of the treatment-emergent adverse events (TEAEs) are based on all TEAEs without consideration of the investigator's opinion regarding relationship to treatment. TEAEs were reported by 134 (90%) subjects in the DVS SR 50-mg group, 146 (94%) subjects in the DVS SR 100-mg group, 149 (95%) subjects in the DVS SR 150-mg group, 147 (97%) subjects in the DVS SR 200-mg group, and 67 (87%) subjects in the placebo group.

CONFIDENTIAL 69 Wyeth

Protocol 3151A2-315-US

CSR-60178

Supportive Table ST 10-4 summarizes the incidence of all TEAEs. Supportive Table ST 10-5 summarizes all TEAEs by severity and investigator's opinion as to drug relationship. The relationship of these events to test article was considered to be possibly or definitely related to test article for 62% who received DVS SR and for 38% who received placebo.

The TEAEs reported by at least 5% of the subjects in any treatment group are summarized in Table 10.2.2-1. Subjects in the 150-mg and 200-mg DVS SR groups reported significantly more TEAEs (p=0.040 and 0.006, respectively) than subjects in the placebo group. In most cases, TEAEs were mild to moderate.

Table 10.2.2-1: Number (%) of Subjects With Treatment-Emergent Adverse Events (Reported by at Least 5% of Subjects in Any Treatment Group)

D. J. C. 4	0	DVS SR	DVS SR	DVS SR	DVS SR	Di l
Body System	Overall p- Value	50 mg	100 mg	150 mg	200 mg	Placebo
Adverse Event		n=149	n=155	n=157	n=151	n=77
Any adverse event	0.014*	134 (89.9)	146 (94.2)	149 (94.9)	147 (97.4)	67 (87.0)
Body as a whole						
Abdominal pain	0.036*	15 (10.1)	5 (3.2)	11 (7.0)	4 (2.6)	4 (5.2)
Accidental injury	0.244	11 (7.4)	16 (10.3)	11 (7.0)	19 (12.6)	11 (14.3)
Asthenia	0.017*	11 (7.4)	30 (19.4)	27 (17.2)	23 (15.2)	7 (9.1)
Back pain	0.273	16 (10.7)	14 (9.0)	10 (6.4)	9 (6.0)	10 (13.0)
Chills	0.120	5 (3.4)	8 (5.2)	6 (3.8)	11 (7.3)	0
Flu syndrome	0.267	6 (4.0)	15 (9.7)	9 (5.7)	10 (6.6)	3 (3.9)
Headache	0.549	48 (32.2)	43 (27.7)	55 (35.0)	42 (27.8)	26 (33.8)
Infection	0.095	23 (15.4)	21 (13.5)	21 (13.4)	15 (9.9)	18 (23.4)
Neck pain	0.284	5 (3.4)	1 (0.6)	4 (2.5)	6 (4.0)	4 (5.2)
Pain	0.130	16 (10.7)	15 (9.7)	13 (8.3)	17 (11.3)	15 (19.5)
Cardiovascular system						
Hypertension	0.255	6 (4.0)	8 (5.2)	10 (6.4)	12 (7.9)	1 (1.3)
Palpitation	0.544	4 (2.7)	5 (3.2)	2 (1.3)	5 (3.3)	4 (5.2)
Digestive system						
Abdominal distension	0.013*	3 (2.0)	0	1 (0.6)	1 (0.7)	4 (5.2)
Anorexia	0.171	7 (4.7)	9 (5.8)	13 (8.3)	15 (9.9)	2 (2.6)
Constipation	0.266	16 (10.7)	27 (17.4)	25 (15.9)	27 (17.9)	8 (10.4)
Diarrhea	0.482	17 (11.4)	12 (7.7)	9 (5.7)	14 (9.3)	6 (7.8)
Dry mouth	0.001**	18 (12.1)	33 (21.3)	31 (19.7)	35 (23.2)	3 (3.9)
Dyspepsia	0.203	18 (12.1)	13 (8.4)	16 (10.2)	13 (8.6)	2 (2.6)
Nausea	<0.001***	41 (27.5)	60 (38.7)	75 (47.8)	68 (45.0)	5 (6.5)
Vomiting	0.028*	8 (5.4)	11 (7.1)	11 (7.0)	17 (11.3)	0
Metabolic and nutritional						
Hypercholesteremia	0.728	6 (4.0)	9 (5.8)	5 (3.2)	9 (6.0)	3 (3.9)

CONFIDENTIAL 70 Wyeth

Protocol 3151A2-315-US

CSR-60178

Table 10.2.2-1: Number (%) of Subjects With Treatment-Emergent Adverse Events (Reported by at Least 5% of Subjects in Any Treatment Group)

Dody System	Overall n	DVS SR	DVS SR	DVS SR	DVS SR	Placebo
Body System	Overall p- Value	50 mg	100 mg	150 mg	200 mg	
Adverse Event		n=149	n=155	n=157	n=151	n=77
Hyperlipemia	0.162	5 (3.4)	8 (5.2)	4 (2.5)	9 (6.0)	0
Peripheral edema	0.651	3 (2.0)	4 (2.6)	4 (2.5)	3 (2.0)	4 (5.2)
Weight gain	0.243	4 (2.7)	9 (5.8)	12 (7.6)	5 (3.3)	3 (3.9)
Musculoskeletal system						
Arthralgia	0.273	18 (12.1)	18 (11.6)	17 (10.8)	8 (5.3)	9 (11.7)
Myalgia	0.275	3 (2.0)	7 (4.5)	5 (3.2)	8 (5.3)	6 (7.8)
Nervous system						
Anxiety	0.235	9 (6.0)	5 (3.2)	11 (7.0)	4 (2.6)	2 (2.6)
Confusion	0.037*	1 (0.7)	4 (2.6)	8 (5.1)	2 (1.3)	0
Dizziness	<0.001***	17 (11.4)	30 (19.4)	29 (18.5)	41 (27.2)	6 (7.8)
Insomnia	0.004**	23 (15.4)	27 (17.4)	43 (27.4)	39 (25.8)	8 (10.4)
Libido decreased	0.206	2 (1.3)	5 (3.2)	3 (1.9)	8 (5.3)	1 (1.3)
Nervousness	0.053	11 (7.4)	12 (7.7)	20 (12.7)	19 (12.6)	2 (2.6)
Somnolence	<0.001***	7 (4.7)	24 (15.5)	30 (19.1)	36 (23.8)	3 (3.9)
Thinking abnormal	0.358	3 (2.0)	4 (2.6)	8 (5.1)	7 (4.6)	1 (1.3)
Tremor	0.248	2 (1.3)	4 (2.6)	4 (2.5)	8 (5.3)	1 (1.3)
Twitching	0.006**	1 (0.7)	1 (0.6)	1 (0.6)	8 (5.3)	1 (1.3)
Vertigo	0.215	4 (2.7)	1 (0.6)	4 (2.5)	2 (1.3)	4 (5.2)
Respiratory system						
Cough increased	0.173	11 (7.4)	8 (5.2)	5 (3.2)	3 (2.0)	5 (6.5)
Pharyngitis	0.778	6 (4.0)	7 (4.5)	11 (7.0)	8 (5.3)	5 (6.5)
Rhinitis	0.500	8 (5.4)	8 (5.2)	5 (3.2)	5 (3.3)	6 (7.8)
Sinus congestion	0.002**	1 (0.7)	4 (2.6)	0	1 (0.7)	5 (6.5)
Sinusitis	0.621	11 (7.4)	14 (9.0)	7 (4.5)	11 (7.3)	5 (6.5)
Upper respiratory infection	0.080	18 (12.1)	16 (10.3)	11 (7.0)	6 (4.0)	9 (11.7)
Skin and appendages						
Rash	0.064	9 (6.0)	3 (1.9)	4 (2.5)	1 (0.7)	2 (2.6)
Sweating	0.023*	2 (1.3)	4 (2.6)	2 (1.3)	9 (6.0)	0
Special senses		` ,	. ,	` ,	` ,	
Abnormal vision	0.107	5 (3.4)	9 (5.8)	14 (8.9)	10 (6.6)	1 (1.3)
Mydriasis	0.010**	1 (0.7)	4 (2.6)	10 (6.4)	9 (6.0)	0
Adverse event associated		()	()	()	()	
with miscellaneous factors	0.129	4 (2.7)	5 (3.2)	6 (3.8)	4 (2.6)	7 (9.1)
Local reaction to procedure	0.063	0	2 (1.3)	4 (2.5)	2 (1.3)	4 (5.2)

Statistical significance at the 0.05, 0.01, and 0.001 levels is denoted by *, **, and ***, respectively.

Source: AE5_TEAE_5% 29SEP05 14:53

TEAEs reported significantly more frequently with DVS SR compared with placebo (p<0.05) were

- dyspepsia and nausea with the 50-mg DVS SR dose;
- dry mouth, nausea, vomiting, dizziness, and somnolence with the 100-mg DVS SR dose;
- dry mouth, nausea, vomiting, dizziness, insomnia, nervousness, somnolence, abnormal vision, and mydriasis with the 150-mg DVS SR dose; and
- chills, dry mouth, nausea, vomiting, hyperlipemia, dizziness, insomnia, nervousness, somnolence, sweating, and mydriasis with the 200-mg DVS SR dose.

The 100-mg, 150-mg, and 200-mg DVS SR doses were associated with a higher incidence of TEAEs of the digestive system (dry mouth, nausea) and the nervous system (confusion, dizziness, insomnia, somnolence, twitching) as well as asthenia and mydriasis than the 50-mg DVS SR dose. The incidence of sweating was significantly higher than that in the placebo group only for the 200-mg DVS SR dose group.

DVS SR-treated subjects reported significantly more TEAEs than placebo-treated subjects during the first week of therapy, with a lower incidence of asthenia, dry mouth, nausea, dizziness, insomnia, nervousness, somnolence, and mydriasis with the 50-mg DVS SR dose than with higher DVS SR doses (Supportive Table ST 10-6). After the first week of treatment, there was no difference between groups in the incidence of new TEAEs.

Nausea was the most common TEAE, reported by 244 subjects (40%) in the DVS SR treatment groups compared with 5 (7%) in the placebo group. The severity of the nausea was reported as mild or moderate for all but 28 events (11.5%) in the DVS SR treatment groups. Most episodes of nausea were reported to occur immediately after the first dose of DVS SR. A significantly lower incidence of nausea was reported during the first week with the 50-mg DVS SR dose (18%) than with the higher DVS SR doses (100 mg=33% [p=0.003], 150 mg=39% [p<0.001], and 200 mg=42% [p<0.001]). During the on-therapy period, the mean duration of nausea episodes reported in DVS SR groups was 14 to 17 days, with a median of 3 days; in the placebo group, it was 12 days, with a median of 2.5 days.

CONFIDENTIAL 72 Wyeth

CSR-60178

10.2.3 Posttherapy-Emergent Adverse Events

Posttherapy-emergent adverse events were also analyzed. These were defined as adverse events that were not present during the last 7 days of test article, or events that were present but became more severe after this 7-day period.

Supportive Table ST 10-7 provides a summary of the number and percentage of subjects with adverse events that emerged during the posttherapy period for all treatment groups by body system regardless of therapy duration. Overall, posttherapy-emergent adverse events were reported by 24 (31%) subjects in the placebo group and by 291 (48%) subjects in the DVS SR groups. The posttherapy-emergent adverse events reported by at least 5% of subjects in any DVS SR group and at a frequency at least twice the rate in the placebo group were headache, vasodilatation, nausea, vomiting, anxiety, dizziness, emotional lability, hostility, insomnia, and tinnitus.

Table 10.2.3-1 shows the number of subjects who reported posttherapy-emergent adverse events (at least 5% of subjects in any treatment group) after withdrawal from the study during the first 12 weeks, and Table 10.2.3-2 shows the number of subjects who reported these events (at least 5% of subjects in any treatment group) after withdrawal from the study beyond the first 12 weeks, or after completion of the study.

CONFIDENTIAL 73 Wyeth

Protocol 3151A2-315-US

CSR-60178

Table 10.2.3-1: Number (%) of Subjects Who Discontinued During Weeks 1 to 12 With Posttherapy-Emergent Adverse Events (Reported by at Least 5% of Subjects in Any Treatment Group)

		DVS SR	DVS SR	DVS SR	DVS SR	
Body System	Overall	50 mg	100 mg	150 mg	200 mg	Placebo
Adverse Event	p-Value	(n=32)	(n=36)	(n=53)	(n=57)	(n=11)
Any adverse event	0.157	8 (25.0)	8 (22.2)	9 (17.0)	20 (35.1)	1 (9.1)
Body as a whole						
Headache	0.084	3 (9.4)	1 (2.8)	0	6 (10.5)	0
Digestive system						
Diarrhea	0.388	2 (6.3)	1 (2.8)	0	1 (1.8)	0
Dry mouth	0.283	1 (3.1)	0	0	3 (5.3)	0
Nausea	0.105	2 (6.3)	0	1 (1.9)	6 (10.5)	0
Nervous system						
Dizziness	0.636	1 (3.1)	2 (5.6)	1 (1.9)	4 (7.0)	0
Insomnia	0.132	0	3 (8.3)	0	3 (5.3)	0
Respiratory system						
Upper respiratory infection	0.300	0	1 (2.8)	0	3 (5.3)	0
Special senses						
Mydriasis	0.133	0	0	0	3 (5.3)	0

Source: AE5_P_T_WK1_12 26OCT05 17:27

CONFIDENTIAL 74 Wyeth

Protocol 3151A2-315-US

CSR-60178

Table 10.2.3-2: Number (%) of Subjects in Study at Start of Week 13 With Posttherapy-Emergent Adverse Events (Reported by at Least 5% of Subjects in Any **Treatment Group)**

-		DVS SR	DVS SR	DVS SR	DVS SR	
Body System	Overall	50 mg	100 mg	150 mg	200 mg	Placebo
Adverse Event	p-Value	(n=117)	(n=119)	(n=104)	(n=94)	(n=66)
Any adverse event	0.015*	61 (52.1)	70 (58.8)	61 (58.7)	54 (57.4)	23 (34.8)
Body as a whole						
Asthenia	0.423	4 (3.4)	8 (6.7)	6 (5.8)	9 (9.6)	3 (4.5)
Chills	0.441	2 (1.7)	6 (5.0)	2 (1.9)	2 (2.1)	1 (1.5)
Headache	0.003**	11 (9.4)	19 (16.0)	22 (21.2)	19 (20.2)	2 (3.0)
Cardiovascular system						
Vasodilatation	0.117	6 (5.1)	14 (11.8)	8 (7.7)	11 (11.7)	2 (3.0)
Digestive system						
Diarrhea	0.940	4 (3.4)	5 (4.2)	5 (4.8)	5 (5.3)	2 (3.0)
Nausea	<0.001***	12 (10.3)	28 (23.5)	13 (12.5)	21 (22.3)	1 (1.5)
Vomiting	0.006**	4 (3.4)	6 (5.0)	3 (2.9)	11 (11.7)	0
Nervous system						
Abnormal dreams	0.273	2 (1.7)	5 (4.2)	7 (6.7)	3 (3.2)	1 (1.5)
Anxiety	0.148	3 (2.6)	4 (3.4)	6 (5.8)	8 (8.5)	1 (1.5)
Depression	0.335	3 (2.6)	4 (3.4)	6 (5.8)	3 (3.2)	0
Dizziness	0.001**	20 (17.1)	29 (24.4)	22 (21.2)	13 (13.8)	1 (1.5)
Emotional lability	0.036*	9 (7.7)	16 (13.4)	8 (7.7)	9 (9.6)	0
Hostility	0.287	9 (7.7)	4 (3.4)	8 (7.7)	3 (3.2)	2 (3.0)
Insomnia	0.242	12 (10.3)	9 (7.6)	13 (12.5)	11 (11.7)	2 (3.0)
Nervousness	0.654	3 (2.6)	4 (3.4)	5 (4.8)	5 (5.3)	1 (1.5)
Paresthesia	0.058	1 (0.9)	7 (5.9)	2 (1.9)	2 (2.1)	0
Special senses						
Tinnitus	0.217	3 (2.6)	8 (6.7)	8 (7.7)	4 (4.3)	1 (1.5)

Statistical significance at the 0.05, 0.01, and 0.001 levels is denoted by *, **, and ***, respectively.

Source: AE5 P T WK13 26OCT05 17:27

Longer therapy duration was associated with a higher incidence of posttherapy-emergent adverse events in any treatment group. For therapy duration greater than 12 weeks, the 50-mg DVS SR dose was associated with a lower incidence of headache, nausea, and vomiting than higher DVS SR doses.

10.2.4 Analysis of Adverse Events

Nausea was the most common adverse event reported by DVS SR-treated subjects. Episodes of nausea were usually mild or moderate, with a mean duration of 14 to 17 days and a median of 3 days, and were likely to occur at the beginning of treatment. Other common adverse events, ie,

CSR-60178

those reported by at least 5% of the DVS SR-treated subjects in any treatment group and at a frequency at least twice the rate for placebo-treated subjects during the on-therapy period, were asthenia, chills, flu syndrome, hypertension, anorexia, dry mouth, dyspepsia, vomiting, hyperlipemia, anxiety, confusion, dizziness, insomnia, libido decreased, nervousness, somnolence, thinking abnormal, tremor, twitching, sweating, abnormal vision, and mydriasis. Most TEAEs tended to occur early during therapy, in the first week. Events in the DVS SR groups were not associated with a rate of discontinuation different from that of the placebo group after the first week of therapy. The 50-mg DVS SR dose was associated with a lower incidence of TEAEs reported during the first week than the higher DVS SR doses.

Posttherapy-emergent adverse events occurred frequently for therapy duration greater than 12 weeks. The 50-mg DVS SR dose was associated with a lower incidence of some posttherapy adverse events.

10.3 Deaths, Serious Adverse Events, Safety-Related Discontinuations, and Other Clinically Important Adverse Events of Clinical Interest

10.3.1 **Deaths**

No deaths occurred during or immediately after this study.

10.3.2 Serious Adverse Events

Serious adverse events were defined in section 6.5.2.1. Decisions regarding which subjects had serious adverse events were made before unblinding. During the study, investigators reported serious adverse events. Subsequently, the sponsor reviewed the data to identify any other subjects with serious adverse events or subjects who had any other adverse events that were considered potentially serious, such as overdose of test article. The sponsor reviewed the case report forms, laboratory test results, vital signs measurements, ECG results, and any relevant correspondence pertaining to subjects with potentially serious medical events. All serious adverse events are included in this section, regardless of whether the event was considered to be associated with the use of the test article.

Twenty-eight (28) subjects reported serious adverse events; 1 received placebo and 27 received DVS SR. Of these, 3 subjects had events considered by the investigators to be possibly or

CONFIDENTIAL 76 Wyeth

CSR-60178

probably related to test article. Subjects 315-204-201176 and 315-206-201251 had elevated alanine transaminase (ALT) and aspartate transaminase (AST) levels that were considered probably or possibly related to test article by both the investigator and the Wyeth medical monitor. Subject 315-213-201636 had cholecystitis that was considered possibly related to test article by the investigator. All other serious adverse events were considered to be either definitely not or probably not related to test article.

One (1) subject (315-208-201359) had an event of intentional overdose that was considered clinically important and reported as a serious adverse event. Two (2) additional subjects had events of intentional misuse, and 3 subjects (315-238-202829, 315-239-202880, and 315-242-203006) had events of accidental overdose; all these events were reportable information to Wyeth. The 3 subjects with intentional misuse of test article are discussed in section 10.3.5.9.

All subjects with serious adverse events or other noteworthy adverse events are listed in Table 10.3.2-1, and their subject numbers hyperlink to narrative descriptions of the events in Supportive Table ST 10-8. Selected serious adverse events are discussed in section 10.3.5 along with adverse events of clinical interest and safety-related discontinuations.

CONFIDENTIAL 77 Wyeth

Table 10.3.2-1: Subjects With Serious Adverse Events

Body System Preferred Term ^a	Subject	Treatment	Age, Years	Study Day ^b	Relationship to Test Article	Severity	Discontinued Because of Identified Adverse Event(s) ^c
Cardiac disorders							
Coronary artery disease	315-208-201372 d,e	DVS SR, 150 mg	50	-144 ^f	PNOT	Severe	Yes
Myocardial infarct	315-208-201372 d,e	DVS SR, 150 mg	50	93 ^g	PNOT	Severe	No
Coronary artery occlusion	315-203-201125	DVS SR, 200 mg	60	27	DNOT	Severe	No
Coronary artery occlusion	315-202-201068	DVS SR, 100 mg	69	321	PNOT	Severe	Yes
Myocardial infarct	315-206-201271	DVS SR, 150 mg	55	294	PNOT	Severe	Yes
Myocardial infarct	315-237-202762	DVS SR, 50 mg	53	132	PNOT	Life- threatening	Yes
Cerebrovascular and spinal vascular	disorders						
Migraine	315-228-202357	DVS SR, 200 mg	48	-36 ^h	DNOT	Moderate	No
Gastrointestinal disorders							
Duodenitis	315-235-202684 d,e	DVS SR, 150 mg	54	22	PNOT	Mild	No
Esophagitis/ gastritis erosive/ hiatus hernia	315-235-202684 d,e	DVS SR, 150 mg	54	22	PNOT	Moderate	No
General disorders and administration	site conditions						
Chest pain	315-228-203715	DVS SR, 50 mg	50	159	DNOT	Mild	No
Noncardiac chest pain	315-201-201009	DVS SR, 150 mg	53	330	DNOT	Severe	No
Hepatobiliary disorders							
Cholecystitis	315-213-201636 ^e	DVS SR, 150 mg	56	338	POS	Severe	No
Cholelithiasis	315-217-201831 ^d	DVS SR, 100 mg	39	108	DNOT	Moderate	No
Cholecystitis	315-217-201831 ^d	DVS SR, 100 mg	39	199	DNOT	Severe	No
Hepatitis cholestatic	315-206-201251	DVS SR, 150 mg	60	182	POS	Severe	Yes
Immune system disorders		-					
Sarcoidosis	315-242-203008	DVS SR, 200 mg	47	142	PNOT	Moderate	Yes
		=					

Table 10.3.2-1: Subjects With Serious Adverse Events

Body System Preferred Term ^a	Subject	Treatment	Age, Years	Study Day b	Relationship to Test Article	Severity	Discontinued Because of Identified Adverse Event(s) ^c
Infections and infestations	J						()
Cellulitis	315-228-202368	DVS SR, 100 mg	56	233	DNOT	Mild	No
Cellulitis	315-229-202405 ^e	DVS SR, 50 mg	54	52	PNOT	Moderate	No
Gastroenteritis	315-228-202379	DVS SR, 150 mg	63	19	DNOT	Mild	No
Mastoiditis	315-201-201002 e	DVS SR, 200 mg	50	105	DNOT	Severe	No
Injury, poisoning, and procedural co	mplications						
Intentional misuse	315-208-201359	DVS SR, 150 mg	47	91	DNOT	Severe	Yes
Investigations							
Liver function test abnormal	315-204-201176	DVS SR, 200 mg	54	93	PRB	Moderate	Yes
Metabolism and nutrition disorders							
Dehydration	315-228-202364	DVS SR, 200 mg	57	207	DNOT	Severe	No
Musculoskeletal and connective tissu	e disorders	_					
Costochondritis	315-203-201119 e	DVS SR, 150 mg	46	50	PNOT	Severe	Yes
Intervertebral disc	315-229-202419 ^d	Placebo	53	13	PNOT	Severe	No
degeneration/inter-vertebral disc protrusion/lumbar spinal							
stenosis/sciatica							
Synovial cyst	315-229-202419 d	Placebo	53	29	PNOT	Moderate	No
Neoplasms benign, malignant and un							
Malignant melanoma	315-231-202507	DVS SR, 150 mg	59	147	PNOT	Moderate	No
Ovarian carcinoma	315-228-203716	DVS SR, 100 mg	78	208	DNOT	Life-	Yes
		_				threatening	
Nervous system disorders							
Brain edema/meningism	315-201-201002 d,e	DVS SR, 200 mg	50	105	DNOT	Mild	No
Headache	315-201-201002 d,e	DVS SR, 200 mg	50	105	DNOT	Severe	No
Cervicobrachial syndrome	315-237-202764	DVS SR, 150 mg	56	212	DNOT	Severe	No

Table 10.3.2-1: Subjects With Serious Adverse Events

Body System Preferred Term ^a	Subject	Treatment	Age, Years	Study Day b	Relationship to Test Article	e Severity	Discontinued Because of Identified Adverse Event(s) ^c
Psychiatric disorders							
Major depression	315-229-202411 ^d	DVS SR, 50 mg	53	132	DNOT	Severe	Yes
Suicidal ideation	315-229-202411 ^d	DVS SR, 50 mg	53	161	DNOT	Severe	No
Respiratory, thoracic, and mediasti	nal disorders						
Respiratory tract infection viral	315-239-202869	DVS SR, 100 mg	58	140	PNOT	Severe	No
Surgical and medical procedures							
Hemorrhoid operation	315-218-201873	DVS SR, 150 mg	58	168 ⁱ	DNOT	Severe	No
Postprocedural complication	315-213-201636 e	DVS SR, 150 mg	56	341 ^g	DNOT	Severe	No

Abbreviations: DNOT=definitely not; PNOT=probably not; POS=possibly; PROB=probably; SGOT=serum glutamic oxaloacetic transaminase (aspartate aminotransferase); and SGPT=serum glutamic pyruvic transaminase (alanine aminotransferase)

- b: Study day is the elapsed day of the onset date relative to first day of test article administration.
- c: Listed serious adverse event was a primary or secondary reason for discontinuation from the study.
- d: More than 1 serious treatment-emergent adverse event within system/organ class.
- e: Subject has other serious treatment-emergent drug-related adverse event(s) in different system/organ class.
- f: These events were diagnosed before first dose of test article but did not meet criteria for a serious adverse event until the subject was actually in the study on therapy.
- g: These events occurred more than 3 days after last dose of test article
- h: This event occurred during the screening period.
- i: This subject had hemorrhoidal bleeding at baseline that eventually necessitated surgery for hemorrhoids while the subject was in the study. Sources: AE1_SAE 29SEP05 14:47 and GSSE Line Listing DVS-233: SAEs from MDD and VMS studies Project Num: 3151A1;3151A2 19Oct05 and GSSE Line Listing DVS-233: Other Reportable Information from MDD and VMS studies Clinical Safety Listing 19-Oct-2005 09:48:30

a: Medical Dictionary for Regulatory Activity (MedDRA) terms. The treatment-emergent adverse events listed occurred during the on-therapy or follow-up periods.

10.3.3 Other Events of Clinical Interest

The sponsor also reviewed the data listings to identify any subjects with other adverse events that were considered of clinical interest because they potentially could be clinically important. The data of all adverse events for COSTART terms of arrhythmia, chest pain, hypotension, depression, hostility, intentional overdose, suicidal ideation, thinking abnormal, and urinary retention were thoroughly reviewed by the sponsor, as were the data and any relevant correspondence pertaining to these subjects.

Based on these resources and the judgment of the medical monitor, 33 DVS SR-treated subjects and 2 placebo-treated subjects were considered to have had adverse events of clinical interest that were not reported as serious adverse events (Table 10.3.2-1). The adverse events of clinical interest that occurred in this study are listed in Table 10.3.3-1. Selected adverse events of clinical interest are discussed in section 10.3.5 along with serious adverse events and safety-related discontinuations. Additional details about these subjects are provided in the subject narratives in Supportive Table ST 10-8.

CONFIDENTIAL 81 Wyeth

Protocol 3151A2-315-US

CSR-60178

Table 10.3.3-1: Subjects With Adverse Events of Clinical Interest

	Subjects With							
Event	Treatment Group	Event, n	Subject Numbers					
Arrhythmia	Placebo	1	315-237-202753					
Chest pain	DVS SR 50 mg	2	315-204-201171 315-208-201361					
	DVS SR 100 mg	4	315-206-201293 315-218-201884 315-220-201958					
	_		315-229-202421					
	DVS SR 150 mg	4	315-206-201297 315-215-201705 315-239-202882					
	•		315-242-203020					
	DVS SR 200 mg	4	315-203-201113 315-203-201147 315-216-201764					
	•		315-233-202613					
Depression	Placebo	1	315-232-202553					
1	DVS SR 50 mg	3	315-208-201374 315-213-201614 315-225-202218					
	DVS SR 100 mg	5	315-202-201073 315-231-202530 315-234-203060					
	Č		315-239-202859 315-241-202960					
	DVS SR 150 mg	3	315-216-201756 315-219-201945 315-228-202363					
	DVS SR 200 mg	3	315-209-201422 315-239-202874 315-239-202875					
Hostility	DVS SR 150 mg	1	315-207-201303					
J	DVS SR 200 mg	1	315-218-201866					
Overdose	DVS SR 50 mg	1	315-207-201313					
	DVS SR 100 mg	1	315-228-202384					
Suicidal ideation	DVS SR 100 mg	1	315-234-203060					
Thinking abnormal	DVS SR 150 mg	1	315-219-201945					
Urinary retention	DVS SR 100 mg	1	315-239-202859					

Source: CLINICAL R&D/CLINICAL PROGRAMMING SAS REPORTS/3151A2 /P315/ SUBJECT NARRATIVES Report narr-sum-1 20DEC05 11:20 [DEV]

10.3.4 Safety-Related Discontinuations

This section summarizes the incidence of adverse events that were the primary or secondary cause for withdrawal from the study. The numbers of adverse events leading to discontinuation given in this section are higher than those given in section 8.1.1, which shows only the primary reasons for discontinuing treatment.

Adverse events led to discontinuation of study participation for 27 (18%) subjects in the DVS SR 50-mg group, 33 (21%) subjects in the DVS SR 100-mg group, 58 (37%) subjects in the DVS SR 150-mg group, 63 (42%) subjects in the DVS SR 200-mg group, and 12 (16%) subjects in the placebo group. Significantly more subjects in the 150-mg and 200-mg DVS SR groups than in the placebo group withdrew from the study because of adverse events (p<0.001), whereas for the 100-mg and 50-mg DVS SR groups the differences from the placebo group were not significant (p=0.379 and p=0.712, respectively). The incidence of discontinuations because of adverse events was significantly higher (p<0.001) in all DVS SR groups than in the placebo

CONFIDENTIAL 82 Wyeth

group during the first week of therapy. After the first week of treatment, there were no significant differences between groups in the incidence of safety-related discontinuations.

Table 10.3.4-1 summarizes the adverse events that were cited as reasons for prematurely withdrawing from the study. Nausea was the most frequent cause for discontinuation of treatment in DVS SR-treated subjects. Adverse events that led to discontinuation significantly more frequently in any DVS SR group than in the placebo group are nausea, dizziness, and somnolence.

CONFIDENTIAL 83 Wyeth

Protocol 3151A2-315-US

CSR-60178

Table 10.3.4-1: Number (%) of Subjects Reporting Adverse Events Resulting in Withdrawal From Study

Body System ^a Adverse Event	DVS SR 50 mg (n=149)	DVS SR 100 mg (n=155)	DVS SR 150 mg (n=157)	DVS SR 200 mg (n=151)	Placebo (n=77)
Any adverse event	27 (18.1)	33 (21.3)	58 (36.9)	63 (41.7)	12 (15.6)
Body as a whole					
Abdominal pain	1 (0.7)	1 (0.6)	1 (0.6)	1 (0.7)	0
Accidental injury	0	0	0	0	1 (1.3)
Asthenia	1 (0.7)	5 (3.2)	7 (4.5)	3 (2.0)	0
Chest pain	0	1 (0.6)	2 (1.3)	0	0
Chills	1 (0.7)	0	0	2 (1.3)	0
Flu syndrome	0	0	0	2 (1.3)	0
Headache	4 (2.7)	2 (1.3)	6 (3.8)	5 (3.3)	0
Malaise	0	1 (0.6)	0	0	0
Neck pain	0	0	1 (0.6)	0	0
Overdose	0	0	1 (0.6)	0	0
Pain	0	0	0	0	1 (1.3)
Sarcoidosis	0	0	0	1 (0.7)	0
Cardiovascular system					
Cardiovascular disorder	0	0	1 (0.6)	0	0
Coronary occlusion	0	1 (0.6)	0	0	0
Hypertension	1 (0.7)	1 (0.6)	3 (1.9)	6 (4.0)	2 (2.6)
Migraine	0	0	0	1 (0.7)	0
Myocardial infarct	1 (0.7)	0	1 (0.6)	0	0
Palpitation	0	1 (0.6)	0	3 (2.0)	0
Tachycardia	0	1 (0.6)	0	1 (0.7)	0
Vasodilatation	0	0	3 (1.9)	0	0
Digestive system					
Abdominal distension	0	0	0	1 (0.7)	1 (1.3)
Anorexia	0	2 (1.3)	2 (1.3)	3 (2.0)	0
Constipation	2 (1.3)	1 (0.6)	1 (0.6)	2 (1.3)	2 (2.6)
Diarrhea	0	0	2 (1.3)	4 (2.6)	0
Dry mouth	1 (0.7)	3 (1.9)	2 (1.3)	6 (4.0)	0
Dyspepsia	1 (0.7)	0	0	0	0
Dysphagia	0	0	0	1 (0.7)	0
Eructation	0	1 (0.6)	0	1 (0.7)	0
Esophagitis	1 (0.7)	0	0	0	0
Gastroesophageal reflux disease	0	0	0	1 (0.7)	0
Liver function tests abnormal	1 (0.7)	1 (0.6)	0	0	0
Nausea	5 (3.4)	11 (7.1)	19 (12.1)	24 (15.9)	0
Rectal hemorrhage	0	0	0	1 (0.7)	0
Tongue edema	0	0	0	1 (0.7)	0

Wyeth **CONFIDENTIAL** 84

Protocol 3151A2-315-US

CSR-60178

Table 10.3.4-1: Number (%) of Subjects Reporting Adverse Events Resulting in Withdrawal From Study

	DVS SR	DVS SR	DVS SR	DVS SR	
Body System ^a	50 mg	100 mg	150 mg	200 mg	Placebo
Adverse Event	(n=149)	(n=155)	(n=157)	(n=151)	(n=77)
Vomiting	2 (1.3)	3 (1.9)	1 (0.6)	5 (3.3)	0
Hemic and lymphatic system					
Anemia	1 (0.7)	0	0	0	0
Metabolic and nutritional					
Hypercholesteremia	0	1 (0.6)	0	2 (1.3)	0
Hyperlipemia	0	2 (1.3)	1 (0.6)	1 (0.7)	0
Peripheral edema	0	0	0	0	1 (1.3)
SGOT increased	0	0	1 (0.6)	1 (0.7)	0
SGPT increased	0	1 (0.6)	1 (0.6)	1 (0.7)	0
Thirst	0	0	0	1 (0.7)	0
Weight gain	0	1 (0.6)	4 (2.5)	1 (0.7)	0
Musculoskeletal system					
Arthralgia	0	0	1 (0.6)	0	0
Musculoskeletal stiffness	0	0	1 (0.6)	0	0
Rheumatoid arthritis	0	0	1 (0.6)	0	0
Nervous system			` ,		
Agitation	0	0	1 (0.6)	0	0
Anxiety	2 (1.3)	1 (0.6)	1 (0.6)	1 (0.7)	0
Ataxia	0	0	0	1 (0.7)	0
Confusion	0	1 (0.6)	4 (2.5)	2 (1.3)	0
Depersonalization	0	1 (0.6)	0	1 (0.7)	0
Depression	2 (1.3)	0	0	0	1 (1.3)
Dizziness	0	4 (2.6)	6 (3.8)	12 (7.9)	0
Euphoria	0	1 (0.6)	0	0	0
Hostility	1 (0.7)	0	0	0	0
Hypesthesia	1 (0.7)	1 (0.6)	0	0	1 (1.3)
Hypokinesia	0	0	0	1 (0.7)	0
Insomnia	6 (4.0)	4 (2.6)	5 (3.2)	8 (5.3)	2 (2.6)
Libido decreased	0	0	0	1 (0.7)	0
Memory impairment	0	0	0	1 (0.7)	0
Nervousness	2 (1.3)	1 (0.6)	4 (2.5)	4 (2.6)	0
Paresthesia	0	1 (0.6)	1 (0.6)	0	0
Somnolence	2 (1.3)	2 (1.3)	6 (3.8)	16 (10.6)	0
Speech disorder	0	0	0 (3.8)	1 (0.7)	0
Thinking abnormal	1 (0.7)	2 (1.3)	5 (3.2)	5 (3.3)	0
Tremor	0 0.7)	0	0	4 (2.6)	0
Trismus	0	-	0	4 (2.6) 0	0
		()	•		
Twitching	0	0	1 (0.6)	1 (0.7)	0
Vertigo	1 (0.7)	0	0	1 (0.7)	0

Wyeth **CONFIDENTIAL 85**

Protocol 3151A2-315-US

CSR-60178

Table 10.3.4-1: Number (%) of Subjects Reporting Adverse Events Resulting in Withdrawal From Study

Body System ^a Adverse Event	DVS SR 50 mg (n=149)	DVS SR 100 mg (n=155)	DVS SR 150 mg (n=157)	DVS SR 200 mg (n=151)	Placebo (n=77)
Respiratory system	·				
Dyspnea	0	0	1 (0.6)	0	0
Laryngismus	0	1 (0.6)	0	0	0
Sinusitis	0	0	0	0	1 (1.3)
Skin and appendages					
Sweating	0	0	0	1 (0.7)	0
Special senses					
Abnormal vision	0	2 (1.3)	1 (0.6)	4 (2.6)	0
Ear pain	0	1 (0.6)	0	0	0
Mydriasis	0	1 (0.6)	0	2 (1.3)	0
Tinnitus	0	2 (1.3)	0	1 (0.7)	0
Urogenital system	1 (0.7)	2 (1.3)	0	2 (1.3)	1 (1.3)
Kidney calculus	0	0	0	0	1 (1.3)
Ovarian carcinoma	0	1 (0.6)	0	0	0
Sexual function abnormal	1 (0.7)	1 (0.6)	0	1 (0.7)	0
Urinary hesitation	0	0	0	1 (0.7)	0

Abbreviations: SGOT=serum glutamic oxaloacetic transaminase (aspartate aminotransferase) and SGPT=serum glutamic pyruvic transaminase (alanine aminotransferase).

Source: AE5 W 29SEP05 14:54

Narratives for subjects who discontinued treatment because of selected adverse events are provided in Supportive Table ST 10-8, and these subjects are identified in Table 10.3.4-2. Some subjects listed in Table 10.3.4-1 were already listed in Table 10.3.2-1 if the adverse event that led to discontinuation was reported as a serious adverse event or in Table 10.3.3-1 if the adverse event that led to discontinuation was considered of clinical interest.

a. This table lists adverse events that were a primary or secondary reason for discontinuation. The number of subjects who discontinued for "any event" does not equal the number of adverse events listed because some subjects had multiple adverse events listed as reasons for discontinuation.

Protocol 3151A2-315-US

CSR-60178

Table 10.3.4-2: Subjects Who Withdrew Because of Selected Adverse Events

Reason for Subject	Treatment	Subjects With	
Narrative	Group	Event, n	Subject Numbers
Depression	Placebo	1	315-232-202553
	DVS SR 50 mg	2	315-208-201374 315-229-202411
Hostility	DVS SR 50 mg	1	315-216-201761
Hypercholesterolemia DVS SR 100 mg		1	315-231-202503
	DVS SR 200 mg	2	315-213-201642 315-218-201888
Hyperlipemia	DVS SR 100 mg	2	315-203-201103 315-231-202503
	DVS SR 150 mg	1	315-219-201910
	DVS SR 200 mg	1	315-213-201638
Hypertension	Placebo	2	315-208-201360 315-236-202704
	DVS SR 50	1	315-215-201702
	DVS SR 100 mg	1	315-231-202530
	DVS SR 150 mg	3	315-207-201316 315-218-201877 315-228-203697
	DVS SR 200 mg	6	315-204-201168 315-205-201216 315-206-201254
			315-207-201309 315-234-203063 315-236-202713
Liver function tests abnormal	DVS SR 50 mg	1	315-233-202627
	DVS SR 100 mg	1	315-206-201277
SGOT increase	DVS SR 100 mg	1	315-209-201437
	DVS SR 150 mg	1	315-206-201251
	DVS SR 200 mg	1	315-204-201176
SGPT increase	DVS SR 150 mg	1	315-206-201251
	DVS SR 200 mg	1	315-204-201176

Abbreviations: SGOT=serum glutamic oxaloacetic transaminase (aspartate aminotransferase) and SGPT=serum glutamic pyruvic transaminase (alanine aminotransferase).

Source: Report narr-sum-1 20DEC05 11:20 [DEV]

Analysis and Discussion of Deaths, Serious Adverse Events, Safety-Related 10.3.5 Discontinuations, and Other Adverse Events of Clinical Interest

This section analyzes selected serious adverse events, safety-related discontinuations, and other adverse events considered of clinical interest that were reported during the on-therapy or posttherapy period.

10.3.5.1 Cardiovascular Events

Six (6) cardiovascular events (3 coronary occlusions with revascularization and 3 myocardial infarctions) were reported in 5 DVS SR-treated subjects during the study. In each case, multiple risk factors for coronary artery disease were present, including family history of coronary heart disease (1 of 5), personal history of angina (2 of 5), smoking (4 of 5), hypertension (4 of 5), high body weight (5 of 5), and hyperlipemia (5 of 5). All subjects had at least 3 risk factors. The

CSR-60178

DVS SR Protocol 3151A2-315-US

patient ages ranged from 50 to 70 years and the time from DVS SR initiation to reported events ranged from 21 to 320 days on therapy. Cardiac catheterizations revealed evidence of extensive occlusion, suggestive of longstanding coronary atherosclerosis for these patients. Events occurred at DVS SR doses ranging from 50 mg to 200 mg daily; there were too few events to assess any dose relationships. All events were considered probably or definitely not related to test article by the investigators and the Wyeth medical monitor but rather were attributed to the underlying multiple risk factors. A brief summary of each case is provided below. Additional details about these subjects are provided in the subject narratives in Supportive Table ST 10-8.

Subject 315-237-202762 was a 53-year-old white, overweight woman (BMI=28 kg/m²) with a family history of coronary artery disease and a personal history of hyperlipemia and tobacco use. She was randomly assigned to receive 50 mg of DVS SR. On study day 132, she reported severe chest pain, and a posterior-inferior myocardial infarction was diagnosed. The subject was withdrawn from the study because of the event, and she underwent bypass revascularization. The investigator considered the event probably not related to test article.

Subject 315-202-201068 was a 69-year-old white, overweight woman (BMI=28 kg/m²) with a history of hypertension and hyperlipemia. She was randomly assigned to receive 100 mg of DVS SR. On study day 321, a cardiac catheterization for ongoing symptoms of unstable angina demonstrated a totally occluded circumflex coronary artery, and a percutaneous transluminal coronary angioplasty was performed. The subject withdrew from the study because of the event. The investigator considered the event probably not related to test article.

Subject 315-206-201271 was a 55-year-old white, overweight woman (BMI=29.3 kg/m²) with a history of hypertension, hyperlipemia, and tobacco use. She was randomly assigned to receive 150 mg of DVS SR. On study day 294, she experienced an episode of chest pain, and an acute inferior myocardial infarction was diagnosed. The subject was withdrawn from the study because of the event and underwent a percutaneous transluminal coronary angioplasty. The investigator considered the event probably not related to test article.

Subject 315-208-201372 was 51-year-old black, obese woman (BMI=30.4 kg/m²) with a history of chest pain for the past 8 months, hyperlipemia, borderline hypertension, and tobacco use. She was randomly assigned to receive 150 mg of DVS SR. On study day 89, a stress test performed for her persistent symptoms of angina revealed ischemic changes on ECG. A cardiac

CONFIDENTIAL 88 Wyeth

CSR-60178

catheterization was performed and showed a 99% occluded right coronary artery. Four (4) days after percutaneous transluminal coronary angioplasty, she was rehospitalized for severe chest pain, and a small non-Q wave myocardial infarction secondary to stent thrombosis was diagnosed. The subject underwent a second transluminal angioplasty with thrombectomy and placement of 2 additional stents. The subject was withdrawn from the study because of the event of coronary occlusion. The investigator considered the event probably not related to test article.

Subject 315-203-201125 was a 60-year-old white, overweight woman (BMI=25.3 kg/m²) with a history of hypertension, hypothyroidism, hyperlipemia, tobacco use, and 2 previous negative stress tests. She was randomly assigned to receive 200 mg of DVS SR. On study day 27, she reported the onset of chest pain. Given her medical history, she was referred for cardiac catheterization, which revealed several occluded coronary arteries, and a percutaneous transluminal coronary angioplasty was performed. The subject withdrew from the study because of unsatisfactory response after 5 months of therapy. The investigator considered the event definitely not related to test article.

10.3.5.2 Chest Pain

Twenty-two (22) DVS SR-treated subjects reported an episode of chest pain during the ontherapy (15 subjects) or posttherapy period (7 subjects).

Seven (7) episodes of chest pain occurred in subjects who reported serious adverse events, with verbatim descriptions of noncardiac chest pain, chest heaviness, atypical chest pain, chest pressure, and chest pain. One (1) subject (315-203-201125) had a diagnosis of coronary occlusion and is discussed in section 10.3.5.1. In other cases of chest pain reported as a serious adverse event, cardiac origin was ruled out, and the event of chest pain was considered definitely or probably not related to test article. Additional details about these subjects are provided in the subject narratives in Supportive Table ST 10-8.

All data about the remaining 15 subjects who reported an episode of chest pain were reviewed by the sponsor. One (1) subject in the DVS SR 50-mg group had an episode of chest pain with a verbatim description of rib pain, and no narrative was prepared for this subject. All other episodes of chest pain were considered to be potentially clinically important. In 8 subjects, the episodes of chest pain occurred in the on-therapy period. Cardiac origin was ruled out in

CONFIDENTIAL 89 Wyeth

CSR-60178

6 subjects, whereas 1 subject was lost to follow-up and 1 subject had a pacemaker malfunction reported by the investigator as a possible reason for the chest pain. In 6 subjects, episodes of chest pain occurred during the posttherapy period and were considered possibly related to discontinuation of test article in 3 cases. Additional details about these subjects are provided in the subject narratives in Supportive Table ST 10-8.

10.3.5.3 Hypertension

Thirteen (13) subjects withdrew from the study because of an adverse event of hypertension, including 2 in the placebo group, 1 each in the 50-mg and 100-mg DVS SR groups, 3 in the 150 mg DVS SR group, and 6 in the 200-mg DVS SR group. Four (4) subjects had histories of hypertension and 3 subjects had increased blood pressure (>140 mm Hg) at baseline. Four (4) subjects (2 in the placebo group and 2 in DVS SR groups) had an increase in supine blood pressure that met criteria for potential clinical importance, and these subjects are also listed in Table 10.5.1.3-1. Additional details about these subjects are provided in the subject narratives in Supportive Table ST 10-8.

10.3.5.4 Increased Liver Function Test Values

Two (2) subjects had increased liver function test values greater than 5 times the upper limits of normal that were reported as serious adverse events.

Subject 315-204-201176 was a 54-year-old white woman who was randomly assigned to receive 200 mg of DVS SR. On study day 93, the subject had an increase of AST/serum glutamic oxaloacetic transaminase (SGOT) levels to greater than 5 times the upper limit of the reference range and an increase of ALT/serum glutamic pyruvic transaminase (SGPT) levels to greater than 3 times the upper limit. Results of these tests 2 weeks later showed that AST/SGOT and ALT/SGPT values were within normal ranges. On study day 152, the AST/SGOT and ALT/SGPT levels increased again to values greater than 5 times the upper limit, and the subject was withdrawn from the study. Liver function tests returned to normal ranges 4 weeks after discontinuation of test article. The investigator considered the event possibly related to test article.

Subject 315-206-201251 was a 60-year-old white, obese woman with a history of hepatitis in 1971 and chronic urinary tract infection treated with nitrofurantoin for the past 3 years. She was

CONFIDENTIAL 90 Wyeth

CSR-60178

randomly assigned to receive 150 mg of DVS SR. On study day 182, the subject had an increase in AST/SGOT and ALT/SGPT levels to greater than 5 times the upper limit of the reference range, and she was withdrawn from the study. After discontinuation of test article, liver function test values continued to increase to greater than 20 times the upper limits and were associated with an increase in bilirubin levels and development of jaundice with extreme fatigue, nausea, and vomiting. Based on the subject's medical history and results from investigations, acute drug hepatotoxicity from test article, nitrofurantoin, ¹³ or the combination of both medications was diagnosed. An autoimmune origin was also suspected based on positive test results for antinuclear anti-smooth muscle antibodies. Corticosteroid was prescribed, and the subject started to improve clinically; liver function test values progressively improved and returned to normal levels within 5 months. The investigator considered the event possibly related to test article.

In addition to the 2 subjects discussed above, the following 3 subjects withdrew from the study because of abnormal liver function test results.

Subject 315-233-202627 was a 71-year-old white woman with a history of hypertension treated with simvastatin (Zocor). She was randomly assigned to receive 50 mg of DVS SR. On study day 79, she had increases in ALT/SGPT and AST/SGOT levels that were greater than 3 times the upper limits of the reference range. The subject was instructed to stop taking test article and to have liver function tests repeated; 3 weeks later, test results showed further increases in ALT/SGPT and AST/SGOT (greater than 5 times the upper limits). The subject was referred to her primary care physician, but she was lost to follow-up and no further information is available. The investigator considered the adverse event possibly related to test article or to concomitant medication of simvastatin.

Subject 315-206-201277 was a 58-year-old white woman with no relevant medical history. She was randomly assigned to receive 100 mg of DVS SR. On study day 27, she had an isolated increase in ALT/SGPT that was 3 times the upper limit. ALT/SGPT returned to normal ranges after discontinuation of test article. The investigator considered the adverse event to be possibly related to test article.

Subject 315-209-201437 was a 54-year-old white woman with a history of hepatitis B (in 1999). She was randomly assigned to receive 100 mg of DVS SR. On study day 175, she had an isolated increase in ALT/SGPT that was greater than 3 times the upper limit. The subject withdrew from

CONFIDENTIAL 91 Wyeth

CSR-60178

the study because of the adverse event. After discontinuation of test article, ALT/SGPT returned to normal levels. The investigator considered the event possibly related to test article.

10.3.5.5 Depression

Thirty-three (33) DVS SR-treated subjects and 3 placebo-treated subjects reported adverse events coded as "depression" in the COSTART dictionary during the on-therapy (23 episodes) or the posttherapy (17 episodes) periods, including 4 DVS SR-treated subjects who reported episodes of depression both on-therapy and posttherapy.

One (1) subject reported a serious adverse event of depression with suicidal thoughts. Subject 315-229-202411 was a 53-year-old white woman with a long history of depression secondary to sexual abuse, prior suicide attempt at age 19, and alcoholism since age 15 that was not disclosed to the investigator during the screening visit. She was randomly assigned to receive 50 mg of DVS SR. On study day 132, the subject was hospitalized for a severe episode of depression with anxiety and suicidal thoughts. She was withdrawn from the study because of this event. The investigator considered the event definitely not related to test article.

Two (2) other subjects (1 in the DVS SR 50-mg group and 1 in the placebo group) withdrew from the study because of the adverse event of depression. Subject 315-208-201374 was a 49-year-old black woman with a history of depression and anxiety since 2000. She was randomly assigned to receive 50 mg of DVS SR. On study day 162, she experienced a moderate episode of depression that was considered probably not related to test article. Venlafaxine was prescribed while the subject was still in the study. She was permanently withdrawn from the study because of the adverse event of depression and concomitant use of prohibited medication. Subject 315-232-202553 was a 46-year-old white woman with a history of depression treated with paroxetine since 2002. She stopped taking paroxetine before entering the screening. She was randomly assigned to receive placebo and withdrew from the study on study day 84 because of "increased depression." The investigator considered the event of depression probably not related to test article.

All data about the remaining events of depression (ie, those that were not reported as a serious adverse event or that did not lead to discontinuation from the study) were reviewed by the sponsor. In most cases, episodes were mild or moderate in intensity, were short-lived, and did

CONFIDENTIAL 92 Wyeth

CSR-60178

DVS SR Protocol 3151A2-315-US

not require prescription of antidepressant medication. However, 13 DVS SR-treated subjects experienced episodes of depression that were considered clinically important (intensity reported as severe, duration greater than 30 days, prescription of antidepressant drug, and/or persistence of the event at last visit) by the sponsor. In all but 3 cases, subjects had no history of depression. Eight (8) subjects reported an episode of depression during therapy, and 8 subjects reported an episode of depression after discontinuation of test article (4 subjects had both on-therapy and posttherapy episodes of depression; 1 did not meet criteria for a narrative). Additional details about these subjects are provided in the subject narratives in Supportive Table ST 10-8.

10.3.5.6 Suicidal Ideation

Two (2) DVS SR-treated subjects reported an adverse event coded as "suicidal ideation" in the COSTART dictionary. Subject 315-229-202411 also reported an episode of depression and was discussed in section 10.3.5.5. Subject 315-234-203060 was a 53-year-old white woman with no history of depression. She was randomly assigned to receive 100 mg of DVS SR and withdrew early from the study because of unsatisfactory response. Two (2) days after discontinuation of test article, she experienced an episode of depression with suicidal thoughts that was not reported as a serious adverse event. These events resolved gradually with no medical intervention and were considered by the investigator to be possibly related to discontinuation of test article.

10.3.5.7 Hostility

During the on-therapy or the posttherapy periods, 38 adverse events coded as "hostility" in the COSTART dictionary were reported by 32 DVS SR-treated subjects and 4 placebo-treated subjects. In most cases, these adverse events were reported with verbatim texts of "irritable" or "irritability." Two (2) subjects (315-207-201303 in the 150-mg DVS SR group and 315-218-201866 in the 200-mg DVS SR group) reported after discontinuing test article adverse events described as "rage," "desire to hurt others," or "aggressiveness," and these events were considered clinically important. Additional details about these 2 subjects are provided in the subject narratives in Supportive Table ST 10-8.

10.3.5.8 Thinking Abnormal

During the on-therapy or the posttherapy periods, 31 DVS SR-treated subjects and 1 placebotreated subject reported an adverse event coded as "thinking abnormal" in the COSTART

CONFIDENTIAL 93 Wyeth

CSR-60178

DVS SR Protocol 3151A2-315-US

dictionary. In most cases, these adverse events were reported with verbatim texts of "difficulty to concentrate" or "lack of concentration." One (1) subject (315-219-201945) in the 150-mg DVS SR group, after missing 3 consecutive days of test article, reported an adverse event described as "decreased clarity of thinking" and "non-suicidal preoccupation of being dead," and this event was considered clinically important. The event resolved with resumption of test article and was considered by the investigator to be possibly related to discontinuation of test article. Additional details about this subject are provided in the subject narratives in Supportive Table ST 10-8.

10.3.5.9 Intentional Overdose

Three (3) intentional overdoses of 1 extra dose were reported during the study, all occurring in DVS SR-treated subjects. One (1) subject (315-208-201359) was randomly assigned to receive 150 mg of DVS SR and she elected to take double doses of the test article for 14 days because of the positive effect on her symptoms. The event was considered serious by the investigator and is listed in Table 10.3.2-1. The 2 other events (subjects 315-207-201313 and 315-228-202384) occurred when the subjects missed their doses of test article (50 mg and 100 mg of DVS SR, respectively) 1 day and they elected to take a double dose the following day. In all cases, the maximum daily dose of DVS SR did not exceed 300 mg. No associated symptoms were reported in any case.

10.3.6 Narratives of Deaths, Serious Adverse Events, Safety-Related Discontinuations, and Other Adverse Events of Clinical Interest

Table 10.3.6-1 lists all subjects with narratives by primary reason for the narrative. Individual subject narratives are provided in Supportive Table ST 10-8. Subjects with serious adverse events were discussed in section 10.3.2, subjects who withdrew because of adverse events were discussed in section 10.3.4, and subjects with adverse events of clinical interest were discussed in section 10.3.3. Subjects with clinically important vital sign measurements will be discussed in section 10.5.1.3, subjects with clinically important laboratory test values will be discussed in section 10.4.3, and subjects with clinically important ECG values will be discussed in section 10.5.3.3.

CONFIDENTIAL 94 Wyeth

Table 10.3.6-1: Summary of Subjects With Narratives by Primary Reason for the Narrative

		Subjects Wit	h
Reason for Subject Narrative	Treatment	Event, n	Subject Number
Serious adverse event	Placebo	1	315-229-202419
	DVS SR 50 mg	4	315-228-203715 315-229-202405 315-229-202411 315-237-202762
	DVS SR 100 mg	5	315-202-201068 315-217-201831 315-228-202368 315-228-203716
			315-239-202869
	DVS SR 150 mg	12	315-201-201009 315-203-201119 315-206-201251 315-206-201271
			315-208-201359 315-208-201372 315-213-201636 315-218-201873
			315-228-202379 315-231-202507 315-235-202684 315-237-202764
	DVS SR 200 mg	6	315-201-201002 315-203-201125 315-204-201176 315-228-202357
			315-228-202364 315-242-203008
Discontinuation due to adverse event	Placebo	3	315-208-201360 315-232-202553 315-236-202704
	DVS SR 50 mg	5	315-208-201374 315-215-201702 315-216-201761 315-229-202411
			315-233-202627
	DVS SR 100 mg	5	315-203-201103 315-206-201277 315-209-201437 315-231-202503
			315-231-202530
	DVS SR 150 mg	5	315-206-201251 315-207-201316 315-218-201877 315-219-201910
			315-228-203697
	DVS SR 200 mg	10	315-204-201168 315-204-201176 315-205-201216 315-206-201254
			315-207-201309 315-213-201638 315-213-201642 315-218-201888
			315-234-203063 315-236-202713
Adverse events of clinical interest	Placebo	2	315-232-202553 315-237-202753
	DVS SR 50 mg	6	315-204-201171 315-207-201313 315-208-201361 315-208-201374
			315-213-201614 315-225-202218
	DVS SR 100 mg	10	315-202-201073 315-206-201293 315-218-201884 315-220-201958
			315-228-202384 315-229-202421 315-231-202530 315-234-203060
			315-239-202859 315-241-202960
	DVS SR 150 mg	8	315-206-201297 315-207-201303 315-215-201705 315-216-201756
			315-219-201945 315-228-202363 315-239-202882 315-242-203020
	DVS SR 200 mg	8	315-203-201113 315-203-201147 315-209-201422 315-216-201764
			315-218-201866 315-233-202613 315-239-202874 315-239-202875

Table 10.3.6-1: Summary of Subjects With Narratives by Primary Reason for the Narrative

		Subjects Wit	h
Reason for Subject Narrative	Treatment	Event, n	Subject Number
Clinically important vital signs values	Placebo	5	315-206-201285 315-208-201360 315-213-201621 315-236-202704 315-239-202852
	DVS SR 50 mg	5	315-203-203531 315-218-201878 315-233-202629 315-240-202906 315-242-203001
	DVS SR 100 mg	5	315-217-201830 315-228-203682 315-228-203701 315-231-202530 315-240-202921
	DVS SR 150 mg	8	315-203-203514 315-204-201157 315-206-201297 315-208-201359 315-208-201364 315-217-201819 315-225-202206 315-239-202882
	DVS SR 200 mg	6	315-206-201254 315-216-201767 315-218-201875 315-231-202509 315-232-202566 315-235-202666
Clinically important laboratory values	Placebo	3	315-202-201066 315-207-201317 315-239-202852
J 1	DVS SR 50 mg	3	315-233-202627 315-233-202629 315-236-202706
	DVS SR 100 mg	2	315-233-202606 315-243-203101
	DVS SR 150 mg	5	315-206-201251 315-210-201466 315-219-201910 315-236-202711 315-238-202831
Clinically important electrocardiogram	DVS SR 200 mg	4	315-202-201090 315-203-201147 315-204-201176 315-216-201767
values	DVS SR 50 mg	2	315-213-201604 315-218-201883
	DVS SR 100 mg	1	315-231-202530

Source: NARR-SUM-2 20DEC05 11:20 [DEV]

10.4 Clinical Laboratory Evaluations

10.4.1 Criteria for Determining Values of Potential Clinical Importance

To maximize uniformity, each laboratory test was performed at a single laboratory, as identified in section 6.5.2.2. All laboratory data for individual subjects were screened against reference interval criteria (Table 10.4.1-1) that, if exceeded, would be considered of potential clinical importance. Some criteria were specified by the Food and Drug Administration (FDA), Neuropharm Division, for the DVS SR Major Depressive Disorder program. To be consistent, the same criteria were used for the DVS SR VMS program. For cholesterol test results, both the FDA's and the sponsor's criteria were applied to the data.

CONFIDENTIAL 97 Wyeth

Table 10.4.1-1: Criteria for Determining Potentially Clinically Important Laboratory
Test Results

Blood Test	Criteria: International System Units ^{a,b}	Criteria: Conventional Units a,b
Hemoglobin	<95 g/L or >165 g/L	<9.5 g/dL or >16.5 g/dL
Hematocrit	<0.32 or >0.50	<32% or >50%
White blood cell count	$<2.8 \times 10^9 / L \text{ or } > 16 \times 10^9 / L$	$<2.8 \times 10^9 / L \text{ or } > 16 \times 10^9 / L$
Platelet count	$<75 \times 10^9 / L \text{ or } > 700 \times 10^9 / L$	$<75x10^9/L \text{ or } >700x10^9/L$
Sodium	<126 mmol/L or >156 mmol/L	<126 mEq/L or $>$ 156 mEq/L
Potassium	<2.5 mmol/L and >6.5 mmol/L	<2.5 mEq/L and $>$ 6.5 mEq/L
Calcium	<2.046 mmol/L or >2.994 mmol/L	<8.2 mg/dL or $>$ 12 mg/dL
Chloride	<90 mmol/L or $>$ 118 mmol/L	<90 mEq/L or $>$ 118 mEq/L
Glucose,	$<$ 2.22 mmol/L or \ge 11.10 mmol/L	<40 mg/dL or $>$ 200 mg/dL
fasting/nonfasting/unknown		
Uric acid	>0.4758 mmol/L	>7.93 mg/dL
Total protein	$<$ 45 g/L or \ge 100 g/L	$<4.5 \text{ g/dL or } \ge 10.0 \text{ g/dL}$
Albumin	<25 g/L	<2.5 g/dL
Total bilirubin	≥ 1.5 x upper limit of normal	≥ 1.5 x upper limit of normal
ALT/SGPT	\geq 3 x upper limit of normal	≥ 3 x upper limit of normal
AST/SGOT	≥ 3 x upper limit of normal	≥ 3 x upper limit of normal
Alkaline phosphatase	≥ 3 x upper limit of normal	≥ 3 x upper limit of normal
BUN	≥ 1.5 x upper limit of normal	≥ 1.5 x upper limit of normal
Creatinine	≥ 1.5 x upper limit of normal	≥ 1.5 x upper limit of normal
Cholesterol, fasting	>7.758 mmol/L	>300 mg/dL
Total cholesterol,	Increase \geq 1.29 mmol/L and value	Increase \geq 50 mg/dL and value
fasting/nonfasting/unknown	\geq 6.75 mmol/L	<u>></u> 260 mg/dL
HDL cholesterol,	Decrease >0.21 mmol/L and value	Decrease $>$ 8.0 mg/dL and value
fasting/nonfasting/unknown	<0.91 mmol/L	<35 mg/d L
LDL cholesterol,	Increase ≥ 1.29 mmol/L and value	Increase \geq 50 mg/dL and value
fasting/nonfasting/unknown	\geq 4.91 mmol/L	≥190 mg/dL
Triglycerides,	\geq 3.7 mmol/L	>330 mg/dL
fasting/nonfasting/unknown		
Urinalysis		
pН	<u><</u> 4 or ≥9	<u><</u> 4 or ≥9
Protein/albumin	Positive value	Positive value
Hemoglobin/blood	Positive value	Positive value
Ketones	Positive value	Positive value

Abbreviations: ALT/SGPT=alanine aminotransferase/serum glutamic pyruvic transaminase,

AST/SGOT=aspartate aminotransferase/serum glutamic oxaloacetic transaminase; HDL=high-density lipoprotein, and LDL=low-density lipoprotein.

10.4.2 Summary of Subjects With Values of Potential Clinical Importance

Table 10.4.2-1 summarizes the numbers of subjects with potentially clinically important values at any time during the on-therapy period grouped by laboratory assessment. If no subject had potentially clinically important values for a given criterion, that category was not listed in the

a. All increases and decreases were compared with baseline.

b. Criteria were defined by the Food and Drug Administration (standard type) or Wyeth (*shown in italic*). Source: Statistical Analysis Plan

table. Supportive Table ST 10-9 provides a summary tabulation of the number and percentage of subjects with laboratory data of potential clinical importance, by data analysis interval and therapy.

No significant difference between groups was observed in the number and percentage of subjects meeting criteria for potential clinical importance for laboratory test results.

CONFIDENTIAL 99 Wyeth

Table 10.4.2-1: Number (%) of Subjects With Potentially Clinically Important Laboratory Test Results/Number of Subjects Tested, On-Therapy Period

	Overall	DVS SR	DVS SR	DVS SR	DVS SR	
Category	p-Value a		100 mg	150 mg	200 mg	Placebo
Total	0.993				30/125 (24.0)	17/77 (22.1)
Blood chemistry		` ,	` ,	, ,	` ′	` /
Potassium, mmol/L						
High	0.360	0/143	0/140	1/131 (0.8)	0/124	1/77 (1.3)
Glucose, mmol/L						
High	0.576	0/143	0/140	1/132 (0.8)	1/124 (0.8)	1/77 (1.3)
Low	0.507	1/143 (0.7)	0/140	0/132	0/124	0/77
Calcium, mmol/L						
Low	0.136	0/143	0/140	0/131	0/124	1/77 (1.3)
Uric acid, mmol/L						, ,
High	0.714	1/143 (0.7)	2/140 (1.4)	2/132 (1.5)	0/124	1/77 (1.3)
SGOT/AST, mU/mL						
High	0.928	1/143 (0.7)	1/140 (0.7)	1/131 (0.8)	2/124 (1.6)	1/77 (1.3)
SGPT/ALT, mU/mL						
High	0.755	1/143 (0.7)	1/140 (0.7)	2/132 (1.5)	2/124 (1.6)	0/77
Hematology						
Hemoglobin, g/L						
High	0.349	0/143	2/140 (1.4)	1/132 (0.8)	0/124	0/77
Low	0.507	1/143 (0.7)	0/140	0/132	0/124	0/77
Hematocrit, L/L						
High	0.307	1/143 (0.7)	3/140 (2.1)	0/132	1/124 (0.8)	0/77
Low	0.507	1/143 (0.7)	0/140	0/132	0/124	0/77
White blood cells, x 10 ⁹ /L						
High	0.405	0/143	0/140	0/132	1/123 (0.8)	0/77
Low	0.093	0/143	4/140 (2.9)	0/132	1/123 (0.8)	1/77 (1.3)
Lipid profile						
Total cholesterol/lipid, mmol/l	L					
High	0.641	9/141 (6.4)	9/139 (6.5)	11/132 (8.3)	13/120 (10.8)	5/77 (6.5)
HDL cholesterol, mmol/L						
Decrease	0.427	3/143 (2.1)	0/140	2/132 (1.5)	1/124 (0.8)	2/77 (2.6)
LDL cholesterol mmol/L						
Increase	0.144	3/143 (2.1)	3/140 (2.1)	2/132 (1.5)	8/124 (6.5)	3/76 (3.9)
Triglycerides /lipid mmol/L						
High	0.676	4/143 (2.8)	3/140 (2.1)	7/132 (5.3)	5/124 (4.0)	3/77 (3.9)
Urinalysis						
Urine protein albumin						
Positive	0.538	5/143 (3.5)	9/140 (6.4)	9/132 (6.8)	6/124 (4.8)	2/77 (2.6)
Urine acetone /ketones						
Positive	0.232	1/143 (0.7)	4/140 (2.9)	0/132	1/124 (0.8)	1/77 (1.3)
Urine hemoglobin blood						
Positive	0.904	8/143 (5.6)	7/140 (5.0)	9/132 (6.8)	8/124 (6.5)	3/77 (3.9)

Abbreviations: SGOT/AST=serum glutamic oxaloacetic transaminase/aspartate aminotransferase;

SGPT/ALT=serum glutamic pyruvic transaminase/alanine aminotransferase; HDL=high-density lipoprotein; LDL=low-density lipoprotein.

Source: LAB5_OT15NOV05

a. Overall p-value from chi-square test.

10.4.3 Individual Clinically Important Abnormalities

Blinded laboratory test data for each subject identified as having laboratory test values of potential clinical importance were reviewed by the sponsor. This review included an evaluation of each subject's laboratory test results, vital signs measurements, and ECG data; adverse event records; any other pertinent sections of the case report forms; and correspondence related to the subject. The sponsor's decision about the clinical importance of each subject's abnormalities was based on the above information.

The sponsor determined that 3 subjects who received placebo and 14 subjects who received DVS SR had clinically important changes in laboratory test results. These subjects are identified in Table 10.4.3-1. Additional details about these subjects are provided in the subject narratives in Supportive Table ST 10-8.

Table 10.4.3-1: Subjects Who Had Clinically Important Changes in Laboratory Test Results

		Subjects With	
Laboratory Test	Treatment	Event, n	Subject Number
Glucose (fasting)	Placebo	1	315-239-202852
	DVS SR 150 mg	1	315-236-202711
	DVS SR 200 mg	1	315-216-201767
SGPT/ALT	DVS SR 50 mg	1	315-233-202627
	DVS SR 150 mg	1	315-206-201251
	DVS SR 200 mg	1	315-204-201176
SGOT/AST	Placebo	1	315-207-201317
	DVS SR 50 mg	1	315-233-202627
	DVS SR 150 mg	1	315-206-201251
	DVS SR 200 mg	1	315-204-201176
Total bilirubin	DVS SR 150 mg	1	315-206-201251
Total cholesterol	Placebo	1	315-202-201066
	DVS SR 50 mg	2	315-233-202629 315-236-202706
	DVS SR 100 mg	1	315-243-203101
	DVS SR 150 mg	2	315-210-201466 315-238-202831
	DVS SR 200 mg	2	315-202-201090 315-203-201147
Triglycerides	DVS SR 100 mg	1	315-233-202606
	DVS SR 150 mg	2	315-210-201466 315-219-201910

Abbreviations: SGOT/AST=serum glutamic oxaloacetic transaminase/aspartate aminotransferase and SGPT/ALT=serum glutamic pyruvic transaminase/alanine aminotransferase.

Source: Report narr-sum-1 20DEC05 11:20 [DEV]

CONFIDENTIAL 101 Wyeth

The remaining subjects who were identified by the screening criteria were not considered to have clinically important laboratory test results. The results were isolated or transient, were associated with tests performed in subjects who had not fasted, were unrelated to adverse events or discontinuations, or were inconsistent with the rest of the clinical picture.

10.4.4 Mean Laboratory Results

Changes from baseline in mean values for laboratory tests were evaluated for within- and between-group differences by using analysis of covariance (ANCOVA) with treatment as a factor and baseline value as a covariate. The results for selected laboratory tests (creatinine, ALT/SGPT, AST/SGOT, alkaline phosphatase, bilirubin, fasting total cholesterol, high-density lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C], and triglycerides) are presented for selected time points in Table 10.4.4-1. The mean data for all laboratory values at all evaluation times are provided in Supportive Table ST 10-10.

CONFIDENTIAL 102 Wyeth

Table 10.4.4-1: Baseline Mean and Mean Changes From Baseline for Selected Laboratory Tests

Treatment		Obse	rved	Base	eline	Cha	nge	Adjı	ısted b	Between- Group
Data Analysis Interval ^a	n	Mean	SD	Mean	SD	Mean	SD	Mean	SE	p-Value ^c
Creatinine, µmol/L										
DVS SR 50 mg										
Week 4	141	78.7	11.6	77.3	11.5	1.4	11.4	1.1	0.8	
Week 12	118	77.5	11.6	77.0	11.4	0.5	11.3	0.2	0.8	
Week 26	100	79.4	11.3	77.8	11.9	1.6	11.4	1.5	0.9	
Final on-therapy	142	79.1	11.0	77.2	11.5	1.9*	11.1	1.6*	0.7	
DVS SR 100 mg										
Week 4	139	80.6	13.9	79.9	11.6	0.7	8.7	1.2	0.8	
Week 12	119	79.3	11.1	80.0	11.7	-0.7	9.0	0.1	0.8	
Week 26	112	80.0	11.1	80.2	11.8	-0.2	7.8	0.6	0.8	
Final on-therapy	140	81.3	12.7	80.1	11.7	1.2	9.1	1.9*	0.7	
DVS SR 150 mg										
Week 4	132	79.9	10.8	78.3	11.1	1.6	9.6	1.7*	0.8	
Week 12	103	78.9	11.7	77.5	10.9	1.4	9.6	1.2	0.9	
Week 26	91	79.0	11.1	76.9	10.7	2.0*	8.9	1.7	0.9	
Final on-therapy	132	79.6	10.6	78.3	11.1	1.3	8.8	1.3	0.8	
DVS SR 200 mg										
Week 4	124	78.7	11.4	76.6	11.3	2.1*	9.3	1.6	0.8	
Week 12	96	77.0	11.0	75.7	11.4	1.3	9.8	0.5	0.9	
Week 26	83	77.7	11.7	75.2	11.9	2.6*	9.7	1.6	1.0	
Final on-therapy	124	77.9	10.8	76.6	11.3	1.3	9.3	0.7	0.8	
Placebo										
Week 4	76	78.0	13.8	78.5	12.1	-0.5	10.2	-0.3	1.1	
Week 12	66	79.3	13.0	79.3	12.4	-0.0	9.6	0.5	1.1	
Week 26	59	81.2	14.1	80.2	12.6	1.0	10.0	1.8	1.1	
Final on-therapy	77	79.3	12.6	78.6	12.0	0.7	9.6	0.9	1.0	

Table 10.4.4-1: Baseline Mean and Mean Changes From Baseline for Selected Laboratory Tests

Treatment		Obse	rved	Base	eline	Cha	nge	Adj	usted b	Between- Group
Data Analysis Interval ^a	n	Mean	SD	Mean	SD	Mean	SD	Mean	SE	p-Value ^c
Total bilirubin, µmol/L										
DVS SR 50 mg										
Week 4	141	8.93	3.85	8.99	3.83	-0.06	2.78	-0.19	0.21	B,C
Week 12	118	8.26	3.62	8.96	3.98	-0.70**	2.47	-0.91***	0.24	C,D
Week 26	100	8.67	3.78	9.17	4.12	-0.50	2.67	-0.69**	0.26	C
Final on-therapy	142	8.71	3.23	8.97	3.82	-0.26	2.81	-0.43*	0.20	B,C
DVS SR 100 mg										
Week 4	139	8.87	3.72	9.40	4.26	-0.53*	2.98	-0.47*	0.22	F
Week 12	119	8.71	3.40	9.58	4.42	-0.88***	2.77	-0.79***	0.24	E,F,G
Week 26	112	8.67	3.79	9.66	4.58	-0.99**	3.29	-0.94***	0.25	F,G
Final on-therapy	140	8.57	3.08	9.43	4.26	-0.86**	3.51	-0.76***	0.21	F
DVS SR 150 mg										
Week 4	132	8.45	2.98	9.50	3.14	-1.05***	2.77	-0.94***	0.22	Н
Week 12	103	8.07	2.72	9.75	3.00	-1.68***	2.51	-1.52***	0.25	I
Week 26	91	8.36	2.80	9.75	3.05	-1.39***	2.44	-1.30***	0.28	I
Final on-therapy	132	8.19	2.85	9.50	3.14	-1.31***	2.78	-1.18***	0.21	I
DVS SR 200 mg										
Week 4	124	7.54	2.36	9.10	4.65	-1.56***	4.07	-1.63***	0.23	J
Week 12	96	7.52	2.52	9.37	5.10	-1.85***	4.67	-1.87***	0.26	J
Week 26	83	7.50	2.60	9.58	5.37	-2.08***	4.95	-2.07***	0.29	J
Final on-therapy	124	7.53	2.33	9.10	4.65	-1.57***	4.11	-1.67***	0.22	J
Placebo										
Week 4	76	9.02	3.39	9.38	3.46	-0.36	2.74	-0.31	0.29	
Week 12	66	9.59	4.55	9.43	3.50	0.16	3.51	0.17	0.32	
Week 26	59	9.65	3.74	9.71	3.60	-0.06	2.91	0.02	0.34	
Final on-therapy	77	9.08	3.33	9.39	3.44	-0.31	3.09	-0.24	0.28	

Table 10.4.4-1: Baseline Mean and Mean Changes From Baseline for Selected Laboratory Tests

Treatment	-	Obse	rved	Base	eline	Cha	nge	Adjı	isted b	Between- Group
Data Analysis Interval a	n	Mean	SD	Mean	SD	Mean	SD	Mean	SE	p-Value °
SGOT/AST, mU/mL										
DVS SR 50 mg										
Week 4	136	22.7	8.4	21.8	7.0	0.9	5.8	0.9	0.7	
Week 12	116	24.3	13.2	21.9	7.3	2.4**	9.7	2.4***	0.7	D
Week 26	97	23.8	11.7	21.6	7.3	2.1**	7.7	2.0	1.8	
Final on-therapy	140	24.7	19.1	21.9	7.0	2.9*	15.5	2.9	1.5	
DVS SR 100 mg										
Week 4	138	22.0	5.8	21.6	6.1	0.5	5.2	0.4	0.7	
Week 12	115	23.4	6.8	21.3	6.2	2.1***	5.8	1.9**	0.7	G
Week 26	111	22.7	7.2	21.5	6.1	1.2*	6.3	1.0	1.7	
Final on-therapy	139	23.2	12.9	21.5	6.1	1.7	12.2	1.7	1.5	
DVS SR 150 mg										
Week 4	129	23.3	8.1	22.5	8.1	0.8	7.2	0.9	0.8	
Week 12	102	24.7	9.8	23.2	8.6	1.5*	7.2	1.7*	0.7	I
Week 26	89	27.5	33.1	22.9	8.2	4.6	33.3	4.8**	1.9	
Final on-therapy	130	25.8	28.5	22.5	8.0	3.3	28.6	3.4*	1.6	
DVS SR 200 mg										
Week 4	120	22.7	16.8	21.9	6.3	0.8	15.5	0.8	0.8	
Week 12	94	23.5	8.2	22.2	6.5	1.3	7.1	1.3	0.8	
Week 26	82	24.4	17.9	22.0	6.2	2.3	17.4	2.3	1.9	
Final on-therapy	123	23.0	15.5	21.9	6.3	1.1	14.9	1.1	1.6	
Placebo										
Week 4	75	22.6	6.5	22.3	5.2	0.3	6.5	0.4	1.0	
Week 12	65	21.6	5.2	22.7	5.3	-1.1	5.6	-1.0	0.9	
Week 26	58	22.5	4.5	22.9	5.5	-0.4	5.1	-0.2	2.3	
Final on-therapy	76	22.9	6.5	22.4	5.1	0.5	6.4	0.5	2.0	

Table 10.4.4-1: Baseline Mean and Mean Changes From Baseline for Selected Laboratory Tests

Treatment		Obse	rved	Base	eline	Cha	nge	Adjı	ısted ^b	Group
Data Analysis Interval ^a	n	Mean	SD	Mean	SD	Mean	SD	Mean	SE	p-Value °
SGPT/ALT, mU/mL										
DVS SR 50 mg										
Week 4	141	21.2	10.9	20.9	9.1	0.3	6.8	0.1	0.8	
Week 12	118	23.3	18.2	21.1	9.3	2.2	15.7	1.9	1.0	D
Week 26	100	21.4	10.1	20.7	9.3	0.7	7.9	0.3	3.0	
Final on-therapy	142	23.3	18.0	20.9	9.0	2.5	15.5	2.2	2.2	
DVS SR 100 mg										
Screening/baseline	155	20.2	8.9	20.2	8.9					
Week 4	139	21.1	11.6	20.6	9.2	0.5	9.3	0.2	0.8	
Week 12	119	21.4	8.8	20.3	9.2	1.1	8.4	0.5	1.0	
Week 26	112	21.1	10.8	20.4	9.1	0.7	9.8	0.2	2.8	
Final on-therapy	140	22.2	11.6	20.5	9.2	1.7	10.7	1.2	2.3	
DVS SR 150 mg										
Week 4	132	23.9	13.4	23.0	12.7	0.8	13.2	1.4	0.8	
Week 12	103	23.4	9.8	24.2	13.6	-0.8	9.6	0.0	1.1	
Week 26	91	29.0	57.2	23.5	13.4	5.5	57.2	6.3*	3.1	
Final on-therapy	132	27.2	47.8	23.0	12.7	4.2	48.2	4.9*	2.3	
DVS SR 200 mg										
Week 4	124	21.7	10.2	21.8	10.0	-0.2	8.6	-0.1	0.8	
Week 12	96	24.0	14.9	22.0	10.7	2.0	10.4	2.1	1.1	J
Week 26	83	25.0	31.0	22.1	11.0	2.9	30.4	3.2	3.2	
Final on-therapy	124	24.2	26.7	21.8	10.0	2.3	26.6	2.5	2.4	
Placebo										
Week 4	76	20.7	8.4	21.2	10.9	-0.5	9.6	-0.6	1.0	
Week 12	66	19.1	7.4	21.5	11.4	-2.3	11.2	-2.5	1.3	
Week 26	59	18.9	6.4	21.6	12.0	-2.7	10.7	-2.7	3.8	
Final on-therapy	77	21.0	8.0	21.2	10.8	-0.2	11.2	-0.3	3.1	

Table 10.4.4-1: Baseline Mean and Mean Changes From Baseline for Selected Laboratory Tests

Treatment		Obse	rved	Base	eline	Cha	nge	Adjı	ısted ^b	- Between- Group
Data Analysis Interval a	n	Mean	SD	Mean	SD	Mean	SD	Mean	SE	p-Value ^c
Alkaline phosphatase, mU/mI										
DVS SR 50 mg										
Week 4	141	86.5	26.4	82.9	24.3	3.5***	10.7	3.6**	1.2	В
Week 12	118	88.4	26.0	83.3	24.1	5.1***	12.2	5.1***	1.1	B,C
Week 26	100	87.0	26.4	83.3	24.8	3.7**	12.6	3.9**	1.4	C
Final on-therapy	142	87.1	25.5	83.3	24.5	3.8**	14.3	3.9***	1.2	
DVS SR 100 mg										
Week 4	139	85.6	23.0	80.2	22.1	5.4***	10.6	5.3***	1.2	
Week 12	119	87.7	24.5	81.5	22.6	6.1***	11.0	6.1***	1.1	F,G
Week 26	112	87.7	24.4	81.4	22.7	6.3***	13.7	6.3***	1.3	Ğ
Final on-therapy	140	87.3	25.0	80.2	22.0	7.0***	13.3	6.8***	1.2	
DVS SR 150 mg										
Week 4	132	88.0	30.3	80.8	21.4	7.2***	23.7	7.1***	1.3	
Week 12	103	87.9	21.8	79.4	20.5	8.6***	11.5	8.4***	1.2	I
Week 26	91	86.8	21.7	79.9	20.8	6.9***	14.1	6.6***	1.4	I
Final on-therapy	132	87.9	21.3	80.8	21.4	7.1***	14.0	6.9***	1.2	
DVS SR 200 mg										
Week 4	124	92.5	26.9	86.5	28.0	6.0***	10.7	6.3***	1.3	
Week 12	96	96.3	29.9	86.8	29.0	9.4***	13.4	9.7***	1.2	J
Week 26	83	95.2	29.0	87.5	29.5	7.7***	16.6	8.4***	1.5	J
Final on-therapy	124	93.2	28.1	86.5	28.0	6.7***	15.1	7.2***	1.2	
Placebo										
Week 4	76	83.5	26.2	80.2	23.5	3.3**	10.1	3.2	1.7	
Week 12	66	81.8	22.5	79.6	22.3	2.2	9.8	2.0	1.4	
Week 26	59	77.9	19.0	76.5	15.6	1.5	13.3	0.7	1.8	
Final on-therapy	77	83.9	26.6	80.3	23.4	3.7*	13.9	3.4*	1.6	

Table 10.4.4-1: Baseline Mean and Mean Changes From Baseline for Selected Laboratory Tests

Treatment	-	Obse	rved	Base	eline	Cha	nge	Adj	usted b	Between- Group
Data Analysis Interval ^a	n	Mean	SD	Mean	SD	Mean	SD	Mean	SE	p-Value ^c
Total cholesterol/lipid (fasting	g), mmol/	L								
DVS SR 50 mg										
Week 4	134	5.609	0.968	5.774	0.986	-0.165*	0.753	-0.177**	0.055	B,C
Week 12	116	5.642	0.977	5.722	0.996	-0.080	0.725	-0.090	0.064	C
Week 26	99	5.689	0.942	5.687	0.949	0.003	0.696	-0.019	0.076	
Final on-therapy	139	5.716	0.935	5.781	1.003	-0.064	0.894	-0.077	0.065	C
DVS SR 100 mg										
Week 4	138	5.685	0.989	5.766	1.082	-0.082	0.649	-0.096	0.054	
Week 12	119	5.660	1.004	5.752	1.103	-0.091	0.785	-0.092	0.063	F
Week 26	108	5.760	1.048	5.735	1.100	0.024	0.877	0.020	0.073	
Final on-therapy	139	5.869	0.999	5.769	1.079	0.100	0.838	0.083	0.065	
DVS SR 150 mg										
Week 4	132	5.801	0.995	5.758	1.038	0.043	0.721	0.025	0.055	I
Week 12	103	5.638	0.904	5.620	1.004	0.017	0.761	-0.028	0.068	
Week 26	91	5.679	0.927	5.673	1.007	0.006	0.844	-0.022	0.079	
Final on-therapy	132	5.905	1.071	5.758	1.038	0.147*	0.727	0.126	0.067	
DVS SR 200 mg										
Week 4	119	5.914	0.903	5.887	0.911	0.027	0.630	0.046	0.058	J
Week 12	96	5.918	1.014	5.805	0.909	0.113	0.910	0.131	0.071	J
Week 26	83	5.842	1.031	5.793	0.902	0.049	0.972	0.066	0.083	J
Final on-therapy	120	5.928	0.981	5.884	0.908	0.045	0.960	0.070	0.070	
Placebo										
Week 4	72	5.788	0.875	6.007	0.837	-0.219*	0.707	-0.167*	0.075	
Week 12	65	5.660	0.751	5.943	0.842	-0.282***	0.580	-0.218*	0.086	
Week 26	58	5.649	0.859	5.920	0.841	-0.271**	0.764	-0.207*	0.099	
Final on-therapy	77	5.854	0.925	5.952	0.854	-0.098	0.825	-0.047	0.088	

Table 10.4.4-1: Baseline Mean and Mean Changes From Baseline for Selected Laboratory Tests

Treatment	-	Obse	rved	Base	eline	Cha	nge	Adj	usted ^b	Between- Group	
Data Analysis Interval ^a	n	Mean	SD	Mean	SD	Mean	SD	Mean	SE	p-Value ^c	
HDL cholesterol (fasting), mr	nol/L										
DVS SR 50 mg											
Week 4	134	1.677	0.450	1.710	0.457	-0.033	0.211	-0.031	0.017	C	
Week 12	116	1.674	0.444	1.685	0.466	-0.011	0.192	-0.010	0.021		
Week 26	99	1.647	0.438	1.688	0.464	-0.041*	0.204	-0.041	0.024		
Final on-therapy	139	1.628	0.429	1.697	0.456	-0.070***	0.240	-0.067***	0.020		
DVS SR 100 mg											
Week 4	138	1.682	0.421	1.683	0.411	-0.001	0.187	-0.002	0.017		
Week 12	119	1.644	0.446	1.670	0.425	-0.026	0.226	-0.027	0.020		
Week 26	108	1.644	0.499	1.662	0.399	-0.018	0.317	-0.021	0.023		
Final on-therapy	139	1.644	0.443	1.682	0.410	-0.038	0.235	-0.038	0.020		
DVS SR 150 mg											
Week 4	132	1.720	0.477	1.699	0.445	0.021	0.186	0.022	0.017	I	
Week 12	103	1.729	0.501	1.703	0.460	0.026	0.256	0.028	0.022		
Week 26	91	1.723	0.505	1.717	0.471	0.005	0.248	0.009	0.026		
Final on-therapy	132	1.673	0.450	1.699	0.445	-0.027	0.259	-0.024	0.020		
DVS SR 200 mg											
Week 4	119	1.641	0.459	1.634	0.416	0.007	0.216	0.003	0.018		
Week 12	96	1.627	0.414	1.604	0.395	0.023	0.214	0.016	0.023		
Week 26	83	1.579	0.376	1.593	0.380	-0.014	0.223	-0.023	0.027		
Final on-therapy	120	1.608	0.419	1.630	0.416	-0.023	0.224	-0.031	0.021		
Placebo											
Week 4	72	1.669	0.460	1.714	0.439	-0.045	0.209	-0.043	0.024		
Week 12	65	1.722	0.440	1.751	0.411	-0.029	0.246	-0.022	0.028		
Week 26	58	1.737	0.403	1.796	0.400	-0.060*	0.187	-0.048	0.032		
Final on-therapy	77	1.665	0.445	1.713	0.434	-0.048	0.262	-0.044	0.027		

Table 10.4.4-1: Baseline Mean and Mean Changes From Baseline for Selected Laboratory Tests

Treatment	-	Obse	rved	Base	eline	Cha	nge	Adj	usted b	Between- Group	
Data Analysis Interval ^a	n	Mean	SD	Mean	SD	Mean	SD	Mean	SE	p-Value ^c	
LDL cholesterol (fasting), mn	nol/L									<u>-</u>	
DVS SR 50 mg											
Week 4	134	3.359	0.879	3.486	0.905	-0.127*	0.691	-0.141**	0.050	C	
Week 12	115	3.384	0.918	3.456	0.918	-0.072	0.633	-0.080	0.059	C	
Week 26	99	3.387	0.869	3.432	0.823	-0.045	0.654	-0.060	0.070		
Final on-therapy	139	3.480	0.832	3.504	0.922	-0.024	0.810	-0.036	0.057		
DVS SR 100 mg											
Week 4	137	3.439	0.906	3.520	0.959	-0.081	0.560	-0.086	0.050		
Week 12	119	3.394	0.911	3.503	0.965	-0.110	0.682	-0.102	0.058	F	
Week 26	107	3.470	0.904	3.507	0.962	-0.036	0.813	-0.025	0.067		
Final on-therapy	139	3.595	0.874	3.520	0.956	0.075	0.718	0.069	0.057		
DVS SR 150 mg											
Week 4	132	3.479	0.892	3.467	0.968	0.012	0.685	-0.008	0.051		
Week 12	103	3.298	0.818	3.335	0.933	-0.037	0.713	-0.084	0.062	Н	
Week 26	89	3.296	0.883	3.351	0.969	-0.055	0.755	-0.098	0.074		
Final on-therapy	132	3.577	0.964	3.467	0.968	0.109	0.638	0.083	0.059		
DVS SR 200 mg											
Week 4	119	3.663	0.863	3.633	0.839	0.030	0.577	0.057	0.054	J	
Week 12	96	3.652	0.953	3.580	0.825	0.073	0.823	0.105	0.064	J	
Week 26	83	3.616	0.968	3.574	0.789	0.041	0.876	0.077	0.076	J	
Final on-therapy	120	3.648	0.895	3.633	0.836	0.015	0.829	0.050	0.061		
Placebo											
Week 4	70	3.462	0.796	3.636	0.744	-0.174*	0.656	-0.147*	0.070		
Week 12	65	3.361	0.665	3.569	0.740	-0.207**	0.552	-0.179*	0.078		
Week 26	58	3.339	0.823	3.531	0.742	-0.192*	0.633	-0.172	0.091		
Final on-therapy	76	3.546	0.824	3.608	0.765	-0.062	0.742	-0.036	0.077		

Table 10.4.4-1: Baseline Mean and Mean Changes From Baseline for Selected Laboratory Tests

Treatment	-	Obse	rved	Bas	eline	Chai	1ge	Adju	isted b	Between- Group
Data Analysis Interval ^a	n	Mean	SD	Mean	SD	Mean	SD	Mean	SE	p-Value ^c
Triglycerides /lipid (fasting), m	mol/L									
DVS SR 50 mg										
Week 4	134	1.25125	0.66649	1.24587	0.62344	0.00539	0.46448	-0.00351	0.04050	
Week 12	116	1.28959	0.75005	1.24230	0.64135	0.04730	0.52542	0.03642	0.04493	
Week 26	99	1.43076	0.84204	1.23700	0.64790	0.19376***	0.49088	0.18584***	0.05604	D
Final on-therapy	139	1.32954	0.63621	1.25068	0.61873	0.07886	0.49076	0.06960	0.04821	
DVS SR 100 mg										
Week 4	138	1.25721	0.71180	1.23904	0.69910	0.01817	0.54169	0.00803	0.03992	
Week 12	119	1.35870	0.68927	1.26107	0.71306	0.09763*	0.48696	0.09106*	0.04435	G
Week 26	108	1.42558	0.79078	1.24975	0.71490	0.17584**	0.54327	0.17015**	0.05364	G
Final on-therapy	139	1.39095	0.80809	1.23800	0.69667	0.15294**	0.62325	0.14095**	0.04823	
DVS SR 150 mg										
Week 4	132	1.31264	0.67393	1.29185	0.64539	0.02079	0.42372	0.02028	0.04078	
Week 12	103	1.35535	0.73749	1.27226	0.64313	0.08309	0.46767	0.07908	0.04766	I
Week 26	91	1.44735	0.86926	1.29115	0.67079	0.15620*	0.70752	0.15776**	0.05842	I
Final on-therapy	132	1.44350	0.75621	1.29185	0.64539	0.15165**	0.57890	0.15125**	0.04945	
DVS SR 200 mg										
Week 4	119	1.32729	0.72715	1.35101	0.72456	-0.02371	0.43044	-0.01345	0.04298	
Week 12	96	1.39515	0.73104	1.35586	0.74440	0.03929	0.54854	0.05442	0.04941	
Week 26	83	1.40948	0.78570	1.36147	0.76717	0.04802	0.60649	0.06190	0.06125	
Final on-therapy	120	1.45275	0.89565	1.35170	0.72155	0.10105	0.69610	0.11352*	0.05190	
Placebo										
Week 4	72	1.44764	0.90566	1.40420	0.68105	0.04344	0.58063	0.06339	0.05531	
Week 12	65	1.26084	0.57128	1.35724	0.57114	-0.09640	0.50604	-0.08096	0.06003	
Week 26	58	1.25280	0.52029	1.29252	0.51737	-0.03971	0.42300	-0.03791	0.07318	
Final on-therapy	77	1.42856	0.76062	1.38487	0.66587	0.04369	0.48788	0.06330	0.06482	

Abbreviations: SD=standard deviation and SE=standard error.

a. All analyses were done independently by data analysis interval by using data with nonmissing baseline values.

b. Adjusted means of change account for unbalance among treatments with respect to all other effects in model. Their standard errors are based on the pooled data across all treatments. Adjusted means should be interpreted with caution for small sample sizes.

Table 10.4.4-1: Baseline Mean and Mean Changes From Baseline for Selected Laboratory Tests

Treatment		Obser	ved	Base	eline	Cha	nge	Adju	ısted ^b	Between- Group
Data Analysis Interval ^a	n	Mean	SD	Mean	SD	Mean	SD	Mean	SE	p-Value c

c. Comparison based on adjusted mean changes from baseline using ANCOVA with baseline as the covariate. Significant ($p \le 0.05$) differences between groups are shown only if the overall comparison was significant: A=DVS SR 50 mg vs DVS SR 100 mg; B=DVS SR 50 mg vs DVS SR 150 mg; C=DVS SR 50 mg vs DVS SR 200 mg; D=DVS SR 50 mg vs placebo; E=DVS SR 100 mg vs DVS SR 150 mg; F=DVS SR 100 mg vs DVS SR 200 mg; G=DVS SR 100 mg vs placebo; and J=DVS SR 200 mg vs placebo. Statistical significance at the 0.05, 0.01, and 0.001 levels is denoted by *, **, and ***, respectively, for within-group comparisons.

Source: LAB3 V2

Subjects in at least 1 DVS SR treatment group experienced significant changes in adjusted mean values from baseline at week 12 or the final on-therapy evaluation for creatinine, total bilirubin, SGOT/AST, SGPT/ALT, alkaline phosphatase, HDL-C, and triglycerides.

In addition, there were significant differences between at least 1 DVS SR treatment group and the placebo group in the adjusted mean changes from baseline at week 12 or the final on-therapy evaluation for total bilirubin, SGOT/AST, SGPT/ALT, alkaline phosphatase, total cholesterol, LDL-C, and triglycerides.

Creatinine

Small (less than 3 μ mol/L) not clinically but statistically significant increases from baseline in adjusted mean creatinine values were observed for the 50-mg and 100-mg DVS SR groups at the final on-therapy evaluation.

There were no statistically significant differences between the DVS SR groups and the placebo group at any dose and at any time point.

Total Bilirubin

Statistically significant decreases from baseline in adjusted mean total bilirubin values were observed for all DVS SR groups at all on-therapy time points except for the 50-mg DVS SR dose at week 4. These decreases were small and not clinically meaningful.

In all DVS SR groups, the decrease in adjusted mean total bilirubin values for at least 1 time point was significantly different from that in the placebo group.

SGOT/AST

In the DVS SR 50-mg, 100-mg, and 150-mg groups, statistically significant increases from baseline in adjusted mean SGOT/AST values were observed at the week 12 or the final ontherapy evaluations. These increases (less than 5 mU/mL)were small and not clinically meaningful.

CONFIDENTIAL 113 Wyeth

The increases in adjusted mean SGOT/AST values at week 12 for the 50-mg, 100-mg, and 150-mg DVS SR groups were significantly different from the decrease in the placebo group.

SGPT/ALT

No significant increases from baseline in adjusted mean SGPT/ALT values were observed at any time point for any DVS SR group.

The changes in adjusted mean SGPT/ALT values at week 12 for the 50-mg and 200-mg DVS SR group were significantly different from the decreases in the placebo group.

Alkaline Phosphatase

Small (less than 10 mU/mL) but statistically significant increases in adjusted mean alkaline phosphatase values were observed in all DVS SR groups at all time points. There was a trend toward greater increase with increasing DVS SR doses. No subject had a clinically important increase in alkaline phosphatase.

The increases in mean adjusted alkaline phosphatase values at week 12 for the 100-mg, 150-mg, and 200-mg DVS SR groups were significantly different from those in the placebo group.

Fasting Total Cholesterol

No significant changes from baseline were observed for the adjusted mean fasting total cholesterol levels in any DVS SR group at the week 12 or the final on-therapy evaluations.

However, the decreases in adjusted mean total cholesterol values observed for the placebo group were significantly different from the changes in the 200-mg DVS SR groups at most time points.

HDL-C

Small but statistically significant decreases (up to -0.067 mmol/L=-2.4 mg/dL) in adjusted mean HDL-C values were observed at the final on-therapy evaluation for the 50-mg DVS SR group. No significant changes from baseline in adjusted mean HDL-C values were observed for any other DVS SR group.

CONFIDENTIAL 114 Wyeth

LDL-C

No significant changes from baseline were observed in the adjusted mean fasting LDL-C levels for any DVS SR group at the week 12 or the final on-therapy evaluations.

The small and insignificant increases from baseline adjusted mean LDL-C values in the 200-mg DVS SR group were significantly different from decreases in the placebo group at most time points.

Triglycerides

Small (up to 0.18 mmol/L or 16 mg/dL) but statistically significant increases in adjusted mean triglyceride values were observed for at least 1 time point in each DVS SR group.

The changes in adjusted mean triglyceride values at week 12 for the 100-mg and 150-mg DVS SR groups were significantly different from the changes in the placebo group.

10.5 Vital Signs, Physical Findings, and Other Observations Related to Safety

10.5.1 Vital Signs

10.5.1.1 Criteria for Determining Values of Potential Clinical Importance

All data on vital signs and weight measurements for individual subjects were screened against reference interval criteria (Table 10.5.1.1-1) that, if exceeded, would be considered of potential clinical importance. The criteria were specified by Wyeth Research, or, in some cases, criteria specified by the FDA, Neuropharm Division, for the DVS SR Major Depressive Disorder program were used.

CONFIDENTIAL 115 Wyeth

Table 10.5.1.1-1: Criteria for Determining Potentially Clinically Important Vital Signs and Weight Results

Variable	Criteria ^a
Supine or standing systolic blood pressure b	Increase of \geq 30 mm Hg and value \geq 160 mm Hg or
	decrease of ≥20 mm Hg and value ≤90 mm Hg
Supine or standing diastolic blood pressure b	Increase of ≥ 20 mm Hg and value ≥ 100 mm Hg or
	decrease of \geq 15 mm Hg and value \leq 50 mm Hg
Supine pulse rate ^c	Increase of \geq 15 beats/min and \geq 120 beats/min
	Decrease of \geq 15 beats/min and \leq 50 beats/min
Postural orthostatic blood pressure change ^c	Decrease of ≥15 mm Hg diastolic last supine to first
	standing or decrease of ≥ 30 mm Hg systolic last supine
	to first standing
Weight ^d	Change of ≥7% in body weight

- a. All increases and decreases are compared with baseline.
- b. Baseline is defined as the average of all values before first dose of test article.
- c. Criteria defined by the US Food and Drug Administration (Neuropharm Division).
- d. Baseline was defined as the last measurement before first dose of test article.

Source: Statistical Analysis Plan

10.5.1.2 Summary of Subjects With Values of Potential Clinical Importance

Table 10.5.1.2-1 summarizes the numbers of subjects with potentially clinically important results in vital signs and weight measurements at any time during the on-therapy period. If no subject had potentially clinically important results for a given criterion, that category was not listed in the table. Supportive Table ST 10-11 provides a summary tabulation of the number and percentage of subjects with vitals signs or weight measurements of potential clinical importance, by data analysis interval and therapy.

More subjects in the placebo group reported potentially important decreases in pulse rate compared with subjects in DVS SR groups.

CONFIDENTIAL 116 Wyeth

Table 10.5.1.2-1: Number (%) of Subjects With Vital Signs of Potential Clinical Importance/Number of Subjects Tested, On-Therapy Period

	Overall	Overall DVS SR		DVS	SR	DVS	SR	DVS	SR		
Category	p-Value ^a	50 1	mg	100	mg	150	mg	200	mg	Plac	eebo
Total	0.420	33/140	(23.6)	44/136	(32.4)	32/128	(25.0)	28/111	(25.2)	17/76	(22.4)
Weight, kg											
Decrease	0.431	9/140	(6.4)	13/136	(9.6)	9/128	(7.0)	7/111	(6.3)	2/76	(2.6)
Increase	0.389	17/140	(12.1)	22/136	(16.2)	18/128	(14.1)	11/111	(9.9)	6/76	(7.9)
Postural blood pressure	change										
Systolic BP, mm Hg	0.584	2/140	(1.4)	2/136	(1.5)	2/127	(1.6)	1/111	(0.9)	3/76	(3.9)
Diastolic BP, mm Hg	0.202	2/140	(1.4)	3/136	(2.2)	5/127	(3.9)	2/111	(1.8)	5/76	(6.6)
Standing blood pressure											
Systolic BP, mm Hg											
Decrease	0.842	5/140	(3.6)	3/136	(2.2)	2/127	(1.6)	2/111	(1.8)	2/76	(2.6)
Increase	0.460	1/140	(0.7)	2/136	(1.5)	1/127	(0.8)	3/111	(2.7)	0/76	
Diastolic BP, mm Hg											
Decrease	0.148	0/140		0/136		0/127		0/111		1/76	(1.3)
Increase	0.193	1/140	(0.7)	5/136	(3.7)	3/127	(2.4)	1/111	(0.9)	0/76	
Supine blood pressure											
Systolic BP, mm Hg											
Decrease	0.813	1/140	(0.7)	2/136	(1.5)	3/127	(2.4)	1/111	(0.9)	1/76	(1.3)
Increase	0.299	2/140	(1.4)	2/136	(1.5)	4/127	(3.1)	6/111	(5.4)	3/76	(3.9)
Diastolic BP, mm Hg											
Increase	0.163	0/140		3/136	(2.2)	5/127	(3.9)	1/111	(0.9)	2/76	(2.6)
Supine pulse, beats/min											
Decrease	<0.001***	0/140		0/136		0/127		0/111		3/76	(3.9)

Abbreviation: BP=blood pressure.

Statistical significance at the 0.001 level is denoted by ***.

Source: VS5_OT 28NOV05 17:12

10.5.1.3 Individual Clinically Important Vital Signs and Weight Results

After examining the blinded records for each subject identified as having potentially clinically important vitals signs results, the sponsor determined that 5 subjects who received placebo and 24 subjects who received DVS SR had clinically important vitals signs and weight results. These subjects are identified in Table 10.5.1.3-1. Additional details about these subjects are provided in the subject narratives in Supportive Table ST 10-8.

a. Overall p-value from chi-square test.

Table 10.5.1.3-1: Subjects Who Had Clinically Important Changes in Vital Signs or Weight Results

		Subjects With	1
Vital Sign	Treatment	Event, n	Subject Number
Orthostatic hypotension	Placebo	2	315-208-201360 315-213-201621
	DVS SR 50 mg	1	315-218-201878
	DVS SR 100 mg	1	315-228-203682
	DVS SR 150 mg	3	315-204-201157 315-208-201359
	Č		315-208-201364
	DVS SR 200 mg	1	315-231-202509
Sustained hypertension	DVS SR 50 mg	3	315-233-202629 315-240-202906
21	Č		315-242-203001
	DVS SR 100 mg	1	315-240-202921
	DVS SR 150 mg	2	315-217-201819 315-239-202882
Increased systolic blood pressure	Placebo	3	315-206-201285 315-208-201360
1			315-236-202704
	DVS SR 50mg	1	315-203-203531
	DVS SR 100 mg	2	315-228-203701 315-231-202530
	DVS SR 150 mg	2	315-203-203514 315-206-201297
	DVS SR 200 mg	5	315-206-201254 315-216-201767
			315-218-201875 315-232-202566
			315-235-202666
Increased diastolic blood pressure	Placebo	2	315-236-202704 315-239-202852
	DVS SR 100 mg	1	315-217-201830
	DVS SR 150 mg	3	315-206-201297 315-208-201359
	8		315-225-202206
	DVS SR 200 mg	1	315-235-202666

Source: Report narr-sum-1 20DEC05 11:20 [DEV]

The remaining subjects identified by the screening criteria were not considered to have clinically important results. The results were isolated or transient, were unrelated to adverse events or discontinuations, or were inconsistent with the rest of the clinical picture.

10.5.1.4 Mean Vital Signs and Weight Results

Changes from baseline in mean values for vital signs and weight measurements were evaluated for within- and between-group differences by using ANCOVA with treatment as a factor and baseline value as a covariate. The mean results for selected vital sign measurements (supine pulse, supine systolic blood pressure, and supine diastolic blood pressure) and for weight for selected time points are presented in Table 10.5.1.4-1. Comparisons of between- and within-

group differences are also presented. The mean data for all vital signs and weight measurements at all time points are provided in Supportive Table ST 10-12.

CONFIDENTIAL 119 Wyeth

Table 10.5.1.4-1: Baseline Mean and Mean Changes From Baseline in Selected Vital Signs and Weight Results

-		Obse	erved	Base	eline	Cha	nge	Adjus	sted ^b	
Treatment										Between-Group
Data Analysis Interval ^a	n	Mean	SD	Mean	SD	Mean	SD	Mean	SE	p-Value ^c
Weight, kg										
DVS SR 50 mg										
Week 4	138	72.03	13.87	72.53	13.73	-0.50***	1.48	-0.50***	0.13	
Week 8	124	72.72	14.20	72.96	14.00	-0.24	1.59	-0.24	0.16	
Week 12	116	72.85	13.87	73.25	13.72	-0.41*	2.09	-0.40	0.21	
Final on-therapy	140	73.40	14.64	72.76	13.77	0.64	4.34	0.64	0.33	
DVS SR 100 mg										
Week 4	135	71.46	12.29	72.00	12.26	-0.54***	1.59	-0.55***	0.14	
Week 8	125	72.00	12.34	72.26	12.13	-0.26	1.85	-0.27	0.16	
Week 12	118	72.11	12.74	72.58	12.52	-0.47*	2.46	-0.47*	0.21	
Final on-therapy	136	72.98	13.09	72.08	12.25	0.91*	4.25	0.90**	0.33	
DVS SR 150 mg										
Week 4	128	72.10	12.79	72.62	13.18	-0.52**	1.85	-0.52***	0.14	
Week 8	114	72.00	12.85	72.45	13.38	-0.45*	2.12	-0.45**	0.17	
Week 12	101	71.89	12.74	72.24	13.28	-0.35	2.51	-0.36	0.23	
Final on-therapy	128	73.15	13.00	72.62	13.18	0.53	3.92	0.53	0.35	
DVS SR 200 mg										
Week 4	111	72.99	12.14	73.44	12.07	-0.46**	1.61	-0.44**	0.15	
Week 8	96	73.34	11.98	73.53	12.03	-0.19	1.85	-0.18	0.19	
Week 12	96	73.15	11.96	73.44	12.00	-0.29	2.15	-0.28	0.23	
Final on-therapy	111	74.66	12.40	73.44	12.07	1.22***	3.38	1.23***	0.37	
Placebo										
Week 4	76	71.40	13.07	71.60	13.23	-0.20	1.16	-0.21	0.18	
Week 8	71	71.64	13.12	71.76	13.24	-0.12	1.72	-0.14	0.22	
Week 12	64	71.61	12.40	71.96	12.51	-0.34	2.09	-0.36	0.28	
Final on-therapy	76	71.73	13.30	71.60	13.23	0.13	2.98	0.12	0.45	
1.0										

Table 10.5.1.4-1: Baseline Mean and Mean Changes From Baseline in Selected Vital Signs and Weight Results

-		Obse	rved	Base	eline	Cha	inge	Adju	sted ^b	
Treatment										Between-Group
Data Analysis Interval ^a	n	Mean	SD	Mean	SD	Mean	SD	Mean	SE	p-Value ^c
Supine systolic BP, mm Hg										
DVS SR 50 mg										
Week 4	139	121.17	13.47	119.83	11.49	1.34	10.62	0.67	0.95	
Week 8	124	120.44	12.90	119.30	11.69	1.13	10.12	0.17	0.98	D
Week 12	117	119.24	12.33	119.79	11.75	-0.56	9.51	-1.27	1.02	
Final on-therapy	140	121.41	14.40	119.79	11.46	1.62	11.81	0.77	1.00	
DVS SR 100 mg										
Week 4	135	122.64	14.50	122.75	12.58	-0.11	11.35	0.05	0.96	
Week 8	125	123.90	13.38	123.02	12.71	0.88	10.05	1.16	0.97	G
Week 12	118	121.72	15.41	122.62	13.13	-0.90	12.28	-0.74	1.01	
Final on-therapy	136	122.76	14.25	122.75	12.53	0.02	11.58	0.21	1.01	
DVS SR 150 mg										
Week 4	127	123.29	13.21	123.71	11.19	-0.42	12.60	0.01	0.99	
Week 8	114	125.22	14.36	123.95	11.14	1.27	12.63	1.85	1.02	I
Week 12	101	123.94	12.87	123.65	11.34	0.29	12.01	0.76	1.09	I
Final on-therapy	127	125.14	13.52	123.71	11.19	1.44	12.99	1.97	1.05	
DVS SR 200 mg										
Week 4	111	123.10	14.25	121.40	11.57	1.70	11.64	1.47	1.06	
Week 8	97	123.71	13.52	121.70	11.75	2.01	12.41	1.85	1.10	J
Week 12	95	122.43	14.96	121.51	11.90	0.92	12.84	0.74	1.12	J
Final on-therapy	111	123.66	13.44	121.40	11.57	2.26	13.08	1.98	1.12	
Placebo										
Week 4	76	122.61	15.30	124.30	12.58	-1.69	12.49	-1.11	1.29	
Week 8	71	119.96	12.90	123.67	12.60	-3.71*	13.12	-3.22*	1.29	
Week 12	64	120.27	12.86	123.84	12.97	-3.58*	10.89	-3.04*	1.37	
Final on-therapy	76	124.38	14.89	124.30	12.58	0.08	13.71	0.82	1.36	

CONFIDENTIAL 121 Wyeth

Table 10.5.1.4-1: Baseline Mean and Mean Changes From Baseline in Selected Vital Signs and Weight Results

-		Obse	rved	Base	eline	Cha	nge	Adjus	sted ^b	
Treatment										Between-Group
Data Analysis Interval a	n	Mean	SD	Mean	SD	Mean	SD	Mean	SE	p-Value ^c
Supine diastolic BP, mm Hg										
DVS SR 50 mg										
Week 4	139	77.03	8.41	76.18	7.53	0.85	6.17	0.77	0.58	
Week 8	124	74.94	8.65	75.64	7.56	-0.70	7.02	-0.95	0.65	A,B,C
Week 12	117	76.04	7.69	76.11	7.46	-0.06	6.51	-0.16	0.65	
Final on-therapy	140	77.03	8.35	76.15	7.51	0.88	7.05	0.75	0.62	
DVS SR 100 mg										
Week 4	135	77.76	8.39	76.28	6.62	1.49**	6.51	1.43*	0.59	
Week 8	125	77.26	8.60	76.36	6.69	0.90	6.93	0.91	0.64	
Week 12	118	77.42	9.00	76.27	6.80	1.14	7.50	1.11	0.64	
Final on-therapy	136	77.17	8.46	76.33	6.63	0.84	6.93	0.78	0.63	
DVS SR 150 mg										
Week 4	127	78.80	8.07	77.17	7.27	1.63*	8.05	1.84**	0.61	
Week 8	114	79.10	8.75	77.24	7.22	1.85*	7.92	2.16**	0.67	I
Week 12	101	77.70	8.39	76.94	7.30	0.76	7.90	0.99	0.70	
Final on-therapy	127	79.13	8.45	77.17	7.27	1.97*	8.78	2.28***	0.65	
DVS SR 200 mg										
Week 4	111	77.58	8.57	76.28	7.84	1.29	7.21	1.24	0.65	
Week 8	97	77.45	8.13	76.47	8.07	0.98	7.86	1.03	0.73	
Week 12	95	77.46	8.23	76.30	8.11	1.17	7.74	1.15	0.72	
Final on-therapy	111	78.53	8.29	76.28	7.84	2.25**	8.29	2.17**	0.69	
Placebo										
Week 4	76	76.68	9.86	76.30	8.14	0.38	8.31	0.34	0.78	
Week 8	71	75.38	9.55	75.93	8.19	-0.55	8.83	-0.69	0.85	
Week 12	64	75.42	8.70	76.05	8.42	-0.63	8.48	-0.74	0.87	
Final on-therapy	76	77.88	8.61	76.30	8.14	1.58	9.35	1.51	0.84	

CONFIDENTIAL 122 Wyeth

Table 10.5.1.4-1: Baseline Mean and Mean Changes From Baseline in Selected Vital Signs and Weight Results

		Obse	rved	Base	eline	Cha	nge	Adjus	sted ^b	
Treatment								· ·		Between-Group
Data Analysis Interval ^a	n	Mean	SD	Mean	SD	Mean	SD	Mean	SE	p-Value ^c
Supine pulse, beats/min										
DVS SR 50 mg										
Week 4	139	69.28	8.78	68.87	7.54	0.41	7.23	0.48	0.59	
Week 8	124	70.17	7.76	68.57	7.41	1.60*	7.93	1.55*	0.68	В
Week 12	117	69.28	9.44	68.78	7.40	0.50	8.46	0.62	0.71	D
Final on-therapy	140	69.59	8.95	68.87	7.51	0.71	7.67	0.79	0.65	B,D
DVS SR 100 mg										
Week 4	135	68.76	8.50	67.74	7.16	1.01	7.32	0.68	0.60	
Week 8	125	70.67	8.40	68.07	7.04	2.60***	8.31	2.33***	0.68	G
Week 12	118	68.59	8.28	67.81	7.21	0.78	9.01	0.43	0.70	G
Final on-therapy	136	70.17	8.08	67.78	7.15	2.39***	8.22	2.00**	0.66	
DVS SR 150 mg										
Week 4	127	70.23	8.29	69.00	8.03	1.23	7.72	1.34*	0.62	
Week 8	114	72.54	8.94	69.00	8.09	3.53***	8.26	3.67***	0.71	I
Week 12	101	70.44	8.50	68.83	8.08	1.60	8.28	1.74*	0.76	I
Final on-therapy	127	71.76	9.71	69.00	8.03	2.77***	9.02	2.90***	0.68	I
DVS SR 200 mg										
Week 4	111	71.30	8.07	69.72	6.90	1.58*	7.36	1.95**	0.66	
Week 8	97	72.63	9.39	69.83	7.05	2.80**	8.32	3.29***	0.77	J
Week 12	95	71.00	8.33	69.35	6.80	1.65	8.16	2.04**	0.78	J
Final on-therapy	111	72.30	8.56	69.72	6.90	2.58**	8.56	3.02***	0.73	J
Placebo										
Week 4	76	68.71	8.25	67.96	6.15	0.75	7.67	0.49	0.80	
Week 8	71	67.62	8.89	67.93	6.20	-0.31	8.22	-0.64	0.90	
Week 12	64	64.48	7.23	67.79	6.12	-3.30***	7.51	-3.67***	0.96	
Final on-therapy	76	68.79	7.83	67.96	6.15	0.83	7.96	0.51	0.88	

Abbreviations: SD=standard deviation and SE=standard error.

a. All analyses were done independently by data analysis interval by using data with nonmissing baseline values.

Table 10.5.1.4-1: Baseline Mean and Mean Changes From Baseline in Selected Vital Signs and Weight Results

		Obse	rved	Base	line	Cha	nge	Adjus	sted ^b	
Treatment										Between-Group
Data Analysis Interval ^a	n	Mean	SD	Mean	SD	Mean	SD	Mean	SE	p-Value ^c
b. Adjusted means of change a	ccount	for unbalar	ice amon	g treatments	with res	pect to all of	her effec	ts in model.	Their sta	andard errors are
based on the pooled data across	all tre	atments. Ac	ljusted m	ean changes	should b	oe interpreted	l with car	ution for sm	all samp	le sizes.
c. Comparison based on adjuste	ed mea	n changes f	rom base	line using A	NCOVA	with baseling	ne as the	covariate. S	ignifican	t (p≤0.05)
differences between groups are	shown	only if the	overall c	omparison w	vas signi	ficant: A=DV	/S SR 50	mg vs DVS	S SR 100	mg;
B=DVS SR 50 mg vs DVS SR	150 m	g; C=DVS S	SR 50 mg	g vs DVS SR	200 mg	; D=DVS SF	R 50 mg v	vs placebo; l	E=DVS S	SR 100 mg vs
DVS SR 150 mg; F=DVS SR 1	00 mg	vs DVS SR	200 mg	G=DVS SF	R 100 mg	ys placebo;	H=DVS	SR 150 mg	vs DVS	SR 200 mg;
I=DVS SR 150 mg vs placebo;	and J=	DVS SR 20	00 mg vs	placebo.						
Statistical significance at the 0.0	05, 0.0	1, and 0.00	l levels i	s denoted by	*, **, aı	nd ***, respe	ctively, 1	for within-gr	roup con	nparisons.

Source: VS3_V2 07NOV05 13:43

CONFIDENTIAL 124 Wyeth

Weight

Significant decreases (less than 0.5 kg) in adjusted mean weight were observed for all treatment groups at 1 or more of the early scheduled evaluations (up to week 12). Significant increases (up to 1.25 kg) in adjusted mean weight were observed at the final on-therapy evaluation for the 100-mg and 200-mg DVS SR groups.

No significant changes in adjusted mean weight values were observed in any DVS SR group compared with changes observed in the placebo group.

Supine Systolic and Diastolic Blood Pressure

No significant increases in adjusted mean supine systolic blood pressure were observed for any DVS SR group at any time point. However, the decreases in the adjusted mean supine systolic blood pressures for the placebo group were significantly different from those for the 50-mg and 100-mg DVS SR groups at week 8 and from those for the 150-mg and 200-mg DVS SR groups at most time points.

Small (less than 4 mm Hg) but statistically significant increases in adjusted mean supine diastolic blood pressure values were observed at week 4 for the 100-mg DVS SR group and at most time points for the 150-mg and 200-mg DVS SR groups. Significant differences from placebo were observed for the 150-mg DVS SR group at week 8 and for the 100-mg, 150-mg, and 200-mg DVS SR groups at time points greater than 12 weeks.

Supine Pulse Rate

Significant increases from baseline in adjusted mean supine pulse rates were observed for all DVS SR groups at most time points. There was a trend toward a dose-dependent increase in adjusted mean pulse rate with increasing therapy duration. There were no discontinuations because of increased pulse rates.

The increases in adjusted mean supine pulse rates were significantly higher than changes observed in the placebo group for the DVS SR 50-mg group at week 12 and for the DVS SR 100-mg, 150-mg, and 200-mg groups at most time points.

CONFIDENTIAL 125 Wyeth

10.5.2 Physical Findings and Other Observations Related to Safety

Routine physical examinations were done at the screening visit and at weeks 12, 26, and 52. Breast and pelvic examinations were done at the screening visit and at week 52. The sponsor reviewed the blinded information available regarding any changes in physical, breast, and pelvic findings and judged the clinical importance of the reported changes. None of the subjects had any clinically important changes in physical findings.

10.5.3 Electrocardiograms

10.5.3.1 Criteria for Determining Values of Potential Clinical Importance

Subjects with potentially clinically important findings in their ECGs were identified by the criteria shown in Table 10.5.3.1-1. ECGs were done at the screening visit and at weeks 12 and 52. These criteria were specified by Wyeth Research, or, in some cases, criteria specified by the FDA, Neuropharm Division, for the DVS SR Major Depressive Disorder program were used. QTc criteria were based on guidance from the European Agency for the Evaluation of Medicinal Products (EMEA) and from the FDA.

Table 10.5.3.1-1: Criteria for Determining Potentially Clinically Important Values in Adult Electrocardiogram Results

Evaluation	Criteria ^{a,b}
Heart rate b	Increase of \geq 15 beats/min and \geq 120 beats/min
	Decrease of \geq 15 beats/min and \leq 50 beats/min
PR interval ^c	≥200 ms
QT interval ^c	≥480 ms
QRS interval ^c	≥120 ms
QTcB and QTcF b,d	>470 ms or increase of \geq 60 ms
Rhythm ^b	Any rhythm other than sinus rhythm
Overall evaluation b	Any evaluation other than normal

Abbreviations: QTcB=QT correction using the Bazett formula and QTcF=QT correction using the Fridericia formula.

- a. All increases and decreases were compared with baseline.
- b. Criteria defined by Wyeth.
- c. Criteria defined by FDA (Neuropharm division).
- d. The QTc criteria were based on guidance from FDA and EMEA (Bazett's and Fridericia's corrections).

Source: Statistical Analysis Plan

CONFIDENTIAL 126 Wyeth

10.5.3.2 Summary of Subjects With ECG Values of Potential Clinical Importance

Table 10.5.3.2-1 summarizes the numbers of subjects with potentially clinically important ECG results at any time during the on-therapy period. If no subject had potentially clinically important values for a given criterion, that category was not listed in the table. Supportive Table ST 10-13 provides a summary tabulation of the number and percentage of subjects with ECG results of potential clinical importance, by data analysis interval and therapy.

No significant difference between groups was observed in the number or percentage of subjects meeting PCI criteria for ECG results.

CONFIDENTIAL 127 Wyeth

Table 10.5.3.2-1: Number (%) of Subjects With ECG Results of Potential Clinical Importance/Number of Subjects Tested, On-Therapy Period

	Overall	DVS SR	DVS SR	DVS SR	DVS SR	
Category	p-Value ^a	50 mg	100 mg	150 mg	200 mg	Placebo
Total ECG	0.092	24/125 (19.2	26/125 (20.8)	19/110 (17.3)	12/103 (11.7)	20/71 (28.2)
Overall evaluation not normal	0.143	17/125 (13.6)	21/125 (16.8)	17/110 (15.5)	9/103 (8.7)	16/71 (22.5)
Heart rate, beats/min						
Decrease	0.164	0/124	0/125	0/110	0/103	1/71 (1.4)
Rhythm						
Not sinus	0.729	5/125 (4.0)	5/125 (4.0)	3/110 (2.7)	2/103 (1.9)	4/71 (5.6)
PR interval, ms						
High	0.334	5/124 (4.0)	6/125 (4.8)	2/109 (1.8)	2/103 (1.9)	5/71 (7.0)
QRS interval, ms						
High	0.834	0/124	1/125 (0.8)	1/110 (0.9)	1/103 (1.0)	1/71 (1.4)
QTcB interval, ms						
Increase	0.973	2/124 (1.6)	1/125 (0.8)	1/110 (0.9)	1/103 (1.0)	1/71 (1.4)
QTcF interval, ms						
Increase	0.508	1/124 (0.8)	0/125	0/110	0/103	0/71
QT interval, ms						
High	0.683	1/124 (0.8)	1/125 (0.8)	0/110	0/103	0/71

Abbreviations: QTcB=QT correction using the Bazett formula; QTcF=QT correction using the Fridericia formula. a. Overall p-value from chi-square test.

Source: ECG5 OT 15NOV05 09:52

10.5.3.3 Individual Clinically Important ECG Results

After examining the blinded records for each subject identified as having potentially clinically important ECG results, the sponsor determined that 3 DVS SR-treated subjects had clinically important ECG findings. These subjects are identified in Table 10.5.3.3-1. Additional details about these subjects are provided in the subject narratives in Supportive Table ST 10-8.

Table 10.5.3.3-1: Subjects With Clinically Important Electrocardiogram Changes

		Subjects With	ı	
Vital Sign	Treatment	Event, n	Subject Number	
QT interval	DVS SR 50 mg	1	315-213-201604	
	DVS SR 100 mg	1	315-231-202530	
QTcF interval	DVS SR 50 mg	1	315-218-201883	

Abbreviation: QTcF=QT correction using the Fridericia formula.

Source: CLINICAL R&D/CLINICAL PROGRAMMING SAS REPORTS/3151A2 /P315/ SUBJECT

NARRATIVES Report narr-sum-1 20DEC05 11:20 [DEV]

The remaining subjects who were identified by the screening criteria for ECG results of potential clinical importance were considered to have ECG results that were not clinically important because they were isolated, transient, unrelated to adverse events or discontinuation, or inconsistent with the rest of the clinical picture.

10.5.3.4 Mean ECG Results

Changes from baseline in mean values for ECG measurements were evaluated for within- and between-group differences by using ANCOVA with treatment as a factor and baseline value as a covariate. The results for heart rate, PR interval, QRS interval, QTcF interval, and QT interval are presented in Table 10.5.3.4-1. The data for all ECG values at all evaluations are provided in Supportive Table ST 10-14.

CONFIDENTIAL 129 Wyeth

Table 10.5.3.4-1: Baseline Mean and Mean Changes From Baseline in Selected ECG Results

	Obs	erved	Basel	ine	Cha	nge	Adju	ısted ^b	
Treatment						O	· ·		Between-Group
Data Analysis Interval a n	Mean	SD	Mean	SD	Mean	SD	Mean	SE	p-Value ^c
Heart rate, beats/min									
DVS SR 50 mg									
Week 12 116	63.47	9.18	63.61	9.74	-0.15	7.38	-0.07	0.61	B,C
Week 52 82	64.12	8.41	62.39	8.32	1.73*	7.07	1.25	0.78	B,C
Final on-therapy 123	64.11	8.61	63.30	9.63	0.80	7.39	0.79	0.64	A,B,C
DVS SR 100 mg									
Week 12 119	64.46	8.14	62.94	9.29	1.52*	8.35	1.31*	0.60	E,G
Week 52 82	66.32	8.06	63.83	9.80	2.49**	8.39	2.70***	0.78	
Final on-therapy 125	66.14	8.91	62.97	9.35	3.17***	8.14	3.01***	0.63	E,G
DVS SR 150 mg									
Week 12 100	66.55	8.76	63.16	9.82	3.39***	7.51	3.28***	0.66	I
Week 52 68	68.01	8.92	63.96	9.25	4.06***	9.07	4.33***	0.85	
Final on-therapy 109	68.17	9.73	63.20	9.57	4.96***	8.68	4.90***	0.68	I
DVS SR 200 mg									
Week 12 95	67.13	8.28	64.75	9.93	2.38**	7.93	2.93***	0.68	J
Week 52 60	68.18	9.04	63.97	10.30	4.22***	8.24	4.50***	0.91	
Final on-therapy 103	67.71	8.57	64.53	9.70	3.17***	8.09	3.68***	0.70	J
Placebo									
Week 12 65	61.63	8.29	62.49	8.17	-0.86	6.93	-1.26	0.82	
Week 52 43	64.84	8.03	62.77	8.71	2.07	9.35	1.77	1.07	
Final on-therapy 71	63.52	8.27	62.54	8.10	0.99	8.30	0.64	0.84	

CONFIDENTIAL 130 Wyeth

Table 10.5.3.4-1: Baseline Mean and Mean Changes From Baseline in Selected ECG Results

		Obse	erved	Basel	ine	Cha	nge	Adju	sted ^b	
Treatment Data Analysis Interval ^a	n	Mean	SD	Mean	SD	Mean	SD	Mean	SE	Between-Group p-Value ^c
PR interval, ms										•
DVS SR 50 mg										
Week 12	116	155.05	21.76	157.14	20.90	-2.09	13.44	-2.54*	1.22	D
Week 52	82	156.52	21.41	158.16	21.77	-1.63	13.57	-2.32	1.58	
Final on-therapy	123	154.72	21.45	156.92	20.90	-2.20	13.37	-2.68*	1.23	D
DVS SR 100 mg										
Week 12	119	156.61	22.16	159.84	24.14	-3.24**	12.82	-2.84*	1.21	G
Week 52	82	157.84	22.56	160.34	23.63	-2.50	14.36	-2.28	1.58	
Final on-therapy	125	156.88	21.79	159.16	24.05	-2.28	13.14	-1.95	1.22	
DVS SR 150 mg										
Week 12	99	156.71	21.06	161.41	30.46	-4.71*	19.66	-3.82**	1.33	I
Week 52	67	156.18	19.45	162.84	33.48	-6.66*	26.30	-5.40**	1.75	I
Final on-therapy	108	157.00	18.89	160.76	29.73	-3.76	22.22	-2.84*	1.31	I
DVS SR 200 mg										
Week 12	93	151.26	16.91	155.70	20.11	-4.44**	15.00	-5.34***	1.37	J
Week 52	60	154.38	15.61	157.72	20.94	-3.33	16.63	-4.20*	1.85	J
Final on-therapy	101	153.10	16.66	156.31	19.84	-3.21*	15.79	-3.92**	1.36	J
Placebo										
Week 12	65	161.02	24.11	158.65	24.49	2.37	14.53	2.39	1.63	
Week 52	43	162.30	23.08	160.12	26.21	2.19	15.68	2.32	2.19	
Final on-therapy	71	159.76	22.57	157.90	23.90	1.86	15.06	1.73	1.62	
QRS interval, ms										
DVS SR 50 mg										
Screening/baseline	148	82.09	6.74	82.09	6.74					
Week 12	116	81.79	6.63	81.96	6.82	-0.16	7.34	-0.33	0.64	D
Week 52	82	83.49	6.67	81.76	6.70	1.73*	7.39	1.39	0.74	
Final on-therapy	123	83.10	6.50	81.82	6.68	1.28	7.27	0.95	0.62	

CONFIDENTIAL 131 Wyeth

Table 10.5.3.4-1: Baseline Mean and Mean Changes From Baseline in Selected ECG Results

		Obse	erved	Basel	ine	Cha	nge	Adju	isted ^b	
Treatment							8	J		Between-Group
Data Analysis Interval ^a	n	Mean	SD	Mean	SD	Mean	SD	Mean	SE	p-Value ^c
DVS SR 100 mg										
Week 12	119	82.77	9.25	82.56	8.56	0.21	8.77	0.30	0.63	
Week 52	82	83.40	8.54	83.05	9.34	0.35	8.61	0.68	0.74	
Final on-therapy	125	82.39	7.92	82.39	8.48	0.00	8.59	-0.02	0.61	G
DVS SR 150 mg										
Week 12	100	82.83	9.41	82.93	11.51	-0.10	8.45	0.15	0.69	
Week 52	68	84.75	10.41	82.43	12.21	2.32*	8.14	2.33**	0.81	
Final on-therapy	109	84.38	9.60	83.06	11.19	1.31	9.07	1.66*	0.65	Н
DVS SR 200 mg										
Week 12	95	80.78	8.21	81.56	8.48	-0.78	6.42	-1.11	0.71	J
Week 52	60	82.32	6.10	81.67	9.76	0.65	8.80	0.27	0.87	
Final on-therapy	103	81.76	6.54	82.16	8.86	-0.40	8.12	-0.54	0.67	J
Placebo										
Week 12	65	84.48	10.44	82.86	10.58	1.62	8.37	1.83*	0.86	
Week 52	43	85.19	9.03	83.44	12.05	1.74	9.77	2.28*	1.02	
Final on-therapy	71	85.38	9.36	82.93	10.39	2.45*	9.38	2.73***	0.81	
QTcF interval, ms										
DVS SR 50 mg										
Week 12	116	399.91	18.63	401.62	18.42	-1.71	16.88	-2.30	1.34	
Week 52	82	402.91	17.40	400.40	19.47	2.51	16.78	1.77	1.73	
Final on-therapy	123	400.98	17.78	401.49	18.06	-0.50	17.49	-1.17	1.35	
DVS SR 100 mg										
Week 12	119	402.23	19.65	401.87	19.09	0.36	14.93	-0.13	1.32	
Week 52	82	403.90	20.76	400.22	17.99	3.68*	15.77	2.86	1.73	
Final on-therapy	125	404.68	20.67	402.05	19.00	2.63	15.85	2.20	1.34	

CONFIDENTIAL 132 Wyeth

Table 10.5.3.4-1: Baseline Mean and Mean Changes From Baseline in Selected ECG Results

		Obse	erved	Basel	ine	Char	1ge	Adju	sted ^b	
Treatment							Ü	ŭ		Between-Group
Data Analysis Interval ^a	n	Mean	SD	Mean	SD	Mean	SD	Mean	SE	p-Value ^c
DVS SR 150 mg										
Week 12	100	404.50	16.56	406.30	18.70	-1.80	17.20	-0.46	1.44	
Week 52	68	405.81	19.51	405.68	17.67	0.13	21.06	1.60	1.91	
Final on-therapy	109	404.63	17.56	406.12	18.29	-1.49	18.80	-0.17	1.44	
DVS SR 200 mg										
Week 12	94	400.22	16.33	400.62	18.57	-0.39	15.07	-1.40	1.49	
Week 52	60	402.22	18.15	400.98	17.79	1.23	16.45	0.73	2.02	
Final on-therapy	102	400.95	16.67	401.17	18.33	-0.22	15.64	-1.02	1.48	
Placebo										
Week 12	65	405.40	18.21	406.28	16.71	-0.88	17.61	0.45	1.79	
Week 52	43	404.26	17.43	405.47	16.25	-1.21	16.25	0.17	2.40	
Final on-therapy	71	404.14	17.34	405.51	16.38	-1.37	15.96	-0.31	1.78	
QT interval, ms										
DVS SR 50 mg										
Week 12	116	394.34	25.67	395.91	26.00	-1.57	22.29	-2.25	1.80	B,C
Week 52	82	395.45	23.89	396.94	25.17	-1.49	20.47	-1.43	2.25	C
Final on-therapy	123	393.56	23.56	396.40	25.60	-2.84	21.44	-3.42	1.79	В
DVS SR 100 mg										
Week 12	119	394.29	27.92	397.89	29.69	-3.61	22.72	-3.51*	1.78	G
Week 52	82	391.83	26.34	394.52	28.99	-2.70	24.61	-3.72	2.26	
Final on-therapy	125	393.43	28.76	398.03	29.95	-4.60*	23.14	-4.50*	1.77	E
DVS SR 150 mg										
Week 12	100	392.27	23.90	401.14	26.89	-8.87***	22.99	-7.51***	1.94	I
Week 52	68	390.69	25.24	398.66	25.75	-7.97*	27.54	-7.13**	2.48	
Final on-therapy	109	389.50	24.27	400.76	26.14	-11.26***	25.04	-10.02***	1.90	I

CONFIDENTIAL 133 Wyeth

Table 10.5.3.4-1: Baseline Mean and Mean Changes From Baseline in Selected ECG Results

		Obse	rved	Basel	ine	Cha	nge	Adju	isted b	· -
Treatment			~~		~~		~~		~=	Between-Group
Data Analysis Interval ^a	n	Mean	SD	Mean	SD	Mean	SD	Mean	SE	p-Value ^c
DVS SR 200 mg										
Week 12	94	386.89	22.46	392.74	26.34	-5.85**	20.83	-7.76***	2.01	J
Week 52	60	387.22	26.29	394.77	26.82	-7.55**	20.35	-8.47**	2.64	
Final on-therapy	102	386.90	24.33	393.69	26.05	-6.78**	20.38	-8.50***	1.97	J
Placebo	•									
Week 12	65	403.29	26.02	402.06	22.97	1.23	20.08	2.95	2.41	
Week 52	43	395.02	22.55	400.79	25.02	-5.77	24.94	-3.97	3.12	
Final on-therapy	71	397.86	23.34	401.15	22.56	-3.30	23.38	-1.90	2.36	

Abbreviations: STD=standard deviation; StdErr=standard error; and QTcF=QT correction using the Fridericia formula

Bource. Legs_v2 0/110 v03 13.43

a. All analyses were done independently by data analysis interval by using data with nonmissing baseline values.

b. Adjusted means of change account for unbalance among treatments with respect to all other effects in model. Their standard errors are based on the pooled data across all treatments. Adjusted mean changes should be interpreted with caution for small sample sizes.

c. Comparison based on adjusted mean changes from baseline using ANCOVA with baseline as the covariate. Significant (p≤0.05) differences between groups are shown only if the overall comparison was significant: A=DVS SR 50 mg vs DVS SR 100 mg; B=DVS SR 50 mg vs DVS SR 150 mg; C=DVS SR 50 mg vs DVS SR 200 mg; D=DVS SR 50 mg vs placebo; E=DVS SR 100 mg vs DVS SR 150 mg; F=DVS SR 100 mg vs DVS SR 100 mg vs placebo; H=DVS SR 150 mg vs DVS SR 200 mg; I=DVS SR 150 mg vs placebo; and J=DVS SR 200 mg vs placebo. Statistical significance at the 0.05, 0.01, and 0.001 levels is denoted by *, **, and ***, respectively, for within-group comparisons. Source: ECG3 V2 07NOV05 13:43

Heart Rate

Consistent with the effects of DVS SR on pulse, significant increases (less than 5 beats per minute) from baseline in adjusted mean heart rate were observed for the 100-mg, 150-mg, and 200-mg DVS SR groups at all time points.

Significant differences between the 100-mg, 150-mg, and 200-mg DVS SR groups compared with the placebo group were observed at week 12 and at the final on-therapy evaluation. Increases in adjusted mean heart rate for the 50-mg DVS SR group were significantly lower than those observed with higher DVS SR doses.

PR Interval

Significant decreases (less than 6 ms) from baseline in the adjusted mean PR interval were observed for all DVS SR groups at most time points.

The decreases in the adjusted mean PR interval for the 50-mg and 100-mg DVS SR groups were significantly different from the changes in the placebo group at week 12 and for the 150-mg and 200-mg DVS SR groups at all points.

QRS Interval

Small (less than 3 ms) but statistically significant increases from baseline in the adjusted mean QRS interval were observed for the 150-mg DVS SR group at week 52 and at the final ontherapy evaluation and for the placebo group at all time points.

QT Interval

Significant dose-dependent decreases from baseline in the adjusted mean QT interval were observed for the 100-mg, 150-mg, and 200-mg DVS SR groups at most time points.

Decreases in the adjusted mean QT interval for the 100-mg, 150-mg and 200-mg DVS SR groups were significantly different from those in the placebo group at week 12.

CONFIDENTIAL 135 Wyeth

Fridericia-Corrected QT Interval

No significant changes from baseline in the adjusted mean QTcF interval were observed for any DVS SR group.

10.6 Safety Conclusions

The most common TEAEs, ie, those reported by at least 5% of the subjects treated with DVS SR in any treatment group and at a frequency at least twice the rate for subjects treated with placebo, were asthenia, chills, flu syndrome, hypertension, anorexia, dry mouth, dyspepsia, nausea, vomiting, hyperlipemia, anxiety, confusion, dizziness, insomnia, libido decreased, nervousness, somnolence, thinking abnormal, tremor, twitching, sweating, abnormal vision, and mydriasis. Most of these events were mild to moderate. Most TEAEs were reported during the first week of therapy. After the first week of therapy, the incidence of new adverse events in the DVS SR groups was not different from the placebo group.

The most common posttherapy-emergent adverse events, ie, those reported by at least 5% of subjects in any DVS SR group and at a frequency at least twice the rate for subjects treated with placebo, were anxiety, headache, dizziness, insomnia, emotional lability, hostility, vasodilatation, nausea, vomiting, and tinnitus. The incidence of these events increased with longer therapy duration.

No deaths occurred during or immediately after this study.

Twenty-eight (28) subjects had serious adverse events. Of these, 5 serious adverse events in 3 subjects were considered possibly or probably related to test article by the investigators: elevated ALT/SGPT and AST/SGOT levels in 2 subjects were considered probably or possibly related to test article, and cholecystitis in 1 subject was considered possibly related to test article.

Five (5) subjects reported cardiovascular events during the course of the study. All events were considered probably or definitely not related to test article by the investigators but rather to underlying multiple risk factors for cardiovascular disease.

CONFIDENTIAL 136 Wyeth

Adverse events were listed as primary or secondary reasons for withdrawal from the study for 27 (18%) subjects in the DVS SR 50-mg group, 33 (21%) subjects in the DVS SR 100-mg group, 58 (37%) subjects in the DVS SR 150-mg group, 63 (42%) subjects in the DVS SR 200-mg group, and 12 (16%) subjects in the placebo group. Significantly more subjects in the 150-mg and 200-mg DVS SR groups than in the placebo group withdrew from the study because of adverse events (p<0.001), whereas for the 100-mg and 50-mg DVS SR groups the differences from the placebo group were not significant. Nausea was the most frequent cause for discontinuation of test article early during therapy in DVS SR-treated subjects. After the first week of treatment, there was no difference between groups in safety-related discontinuations.

DVS SR treatment was associated in few subjects with clinically important changes in laboratory test results, vital signs measurements, or ECG assessments.

In all the DVS SR groups, statistically significant changes from baseline in mean bilirubin, alkaline phosphatase, and fasting triglyceride values were observed for at least 1 evaluation, but the changes did not appear to be clinically important. In the 50-mg, 100-mg, and 150-mg DVS SR groups, significant increases from baseline were observed for at least 1 evaluation for adjusted mean levels of AST/SGOT. No significant changes from baseline were observed in mean ALT/SGPT values at any time point for any DVS SR group. No pattern was observed in the few data points with statistically significant changes from baseline in other laboratory test values. None of the mean changes in laboratory test values appeared to be clinically important.

Treatment with DVS SR was associated with small but significant increases from baseline in mean pulse rate and diastolic, but not systolic, blood pressure measurements. Significant decreases from baseline in mean body weight were observed in early weeks of the study for all DVS SR groups, and small, significant increases in body weight were observed at later time points for the 100-mg and 200-mg DVS SR groups.

Small but statistically significant mean changes from baseline in some ECG parameters were observed in the DVS SR treatment groups, but most of those changes were attributable to the increases observed in mean heart rate. A decrease in PR interval was observed in all DVS SR treatment groups. An increase in QRS interval was observed only in the 150-mg DVS SR group. Decreases in the mean QT interval were observed for the 100-mg, 150-mg, and 200-mg DVS SR

CONFIDENTIAL 137 Wyeth

doses, but the Fridericia-corrected mean QT interval showed no significant mean difference for any DVS SR group.

11.0 RESULTS OF OTHER ANALYSES: HEALTH OUTCOMES ASSESSMENTS

11.1 Subject Satisfaction

The number and percentage of subjects who reported being satisfied or extremely satisfied in the SS questionnaire are shown in Table 11.1-1. At week 12, compared with the placebo group results at the p=0.048 level, the 200-mg DVS SR group results were different in the ability to control hot flushes during the night; the 150-mg DVS SR group results were different in the ability to control hot flushes during the night and the effect on mood or emotion; and the 100-mg DVS SR group results were different in the ability to control hot flushes during the day and the night and the effect on mood or emotions. The 50-mg DVS SR group results were not different from the placebo group for any measure.

CONFIDENTIAL 138 Wyeth

Table 11.1-1: Satisfaction Survey: Number (%) of Subjects Reporting Being Satisfied or Extremely Satisfied

_		Num	ber of Su	bjects	Overall	p-Value
Time Point	Treatment	Total	n	%	p-Value	vs Placebo
	Ability to Co	ontrol Hot F	lashes D	uring the D	ay	
Week 12	DVS SR 50 mg	121	71	58.68	0.009	0.394
	DVS SR 100 mg	122	91	74.59		0.002
	DVS SR 150 mg	105	70	66.67		0.058
	DVS SR 200 mg	95	54	56.84		0.562
	Placebo	67	35	52.24		
Week 52	DVS SR 50 mg	82	59	71.95	0.498	0.297
	DVS SR 100 mg	83	63	75.90		0.122
	DVS SR 150 mg	70	52	74.29		0.197
	DVS SR 200 mg	63	42	66.67		0.695
	Placebo	46	29	63.04		
	Ability to Co	ntrol Hot F	lashes Du	ring the Ni	ight	
Week 12	DVS SR 50 mg	121	76	62.81	0.003	0.224
	DVS SR 100 mg	122	97	79.51		< 0.001
	DVS SR 150 mg	105	75	71.43		0.018
	DVS SR 200 mg	95	67	70.53		0.029
	Placebo	67	36	53.73		
Week 52	DVS SR 50 mg	82	52	63.41	0.017	0.598
	DVS SR 100 mg	83	67	80.72		0.007
	DVS SR 150 mg	70	55	78.57		0.021
	DVS SR 200 mg	64	48	75.00		0.070
	Placebo	46	27	58.70		
	E	ffect on Qua	ality of Sl	еер		
Week 12	DVS SR 50 mg	120	70	58.33	0.407	0.680
	DVS SR 100 mg	122	83	68.03		0.080
	DVS SR 150 mg	105	66	62.86		0.319
	DVS SR 200 mg	95	57	60.00		0.544
	Placebo	67	37	55.22		
Week 52	DVS SR 50 mg	82	50	60.98	0.059	0.991
	DVS SR 100 mg	83	65	78.31		0.034
	DVS SR 150 mg	70	53	75.71		0.088
	DVS SR 200 mg	64	42	65.63		0.609
	Placebo	46	28	60.87		
	Eff	ect on Mood	d or Emo	tions		
Week 12	DVS SR 50 mg	121	81	66.94	0.072	0.233
	DVS SR 100 mg	122	93	76.23		0.010
	DVS SR 150 mg	105	78	74.29		0.027
	DVS SR 200 mg	95	63	66.32		0.293
	Placebo	67	39	58.21		
Week 52	DVS SR 50 mg	82	62	75.61	0.467	0.317
	DVS SR 100 mg	83	66	79.52		0.127
	DVS SR 150 mg	70	55	78.57		0.179
	DVS SR 200 mg	64	45	70.31		0.744
	Placebo	46	31	67.39		

CONFIDENTIAL 139 Wyeth

Protocol 3151A2-315-US

CSR-60178

Table 11.1-1: Satisfaction Survey: Number (%) of Subjects Reporting Being Satisfied or Extremely Satisfied

				bjects		p-Value
Time Point	Treatment	Total	n		p-Value	vs Placebo
		Effect on Inte				
Week 12	DVS SR 50 mg	115	32	27.83	0.847	0.360
	DVS SR 100 mg	119	35	29.41		0.489
	DVS SR 150 mg	103	28	27.18		0.324
	DVS SR 200 mg	91	29	31.87	•	0.744
	Placebo	64	22	34.38	•	•
Week 52	DVS SR 50 mg	81	32	39.51	0.428	0.435
	DVS SR 100 mg	82	26	31.71		0.095
	DVS SR 150 mg	70	26	37.14		0.311
	DVS SR 200 mg	63	28	44.44		0.819
	Placebo	45	21	46.67		•
	Eff	ect on Ability	to Conce	entrate		
Week 12	DVS SR 50 mg	121	68	56.20	0.309	0.506
	DVS SR 100 mg	121	84	69.42	•	0.252
	DVS SR 150 mg	105	68	64.76		0.636
	DVS SR 200 mg	95	59	62.11	•	0.906
	Placebo	67	41	61.19		
Week 52	DVS SR 50 mg	82	56	68.29	0.764	0.351
	DVS SR 100 mg	83	61	73.49		0.746
	DVS SR 150 mg	70	53	75.71		0.963
	DVS SR 200 mg	64	44	68.75		0.399
	Placebo	46	35	76.09		
	7	Folerability to	Side Eff	fects		
Week 12	DVS SR 50 mg	121	98	80.99	0.513	0.430
	DVS SR 100 mg	122	92	75.41		0.913
	DVS SR 150 mg	104	78	75.00		0.868
	DVS SR 200 mg	95	67	70.53		0.431
	Placebo	67	51	76.12		
Week 52	DVS SR 50 mg	82	68	82.93	0.649	0.786
	DVS SR 100 mg	83	69	83.13		0.808
	DVS SR 150 mg	70	58	82.86		0.784
	DVS SR 200 mg	64	48	75.00		0.213
	Placebo	46	39	84.78		
		Overall Sat				
Week 12	DVS SR 50 mg	121	83	68.60	0.118	0.840
	DVS SR 100 mg	122	97	79.51	•	0.060
	DVS SR 150 mg	105	82	78.10		0.112
	DVS SR 200 mg	95	65	68.42		0.866
	Placebo	67	45	67.16		
Week 52	DVS SR 50 mg	82	61	74.39	0.109	0.557
,, , , , , , , , , , , , , , , , , , ,	DVS SR 100 mg	83	72	86.75		0.018
	DVS SR 150 mg	70	56	80.00	•	0.199
	DVS SR 200 mg	64	46	71.88	•	0.792
	Placebo	46	32	69.57	•	€.7,2 <u>=</u>
	1 140000	70	24	07.51	•	•

Source: ss_itt_group_final_05.doc October 24, 2005 14:48

Complete SS results are given in Supportive Table ST 11-1.

11.2 Sexual Function Questionnaire

There were no significant differences between any DVS SR group and the placebo group in the arousal, desire, orgasm, overall satisfaction, or total severity scores as measured by the SFQ. Results are shown in Supportive Table ST 11-2. Consistent with the SFQ results, there was no significance difference between any DVS SR group and placebo group in the incidence of libido decreased, abnormal orgasm, anorgasmia, or sexual function abnormal.

11.3 EuroQuality of Life Visual Analogue Scale

None of the DVS SR groups had statistically significant differences from those in the placebo group on the EQ VAS. Results are shown in Supportive Table ST 11-3.

12.0 DISCUSSION AND OVERALL CONCLUSIONS

Overall, DVS SR appears to be safe and more effective than placebo in alleviating hot flushes and other symptoms associated with menopause. The 100-mg DVS SR dose demonstrated the most significant improvement in primary and key secondary efficacy endpoints.

The 100-mg DVS SR dose was effective in reducing the number and severity of hot flushes, reaching a 64% reduction in the number of moderate to severe hot flushes at week 12. Nearly 50% of subjects had at least a 75% reduction from baseline in the number of hot flushes compared with less than 30% in the placebo group. Additional benefits included reductions in the number of awakenings caused by hot flushes and in the total mood disturbance score. These results are consistent with the assessment from the subjects regarding the ability of 100-mg DVS SR to reduce their hot flushes during the day and at night and to improve mood and emotions.

The 150-mg dose yielded results similar to the 100-mg dose for parameters based on the number of hot flushes, but data were less consistent for other endpoints, precluding a definite conclusion on the efficacy of this dose. The 200-mg dose significantly improved the severity of hot flushes but did not significantly decrease their number, which may partly be due to the higher engagement of norepinephrine activity at this dose level, as evidenced by the incidence of

CONFIDENTIAL 141 Wyeth

sweating reported by subjects in the 200-mg DVS SR group. The 50-mg dose only differed from placebo during the first weeks of treatment and is not considered effective.

No deaths occurred during or immediately after this study. No clear safety signal emerged from the serious adverse events reported in 28 subjects; the 5 cardiovascular events were all considered definitely not or probably not related to study drug.

The most frequently reported treatment-emergent adverse events were nausea, dizziness, dry mouth, insomnia, and somnolence. In most cases, these events were mild or moderate in severity and occurred at the beginning of therapy. Adverse events led to withdrawal from the study for 26% of subjects in the DVS SR groups and 16% of subjects in the placebo group (significantly different from the placebo group for 150-mg and 200-mg DVS SR groups). Otherwise, tolerability to side effects was generally good in all treatment groups, although to a lesser extent in the 200-mg DVS SR dose group. The 50-mg DVS SR dose, although not effective for the treatment of hot flushes, was associated with a lower incidence of treatment-emergent adverse events, especially during the first week of therapy. This result suggests that some subjects may start with the 50-mg DVS SR dose before increasing to 100 mg to improve the early tolerability.

Posttherapy adverse events were reported by 31% of subjects in the placebo group and by 48% of subjects in the DVS SR groups and were more frequent with longer therapy duration. Posttherapy-emergent adverse events reported by at least 5% of subjects in any DVS SR group were similar to adverse events frequently reported at the beginning of therapy but also included headache, emotional lability, and hostility. Data with the 50-mg DVS SR dose suggest that some individual subjects may benefit from progressively decreasing DVS SR doses at the end of treatment, in particular for therapy duration greater than 12 weeks.

In conclusion, 100-mg DVS SR appears to be a safe and effective option for the treatment of VMS in postmenopausal women.

CONFIDENTIAL 142 Wyeth

13.0 REFERENCE LIST

- Lockley SW, Skene DJ, Arendt J. Comparison between subjective and actigraphic measurement of sleep and sleep rhythms. *J Sleep Res.* 1999 Sep;8(3):175-83.
- Lorr M, McNair DM, Droppleman LF. *Manual for the Profile of Mood States*. San Diego, CA: Educational and Industrial Testing Service; 1971.
- Lerner D, Amick BC, Rogers WH, Malspeis S, Bungay K, Cynn D. The Work Limitations Questionnaire. *Med Care*. 2001;39(1):72-85.
- O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. *Biometrics*. 1979;35:549-556.
- Fehnel SE, Manjunath R. Measuring women's satisfaction with the treatment of menopausal symptoms. RTI Health Solutions Project B0323, 2003.
- Vanderkooy JD, Kennedy SH, Bagby RM. Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. *Can J Psychiatry*. 2002;47:174-180.
- Kennedy SH, Eisfeld BS, Dickens SE, Bacchiochi JR, Bagby RM. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. *J Clin Psychiatry*. 2000;61:276-281.
- ⁸ Kennedy SH, Dickens SE, Eisfeld BS, Bagby, RM. Sexual dysfunction before antidepressant therapy in major depression. *J Affect Disord*. 1999;56:201-208.
- Kennedy SH, Ralevski E, Dickens S, Bagby RM. Distinct areas of sexual dysfunction in men and women with major depression. Halifax:Canadian Psychiatric Association,1998.
- Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. *Fertil Steril*. 2001;75:1065-1079.
- Notelovitz M, Lenihan JP Jr, McDermott M, Kerber IJ, Nanavati N, Arce JC. Initial 17β-estradiol dose for treating vasomotor symptoms. *Obstet Gynecol*. 2000;95:726-731.
- Speroff L, Symons J, Kempfert N, Rowan J. The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (FemHRT®) on the frequency and intensity of vasomotor symptoms. *Menopause*. 2000;7:383-390.
- Lee ML. Drug-induced hepatotoxicity. *N Engl J Med*. 2003;349:474-85.

Protocol 3151A2-315-US

CSR-60178

14.0 CLINICAL DATA REPORT ERRATA

Data errors for this study that were discovered after the final update of the database are identified in this section. These data errors were evaluated by the Wyeth Research medical monitors and biostatisticians to decide if the database/clinical data reports should be updated or if the errors should be corrected only in the main text of the clinical study report. The database was not updated for the errata listed in this section.

A summary of the errata is provided in Table 14.0-1. Documentation of all data errors for this study is provided on the errata forms and in the material after Table 14.0-1.

Table 14.0-1: Summary of Errata

Subject	Treatment	CDRs	
Number	Group	Affected	Description
NA	NA	AE CDRs	The Oracle Clinical derivation for treatment-emergent adverse events (TEAE) was incorrectly setting TEAE=Yes for AEs with a posttherapy start date for 13 subjects with only 1 day of study medication (derivation problem if treatment duration was only 1 day). No changes were made to the Oracle Clinical database. Clinical programming manually reset the TEAE flag to "No" for the affected subjects.
315-239-202851	NA	NA	These 4 subjects were randomly assigned to treatment groups in
315-202-201051			error; all 4 subjects did not meet protocol inclusion/exclusion criteria, but study site personnel inadvertently entered the subjects
315-217-201803			in the CORE system. No test article was dispensed to these
315-241-202951			4 subjects, and they were subsequently treated as screen failures and appear as screen failures on the database. In addition, these 4 subjects are not listed on the screen failure log (derived from the enrollment log) that LBR Regulatory maintained for the study. Instead, these 4 subjects are listed as early terminations because of "randomization in error" on the enrollment log, and therefore the total number of screen failures on the database does not match the number of screen failures based on the enrollment
			log (458). The 4 subjects listed account for this discrepancy.

Abbreviations: AE=adverse event; CDR=clinical data report; CORE=clinical operations randomization environment; CRO=contract research organization; NA=not available; and TEAE=treatment emergent adverse event.

CONFIDENTIAL 144 Wyeth

Protocol 3151A2-315-US

CSR-60178

DIRECTIONS: Data Analys	t, Clinical Writer and CPT Medi	cal Monitor complete this f	form.	35142315 -	
Completed form must be place	ed in the clinical study file in W	yeth official electronic repo	sitory.		ı c
			the model (see the 1994) described		
	2Aug2005			w.	
PROJECT NUMBER 3	151A2				
	15		,	A. Mariana and A. Mar	in light 1911
DESCRIPTION OF PROB	LEM: (Attach appropriate docu	mentation, eg, CRP of ana	lysis)	r ≒ Vès for AEs w	ith a 🔭 🖰
The Oracle Clinical derivation	n for treatment emergent adverse 3 subjects with only 1 day of stud	event (TEAE) is incorrectly iv medication (derivation p	roblem if only	l day treatment du	ration). —
EDECTEV DATA PRESEN	TATIONS AND ANALYSES 0	L WALION WITHOUT	D:		
All adverse event CDRs base	d on final frozen Oracle Clinical	database.			
RECOMMENDED SOLU	rion:				
RECUMINIENDED SOLO	latabase? No change to Oracle C	Vinical database Use CIDI	ER database TE	AE derivation to c	orrect
X No changes necessary to o	latabase? No change to Oracle Clatabase and rerun all AE CDRs.	This will also correct TEA	E derivation in	SAS ERS datasets	3.
	nterim submission, re-create snap				
Correct ine database. 17					
	하다 그 이 이 시간 하는데 그는 얼마 같아.				
SIGNATURES:	ned certifies that he/she has revie	ewed all the information in	cluded on this j	form)	
Data Analyst (The undersign	ned certifies that he/she has revie				ET
Data Analyst (The undersig	Krz				ET Time Zone
Data Analyst (The undersig KEQIW CAI Name (Print)	Signature	Date	8/22/05	/4:00 Time (24-hr clock)	ET Time Zone
Data Analyst (The undersig KEQIW CAI Name (Print)	Signature	Date	8/22/05	/4:00 Time (24-hr clock)	ET Time Zone
Data Analyst (The undersignate of Print) Clinical Writer (The undersignate of Print)	Signature Signed certifies that he/she has rev	Date viewed all the information is	8/2 2/ 05 e included on this	14:00 Time (24-hr clock) form)	Time Zone
Data Analyst (The undersigned Form) Name (Print) Clinical Writer (The undersigned Form) ROSCHARY LORGENAR	Signature Signature Signed certifies that he/she has rev Democry	Date viewed all the information is	8/2 2/ 05 e included on this	14:00 Time (24-hr clock) form)	Time Zone
Data Analyst (The undersignate Analyst (The undersignate (The unde	Signature Signed certifies that he/she has rev Signature	Date of the information of the continuer of the Date of the Continuer of t	8/22/05 e included on this lug 20ds	14:00 Time (24-hr clock) Form)	EST.
Data Analyst (The undersignate Analyst (The undersignate (The unde	Signature Signed certifies that he/she has rev Signature	Date of the information of the continuer of the Date of the Continuer of t	8/22/05 e included on this lug 20ds	14:00 Time (24-hr clock) Form)	EST.
Data Analyst (The undersignate (Print) CII Name (Print) Clinical Writer (The undersity of the Undersity of the Undersity of the Undersity of the University of the Universit	Signature Signature Signature Signature Cal Monitor (The undersigned cel	Date of the information of the i	122/05 included on this Lug 20ds c weed all the info	Time (24-hr clock) form) [()-7- Time (24-hr clock) ormation included	Time Zone UNITED TO Time Zone on this form,
Data Analyst (The undersignate of Print) Clinical Writer (The undersignate of Print) Clinical Writer (The undersignate of Print) Clinical Project Team Medical Project Team Medical OUVICE	Signature Signature Signature Signature Signature Cal Monitor (The undersigned cells)	Date of the information of the i	122/05 included on this Lug 20ds c weed all the info	Time (24-hr clock) form) [()-7- Time (24-hr clock) ormation included	Time Zone UNITED TO Time Zone on this form,
Data Analyst (The undersignate of Print) Clinical Writer (The undersignate of Print) Clinical Project Team Medical Project Team Medical Name (Print)	Signature Signed certifies that he/she has rev Signature Cal Monitor (The undersigned cel Signature	Date piewed all the information is both the Date of Da	8/22/05 e included on this lug 2 ods e ewed all the info	Time (24-hr clock) Form) Time (24-hr clock) Time (24-hr clock) Time (24-hr clock) Time (24-hr clock)	Time Zone ### Continue Zone ### Continue Zone ### Continue Zone ### Continue Zone
Data Analyst (The undersignate (Print) Clinical Writer (The undersignate (Print) Clinical Project Team Medical Project Team Medical Name (Print)	Signature Signed certifies that he/she has rev Signature Cal Monitor (The undersigned cel Signature	Date piewed all the information is buttured. 25 Tiffies that he/she has reviewed all the particular to the particular t	included on this lug 20ds weed all the info Jug 09	Time (24-hr clock) Form) Time (24-hr clock) Time (24-hr clock) Time (24-hr clock) Time (24-hr clock)	Time Zone ### Continue Zone ### Time Zone ### Time Zone ### Time Zone
Data Analyst (The undersignate of Print) Clinical Writer (The undersignate of Print) Clinical Writer (The undersignate of Print) Clinical Project Team Medit of Print) * Therapeutic Area Director	Signature Signature Signature Signature Signature Cal Monitor (The undersigned cells) Signature (The undersigned certifies that it	Date piewed all the information is buttured. 25 Tiffies that he/she has reviewed all the particular to the particular t	included on this lug 20ds weed all the info Jug 09	Time (24-hr clock) Form) Time (24-hr clock) Time (24-hr clock) Time (24-hr clock) Time (24-hr clock)	Time Zone ### Continue Zone ### Time Zone ### Time Zone ### Time Zone
Data Analyst (The undersignate (Print) Clinical Writer (The undersignate (Print) Clinical Project Team Medical Project Team Medical Name (Print)	Signature Signature Signature Signature Cal Monitor (The undersigned certifies that in the undersigned certifies that in the undersigned certifies that in the unit the un	Date piewed all the information is buttured. 25 Tiffies that he/she has reviewed all the particular to the particular t	included on this lug 20ds weed all the info Jug 09 included on this	Time (24-hr clock) Form) Time (24-hr clock) Time (24-hr clock) Time (24-hr clock) Time (24-hr clock)	Time Zone ### Continue Zone ### Time Zone ### Time Zone ### Time Zone
Data Analyst (The undersignate of Print) Clinical Writer (The undersignate of Print) Clinical Writer (The undersignate of Print) Clinical Project Team Medical Project Team Medical OLV Constitution of Print)	Signature Signature Signature Signature Signature Cal Monitor (The undersigned cells) Signature (The undersigned certifies that it	Date piewed all the information is buttured. 25 Tiffies that he/she has reviewed all the particular to the particular t	included on this lug 20ds weed all the info Jug 09 included on this	Time (24-hr clock) Form) Time (24-hr clock) Time (24-hr clock) Time (24-hr clock) Time (24-hr clock)	Time Zone Charles Cha
Data Analyst (The undersignate of Print) Clinical Writer (The undersignate of Print) Clinical Project Team Medit of Print) * Therapeutic Area Director Cingen (Print)	Signature Signature Signature Signature Cal Monitor (The undersigned certifies that is signature) Signature Signature Signature	Date of the programming of the programming of the part	included on this lug 20ds weed all the info information in information in te or AVP of Bios	Time (24-hr clock) Form) Time (24-hr clock) Time (24-hr clock) Time (24-hr clock) Cluded on this form Time (24-hr clock) Cluded on this form Time (24-hr clock)	Time Zone ### Continue Tone ### Continue Tone ### Time Zone
Data Analyst (The undersignate of Print) Clinical Writer (The undersignate of Print) Clinical Project Team Medit of Print) * Therapeutic Area Director Cingen (Print)	Signature Signature Signature Signature Cal Monitor (The undersigned certifies that is signature) Signature Signature Signature	Date of the programming of the programming of the part	included on this lug 20ds weed all the info information in information in te or AVP of Bios	Time (24-hr clock) Form) Time (24-hr clock) Time (24-hr clock) Time (24-hr clock) Cluded on this form Time (24-hr clock) Cluded on this form Time (24-hr clock)	Time Zone ### Continue Tone ### Continue Tone ### Time Zone
Data Analyst (The undersignate of Print) Clinical Writer (The undersignate of Print) Clinical Writer (The undersignate of Print) Clinical Project Team Medic Septic OUV Canada of Print) * Therapeutic Area Director Cinques (Drint) * VP of Clinical Operations Information Systems (The undersignate of Print)	Signature Signature Signature Signature Cal Monitor (The undersigned certifies that he/she has revenue to the signature of the undersigned certifies that he/she has revenue to the he/she he	Date of the information of the i	included on this lug 20ds weed all the info information in information in te or AVP of Bios	Time (24-hr clock) s form) (1) 2-7 Time (24-hr clock) romation included Time (24-hr clock) Time (24-hr clock) cluded on this form Time (24-hr clock) statistics and Clinic on this form.)	Time Zone ### Continue Tone ### Continue Tone ### Time Zone



Protocol 3151A2-315-US

CSR-60178

DIRECTIONS: Data Analyst, Completed form must be placed				3151A2 315	— б.
					1
DATE 288	Sep2005				e track ex
PROJECT NUMBER 315	51A2				
STUDY NUMBER 315	5-33-3			en and a second	
DESCRIPTION OF PROBLE The Oracle Clinical derivation of posttreatment start date for 13 s SPECIFY DATA PRESENTA	for treatment emergent subjects with only 1 da ATIONS AND ANAL	adverse event (TE y of study medicati YSES or ANALY	AE) is incorrectly setting T on (derivation problem if or	EAE = Yes for AEs wi ally 1 day treatment du	ith a ration).
All adverse event CDRs based o	on final frozen Oracle	Clinical database.			
RECOMMENDED SOLUTION	ON:		요 그는 아는 그리면 생각 경험을 받다. 일반 기업 교육 교육 교육 교육 교육		
CIDER derivation for TEAE. CIDER derivation. Due to the liatch rerun, and CIDER refresh No') the affected TEAE derivation database. Affects will be database.	kelihood that unforese process, it has been do tions for the 13 patiest the reaun, and the SAS	en changes may oc ecided that Clinical	cur to the OC and CIDER d Programming will correct (1 1 CIDER AE database ex	atabases during the un reset from TEAE = 'Y xtraution Control	freeze, 'es' to 'adazcahe
Correct the database. If inte	erim submission, re-cre	eate snapshot.		is form)	
Correct the database. If inte	erim submission, re-cre	eate snapshot.	information included on th		ET
Correct the database. If inte IGNATURES: Data Analyst (The undersigned Leqin Qi	erim submission, re-cre	eate snapshot.	information included on th	is form) 5 08:35 Time (24-hr clock)	ET Time Zoi
Correct the database. If inte IGNATURES: Data Analyst (The undersigned Leqin Qi ame (Print)	rim submission, re-cre I certifies that he/she h Signature	eate snapshot.	information included on th 29SEP2002 Date	5 08:35 Time (24-hr clock)	ET Time Zoo
Correct the database. If inte IGNATURES: Data Analyst (The undersigned Leqin Qi ame (Print)	rim submission, re-cre I certifies that he/she h Signature Ed certifies that he/she	eate snapshot. The as reviewed all the shape	information included on th 298EP2002 Date e information included on t	5 08:35 Time (24-hr clock)	ET Time Zoo
Correct the database. If inte IGNATURES: Data Analyst (The undersigned Leqin Qi ame (Print) Clinical Writer (The undersigned Leques Writer)	rim submission, re-cre I certifies that he/she h Signature Ed certifies that he/she	eate snapshot. The as reviewed all the shape	information included on th 298EP2002 Date e information included on t	5 08:35 Time (24-hr clock)	ET
Correct the database. If inte	rim submission, re-cre I certifies that he/she h Signature Ed certifies that he/she	eate snapshot.	information included on th 29SEP2002 Date	5 08:35 Time (24-hr clock)	ET Time Zon
Correct the database. If inte IGNATURES: Data Analyst (The undersigned ame (Print) Clinical Writer (The undersigned cosemary Horstman ame (Print)	rim submission, re-cre I certifies that he/she h Signature ad certifies that he/she Aplowe Signature	nas reviewed all the	information included on th 29SEP2002 Date pare information included on the continuous of the conti	15 08:35 Time (24-hr clock) his form 15 2 4 Time (24-hr clock)	EV Time Zon
Correct the database. If inte	rim submission, re-cre I certifies that he/she h Signature ad certifies that he/she Aplowe Signature	nas reviewed all the	information included on th 298EP2009 Date e information included on to 060CP2015 Date e/she has reviewed all the in	DB: 35 Time (24-hr clock) his form	EV Time Zon
Correct the database. If inte IGNATURES: Data Analyst (The undersigned database) Leqin Qi ame (Print) Clinical Writer (The undersigned database) Cosemary Horstman dame (Print) Clinical Project Team Medical Modification of the colorer database of the colorer database of the colorer database of the colorer database. If interest database data	rim submission, re-cre I certifies that he/she h Signature ad certifies that he/she Aplowe Signature	nas reviewed all the	information included on th 29SEP2002 Date pare information included on the continuous of the conti	DB: 35 Time (24-hr clock) his form	EV Time Zon
Correct the database. If inte IGNATURES: Data Analyst (The undersigned decin Qi ame (Print) Clinical Writer (The undersigned decin Qi ame (Print) Clinical Project Team Medical I dephie Olivier ame (Print)	Signature Monitor (The Undersign	has reviewed all the	information included on th 29SEP2002 Date e information included on the included of the inc	Time (24-hr clock) his form	ET Time Zon
Correct the database. If inte IGNATURES: Data Analyst (The undersigned decin Qi ame (Print) Clinical Writer (The undersigned decin Qi ame (Print) Clinical Project Team Medical I dephie Olivier ame (Print)	Signature Monitor (The Undersign	has reviewed all the	information included on th 29SEP2009 Date to information included on to 060CP2015 Date e/she has reviewed all the in 29 Lp 2005 Date eviewed all the information included on the information	Time (24-hr clock) his form) 15 24 Time (24-hr clock) nformation included on 8:42 Time (24-hr clock)	Time Zon this form Time Zon Time Zon
Correct the database. If inte IGNATURES: Data Analyst (The undersigned leqin Qi ame (Print) Clinical Writer (The undersigned legin Qi ame (Print) Clinical Project Team Medical Incoming the Olivier ame (Print) Therapeutic Area Director (The Incoming In	Signature Monitor (The Undersign	has reviewed all the	information included on th 29SEP2002 Date e information included on the included of the inc	Time (24-hr clock) his form) 15 24 Time (24-hr clock) nformation included on 8:42 Time (24-hr clock)	ET Time Zon
Correct the database. If inte IGNATURES: Data Analyst (The undersigned decin Qi ame (Print) Clinical Writer (The undersigned decin Qi ame (Print) Clinical Project Team Medical I decin Qi ame (Print) Clinical Project Team Medical I decin Qi ame (Print) Therapeutic Area Director (The inger Constantine	Signature Monitor (The Undersign	has reviewed all the	information included on th 29SEP2009 Date to information included on to 060CP2015 Date e/she has reviewed all the in 29 Lp 2005 Date eviewed all the information included on the information	Time (24-hr clock) his form) 15 24 Time (24-hr clock) nformation included on 8:42 Time (24-hr clock)	Time Zon this form Time Zon Time Zon
Correct the database. If inte	Signature Monitor (The undersigned certifies Signature Monitor (The undersigned certifies Signature	has reviewed all the has reviewed all the wife for the world with the wife for the world with th	information included on th 29SEP2009 Date 1060CF2015 Date 1080 Date 1090 Date	Time (24-hr clock) his form) 15 24 Time (24-hr clock) formation included on 8:42 Time (24-hr clock) included on this form.) 14 - (1) Time (24-hr clock) ostatistics and Clinical	Time Zon Time Zon Time Zon
opy of the final CIDER AE da Correct the database. If inte SIGNATURES: Data Analyst (The undersigned Keqin Qi Name (Print) Clinical Writer (The undersigned Rosemary Horstman Name (Print) Clinical Project Team Medical I Cophie Olivier Name (Print) Therapeutic Area Director (The Singer Constantine Name (Print) VP of Clinical Operations or Antormation Systems (The under Lobert Maguire	Signature Monitor (The undersigned certifies Signature Monitor (The undersigned certifies Signature	has reviewed all the has reviewed all the wife for the world with the wife for the world with th	information included on th 29SEP2009 Date 1060CF2015 Date 1080 Date 1090 Date	Time (24-hr clock) his form) 15 24 Time (24-hr clock) formation included or Time (24-hr clock) included on this form.) Time (24-hr clock) ostatistics and Clinical don this form.)	Time Zon Time Zon Time Zon

CONFIDENTIAL 146 Wyeth

Protocol 3151A2-315-US

CSR-60178

Combrone form finascoc	placed in the cl	Writer and CP1 N linical study file in	Medical Monitor comp Wyeth official electr	lete this form. onic repository.	3151.	A2 315		(
				f	D	P	1	
DATE	20 21 200	المستشدد المستشدد						4
	28-Nov-200	CI.						
PROJECT NUMBER	3151A2							
STUDY NUMBER	315		elle Maringiahi manakan kanakan kan					
DESCRIPTION OF PR								Ž.
The following 4 subjects however study site person 4 subjects and they were s	mel inadvertent	tly randomized the	subjects in the CORE	system). No test art	icle was d	xclusion c ispensed t	riteria o these	
239-202851								
202-201051		1.5						
217-201803								
241-202951								
maintained for the study. I log, and therefore the actuence incompany and therefore the actuence incompany and the study. The study is a study of the study in the study in the study in the study. The study is a study in the study in the study in the study in the study. The study is a study in the study. The study is a study in the study in t	al number of so 4 subjects liste	creen failures in the ed above account f	e study does not mate or this discrepancy.	n the number of scree	n failures	based on	the	
SPECIFY DATA PRESI	ENTATIONS A	AND ANALYSE	S or ANALYSIS AFI	ECTED:				
RECOMMENDED SOL ✓ No changes necessary	UTION:	o reports or analys	ses required to be re-re	n based on this errata				
RECOMMENDED SOL No changes necessary Correct the database. I	UTION: to database. No			n based on this errata				
No changes necessary☐ Correct the database. I	UTION: to database. No			n based on this errata				
No changes necessary ☐ Correct the database. I	UTION: to database. No	ussion, re-create si	napshot.		•			
No changes necessary☐ Correct the database. I	UTION: to database. No	ussion, re-create si	napshot.	tion included on this	form)			
No changes necessary Correct the database. I SIGNATURES: Data Añalyst (The unders)	UTION: to database. No	ussion, re-create si	napshot.		form)	:55	EST	
No changes necessary Correct the database. I BIGNATURES: Data Analyst (The underst	UTION: to database. No	ussion, re-create si	napshot.	tion included on this	form)	: 55 4-hr clock)	EST Time	Z
No changes necessary Correct the database. I GIGNATURES: Data Añalyst (The understate) Keqin Qi Jame (Print)	UTION: to database. No if interim subm	that he/she has re	napshot. viewed all the informa	tion included on this 29 NOV 05 Date	form) // Time (2		EST Time	z
No changes necessary Correct the database. I GIGNATURES: Data Analyst (The undersitate) Leqin Qi Lame (Print) Clinical Writer (The undersitate)	UTION: to database. No if interim subm	that he/she has re	napshot. viewed all the informa	tion included on this 29 NOV 05 Date attion included on this	form) Time (2	4-hr clock)	EST Time	z
No changes necessary Correct the database. I GIGNATURES: Data Analyst (The undersited of the undersi	UTION: to database. No if interim subm	that he/she has resistant signature	napshot. viewed all the informa	tion included on this 29 NOV 05 Date	form) // Time (2 form) // 4	4-hr clock)	EST	
No changes necessary Correct the database. I GIGNATURES: Data Analyst (The undersitate) Leqin Qi Lame (Print) Clinical Writer (The undersitate)	UTION: to database. No if interim subm	that he/she has re	napshot. viewed all the informa	tion included on this 29 NOV 05 Date attion included on this	form) Time (2 form)	4-hr clock)	EST Time	
No changes necessary Correct the database. I GIGNATURES: Data Analyst (The undersited of the undersi	UTION: to database. No If interim subm igned certifies is signed certifies.	that he/she has resistant he/s	napshot. viewed all she informa eviewed all the inform	tion included on this 29 NOV 05 Date ation included on this 30 Nov 05	form) Time (2) Time (2)	4-hr clock) 4-hr clock)	Time	Z
No changes necessary Correct the database. I GIGNATURES: Data Analyst (The understance (Print) Clinical Writer (The understance (Print) Clinical Project Team Med	UTION: to database. No If interim subm igned certifies is signed certifies.	that he/she has resistant he/s	napshot. viewed all she informa eviewed all the inform	tion included on this, 29 NOV 05 Date ation included on this 30 Nov 05 Date	form) // Time (2 s form) // Yime (2 rmation i.	4-hr clock) 4-hr clock)	Time	Z
No changes necessary Correct the database. I GIGNATURES: Data Analyst (The undersited of the undersi	UTION: to database. No If interim subm igned certifies is signed certifies.	that he/she has resistant he/s	napshot. viewed all she informa eviewed all the inform	tion included on this 29 NOV 05 Date attion included on this Whov 05 Date reviewed all the info	form) Time (2 Time (2 rmation i	4-hr clock) 4-hr clock) ncluded of	Time n this f EST	Zo
No changes necessary Correct the database. I GIGNATURES: Data Analyst (The understance (Print) Clinical Writer (The understance (Print) Clinical Project Team Med	UTION: to database. No If interim subm igned certifies is signed certifies.	that he/she has resistant he/s	napshot. viewed all she informa eviewed all the inform	tion included on this, 29 NOV 05 Date ation included on this 30 Nov 05 Date	form) Time (2 Time (2 rmation i	4-hr clock) 4-hr clock)	Time	Zo

Name (Print)

* VP of Clinical Operations or AVP of Global Biostatistics and Clinical Programming or AVP of Biostatistics and Clinical Information Systems (The undersigned certifies that he/she has reviewed all the information included on this form.)

^{*} Necessary only if the problem is to be corrected Form 10467 (12/2003)

15.0 SUPPORTIVE TABLES

LIST OF SUPPORTIVE TABLES

ST 6-1: Summary Statistics for Hot Flush Number and Severity, Week 12 Analysis	151
ST 6-2: Results of the Initial Analysis at 12 Weeks Compared With the Final Analyses at Weeks 4 and 12	175
ST 8-1: Enrollment Log for Screen Failures	
ST 8-2: Number (%) of Subjects Excluded from Per-Protocol Population for Vasomotor Symptom Data	
ST 8-3: Demographic and Baseline Characteristics for ITT Population	200
ST 8-4: Number (%) of Subjects Reporting Nonstudy Medications	203
ST 9-1: Demographic and Baseline Characteristics for ITT Population for Vasomotor Symptom Data	277
ST 9-2: Number (%) of Subjects With Compliance Rates for Each Treatment Interval	280
ST 9-3: Reduction in Average Daily Number of Moderate and Severe Hot Flushes for the ITT LOCF Population	282
ST 9-4: Reduction in Average Daily Number of Moderate and Severe Hot Flushes for the ITT Observed Data Group	285
ST 9-5: Reduction in the Average Daily Severity Score for the ITT LOCF Population	289
ST 9-6: Reduction in the Average Daily Severity Score for the ITT Observed Data Population	292
ST 9-7: Daily Mean Number of Times Awakened for the ITT Observed Data Population	296
ST 9-8: Profile of Mood States Scores	299
ST 9-9: Reduction in Average Daily Number of Mild, Moderate, and Severe Hot Flushes for the ITT LOCF Population	305
ST 9-10: Reduction in Average Daily Number of Mild, Moderate, and Severe Hot Flushes for the ITT Observed Data Population	308
ST 9-11: Reduction in Weekly Weighted Score of Moderate and Severe Hot Flushes for the ITT LOCF Population	314
ST 9-12: Reduction in Weekly Weighted Score of Moderate and Severe Hot Flushes for the ITT Observed Data Population	317

CONFIDENTIAL 148 Wyeth

CSR-60178

DVS SR

Protocol 3151A2-315-US

ST 9-13: Number and Percentage of Subjects With ≥75% Decrease in Average Daily Number of Moderate and Severe Hot Flushes for the ITT Observed Data Population	
ST 9-14: Number and Percentage of Subjects With ≥50% Decrease in Average Daily Number of Moderate and Severe Hot Flushes for the ITT LOCF Population	321
ST 9-15: Number and Percentage of Subjects With ≥50% Decrease in Average Daily Number of Moderate and Severe Hot Flushes for the ITT Observed Data Population	322
ST 9-16: Number and Percentage of Subjects With ≥50% Decrease in Average Daily Number of Mild, Moderate and Severe Hot Flushes for the ITT LOCF Population	323
ST 9-17: Number and Percentage of Subjects With ≥50% Decrease in Average Daily Number of Mild, Moderate, and Severe Hot Flushes for the ITT Observed Data Population	324
ST 9-18: Daily Mean Sleep Quality Score for the ITT Observed Data Population	325
ST 9-19: Sleep Studies: How Long It Took Subjects to Fall Asleep for the ITT Observed Data Population	327
ST 9-20: Sleep Studies: How Long Subjects Slept for the ITT Observed Data Population	330
ST 9-21: Reduction in Average Daily Number of Moderate and Severe Hot Flushes for the PP Population	332
ST 9-22: Reduction in the Average Severity Score for the PP Population	33
ST 9-23: Summary Statistics for Hot Flush Number and Severity: Final Analysis (PP)	338
ST 9-24: Summary Statistics for Sleep Parameters: Final Analysis (PP)	362
ST 9-25: Decrease in Number of Hot Flushes of at Least 50% and at Least 75%: Final Analysis (PP)	380
ST 9-26: Comparison of Unadjusted and Dunnett's-Method Adjusted p-Values for the Primary Endpoints	390
ST 10-1: Number (%) of Subjects Reporting Adverse Events	394
ST 10-2: Number (%) of Subjects Reporting Adverse Events by Severity and Drug Relationship	404
ST 10-3: Number (%) of Subjects Reporting Posttherapy Adverse Events by Severity and Drug Relationship	458
ST 10-4: Number (%) of Subjects Reporting Treatment-Emergent Adverse Events	498

DVS	SR	Protocol 3151A2-315-US CSR-6	0178
		5: Number (%) of Subjects Reporting Treatment-Emergent Adverse Events by Severity and Drug Relationship	573
		6: Number (%) of Subjects Reporting Treatment-Emergent Adverse Events Vith Start Date During Week 1	621
		7: Number (%) of Subjects Reporting Posttherapy-Emergent Adverse Events y Severity and Drug Relationship	655
	ST 10-	8: Subject Narratives	680
		9: Number (%) of Subjects With Laboratory Test Results of Potential Clinical mportance / Number Tested	874
		10: Descriptive Statistics and Analysis Within and Between Treatment Groups for Laboratory Tests	946
		11: Number (%) of Subjects With Vital Signs of Potential Clinical mportance	.1104
		12: Descriptive Statistics and Analysis Within and Between Treatment Groups for Vital Signs and Physical Characteristics	.1157
	ST 10-	13: Number (%) of Subjects With ECG Results of Potential Clinical Interest	.1196
		14: Descriptive Statistics and Analysis Within and Between Treatment Groups for ECG Results	.1224
	ST 11-	1: Summary Statistics for Subject Satisfaction Survey	.1252
	ST 11-	2: Summary Statistics for Sexual Function Questionnaire	.1268
	ST 11-	3: Summary Statistics for Quality of Life Scale	.1278

CONFIDENTIAL 150 Wyeth

ST 6-1: Summary Statistics for Hot Flush Number and Severity, Week 12 Analysis

Table xxx. Summary statistics for hot flush number and severity DVS-233 SR protocol 315: week 12 analysis (ITT, LOCF)

13:20 Tuesday, December 7, 2004

1

TEST NAME=AVERAGE DAILY NUMBER OF MILD, MODERATE AND SEVERE HOT FLUSHES

	Time	No. of	Base	eline	Obser	ved	Change	from bs	%change	from baseline
Treatment	slot	pairs			mean				mean	SD
GROUP V		120	13.1	6.7						
	WEEK 1	120	13.1	6.7	8.2	6.4	-4.9	3.6	-39.0	26.9
	WEEK 2	120	13.1	6.7	6.7	6.6	-6.5	4.3	-51.0	30.1
	WEEK 3	120	13.1	6.7	6.5	6.5	-6.6	4.1	-52.8	29.2
	WEEK 4	120	13.1	6.7	6.2	6.5	-6.9	4.1	-54.9	28.6
	WEEK 5	120	13.1	6.7	6.3	6.6	-6.8	4.0	-54.9	29.3
	WEEK 6	120	13.1	6.7	6.2	6.5	-6.9	4.2	-55.1	30.9
	WEEK 7	120	13.1	6.7	6.0	6.5	-7.1	4.3	-57.2	31.5
	WEEK 8	120	13.1	6.7	6.0	6.6	-7.1	4.4	-56.9	32.3
	WEEK 9	120	13.1	6.7	5.9	6.7	-7.3	4.7	-57.7	33.8
	WEEK 10	120	13.1	6.7	5.8	6.5	-7.3	4.8	-58.4	32.6
	WEEK 11	120	13.1	6.7	6.0	6.7	-7.1	4.8	-56.7	33.8
	WEEK 12	120	13.1	6.7	6.1	6.7	-7.1	5.0	-56.4	34.4
GROUP W	SCREENING/BASELINE	137	12.7	6.5						
	WEEK 1	136	12.7	6.6	7.7	4.7	-5.1	6.8	-37.9	29.7
	WEEK 2	137	12.7	6.5	6.3	4.9	-6.4	7.0	-49.5	32.6
	WEEK 3	137	12.7	6.5	6.0	4.9	-6.7	6.9	-52.4	31.9
	WEEK 4	137	12.7	6.5	5.9	5.0	-6.8	6.9	-53.1	31.8
	WEEK 5	137	12.7	6.5	5.1	3.9	-7.6	6.8	-57.5	28.4
	WEEK 6	137	12.7	6.5	5.1	4.0	-7.6	6.9	-57.6	29.9
	WEEK 7	137	12.7	6.5	5.2	4.1	-7.5	6.9	-57.5	30.1
	WEEK 8	137	12.7	6.5	5.2	4.3	-7.5	7.1	-56.9	34.0
	WEEK 9	137	12.7	6.5	5.2	4.4	-7.5	7.1	-56.5	36.0
	WEEK 10	137	12.7	6.5	5.2	4.4	-7.4	7.1	-56.6	33.6

DVS SR		CSR-60178								
	WEEK 11	137	12.7	6.5	5.3	4.7	-7.4	7.1	-56.6	34.2
	WEEK 12	137	12.7	6.5	5.3	4.2	-7.4	7.0	-56.2	32.8
GROUP X	SCREENING/BASELINE	141	12.4	4.3						
	WEEK 1	141	12.4	4.3	8.8	4.3	-3.6	3.7	-27.9	25.4
	WEEK 2	141	12.4	4.3	7.5	4.7	-4.8	4.1	-38.8	28.5
	WEEK 3	141	12.4	4.3	6.9	4.8	-5.4	4.2	-43.9	28.7
	WEEK 4	141	12.4	4.3	6.5	4.8	-5.9	4.2	-47.3	28.4
	WEEK 5	141	12.4	4.3	6.3	5.1	-6.1	4.2	-49.6	27.7
	WEEK 6	141	12.4	4.3	6.3	5.2	-6.0	4.3	-49.7	29.4
	WEEK 7	141	12.4	4.3	6.3	5.2	-6.0	4.3	-50.2	29.7
	WEEK 8	141	12.4	4.3	6.4	5.3	-6.0	4.4	-49.4	31.0
	WEEK 9	141	12.4	4.3	6.1	4.9	-6.2	4.3	-50.8	28.6
	WEEK 10	141	12.4	4.3	6.2	4.8	-6.2	4.7	-50.0	29.8
	WEEK 11	141	12.4	4.3	6.1	5.0	-6.3	4.7	-51.2	31.0
	WEEK 12	141	12.4	4.3	6.0	5.0	-6.3	4.9	-51.1	31.8

Table xxx. Summary statistics for hot flush number and severity DVS-233 SR protocol 315: week 12 analysis (ITT, LOCF)

13:20 Tuesday, December 7, 2004

2

TEST NAME=AVERAGE DAILY NUMBER OF MILD, MODERATE AND SEVERE HOT FLUSHES

	Time	No. of	Base	line	Obser	rved	Change i	from bs	%change	from baseline
Treatment	slot	pairs	mean	SD	mean	SD	mean	SD	mean	SD
GROUP Z	SCREENING/BASELINE	145	11.9	4.6						
	WEEK 1	145	11.9	4.6	7.2	4.0	-4.7	4.8	-37.6	29.9
	WEEK 2	145	11.9	4.6	5.9	4.0	-6.1	5.0	-49.7	31.0
	WEEK 3	145	11.9	4.6	5.5	4.2	-6.5	5.0	-53.4	32.3
	WEEK 4	145	11.9	4.6	5.4	4.0	-6.6	5.1	-54.0	31.7
	WEEK 5	145	11.9	4.6	5.2	4.1	-6.7	5.2	-55.5	32.3
	WEEK 6	145	11.9	4.6	5.1	4.0	-6.8	5.3	-55.6	33.3
	WEEK 7	145	11.9	4.6	5.0	4.0	-6.9	5.2	-56.8	33.1
	WEEK 8	145	11.9	4.6	5.0	4.1	-6.9	5.3	-57.0	33.8
	WEEK 9	145	11.9	4.6	4.9	4.1	-7.1	5.2	-58.8	32.8
	WEEK 10	145	11.9	4.6	4.9	4.3	-7.0	5.3	-58.5	34.3
	WEEK 11	145	11.9	4.6	4.9	4.5	-7.0	5.4	-58.3	35.0
	WEEK 12	145	11.9	4.6	4.9	4.3	-7.0	5.4	-58.3	34.6
Placebo	SCREENING/BASELINE	77	11.9	4.6						
	WEEK 1	77	11.9	4.6	9.8	5.0	-2.1	3.2	-17.9	26.8
	WEEK 2	77	11.9	4.6	8.5	5.2	-3.4	4.0	-27.8	30.5
	WEEK 3	77	11.9	4.6	7.9	5.5	-4.0	4.3	-34.0	31.8
	WEEK 4	77	11.9	4.6	7.2	5.0	-4.7	3.9	-40.2	28.4
	WEEK 5	77	11.9	4.6	6.9	5.1	-5.0	4.2	-42.2	30.8
	WEEK 6	77	11.9	4.6	6.7	5.6	-5.2	4.2	-45.8	31.8
	WEEK 7	77	11.9	4.6	6.6	5.9	-5.3	4.5	-47.1	33.5
	WEEK 8	77	11.9	4.6	6.4	5.7	-5.5	4.4	-47.9	33.0
	WEEK 9	77	11.9	4.6	6.5	5.4	-5.4	4.2	-46.7	31.9
	WEEK 10	77	11.9	4.6	6.4	5.5	-5.5	4.4	-47.8	32.3
	WEEK 11	77	11.9	4.6	6.4	5.3	-5.5	4.1	-47.7	31.5
	WEEK 12	77	11.9	4.6	6.5	5.4	-5.4	4.5	-46.7	33.2

Table xxx. Summary statistics for hot flush number and severity DVS-233 SR protocol 315: week 12 analysis (ITT, LOCF)

13:20 Tuesday, December 7, 2004

3

TEST NAME=AVERAGE DAILY NUMBER OF MODERATE AND SEVERE HOT FLUSHES

	Time	No. of	Base	eline	Obse	erved	Change	from bs	%change	from baseline
Treatment	slot	pairs		SD		SD			mean	SD
GROUP V	SCREENING/BASELINE	120	11.1	4.3						
	WEEK 1	120	11.1	4.3	6.2	4.9	-4.9	3.4	-45.7	28.8
	WEEK 2	120	11.1	4.3	4.9	5.1	-6.2	3.9	-57.4	31.5
	WEEK 3	120	11.1	4.3	4.9	5.1	-6.2	3.8	-58.4	30.6
	WEEK 4	120	11.1	4.3	4.7	5.1	-6.4	3.8	-60.2	30.0
	WEEK 5	120	11.1	4.3	4.7	5.3	-6.5	3.8	-61.0	31.7
	WEEK 6	120	11.1	4.3	4.7	5.3	-6.5	4.0	-60.7	34.0
	WEEK 7	120	11.1	4.3	4.5	5.3	-6.6	4.2	-61.9	34.3
	WEEK 8	120	11.1	4.3	4.5	5.4	-6.6	4.3	-61.6	36.4
	WEEK 9	120	11.1	4.3	4.4	5.5	-6.7	4.5	-62.4	38.5
	WEEK 10	120	11.1	4.3	4.4	5.4	-6.7	4.3	-62.5	36.4
	WEEK 11	120	11.1	4.3	4.6	5.4	-6.5	4.3	-60.5	36.7
	WEEK 12	120	11.1	4.3	4.7	5.6	-6.4	4.6	-59.7	39.0
GROUP W	SCREENING/BASELINE	137	11.2	6.4						
	WEEK 1	136	11.2	6.4	6.1	4.3	-5.1	6.7	-43.6	31.3
	WEEK 2	137	11.2	6.4	4.9	4.5	-6.3	7.1	-54.8	34.6
	WEEK 3	137	11.2	6.4	4.7	4.5	-6.5	7.1	-57.4	33.6
	WEEK 4	137	11.2	6.4	4.6	4.6	-6.6	7.1	-58.0	33.6
	WEEK 5	137	11.2	6.4	3.9	3.6	-7.3	7.0	-62.8	30.8
	WEEK 6	137	11.2	6.4	4.0	3.8	-7.2	7.0	-62.2	32.2
	WEEK 7	137	11.2	6.4	4.0	3.8	-7.2	7.0	-62.6	32.3
	WEEK 8	137	11.2	6.4	4.2	4.1	-7.1	7.2	-60.9	36.5
	WEEK 9	137	11.2	6.4	4.1	4.1	-7.1	7.2	-61.1	37.9
	WEEK 10	137	11.2	6.4	4.2	4.1	-7.0	7.1	-61.0	35.2
	WEEK 11	137	11.2	6.4	4.2	4.4	-7.0	7.2	-61.2	36.1

DVS SR		Protocol 3151A2-315-US									
	WEEK 12	137	11.2	6.4	4.2	4.0	-7.0	7.1	-60.3	35.1	
GROUP X	SCREENING/BASELINE	141	10.8	4.1							
	WEEK 1	141	10.8	4.1	7.1	4.1	-3.7	3.6	-33.0	29.0	
	WEEK 2	141	10.8	4.1	6.0	4.3	-4.8	3.8	-43.9	31.5	
	WEEK 3	141	10.8	4.1	5.5	4.6	-5.3	3.9	-49.1	32.4	
	WEEK 4	141	10.8	4.1	5.2	4.5	-5.7	3.8	-52.5	31.1	
	WEEK 5	141	10.8	4.1	5.2	4.9	-5.6	4.1	-53.1	32.0	
	WEEK 6	141	10.8	4.1	5.2	5.0	-5.6	4.3	-52.9	35.1	
	WEEK 7	141	10.8	4.1	5.2	5.1	-5.6	4.4	-53.1	36.2	
	WEEK 8	141	10.8	4.1	5.2	5.1	-5.6	4.5	-52.7	37.1	
	WEEK 9	141	10.8	4.1	5.1	4.7	-5.8	4.5	-53.1	36.6	
	WEEK 10	141	10.8	4.1	5.1	4.6	-5.7	4.7	-52.6	35.8	
	WEEK 11	141	10.8	4.1	5.0	4.8	-5.9	4.6	-54.3	35.3	
	WEEK 12	141	10.8	4.1	4.9	4.8	-5.9	4.8	-54.5	36.9	

Table xxx. Summary statistics for hot flush number and severity DVS-233 SR protocol 315: week 12 analysis (ITT, LOCF)

13:20 Tuesday, December 7, 2004

4

TEST NAME=AVERAGE DAILY NUMBER OF MODERATE AND SEVERE HOT FLUSHES

	Time	No. of	Base	eline	Obse	rved	Change	from bs	%change	from baseline
Treatment	slot	pairs	mean	SD	mean	SD	mean	SD	mean	SD
GROUP Z	SCREENING/BASELINE	145	10.5	4.1						
	WEEK 1	145	10.5	4.1	5.8	3.5	-4.7	4.3	-42.1	32.0
	WEEK 2	145	10.5	4.1	4.5	3.5	-6.0	4.5	-55.2	31.8
	WEEK 3	145	10.5	4.1	4.3	3.6	-6.2	4.5	-58.2	32.7
	WEEK 4	145	10.5	4.1	4.2	3.5	-6.3	4.6	-58.9	32.5
	WEEK 5	145	10.5	4.1	4.0	3.7	-6.5	4.7	-60.9	34.0
	WEEK 6	145	10.5	4.1	3.9	3.6	-6.6	4.7	-61.7	33.8
	WEEK 7	145	10.5	4.1	3.8	3.6	-6.7	4.6	-62.7	33.2
	WEEK 8	145	10.5	4.1	3.8	3.7	-6.7	4.8	-62.9	34.5
	WEEK 9	145	10.5	4.1	3.6	3.6	-6.9	4.7	-64.8	33.2
	WEEK 10	145	10.5	4.1	3.7	3.7	-6.8	4.7	-64.4	35.0
	WEEK 11	145	10.5	4.1	3.7	3.9	-6.8	4.7	-64.5	35.6
	WEEK 12	145	10.5	4.1	3.7	3.8	-6.8	4.8	-64.2	35.7
Placebo	SCREENING/BASELINE	77	11.0	4.6	•					•
	WEEK 1	77	11.0	4.6	8.8	4.9	-2.2	3.2	-19.7	29.4
	WEEK 2	77	11.0	4.6	7.4	5.2	-3.6	4.2	-32.4	34.3
	WEEK 3	77	11.0	4.6	6.6	5.1	-4.4	4.2	-40.3	34.3
	WEEK 4	77	11.0	4.6	5.9	4.7	-5.2	4.2	-46.7	32.9
	WEEK 5	77	11.0	4.6	5.6	4.8	-5.4	4.2	-49.4	32.8
	WEEK 6	77	11.0	4.6	5.5	5.0	-5.5	4.0	-51.9	33.3
	WEEK 7	77	11.0	4.6	5.5	5.3	-5.5	4.2	-52.5	34.5
	WEEK 8	77	11.0	4.6	5.5	5.7	-5.5	4.5	-52.6	36.7
	WEEK 9	77	11.0	4.6	5.5	5.3	-5.6	4.4	-52.2	35.9
	WEEK 10	77	11.0	4.6	5.4	5.3	-5.6	4.4	-52.8	36.6
	WEEK 11	77	11.0	4.6	5.4	5.3	-5.6	4.2	-52.8	35.6
	WEEK 12	77	11.0	4.6	5.6	5.4	-5.4	4.5	-50.8	37.3

Table xxx. Summary statistics for hot flush number and severity DVS-233 SR protocol 315: week 12 analysis (ITT, LOCF)

13:20 Tuesday, December 7, 2004

5

TEST NAME=AVERAGE DAILY SEVERITY SCORE OF MILD, MODERATE AND SEVERE HOT FLUSHES

	Time	No. of	Base	eline	Obse	rved	Change :	from bs	%change	from baseline
Treatment	slot	pairs	mean	SD	mean	SD	mean	SD	mean	SD
GROUP V	SCREENING/BASELINE	120	2.4	0.3						
	WEEK 1	120	2.4	0.3	2.0	0.5	-0.4	0.5	-15.5	20.4
	WEEK 2	120	2.4	0.3	1.8	0.7	-0.5	0.7	-22.4	29.4
	WEEK 3	120	2.4	0.3	1.9	0.7	-0.5	0.7	-20.3	29.4
	WEEK 4	120	2.4	0.3	1.8	0.8	-0.5	0.8	-22.0	31.6
	WEEK 5	120	2.4	0.3	1.8	0.8	-0.6	0.8	-23.4	31.0
	WEEK 6	120	2.4	0.3	1.8	0.8	-0.6	0.8	-25.1	32.7
	WEEK 7	120	2.4	0.3	1.7	0.9	-0.7	0.9	-27.1	36.7
	WEEK 8	120	2.4	0.3	1.7	0.9	-0.6	0.9	-26.2	36.1
	WEEK 9	120	2.4	0.3	1.7	0.9	-0.7	0.9	-29.1	35.5
	WEEK 10	120	2.4	0.3	1.7	0.9	-0.7	0.9	-27.8	36.5
	WEEK 11	120	2.4	0.3	1.7	0.9	-0.7	0.9	-27.8	36.8
	WEEK 12	120	2.4	0.3	1.7	0.9	-0.7	0.9	-27.1	37.2
GROUP W	SCREENING/BASELINE	137	2.4	0.3			•			
	WEEK 1	136	2.4	0.3	2.1	0.5	-0.3	0.5	-13.0	20.4
	WEEK 2	137	2.4	0.3	1.9	0.7	-0.5	0.7	-19.9	27.2
	WEEK 3	137	2.4	0.3	1.8	0.7	-0.5	0.7	-22.0	29.0
	WEEK 4	137	2.4	0.3	1.9	0.7	-0.5	0.7	-21.2	30.3
	WEEK 5	137	2.4	0.3	1.8	0.7	-0.6	0.7	-23.5	30.0
	WEEK 6	137	2.4	0.3	1.8	0.7	-0.6	0.7	-23.8	30.0
	WEEK 7	137	2.4	0.3	1.8	0.7	-0.6	0.7	-23.9	29.7
	WEEK 8	137	2.4	0.3	1.8	0.7	-0.5	0.7	-22.6	29.1
	WEEK 9	137	2.4	0.3	1.8	0.7	-0.6	0.7	-24.2	31.0
	WEEK 10	137	2.4	0.3	1.8	0.8	-0.6	0.7	-24.4	31.5
	WEEK 11	137	2.4	0.3	1.8	0.8	-0.6	0.8	-25.4	32.5
	WEEK 12	137	2.4	0.3	1.8	0.7	-0.6	0.7	-22.9	29.7

DVS SR	Protocol 3151A2-315-US								CSR-60178		
GROUP X	SCREENING/BASELINE	141	2.4	0.3							
	WEEK 1	141	2.4	0.3	2.2	0.4	-0.2	0.4	-8.5	15.7	
	WEEK 2	141	2.4	0.3	2.1	0.5	-0.3	0.5	-11.7	20.3	
	WEEK 3	141	2.4	0.3	2.1	0.6	-0.3	0.6	-13.4	24.0	
	WEEK 4	141	2.4	0.3	2.0	0.6	-0.4	0.6	-15.4	24.8	
	WEEK 5	141	2.4	0.3	2.0	0.6	-0.3	0.6	-13.7	26.7	
	WEEK 6	141	2.4	0.3	2.0	0.6	-0.4	0.6	-14.5	26.5	
	WEEK 7	141	2.4	0.3	2.0	0.7	-0.4	0.6	-14.3	28.1	
	WEEK 8	141	2.4	0.3	2.0	0.7	-0.4	0.7	-14.7	29.0	
	WEEK 9	141	2.4	0.3	2.1	0.6	-0.3	0.6	-12.3	27.4	
	WEEK 10	141	2.4	0.3	2.1	0.6	-0.3	0.6	-12.6	27.4	
	WEEK 11	141	2.4	0.3	2.0	0.6	-0.4	0.6	-14.1	28.1	
	WEEK 12	141	2.4	0.3	2.0	0.7	-0.4	0.7	-15.3	29.0	

Table xxx. Summary statistics for hot flush number and severity DVS-233 SR protocol 315: week 12 analysis (ITT, LOCF)

13:20 Tuesday, December 7, 2004

6

TEST NAME=AVERAGE DAILY SEVERITY SCORE OF MILD, MODERATE AND SEVERE HOT FLUSHES

	Time	No. of	Baseline mean SD		Observed mean SD		Change from bs mean SD		%change from baseline		
Treatment	slot	pairs							mean SD		
GROUP Z	SCREENING/BASELINE	145	2.4	0.3							
	WEEK 1	145	2.4	0.3	2.0	0.6	-0.4	0.6	-17.1	24.5	
	WEEK 2	145	2.4	0.3	1.8	0.7	-0.5	0.7	-22.4	29.3	
	WEEK 3	145	2.4	0.3	1.8	0.8	-0.6	0.8	-24.2	32.5	
	WEEK 4	145	2.4	0.3	1.8	0.7	-0.6	0.8	-23.4	30.7	
	WEEK 5	145	2.4	0.3	1.7	0.8	-0.7	0.8	-27.1	32.0	
	WEEK 6	145	2.4	0.3	1.7	0.8	-0.7	0.8	-26.9	32.4	
	WEEK 7	145	2.4	0.3	1.7	0.8	-0.7	0.8	-28.5	32.8	
	WEEK 8	145	2.4	0.3	1.7	0.8	-0.7	0.8	-29.5	33.5	
	WEEK 9	145	2.4	0.3	1.7	0.8	-0.7	0.8	-30.1	34.7	
	WEEK 10	145	2.4	0.3	1.7	0.8	-0.7	0.8	-29.7	34.1	
	WEEK 11	145	2.4	0.3	1.6	0.8	-0.7	0.8	-30.7	33.7	
	WEEK 12	145	2.4	0.3	1.6	0.8	-0.7	0.8	-30.5	34.3	
Placebo	SCREENING/BASELINE	77	2.5	0.3							
	WEEK 1	77	2.5	0.3	2.4	0.4	-0.1	0.3	-4.1	12.4	
	WEEK 2	77	2.5	0.3	2.2	0.6	-0.3	0.6	-10.2	22.4	
	WEEK 3	77	2.5	0.3	2.1	0.7	-0.3	0.7	-12.7	27.2	
	WEEK 4	77	2.5	0.3	2.1	0.7	-0.4	0.7	-15.7	28.5	
	WEEK 5	77	2.5	0.3	2.0	0.7	-0.5	0.8	-17.6	29.5	
	WEEK 6	77	2.5	0.3	2.0	0.8	-0.5	0.8	-18.9	31.2	
	WEEK 7	77	2.5	0.3	2.0	0.8	-0.5	0.8	-19.9	32.3	
	WEEK 8	77	2.5	0.3	1.9	0.8	-0.5	0.8	-20.2	32.8	
	WEEK 9	77	2.5	0.3	2.0	0.8	-0.5	0.8	-19.4	31.2	
	WEEK 10	77	2.5	0.3	2.0	0.8	-0.5	0.8	-19.8	31.2	
	WEEK 11	77	2.5	0.3	2.0	0.7	-0.5	0.8	-18.4	30.8	
	WEEK 12	77	2.5	0.3	2.0	0.8	-0.5	0.8	-17.9	32.5	

Table xxx. Summary statistics for hot flush number and severity DVS-233 SR protocol 315: week 12 analysis (ITT, LOCF)

13:20 Tuesday, December 7, 2004

7

TEST NAME=WEEKLY WEIGHTED SCORE OF MODERATE AND SEVERE HOT FLUSHES

	Time	No. of	Base	eline	Observed		- Change from bs		%change	from baseline
Treatment	slot	pairs	mean	SD	mean	SD	mean	SD	mean	SD
GROUP V	SCREENING/BASELINE	120	199.4	82.7						
	WEEK 1	120	199.4	82.7	106.7	88.9	-92.7	63.3	-47.9	29.2
	WEEK 2	120	199.4	82.7	83.3	92.6	-116.1	73.1	-60.1	31.7
	WEEK 3	120	199.4	82.7	81.5	92.7	-117.9	68.7	-61.5	29.7
	WEEK 4	120	199.4	82.7	75.5	92.9	-123.9	68.7	-64.9	28.7
	WEEK 5	120	199.4	82.7	75.7	96.7	-123.7	69.2	-65.4	30.5
	WEEK 6	120	199.4	82.7	77.0	96.3	-122.4	71.8	-64.4	32.9
	WEEK 7	120	199.4	82.7	74.1	95.8	-125.4	73.9	-65.5	33.0
	WEEK 8	120	199.4	82.7	73.4	96.3	-126.0	75.6	-65.5	35.1
	WEEK 9	120	199.4	82.7	71.9	99.4	-127.5	78.6	-66.5	37.5
	WEEK 10	120	199.4	82.7	72.1	97.6	-127.3	76.8	-66.5	35.6
	WEEK 11	120	199.4	82.7	75.9	98.7	-123.5	76.1	-64.6	35.5
	WEEK 12	120	199.4	82.7	76.4	100.4	-123.0	79.5	-64.0	37.6
GROUP W	SCREENING/BASELINE	137	200.9	111.5						
	WEEK 1	136	201.3	111.8	104.8	82.2	-96.5	113.2	-46.3	31.3
	WEEK 2	137	200.9	111.5	85.1	85.9	-115.9	120.6	-57.3	34.1
	WEEK 3	137	200.9	111.5	79.8	84.2	-121.2	121.3	-60.0	33.3
	WEEK 4	137	200.9	111.5	79.1	85.9	-121.9	119.6	-60.8	33.2
	WEEK 5	137	200.9	111.5	64.3	64.1	-136.6	118.7	-66.2	30.3
	WEEK 6	137	200.9	111.5	65.4	65.8	-135.6	117.3	-65.7	30.9
	WEEK 7	137	200.9	111.5	65.5	67.7	-135.4	117.0	-66.1	30.8
	WEEK 8	137	200.9	111.5	67.1	70.9	-133.9	118.8	-65.0	34.3
	WEEK 9	137	200.9	111.5	65.9	70.0	-135.1	118.0	-65.8	35.1
	WEEK 10	137	200.9	111.5	67.8	70.7	-133.1	117.0	-65.2	32.6
	WEEK 11	137	200.9	111.5	67.8	75.4	-133.1	118.3	-65.4	33.2
	WEEK 12	137	200.9	111.5	67.0	69.4	-133.9	118.3	-65.0	33.0

DVS SR		Protocol	Protocol 3151A2-315-US								
GROUP X	SCREENING/BASELINE	141	193.2	77.1							
	WEEK 1	141	193.2	77.1	124.7	73.3	-68.4	67.2	-34.1	29.7	
	WEEK 2	141	193.2	77.1	104.7	77.1	-88.4	71.9	-45.3	32.5	
	WEEK 3	141	193.2	77.1	96.3	83.4	-96.9	71.7	-50.3	33.2	
	WEEK 4	141	193.2	77.1	86.2	70.3	-106.9	75.3	-54.8	31.8	
	WEEK 5	141	193.2	77.1	88.1	86.8	-105.1	76.9	-55.1	33.7	
	WEEK 6	141	193.2	77.1	88.0	87.0	-105.2	80.9	-55.0	36.7	
	WEEK 7	141	193.2	77.1	88.4	87.9	-104.8	82.9	-54.8	38.1	
	WEEK 8	141	193.2	77.1	88.8	87.9	-104.3	84.5	-54.4	38.6	
	WEEK 9	141	193.2	77.1	85.6	82.2	-107.6	86.5	-55.1	39.2	
	WEEK 10	141	193.2	77.1	86.1	79.8	-107.1	91.0	-54.4	37.8	
	WEEK 11	141	193.2	77.1	84.1	82.5	-109.0	89.2	-56.0	36.9	
	WEEK 12	141	193.2	77.1	76.8	76.5	-116.4	87.8	-59.1	36.0	

Table xxx. Summary statistics for hot flush number and severity DVS-233 SR protocol 315: week 12 analysis (ITT, LOCF)

13:20 Tuesday, December 7, 2004

8

TEST NAME=WEEKLY WEIGHTED SCORE OF MODERATE AND SEVERE HOT FLUSHES

	Time	No. of	Base	eline	Obse	rved	Change	from bs	%change	from baseline
Treatment	slot	pairs	mean	SD	mean	SD	mean	SD	mean	SD
GROUP Z	SCREENING/BASELINE	145	189.9	79.7						
	WEEK 1	145	189.9	79.7	101.8	62.8	-88.0	83.9	-43.5	33.3
	WEEK 2	145	189.9	79.7	78.4	62.5	-111.5	85.6	-56.8	32.6
	WEEK 3	145	189.9	79.7	71.7	65.8	-118.1	85.7	-61.2	32.6
	WEEK 4	145	189.9	79.7	68.5	61.5	-121.3	85.0	-62.7	30.9
	WEEK 5	145	189.9	79.7	65.0	65.0	-124.9	86.7	-64.9	32.6
	WEEK 6	145	189.9	79.7	63.0	63.5	-126.9	87.9	-65.8	32.0
	WEEK 7	145	189.9	79.7	62.1	62.2	-127.7	86.0	-66.5	31.6
	WEEK 8	145	189.9	79.7	60.8	61.5	-129.1	88.1	-66.9	32.6
	WEEK 9	145	189.9	79.7	58.0	60.7	-131.9	86.6	-68.7	31.1
	WEEK 10	145	189.9	79.7	57.6	60.3	-132.3	83.5	-69.5	29.4
	WEEK 11	145	189.9	79.7	57.3	62.2	-132.6	83.5	-69.7	30.2
	WEEK 12	145	189.9	79.7	56.5	60.8	-133.3	85.4	-69.8	30.2
Placebo	SCREENING/BASELINE	77	198.3	84.6					•	
	WEEK 1	77	198.3	84.6	155.4	91.4	-42.9	61.6	-21.6	30.9
	WEEK 2	77	198.3	84.6	130.2	90.2	-68.1	79.0	-33.5	34.9
	WEEK 3	77	198.3	84.6	114.4	85.9	-83.9	80.9	-41.7	34.5
	WEEK 4	77	198.3	84.6	102.6	81.7	-95.7	82.7	-47.5	34.3
	WEEK 5	77	198.3	84.6	94.1	76.7	-104.2	87.6	-51.3	33.6
	WEEK 6	77	198.3	84.6	89.0	77.6	-109.3	86.7	-54.6	34.1
	WEEK 7	77	198.3	84.6	85.9	76.6	-112.5	87.7	-56.1	34.4
	WEEK 8	77	198.3	84.6	86.1	86.1	-112.2	93.7	-56.5	37.3
	WEEK 9	77	198.3	84.6	83.7	77.4	-114.6	90.5	-57.2	34.6
	WEEK 10	77	198.3	84.6	83.2	78.0	-115.1	92.4	-57.4	35.3
	WEEK 11	77	198.3	84.6	82.5	76.3	-115.8	86.5	-58.2	33.7
	WEEK 12	77	198.3	84.6	84.6	78.3	-113.7	92.0	-56.8	35.9

Table xxx Within and between group comparisons for hot flush number and severity DVS-233 SR protocol 315: week 12 analysis (ITT, LOCF)

13:20 Tuesday, December 7, 2004

9

TEST NAME=AVERAGE DAILY NUMBER OF MILD, MODERATE AND SEVERE HOT FLUSHES

Treatment	slot	pairs	Adjusted mean	SE	placebo	within group
GROUP V	WEEK 1	120		0.37		
	WEEK 2	120	-6.12	0.39	0.000	0.000
	WEEK 3	120	-6.31	0.40	0.002	0.000
	WEEK 4	120	-6.55	0.40	0.017	0.000
	WEEK 5	120	-6.54	0.39	0.063	0.000
	WEEK 6	120	-6.64	0.41	0.127	0.000
	WEEK 7	120	-6.90	0.41	0.075	0.000
	WEEK 8	120	-6.86	0.42	0.137	0.000
	WEEK 9	120	-6.95	0.41	0.068	0.000
	WEEK 10	120	-7.07	0.42	0.094	0.000
	WEEK 11	120	-6.85	0.43	0.192	0.000
	WEEK 12	120	-6.78	0.43	0.180	0.000
GROUP W	WEEK 1	136	-5.01	0.35	0.000	0.000
	WEEK 2	137	-6.34	0.37	0.000	0.000
	WEEK 3	137	-6.63	0.38	0.000	0.000
	WEEK 4	137	-6.71	0.37	0.007	0.000
	WEEK 5	137	-7.54	0.37	0.000	0.000
	WEEK 6	137	-7.57	0.38	0.002	0.000
	WEEK 7	137	-7.49	0.39	0.006	0.000
	WEEK 8	137	-7.47	0.39	0.013	0.000
	WEEK 9	137	-7.43	0.39	0.008	0.000
	WEEK 10	137	-7.44	0.39	0.021	0.000
	WEEK 11	137	-7.39	0.40	0.031	0.000
	WEEK 12	137	-7.36	0.40	0.024	0.000

DVS SR		Protocol 3151A2-315-US							
GROUP X	WEEK 1	141	-3.63	0.34	0.038	0.000			
	WEEK 2	141	-4.85	0.37	0.056	0.000			
	WEEK 3	141	-5.48	0.37	0.055	0.000			
	WEEK 4	141	-5.89	0.37	0.169	0.000			
	WEEK 5	141	-6.16	0.37	0.198	0.000			
	WEEK 6	141	-6.17	0.38	0.418	0.000			
	WEEK 7	141	-6.18	0.38	0.498	0.000			
	WEEK 8	141	-6.08	0.39	0.759	0.000			
	WEEK 9	141	-6.32	0.38	0.384	0.000			
	WEEK 10	141	-6.33	0.39	0.572	0.000			
	WEEK 11	141	-6.46	0.40	0.455	0.000			
	WEEK 12	141	-6.46	0.40	0.376	0.000			

ANCOVA: change = treat + site + baseline

CONFIDENTIAL 164 Wyeth

Table xxx Within and between group comparisons for hot flush number and severity DVS-233 SR protocol 315: week 12 analysis (ITT, LOCF)

13:20 Tuesday, December 7, 2004

10

TEST NAME=AVERAGE DAILY NUMBER OF MILD, MODERATE AND SEVERE HOT FLUSHES

Treatment	Time slot	No. of pairs	Adjusted mean	change	p-value vs. placebo	within
GROUP Z	WEEK 1	145	-4.96	0.33	0.000	0.000
	WEEK 2	145	-6.30	0.36	0.000	0.000
	WEEK 3	145	-6.63	0.37	0.000	0.000
	WEEK 4	145	-6.81	0.36	0.004	0.000
	WEEK 5	145	-7.06	0.36	0.005	0.000
	WEEK 6	145	-7.17	0.37	0.014	0.000
	WEEK 7	145	-7.24	0.37	0.016	0.000
	WEEK 8	145	-7.27	0.38	0.029	0.000
	WEEK 9	145	-7.42	0.38	0.008	0.000
	WEEK 10	145	-7.41	0.38	0.023	0.000
	WEEK 11	145	-7.40	0.39	0.028	0.000
	WEEK 12	145	-7.42	0.39	0.017	0.000
Placebo	WEEK 1	77	-2.48	0.45		0.000
	WEEK 2	77	-3.71	0.49	•	0.000
	WEEK 3	77	-4.32	0.49	•	0.000
	WEEK 4	77	-5.07	0.49	•	0.000
	WEEK 5	77	-5.39	0.48	•	0.000
	WEEK 6	77	-5.68	0.50	•	0.000
	WEEK 7	77	-5.76	0.50	•	0.000
	WEEK 8	77	-5.89	0.52	•	0.000
	WEEK 9	77	-5.77	0.51		0.000
	WEEK 10	77	-5.97	0.52	•	0.000
	WEEK 11	77	-5.97	0.53		0.000
	WEEK 12	77	-5.89	0.53	•	0.000
	Anna I alka i haaalla.	_				

ANCOVA: change = treat + site + baseline

Table xxx Within and between group comparisons for hot flush number and severity DVS-233 SR protocol 315: week 12 analysis (ITT, LOCF)

13:20 Tuesday, December 7, 2004

11

TEST NAME=AVERAGE DAILY NUMBER OF MODERATE AND SEVERE HOT FLUSHES

Treatment	Time slot		Adjusted mean	change	p-value vs. placebo	within
GROUP V	WEEK 1	120	-4.88	0.34	0.000	0.000
	WEEK 2	120	-6.11	0.37	0.000	0.000
	WEEK 3	120	-6.21	0.38	0.003	0.000
	WEEK 4	120	-6.42	0.38	0.040	0.000
	WEEK 5	120	-6.49	0.38	0.104	0.000
	WEEK 6	120	-6.52	0.39	0.158	0.000
	WEEK 7	120	-6.67	0.39	0.098	0.000
	WEEK 8	120	-6.63	0.41	0.111	0.000
	WEEK 9	120	-6.69	0.40	0.086	0.000
	WEEK 10	120	-6.74	0.40	0.098	0.000
	WEEK 11	120	-6.53	0.41	0.184	0.000
	WEEK 12	120	-6.46	0.41	0.132	0.000
GROUP W	WEEK 1	136	-5.07	0.33	0.000	0.000
	WEEK 2	137	-6.16	0.35	0.000	0.000
	WEEK 3	137	-6.45	0.36	0.001	0.000
	WEEK 4	137	-6.47	0.35	0.029	0.000
	WEEK 5	137	-7.25	0.36	0.003	0.000
	WEEK 6	137	-7.19	0.36	0.010	0.000
	WEEK 7	137	-7.19	0.37	0.011	0.000
	WEEK 8	137	-7.03	0.39	0.023	0.000
	WEEK 9	137	-7.01	0.38	0.022	0.000
	WEEK 10	137	-6.99	0.38	0.035	0.000
	WEEK 11	137	-6.99	0.38	0.036	0.000
	WEEK 12	137	-6.93	0.38	0.021	0.000

DVS SR		Protocol 3151A2-315-US							
GROUP X	WEEK 1	141	-3.78	0.32	0.003	0.000			
	WEEK 2	141	-4.87	0.34	0.031	0.000			
	WEEK 3	141	-5.40	0.35	0.104	0.000			
	WEEK 4	141	-5.77	0.35	0.332	0.000			
	WEEK 5	141	-5.81	0.35	0.626	0.000			
	WEEK 6	141	-5.82	0.36	0.795	0.000			
	WEEK 7	141	-5.81	0.37	0.789	0.000			
	WEEK 8	141	-5.76	0.38	0.802	0.000			
	WEEK 9	141	-5.87	0.37	0.665	0.000			
	WEEK 10	141	-5.90	0.37	0.749	0.000			
	WEEK 11	141	-6.05	0.38	0.560	0.000			
	WEEK 12	141	-6.10	0.38	0.331	0.000			

ANCOVA: change = treat + site + baseline

CONFIDENTIAL 167 Wyeth

Table xxx Within and between group comparisons for hot flush number and severity DVS-233 SR protocol 315: week 12 analysis (ITT, LOCF)

13:20 Tuesday, December 7, 2004

12

TEST NAME=AVERAGE DAILY NUMBER OF MODERATE AND SEVERE HOT FLUSHES

Treatment	Time slot	No. of pairs	Adjusted mean	change	p-value vs. placebo	within
GROUP Z	WEEK 1	145	-4.94	0.31	0.000	0.000
	WEEK 2	145	-6.22	0.34	0.000	0.000
	WEEK 3	145	-6.48	0.35	0.000	0.000
	WEEK 4	145	-6.62	0.34	0.014	0.000
	WEEK 5	145	-6.86	0.35	0.021	0.000
	WEEK 6	145	-6.97	0.35	0.026	0.000
	WEEK 7	145	-7.04	0.36	0.020	0.000
	WEEK 8	145	-7.07	0.37	0.018	0.000
	WEEK 9	145	-7.21	0.37	0.008	0.000
	WEEK 10	145	-7.20	0.37	0.013	0.000
	WEEK 11	145	-7.22	0.37	0.013	0.000
	WEEK 12	145	-7.22	0.37	0.005	0.000
Placebo	WEEK 1	77	-2.25	0.42		0.000
	WEEK 2	77	-3.66	0.46	•	0.000
	WEEK 3	77	-4.47	0.47		0.000
	WEEK 4	77	-5.22	0.46		0.000
	WEEK 5	77	-5.54	0.47		0.000
	WEEK 6	77	-5.67	0.48		0.000
	WEEK 7	77	-5.65	0.48		0.000
	WEEK 8	77	-5.61	0.50		0.000
	WEEK 9	77	-5.61	0.50		0.000
	WEEK 10	77	-5.71	0.49	•	0.000
	WEEK 11	77	-5.69	0.50		0.000
	WEEK 12	77	-5.50	0.50	•	0.000
	Annual Carte Caracatta	_				

ANCOVA: change = treat + site + baseline

Table xxx Within and between group comparisons for hot flush number and severity DVS-233 SR protocol 315: week 12 analysis (ITT, LOCF)

13:20 Tuesday, December 7, 2004

13

TEST NAME=AVERAGE DAILY SEVERITY SCORE OF MILD, MODERATE AND SEVERE HOT FLUSHES

Treatment	slot	pairs	Adjusted mean	SE	vs. placebo	group
GROUP V	WEEK 1	120		0.04		
	WEEK 2	120	-0.57	0.06	0.001	0.000
	WEEK 3	120	-0.53	0.06	0.028	0.000
	WEEK 4	120	-0.57	0.07	0.066	0.000
	WEEK 5	120	-0.62	0.07	0.085	0.000
	WEEK 6	120	-0.66	0.07	0.079	0.000
	WEEK 7	120	-0.73	0.07	0.045	0.000
	WEEK 8	120	-0.70	0.07	0.091	0.000
	WEEK 9	120	-0.77	0.07	0.012	0.000
	WEEK 10	120	-0.75	0.07	0.029	0.000
	WEEK 11	120	-0.76	0.07	0.009	0.000
	WEEK 12	120	-0.74	0.07	0.010	0.000
GROUP W	WEEK 1	136	-0.32	0.04	0.001	0.000
	WEEK 2	137	-0.49	0.05	0.006	0.000
	WEEK 3	137	-0.55	0.06	0.014	0.000
	WEEK 4	137	-0.53	0.06	0.138	0.000
	WEEK 5	137	-0.60	0.06	0.113	0.000
	WEEK 6	137	-0.61	0.06	0.178	0.000
	WEEK 7	137	-0.62	0.07	0.303	0.000
	WEEK 8	137	-0.59	0.07	0.499	0.000
	WEEK 9	137	-0.62	0.07	0.223	0.000
	WEEK 10	137	-0.64	0.07	0.243	0.000
	WEEK 11	137	-0.66	0.07	0.084	0.000
	WEEK 12	137	-0.59	0.07	0.189	0.000

DVS SR			CSR-60178				
GROUP X	WEEK 1	141	-0.21	0.04	0.076	0.000	
	WEEK 2	141	-0.28	0.05	0.716	0.000	
	WEEK 3	141	-0.33	0.06	0.861	0.000	
	WEEK 4	141	-0.37	0.06	0.915	0.000	
	WEEK 5	141	-0.37	0.06	0.484	0.000	
	WEEK 6	141	-0.40	0.06	0.454	0.000	
	WEEK 7	141	-0.40	0.06	0.307	0.000	
	WEEK 8	141	-0.41	0.06	0.351	0.000	
	WEEK 9	141	-0.36	0.06	0.198	0.000	
	WEEK 10	141	-0.37	0.06	0.192	0.000	
	WEEK 11	141	-0.41	0.07	0.575	0.000	
	WEEK 12	141	-0.43	0.07	0.813	0.000	

ANCOVA: change = treat + site + baseline

CONFIDENTIAL 170 Wyeth

Table xxx Within and between group comparisons for hot flush number and severity DVS-233 SR protocol 315: week 12 analysis (ITT, LOCF)

13:20 Tuesday, December 7, 2004

14

TEST NAME=AVERAGE DAILY SEVERITY SCORE OF MILD, MODERATE AND SEVERE HOT FLUSHES

Treatment	Time slot	pairs	Adjusted mean	SE	vs. placebo	
GROUP Z	WEEK 1	145		0.04		0.000
	WEEK 2	145	-0.55	0.05	0.001	0.000
	WEEK 3	145	-0.60	0.06	0.003	0.000
	WEEK 4	145	-0.57	0.06	0.054	0.000
	WEEK 5	145	-0.68	0.06	0.019	0.000
	WEEK 6	145	-0.67	0.06	0.048	0.000
	WEEK 7	145	-0.72	0.06	0.042	0.000
	WEEK 8	145	-0.74	0.06	0.029	0.000
	WEEK 9	145	-0.76	0.06	0.011	0.000
	WEEK 10	145	-0.76	0.06	0.017	0.000
	WEEK 11	145	-0.79	0.06	0.003	0.000
	WEEK 12	145	-0.78	0.06	0.002	0.000
Placebo	WEEK 1	77	-0.09	0.05		0.099
	WEEK 2	77	-0.25	0.07		0.001
	WEEK 3	77	-0.31	0.08		0.000
	WEEK 4	77	-0.38	0.08		0.000
	WEEK 5	77	-0.44	0.08		0.000
	WEEK 6	77	-0.47	0.08		0.000
	WEEK 7	77	-0.51	0.09		0.000
	WEEK 8	77	-0.51	0.09		0.000
	WEEK 9	77	-0.49	0.09		0.000
	WEEK 10	77	-0.51	0.09		0.000
	WEEK 11	77	-0.47	0.09		0.000
	WEEK 12	77	-0.45	0.09	•	0.000

ANCOVA: change = treat + site + baseline

Table xxx Within and between group comparisons for hot flush number and severity DVS-233 SR protocol 315: week 12 analysis (ITT, LOCF)

13:20 Tuesday, December 7, 2004

15

TEST NAME=WEEKLY WEIGHTED SCORE OF MODERATE AND SEVERE HOT FLUSHES

Treatment	Time slot		mean	SE	vs. placebo	group
GROUP V	WEEK 1			6.26		
	WEEK 2	120	-115.1	6.70	0.000	0.000
	WEEK 3	120	-117.3	6.78	0.002	0.000
	WEEK 4	120	-123.5	6.63	0.007	0.000
	WEEK 5	120	-123.9	6.71	0.071	0.000
	WEEK 6	120	-122.8	6.77	0.239	0.000
	WEEK 7	120	-126.1	6.79	0.243	0.000
	WEEK 8	120	-125.7	7.03	0.240	0.000
	WEEK 9	120	-126.9	6.87	0.245	0.000
	WEEK 10	120	-127.6	6.80	0.258	0.000
	WEEK 11	120	-124.1	6.90	0.491	0.000
	WEEK 12	120	-123.5	6.79	0.381	0.000
GROUP W	WEEK 1	136	-95.10	5.91	0.000	0.000
	WEEK 2	137	-114.0	6.31	0.000	0.000
	WEEK 3	137	-119.5	6.38	0.001	0.000
	WEEK 4	137	-119.7	6.24	0.018	0.000
	WEEK 5	137	-135.4	6.32	0.003	0.000
	WEEK 6	137	-134.6	6.37	0.019	0.000
	WEEK 7	137	-134.4	6.39	0.046	0.000
	WEEK 8	137	-132.7	6.61	0.063	0.000
	WEEK 9	137	-133.3	6.47	0.071	0.000
	WEEK 10	137	-132.0	6.40	0.114	0.000
	WEEK 11	137	-132.1	6.49	0.143	0.000
	WEEK 12	137	-132.4	6.39	0.080	0.000

DVS SR		Protocol 3	3151A2-31	5-US			CSR-60178
GROUP X	WEEK 1	141	-70.20	5.80	0.004	0.000	
	WEEK 2	141	-90.23	6.22	0.030	0.000	
	WEEK 3	141	-99.07	6.29	0.148	0.000	
	WEEK 4	141	-109.1	6.15	0.184	0.000	
	WEEK 5	141	-108.1	6.22	0.758	0.000	
	WEEK 6	141	-108.7	6.28	0.871	0.000	
	WEEK 7	141	-108.3	6.30	0.600	0.000	
	WEEK 8	141	-107.5	6.52	0.611	0.000	
	WEEK 9	141	-110.2	6.38	0.679	0.000	
	WEEK 10	141	-110.5	6.31	0.615	0.000	
	WEEK 11	141	-112.8	6.40	0.706	0.000	
	WEEK 12	141	-120.1	6.30	0.569	0.000	

ANCOVA: change = treat + site + baseline

CONFIDENTIAL 173 Wyeth

Table xxx Within and between group comparisons for hot flush number and severity DVS-233 SR protocol 315: week 12 analysis (ITT, LOCF)

13:20 Tuesday, December 7, 2004

16

TEST NAME=WEEKLY WEIGHTED SCORE OF MODERATE AND SEVERE HOT FLUSHES

Treatment	Time slot	No. of pairs	Adjusted mean	=	p-value vs. placebo	-
GROUP Z	WEEK 1	 145	-91.93	5.71	0.000	0.000
	WEEK 2	145	-115.2	6.11	0.000	0.000
	WEEK 3	145	-121.7	6.19	0.000	0.000
	WEEK 4	145	-125.4	6.05	0.003	0.000
	WEEK 5	145	-130.0	6.12	0.014	0.000
	WEEK 6	145	-132.5	6.18	0.030	0.000
	WEEK 7	145	-133.2	6.20	0.056	0.000
	WEEK 8	145	-134.4	6.41	0.042	0.000
	WEEK 9	145	-137.0	6.27	0.030	0.000
	WEEK 10	145	-138.1	6.20	0.028	0.000
	WEEK 11	145	-138.7	6.29	0.034	0.000
	WEEK 12	145	-139.4	6.19	0.014	0.000
Placebo	WEEK 1	77	-43.24	7.70	•	0.000
	WEEK 2	77	-68.17	8.24		0.000
	WEEK 3	77	-84.21	8.34		0.000
	WEEK 4	77	-95.77	8.16		0.000
	WEEK 5	77	-105.0	8.26		0.000
	WEEK 6	77	-110.4	8.33		0.000
	WEEK 7	77	-113.7	8.36		0.000
	WEEK 8	77	-112.9	8.64		0.000
	WEEK 9	77	-114.5	8.46		0.000
	WEEK 10	77	-115.6	8.37		0.000
	WEEK 11	77	-116.7	8.49		0.000
	WEEK 12	77	-114.3	8.35		0.000
1	the second second second	1 1 1				

ANCOVA: change = treat + site + baseline

ST 6-2: Results of the Initial Analysis at 12 Weeks Compared With the Final Analyses at Weeks 4 and 12

Results of the Initial Analysis at 12 Weeks Compared With the Final Analyses at Weeks 4 and 12

		Adjusted	l Mean	p-Value vs	Placebo
Treatment	Time Point	Initial 12	Final	Initial 12	Final
Number of moderate to	severe hot flush	es			
DVS SR 50 mg	Week 4	-5.77	-5.77	0.332.	0.331
	Week 12	-6.10	-6.10	0.331	0.326
DVS SR 100 mg	Week 4	-6.62	-6.62	0.014	0.013
•	Week 12	-7.22	-7.23	0.005	0.005
DVS SR 150 mg	Week 4	-6.47	-6.48	0.029	0.027
•	Week 12	-6.93	-6.94	0.021	0.020
DVS SR 200 mg	Week 4	-6.42	-6.42	0.040	0.040
· ·	Week 12	-6.46	-6.46	0.132	0.130
Placebo	Week 4	-5.22	-5.22		
	Week 12	-5.50	-5.50		
Severity of hot flushes					
DVS SR 50 mg	Week 4	-0.37	-0.37	0.915	0.913
Č	Week 12	-0.43	-0.43	0.813	0.754
DVS SR 100 mg	Week 4	-0.57	-0.57	0.054	0.054
· ·	Week 12	-0.78	-0.80	0.002	0.002
DVS SR 150 mg	Week 4	-0.53	-0.53	0.138	0.138
Č	Week 12	-0.59	-0.59	0.189	0.235
DVS SR 200 mg	Week 4	-0.57	-0.57	0.066	0.072
S	Week 12	-0.74	-0.74	0.010	0.013
Placebo	Week 4	-0.38	-0.39		
	Week 12	-0.45	-0.47		

Source: clinical r&d/clinical biostatistics sas

reports/3151a2/315/p315_interim2004_12week/hf_itt_locf_ancova_wk12_interim04.doc, clinical r&d/clinical biostatistics sas

reports/3151a2/315/315_nda_2005/hf_itt_locf_ancova_final_05.html

ST 8-1: Enrollment Log for Screen Failures

Name	Site .	Initials	DOB	Sub#	W/O	W/O SF	Visit-01A-IC	Visit-01B	SF or ET	SFC	Comments
Ackerman, R.	207	DMC	06/11/1949	201302	N	0 Yes	18-Dec-03		02/22/2004	104	pt withdrew consent: 7-01
Ackerman, R.	207	B-S	02/21/1954	201304	N	0 Yes	22-Dec-03	19-Jan-04	01/22/2004	I01	low FSH(3.9)
Ackerman, R.	207	J-R	07/03/1963			0 Yes			01/05/2004		failed due to hepatitis B not enough hot flashes in
Ackerman, R.	207	RAE	06/15/1934	201306	N	0 Yes	05-Jan-04	05-Jan-04	01/21/2004	102	diary per pt, she is only having 3-4 hot flushes per day and
Ackerman, R.	207	D-B	04/20/1953			0 Yes			02/11/2004		wishes to withdraw consent
Ackerman, R.	207	PDN	01/08/1955	201310	N	0 Yes	22-Jan-04	22-Jan-04	02/19/2004	102	not enough hot flushes
Ackerman, R.	207	N-R	11/28/1954	201312	N	0 Yes	29-Jan-04	29-Jan-04	02/03/2004	E05	uncontrolled diabetes
Ackerman, R.	207	DFR	07/16/1948	201315	N	0 Yes	13-Feb-04		03/30/2004	104	LTFU, pt no showed 1B visit enrollment closed during
Ackerman, R.	207	V-H	08/20/1952	201319	N	0 Yes	09-Mar-04		04/01/2004	ECW	washout enrollment closed during
Ackerman, R.	207	PAP	01/25/1953	201321	N	0 Yes	11-Mar-04		04/01/2004	ECW	washout enrollment closed during
Archer, D.	208	BGD	10/15/1946	201353	N	0 Yes	10-Mar-04		03/31/2004	ECW	washout enrollment closed during
Archer, D.	208	SPS	08/16/1935	201354	N	0 Yes	12-Mar-04		03/31/2004	ECW	washout enrollment closed during
Archer, D.	208	PAF	07/04/1953	201355	N	0 Yes	16-Mar-04		03/31/2004	ECW	washout
Archer, D.	208	BLM	05/22/1957	201356	N	0 Yes	17-Mar-04	13-Apr-04	04/13/2004	102	not enough hot flashes
Archer, D.	208	VDW	01/22/1965	201358	N	0 Yes	24-Mar-04	24-Mar-04	03/31/2004	I01	not menopausal
Archer, D.	208	LRT	08/11/1949	201363	N	0 Yes	26-Mar-04	26-Mar-04	03/26/2004	E07	high BP
Archer, D.	208	DAP	05/20/1954	201365	N	0 Yes	05-Apr-04	05-Apr-04	04/05/2004	l01	not menopausal(FSH < 40) enrollment closed during
Archer, D.	208	ANA	09/25/1953	201366	N	0 Yes	06-Apr-04	06-Apr-04	04/26/2004	ECS	screening enrollment closed during
Archer, D.	208	PSK	07/08/1954	201367	N	0 Yes	08-Apr-04	08-Apr-04	04/26/2004	ECS	screening
Archer, D.	208	MLW	11/05/1948	201368	N	0 Yes	09-Apr-04	09-Apr-04	04/09/2004	E07	high BP

Name	Site	. Initials	DOB	Sub#	W/O	W/O	SF	Visit-01A-IC	Visit-01B	SF or ET	SFC	Comments
Arobor D	208	RFH	09/19/1948	201260	NI	0	Yes	09-Apr-04	00 Apr 04	04/14/2004	E10	not enough hot flashes and E10
Archer, D.	200	КГП	09/19/1940	201309	IN	U	165	09-Apr-04	09-Apr-04	04/14/2004	· 🗆 10	enrollment closed during
Archer, D.	208	MGS	09/21/1957	201370	N	0	Yes	13-Apr-04	13-Apr-04	04/26/2004	ECS	screening
Archer, D.	208	JBJ	01/14/1950	201371	N	0	Yes	12-Apr-04	12-Apr-04	04/12/2004	E06	CNS disorder
Archer, D.	208	LMH	11/10/1949	201373	Ν	0	Yes	13-Apr-04	13-Apr-04	04/13/2004	·101	not menopausal
												enrollment closed during
Archer, D.	208	DCD	02/27/1958	201376	N	0	Yes	13-Apr-04	13-Apr-04	04/26/2004	ECS	screening
Berger, M.	209	DKK	09/22/1948	201402	N	0	Yes	21lan-04	21-Jan-04	02/11/2004	F05	pt had colon masses removed - discovered after screening
Derger, IVI.	200	DICIC	00/22/1040	201402		O	100	21 0411 04	21 0011 04	02/11/2004	LUU	does not meet hot flash
Berger, M.	209	SAB	09/04/1950	201404	Ν	0	Yes	22-Jan-04	22-Jan-04	02/05/2004	102	criteria
Berger, M.	209	SLE	09/09/1959	201405	N	0	Yes	27-Jan-04	27-Jan-04	01/27/2004	· 101	FSH L40
5		5	00/00/40=0	004400		_	. ,			0.4.10.0.10.0.0.4	10.4	consent and vitals only/pt
Berger, M.	209	RLA	09/08/1950	201406	N	0	Yes	30-Jan-04	30-Jan-04	01/30/2004	104	withdrew consent excluded because of
Berger, M.	209	BJW	12/16/1951	201407	N	0	Yes	02-Feb-04	02-Feb-04	02/02/2004	F10	increased cholesterol
Berger, M.	209	FCV	11/25/1951			_	Yes			02/02/2004		abnormal EKG
20.go.,	_00		11/20/1001	201.00		Ū	. 00	02 : 05 0 :	02 . 05 0 .	02/02/2001		pt using exclusionary
Berger, M.	209	VMM	09/26/1948	201409	N	0	Yes	05-Feb-04	05-Feb-04	02/10/2004	E12	medication
Berger, M.	209	CKF	02/27/1952	201410	N	0	Yes	06-Feb-04	06-Feb-04	02/20/2004	E10	labs/CBC
Berger, M.	209	MLP	07/02/1958	201412	N	0	Yes	10-Feb-04	06-Apr-04	04/06/2004	E10	labs- hemoglobin, anemic
5		5. .	00/00/4040			_		40 = 1 04		00/07/000	1404/0	pt withdrew consent/unable to
Berger, M.	209	BLJ	02/03/1949	201414	N	0	Yes	12-Feb-04		03/07/2004	· WWO	washout
Berger, M.	209	CAH	02/11/1950	201416	N	0	Yes	13-Feb-04	12-Mar-04	03/24/2004	.102	not enough hot flashes and abnormal labs
20.go.,	_00	O/ II !	02/11/1000	201110		Ū	. 00	.0.000.	12 11101 01	00/2 1/200 1	.02	pt withdrew consent during
Berger, M.	209	SAW	01/13/1947	201419	N	0	Yes	17-Feb-04		04/20/2004	WWO	
Berger, M.	209	BMM	06/10/1951	201420	N	0	Yes	18-Feb-04	18-Feb-04	03/29/2004	104	withdrew consent
Berger, M.	209	EBO	09/08/1947	201421	N	0	Yes	24-Feb-04		03/04/2004	104	pt withdrew consent
Berger, M.	209	EAP	01/16/1952	201426	Ν	0	Yes	01-Mar-04	01-Mar-04	03/29/2004	102	not enough hot flashes
Dannan M	200		00/00/4047	004407	N.	^	V	00 Man 04		00/05/000	E0\4'	Enrollment closed during
Berger, M.	209	LLG	09/30/1947	201427	IN	U	Yes	02-Mar-04		03/25/2004	- ECVV	washout

Name	Site .	Initials	DOB	Sub#	W/O	W/O SF	Visit-01A-IC	Visit-01B	SF or ET	SFC	Comments
Berger, M.	209	AGS	01/05/1956	201428	N	0 Yes	04-Mar-04	04-Mar-04	03/18/2004	102	not enough hot flushes
Berger, M.	209	AML	06/09/1939	201429	Ν	0 Yes	05-Mar-04	12-Mar-04	03/23/2004	102	not enough hot flushes
Berger, M.	209	MSA	05/14/1949	201430	N	0 Yes	05-Mar-04	05-Mar-04	04/02/2004	102	not enough hot flushes
Berger, M.	209	V-E	01/31/1951	201432	N	0 Yes	11-Mar-04	11-Mar-04	04/15/2004	E10	EKG
Berger, M.	209	JAB	01/19/1968	201433	N	0 Yes	12-Mar-04	12-Mar-04	03/24/2004	E10	triglycerides
Berger, M.	209	SKB	03/25/1949	201434	N	0 Yes	12-Mar-04		03/12/2004	E14	pt on Ambien
Berger, M.	209	GGP	02/13/1949	201435	N	0 Yes	12-Mar-04		03/25/2004	ECW	unable to randomize by 4/26
Berger, M.	209	JAJ	01/24/1951	201438	N	0 Yes	15-Mar-04	12-Apr-04	04/26/2004	ECS	too late to randomize
Berger, M.	209	PJD	10/05/1959	201439	Ν	0 Yes	16-Mar-04	16-Mar-04	04/06/2004	E07	diastolic>100
Berger, M.	209	PAG	09/23/1950	201440	N	0 Yes	16-Mar-04		04/15/2004	wwo	withdrew consent during washout due to work schedule Enrollment closed during
Berger, M.	209	TML	03/18/1950	201441	N	0 Yes	16-Mar-04		03/26/2004	ECW	washout
Berger, M.	209	CAL	02/13/1949	201442	N	0 Yes	19-Mar-04	19-Mar-04	03/22/2004	E10	Cholesterol/LDL
Berger, M.	209	MRR	04/13/1955	201443	N	0 Yes	19-Mar-04	19-Mar-04	03/19/2004	101	FSH level
Berger, M.	209	JMP	12/11/1949	201444	N	0 Yes	22-Mar-04	22-Mar-04	04/07/2004	102	not enough hot flushes
Berger, M.	209	VJW	06/25/1951	201445	N	0 Yes	23-Mar-04	23-Mar-04	03/23/2004	E14	use of psychoactive meds
Berger, M.	209	BAB	04/01/1950	201446	N	0 Yes	23-Mar-04	23-Mar-04	03/29/2004	E10	liver enzymes x2ULN
Berger, M.	209	LJC	08/19/1948	201447	N	0 Yes	23-Mar-04	23-Mar-04	03/29/2004	E10	triglycerides
Berger, M.	209	CJP	03/04/1950	201450	Ν	0 Yes	26-Mar-04	26-Mar-04	04/13/2004	101	FSH<40
Brenner, R.	237	AMG	11/17/1946	202755	N	0 Yes	20-Jan-04	20-Jan-04	02/17/2004	102	inclusion criteria not met
Brenner, R.	237	H-K	05/19/1952	202763	N	0 Yes	08-Mar-04	08-Mar-04	04/21/2004	102	inclusion criteria not met
Brenner, R.	237	BJC	11/29/1948	202765	N	0 Yes	11-Mar-04	11-Mar-04	04/05/2004	I01	FSH level
Brenner, R.	237	М-Н	09/25/1952	202766	N	0 Yes	17-Mar-04	17-Mar-04	04/14/2004	E10	clinically significant cholesterol level enrollment closed during
Brenner, R.	237	VMP	04/03/1950	202767	N	0 Yes	25-Mar-04	25-Mar-04	04/26/2004	ECS	screening
Clevinger, S.	210	GLS	07/08/1943	201452	N	0 Yes	12-Feb-04	19-Feb-04	02/23/2004	101	FSH 35.9
Clevinger, S.	210	DLW	09/16/1949	201453	N	0 Yes	12-Feb-04	17-Feb-04	02/24/2004	102	<50 hot flashes
Clevinger, S.	210	RTM	10/03/1939	201458	N	0 Yes	27-Feb-04	08-Mar-04	03/04/2004	102	insufficient hot flushes

Name	Site	. Initials	DOB	Sub #	W/O	W/O SF	Visit-01A-IC	Visit-01B	SF or ET	SFC	Comments
Clevinger, S.	210	VEB	07/15/1950	201459	9 N	0 Yes	27-Feb-04	08-Mar-04	03/09/2004	102	insufficient hot flushes
Clevinger, S.	210	SMF	05/26/1950	201460	N	0 Yes	01-Mar-04	04-Mar-04	03/09/2004	E05	hx of hyperthyroidism
Clevinger, S.	210	CMR	02/27/1950	201462	2 N	0 Yes	01-Mar-04	01-Mar-04	03/09/2004	E14	conflicting med records
Clevinger, S.	210	YKM	04/07/1953	201463	3 N	0 Yes	02-Mar-04	11-Mar-04	03/16/2004	102	insufficient hot flushes
Clevinger, S.	210	BWB	09/25/1951	20146	5 N	0 Yes	04-Mar-04	04-Mar-04	03/17/2004	E05	ALT/AST
Olas is seen 0	040	LND	00/00/4040	00440	. N.I	0)/	00 M 04		0.4/4.4/000.4	E0\4/	study closed prior to washout
Clevinger, S.	210	LNB	09/20/1949			0 Yes	08-Mar-04		04/14/2004		date
Clevinger, S.	210	JCH	12/18/1947			0 Yes			03/17/2004		cardiac- ECG Abnormal
Clevinger, S.	210	DVS	08/05/1947	201472	2 N	0 Yes	11-Mar-04	14-Apr-04	04/14/2004	E05	medical history (E05, E06)
											signed ICF, EKG, history, then never showed back up - did
Clevinger, S.	210	PAM	03/19/1952	201474	4 N	0 Yes	12-Mar-04	14-Apr-04	04/14/2004	105	not return calls
Clevinger, S.	210	ALO	10/06/1958	20147	5 N	0 Yes	15-Mar-04		03/22/2004	102	insufficient hot flushes
											exclusionary med from
Clevinger, S.	210	BSK	11/15/1951	201477	7 N	0 Yes	16-Mar-04	13-Apr-04	04/14/2004	E14	medical records
Cowan, B.	211	CAW	12/06/1947	201503	2 NI	0 Yes	09-Mar-04		04/05/2004	.\\\\\	withdrew consent during washout
Cowan, B.	211	JFJ	02/16/1954			0 Yes		12-Mar-04	03/29/2004		abnormal labs
Cowan, B.	211	BJD	07/10/1948			0 Yes	15-Mar-04	12 11101 01	03/15/2004	_	body mass >40
Cowan, B.	211	L-S	05/19/1957			0 Yes		17-Mar-04	03/22/2004		abnormal ECG
Cowan, B.	211	CCC	11/23/1957			0 Yes			04/20/2004		abnormal lab
Dietrich, J.	213	000	07/10/1952			0 Yes			02/25/2004		not enough hot flashes
Dietrich, J.	213	BLW	04/28/1948			0 Yes	20-Jan-04	10 1 05 0 1	01/23/2004		current hx of depression
Dietrich, J.	213	BEA	01/22/1950			0 Yes		27₋ lan₋04	01/29/2004		FSH 33.8
Dietrich, J.	213	LMM	05/01/1944			0 Yes			02/17/2004		seizures
Dietrich, J.	213	DJO	07/06/1954			0 Yes			03/08/2004		hypersensitivity to venlafaxine
Dietrich, J.	213	VFG	04/01/1947			0 Yes			02/18/2004		withdrew consent
	213	P-C	12/21/1937			0 Yes	20-Jan-04 27-Jan-04	00-1 60-04	02/13/2004		
Dietrich, J. Dietrich, J.	213	KMG	05/07/1952			0 Yes		30 Jan 04	02/03/2004		using psychoactive meds unstable doses of tramadol
ŕ								30-Jan-04			
Dietrich, J.	213	CDS	09/18/1949	201618	3 IN	0 Yes	30-Jan-04		02/02/2004	EU3	hx of seizure

Name	Site	. Initials	DOB	Sub#	W/O	W/O SF	Visit-01A-IC	Visit-01B	SF or ET	SFC	Comments
Dietrich, J.	213	M-M	03/21/1951	201619	N	0 Yes	30-Jan-04		03/23/2004	105	LTFU
											labs-elevated triglycerides
Dietrich, J.	213	RAZ	08/23/1953			0 Yes		06-Apr-04	04/08/2004		2xUNL
Dietrich, J.	213	D-L	11/10/1948			0 Yes	11-Feb-04		02/17/2004		withdrew consent
Dietrich, J.	213	MLK	05/27/1961	201627	'N	0 Yes	16-Feb-04		03/19/2004	104	LTFU
Dietrich, J.	213	LML	02/12/1934	201629	N	0 Yes	17-Feb-04		02/19/2004	104	withdrew consent
Dietrich, J.	213	BLE	05/16/1947	201630	N	0 Yes	18-Feb-04	08-Mar-04	04/26/2004	E10	
Dietrich, J.	213	RMD	02/12/1949	201631	l N	0 Yes	12-Feb-04		03/15/2004	105	withdrew consent
Dietrich, J.	213	MAS	08/11/1953	201632	2 N	0 Yes	25-Feb-04		03/25/2004	E10	elevated LFT X2UNL
Dietrich, J.	213	BED	07/11/1949	201633	3 N	0 Yes	27-Feb-04		04/14/2004	E14	use of pyschoactive meds
											enrollment closed during
Dietrich, J.	213	CLH	01/24/1949			0 Yes	01-Mar-04		04/05/2004	_	washout
Dietrich, J.	213	JLG	10/26/1959			0 Yes		03-Mar-04	04/01/2004		no hot flashes
Dietrich, J.	213	C-R	05/02/1946			0 Yes	05-Mar-04		03/19/2004		not enough hot flashes
Dietrich, J.	213	PSH	06/06/1953	201640) N	0 Yes	11-Mar-04	06-Apr-04	04/01/2004	E02	DHEA
Dockery, J.	201	J-B	03/04/1956	201010	N (0 Yes	05-Mar-04		04/20/2004	105	back on HRT
Dockery, J.	201	TAS	02/07/1953	201011	l N	0 Yes	10-Mar-04	10-Mar-04	04/05/2004	E07	hypertensive
Dockery, J.	201	GMS	11/05/1956	201013	3 N	0 Yes	11-Mar-04		04/20/2004	105	back on HRT
											enrollment closed during
Dockery, J.	201	CMY	06/22/1948	201014	ŀN	0 Yes	16-Mar-04		04/20/2004	ECW	washout
Dunston, K.	202	SLD	12/31/1947	201053	ΣNI	0 Yes	19 Nov 03	24 Nov 03	12/23/2003	IU3	hot flashes < 50 in any 7 consecutive days
Durision, K.	202	SLD	12/31/1947	201053) IN	0165	10-1107-03	24-1107-03	12/23/2003	102	<50 hot flashes in any 7
Dunston, K.	202	JSE	06/25/1951	201055	5 N	0 Yes	21-Nov-03	26-Nov-03	12/24/2003	102	consecutive days
Dunston, K.	202	G-L	07/25/1949	201060	N	0 Yes	22-Dec-03		12/22/2003	104	LTFU; only ICF done
,											<50 hot flashes in any 7 day
Dunston, K.	202	KPL	11/30/1946	201062	2 N	0 Yes	06-Jan-04	06-Jan-04	02/03/2004	102	period
Dunston, K.	202	SBG	02/05/1951	201063	3 N	0 Yes	20-Jan-04	20-Jan-04	12/20/2003	104	LTFU
Dunston, K.	202	MAR	09/20/1950	201065	5 N	0 Yes	22-Jan-04	22-Jan-04	01/30/2004	E10	abnormal ECG
											did not meet inclusion criteria
Dunston, K.	202	HJP	01/24/1946	201069	N	0 Yes	27-Jan-04	18-Mar-04	03/26/2004	101	#1 as per labs

Name	Site	. Initials	DOB	Sub#	W/O	W/O SF	Visit-01A-IC	Visit-01B	SF or ET	SFC	Comments
Dunston, K.	202	SMW	03/06/1954	201070	N	0 Yes	29-Jan-04	16-Feb-04	03/19/2004	02	did not meet inclusion criteria
Dunston, K.	202	GKH	12/20/1958	201074	١N	0 Yes	03-Feb-04	03-Feb-04	03/02/2004	02	did not meet inclusion criteria #2
Dunston, K.	202	JTB	06/27/1955	201079	N	0 Yes	16-Feb-04		04/01/2004	Ξ04	menses within 6 months
Dunston, K.	202	BJH	05/20/1953	201080	N	0 Yes	16-Feb-04		02/17/20041	04	pt called, withdrew consent during washout
Dunston, K.	202	MMK	10/01/1955			0 Yes		23-Feb-04	03/22/2004		not enough hot flashes
Dunston, K.	202	MES	04/26/1947	201096	: NI	0 Yes	27 Eab 04	27 Eab 04	04/06/2004	02	did not meet inclusion criteria #2
Durision, K.	202	IVIES	04/20/1947	201000) IN	0 165	27-1-60-04	27-1-60-04	04/00/2004 1	02	Enrollment closed during
Dunston, K.	202	CAD	07/17/1953	201087	'N	0 Yes	27-Feb-04		03/25/2004	ECW	washout
5		5.04/	40/05/4005	004000		01/	o= = . o.		00/05/0004	-0.47	Enrollment closed during
Dunston, K.	202	DMW	12/25/1965	201088	3 N	0 Yes	27-Feb-04		03/25/2004	=CW	washout Enrollment closed during
Dunston, K.	202	SBJ	12/22/1944	201089	N	0 Yes	27-Feb-04		03/25/2004	ECW	washout
Dunston, K.	202	LSJ	01/10/1948	201091	l N	0 Yes	24-Mar-04	24-Mar-04	04/26/2004	ECS	
											not enough hot flushes per
Erdy, G.	215	PLE	03/01/1951			0 Yes			02/02/2004 I		day
Erdy, G.	215	RJB	02/27/1936	201703	3 N	0 Yes	30-Jan-04	29-Mar-04	03/29/2004 I	02	not enough hot flushes
Erdy, G.	215	LRM	03/05/1953	201704	١N	0 Yes	06-Feb-04	05-Mar-04	03/19/2004 I	01	FSH too low
Erdy, G.	215	EJE	12/01/1955	201706	8N	0 Yes	02-Feb-04	02-Feb-04	02/02/2004	02	not enough hot flushes
Erdy, G.	215	RSB	12/06/1959	201707	'N	0 Yes	11-Feb-04	17-Mar-04	03/24/2004	02	not enough hot flushes
Erdy, G.	215	TGM	08/19/1957	201708	3 N	0 Yes	12-Feb-04		03/19/20041	05	withdrew consent
•											pt withdrew consent during
Erdy, G.	215	SSB	02/15/1945	201709	N	0 Yes	12-Feb-04		03/22/2004 \	NWO	washout
Erdy, G.	215	GAF	07/16/1948	201711	l N	0 Yes	17-Feb-04	17-Feb-04	02/24/2004 I	02	not enough hot flushes
Erdy, G.	215	CAB	08/04/1955	201712	2 N	0 Yes	18-Feb-04	18-Feb-04	03/26/2004 I	05	LTFU
											enrollment closed during
Erdy, G.	215	PLM	02/24/1951	201715	δN	0 Yes	03-Mar-04		04/20/2004	=CW	washout
Erdy, G.	215	JAM	10/01/1939	201716	S NI	0 Yes	08-Mar-04		03/11/2004\	۸۸۸۸	withdrew consent during washout
			05/01/1939			0 Yes		11 10001			number of hot flashes
Erdy, G.	215	LJM	03/01/1948	201717	IN	o res	00-IVIAI-04	14-Apr-04	04/21/2004 I	02	number of not hasnes

Name	Site	. Initials	DOB	Sub#	W/O V	V/O SF	Visit-01A-IC	Visit-01B	SF or ET	SFC	Comments
											withdrew consent during
Erdy, G.	215	D-A	08/08/1943	201720	N	0 Yes	17-Mar-04		04/12/2004	wwo	washout
Erdy, G.	215	RMG	02/15/1943	201721	N	0 Yes	17-Mar-04		04/20/2004	ECW	enrollment closed during washout
Erdy, G.	215	KJL	09/25/1948	201725	N	0 Yes	26-Mar-04	26-Mar-04	04/02/2004	102	not enough hot flushes
_											elevated liver enzymes,
Farmer, M.	216	SSF	02/13/1950			0 Yes			01/13/2004	_	x2UNL
Farmer, M.	216	HDP	01/15/1952	201753	N	0 Yes	22-Jan-04	17-Feb-04	02/17/2004	E14	use of Aricept
											hysterectomy scheduled after the subject signed the
Farmer, M.	216	BLG	03/09/1947	201757	N	0 Yes	30-Jan-04	20-Feb-04	03/09/2004	104	informed consent form
											too few flushes recorded in
Farmer, M.	216	NTT	07/08/1948			0 Yes			03/10/2004		diary
Farmer, M.	216	NER	06/08/1945			0 Yes			01/28/2004		hx of seizures
Farmer, M.	216	CAG	05/19/1957	201763	N	0 Yes	05-Feb-04	05-Feb-04	02/12/2004	E10	abnormal labs
Farmer, M.	216	RMW	02/15/1962	201765	N	0 Yes	09-Feb-04	24-Mar-04	03/24/2004	E07	HTN
											subject referred to PCP for follow up and clearance re:
Farmer, M.	216	BJK	08/12/1948	201766	N	0 Yes	10-Feb-04		03/19/2004	E05	heart during med history
Farmer, M.	216	J-T	10/27/1952	201768	N	0 Yes	12-Feb-04	12-Feb-04	02/12/2004	E05	hx of GAD
											uncontrolled high blood
Farmer, M.	216	RMD	03/15/1950	201769	N	0 Yes	13-Feb-04		02/13/2004	E07	pressure
Farmer, M.	216	A-P	01/26/1953	201770	N	0 Yes	13-Feb-04		02/13/2004	101	not 6 months since last period
Farmer, M.	216	JPB	09/10/1949	201772	N	0 Yes	18-Feb-04		02/18/2004	E07	uncontrolled HTN
Farmer, M.	216	TSJ	08/03/1949	201774	N	0 Yes	18-Feb-04	07-Apr-04	04/14/2004	105	withdrew consent
Farmer, M.	216	PCB	01/22/1953	201776	N	0 Yes	24-Feb-04		04/12/2004	102	too few hot flushes
Farmer, M.	216	MJH	05/14/1952	201777	N	0 Yes	26-Feb-04		02/26/2004	E07	elevated BP
Farmer, M.	216	DJR	08/23/1950	201779	N	0 Yes	04-Mar-04	25-Mar-04	03/25/2004	E14	use of psychoactive meds
Farmer, M.	216	HCL	08/02/1952	201780	N	0 Yes	09-Mar-04	09-Mar-04	03/24/2004	102	too few hot flushes
Farmer, M.	216	DMI	02/17/1949	201782	N	0 Yes	11-Mar-04	11-Mar-04	03/19/2004	102	to few hot flushes
•											enrollment closed during
Farmer, M.	216	PCD	10/16/1948	201789	N	0 Yes	19-Mar-04		04/14/2004	ECW	washout

Name	Site	. Initials	DOB	Sub#	W/O	W/O SF	Visit-01A-IC	Visit-01B	SF or ET	SFC	Comments
Farmer, M.	216	LHJ	07/31/1949	201790	N	0 Yes	19-Mar-04		03/19/2004	103	BMI>40
Farmer, M.	216	PAO	04/19/1953	201791	N	0 Yes	23-Mar-04	23-Mar-04	03/31/2004	105	withdrew consent
Farmer, M.	216	CEM	09/14/1954	201794	N	0 Yes	26-Mar-04		04/15/2004	102	subject no longer has flushes
Feldman, R.	217	M-B	11/29/1937	201805	N	0 Yes	15-Jan-04		02/12/2004	104	withdrew consent
Feldman, R.	217	V-C	07/13/1957	201810	N	0 Yes	30-Jan-04	30-Jan-04	01/30/2004	102	does not meet hotflash criteria
Feldman, R.	217	GCR	06/20/1949	201813	3 N	0 Yes	03-Feb-04	03-Feb-04	02/25/2004	102	insufficient hot flushes
	0.1=		00/00/4040	00101		224			00/00/0004		physical exam reveals
Feldman, R.	217	MLB	09/08/1948			0 Yes			02/03/2004		uncontrolled HTN
Feldman, R.	217	I-C	02/01/1948			0 Yes			02/25/2004		insufficient hot flashes
Feldman, R.	217	T-C	08/08/1942	201816	N	0 Yes	09-Feb-04	09-Feb-04	03/10/2004	104	lost to follow up
Feldman, R.	217	JDW	07/23/1955	201820	N	0 Yes	25-Feb-04	25-Feb-04	04/13/2004	104	lost to follow up
Feldman, R.	217	ZMP	06/27/1943	201823	8 N	0 Yes	03-Mar-04	03-Mar-04	03/23/2004	102	insufficient hot flashes
Feldman, R.	217	BAS	12/15/1952	201825	N	0 Yes	10-Mar-04	10-Mar-04	03/23/2004	E10	elevated triglycerides
Feldman, R.	217	S-H	01/18/1950	201829	N	0 Yes	15-Mar-04	15-Mar-04	03/15/2004	105	withdrew consent
Feldman, R.	217	MVC	10/14/1953	201834	N	0 Yes	24-Mar-04	24-Mar-04	03/31/2004	101	FSH does not qualify
Floyd, S.	218	EWG	04/07/1937	201851	N	0 Yes	18-Dec-03	18-Dec-03	01/05/2004	104	withdrew consent
Floyd, S.	218	AJD	03/05/1953	201861	Ν	0 Yes	10-Feb-04	10-Feb-04	03/10/2004	E10	abnormal labs
Floyd, S.	218	RDB	09/10/1952	201862	2 N	0 Yes	10-Feb-04		02/19/2004	104	pt changed mind - time constraints
											8wks planned washout, so
Floyd, S.	218	DAS	07/21/1948			0 Yes	19-Feb-04		02/20/2004		withdrew consent
Floyd, S.	218	BJF	06/29/1951			0 Yes	26-Feb-04	28-Feb-04	04/15/2004		site study full
Floyd, S.	218	AMS	03/27/1952	201881	N	0 Yes	11-Mar-04		04/05/2004	104	withdrew consent -lost interest
Floyd, S.	218	SMB	11/22/1949	201882	? N	0 Yes	11-Mar-04	08-Apr-04	04/15/2004	105	site study full
Floyd, S.	218	SJB	09/10/1940	201886	S N	0 Yes	15-Mar-04		04/08/2004	102	not enough hot flashes inadequate vasomotor
Fowler, S.	219	DLL	05/06/1951	201901	N	0 Yes	12-Feb-04	08-Mar-04	03/18/2004	102	symptoms per day inadequate vasomotor
Fowler, S.	219	DEM	03/08/1954	201903	3 N	0 Yes	17-Feb-04	04-Mar-04	03/17/2004	102	symptoms
Fowler, S.	219	LGL	11/19/1951	201905	N	0 Yes	23-Feb-04	23-Feb-04	03/03/2004	102	inadequate vasomotor

Name	Site	. Initials	DOB	Sub#	W/O	W/O SF	Visit-01A-IC	Visit-01B	SF or ET	SFC	Comments
Fowler, S.	219	MMW	10/09/1949	201907	'N	0 Yes	24-Feb-04	24-Mar-04	04/02/2004	102	inadequate hot flushes
Fowler, S.	219	JEA	11/11/1949	201009	. NI	0 Yes	25 Eab 04	25 Eab 04	03/10/2004	102	inadequate hot flushes per diary card review
i Owier, S.	219	JLA	11/11/1343	201900) IN	0 163	25-1 65-04	23-1 60-04	03/10/2004	102	enrollment closed during
Fowler, S.	219	RHM	06/29/1952	201909	N	0 Yes	01-Mar-04		03/30/2004	ECW	washout
F 1 0	040	005	00/00/4050	004044		0)/	00.14	00.14 04	00/00/0004	-0\4/	enrollment deadline precedes
Fowler, S.	219	SRF	06/23/1950	201911	N	0 Yes	02-Mar-04	02-Mar-04	03/30/2004	ECW	washout phase Enrollment closed during
Fowler, S.	219	EWM	08/23/1950	201912	2 N	0 Yes	02-Mar-04		03/22/2004	ECW	washout
, -											enrollment closed during
Fowler, S.	219	SMR	01/19/1950	201913	3 N	0 Yes	02-Mar-04		03/30/2004	ECW	washout
Faudan O	040	O ID	00/00/4050	004047	, N.I.	0\/	00 Man 04		00/40/0004	E0\4/	Enrollment closed during
Fowler, S.	219	SJB	02/22/1953	201917	N	0 Yes	02-Mar-04		03/19/2004	ECW	washout Enrollment closed during
Fowler, S.	219	PKT	07/10/1949	201918	8 N	0 Yes	08-Mar-04		03/26/2004	ECW	washout
Fowler, S.	219	SDC	08/04/1948			0 Yes		09-Mar-04	03/24/2004		not menopausal
, -											Enrollment closed during
Fowler, S.	219	PLD	05/05/1947	201920	N	0 Yes	09-Mar-04		03/24/2004	ECW	washout
Foundary C	240	A A I I	00/44/4040	204022	. N.I	0.V.	10 Mar 04		02/22/2004		Enrollment closed during
Fowler, S.	219	AAH	06/11/1942	201922	: IN	0 Yes	10-Mar-04		03/22/2004	ECW	washout Enrollment closed during
Fowler, S.	219	L-L	11/19/1950	201923	8 N	0 Yes	10-Mar-04		03/26/2004	ECW	washout
											Enrollment closed during
Fowler, S.	219	MKS	12/02/1947	201924	N	0 Yes	10-Mar-04		03/30/2004	ECW	washout
Foundary C	240	DAG	00/04/4054	204025	· N.I	0.V.	10 Mar 04		02/24/2004		pt notified enrollment end date
Fowler, S.	219	DAG	08/24/1951	201925	N	0 Yes	10-Mar-04		03/24/2004	ECW	prior to end of w/o enrollment closed during
Fowler, S.	219	PBK	03/22/1950	201926	i N	0 Yes	10-Mar-04		03/20/2004	ECW	washout
					-						Enrollment closed during
Fowler, S.	219	CLV	08/26/1951	201927	'N	0 Yes	10-Mar-04		03/19/2004	ECW	washout
Facilia 0	040	01.1	00/07/4050	004000		0)/	40 M = - 04	40 M 04	00/40/0004	- 0	inadequately controlled
Fowler, S.	219	SLL	03/07/1952	201928	N i	0 Yes	12-Mar-04	12-iviar-04	03/16/2004	⊏ 05	diabetes by labs Enrollment closed during
Fowler, S.	219	IMR	12/29/1946	201932	2 N	0 Yes	15-Mar-04		03/22/2004	ECW	washout
- , -	-								, , ,		-

Name	Site	. Initials	DOB	Sub#	W/O	W/O	SF	Visit-01A-IC	Visit-01B	SF or ET	SFC	Comments
	040	11.68.4	00/40/4050	004000		0.1	.,	44.1404		00/40/0004	E014/	Enrollment closed during
Fowler, S.	219	JKM	02/13/1950	201933	N	0	Yes	11-Mar-04		03/19/2004	ECW	washout pt withdrew during washout
Fowler, S.	219	RAH	01/31/1953	201934	N	0	Yes	15-Mar-04		03/29/2004	wwo	due to intolerable moods
Fowler, S.	219	YMG	03/23/1949	201935	N	0	Yes	16-Mar-04	16-Mar-04	03/29/2004	102	not enough hot flashes
Fowler, S.	219	PJS	10/11/1952	201937	N	0	Yes	17-Mar-04	17-Mar-04	03/17/2004	E10	abnormal EKG
												enrollment closed during
Fowler, S.	219	BTG	02/05/1953	201938	N	0	Yes	17-Mar-04		03/26/2004	ECW	washout enrollment closed during
Fowler, S.	219	RMB	10/24/1948	201940	N	0	Yes	15-Mar-04		03/30/2004	ECW	washout
Fowler, S.	219	MCB	10/29/1953	201943	N	0	Yes	23-Mar-04	23-Mar-04	04/02/2004	102	insufficient hot flushes
												uncontrolled HTN and
Fowler, S.	219	K-L	04/12/1949				Yes	26-Mar-04		03/26/2004		postural hypotensive changes
Funk, S.	220	MPR	12/02/1947			_	Yes			03/10/2004	_	too few hot flushes
Funk, S.	220	LML	05/01/1947	201956	N	0	Yes	10-Feb-04	10-Feb-04	02/20/2004	E10	did not meet inclusion criteria
Funk, S.	220	KWC	12/13/1949	201068	N	Ο,	Yes	16-Mar-04	16_Mar_0/	04/13/2004	105	changed her mind after screening completed
Funk, S.	220	HMW	12/19/1947				Yes			03/24/2004		elevated glucose
r driit, O.			12/10/10 1/	201010	••	Ŭ		ZZ Widi 01	ZZ Mai o i	00/2 1/2001	_ 10	withdrew consent after
Funk, S.	220	JZJ	02/13/1951	201971	N	0	Yes	23-Mar-04	23-Mar-04	04/05/2004	105	screening completed
Funk, S.	220	C-G	05/07/1952	201974	N	0	Yes	24-Mar-04	24-Mar-04	03/24/2004	E07	elevated blood pressure
Funk, S.	220	P-J	08/21/1942	201975	N	0	Yes	18-Mar-04		04/12/2004	ECW	too few hot flushes
Funk, S.	220	DLM	08/06/1947	201976	N	0	Yes	25-Mar-04		04/20/2004	102	too few hot flushes
Funk, S.	220	KAB	04/23/1949	201978	N	0	Yes	25-Mar-04		03/25/2004	E07	elevated BP
Gass, M.	221	YRS	05/07/1955	202002	N	0	Yes	22-Mar-04	22-Mar-04	03/26/2004	101	FSH levels>40
Goldsmith, C.	243	SLH	10/27/1947	203105	N	0	Yes	11-Mar-04	11-Mar-04	03/29/2004	105	withdrew consent
Goldsmith, C.	243	JIC	09/24/1950	203106	N	0	Yes	12-Mar-04	12-Mar-04	04/06/2004	E10	ECG - inverted T curves
Goldsmith, C.	243	CEB	08/14/1953	203107	N	0	Yes	19-Mar-04	19-Mar-04	03/19/2004	E10	failed Gynecology exam
Hecht, B.	223	MEA	07/20/1943	202101	N	0	Yes	12-Dec-03	02-Feb-04	02/17/2004	104	site closure
Hecht, B.	223	LJS	08/29/1941	202102	N	0	Yes	29-Dec-03		12/29/2003	104	withdrew consent
Hecht, B.	223	JMS	03/09/1943	202104	N	0	Yes	12-Jan-04	27-Jan-04	02/17/2004	104	Site Closure

Name	Site	. Initials	DOB	Sub#	W/O	W/O SF	Visit-01A-IC	Visit-01B	SF or ET	SFC	Comments
Hecht, B.	223	SAS	05/22/1954	202105	N	0 Yes	15-Jan-04		02/17/2004	104	site closure
Hecht, B.	223	GAA	12/26/1947	202106	N	0 Yes	16-Jan-04	23-Jan-04	01/23/2004	102	not enough hot flushes
Hecht, B.	223	SAM	05/23/1952	202107	'N	0 Yes	16-Jan-04	16-Jan-04	01/19/2004	101	FSH <40
Hecht, B.	223	MKL	01/03/1946	202108	N	0 Yes	19-Jan-04	28-Jan-04	02/17/2004	104	site closure
Hecht, B.	223	MMB	10/23/1943	202109	N	0 Yes	19-Jan-04		02/17/2004	104	site closure
Hecht, B.	223	MAM	11/27/1945	202110	N	0 Yes	19-Jan-04		02/17/2004	104	site closure
Hecht, B.	223	HMS	02/12/1949	202111	N	0 Yes	20-Jan-04	27-Jan-04	02/17/2004	104	site closure
Hecht, B.	223	LAB	12/14/1970	202112	!N	0 Yes	21-Jan-04		02/17/2004	104	site closure
Hecht, B.	223	SJH	09/18/1948	202113	N	0 Yes	22-Jan-04	22-Jan-04	02/11/2004	102	<50 hot flushes
Hedrick, Jr., R.	203	GHH	02/11/1950	201104	·N	0 Yes	16-Jan-04	16-Jan-04	02/06/2004	104	withdrew consent
Hedrick, Jr., R.	203	HMJ	09/27/1954	201105	N	0 Yes	16-Jan-04	16-Jan-04	01/16/2004	101	FSH<40
Hedrick, Jr., R.	203	SKA	09/08/1951	201106	N	0 Yes	19-Jan-04	19-Jan-04	02/18/2004	E05	clinically significant medical history
Hadrial In D	202	D 1147	40/00/4055	004400	. N.I	0\/	04 lan 04		00/00/0004	E00	hx of major depression
Hedrick, Jr., R.	203	RJW	12/02/1955			0 Yes	21-Jan-04	04 1=== 0.4	02/06/2004		disorder
Hedrick, Jr., R.	203	VEH	04/17/1955			0 Yes			01/21/2004		BMI>40
Hedrick, Jr., R.	203	EMM	10/29/1945	201117	IN	0 Yes	29-Jan-04	29-Jan-04	03/16/2004	E10	clinically significant lab results does not meet hot flush
Hedrick, Jr., R.	203	WBM	02/20/1937	201120	N	0 Yes	29-Jan-04	29-Jan-04	02/23/2004	102	criteria
Hedrick, Jr., R.	203	BEC	09/18/1949	201122	!N	0 Yes	29-Jan-04	16-Mar-04	04/21/2004	105	withdrew consent
Hedrick, Jr., R.	203	LSM	10/05/1946	201129	N	0 Yes	02-Feb-04	02-Feb-04	02/09/2004	E10	clinically significant lab results clinically significant ECG
Hedrick, Jr., R.	203	PBR	03/24/1945	201130	N	0 Yes	02-Feb-04	09-Mar-04	03/25/2004	E10	results
Hedrick, Jr., R.	203	BSC	07/20/1957	201132	!N	0 Yes	03-Feb-04		02/10/2004	102	did not meet hot flush criteria
Hedrick, Jr., R.	203	LWW	02/22/1949	201133	N	0 Yes	03-Feb-04		02/03/2004	E06	current hx of anxiety
lladelalı le D	202	N4A C	00/00/4050	004400	· KI	0\/	04 5-6 04	00 Fab 04	00/40/0004	10.4	withdrew consent during
Hedrick, Jr., R.	203	MAC	03/29/1952	201136) IN	0 Yes	04-Feb-04	23-Feb-04	03/10/2004	104	washout unable to discontinue vaginal
Hedrick, Jr., R.	203	PAL	12/17/1952	201137	'N	0 Yes	04-Feb-04		02/04/2004	E02	HRT
Hedrick, Jr., R.	203	DSM	06/22/1951	201138	N	0 Yes	04-Feb-04	03-Mar-04	03/03/2004	E14	use of excluded medication
Hedrick, Jr., R.	203	GRL	04/21/1947	201139	N	0 Yes	04-Feb-04	04-Feb-04	03/16/2004	104	lost to follow up

Name	Site	Initials	DOB	Sub#	W/O	W/O SF	Visit-01A-IC	Visit-01B	SF or ET	SFC	Comments
Hedrick, Jr., R.	203	SEW	10/25/1956			0 Yes			02/05/20041		withdrew consent
Hedrick, Jr., R.	203	DBM	07/15/1946			0 Yes			03/04/2004		clinically significant lab results
											clinically significant ECG
Hedrick, Jr., R.	203	MMH	03/19/1956	201148	BN	0 Yes	11-Feb-04	11-Feb-04	03/16/2004 F	E10	results
Hedrick, Jr., R.	203	KWH	01/21/1936	201140	N	0 Yes	11-Feb-04	11_Feh_04	02/18/2004	=05	clinically significant medical history
ricarion, or., re.	200	120011	01/21/1000	2011-0	/ I V	0 1 0 3	11-1 CD-04	11-1 00-04	02/10/20041	_00	elevated blood pressure at
Hedrick, Jr., R.	203	EMG	11/26/1954	203519	N	0 Yes	18-Feb-04		02/18/2004	Ξ07	screening visit
Hedrick, Jr., R.	203	EAF	09/14/1964	203525	δN	0 Yes	25-Feb-04	25-Feb-04	03/01/20041	01	FSH<40
Hedrick, Jr., R.	203	JVS	11/19/1949	203528	3 N	0 Yes	11-Mar-04	11-Mar-04	03/16/2004 I	01	FSH<40
Ho, L.	204	LNP	12/20/1948	201154	١N	0 Yes	06-Feb-04	08-Mar-04	03/08/2004	E08	malignancy
Ho, L.	204	TSF	05/10/1950	201155	δN	0 Yes	06-Feb-04	06-Feb-04	03/19/2004	Ξ10	ECG
Ho, L.	204	MKL	03/10/1951	201156	δN	0 Yes	06-Feb-04	06-Feb-04	02/08/2004 I	01	FSH levels>40
	004	D D	00/44/4040	004400		0)/	07.5.1.04	07.5.1.04	0.4/0.0/0.00.4.5	-00	enrollment closed during
Ho, L.	204	B-P	09/11/1949	201162	2 IN	0 Yes	27-Feb-04	27-Feb-04	04/26/2004 B	=CS	screening enrollment closed during
Ho, L.	204	CLS	02/24/1950	201166	S N	0 Yes	04-Mar-04	04-Mar-04	04/26/2004	ECS	screeing
Ho, L.	204	PLS	11/08/1949	201169	N	0 Yes	12-Mar-04	12-Mar-04	03/26/2004	01	FSH level
											lost to follow up per sitewas
Ho, L.	204	CKL	08/06/1947	201173	3 N	0 Yes	15-Mar-04		04/23/2004\	NWO	in 4 wk washout
Ho, L.	204	MEW	09/28/1949	201174	l NI	0 Yes	16 Mar 04	16 Mar 04	04/26/2004 [=CS	enrollment closed during screening
Kim, E.	205	J-R	12/21/1957			0 Yes			12/18/2003		LFT elevated, x2UNL
Kim, E.	205	LSR	06/24/1949			0 Yes			02/04/2004		<50 hot flashes
Kim, E.	205	JKB	02/07/1951			0 Yes			02/04/20041	_	<50 hot flashes
Kim, E.	205	CRS	10/22/1951			0 Yes			02/09/20041		withdrew consent - no time
Kim, E.	205	DLM	08/10/1948			0 Yes			03/19/2004 [Elevated LFT
Kiiii, L.	200	DLIVI	00/10/1940	201211	IN	0 163	04-1 60-04	13-Mai-04	03/19/20041	_10	Withdrew consent during
Kim, E.	205	RBZ	06/28/1951	201214	N	0 Yes	09-Feb-04		02/26/2004	WWO	washout
											Withdrew consent during
Kim, E.	205	SJB	10/17/1947			0 Yes	10-Feb-04		03/05/2004		
Kim, E.	205	AMR	01/06/1950	201222	2 N	0 Yes	11-Feb-04		02/13/2004\	wwo	Withdrew consent during

Name	Site	. Initials	DOB	Sub#	W/O	W/O SF	Visit-01A-IC	Visit-01B	SF or ET	SFC	Comments
											washout
Kim, E.	205	JBA	03/31/1941	201224	·N	0 Yes	12-Feb-04		03/19/2004	WWO	withdrew during washout
Kim, E.	205	RSG	05/27/1948	201234	·N	0 Yes	25-Feb-04		03/24/2004	WWO	did not show for 1B
Kim, E.	205	JLD	11/19/1952	201236	N	0 Yes	01-Mar-04	01-Mar-04	03/19/2004	104	subject withdrew consent
Kim, E.	205	CMS	03/11/1949	201240	N	0 Yes	03-Mar-04		03/08/2004	104	does not wish to washout for study -withdrew consent enrollment closed during
Kim, E.	205	WKB	03/15/1952	201243	N	0 Yes	04-Mar-04		03/29/2004	ECW	washout
Kim, E.	205	LLJ	04/17/1953	201244	·N	0 Yes	04-Mar-04		03/24/2004	wwo	withdrew consent
											did not meet minimum of
ا العاميدال	244	SLD	03/05/1941	202454	N.I.	0 Yes	15 Max 04	10 000 01	04/04/0004	100	moderate to severe hot
Kirby, II, L.	244	SLD	03/03/1941	203131	IN	o res	15-Mai-04	12-Apr-04	04/21/2004	102	flashes per day Withdrew Consent During
Kirby, II, L.	244	JAT	10/11/1950	203152	!N	0 Yes	15-Mar-04		03/26/2004	wwo	Washout
•											taking meds for VSpt
Kirby II I	244	EAS	02/16/1942	202154	N.I.	0 Yes	22 Mar 04	22 Mar 04	03/26/2004	T12	withdrew consent to washout
Kirby, II, L.	244										due to family emergency did not meet hot flash criteria
Kirby, II, L.	244	LJC	05/24/1950	203155) IN	0 Yes	20-Mar-04	26-Mar-04	04/08/2004	102	withdrew consent - breast
											biopsy scheduled 4/22/04. not
											enough time to get results
Lopez-Cintron, J.	225	KD	09/03/1947	202202	N	0 Yes	24 Feb 04	30 Mar 04	04/21/2004	105	before enrollment close on 4/23
Lopez-Cirition, 5.	223	ND	03/03/134/	202202	. IN	0 163	24-1 60-04	30-Mai-04	04/21/2004	103	Withdrew consent during
Lopez-Cintron, J.	225	JEP	05/15/1933	202205	N	0 Yes	08-Mar-04		03/11/2004	WWO	washout
Lopez-Cintron, J.	225	HMM	01/15/1948	202213	N	0 Yes	18-Mar-04	18-Mar-04	04/22/2004	102	not enough hot flashes
Lana - Olataa - I	005	IDD	00/04/4050	000040		0)/	00 M 04		00/00/0004	E0\4/	Enrollment closed during
Lopez-Cintron, J.	225	JDR	09/04/1950	202216) IN	0 Yes	23-Mar-04		03/23/2004	ECVV	washout after 1B visit, pt stated she
											forgot she was taking black
Lopez-Cintron, J.	225	C-C	09/27/1952	202217	'N	0 Yes	24-Mar-04	24-Mar-04	03/24/2004	E13	cohosh
Lana - Olata	005	D 0	00/07/4050	000010		0.1/	05.1404		00/05/0004	E0\47	pt ineligible-4 wk washout
Lopez-Cintron, J.	225	P-S	08/27/1950	202219	IN	0 Yes	25-Mar-04		03/25/2004	ECW	/enrollment closing

Name	Site	. Initials	DOB	Sub#	W/O	W/O SF	Visit-01A-IC	Visit-01B	SF or ET	SFC	Comments
Miller, P.	227	DAM	08/27/1949	202301	Ν	0 Yes	25-Mar-04		03/25/2004	ECW	subject taking Black cohosh
Miller, S.	228	KRG	12/25/1948	202354	N	0 Yes	29-Jan-04	29-Jan-04	03/19/2004	105	withdrew consent
											less than 12 months of
											spontaneous amenorrhea with
Miller, S.	228	LPM	11/24/1954	202358	3 N	0 Yes	02-Feb-04	02-Feb-04	02/26/2004	101	serum FSH levels<40mIU/MI
Miller, S.	228	MAJ	04/07/1950	202359	N	0 Yes	02-Feb-04		03/19/2004	WWO	withdrew during washout
Miller, S.	228	MEV	04/06/1957	202365	N	0 Yes	03-Feb-04	03-Feb-04	02/19/2004	101	FSH too low
Miller, S.	228	LMW	03/07/1950	202374	N	0 Yes	09-Feb-04	09-Feb-04	03/01/2004	101	FSH<40
Miller, S.	228	MYH	04/22/1952	202376	N	0 Yes	12-Feb-04	08-Apr-04	04/19/2004	ECS	enrollment closed
											enrollment closed during
Miller, S.	228	JLO	12/14/1947	202377	'N	0 Yes	16-Feb-04		04/14/2004	ECW	washout
		011.4	0.444.044.0.00			23.4	00 = 1 04		0.4/0.0/0.004		began menstrual cycle
Miller, S.	228	CIM	04/12/1950	202380	N	0 Yes	23-Feb-04		04/09/2004	E04	2/16/04
Millor C	228	DVT	10/10/1951	202201	NI.	0 Yes	23-Feb-04		04/14/2004	ECW	enrollment closed during washout
Miller, S.	220	ואט	10/10/1951	202301	IN	0 165	23-F60-04		04/14/2004	ECVV	enrollment closed during
Miller, S.	228	DES	09/07/1949	202382	N	0 Yes	23-Feb-04		04/14/2004	ECW	washout
						0.00	_0.000.		• • • .		enrollment closed during
Miller, S.	228	JGA	08/02/1949	202387	'N	0 Yes	25-Feb-04		04/14/2004	ECW	washou
											enrollment closed during
Miller, S.	228	DTA	04/19/1958	202388	3 N	0 Yes	25-Feb-04		04/14/2004	ECW	washou
Miller, S.	228	MVT	10/14/1952	202392	2 N	0 Yes	26-Feb-04	26-Feb-04	03/09/2004	102	FSH<40
_											enrollment closed during
Miller, S.	228	LCG	05/06/1951	202393	3 N	0 Yes	26-Feb-04	25-Mar-04	04/19/2004	ECS	screening
Millor C	220	EDW/	07/07/1050	202204	NI.	0.V00	26 Fab 04	OF Mar 04	04/40/2004	FCC	enrollment closed during
Miller, S.	228	FPW	07/07/1950	202394	· IN	0 Yes	26-Feb-04	25-Mar-04	04/19/2004	ECS	screening enrollment closed during
Miller, S.	228	SLA	08/08/1951	203680	N	0 Yes	08-Mar-04	08-Mar-04	04/19/2004	ECS	screening
Willier, O.	220	OLA	00/00/1001	200000	, I V	0 100	oo mar o+	OO Mai O+	04/10/2004	LOC	enrollment closed during
Miller, S.	228	AKP	01/03/1948	203690	N	0 Yes	08-Mar-04		04/14/2004	ECW	washout
											enrollment closed during
Miller, S.	228	NAE	08/28/1950	203692	2 N	0 Yes	09-Mar-04		04/14/2004	ECW	washout
Miller, S.	228	L-D	04/22/1951	203694	N	0 Yes	10-Mar-04		04/14/2004	ECW	enrollment closed during

Name	Site	. Initials	DOB	Sub#	W/O	W/O SF	Visit-01A-IC	Visit-01B	SF or ET	SFC	Comments
											washout
Miller, S.	228	EGC	04/29/1955	203696	δN	0 Yes	11-Mar-04		04/19/2004	4ECS	enrollment closed
Millor C	220	СТ	00/46/4040	202600	. KI	0.\/aa	15 Mar 04	15 Mar 04	04/40/200	1 500	enrollment closed during
Miller, S.	228	E-T	09/16/1949	203698) IN	0 Yes	15-14	15-Mar-04	04/19/2004	+EC2	screening enrollment closed during
Miller, S.	228	P-O	12/10/1941	203699	N	0 Yes	15-Mar-04		04/14/2004	4 ECW	washout
			00/40/40=0			0.14	40.14	40.14	0.4.4.0.40.00	. = 0.0	enrollment closed during
Miller, S.	228	MMA	08/12/1953	203702	2 N	0 Yes	16-Mar-04	16-Mar-04	04/19/2004	4 ECS	screening enrollment closed during
Miller, S.	228	MAH	10/28/1947	203704	ł N	0 Yes	16-Mar-04		04/14/2004	4 ECW	washout
											enrollment closed during
Miller, S.	228	JKC	09/25/1952			0 Yes	16-Mar-04		04/14/2004		washout
Miller, S.	228	MDT	11/30/1950	203713	3 N	0 Yes	22-Mar-04	22-Mar-04	03/30/2004	4 IO1	FSH<40
Miller, S.	228	RDS	06/22/1961	203717	'N	0 Yes	25-Mar-04	25-Mar-04	04/19/2004	4FCS	enrollment closed during screening
Miller, S.	228	SAR	05/11/1948			0 Yes		26-Mar-04			FSH 20 I/E >40
Miller, S.	228	IRG	10/01/1951			0 Yes		24-Mar-04			FSH 3.9 I/E >40
Muse, K.	229	JEW	05/06/1954	202402	2 N	0 Yes	09-Mar-04	30-Mar-04	04/06/2004	4 E05	triglycerides 399
											enrollment closed during
Muse, K.	229	BFH	05/31/1944			0 Yes	11-Mar-04		03/22/2004		washout
Muse, K.	229	SRD	01/07/1944	202407	'N	0 Yes	11-Mar-04	08-Apr-04	04/08/2004	4 E05	BP high
Muse, K.	229	LLP	08/01/1961	202408	R NI	0 Yes	17-Mar-04		03/30/2004	1 F02	started hormone for ovarian cyst
Mase, IX.	220	LL!	00/01/1001	202-100	, , ,	0 100	17 Ivial 04		00/00/200	1 202	started back on Lexipro last
Muse, K.	229	MJP	02/14/1952	202409	N	0 Yes	18-Mar-04		03/30/2004	4E14	night
Muse, K.	229	BAB	12/15/1936	202418	3 N	0 Yes	25-Mar-04	31-Mar-04	04/05/2004	4 E05	anemia, Hgb 6.5, Hct 22.8
Muga K	229	BLW	12/13/1953	202420	\ NI	0 Yes	26 Mar 04	07 Apr 04	04/14/200	1 101	FSH 14.0 and E14 using 3
Muse, K. Muse, K.	229	PJB	01/28/1944			0 Yes	26-Mar-04	07-Apr-04	03/30/2004		psychoactive meds withdrew consent
	231	BEM	10/12/1945			0 Yes		06-Jan-04			
Nordland, R. Nordland, R.	231	B⊑IVI M-K	07/29/1950			0 Yes		16-Feb-04			not enough hot flushes
*	_									-	not enough hot flushes
Nordland, R.	231	C-W	10/18/1949	202506) IN	0 Yes	10-Feb-04	16-Feb-04	U3/U8/2004	+ 102	too few hot flushes

Name	Site	. Initials	DOB	Sub#	W/O	W/O SF	Visit-01A-IC	Visit-01B	SF or ET	SFC	Comments
Nordland, R.	231	C-M	07/13/1943	202510	N	0 Yes	18-Feb-04	18-Feb-04	03/08/2004	102	not enough hot flushes
Nordland, R.	231	D-S	07/22/1951	202516	N	0 Yes	08-Mar-04	08-Mar-04	04/13/2004	102	too few hot flushes
Nordland, R.	231	ELB	04/30/1949	202517	'N	0 Yes	09-Mar-04	09-Mar-04	03/09/2004	102	too few hot flushes
Nordland, R.	231	MLW	10/02/1948	202518	8 N	0 Yes	10-Mar-04	10-Mar-04	03/10/2004	102	too few hot flushes
											enrollment closed during
Nordland, R.	231	ECB	02/21/1949	202519	N	0 Yes	12-Mar-04		04/12/2004	ECW	washout
Nordland, R.	231	SKB	08/30/1951	202520	N	0 Yes	12-Mar-04	12-Mar-04	04/14/2004	104	travelling and can't make visit 2 before 4/23/04
Nordland, R.	231	CAH	12/17/1951			0 Yes			04/14/2004		LTFU
Nordland, R.	231	A-O	06/16/1939			0 Yes	17-Mar-04	10 Mai 01	03/17/2004		too few hot flushes off Evista
Nordiand, IX.	201	λ-0	00/10/1333	202020	/ I N	0 1 03	17-Mai-04		00/11/2004	102	withdrew consent during
Nordland, R.	231	J-G	07/20/1948	202527	'N	0 Yes	19-Mar-04		04/08/2004	WWO	•
Nordland, R.	231	CLW	01/17/1952	202528	8 N	0 Yes	22-Mar-04	22-Mar-04	04/20/2004	102	too few hot flushes
Noss, M.	232	LAA	09/21/1952	202552	2 N	0 Yes	12-Jan-04	12-Jan-04	01/29/2004	104	withdrew consent
Noss, M.	232	KSF	05/23/1953	202554	N	0 Yes	13-Jan-04	13-Jan-04	03/01/2004	E10	prolonged QT interval
Noss, M.	232	VRS	07/03/1961	202555	N	0 Yes	22-Jan-04	22-Jan-04	01/22/2004	103	BMI
Noss, M.	232	RLB	11/18/1951	202559	N	0 Yes	30-Jan-04	30-Jan-04	01/30/2004	103	BMI and FSH level
Noss, M.	232	P-J	09/24/1946	202567	'N	0 Yes	12-Feb-04	11-Mar-04	03/19/2004	E10	elevated liver enzymes x2UNL
Noss, M.	232	SJB	07/28/1952	202568	8 N	0 Yes	13-Feb-04	13-Feb-04	03/19/2004	105	withdrew consent
											withdrew consent during
Noss, M.	232	JAD	12/21/1951			0 Yes	16-Feb-04		04/01/2004		
Noss, M.	232	O-R	01/18/1948			0 Yes			03/08/2004		not enough hot flashes
Noss, M.	232	S-G	03/28/1950	202576	δN	0 Yes	27-Feb-04	27-Feb-04	02/27/2004	E07	high BP
Noss M	232	K-P	08/18/1952	202577	' NI	0 Yes	01 Mar 04	01 Mar 04	03/01/2004	E07	high BP
Noss, M.											high BP
Noss, M.	232	BLH	02/05/1950			0 Yes			03/26/2004		not enough hot flashes
Noss, M.	232	MMB	08/10/1952			0 Yes			04/02/2004		not enough hot flashes
Noss, M.	232	LJB	09/05/1930	202584	·N	0 Yes	15-Mar-04	15-Mar-04	03/31/2004	102	not enough hot flashes
Noss, M.	232	DLW	09/05/1958	202585	N	0 Yes	15-Mar-04		04/01/2004	FCW	enrollment closed during washout
Noss, M.	232	SPS	10/05/1952			0 Yes	15-Mar-04		04/20/2004		not enough hot flashes
14033, IVI.	202	51 5	10/00/1902	202000	, 1 N	0 163	13-Mai-04		0-7/20/2004	102	not chough not hashes

Name	Site	. Initials	DOB	Sub #	W/O	W/O SF	Visit-01A-IC	Visit-01B	SF or ET	SFC	Comments
Noss, M.	232	CLK	05/07/1951	202587	N N	0 Yes	15-Mar-04	15-Apr-04	04/23/2004	102	not enough hot flashes
Noss, M.	232	TBB	05/27/1951	202588	3 N	0 Yes	17-Mar-04	29-Mar-04	03/29/2004	102	not enough hot flashes
Noss, M.	232	MRB	03/21/1950	202589	N	0 Yes	17-Mar-04	17-Mar-04	04/26/2004	102	diary information
Noss, M.	232	M-C	09/30/1947	202590	N	0 Yes	19-Mar-04	18-Mar-04	04/02/2004	102	not enough hot flashes
Noss, M.	232	IDG	08/21/1953	202593	3 N	0 Yes	25-Mar-04	25-Mar-04	04/09/2004	102	not enough hot flashes PI withdrew subject from the
Noss, M.	232	CAF	12/31/1952	202596	δN	0 Yes	26-Mar-04	26-Mar-04	03/26/2004	104	study
Osterling, D.	233	PCB	04/30/1942	202610	N	0 Yes	18-Feb-04		02/19/2004	104	withdrew consent
Osterling, D.	233	SBG	07/11/1953	202616	δN	0 Yes	26-Feb-04	26-Feb-04	02/26/2004	104	withdrew from study
Osterling, D.	233	J-H	01/06/1948	202620	N	0 Yes	02-Mar-04	02-Mar-04	03/31/2004	104	withdrew consent
Osterling, D.	233	KLM	11/19/1946	202622	2 N	0 Yes	03-Mar-04	03-Mar-04	03/04/2004	102	not enough hot flashes
Osterling, D.	233	KBH	09/25/1952	202623	3 N	0 Yes	04-Mar-04	04-Mar-04	03/09/2004	l01	FSH low
Osterling, D.	233	LLW	12/02/1948	202626	δN	0 Yes	10-Mar-04	10-Mar-04	04/01/2004	l01	FSH low
Osterling, D.	233	NAD	12/14/1949	202628	3 N	0 Yes	11-Mar-04	11-Mar-04	04/07/2004	105	withdrew consent
Osterling, D.	233	LGP	07/03/1947	202634	١N	0 Yes	25-Mar-04	25-Mar-04	03/31/2004	105	withdrew consent
Osterling, D.	233	KAZ	07/06/1960	202636	δN	0 Yes	26-Mar-04		04/05/2004	105	withdrew consent withdrew consent during
Rankin, M.	234	PTC	02/10/1952	203053	3 N	0 Yes	15-Mar-04		03/16/2004	WWO	washout
Rankin, M.	234	DKL	01/02/1950	203054	١N	0 Yes	15-Mar-04	15-Apr-04	04/20/2004	102	not enough hot flashes
Rankin, M.	234	KAS	04/01/1950	203055	5 N	0 Yes	16-Mar-04	12-Apr-04	04/18/2004	105	withdrew consent
Rankin, M.	234	L-F	06/11/1952	203057	'N	0 Yes	17-Mar-04	17-Mar-04	04/06/2004	E09	glaucoma
Rankin, M.	234	JAF	09/19/1953	203059	N	0 Yes	18-Mar-04	18-Mar-04	04/26/2004	ECS	
Rankin, M.	234	GDJ	08/05/1951	203061	l N	0 Yes	23-Mar-04	23-Mar-04	03/25/2004	E13	use of meds for VS
Robinson, M.	235	CEB	06/24/1961	202651	l N	0 Yes	13-Jan-04	14-Jan-04	01/14/2004	E13	on exclusionary med subj withdrew - taking trip to
Robinson, M.	235	BAM	03/31/1935	202653	3 N	0 Yes	14-Jan-04	14-Jan-04	01/14/2004	104	Europe
Robinson, M.	235	NBP	08/29/1946	202661	l N	0 Yes	02-Feb-04	02-Feb-04	03/01/2004	104	did not show for appt., LTFU
Robinson, M.	235	JLW	08/23/1947	202663	3 N	0 Yes	09-Feb-04	09-Feb-04	03/19/2004	102	insufficient hot flashes
Robinson, M.	235	MAB	04/22/1949	202670	N	0 Yes	16-Feb-04	16-Feb-04	03/12/2004	102	too few hot flashes
Robinson, M.	235	CJG	05/14/1950	202674	١N	0 Yes	02-Mar-04		03/19/2004	105	LTFU for 1B visit per site

Name	Site	. Initials	DOB	Sub#	W/O	W/O SF	Visit-01A-IC	Visit-01B	SF or ET	SFC	Comments
Robinson, M.	235	CKB	01/14/1953	202675	N	0 Yes	03-Mar-04	03-Mar-04	03/03/2004	E10	ECG
Robinson, M.	235	MAH	05/14/1954	202677	'N	0 Yes	08-Mar-04	08-Mar-04	03/10/2004	102	not enough hot flashes
Robinson, M.	235	DMC	02/28/1950	202679	N	0 Yes	10-Mar-04	10-Mar-04	03/10/2004	E10	labs
Robinson, M.	235	LBO	08/16/1948	202682	N.	0 Yes	24-Mar-04	24-Mar-04	03/24/2004	101	FSH level
Robinson, M.	235	EMT	09/08/1947	202683	N	0 Yes	24-Mar-04	24-Mar-04	03/24/2004	101	FSH level
Scutella, M.	236	BAD	12/29/1948	202705	N	0 Yes	11-Feb-04	11-Feb-04	02/26/2004	102	did not meet hot flash criteria
Scutella, M.	236	LJF	08/01/1951	202707	'N	0 Yes	11-Feb-04	11-Feb-04	02/24/2004	102	did not meet inclusion criteria
Scutella, M.	236	SMS	09/02/1950	202708	N	0 Yes	11-Feb-04	11-Mar-04	04/09/2004	102	did not meet hot flash criteria
Scutella, M.	236	BMG	07/03/1952	202714	·N	0 Yes	16-Feb-04	16-Feb-04	03/08/2004	102	did not meet hot flash criteria
											enrollment closed during
Scutella, M.	236	PDC	09/17/1950	-		0 Yes	19-Feb-04		04/20/2004	_	washout
Scutella, M.	236	PLL	03/27/1959	202718	5 N	0 Yes	20-Feb-04	26-Mar-04	03/26/2004	E10	ALT 2x normal level
Scutella, M.	236	JEA	06/26/1953	202719	N	0 Yes	20-Feb-04		02/23/2004	wwo	Withdrew consent during washout
Scutella, M.	236	PLS	08/20/1952			0 Yes		24-Feb-04	03/19/2004	_	did not meet hot flash criteria
Scutella, M.	236	J-S	04/11/1949			0 Yes	26-Feb-04	24-1 00-04	03/24/2004	_	study closing enrollment
Scutella, M.	236	D-C	09/16/1953			0 Yes	01-Mar-04		04/14/2004		FSH<40
Scutella, M.	236	KAZ	04/08/1951			0 Yes		05_Mar_04	03/26/2004		not enough hot flashes
Scutella, M.	236	CJA	12/25/1950			0 Yes			03/20/2004		PC, ECG, Lab Tests
Scutella, M.	236	CAN	09/27/1948			0 Yes			03/15/2004		not enough hot flashes
Sculella, IVI.	230	CAN	09/27/1946	202133	IN	0 168	1 1-Wai-04	1 1-1VIa1-04	03/20/2004	102	enrollment closed during
Scutella, M.	236	BMA	06/27/1950	202735	N	0 Yes	11-Mar-04	16-Apr-04	04/26/2004	ECS	screening
Smith, R.	238	PJB	08/01/1945	202803	N	0 Yes	28-Jan-04	28-Jan-04	01/30/2004	101	FSH=31
Smith, R.	238	BJA	04/11/1956	202806	N	0 Yes	09-Feb-04	10-Feb-04	02/10/2004	104	Withdrew consent
Smith, R.	238	ASK	04/21/1953	202807	'N	0 Yes	10-Feb-04	10-Feb-04	02/23/2004	102	<50 hot flushes
Smith, R.	238	KJS	07/26/1943	202811	N	0 Yes	18-Feb-04	18-Feb-04	02/18/2004	104	Withdrew consent
Smith, R.	238	JLS	04/25/1937	202812	. N	0 Yes	19-Feb-04	19-Feb-04	02/23/2004	101	FSH= 30.9
•											clinically important cardial
Smith, R.	238	JGS	10/25/1930	202816	N	0 Yes	24-Feb-04	24-Feb-04	02/26/2004	E05	problem
Smith, R.	238	KRK	10/21/1950	202820	N	0 Yes	26-Feb-04	26-Feb-04	03/15/2004	102	does not meet hot flush

Name	Site	. Initials	DOB	Sub#	W/O	W/O SF	Visit-01A-IC	Visit-01B	SF or ET	SFC	Comments
											criteria
Smith, R.	238	CAH	06/05/1952	202823	8 N	0 Yes	04-Mar-04	04-Mar-04	03/04/2004	I01	FSH=22.7
0 ''' D	000	0.4.0	00/04/4045	000004		0)/	04.84 04		0.4/0.5/0.004	-0\A/	enrollment closed during
Smith, R.	238	SAB	03/21/1945	202824	·N	0 Yes	04-Mar-04		04/05/2004	ECW	washout enrollment closed during
Smith, R.	238	CMN	12/15/1949	202827	'N	0 Yes	05-Mar-04		04/05/2004	ECW	washout
,											withdrew consent due to work
Smith, R.	238	G-L	07/30/1947	202828	3 N	0 Yes	08-Mar-04	08-Mar-04	03/15/2004	104	schedule
Smith, R.	238	LLD	05/17/1953	202834	NI	0 Yes	19 Mar 04	19 Mar 04	03/30/2004	104	withdrew consent due to son's health
*		S-F									
Soper, H.	239	5-F	12/10/1946	202853) IN	0 Yes	17-Dec-03	17-Dec-03	01/15/2004	102	not enough hot flushes pt withdrew consent due to
											wants to resolve cholesterol
Soper, H.	239	BAG	12/08/1942	202854	N	0 Yes	19-Dec-03	04-Feb-04	02/20/2004	104	elevated
0 11	000	DOM	0.4/0.4/4.0.40	000050		0.17	40 1 04		00/40/0004	140410	Withdrew consent during
Soper, H.	239	BOK	04/21/1949			0 Yes	10-Jan-04		02/16/2004		washout
Soper, H.	239	PCW	03/21/1938	202858	3 N	0 Yes	12-Jan-04		01/21/2004	I01	No labs done
Soper, H.	239	SHB	07/13/1940	202861	N	0 Yes	19-Jan-04		02/16/2004	wwo	Withdrew consent during washout
Soper, H.	239	RAP	06/19/1957			0 Yes		04-Feh-04	02/24/2004	_	not enough hot flashes
Soper, H.	239	LFT	05/21/1952			0 Yes			03/03/2004	-	hot flashes stopped
•	239	BJY	09/12/1949			0 Yes			02/04/2004		FSH<40
Soper, H.											
Soper, H.	239	DKC	01/18/1948	202866) IN	0 Yes	04-Feb-04	04-Feb-04	03/08/2004	102	not enough hot flashes subject withdrew consent,
Soper, H.	239	CWP	02/10/1947	202867	'N	0 Yes	05-Feb-04	05-Feb-04	02/20/2004	104	chose to go back on HRT
Soper, H.	239	JHG	11/09/1946	202868	8 N	0 Yes	09-Feb-04	09-Feb-04	02/20/2004	E07	BP>160/100
Soper, H.	239	SMK	04/11/1945	202870	N	0 Yes	10-Feb-04		02/18/2004	E13	back on HRT
Soper, H.	239	DCS	08/23/1948	202876	N	0 Yes	01-Mar-04	01-Mar-04	04/12/2004	105	withdrew consent
•											withdrew consent during
Soper, H.	239	RCK	04/14/1960	202877	'N	0 Yes	04-Mar-04		03/23/2004	WWO	washout
Soper, H.	239	JAL	08/22/1948	202881	N	0 Yes	09-Mar-04	09-Mar-04	03/30/2004	101	FSH level 38.0
Soper, H.	239	TBH	02/01/1943	202884	N	0 Yes	25-Mar-04	25-Mar-04	03/30/2004	101	FSH

Name	Site	. Initials	DOB	Sub#	W/O	W/O SF	Visit-01A-IC	Visit-01B	SF or ET	SFC	Comments
											high cholesterol, high
Speller, M.	240	SFM	03/13/1953	202903	3 N	0 Yes	19-Jan-04	26-Jan-04	02/06/2004	E10	LDL/VLDL, SGPT elevated
Speller, M.	240	SLC	06/02/1949	202905	δN	0 Yes	19-Jan-04		02/17/2004	104	withdrew consent
Speller, M.	240	MEH	10/26/1942	202909	N	0 Yes	22-Jan-04	02-Feb-04	02/20/2004	E10	abnormal labs
Speller, M.	240	BAM	02/21/1940	202911	l N	0 Yes	28-Jan-04		02/06/2004	104	withdrew consent, no 1B visit
Speller, M.	240	SDB	12/31/1948	202914	١N	0 Yes	02-Feb-04		02/09/2004	104	withdrew consent, no 1B visit
Speller, M.	240	LJS	11/21/1954	202915	5 N	0 Yes	02-Feb-04		02/09/2004	102	not enough hot flashes
Speller, M.	240	SLF	06/02/1950	202919	N	0 Yes	11-Feb-04		02/23/2004	104	withdrew consent, no 1B
Speller, M.	240	BBS	07/03/1951	202920	N	0 Yes	16-Feb-04		02/27/2004	102	not enough hot flashes
Speller, M.	240	LRC	06/22/1951	202924	١N	0 Yes	24-Feb-04	02-Mar-04	03/09/2004	102	insufficient hot flushes
Speller, M.	240	PMT	05/04/1956	202925	5 N	0 Yes	04-Mar-04	11-Mar-04	03/19/2004	102	not enough hot flashes
Speroff, L.	241	SMN	12/26/1961	202952	2 N	0 Yes	18-Mar-04	18-Mar-04	03/25/2004	101	FSH level <40
Speroff, L.	241	RLS	01/09/1940	202954	١N	0 Yes	19-Mar-04	19-Mar-04	04/14/2004	102	<50 hot flashes per week
Speroff, L.	241	JLT	11/24/1950	202955	5 N	0 Yes	23-Mar-04	23-Mar-04	03/23/2004	E11	malabsorption disorder
Speroff, L.	241	SJS	06/15/1967	202957	'N	0 Yes	23-Mar-04	23-Mar-04	04/16/2004	102	<50 hot flashes per week
Speroff, L.	241	L-K	11/16/1943	202959	N	0 Yes	25-Mar-04	12-Apr-04	04/12/2004	104	unable to return to clinic within visit 2 window
Spratt, D.	242	SCT	08/16/1954	203004	١N	0 Yes	22-Mar-04	22-Mar-04	04/05/2004	105	withdrew consent
Spratt, D.	242	L-E	07/05/1948	203007	'N	0 Yes	23-Mar-04	23-Mar-04	04/14/2004	105	withdrew consent
Spratt, D.	242	LMC	05/13/1953	203012	2 N	0 Yes	24-Mar-04	24-Mar-04	04/21/2004	ECS	enrollment met
Spratt, D.	242	BMH	05/27/1956	203013	3 N	0 Yes	24-Mar-04	24-Mar-04	04/21/2004	ECS	enrollment met
Spratt, D.	242	KMG	04/30/1953	203024	١N	0 Yes	26-Mar-04	26-Mar-04	04/21/2004	ECS	enrollment met
											ALT & AST greater than 2
Yankaskas, M.	206	DCJ	01/05/1952			0 Yes			02/02/2004		times ULN
Yankaskas, M.	206	KPC	04/18/1950			0 Yes			03/05/2004		too busy to make visits
Yankaskas, M.	206	LSR	01/18/1953	201278	3 N	0 Yes	26-Feb-04	26-Feb-04	03/24/2004	102	not enough hot flushes cholesterol/triglycerides too
Yankaskas, M.	206	DJH	09/21/1945	201281	l N	0 Yes	01-Mar-04	01-Mar-04	04/20/2004	E10	elevated
Yankaskas, M.	206	DMR	11/07/1952	201282	2 N	0 Yes	02-Mar-04	02-Mar-04	03/02/2004	101	FSH too low
Yankaskas, M.	206	JAT	02/25/1957	201294	١N	0 Yes	24-Mar-04	24-Mar-04	04/23/2004	102	not enough hot flushes
•											•

CSR-60178

Protocol 3151A2-315-US

DVS SR

I04 I05

WWO

Will not comply ICF Withdrawn

Withdrew Consent during washout

Name	Site	Initials	DOB	Sub#	W/O	W/O SF	Visit-01A-IC	Visit-01B	SF or ET	SFC	Comments
											having blurred vision and floaters, Dr feels she needs complete workup before
Yankaskas, N		LMT	08/11/1938	201295	5 N	0 Yes	24-Mar-04	24-Mar-04	03/31/2004	E09	entering study
Screen Failure											
E01	• •	•	venlafaxine								
E02	Hormonal										
E03	History of										
E04	MI w/in 6		0.00								
E05 E06	Liver or ki CNS disor	-	ase								
			× 100								
E07	SBP > 160 Cancer	OI DBP -	× 100								
E08 E09	eye pressu	ro / alouec	ama.								
E10	PE, ECG,	_									
E11	Untreated										
E12	Use of Inv										
E13	Use of me										
E14	Use of psy										
ECS			luring screening	ıσ							
ECW			luring washout								
I01	Not menor		ioning washed	•							
I02	< 50 hot fl										
103	BMI										

ST 8-2: Number (%) of Subjects Excluded from Per-Protocol Population for Vasomotor Symptom Data

Page

1

28JUL05 17:28 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT EE4_SYM NUMBER (%) OF SUBJECTS EXCLUDED FROM EFFICACY EVALUABLE POPULATION FOR VASOMOTOR SYMPTOM DATA

Data Analysis Interval Criteria Description	DVS S	SR 50 mg n=149	DVS S	R 100 n =155	ng DVS S	SR 150 mg n=157	DVS S	SR 200 mg =151	P.I r	lacebo n= 77
Week 1 VALID DATA ANALYSIS INTERVAL INVALID DATA ANALYSIS INTERVAL >= 5 DAYS DATA FOR THE WEEK >=7MOD+SEV HF/DAY OR >=50HF FOR BASELINE WEEK COMPLIANT >= 80% DOSE FOR THE WEEK NO PROT. VIOLATION - MED. MONITOR	1 40	(100)	1	(100)	1	(100)	1 - 1	(100)		(100)
Week 2 VALID DATA ANALYSIS INTERVAL INVALID DATA ANALYSIS INTERVAL >= 5 DAYS DATA FOR THE WEEK >=7MOD+SEV HF/DAY OR >=50HF FOR BASELINE WEEK COMPLIANT >= 80% DOSE FOR THE WEEK NO PROT. VIOLATION - MED. MONITOR	139 133 6 1 0 3	(93) (89) (4) (<1) (2) (2)	143 135 8 3 0 4 4	(92) (87) (5) (2) (3) (3)	133	(85) (79)	115	(76) (69) (7) (3) (5) (1)	77 74	(100)
Week 3 VALID DATA ANALYSIS INTERVAL INVALID DATA ANALYSIS INTERVAL >= 5 DAYS DATA FOR THE WEEK >=7MOD+SEV HF/DAY OR >=50HF FOR BASELINE WEEK COMPLIANT >= 80% DOSE FOR THE WEEK NO PROT. VIOLATION - MED. MONITOR	138 127 11 1 0 7 4	(93) (85) (7) (<1) (5) (3)	140 132 8 4 0 4	(90) (85) (5) (3) (3)	128 119 9 3 1 6 2	(82) (76) (6) (2) (<1) (4) (1)	112 103 9 4 0 6 2	(74) (68) (6) (3) (4) (1)	74	
Week 4 VALID DATA ANALYSIS INTERVAL INVALID DATA ANALYSIS INTERVAL >= 5 DAYS DATA FOR THE WEEK >=7MOD+SEV HF/DAY OR >=50HF FOR BASELINE WEEK COMPLIANT >= 80% DOSE FOR THE WEEK NO PROT. VIOLATION - MED. MONITOR	138 126 12 5 0 8	(93) (85) (8) (3) (5) (2)	136 124 12 3 0 8 4	(88) (80) (8) (2) (5) (3)	125	(80)	110 93 17 9 0 14	1621	73 4 0 0	(100) (95) (5) (1) (4)
Week 5 VALID DATA ANALYSIS INTERVAL INVALID DATA ANALYSIS INTERVAL >= 5 DAYS DATA FOR THE WEEK >=7MOD+SEV HF/DAY OR >=50HF FOR BASELINE WEEK COMPLIANT >= 80% DOSE FOR THE WEEK NO PROT. VIOLATION - MED. MONITOR RESENTS THE NUMBER OF SUBJECTS IN EACH THERAPY GROUP	131 119 12 3 0 7 3	(88) (80) (8) (2) (5) (2)	131 124 7 2 0 4	(85) (80) (5) (1) (3) (<1)	121 110 11 3 1 5	(77) (70) (7) (2) (<1) (3) (2)	103 95 8 3 0 6	(68) (63) (5) (2) (4) (<1)	76 70 6 2 0 4 2	(99) (91) (8) (3) (5) (3)

N REPRESENTS THE NUMBER OF SUBJECTS IN EACH THERAPY GROUP INCLUDED OR EXCLUDED AND NUMBER EXCLUDED FOR EACH CRITERIA

A SUBJECT MAY HAVE BEEN EXCLUDED FOR MORE THAN ONE REASON.

2

Page

28JUL05 17:28 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT EE4_SYM NUMBER (%) OF SUBJECTS EXCLUDED FROM EFFICACY EVALUABLE POPULATION FOR VASOMOTOR SYMPTOM DATA

Data Analysis Interval Criteria Description	DVS Si	 R 50 mg =149	DVS SI	R 100 mg =155	J DVS SI	atment - R 150 mg =157	DVS SF	R 200 mg =151		acebo = 77
Week 6 VALID DATA ANALYSIS INTERVAL INVALID DATA ANALYSIS INTERVAL >= 5 DAYS DATA FOR THE WEEK >=7MOD+SEV HF/DAY OR >=50HF FOR BASELINE WEEK COMPLIANT >= 80% DOSE FOR THE WEEK NO PROT. VIOLATION - MED. MONITOR	131 119 12 2 0 8 3	(88) (80) (8) (1) (5) (2)	131 125 6 3 0 3	(85) (81) (4) (2) (2) (1)	119 109 10 1 1 1 5	(76) (69) (6) (<1) (<1) (3) (3)	102 96 6 0 0 5	(68) (64) (4) (3) (<1)	74 70 4 2 0 3	(96) (91) (5) (3) (4) (1)
Week 7 VALID DATA ANALYSIS INTERVAL INVALID DATA ANALYSIS INTERVAL >= 5 DAYS DATA FOR THE WEEK >=7MOD+SEV HF/DAY OR >=50HF FOR BASELINE WEEK COMPLIANT >= 80% DOSE FOR THE WEEK NO PROT. VIOLATION - MED. MONITOR	130 121 9 1	(87) (81) (6) (<1) (4) (2)	129 126 3 0 0 1 2	(83) (81) (2) (<1) (1)	116 108 8 0 1 4	(74) (69) (5) (<1) (3) (2)	101 95 6 0 0 5	(67) (63) (4) (3) (<1)	72 69 3 1 0 2	(94) (90) (4) (1) (3)
Week 8 VALID DATA ANALYSIS INTERVAL INVALID DATA ANALYSIS INTERVAL >= 5 DAYS DATA FOR THE WEEK >=7MOD+SEV HF/DAY OR >=50HF FOR BASELINE WEEK COMPLIANT >= 80% DOSE FOR THE WEEK NO PROT. VIOLATION - MED. MONITOR	130 120 10 3 0 6	(87) (81) (7) (2) (4) (2)	128 122 6 0 0 4 2	(83) (79) (4) (3) (1)	115 103 12 3 1 8 3	(73) (66) (8) (2) (<1) (5) (2)	101 92 9 1 0 7	(67) (61) (6) (<1) (5) (<1)	71 65 6 2 0 5	(92) (84) (8) (3) (6) (1)
Week 9 VALID DATA ANALYSIS INTERVAL INVALID DATA ANALYSIS INTERVAL >= 5 DAYS DATA FOR THE WEEK >=7MOD+SEV HF/DAY OR >=50HF FOR BASELINE WEEK COMPLIANT >= 80% DOSE FOR THE WEEK NO PROT. VIOLATION - MED. MONITOR	127 116 11 1 0 7	(85) (78) (7) (<1) (5) (2)	128 120 8 4 0 4 2	(83) (77) (5) (3) (3)	113 102 11 5 1 6	(72) (65) (7) (3) (<1) (4) (2)	100 89 11 2 0 9	(66) (59) (7) (1) (6) (<1)	71 64 7 3 0 6	(92) (83) (9) (4) (8)
Week 10 VALID DATA ANALYSIS INTERVAL INVALID DATA ANALYSIS INTERVAL >= 5 DAYS DATA FOR THE WEEK >=7MOD+SEV HF/DAY OR >=50HF FOR BASELINE WEEK COMPLIANT >= 80% DOSE FOR THE WEEK NO PROT. VIOLATION - MED. MONITOR	125 118 7 1 0 4	(84) (79) (5) (<1) (3) (2)	124 115 9 3 0 5	(80) (74) (6) (2) (3) (2)	111 106 5 0 1 1	(71) (68) (3) (<1) (<1) (2)	100 91 9 3 0 7	(66) (60) (6) (2) (5) (<1)	70 65 5 0 0 4	(91) (84) (6) (5) (1)

N REPRESENTS THE NUMBER OF SUBJECTS IN EACH THERAPY GROUP INCLUDED OR EXCLUDED AND NUMBER EXCLUDED FOR EACH CRITERIA. A SUBJECT MAY HAVE BEEN EXCLUDED FOR MORE THAN ONE REASON.

Page

3

28JUL05 17:28 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT EE4_SYM NUMBER (%) OF SUBJECTS EXCLUDED FROM EFFICACY EVALUABLE POPULATION FOR VASOMOTOR SYMPTOM DATA

Data Analysis Interval DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Criteria Description n=149n=155 n=157 Week 11 125 (84) 123 (79)110 (90)(84) VALID DATA ANALYSIS INTERVAL 116 (78)116 (75)104 (66) (62)65 INVALID DATA ANALYSIS INTERVAL (6) (5) 6 (4) (3) (5) >= 5 DAYS DATA FOR THE WEEK (<1)(1) (<1)(<1) (1) >=7MOD+SEV HF/DAY OR >=50HF FOR BASELINE WEEK 0 (<1)COMPLIANT >= 80% DOSE FOR THE WEEK (3) 1 (<1) (1)(4)NO PROT. VIOLATION - MED. MONITOR (<1)(1)Week 12 125 (84) 123 110 (70)(65)(88)107 115 93 VALID DATA ANALYSIS INTERVAL (72)(74)100 (64) (62)62 (81)INVALID DATA ANALYSIS INTERVAL 18 (12)(5) 10 (6) (3) (8) >= 5 DAYS DATA FOR THE WEEK (5) 2 (1) 4 (3) (<1) (6) >=7MOD+SEV HF/DAY OR >=50HF FOR BASELINE WEEK (<1)COMPLIANT >= 80% DOSE FOR THE WEEK (7) 5 (3) 6 (3) 10 (4) (5) NO PROT. VIOLATION - MED. MONITOR (4) (2) (<1)(1)

N REPRESENTS THE NUMBER OF SUBJECTS IN EACH THERAPY GROUP INCLUDED OR EXCLUDED AND NUMBER EXCLUDED FOR EACH CRITERIA. A SUBJECT MAY HAVE BEEN EXCLUDED FOR MORE THAN ONE REASON.

ST 8-3: Demographic and Baseline Characteristics for ITT Population

Page

1

05AUG05 16:19 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT DEMOS DEMOGRAPHIC AND BASELINE CHARACTERISTICS

				M		
CHARACTERISTIC	P-Value	DVS SR 50 ma	DVS SR 100 mg (n = 155)	DVS SR 150 ma	DVS SR 200 ma	Placebo
AGE (YEAR) N MEAN STANDARD DEVIATION MINIMUM MAXIMUM MEDIAN	0.574(A)	149 53.07 4.48 41.00 71.00 53.00	155 53.34 5.61 29.00 78.00 53.00	53.46 4.66	151 53.46 4.40 37.00 67.00 53.00	77 54.22 5.44 41.00 73.00 53.00
SEX Female		149 (100)	155 (100)	157 (100)	151 (100)	77 (100)
RACE Arabic Black Native American Oriental(Asian) Other Other:Pacific Islander. White	0.554(B)	1 (0.67) 15 (10.07) 6 (4.03) 127 (85.23)	1 (0.65)	1 (0.64)	12 (7.95) 1 (0.66) 5 (3.31) 133 (88.08)	
ETHNICITY Hispanic or Latino Non-Hispanic and Non-Latino	0.838(B)	14 (9.40) 135 (90.60)	13 (8.39) 142 (91.61)	12 (7.64) 145 (92.36)	9 (5.96) 142 (94.04)	7 (9.09) 70 (90.91)
HEIGHT (CM) N MEAN STANDARD DEVIATION MINIMUM MAXIMUM MEDIAN	0.510(A)	149 163.00 6.56 151.20 180.60 162.60	155 162.97 6.49 147.30 180.40 162.60	157 163.95 6.95 146.00 185.00 163.80	5.94 145.70 175.30	77 163.23 7.09 142.20 182.80 163.00
WEIGHT (KG) N MEAN STANDARD DEVIATION MINIMUM MAXIMUM	0.961(A)	13.65	155 71.81 12.60 43.40 105.90	157 71.64 13.03 45.90 108.60	151 72.49 12.03 48.60 113.20	77 71.59 13.15 48.10 104.50

NOTE: YEARS SINCE NATURAL MENOPAUSE REFERS ONLY TO WOMEN WITH UTERUS. MISSING REFERS TO WOMEN WITH NO UTERUS OR SURGICAL MENOPAUSE.

⁽A) One-way Analysis Of Variance With Treatment As Factor.

⁽B) P-value for Chi-Square.

2

Page

05AUG05 16:19 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT DEMO5 DEMOGRAPHIC AND BASELINE CHARACTERISTICS

CHARACTERISTIC	P-Value	DVS SR 50 mg	DVS SR 100 mg (n = 155)	DVS SR 150 mg	DVS SR 200 mg	Placebo (n = 77)
MEDIAN		70.90	70.70	69.90	71.80	70.00
BMI (KG/M2) N MEAN STANDARD DEVIATION MINIMUM MAXIMUM MEDIAN	0.862(A)	27.21 4.56 18.23	27.06 4.67 17.83 39.14	26.65	4.57 17.26 40.88	77 26.87 4.75 19.79 40.22 25.78
DURATION ON THERAPY (DAYS) N MEAN STANDARD DEVIATION MINIMUM MAXIMUM MEDIAN	<0.001(A)	149 255.91 139.74 1.00 385.00 357.00	155 250.58 142.62 1.00 385.00 357.00	157 215.38 156.36 1.00 387.00 287.00	151 199.66 161.04 1.00 385.00 223.00	77 271.87 126.59 28.00 379.00 357.00
STUDY COMPLETE No Yes	0.040(B)		68 (43.87) 87 (56.13)			
YEARS SINCE NATURAL MENOPAUSE N MEAN STANDARD DEVIATION MINIMUM MAXIMUM MEDIAN MISSING	0.134(A)	99 4.39 4.38 0.55 23.70 3.18	96 4.44 3.81 0.49 16.92 3.08	4.68 4.64 0.59	93 4.87 4.34 0.49 21.71 3.94	46 6.43 6.95 0.54 35.13 3.95
YEARS SINCE SURGICAL MENOPAUSE N MEAN STANDARD DEVIATION MINIMUM MAXIMUM MEDIAN	0.379(A)	31 7.99 5.89 0.72 23.19 7.17	11.02 7.82 0.21	34 10.50 9.55 0.75 36.90 6.97	12.38 10.67 1.21	18 11.20 9.54 1.03 28.06 7.09

NOTE: YEARS SINCE NATURAL MENOPAUSE REFERS ONLY TO WOMEN WITH UTERUS. MISSING REFERS TO WOMEN WITH NO UTERUS OR SURGICAL MENOPAUSE.

(A) One-way Analysis Of Variance With Treatment As Factor.

(B) P-value for Chi-Square.

CONFIDENTIAL 201 Wyeth

3

Page

05AUG05 16:19 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT DEMO5 DEMOGRAPHIC AND BASELINE CHARACTERISTICS

CHARACTERISTIC	P-Value	DVS SR 50 mg (n = 149)	DVS SR 100 mg (n = 155)	DVS SR 150 mg		Placebo (n = 77)
MISSING		118	121	123	118	59
TYPE OF MENOPAUSE Natural Surgical (Bilateral oophorectomy)	0.995(B)	118 (79.19) 31 (20.81)	121 (78.06) 34 (21.94)	123 (78.34) 34 (21.66)	118 (78.15) 33 (21.85)	59 (76.62) 18 (23.38)
Surgical (Bilateral oophorectomy) PRIMARY DIAGNOSIS Healthy Postmenopausal Woman		31 (20.81) 149 (100)	34 (21.94) 155 (100)	34 (21.66) 157 (100)	33 (21.85) 151 (100)	18 (23.3 77 (100

NOTE: YEARS SINCE NATURAL MENOPAUSE REFERS ONLY TO WOMEN WITH UTERUS. MISSING REFERS TO WOMEN WITH NO UTERUS OR SURGICAL MENOPAUSE.

⁽A) One-way Analysis Of Variance With Treatment As Factor.

⁽B) P-value for Chi-Square.

ST 8-4: Number (%) of Subjects Reporting Nonstudy Medications

Page

1

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL

CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: PRIOR

	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg								
ATC Classification [1]		=149				=157		=151	
ANY NON-STUDY MEDICATION	130	(87.2)	137	(88.4)	143	(91.1)	142	(94.0)	
## ALL OTHER THERAPEUTIC PRODUCTS V03 - ATC 2	0		1	(0.6)	1	(0.6)	0		
## ANTIBACTERIALS FOR SYSTEMIC USE J01 - ATC 2	0		0		0		1	(0.7)	
## BILE AND LIVER THERAPY A05 - ATC 2	0		1	(0.6)	1	(0.6)	0		
## COUGH AND COLD PREPARATIONS R05 - ATC 2	0		0		1	(0.6)	2	(1.3)	
## DIURETICS C03 - ATC 2	0		0		0		1	(0.7)	
## LAXATIVES A06 - ATC 2	1	(0.7)	0		0		0		
## MINERAL SUPPLEMENTS A12 - ATC 2	0		2	(1.3)	1	(0.6)	3	(2.0)	
## NASAL PREPARATIONS R01 - ATC 2	0		1	(0.6)	0		0		
Classification Unknown	1	(0.7)	0		0		0		
ACE INHIBITORS, COMBINATIONS C09B	0		0		2	(1.3)	2	(1.3)	
ADRENERGICS, INHALANTS R03A	5	(3.4)	5	(3.2)	5	(3.2)	6	(4.0)	
AGENTS AFFECTING THE VIRUS DIRECTLY J05A	0		2	(1.3)	2	(1.3)	1	(0.7)	
ALL OTHER THERAPEUTIC PRODUCTS V03A	12	(8.1)	16	(10.3)	8	(5.1)	16	(10.6)	
ALLERGENS V01A	2	(1.3)	1	(0.6)	2	(1.3)	1	(0.7)	
AMINOGLYCOSIDE ANTIBACTERIALS J01G	0		0		0		1	(0.7)	
ANDROGENS AND FEMALE SEX HORMONES IN COMB G03E	0		0		0		1	(0.7)	
ANDROGENS G03B	0		1	(0.6)	1	(0.6)	1	(0.7)	

NOTE: [1] - Classification Totals Are Not Necessarily The Sum Of The Individual Non-Study Medications Since A Subject May Report
Two or More Different Non-Study Medications In The Same Classification.

^{## -} Anatomical-Therapeutic-Chemical Classification Could Not Be Found at the Requested Level.

Page

2

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: PRIOR

ATC Classification [1]	Treatment Placebo n= 77
ANY NON-STUDY MEDICATION	72 (93.5)
## ALL OTHER THERAPEUTIC PRODUCTS V03 - ATC 2	2 (2.6)
## ANTIBACTERIALS FOR SYSTEMIC USE J01 - ATC 2	0
## BILE AND LIVER THERAPY A05 - ATC 2	0
## COUGH AND COLD PREPARATIONS R05 - ATC 2	0
## DIURETICS C03 - ATC 2	0
## LAXATIVES A06 - ATC 2	0
## MINERAL SUPPLEMENTS A12 - ATC 2	2 (2.6)
## NASAL PREPARATIONS R01 - ATC 2	0
Classification Unknown	0
ACE INHIBITORS, COMBINATIONS C09B	0
ADRENERGICS, INHALANTS R03A	3 (3.9)
AGENTS AFFECTING THE VIRUS DIRECTLY J05A	0
ALL OTHER THERAPEUTIC PRODUCTS V03A	7 (9.1)
ALLERGENS V01A	0
AMINOGLYCOSIDE ANTIBACTERIALS J01G	0
ANDROGENS AND FEMALE SEX HORMONES IN COMB G03E	0
ANDROGENS G03B	0

Page

3

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT NMED4 ATC3

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL

CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: PRIOR

ATC Classification [1]			DVS S	DVS SR 100 mg		tment DVS SR 150 mg n=157		 R 200 mg =151
ANGIOTENSIN II ANTAGONISTS, COMBINATIONS C09D	2	(1.3)	0		1	(0.6)	3	(2.0)
ANGIOTENSIN II ANTAGONISTS, PLAIN C09C	1	(0.7)	0		1	(0.6)	0	
ANTACIDS A02A	6	(4.0)	6	(3.9)	9	(5.7)	7	(4.6)
ANTI-ACNE PREPARATIONS FOR TOPICAL USE D10A	1	(0.7)	2	(1.3)	0		0	
ANTI-PARATHYROID HORMONES H05B	0		0		1	(0.6)	0	
ANTIADRENERGIC AGENTS, CENTRALLY ACTING C02A	0		0		0		1	(0.7)
ANTIBIOTICS FOR TOPICAL USE D06A	0		0		1	(0.6)	0	
ANTIDEPRESSANTS N06A	5	(3.4)	7	(4.5)	5	(3.2)	3	(2.0)
ANTIDIARRHOEAL MICROORGANISMS A07F	0		1	(0.6)	0		2	(1.3)
ANTIEPILEPTICS NO3A	1	(0.7)	0		1	(0.6)	1	(0.7)
ANTIFLATULENTS A02D	1	(0.7)	1	(0.6)	1	(0.6)	1	(0.7)
ANTIFUNGALS FOR TOPICAL USE D01A	0		4	(2.6)	4	(2.5)	0	
ANTIGLAUCOMA PREPARATIONS AND MIOTICS S01E	2	(1.3)	2	(1.3)	0		0	
ANTIHEMORRHOIDALS FOR TOPICAL USE C05A		1	(0.7)	0		0		0
ANTIHISTAMINES FOR SYSTEMIC USE R06A	16	(10.7)	26	(16.8)	18	(11.5)	24	(15.9)
ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION C02L	0		0		2	(1.3)	0	
ANTIINFECTIVES S01A	0		1	(0.6)	1	(0.6)	0	

NOTE: [1] - Classification Totals Are Not Necessarily The Sum Of The Individual Non-Study Medications Since A Subject May Report Two or More Different Non-Study Medications In The Same Classification. ## - Anatomical-Therapeutic-Chemical Classification Could Not Be Found at the Requested Level.

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 4

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: PRIOR

ATC Classification [1]	Treatment Placebo n= 77
ANGIOTENSIN II ANTAGONISTS, COMBINATIONS C09D	1 (1.3)
ANGIOTENSIN II ANTAGONISTS, PLAIN C09C	0
ANTACIDS A02A	3 (3.9)
ANTI-ACNE PREPARATIONS FOR TOPICAL USE D10A	0
ANTI-PARATHYROID HORMONES H05B	1 (1.3)
ANTIADRENERGIC AGENTS, CENTRALLY ACTING C02A	0
ANTIBIOTICS FOR TOPICAL USE D06A	0
ANTIDEPRESSANTS NO6A	2 (2.6)
ANTIDIARRHOEAL MICROORGANISMS A07F	0
ANTIEPILEPTICS NO3A	1 (1.3)
ANTIFLATULENTS A02D	0
ANTIFUNGALS FOR TOPICAL USE D01A	0
ANTIGLAUCOMA PREPARATIONS AND MIOTICS S01E	0
ANTIHAEMORRHOIDALS FOR TOPICAL USE C05A	0
ANTIHISTAMINES FOR SYSTEMIC USE R06A	10 (13.0)
ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION C02L	0
ANTIINFECTIVES S01A	0

Page

5

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT NMED4 ATC3 NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL

CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: PRIOR

	Treatment								
ATC Classification [1]		R 50 mg =149		R 100 mg =155		R 150 mg =157		R 200 m	
ANTIINFECTIVES/ANTISEPT., EXCL COMB WITH CORTICOST. G01A	2	(1.3)	1	(0.6)	0		1	(0.7)	
ANTIINFLAMMATORY/ANTIRHEUMATIC PROD., NON-STEROIDS M01A	58	(38.9)	49	(31.6)	52	(33.1)	58	(38.4)	
ANTIMALARIALS P01B	0		1	(0.6)	1	(0.6)	0		
ANTIMETABOLITES L01B	1	(0.7)	1	(0.6)	2	(1.3)	1	(0.7)	
ANTIMIGRAINE PREPARATIONS N02C	2	(1.3)	2	(1.3)	1	(0.6)	2	(1.3)	
ANTIMYCOTICS FOR SYSTEMIC USE, EXCL GRISEOFULVIN J02A	0		0		1	(0.6)	0		
ANTIOBESITY PREPARATIONS, EXCL DIET PRODUCTS A08A	2	(1.3)	0		1	(0.6)	0		
ANTIPROPULSIVES A07D	1	(0.7)	0		0		2	(1.3)	
ANTIPRURITICS, INCL ANTIHIST, ANAESTHET, ETC. D04A	2	(1.3)	0		0		0		
ANTIPSORIATICS FOR SYTEMIC USE D05B	0		0		1	(0.6)	0		
ANTIPSORIATICS FOR TOPICAL USE D05A	0		0		1	(0.6)	0		
ANTISEPTICS AND DISINFECTANTS D08A	0		0		0		1	(0.7)	
ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS A03C	0		0		0		1	(0.7)	
ANTITHROMBOTIC AGENTS B01A	0		1	(0.6)	1	(0.6)	0		
ANTITUSSIVES, EXCL COMBINATIONS WITH EXPECTORANTS R05D	2	(1.3)	1	(0.6)	4	(2.5)	2	(1.3)	
ANXIOLYTICS N05B	1	(0.7)	1	(0.6)	1	(0.6)	2	(1.3)	

Page

6

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: PRIOR

ATC Classification [1]	Treatment Placebo n= 77	
ANTIINFECTIVES/ANTISEPT., EXCL COMB WITH CORTICOST. G01A	0	
ANTIINFLAMMATORY/ANTIRHEUMATIC PROD.,NON-STEROIDS M01A	26 (33.8)	
ANTIMALARIALS P01B	0	
ANTIMETABOLITES L01B	2 (2.6)	
ANTIMIGRAINE PREPARATIONS NO2C	0	
ANTIMYCOTICS FOR SYSTEMIC USE, EXCL GRISEOFULVIN J02A	0	
ANTIOBESITY PREPARATIONS, EXCL DIET PRODUCTS A08A	0	
ANTIPROPULSIVES A07D	0	
ANTIPRURITICS, INCL ANTIHIST, ANAESTHET, ETC. D04A	0	
ANTIPSORIATICS FOR SYTEMIC USE D05B	0	
ANTIPSORIATICS FOR TOPICAL USE D05A	0	
ANTISEPTICS AND DISINFECTANTS D08A	0	
ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS A03C	0	
ANTITHROMBOTIC AGENTS B01A	0	
ANTITUSSIVES, EXCL COMBINATIONS WITH EXPECTORANTS R05D	0	
ANXIOLYTICS N05B	1 (1.3)	

NOTE: [1] - Classification Totals Are Not Necessarily The Sum Of The Individual Non-Study Medications Since A Subject May Report Two or More Different Non-Study Medications In The Same Classification. ## - Anatomical-Therapeutic-Chemical Classification Could Not Be Found at the Requested Level.

Page

7

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT NMED4 ATC3 NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL

CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: PRIOR

	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg								
ATC Classification [1]		R 50 mg =149		R 100 mg =155		R 150 mg =157		R 200 mg =151	
ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON C02D	3	(2.0)	2	(1.3)	7	(4.5)	3	(2.0)	
ASCORBIC ACID (VIT C), INCL COMBINATIONS A11G	18	(12.1)	26	(16.8)	19	(12.1)	21	(13.9)	
BELLADONNA AND DERIVATIVES, PLAIN A03B	0		0		1	(0.6)	0		
BETA BLOCKING AGENTS AND OTHER DIURETICS CO7C	0		0		0		1	(0.7)	
BETA BLOCKING AGENTS AND THIAZIDES C07B	0		0		2	(1.3)	0		
BETA BLOCKING AGENTS, PLAIN C07A	5	(3.4)	15	(9.7)	7	(4.5)	5	(3.3)	
BETA-LACTAM ANTIBACTERIALS, PENICILLINS J01C	1	(0.7)	1	(0.6)	4	(2.5)	4	(2.6)	
BLOOD AND RELATED PRODUCTS B05A	0		0		0		1	(0.7)	
CALCIUM A12A	47	(31.5)	53	(34.2)	50	(31.8)	53	(35.1)	
CAPILLARY STABILIZING AGENTS C05C	0		1	(0.6)	0		0		
CHOLESTEROL AND TRIGLYCERIDE REDUCERS C10A	18	(12.1)	19	(12.3)	24	(15.3)	34	(22.5)	
CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02A	1	(0.7)	4	(2.6)	3	(1.9)	1	(0.7)	
CORTICOSTEROIDS, OTHER COMBINATIONS D07X	0		1	(0.6)	0		0		
CORTICOSTEROIDS, PLAIN D07A	1	(0.7)	1	(0.6)	1	(0.6)	0		
COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS R05F	0		1	(0.6)	1	(0.6)	1	(0.7)	
DECONGESTANTS AND ANTIALLERGICS S01G	0		1	(0.6)	1	(0.6)	1	(0.7)	
DIET FORMULATIONS FOR TREATMENT OF OBESITY V06A	0		0		1	(0.6)	0		
DIGESTIVES, INCL ENZYMES A09A	0		1	(0.6)	2	(1.3)	0		

8

Page

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: PRIOR

ATC Classification [1]	Pl	eatment acebo = 77
ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON CO2D	1	(1.3)
ASCORBIC ACID (VIT C), INCL COMBINATIONS A11G	11	(14.3)
BELLADONNA AND DERIVATIVES, PLAIN A03B	0	
BETA BLOCKING AGENTS AND OTHER DIURETICS C07C	0	
BETA BLOCKING AGENTS AND THIAZIDES C07B	2	(2.6)
BETA BLOCKING AGENTS, PLAIN CO7A	7	(9.1)
BETA-LACTAM ANTIBACTERIALS, PENICILLINS J01C	0	
BLOOD AND RELATED PRODUCTS B05A	0	
CALCIUM A12A	29	(37.7)
CAPILLARY STABILIZING AGENTS C05C	0	
CHOLESTEROL AND TRIGLYCERIDE REDUCERS C10A	8	(10.4)
CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02A	2	(2.6)
CORTICOSTEROIDS, OTHER COMBINATIONS D07X	0	
CORTICOSTEROIDS, PLAIN D07A	0	
COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS ROSF	0	
DECONGESTANTS AND ANTIALLERGICS S01G	0	
DIET FORMULATIONS FOR TREATMENT OF OBESITY V06A	0	
DIGESTIVES, INCL ENZYMES A09A	0	

9

Page

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT NMED4 ATC3

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: PRIOR

	Treatment							
ATC Classification [1]			DVS SR 100 mg n=155					
DIURETICS AND POTASSIUM-SPARING AGENTS IN COMB C03E	5	(3.4)	4	(2.6)	2	(1.3)	5	(3.3)
DRUGS AFFECTING MINERALIZATION M05B	10	(6.7)	9	(5.8)	11	(7.0)	7	(4.6)
DRUGS FOR TREATMENT OF PEPTIC ULCER A02B	13	(8.7)	23	(14.8)	14	(8.9)	18	(11.9)
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY G04C	0		0		0		1	(0.7)
ESTROGENS G03C	0		2	(1.3)	1	(0.6)	0	
EXPECTORANTS, EXCL COMBINATIONS WITH ANTITUSSIVES R05C	2	(1.3)	2	(1.3)	1	(0.6)	4	(2.6)
HIGH-CEILING DIURETICS CO3C	1	(0.7)	1	(0.6)	3	(1.9)	0	
HORMONES AND RELATED AGENTS L02A	1	(0.7)	3	(1.9)	0		4	(2.6)
HYPNOTICS AND SEDATIVES NO5C	3	(2.0)	3	(1.9)	6	(3.8)	2	(1.3)
I.V. SOLUTION ADDITIVES B05X	0		2	(1.3)	1	(0.6)	0	
IMMUNOSUPPRESSIVE AGENTS L04A	0		0		1	(0.6)	2	(1.3)
INSULINS A10A	1	(0.7)	0		1	(0.6)	0	
INTESTINAL ADSORBENTS A07B	0		1	(0.6)	1	(0.6)	0	
INTESTINAL ANTIINFLAMMATORY AGENTS A07E	0		0		0		1	(0.7)
IRON PREPARATIONS B03A	2	(1.3)	2	(1.3)	1	(0.6)	1	(0.7)
IRRIGATING SOLUTIONS B05C	1	(0.7)	0		1	(0.6)	0	
LAXATIVES A06A	10	(6.7)	11	(7.1)	7	(4.5)	13	

Two or More Different Non-Study Medications In The Same Classification.
- Anatomical-Therapeutic-Chemical Classification Could Not Be Found at the Requested Level.

Page 10

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: PRIOR

ATC Classification [1]	Treatment Placebo n= 77
DIURETICS AND POTASSIUM-SPARING AGENTS IN COMB C03E	3 (3.9)
DRUGS AFFECTING MINERALIZATION M05B	5 (6.5)
DRUGS FOR TREATMENT OF PEPTIC ULCER A02B	6 (7.8)
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY G04C	0
ESTROGENS G03C	2 (2.6)
EXPECTORANTS, EXCL COMBINATIONS WITH ANTITUSSIVES R05C	1 (1.3)
HIGH-CEILING DIURETICS CO3C	0
HORMONES AND RELATED AGENTS L02A	2 (2.6)
HYPNOTICS AND SEDATIVES NO5C	0
I.V. SOLUTION ADDITIVES B05X	0
IMMUNOSUPPRESSIVE AGENTS L04A	2 (2.6)
INSULINS A10A	0
INTESTINAL ADSORBENTS A07B	0
INTESTINAL ANTIINFLAMMATORY AGENTS A07E	0
IRON PREPARATIONS B03A	1 (1.3)
IRRIGATING SOLUTIONS B05C	0
LAXATIVES A06A	4 (5.2)

Page 11

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT NMED4 ATC3 NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL

CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: PRIOR

	Treatment							
ATC Classification [1]	DVS SR 50 mg n=149		DVS SR 100 mg n=155					
LIVER THERAPY, LIPOTROPICS A05B	1	(0.7)	1	(0.6)	1	(0.6)	0	
LOW-CEILING DIURETICS, EXCL THIAZIDES C03B	0		0		1	(0.6)	0	
LOW-CEILING DIURETICS, THIAZIDES CO3A	5	(3.4)	6	(3.9)	6	(3.8)	4	(2.6)
MACROLIDES AND LINCOSAMIDES J01F	0		3	(1.9)	1	(0.6)	5	(3.3)
MULTIVITAMINS, COMBINATIONS A11A	48	(32.2)	62	(40.0)	66	(42.0)	73	(48.3)
MULTIVITAMINS, PLAIN A11B	1	(0.7)	4	(2.6)	0		2	(1.3)
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS M03B	2	(1.3)	4	(2.6)	8	(5.1)	5	(3.3)
NASAL DECONGESTANTS FOR SYSTEMIC USE R01B	9	(6.0)	12	(7.7)	6	(3.8)	12	(7.9)
NASAL DECONGESTANTS FOR TOPICAL USE R01A	7	(4.7)	5	(3.2)	16	(10.2)	6	(4.0)
OPIOIDS NO2A	0		5	(3.2)	8	(5.1)	5	(3.3)
ORAL BLOOD GLUCOSE LOWERING DRUGS A10B	1	(0.7)	1	(0.6)	1	(0.6)	2	(1.3)
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS A16A	0		0		1	(0.6)	1	(0.7)
OTHER ANALGESICS AND ANTIPYRETICS NO2B	56	(37.6)	60	(38.7)	61	(38.9)	56	(37.1)
OTHER ANTI-ASTHMATICS FOR SYSTEMIC USE R03D	2	(1.3)	2	(1.3)	3	(1.9)	6	(4.0)
OTHER ANTI-ASTHMATICS, INHALANTS R03B	0		0		0		1	(0.7)
OTHER ANTIBACTERIALS J01X	2	(1.3)	1	(0.6)	0		1	(0.7)
OTHER ANTIHYPERTENSIVES C02K	0		1	(0.6)	0		0	
OTHER BETA-LACTAM ANTIBACTERIALS J01D	1	(0.7)	1	(0.6)	0		2	(1.3)

Page 12

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: PRIOR

ATC Classification [1]	Treatment Placebo n= 77
LIVER THERAPY, LIPOTROPICS A05B	1 (1.3)
LOW-CEILING DIURETICS, EXCL THIAZIDES C03B	0
LOW-CEILING DIURETICS, THIAZIDES CO3A	4 (5.2)
MACROLIDES AND LINCOSAMIDES J01F	0
MULTIVITAMINS, COMBINATIONS A11A	33 (42.9)
MULTIVITAMINS, PLAIN A11B	0
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS M03B	4 (5.2)
NASAL DECONGESTANTS FOR SYSTEMIC USE R01B	7 (9.1)
NASAL DECONGESTANTS FOR TOPICAL USE R01A	2 (2.6)
OPIOIDS NO2A	2 (2.6)
ORAL BLOOD GLUCOSE LOWERING DRUGS A10B	2 (2.6)
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS A16A	0
OTHER ANALGESICS AND ANTIPYRETICS NO2B	30 (39.0)
OTHER ANTI-ASTHMATICS FOR SYSTEMIC USE R03D	2 (2.6)
OTHER ANTI-ASTHMATICS, INHALANTS R03B	0
OTHER ANTIBACTERIALS J01X	0
OTHER ANTIHYPERTENSIVES CO2K	0
OTHER BETA-LACTAM ANTIBACTERIALS J01D	1 (1.3)

Page 13

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT NMED4 ATC3 NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL

CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: PRIOR

	Treatment							
ATC Classification [1]				DVS SR 100 mg n=155			DVS S	
OTHER CARDIAC PREPARATIONS C01E	1	(0.7)	2	(1.3)	0		1	(0.7)
OTHER COLD COMBINATION PREPARATIONS R05X	1	(0.7)	2	(1.3)	4	(2.5)	7	(4.6)
OTHER DRUGS FOR DISORD. OF MUSCULO-SKELETAL SYST. M05A	6	(4.0)	7	(4.5)	3	(1.9)	6	(4.0)
OTHER DRUGS FOR DISORDER OF THE MUSC-SKEL SYSTEM M09A	5	(3.4)	2	(1.3)	1	(0.6)	7	(4.6)
OTHER GYNAECOLOGICALS G02C	13	(8.7)	11	(7.1)	7	(4.5)	7	(4.6)
OTHER MINERAL SUPPLEMENTS A12C	4	(2.7)	9	(5.8)	6	(3.8)	10	(6.6)
OTHER NUTRIENTS V06D	8	(5.4)	5	(3.2)	1	(0.6)	5	(3.3)
OTHER OPHTHALMOLOGICALS S01X	0		0		0		0	
OTHER PLAIN VITAMIN PREPARATIONS A11H	26	(17.4)	39	(25.2)	35	(22.3)	39	(25.8)
OTHER SEX HORM. & MODULATORS OF THE GENITAL SYSTEM G03X	0		0		0		2	(1.3)
OTHER UROLOGICALS, INCL ANTISPASMODICS G04B	0		5	(3.2)	0		2	(1.3)
OTHER VITAMIN PRODUCTS, COMBINATIONS A11J	6	(4.0)	5	(3.2)	7	(4.5)	9	(6.0)
PERIPHERAL VASODILATORS CO4A	2	(1.3)	0		3	(1.9)	3	(2.0)
POTASSIUM A12B	2	(1.3)	2	(1.3)	3	(1.9)	2	(1.3)
POTASSIUM-SPARING AGENTS C03D	1	(0.7)	1	(0.6)	1	(0.6)	1	(0.7)
PROGESTOGENS AND ESTROGENS IN COMBINATION G03F	0		0		1	(0.6)	0	
PROGESTOGENS G03D	1	(0.7)	1	(0.6)	1	(0.6)	0	

NOTE: [1] - Classification Totals Are Not Necessarily The Sum Of The Individual Non-Study Medications Since A Subject May Report Two or More Different Non-Study Medications In The Same Classification. ## - Anatomical-Therapeutic-Chemical Classification Could Not Be Found at the Requested Level.

Page 14

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: PRIOR

ATC Classification [1]	Treatment Placebo n= 77
OTHER CARDIAC PREPARATIONS C01E	0
OTHER COLD COMBINATION PREPARATIONS R05X	0
OTHER DRUGS FOR DISORD. OF MUSCULO-SKELETAL SYST. M05A	4 (5.2)
OTHER DRUGS FOR DISORDER OF THE MUSC-SKEL SYSTEM M09A	0
OTHER GYNAECOLOGICALS G02C	6 (7.8)
OTHER MINERAL SUPPLEMENTS A12C	3 (3.9)
OTHER NUTRIENTS V06D	2 (2.6)
OTHER OPHTHALMOLOGICALS S01X	1 (1.3)
OTHER PLAIN VITAMIN PREPARATIONS A11H	12 (15.6)
OTHER SEX HORM. & MODULATORS OF THE GENITAL SYSTEM G03X	0
OTHER UROLOGICALS, INCL ANTISPASMODICS G04B	0
OTHER VITAMIN PRODUCTS, COMBINATIONS A11J	2 (2.6)
PERIPHERAL VASODILATORS CO4A	1 (1.3)
POTASSIUM A12B	2 (2.6)
POTASSIUM-SPARING AGENTS CO3D	0
PROGESTOGENS AND ESTROGENS IN COMBINATION G03F	0
PROGESTOGENS G03D	0

Page 15

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT NMED4 ATC3

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL

CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: PRIOR

	Treatment									
ATC Classification [1]		DVS SR 50 mg n=149		VS SR 50 mg DVS SR 100 mg n=149 n=155			ng DVS SR 150 mg n=157			R 200 mg =151
PROPULSIVES A03F	1	(0.7)	0		2	(1.3)	0			
PROTECTIVES AGAINST UV-RADIATION D02B	0		0		0		1	(0.7)		
PROTEIN SUPPLEMENTS V06B	1	(0.7)	0		0		0			
PSYCHOSTIMULANTS N06B	0		1	(0.6)	0		0			
QUINOLONE ANTIBACTERIALS J01M	1	(0.7)	2	(1.3)	2	(1.3)	1	(0.7)		
RENIN-ANGIOTENSIN SYSTEM, AGENTS ACTING ON CO2E	6	(4.0)	7	(4.5)	9	(5.7)	9	(6.0)		
STOMATOLOGICALS, MOUTH PREPARATIONS A01A	0		1	(0.6)	0		0			
SULFONAMIDES AND TRIMETHOPRIM J01E	0		1	(0.6)	0		1	(0.7)		
SYNTHETICS, INCL PAPAVERINE A03A	0		0		0		1	(0.7)		
TETRACYCLINES J01A	0		1	(0.6)	1	(0.6)	2	(1.3)		
THYROID PREPARATIONS H03A	15	(10.1)	19	(12.3)	19	(12.1)	21	(13.9)		
TONICS A13A	1	(0.7)	0		1	(0.6)	0			
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN M02A	1	(0.7)	0		0		0			
URINARY ANTISEPTICS AND ANTIINFECTIVES G04A	1	(0.7)	0		2	(1.3)	1	(0.7)		
VIRAL VACCINES J07B	0		0		0		1	(0.7)		
VIT A AND D, INCL COMBINATIONS OF THE TWO A11C	1	(0.7)	4	(2.6)	5	(3.2)	3	(2.0)		
VITAMIN B-COMPLEX, INCL COMBINATIONS A11E	9	(6.0)	4	(2.6)	8	(5.1)	10	(6.6)		
VITAMIN B12 AND FOLIC ACID B03B	4	(2.7)	6	(3.9)	6	(3.8)	10	(6.6)		

Page 16

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: PRIOR

ATC Classification [1]	Treatment Placebo n= 77
PROPULSIVES A03F	1 (1.3)
PROTECTIVES AGAINST UV-RADIATION D02B	0
PROTEIN SUPPLEMENTS V06B	0
PSYCHOSTIMULANTS N06B	0
QUINOLONE ANTIBACTERIALS J01M	2 (2.6)
RENIN-ANGIOTENSIN SYSTEM, AGENTS ACTING ON C02E	8 (10.4)
STOMATOLOGICALS, MOUTH PREPARATIONS A01A	0
SULFONAMIDES AND TRIMETHOPRIM J01E	0
SYNTHETICS, INCL PAPAVERINE A03A	1 (1.3)
TETRACYCLINES J01A	2 (2.6)
THYROID PREPARATIONS H03A	11 (14.3)
TONICS A13A	0
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN M02A	0
URINARY ANTISEPTICS AND ANTIINFECTIVES G04A	1 (1.3)
VIRAL VACCINES J07B	0
VIT A AND D, INCL COMBINATIONS OF THE TWO A11C	0
VITAMIN B-COMPLEX, INCL COMBINATIONS A11E	3 (3.9)
VITAMIN B12 AND FOLIC ACID B03B	4 (5.2)

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 17

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: PRIOR

ATC Classification [1]			DVS SR 150	mg DVS SR 200 mg n=151
VITAMIN K AND OTHER HAEMOSTATICS B02B	0	1 (0.6)	0	1 (0.7)

DVS SR

Protocol 3151A2-315-US

CSR-60178

190CT05 16:35
REPORT NMED4_ATC3

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL

CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: PRIOR

ATC Classification [1]

ATC Classification [1]

VITAMIN K AND OTHER HAEMOSTATICS B02B 0

CONFIDENTIAL 220 Wyeth

NOTE: [1] - Classification Totals Are Not Necessarily The Sum Of The Individual Non-Study Medications Since A Subject May Report
Two or More Different Non-Study Medications In The Same Classification.
- Anatomical-Therapeutic-Chemical Classification Could Not Be Found at the Requested Level.

Page 19

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT NMED4 ATC3

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL

CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT

ATC Classification [1]	DVS SR 50 mg n=149			Trea g DVS SR 100 mg n=155		 R 150 mg =157	DVS SR 200 m n=151	
ANY NON-STUDY MEDICATION	143	(96.0)	146	(94.2)	150	(95.5)	146	(96.7)
## ALL OTHER THERAPEUTIC PRODUCTS V03 - ATC 2	1	(0.7)	2	(1.3)	2	(1.3)	0	
## ANAESTHETICS NO1 - ATC 2	1	(0.7)	0		1	(0.6)	0	
## ANALGESICS NO2 - ATC 2	0		0		0		0	
## ANTACIDS, DRUGS FOR TREATM.OF PEPT.ULC.AND ANTIFL. A02 - ATC 2	1	(0.7)	1	(0.6)	0		0	
## ANTIBACTERIALS FOR SYSTEMIC USE J01 - ATC 2	1	(0.7)	0		1	(0.6)	0	
## ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS M01 - ATC 2	1	(0.7)	0		0		0	
## BILE AND LIVER THERAPY A05 - ATC 2	0		2	(1.3)	1	(0.6)	0	
## COUGH AND COLD PREPARATIONS R05 - ATC 2	3	(2.0)	0		0		2	(1.3)
## LAXATIVES A06 - ATC 2	1	(0.7)	0		0		0	
## MINERAL SUPPLEMENTS A12 - ATC 2	0		2	(1.3)	1	(0.6)	3	(2.0)
## NASAL PREPARATIONS R01 - ATC 2	1	(0.7)	0		0		0	
## THROAT PREPARATIONS R02 - ATC 2	0		0		2	(1.3)	0	
Classification Unknown	1	(0.7)	0		0		0	
ACE INHIBITORS, COMBINATIONS C09B	1	(0.7)	1	(0.6)	2	(1.3)	2	(1.3)
ADRENERGICS, INHALANTS R03A	6	(4.0)	7	(4.5)	9	(5.7)	7	(4.6)
AGENTS AFFECTING THE VIRUS DIRECTLY J05A	3	(2.0)	5	(3.2)	4	(2.5)	4	(2.6)

Page

20

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT

ATC Classification [1]	Pl	eatment - acebo = 77
ANY NON-STUDY MEDICATION	73	(94.8)
## ALL OTHER THERAPEUTIC PRODUCTS V03 - ATC 2	2	(2.6)
## ANAESTHETICS NO1 - ATC 2	1	(1.3)
## ANALGESICS NO2 - ATC 2	1	(1.3)
## ANTACIDS, DRUGS FOR TREATM.OF PEPT.ULC.AND ANTIFL. A02 - ATC 2	0	
## ANTIBACTERIALS FOR SYSTEMIC USE J01 - ATC 2	0	
## ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS M01 - ATC 2	0	
## BILE AND LIVER THERAPY A05 - ATC 2	0	
## COUGH AND COLD PREPARATIONS R05 - ATC 2	1	(1.3)
## LAXATIVES A06 - ATC 2	0	
## MINERAL SUPPLEMENTS A12 - ATC 2	3	(3.9)
## NASAL PREPARATIONS R01 - ATC 2	1	(1.3)
## THROAT PREPARATIONS RO2 - ATC 2	0	
Classification Unknown	0	
ACE INHIBITORS, COMBINATIONS C09B	0	
ADRENERGICS, INHALANTS RO3A	5	(6.5)
AGENTS AFFECTING THE VIRUS DIRECTLY J05A	0	

CLASSIFICATION: THERAPEUTIC SUBGROUP

Page 21

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT NMED4 ATC3 NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL

Time Period: CONCOMITANT

ATC Classification [1]	DVS S n	DVS SR 50 mg n=149		DVS SR 100 mg n=155		DVS SR 150 mg n=157		R 200 mg =151	
ALL OTHER NON-THERAPEUTIC PRODUCTS V07A	0		0	•	0		1	(0.7)	
ALL OTHER THERAPEUTIC PRODUCTS V03A	15	(10.1)	11	(7.1)	9	(5.7)	17	(11.3)	
ALLERGENS V01A	2	(1.3)	1	(0.6)	2	(1.3)	1	(0.7)	
AMINOGLYCOSIDE ANTIBACTERIALS J01G	0		0		0		2	(1.3)	
ANAESTHETICS, GENERAL N01A	3	(2.0)	1	(0.6)	3	(1.9)	1	(0.7)	
ANDROGENS G03B	0		1	(0.6)	1	(0.6)	0		
ANGIOTENSIN II ANTAGONISTS, COMBINATIONS C09D	2	(1.3)	0		3	(1.9)	4	(2.6)	
ANGIOTENSIN II ANTAGONISTS, PLAIN C09C	2	(1.3)	1	(0.6)	1	(0.6)	0		
ANTACIDS A02A	13	(8.7)	8	(5.2)	13	(8.3)	13	(8.6)	
ANTI-ACNE PREPARATIONS FOR TOPICAL USE D10A	1	(0.7)	2	(1.3)	0		1	(0.7)	
ANTI-PARATHYROID HORMONES H05B	0		0		1	(0.6)	0		
ANTIADRENERGIC AGENTS, CENTRALLY ACTING C02A	0		0		1	(0.6)	0		
ANTIBIOTICS FOR TOPICAL USE D06A	1	(0.7)	0		1	(0.6)	1	(0.7)	
ANTIDEPRESSANTS NO6A	6	(4.0)	2	(1.3)	2	(1.3)	1	(0.7)	
ANTIDIARRHOEAL MICROORGANISMS A07F	0		1	(0.6)	0		2	(1.3)	
ANTIEMETICS AND ANTINAUSEANTS A04A	2	(1.3)	1	(0.6)	1	(0.6)	1	(0.7)	
ANTIEPILEPTICS NO3A	2	(1.3)	1	(0.6)	1	(0.6)	1	(0.7)	
ANTIFLATULENTS A02D	3	(2.0)	3	(1.9)	0		1	(0.7)	

NOTE: [1] - Classification Totals Are Not Necessarily The Sum Of The Individual Non-Study Medications Since A Subject May Report Two or More Different Non-Study Medications In The Same Classification. ## - Anatomical-Therapeutic-Chemical Classification Could Not Be Found at the Requested Level.

Page 22

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT

ATC Classification [1]	Treatment Placebo n= 77
ALL OTHER NON-THERAPEUTIC PRODUCTS V07A	0
ALL OTHER THERAPEUTIC PRODUCTS V03A	7 (9.1)
ALLERGENS V01A	0
AMINOGLYCOSIDE ANTIBACTERIALS J01G	0
ANAESTHETICS, GENERAL N01A	0
ANDROGENS G03B	0
ANGIOTENSIN II ANTAGONISTS, COMBINATIONS C09D	1 (1.3)
ANGIOTENSIN II ANTAGONISTS, PLAIN C09C	0
ANTACIDS A02A	5 (6.5)
ANTI-ACNE PREPARATIONS FOR TOPICAL USE D10A	0
ANTI-PARATHYROID HORMONES H05B	1 (1.3)
ANTIADRENERGIC AGENTS, CENTRALLY ACTING C02A	0
ANTIBIOTICS FOR TOPICAL USE D06A	1 (1.3)
ANTIDEPRESSANTS NO6A	1 (1.3)
ANTIDIARRHOEAL MICROORGANISMS A07F	0
ANTIEMETICS AND ANTINAUSEANTS A04A	0
ANTIEPILEPTICS NO3A	1 (1.3)
ANTIFLATULENTS A02D	0

Page 23

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT NMED4 ATC3

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT

ATC Classification [1]			DVS S	R 100 mg	DVS S	 R 150 mg =157	DVS S	
ANTIFUNGALS FOR TOPICAL USE D01A	2	(1.3)	8	(5.2)	3	(1.9)	0	
ANTIGLAUCOMA PREPARATIONS AND MIOTICS S01E	3	(2.0)	3	(1.9)	0		0	
ANTIHAEMORRHOIDALS FOR TOPICAL USE C05A	2	(1.3)	0		2	(1.3)	1	(0.7)
ANTIHISTAMINES FOR SYSTEMIC USE RO6A	36	(24.2)	46	(29.7)	34	(21.7)	33	(21.9)
ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION C02L	0		0		2	(1.3)	0	
ANTIINFECTIVES S01A	0		2	(1.3)	2	(1.3)	0	
ANTIINFECTIVES S03A	1	(0.7)	0		0		0	
ANTIINFECTIVES/ANTISEPT., EXCL COMB WITH CORTICOST. G01A	2	(1.3)	1	(0.6)	0		2	(1.3)
ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMB S01C	1	(0.7)	0		0		0	
ANTIINFLAMMATORY AGENTS S01B	1	(0.7)	0		0		0	
ANTIINFLAMMATORY/ANTIRHEUMATIC PROD.,NON-STEROIDS M01A	92	(61.7)	71	(45.8)	73	(46.5)	77	(51.0)
ANTIMALARIALS P01B	1	(0.7)	1	(0.6)	1	(0.6)	1	(0.7)
ANTIMETABOLITES L01B	1	(0.7)	2	(1.3)	2	(1.3)	1	(0.7)
ANTIMIGRAINE PREPARATIONS NO2C	4	(2.7)	1	(0.6)	1	(0.6)	4	(2.6)
ANTIMYCOTICS FOR SYSTEMIC USE, EXCL GRISEOFULVIN J02A	1	(0.7)	0		1	(0.6)	0	
ANTIOBESITY PREPARATIONS, EXCL DIET PRODUCTS A08A	1	(0.7)	0		1	(0.6)	1	(0.7)

NOTE: [1] - Classification Totals Are Not Necessarily The Sum Of The Individual Non-Study Medications Since A Subject May Report Two or More Different Non-Study Medications In The Same Classification. ## - Anatomical-Therapeutic-Chemical Classification Could Not Be Found at the Requested Level.

Page 24

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT

ATC Classification [1]	Treatment Placebo n= 77
ANTIFUNGALS FOR TOPICAL USE D01A	1 (1.3)
ANTIGLAUCOMA PREPARATIONS AND MIOTICS S01E	0
ANTIHAEMORRHOIDALS FOR TOPICAL USE C05A	0
ANTIHISTAMINES FOR SYSTEMIC USE R06A	21 (27.3)
ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION C02L	0
ANTIINFECTIVES S01A	0
ANTIINFECTIVES S03A	0
ANTIINFECTIVES/ANTISEPT., EXCL COMB WITH CORTICOST. G01A	1 (1.3)
ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMB S01C	0
ANTIINFLAMMATORY AGENTS S01B	0
ANTIINFLAMMATORY/ANTIRHEUMATIC PROD.,NON-STEROIDS M01A	42 (54.5)
ANTIMALARIALS P01B	0
ANTIMETABOLITES L01B	2 (2.6)
ANTIMIGRAINE PREPARATIONS NO2C	2 (2.6)
ANTIMYCOTICS FOR SYSTEMIC USE, EXCL GRISEOFULVIN J02A	0
ANTIOBESITY PREPARATIONS, EXCL DIET PRODUCTS A08A	0

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT NMED4 ATC3

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL

Page 25

CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT

	Treatment								
ATC Classification [1]		DVS SR 50 mg n=149		DVS SR 100 mg n=155		DVS SR 150 mg n=157		R 200 mg =151	
ANTIPROPULSIVES A07D	3	(2.0)	0		1	(0.6)	4	(2.6)	
ANTIPRURITICS, INCL ANTIHIST, ANAESTHET, ETC. D04A	2	(1.3)	1	(0.6)	7	(4.5)	5	(3.3)	
ANTIPSORIATICS FOR SYTEMIC USE D05B	0		0		1	(0.6)	0		
ANTIPSORIATICS FOR TOPICAL USE D05A	0		0		1	(0.6)	0		
ANTISEPTICS AND DISINFECTANTS D08A	1	(0.7)	1	(0.6)	0		2	(1.3)	
ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS A03C	0		0		0		1	(0.7)	
ANTITHROMBOTIC AGENTS B01A	2	(1.3)	0		2	(1.3)	1	(0.7)	
ANTITUSSIVES, EXCL COMBINATIONS WITH EXPECTORANTS R05D	15	(10.1)	12	(7.7)	7	(4.5)	7	(4.6)	
ANXIOLYTICS N05B	4	(2.7)	3	(1.9)	9	(5.7)	2	(1.3)	
ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON C02D	3	(2.0)	2	(1.3)	8	(5.1)	5	(3.3)	
ASCORBIC ACID (VIT C), INCL COMBINATIONS A11G	19	(12.8)	26	(16.8)	19	(12.1)	23	(15.2)	
BACTERIAL VACCINES J07A	3	(2.0)	0		1	(0.6)	1	(0.7)	
BELLADONNA AND DERIVATIVES, PLAIN A03B	0		0		1	(0.6)	1	(0.7)	
BETA BLOCKING AGENTS AND OTHER DIURETICS CO7C	0		1	(0.6)	0		1	(0.7)	
BETA BLOCKING AGENTS AND THIAZIDES C07B	0		0		2	(1.3)	0		
BETA BLOCKING AGENTS, PLAIN CO7A	7	(4.7)	14	(9.0)	10	(6.4)	7	(4.6)	
BETA-LACTAM ANTIBACTERIALS, PENICILLINS J01C	16	(10.7)	9	(5.8)	11	(7.0)	12	(7.9)	

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT

ATC Classification [1]	Pl	eatment acebo = 77
ANTIPROPULSIVES A07D	1	(1.3)
ANTIPRURITICS, INCL ANTIHIST, ANAESTHET, ETC. D04A	1	(1.3)
ANTIPSORIATICS FOR SYTEMIC USE D05B	0	
ANTIPSORIATICS FOR TOPICAL USE D05A	0	
ANTISEPTICS AND DISINFECTANTS D08A	1	(1.3)
ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS A03C	0	
ANTITHROMBOTIC AGENTS B01A	0	
ANTITUSSIVES, EXCL COMBINATIONS WITH EXPECTORANTS R05D	7	(9.1)
ANXIOLYTICS N05B	3	(3.9)
ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON CO2D	1	(1.3)
ASCORBIC ACID (VIT C), INCL COMBINATIONS A11G	15	(19.5)
BACTERIAL VACCINES J07A	1	(1.3)
BELLADONNA AND DERIVATIVES, PLAIN A03B	0	
BETA BLOCKING AGENTS AND OTHER DIURETICS CO7C	0	
BETA BLOCKING AGENTS AND THIAZIDES C07B	2	(2.6)
BETA BLOCKING AGENTS, PLAIN CO7A	9	(11.7)
BETA-LACTAM ANTIBACTERIALS, PENICILLINS J01C	4	(5.2)

Page 26

NOTE: [1] - Classification Totals Are Not Necessarily The Sum Of The Individual Non-Study Medications Since A Subject May Report Two or More Different Non-Study Medications In The Same Classification. ## - Anatomical-Therapeutic-Chemical Classification Could Not Be Found at the Requested Level.

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT NMED4 ATC3

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL

Page 27

CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT

					tment DVS SR 150 mg			
ATC Classification [1]		=149		=155		=157		=151
BLOOD AND RELATED PRODUCTS B05A	0		0		0		1	(0.7)
CALCIUM A12A	47	(31.5)	54	(34.8)	49	(31.2)	54	(35.8)
CAPILLARY STABILIZING AGENTS C05C	0		1	(0.6)	0		0	
CARDIAC GLYCOSIDES C01A	1	(0.7)	0		0		0	
CARDIOVASCULAR SYSTEM V09G	0		0		1	(0.6)	0	
CHOLESTEROL AND TRIGLYCERIDE REDUCERS C10A	28	(18.8)	36	(23.2)	33	(21.0)	50	(33.1)
COMBINATIONS OF ANTIHYPERTENSIVES IN ATC-GR. C02 C02N	0		0		0		1	(0.7)
CONTRAST MEDIA V04A	0		0		1	(0.6)	0	
CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION S02C	0		0		1	(0.6)	0	
CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02A	7	(4.7)	13	(8.4)	16	(10.2)	7	(4.6)
CORTICOSTEROIDS, COMB WITH ANTIBIOTICS D07C	2	(1.3)	0		0		0	
CORTICOSTEROIDS, OTHER COMBINATIONS D07X	0		1	(0.6)	0		0	
CORTICOSTEROIDS, PLAIN D07A	7	(4.7)	2	(1.3)	6	(3.8)	6	(4.0)
COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS R05F	5	(3.4)	5	(3.2)	3	(1.9)	1	(0.7)
DECONGESTANTS AND ANTIALLERGICS S01G	1	(0.7)	1	(0.6)	1	(0.6)	1	(0.7)
DIAGNOSTIC RADIOPHARMACEUTICALS V04D	0		0		1	(0.6)	0	
DIET FORMULATIONS FOR TREATMENT OF OBESITY V06A	0		0		1	(0.6)	0	

NOTE: [1] - Classification Totals Are Not Necessarily The Sum Of The Individual Non-Study Medications Since A Subject May Report

Two or More Different Non-Study Medications In The Same Classification. ## - Anatomical-Therapeutic-Chemical Classification Could Not Be Found at the Requested Level.

Page 28

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT

ATC Classification [1]	Treatment Placebo n= 77
BLOOD AND RELATED PRODUCTS B05A	0
CALCIUM A12A	33 (42.9)
CAPILLARY STABILIZING AGENTS C05C	0
CARDIAC GLYCOSIDES C01A	0
CARDIOVASCULAR SYSTEM V09G	0
CHOLESTEROL AND TRIGLYCERIDE REDUCERS C10A	14 (18.2)
COMBINATIONS OF ANTIHYPERTENSIVES IN ATC-GR. ${\tt C02}$	0
CONTRAST MEDIA V04A	0
CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION S02C	1 (1.3)
CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02A	9 (11.7)
CORTICOSTEROIDS, COMB WITH ANTIBIOTICS D07C	0
CORTICOSTEROIDS, OTHER COMBINATIONS D07X	0
CORTICOSTEROIDS, PLAIN D07A	0
COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS R05F	4 (5.2)
DECONGESTANTS AND ANTIALLERGICS S01G	1 (1.3)
DIAGNOSTIC RADIOPHARMACEUTICALS V04D	0
DIET FORMULATIONS FOR TREATMENT OF OBESITY V06A	0

NOTE: [1] - Classification Totals Are Not Necessarily The Sum Of The Individual Non-Study Medications Since A Subject May Report Two or More Different Non-Study Medications In The Same Classification. ## - Anatomical-Therapeutic-Chemical Classification Could Not Be Found at the Requested Level.

Page 29

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT NMED4 ATC3

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL

CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT

	Treatment								
ATC Classification [1]	DVS S	DVS SR 50 mg n=149		DVS SR 100 mg n=155		DVS SR 150 mg		R 200 mg =151	
DIGESTIVES, INCL ENZYMES A09A	1	(0.7)	2	(1.3)	4	(2.5)	0		
DIURETICS AND POTASSIUM-SPARING AGENTS IN COMB C03E	6	(4.0)	4	(2.6)	3	(1.9)	7	(4.6)	
DOPAMINERGIC AGENTS NO4B	0		1	(0.6)	0		0		
DRUGS AFFECTING MINERALIZATION M05B	11	(7.4)	12	(7.7)	12	(7.6)	7	(4.6)	
DRUGS FOR TREATMENT OF PEPTIC ULCER A02B	25	(16.8)	31	(20.0)	22	(14.0)	23	(15.2)	
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY G04C	0		0		0		1	(0.7)	
EMOLLIENTS AND PROTECTIVES D02A	0		1	(0.6)	0		1	(0.7)	
ESTROGENS G03C	0		1	(0.6)	0		0		
EXPECTORANTS, EXCL COMBINATIONS WITH ANTITUSSIVES R05C	6	(4.0)	8	(5.2)	2	(1.3)	11	(7.3)	
GLYCOGENOLYTIC HORMONES H04A	1	(0.7)	0		0		0		
HIGH-CEILING DIURETICS C03C	4	(2.7)	0		4	(2.5)	0		
HORMONE ANTAGONISTS AND RELATED AGENTS L02B	0		0		1	(0.6)	0		
HORMONES AND RELATED AGENTS L02A	0		1	(0.6)	0		0		
HYPNOTICS AND SEDATIVES NO5C	11	(7.4)	5	(3.2)	9	(5.7)	6	(4.0)	
I.V. SOLUTION ADDITIVES B05X	0		3	(1.9)	3	(1.9)	1	(0.7)	
I.V. SOLUTIONS B05B	0		1	(0.6)	0		0		
IMMUNOSUPPRESSIVE AGENTS L04A	0		0		1	(0.6)	2	(1.3)	

Page

30

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT

ATC Classification [1]	Treatment Placebo n= 77	
DIGESTIVES, INCL ENZYMES A09A	0	
DIURETICS AND POTASSIUM-SPARING AGENTS IN COMB C03E	4 (5.2)	
DOPAMINERGIC AGENTS NO 4B	1 (1.3)	
DRUGS AFFECTING MINERALIZATION M05B	7 (9.1)	
DRUGS FOR TREATMENT OF PEPTIC ULCER A02B	7 (9.1)	
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY G04C	0	
EMOLLIENTS AND PROTECTIVES D02A	0	
ESTROGENS G03C	0	
EXPECTORANTS, EXCL COMBINATIONS WITH ANTITUSSIVES R05C	6 (7.8)	
GLYCOGENOLYTIC HORMONES H04A	0	
HIGH-CEILING DIURETICS CO3C	0	
HORMONE ANTAGONISTS AND RELATED AGENTS L02B	0	
HORMONES AND RELATED AGENTS L02A	0	
HYPNOTICS AND SEDATIVES NO5C	4 (5.2)	
I.V. SOLUTION ADDITIVES B05X	0	
I.V. SOLUTIONS B05B	0	
IMMUNOSUPPRESSIVE AGENTS L04A	2 (2.6)	

Page 31

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT NMED4 ATC3

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL

CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT

	Treatment							
ATC Classification [1]		DVS SR 50 mg n=149		DVS SR 100 mg n=155				SR 200 mg n=151
INSULINS A10A	1	(0.7)	0		1	(0.6)	0	
INTESTINAL ADSORBENTS A07B	2	(1.3)	3	(1.9)	7	(4.5)	2	(1.3)
INTESTINAL ANTIINFECTIVES A07A	0		0		0		1	(0.7)
INTESTINAL ANTIINFLAMMATORY AGENTS A07E	0		0		0		1	(0.7)
IRON PREPARATIONS B03A	2	(1.3)	4	(2.6)	2	(1.3)	1	(0.7)
IRRIGATING SOLUTIONS B05C	2	(1.3)	0		1	(0.6)	0	
LAXATIVES A06A	21	(14.1)	26	(16.8)	15	(9.6)	23	(15.2)
LIVER THERAPY, LIPOTROPICS A05B	1	(0.7)	1	(0.6)	1	(0.6)	0	
LOCAL ANAESTHETICS N01B	0		0		2	(1.3)	1	(0.7)
LOCAL ANAESTHETICS S01H	0		0		2	(1.3)	0	
LOW-CEILING DIURETICS, EXCL THIAZIDES CO3B	0		1	(0.6)	1	(0.6)	0	
LOW-CEILING DIURETICS, THIAZIDES CO3A	7	(4.7)	8	(5.2)	8	(5.1)	7	(4.6)
MACROLIDES AND LINCOSAMIDES J01F	10	(6.7)	14	(9.0)	12	(7.6)	10	(6.6)
MULTIVITAMINS, COMBINATIONS A11A	50	(33.6)	69	(44.5)	70	(44.6)	74	(49.0)
MULTIVITAMINS, PLAIN A11B	1	(0.7)	4	(2.6)	0		2	(1.3)
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS M03B	9	(6.0)	8	(5.2)	13	(8.3)	8	(5.3)
MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS M03A	1	(0.7)	0		0		0	
MYDRIATICS AND CYCLOPLEGICS S01F	1	(0.7)	0		1	(0.6)	0	

Page 32

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT

Treatment Placebo n= 77
1 (1.3)
1 (1.3)
0
0
1 (1.3)
0
6 (7.8)
0
2 (2.6)
0
0
4 (5.2)
7 (9.1)
34 (44.2)
0
5 (6.5)
0
0

Page 33

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT NMED4 ATC3

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL

CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT

ATC Classification [1]		R 50 mg =149		R 100 mg =155				R 200 mg =151
NASAL DECONGESTANTS FOR SYSTEMIC USE R01B	17	(11.4)	20	(12.9)	13	(8.3)	19	(12.6)
NASAL DECONGESTANTS FOR TOPICAL USE R01A	12	(8.1)	8	(5.2)	15	(9.6)	8	(5.3)
OPIOIDS NO2A	12	(8.1)	10	(6.5)	16	(10.2)	10	(6.6)
ORAL BLOOD GLUCOSE LOWERING DRUGS A10B	1	(0.7)	2	(1.3)	1	(0.6)	3	(2.0)
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS A16A	0		0		1	(0.6)	0	
OTHER ANALGESICS AND ANTIPYRETICS NO2B	83	(55.7)	85	(54.8)	81	(51.6)	67	(44.4)
OTHER ANTI-ASTHMATICS FOR SYSTEMIC USE RO3D	3	(2.0)	3	(1.9)	3	(1.9)	6	(4.0)
OTHER ANTI-ASTHMATICS, INHALANTS R03B	0		0		0		1	(0.7)
OTHER ANTIBACTERIALS J01X	6	(4.0)	1	(0.6)	0		1	(0.7)
OTHER ANTIHYPERTENSIVES C02K	0		1	(0.6)	0		0	
OTHER BETA-LACTAM ANTIBACTERIALS J01D	7	(4.7)	7	(4.5)	2	(1.3)	5	(3.3)
OTHER CARDIAC PREPARATIONS C01E	1	(0.7)	3	(1.9)	0		1	(0.7)
OTHER COLD COMBINATION PREPARATIONS R05X	5	(3.4)	6	(3.9)	11	(7.0)	8	(5.3)
OTHER DRUGS FOR DISORD. OF MUSCULO-SKELETAL SYST. M05A	6	(4.0)	7	(4.5)	3	(1.9)	7	(4.6)
OTHER DRUGS FOR DISORDER OF THE MUSC-SKEL SYSTEM M09A	5	(3.4)	1	(0.6)	2	(1.3)	8	(5.3)
OTHER MINERAL SUPPLEMENTS A12C	5	(3.4)	10	(6.5)	10	(6.4)	13	(8.6)
OTHER NUTRIENTS V06D	5	(3.4)	5	(3.2)	2	(1.3)	2	(1.3)

NOTE: [1] - Classification Totals Are Not Necessarily The Sum Of The Individual Non-Study Medications Since A Subject May Report Two or More Different Non-Study Medications In The Same Classification. ## - Anatomical-Therapeutic-Chemical Classification Could Not Be Found at the Requested Level.

Page 34

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT

ATC Classification [1]	Pl	eatment acebo = 77
NASAL DECONGESTANTS FOR SYSTEMIC USE R01B	13	(16.9)
NASAL DECONGESTANTS FOR TOPICAL USE R01A	5	(6.5)
OPIOIDS NO2A	9	(11.7)
ORAL BLOOD GLUCOSE LOWERING DRUGS A10B	2	(2.6)
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS A16A	0	
OTHER ANALGESICS AND ANTIPYRETICS NO2B	49	(63.6)
OTHER ANTI-ASTHMATICS FOR SYSTEMIC USE RO3D	2	(2.6)
OTHER ANTI-ASTHMATICS, INHALANTS R03B	0	
OTHER ANTIBACTERIALS J01X	0	
OTHER ANTIHYPERTENSIVES C02K	0	
OTHER BETA-LACTAM ANTIBACTERIALS J01D	6	(7.8)
OTHER CARDIAC PREPARATIONS C01E	0	
OTHER COLD COMBINATION PREPARATIONS R05X	4	(5.2)
OTHER DRUGS FOR DISORD. OF MUSCULO-SKELETAL SYST. M05A	5	(6.5)
OTHER DRUGS FOR DISORDER OF THE MUSC-SKEL SYSTEM M09A	1	(1.3)
OTHER MINERAL SUPPLEMENTS A12C	6	(7.8)
OTHER NUTRIENTS V06D	2	(2.6)

Page 35

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT NMED4 ATC3 NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL

CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT

	Treatment							
ATC Classification [1]		3R 50 mg n=149		R 100 mg =155		R 150 mg =157		R 200 mg =151
OTHER OPHTHALMOLOGICALS S01X	1	(0.7)	1	(0.6)	0		0	
OTHER PLAIN VITAMIN PREPARATIONS A11H	27	(18.1)	39	(25.2)	37	(23.6)	42	(27.8)
OTHER RESPIRATORY SYSTEM PRODUCTS R07A	0		0		1	(0.6)	1	(0.7)
OTHER UROLOGICALS, INCL ANTISPASMODICS G04B	1	(0.7)	7	(4.5)	0		2	(1.3)
OTHER VITAMIN PRODUCTS, COMBINATIONS A11J	8	(5.4)	4	(2.6)	7	(4.5)	9	(6.0)
PERIPHERAL VASODILATORS CO4A	2	(1.3)	0		3	(1.9)	4	(2.6)
POTASSIUM A12B	3	(2.0)	3	(1.9)	3	(1.9)	2	(1.3)
POTASSIUM-SPARING AGENTS C03D	2	(1.3)	2	(1.3)	1	(0.6)	1	(0.7)
PROPULSIVES A03F	3	(2.0)	0		3	(1.9)	0	
PSYCHOSTIMULANTS N06B	0		1	(0.6)	0		0	
QUINOLONE ANTIBACTERIALS J01M	6	(4.0)	10	(6.5)	9	(5.7)	4	(2.6)
RENIN-ANGIOTENSIN SYSTEM, AGENTS ACTING ON CO2E	6	(4.0)	9	(5.8)	11	(7.0)	10	(6.6)
SELECT CA CHANNEL BLOCKER W/ MAINLY VASC EFFECT C08C	0		1	(0.6)	0		0	
STOMATOLOGICALS, MOUTH PREPARATIONS A01A	0		1	(0.6)	0		0	
SULFONAMIDES AND TRIMETHOPRIM J01E	4	(2.7)	3	(1.9)	2	(1.3)	0	
SYNTHETICS, INCL PAPAVERINE A03A	1	(0.7)	2	(1.3)	2	(1.3)	0	
TETRACYCLINES J01A	1	(0.7)	4	(2.6)	1	(0.6)	2	(1.3)
THROAT PREPARATIONS R02A	1	(0.7)	0		1	(0.6)	0	

Page 36

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT

ATC Classification [1]	Treatment Placebo n= 77
OTHER OPHTHALMOLOGICALS S01X	2 (2.6)
OTHER PLAIN VITAMIN PREPARATIONS A11H	13 (16.9)
OTHER RESPIRATORY SYSTEM PRODUCTS R07A	0
OTHER UROLOGICALS, INCL ANTISPASMODICS G04B	0
OTHER VITAMIN PRODUCTS, COMBINATIONS A11J	5 (6.5)
PERIPHERAL VASODILATORS C04A	1 (1.3)
POTASSIUM A12B	2 (2.6)
POTASSIUM-SPARING AGENTS C03D	0
PROPULSIVES A03F	1 (1.3)
PSYCHOSTIMULANTS N06B	1 (1.3)
QUINOLONE ANTIBACTERIALS J01M	4 (5.2)
RENIN-ANGIOTENSIN SYSTEM, AGENTS ACTING ON CO2E	8 (10.4)
SELECT CA CHANNEL BLOCKER W/ MAINLY VASC EFFECT C08C	0
STOMATOLOGICALS, MOUTH PREPARATIONS A01A	0
SULFONAMIDES AND TRIMETHOPRIM J01E	1 (1.3)
SYNTHETICS, INCL PAPAVERINE A03A	1 (1.3)
TETRACYCLINES J01A	2 (2.6)
THROAT PREPARATIONS R02A	0

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 37

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT

ATC Classification [1]		DVS SR 50 mg n=149		DVS SR 100 mg n=155		tment DVS SR 150 mg n=157		 R 200 mg =151
THYROID PREPARATIONS H03A	17	(11.4)	20	(12.9)	19	(12.1)	21	(13.9)
TONICS A13A	0		0		1	(0.6)	0	
URINARY ANTISEPTICS AND ANTIINFECTIVES G04A	2	(1.3)	3	(1.9)	3	(1.9)	2	(1.3)
VASODILATORS USED IN CARDIAC DISEASES CO1D	0		1	(0.6)	3	(1.9)	2	(1.3)
VIRAL VACCINES J07B	1	(0.7)	1	(0.6)	1	(0.6)	1	(0.7)
VIT A AND D, INCL COMBINATIONS OF THE TWO A11C	1	(0.7)	6	(3.9)	6	(3.8)	4	(2.6)
VIT B1, PLAIN AND IN COMB WITH VITAMIN B6 AND B12 A11D	1	(0.7)	0		0		0	
VITAMIN B-COMPLEX, INCL COMBINATIONS A11E	9	(6.0)	5	(3.2)	6	(3.8)	6	(4.0)
VITAMIN B12 AND FOLIC ACID B03B	6	(4.0)	5	(3.2)	7	(4.5)	11	(7.3)
VITAMIN K AND OTHER HAEMOSTATICS B02B	0		1	(0.6)	0		0	

NOTE: [1] - Classification Totals Are Not Necessarily The Sum Of The Individual Non-Study Medications Since A Subject May Report Two or More Different Non-Study Medications In The Same Classification. ## - Anatomical-Therapeutic-Chemical Classification Could Not Be Found at the Requested Level.

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Page 38

Time Period: CONCOMITANT

ATC Classification [1]	Treatment Placebo n= 77
THYROID PREPARATIONS H03A	11 (14.3)
TONICS A13A	0
URINARY ANTISEPTICS AND ANTIINFECTIVES G04A	1 (1.3)
VASODILATORS USED IN CARDIAC DISEASES C01D	0
VIRAL VACCINES J07B	1 (1.3)
VIT A AND D, INCL COMBINATIONS OF THE TWO A11C	0
VIT B1, PLAIN AND IN COMB WITH VITAMIN B6 AND B12 A11D	0
VITAMIN B-COMPLEX, INCL COMBINATIONS A11E	4 (5.2)
VITAMIN B12 AND FOLIC ACID B03B	5 (6.5)
VITAMIN K AND OTHER HAEMOSTATICS B02B	0

Page

39

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT NMED4 ATC3 NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL

CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: AFTER

ATC Classification [1]			DVS SR 100 mg n=155				DVS S	R 200 mg
ANY NON-STUDY MEDICATION	135	(90.6)	142	(91.6)	140	(89.2)	147	(97.4)
## ALL OTHER THERAPEUTIC PRODUCTS V03 - ATC 2	0		2	(1.3)	0		0	
## BILE AND LIVER THERAPY A05 - ATC 2	0		1	(0.6)	1	(0.6)	0	
## DIURETICS C03 - ATC 2	0		1	(0.6)	0		0	
## LAXATIVES A06 - ATC 2	1	(0.7)	0		0		0	
## MINERAL SUPPLEMENTS A12 - ATC 2	0		1	(0.6)	1	(0.6)	3	(2.0)
## OPHTHALMOLOGICALS S01 - ATC 2	0		1	(0.6)	0		0	
ACE INHIBITORS, COMBINATIONS C09B	1	(0.7)	1	(0.6)	2	(1.3)	1	(0.7)
ADRENERGICS, INHALANTS R03A	7	(4.7)	3	(1.9)	6	(3.8)	7	(4.6)
AGENTS AFFECTING THE VIRUS DIRECTLY J05A	0		1	(0.6)	3	(1.9)	0	
ALL OTHER THERAPEUTIC PRODUCTS V03A	11	(7.4)	10	(6.5)	11	(7.0)	15	(9.9)
ALLERGENS V01A	2	(1.3)	1	(0.6)	2	(1.3)	1	(0.7)
ANAESTHETICS, GENERAL N01A	0		0		1	(0.6)	1	(0.7)
ANDROGENS G03B	0		1	(0.6)	0		0	
ANGIOTENSIN II ANTAGONISTS, COMBINATIONS C09D	1	(0.7)	0		2	(1.3)	4	(2.6)
ANGIOTENSIN II ANTAGONISTS, PLAIN C09C	1	(0.7)	1	(0.6)	1	(0.6)	0	
ANTACIDS A02A	4	(2.7)	4	(2.6)	9	(5.7)	8	(5.3)
ANTI-ACNE PREPARATIONS FOR TOPICAL USE D10A	1	(0.7)	2	(1.3)	0		0	

Page

40

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: AFTER

ATC Classification [1]		Pl	eatment acebo = 77
ANY NON-STUDY MEDICATION		69	(89.6)
## ALL OTHER THERAPEUTIC PRODUCTS V03 - AT	C 2	2	(2.6)
## BILE AND LIVER THERAPY A05 - ATC 2		0	
## DIURETICS C03 - ATC 2		0	
## LAXATIVES A06 - ATC 2		0	
## MINERAL SUPPLEMENTS A12 - ATC 2		2	(2.6)
## OPHTHALMOLOGICALS S01 - ATC 2		0	
ACE INHIBITORS, COMBINATIONS C09B		0	
ADRENERGICS, INHALANTS R03A		3	(3.9)
AGENTS AFFECTING THE VIRUS DIRECTLY J05A		0	
ALL OTHER THERAPEUTIC PRODUCTS V03A		3	(3.9)
ALLERGENS V01A		0	
ANAESTHETICS, GENERAL N01A		0	
ANDROGENS G03B		0	
ANGIOTENSIN II ANTAGONISTS, COMBINATIONS C	09D	1	(1.3)
ANGIOTENSIN II ANTAGONISTS, PLAIN C09C		0	
ANTACIDS A02A		2	(2.6)
ANTI-ACNE PREPARATIONS FOR TOPICAL USE D10	A	0	

Page

41

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT NMED4 ATC3 NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: AFTER

ATC Classification [1]	DVS S		DVS S		DVS S	R 150 mg =157	DVS S	
ANTI-PARATHYROID HORMONES H05B	0		0		1	(0.6)	0	
ANTIADRENERGIC AGENTS, CENTRALLY ACTING C02A	0		0		1	(0.6)	0	
ANTIBIOTICS FOR TOPICAL USE D06A	1	(0.7)	0		1	(0.6)	0	
ANTIDEPRESSANTS NO6A	12	(8.1)	15	(9.7)	1,1	(7.0)	12	(7.9)
ANTIDIARRHOEAL MICROORGANISMS A07F	0		1	(0.6)	0		2	(1.3)
ANTIEMETICS AND ANTINAUSEANTS A04A	0		2	(1.3)	0		0	
ANTIEPILEPTICS NO3A	3	(2.0)	1	(0.6)	2	(1.3)	1	(0.7)
ANTIFLATULENTS A02D	1	(0.7)	2	(1.3)	0		0	
ANTIFUNGALS FOR TOPICAL USE D01A	0		0		1	(0.6)	0	
ANTIGLAUCOMA PREPARATIONS AND MIOTICS S01E	3	(2.0)	2	(1.3)	0		0	
ANTIHAEMORRHOIDALS FOR TOPICAL USE C05A	2	(1.3)	0		0		1	(0.7)
ANTIHISTAMINES FOR SYSTEMIC USE R06A	17	(11.4)	24	(15.5)	28	(17.8)	24	(15.9)
ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION C02L	0		0		2	(1.3)	0	
ANTIINFECTIVES S01A	0		1	(0.6)	1	(0.6)	0	
ANTIINFECTIVES/ANTISEPT., EXCL COMB WITH CORTICOST. G01A	2	(1.3)	1	(0.6)	0		2	(1.3)
ANTIINFLAMMATORY AGENTS S01B	1	(0.7)	0		0		0	
ANTIINFLAMMATORY/ANTIRHEUMATIC PROD.,NON-STEROIDS M01A	61	(40.9)	44	(28.4)	44	(28.0)	60	(39.7)

NOTE: [1] - Classification Totals Are Not Necessarily The Sum Of The Individual Non-Study Medications Since A Subject May Report Two or More Different Non-Study Medications In The Same Classification. ## - Anatomical-Therapeutic-Chemical Classification Could Not Be Found at the Requested Level.

Page

42

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: AFTER

ATC Classification [1]	Treatment - Placebo n= 77	-
ANTI-PARATHYROID HORMONES H05B	1 (1.3)	
ANTIADRENERGIC AGENTS, CENTRALLY ACTING C	C02A 0	
ANTIBIOTICS FOR TOPICAL USE D06A	0	
ANTIDEPRESSANTS NO6A	2 (2.6)	
ANTIDIARRHOEAL MICROORGANISMS A07F	0	
ANTIEMETICS AND ANTINAUSEANTS A04A	0	
ANTIEPILEPTICS NO3A	1 (1.3)	
ANTIFLATULENTS A02D	0	
ANTIFUNGALS FOR TOPICAL USE D01A	1 (1.3)	
ANTIGLAUCOMA PREPARATIONS AND MIOTICS S01	E 0	
ANTIHAEMORRHOIDALS FOR TOPICAL USE C05A	0	
ANTIHISTAMINES FOR SYSTEMIC USE R06A	12 (15.6)	
ANTIHYPERTENSIVES AND DIURETICS IN COMBINCO2L	MATION 0	
ANTIINFECTIVES S01A	0	
ANTIINFECTIVES/ANTISEPT., EXCL COMB WITH CORTICOST. G01A	0	
ANTIINFLAMMATORY AGENTS S01B	0	
ANTIINFLAMMATORY/ANTIRHEUMATIC PROD., NON-M01A	STEROIDS 27 (35.1)	

Page

43

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT NMED4 ATC3

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: AFTER

ATC Classification [1]	DVS SI	R 50 mg =149	DVS S	Treat R 100 mg =155	DVS SI	R 150 mg =157	DVS SE	 R 200 mg =151
ANTIMALARIALS P01B	0		1	(0.6)	1	(0.6)	0	
ANTIMETABOLITES L01B	1	(0.7)	2	(1.3)	3	(1.9)	1	(0.7)
ANTIMIGRAINE PREPARATIONS NO2C	1	(0.7)	0		0		2	(1.3)
ANTIMYCOTICS FOR SYSTEMIC USE, EXCL GRISEOFULVIN J02A	0		0		1	(0.6)	1	(0.7)
ANTIOBESITY PREPARATIONS, EXCL DIET PRODUCTS A08A	1	(0.7)	0		1	(0.6)	0	
ANTIPROPULSIVES A07D	1	(0.7)	1	(0.6)	2	(1.3)	1	(0.7)
ANTIPRURITICS, INCL ANTIHIST, ANAESTHET, ETC. D04A	2	(1.3)	0		0		1	(0.7)
ANTIPSORIATICS FOR SYTEMIC USE D05B	0		0		1	(0.6)	0	
ANTIPSORIATICS FOR TOPICAL USE D05A	0		0		1	(0.6)	0	
ANTIPSYCHOTICS N05A	1	(0.7)	0		0		0	
ANTISEPTICS AND DISINFECTANTS D08A	1	(0.7)	0		0		0	
ANTISMOKING AGENTS N07B	0		0		1	(0.6)	0	
ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS A03C	0		0		0		1	(0.7)
ANTITHROMBOTIC AGENTS B01A	1	(0.7)	1	(0.6)	4	(2.5)	1	(0.7)
ANTITUSSIVES, EXCL COMBINATIONS WITH EXPECTORANTS R05D	2	(1.3)	2	(1.3)	3	(1.9)	2	(1.3)
ANXIOLYTICS N05B	1	(0.7)	1	(0.6)	5	(3.2)	2	(1.3)
ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON C02D	3	(2.0)	2	(1.3)	9	(5.7)	5	(3.3)

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 44

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: AFTER

ATC Classification [1]	Treatment Placebo n= 77
ANTIMALARIALS P01B	0
ANTIMETABOLITES L01B	2 (2.6)
ANTIMIGRAINE PREPARATIONS NO2C	0
ANTIMYCOTICS FOR SYSTEMIC USE, EXCL GRISEOFULVIN J02A	0
ANTIOBESITY PREPARATIONS, EXCL DIET PRODUCTS A08A	0
ANTIPROPULSIVES A07D	0
ANTIPRURITICS, INCL ANTIHIST, ANAESTHET, ETC. D04A	0
ANTIPSORIATICS FOR SYTEMIC USE D05B	0
ANTIPSORIATICS FOR TOPICAL USE D05A	0
ANTIPSYCHOTICS N05A	0
ANTISEPTICS AND DISINFECTANTS D08A	0
ANTISMOKING AGENTS N07B	0
ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS A03C	0
ANTITHROMBOTIC AGENTS B01A	0
ANTITUSSIVES, EXCL COMBINATIONS WITH EXPECTORANTS R05D	3 (3.9)
ANXIOLYTICS N05B	0
ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON CO2D	1 (1.3)

Page

45

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT NMED4 ATC3

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL

CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: AFTER

				Trea	tment			
ATC Classification [1]		R 50 mg =149		R 100 mg =155		R 150 mg =157		R 200 mg =151
ASCORBIC ACID (VIT C), INCL COMBINATIONS A11G	19	(12.8)	21	(13.5)	16	(10.2)	23	(15.2)
BACTERIAL VACCINES J07A	1	(0.7)	0		0		0	
BELLADONNA AND DERIVATIVES, PLAIN A03B	0		0		1	(0.6)	0	
BETA BLOCKING AGENTS AND OTHER DIURETICS C07C	0		1	(0.6)	0		1	(0.7)
BETA BLOCKING AGENTS AND THIAZIDES C07B	0		0		2	(1.3)	0	
BETA BLOCKING AGENTS, PLAIN CO7A	7	(4.7)	13	(8.4)	12	(7.6)	5	(3.3)
BETA-LACTAM ANTIBACTERIALS, PENICILLINS J01C	3	(2.0)	4	(2.6)	2	(1.3)	4	(2.6)
BLOOD AND RELATED PRODUCTS B05A	0		0		0		1	(0.7)
CALCIUM A12A	46	(30.9)	52	(33.5)	47	(29.9)	55	(36.4)
CAPILLARY STABILIZING AGENTS C05C	0		1	(0.6)	0		0	
CARDIAC GLYCOSIDES C01A	1	(0.7)	0		0		0	
CHEMOTHERAPEUTICS FOR TOPICAL USE D06B	0		0		1	(0.6)	0	
CHOLESTEROL AND TRIGLYCERIDE REDUCERS C10A	27	(18.1)	31	(20.0)	34	(21.7)	46	(30.5)
COMBINATIONS OF ANTIHYPERTENSIVES IN ATC-GR. C02	0		0		0		1	(0.7)
CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION S03C	0		0		1	(0.6)	0	
CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02A	2	(1.3)	2	(1.3)	3	(1.9)	2	(1.3)
CORTICOSTEROIDS, PLAIN D07A	1	(0.7)	1	(0.6)	3	(1.9)	1	(0.7)
· · · · · · · · · · · · · · · · · · ·	-	(/	_	(/	,	(/	_	, - •

Page

46

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: AFTER

ATC Classification [1]	Treatment Placebo n= 77
ASCORBIC ACID (VIT C), INCL COMBINATIONS A11G	9 (11.7)
BACTERIAL VACCINES J07A	0
BELLADONNA AND DERIVATIVES, PLAIN A03B	0
BETA BLOCKING AGENTS AND OTHER DIURETICS C07C	0
BETA BLOCKING AGENTS AND THIAZIDES C07B	2 (2.6)
BETA BLOCKING AGENTS, PLAIN CO7A	9 (11.7)
BETA-LACTAM ANTIBACTERIALS, PENICILLINS J01C	0
BLOOD AND RELATED PRODUCTS B05A	0
CALCIUM A12A	29 (37.7)
CAPILLARY STABILIZING AGENTS C05C	0
CARDIAC GLYCOSIDES C01A	0
CHEMOTHERAPEUTICS FOR TOPICAL USE D06B	0
CHOLESTEROL AND TRIGLYCERIDE REDUCERS C10A	15 (19.5)
COMBINATIONS OF ANTIHYPERTENSIVES IN ATC-GR. C02 C02N	0
CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION S03C	0
CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02A	2 (2.6)
CORTICOSTEROIDS, PLAIN D07A	0

Page

47

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT NMED4 ATC3 NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL

CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: AFTER

				TreaR 100 mg				
ATC Classification [1]		=149				=157		=151
COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS R05F	1	(0.7)	1	(0.6)	0		1	(0.7)
DECONGESTANTS AND ANTIALLERGICS S01G	0		0		1	(0.6)	1	(0.7)
DIET FORMULATIONS FOR TREATMENT OF OBESITY V06A	0		0		1	(0.6)	0	
DIGESTIVES, INCL ENZYMES A09A	0		1	(0.6)	3	(1.9)	0	
DIURETICS AND POTASSIUM-SPARING AGENTS IN COMB C03E	6	(4.0)	4	(2.6)	3	(1.9)	5	(3.3)
DOPAMINERGIC AGENTS NO4B	0		0		0		0	
DRUGS AFFECTING MINERALIZATION M05B	11	(7.4)	12	(7.7)	10	(6.4)	7	(4.6)
DRUGS FOR TREATMENT OF PEPTIC ULCER A02B	13	(8.7)	21	(13.5)	20	(12.7)	22	(14.6)
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY G04C	0		0		0		1	(0.7)
EMOLLIENTS AND PROTECTIVES D02A	0		0		1	(0.6)	0	
EXPECTORANTS, EXCL COMBINATIONS WITH ANTITUSSIVES R05C	3	(2.0)	4	(2.6)	1	(0.6)	6	(4.0)
HIGH-CEILING DIURETICS CO3C	2	(1.3)	0		3	(1.9)	0	
HORMONES AND RELATED AGENTS L02A	3	(2.0)	4	(2.6)	1	(0.6)	6	(4.0)
HYPNOTICS AND SEDATIVES N05C	4	(2.7)	3	(1.9)	6	(3.8)	2	(1.3)
I.V. SOLUTION ADDITIVES B05X	0		2	(1.3)	1	(0.6)	0	
I.V. SOLUTIONS B05B	1	(0.7)	0		0		0	
IMMUNOSUPPRESSIVE AGENTS L04A	0		0		1	(0.6)	2	(1.3)

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 48

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: AFTER

ATC Classification [1]	Pla	eatment acebo = 77
COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS R05F	0	
DECONGESTANTS AND ANTIALLERGICS S01G	0	
DIET FORMULATIONS FOR TREATMENT OF OBESITY V06A	0	
DIGESTIVES, INCL ENZYMES A09A	0	
DIURETICS AND POTASSIUM-SPARING AGENTS IN COMB C03E	4	(5.2)
DOPAMINERGIC AGENTS NO4B	1	(1.3)
DRUGS AFFECTING MINERALIZATION M05B	7	(9.1)
DRUGS FOR TREATMENT OF PEPTIC ULCER A02B	7	(9.1)
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY G04C	0	
EMOLLIENTS AND PROTECTIVES D02A	0	
EXPECTORANTS, EXCL COMBINATIONS WITH ANTITUSSIVES R05C	1	(1.3)
HIGH-CEILING DIURETICS C03C	0	
HORMONES AND RELATED AGENTS L02A	0	
HYPNOTICS AND SEDATIVES NO5C	1	(1.3)
I.V. SOLUTION ADDITIVES B05X	0	
I.V. SOLUTIONS B05B	0	
IMMUNOSUPPRESSIVE AGENTS L04A	2	(2.6)

Page

49

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT NMED4 ATC3 NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: AFTER

				Trea				
ATC Classification [1]		=149		R 100 mg =155		=157		=151
INSULINS A10A	1	(0.7)	0		1	(0.6)	0	
INTESTINAL ADSORBENTS A07B	0		2	(1.3)	2	(1.3)	4	(2.6)
INTESTINAL ANTIINFLAMMATORY AGENTS A07E	0		0		0		1	(0.7)
IRON PREPARATIONS B03A	3	(2.0)	3	(1.9)	1	(0.6)	1	(0.7)
IRRIGATING SOLUTIONS B05C	2	(1.3)	1	(0.6)	0		1	(0.7)
LAXATIVES A06A	13	(8.7)	15	(9.7)	10	(6.4)	15	(9.9)
LIVER THERAPY, LIPOTROPICS A05B	1	(0.7)	1	(0.6)	0		0	
LOW-CEILING DIURETICS, EXCL THIAZIDES CO3B	0		0		1	(0.6)	0	
LOW-CEILING DIURETICS, THIAZIDES CO3A	5	(3.4)	6	(3.9)	9	(5.7)	5	(3.3)
MACROLIDES AND LINCOSAMIDES J01F	1	(0.7)	5	(3.2)	1	(0.6)	2	(1.3)
MULTIVITAMINS, COMBINATIONS A11A	51	(34.2)	63	(40.6)	65	(41.4)	69	(45.7)
MULTIVITAMINS, PLAIN A11B	1	(0.7)	4	(2.6)	0		2	(1.3)
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS M03B	3	(2.0)	2	(1.3)	9	(5.7)	3	(2.0)
NASAL DECONGESTANTS FOR SYSTEMIC USE R01B	6	(4.0)	10	(6.5)	3	(1.9)	11	(7.3)
NASAL DECONGESTANTS FOR TOPICAL USE R01A	7	(4.7)	7	(4.5)	13	(8.3)	7	(4.6)
DPIOIDS NO2A	1	(0.7)	6	(3.9)	7	(4.5)	2	(1.3)
DRAL BLOOD GLUCOSE LOWERING DRUGS A10B	1	(0.7)	2	(1.3)	1	(0.6)	3	(2.0)
OTHER ANALGESICS AND ANTIPYRETICS NO2B	56	(37.6)	50	(32.3)	53	(33.8)	47	(31.1)

NOTE: [1] - Classification Totals Are Not Necessarily The Sum Of The Individual Non-Study Medications Since A Subject May Report Two or More Different Non-Study Medications In The Same Classification. ## - Anatomical-Therapeutic-Chemical Classification Could Not Be Found at the Requested Level.

Page

50

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: AFTER

ATC Classification [1]	Pla	eatment acebo = 77
INSULINS A10A	1	(1.3)
INTESTINAL ADSORBENTS A07B	1	(1.3)
INTESTINAL ANTIINFLAMMATORY AGENTS A07E	0	
IRON PREPARATIONS B03A	1	(1.3)
IRRIGATING SOLUTIONS B05C	0	
LAXATIVES A06A	2	(2.6)
LIVER THERAPY, LIPOTROPICS A05B	0	
LOW-CEILING DIURETICS, EXCL THIAZIDES C03B	0	
LOW-CEILING DIURETICS, THIAZIDES CO3A	4	(5.2)
MACROLIDES AND LINCOSAMIDES J01F	0	
MULTIVITAMINS, COMBINATIONS A11A	32	(41.6)
MULTIVITAMINS, PLAIN A11B	0	
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS M03B	3	(3.9)
NASAL DECONGESTANTS FOR SYSTEMIC USE R01B	7	(9.1)
NASAL DECONGESTANTS FOR TOPICAL USE R01A	2	(2.6)
OPIOIDS NO2A	3	(3.9)
ORAL BLOOD GLUCOSE LOWERING DRUGS A10B	2	(2.6)
OTHER ANALGESICS AND ANTIPYRETICS NO2B	29	(37.7)

Page 51

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT NMED4 ATC3 NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL

CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: AFTER

ATC Classification [1]	DVS S		DVS S	Trea R 100 mg =155	DVS S		DVS S	
OTHER ANTI-ASTHMATICS FOR SYSTEMIC USE R03D	2	(1.3)	2	(1.3)	3	(1.9)	6	(4.0)
OTHER ANTI-ASTHMATICS, INHALANTS R03B	0		0		0		1	(0.7)
OTHER ANTIBACTERIALS J01X	2	(1.3)	1	(0.6)	0		1	(0.7)
OTHER ANTIHYPERTENSIVES C02K	0		1	(0.6)	0		0	
OTHER BETA-LACTAM ANTIBACTERIALS J01D	2	(1.3)	1	(0.6)	1	(0.6)	2	(1.3)
OTHER CARDIAC PREPARATIONS C01E	1	(0.7)	3	(1.9)	0		1	(0.7)
OTHER COLD COMBINATION PREPARATIONS R05X	1	(0.7)	0		1	(0.6)	3	(2.0)
OTHER DRUGS FOR DISORD. OF MUSCULO-SKELETAL SYST. M05A	5	(3.4)	7	(4.5)	3	(1.9)	7	(4.6)
OTHER DRUGS FOR DISORDER OF THE MUSC-SKEL SYSTEM M09A	4	(2.7)	0		1	(0.6)	7	(4.6)
OTHER GYNAECOLOGICALS G02C	3	(2.0)	2	(1.3)	1	(0.6)	0	
OTHER MINERAL SUPPLEMENTS A12C	5	(3.4)	8	(5.2)	6	(3.8)	12	(7.9)
OTHER NUTRIENTS V06D	6	(4.0)	4	(2.6)	2	(1.3)	3	(2.0)
OTHER OPHTHALMOLOGICALS S01X	0		1	(0.6)	0		0	
OTHER PLAIN VITAMIN PREPARATIONS A11H	26	(17.4)	35	(22.6)	29	(18.5)	40	(26.5)
OTHER SEX HORM. & MODULATORS OF THE GENITAL SYSTEM G03X	1	(0.7)	0		0		1	(0.7)
OTHER UROLOGICALS, INCL ANTISPASMODICS G04B	0		5	(3.2)	0		1	(0.7)
OTHER VITAMIN PRODUCTS, COMBINATIONS A11J	7	(4.7)	4	(2.6)	6	(3.8)	8	(5.3)

Page 52

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: AFTER

 ATC Classification [1]	Treatment Placebo n= 77
OTHER ANTI-ASTHMATICS FOR SYSTEMIC USE R03D	2 (2.6)
OTHER ANTI-ASTHMATICS, INHALANTS R03B	0
OTHER ANTIBACTERIALS J01X	0
OTHER ANTIHYPERTENSIVES C02K	0
OTHER BETA-LACTAM ANTIBACTERIALS J01D	0
OTHER CARDIAC PREPARATIONS C01E	0
OTHER COLD COMBINATION PREPARATIONS R05X	1 (1.3)
OTHER DRUGS FOR DISORD. OF MUSCULO-SKELETAL SYST. M05A	2 (2.6)
OTHER DRUGS FOR DISORDER OF THE MUSC-SKEL SYSTEM M09A	1 (1.3)
OTHER GYNAECOLOGICALS G02C	0
OTHER MINERAL SUPPLEMENTS A12C	2 (2.6)
OTHER NUTRIENTS V06D	1 (1.3)
OTHER OPHTHALMOLOGICALS S01X	2 (2.6)
OTHER PLAIN VITAMIN PREPARATIONS A11H	9 (11.7)
OTHER SEX HORM. & MODULATORS OF THE GENITAL SYSTEM G03X	0
OTHER UROLOGICALS, INCL ANTISPASMODICS G04B	0
OTHER VITAMIN PRODUCTS, COMBINATIONS AllJ	4 (5.2)

CLASSIFICATION: THERAPEUTIC SUBGROUP

Page 53

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT NMED4 ATC3 NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL

Time Period: AFTER

ATC Classification [1]	DVS SI	R 50 mg =149	DVS S	Trea [.] R 100 mg =155	DVS S	R 150 mg =157	DVS S	 R 200 mg =151
PERIPHERAL VASODILATORS C04A	2	(1.3)	0		3	(1.9)	2	(1.3)
POTASSIUM A12B	3	(2.0)	3	(1.9)	5	(3.2)	2	(1.3)
POTASSIUM-SPARING AGENTS C03D	1	(0.7)	1	(0.6)	1	(0.6)	0	
PROGESTOGENS AND ESTROGENS IN COMBINATION G03F	0		3	(1.9)	1	(0.6)	2	(1.3)
PROGESTOGENS G03D	1	(0.7)	2	(1.3)	2	(1.3)	0	
PROPULSIVES A03F	1	(0.7)	0		4	(2.5)	0	
PSYCHOSTIMULANTS N06B	0		1	(0.6)	0		0	
QUINOLONE ANTIBACTERIALS J01M	2	(1.3)	1	(0.6)	3	(1.9)	1	(0.7)
RENIN-ANGIOTENSIN SYSTEM, AGENTS ACTING ON CO2E	5	(3.4)	8	(5.2)	13	(8.3)	9	(6.0)
SELECT CA CHANNEL BLOCKER W/ MAINLY VASC EFFECT C08C	0		1	(0.6)	0		0	
STOMATOLOGICALS, MOUTH PREPARATIONS A01A	0		1	(0.6)	0		0	
SULFONAMIDES AND TRIMETHOPRIM J01E	0		0		1	(0.6)	0	
SYNTHETICS, INCL PAPAVERINE A03A	0		2	(1.3)	0		1	(0.7)
TETRACYCLINES J01A	0		1	(0.6)	1	(0.6)	2	(1.3)
THROAT PREPARATIONS R02A	0		0		1	(0.6)	0	
THYROID PREPARATIONS H03A	17	(11.4)	20	(12.9)	19	(12.1)	21	(13.9)
TONICS A13A	0		0		1	(0.6)	0	
URINARY ANTISEPTICS AND ANTIINFECTIVES G04A	1	(0.7)	2	(1.3)	2	(1.3)	1	(0.7)

NOTE: [1] - Classification Totals Are Not Necessarily The Sum Of The Individual Non-Study Medications Since A Subject May Report Two or More Different Non-Study Medications In The Same Classification. ## - Anatomical-Therapeutic-Chemical Classification Could Not Be Found at the Requested Level.

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 54

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: AFTER

ATC Classification [1]	Pl	eatment acebo = 77	
PERIPHERAL VASODILATORS C04A	1	(1.3)	
POTASSIUM A12B	2	(2.6)	
POTASSIUM-SPARING AGENTS C03D	0		
PROGESTOGENS AND ESTROGENS IN COMBINATION G03F	0		
PROGESTOGENS G03D	0		
PROPULSIVES A03F	1	(1.3)	
PSYCHOSTIMULANTS N06B	0		
QUINOLONE ANTIBACTERIALS J01M	1	(1.3)	
RENIN-ANGIOTENSIN SYSTEM, AGENTS ACTING ON CO2E	7	(9.1)	
SELECT CA CHANNEL BLOCKER W/ MAINLY VASC EFFECT C08C	0		
STOMATOLOGICALS, MOUTH PREPARATIONS A01A	0		
SULFONAMIDES AND TRIMETHOPRIM J01E	0		
SYNTHETICS, INCL PAPAVERINE A03A	1	(1.3)	
TETRACYCLINES J01A	1	(1.3)	
THROAT PREPARATIONS R02A	0		
THYROID PREPARATIONS H03A	11	(14.3)	
TONICS A13A	0		
URINARY ANTISEPTICS AND ANTIINFECTIVES GO4A	0		

Page 55

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: AFTER

ATC Classification [1]	DVS SR n=	DVS SR 100 mg n=155				DVS SI	 R 200 mg =151	
VASODILATORS USED IN CARDIAC DISEASES CO1D	0		1	(0.6)	3	(1.9)	0	
VIT A AND D, INCL COMBINATIONS OF THE TWO A11C	0		5	(3.2)	4	(2.5)	4	(2.6)
VIT B1, PLAIN AND IN COMB WITH VITAMIN B6 AND B12 A11D	1	(0.7)	0		0		0	
VITAMIN B-COMPLEX, INCL COMBINATIONS AllE	7	(4.7)	4	(2.6)	6	(3.8)	5	(3.3)
VITAMIN B12 AND FOLIC ACID B03B	5	(3.4)	4	(2.6)	7	(4.5)	10	(6.6)
VITAMIN K AND OTHER HAEMOSTATICS B02B	0		1	(0.6)	0		0	

CONFIDENTIAL Wyeth 257

NOTE: [1] - Classification Totals Are Not Necessarily The Sum Of The Individual Non-Study Medications Since A Subject May Report Two or More Different Non-Study Medications In The Same Classification. ## - Anatomical-Therapeutic-Chemical Classification Could Not Be Found at the Requested Level.

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 56

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: AFTER

ATC Classification [1]	Treatment Placebo n= 77
VASODILATORS USED IN CARDIAC DISEASES C01D	0
VIT A AND D, INCL COMBINATIONS OF THE TWO A11C	0
VIT B1, PLAIN AND IN COMB WITH VITAMIN B6 AND B12 A11D	0
VITAMIN B-COMPLEX, INCL COMBINATIONS A11E	3 (3.9)
VITAMIN B12 AND FOLIC ACID B03B	4 (5.2)
VITAMIN K AND OTHER HAEMOSTATICS B02B	0

NOTE: [1] - Classification Totals Are Not Necessarily The Sum Of The Individual Non-Study Medications Since A Subject May Report
Two or More Different Non-Study Medications In The Same Classification.
- Anatomical-Therapeutic-Chemical Classification Could Not Be Found at the Requested Level.

Page 57

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT NMED4 ATC3

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT BUT NOT PRIOR

				Trea	tment		450		
ATC Classification [1]	DVS S		DVS S		DVS S	7S SR 150 mg I n=157			
ANY NON-STUDY MEDICATION	120	(80.5)	112	(72.3)	109	(69.4)	96	(63.6)	
## ALL OTHER THERAPEUTIC PRODUCTS V03 - ATC 2	1	(0.7)	1	(0.6)	2	(1.3)	0		
## ANAESTHETICS NO1 - ATC 2	1	(0.7)	0		1	(0.6)	0		
## ANALGESICS NO2 - ATC 2	0		0		0		0		
## ANTACIDS, DRUGS FOR TREATM.OF PEPT.ULC.AND ANTIFL. A02 - ATC 2	1	(0.7)	1	(0.6)	0		0		
## ANTIBACTERIALS FOR SYSTEMIC USE J01 - ATC 2	1	(0.7)	0		1	(0.6)	0		
## ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS M01 - ATC 2	1	(0.7)	0		0		0		
## BILE AND LIVER THERAPY A05 - ATC 2	0		1	(0.6)	0		0		
## COUGH AND COLD PREPARATIONS R05 - ATC 2	3	(2.0)	0		0		1	(0.7)	
## MINERAL SUPPLEMENTS A12 - ATC 2	0		0		0		0		
## NASAL PREPARATIONS R01 - ATC 2	1	(0.7)	0		0		0		
## THROAT PREPARATIONS R02 - ATC 2	0		0		2	(1.3)	0		
ACE INHIBITORS, COMBINATIONS C09B	1	(0.7)	1	(0.6)	0		0		
ADRENERGICS, INHALANTS R03A	3	(2.0)	3	(1.9)	5	(3.2)	1	(0.7)	
AGENTS AFFECTING THE VIRUS DIRECTLY J05A	3	(2.0)	5	(3.2)	2	(1.3)	4	(2.6)	
ALL OTHER NON-THERAPEUTIC PRODUCTS V07A	0		0		0		1	(0.7)	
ALL OTHER THERAPEUTIC PRODUCTS V03A	7	(4.7)	3	(1.9)	5	(3.2)	6	(4.0)	

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 58

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT BUT NOT PRIOR

ATC Classification [1]	Pl	eatment acebo = 77
ANY NON-STUDY MEDICATION	62	(80.5)
## ALL OTHER THERAPEUTIC PRODUCTS V03 - ATC 2	0	
## ANAESTHETICS NO1 - ATC 2	1	(1.3)
## ANALGESICS NO2 - ATC 2	1	(1.3)
## ANTACIDS, DRUGS FOR TREATM.OF PEPT.ULC.AND ANTIFL. A02 - ATC 2	0	
## ANTIBACTERIALS FOR SYSTEMIC USE J01 - ATC 2	0	
## ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS M01 - ATC 2	0	
## BILE AND LIVER THERAPY A05 - ATC 2	0	
## COUGH AND COLD PREPARATIONS R05 - ATC 2	1	(1.3)
## MINERAL SUPPLEMENTS A12 - ATC 2	1	(1.3)
## NASAL PREPARATIONS R01 - ATC 2	1	(1.3)
## THROAT PREPARATIONS R02 - ATC 2	0	
ACE INHIBITORS, COMBINATIONS C09B	0	
ADRENERGICS, INHALANTS R03A	2	(2.6)
AGENTS AFFECTING THE VIRUS DIRECTLY J05A	0	
ALL OTHER NON-THERAPEUTIC PRODUCTS V07A	0	
ALL OTHER THERAPEUTIC PRODUCTS V03A	6	(7.8)

Page 59

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT NMED4 ATC3

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL

CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT BUT NOT PRIOR

				Trea	tment.								
C Classification [1] DVS SR 50 mg DVS n=149								DVS SR 100 mg				DVS SR 200 mg	
AMINOGLYCOSIDE ANTIBACTERIALS J01G	0		0		0		1	(0.7)					
ANAESTHETICS, GENERAL N01A	3	(2.0)	1	(0.6)	3	(1.9)	1	(0.7)					
ANGIOTENSIN II ANTAGONISTS, COMBINATIONS C09D	0		0		2	(1.3)	1	(0.7)					
ANGIOTENSIN II ANTAGONISTS, PLAIN C09C	1	(0.7)	1	(0.6)	0		0						
ANTACIDS A02A	10	(6.7)	5	(3.2)	8	(5.1)	7	(4.6)					
ANTI-ACNE PREPARATIONS FOR TOPICAL USE D10A	0		0		0		1	(0.7)					
ANTIADRENERGIC AGENTS, CENTRALLY ACTING CO2A	0		0		1	(0.6)	0						
ANTIBIOTICS FOR TOPICAL USE D06A	1	(0.7)	0		0		1	(0.7)					
ANTIDEPRESSANTS NO6A	6	(4.0)	1	(0.6)	2	(1.3)	1	(0.7)					
ANTIEMETICS AND ANTINAUSEANTS A04A	2	(1.3)	1	(0.6)	1	(0.6)	1	(0.7)					
ANTIEPILEPTICS NO3A	1	(0.7)	1	(0.6)	1	(0.6)	0						
ANTIFLATULENTS A02D	2	(1.3)	2	(1.3)	0		1	(0.7)					
ANTIFUNGALS FOR TOPICAL USE D01A	2	(1.3)	5	(3.2)	1	(0.6)	0						
ANTIGLAUCOMA PREPARATIONS AND MIOTICS S01E	1	(0.7)	1	(0.6)	0		0						
ANTIHAEMORRHOIDALS FOR TOPICAL USE C05A	1	(0.7)	0		2	(1.3)	1	(0.7)					
ANTIHISTAMINES FOR SYSTEMIC USE R06A	29	(19.5)	33	(21.3)	21	(13.4)	20	(13.2)					
ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION CO2L	0		0		1	(0.6)	0						
ANTIINFECTIVES S01A	0		1	(0.6)	1	(0.6)	0						

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL

Page

60

CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT BUT NOT PRIOR

ATC Classification [1]	Pl	eatment acebo = 77
AMINOGLYCOSIDE ANTIBACTERIALS J01G	0	
ANAESTHETICS, GENERAL N01A	0	
ANGIOTENSIN II ANTAGONISTS, COMBINATIONS C09D	0	
ANGIOTENSIN II ANTAGONISTS, PLAIN C09C	0	
ANTACIDS A02A	3	(3.9)
ANTI-ACNE PREPARATIONS FOR TOPICAL USE D10A	0	
ANTIADRENERGIC AGENTS, CENTRALLY ACTING C02A	0	
ANTIBIOTICS FOR TOPICAL USE D06A	1	(1.3)
ANTIDEPRESSANTS NO6A	1	(1.3)
ANTIEMETICS AND ANTINAUSEANTS A04A	0	
ANTIEPILEPTICS NO3A	0	
ANTIFLATULENTS A02D	0	
ANTIFUNGALS FOR TOPICAL USE D01A	1	(1.3)
ANTIGLAUCOMA PREPARATIONS AND MIOTICS S01E	0	
ANTIHAEMORRHOIDALS FOR TOPICAL USE C05A	0	
ANTIHISTAMINES FOR SYSTEMIC USE R06A	16	(20.8)
ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION CO2L	0	
ANTIINFECTIVES S01A	0	

Page

61

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT NMED4 ATC3

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL

CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT BUT NOT PRIOR

				Trea	tment.	nt		
ATC Classification [1]			DVS S			R 150 mg =157		SR 200 mg n=151
ANTIINFECTIVES S03A	1	(0.7)	0		0		0	
ANTIINFECTIVES/ANTISEPT., EXCL COMB WITH CORTICOST. G01A	0		0		0		1	(0.7)
ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMB S01C	1	(0.7)	0		0		0	
ANTIINFLAMMATORY AGENTS S01B	1	(0.7)	0		0		0	
ANTIINFLAMMATORY/ANTIRHEUMATIC PROD., NON-STEROIDS M01A	64	(43.0)	58	(37.4)	43	(27.4)	48	(31.8)
ANTIMALARIALS P01B	1	(0.7)	0		0		1	(0.7)
ANTIMETABOLITES L01B	0		1	(0.6)	0		0	
ANTIMIGRAINE PREPARATIONS NO2C	2	(1.3)	1	(0.6)	1	(0.6)	2	(1.3)
ANTIMYCOTICS FOR SYSTEMIC USE, EXCL GRISEOFULVIN J02A	1	(0.7)	0		0		0	
ANTIOBESITY PREPARATIONS, EXCL DIET PRODUCTS A08A	0		0		0		1	(0.7)
ANTIPROPULSIVES A07D	3	(2.0)	0		1	(0.6)	4	(2.6)
ANTIPRURITICS, INCL ANTIHIST, ANAESTHET, ETC. D04A	0		1	(0.6)	7	(4.5)	5	(3.3)
ANTISEPTICS AND DISINFECTANTS D08A	1	(0.7)	1	(0.6)	0		1	(0.7)
ANTITHROMBOTIC AGENTS B01A	2	(1.3)	0		1	(0.6)	1	(0.7)
ANTITUSSIVES, EXCL COMBINATIONS WITH EXPECTORANTS R05D	14	(9.4)	12	(7.7)	5	(3.2)	6	(4.0)
ANXIOLYTICS N05B	4	(2.7)	3	(1.9)	9	(5.7)	2	(1.3)

Page

62

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT BUT NOT PRIOR

ATC Classification [1]	Pl	reatment acebo = 77
ANTIINFECTIVES S03A	0	
ANTIINFECTIVES/ANTISEPT., EXCL COMB WITH CORTICOST. G01A	1	(1.3)
ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMB S01C	0	
ANTIINFLAMMATORY AGENTS S01B	0	
ANTIINFLAMMATORY/ANTIRHEUMATIC PROD., NON-STEROIDS M01A	29	(37.7)
ANTIMALARIALS P01B	0	
ANTIMETABOLITES L01B	0	
ANTIMIGRAINE PREPARATIONS NO2C	2	(2.6)
ANTIMYCOTICS FOR SYSTEMIC USE, EXCL GRISEOFULVIN J02A	0	
ANTIOBESITY PREPARATIONS, EXCL DIET PRODUCTS A08A	0	
ANTIPROPULSIVES A07D	1	(1.3)
ANTIPRURITICS, INCL ANTIHIST, ANAESTHET, ETC. D04A	1	(1.3)
ANTISEPTICS AND DISINFECTANTS D08A	1	(1.3)
ANTITHROMBOTIC AGENTS B01A	0	
ANTITUSSIVES, EXCL COMBINATIONS WITH EXPECTORANTS R05D	7	(9.1)
ANXIOLYTICS N05B	3	(3.9)

Page

63

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT NMED4 ATC3

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL

CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT BUT NOT PRIOR

	Treatment							
ATC Classification [1]			DVS SR 100 mg		DVS SR 150 mg		DVS S	
ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON CO2D	0		0		2	(1.3)	3	(2.0)
ASCORBIC ACID (VIT C), INCL COMBINATIONS A11G	2	(1.3)	2	(1.3)	2	(1.3)	4	(2.6)
BACTERIAL VACCINES J07A	3	(2.0)	0		1	(0.6)	1	(0.7)
BELLADONNA AND DERIVATIVES, PLAIN A03B	0		0		0		1	(0.7)
BETA BLOCKING AGENTS AND OTHER DIURETICS CO7C	0		1	(0.6)	0		0	
BETA BLOCKING AGENTS, PLAIN CO7A	3	(2.0)	2	(1.3)	3	(1.9)	3	(2.0)
BETA-LACTAM ANTIBACTERIALS, PENICILLINS J01C	15	(10.1)	9	(5.8)	10	(6.4)	12	(7.9)
CALCIUM A12A	0		4	(2.6)	2	(1.3)	1	(0.7)
CARDIAC GLYCOSIDES C01A	1	(0.7)	0		0		0	
CARDIOVASCULAR SYSTEM V09G	0		0		1	(0.6)	0	
CHOLESTEROL AND TRIGLYCERIDE REDUCERS C10A	12	(8.1)	25	(16.1)	13	(8.3)	29	(19.2)
COMBINATIONS OF ANTIHYPERTENSIVES IN ATC-GR. C02 C02N	0		0		0		1	(0.7)
CONTRAST MEDIA V04A	0		0		1	(0.6)	0	
CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION SO2C	0		0		1	(0.6)	0	
CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN H02A	7	(4.7)	11	(7.1)	13	(8.3)	7	(4.6)
CORTICOSTEROIDS, COMB WITH ANTIBIOTICS D07C	2	(1.3)	0		0		0	
CORTICOSTEROIDS, PLAIN D07A	6	(4.0)	1	(0.6)	6	(3.8)	6	(4.0)

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 64

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT BUT NOT PRIOR

ATC Classification [1]	Treatment Placebo n= 77
ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON	ON C02D 0
ASCORBIC ACID (VIT C), INCL COMBINATIONS A	A11G 4 (5.2)
BACTERIAL VACCINES J07A	1 (1.3)
BELLADONNA AND DERIVATIVES, PLAIN A03B	0
BETA BLOCKING AGENTS AND OTHER DIURETICS (C07C 0
BETA BLOCKING AGENTS, PLAIN C07A	2 (2.6)
BETA-LACTAM ANTIBACTERIALS, PENICILLINS JO	TO1C 4 (5.2)
CALCIUM A12A	4 (5.2)
CARDIAC GLYCOSIDES C01A	0
CARDIOVASCULAR SYSTEM V09G	0
CHOLESTEROL AND TRIGLYCERIDE REDUCERS C107	A 8 (10.4)
COMBINATIONS OF ANTIHYPERTENSIVES IN ATC-CC2N	GR. C02 0
CONTRAST MEDIA VO4A	0
CORTICOSTEROIDS AND ANTIINFECTIVES IN COME S02C	BINATION 1 (1.3)
CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN HO	7 (9.1)
CORTICOSTEROIDS, COMB WITH ANTIBIOTICS DOT	7c 0
CORTICOSTEROIDS, PLAIN D07A	0

Page

65

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT NMED4 ATC3

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL

CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT BUT NOT PRIOR

ATC Classification [1]	DVS SR 50 mg n=149		Treat DVS SR 100 mg n=155		tment DVS SR 150 mg n=157		DVS SE	200 mg 151	
COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS R05F	5	(3.4)	5	(3.2)	3	(1.9)	1	(0.7)	
DECONGESTANTS AND ANTIALLERGICS S01G	1	(0.7)	0		0		0		
DIAGNOSTIC RADIOPHARMACEUTICALS V04D	0		0		1	(0.6)	0		
DIGESTIVES, INCL ENZYMES A09A	1	(0.7)	2	(1.3)	2	(1.3)	0		
DIURETICS AND POTASSIUM-SPARING AGENTS IN COMB C03E	1	(0.7)	0		1	(0.6)	2	(1.3)	
DOPAMINERGIC AGENTS NO 4B	0		1	(0.6)	0		0		
DRUGS AFFECTING MINERALIZATION M05B	1	(0.7)	3	(1.9)	1	(0.6)	1	(0.7)	
DRUGS FOR TREATMENT OF PEPTIC ULCER A02B	16	(10.7)	15	(9.7)	8	(5.1)	7	(4.6)	
EMOLLIENTS AND PROTECTIVES D02A	0		1	(0.6)	0		1	(0.7)	
ESTROGENS G03C	0		1	(0.6)	0		0		
EXPECTORANTS, EXCL COMBINATIONS WITH ANTITUSSIVES R05C	6	(4.0)	7	(4.5)	1	(0.6)	9	(6.0)	
GLYCOGENOLYTIC HORMONES H04A	1	(0.7)	0		0		0		
HIGH-CEILING DIURETICS CO3C	3	(2.0)	0		1	(0.6)	0		
HORMONE ANTAGONISTS AND RELATED AGENTS L02B	0		0		1	(0.6)	0		
HORMONES AND RELATED AGENTS L02A	0		1	(0.6)	0		0		
HYPNOTICS AND SEDATIVES NO5C	10	(6.7)	5	(3.2)	9	(5.7)	5	(3.3)	
I.V. SOLUTION ADDITIVES B05X	0		1	(0.6)	2	(1.3)	1	(0.7)	

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL

Page

66

CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT BUT NOT PRIOR

ATC Classification [1]	Treatment Placebo n= 77
COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS R05F	4 (5.2)
DECONGESTANTS AND ANTIALLERGICS S01G	1 (1.3)
DIAGNOSTIC RADIOPHARMACEUTICALS V04D	0
DIGESTIVES, INCL ENZYMES A09A	0
DIURETICS AND POTASSIUM-SPARING AGENTS IN COMB C03E	1 (1.3)
DOPAMINERGIC AGENTS NO 4B	1 (1.3)
DRUGS AFFECTING MINERALIZATION M05B	2 (2.6)
DRUGS FOR TREATMENT OF PEPTIC ULCER A02B	3 (3.9)
EMOLLIENTS AND PROTECTIVES D02A	0
ESTROGENS G03C	0
EXPECTORANTS, EXCL COMBINATIONS WITH ANTITUSSIVES R05C	6 (7.8)
GLYCOGENOLYTIC HORMONES H04A	0
HIGH-CEILING DIURETICS C03C	0
HORMONE ANTAGONISTS AND RELATED AGENTS L02B	0
HORMONES AND RELATED AGENTS L02A	0
HYPNOTICS AND SEDATIVES NO5C	4 (5.2)
I.V. SOLUTION ADDITIVES B05X	0

NOTE: [1] - Classification Totals Are Not Necessarily The Sum Of The Individual Non-Study Medications Since A Subject May Report Two or More Different Non-Study Medications In The Same Classification. ## - Anatomical-Therapeutic-Chemical Classification Could Not Be Found at the Requested Level.

Page

67

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT NMED4 ATC3

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL

CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT BUT NOT PRIOR

	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg							
Classification [1]		R 50 mg =149	DVS S	R 100 mg =155	DVS SI	R 150 mg	DVS S	R 200 m =151
I.V. SOLUTIONS B05B	0		1	(0.6)	0		0	
INSULINS A10A	0		0		0		0	
INTESTINAL ADSORBENTS A07B	2	(1.3)	3	(1.9)	7	(4.5)	2	(1.3)
INTESTINAL ANTIINFECTIVES A07A	0		0		0		1	(0.7)
IRON PREPARATIONS B03A	0		2	(1.3)	1	(0.6)	0	
IRRIGATING SOLUTIONS B05C	1	(0.7)	0		1	(0.6)	0	
LAXATIVES A06A	12	(8.1)	18	(11.6)	10	(6.4)	13	(8.6)
LOCAL ANAESTHETICS N01B	0		0		2	(1.3)	1	(0.7)
LOCAL ANAESTHETICS S01H	0		0		2	(1.3)	0	
LOW-CEILING DIURETICS, EXCL THIAZIDES C03B	0		1	(0.6)	0		0	
LOW-CEILING DIURETICS, THIAZIDES C03A	3	(2.0)	3	(1.9)	3	(1.9)	3	(2.0)
MACROLIDES AND LINCOSAMIDES J01F	10	(6.7)	14	(9.0)	12	(7.6)	9	(6.0)
MULTIVITAMINS, COMBINATIONS A11A	2	(1.3)	9	(5.8)	5	(3.2)	2	(1.3)
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS M03B	7	(4.7)	7	(4.5)	5	(3.2)	6	(4.0)
MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS M03A	1	(0.7)	0		0		0	
MYDRIATICS AND CYCLOPLEGICS S01F	1	(0.7)	0		1	(0.6)	0	
NASAL DECONGESTANTS FOR SYSTEMIC USE R01B	12	(8.1)	15	(9.7)	9	(5.7)	13	(8.6)
NASAL DECONGESTANTS FOR TOPICAL USE R01A	6	(4.0)	4	(2.6)	4	(2.5)	5	(3.3)

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL

Page

68

CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT BUT NOT PRIOR

ATC Classification [1]	Pl	eatment acebo = 77
I.V. SOLUTIONS B05B	0	
INSULINS A10A	1	(1.3)
INTESTINAL ADSORBENTS A07B	1	(1.3)
INTESTINAL ANTIINFECTIVES A07A	0	
IRON PREPARATIONS B03A	0	
IRRIGATING SOLUTIONS B05C	0	
LAXATIVES A06A	2	(2.6)
LOCAL ANAESTHETICS N01B	2	(2.6)
LOCAL ANAESTHETICS S01H	0	
LOW-CEILING DIURETICS, EXCL THIAZIDES C03B	0	
LOW-CEILING DIURETICS, THIAZIDES C03A	0	
MACROLIDES AND LINCOSAMIDES J01F	7	(9.1)
MULTIVITAMINS, COMBINATIONS A11A	1	(1.3)
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS M03B	2	(2.6)
MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS M03A	0	
MYDRIATICS AND CYCLOPLEGICS S01F	0	
NASAL DECONGESTANTS FOR SYSTEMIC USE R01B	10	(13.0)
NASAL DECONGESTANTS FOR TOPICAL USE R01A	3	(3.9)

Page

69

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT NMED4 ATC3

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT BUT NOT PRIOR

	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg								
ATC Classification [1]		DVS SR 50 mg 1 n=149				DVS SR 150 mg n=157		R 200 mg =151	
OPIOIDS N02A	12	(8.1)	7	(4.5)	12	(7.6)	9	(6.0)	
ORAL BLOOD GLUCOSE LOWERING DRUGS A10B	0		1	(0.6)	1	(0.6)	1	(0.7)	
OTHER ANALGESICS AND ANTIPYRETICS NO2B	61	(40.9)	59	(38.1)	61	(38.9)	41	(27.2)	
OTHER ANTI-ASTHMATICS FOR SYSTEMIC USE R03D	1	(0.7)	1	(0.6)	0		0		
OTHER ANTIBACTERIALS J01X	4	(2.7)	0		0		0		
OTHER BETA-LACTAM ANTIBACTERIALS J01D	7	(4.7)	7	(4.5)	2	(1.3)	4	(2.6)	
OTHER CARDIAC PREPARATIONS C01E	0		1	(0.6)	0		0		
OTHER COLD COMBINATION PREPARATIONS R05X	5	(3.4)	6	(3.9)	9	(5.7)	5	(3.3)	
OTHER DRUGS FOR DISORD. OF MUSCULO-SKELETAL SYST. M05A	0		0		0		1	(0.7)	
OTHER DRUGS FOR DISORDER OF THE MUSC-SKEL SYSTEM M09A	0		0		1	(0.6)	1	(0.7)	
OTHER MINERAL SUPPLEMENTS A12C	1	(0.7)	3	(1.9)	4	(2.5)	3	(2.0)	
OTHER NUTRIENTS V06D	2	(1.3)	1	(0.6)	1	(0.6)	0		
OTHER OPHTHALMOLOGICALS S01X	1	(0.7)	1	(0.6)	0		0		
OTHER PLAIN VITAMIN PREPARATIONS A11H	1	(0.7)	2	(1.3)	4	(2.5)	6	(4.0)	
OTHER RESPIRATORY SYSTEM PRODUCTS R07A	0		0		1	(0.6)	1	(0.7)	
OTHER UROLOGICALS, INCL ANTISPASMODICS G04B	1	(0.7)	3	(1.9)	0		0		
OTHER VITAMIN PRODUCTS, COMBINATIONS A11J	3	(2.0)	0		2	(1.3)	2	(1.3)	

Page

70

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT BUT NOT PRIOR

ATC Classification [1]	Treatment Placebo n= 77	
OPIOIDS NO2A	8 (10.4)	
ORAL BLOOD GLUCOSE LOWERING DRUGS A10B	0	
OTHER ANALGESICS AND ANTIPYRETICS NO2B	39 (50.6)	
OTHER ANTI-ASTHMATICS FOR SYSTEMIC USE R03D	0	
OTHER ANTIBACTERIALS J01X	0	
OTHER BETA-LACTAM ANTIBACTERIALS J01D	6 (7.8)	
OTHER CARDIAC PREPARATIONS C01E	0	
OTHER COLD COMBINATION PREPARATIONS R05X	4 (5.2)	
OTHER DRUGS FOR DISORD. OF MUSCULO-SKELETAL SYST. M05A	1 (1.3)	
OTHER DRUGS FOR DISORDER OF THE MUSC-SKEL SYSTEM M09A	1 (1.3)	
OTHER MINERAL SUPPLEMENTS A12C	3 (3.9)	
OTHER NUTRIENTS V06D	1 (1.3)	
OTHER OPHTHALMOLOGICALS S01X	1 (1.3)	
OTHER PLAIN VITAMIN PREPARATIONS A11H	4 (5.2)	
OTHER RESPIRATORY SYSTEM PRODUCTS R07A	0	
OTHER UROLOGICALS, INCL ANTISPASMODICS G04B	0	
OTHER VITAMIN PRODUCTS, COMBINATIONS A11J	3 (3.9)	

Page 71

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT NMED4 ATC3

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT BUT NOT PRIOR

ATC Classification [1]	DVS SI	R 50 mg =149	DVS SI	R 100 mg =155	DVS SI	R 150 mg =157	DVS SE	R 200 mg =151	
PERIPHERAL VASODILATORS C04A	0		0		0		1	(0.7)	
POTASSIUM A12B	1	(0.7)	1	(0.6)	0		0		
POTASSIUM-SPARING AGENTS C03D	1	(0.7)	2	(1.3)	0		0		
PROPULSIVES A03F	2	(1.3)	0		1	(0.6)	0		
PSYCHOSTIMULANTS N06B	0		0		0		0		
QUINOLONE ANTIBACTERIALS J01M	6	(4.0)	10	(6.5)	8	(5.1)	4	(2.6)	
RENIN-ANGIOTENSIN SYSTEM, AGENTS ACTING ON C02E	0		4	(2.6)	3	(1.9)	3	(2.0)	
SELECT CA CHANNEL BLOCKER W/ MAINLY VASC EFFECT C08C	0		1	(0.6)	0		0		
SULFONAMIDES AND TRIMETHOPRIM J01E	4	(2.7)	3	(1.9)	2	(1.3)	0		
SYNTHETICS, INCL PAPAVERINE A03A	1	(0.7)	2	(1.3)	2	(1.3)	0		
TETRACYCLINES J01A	1	(0.7)	3	(1.9)	0		1	(0.7)	
THROAT PREPARATIONS R02A	1	(0.7)	0		1	(0.6)	0		
THYROID PREPARATIONS H03A	3	(2.0)	5	(3.2)	1	(0.6)	1	(0.7)	
URINARY ANTISEPTICS AND ANTIINFECTIVES G04A	1	(0.7)	3	(1.9)	3	(1.9)	1	(0.7)	
VASODILATORS USED IN CARDIAC DISEASES CO1D	0		1	(0.6)	3	(1.9)	2	(1.3)	
VIRAL VACCINES J07B	1	(0.7)	1	(0.6)	1	(0.6)	1	(0.7)	
VIT A AND D, INCL COMBINATIONS OF THE TWO A11C	0		2	(1.3)	1	(0.6)	1	(0.7)	

NOTE: [1] - Classification Totals Are Not Necessarily The Sum Of The Individual Non-Study Medications Since A Subject May Report Two or More Different Non-Study Medications In The Same Classification. ## - Anatomical-Therapeutic-Chemical Classification Could Not Be Found at the Requested Level.

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 72

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT BUT NOT PRIOR

ATC Classification [1]	Treatment Placebo n= 77
PERIPHERAL VASODILATORS C04A	0
POTASSIUM A12B	0
POTASSIUM-SPARING AGENTS CO3D	0
PROPULSIVES A03F	0
PSYCHOSTIMULANTS N06B	1 (1.3)
QUINOLONE ANTIBACTERIALS J01M	4 (5.2)
RENIN-ANGIOTENSIN SYSTEM, AGENTS ACTING ON C02E	0
SELECT CA CHANNEL BLOCKER W/ MAINLY VASC EFFECT C08C	0
SULFONAMIDES AND TRIMETHOPRIM J01E	1 (1.3)
SYNTHETICS, INCL PAPAVERINE A03A	0
TETRACYCLINES J01A	1 (1.3)
THROAT PREPARATIONS R02A	0
THYROID PREPARATIONS H03A	2 (2.6)
URINARY ANTISEPTICS AND ANTIINFECTIVES G04A	1 (1.3)
VASODILATORS USED IN CARDIAC DISEASES CO1D	0
VIRAL VACCINES J07B	1 (1.3)
VIT A AND D, INCL COMBINATIONS OF THE TWO A11C	0

Page 73

190CT05 16:35 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT NMED4 ATC3

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL

CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT BUT NOT PRIOR

ATC Classification [1]	DVS SR	50 mg	Trea g DVS SR 100 mg n=155		DVS SR 150 mg		DVS SR 200 m	
VIT B1, PLAIN AND IN COMB WITH VITAMIN B6 AND B12 A11D	1	(0.7)	0		0		0	
VITAMIN B-COMPLEX, INCL COMBINATIONS A11E	2	(1.3)	2	(1.3)	1	(0.6)	1	(0.7)
VITAMIN B12 AND FOLIC ACID B03B	2	(1.3)	0		1	(0.6)	2	(1.3)

CONFIDENTIAL 275 Wyeth

NOTE: [1] - Classification Totals Are Not Necessarily The Sum Of The Individual Non-Study Medications Since A Subject May Report Two or More Different Non-Study Medications In The Same Classification. ## - Anatomical-Therapeutic-Chemical Classification Could Not Be Found at the Requested Level.

190CT05 16:35 REPORT NMED4 ATC3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 74

NUMBER OF SUBJECTS (%) REPORTING NON-STUDY MEDICATIONS USING ATC3 LEVEL CLASSIFICATION: THERAPEUTIC SUBGROUP

Time Period: CONCOMITANT BUT NOT PRIOR

ATC Classification [1]	Treatment Placebo n= 77
VIT B1, PLAIN AND IN COMB WITH VITAMIN B6 AND B12 A11D	0
VITAMIN B-COMPLEX, INCL COMBINATIONS A11E	1 (1.3)
VITAMIN B12 AND FOLIC ACID B03B	1 (1.3)

NOTE: [1] - Classification Totals Are Not Necessarily The Sum Of The Individual Non-Study Medications Since A Subject May Report
Two or More Different Non-Study Medications In The Same Classification.
- Anatomical-Therapeutic-Chemical Classification Could Not Be Found at the Requested Level.

ST 9-1: Demographic and Baseline Characteristics for ITT Population for Vasomotor Symptom Data

260CT05 17:26 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 1

REPORT DEMO5_ITT_SYM DEMOGRAPHIC AND BASELINE CHARACTERISTICS INTENT-TO-TREAT POPULATION FOR VASOMOTOR SYMPTOM DATA

				Troatmont		
CHARACTERISTIC	P-Value	DVS SR 50 mg	DVS SR 100 mg (n = 145)	DVS SR 150 mg	DVS SR 200 mg	Placebo
AGE (YEAR)						
N MEAN STANDARD DEVIATION MINIMUM MAXIMUM MEDIAN	0.654(A)	141 53.21 4.44 42.00 71.00 53.00	145 53.48 5.33 39.00 78.00 53.00	137 53.29 4.59 37.00 70.00 53.00	120 53.51 4.51 37.00 67.00 53.00	77 54.22 5.44 41.00 73.00 53.00
SEX						
Female		141 (100)	145 (100)	137 (100)	120 (100)	77 (100)
RACE Arabic Black Native American	0.537(B)	1 (0.71) 14 (9.93)	14 (9.66) 1 (0.69)	12 (8.76)	10 (8.33)	10 (12.99) 1 (1.30)
Oriental(Asian) Other		4 (2.84)	5 (3.45)	7 (5.11)	1 (0.83) 4 (3.33)	7 (9.09)
Other:Pacific Islander. White		122 (86.52)	125 (86.21)	1 (0.73) 117 (85.40)	105 (87.50)	59 (76.62)
ETHNICITY Hispanic or Latino Non-Hispanic and Non-Latino	0.948(B)	12 (8.51) 129 (91.49)			8 (6.67) 112 (93.33)	7 (9.09) 70 (90.91)
HEIGHT (CM) N MEAN STANDARD DEVIATION MINIMUM MAXIMUM MEDIAN	0.432(A)	141 163.32 6.55 151.20 180.60 162.60	145 162.94 6.44 147.30 180.40 162.60	137 164.19 6.94 149.90 185.00 163.80	120 164.12 5.98 145.70 175.30 164.00	77 163.23 7.09 142.20 182.80 163.00
WEIGHT (KG) N MEAN STANDARD DEVIATION MINIMUM	0.786(A)	141 72.82 13.65 50.00	145 72.05 12.30 43.40	137 72.10 13.12 45.90	120 73.63 11.94 49.50	77 71.59 13.15 48.10

NOTE: YEARS SINCE NATURAL MENOPAUSE REFERS ONLY TO WOMEN WITH UTERUS. MISSING REFERS TO WOMEN WITH NO UTERUS OR SURGICAL MENOPAUSE.

CONFIDENTIAL 277 Wyeth

⁽A) One-way Analysis Of Variance With Treatment As Factor.

⁽B) P-value for Chi-Square.

2

Page

260CT05 17:26 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT DEMO5_ITT_SYM DEMOGRAPHIC AND BASELINE CHARACTERISTICS INTENT-TO-TREAT POPULATION FOR VASOMOTOR SYMPTOM DATA

CHARACTERISTIC	P-Value	DVS SR 50 mg (n = 141)	DVS SR 100 mg (n = 145)	Treatment DVS SR 150 mg (n = 137)	DVS SR 200 mg (n = 120)	Placebo (n = 77)
MAXIMUM MEDIAN		112.50 70.90		108.60 70.00		104.50 70.00
BMI (KG/M2) N MEAN STANDARD DEVIATION MINIMUM MAXIMUM MEDIAN MISSING	0.756(A)	140 27.11 4.51 17.90 37.80 27.25		137 26.63 4.47 14.90 39.10 25.90	120 27.33 4.57 19.10 41.00 26.60	77 26.72 4.72 19.40 39.60 25.80
DURATION ON THERAPY (DAYS) N MEAN STANDARD DEVIATION MINIMUM MAXIMUM MEDIAN	0.422(A)	270.31 129.43	267.57 131.33 7.00	137 246.31 143.11 5.00 387.00 357.00	120 250.23 141.84 5.00 385.00 356.00	77 271.87 126.59 28.00 379.00 357.00
STUDY COMPLETE No Yes	0.758(B)	53 (37.59) 88 (62.41)	58 (40.00) 87 (60.00)	61 (44.53) 76 (55.47)	51 (42.50) 69 (57.50)	29 (37.66) 48 (62.34)
YEARS SINCE NATURAL MENOPAUSE N MEAN STANDARD DEVIATION MINIMUM MAXIMUM MEDIAN MISSING	0.063(A)	93 4.35 4.38 0.55 23.70 3.18	91 4.19 3.46 0.49 16.92 2.97	86 4.37 4.16 0.59 19.16 3.09	79 4.92 4.47 0.49 21.71 3.65	46 6.43 6.95 0.54 35.13 3.95
YEARS SINCE SURGICAL MENOPAUSE N MEAN STANDARD DEVIATION	0.335(A)	30 8.01 5.98	30 10.80 7.42	31 11.02 9.82	26 13.07 11.61	18 11.20 9.54

NOTE: YEARS SINCE NATURAL MENOPAUSE REFERS ONLY TO WOMEN WITH UTERUS. MISSING REFERS TO WOMEN WITH NO UTERUS OR SURGICAL MENOPAUSE.

CONFIDENTIAL 278 Wyeth

⁽A) One-way Analysis Of Variance With Treatment As Factor.(B) P-value for Chi-Square.

3

Page

260CT05 17:26 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT DEMO5_ITT_SYM DEMOGRAPHIC AND BASELINE CHARACTERISTICS INTENT-TO-TREAT POPULATION FOR VASOMOTOR SYMPTOM DATA

CHARACTERISTIC	P-Value	DVS SR 50 mg (n = 141)	DVS SR 100 mg (n = 145)	Treatment DVS SR 150 mg (n = 137)		Placebo (n = 77)
MINIMUM MAXIMUM MEDIAN MISSING		0.72 23.19 7.36 111	0.21 26.15 9.12 115	0.75 36.90 7.08 106	1.21 44.14 9.11 94	1.03 28.06 7.09
TYPE OF MENOPAUSE Natural Surgical (Bilateral oophorectomy)	0.990(B)	111 (78.72) 30 (21.28)	115 (79.31) 30 (20.69)	106 (77.37) 31 (22.63)	94 (78.33) 26 (21.67)	59 (76.62) 18 (23.38)
PRIMARY DIAGNOSIS Healthy Postmenopausal Woman		141 (100)	145 (100)	137 (100)	120 (100)	77 (100)

NOTE: YEARS SINCE NATURAL MENOPAUSE REFERS ONLY TO WOMEN WITH UTERUS. MISSING REFERS TO WOMEN WITH NO UTERUS OR SURGICAL MENOPAUSE. (A) One-way Analysis Of Variance With Treatment As Factor.(B) P-value for Chi-Square.

CONFIDENTIAL 279 Wyeth

ST 9-2: Number (%) of Subjects With Compliance Rates for Each Treatment Interval

26JUL05 15:26 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 Page 1

REPORT SMED4 C NUMBER (%) OF SUBJECTS WITH STUDY MEDICATION COMPLIANCE FOR EACH TREATMENT INTERVAL

TREATMENT INTERVAL COMPLIANCE	DVS SR	50 mg	DVS SR 100 mg	DVS SR 150 mg	DVS SR 200 mg	Placebo
Week 1 COMPLIANCE < 80% COMPLIANCE >= 80% Week 2		149 (9) 149 (91)	12/ 155 (8) 143/ 155 (92)	28/ 157 (18) 129/ 157 (82)	41/ 151 (27) 110/ 151 (73)	1/ 77 (1) 76/ 77 (99)
COMPLIANCE < 80% COMPLIANCE >= 80% Week 3	3/	139 (2)	4/ 143 (3)	5/ 133 (4)	7/ 115 (6)	1/ 77 (1)
	136/	139 (98)	139/ 143 (97)	128/ 133 (96)	108/ 115 (94)	76/ 77 (99)
COMPLIANCE < 80% COMPLIANCE >= 80% Week 4	7/	138 (5)	4/ 140 (3)	6/ 128 (5)	6/ 112 (5)	0/ 77
	131/	138 (95)	136/ 140 (97)	122/ 128 (95)	106/ 112 (95)	77/ 77 (100)
COMPLIANCE < 80%	8/	138 (6)	8/ 136 (6)	4/ 125 (3)	14/ 110 (13)	1/ 77 (1)
	130/	138 (94)	128/ 136 (94)	121/ 125 (97)	96/ 110 (87)	76/ 77 (99)
COMPLIANCE < 80%	7/	131 (5)	4/ 131 (3)	5/ 121 (4)	6/ 103 (6)	4/ 76 (5)
	124/	131 (95)	127/ 131 (97)	116/ 121 (96)	97/ 103 (94)	72/ 76 (95)
COMPLIANCE < 80%	8/	131 (6)	3/ 131 (2)	5/ 119 (4)	5/ 102 (5)	3/ 74 (4)
	123/	131 (94)	128/ 131 (98)	114/ 119 (96)	97/ 102 (95)	71/ 74 (96)
	6/	130 (5)	1/ 129 (< 1)	4/ 116 (3)	5/ 101 (5)	2/ 72 (3)
	124/	130 (95)	128/ 129 (99)	112/ 116 (97)	96/ 101 (95)	70/ 72 (97)
COMPLIANCE < 80%		130 (5) 130 (95)	4/ 128 (3) 124/ 128 (97)	8/ 115 (7) 107/ 115 (93)	7/ 101 (7) 94/ 101 (93)	5/ 71 (7) 66/ 71 (93)
COMPLIANCE < 80%	7/	127 (6)	4/ 128 (3)	6/ 113 (5)	9/ 100 (9)	6/ 71 (8)
	120/	127 (94)	124/ 128 (97)	107/ 113 (95)	91/ 100 (91)	65/ 71 (92)
COMPLIANCE < 80% COMPLIANCE >= 80%	4/	125 (3)	5/ 124 (4)	1/ 111 (< 1)	7/ 100 (7)	4/ 70 (6)
	121/	125 (97)	119/ 124 (96)	110/ 111 (99)	93/ 100 (93)	66/ 70 (94)
Week 11 COMPLIANCE < 80% COMPLIANCE >= 80%	2/ 123/	125 (2) 125 (98)	4/ 123 (3) 119/ 123 (97)	1/ 110 (< 1) 109/ 110 (99)	2/ 98 (2) 96/ 98 (98)	3/ 69 (4) 66/ 69 (96)
COMPLIANCE >= 80%	10/	125 (8)	5/ 123 (4)	6/ 110 (5)	4/ 98 (4)	4/ 68 (6)
	115/	125 (92)	118/ 123 (96)	104/ 110 (95)	94/ 98 (96)	64/ 68 (94)
Week 13-16 COMPLIANCE < 80% COMPLIANCE >= 80%		117 (8) 117 (92)	8/ 119 (7) 111/ 119 (93)	9/ 104 (9) 95/ 104 (91)	10/ 94 (11) 84/ 94 (89)	7/ 66 (11) 59/ 66 (89)
Week 17-20 COMPLIANCE < 80% COMPLIANCE >= 80%	7/ 103/	110 (6) 110 (94)	2/ 113 (2) 111/ 113 (98)	3/ 96 (3) 93/ 96 (97)	3/ 87 (3) 84/ 87 (97)	1/ 60 (2) 59/ 60 (98)

NOTE: COMPLIANCE <80% IS DEFINED AS A SUBJECT WHO TOOK LESS THAN 17 TABLETS PER WEEK OR 68 TABLETS PER 4 WEEKS.

Page

26JUL05 15:26 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT SMED4_C NUMBER (%) OF SUBJECTS WITH STUDY MEDICATION COMPLIANCE FOR EACH TREATMENT INTERVAL

TREATMENT INTERVAL COMPLIANCE	DVS SR	50 mg	DVS SR	100 mg	DVS SR	150 mg	DVS SR	200 mg	Placebo	
Week 21-24										
COMPLIANCE < 80%	5/	106 (5)	4 /	112 (4)	5/	93 (5)	4/	84 (5)	2/	59 (3)
COMPLIANCE >= 80%	101/	106 (95)	108/	112 (96)	88/	93 (95)	80/	84 (95)	57/	59 (97)
Week 25-28										
COMPLIANCE < 80%	8/	103 (8)	17/		9/	90 (10)	8/	82 (10)	9/	59 (15)
COMPLIANCE >= 80%	95/	103 (92)	94/	111 (85)	81/	90 (90)	74/	82 (90)	50/	59 (85)
Week 29-32		0.7 (1)	0 /	00 / 01	- /	06 (5)	0 /		0 /	50 / C)
COMPLIANCE < 80%	4/	97 (4)	2/	99 (2)	6/	86 (7)	3/	77 (4)	3/	52 (6)
COMPLIANCE >= 80%	93/	97 (96)	97/	99 (98)	80/	86 (93)	74/	77 (96)	49/	52 (94)
Week 33-36	2 /	04 (2)	4 /	07 (4)	4 /	04 (5)	F /	75 / 7)	0 /	F.O.
COMPLIANCE < 80% COMPLIANCE >= 80%	3/ 91/	94 (3) 94 (97)	4/ 93/	97 (4) 97 (96)	4/ 80/	84 (5) 84 (95)	5/ 70/	75 (7) 75 (93)	0/ 50/	50 50 (100)
Week 37-40	91/	94 (97)	93/	97 (90)	007	04 (93)	707	13 (93)	307	30 (100)
COMPLIANCE < 80%	4 /	94 (4)	6/	96 (6)	6/	82 (7)	4 /	72 (6)	2/	50 (4)
COMPLIANCE >= 80%	90/	94 (96)	90/	96 (94)	76/	82 (93)	68/	72 (94)	48/	50 (96)
Week 41-44	507	J4 (J0)	307	50 (54)	707	02 (33)	007	72 (34)	407	30 (30)
COMPLIANCE < 80%	3/	91 (3)	8/	93 (9)	8/	81 (10)	3/	71 (4)	3/	49 (6)
COMPLIANCE >= 80%	88/	91 (97)	85/	93 (91)	73/	81 (90)	68/	71 (96)	46/	49 (94)
Week 45-48		,		,		- (/		, ,		,
COMPLIANCE < 80%	1/	89 (1)	2/	88 (2)	4 /	77 (5)	1/	70 (1)	1/	48 (2)
COMPLIANCE >= 80%	88/	89 (99)	86/	88 (98)	73/	77 (95)	69/	70 (99)	47/	48 (98)
Week 49-52										
COMPLIANCE < 80%	25/	88 (28)	19/	86 (22)	23/	75 (31)	26/	69 (38)	16/	48 (33)
COMPLIANCE >= 80%	63/	88 (72)	67/	86 (78)	52/	75 (69)	43/	69 (62)	32/	48 (67)
Week 53-56										
COMPLIANCE < 80%	28/	28 (100)	28/	28 (100)	21/	22 (95)	18/	18 (100)	16/	16 (100)
COMPLIANCE >= 80%	0/	28	0/	28	1/	22 (5)	0/	18	0/	16

NOTE: COMPLIANCE <80% IS DEFINED AS A SUBJECT WHO TOOK LESS THAN 17 TABLETS PER WEEK OR 68 TABLETS PER 4 WEEKS.

ST 9-3: Reduction in Average Daily Number of Moderate and Severe Hot Flushes for the ITT LOCF Population

Reduction in Average Daily Number of Moderate and Severe Hot Flushes for the ITT LOCF Population

	Adjusted Change-								
Treatment	Time Point	Pairs, n	Mean	SE	p-Value vs Placebo				
DVS SR 50 mg	Week 1	141	-3.78	0.32	0.003				
_	Week 2	141	-4.87	0.34	0.031				
	Week 3	141	-5.40	0.35	0.103				
	Week 4	141	-5.77	0.35	0.331				
	Week 5	141	-5.81	0.35	0.627				
	Week 6	141	-5.82	0.36	0.795				
	Week 7	141	-5.81	0.36	0.794				
	Week 8	141	-5.77	0.38	0.798				
	Week 9	141	-5.88	0.37	0.657				
	Week 10	141	-5.90	0.37	0.755				
	Week 11	141	-6.05	0.38	0.554				
	Week 12	141	-6.10	0.38	0.326				
DVS SR 100 mg	Week 1	145	-4.94	0.31	< 0.001				
-	Week 2	145	-6.22	0.34	< 0.001				
	Week 3	145	-6.48	0.35	< 0.001				
	Week 4	145	-6.62	0.34	0.013				
	Week 5	145	-6.86	0.35	0.020				
	Week 6	145	-6.97	0.35	0.026				
	Week 7	145	-7.04	0.36	0.019				
	Week 8	145	-7.07	0.37	0.018				
	Week 9	145	-7.21	0.37	0.008				
	Week 10	145	-7.20	0.37	0.013				
	Week 11	145	-7.22	0.37	0.013				
	Week 12	145	-7.23	0.37	0.005				
DVS SR 150 mg	Week 1	136	-5.07	0.33	< 0.001				
_	Week 2	137	-6.18	0.35	< 0.001				
	Week 3	137	-6.47	0.36	0.001				
	Week 4	137	-6.48	0.35	0.027				
	Week 5	137	-7.26	0.36	0.003				
	Week 6	137	-7.20	0.36	0.009				

DVS SR Protocol 3151A2-315-US CSR-60178

Reduction in Average Daily Number of Moderate and Severe Hot Flushes for the ITT LOCF Population

			Adjusted	d Change-	
Treatment	Time Point	Pairs, n	Mean	SE	p-Value vs Placebo
	Week 7	137	-7.20	0.37	0.010
	Week 8	137	-7.04	0.39	0.022
	Week 9	137	-7.03	0.38	0.021
	Week 10	137	-7.00	0.38	0.034
	Week 11	137	-7.00	0.38	0.035
	Week 12	137	-6.94	0.38	0.020
DVS SR 200 mg	Week 1	120	-4.88	0.34	< 0.001
_	Week 2	120	-6.11	0.37	< 0.001
	Week 3	120	-6.21	0.38	0.003
	Week 4	120	-6.42	0.38	0.040
	Week 5	120	-6.49	0.38	0.104
	Week 6	120	-6.52	0.39	0.157
	Week 7	120	-6.67	0.39	0.098
	Week 8	120	-6.63	0.41	0.111
	Week 9	120	-6.69	0.40	0.086
	Week 10	120	-6.74	0.40	0.098
	Week 11	120	-6.53	0.41	0.183
	Week 12	120	-6.46	0.41	0.130
Placebo	Week 1	77	-2.25	0.42	
	Week 2	77	-3.66	0.46	
	Week 3	77	-4.47	0.47	
	Week 4	77	-5.22	0.46	
	Week 5	77	-5.54	0.47	
	Week 6	77	-5.67	0.48	
	Week 7	77	-5.65	0.48	
	Week 8	77	-5.61	0.50	
	Week 9	77	-5.61	0.50	
	Week 10	77	-5.71	0.49	
	Week 11	77	-5.69	0.50	
	Week 12	77	-5.50	0.50	

Reduction in Average Daily Number of Moderate and Severe Hot Flushes for the ITT LOCF Population

Adjusted	Change-
----------	---------

Treatment Time Point Pairs, n Mean SE p-Value vs Placebo

Abbreviations: ITT=intent to treat; LOCF=last observation carried forward; and

SE=standard error.

Analysis of covariance: change=treat+site+baseline.

Source: CLINICAL R&D/CLINICAL BIOSTATS SAS REPORTS/315/315_NDA /hf itt locf ancova final 05.html TEST NAME=AVERAGE DAILY NUMBER OF

MODERATE AND SEVERE HOT FLUSHES

ST 9-4: Reduction in Average Daily Number of Moderate and Severe Hot Flushes for the ITT Observed Data Group

Reduction in Average Daily Number of Moderate and Severe Hot Flushes for the ITT Observed Data Group

		Data Gr	Adjusted	Change	
Treatment	Time Point	Pairs, n	Mean	SE	p-Value vs Placebo
DVS SR 50 mg	Week 1	141	-3.78	0.32	0.003
	Week 2	138	-5.03	0.33	0.015
	Week 3	137	-5.61	0.34	0.055
	Week 4	137	-6.01	0.34	0.198
	Week 5	130	-6.06	0.35	0.419
	Week 6	130	-5.83	0.34	0.790
	Week 7	129	-5.81	0.35	0.942
	Week 8	129	-5.76	0.37	0.959
	Week 9	126	-5.77	0.36	0.917
	Week 10	124	-5.85	0.36	0.775
	Week 11	125	-6.00	0.37	0.947
	Week 12	125	-6.06	0.36	0.967
	Week 13-16	116	-6.57	0.35	0.114
	Week 17-20	109	-6.83	0.38	0.034
	Week 21-24	106	-6.81	0.39	0.038
	Week 25-28	103	-6.85	0.36	0.328
	Week 29-32	97	-7.02	0.36	0.464
	Week 33-36	94	-7.20	0.36	0.304
	Week 37-40	94	-7.38	0.36	0.306
	Week 41-44	91	-7.61	0.35	0.098
	Week 45-48	89	-7.59	0.36	0.190
	Week 49-52	88	-7.51	0.37	0.317
	Week 53-56	28	-7.18	0.62	0.644
DVS SR 100 mg	Week 1	145	-4.94	0.31	< 0.001
· ·	Week 2	142	-6.35	0.33	< 0.001
	Week 3	139	-6.66	0.34	< 0.001
	Week 4	135	-6.92	0.34	0.003
	Week 5	131	-7.27	0.35	0.003
	Week 6	131	-7.19	0.34	0.006
	Week 7	129	-7.28	0.35	0.007
	Week 8	128	-7.40	0.37	0.005

DVS SR Protocol 3151A2-315-US CSR-60178

Reduction in Average Daily Number of Moderate and Severe Hot Flushes for the ITT Observed
Data Group

	Adjusted Change							
Treatment	Time Point	Pairs, n	Mean	SE	p-Value vs Placebo			
	Week 9	126	-7.65	0.36	0.001			
	Week 10	122	-7.67	0.36	0.004			
	Week 11	121	-7.79	0.37	0.002			
	Week 12	121	-7.80	0.36	0.003			
	Week 13-16	115	-7.69	0.34	< 0.001			
	Week 17-20	111	-7.70	0.36	< 0.001			
	Week 21-24	110	-7.76	0.37	< 0.001			
	Week 25-28	108	-8.01	0.35	0.003			
	Week 29-32	96	-8.20	0.35	0.007			
	Week 33-36	94	-8.00	0.35	0.015			
	Week 37-40	93	-8.12	0.36	0.021			
	Week 41-44	90	-8.36	0.35	0.003			
	Week 45-48	85	-8.39	0.36	0.007			
	Week 49-52	83	-8.26	0.37	0.024			
	Week 53-56	26	-8.79	0.61	0.035			
DVS SR 150 mg	Week 1	136	-5.07	0.33	< 0.001			
S	Week 2	131	-6.34	0.34	< 0.001			
	Week 3	128	-6.63	0.36	< 0.001			
	Week 4	125	-6.68	0.36	0.014			
	Week 5	121	-7.56	0.37	0.001			
	Week 6	119	-7.22	0.36	0.006			
	Week 7	116	-7.35	0.37	0.006			
	Week 8	115	-7.10	0.39	0.025			
	Week 9	110	-7.05	0.39	0.025			
	Week 10	111	-7.06	0.38	0.079			
	Week 11	110	-7.07	0.39	0.066			
	Week 12	109	-7.00	0.39	0.111			
	Week 13-16	104	-7.26	0.37	0.006			
	Week 17-20	96	-7.36	0.40	0.004			
	Week 21-24	92	-7.27	0.41	0.007			
	Week 25-28	90	-7.45	0.38	0.052			
	Week 29-32	85	-7.66	0.38	0.080			
	Week 33-36	84	-7.57	0.37	0.103			

DVS SR Protocol 3151A2-315-US CSR-60178

Reduction in Average Daily Number of Moderate and Severe Hot Flushes for the ITT Observed
Data Group

		Data Gr	Adjusted	Change	
Treatment	Time Point	Pairs, n	Mean	SE	p-Value vs Placebo
	Week 37-40	82	-7.45	0.39	0.270
	Week 41-44	81	-7.65	0.37	0.095
	Week 45-48	77	-7.77	0.39	0.117
	Week 49-52	75	-7.81	0.40	0.142
	Week 53-56	21	-7.48	0.71	0.488
DVS SR 200 mg	Week 1	120	-4.88	0.34	< 0.001
	Week 2	113	-6.53	0.37	< 0.001
	Week 3	110	-6.61	0.39	< 0.001
	Week 4	108	-6.94	0.38	0.005
	Week 5	102	-7.10	0.40	0.012
	Week 6	102	-7.04	0.39	0.020
	Week 7	101	-7.14	0.39	0.020
	Week 8	101	-7.08	0.41	0.032
	Week 9	99	-7.11	0.41	0.023
	Week 10	99	-7.26	0.41	0.040
	Week 11	97	-6.98	0.42	0.100
	Week 12	97	-6.92	0.41	0.153
	Week 13-16	94	-7.52	0.39	0.002
	Week 17-20	87	-7.48	0.42	0.002
	Week 21-24	84	-7.73	0.43	0.001
	Week 25-28	82	-7.74	0.40	0.017
	Week 29-32	76	-8.01	0.41	0.021
	Week 33-36	74	-7.99	0.40	0.021
	Week 37-40	71	-8.23	0.42	0.018
	Week 41-44	70	-8.25	0.40	0.008
	Week 45-48	69	-8.31	0.41	0.014
	Week 49-52	69	-8.16	0.42	0.042
	Week 53-56	18	-7.69	0.73	0.356
Placebo	Week 1	77	-2.25	0.42	
	Week 2	77	-3.72	0.44	
	Week 3	77	-4.55	0.45	
	Week 4	77	-5.31	0.44	
	Week 5	76	-5.61	0.45	

DVS SR Protocol 3151A2-315-US CSR-60178

Reduction in Average Daily Number of Moderate and Severe Hot Flushes for the ITT Observed
Data Group

			Adjusted	Change	
Treatment	Time Point	Pairs, n	Mean	SE	p-Value vs Placebo
	Week 6	74	-5.68	0.44	
	Week 7	72	-5.77	0.46	
	Week 8	70	-5.73	0.49	
	Week 9	71	-5.71	0.47	
	Week 10	70	-6.02	0.47	
	Week 11	69	-5.96	0.48	
	Week 12	67	-6.04	0.49	
	Week 13-16	66	-5.70	0.45	
	Week 17-20	60	-5.56	0.49	
	Week 21-24	59	-5.53	0.50	
	Week 25-28	58	-6.29	0.47	
	Week 29-32	51	-6.59	0.49	
	Week 33-36	50	-6.61	0.47	
	Week 37-40	50	-6.79	0.49	
	Week 41-44	49	-6.69	0.47	
	Week 45-48	48	-6.85	0.48	
	Week 49-52	48	-6.93	0.49	
	Week 53-56	15	-6.74	0.78	

Abbreviation: ITT=intent to treat and SE=standard error.

Analysis of covariance: change=treat+site+baseline

Source: CLINICAL R&D/CLINICAL BIOSTATISTICS SAS REPORTS/3151A2/315/

 $315_NDA_2005/\ hf_itt_ancova_final_05.html/\ TEST\ NAME=AVERAGE\ DAILY\ NUMBER\ OF$

MODERATE AND SEVERE HOT FLUSHES

ST 9-5: Reduction in the Average Daily Severity Score for the ITT LOCF Population

Reduction in the Average Daily Severity Score for the ITT LOCF Population

			Adjusted	Change	
Treatment	Time Point	Pairs, n	Mean	SE	p-Value vs Placebo
DVS SR 50 mg	Week 1	141	-0.21	0.04	0.076
	Week 2	141	-0.28	0.05	0.716
	Week 3	141	-0.33	0.06	0.861
	Week 4	141	-0.37	0.06	0.913
	Week 5	141	-0.37	0.06	0.484
	Week 6	141	-0.40	0.06	0.450
	Week 7	141	-0.40	0.06	0.307
	Week 8	141	-0.41	0.06	0.352
	Week 9	141	-0.36	0.06	0.197
	Week 10	141	-0.37	0.07	0.194
	Week 11	141	-0.41	0.07	0.528
	Week 12	141	-0.43	0.07	0.754
DVS SR 100 mg	Week 1	145	-0.41	0.04	< 0.001
C	Week 2	145	-0.55	0.05	0.001
	Week 3	145	-0.60	0.06	0.003
	Week 4	145	-0.57	0.06	0.054
	Week 5	145	-0.68	0.06	0.019
	Week 6	145	-0.67	0.06	0.048
	Week 7	145	-0.72	0.06	0.042
	Week 8	145	-0.74	0.06	0.029
	Week 9	145	-0.76	0.06	0.011
	Week 10	145	-0.76	0.06	0.018
	Week 11	145	-0.79	0.06	0.004
	Week 12	145	-0.80	0.06	0.002
DVS SR 150 mg	Week 1	136	-0.32	0.04	0.001
Č	Week 2	137	-0.49	0.05	0.006
	Week 3	137	-0.55	0.06	0.014
	Week 4	137	-0.53	0.06	0.138
	Week 5	137	-0.60	0.06	0.112
	Week 6	137	-0.61	0.06	0.176
	Week 7	137	-0.62	0.07	0.301

DVS SR Protocol 3151A2-315-US CSR-60178

			Adjusted	Change	
Treatment	Time Point	Pairs, n	Mean	SE	p-Value vs Placebo
	Week 8	137	-0.59	0.07	0.488
	Week 9	137	-0.62	0.07	0.228
	Week 10	137	-0.64	0.07	0.234
	Week 11	137	-0.66	0.07	0.099
	Week 12	137	-0.59	0.07	0.235
DVS SR 200 mg	Week 1	120	-0.39	0.04	< 0.001
	Week 2	120	-0.57	0.06	0.001
	Week 3	120	-0.53	0.06	0.028
	Week 4	120	-0.57	0.07	0.072
	Week 5	120	-0.62	0.07	0.086
	Week 6	120	-0.66	0.07	0.079
	Week 7	120	-0.73	0.07	0.045
	Week 8	120	-0.70	0.07	0.092
	Week 9	120	-0.77	0.07	0.012
	Week 10	120	-0.75	0.07	0.030
	Week 11	120	-0.76	0.07	0.011
	Week 12	120	-0.74	0.07	0.013
Placebo	Week 1	77	-0.09	0.05	
	Week 2	77	-0.25	0.07	
	Week 3	77	-0.31	0.08	
	Week 4	77	-0.39	0.08	
	Week 5	77	-0.44	0.08	
	Week 6	77	-0.47	0.08	
	Week 7	77	-0.51	0.09	
	Week 8	77	-0.51	0.09	
	Week 9	77	-0.49	0.09	
	Week 10	77	-0.51	0.09	
	Week 11	77	-0.48	0.09	
	337 1 10		0.45	0.00	

-0.47

0.09

77

Week 12

Reduction in the Average Daily Severity Score for the ITT LOCF Population

	Adjusted Change								
Treatment	Time Point	Pairs, n	Mean	SE	p-Value vs Placebo				
Abbreviations: I	Abbreviations: ITT=intent to treat; LOCF=last observation carried forward; and SE=standard error								
Analysis of covar	riance: change=treat	+site+baselir	ne.						

Source: CLINICAL R&D/CLINICAL BIOSTATISTICS SAS REPORTS/3151A2/315/315_NDA_2005/hf_itt_locf_ancova_final_05.html/ TEST NAME=AVERAGE DAILY SEVERITY SCORE OF MILD, MODERATE AND SEVERE HOT FLUSHES

CONFIDENTIAL 291 Wyeth

ST 9-6: Reduction in the Average Daily Severity Score for the ITT Observed Data Population

			Adjusted	Change	
Treatment	Time Point	Pairs, n	Mean	SE	p-Value vs Placeb
DVS SR 50 mg	Week 1	141	-0.21	0.04	0.076
	Week 2	138	-0.29	0.06	0.686
	Week 3	137	-0.34	0.06	0.836
	Week 4	137	-0.39	0.06	0.961
	Week 5	130	-0.38	0.07	0.425
	Week 6	130	-0.40	0.07	0.368
	Week 7	129	-0.41	0.07	0.227
	Week 8	129	-0.43	0.07	0.230
	Week 9	126	-0.34	0.07	0.081
	Week 10	124	-0.36	0.07	0.067
	Week 11	125	-0.41	0.07	0.225
	Week 12	125	-0.43	0.07	0.288
	Week 13-16	116	-0.57	0.07	0.995
	Week 17-20	109	-0.64	0.08	0.802
	Week 21-24	106	-0.64	0.08	0.905
	Week 25-28	103	-0.63	0.09	0.575
	Week 29-32	97	-0.69	0.09	0.686
	Week 33-36	94	-0.79	0.09	0.788
	Week 37-40	94	-0.76	0.10	0.873
	Week 41-44	91	-0.73	0.09	0.650
	Week 45-48	89	-0.76	0.10	0.883
	Week 49-52	88	-0.76	0.10	0.913
	Week 53-56	28	-0.61	0.22	0.568
DVS SR 100 mg	Week 1	145	-0.41	0.04	< 0.001
	Week 2	142	-0.56	0.05	0.001
	Week 3	139	-0.62	0.06	0.003
	Week 4	135	-0.60	0.06	0.044
	Week 5	131	-0.72	0.06	0.013
	Week 6	131	-0.72	0.07	0.037
	Week 7	129	-0.78	0.07	0.040
	Week 8	128	-0.81	0.07	0.027
	Week 9	126	-0.83	0.07	0.008

DVS SR Protocol 3151A2-315-US CSR-60178

Reduction in	the Average Dai	ly Severity So	ore for the	ITT Obser	ved Data Population
			Adjusted	Change	-
Treatment	Time Point	Pairs, n	Mean	SE	p-Value vs Placebo
	Week 10	122	-0.84	0.07	0.022
	Week 11	121	-0.87	0.07	0.005
	Week 12	121	-0.88	0.07	0.006
	Week 13-16	115	-0.87	0.07	0.012
	Week 17-20	111	-0.88	0.08	0.037
	Week 21-24	110	-0.84	0.08	0.099
	Week 25-28	108	-0.90	0.08	0.136
	Week 29-32	96	-1.01	0.09	0.076
	Week 33-36	94	-0.97	0.09	0.136
	Week 37-40	93	-0.97	0.09	0.123
	Week 41-44	90	-1.01	0.09	0.020
	Week 45-48	85	-1.03	0.10	0.071
	Week 49-52	83	-0.99	0.10	0.111
	Week 53-56	26	-1.17	0.21	0.274
DVS SR 150 mg	Week 1	136	-0.32	0.04	0.001
	Week 2	131	-0.51	0.06	0.006
	Week 3	128	-0.57	0.06	0.015
	Week 4	125	-0.55	0.07	0.143
	Week 5	121	-0.62	0.07	0.142
	Week 6	119	-0.63	0.07	0.232
	Week 7	116	-0.65	0.07	0.358
	Week 8	115	-0.61	0.07	0.655
	Week 9	110	-0.65	0.08	0.323
	Week 10	111	-0.69	0.08	0.314
	Week 11	110	-0.72	0.08	0.140
	Week 12	109	-0.64	0.08	0.466
	Week 13-16	104	-0.71	0.08	0.246
	Week 17-20	96	-0.75	0.09	0.279
	Week 21-24	92	-0.73	0.09	0.445
	Week 25-28	90	-0.77	0.09	0.639
	Week 29-32	85	-0.80	0.10	0.753
	Week 33-36	84	-0.78	0.10	0.849
	Week 37-40	82	-0.75	0.10	0.942
	Week 41-44	81	-0.79	0.10	0.413

DVS SR Protocol 3151A2-315-US CSR-60178

			Adjusted	Change	
Treatment	Time Point	Pairs, n	Mean	SE	p-Value vs Placebo
	Week 45-48	77	-0.81	0.10	0.682
	Week 49-52	75	-0.75	0.10	0.937
	Week 53-56	21	-0.53	0.25	0.462
DVS SR 200 mg	Week 1	120	-0.39	0.04	< 0.001
	Week 2	113	-0.60	0.06	< 0.001
	Week 3	110	-0.56	0.07	0.020
	Week 4	108	-0.61	0.07	0.044
	Week 5	102	-0.67	0.07	0.059
	Week 6	102	-0.72	0.08	0.045
	Week 7	101	-0.81	0.08	0.029
	Week 8	101	-0.77	0.08	0.079
	Week 9	99	-0.85	0.08	0.008
	Week 10	99	-0.84	0.08	0.026
	Week 11	97	-0.83	0.08	0.018
	Week 12	97	-0.80	0.08	0.040
	Week 13-16	94	-0.86	0.08	0.018
	Week 17-20	87	-0.89	0.09	0.040
	Week 21-24	84	-0.91	0.09	0.042
	Week 25-28	82	-0.91	0.10	0.148
	Week 29-32	76	-0.97	0.10	0.154
	Week 33-36	74	-0.98	0.10	0.137
	Week 37-40	71	-1.00	0.11	0.101
	Week 41-44	70	-1.04	0.11	0.016
	Week 45-48	69	-1.01	0.11	0.094
	Week 49-52	69	-1.08	0.11	0.035
	Week 53-56	18	-1.06	0.26	0.483
Placebo	Week 1	77	-0.09	0.05	
	Week 2	77	-0.26	0.07	
	Week 3	77	-0.32	0.08	
	Week 4	77	-0.39	0.08	
	Week 5	76	-0.46	0.08	
	Week 6	74	-0.49	0.09	
	Week 7	72	-0.55	0.09	
	Week 8	70	-0.56	0.09	

DVS SR Protocol 3151A2-315-US CSR-60178

Reduction in the Average Daily Severity Score for the ITT Observed Data Population
--

			Adjusted	Change	
Treatment	Time Point	Pairs, n	Mean	SE	p-Value vs Placebo
	Week 9	71	-0.53	0.09	
	Week 10	70	-0.57	0.09	
	Week 11	69	-0.55	0.09	
	Week 12	67	-0.55	0.10	
	Week 13-16	66	-0.57	0.10	
	Week 17-20	60	-0.61	0.11	
	Week 21-24	59	-0.62	0.11	
	Week 25-28	58	-0.70	0.11	
	Week 29-32	51	-0.75	0.12	
	Week 33-36	50	-0.75	0.12	
	Week 37-40	50	-0.74	0.13	
	Week 41-44	49	-0.66	0.12	
	Week 45-48	48	-0.74	0.13	
	Week 49-52	48	-0.74	0.13	
	Week 53-56	15	-0.81	0.28	

Abbreviations: ITT=intent to treat and SE=standard error.

Analysis of covariance: change=treat+site+baseline.

Source: CLINICAL R&D/CLINICAL BIOSTATISTICS SAS REPORTS/3151A2/315/315 NDA 2005 /hf_itt_ancova_final_05.html TEST NAME=AVERAGE DAILY SEVERITY SCORE OF MILD, MODERATE AND SEVERE HOT FLUSHES

ST 9-7: Daily Mean Number of Times Awakened for the ITT Observed Data Population

--Adjusted change--

Treatment	Time slot	No. of pairs	mean SE	p-value vs. placebo	p-value within group
DVS SR 50 mg	Week 1	138	-0.91 0.14	0.629	< 0.001
	Week 2	136	-1.53 0.14	0.912	< 0.001
	Week 3	135	-1.90 0.14	0.700	< 0.001
	Week 4	135	-2.04 0.14	0.907	< 0.001
	Week 5	128	-1.91 0.15	0.685	< 0.001
	Week 6	128	-1.98 0.14	0.588	< 0.001
	Week 7	127	-1.97 0.13	0.308	< 0.001
	Week 8	127	-2.03 0.14	0.671	< 0.001
	Week 9	124	-2.04 0.14	0.664	< 0.001
	Week 10	122	-2.19 0.14	0.917	< 0.001
	Week 11	121	-2.22 0.14	0.890	< 0.001
	Week 12	111	-2.30 0.14	0.672	< 0.001
DVS SR 100 mg	Week 1	145	-1.48 0.14	0.050	< 0.001
	Week 2	142	-2.06 0.13	0.011	< 0.001
	Week 3	139	-2.18 0.14	0.102	< 0.001
	Week 4	134	-2.36 0.14	0.117	< 0.001
	Week 5	128	-2.44 0.14	0.054	< 0.001
	Week 6	129	-2.47 0.14	0.095	< 0.001
	Week 7	126	-2.67 0.13	0.023	< 0.001
	Week 8	125	-2.65 0.14	0.017	< 0.001
	Week 9	124	-2.75 0.14	0.007	< 0.001

--Adjusted change--

Treatment	Time slot	No. of pairs	mean SE	p-value vs. placebo	p-value within group
	Week 10	120	-2.86 0.13	0.003	< 0.001
	Week 11	119	-2.80 0.14	0.006	< 0.001
	Week 12	105	-2.77 0.14	0.013	< 0.001
DVS SR 150 mg	Week 1	134	-1.46 0.15	0.063	< 0.001
	Week 2	130	-1.93 0.14	0.059	< 0.001
	Week 3	125	-2.11 0.15	0.194	< 0.001
	Week 4	124	-2.17 0.14	0.482	< 0.001
	Week 5	120	-2.32 0.15	0.165	< 0.001
	Week 6	119	-2.51 0.15	0.073	< 0.001
	Week 7	116	-2.50 0.14	0.154	< 0.001
	Week 8	115	-2.51 0.14	0.087	< 0.001
	Week 9	110	-2.51 0.15	0.102	< 0.001
	Week 10	111	-2.49 0.14	0.205	< 0.001
	Week 11	108	-2.53 0.15	0.131	< 0.001
	Week 12	97	-2.69 0.15	0.034	< 0.001
DVS SR 200 mg	Week 1	119	-1.23 0.15	0.382	< 0.001
	Week 2	112	-2.06 0.15	0.015	< 0.001
	Week 3	109	-2.28 0.16	0.050	< 0.001
	Week 4	107	-2.38 0.15	0.109	< 0.001
	Week 5	100	-2.39 0.16	0.106	< 0.001
	Week 6	100	-2.34 0.16	0.300	< 0.001
	Week 7	99	-2.47 0.15	0.212	< 0.001
	Week 8	99	-2.42 0.15	0.208	< 0.001

--Adjusted change--

Treatment	Time slot	No. of pairs	mean SE	p-value vs. placebo	p-value within group
	Week 9	97	-2.59 0.16	0.055	< 0.001
	Week 10	97	-2.63 0.15	0.061	< 0.001
	Week 11	96	-2.67 0.15	0.036	< 0.001
	Week 12	91	-2.68 0.15	0.043	< 0.001
Placebo	Week 1	77	-1.02 0.19		< 0.001
	Week 2	77	-1.50 0.18		< 0.001
	Week 3	77	-1.82 0.18		< 0.001
	Week 4	77	-2.01 0.18		< 0.001
	Week 5	76	-2.00 0.18		< 0.001
	Week 6	74	-2.10 0.18		< 0.001
	Week 7	72	-2.18 0.17		< 0.001
	Week 8	70	-2.12 0.18		< 0.001
	Week 9	71	-2.14 0.18		< 0.001
	Week 10	70	-2.21 0.17		< 0.001
	Week 11	68	-2.19 0.18		< 0.001
	Week 12	63	-2.21 0.18		< 0.001

Abbreviations: ITT=intent to treat and SE=standard error.

Analysis of covariance: change=treat+site+baseline.

Source: CLINICAL R&D/CLINICAL BIOSTATISTICS SAS REPORTS/3151A2/315/

315_NDA_2005/sleep_itt_ancova_final_05.html TEST NAME=DAILY MEAN NUMBER OF TIMES AWAKENED

ST 9-8: Profile of Mood States Scores

ANGER HOSTIL	ITY		-Baseli	ine-	-Obser	ved-	Chang baselir	
		No.						
	Time	of						
Treatment	slot	pairs	mean	SD	mean	SD	mean	SD
DVS SR 50 mg	Screening/baseline	147	8.8	8.4				
	Week 12	109	9.3	9.0	3.7	4.8	-5.5	8.5
DVS SR 100 mg	Screening/baseline	152	8.9	8.9				
	Week 12	116	8.1	8.2	3.3	4.5	-4.8	7.9
DVS SR 150 mg	Screening/baseline	156	8.9	9.0				
	Week 12	97	7.8	7.5	3.2	4.4	-4.6	5.8
DVS SR 200 mg	Screening/baseline	149	10.1	9.4				
	Week 12	86	9.8	9.8	4.6	5.8	-5.1	9.4
Placebo	Screening/baseline	76	7.7	8.4				
	Week 12	61	7.9	7.9	5.6	6.2	-2.3	5.2
CONFUSION BEWILDERMENT			-Baseline-				Change from baseline	
CONFUSION BE	EWILDERMENT		-Basel	ine-	-Obser	ved-	_	
CONFUSION BE	WILDERMENT	No.	-Basel	ine-	-Obser	ved-	_	
CONFUSION BE	Time	No. of	-Basel	ine-	-Obser	ved-	_	
CONFUSION BE			-Basel	ine-	-Obser	ved-	_	
	Time	of		<u> </u>			baselin	ne
Treatment	Time slot	of pairs	mean	SD			baselin	ne
Treatment	Time slot Screening/baseline	of pairs 149	mean 7.9	SD 5.1	mean	SD	mean .	SD .
Treatment DVS SR 50 mg	Time slot Screening/baseline Week 12	of pairs 149 112	mean 7.9 7.5	SD 5.1 4.9	mean	SD	mean .	SD .
Treatment DVS SR 50 mg	Time slot Screening/baseline Week 12 Screening/baseline	of pairs 149 112 151	mean 7.9 7.5 7.5	SD 5.1 4.9 5.0	mean 4.7	SD 3.8	mean -2.9	SD . 5.0
Treatment DVS SR 50 mg DVS SR 100 mg	Time slot Screening/baseline Week 12 Screening/baseline Week 12	of pairs 149 112 151 117	mean 7.9 7.5 7.5 7.6	SD 5.1 4.9 5.0 5.0	mean 4.7	SD 3.8	mean -2.9	SD . 5.0
Treatment DVS SR 50 mg DVS SR 100 mg	Time slot Screening/baseline Week 12 Screening/baseline Week 12 Screening/baseline	of pairs 149 112 151 117 157	mean 7.9 7.5 7.5 7.6 7.9	SD 5.1 4.9 5.0 5.0 5.7	mean 4.7 4.3	SD 3.8 3.1	mean	SD 5.0 4.6
Treatment DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	Time slot Screening/baseline Week 12 Screening/baseline Week 12 Screening/baseline Week 12	of pairs 149 112 151 117 157 98	mean 7.9 7.5 7.5 7.6 7.9 7.0	SD 5.1 4.9 5.0 5.0 5.7 4.8	mean 4.7 4.3	SD 3.8 3.1	mean	SD 5.0 4.6
Treatment DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	Time slot Screening/baseline Week 12 Screening/baseline Week 12 Screening/baseline Week 12 Screening/baseline	of pairs 149 112 151 117 157 98 149	mean 7.9 7.5 7.5 7.6 7.9 7.0 8.1	SD 5.1 4.9 5.0 5.0 5.7 4.8 5.1	mean . 4.7 . 4.3 . 4.6	SD	mean2.93.22.5	SD

DVS SR Protocol 3151A2-315-US CSR-60178

DEPRESSION DEJECTION			-Baseline-		-Observed-		Change from baseline	
		No.						
	Time	of						
Treatment	slot	pairs	mean	SD	mean	SD	mean	SD
DVS SR 50 mg	Screening/baseline	148	10.9	10.6				
	Week 12	108	10.4	10.8	4.4	6.3	-6.0	10.6
DVS SR 100 mg	Screening/baseline	150	10.7	11.3				
	Week 12	113	10.3	10.9	3.6	4.8	-6.7	10.2
DVS SR 150 mg	Screening/baseline	156	10.2	12.5				
	Week 12	97	8.4	10.6	3.9	6.0	-4.6	8.0
DVS SR 200 mg	Screening/baseline	148	12.5	11.6				
	Week 12	85	13.2	12.6	6.0	8.0	-7.1	11.1
Placebo	Screening/baseline	76	10.2	10.8	•			
	Week 12	60	10.2	9.6	6.0	6.4	-4.2	7.3

FATIGUE INER		-Baseline-		-Observed-		Change from baseline		
THITGGE ITVER	1111	No.	Buser		00501	700	ousem	10
	Time	of						
Treatment	slot	pairs	mean	SD	mean	SD	mean	SD
DVS SR 50 mg	Screening/baseline	149	11.7	6.4	•			
	Week 12	111	11.7	6.3	7.5	6.4	-4.3	6.9
DVS SR 100 mg	Screening/baseline	152	12.5	7.3				
	Week 12	116	12.3	7.4	7.0	5.8	-5.3	7.3
DVS SR 150 mg	Screening/baseline	156	12.4	7.4				
	Week 12	97	11.4	6.8	7.0	5.8	-4.3	6.8
DVS SR 200 mg	Screening/baseline	149	12.8	6.9				
	Week 12	85	12.3	6.6	7.7	6.3	-4.6	7.5
Placebo	Screening/baseline	77	11.6	6.7				
	Week 12	61	11.6	6.5	8.1	6.3	-3.6	6.8
	·							

DVS SR Protocol 3151A2-315-US CSR-60178

TENSION ANXIETY			-Basel	ine-	-Obser	ved-	Change baselin	
		No.						
	Time	of						
Treatment	slot	pairs	mean	SD	mean	SD	mean	SD
DVS SR 50 mg	Screening/baseline	149	12.3	7.2	•	•		
	Week 12	110	11.9	7.1	6.5	5.7	-5.5	6.9
DVS SR 100 mg	Screening/baseline	152	12.5	7.7	•			
	Week 12	116	12.1	7.5	5.5	4.3	-6.6	7.4
DVS SR 150 mg	Screening/baseline	156	12.2	8.0				
	Week 12	97	10.6	6.5	6.0	4.3	-4.6	5.8
DVS SR 200 mg	Screening/baseline	150	12.8	7.2				
	Week 12	87	12.2	7.3	7.3	6.0	-4.9	7.1
Placebo	Screening/baseline	76	12.5	7.9				
	Week 12	61	12.4	7.9	8.3	5.9	-4.1	6.6
TOTAL MOOD DISTURBANCE								
TOTAL MOOD I	DISTURBANCE	No.	-Basel	ine-	-Obser	ved-	Change baselin	
TOTAL MOOD I	DISTURBANCE Time	No. of	-Baseli	ine-	-Obser	ved-	_	
TOTAL MOOD I			-Baseli	ine- SD	-Obser	ved- SD	_	
	Time slot	of	_				baselin	ne
Treatment	Time	of pairs	mean	SD	mean		baselin	ne
Treatment	Time slot Screening/baseline	of pairs 140	mean 36.6	SD 34.7	mean	SD .	baselin mean	SD .
Treatment DVS SR 50 mg	Time slot Screening/baseline Week 12	of pairs 140 95	mean 36.6 38.6	SD 34.7 34.8	mean	SD .	baselin mean	SD .
Treatment DVS SR 50 mg	Time slot Screening/baseline Week 12 Screening/baseline	of pairs 140 95 148	mean 36.6 38.6 34.6	SD 34.7 34.8 37.6	mean 6.8	SD 23.7	mean -31.8	SD
Treatment DVS SR 50 mg DVS SR 100 mg	Time slot Screening/baseline Week 12 Screening/baseline Week 12	of pairs 140 95 148 111	mean 36.6 38.6 34.6 34.3	SD 34.7 34.8 37.6 37.8	mean 6.8	SD 23.7	mean -31.8	SD
Treatment DVS SR 50 mg DVS SR 100 mg	Time slot Screening/baseline Week 12 Screening/baseline Week 12 Screening/baseline	of pairs 140 95 148 111 149	mean 36.6 38.6 34.6 34.3 35.5	SD 34.7 34.8 37.6 37.8 40.0	mean 6.8 4.4	SD 23.7 21.3	mean -31.829.9	SD 32.1 34.2
Treatment DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	Time slot Screening/baseline Week 12 Screening/baseline Week 12 Screening/baseline Week 12	of pairs 140 95 148 111 149 91	mean 36.6 38.6 34.6 34.3 35.5 30.2	SD 34.7 34.8 37.6 37.8 40.0 34.4	mean 6.8 4.4	SD 23.7 21.3	mean -31.829.9	SD 32.1 34.2
Treatment DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	Time slot Screening/baseline Week 12 Screening/baseline Week 12 Screening/baseline Week 12 Screening/baseline	of pairs 140 95 148 111 149 91 143	mean 36.6 38.6 34.6 34.3 35.5 30.2 41.4	SD 34.7 34.8 37.6 37.8 40.0 34.4 36.4	mean . 6.8 . 4.4 . 6.1	SD 23.7 21.3 22.7	mean -31.8 -29.9 -24.1	SD

VIGOR ACTIVITY			-Baseline-		-Observed-		Change from baseline	
		No.						
	Time	of						
Treatment	slot	pairs	mean	SD	mean	SD	mean	SD
DVS SR 50 mg	Screening/baseline	148	14.2	6.4				
	Week 12	109	14.4	6.4	18.4	6.3	4.1	6.3
DVS SR 100 mg	Screening/baseline	152	15.8	6.6				
_	Week 12	117	15.8	6.8	18.6	6.0	2.8	6.2
DVS SR 150 mg	Screening/baseline	155	15.3	6.0				
	Week 12	96	15.2	6.0	18.3	5.9	3.1	5.8
DVS SR 200 mg	Screening/baseline	149	14.3	5.8				
_	Week 12	86	14.2	5.6	18.6	5.9	4.4	6.4
Placebo	Screening/baseline	75	15.7	6.4	•		•	
	Week 12	60	16.1	6.5	18.0	5.8	2.0	5.4

Adjusted						
ANGER HOSTIL	change					
		No.			p-value	p-value
	Time	of			VS.	within
Treatment	slot	pairs	mean	SE	placebo	group
DVS SR 50 mg	Week 12	109	-5.79	0.77	0.009	< 0.001
DVS SR 100 mg	Week 12	116	-4.99	0.74	0.047	< 0.001
DVS SR 150 mg	Week 12	97	-4.85	0.82	0.071	< 0.001
DVS SR 200 mg	Week 12	86	-5.58	0.87	0.020	< 0.001
Placebo	Week 12	61	-2.56	1.01	•	0.012

CONFUSION BEWILDERMENT			Adjusted change				
		No.	- viimilge		p-value	p-value	
	Time	of			VS.	within	
Treatment	slot	pairs	mean	SE	placebo	group	
DVS SR 50 mg	Week 12	112	-3.08	0.46	0.545	< 0.001	
DVS SR 100 mg	Week 12	117	-3.36	0.44	0.324	< 0.001	
DVS SR 150 mg	Week 12	98	-2.63	0.49	0.993	< 0.001	
DVS SR 200 mg	Week 12	86	-2.88	0.52	0.754	< 0.001	
Placebo	Week 12	61	-2.64	0.61		< 0.001	
DEPRESSION DEJECTION			Adjusted change				
		No.			p-value	p-value	
	Time	of			VS.	within	
Treatment	slot	pairs	mean	SE	placebo	group	
DVS SR 50 mg	Week 12	108	-6.00	0.99	0.203	< 0.001	
DVS SR 100 mg	Week 12	113	-6.54	0.95	0.103	< 0.001	
DVS SR 150 mg	Week 12	97	-4.71	1.04	0.651	< 0.001	
DVS SR 200 mg	Week 12	85	-7.20	1.12	0.054	< 0.001	
	WCCK 12	0.5	7.20	1.12	0.05	0.001	

	Adju	sted					
FATIGUE INERTIA			change				
		No.			p-value	p-value	
	Time	of			VS.	within	
Treatment	slot	pairs	mean	SE	placebo	group	
DVS SR 50 mg	Week 12	111	-4.52	0.72	0.516	< 0.001	
DVS SR 100 mg	Week 12	116	-5.50	0.69	0.130	< 0.001	
DVS SR 150 mg	Week 12	97	-4.66	0.77	0.455	< 0.001	
DVS SR 200 mg	Week 12	85	-4.87	0.82	0.367	< 0.001	
Placebo	Week 12	61	-3.77	0.95		< 0.001	

DVS SR Protocol 3151A2-315-US CSR-60178

--Adjusted

TENSION ANXIETY			change				
		No.			p-value	p-value	
	Time	of			VS.	within	
Treatment	slot	pairs	mean	SE	placebo	group	
DVS SR 50 mg	Week 12	110	-5.86	0.68	0.232	< 0.001	
DVS SR 100 mg	Week 12	116	-6.85	0.65	0.034	< 0.001	
DVS SR 150 mg	Week 12	97	-5.06	0.72	0.656	< 0.001	
DVS SR 200 mg	Week 12	87	-5.39	0.76	0.470	< 0.001	
Placebo	Week 12	61	-4.56	0.89		< 0.001	
TOTAL MOOD I	DISTURBA	ANCE	Adju	sted			
SCORE			change				
		No.			p-value	p-value	
	Time	of			VS.	within	
Treatment	slot	pairs	mean	SE	placebo	group	
DVS SR 50 mg	Week 12	95	-33.12	3.50	0.015	< 0.001	
DVS SR 100 mg	Week 12	111	-30.32	3.20	0.047	< 0.001	
DVS SR 150 mg	Week 12	91	-25.90	3.58	0.272	< 0.001	
DVS SR 200 mg	Week 12	79	-31.55	3.85	0.040	< 0.001	
Placebo	Week 12	59	-19.84	4.37		< 0.001	
			Adjusted				
VIGOR ACTIVITY			change				
-		No.			p-value	p-value	
	Time	of			VS.	within	
Treatment	slot	pairs	mean	SE	placebo	group	
DVS SR 50 mg	Week 12	109	4.23	0.62	0.027	< 0.001	
DVS SR 100 mg	Week 12	117	2.86	0.59	0.398	< 0.001	
DVS SR 150 mg	Week 12	96	3.23	0.66	0.241	< 0.001	
DVS SR 200 mg	Week 12	86	4.53	0.70	0.017	< 0.001	
Placebo	Week 12	60	2.03	0.82		0.014	

Source: CLINICAL R&D/CLINICAL BIOSTATISTICS SAS REPORTS/3151A2/315/ 315_NDA_2005/poms_itt_anova_final_05_csr.rtf

ST 9-9: Reduction in Average Daily Number of Mild, Moderate, and Severe Hot Flushes for the ITT LOCF Population

Reduction in Average Daily Number of Mild, Moderate, and Severe Hot Flushes for the ITT LOCF Population

Adjusted Change								
TID 4	TE! ID!	ъ.						
Treatment 50	Time Point	Pairs, n	Mean	SE	p-Value vs Placebo			
DVS SR 50 mg	Week 1	141	-3.63	0.34	0.037			
	Week 2	141	-4.85	0.37	0.056			
	Week 3	141	-5.48	0.37	0.055			
	Week 4	141	-5.89	0.37	0.168			
	Week 5	141	-6.16	0.37	0.200			
	Week 6	141	-6.18	0.38	0.417			
	Week 7	141	-6.18	0.38	0.501			
	Week 8	141	-6.09	0.39	0.754			
	Week 9	141	-6.33	0.38	0.376			
	Week 10	141	-6.33	0.39	0.578			
	Week 11	141	-6.47	0.40	0.447			
	Week 12	141	-6.47	0.40	0.365			
DVS SR 100 mg	Week 1	145	-4.96	0.33	< 0.001			
	Week 2	145	-6.30	0.36	< 0.001			
	Week 3	145	-6.63	0.37	< 0.001			
	Week 4	145	-6.81	0.36	0.004			
	Week 5	145	-7.07	0.36	0.005			
	Week 6	145	-7.18	0.37	0.014			
	Week 7	145	-7.25	0.37	0.016			
	Week 8	145	-7.27	0.38	0.029			
	Week 9	145	-7.42	0.38	0.008			
	Week 10	145	-7.41	0.38	0.023			
	Week 11	145	-7.40	0.39	0.028			
	Week 12	145	-7.44	0.39	0.016			
DVS SR 150 mg	Week 1	136	-5.02	0.35	< 0.001			
	Week 2	137	-6.37	0.37	< 0.001			
	Week 3	137	-6.65	0.38	< 0.001			
	Week 4	137	-6.72	0.37	0.006			
	Week 5	137	-7.56	0.37	< 0.001			
	Week 6	137	-7.59	0.38	0.002			
	Week 7	137	-7.51	0.39	0.005			

DVS SR Protocol 3151A2-315-US CSR-60178

Reduction in Average Daily Number of Mild, Moderate, and Severe Hot Flushes for the ITT LOCF Population

			Adjusted	Change	
Treatment	Time Point	Pairs, n	Mean	SE	p-Value vs Placebo
	Week 8	137	-7.49	0.39	0.012
	Week 9	137	-7.45	0.39	0.008
	Week 10	137	-7.45	0.40	0.021
	Week 11	137	-7.41	0.40	0.028
	Week 12	137	-7.40	0.40	0.020
DVS SR 200 mg	Week 1	120	-4.64	0.37	< 0.001
-	Week 2	120	-6.12	0.39	< 0.001
	Week 3	120	-6.30	0.40	0.002
	Week 4	120	-6.55	0.40	0.016
	Week 5	120	-6.53	0.39	0.064
	Week 6	120	-6.64	0.41	0.128
	Week 7	120	-6.90	0.41	0.076
	Week 8	120	-6.86	0.42	0.138
	Week 9	120	-6.95	0.41	0.069
	Week 10	120	-7.07	0.42	0.095
	Week 11	120	-6.85	0.43	0.193
	Week 12	120	-6.79	0.43	0.175
Placebo	Week 1	77	-2.47	0.45	
	Week 2	77	-3.71	0.48	
	Week 3	77	-4.32	0.49	
	Week 4	77	-5.07	0.49	
	Week 5	77	-5.39	0.49	
	Week 6	77	-5.68	0.50	
	Week 7	77	-5.76	0.50	
	Week 8	77	-5.89	0.52	
	Week 9	77	-5.77	0.51	
	Week 10	77	-5.98	0.52	
	Week 11	77	-5.98	0.53	
	Week 12	77	-5.88	0.53	

Reduction in Average Daily Number of Mild, Moderate, and Severe Hot Flushes for the ITT LOCF Population

--Adjusted Change--

Treatment Time Point Pairs, n Mean SE p-Value vs Placebo

Abbreviations: ITT=intent to treat; LOCF=last observation carried forward; and

SE=standard error.

Analysis of covariance: change=treat+site+baseline.

Source: Source: CLINICAL R&D/CLINICAL BIOSTATISTICS SAS REPORTS/3151A2/315/315_NDA_2005/hf_itt_locf_ancova_final_05.html/TEST_NAME=AVERAGE_DAILY

NUMBER OF MILD, MODERATE AND SEVERE HOT FLUSHES

ST 9-10: Reduction in Average Daily Number of Mild, Moderate, and Severe Hot Flushes for the ITT Observed Data Population

Treatment	Time slot	No. of pairs	mean SE	p-value vs. placebo	p-value within group
DVS SR 50 mg	Week 1	141	-3.63 0.34	0.037	< 0.001
	Week 2	138	-4.98 0.36	0.036	< 0.001
	Week 3	137	-5.67 0.37	0.032	< 0.001
	Week 4	137	-6.10 0.36	0.101	< 0.001
	Week 5	130	-6.44 0.37	0.091	< 0.001
	Week 6	130	-6.26 0.36	0.288	< 0.001
	Week 7	129	-6.23 0.37	0.436	< 0.001
	Week 8	129	-6.14 0.38	0.702	< 0.001
	Week 9	126	-6.32 0.37	0.364	< 0.001
	Week 10	124	-6.40 0.38	0.745	< 0.001
	Week 11	125	-6.53 0.39	0.539	< 0.001
	Week 12	125	-6.53 0.39	0.738	< 0.001
	Week 13-16	116	-7.12 0.37	0.058	< 0.001
	Week 17-20	109	-7.45 0.40	0.019	< 0.001
	Week 21-24	106	-7.45 0.41	0.030	< 0.001
	Week 25-28	103	-7.59 0.39	0.159	< 0.001
	Week 29-32	97	-7.88 0.41	0.129	< 0.001
	Week 33-36	94	-8.10 0.40	0.025	< 0.001
	Week 37-40	94	-8.24 0.41	0.038	< 0.001
	Week 41-44	91	-8.52 0.40	0.016	< 0.001

DVS SR Protocol 3151A2-315-US CSR-60178

Treatment	Time slot	No. of pairs	mean SE	p-value vs. placebo	p-value within group
	Week 45-48	89	-8.50 0.41	0.047	< 0.001
	Week 49-52	88	-8.51 0.44	0.087	< 0.001
	Week 53-56	28	-8.34 0.79	0.328	< 0.001
DVS SR 100 mg	Week 1	145	-4.96 0.33	0.000	< 0.001
	Week 2	142	-6.38 0.35	0.000	< 0.001
	Week 3	139	-6.79 0.36	0.000	< 0.001
	Week 4	135	-7.10 0.36	0.001	< 0.001
	Week 5	131	-7.46 0.36	0.001	< 0.001
	Week 6	131	-7.41 0.36	0.002	< 0.001
	Week 7	129	-7.52 0.36	0.003	< 0.001
	Week 8	128	-7.62 0.38	0.005	< 0.001
	Week 9	126	-7.89 0.37	0.000	< 0.001
	Week 10	122	-7.89 0.38	0.006	< 0.001
	Week 11	121	-7.97 0.39	0.004	< 0.001
	Week 12	121	-8.02 0.39	0.007	< 0.001
	Week 13-16	115	-8.00 0.37	0.001	< 0.001
	Week 17-20	111	-8.02 0.39	0.001	< 0.001
	Week 21-24	110	-8.11 0.40	0.002	< 0.001
	Week 25-28	108	-8.41 0.37	0.006	< 0.001
	Week 29-32	96	-8.64 0.39	0.008	< 0.001
	Week 33-36	94	-8.39 0.39	0.007	< 0.001
	Week 37-40	93	-8.56 0.41	0.010	< 0.001

DVS SR Protocol 3151A2-315-US CSR-60178

Treatment	Time slot	No. of pairs	mean SE	p-value vs. placebo	p-value within group
	Week 41-44	90	-8.73 0.40	0.006	< 0.001
	Week 45-48	85	-8.64 0.41	0.029	< 0.001
	Week 49-52	83	-8.44 0.44	0.111	< 0.001
	Week 53-56	26	-9.64 0.76	0.043	< 0.001
OVS SR 150 mg	Week 1	136	-5.02 0.35	0.000	< 0.001
	Week 2	131	-6.47 0.37	0.000	< 0.001
	Week 3	128	-6.80 0.38	0.000	< 0.001
	Week 4	125	-6.87 0.38	0.004	< 0.001
	Week 5	121	-7.81 0.38	0.000	< 0.001
	Week 6	119	-7.60 0.38	0.001	< 0.001
	Week 7	116	-7.61 0.39	0.002	< 0.001
	Week 8	115	-7.55 0.40	0.009	< 0.001
	Week 9	110	-7.45 0.40	0.007	< 0.001
	Week 10	111	-7.51 0.41	0.037	< 0.001
	Week 11	110	-7.48 0.42	0.040	< 0.001
	Week 12	109	-7.45 0.41	0.080	< 0.001
	Week 13-16	104	-7.72 0.39	0.004	< 0.001
	Week 17-20	96	-7.71 0.43	0.008	< 0.001
	Week 21-24	92	-7.57 0.44	0.023	< 0.001
	Week 25-28	90	-7.83 0.41	0.081	< 0.001
	Week 29-32	85	-8.12 0.43	0.069	< 0.001
	Week 33-36	84	-7.95 0.42	0.051	< 0.001

DVS SR Protocol 3151A2-315-US CSR-60178

Treatment	Time slot	No. of pairs	mean SE	p-value vs. placebo	p-value within group
	Week 37-40	82	-7.83 0.44	0.161	<0.001
	Week 41-44	81	-7.83 0.43	0.195	< 0.001
	Week 45-48	77	-7.95 0.44	0.272	< 0.001
	Week 49-52	75	-7.97 0.47	0.372	< 0.001
	Week 53-56	21	-8.04 0.88	0.507	< 0.001
OVS SR 200 mg	Week 1	120	-4.64 0.37	0.000	< 0.001
	Week 2	113	-6.46 0.40	0.000	< 0.001
	Week 3	110	-6.61 0.41	0.000	< 0.001
	Week 4	108	-6.97 0.41	0.003	< 0.001
	Week 5	102	-7.06 0.42	0.009	< 0.001
	Week 6	102	-7.12 0.41	0.016	< 0.001
	Week 7	101	-7.36 0.42	0.011	< 0.001
	Week 8	101	-7.32 0.43	0.029	< 0.001
	Week 9	99	-7.38 0.42	0.011	< 0.001
	Week 10	99	-7.63 0.43	0.027	< 0.001
	Week 11	97	-7.33 0.45	0.077	< 0.001
	Week 12	97	-7.30 0.44	0.140	< 0.001
	Week 13-16	94	-7.91 0.41	0.002	< 0.001
	Week 17-20	87	-8.02 0.45	0.002	< 0.001
	Week 21-24	84	-8.29 0.46	0.001	< 0.001
	Week 25-28	82	-8.30 0.43	0.015	< 0.001
	Week 29-32	76	-8.66 0.45	0.010	< 0.001

DVS SR Protocol 3151A2-315-US CSR-60178

Treatment	Time slot	No. of pairs	mean SE	p-value vs. placebo	p-value within group
	Week 33-36	74	-8.65 0.45	0.003	< 0.001
	Week 37-40	71	-8.84 0.47	0.005	< 0.001
	Week 41-44	70	-8.85 0.46	0.005	< 0.001
	Week 45-48	69	-8.97 0.47	0.010	< 0.001
	Week 49-52	69	-8.90 0.49	0.029	< 0.001
	Week 53-56	18	-8.72 0.92	0.229	< 0.001
lacebo	Week 1	77	-2.47 0.45		< 0.001
	Week 2	77	-3.77 0.47		< 0.001
	Week 3	77	-4.39 0.48		< 0.001
	Week 4	77	-5.15 0.47		< 0.001
	Week 5	76	-5.45 0.47		< 0.001
	Week 6	74	-5.64 0.47		< 0.001
	Week 7	72	-5.77 0.48		< 0.001
	Week 8	70	-5.90 0.50		< 0.001
	Week 9	71	-5.78 0.49		< 0.001
	Week 10	70	-6.20 0.50		< 0.001
	Week 11	69	-6.15 0.52		< 0.001
	Week 12	67	-6.32 0.52		< 0.001
	Week 13-16	66	-6.00 0.48		< 0.001
	Week 17-20	60	-5.93 0.53		< 0.001
	Week 21-24	59	-6.02 0.54		< 0.001
	Week 25-28	58	-6.72 0.51		< 0.001

DVS SR Protocol 3151A2-315-US CSR-60178

Treatment	Time slot	No. of pairs	mean SE	p-value vs. placebo	p-value within group
	Week 29-32	51	-6.89 0.54		< 0.001
	Week 33-36	50	-6.65 0.54		< 0.001
	Week 37-40	50	-6.89 0.55		< 0.001
	Week 41-44	49	-6.98 0.53		< 0.001
	Week 45-48	48	-7.21 0.55		< 0.001
	Week 49-52	48	-7.33 0.58		< 0.001
	Week 53-56	15	-7.16 0.99		< 0.001

ST 9-11: Reduction in Weekly Weighted Score of Moderate and Severe Hot Flushes for the ITT LOCF Population

Reduction in Weekly Weighted Score of Moderate and Severe Hot Flushes for the ITT								
	LOCF PopulationAdjusted Change							
Treatment	Time Point	Pairs, n	Aujusteu Mean	SE	p-Value vs Placebo			
DVS SR 50 mg	Week 1	141	-70.13	5.80	0.005			
DVS SIC 50 mg	Week 2	141	-70.13 -90.14	6.21	0.003			
	Week 3	141	-98.99	6.29	0.149			
	Week 4	141	-109.0	6.14	0.149			
	Week 5	141	-109.0	6.21	0.757			
	Week 6	141	-108.7	6.27	0.871			
	Week 7	141	-108.7	6.29	0.597			
	Week 8	141	-108.5	6.50	0.616			
	Week 9	141	-1107.0	6.36	0.680			
	Week 10	141	-110.2	6.30	0.610			
	Week 11	141	-112.9	6.38	0.705			
	Week 12	141	-112.9	6.29	0.703			
DVS SR 100 mg	Week 1	145	-91.95	5.71	< 0.001			
DVS SK 100 mg	Week 2	145	-115.3	6.11	< 0.001			
	Week 3	145	-113.3	6.18	< 0.001			
	Week 4	145	-121.7	6.04	0.003			
	Week 5	145	-130.0	6.11	0.003			
	Week 6	145	-130.0	6.17	0.013			
	Week 7	145	-132.3	6.19	0.056			
	Week 8	145	-134.4	6.40	0.030			
	Week 9	145	-137.0	6.26	0.029			
	Week 10	145	-137.0	6.20	0.029			
	Week 11	145	-138.8	6.28	0.028			
	Week 12	145	-139.5	6.19	0.012			
DVS SR 150 mg	Week 1	136	-95.44	5.91	< 0.012			
D V S SIC 130 IIIg	Week 2	137	-114.5	6.30	< 0.001			
	Week 3	137	-119.9	6.38	0.001			
	Week 4	137	-110.5	6.23	0.016			
	Week 5	137	-135.8	6.31	0.010			
	Week 6	137	-135.1	6.37	0.005			
	Week 7	137	-134.8	6.38	0.041			

DVS SR Protocol 3151A2-315-US CSR-60178

Reduction in Weekly Weighted Score of Moderate and Severe Hot Flushes for the ITT								
LOCF Population								
Adjusted Change								
Treatment	Time Point	Pairs, n	Mean	SE	p-Value vs Placebo			
	Week 8	137	-133.2	6.60	0.056			

Adjusted Change						
Treatment	Time Point	Pairs, n	Mean	SE	p-Value vs Placebo	
	Week 8	137	-133.2	6.60	0.056	
	Week 9	137	-133.8	6.45	0.064	
	Week 10	137	-132.4	6.40	0.106	
	Week 11	137	-132.5	6.47	0.136	
	Week 12	137	-132.8	6.38	0.066	
DVS SR 200 mg	Week 1	120	-91.97	6.26	< 0.001	
_	Week 2	120	-115.0	6.69	< 0.001	
	Week 3	120	-117.3	6.78	0.002	
	Week 4	120	-123.5	6.62	0.007	
	Week 5	120	-123.9	6.70	0.071	
	Week 6	120	-122.8	6.76	0.238	
	Week 7	120	-126.1	6.78	0.243	
	Week 8	120	-125.7	7.01	0.239	
	Week 9	120	-126.9	6.86	0.244	
	Week 10	120	-127.6	6.80	0.258	
	Week 11	120	-124.1	6.88	0.498	
	Week 12	120	-123.6	6.78	0.357	
Placebo	Week 1	77	-43.24	7.70		
	Week 2	77	-68.16	8.23		
	Week 3	77	-84.20	8.34		
	Week 4	77	-95.76	8.14		
	Week 5	77	-105.0	8.24		
	Week 6	77	-110.4	8.32		
	Week 7	77	-113.7	8.35		
	Week 8	77	-112.9	8.63		
	Week 9	77	-114.5	8.44		
	Week 10	77	-115.7	8.36		
	Week 11	77	-116.9	8.46		
	Week 12	77	-113.8	8.34		

Reduction in Weekly Weighted Score of Moderate and Severe Hot Flushes for the ITT LOCF Population

--Adjusted Change--

Treatment Time Point Pairs, n Mean SE p-Value vs Placebo

Abbreviations: ITT=intent to treat; LOCF=last observation carried forward; and

SE=standard error.

Analysis of covariance: change=treat+site+baseline.

Source: CLINICAL R&D/CLINICAL BIOSTATS SAS REPORTS/315/315_NDA /hf_itt_locf_ancova_final_05.htmlTEST NAME=WEEKLY WEIGHTED SCORE OF

MODERATE AND SEVERE HOT FLUSHES

ST 9-12: Reduction in Weekly Weighted Score of Moderate and Severe Hot Flushes for the ITT Observed Data Population

Reduction in Weekly Weighted Score of Moderate and Severe Hot Flushes for the ITT								
Observed Data Population								
			Adjusted	d Change				
Treatment	Time Point	Pairs, n	Mean	SE	p-Value vs Placebo			
DVS SR 50 mg	Week 1	141	-70.13	5.80	0.005			
	Week 2	138	-92.68	6.04	0.016			
	Week 3	137	-102.2	6.17	0.099			
	Week 4	137	-113.1	6.01	0.114			
	Week 5	130	-111.4	6.25	0.684			
	Week 6	130	-108.1	6.11	0.952			
	Week 7	129	-106.8	6.17	0.811			
	Week 8	129	-106.1	6.40	0.828			
	Week 9	126	-107.0	6.29	0.787			
	Week 10	124	-107.1	6.33	0.629			
	Week 11	125	-109.8	6.42	0.755			
	Week 12	125	-117.1	6.28	0.657			
DVS SR 100 mg	Week 1	145	-91.95	5.71	< 0.001			
	Week 2	142	-117.1	5.92	< 0.001			
	Week 3	139	-124.4	6.09	< 0.001			
	Week 4	135	-129.0	6.01	0.001			
	Week 5	131	-135.1	6.20	0.005			
	Week 6	131	-134.7	6.06	0.008			
	Week 7	129	-135.3	6.13	0.009			
	Week 8	128	-138.5	6.38	0.004			
	Week 9	126	-142.2	6.24	0.001			
	Week 10	122	-143.4	6.30	0.002			
	Week 11	121	-144.2	6.42	0.003			
	Week 12	121	-145.0	6.28	0.002			
DVS SR 150 mg	Week 1	136	-95.44	5.91	< 0.001			
	Week 2	131	-116.5	6.24	< 0.001			
	Week 3	128	-122.1	6.42	< 0.001			
	Week 4	125	-121.7	6.31	0.016			
	Week 5	121	-139.3	6.54	0.002			
	Week 6	119	-134.6	6.45	0.010			
	Week 7	116	-135.2	6.56	0.011			

DVS SR Protocol 3151A2-315-US CSR-60178

Reduction in Weekly Weighted Score of Moderate and Severe Hot Flushes for the ITT
Observed Data Population

			ıta Populatı Adjusted		
Treatment	Time Point	Pairs, n	Mean	SE	p-Value vs Placebo
	Week 8	115	-132.4	6.82	0.024
	Week 9	110	-131.8	6.75	0.033
	Week 10	111	-130.4	6.69	0.074
	Week 11	110	-131.0	6.83	0.089
	Week 12	109	-131.4	6.71	0.073
DVS SR 200 mg	Week 1	120	-91.97	6.26	< 0.001
	Week 2	113	-121.8	6.71	< 0.001
	Week 3	110	-123.1	6.91	< 0.001
	Week 4	108	-130.6	6.78	0.001
	Week 5	102	-131.5	7.10	0.021
	Week 6	102	-128.4	6.93	0.057
	Week 7	101	-131.5	6.99	0.034
	Week 8	101	-130.7	7.25	0.041
	Week 9	99	-131.0	7.12	0.045
	Week 10	99	-132.7	7.09	0.050
	Week 11	97	-127.6	7.30	0.179
	Week 12	97	-127.5	7.15	0.165
Placebo	Week 1	77	-43.24	7.70	
	Week 2	77	-69.20	7.91	
	Week 3	77	-85.82	8.06	
	Week 4	77	-97.84	7.84	
	Week 5	76	-107.3	8.01	
	Week 6	74	-108.7	7.92	
	Week 7	72	-109.2	8.11	
	Week 8	70	-108.3	8.52	
	Week 9	71	-109.7	8.21	
	Week 10	70	-112.0	8.21	
	Week 11	69	-113.0	8.41	
	Week 12	67	-112.6	8.37	

Reduction in Weekly Weighted Score of Moderate and Severe Hot Flushes for the ITT
Observed Data Population

--Adjusted Change--

Treatment Time Point Pairs, n Mean SE p-Value vs Placebo

Abbreviations: ITT=intent to treat and SE=standard error.

Analysis of covariance: change=treat+site+baseline.

Source: CLINICAL R&D/CLINICAL BIOSTATISTICS SAS REPORTS/3151A2/315/315_NDA_2005 /hf_itt_ancova_final_05.html TEST NAME=WEEKLY WEIGHTED

SCORE OF MODERATE AND SEVERE HOT FLUSHES

CONFIDENTIAL 319 Wyeth

ST 9-13: Number and Percentage of Subjects With ≥75% Decrease in Average Daily Number of Moderate and Severe Hot Flushes for the ITT Observed Data Population

Number and Percentage of Subjects With ≥75% Decrease in Average Daily Number of Moderate and Severe Hot Flushes for the ITT Observed Data Population

			Decrease ≥75%		Relative Ratio	ve Ratio95% CI		p-Value
Treatment	Time Period	Pairs, n	n	%	vs Placebo	Lower	Upper	vs Placebo
DVS SR 50 mg	Week 4	137	34	24.82	1.49	0.74	3.00	0.260
	Week 12	125	44	35.20	1.11	0.59	2.09	0.735
DVS SR 100 mg	Week 4	135	52	38.52	2.83	1.44	5.56	0.003
	Week 12	121	68	56.20	2.65	1.42	4.95	0.002
DVS SR 150 mg	Week 4	125	48	38.40	2.82	1.43	5.59	0.003
	Week 12	109	49	44.95	1.68	0.89	3.18	0.109
DVS SR 200 mg	Week 4	108	38	35.19	2.45	1.21	4.94	0.012
	Week 12	97	48	49.48	2.01	1.05	3.84	0.035
Placebo	Week 4	77	14	18.18				
	Week 12	67	22	32.84				

Abbreviations: CI=confidence interval and ITT=intent to treat.

Logistic: decrease 75%=treat+site. This value is the ratio of having at least 75% reduction compared with placebo.

Source: CLINICAL R&D/CLINICAL BIOSTATISTICS SAS REPORTS/3151A2/315/ 315_NDA_2005

hf_itt_reduction_final_05_csr_v24.rtf October 17, 2005 04:03

ST 9-14: Number and Percentage of Subjects With ≥50% Decrease in Average Daily Number of Moderate and Severe Hot Flushes for the ITT LOCF Population

Number and Percentage of Subjects With ≥50% Decrease in Average Daily Number of Moderate and Severe Hot Flushes for the ITT LOCF Population

			Decrea	ıse≥50%		95	% CI	
Treatment	Time Period	Pairs, n	n	%	Relative Ratio vs Placebo	Lower	Upper	p-Value vs Placebo
DVS SR 50 mg	Week 4	141	83	58.87	1.32	0.75	2.31	0.331
	Week 12	141	92	65.25	1.33	0.75	2.36	0.326
DVS SR 100 mg	Week 4	145	96	66.21	1.81	1.03	3.18	0.040
	Week 12	145	100	68.97	1.57	0.88	2.80	0.123
DVS SR 150 mg	Week 4	137	87	63.50	1.61	0.91	2.84	0.101
	Week 12	137	95	69.34	1.60	0.89	2.86	0.116
DVS SR 200 mg	Week 4	120	82	68.33	2.01	1.11	3.63	0.021
_	Week 12	120	76	63.33	1.23	0.68	2.22	0.484
Placebo	Week 4	77	40	51.95				
	Week 12	77	45	58.44		•		

Abbreviations: CI=confidence interval and ITT=intent to treat.

Logistic: decrease 50%=treat+site. This value is the ratio of having 50% reduction compared with placebo.

Source: CLINICAL R&D/CLINICAL BIOSTATISTICS SAS REPORTS/3151A2/315/ 315_NDA_2005

hf itt locf reduction final 05 csr v22.rtf October 17, 2005 04:26

ST 9-15: Number and Percentage of Subjects With ≥50% Decrease in Average Daily Number of Moderate and Severe Hot Flushes for the ITT Observed Data Population

Number and Percentage of Subjects With ≥50% Decrease in Average Daily Number of Moderate and Severe Hot Flushes for the ITT Observed Data Population

			Decreas	se ≥50%	95%	6 CI		
					Relative Ratio			p-Value
Treatment	Time Period	Pairs, n	n	%	vs Placebo	Lower	Upper	vs Placebo
DVS SR 50 mg	Week 4	137	83	60.58	1.42	0.81	2.49	0.226
	Week 12	125	83	66.40	1.18	0.63	2.19	0.608
DVS SR 100 mg	Week 4	135	94	69.63	2.12	1.19	3.78	0.011
	Week 12	121	93	76.86	1.98	1.03	3.80	0.041
DVS SR 150 mg	Week 4	125	80	64.00	1.64	0.92	2.93	0.092
_	Week 12	109	79	72.48	1.57	0.82	3.01	0.174
DVS SR 200 mg	Week 4	108	78	72.22	2.42	1.31	4.48	0.005
	Week 12	97	67	69.07	1.33	0.69	2.58	0.391
Placebo	Week 4	77	40	51.95				
	Week 12	67	42	62.69				

Abbreviations: CI=confidence interval; ITT=intent to treat; and LOCF=last observation carried forward. Logistic: decrease 50%=treat+site. This value is the ratio of having 50% reduction compared with placebo. Source: CLINICAL R&D/CLINICAL BIOSTATISTICS SAS REPORTS/3151A2/315/315_NDA_2005 hf_itt_reduction_final_05_final_05_csr_v22.rtf October 18, 2005_10:42

ST 9-16: Number and Percentage of Subjects With ≥50% Decrease in Average Daily Number of Mild, Moderate and Severe Hot Flushes for the ITT LOCF Population

Number and Percentage of Subjects With ≥50% Decrease in Average Daily Number of Mild, Moderate and Severe Hot Flushes for the ITT LOCF Population

		-	-Decrease ≥50%95% CI			6 CI		
					Relative Ratio			p-Value vs
Treatment	Time Period	Pairs, n	n	%	vs Placebo	Lower	Upper	Placebo
DVS SR 50 mg	Week 4	141	70	49.65	1.83	1.03	3.24	0.040
-	Week 12	141	81	57.45	1.07	0.61	1.87	0.816
DVS SR 100 mg	Week 4	145	86	59.31	2.73	1.53	4.85	0.001
-	Week 12	145	93	64.14	1.41	0.80	2.49	0.230
DVS SR 150 mg	Week 4	137	82	59.85	2.78	1.55	4.96	0.001
-	Week 12	137	88	64.23	1.41	0.80	2.50	0.235
DVS SR 200 mg	Week 4	120	66	55.00	2.27	1.26	4.10	0.007
C	Week 12	120	69	57.50	1.08	0.60	1.92	0.804
Placebo	Week 4	77	27	35.06				
	Week 12	77	43	55.84				

Abbreviation: CI=confidence interval.

Source: Cabinets/CLINICAL R&D/CLINICAL BIOSTATISTICS SAS REPORTS/3151A2/315/

315_NDA_2005 hf_itt_locf_reduction_final_05_csr_v21.rtf

ST 9-17: Number and Percentage of Subjects With ≥50% Decrease in Average Daily Number of Mild, Moderate, and Severe Hot Flushes for the ITT Observed Data Population

Number and Percentage of Subjects With ≥50% Decrease in Average Daily Number of Mild, Moderate and Severe Hot Flushes for the ITT Observed Data Population

			-Decreas	se ≥50%-		95% CI		
T 4 4	T' D	D - 1		0/	Relative Ratio	T	TT	p-Value vs
Treatment	Time Period	Pairs, n	n	%	vs Placebo	Lower	Upper	Placebo
DVS SR 50 mg	Week 4	137	70	51.09	1.94	1.09	3.46	0.024
	Week 12	125	73	58.40	1.08	0.59	1.98	0.795
DVS SR 100 mg	Week 4	135	85	62.96	3.17	1.76	5.69	0.000
	Week 12	121	87	71.90	1.99	1.06	3.73	0.032
DVS SR 150 mg	Week 4	125	76	60.80	2.89	1.60	5.23	0.000
	Week 12	109	73	66.97	1.57	0.84	2.95	0.160
DVS SR 200 mg	Week 4	108	62	57.41	2.50	1.36	4.58	0.003
_	Week 12	97	61	62.89	1.31	0.69	2.47	0.411
Placebo	Week 4	77	27	35.06				
	Week 12	67	38	56.72				

Abbreviation: CI=confidence interval.

Source: Cabinets/CLINICAL R&D/CLINICAL BIOSTATISTICS SAS REPORTS/3151A2/315/ 315_NDA_2005

hf_itt_reduction_final_05_csr_v21.rtf

ST 9-18: Daily Mean Sleep Quality Score for the ITT Observed Data Population

	an Siccp Quan	ty Score for			ita Population
			Adjusted	Change	
Treatment	Time Point	Pairs, n	Mean	SE	p-Value vs Placebo
DVS SR 50 mg	Week 1	139	0.26	0.06	0.702
	Week 2	136	0.53	0.06	0.589
	Week 3	135	0.61	0.06	0.897
	Week 4	135	0.71	0.06	0.649
	Week 5	129	0.59	0.06	0.884
	Week 6	129	0.62	0.07	0.581
	Week 7	128	0.62	0.07	0.634
	Week 8	128	0.66	0.06	0.179
	Week 9	124	0.72	0.06	0.704
	Week 10	123	0.74	0.07	0.808
	Week 11	122	0.76	0.07	0.785
	Week 12	112	0.72	0.08	0.809
DVS SR 100 mg	Week 1	145	0.25	0.06	0.590
· ·	Week 2	141	0.58	0.06	0.263
	Week 3	138	0.60	0.06	0.979
	Week 4	135	0.70	0.06	0.778
	Week 5	129	0.76	0.06	0.120
	Week 6	130	0.81	0.06	0.203
	Week 7	128	0.85	0.07	0.105
	Week 8	127	0.84	0.06	0.733
	Week 9	124	0.82	0.06	0.506
	Week 10	120	0.88	0.07	0.264
	Week 11	119	0.91	0.07	0.285
	Week 12	105	0.88	0.08	0.254
DVS SR 150 mg	Week 1	134	0.26	0.06	0.663
J	Week 2	130	0.51	0.06	0.717
	Week 3	126	0.56	0.06	0.736
	Week 4	124	0.62	0.06	0.638
	Week 5	119	0.77	0.07	0.114
	Week 6	119	0.79	0.07	0.306
	Week 7	116	0.77	0.07	0.381
	Week 8	115	0.84	0.07	0.707

DVS SR Protocol 3151A2-315-US CSR-60178

Daily Mo	ean Sleep Quali	ity Score for	the ITT O	bserved Da	ta Population
				l Change	
Treatment	Time Point	Pairs, n	Mean	SE	p-Value vs Placebo
	Week 9	110	0.88	0.07	0.217
	Week 10	111	0.82	0.07	0.610
	Week 11	108	0.90	0.08	0.346
	Week 12	97	0.91	0.08	0.189
DVS SR 200 mg	Week 1	120	0.27	0.06	0.740
C	Week 2	112	0.62	0.07	0.156
	Week 3	109	0.60	0.07	0.981
	Week 4	107	0.67	0.07	0.968
	Week 5	100	0.67	0.07	0.577
	Week 6	100	0.70	0.07	0.887
	Week 7	99	0.72	0.08	0.701
	Week 8	99	0.77	0.07	0.802
	Week 9	97	0.78	0.07	0.819
	Week 10	97	0.76	0.07	0.983
	Week 11	96	0.76	0.08	0.775
	Week 12	91	0.84	0.08	0.446
Placebo	Week 1	77	0.30	0.08	
	Week 2	77	0.47	0.08	
	Week 3	77	0.60	0.08	
	Week 4	77	0.67	0.08	
	Week 5	76	0.61	0.08	
	Week 6	73	0.68	0.08	
	Week 7	71	0.68	0.09	
	Week 8	70	0.80	0.09	
	Week 9	71	0.75	0.08	
	Week 10	70	0.77	0.09	
	Week 11	68	0.79	0.09	
	Week 12	63	0.74	0.10	

Abbreviations: ITT=intent to treat and SE=standard error.

Analysis of covariance: change=treat+site+baseline.

Source: CLINICAL R&D/CLINICAL BIOSTATISTICS SAS REPORTS/3151A2/315/315_NDA_2005/sleep_itt_ancova_final_05.html TEST NAME=DAILY MEAN QUALITY SCORE OF SLEEP

ST 9-19: Sleep Studies: How Long It Took Subjects to Fall Asleep for the ITT Observed Data Population

			Adjusted	Change		
Treatment	Time Point	Pairs, n	Mean	SE	p-Value vs Placebo	p-Value Within Group
DVS SR 50 mg	Week 1	138	0.84	2.36	0.283	0.723
	Week 2	136	-5.01	2.21	0.731	0.024
	Week 3	134	-7.34	2.32	0.735	0.002
	Week 4	134	-6.77	2.18	0.993	0.002
	Week 5	128	-4.79	2.47	0.244	0.053
	Week 6	128	-4.98	2.58	0.378	0.054
	Week 7	127	-5.20	2.60	0.313	0.046
	Week 8	127	-5.03	2.47	0.159	0.043
	Week 9	123	-5.89	2.42	0.235	0.015
	Week 10	122	-7.57	2.36	0.313	0.001
	Week 11	121	-8.23	2.30	0.245	< 0.001
	Week 12	111	-6.04	2.47	0.418	0.015
DVS SR 100 mg	Week 1	144	2.36	2.31	0.139	0.307
2 1 5 511 100 1118	Week 2	141	-3.48	2.16	0.437	0.108
	Week 3	138	-3.55	2.28	0.174	0.120
	Week 4	134	-5.45	2.17	0.713	0.012
	Week 5	128	-7.20	2.45	0.585	0.003
	Week 6	129	-6.70	2.56	0.642	0.009
	Week 7	127	-9.03	2.58	0.927	0.001
	Week 8	126	-9.50	2.47	0.771	< 0.001
	Week 9	123	-9.05	2.40	0.711	< 0.001
	Week 10	119	-8.77	2.36	0.494	< 0.001
	Week 11	118	-10.00	2.30	0.499	< 0.001
	Week 12	104	-11.03	2.54	0.654	< 0.001
DVS SR 150 mg	Week 1	133	2.85	2.40	0.112	0.237
D V D DIK 130 IIIg	Week 2	129	-3.40	2.29	0.431	0.138
	Week 3	125	-4.29	2.42	0.254	0.077
	Week 4	123	-4.29 -2.46	2.42	0.229	0.284
	Week 5	119	-2.40 -3.97	2.29	0.229	0.284
	Week 6	119	-3.97 -4.31	2.38	0.176	0.123
	Week 6 Week 7	119	-4.31 -6.54	2.71	0.303	0.112

DVS SR Protocol 3151A2-315-US CSR-60178

Sleep Studie	es: How Long It	t Took Subje	cts to Fall A	sleep for th	e ITT Observed D	oata Population
			Adjusted	Change		
					p-Value vs	p-Value Within
Treatment	Time Point	Pairs, n	Mean	SE	Placebo	Group
	Week 8	113	-6.61	2.63	0.322	0.012
	Week 9	110	-8.75	2.56	0.661	0.001
	Week 10	111	-10.27	2.47	0.779	< 0.001
	Week 11	107	-9.43	2.44	0.416	< 0.001
	Week 12	96	-9.66	2.65	0.916	< 0.001
DVS SR 200 mg	Week 1	121	-1.54	2.51	0.660	0.539
_	Week 2	113	-12.08	2.45	0.113	< 0.001
	Week 3	110	-9.45	2.59	0.827	< 0.001
	Week 4	108	-11.00	2.45	0.242	< 0.001
	Week 5	101	-10.04	2.80	0.864	< 0.001
	Week 6	101	-6.50	2.93	0.624	0.027
	Week 7	100	-8.19	2.94	0.781	0.006
	Week 8	100	-11.10	2.80	0.918	< 0.001
	Week 9	98	-12.99	2.73	0.535	< 0.001
	Week 10	98	-11.10	2.64	0.951	< 0.001
	Week 11	97	-14.01	2.58	0.693	< 0.001
	Week 12	92	-13.74	2.73	0.269	< 0.001
Placebo	Week 1	77	-3.26	3.10		0.292
	Week 2	77	-6.23	2.88		0.031
	Week 3	77	-8.60	3.01		0.004
	Week 4	77	-6.73	2.82		0.017
	Week 5	76	-9.33	3.14		0.003
	Week 6	74	-8.62	3.32		0.010
	Week 7	72	-9.41	3.39		0.006
	Week 8	70	-10.66	3.26		0.001
	Week 9	71	-10.48	3.12		0.001
	Week 10	70	-11.34	3.03		< 0.001
	Week 11	68	-12.49	2.99		< 0.001
	Week 12	63	-9.23	3.20		0.004

Sleep Studies: How Long It Took Subjects to Fall Asleep for the ITT Observed Data Population										
Adjusted Change										
				_	p-Value vs	p-Value Within				
Treatment	Time Point	Pairs, n	Mean	SE	Placebo	Group				

Abbreviations: ITT=intent to treat and SE=standard error.

Analysis of covariance: change=treat+site+baseline.

Source: CLINICAL R&D/CLINICAL BIOSTATISTICS SAS REPORTS/3151A2/315/

315_NDA_2005/sleep_itt_ancova_final_05.html TEST NAME=DAILY MEAN MINUTES TO FALL

ASLEEP

CONFIDENTIAL 329 Wyeth

ST 9-20: Sleep Studies: How Long Subjects Slept for the ITT Observed Data Population

Slee	Sleep Studies: How Long Subjects Slept for the ITT Observed Data Population									
	•	<u> </u>	Adjusted	Change						
TD 4	Tr. D	ъ.	_		p-Value vs	p-Value Within				
Treatment	Time Point	Pairs, n	Mean	SE	Placebo	Group				
DVS SR 50 mg	Week 1	139	11.57	5.02	0.769	0.022				
	Week 2	136	23.97	4.53	0.372	< 0.001				
	Week 3	135	22.81	4.79	0.925	< 0.001				
	Week 4	135	24.73	4.85	0.712	< 0.001				
	Week 5	130	23.53	4.85	0.366	< 0.001				
	Week 6	130	22.28	4.62	0.738	< 0.001				
	Week 7	129	26.51	4.40	0.955	< 0.001				
	Week 8	129	27.21	4.43	0.590	< 0.001				
	Week 9	125	25.56	4.74	0.416	< 0.001				
	Week 10	124	29.34	4.73	0.389	< 0.001				
	Week 11	123	34.65	4.81	0.749	< 0.001				
	Week 12	113	34.27	5.19	0.322	< 0.001				
DVS SR 100 mg	Week 1	143	11.98	4.94	0.807	0.016				
	Week 2	141	25.02	4.42	0.296	< 0.001				
	Week 3	138	23.93	4.71	0.959	< 0.001				
	Week 4	134	26.19	4.84	0.579	< 0.001				
	Week 5	128	36.75	4.85	0.418	< 0.001				
	Week 6	129	35.96	4.60	0.133	< 0.001				
	Week 7	127	39.58	4.40	0.076	< 0.001				
	Week 8	126	35.48	4.44	0.544	< 0.001				
	Week 9	123	31.07	4.74	0.930	< 0.001				
	Week 10	119	40.34	4.76	0.550	< 0.001				
	Week 11	118	43.67	4.83	0.139	< 0.001				
	Week 12	104	45.07	5.37	0.026	< 0.001				
DVS SR 150 mg	Week 1	132	14.11	5.16	0.985	0.006				
Č	Week 2	129	25.75	4.69	0.260	< 0.001				
	Week 3	125	18.06	5.01	0.483	< 0.001				
	Week 4	123	20.84	5.11	0.897	< 0.001				
	Week 5	119	22.23	5.12	0.292	< 0.001				
	Week 6	119	27.14	4.87	0.753	< 0.001				
	Week 7	115	31.36	4.69	0.542	< 0.001				
	.,		21.20		0.0.2	0.001				

DVS SR Protocol 3151A2-315-US CSR-60178

Slee	ep Studies: How	v Long Subje	cts Slept for	the ITT Ob	served Data Pop	ulation
			Adjusted	Change		_
					p-Value vs	p-Value Within
Treatment	Time Point	Pairs, n	Mean	SE	Placebo	Group
	Week 8	113	29.39	4.75	0.818	< 0.001
	Week 9	110	33.40	5.06	0.831	< 0.001
	Week 10	111	32.97	4.98	0.713	< 0.001
	Week 11	107	32.85	5.14	0.934	< 0.001
	Week 12	96	32.87	5.61	0.426	< 0.001
DVS SR 200 mg	Week 1	120	17.38	5.41	0.683	0.001
	Week 2	113	30.69	5.01	0.080	< 0.001
	Week 3	110	31.84	5.34	0.299	< 0.001
	Week 4	108	28.19	5.45	0.437	< 0.001
	Week 5	101	29.80	5.53	0.932	< 0.001
	Week 6	101	29.45	5.27	0.550	< 0.001
	Week 7	99	25.42	5.05	0.843	< 0.001
	Week 8	100	26.93	5.05	0.584	< 0.001
	Week 9	98	30.10	5.38	0.837	< 0.001
	Week 10	98	29.79	5.33	0.447	< 0.001
	Week 11	97	32.33	5.43	0.986	< 0.001
	Week 12	92	36.58	5.79	0.224	< 0.001
Placebo	Week 1	77	13.96	6.62		0.035
	Week 2	77	17.47	5.89		0.003
	Week 3	77	23.53	6.21		< 0.001
	Week 4	77	21.87	6.29		0.001
	Week 5	76	30.49	6.21		< 0.001
	Week 6	73	24.77	6.02		< 0.001
	Week 7	71	26.91	5.82		< 0.001
	Week 8	70	31.09	5.89		< 0.001
	Week 9	71	31.74	6.16		< 0.001
	Week 10	70	35.80	6.13		< 0.001
	Week 11	68	32.19	6.30		< 0.001
	Week 12	62	25.99	6.84		< 0.001

Abbreviations: ITT=intent to treat and SE=standard error.

Analysis of covariance: change=treat+site+baseline.

Source: CLINICAL R&D/CLINICAL BIOSTATISTICS SAS REPORTS/3151A2/315/

315_NDA_2005/sleep_itt_ancova_final_05.html TEST NAME=DAILY MEAN MINUTES SLEPT

ST 9-21: Reduction in Average Daily Number of Moderate and Severe Hot Flushes for the PP Population

Reduction in A	Average Daily I	Number of M	Ioderate ar	nd Severe H	Iot Flushes for the PP
		Popi	ulation		
			Adjusted	l Change	
Treatment	Time Point	Pairs, n	Mean	SE	p-Value vs Placebo
DVS SR 50 mg	Week 1	133	-3.93	0.31	0.001
	Week 2	133	-5.09	0.34	0.019
	Week 3	127	-5.65	0.36	0.052
	Week 4	126	-6.07	0.36	0.132
	Week 5	119	-6.18	0.37	0.421
	Week 6	119	-5.67	0.36	0.855
	Week 7	121	-5.75	0.36	0.615
	Week 8	120	-5.66	0.38	0.680
	Week 9	116	-5.87	0.38	0.941
	Week 10	118	-5.87	0.37	0.809
	Week 11	116	-6.19	0.37	0.678
	Week 12	107	-6.59	0.37	0.218
DVS SR 100 mg	Week 1	139	-5.00	0.30	< 0.001
	Week 2	135	-6.45	0.34	< 0.001
	Week 3	132	-6.79	0.35	< 0.001
	Week 4	124	-7.12	0.36	0.001
	Week 5	124	-7.19	0.36	0.011
	Week 6	125	-7.26	0.35	0.008
	Week 7	126	-7.30	0.35	0.027
	Week 8	122	-7.47	0.37	0.012
	Week 9	120	-7.73	0.37	0.002
	Week 10	115	-7.75	0.37	0.004
	Week 11	116	-7.84	0.36	0.001
	Week 12	115	-7.96	0.35	< 0.001
DVS SR 150 mg	Week 1	124	-5.46	0.32	< 0.001
	Week 2	124	-6.37	0.35	< 0.001
	Week 3	119	-6.65	0.38	< 0.001
	Week 4	117	-6.73	0.37	0.009
	Week 5	110	-7.47	0.39	0.003
	Week 6	109	-7.32	0.38	0.008

DVS SR Protocol 3151A2-315-US CSR-60178

			ulation		Hot Flushes for the PP
			Adjusted	Change	
Treatment	Time Point	Pairs, n	Mean	SE	p-Value vs Placebo
	Week 7	108	-7.35	0.38	0.026
	Week 8	103	-7.05	0.41	0.074
	Week 9	102	-7.15	0.40	0.035
	Week 10	106	-7.08	0.39	0.080
	Week 11	104	-7.12	0.39	0.052
	Week 12	100	-7.06	0.38	0.045
DVS SR 200 mg	Week 1	104	-5.28	0.35	< 0.001
	Week 2	104	-6.68	0.39	< 0.001
	Week 3	103	-6.70	0.40	< 0.001
	Week 4	93	-7.11	0.42	0.002
	Week 5	95	-7.21	0.41	0.015
	Week 6	96	-7.04	0.40	0.034
	Week 7	95	-7.20	0.41	0.055
	Week 8	92	-7.27	0.44	0.038
	Week 9	89	-7.34	0.43	0.019
	Week 10	91	-7.32	0.42	0.038
	Week 11	94	-7.11	0.41	0.058
	Week 12	93	-7.09	0.40	0.043
Placebo	Week 1	74	-2.27	0.40	
	Week 2	74	-3.79	0.45	
	Week 3	74	-4.52	0.46	
	Week 4	73	-5.21	0.46	
	Week 5	70	-5.71	0.47	
	Week 6	70	-5.78	0.46	
	Week 7	69	-6.04	0.47	
	Week 8	65	-5.91	0.50	
	Week 9	64	-5.83	0.50	
	Week 10	65	-6.02	0.48	
	Week 11	65	-5.94	0.48	
	Week 12	62	-5.87	0.47	

Reduction in Average Daily Number of Moderate and Severe Hot Flushes for the PP
Population

--Adjusted Change--

Treatment Time Point Pairs, n Mean SE p-Value vs Placebo

Abbreviations: PP=per protocol and SE=standard error.

Analysis of covariance: change=treat+site+baseline.

Source: CLINICAL R&D/CLINICAL BIOSTATISTICS SAS REPORTS/3151A2 /315/315_NDA_2005/hf_ee_ancova_final_05.html/TEST NAME=AVERAGE DAILY NUMBER OF MODERATE AND SEVERE HOT FLUSHES

CONFIDENTIAL 334 Wyeth

ST 9-22: Reduction in the Average Severity Score for the PP Population

			Adjusted Change									
Treatment	Time Point	Pairs, n	Mean	SE	p-Value vs Placebo							
DVS SR 50 mg	Week 1	133	-0.21	0.04	0.076							
	Week 2	133	-0.29	0.06	0.819							
	Week 3	127	-0.34	0.06	0.915							
	Week 4	126	-0.37	0.07	0.940							
	Week 5	119	-0.38	0.07	0.316							
	Week 6	119	-0.37	0.07	0.225							
	Week 7	121	-0.40	0.07	0.161							
	Week 8	120	-0.39	0.07	0.073							
	Week 9	116	-0.33	0.07	0.062							
	Week 10	118	-0.36	0.07	0.045							
	Week 11	116	-0.39	0.07	0.144							
	Week 12	107	-0.43	0.08	0.439							
DVS SR 100 mg	Week 1	139	-0.42	0.04	< 0.001							
	Week 2	135	-0.57	0.06	0.001							
	Week 3	132	-0.64	0.06	0.002							
	Week 4	124	-0.62	0.07	0.022							
	Week 5	124	-0.71	0.07	0.047							
	Week 6	125	-0.74	0.07	0.036							
	Week 7	126	-0.77	0.07	0.077							
	Week 8	122	-0.81	0.07	0.083							
	Week 9	120	-0.83	0.07	0.018							
	Week 10	115	-0.84	0.07	0.046							
	Week 11	116	-0.87	0.07	0.013							
	Week 12	115	-0.90	0.08	0.003							
DVS SR 150 mg	Week 1	124	-0.35	0.04	< 0.001							
	Week 2	124	-0.51	0.06	0.011							
	Week 3	119	-0.58	0.07	0.017							
	Week 4	117	-0.56	0.07	0.078							
	Week 5	110	-0.64	0.07	0.193							
	Week 6	109	-0.64	0.07	0.247							
	Week 7	108	-0.65	0.08	0.454							

DVS SR Protocol 3151A2-315-US CSR-60178

			Adjusted	Change	
Treatment	Time Point	Pairs, n	Mean	SE	p-Value vs Placebo
	Week 8	103	-0.62	0.08	0.937
	Week 9	102	-0.67	0.08	0.331
	Week 10	106	-0.70	0.08	0.396
	Week 11	104	-0.74	0.08	0.162
	Week 12	100	-0.66	0.08	0.298
DVS SR 200 mg	Week 1	104	-0.42	0.05	< 0.001
_	Week 2	104	-0.62	0.06	< 0.001
	Week 3	103	-0.57	0.07	0.025
	Week 4	93	-0.60	0.08	0.042
	Week 5	95	-0.69	0.08	0.093
	Week 6	96	-0.71	0.08	0.084
	Week 7	95	-0.81	0.08	0.048
	Week 8	92	-0.77	0.08	0.188
	Week 9	89	-0.84	0.08	0.022
	Week 10	91	-0.81	0.08	0.089
	Week 11	94	-0.86	0.08	0.022
	Week 12	93	-0.81	0.09	0.028
Placebo	Week 1	74	-0.09	0.06	
	Week 2	74	-0.27	0.07	
	Week 3	74	-0.33	0.08	
	Week 4	73	-0.37	0.09	
	Week 5	70	-0.49	0.09	
	Week 6	70	-0.51	0.09	
	Week 7	69	-0.57	0.09	
	Week 8	65	-0.61	0.10	
	Week 9	64	-0.55	0.10	
	Week 10	65	-0.60	0.10	
	Week 11	65	-0.57	0.10	
	Week 12	62	-0.52	0.10	

	Reduction in the A	verage Sever	rity Score for	r the PP Po	pulation
			Adjusted	Change	
Гreatment	Time Point	Pairs, n	Mean	SE	p-Value vs Placebo
Abbreviations: P	P=ner protocol and S	E=standard e	rror		

Abbreviations: PP=per protocol and SE=standard error. Analysis of covariance: change=treat+site+baseline.

Source: CLINICAL R&D/CLINICAL BIOSTATISTICS SAS REPORTS/3151A2/315/315_NDA_2005/hf_ee_ancova_final_05.html/TEST NAME=AVERAGE DAILY SEVERITY

SCORE OF MILD, MODERATE AND SEVERE HOT FLUSHES

ST 9-23: Summary Statistics for Hot Flush Number and Severity: Final Analysis (PP)

Summary statistics for hot flush number and severity DVS-233 SR protocol 315: final analysis (EE) $\,$

07:43 Friday, July 29, 2005

1

TEST NAME=AVERAGE DAILY NUMBER OF MILD, MODERATE AND SEVERE HOT FLUSHES

	Time	No. of	Base	line	Obse	rved	Change f	from bs	%change	from baseline
Treatment	slot	pairs	mean	SD	mean	SD	mean	SD	mean	SD
DVS SR 50 mg	Screening/baseline	138	12.4	4.4						
	Week 1	133	12.4	4.4	8.8	4.4	-3.6	3.7	-28.2	25.5
	Week 2	133	12.4	4.4	7.5	4.7	-4.9	4.1	-39.3	28.5
	Week 3	127	12.4	4.4	6.8	4.9	-5.6	4.2	-45.3	28.8
	Week 4	126	12.3	4.1	6.2	4.3	-6.1	4.1	-48.9	27.1
	Week 5	119	12.5	4.5	6.0	5.0	-6.5	4.1	-52.5	25.3
	Week 6	119	12.5	4.5	6.4	5.4	-6.1	4.4	-50.3	28.2
	Week 7	121	12.5	4.5	6.3	5.4	-6.2	4.3	-51.5	28.8
	Week 8	120	12.5	4.5	6.3	5.4	-6.1	4.5	-50.5	30.1
	Week 9	116	12.5	4.6	6.0	5.0	-6.5	4.4	-52.6	27.5
	Week 10	118	12.6	4.5	6.1	4.9	-6.5	4.7	-51.7	28.5
	Week 11	116	12.4	4.1	5.7	4.2	-6.7	4.7	-53.3	29.3
	Week 12	107	12.4	4.2	5.4	3.7	-7.0	4.6	-55.4	27.5
DVS SR 100 mg	Screening/baseline	140	12.0	4.6					•	
	Week 1	139	12.0	4.6	7.2	4.0	-4.8	4.9	-38.0	30.2
	Week 2	135	11.9	4.6	5.7	3.9	-6.2	5.1	-50.6	31.3
	Week 3	132	12.0	4.6	5.3	4.1	-6.7	5.1	-55.2	32.2
	Week 4	124	12.0	4.7	5.0	3.7	-7.1	5.1	-57.3	30.2
	Week 5	124	12.1	4.7	5.0	3.9	-7.1	5.3	-57.6	31.7
	Week 6	125	12.0	4.7	4.6	3.8	-7.4	5.3	-60.3	31.4
	Week 7	126	12.0	4.7	4.6	3.8	-7.5	5.2	-60.9	31.2
	Week 8	122	11.9	4.7	4.4	3.7	-7.6	5.1	-62.4	31.1
	Week 9	120	12.1	4.8	4.3	3.6	-7.9	5.1	-64.2	29.4
	Week 10	115	12.1	4.8	4.2	3.8	-7.8	5.1	-64.9	29.3

DVS SR			CSR-60178							
	Week 11	116	12.1	4.8	4.2	4.0	-7.8	5.2	-64.8	30.1
	Week 12	115	12.0	4.8	4.1	3.8	-8.0	5.3	-65.8	29.9
DVS SR 150 mg	Screening/baseline	132	12.8	6.6		•				
	Week 1	124	12.8	6.8	7.4	4.4	-5.4	6.8	-40.4	28.4
	Week 2	124	13.0	6.8	6.2	5.0	-6.7	7.2	-51.0	32.4
	Week 3	119	13.0	6.9	6.0	5.1	-7.0	7.2	-53.1	32.3
	Week 4	117	13.1	6.9	5.9	5.2	-7.1	7.3	-54.3	32.1
	Week 5	110	12.9	7.0	5.1	4.0	-7.8	7.3	-58.8	28.5
	Week 6	109	12.5	4.3	4.9	3.7	-7.6	4.7	-59.9	28.5
	Week 7	108	12.3	4.2	4.8	3.9	-7.5	4.6	-60.4	28.9
	Week 8	103	12.1	4.2	4.9	4.1	-7.2	4.9	-59.0	34.6
	Week 9	102	12.2	4.2	4.9	4.4	-7.3	5.0	-58.5	37.1
	Week 10	106	12.1	4.1	4.8	4.3	-7.3	4.9	-59.0	34.1
	Week 11	104	12.2	4.2	4.9	4.7	-7.3	5.1	-59.2	34.8
	Week 12	100	12.1	4.0	4.8	4.1	-7.2	4.8	-59.2	33.5

Summary statistics for hot flush number and severity DVS-233 SR protocol 315: final analysis (EE) $\,$

07:43 Friday, July 29, 2005

32.9

2

Treatment	Time slot	No. of pairs	Basel		Obser		Change mean		%change mean	from baseline
DVS SR 200 mg	Screening/baseline	110	12.6	4.4						
	Week 1	104	12.6	4.5	7.5	4.8	-5.1	3.5	-41.3	26.3
	Week 2	104	12.6	4.4	5.9	4.7	-6.7	4.3	-53.8	29.5
	Week 3	103	12.5	4.4	5.8	4.6	-6.7	3.9	-54.7	27.9
	Week 4	93	12.6	4.1	5.3	4.2	-7.3	4.1	-58.6	26.6
	Week 5	95	12.4	4.1	5.2	4.4	-7.2	3.9	-59.5	27.8
	Week 6	96	12.6	4.5	5.4	4.6	-7.2	4.0	-59.1	29.6
	Week 7	95	12.5	4.4	5.0	4.6	-7.5	4.2	-61.6	30.8
	Week 8	92	12.6	4.0	4.9	4.3	-7.7	4.2	-62.4	29.9
	Week 9	89	12.5	4.0	4.8	4.5	-7.8	4.5	-62.6	31.6
	Week 10	91	12.3	3.9	4.6	4.3	-7.7	4.3	-63.3	30.5
	Week 11	94	12.5	4.4	5.0	4.7	-7.5	4.9	-61.3	33.4
	Week 12	93	12.6	4.3	5.1	4.8	-7.5	5.1	-60.6	34.1
Placebo	Screening/baseline	77	11.9	4.6						
	Week 1	74	11.8	4.6	9.7	5.0	-2.1	3.1	-17.7	27.1
	Week 2	74	11.8	4.6	8.5	5.3	-3.3	3.9	-28.0	30.5
	Week 3	74	11.7	4.6	7.9	5.6	-3.9	4.3	-33.5	32.3
	Week 4	73	11.7	4.6	7.2	5.0	-4.5	3.9	-39.3	28.5
	Week 5	70	11.7	4.5	6.8	5.1	-4.9	4.3	-42.2	31.9
	Week 6	70	11.5	4.1	6.4	5.2	-5.1	4.3	-46.0	32.4
	Week 7	69	11.3	3.8	5.8	4.7	-5.5	4.3	-49.2	32.9
	Week 8	65	11.7	4.2	6.0	5.5	-5.7	4.6	-50.5	33.7
	Week 9	64	11.6	4.0	6.2	5.1	-5.5	4.1	-48.7	31.5
	Week 10	65	11.7	4.1	5.9	5.2	-5.7	4.5	-50.5	32.2
	Week 11	65	11.7	4.2	6.0	5.0	-5.7	4.2	-49.5	31.2

4.0

5.9

11.6

62

Week 12

4.3 -5.7 4.5 -48.0

Summary statistics for hot flush number and severity DVS-233 SR protocol 315: final analysis (EE) $\,$

07:43 Friday, July 29, 2005

3

TEST NAME=AVERAGE DAILY NUMBER OF MODERATE AND SEVERE HOT FLUSHES

	Time	No. of	Base	line	Obser	ved	Change f	rom bs	%change	from baseline
Treatment	slot	pairs	mean	SD	mean	SD	mean	SD	mean	SD
DVS SR 50 mg	Screening/baseline	138	10.9	4.1						
	Week 1	133	10.9	4.1	7.1	4.1	-3.8	3.6	-33.7	29.0
	Week 2	133	10.9	4.2	6.0	4.3	-4.9	3.9	-44.8	31.3
	Week 3	127	10.9	4.2	5.4	4.8	-5.5	3.9	-50.9	32.3
	Week 4	126	10.8	3.7	5.0	4.2	-5.8	3.9	-53.8	31.0
	Week 5	119	10.9	4.2	5.0	5.0	-5.9	4.0	-55.5	30.6
	Week 6	119	10.9	4.2	5.2	5.3	-5.7	4.5	-53.0	35.9
	Week 7	121	10.9	4.2	5.2	5.3	-5.7	4.5	-53.9	37.2
	Week 8	120	10.9	4.2	5.2	5.3	-5.7	4.6	-53.0	38.0
	Week 9	116	10.9	4.3	5.0	5.0	-5.9	4.7	-53.7	38.0
	Week 10	118	11.0	4.2	5.1	4.8	-5.9	4.9	-53.4	36.5
	Week 11	116	10.8	3.8	4.7	4.0	-6.1	4.7	-55.3	35.4
	Week 12	107	10.8	3.8	4.3	3.6	-6.5	4.6	-58.2	34.6
DVS SR 100 mg	Screening/baseline	140	10.6	4.1					•	•
	Week 1	139	10.6	4.1	5.9	3.5	-4.7	4.4	-42.2	32.0
	Week 2	135	10.5	4.0	4.4	3.2	-6.1	4.5	-55.7	31.7
	Week 3	132	10.5	4.0	4.1	3.4	-6.5	4.6	-60.0	32.3
	Week 4	124	10.6	4.1	3.9	3.2	-6.7	4.6	-62.0	31.1
	Week 5	124	10.6	4.0	3.8	3.5	-6.8	4.7	-63.1	32.7
	Week 6	125	10.6	4.0	3.5	3.4	-7.1	4.7	-66.1	31.6
	Week 7	126	10.6	4.1	3.5	3.3	-7.2	4.6	-66.6	31.5
	Week 8	122	10.5	4.0	3.2	3.1	-7.2	4.6	-68.1	31.6
	Week 9	120	10.6	4.1	3.1	3.0	-7.5	4.6	-70.0	29.6
	Week 10	115	10.5	4.1	3.0	3.0	-7.5	4.5	-71.0	28.0
	Week 11	116	10.6	4.1	3.0	3.1	-7.6	4.5	-71.3	28.5
	Week 12	115	10.5	4.1	2.9	3.0	-7.7	4.6	-72.0	28.7

DVS SR		CSR-60178									
DVS SR 150 mg	Screening/baseline	132	11.3	6.5							
	Week 1	124	11.3	6.6	5.8	3.9	-5.5	6.8	-46.4	29.6	
	Week 2	124	11.4	6.6	4.9	4.6	-6.5	7.3	-56.3	34.1	
	Week 3	119	11.5	6.7	4.7	4.6	-6.8	7.5	-58.1	33.7	
	Week 4	117	11.6	6.8	4.7	4.7	-6.9	7.4	-59.6	33.5	
	Week 5	110	11.5	6.9	3.9	3.7	-7.6	7.4	-64.5	30.3	
	Week 6	109	11.0	3.8	3.7	3.3	-7.3	4.2	-64.8	29.9	
	Week 7	108	10.9	3.7	3.6	3.4	-7.2	4.1	-65.9	30.1	
	Week 8	103	10.7	3.7	3.9	3.8	-6.9	4.5	-63.2	36.4	
	Week 9	102	10.8	3.7	3.8	4.0	-7.0	4.5	-63.9	38.3	
	Week 10	106	10.7	3.7	3.8	3.9	-6.9	4.4	-64.1	34.8	
	Week 11	104	10.8	3.7	3.9	4.2	-6.9	4.5	-64.5	35.7	
	Week 12	100	10.7	3.6	3.9	3.8	-6.9	4.3	-63.5	34.6	

Summary statistics for hot flush number and severity DVS-233 SR protocol 315: final analysis (EE) $\,$

07:43 Friday, July 29, 2005

4

	Time	No. of	Basel	ine	Obser	ved	Change	from bs	%change	from baseline
Treatment	slot	pairs	mean	SD	mean	SD	mean	SD	mean	SD
DVS SR 200 mg	Screening/baseline	110	10.9	3.6						
	Week 1	104	10.9	3.6	5.7	3.8	-5.2	3.2	-48.9	27.1
	Week 2	104	10.9	3.6	4.3	3.9	-6.6	3.9	-60.8	30.6
	Week 3	103	10.9	3.6	4.4	3.9	-6.5	3.7	-60.7	29.0
	Week 4	93	11.0	3.6	4.1	3.8	-6.9	3.8	-64.0	27.5
	Week 5	95	10.7	3.5	3.8	3.9	-6.9	3.6	-66.0	28.9
	Week 6	96	10.9	3.6	3.9	4.0	-6.9	3.9	-65.1	32.2
	Week 7	95	10.8	3.5	3.7	4.1	-7.0	4.1	-66.1	33.1
	Week 8	92	11.0	3.5	3.7	4.1	-7.3	4.1	-67.1	34.2
	Week 9	89	11.0	3.6	3.6	4.1	-7.4	4.1	-68.0	31.8
	Week 10	91	10.8	3.6	3.6	4.0	-7.3	3.9	-68.3	31.4
	Week 11	94	11.0	3.6	3.9	4.3	-7.1	4.3	-65.3	36.1
	Week 12	93	11.0	3.6	4.0	4.5	-7.0	4.7	-63.8	39.3
Placebo	Screening/baseline	77	11.0	4.6						
	Week 1	74	10.9	4.6	8.8	4.9	-2.1	3.2	-19.6	29.8
	Week 2	74	10.9	4.6	7.3	5.3	-3.6	4.2	-32.7	34.4
	Week 3	74	10.9	4.6	6.6	5.2	-4.3	4.2	-39.9	34.9
	Week 4	73	10.8	4.6	5.9	4.8	-4.9	4.2	-45.6	33.2
	Week 5	70	10.7	4.5	5.3	4.6	-5.4	4.4	-50.2	33.9
	Week 6	70	10.7	4.0	5.1	4.4	-5.6	4.1	-52.7	34.0
	Week 7	69	10.5	3.9	4.7	4.3	-5.7	4.2	-55.0	34.3
	Week 8	65	10.9	4.1	5.0	5.4	-5.9	4.7	-56.0	37.7
	Week 9	64	10.7	4.0	5.0	4.9	-5.7	4.4	-55.0	35.5
	Week 10	65	10.8	4.1	4.8	4.9	-5.9	4.6	-56.2	36.8
	Week 11	65	10.8	4.1	5.0	4.9	-5.8	4.3	-55.6	35.7
	Week 12	62	10.8	4.1	5.0	4.3	-5.7	4.5	-52.9	36.1

Summary statistics for hot flush number and severity DVS-233 SR protocol 315: final analysis (EE) $\,$

07:43 Friday, July 29, 2005

5

TEST NAME=AVERAGE DAILY SEVERITY SCORE OF MILD, MODERATE AND SEVERE HOT FLUSHES

	Time	No. of	Base	eline	Obse	rved	Change f	rom bs	%change	from baseline
Treatment	slot	pairs	mean	SD	mean	SD	mean	SD	mean	SD
DVS SR 50 mg	Screening/baseline	138	2.4	0.3						
	Week 1	133	2.4	0.3	2.1	0.4	-0.2	0.4	-8.7	15.9
	Week 2	133	2.4	0.3	2.1	0.5	-0.3	0.5	-11.8	20.0
	Week 3	127	2.4	0.3	2.1	0.6	-0.3	0.6	-13.4	24.0
	Week 4	126	2.4	0.3	2.0	0.6	-0.4	0.6	-15.2	24.9
	Week 5	119	2.4	0.3	2.0	0.7	-0.3	0.6	-14.1	27.7
	Week 6	119	2.4	0.3	2.0	0.6	-0.3	0.6	-13.6	26.8
	Week 7	121	2.4	0.3	2.0	0.7	-0.3	0.7	-14.2	29.1
	Week 8	120	2.4	0.3	2.0	0.6	-0.3	0.6	-13.8	28.9
	Week 9	116	2.4	0.3	2.1	0.6	-0.3	0.6	-11.0	27.8
	Week 10	118	2.4	0.3	2.1	0.6	-0.3	0.6	-11.8	27.7
	Week 11	116	2.4	0.3	2.0	0.6	-0.3	0.6	-12.9	28.4
	Week 12	107	2.4	0.3	2.0	0.7	-0.4	0.7	-15.2	30.8
DVS SR 100 mg	Screening/baseline	140	2.4	0.3						
	Week 1	139	2.4	0.3	2.0	0.6	-0.4	0.6	-17.0	24.8
	Week 2	135	2.4	0.3	1.8	0.7	-0.6	0.7	-22.7	30.0
	Week 3	132	2.4	0.3	1.8	0.8	-0.6	0.8	-25.5	33.5
	Week 4	124	2.4	0.3	1.8	0.8	-0.6	0.8	-25.0	32.0
	Week 5	124	2.4	0.3	1.7	0.8	-0.7	0.8	-28.6	32.9
	Week 6	125	2.4	0.3	1.7	0.8	-0.7	0.8	-29.6	33.4
	Week 7	126	2.4	0.3	1.7	0.8	-0.7	0.8	-30.5	33.4
	Week 8	122	2.4	0.3	1.6	0.8	-0.8	0.8	-32.3	34.6
	Week 9	120	2.4	0.3	1.6	0.8	-0.8	0.9	-33.0	35.8
	Week 10	115	2.4	0.3	1.6	0.8	-0.8	0.9	-32.6	35.3
	Week 11	116	2.4	0.3	1.6	0.8	-0.8	0.8	-33.7	34.4
	Week 12	115	2.4	0.3	1.5	0.9	-0.9	0.9	-35.3	36.3

DVS SR			CSR-60178							
DVS SR 150 mg	Screening/baseline	132	2.4	0.3				•		
	Week 1	124	2.4	0.3	2.0	0.5	-0.3	0.5	-13.9	20.9
	Week 2	124	2.4	0.3	1.9	0.7	-0.5	0.7	-20.0	27.3
	Week 3	119	2.4	0.3	1.8	0.7	-0.5	0.7	-22.0	29.3
	Week 4	117	2.4	0.3	1.8	0.7	-0.5	0.7	-21.8	30.7
	Week 5	110	2.4	0.3	1.8	0.7	-0.6	0.7	-24.4	30.2
	Week 6	109	2.4	0.3	1.8	0.7	-0.6	0.7	-24.1	29.6
	Week 7	108	2.4	0.3	1.8	0.7	-0.6	0.7	-24.7	29.7
	Week 8	103	2.4	0.3	1.8	0.7	-0.6	0.7	-23.4	29.4
	Week 9	102	2.4	0.3	1.8	0.7	-0.6	0.7	-25.9	30.6
	Week 10	106	2.4	0.3	1.7	0.8	-0.6	0.7	-26.4	31.9
	Week 11	104	2.4	0.3	1.7	0.8	-0.7	0.8	-27.6	33.3
	Week 12	100	2.4	0.3	1.8	0.7	-0.6	0.7	-24.8	30.3

Summary statistics for hot flush number and severity DVS-233 SR protocol 315: final analysis (EE) $\,$

07:43 Friday, July 29, 2005

6

TEST NAME=AVERAGE DAILY SEVERITY SCORE OF MILD, MODERATE AND SEVERE HOT FLUSHES

	Time	No. of	Base	eline	Obse	rved	Change	from bs	%change	e from baseline
Treatment	slot	pairs			mean			SD	mean	SD
DVS SR 200 mg			2.4							
	Week 1	104	2.4	0.3	2.0	0.5	-0.4	0.5	-17.4	20.2
	Week 2	104	2.4	0.3	1.8	0.7	-0.6	0.7	-24.5	30.2
	Week 3	103	2.4	0.3	1.8	0.7	-0.5	0.7	-21.7	30.3
	Week 4	93	2.4	0.3	1.8	0.8	-0.6	0.8	-23.7	32.8
	Week 5	95	2.4	0.3	1.7	0.8	-0.7	0.8	-27.2	31.6
	Week 6	96	2.4	0.3	1.7	0.8	-0.7	0.8	-27.9	32.7
	Week 7	95	2.4	0.3	1.6	0.9	-0.7	0.9	-30.8	38.4
	Week 8	92	2.4	0.3	1.7	0.9	-0.7	0.9	-29.8	37.3
	Week 9	89	2.4	0.3	1.6	0.9	-0.8	0.9	-33.1	35.1
	Week 10	91	2.4	0.3	1.6	0.9	-0.8	0.9	-31.2	36.4
	Week 11	94	2.4	0.3	1.6	0.9	-0.8	0.9	-31.8	37.5
	Week 12	93	2.4	0.3	1.6	0.9	-0.7	0.9	-30.3	38.2
Placebo	Screening/baseline	77	2.5	0.3						
	Week 1	74	2.5	0.3	2.4	0.4	-0.1	0.3	-4.1	12.5
	Week 2	74	2.5	0.3	2.2	0.6	-0.3	0.6	-10.5	22.7
	Week 3	74	2.5	0.3	2.1	0.7	-0.3	0.7	-13.1	27.6
	Week 4	73	2.5	0.3	2.1	0.7	-0.4	0.7	-15.2	28.3
	Week 5	70	2.5	0.3	2.0	0.7	-0.5	0.8	-19.8	29.9
	Week 6	70	2.5	0.3	1.9	0.8	-0.5	0.8	-20.7	31.8
	Week 7	69	2.5	0.3	1.9	0.8	-0.6	0.8	-22.5	32.8
	Week 8	65	2.5	0.3	1.8	0.8	-0.6	0.9	-23.9	33.9
	Week 9	64	2.5	0.3	1.9	0.8	-0.6	0.8	-21.9	32.1
	Week 10	65	2.5	0.3	1.9	0.8	-0.6	0.8	-23.6	32.3
	Week 11	65	2.5	0.3	1.9	0.8	-0.6	0.8	-22.6	31.5
	Week 12	62	2.5	0.3	2.0	0.8	-0.5	0.8	-21.0	33.9

Summary statistics for hot flush number and severity DVS-233 SR protocol 315: final analysis (EE) $\,$

07:43 Friday, July 29, 2005

7

TEST NAME=WEEKLY WEIGHTED SCORE OF MODERATE AND SEVERE HOT FLUSHES

	Time	No. of	Base	eline	Obse	rved	Change	from bs	%change	from baseline
Treatment	slot	pairs	mean	SD	mean	SD	mean	SD	mean	SD
DVS SR 50 mg	Screening/baseline	138	194.4	77.4						
	Week 1	133	193.6	78.3	123.8	74.2	-69.8	67.8	-34.9	29.5
	Week 2	133	195.4	78.5	105.2	78.7	-90.2	72.8	-45.8	32.6
	Week 3	127	195.0	79.5	95.8	87.0	-99.3	72.5	-51.6	33.4
	Week 4	126	193.2	68.9	87.0	71.7	-106.2	72.6	-54.7	32.0
	Week 5	119	194.1	79.5	86.2	87.2	-107.9	75.9	-56.3	32.3
	Week 6	119	194.6	79.7	91.0	91.6	-103.6	84.8	-53.7	38.1
	Week 7	121	194.2	79.5	90.3	92.2	-103.9	85.9	-54.3	39.6
	Week 8	120	194.5	79.6	91.6	92.0	-102.8	87.2	-53.4	39.9
	Week 9	116	194.5	80.2	87.9	86.3	-106.5	90.8	-54.1	40.6
	Week 10	118	195.5	79.8	88.5	83.2	-107.0	94.5	-53.7	38.6
	Week 11	116	192.5	75.1	83.0	73.4	-109.4	91.2	-55.5	37.2
	Week 12	107	194.2	76.8	76.9	67.9	-117.3	91.4	-58.3	36.7
DVS SR 100 mg	Screening/baseline	140	191.3	80.7	•					
	Week 1	139	191.6	80.9	102.7	63.4	-88.8	84.9	-43.5	33.4
	Week 2	135	190.6	79.4	77.4	59.7	-113.1	87.4	-57.0	32.6
	Week 3	132	191.3	80.0	70.9	63.6	-120.4	88.6	-61.3	33.3
	Week 4	124	191.6	81.3	66.8	59.2	-124.9	88.9	-63.3	31.5
	Week 5	124	192.1	80.3	64.8	63.0	-127.3	89.5	-64.8	33.0
	Week 6	125	191.5	80.2	60.3	61.7	-131.2	89.8	-67.3	32.4
	Week 7	126	192.4	81.4	59.1	59.6	-133.3	89.5	-67.9	31.9
	Week 8	122	189.7	80.9	54.4	53.7	-135.3	89.3	-69.6	32.2
	Week 9	120	193.1	82.1	52.0	52.1	-141.1	89.8	-71.5	30.1
	Week 10	115	190.9	81.0	51.3	52.5	-139.6	86.4	-72.1	28.7
	Week 11	116	191.5	80.4	50.6	54.5	-140.9	85.8	-72.6	29.1
	Week 12	115	191.0	81.1	48.8	52.9	-142.1	88.4	-73.1	29.7

CSR-60178

DVS SR	Protocol 3151A2-315-US											
DVS SR 150 mg	Screening/baseline	132	202.5	113.2								
	Week 1	124	201.3	115.0	99.8	70.3	-101.4	112.5	-48.2	29.8		
	Week 2	124	204.4	115.9	85.7	87.7	-118.6	124.6	-57.7	34.2		
	Week 3	119	206.0	117.4	82.6	87.2	-123.4	128.1	-59.5	33.9		
	Week 4	117	207.6	118.3	81.7	89.7	-125.9	126.7	-60.8	33.7		
	Week 5	110	204.6	118.8	65.8	65.6	-138.8	124.9	-66.2	30.6		
	Week 6	109	197.2	76.0	63.4	58.8	-133.8	78.1	-66.5	30.2		
	Week 7	108	194.3	74.3	62.4	61.9	-131.9	75.9	-67.3	30.3		
	Week 8	103	190.4	73.6	64.7	66.9	-125.7	78.7	-65.2	35.2		
	Week 9	102	193.4	73.9	64.0	66.2	-129.3	78.5	-66.0	36.5		
	Week 10	106	191.1	73.4	64.7	67.3	-126.4	75.4	-66.0	33.1		
	Week 11	104	192.0	73.5	65.0	73.3	-127.0	77.4	-66.4	33.6		
	Week 12	100	190.2	71.8	64.8	65.7	-125.4	74.4	-65.4	33.7		

Summary statistics for hot flush number and severity DVS-233 SR protocol 315: final analysis (EE) $\,$

07:43 Friday, July 29, 2005

8

TEST NAME=WEEKLY WEIG	HTED SCORE OF	MODERATE AND	SEVERE HOT	FLUSHES
-----------------------	---------------	--------------	------------	---------

	Time	No. ofBaseline-			Obse	rved	l Change from bs		s %change from base	
Treatment	slot	-	mean					SD	mean	SD
DVS SR 200 mg				71.5						
	Week 1	104	196.5	73.1	98.3	66.4	-98.2	60.2	-50.4	28.0
	Week 2	104	196.2	72.1	74.8	69.7	-121.4	73.2	-62.2	31.3
	Week 3	103	195.5	71.7	76.1	71.1	-119.4	69.0	-61.9	29.6
	Week 4	93	198.9	73.8	70.9	71.9	-128.0	71.3	-65.3	28.1
	Week 5	95	193.2	71.7	66.3	73.1	-127.0	66.0	-67.6	28.8
	Week 6	96	195.6	72.5	68.1	72.5	-127.5	69.7	-66.7	31.8
	Week 7	95	194.0	70.3	65.0	72.9	-128.9	73.1	-67.4	33.0
	Week 8	92	197.6	72.1	64.4	73.7	-133.2	75.9	-67.8	35.4
	Week 9	89	198.9	72.4	62.9	74.7	-136.1	73.6	-69.7	31.3
	Week 10	91	195.6	73.1	62.7	72.9	-132.9	71.4	-69.6	31.0
	Week 11	94	196.8	73.0	67.7	77.8	-129.0	77.2	-66.5	35.9
	Week 12	93	197.0	72.9	68.6	80.0	-128.4	82.0	-65.4	38.7
Placebo	Screening/baseline	77	198.3	84.6						
	Week 1	74	195.9	85.1	155.8	91.1	-40.1	59.5	-20.6	30.2
	Week 2	74	196.4	85.1	128.8	91.6	-67.6	79.0	-33.8	35.1
	Week 3	74	195.9	85.1	113.8	87.4	-82.1	81.9	-41.4	35.1
	Week 4	73	194.6	84.9	103.4	82.8	-91.2	81.0	-46.5	34.6
	Week 5	70	193.2	80.9	92.6	79.6	-100.6	85.2	-51.3	34.7
	Week 6	70	193.4	78.0	90.7	80.2	-102.7	79.5	-53.4	34.7
	Week 7	69	190.6	77.0	83.7	78.5	-106.9	81.8	-56.1	35.5
	Week 8	65	196.1	80.0	86.4	91.5	-109.7	88.8	-57.2	38.3
	Week 9	64	194.5	78.4	86.6	82.7	-107.8	84.6	-56.1	36.5
	Week 10	65	195.9	78.9	83.9	83.8	-112.0	88.9	-57.7	37.3
	Week 11	65	197.4	79.3	85.8	81.6	-111.6	81.5	-57.5	35.5
	Week 12	62	197.3	80.4	89.2	78.5	-108.1	88.6	-54.2	36.7

Within and between group comparisons for hot flush number and severity DVS-233 SR protocol 315: final analysis (EE) $\,$

07:43 Friday, July 29, 2005

CSR-60178

9

TEST NAME=AVERAGE DAILY NUMBER OF MILD, MODERATE AND SEVERE HOT FLUSHES

Treatment	Time slot	No. of pairs		_	p-value · vs. placebo	within
DVS SR 50 mg	Week 1	133	-3.69	0.34	0.028	0.000
	Week 2	133	-5.01	0.37	0.042	0.000
	Week 3	127	-5.68	0.39	0.031	0.000
	Week 4	126	-6.18	0.37	0.061	0.000
	Week 5	119	-6.58	0.38	0.072	0.000
	Week 6	119	-6.07	0.38	0.491	0.000
	Week 7	121	-6.19	0.37	0.907	0.000
	Week 8	120	-6.07	0.39	0.995	0.000
	Week 9	116	-6.45	0.39	0.367	0.000
	Week 10	118	-6.42	0.39	0.701	0.000
	Week 11	116	-6.72	0.40	0.368	0.000
	Week 12	107	-7.06	0.39	0.201	0.000
DVS SR 100 mg	Week 1	139	-5.04	0.33	0.000	0.000
	Week 2	135	-6.53	0.36	0.000	0.000
	Week 3	132	-6.94	0.38	0.000	0.000
	Week 4	124	-7.35	0.37	0.000	0.000
	Week 5	124	-7.40	0.37	0.002	0.000
	Week 6	125	-7.55	0.37	0.002	0.000
	Week 7	126	-7.58	0.36	0.014	0.000
	Week 8	122	-7.74	0.38	0.008	0.000
	Week 9	120	-7.98	0.38	0.001	0.000
	Week 10	115	-7.96	0.39	0.005	0.000
	Week 11	116	-8.03	0.40	0.003	0.000
	Week 12	115	-8.21	0.37	0.002	0.000

DVS SR		Protocol 3151A2-315-US								
DVS SR 150 mg	Week 1	124	-5.34	0.35	0.000	0.000				
	Week 2	124	-6.52	0.38	0.000	0.000				
	Week 3	119	-6.80	0.40	0.000	0.000				
	Week 4	117	-6.88	0.39	0.003	0.000				
	Week 5	110	-7.70	0.40	0.000	0.000				
	Week 6	109	-7.68	0.40	0.001	0.000				
	Week 7	108	-7.63	0.40	0.014	0.000				
	Week 8	103	-7.46	0.42	0.033	0.000				
	Week 9	102	-7.50	0.42	0.013	0.000				
	Week 10	106	-7.50	0.41	0.041	0.000				
	Week 11	104	-7.48	0.42	0.042	0.000				
	Week 12	100	-7.55	0.41	0.043	0.000				

ANCOVA: change = treat + site + baseline

CONFIDENTIAL 351 Wyeth

> Within and between group comparisons for hot flush number and severity DVS-233 SR protocol 315: final analysis (EE)

07:43 Friday, July 29, 2005

10

TEST NAME=AVERAGE DAILY NUMBER OF MILD, MODERATE AND SEVERE HOT FLUSHES

Treatment	Time slot	No. of pairs	Adjusted mean	_	p-value vs. placebo	within
DVS SR 200 mg	Week 1	104	-4.94	0.38	0.000	0.000
	Week 2	104	-6.58	0.41	0.000	0.000
	Week 3	103	-6.66	0.43	0.000	0.000
	Week 4	93	-7.22	0.43	0.001	0.000
	Week 5	95	-7.26	0.43	0.006	0.000
	Week 6	96	-7.14	0.42	0.019	0.000
	Week 7	95	-7.49	0.42	0.031	0.000
	Week 8	92	-7.59	0.45	0.024	0.000
	Week 9	89	-7.65	0.45	0.008	0.000
	Week 10	91	-7.65	0.45	0.028	0.000
	Week 11	94	-7.45	0.45	0.051	0.000
	Week 12	93	-7.49	0.43	0.057	0.000
Placebo	Week 1	74	-2.49	0.44	•	0.000
	Week 2	74	-3.80	0.48		0.000
	Week 3	74	-4.34	0.50		0.000
	Week 4	73	-5.07	0.48		0.000
	Week 5	70	-5.48	0.49		0.000
	Week 6	70	-5.66	0.49		0.000
	Week 7	69	-6.12	0.49		0.000
	Week 8	65	-6.06	0.52		0.000
	Week 9	64	-5.88	0.51		0.000
	Week 10	65	-6.18	0.52		0.000
	Week 11	65	-6.14	0.53		0.000
	Week 12	62	-6.26	0.51	•	0.000

ANCOVA: change = treat + site + baseline

Within and between group comparisons for hot flush number and severity DVS-233 SR protocol 315: final analysis (EE) $\,$

07:43 Friday, July 29, 2005

CSR-60178

11

TEST NAME=AVERAGE DAILY NUMBER OF MODERATE AND SEVERE HOT FLUSHES

Treatment	Time slot	pairs	Adjusted mean	SE	placebo	within group
DVS SR 50 mg	Week 1	133		0.31		
	Week 2	133	-5.09	0.34	0.019	0.000
	Week 3	127	-5.65	0.36	0.052	0.000
	Week 4	126	-6.07	0.36	0.132	0.000
	Week 5	119	-6.18	0.37	0.421	0.000
	Week 6	119	-5.67	0.36	0.855	0.000
	Week 7	121	-5.75	0.36	0.615	0.000
	Week 8	120	-5.66	0.38	0.680	0.000
	Week 9	116	-5.87	0.38	0.941	0.000
	Week 10	118	-5.87	0.37	0.809	0.000
	Week 11	116	-6.19	0.37	0.678	0.000
	Week 12	107	-6.59	0.37	0.218	0.000
DVS SR 100 mg	Week 1	139	-5.00	0.30	0.000	0.000
	Week 2	135	-6.45	0.34	0.000	0.000
	Week 3	132	-6.79	0.35	0.000	0.000
	Week 4	124	-7.12	0.36	0.001	0.000
	Week 5	124	-7.19	0.36	0.011	0.000
	Week 6	125	-7.26	0.35	0.008	0.000
	Week 7	126	-7.30	0.35	0.027	0.000
	Week 8	122	-7.47	0.37	0.012	0.000
	Week 9	120	-7.73	0.37	0.002	0.000
	Week 10	115	-7.75	0.37	0.004	0.000
	Week 11	116	-7.84	0.36	0.001	0.000
	Week 12	115	-7.96	0.35	0.000	0.000

DVS SR	Protocol 3	Protocol 3151A2-315-US					
DVS SR 150 mg	Week 1	124	-5.46	0.32	0.000	0.000	
	Week 2	124	-6.37	0.35	0.000	0.000	
	Week 3	119	-6.65	0.38	0.000	0.000	
	Week 4	117	-6.73	0.37	0.009	0.000	
	Week 5	110	-7.47	0.39	0.003	0.000	
	Week 6	109	-7.32	0.38	0.008	0.000	
	Week 7	108	-7.35	0.38	0.026	0.000	
	Week 8	103	-7.05	0.41	0.074	0.000	
	Week 9	102	-7.15	0.40	0.035	0.000	
	Week 10	106	-7.08	0.39	0.080	0.000	
	Week 11	104	-7.12	0.39	0.052	0.000	
	Week 12	100	-7.06	0.38	0.045	0.000	

ANCOVA: change = treat + site + baseline

CONFIDENTIAL 354 Wyeth

Within and between group comparisons for hot flush number and severity DVS-233 SR protocol 315: final analysis (EE)

07:43 Friday, July 29, 2005

12

TEST NAME=AVERAGE DAILY NUMBER OF MODERATE AND SEVERE HOT FLUSHES

Treatment	Time slot	No. of pairs	Adjusted mean	change	-	
DVS SR 200 mg	Week 1	104	-5.28	0.35	0.000	0.000
	Week 2	104	-6.68	0.39	0.000	0.000
	Week 3	103	-6.70	0.40	0.000	0.000
	Week 4	93	-7.11	0.42	0.002	0.000
	Week 5	95	-7.21	0.41	0.015	0.000
	Week 6	96	-7.04	0.40	0.034	0.000
	Week 7	95	-7.20	0.41	0.055	0.000
	Week 8	92	-7.27	0.44	0.038	0.000
	Week 9	89	-7.34	0.43	0.019	0.000
	Week 10	91	-7.32	0.42	0.038	0.000
	Week 11	94	-7.11	0.41	0.058	0.000
	Week 12	93	-7.09	0.40	0.043	0.000
Placebo	Week 1	74	-2.27	0.40		0.000
	Week 2	74	-3.79	0.45		0.000
	Week 3	74	-4.52	0.46		0.000
	Week 4	73	-5.21	0.46		0.000
	Week 5	70	-5.71	0.47		0.000
	Week 6	70	-5.78	0.46		0.000
	Week 7	69	-6.04	0.47		0.000
	Week 8	65	-5.91	0.50		0.000
	Week 9	64	-5.83	0.50	•	0.000
	Week 10	65	-6.02	0.48	•	0.000
	Week 11	65	-5.94	0.48		0.000
	Week 12	62	-5.87	0.47	•	0.000

ANCOVA: change = treat + site + baseline

Within and between group comparisons for hot flush number and severity DVS-233 SR protocol 315: final analysis (EE) $\,$

07:43 Friday, July 29, 2005

13

TEST NAME=AVERAGE DAILY SEVERITY SCORE OF MILD, MODERATE AND SEVERE HOT FLUSHES

Treatment	Time slot	No. of pairs	Adjusted mean	-	p-value - vs. placebo	within
DVS SR 50 mg	Week 1	133	-0.21	0.04	0.076	0.000
	Week 2	133	-0.29	0.06	0.819	0.000
	Week 3	127	-0.34	0.06	0.915	0.000
	Week 4	126	-0.37	0.07	0.940	0.000
	Week 5	119	-0.38	0.07	0.316	0.000
	Week 6	119	-0.37	0.07	0.225	0.000
	Week 7	121	-0.40	0.07	0.161	0.000
	Week 8	120	-0.39	0.07	0.073	0.000
	Week 9	116	-0.33	0.07	0.062	0.000
	Week 10	118	-0.36	0.07	0.045	0.000
	Week 11	116	-0.39	0.07	0.144	0.000
	Week 12	107	-0.43	0.08	0.439	0.000
DVS SR 100 mg	Week 1	139	-0.42	0.04	0.000	0.000
	Week 2	135	-0.57	0.06	0.001	0.000
	Week 3	132	-0.64	0.06	0.002	0.000
	Week 4	124	-0.62	0.07	0.022	0.000
	Week 5	124	-0.71	0.07	0.047	0.000
	Week 6	125	-0.74	0.07	0.036	0.000
	Week 7	126	-0.77	0.07	0.077	0.000
	Week 8	122	-0.81	0.07	0.083	0.000
	Week 9	120	-0.83	0.07	0.018	0.000
	Week 10	115	-0.84	0.07	0.046	0.000
	Week 11	116	-0.87	0.07	0.013	0.000
	Week 12	115	-0.90	0.08	0.003	0.000

DVS SR		Protocol 3	Protocol 3151A2-315-US					
DVS SR 150 mg	Week 1	124	-0.35	0.04	0.000	0.000		
	Week 2	124	-0.51	0.06	0.011	0.000		
	Week 3	119	-0.58	0.07	0.017	0.000		
	Week 4	117	-0.56	0.07	0.078	0.000		
	Week 5	110	-0.64	0.07	0.193	0.000		
	Week 6	109	-0.64	0.07	0.247	0.000		
	Week 7	108	-0.65	0.08	0.454	0.000		
	Week 8	103	-0.62	0.08	0.937	0.000		
	Week 9	102	-0.67	0.08	0.331	0.000		
	Week 10	106	-0.70	0.08	0.396	0.000		
	Week 11	104	-0.74	0.08	0.162	0.000		
	Week 12	100	-0.66	0.08	0.298	0.000		

ANCOVA: change = treat + site + baseline

CONFIDENTIAL 357 Wyeth

Within and between group comparisons for hot flush number and severity DVS-233 SR protocol 315: final analysis (EE)

07:43 Friday, July 29, 2005

14

TEST NAME=AVERAGE DAILY SEVERITY SCORE OF MILD, MODERATE AND SEVERE HOT FLUSHES

Treatment	Time slot	No. of pairs	Adjusted mean	_	p-value vs. placebo	within
DVS SR 200 mg	Week 1	104	-0.42	0.05	0.000	0.000
	Week 2	104	-0.62	0.06	0.000	0.000
	Week 3	103	-0.57	0.07	0.025	0.000
	Week 4	93	-0.60	0.08	0.042	0.000
	Week 5	95	-0.69	0.08	0.093	0.000
	Week 6	96	-0.71	0.08	0.084	0.000
	Week 7	95	-0.81	0.08	0.048	0.000
	Week 8	92	-0.77	0.08	0.188	0.000
	Week 9	89	-0.84	0.08	0.022	0.000
	Week 10	91	-0.81	0.08	0.089	0.000
	Week 11	94	-0.86	0.08	0.022	0.000
	Week 12	93	-0.81	0.09	0.028	0.000
Placebo	Week 1	74	-0.09	0.06		0.114
	Week 2	74	-0.27	0.07	•	0.000
	Week 3	74	-0.33	0.08		0.000
	Week 4	73	-0.37	0.09		0.000
	Week 5	70	-0.49	0.09	•	0.000
	Week 6	70	-0.51	0.09	•	0.000
	Week 7	69	-0.57	0.09	•	0.000
	Week 8	65	-0.61	0.10		0.000
	Week 9	64	-0.55	0.10	•	0.000
	Week 10	65	-0.60	0.10		0.000
	Week 11	65	-0.57	0.10		0.000
	Week 12	62	-0.52	0.10	•	0.000

ANCOVA: change = treat + site + baseline

Within and between group comparisons for hot flush number and severity DVS-233 SR protocol 315: final analysis (EE) $\,$

07:43 Friday, July 29, 2005

15

TEST NAME=WEEKLY WEIGHTED SCORE OF MODERATE AND SEVERE HOT FLUSHES

Treatment	Time slot	pairs	Adjusted mean	SE	placebo	within group
DVS SR 50 mg	Week 1	133		5.50		
	Week 2	133	-93.68	6.18	0.022	0.000
	Week 3	127	-103.0	6.52	0.102	0.000
	Week 4	126	-111.1	6.42	0.152	0.000
	Week 5	119	-113.1	6.45	0.456	0.000
	Week 6	119	-104.9	6.39	0.930	0.000
	Week 7	121	-105.6	6.41	0.576	0.000
	Week 8	120	-103.8	6.72	0.557	0.000
	Week 9	116	-108.2	6.63	0.929	0.000
	Week 10	118	-107.7	6.50	0.651	0.000
	Week 11	116	-112.5	6.51	0.934	0.000
	Week 12	107	-119.7	6.59	0.262	0.000
DVS SR 100 mg	Week 1	139	-92.78	5.34	0.000	0.000
	Week 2	135	-118.8	6.09	0.000	0.000
	Week 3	132	-125.3	6.37	0.000	0.000
	Week 4	124	-130.9	6.42	0.001	0.000
	Week 5	124	-132.8	6.30	0.008	0.000
	Week 6	125	-134.3	6.22	0.005	0.000
	Week 7	126	-135.3	6.26	0.020	0.000
	Week 8	122	-139.0	6.56	0.008	0.000
	Week 9	120	-143.9	6.41	0.001	0.000
	Week 10	115	-143.1	6.48	0.004	0.000
	Week 11	116	-145.0	6.41	0.001	0.000
	Week 12	115	-146.9	6.29	0.000	0.000

DVS SR		Protocol 3	Protocol 3151A2-315-US					
DVS SR 150 mg	Week 1	124	-101.0	5.69	0.000	0.000		
	Week 2	124	-116.5	6.42	0.000	0.000		
	Week 3	119	-121.6	6.79	0.001	0.000		
	Week 4	117	-122.8	6.69	0.011	0.000		
	Week 5	110	-137.4	6.81	0.002	0.000		
	Week 6	109	-135.5	6.78	0.004	0.000		
	Week 7	108	-135.0	6.86	0.026	0.000		
	Week 8	103	-130.8	7.24	0.066	0.000		
	Week 9	102	-133.2	7.03	0.028	0.000		
	Week 10	106	-131.2	6.85	0.079	0.000		
	Week 11	104	-131.8	6.88	0.060	0.000		
	Week 12	100	-131.0	6.83	0.030	0.000		

ANCOVA: change = treat + site + baseline

CONFIDENTIAL 360 Wyeth

Within and between group comparisons for hot flush number and severity DVS-233 SR protocol 315: final analysis (EE) $\,$

07:43 Friday, July 29, 2005

16

Treatment	Time slot	No. of pairs	Adjusted mean	_	p-value - vs. placebo	within
DVS SR 200 mg	Week 1	104	-98.47	6.22	0.000	0.000
	Week 2	104	-123.2	6.99	0.000	0.000
	Week 3	103	-123.1	7.26	0.001	0.000
	Week 4	93	-130.5	7.49	0.002	0.000
	Week 5	95	-132.2	7.29	0.014	0.000
	Week 6	96	-129.5	7.17	0.026	0.000
	Week 7	95	-132.0	7.27	0.058	0.000
	Week 8	92	-132.6	7.65	0.051	0.000
	Week 9	89	-135.2	7.54	0.021	0.000
	Week 10	91	-133.8	7.40	0.052	0.000
	Week 11	94	-130.1	7.27	0.091	0.000
	Week 12	93	-130.6	7.15	0.037	0.000
Placebo	Week 1	74	-41.77	7.20		0.000
	Week 2	74	-70.82	8.12	•	0.000
	Week 3	74	-85.95	8.37	•	0.000
	Week 4	73	-96.46	8.22	•	0.000
	Week 5	70	-105.4	8.29	•	0.000
	Week 6	70	-105.8	8.23	•	0.000
	Week 7	69	-111.4	8.38	•	0.000
	Week 8	65	-110.2	8.88	•	0.000
	Week 9	64	-109.2	8.66	•	0.000
	Week 10	65	-112.4	8.54		0.000
	Week 11	65	-111.7	8.48		0.000
	Week 12	62	-108.0	8.48		0.000

ANCOVA: change = treat + site + baseline

ST 9-24: Summary Statistics for Sleep Parameters: Final Analysis (PP)

Summary statistics for sleep parameters DVS-233 SR protocol 315: final analysis (EE) $\frac{1}{2}$

07:45 Friday, July 29, 2005

1

TEST	NAME=DAILY	MEAN	MINUTES	SLEPT
			Time	

	Time	No. of	Base	line	Observed		Change from	baseline
Treatment	slot	pairs	mean	SD	mean SD		mean	SD
DVS SR 50 mg	Screening/baseline	137	377.5	66.1				
	Week 1	130	378.5	63.5	388.9 7	0.1	10.4	47.3
	Week 2	131	377.5	65.7	401.1 6	7.1	23.6	45.1
	Week 3	126	379.8	62.7	402.3 5	6.0	22.5	48.5
	Week 4	125	379.8	62.1	403.7 5	3.9	23.9	47.8
	Week 5	119	380.7	63.7	404.6 6	1.6	23.9	48.9
	Week 6	120	378.7	64.5	402.0 5	6.8	23.3	49.9
	Week 7	121	380.3	63.6	405.1 5	9.6	24.8	52.4
	Week 8	121	377.5	66.2	403.2 6	3.3	25.7	50.6
	Week 9	116	377.1	67.2	402.5 6	7.4	25.4	52.9
	Week 10	118	377.3	65.5	405.3 6	3.2	28.0	55.7
	Week 11	112	378.5	67.3	409.2 6	1.6	30.7	60.6
	Week 12	81	371.8	72.5	408.5 7	3.7	36.6	63.1
DVS SR 100 mg	Screening/baseline	138	382.3	64.0				
	Week 1	137	382.0	64.1	393.9 6	6.3	11.9	56.0
	Week 2	133	382.5	63.5	409.5 5	9.4	27.1	46.3
	Week 3	130	381.5	64.4	407.2 6	2.7	25.7	49.1
	Week 4	124	381.7	65.8	409.3 6	0.8	27.6	50.6
	Week 5	121	381.6	65.5	414.6 6	3.6	33.0	49.3
	Week 6	123	380.9	65.6	416.2 6	2.4	35.3	50.0
	Week 7	124	380.9	66.1	418.1 5	3.1	37.2	53.6
	Week 8	119	380.5	67.2	411.8 5	9.6	31.3	55.4
	Week 9	117	380.1	67.2	411.4 6	1.6	31.4	54.2
	Week 10	113	382.4	65.5	417.7 6	3.5	35.3	51.6
	Week 11	111	381.6	65.4	421.5 6	3.0	39.8	58.2

DVS SR		Protocol 3151A2-315-US								
	Week 12	85	383.6	65.9	430.1	61.6	46.5	50.6		
DVS SR 150 mg	Screening/baseline	130	372.4	65.5						
	Week 1	122	370.5	66.9	384.1	77.9	13.6	58.8		
	Week 2	122	372.7	65.8	397.0	70.8	24.3	44.1		
	Week 3	118	372.2	66.9	389.9	74.2	17.7	53.1		
	Week 4	116	373.6	65.5	392.3	71.2	18.7	50.7		
	Week 5	108	377.2	64.7	397.6	70.3	20.4	54.9		
	Week 6	110	376.0	65.0	402.1	70.0	26.1	57.9		
	Week 7	108	376.9	64.7	406.2	62.0	29.4	53.6		
	Week 8	103	378.7	65.4	405.9	63.1	27.3	52.5		
	Week 9	102	376.3	67.9	410.2	68.1	33.9	53.5		
	Week 10	107	377.0	66.4	406.3	72.6	29.3	53.7		
	Week 11	101	376.5	64.1	403.9	72.9	27.4	48.8		
	Week 12	79	379.3	63.6	407.2	67.2	27.8	45.6		

Summary statistics for sleep parameters DVS-233 SR protocol 315: final analysis (EE)

07:45 Friday, July 29, 2005

2

	Time	No. of -	Basel	ine	Obser	ved	Change from	n baseline
Treatment	slot	pairs	mean	SD	mean	SD	mean	SD
DVS SR 200 mg	Screening/baseline	111	381.1	61.4				
	Week 1	106	379.4	61.8	395.1	86.0	15.8	87.9
	Week 2	104	379.8	60.9	409.1	86.6	29.3	78.0
	Week 3	103	378.9	60.6	411.2	82.4	32.3	77.9
	Week 4	92	378.6	60.9	411.7	88.0	33.1	87.7
	Week 5	94	377.2	62.5	407.1	64.8	29.9	68.4
	Week 6	94	379.3	61.0	406.0	62.0	26.7	49.0
	Week 7	93	377.5	59.8	398.5	58.2	20.9	57.4
	Week 8	90	379.3	62.4	403.0	63.0	23.8	53.9
	Week 9	87	379.0	61.5	407.0	64.1	28.0	63.6
	Week 10	91	378.4	61.2	405.3	65.3	26.9	57.6
	Week 11	94	380.0	61.1	409.3	60.1	29.3	54.4
	Week 12	77	380.7	62.2	410.3	63.7	29.6	61.6
Placebo	Screening/baseline	77	376.8	60.7		•		•
	Week 1	74	376.3	61.6	388.5	52.3	12.2	40.5
	Week 2	73	376.0	62.0	394.1	50.8	18.2	48.7
	Week 3	74	376.1	61.6	400.0	51.2	23.9	63.0
	Week 4	73	376.6	61.9	397.2	51.4	20.6	60.1
	Week 5	68	381.8	52.1	403.1	58.8	21.3	65.2
	Week 6	69	377.8	59.8	400.3	52.7	22.5	59.1
	Week 7	68	378.3	60.2	402.8	49.9	24.6	56.7
	Week 8	64	378.2	59.7	409.0	48.9	30.8	61.5
	Week 9	64	379.3	60.0	409.1	51.6	29.7	57.5
	Week 10	65	375.2	63.9	410.7	50.1	35.5	67.7
	Week 11	62	375.6	59.7	403.3	45.2	27.8	59.5
	Week 12	50	378.1	59.4	399.6	52.2	21.5	53.5

Summary statistics for sleep parameters DVS-233 SR protocol 315: final analysis (EE)

07:45 Friday, July 29, 2005

3

TEST NAME=DAILY MEAN MINUTES TO FALL ASLEEP

	Time	No. of	Base	line	Obse	rved	Change fro	m baseline
Treatment	slot	pairs	mean	SD	mean	SD	mean	SD
DVS SR 50 mg	Screening/baseline	135	37.4	37 . 0				
	Week 1	130	37.1	36.6	37.6	35.9	0.4	22.9
	Week 2	130	36.6	36.3	32.6	35.1	-4.0	20.7
	Week 3	125	36.3	36.5	30.0	31.2	-6.2	22.0
	Week 4	124	35.9	35.5	28.7	28.8	-7.2	20.9
	Week 5	117	36.0	36.0	31.7	36.2	-4.3	23.3
	Week 6	117	37.1	37.0	31.5	31.5	-5.7	23.6
	Week 7	119	37.0	37.4	32.9	35.6	-4.1	27.9
	Week 8	119	38.1	38.2	33.4	39.0	-4.7	32.6
	Week 9	114	37.1	37.7	33.2	39.2	-3.9	30.3
	Week 10	116	38.4	38.4	31.8	30.7	-6.6	28.4
	Week 11	110	37.8	37.8	30.6	31.1	-7.2	29.8
	Week 12	79	40.9	42.6	33.0	39.4	-7.9	37.0
DVS SR 100 mg	Screening/baseline	139	33.2	28.9				
	Week 1	138	33.2	29.0	36.2	31.7	3.0	25.4
	Week 2	134	32.7	27.9	29.1	29.6	-3.7	22.0
	Week 3	131	33.5	29.5	29.8	30.2	-3.7	23.4
	Week 4	124	33.4	30.0	28.6	34.7	-4.8	24.0
	Week 5	121	32.5	28.4	27.8	32.5	-4.8	24.9
	Week 6	123	33.6	30.1	28.1	35.1	-5.5	26.9
	Week 7	124	33.7	30.1	27.1	32.1	-6.6	24.1
	Week 8	120	33.8	30.5	26.6	30.0	-7.2	22.4
	Week 9	117	34.5	30.6	27.7	30.4	-6.7	24.2
	Week 10	113	34.5	30.9	28.3	34.0	-6.2	27.2
	Week 11	111	33.8	29.3	27.6	32.2	-6.3	26.7
	Week 12	84	36.3	33.8	23.7	32.4	-12.5	22.6

DVS SR			CSR-60178						
DVS SR 150 mg	Screening/baseline	131	37.5	33.6					
DVS 51(150 mg	Week 1	122	38.0	34.3	41.7	42.1	3.8	· 31.5	
	Week 2	122	38.1	34.4	34.9	37.5	-3.2	28.2	
	Week 3	118	38.7	34.7	35.0	40.9	-3.7	31.5	
	Week 4	117	38.0	34.4	35.9	39.0	-2.2	30.6	
	Week 5	108	36.5	32.8	34.5	40.6	-2.0	35.2	
	Week 6	110	38.0	34.5	33.8	40.0	-4.2	35.3	
	Week 7	108	38.0	34.7	32.6	38.7	-5.4	32.9	
	Week 8	103	38.5	35.3	31.5	32.7	-7.1	30.1	
	Week 9	102	39.2	35.9	31.2	34.5	-8.0	31.9	
	Week 10	107	38.7	35.2	30.3	32.9	-8.4	28.5	
	Week 11	101	39.0	35.8	31.2	35.9	-7.8	30.4	
	Week 12	79	35.4	32.0	27.3	31.5	-8.0	25.6	

Summary statistics for sleep parameters DVS-233 SR protocol 315: final analysis (EE)

07:45 Friday, July 29, 2005

4

	Time	No. of	Basel	ine	Obser	ved	Change from	n baseline
Treatment	slot	pairs	mean	SD	mean	SD	mean	SD
DVS SR 200 mg	Screening/baseline	111	37.8	39.1				
	Week 1	106	38.3	39.8	35.6	34.9	-2.8	38.3
	Week 2	104	38.9	40.0	27.1	36.2	-11.8	35.1
	Week 3	102	37.7	38.8	27.2	30.5	-10.5	32.3
	Week 4	92	39.6	41.9	27.1	33.9	-12.5	34.9
	Week 5	93	39.6	41.3	29.4	30.9	-10.2	35.5
	Week 6	95	39.1	41.0	30.5	36.7	-8.6	37.3
	Week 7	94	39.0	41.6	32.2	39.0	-6.8	42.2
	Week 8	90	39.6	42.6	26.7	33.3	-13.0	38.4
	Week 9	87	41.4	43.0	27.8	33.1	-13.6	39.2
	Week 10	91	40.6	42.2	30.0	36.2	-10.6	36.0
	Week 11	94	39.6	41.9	26.6	28.7	-12.9	33.3
	Week 12	77	39.8	43.1	25.3	25.2	-14.6	39.3
Placebo	Screening/baseline	77	40.3	33.9				
	Week 1	74	40.5	34.3	36.3	29.5	-4.2	15.7
	Week 2	74	40.3	34.5	32.8	25.4	-7.5	20.1
	Week 3	73	41.1	34.3	31.8	23.5	-9.2	26.9
	Week 4	73	40.9	34.4	33.1	30.0	-7.7	30.0
	Week 5	69	40.4	35.0	31.0	26.4	-9.4	24.0
	Week 6	70	41.1	34.9	30.5	25.0	-10.6	23.5
	Week 7	69	40.7	35.1	30.0	26.7	-10.8	23.7
	Week 8	64	38.9	33.6	27.3	26.2	-11.5	21.5
	Week 9	64	39.4	34.1	28.6	26.7	-10.8	19.6
	Week 10	65	41.2	35.9	29.0	26.5	-12.1	28.6
	Week 11	63	41.6	36.3	28.0	26.1	-13.6	23.2
	Week 12	51	42.2	33.6	30.6	26.3	-11.6	22.8

Summary statistics for sleep parameters DVS-233 SR protocol 315: final analysis (EE)

07:45 Friday, July 29, 2005

5

TEST NAME=DAILY MEAN NUMBER OF TIMES AWAKENED

	Time	No. of -	Base	line	Obse	rved	Change from	m baseline
Treatment	slot	pairs	mean	SD	mean	SD	mean	SD
DVS SR 50 mg	Screening/baseline	135	3.7	1.7				
	Week 1	130	3.7	1.7	2.8	1.7	-0.9	1.6
	Week 2	131	3.7	1.7	2.3	1.5	-1.5	1.8
	Week 3	126	3.8	1.7	1.9	1.4	-1.9	1.7
	Week 4	125	3.8	1.7	1.7	1.3	-2.0	1.7
	Week 5	117	3.8	1.7	1.8	2.0	-1.9	2.1
	Week 6	118	3.8	1.7	1.8	2.1	-2.0	2.1
	Week 7	119	3.8	1.7	1.8	2.0	-2.0	2.0
	Week 8	119	3.8	1.7	1.8	2.1	-2.0	2.1
	Week 9	114	3.8	1.8	1.7	2.1	-2.0	2.1
	Week 10	116	3.8	1.8	1.6	1.8	-2.2	1.9
	Week 11	110	3.8	1.8	1.6	1.7	-2.2	1.9
	Week 12	79	3.8	1.8	1.6	1.7	-2.2	2.0
DVS SR 100 mg	Screening/baseline	140	3.7	1.9				
	Week 1	139	3.7	1.9	2.2	1.6	-1.5	1.8
	Week 2	135	3.7	1.9	1.6	1.5	-2.0	1.9
	Week 3	131	3.7	1.9	1.5	1.5	-2.2	2.0
	Week 4	124	3.7	1.9	1.4	1.4	-2.3	1.9
	Week 5	119	3.7	2.0	1.3	1.4	-2.4	2.1
	Week 6	123	3.7	1.9	1.2	1.4	-2.5	2.1
	Week 7	122	3.7	1.9	1.0	1.3	-2.6	2.0
	Week 8	119	3.7	1.8	1.1	1.2	-2.6	1.9
	Week 9	118	3.8	1.9	1.0	1.2	-2.8	2.0
	Week 10	114	3.8	1.9	1.0	1.3	-2.8	1.9
	Week 11	112	3.7	1.9	1.0	1.4	-2.8	2.0
	Week 12	85	3.8	2.1	1.0	1.4	-2.8	2.0

DVS SR		Protocol 3151A2-315-US								
DVS SR 150 mg	Screening/baseline	132	3.9	2.8						
_	Week 1	123	3.9	2.8	2.2	1.8	-1.7	2.4		
	Week 2	123	3.9	2.8	1.9	2.3	-2.0	2.8		
	Week 3	117	4.0	2.8	1.8	2.4	-2.2	2.8		
	Week 4	117	4.0	2.8	1.7	2.3	-2.3	2.8		
	Week 5	109	3.8	2.2	1.5	1.9	-2.3	2.1		
	Week 6	110	3.7	2.1	1.2	1.2	-2.5	2.1		
	Week 7	109	3.7	2.1	1.2	1.3	-2.5	2.1		
	Week 8	104	3.6	2.0	1.2	1.3	-2.4	2.0		
	Week 9	101	3.7	2.0	1.3	1.5	-2.4	2.0		
	Week 10	106	3.6	2.0	1.3	1.5	-2.3	2.1		
	Week 11	101	3.7	2.1	1.3	1.7	-2.4	2.2		
	Week 12	79	3.6	2.2	1.0	1.2	-2.6	2.2		

Summary statistics for sleep parameters DVS-233 SR protocol 315: final analysis (EE)

07:45 Friday, July 29, 2005

6

TEST NAME=DAILY MEAN NUMBER OF TIMES AWAKENED

	Time	No. of -	Basel	ine	Observ	red	Change from	baseline
Treatment	slot	pairs	mean		mean S	SD	mean	SD
DVS SR 200 mg	Screening/baseline		3.8	2.5				
	Week 1	105	3.8	2.5	2.3	2.0	-1.4	1.9
	Week 2	103	3.7	2.5	1.7	1.7	-2.0	2.3
	Week 3	100	3.7	2.5	1.5	1.6	-2.2	2.4
	Week 4	91	3.8	2.6	1.4	1.6	-2.4	2.6
	Week 5	92	3.7	2.6	1.4	1.7	-2.4	2.4
	Week 6	94	3.7	2.5	1.4	1.5	-2.3	2.5
	Week 7	93	3.7	2.3	1.2	1.4	-2.4	2.3
	Week 8	89	3.8	2.6	1.3	1.5	-2.5	2.6
	Week 9	87	3.8	2.6	1.2	1.4	-2.7	2.6
	Week 10	90	3.8	2.6	1.2	1.4	-2.6	2.6
	Week 11	93	3.8	2.6	1.1	1.4	-2.7	2.6
	Week 12	76	3.7	2.4	1.1	1.5	-2.6	2.6
Placebo	Screening/baseline	77	3.5	2.1		•		
	Week 1	73	3.4	2.0	2.6	1.7	-0.8	1.3
	Week 2	74	3.5	2.1	2.2	1.6	-1.3	1.8
	Week 3	74	3.5	2.1	1.9	1.5	-1.6	1.9
	Week 4	73	3.5	2.1	1.7	1.5	-1.7	1.9
	Week 5	69	3.3	2.0	1.6	1.5	-1.7	2.1
	Week 6	69	3.6	2.2	1.6	1.6	-2.0	2.4
	Week 7	69	3.6	2.1	1.5	1.5	-2.1	2.3
	Week 8	64	3.7	2.2	1.6	1.4	-2.2	2.3
	Week 9	64	3.6	2.2	1.5	1.4	-2.1	2.4
	Week 10	65	3.6	2.2	1.5	1.5	-2.1	2.5
	Week 11	63	3.7	2.3	1.6	1.5	-2.1	2.4
	Week 12	51	3.6	2.3	1.7	1.6	-2.0	2.7

Summary statistics for sleep parameters DVS-233 SR protocol 315: final analysis (EE)

07:45 Friday, July 29, 2005

7

TEST NAME=DAILY MEAN QUALITY SCORE OF SLEEP

	Time	No. ofBaseline		Observ	red	Change from	baseline	
Treatment	slot	pairs	mean	SD	mean S	SD	mean	SD
DVS SR 50 mg	Screening/baseline	136	2.8	0.7				
	Week 1	131	2.8	0.7	3.1	0.7	0.3	0.7
	Week 2	131	2.8	0.7	3.4	0.7	0.5	0.7
	Week 3	126	2.8	0.7	3.5	0.8	0.6	0.7
	Week 4	125	2.8	0.7	3.5	0.8	0.7	0.8
	Week 5	118	2.8	0.7	3.4	0.8	0.6	0.8
	Week 6	119	2.8	0.7	3.5	0.8	0.7	0.8
	Week 7	120	2.8	0.7	3.5	0.8	0.6	0.8
	Week 8	120	2.8	0.7	3.5	0.8	0.7	0.9
	Week 9	115	2.8	0.7	3.5	0.8	0.7	0.8
	Week 10	117	2.8	0.7	3.6	0.7	0.8	0.9
	Week 11	111	2.8	0.7	3.6	0.8	0.8	0.9
	Week 12	80	2.8	0.7	3.6	0.8	0.8	0.9
DVS SR 100 mg	Screening/baseline	140	2.8	0.7				
	Week 1	139	2.8	0.7	3.1	0.8	0.3	0.8
	Week 2	134	2.8	0.7	3.5	0.8	0.6	0.8
	Week 3	131	2.8	0.7	3.5	0.8	0.7	0.8
	Week 4	124	2.8	0.7	3.5	0.7	0.8	0.7
	Week 5	122	2.8	0.7	3.6	0.8	0.8	0.7
	Week 6	123	2.8	0.7	3.7	0.8	0.8	0.8
	Week 7	125	2.8	0.7	3.7	0.8	0.9	0.8
	Week 8	121	2.8	0.8	3.7	0.7	0.9	0.8
	Week 9	118	2.8	0.8	3.7	0.7	0.9	0.8
	Week 10	114	2.8	0.8	3.7	0.7	0.9	0.8
	Week 11	111	2.8	0.8	3.8	0.8	0.9	0.9
	Week 12	85	2.8	0.8	3.8	0.8	1.0	0.9

DVS SR		Protocol 3151A2-315-US								
DVS SR 150 mg	Screening/baseline	132	2.9	0.8						
-	Week 1	123	2.9	0.8	3.1	0.8	0.3	0.9		
	Week 2	122	2.9	0.8	3.4	0.8	0.5	0.9		
	Week 3	119	2.9	0.8	3.5	0.8	0.6	0.9		
	Week 4	118	2.9	0.8	3.5	0.8	0.6	0.9		
	Week 5	108	2.9	0.8	3.7	0.7	0.8	0.9		
	Week 6	110	2.9	0.8	3.7	0.8	0.7	0.9		
	Week 7	109	2.9	0.8	3.6	0.8	0.7	0.9		
	Week 8	104	2.9	0.8	3.7	0.8	0.8	0.9		
	Week 9	102	2.9	0.8	3.8	0.8	0.9	0.9		
	Week 10	107	2.9	0.8	3.7	0.8	0.8	0.9		
	Week 11	102	2.9	0.8	3.7	0.8	0.8	1.0		
	Week 12	79	3.0	0.8	3.8	0.8	0.8	0.9		

Summary statistics for sleep parameters DVS-233 SR protocol 315: final analysis (EE)

07:45 Friday, July 29, 2005

8

TEST NAME=DAILY MEAN QUALITY SCORE OF SLEEP

	Time	No. of -	Base	line	Obse	erved	Change fro	m baseline
Treatment	slot	pairs	mean	SD	mean	SD	mean	SD
DVS SR 200 mg	Screening/baseline	110	2.8	0.7				
	Week 1	105	2.8	0.7	3.1	0.8	0.3	0.9
	Week 2	101	2.8	0.7	3.5	0.8	0.7	0.9
	Week 3	101	2.8	0.7	3.5	0.8	0.6	0.8
	Week 4	91	2.8	0.7	3.6	0.8	0.7	0.8
	Week 5	93	2.8	0.7	3.5	0.7	0.7	0.8
	Week 6	94	2.8	0.7	3.5	0.8	0.7	0.9
	Week 7	93	2.9	0.7	3.5	0.8	0.7	1.0
	Week 8	89	2.8	0.7	3.6	0.8	0.8	0.9
	Week 9	87	2.8	0.7	3.6	0.7	0.8	0.8
	Week 10	90	2.8	0.7	3.6	0.7	0.8	0.8
	Week 11	93	2.8	0.7	3.6	0.7	0.8	0.8
	Week 12	76	2.8	0.7	3.7	0.8	0.8	0.9
Placebo	Screening/baseline	77	2.9	0.6				
	Week 1	74	2.9	0.6	3.2	0.6	0.2	0.5
	Week 2	74	2.9	0.6	3.4	0.6	0.4	0.6
	Week 3	74	2.9	0.6	3.5	0.6	0.5	0.7
	Week 4	73	2.9	0.6	3.5	0.6	0.6	0.7
	Week 5	69	3.0	0.6	3.5	0.7	0.5	0.7
	Week 6	69	2.9	0.6	3.5	0.7	0.6	0.7
	Week 7	68	2.9	0.6	3.5	0.7	0.6	0.8
	Week 8	63	2.9	0.6	3.6	0.6	0.7	0.6
	Week 9	64	2.9	0.6	3.7	0.6	0.7	0.7
	Week 10	65	2.9	0.6	3.7	0.7	0.7	0.8
	Week 11	63	2.9	0.6	3.6	0.7	0.7	0.8
	Week 12	51	2.9	0.6	3.6	0.7	0.7	0.8

DVS SR

Protocol 3151A2-315-US

CSR-60178

9

Within and between group comparisons for sleep parameters $$\tt DVS-233$ SR protocol 315: final analysis (EE)

07:45 Friday, July 29, 2005

TEST NAME=DAILY MEAN MINUTES SLEPT

Treatment		No. of pairs	Adjusted mean	_	-	
DVS SR 50 mg	Week 1	130	13.04	5.16	0.889	0.012
	Week 2	131	24.79	4.55	0.422	0.000
	Week 3	126	22.85	4.95	0.895	0.000
	Week 4	125	24.20	5.07	0.690	0.000
	Week 5	119	24.19	4.90	0.866	0.000
	Week 6	120	24.57	4.53	0.987	0.000
	Week 7	121	26.78	4.47	0.940	0.000
	Week 8	121	27.23	4.48	0.400	0.000
	Week 9	116	26.04	4.90	0.523	0.000
	Week 10	118	29.18	4.89	0.451	0.000
	Week 11	112	32.85	5.04	0.715	0.000
	Week 12	81	35.85	5.97	0.110	0.000
DVS SR 100 mg	Week 1	137	15.03	4.98	0.918	0.003
	Week 2	133	28.22	4.47	0.203	0.000
	Week 3	130	26.23	4.85	0.766	0.000
	Week 4	124	27.79	5.04	0.398	0.000
	Week 5	121	33.46	4.82	0.177	0.000
	Week 6	123	36.44	4.44	0.103	0.000
	Week 7	124	38.88	4.38	0.078	0.000
	Week 8	119	33.34	4.43	0.996	0.000
	Week 9	117	31.78	4.80	0.926	0.000
	Week 10	113	37.69	4.93	0.744	0.000
	Week 11	111	43.43	4.99	0.096	0.000
	Week 12	85	49.48	5.90	0.002	0.000

DVS SR	Protocol 3	CSR-60178					
DVS SR 150 mg	Week 1	122	14.94	5.35	0.928	0.005	
	Week 2	122	25.16	4.74	0.400	0.000	
	Week 3	118	17.47	5.17	0.421	0.001	
	Week 4	116	19.16	5.28	0.823	0.000	
	Week 5	108	20.72	5.21	0.790	0.000	
	Week 6	110	27.41	4.79	0.711	0.000	
	Week 7	108	30.90	4.77	0.527	0.000	
	Week 8	103	30.23	4.83	0.676	0.000	
	Week 9	102	34.73	5.20	0.649	0.000	
	Week 10	107	32.11	5.13	0.709	0.000	
	Week 11	101	29.96	5.32	0.993	0.000	
	Week 12	79	28.63	6.03	0.420	0.000	

ANCOVA: change = treat + site + baseline

CONFIDENTIAL 375 Wyeth

DVS SR

Protocol 3151A2-315-US

CSR-60178

10

Within and between group comparisons for sleep parameters DVS-233 SR protocol 315: final analysis (EE)

07:45 Friday, July 29, 2005

TEST NAME=DAILY MEAN MINUTES SLEPT

Treatment	Time slot	No. of pairs	Adjusted c	change	p-value vs. placebo	within
DVS SR 200 mg	Week 1	106	18.62	5.73	0.608	0.001
	Week 2	104	30.90	5.11	0.119	0.000
	Week 3	103	32.99	5.50	0.269	0.000
	Week 4	92	34.52	5.93	0.116	0.000
	Week 5	94	29.63	5.56	0.414	0.000
	Week 6	94	27.94	5.15	0.670	0.000
	Week 7	93	22.23	5.13	0.599	0.000
	Week 8	90	27.65	5.18	0.460	0.000
	Week 9	87	30.09	5.64	0.907	0.000
	Week 10	91	29.82	5.57	0.525	0.000
	Week 11	94	32.58	5.54	0.749	0.000
	Week 12	77	29.93	6.19	0.347	0.000
Placebo	Week 1	74	14.19	6.67		0.034
	Week 2	73	18.89	5.97	•	0.002
	Week 3	74	23.90	6.33	•	0.000
	Week 4	73	20.99	6.47		0.001
	Week 5	68	22.86	6.37	•	0.000
	Week 6	69	24.68	5.88	•	0.000
	Week 7	68	26.23	5.87	•	0.000
	Week 8	64	33.38	5.99	•	0.000
	Week 9	64	31.06	6.39	•	0.000
	Week 10	65	35.11	6.43	•	0.000
	Week 11	62	29.89	6.62	•	0.000
	Week 12	50	21.14	7.35	•	0.004

ANCOVA: change = treat + site + baseline

CSR-60178

11

Within and between group comparisons for sleep parameters DVS-233 SR protocol 315: final analysis (EE)

07:45 Friday, July 29, 2005

TEST NAME=DAILY MEAN MINUTES TO FALL ASLEEP

Treatment	Time slot	No. of pairs	Adjusted mean	3	placebo	within group
DVS SR 50 mg	Week 1	130		2.36		
	Week 2	130	-4.49	2.14	0.577	0.037
	Week 3	125	-7.13	2.24	0.776	0.002
	Week 4	124	-7.24	2.32	0.832	0.002
	Week 5	117	-4.86	2.50	0.313	0.053
	Week 6	117	-6.31	2.54	0.499	0.013
	Week 7	119	-5.41	2.63	0.317	0.040
	Week 8	119	-4.43	2.48	0.089	0.075
	Week 9	114	-5.33	2.56	0.176	0.038
	Week 10	116	-7.86	2.46	0.283	0.002
	Week 11	110	-8.42	2.42	0.162	0.001
	Week 12	79	-6.90	3.00	0.673	0.022
DVS SR 100 mg	Week 1	138	1.12	2.27	0.212	0.623
	Week 2	134	-5.18	2.10	0.718	0.014
	Week 3	131	-5.21	2.18	0.410	0.017
	Week 4	124	-5.88	2.30	0.875	0.011
	Week 5	121	-7.24	2.45	0.678	0.003
	Week 6	123	-7.49	2.47	0.700	0.003
	Week 7	124	-9.03	2.56	0.887	0.000
	Week 8	120	-9.72	2.43	0.697	0.000
	Week 9	117	-9.39	2.49	0.717	0.000
	Week 10	113	-9.24	2.46	0.472	0.000
	Week 11	111	-9.69	2.38	0.284	0.000
	Week 12	84	-14.08	2.95	0.246	0.000

DVS SR		Protocol 3151A2-315-US							
DVS SR 150 mg	Week 1	122	3.25	2.44	0.076	0.183			
	Week 2	122	-3.58	2.23	0.416	0.109			
	Week 3	118	-4.14	2.33	0.269	0.076			
	Week 4	117	-2.49	2.39	0.286	0.299			
	Week 5	108	-3.47	2.64	0.183	0.189			
	Week 6	110	-5.21	2.66	0.348	0.050			
	Week 7	108	-6.89	2.79	0.525	0.014			
	Week 8	103	-7.66	2.65	0.382	0.004			
	Week 9	102	-8.40	2.69	0.556	0.002			
	Week 10	107	-10.01	2.56	0.604	0.000			
	Week 11	101	-9.25	2.53	0.246	0.000			
	Week 12	79	-10.33	2.99	0.742	0.001			

ANCOVA: change = treat + site + baseline

CONFIDENTIAL 378 Wyeth

CSR-60178

12

Within and between group comparisons for sleep parameters DVS-233 SR protocol 315: final analysis (EE)

07:45 Friday, July 29, 2005

TEST NAME=DAILY MEAN MINUTES TO FALL ASLEEP

Treatment	Time slot		_	_	p-value - vs. placebo	within
DVS SR 200 mg	Week 1	106	-3.73	2.62	0.961	0.154
	Week 2	104	-12.01	2.41	0.121	0.000
	Week 3	102	-10.87	2.49	0.465	0.000
	Week 4	92	-12.32	2.70	0.135	0.000
	Week 5	93	-10.52	2.84	0.698	0.000
	Week 6	95	-8.40	2.84	0.882	0.003
	Week 7	94	-7.39	2.98	0.614	0.013
	Week 8	90	-12.77	2.85	0.726	0.000
	Week 9	87	-13.58	2.93	0.528	0.000
	Week 10	91	-11.14	2.78	0.819	0.000
	Week 11	94	-14.22	2.64	0.920	0.000
	Week 12	77	-13.16	3.07	0.346	0.000
Placebo	Week 1	74	-3.54	3.05		0.246
	Week 2	74	-6.42	2.79		0.022
	Week 3	73	-8.14	2.88	•	0.005
	Week 4	73	-6.46	2.95		0.029
	Week 5	69	-8.89	3.21		0.006
	Week 6	70	-9.03	3.24		0.006
	Week 7	69	-9.62	3.41		0.005
	Week 8	64	-11.28	3.29		0.001
	Week 9	64	-10.86	3.31	•	0.001
	Week 10	65	-12.09	3.21	•	0.000
	Week 11	63	-13.82	3.13		0.000
	Week 12	51	-8.82	3.61	•	0.015

ANCOVA: change = treat + site + baseline

DVS SR

Protocol 3151A2-315-US

CSR-60178

13

Within and between group comparisons for sleep parameters DVS-233 SR protocol 315: final analysis (EE)

07:45 Friday, July 29, 2005

TEST NAME=DAILY MEAN NUMBER OF TIMES AWAKENED

Treatment	Time slot	No. of pairs	Adjusted mean	3	vs. placebo	
DVS SR 50 mg	Week 1	130	-0.98			0.000
	Week 2	131	-1.50	0.14	0.982	0.000
	Week 3	126	-1.94	0.14	0.689	0.000
	Week 4	125	-2.07	0.15	0.798	0.000
	Week 5	117	-1.93	0.15	0.699	0.000
	Week 6	118	-1.97	0.15	0.602	0.000
	Week 7	119	-1.94	0.14	0.248	0.000
	Week 8	119	-1.96	0.14	0.487	0.000
	Week 9	114	-2.06	0.15	0.513	0.000
	Week 10	116	-2.16	0.14	0.714	0.000
	Week 11	110	-2.20	0.15	0.964	0.000
	Week 12	79	-2.16	0.17	0.553	0.000
DVS SR 100 mg	Week 1	139	-1.52	0.12	0.015	0.000
	Week 2	135	-2.10	0.14	0.009	0.000
	Week 3	131	-2.26	0.14	0.073	0.000
	Week 4	124	-2.40	0.14	0.088	0.000
	Week 5	119	-2.42	0.15	0.107	0.000
	Week 6	123	-2.52	0.14	0.061	0.000
	Week 7	122	-2.67	0.14	0.032	0.000
	Week 8	119	-2.65	0.14	0.024	0.000
	Week 9	118	-2.79	0.15	0.016	0.000
	Week 10	114	-2.85	0.14	0.007	0.000
	Week 11	112	-2.83	0.14	0.008	0.000
	Week 12	85	-2.76	0.17	0.003	0.000

DVS SR		Protocol 3	CSR-60178				
DVS SR 150 mg	Week 1	123	-1.72	0.13	0.001	0.000	
	Week 2	123	-1.95	0.15	0.055	0.000	
	Week 3	117	-2.12	0.15	0.247	0.000	
	Week 4	117	-2.22	0.15	0.376	0.000	
	Week 5	109	-2.31	0.16	0.256	0.000	
	Week 6	110	-2.54	0.15	0.060	0.000	
	Week 7	109	-2.51	0.15	0.161	0.000	
	Week 8	104	-2.47	0.15	0.151	0.000	
	Week 9	101	-2.49	0.16	0.261	0.000	
	Week 10	106	-2.46	0.15	0.360	0.000	
	Week 11	101	-2.47	0.15	0.259	0.000	
	Week 12	79	-2.63	0.17	0.016	0.000	

ANCOVA: change = treat + site + baseline

CONFIDENTIAL 381 Wyeth

CSR-60178

14

Within and between group comparisons for sleep parameters DVS-233 SR protocol 315: final analysis (EE)

07:45 Friday, July 29, 2005

TEST NAME=DAILY MEAN NUMBER OF TIMES AWAKENED

Treatment	Time slot	No. of pairs	Adjusted o	change	p-value vs. placebo	within
DVS SR 200 mg	Week 1	105	-1.49	0.14	0.030	0.000
	Week 2	103	-2.10	0.16	0.015	0.000
	Week 3	100	-2.35	0.16	0.037	0.000
	Week 4	91	-2.47	0.17	0.062	0.000
	Week 5	92	-2.39	0.17	0.157	0.000
	Week 6	94	-2.39	0.16	0.225	0.000
	Week 7	93	-2.48	0.16	0.215	0.000
	Week 8	89	-2.45	0.17	0.185	0.000
	Week 9	87	-2.61	0.17	0.119	0.000
	Week 10	90	-2.65	0.16	0.091	0.000
	Week 11	93	-2.73	0.16	0.032	0.000
	Week 12	76	-2.58	0.18	0.027	0.000
Placebo	Week 1	73	-1.02	0.17		0.000
	Week 2	74	-1.51	0.19		0.000
	Week 3	74	-1.85	0.18		0.000
	Week 4	73	-2.01	0.19		0.000
	Week 5	69	-2.03	0.20		0.000
	Week 6	69	-2.09	0.19		0.000
	Week 7	69	-2.20	0.18		0.000
	Week 8	64	-2.13	0.19		0.000
	Week 9	64	-2.21	0.19		0.000
	Week 10	65	-2.25	0.18		0.000
	Week 11	63	-2.21	0.19	•	0.000
	Week 12	51	-2.00	0.21	•	0.000

ANCOVA: change = treat + site + baseline

DVS SR

Protocol 3151A2-315-US

CSR-60178

15

Within and between group comparisons for sleep parameters $$\operatorname{DVS-233}$$ SR protocol 315: final analysis (EE)

07:45 Friday, July 29, 2005

TEST NAME=DAILY MEAN QUALITY SCORE OF SLEEP

Treatment	Time slot	No. of pairs	Adjusted mean	_	p-value vs. placebo	within
DVS SR 50 mg	Week 1	131	0.30	0.06	0.947	0.000
	Week 2	131	0.54	0.06	0.553	0.000
	Week 3	126	0.62	0.06	0.851	0.000
	Week 4	125	0.70	0.06	0.622	0.000
	Week 5	118	0.61	0.07	0.964	0.000
	Week 6	119	0.65	0.07	0.686	0.000
	Week 7	120	0.63	0.07	0.775	0.000
	Week 8	120	0.67	0.07	0.228	0.000
	Week 9	115	0.72	0.07	0.614	0.000
	Week 10	117	0.74	0.07	0.568	0.000
	Week 11	111	0.76	0.08	0.715	0.000
	Week 12	80	0.76	0.09	0.706	0.000
DVS SR 100 mg	Week 1	139	0.30	0.06	0.893	0.000
	Week 2	134	0.63	0.06	0.142	0.000
	Week 3	131	0.65	0.06	0.639	0.000
	Week 4	124	0.72	0.06	0.461	0.000
	Week 5	122	0.76	0.06	0.163	0.000
	Week 6	123	0.84	0.07	0.183	0.000
	Week 7	125	0.84	0.07	0.111	0.000
	Week 8	121	0.83	0.07	0.769	0.000
	Week 9	118	0.83	0.07	0.590	0.000
	Week 10	114	0.89	0.07	0.466	0.000
	Week 11	111	0.94	0.07	0.244	0.000
	Week 12	85	0.98	0.09	0.053	0.000

DVS SR		Protocol 3	CSR-60178				
DVS SR 150 mg	Week 1	123	0.30	0.06	0.955	0.000	
	Week 2	122	0.52	0.07	0.670	0.000	
	Week 3	119	0.59	0.07	0.943	0.000	
	Week 4	118	0.63	0.07	0.892	0.000	
	Week 5	108	0.79	0.07	0.103	0.000	
	Week 6	110	0.79	0.07	0.389	0.000	
	Week 7	109	0.76	0.07	0.365	0.000	
	Week 8	104	0.83	0.07	0.787	0.000	
	Week 9	102	0.90	0.07	0.275	0.000	
	Week 10	107	0.83	0.07	0.796	0.000	
	Week 11	102	0.88	0.08	0.524	0.000	
	Week 12	79	0.87	0.09	0.240	0.000	

ANCOVA: change = treat + site + baseline

CONFIDENTIAL 384 Wyeth

CSR-60178

16

Within and between group comparisons for sleep parameters DVS-233 SR protocol 315: final analysis (EE) $^{\circ}$

07:45 Friday, July 29, 2005

TEST NAME=DAILY MEAN QUALITY SCORE OF SLEEP

Treatment	Time slot	No. of pairs	Adjusted mean	3	=	
DVS SR 200 mg	Week 1	105	0.31	0.07	0.965	0.000
	Week 2	101	0.66	0.07	0.089	0.000
	Week 3	101	0.64	0.07	0.731	0.000
	Week 4	91	0.73	0.07	0.436	0.000
	Week 5	93	0.68	0.07	0.574	0.000
	Week 6	94	0.70	0.08	0.998	0.000
	Week 7	93	0.68	0.08	0.820	0.000
	Week 8	89	0.78	0.08	0.836	0.000
	Week 9	87	0.77	0.08	0.979	0.000
	Week 10	90	0.77	0.08	0.773	0.000
	Week 11	93	0.77	0.08	0.797	0.000
	Week 12	76	0.83	0.09	0.387	0.000
Placebo	Week 1	74	0.31	0.08		0.000
	Week 2	74	0.48	0.08	•	0.000
	Week 3	74	0.60	0.08	•	0.000
	Week 4	73	0.65	0.08	•	0.000
	Week 5	69	0.61	0.08	•	0.000
	Week 6	69	0.70	0.09		0.000
	Week 7	68	0.66	0.09	•	0.000
	Week 8	63	0.80	0.09	•	0.000
	Week 9	64	0.77	0.09		0.000
	Week 10	65	0.80	0.09		0.000
	Week 11	63	0.80	0.10		0.000
	Week 12	51	0.71	0.11		0.000

ANCOVA: change = treat + site + baseline

ST 9-25: Decrease in Number of Hot Flushes of at Least 50% and at Least 75%: Final Analysis (PP)

Number of hot flush decrease 50% or more DVS-233 SR protocol 315: final analysis (EE)

10:33 Friday, October 14, 2005

1

TEST NAME=AVERAGE DAILY NUMBER OF MILD, MODERATE AND SEVERE HOT FLUSHES

Treatment	Time slot	No. of pairs	-Decrease 50		Relative ratio vs. placebo	95% Lower CI	CI Upper CI	p-value vs. placebo
DVS SR 50 mg	Week 4	126	65	51.59	2.06	1.13	3.74	0.018
	Week 12	107	66	61.68	1.30	0.68	2.46	0.426
DVS SR 100 mg	Week 4	124	80	64.52	3.50	1.90	6.44	0.000
	Week 12	115	85	73.91	2.30	1.19	4.43	0.013
DVS SR 150 mg	Week 4	117	72	61.54	3.11	1.68	5.73	0.000
-	Week 12	100	67	67.00	1.62	0.84	3.13	0.149
DVS SR 200 mg	Week 4	93	54	58.06	2.66	1.41	5.02	0.003
	Week 12	93	60	64.52	1.47	0.76	2.85	0.255
Placebo	Week 4	73	25	34.25				
	Week 12	62	35	56.45				

logistic: decrease = treat + site

this is the ratio of having at least 50% reduction compared to placebo

Number of hot flush decrease 50% or more DVS-233 SR protocol 315: final analysis (EE)

10:33 Friday, October 14, 2005

2

TEST NAME=AVERAGE DAILY NUMBER OF MODERATE AND SEVERE HOT FLUSHES

Treatment	Time slot	No. of pairs	-Decrease 509		Relative ratio vs. placebo	95% Lower CI	CI Upper CI	p-value vs. placebo
DVS SR 50 mg	Week 4	126	 78	61.90	1.66	0.93	2.98	0.089
	Week 12	107	74	69.16	1.46	0.75	2.81	0.264
DVS SR 100 mg	Week 4	124	87	70.16	2.42	1.33	4.42	0.004
	Week 12	115	89	77.39	2.22	1.13	4.37	0.021
DVS SR 150 mg	Week 4	117	77	65.81	1.99	1.09	3.61	0.025
	Week 12	100	72	72.00	1.66	0.84	3.26	0.142
DVS SR 200 mg	Week 4	93	69	74.19	3.00	1.56	5.77	0.001
-	Week 12	93	65	69.89	1.52	0.77	3.01	0.228
Placebo	Week 4	73	36	49.32				
	Week 12	62	38	61.29	•			

logistic: decrease = treat + site this is the ratio of having at least 50% reduction compared to placebo

Relative

Number of hot flush decrease 75% or more DVS-233 SR protocol 315: final analysis (EE)

10:33 Friday, October 14, 2005

n-value

3

TEST NAME=AVERAGE DAILY NUMBER OF MILD, MODERATE AND SEVERE HOT FLUSHES

					relative			p-varue
	Time	No. of	-Decrease 759	% or more-	ratio vs.	95%	CI	vs.
Treatment	slot	pairs	No.	Percent	placebo	Lower CI	Upper CI	placebo
DVS SR 50 mg	Week 4	126	23	18.25	1.85	0.78	4.40	0.163
	Week 12	107	22	20.56	1.36	0.59	3.10	0.471
DVS SR 100 mg	Week 4	124	41	33.06	4.04	1.77	9.25	0.001
	Week 12	115	50	43.48	4.14	1.90	9.00	0.000
DVS SR 150 mg	Week 4	117	33	28.21	3.25	1.40	7.53	0.006
	Week 12	100	37	37.00	3.18	1.44	7.04	0.004
DVS SR 200 mg	Week 4	93	28	30.11	3.49	1.47	8.25	0.004
	Week 12	93	40	43.01	4.09	1.84	9.08	0.001
Placebo	Week 4	73	8	10.96				
	Week 12	62	10	16.13				•

logistic: decrease = treat + site

this is the ratio of having at least 75% reduction compared to placebo

Relative

Number of hot flush decrease 75% or more DVS-233 SR protocol 315: final analysis (EE)

10:33 Friday, October 14, 2005

n-value

4

TEST NAME=AVERAGE DAILY NUMBER OF MODERATE AND SEVERE HOT FLUSHES

					Relative			p-varue
	Time	No. of	-Decrease 759	de or more-	ratio vs.	95%	CI	VS.
Treatment	slot	pairs	No.	Percent	placebo	Lower CI	Upper CI	placebo
DVS SR 50 mg	Week 4	126	31	24.60	1.51	0.73	3.11	0.267
	Week 12	107	40	37.38	1.38	0.71	2.70	0.344
DVS SR 100 mg	Week 4	124	49	39.52	3.04	1.51	6.12	0.002
	Week 12	115	67	58.26	3.26	1.69	6.30	0.000
DVS SR 150 mg	Week 4	117	46	39.32	2.99	1.48	6.07	0.002
	Week 12	100	45	45.00	1.90	0.97	3.72	0.061
DVS SR 200 mg	Week 4	93	33	35.48	2.56	1.22	5.34	0.013
	Week 12	93	47	50.54	2.39	1.21	4.71	0.012
Placebo	Week 4	73	13	17.81	•			
	Week 12	62	19	30.65	•			•

logistic: decrease = treat + site
this is the ratio of having at least 75% reduction compared to placebo

ST 9-26: Comparison of Unadjusted and Dunnett's-Method Adjusted p-Values for the Primary Endpoints

Comparison of Unadjusted and Dunnett's-Method Adjusted p-Values for the Primary Endpoints: Average Daily Number of Moderate and Severe Hot Flushes

		Tiusnes	Dunnett's Adjusted
Treatment	Time Period	p-Value vs Placebo	p-Value vs Placebo
DVS SR 50 mg	Week 1	0.003	0.011
-	Week 2	0.031	0.091
	Week 3	0.103	0.264
	Week 4	0.331	0.680
	Week 5	0.627	0.956
	Week 6	0.795	0.996
	Week 7	0.794	0.995
	Week 8	0.798	0.996
	Week 9	0.657	0.968
	Week 10	0.755	0.991
	Week 11	0.554	0.916
	Week 12	0.326	0.673
DVS SR 100 mg	Week 1	0.000	0.000
-	Week 2	0.000	0.000
	Week 3	0.000	0.002
	Week 4	0.013	0.042
	Week 5	0.020	0.062
	Week 6	0.026	0.078
	Week 7	0.019	0.059
	Week 8	0.018	0.055
	Week 9	0.008	0.027
	Week 10	0.013	0.041
	Week 11	0.013	0.040
	Week 12	0.005	0.016
DVS SR 150 mg	Week 1	0.000	0.000
	Week 2	0.000	0.000
	Week 3	0.001	0.002
	Week 4	0.027	0.079
	Week 5	0.003	0.009

DVS SR Protocol 3151A2-315-US CSR-60178

Comparison of Unadjusted and Dunnett's-Method Adjusted p-Values for the Primary Endpoints: Average Daily Number of Moderate and Severe Hot Flushes

_			Dunnett's Adjusted
Treatment	Time Period	p-Value vs Placebo	p-Value vs Placebo
	Week 6	0.009	0.030
	Week 7	0.010	0.031
	Week 8	0.022	0.065
	Week 9	0.021	0.063
	Week 10	0.034	0.099
	Week 11	0.035	0.100
	Week 12	0.020	0.060
DVS SR 200 mg	Week 1	0.000	0.000
-	Week 2	0.000	0.000
	Week 3	0.003	0.011
	Week 4	0.040	0.115
	Week 5	0.104	0.266
	Week 6	0.157	0.378
	Week 7	0.098	0.252
	Week 8	0.111	0.281
	Week 9	0.086	0.225
	Week 10	0.098	0.253
	Week 11	0.183	0.429
	Week 12	0.130	0.322

Source: Cabinets/CLINICAL R&D/CLINICAL BIOSTATISTICS SAS REPORTS/3151A2/315/ 315_NDA_2005/hf_itt_locf_ancova_dunnett_csr_2...

Comparison of Unadjusted and Dunnett's-Method Adjusted p-Values for the Primary Endpoints: Average Daily Severity Score of Mild, Moderate, and Severe Hot Flushes

		p-Value	Dunnett's Adjusted p-Value
	Time	vs	VS
Treatment	Period	Placebo	Placebo
DVS SR 50 mg	Week 1	0.076	0.201
8	Week 2	0.716	0.984
	Week 3	0.861	0.999
	Week 4	0.913	1.000
	Week 5	0.484	0.860
	Week 6	0.450	0.827
	Week 7	0.307	0.642
	Week 8	0.352	0.708
	Week 9	0.197	0.454
	Week 10	0.194	0.448
	Week 11	0.528	0.897
	Week 12	0.754	0.991
DVS SR 100 mg	Week 1	0.000	0.000
_	Week 2	0.001	0.002
	Week 3	0.003	0.010
	Week 4	0.054	0.150
	Week 5	0.019	0.058
	Week 6	0.048	0.135
	Week 7	0.042	0.119
	Week 8	0.029	0.085
	Week 9	0.011	0.034
	Week 10	0.018	0.054
	Week 11	0.004	0.012
	Week 12	0.002	0.007
DVS SR 150 mg	Week 1	0.001	0.002
	Week 2	0.006	0.020
	Week 3	0.014	0.044
	Week 4	0.138	0.337

Comparison of Unadjusted and Dunnett's-Method Adjusted p-Values for the Primary Endpoints: Average Daily Severity Score of Mild, Moderate, and Severe Hot Flushes

		- Value	Dunnett's Adjusted
	75. *	p-Value	p-Value
T	Time	vs	vs
Treatment	Period	Placebo	Placebo
	Week 5	0.112	0.282
	Week 6	0.176	0.415
	Week 7	0.301	0.633
	Week 8	0.488	0.865
	Week 9	0.228	0.511
	Week 10	0.234	0.522
	Week 11	0.099	0.254
	Week 12	0.235	0.525
DVS SR 200 mg	Week 1	0.000	0.000
_	Week 2	0.001	0.002
	Week 3	0.028	0.083
	Week 4	0.072	0.193
	Week 5	0.086	0.224
	Week 6	0.079	0.210
	Week 7	0.045	0.127
	Week 8	0.092	0.237
	Week 9	0.012	0.036
	Week 10	0.030	0.086
	Week 11	0.011	0.034
	Week 12	0.013	0.040

Source: Cabinets/CLINICAL R&D/CLINICAL BIOSTATISTICS SAS REPORTS/3151A2/315/ 315_NDA_2005/hf_itt_locf_ancova_dunnett_csr_3...

ST 10-1: Number (%) of Subjects Reporting Adverse Events

Page 1

29SEP05 14:48 REPORT adverse event5 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

	Overall DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo											
Body System [1] Adverse Event	Overall P-Value *		R 50 mg =149		R 100 mg	DVS S		DVS S	SR 200 mg			
ANY ADVERSE EVENT	0.014*	139	(93.3)	150	(96.8)	153	(97.5)	151	(100)	72	(93.5)	
BODY AS A WHOLE	0.307	106	(71.1)	118	(76.1)	118	(75.2)	108	(71.5)	49	(63.6)	
ABDOMINAL PAIN	0.045*	17	(11.4)	8	(5.2)	14	(8.9)	5	(3.3)	4	(5.2)	
ABSCESS	0.468	0		0		0		1	(0.7)	0		
ACCIDENTAL INJURY	0.200	15	(10.1)	18	(11.6)	12	(7.6)	24	(15.9)	11	(14.3)	
ACCIDENTAL OVERDOSE	0.485	0		1	(0.6)	0		0		0		
ALLERGIC REACTION	0.123	6	(4.0)	1	(0.6)	2	(1.3)	4	(2.6)	0		
ASTHENIA	0.007**	15	(10.1)	37	(23.9)	33	(21.0)	35	(23.2)	10	(13.0)	
BACK PAIN	0.321	19	(12.8)	18	(11.6)	13	(8.3)	11	(7.3)	11	(14.3)	
BODY ODOR	0.494	0		0		1	(0.6)	0		0		
CELLULITIS	0.683	1	(0.7)	2	(1.3)	0		2	(1.3)	1	(1.3)	
CHEST PAIN	0.437	4	(2.7)	5	(3.2)	7	(4.5)	6	(4.0)	0		
CHILLS	0.049*	6	(4.0)	13	(8.4)	8	(5.1)	15	(9.9)	1	(1.3)	
CYST	0.403	6 2	(1.3)	0				1	(0.7)	1	(1.3)	
FACE EDEMA	0.313	3	(2.0)	1	(0.6)	0		2	(1.3)	0		
FEVER	0.050	3	(2.0)	2	(1.3)	0		6	(4.0)	0		
FLU SYNDROME	0.312	7	(4.7)	16	(10.3)	11	(7.0)	14	(9.3)	4	(5.2)	
GENERALIZED EDEMA	0.973	1	(0.7)	1	(0.6)	1	(0.6)	1	(0.7)	0		
HANGOVER EFFECT	0.093	0		0		0		0		1	(1.3)	
HEADACHE	0.434	65	(43.6)	72	(46.5)	77	(49.0)	71	(47.0)	28	(36.4)	
HEAT STROKE	0.093	0		0		0		0		1	(1.3)	
INFECTION	0.244	32	(21.5)	23	(14.8)	27	(17.2)	23	(15.2)	19	(24.7)	
INJECTION SITE HEMORRHAGE	0.485	0	, ,	1	(0.6)	0	, ,	0	, ,	0	, ,	
LAB TEST ABNORMAL	0.122	2	(1.3)	0		0		0		0		
MALAISE	0.246	0		4	(2.6)	2	(1.3)	2	(1.3)	0		
MONILIASIS	0.599	1	(0.7)	2	(1.3)	0	, ,	1	(0.7)	0		
NECK PAIN	0.063	6	(4.0)	1	(0.6)	6	(3.8)	11	(7.3)	4	(5.2)	
NEOPLASM	0.458	1	(0.7)	0	, ,	0	, ,	0	, ,	0	, ,	
NON-SPECIFIED DRUG REACTION	0.485	0	,	1	(0.6)	0		0		0		
OVERDOSE	0.494	Õ		0	/	ĺ	(0.6)	Ö		Õ		
PAIN	0.563	20	(13.4)	20	(12.9)	18	(11.5)	20	(13.2)	15	(19.5)	
PELVIC PAIN	0.323	2	(1.3)	-ĭ	(0.6)	0		0	/	0	,	
PHOTOSENSITIVITY REACTION	0.485	0	,,	$\overline{1}$	(0.6)	Õ		Õ		Õ		
SARCOIDOSIS	0.468			0	(/	Õ		ĭ	(0.7)			
WITHDRAWAL SYNDROME	0.360	0		ĭ	(0.6)	2	(1.3)	0	(/	0		

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

Page

2

29SEP05 14:48 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5

Rody System [1] Adverse Event	Overall P-Value *			DVS SR 100 mg n=155		DVS SR 150 mg n=157		DVS SR 200 mg n=151		Placebo n= 77	
CARDIOVASCULAR SYSTEM	0.011*	21	(14.1)	39	(25.2)	38	(24.2)	46	(30.5)	14	(18.2)
ARRHYTHMIA	0.093	0		0		0		0		1	(1.3)
CARDIOVASCULAR DISORDER	0.494	0		0		1	(0.6)	0		0	
CARDIOVASCULAR PHYSICAL FINDING	0.458	1	(0.7)	0		0		0		0	
CORONARY ARTERY DISORDER	0.468	0		0		0		1	(0.7)	0	
CORONARY OCCLUSION	0.643	0		1	(0.6)	0		1	(0.7)	0	
HYPERTENSION	0.193	7	(4.7)	9	(5.8)	14	(8.9)	14	(9.3)	2 2	(2.6)
MIGRAINE	0.225	2 1	(1.3)	4	(2.6)	5 2	(3.2)	9	(6.0)	2	(2.6)
MYOCARDIAL INFARCT	0.353		(0.7)	0			(1.3)	0		0	
PALPITATION	0.404	4	(2.7)	6	(3.9)	2	(1.3)	7	(4.6)	4	(5.2)
PERIPHERAL VASCULAR DISORDER	0.627	1	(0.7)	0		0		1	(0.7)	0	
SYNCOPE	0.494	0		0		1 4	(0.6)	0		0	
TACHYCARDIA	0.650	5	(3.4)	4	(2.6)		(2.5)	4	(2.6)		
VARICOSE VEIN	0.093	0		0	(4.0.0)	0		0	(40.6)	1	(1.3)
VASODILATATION	0.392	8	(5.4)	16	(10.3)	16	(10.2)	16	(10.6)	5	(6.5)
DIGESTIVE SYSTEM	<0.001***	91	(61.1)	115	(74.2)	124	(79.0)	117	(77.5)	31	(40.3)
ABDOMINAL DISTENSION	0.013*	3	(2.0)	0		1	(0.6)	1	(0.7)	4	(5.2)
ANOREXIA	0.136	7	(4.7)	10	(6.5)	13	(8.3)	16	(10.6)	2	(2.6)
BLOOD IN STOOL	0.637	1	(0.7)	1	(0.6)	0		0		0	
CHOLECYSTITIS	0.658	0		1	(0.6)	1		0		Ō	
CHOLELITHIASIS	0.353	0		2	(1.3)	1	(0.6)	0		0	
COLITIS	0.108	3		0		0		1	(0.7)	0	
CONSTIPATION	0.298	17	(11.4)	27	(17.4)	27	(17.2)	27	(17.9)	8	(10.4)
DIARRHEA	0.391	24	(16.1)	17	(11.0)	15	(9.6)	19	(12.6)	7	(9.1)
DRY MOUTH	0.002**	20	(13.4)	34	(21.9)	32	(20.4)	39	(25.8)	5	(6.5)
DUODENITIS	0.494	0		0		1	(0.6)	0		0	
DYSPEPSIA	0.129	19	(12.8)	18	(11.6)	20	(12.7)	14	(9.3)	2	(2.6)
DYSPHAGIA	0.856	1	(0.7)	2	(1.3)	2	(1.3)	2	(1.3)	0	
ERUCTATION	0.236	4	(2.7)	1 1	(0.6)	1	(0.6)	1	(0.7)	0	
ESOPHAGEAL ULCER	0.485	0	(0 7)		(0.6)	0	(0.6)	0			
ESOPHAGITIS	0.642	1	(0.7)	0	(0 ()	1 2	(0.6)	0	(2.0)	0	/1 21
FLATULENCE	0.809	1	(0.7)	1		2	(1.3)	3	(2.0)	1	(1.3)
GAMMA GLUTAMYL TRANSPEPTIDASE INCREASED	0.485	0		1	(0.6)	0		0		0 1	/1 2\
GASTRITIS GASTROENTERITIS	0.093	•	(0.7)	•	(2.2)	8	/F 1\	•	(0.0)		(1.3)
CASTIROR NOTER FOLIS	0.451	4	(2.7)	5	(3.2)	8	(5.1)	3	(2.0)	1	(1.3)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.
Overall P-Value: P-value for Chi-Square.

Page

3

29SEP05 14:48 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5

ody System [1] Adverse Event	Overall P-Value *	DVS S	R 50 mg =149	DVS S	R 100 mg =155	DVS S			R 200 mg =151		acebo = 77
GASTROINTESTINAL DISORDER GASTROINTESTINAL PHYSICAL FINDING GINGIVITIS GLOSSITIS HEMORRHAGIC GASTRITIS	0.135 0.458 0.318 0.555 0.494	0 1 0 1 0	(0.7) (0.7)	1 0 1 1 0	(0.6) (0.6) (0.6)	3 0 0 0	(1.9)	0 0 0 0		0 0 1 1 0	(1.3) (1.3)
HEPATITIS HIATAL HERNIA ILEUS INCREASED APPETITE JAUNDICE LIVER FUNCTION TESTS ABNORMAL	0.494 0.642 0.494 0.854 0.494 0.433	0 1 0 3 0 4	(0.7) (2.0) (2.7)	0 0 0 4 0 1	(2.6)	1 1 1 6 1 4	(0.6) (0.6) (0.6) (3.8) (0.6) (2.5)	0 0 0 3 0 1	(2.0)	0 0 0 2 0 1	(2.6) (1.3)
NAUSEA NAUSEA AND VOMITING ORAL MONILIASIS PANCREAS DISORDER PANCREATITIS PEPTIC ULCER	<0.001*** 0.540 0.485 0.494 0.494 0.642	52 0 0 0 0 1	(34.9)	80 2 1 0 0	(51.6) (1.3) (0.6)	84 1 0 1 1	(53.5) (0.6) (0.6) (0.6) (0.6)	85 2 0 0 0	(56.3) (1.3)	6 0 0 0 0	(7.8)
PERIODONTAL ABSCESS PERIODONTITIS RECTAL DISORDER RECTAL HEMORRHAGE SIALADENITIS STOOLS ABNORMAL	0.853 0.642 0.708 0.609 0.468 0.147	1 1 1 0 0	(0.7) (0.7) (0.7) (0.7)	1 0 0 0 0	(0.6)	1 1 2 2 0 2	(0.6) (0.6) (1.3) (1.3)	2 0 1 1 1 0	(1.3) (0.7) (0.7) (0.7)	0 0 1 0 0	(1.3)
TONGUE EDEMA TOOTH CARIES ULCERATIVE STOMATITIS VOMITING	0.128 0.690 0.141 <0.001***	0 1 0 12	(0.7) (8.1)	0 0 2 18	(1.3) (11.6)	0 2 0 15	(1.3) (9.6)	2 2 0 29	(1.3) (1.3) (19.2)	0 1 0 0	(1.3)
NDOCRINE SYSTEM DIABETES MELLITUS GOITER HYPERTHYROIDISM HYPOTHYROIDISM PARATHYROID DISORDER	0.934 0.643 0.799 0.494 0.637 0.642 0.312	3 0 1 0 1 1	(2.0) (0.7) (0.7) (0.7)	2 1 1 0 1 0	(1.3) (0.6) (0.6) (0.6)	2 0 0 1 0	(1.3) (0.6) (0.6)	3 1 1 0 0 0	(2.0) (0.7) (0.7)	2 0 1 0 0 0	(2.6) (1.3)
THYROID DISORDER EMIC AND LYMPHATIC SYSTEM	0.262	3	(2.0)	10	(6.5)	10	(6.4)	7	(4.6)	2	(2.6)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.
Overall P-Value: P-value for Chi-Square.

Page

4

29SEP05 14:48 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5

Body System [1] Adverse Event	Overall P-Value *		R 50 mg =149	DVS S	DVS SR 100 mg n=155		atment R 150 mg =157		DVS SR 200 mg n=151		acebo = 77
ANEMIA ECCHYMOSIS GRANULOCYTOSIS LEUKOCYTOSIS LEUKOPENIA LYMPHADENOPATHY LYMPHOPENIA	0.614 0.214 0.468 0.643 0.003** 0.973	1 1 0 0 0 1	(0.7) (0.7)	1 5 0 1 0 1	(0.6) (3.2) (0.6) (0.6)	2 6 0 0 0 1	(1.3) (3.8)	0 4 1 1 0 1	(2.6) (0.7) (0.7) (0.7) (0.7)	0 0 0 0 2 0	(2.6)
NEUTROPENIA THROMBOCYTHEMIA THROMBOCYTOPENIA	0.141 0.494 0.468	0 0		2 0 0	(1.3)	0 1 0	(0.6)	0 0 1	(0.7)	0 0	
METABOLIC AND NUTRITIONAL ALKALINE PHOSPHATASE INCREASED DEHYDRATION GLUCOSE TOLERANCE DECREASED	0.058 0.594 0.643 0.494	19 0 0	(12.8)	32 1 1 0	(20.6) (0.6) (0.6)	35 1 0 1	(22.3) (0.6) (0.6)	39 2 1 0	(25.8) (1.3) (0.7)	13 0 0 0	(16.9)
HYPERCALCEMIA HYPERCHOLESTEREMIA HYPERGLYCEMIA HYPERKALEMIA HYPERKALEMIA HYPERLIPEMIA	0.458 0.600 0.308 0.468 0.269	1 6 1 0 8	(0.7) (4.0) (0.7) (5.4)	0 9 0 0 8	(5.8) (5.2)	0 7 0 0 7	(4.5) (4.5)	0 12 0 1	(7.9) (0.7) (6.6)	0 5 1 0	(6.5) (1.3)
HYPOMAGNESEMIA PERIPHERAL EDEMA SGOT INCREASED SGPT INCREASED	0.494 0.823 0.103 0.103	0 4 0 0	(2.7)	0 5 1	(3.2) (0.6) (0.6)	1 5 1	(0.6) (3.2) (0.6) (0.6)	0 7 4 4	(4.6) (2.6) (2.6)	0 4 0 0	(5.2)
THIRST WEIGHT GAIN WEIGHT LOSS	0.594 0.243 0.147	0 4 0	(2.7)	1 9 0	(0.6) (5.8)	1 12 2	(0.6) (7.6) (1.3)	2 5 0	(1.3) (3.3)	0 3 0	(3.9)
MUSCULOSKELETAL SYSTEM ARTHRALGIA ARTHRITIS ARTHROSIS BONE DISORDER BURSITIS FIBROMYALGIA	0.337 0.583 0.871 0.147 0.594 0.609 0.468	36 18 2 0 0 1	(24.2) (12.1) (1.3) (0.7)	47 23 3 0 1 0	(30.3) (14.8) (1.9) (0.6)	40 19 2 2 1 2 0	(25.5) (12.1) (1.3) (1.3) (0.6) (1.3)	30 13 4 0 2 1	(19.9) (8.6) (2.6) (1.3) (0.7) (0.7)	19 9 2 0 0 0	(24.7) (11.7) (2.6)
GENERALIZED SPASM JOINT DISORDER	0.458 0.790	1 5	(0.7) (3.4)	0 3	(1.9)	0 2	(1.3)	0 3	(2.0)	0 2	(2.6)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.
Overall P-Value: P-value for Chi-Square.

Page

5

29SEP05 14:48 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5

Body System [1] Adverse Event	Overall P-Value *	DVS SR 50 mg n=149		DVS SR 100 mg n=155		DVS SR 150 mg n=157		DVS SR 200 mg n=151		Placebo n= 77	
LEG CRAMPS	0.619	2	(1.3)	6	(3.9)	5	(3.2)	3		3	(3.9)
MUSCLE CRAMP	0.539	2	(1.3)	2	(1.3)	0		2	(1.3)	0	
MUSCLE SPASMS	0.497	2	(1.3)	3	(1.9)	4	(2.5)	1	(0.7)	0	
MUSCULOSKELETAL STIFFNESS	0.074	1 6	(0.7)	3	(1.9)	./	(4.5)	2	(1.3)	0	(0 1)
MYALGIA	0.557	6	(4.0)	10	(6.5)	8	(5.1)	11	(7.3)	7	(9.1)
MYASTHENIA	0.129 0.147	2	(1.3)	3 1	(1.9) (0.6)	1	(0.6)	0		0 2	(2.6)
OSTEOPOROSIS PLANTAR FASCIITIS	0.147	0	(1.3)	0	(0.6)		(0.6)	0		0	(2.0)
RHEUMATOID ARTHRITIS	0.494	0		0		1 1	(0.6)	0		0	
TENOSYNOVITIS	0.394	4	(2.7)	1	(0.6)	1	(0.6)	1	(0.7)	1	(1.3)
1ENOSINOVIIIS	0.334	7	(2.7)	Τ.	(0.0)	Τ.	(0.0)	1	(0.7)	Τ.	(1.5)
NERVOUS SYSTEM	<0.001***	87	(58.4)	107	(69.0)	116	(73.9)	120	(79.5)	31	(40.3)
ABNORMAL DREAMS	0.246	6	(4.0)	6	(3.9)	12	(7.6)	8	(5.3)	1	(1.3)
ABNORMAL/CHANGED BEHAVIOR	0.637	1	(0.7)	1	(0.6)	0		0		0	
AGITATION	0.446	2	(1.3)	1	(0.6)	3	(1.9)	2	(1.3)	3	(3.9)
ANXIETY	0.488	13		10	(6.5)	16		12	(7.9)	3	(3.9)
APATHY	0.642	1	(0.7)	0		1	(0.6)	0			
ATAXIA	0.037*	0		4	(2.6)	0		1	(0.7)	0	
BRAIN EDEMA	0.468	Ö			, ,	0		1		0	
CARPAL TUNNEL SYNDROME	0.506	0		1	(0.6)	2	(1.3) (0.6)	3		1	(1.3)
CERVICAL RADICULOPATHY	0.494	0		0		1	(0.6)	0		0	
CIRCUMORAL PARESTHESIA	0.821	1	(0.7) (0.7)	0		1	(0.6)	1	(0.7)	0 0	
CNS ANOMALY	0.458	Ţ		0		0		0		0	
CONFUSION	0.014*	2	(1.3)	6 3	(3.9)	11	(7.0)	3			
DEPERSONALIZATION	0.300 0.984	1 9	(0.7)	3 9	(1.9)	0	/F 1\	7	(0.7)	0	/F 0\
DEPRESSION DIZZINESS	<0.984	33	(6.0) (22.1)	51	(5.8) (32.9)	8 49	(5.1) (31.2)	51	(4.6) (33.8)	4 6	(5.2) (7.8)
EMOTIONAL LABILITY	0.134	10	(6.7)	16	(10.3)	9	(51.2)	11	(7.3)	1	(1.3)
ENERGY INCREASED	0.134	0	(0.7)	1.0	(10.3)	2	(1.3)	0	(7.3)	1	(1.3)
EUPHORIA	0.485	0			(0.6)	0	(1.5)	0			(1.5)
FACIAL PARALYSIS	0.494	0		1	(0.0)	1	(0.6)	0		0	
FEELING DRUNK	0.458	1	(0.7)	0		0		0		0	
HALLUCINATIONS	0.494	Ō	(0.7)	ő		ĭ		Ő		ő	
HOSTILITY	0.189	12	(8.1)		(3.2)	12	(7.6)	5	(3.3)		(6.5)
HYPERESTHESIA	0.458	1	(0.7)	Õ	(/	0	(/	Õ	(/	5 0	()
HYPERKINESIA	0.325	2	(1.3)	0		1	(0.6)	0		0	
HYPERTONIA	0.326	1	(0.7)	Ô		0	,	2	(1.3)	Ô	

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.
Overall P-Value: P-value for Chi-Square.

Page

6

29SEP05 14:48 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5

Body System [1] Adverse Event	Overall P-Value *		R 50 mg =149	DVS S	R 100 mg =155	DVS S	atment - R 150 mg =157	DVS S	R 200 mg	Pl.	acebo = 77
HYPESTHESIA HYPOKINESIA HYPOTONIA	0.442 0.468 0.627	4 0 1	(2.7)	5 0 0	(3.2)	1 0 0	(0.6)	2 1 1	(1.3) (0.7) (0.7)	1 0 0	(1.3)
INSOMNIA LIBIDO DECREASED	<0.001*** 0.372	35 2	(23.5)	38 5	(24.5) (3.2)	57 4	(36.3) (2.5)	52 8	(34.4) (5.3)	10	(13.0) (2.6)
LIBIDO INCREASED MEMORY IMPAIRMENT MOTION SICKNESS	0.494 0.923 0.344	0 1 1	(0.7) (0.7)	0 2 2	(1.3) (1.3)	1 3	(0.6) (1.9)	0 2 0	(1.3)	0 1	(1.3)
MOVEMENT DISORDER NERVE COMPRESSION NERVOUSNESS NEURALGIA	0.468 0.658 0.072 0.312	1 0 0 14 0	(9.4)	2 0 1 16 0	(0.6) (10.3)	0 0 1 25 0	(0.6) (15.9)	1 0 23 1	(0.7) (15.2) (0.7)	0 0 0 4 1	(5.2) (1.3)
NEUROSIS PARESTHESIA PTOSIS RESTLESS LEGS SYNDROME	0.468 <0.001*** 0.468 0.609	0 1 0 0	(0.7)	0 14 0 2	(9.0) (1.3)	0	(3.8)	1 5 1	(0.7) (3.3) (0.7) (0.7)	0 0 0	
SLEEP DISORDER SOMNOLENCE SPEECH DISORDER	0.714 <0.001*** 0.648	0 8 0	(5.4)	2 1 29 0	(0.6) (18.7)	1 2 32 1	(1.3) (20.4) (0.6)	1 37 1	(0.7) (24.5) (0.7)	1 3 0	(1.3) (3.9)
SUICIDAL IDEATION THINKING ABNORMAL TREMOR TRISMUS	0.637 0.277 0.053 0.815	1 5 3 2	(0.7) (3.4) (2.0) (1.3)	1 6 7 2	(0.6) (3.9) (4.5) (1.3)	0 10 5 2	(6.4) (3.2) (1.3)	0 10 12 3	(6.6) (7.9) (2.0)	0 1 1 0	(1.3) (1.3)
TWITCHING VERTIGO	0.014* 0.486	2 5	(1.3) (3.4)	1 2	(0.6) (1.3)	1 7	(0.6) (4.5)	8 5	(5.3) (3.3)	1 4	(1.3) (5.2)
RESPIRATORY SYSTEM APNEA ASTHMA	0.876 0.468 0.828	56 0 1	(37.6) (0.7)	59 0 1	(38.1)	54 0 1	(34.4)	51 1 0	(33.8) (0.7)	30 0 0	(39.0)
BRONCHITIS COUGH INCREASED DYSPNEA	0.065 0.189 0.096	7 15 2	(4.7) (10.1) (1.3)	0 10 2	(6.5) (1.3)	2 6 7	(1.3) (3.8) (4.5)	5 7 2	(3.3) (4.6) (1.3)	2 6 0	(2.6) (7.8)
EPISTAXIS LARYNGISMUS LARYNGITIS	0.219 0.637 0.637	0 1 1	(0.7) (0.7)	1 1 1	(0.6) (0.6) (0.6)	4 0 0	(2.5)	4 0 0	(2.6)	1 0 0	(1.3)
LUNG DISORDER NOSE DRYNESS	0.863 0.494	3 0	(2.0)	3	(1.9)	2 1	(1.3) (0.6)	1 0	(0.7)	<u>1</u> 0	(1.3)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.
Overall P-Value: P-value for Chi-Square.

Page

7

29SEP05 14:48 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5

Body System [1] Adverse Event	Overall P-Value *	DVS SR 50 mg		DVS SR 100 mg n=155		DVS SR 150 mg n=157		DVS SR 200 mg		Placebo n= 77	
PHARYNGITIS PNEUMONIA PULMONARY PHYSICAL FINDING RHINITIS RHINITIS ALLERGIC SINUS CONGESTION SINUSITIS UPPER RESPIRATORY INFECTION VOICE ALTERATION WHEEZING YAWN	0.869 0.360 0.818 0.440 0.478 0.004** 0.246 0.440 0.494 0.495 0.354	3 2 12	(6.7) (0.7) (6.7) (2.0) (1.3) (8.1) (12.1)	21	(7.1) (0.6) (0.6) (0.6) (2.6) (12.3) (13.5) (0.6) (0.6)	0	(6.4) (9.6) (0.6)	7 2 3 18 12 0 0	(9.3) (0.7) (4.6) (1.3) (2.0) (11.9) (7.9)	5 0 0 7 1 6 5 11 0	(6.5) (9.1) (1.3) (7.8) (6.5) (14.3)
SKIN AND APPENDAGES ACNE CONTACT DERMATITIS DERMATITIS ATOPIC DRY SKIN ERYTHEMA EXFOLIATIVE DERMATITIS FUNGAL DERMATITIS HERPES SIMPLEX HERPES ZOSTER IMPETIGO MACULOPAPULAR RASH NAIL DISORDER NIGHT SWEATS	0.307 0.823 0.721 0.458 0.724 0.468 0.318 0.316 0.532 0.468 0.458 0.458	2 1 1 2 0 0	(20.1) (1.3) (0.7) (0.7) (1.3) (0.7) (1.3)	33 1 3 0 2 0 0 1 4 2 0 0 0 4 6	(0.6) (1.9) (1.3) (0.6) (2.6) (1.3)	29 22 0 33 0 0 0 3 1 0 1 0 4 6	(1.3) (1.3) (1.9) (1.9) (0.6) (0.6) (2.5)	25 1 2 0 1 1 1 0 5 0 1 0 1 0 0 1 0 0 0 0 0 0 0	(16.6) (0.7) (1.3) (0.7) (0.7) (0.7) (3.3) (0.7)	8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	(10.4)
PRURITUS PSORIASIS RASH SEBORRHEA SEBORRHEIC KERATOSIS SKIN BENIGN NEOPLASM SKIN CARCINOMA SKIN DISCOLORATION SKIN DISORDER SKIN HYPERTROPHY SKIN MELANOMA	0.057 0.494 0.097 0.468 0.494 0.838 0.093 0.643 0.299 0.458 0.494	0 9 0 0 1 0 0 1 1	(4.0) (6.0) (0.7) (0.7) (0.7)	0 4 0 0	(3.9) (2.6) (1.3) (0.6) (0.6)	0 1 2 0 1 0 1		0 1 1 0 1 0 1 0	(0.7) (0.7) (0.7) (0.7)	0 3 0 0 0 1 0 2	(3.9) (1.3) (2.6)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.
Overall P-Value: P-value for Chi-Square.

8

Page

29SEP05 14:48 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5

Body System [1] Adverse Event	Overall P-Value *	DVS S	R 50 mg =149	DVS S	R 100 mg	DVS S	atment - R 150 mg =157	DVS S	R 200 mg	Pl n	acebo = 77
SKIN ULCER SKIN WRINKLING SUNBURN SWEATING URTICARIA	0.494 0.494 0.485 0.093 0.399	0 0 0 4 3	(2.7) (2.0)	0 0 1 6 4	(0.6) (3.9) (2.6)	1 1 0 4 0	(0.6) (0.6) (2.5)	0 0 0 10 2	(6.6) (1.3)	0 0 0 0	(1.3)
SPECIAL SENSES ABNORMAL VISION CATARACT SPECIFIED CONJUNCTIVITIS CORNEAL LESION DRY EYES	<0.001*** 0.040* 0.548 0.306 0.648 0.643	19 6 1 0 0	(12.8) (4.0) (0.7)	39 13 0 3 0 1 2	(25.2) (8.4) (1.9) (0.6)	43 17 0 1 1	(27.4) (10.8) (0.6) (0.6)	44 13 1 1 1 1	(29.1) (8.6) (0.7) (0.7) (0.7) (0.7)	6 1 1 0 0 0	(7.8) (1.3) (1.3)
EAR DISORDER EAR PAIN EYE DISORDER EYE PAIN GLAUCOMA HYPERACUSIS	0.838 0.772 0.361 0.248 0.458 0.828	1 0 1 1	(0.7) (0.7) (0.7) (0.7) (0.7)	4 2 1 0 1	(1.3) (2.6) (1.3) (0.6)	2 3 3 1 0	(1.3) (1.9) (1.9) (0.6)	3 1 4 0	(2.0) (0.7)	1 0 0 0 0	(1.3)
LACRIMATION DISORDER MIOSIS MYDRIASIS OTITIS EXTERNA OTITIS MEDIA PAROSMIA PHOTOPHOBIA RETINAL DETACHMENT	0.093 0.494 0.002** 0.353 0.594 0.818 0.538 0.458	0 0 1 1 0 1 2	(0.7) (0.7) (0.7) (1.3) (0.7)	0 0 4 0 1 1 1 0	(2.6) (0.6) (0.6) (0.6)	0 1 10 2 1 0 2	(0.6) (6.4) (1.3) (0.6) (1.3)	0 0 12 0 2 1 0	(7.9) (1.3) (0.7)	1 0 0 0 0 0 0	(1.3)
TASTE PERVERSION TINNITUS VESTIBULAR DISORDER VITREOUS DISORDER	0.458 0.359 0.058 0.561 0.333	1 5 0	(0.7) (0.7) (3.4)	15 0 1	(1.9) (9.7) (0.6)	5 9 1 0	(3.2) (5.7) (0.6)	3 8 1 2	(2.0) (5.3) (0.7) (1.3)	0 1 1 0	(1.3) (1.3)
UROGENITAL SYSTEM ABNORMAL EJACULATION/ORGASM ALBUMINURIA ANORGASMIA	0.551 0.494 0.494 0.468	18 0 0 0	(12.1)	26 0 0	(16.8)	25 1 1 0	(15.9) (0.6) (0.6)	20 0 0 1	(13.2)	15 0 0 0	(19.5)
BREAST CYST BREAST DISORDER	0.197 0.458	3 1	(2.0) (0.7)	0		1	(0.6)	0		1 0	(1.3)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.
Overall P-Value: P-value for Chi-Square.

9

Page

29SEP05 14:48 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5

ody System [1] Adverse Event	Overall P-Value *				R 100 mg =155	DVS SE	DVS SR 150 mg DVS SR 200 mg n=157 n=151				acebo = 77
BREAST NEOPLASM	0.425	1	(0.7)	2	(1.3)	0		0		1	(1.3)
BREAST PAIN	0.060	0	(0.7)	3	(1.9)		(1.3)		(1.3)	4	(5.2)
CERVICITIS	0.485	Õ		1	(0.6)	2	(1.0)	2	(1.0)	Õ	(0.2)
CERVIX DISORDER	0.485	0		1	(0.6)	0		Ô		Ō	
CERVIX NEOPLASM	0.210	Ö		Ō	(/	2 2 0	(1.3)	Õ		Ĭ	(1.3)
CYSTITIS	0.830	1	(0.7)	3	(1.9)	2.	(1.3)		(0.7)		(1.3)
DYSURIA	0.468	Ō	(0.7)	Ô	(1.5)	0	(1.0)	1	(0.7)	1	(1.0)
FIBROCYSTIC BREAST	0.356	0		Ô			(1.3)		(0.7)	Ö	
HEMATURIA	0.151	Ŏ		Õ		2 1	(0.6)	1 2	(1.3)	2	(2.6)
KIDNEY CALCULUS	0.433	i i	(0.7)	Ô		2	(1.3)	0	(= /	1	(1.3)
LEUKORRHEA	0.832	Ō	(0.7)	ĭ	(0.6)	2 1	(0.6)	ĭ	(0.7)	1	(1.0)
MASTITIS	0.093	Õ		0	(/	0	(/	0	(/	i i	(1.3)
METRORRHAGIA	0.688	3	(2.0)	ĭ	(0.6)	2	(1.3)	2	(1.3)	Ô	(1.0)
OLTGURTA	0.658	Õ	(= /	1	(0.6)	1	(0.6)	0	(= /	Ö	
OVARIAN CARCINOMA	0.485	Ŏ		ī	(0.6)	0	(0.0)	Ô		Õ	
OVARIAN CYST	0.093	0		0	(/	0		Ô		i i	(1.3)
PYELONEPHRITIS	0.312	Õ		Õ		Õ		ĭ	(0.7)	ī	(1.3)
SEXUAL FUNCTION ABNORMAL	0.632	i i	(0.7)	ĭ	(0.6)	3	(1.9)	2	(1.3)	0	(=)
URINARY FREQUENCY	0.335	Ō	(0.7)	Ō	(0.0)	ĭ	(0.6)	2	(1.3)	Ŏ	
URINARY HESITATION	0.468	Õ		Ô		0	(/	1	(0.7)	Ö	
URINARY INCONTINENCE	0.832	Õ		ĭ	(0.6)	ĭ	(0.6)	1 1	(0.7)	Ŏ	
URINARY RETENTION	0.485	0		1	(0.6)	0	(/	0	(/	Ō	
URINARY TRACT DISORDER	0.458	ĭ	(0.7)	Ō	(0.0)	Ŏ		Ŏ		Ŏ	
URINARY TRACT INFECTION	0.635	6	(4.0)	4	(2.6)		(3.8)		(1.3)		(2.6)
URINARY URGENCY	0.458	ĭ	(0.7)	Ô	(=•0)	6 0	(0.0)	2	(±•0)	2	(2.0)
URINE ABNORMALITY	0.346	0	(/	2	(1.3)	Ö		1	(0.7)		
UTERINE FIBROIDS ENLARGED	0.494	Õ		Ō	(=•0)	1	(0.6)	Ō	, ,	0	
UTERINE HEMORRHAGE	0.360	0			(0.6)	2	(1.3)			Ö	
VAGINAL DRYNESS	0.165	Õ		1 3	(1.9)	2	(=•0)	0 2	(1.3)	2	(2.6)
VAGINAL HEMORRHAGE	0.077	0		5	(3.2)	ĭ	(0.6)	1	(0.7)	2	(2.6)
VAGINAL MONILIASIS	0.485	Õ		ĭ	(0.6)	Ō	(0.0)	Ō	, ,	ō	(2.0)
VAGINITIS	0.449	1	(0.7)	3	(1.9)	1	(0.6)	Ö		1	(1.3)
VULVOVAGINAL DISORDER	0.325	2	(1.3)	Ő	(=•=)	ī	(0.6)	Ŏ		Ō	(1.0)
ERMS NOT CLASSIFIABLE	0.350	1	(0.7)	0		3	(1.9)	2	(1.3)	0	
REACTION UNEVALUABLE	0.350	1	(0.7)	0		3	(1.9)	2	(1.3)	0	

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.
Overall P-Value: P-value for Chi-Square.

Page 10

29SEP05 14:48 REPORT AE5

CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS

3.2) 6 (3.8) 6 (4.0) 7 1.9) 2 (1.3) 4 (2.6) 3	(9.1) (3.9)
3	. ,

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

ST 10-2: Number (%) of Subjects Reporting Adverse Events by Severity and Drug Relationship

1

Page

29SEP05 14:50 REPORT AE4 SEV DR CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] ----- Treatment -----DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Adverse Event Severity / Drug Relationship [2] n=155 n=157 n=151 n = 77ANY ADVERSE EVENT 139 (93.3)150 (96.8)153 (97.5)151 (100 72 (93.5)(42.3)(23.2)37 (23.6)28 39 (50.6)All Severity / Not Rel. 63 36 (18.5)All Severity / Related 76 (51.0)114 (73.5)116 (73.9)123 (81.5)33 (42.9)Mild / Not Rel. 11 (7.4)(4.5)8 (5.1)(1.3)11 (14.3)27 29 26 Mild / Related 21 (14.1)(17.4)(18.5)(17.2)(9.1)/ Not Rel. 31 12 (7.7)12 (7.6)16 (10.6)17 (22.1)Moderate (20.8)Moderate / Related 41 (27.5)50 (32.3)46 (29.3)61 (40.4)22 (28.6)/ Not Rel. 20 (13.4)16 (10.3)17 (10.8)10 (6.6)11 (14.3)Severe 14 (9.4)37 (23.9)41 (26.1)36 (23.8)Severe / Related (5.2)Life Threatening / Not Rel. (0.7)(0.6)BODY AS A WHOLE 106 118 (76.1)118 (75.2)108 49 (71.1)(71.5)(63.6)All Severity / Not Rel. 62 (41.6)58 (37.4)57 (36.3)50 (33.1)37 (48.1)All Severity / Related 44 (29.5)60 (38.7)61 (38.9)58 (38.4)12 (15.6)19 (12.8)26 (16.8)24 (15.3)18 (13.0)Mild / Not Rel. (11.9)10 Mild / Related 18 (12.1)20 (12.9)24 (15.3)18 (11.9)(3.9)/ Not Rel. (24.2)23 (14.8)25 (15.9)(14.6)21 (27.3)Moderate 21 29 (18.7)20 (12.7)31 (20.5)8 (10.4)Moderate / Related (14.1)/ Not Rel. (4.7)9 (5.8)8 10 (6.6)6 Severe (5.1)(7.8)/ Related 5 (3.4)11 (7.1)17 (10.8)(6.0)(1.3)Severe ABDOMINAL PAIN (11.4)8 (5.2)14 (8.9)(3.3)(5.2)/ Not Rel. 11 (7.4)(3.2)(3.2)(5.2)All Severity (4.0)3 (1.9)9 (3.3)0 All Severity / Related 6 (5.7)Mild / Not Rel. 6 (4.0)1 (0.6)3 (1.9)0 (3.9)3 / Related (1.3)(0.6)(3.2)(0.7)Mild 0 / Not Rel. 1 1 (0.6)(1.3)Moderate (3.4)(0.6)/ Related (2.0)1 (0.6)3 (1.9)(2.6)0 Moderate / Not Rel. 1 0 Severe (1.9)(0.6)(0.7)1 1 0 Severe / Related (0.6)(0.6)0 0 0 0 0 ABSCESS (0.7)0 0 (0.7)All Severity / Not Rel. 0 0 / Not Rel. 0 0 0 (0.7)0 Moderate 18 (15.9)ACCIDENTAL INJURY (10.1)(11.6)12 (7.6)11 (14.3)/ Not Rel. (10.1)(11.0)12 (15.9)(14.3)All Severity

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

Page

2

CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT AE4_SEV_DR NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

29SEP05 14:50

y System [1] dverse Event									
Severity / Drug Relationship [2]	n=149	n=155	n=157	n=151	n= 77				
All Severity / Related Mild / Not Rel. Moderate / Not Rel. Moderate / Related Severe / Not Rel.	0 3 (2.0) 9 (6.0) 0 3 (2.0)	1 (0.6) 7 (4.5) 8 (5.2) 1 (0.6) 2 (1.3)	0 5 (3.2) 6 (3.8) 0 1 (0.6)	0 8 (5.3) 14 (9.3) 0 2 (1.3)	0 4 (5.2) 4 (5.2) 0 3 (3.9)				
CCIDENTAL OVERDOSE All Severity / Not Rel. Mild / Not Rel.	0 0 0	1 (0.6) 1 (0.6) 1 (0.6)	0 0 0	0 0 0	0 0 0				
LLERGIC REACTION All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel.	6 (4.0) 5 (3.4) 1 (0.7) 3 (2.0) 1 (0.7) 2 (1.3)	1 (0.6) 1 (0.6) 0 1 (0.6) 0	2 (1.3) 2 (1.3) 0 1 (0.6) 0 (0.6)	4 (2.6) 4 (2.6) 0 4 (2.6) 0	0 0 0 0 0				
STHENIA All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	15 (10.1) 4 (2.7) 11 (7.4) 1 (0.7) 5 (3.4) 3 (2.0) 6 (4.0) 0	37 (23.9) 7 (4.5) 30 (19.4) 5 (3.2) 11 (7.1) 2 (1.3) 16 (10.3) 0 3 (1.9)	33 (21.0) 7 (4.5) 26 (16.6) 5 (3.2) 12 (7.6) 2 (1.3) 7 (4.5) 0 7 (4.5)	35 (23.2) 8 (5.3) 27 (17.9) 5 (3.3) 15 (9.9) 2 (1.3) 10 (6.6) 1 (0.7) 2 (1.3)	10 (13.0) 4 (5.2) 6 (7.8) 4 (5.2) 3 (3.9) 0 0 0 (3.9)				
ACK PAIN All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel.	19 (12.8) 19 (12.8) 0 9 (6.0) 0 9 (6.0) 0 1 (0.7)	18 (11.6) 18 (11.6) 0 12 (7.7) 0 6 (3.9) 0	13 (8.3) 13 (8.3) 0 4 (2.5) 0 7 (4.5) 0 2 (1.3)	11 (7.3) 8 (5.3) 3 (2.0) 4 (2.6) 2 (1.3) 3 (2.0) 1 (0.7) 1 (0.7)	11 (14.3) 11 (14.3) 0 7 (9.1) 0 4 (5.2) 0				
DDY ODOR	0	0	1 (0.6)	0	0				

3

Page

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationship [2]			R 50 mg =149			DVS SE	atment R 150 mg =157	DVS SI	 R 200 mg =151		acebo 77
All Severity Moderate	/ Related / Related	0		0		1 1	(0.6) (0.6)	0		0	
CELLULITIS All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	1 1 0 1	(0.7) (0.7) (0.7)	2 2 1 1	(1.3) (1.3) (0.6) (0.6)	0 0 0		2 2 1 1	(1.3) (1.3) (0.7) (0.7)	1 1 0 1	(1.3) (1.3) (1.3)
CHEST PAIN All Severity All Severity Mild Mild Moderate Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related / Not Rel.	4 4 0 3 0 1 0 0	(2.7) (2.7) (2.0) (0.7)	5 2 3 1 2 1 1	(3.2) (1.3) (1.9) (0.6) (1.3) (0.6) (0.6)	7 7 0 1 0 3 0 3	(4.5) (4.5) (0.6) (1.9) (1.9)	6 5 1 2 1 2 0 1	(4.0) (3.3) (0.7) (1.3) (0.7) (1.3)	0 0 0 0 0 0 0	
CHILLS All Severity All Severity Mild Mild Moderate Moderate Severe Severe	/ Not Rel. / Related	6 1 5 1 2 0 2 0	(4.0) (0.7) (3.4) (0.7) (1.3) (1.3)	13 6 7 1 3 4 2 1 2	(8.4) (3.9) (4.5) (0.6) (1.9) (2.6) (1.3) (0.6) (1.3)	8 3 5 3 2 0 3 0	(5.1) (1.9) (3.2) (1.9) (1.3)	15 3 12 1 8 2 2 0 2	(9.9) (2.0) (7.9) (0.7) (5.3) (1.3) (1.3)	1 0 1 0 0 0	(1.3) (1.3) (1.3)
CYST All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	2 2 2 0	(1.3) (1.3) (1.3)	0 0 0		0 0 0		1 1 1 0	(0.7) (0.7) (0.7)	1 1 0 1	(1.3) (1.3) (1.3)
FACE EDEMA All Severity All Severity Mild Mild	/ Not Rel. / Related / Not Rel. / Related	3 3 0 2 0	(2.0) (2.0) (1.3)	1 1 0 0 0	(0.6) (0.6)	0 0 0 0		2 1 1 0 1	(1.3) (0.7) (0.7) (0.7)	0 0 0 0	

Page

4

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

dy System [1] Adverse Event Severity / Drug	Relationship [2]	DVS S	 R 50 mg =149	DVS S	R 100 mg =155	DVS S	atment - R 150 mg =157		 R 200 mg =151		acebo = 77
Moderate Severe	/ Not Rel. / Not Rel.	1 0	(0.7)	1 0	(0.6)	0		0	(0.7)	0	
FEVER All Severity All Severity Mild Mild Moderate	/ Not Rel. / Related / Not Rel. / Related / Not Rel.	3 1 2 1 2 0	(2.0) (0.7) (1.3) (0.7) (1.3)	2 2 0 1 0	(1.3) (1.3) (0.6) (0.6)	0 0 0 0 0		6 0 2 0 4	(4.0) (4.0) (1.3) (2.6)	0 0 0 0 0	
FLU SYNDROME All Severity All Severity Mild Moderate Moderate Severe Severe	/ Not Rel. / Related / Not Rel. / Not Rel. / Related / Not Rel. / Related	7 7 0 3 3 0 1 0	(4.7) (4.7) (2.0) (2.0) (0.7)	16 15 1 8 6 1	(10.3) (9.7) (0.6) (5.2) (3.9) (0.6) (0.6)	11 10 1 6 2 1 2	(7.0) (6.4) (0.6) (3.8) (1.3) (0.6) (1.3)	14 11 3 4 6 0 1 3	(9.3) (7.3) (2.0) (2.6) (4.0) (0.7) (2.0)	4 4 0 1 2 0 1 0	(5.2) (5.2) (1.3) (2.6) (1.3)
GENERALIZED EDEMA All Severity All Severity Mild Mild Moderate	/ Not Rel. / Related / Not Rel. / Related / Not Rel.	1 0 1 0 1	(0.7) (0.7) (0.7)	1 0 1 0 1 0	(0.6) (0.6) (0.6)	1 1 0 1 0	(0.6) (0.6) (0.6)	1 1 0 0 0 1	(0.7) (0.7)	0 0 0 0 0	
IANGOVER EFFECT All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		0 0 0		1 1 1	(1.3) (1.3) (1.3)
HEADACHE All Severity All Severity Mild Mild Moderate Moderate	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related	65 31 34 17 15 11	(43.6) (20.8) (22.8) (11.4) (10.1) (7.4) (10.7)	72 33 39 15 15 15	(46.5) (21.3) (25.2) (9.7) (9.7) (9.7) (11.6)	77 32 45 20 20 8 15	(49.0) (20.4) (28.7) (12.7) (12.7) (5.1) (9.6)	71 27 44 14 15 11 25	(47.0) (17.9) (29.1) (9.3) (9.9) (7.3) (16.6)	28 14 14 5 5 8	(36.4) (18.2) (18.2) (6.5) (6.5) (10.4) (10.4)

Page

5

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT AE4_SEV_DR NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug	Relationship [2]	DVS S	 R 50 mg =149		 R 100 mg =155	DVS S	atment R 150 mg =157		 R 200 mg =151		 acebo = 77
Severe Severe	/ Not Rel. / Related		(2.0)	3 6	(1.9) (3.9)	4 10	(2.5)	2 4	(1.3) (2.6)	1 1	(1.3) (1.3)
HEAT STROKE All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		0 0 0		1 1 1	(1.3) (1.3) (1.3)
INFECTION All Severity All Severity Mild Moderate Moderate Severe	/ Not Rel. / Related / Not Rel. / Not Rel. / Related / Not Rel.	32 32 0 15 16 0	(21.5) (21.5) (10.1) (10.7) (0.7)	23 23 0 14 8 0	(14.8) (14.8) (9.0) (5.2) (0.6)	27 27 0 15 10 0 2	(17.2) (17.2) (9.6) (6.4) (1.3)	23 23 0 10 11 0 2	(15.2) (15.2) (6.6) (7.3) (1.3)	19 18 1 7 11 1	(24.7) (23.4) (1.3) (9.1) (14.3) (1.3)
INJECTION SITE HEA All Severity Mild	MORRHAGE / Not Rel. / Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
LAB TEST ABNORMAL All Severity All Severity Mild Moderate	/ Not Rel. / Related / Related / Not Rel.	2 1 1 1	(1.3) (0.7) (0.7) (0.7) (0.7)	0 0 0 0		0 0 0 0		0 0 0 0		0 0 0 0	
MALAISE All Severity All Severity Mild Mild Moderate Moderate	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related	0 0 0 0 0		4 2 2 2 2 2 0	(2.6) (1.3) (1.3) (1.3) (1.3)	2 0 0 0 2	(1.3) (1.3)	2 0 2 0 0 0	(1.3) (1.3) (1.3)	0 0 0 0 0	
MONILIASIS All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	1 1 0 1	(0.7) (0.7) (0.7)	2 2 2 0	(1.3) (1.3) (1.3)	0 0 0		1 1 1 0	(0.7) (0.7) (0.7)	0 0 0	

Page

6

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4 SEV DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS
By Severity And Drug Relationship

Body System [1] Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Severity / Drug Relationship [2] n=149 n=155 n=157 n = 77NECK PAIN (4.0)(0.6)(3.8)(7.3)(5.2)1 All Severity / Not Rel. 6 (4.0)(0.6)(2.5)10 (6.6)4 (5.2)All Severity / Related 0 0 (1.3)1 (0.7)0 / Not Rel. 3 Mild (2.7)(0.6)(1.9)4 (2.6)(3.9)Mild / Related 0 0 1 (0.6)(0.7)0 Moderate / Not Rel. (1.3)(3.3)1 (1.3)Moderate / Related 0 1 (0.6)0 Severe / Not Rel. 0 0 1 (0.6)(0.7)0 0 0 0 0 NEOPLASM (0.7)(0.7)All Severity / Not Rel. 1 0 0 0 0 / Not Rel. Moderate (0.7)0 0 NON-SPECIFIED DRUG REACTION 0 (0.6)0 0 0 1 / Not Rel. All Severity 0 1 (0.6)0 0 0 Mild / Not Rel. 0 (0.6)0 0 0 OVERDOSE 0 0 0 1 (0.6)0 All Severity / Not Rel. 0 0 1 (0.6)0 0 1 Severe / Not Rel. 0 (0.6)0 0 PAIN 20 (13.4)(12.9)18 (11.5)(13.2)(19.5)(11.6)All Severity / Not Rel. 19 (12.8)18 16 (10.2)18 (11.9)14 (18.2)All Severity / Related (1.3)(0.7)(1.3)(1.3)(1.3)/ Not Rel. (6.7)11 (7.1)(5.1)(6.0)(9.1)Mild / Related (0.6)1 (0.6)0 0 Moderate / Not Rel. 5 8 (5.4)(3.2)5 (3.2)8 (5.3)5 (6.5)(0.7)(1.3)Moderate / Related (0.6)(0.6)(1.3)Severe / Not Rel. (0.7)(1.3)(1.9)(0.7)2 (2.6)PELVIC PAIN (1.3)(0.6)0 All Severity / Not Rel. (1.3)1 (0.6)0 0 0 / Not Rel. Mild 1 (0.7)1 (0.6)0 Ω 0 0 Moderate / Not Rel. (0.7)0 0 0 PHOTOSENSITIVITY REACTION 0 (0.6)0 0 0 All Severity / Not Rel. 0 1 (0.6)0 0

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

Page

7

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4 SEV DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Severity / Drug Relationship [2] n=149 n=155 n=157 n = 770 0 Mild / Not Rel. 0 (0.6)0 SARCOIDOSIS Ω 0 0 1 (0.7)0 All Severity / Not Rel. 0 0 0 0 / Not Rel. 0 0 0 1 (0.7)0 Moderate WITHDRAWAL SYNDROME 0 (0.6)(1.3)0 2 All Severity / Related 0 1 (0.6)(1.3)0 0 Mild / Related 0 1 (0.6)1 (0.6)0 0 Severe / Related 0 0 1 (0.6)0 0 CARDIOVASCULAR SYSTEM 21 (14.1) (25.2)38 (24.2)(30.5)14 (18.2)All Severity / Not Rel. (6.0)13 (8.4)19 (12.1)(11.3)(7.8)19 All Severity (8.1)26 (12.1)29 (10.4)/ Related 12 (16.8)(19.2)8 / Not Rel. Mild (2.7)(4.5)9 (5.7)(4.0)(1.3)Mild / Related (4.7)12 (7.7)(2.5)11 (7.3)(1.3)(1.3)Moderate / Not Rel. (1.9)(2.5)(5.3)(6.5)/ Related (5.7)(9.3)Moderate (3.4)(5.2)14 (6.5)/ Not Rel. (1.3)(1.9)(3.8)(2.0)0 Severe / Related 0 6 (3.9)6 (3.8)(2.6)2 (2.6)Life Threatening / Not Rel. (0.7)0 0 ARRHYTHMIA Ω 0 0 0 (1.3)All Severity / Related 0 0 0 0 (1.3)Moderate / Related 0 0 0 (1.3)Ω CARDIOVASCULAR DISORDER Ω 1 (0.6)Ω Ω All Severity / Not Rel. 0 0 (0.6)0 0 Severe / Not Rel. 0 0 1 (0.6)0 0 CARDIOVASCULAR PHYSICAL FINDING (0.7)0 All Severity / Not Rel. (0.7)0 0 0 0 Mild / Not Rel. (0.7)0 Ω 0 0 CORONARY ARTERY DISORDER 0 0 0 (0.7)0 All Severity / Not Rel. (0.7)Ω 0 0 1 Ω Moderate / Not Rel. (0.7)

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

29SEP05 14:50 REPORT AE4 SEV DR CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page

8

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Severity / Drug Relationship [2] n=149 n=155 n=157 n = 77CORONARY OCCLUSION 0 (0.6)0 (0.7)0 All Severity / Not Rel. (0.7)0 1 (0.6)0 1 0 Severe / Not Rel. 0 (0.6)0 1 (0.7)0 HYPERTENSION (4.7)(5.8)14 (8.9)(9.3)(2.6)3 All Severity / Not Rel. (1.3)(1.9)8 (5.1)(2.0)6 All Severity / Related (3.4)(3.9)(3.8)(7.3)(2.6)3 Mild / Not Rel. (1.3)(1.9)5 (3.2)1 (0.7)0 Mild / Related (2.0)4 (2.6)3 (1.9)4 (2.6)0 Moderate / Not Rel. 0 (1.3)(1.3)0 2 (1.3)Moderate / Related (1.3)2 (1.3)(4.6)(1.3)Severe / Not Rel. 1 (0.6)Severe / Related 0 (0.6)(1.3)MIGRAINE (1.3) (1.3)4 (2.6) (1.3) 5 (3.2)(6.0) (5.3) (2.6)All Severity / Not Rel. (0.6)(2.6)2 All Severity / Related Ω (1.3)(2.5)(0.7)0 / Not Rel. 0 (1.3)Mild (0.6)(0.6)0 / Related (0.7)2 Moderate / Not Rel. 1 (0.7)(0.6)0 5 (3.3)(2.6)Moderate / Related 0 1 (0.6)1 (0.6)0 0 Severe / Not Rel. (0.7)0 0 (0.7)0 Severe / Related 1 (0.6)3 (1.9)0 0 MYOCARDIAL INFARCT (0.7)(1.3)0 / Not Rel. 0 All Severity (0.7)(1.3)0 0 / Not Rel. Severe Ω 0 (1.3)Ω 0 Life Threatening / Not Rel. (0.7)0 0 0 (1.3)PALPITATION (2.7)6 (3.9)(4.6)(5.2)All Severity / Not Rel. (0.7)(0.6)(1.3)(0.7)(3.9)5 0 All Severity / Related (2.0)(3.2)(4.0)1 (1.3)Mild / Not Rel. (0.7)0 (1.3)1 (0.7)1 (1.3)Mild / Related (1.3)5 (3.2)0 (2.0)0 Moderate / Not Rel. (0.6)0 2 (2.6)/ Related Moderate (0.7)0 0 (1.3)(1.3)Severe / Related (0.7)

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

9

Page

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationship [2]	DVS SR 50 mg n=149	DVS SR 100 mg n=155	- Treatment DVS SR 150 mg DVS SR 200 mg n=157 n=151	Placebo n= 77
PERIPHERAL VASCULAR DISORDER All Severity / Not Rel. All Severity / Related Mild / Not Rel. Moderate / Related	1 (0.7) 1 (0.7) 0 1 (0.7)	0 0 0 0 0	0 1 (0.7) 0 0 1 (0.7) 0 1 (0.7) 0 1 (0.7)	0 0 0 0
SYNCOPE All Severity / Not Rel. Moderate / Not Rel.	0 0 0	0 0 0	1 (0.6) 0 1 (0.6) 0 1 (0.6) 0	0 0 0
TACHYCARDIA All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related	5 (3.4) 1 (0.7) 4 (2.7) 1 (0.7) 4 (2.7) 0	4 (2.6) 0 (2.6) 0 (0.6) 1 (0.6) 3 (1.9)	4 (2.5) 4 (2.6) 2 (1.3) 1 (0.7) 2 (1.3) 3 (2.0) 2 (1.3) 0 1 (0.6) 3 (2.0) 0 1 (0.7)	0 0 0 0 0
VARICOSE VEIN All Severity / Not Rel. Moderate / Not Rel.	0 0 0	0 0 0	0 0 0 0	1 (1.3) 1 (1.3) 1 (1.3)
VASODILATATION All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	8 (5.4) 3 (2.0) 5 (3.4) 1 (0.7) 1 (0.7) 1 (0.7) 4 (2.7) 1 (0.7)	16 (10.3) 6 (3.9) 10 (6.5) 3 (1.9) 3 (1.9) 1 (0.6) 2 (1.3) 2 (1.3) 5 (3.2)	16 (10.2) 16 (10.6) 6 (3.8) 7 (4.6) 10 (6.4) 9 (6.0) 2 (1.3) 3 (2.0) 1 (0.6) 1 (0.7) 1 (0.6) 3 (2.0) 6 (3.8) 5 (3.3) 3 (1.9) 1 (0.7) 3 (1.9) 3 (2.0)	5 (6.5) 1 (1.3) 4 (5.2) 0 (1.3) 1 (1.3) 2 (2.6) 0 (1.3)
DIGESTIVE SYSTEM All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related	91 (61.1) 33 (22.1) 58 (38.9) 13 (8.7) 32 (21.5)	98 (63.2) 8 (5.2)	124 (79.0) 117 (77.5) 30 (19.1) 16 (10.6) 94 (59.9) 101 (66.9) 13 (8.3) 6 (4.0) 42 (26.8) 35 (23.2)	31 (40.3) 7 (9.1) 24 (31.2) 6 (7.8) 12 (15.6)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.
[2] - Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

Page 10

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationship [DVS SR 50 n=149			R 100 mg =155	DVS S	atment - R 150 mg =157		R 200 mg =151		 acebo = 77
Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	22 (14. 6 (4.	.4) .8) .0)	6 37 3 20	(3.9) (23.9) (1.9) (12.9)	13 36 4 16	(8.3) (22.9) (2.5) (10.2)	7 55 3 11	(4.6) (36.4) (2.0) (7.3)	1 11 0 1	(1.3) (14.3) (1.3)
ABDOMINAL DISTENSION All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Related	1 (0. 2 (1. 0 0 1 (0.	.0) .7) .3)	0 0 0 0 0		1 1 0 1 0 0 0	(0.6) (0.6) (0.6)	1 1 0 0 0 1 0	(0.7) (0.7)	4 1 3 0 1 1 1	(5.2) (1.3) (3.9) (1.3) (1.3) (1.3) (1.3)
ANOREXIA All Severity / Not Rel. All Severity / Related Mild / Related Moderate / Not Rel. Moderate / Related Severe / Related	0 7 (4.	.7) .7) .7)	10 1 9 4 1 3 2	(6.5) (0.6) (5.8) (2.6) (0.6) (1.9) (1.3)	13 0 13 7 0 5	(8.3) (8.3) (4.5) (3.2) (0.6)	16 0 16 8 0 7	(10.6) (10.6) (5.3) (4.6) (0.7)	2 0 2 1 0 1	(2.6) (2.6) (1.3) (1.3)
BLOOD IN STOOL All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	1 (0.	.7) .7) .7)	1 1 0 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
CHOLECYSTITIS All Severity / Not Rel. All Severity / Related Severe / Not Rel. Severe / Related	0 0 0 0		1 1 0 1 0	(0.6) (0.6) (0.6)	1 0 1 0 1	(0.6) (0.6) (0.6)	0 0 0 0		0 0 0 0	
CHOLELITHIASIS All Severity / Not Rel. All Severity / Related Moderate / Not Rel.	0 0 0 0		2 2 0 2	(1.3) (1.3) (1.3)	1 0 1 0	(0.6) (0.6)	0 0 0		0 0 0	

Page 11

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Dru	g Relationship [2]		 R 50 mg =149	DVS S	 R 100 mg =155	DVS S	R 150 mg		 R 200 mg =151		 acebo = 77
Severe	/ Related	0		0		1	(0.6)	0		0	
COLITIS All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	3 3 1 2	(2.0) (2.0) (0.7) (1.3)	0 0 0 0		0 0 0		1 1 1 0	(0.7) (0.7) (0.7)	0 0 0	
CONSTIPATION All Severity All Severity Mild Mild Moderate Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related / Related / Related	17 5 12 4 7 1 4	(11.4) (3.4) (8.1) (2.7) (4.7) (0.7) (2.7) (0.7)	27 3 24 2 12 1 10 2	(17.4) (1.9) (15.5) (1.3) (7.7) (0.6) (6.5) (1.3)	27 6 21 4 12 2 6 3	(17.2) (3.8) (13.4) (2.5) (7.6) (1.3) (3.8) (1.9)	27 5 22 3 9 2 10 3	(17.9) (3.3) (14.6) (2.0) (6.0) (1.3) (6.6) (2.0)	8 3 5 2 1 1 3	(10.4) (3.9) (6.5) (2.6) (1.3) (1.3) (3.9) (1.3)
DIARRHEA All Severity All Severity Mild Mild Moderate Moderate Severe Severe	/ Not Rel. / Related	24 16 8 8 6 4 2 4	(16.1) (10.7) (5.4) (5.4) (4.0) (2.7) (1.3) (2.7)	17 5 12 4 7 1 5 0	(11.0) (3.2) (7.7) (2.6) (4.5) (0.6) (3.2)	15 6 9 5 5 1 3 0	(9.6) (3.8) (5.7) (3.2) (3.2) (0.6) (1.9)	19 5 14 3 5 2 8 0	(12.6) (3.3) (9.3) (2.0) (3.3) (1.3) (5.3)	7 4 3 4 2 0 1 0 0	(9.1) (5.2) (3.9) (5.2) (2.6) (1.3)
DRY MOUTH All Severity All Severity Mild Mild Moderate Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related / Related / Related	20 0 20 0 15 0 5	(13.4) (13.4) (10.1) (3.4)	34 4 30 4 14 0 13 3	(21.9) (2.6) (19.4) (2.6) (9.0) (8.4) (1.9)	32 1 31 0 22 1 8 1	(20.4) (0.6) (19.7) (14.0) (0.6) (5.1) (0.6)	39 1 38 1 25 0 10 3	(25.8) (0.7) (25.2) (0.7) (16.6) (6.6) (2.0)	5 0 5 0 2 0 3	(6.5) (6.5) (2.6) (3.9)
DUODENITIS All Severity	/ Not Rel.	0		0		1 1	(0.6) (0.6)	0		0	

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.
[2] - Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

CONFIDENTIAL Wyeth 414

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

Page 12

Body System [1] Adverse Event Severity / Drug	Relationship [2]		R 50 mg =149		 R 100 mg =155	DVS S	atment - R 150 mg =157		 R 200 mg =151		 icebo = 77
Mild	/ Not Rel.	0		0		1	(0.6)	0		0	
DYSPEPSIA All Severity All Severity Mild Mild Moderate Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related / Not Rel.	19 10 9 8 6 2 3 0	(12.8) (6.7) (6.0) (5.4) (4.0) (1.3) (2.0)	18 10 8 6 4 2 4 2	(11.6) (6.5) (5.2) (3.9) (2.6) (1.3) (2.6) (1.3)	20 12 8 5 4 6 4	(12.7) (7.6) (5.1) (3.2) (2.5) (3.8) (2.5) (0.6)	14 5 9 3 6 2 3	(9.3) (3.3) (6.0) (2.0) (4.0) (1.3) (2.0)	2 0 2 0 2 0 0	(2.6) (2.6) (2.6)
DYSPHAGIA All Severity All Severity Mild Mild Moderate	/ Not Rel. / Related / Not Rel. / Related / Related	1 0 1 0 1 0	(0.7) (0.7) (0.7)	2 0 2 0 1 1	(1.3) (1.3) (0.6) (0.6)	2 2 0 2 0 0	(1.3) (1.3) (1.3)	2 1 1 0 1	(1.3) (0.7) (0.7) (0.7)	0 0 0 0	
ERUCTATION All Severity All Severity Mild Moderate	/ Not Rel. / Related / Not Rel. / Related	4 4 0 4 0	(2.7) (2.7) (2.7)	1 0 1 0 1	(0.6) (0.6) (0.6)	1 1 0 1 0	(0.6) (0.6) (0.6)	1 0 1 0 1	(0.7) (0.7) (0.7)	0 0 0 0	
ESOPHAGEAL ULCER All Severity Moderate	/ Not Rel. / Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
ESOPHAGITIS All Severity All Severity Mild Moderate	/ Not Rel. / Related / Related / Not Rel.	1 0 1 1 0	(0.7) (0.7) (0.7)	0 0 0 0		1 1 0 0 1	(0.6) (0.6)	0 0 0 0		0 0 0 0	
FLATULENCE All Severity All Severity	/ Not Rel. / Related	1 0 1	(0.7) (0.7)	1 0 1	(0.6) (0.6)	2 2 0	(1.3) (1.3)	3 1 2	(2.0) (0.7) (1.3)	1 0 1	(1.3) (1.3)

Page 13

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4 SEV DR

- - NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS
By Severity And Drug Relationship

ody System [1]							atment -				
Adverse Event Severity / Drug	Relationship [2]		R 50 mg =149		R 100 mg =155		R 150 mg =157		R 200 mg =151		acebo = 77
Mild Mild Moderate Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Related	0 1 0 0	(0.7)	0 0 0 1 0	(0.6)	1 0 1 0 0	(0.6)	1 1 0 0 1	(0.7) (0.7)	0 1 0 0	(1.3)
GAMMA GLUTAMYL TR All Severity Moderate	ANSPEPTIDASE INCREASED / Related / Related	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
GASTRITIS All Severity Moderate	/ Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		0 0 0		1 1 1	(1.3) (1.3) (1.3)
GASTROENTERITIS All Severity Mild Moderate Severe	/ Not Rel. / Not Rel. / Not Rel. / Not Rel.	4 4 3 1 0	(2.7) (2.7) (2.0) (0.7)	5 5 3 1 1	(3.2) (3.2) (1.9) (0.6) (0.6)	8 8 4 3 1	(5.1) (5.1) (2.5) (1.9) (0.6)	3 3 1 1 1	(2.0) (2.0) (0.7) (0.7) (0.7)	1 1 0 0	(1.3) (1.3) (1.3)
GASTROESOPHAGEAL All Severity All Severity Mild Mild Moderate Moderate Severe	REFLUX DISEASE / Not Rel. / Related / Not Rel. / Related / Not Rel. / Related / Related / Related	3 2 1 1 0 1 1 0	(2.0) (1.3) (0.7) (0.7) (0.7)	3 0 3 0 1 0 1	(1.9) (1.9) (0.6) (0.6) (0.6)	1 0 0 0 1 0	(0.6) (0.6)	6 3 3 1 0 2	(4.0) (2.0) (2.0) (2.0) (2.0) (0.7) (1.3)	0 0 0 0 0 0 0 0 0	
GASTROINTESTINAL All Severity All Severity Mild Moderate	DISORDER / Not Rel. / Related / Related / Not Rel.	0 0 0 0		1 1 0 0	(0.6) (0.6)	3 1 2 2 1	(1.9) (0.6) (1.3) (1.3) (0.6)	0 0 0 0		0 0 0 0	
GASTROINTESTINAL All Severity	PHYSICAL FINDING / Related	1 1	(0.7) (0.7)	0		0		0		0	

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

CONFIDENTIAL 416 Wyeth

Different Adverse Events In The Same Body System.
[2] - Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

Page 14

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

dy System [1]			Treatment	
Adverse Event	DVS SR 50 mg	DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg n=157 n=151	Placebo
Severity / Drug Relationship [2]	n=149	n=155		n= 77
Mild / Related	1 (0.7)	0	0 0	0
GINGIVITIS All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	0 0 0 0	1 (0.6) 1 (0.6) 0 1 (0.6)	0 0 0 0 0 0 0 0 0	1 (1.3) 1 (1.3) 1 (1.3)
GLOSSITIS All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related	1 (0.7) 1 (0.7) 0 1 (0.7)	1 (0.6)	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	1 (1.3) 1 (1.3) 0 1 (1.3)
HEMORRHAGIC GASTRITIS	0	0	1 (0.6) 0	0
All Severity / Not Rel.	0	0	1 (0.6) 0	0
Moderate / Not Rel.	0	0	1 (0.6) 0	0
HEPATITIS	0	0	1 (0.6) 0	0
All Severity / Related	0	0	1 (0.6) 0	0
Severe / Related	0	0	1 (0.6) 0	0
HIATAL HERNIA All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	1 (0.7)	0	1 (0.6) 0	0
	1 (0.7)	0	1 (0.6) 0	0
	1 (0.7)	0	0 0	0
	0	0	1 (0.6) 0	0
ILEUS All Severity / Not Rel. Severe / Not Rel.	0	0	1 (0.6) 0	0
	0	0	1 (0.6) 0	0
	0	0	1 (0.6) 0	0
INCREASED APPETITE All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related	3 (2.0) 3 (2.0) 0 (0.7) 0 (1.3)	4 (2.6) 0 1 (0.6)	6 (3.8) 3 (2.0) 3 (1.9) 0 3 (1.9) 3 (2.0) 2 (1.3) 0 2 (1.3) 2 (1.3) 0 0 1 (0.7)	2 (2.6) 0 (2.6) 0 (2.6) 0 0 2 (2.6)

Page

15

CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS

By Severity And Drug Relationship

29SEP05 14:50

Body System [1] Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Severity / Drug Relationship [2] n=149 n=155 n=157 n=151 n = 77Severe / Not Rel. 0 (0.6)0 Severe / Related 0 (0.6)1 (0.6)0 0 0 0 0 JAUNDICE 1 (0.6)0 All Severity / Related Λ 0 1 (0.6)0 0 Mild / Related 0 (0.6)0 0 LIVER FUNCTION TESTS ABNORMAL (2.7)1 (0.6)(2.5)1 (0.7)(1.3)All Severity / Not Rel. / Related (1.3)0 (0.6)1 (0.7)0 All Severity (1.3)(0.6)(1.9)(1.3)Mild / Not Rel. (1.3)0 1 (0.6)(0.7)0 Mild / Related (0.6)2 (1.3)0 Moderate / Related (0.7)0 (0.6)0 (1.3)0 0 0 0 Severe / Related (0.7)NAUSEA (34.9)(51.6)(53.5)(56.3)(7.8)7 All Severity / Not Rel. 15 (10.1)(4.5)12 (7.6)(4.0)(1.3)All Severity / Related 37 (24.8)73 (47.1)72 (45.9)(52.3)79 (6.5)/ Not Rel. (3.4)(3.2)(4.5)(2.0)(1.3)39 38 Mild / Related 16 (10.7) (25.2)(24.2)34 (22.5)(5.2)Moderate / Not Rel. (6.0)(0.6)3 (1.9)(1.3)0 Moderate / Related 19 (12.8) 20 (12.9)24 (15.3)39 (25.8)(1.3)Severe / Not Rel. (0.7)(0.6)(1.3)(0.7)0 (1.3)Severe / Related 14 (9.0)10 (6.4)6 (4.0)0 2 NAUSEA AND VOMITING 0 (1.3)1 (0.6)(1.3)0 All Severity / Not Rel. Ω 0 1 (0.6)0 All Severity / Related 0 (1.3)0 (1.3)0 Mild / Related 0 1 (0.6)0 0 Moderate / Not Rel. 0 0 1 (0.6)0 0 Moderate / Related (1.3)0 Severe / Related 0 (0.6)0 0 0 0 0 ORAL MONILIASIS (0.6)0 0 All Severity / Not Rel. 0 (0.6)0 0 0 / Not Rel. Moderate (0.6)0 0 0

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

Page 16

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

dy System [1] Adverse Event Severity / Drug	Relationship [2]	DVS SF n=	R 50 mg =149	DVS SI		DVS SI	atment R 150 mg =157	DVS SI	R 200 mg =151	Pla n=	cebo 77
PANCREAS DISORDER All Severity Severe	/ Not Rel. / Not Rel.	0 0 0		0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
PANCREATITIS All Severity Severe	/ Related / Related	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
PEPTIC ULCER All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	1 1 0 1	(0.7) (0.7) (0.7)	0 0 0		1 1 1 0	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
PERIODONTAL ABSCES All Severity Mild Moderate Severe	S / Not Rel.	1 1 0 0	(0.7) (0.7) (0.7)	1 1 0 1 0	(0.6) (0.6) (0.6)	1 1 0 1 0	(0.6) (0.6) (0.6)	2 2 0 1 1	(1.3) (1.3) (0.7) (0.7)	0 0 0 0	
PERIODONTITIS All Severity Moderate Severe	/ Not Rel. / Not Rel. / Not Rel.	1 1 0 1	(0.7) (0.7) (0.7)	0 0 0		1 1 1 0	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
RECTAL DISORDER All Severity Mild Moderate Severe	/ Not Rel. / Not Rel. / Not Rel. / Not Rel.	1 1 0 0 1	(0.7) (0.7)	0 0 0 0		2 2 1 1 0	(1.3) (1.3) (0.6) (0.6)	1 1 0 0	(0.7) (0.7) (0.7)	1 1 0 0	(1.3) (1.3) (1.3)
RECTAL HEMORRHAGE All Severity All Severity Moderate Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Not Rel.	1 1 0 1 0	(0.7) (0.7) (0.7)	0 0 0 0 0		2 2 0 1 0	(1.3) (1.3) (0.6) (0.6)	1 0 1 0 1	(0.7) (0.7) (0.7)	0 0 0 0	

Page 17

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

ody System [1] Adverse Event Severity / Drug Relationship [2]	DVS SR 50 mg n=149	DVS SR 100 mg n=155	Treatment - DVS SR 150 mg n=157		Placebo n= 77
SIALADENITIS All Severity / Not Rel. Moderate / Not Rel.	0 0 0	0 0 0	0 0 0	1 (0.7) 1 (0.7) 1 (0.7)	0 0 0
STOOLS ABNORMAL All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related	0 0 0 0	0 0 0 0	2 (1.3) 1 (0.6) 1 (0.6) 1 (0.6) 1 (0.6)	0 0 0 0	0 0 0 0 0
TONGUE EDEMA All Severity / Not Rel. All Severity / Related Mild / Not Rel. Moderate / Related	0 0 0 0	0 0 0 0	0 0 0 0	2 (1.3) 1 (0.7) 1 (0.7) 1 (0.7) 1 (0.7)	0 0 0 0 0
TOOTH CARIES All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	1 (0.7) 1 (0.7) 0 (0.7)	0 0 0	2 (1.3) 2 (1.3) 0 2 (1.3)	2 (1.3) 2 (1.3) 2 (1.3) 0	1 (1.3) 1 (1.3) 0 1 (1.3)
ULCERATIVE STOMATITIS All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	0 0 0 0	2 (1.3) 2 (1.3) 1 (0.6) 1 (0.6)	0 0 0 0	0 0 0 0	0 0 0 0
VOMITING All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Related	12 (8.1) 3 (2.0) 9 (6.0) 0 7 (4.7) 3 (2.0) 1 (0.7) 1 (0.7)	18 (11.6) 7 (4.5) 11 (7.1) 2 (1.3) 1 (0.6) 5 (3.2) 8 (5.2) 2 (1.3)	15 (9.6) 3 (1.9) 12 (7.6) 2 (1.3) 4 (2.5) 1 (0.6) 6 (3.8) 2 (1.3)	29 (19.2) 4 (2.6) 25 (16.6) 2 (1.3) 6 (4.0) 2 (1.3) 18 (11.9) 1 (0.7)	0 0 0 0 0 0
NDOCRINE SYSTEM All Severity / Not Rel.	3 (2.0) 2 (1.3)	2 (1.3) 2 (1.3)	2 (1.3) 2 (1.3)	3 (2.0) 3 (2.0)	2 (2.6) 2 (2.6)

29SEP05 14:50 REPORT AE4_SEV_DR CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 18

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Re	lationship [2]	DVS SF n=	R 50 mg =149	DVS SF		DVS SR		DVS SI	R 200 mg	Pla n=	 .cebo : 77
Mild / Moderate /	Related Not Rel. Not Rel. Related	1 2 0 1	(0.7) (1.3) (0.7)	0 2 0 0	(1.3)	0 1 1 0	(0.6)	0 2 1 0	(1.3)	0 2 0 0	(2.6)
	Not Rel. Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
	Not Rel. Not Rel.	1 1 1	(0.7) (0.7) (0.7)	1 1 1	(0.6) (0.6) (0.6)	0 0 0		1 1 1	(0.7) (0.7) (0.7)	1 1 1	(1.3) (1.3) (1.3)
	Not Rel. Not Rel.	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
All Severity / Mild /	Not Rel. Related Not Rel. Related	1 0 1 0 1	(0.7) (0.7) (0.7)	1 1 0 1 0	(0.6) (0.6) (0.6)	0 0 0 0		0 0 0 0		0 0 0 0	
	Not Rel. Not Rel.	1 1 1	(0.7) (0.7) (0.7)	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
Mild /	Not Rel. Not Rel. Not Rel.	0 0 0		0 0 0		0 0 0		1 1 0 1	(0.7) (0.7) (0.7)	1 1 1 0	(1.3) (1.3) (1.3)
	Not Rel.	3 3 0 3 0	(2.0) (2.0) (2.0)	10 6 4 4 3	(6.5) (3.9) (2.6) (2.6) (1.9)	10 7 3 5 2	(6.4) (4.5) (1.9) (3.2) (1.3)	7 7 0 5 0	(4.6) (4.6) (3.3)	2 2 0 2 0	(2.6) (2.6) (2.6)

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

Page 19

Body System [1] Adverse Event Severity / Drug	g Relationship [2]	DVS SF	R 50 mg =149	DVS SE		DVS SF	atment R 150 mg =157	DVS SI	 R 200 mg =151	Pla n=	 icebo : 77
Moderate Moderate Severe	/ Not Rel. / Related / Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	2 1 0	(1.3) (0.6)	2 0 0	(1.3)	0 0 0	
ANEMIA All Severity Mild	/ Not Rel. / Not Rel.	1 1 1	(0.7) (0.7) (0.7)	1 1 1	(0.6) (0.6) (0.6)	2 2 2	(1.3) (1.3) (1.3)	0 0 0		0 0 0	
ECCHYMOSIS All Severity All Severity Mild Mild Moderate Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related / Not Rel.	1 0 1 0 0 0	(0.7) (0.7) (0.7)	5 2 3 1 2 0 1 1	(3.2) (1.3) (1.9) (0.6) (1.3) (0.6) (0.6)	2	(3.8) (2.5) (1.3) (1.3) (1.3) (1.3)	4 4 0 3 0 1 0 0	(2.6) (2.6) (2.0) (0.7)	0 0 0 0 0	
GRANULOCYTOSIS All Severity Moderate	/ Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
LEUKOCYTOSIS All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	0 0 0		1 1 1 0	(0.6) (0.6) (0.6)	0 0 0		1 1 0 1	(0.7) (0.7) (0.7)	0 0 0	
LEUKOPENIA All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		0 0 0		2 2 2	(2.6) (2.6) (2.6)
LYMPHADENOPATHY All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	1 1 1 0	(0.7) (0.7) (0.7)	1 1 0 1	(0.6) (0.6)	1 1 1 0	(0.6) (0.6) (0.6)	1 1 1 0	(0.7) (0.7) (0.7)	0 0 0	
LYMPHOPENIA All Severity	/ Not Rel.	0		0		0		1 1	(0.7) (0.7)	0	

Page

20

29SEP05 14:50 REPORT AE4 SEV DR

CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS
By Severity And Drug Relationship

Body System [1] Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Severity / Drug Relationship [2] n=149 n=155 n=157 n = 770 Moderate / Not Rel. 0 0 (0.7)0 NEUTROPENIA 0 (1.3)0 0 0 All Severity / Not Rel. 0 (0.6)0 0 0 / Related All Severity Λ 1 (0.6)Λ 0 Λ Mild / Not Rel. 1 (0.6)0 0 0 Mild / Related 0 (0.6)0 0 0 THROMBOCYTHEMIA 0 0 1 (0.6)0 0 All Severity / Related 0 0 (0.6)0 0 Moderate / Related 0 0 1 (0.6)0 0 0 THROMBOCYTOPENIA 0 0 (0.7)0 0 0 (0.7)All Severity / Not Rel. Ω 0 Mild / Not Rel. 0 0 0 (0.7)0 METABOLIC AND NUTRITIONAL (12.8)(20.6)35 (22.3)13 (16.9)All Severity 14 (9.0) 16 (10.2)(13.2)(11.7)/ Not Rel. 11 (7.4)20 All Severity / Related (5.4)18 (11.6)19 (12.1)(12.6)(5.2)9 Mild / Not Rel. (4.7)(5.8)11 (7.0)11 (7.3)(5.2)/ Related 3 6 Mild (2.0)(3.9)10 (6.4)(3.3)(2.6)Moderate / Not Rel. (2.7)(1.9)(2.5)(4.0)(6.5)Moderate / Related (2.7)10 (6.5)8 (5.1)13 (8.6)(2.6)(1.3)(2.0)Severe / Not Rel. 0 1 (0.6)0 Severe / Related (0.7)(1.3)(0.6)(0.7)0 ALKALINE PHOSPHATASE INCREASED Ω (0.6)1 (0.6)(1.3)(0.7)Ω All Severity / Not Rel. 0 0 0 All Severity / Related 0 1 (0.6)1 (0.6)1 (0.7)0 Mild / Related 0 0 1 (0.6)0 0 Moderate / Not Rel. (0.7)0 Moderate / Related 0 1 (0.6)0 (0.7)0 0 DEHYDRATION (0.6)0 (0.7)0 All Severity / Not Rel. 0 (0.6)0 (0.7)0 Severe / Not Rel. (0.6)0 (0.7)0

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

Page 21

dy System [1] Adverse Event Severity / Drug Relationship [2]	DVS SR 50 mg n=149		Treatment DVS SR 150 mg n=157	DVS SR 200 mg	Placebo n= 77
GLUCOSE TOLERANCE DECREASED All Severity / Not Rel. Mild / Not Rel.	0 0 0	0 0 0	1 (0.6) 1 (0.6) 1 (0.6)	0 0 0	0 0 0
HYPERCALCEMIA All Severity / Not Rel. Mild / Not Rel.	1 (0.7) 1 (0.7) 1 (0.7)	0 0 0	0 0 0	0 0 0	0 0 0
HYPERCHOLESTEREMIA All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related	6 (4.0) 2 (1.3) 4 (2.7) 1 (0.7) 3 (2.0) 1 (0.7) 1 (0.7)	9 (5.8) 3 (1.9) 6 (3.9) 3 (1.9) 2 (1.3) 0 4 (2.6)	7 (4.5) 3 (1.9) 4 (2.5) 2 (1.3) 2 (1.3) 1 (0.6) 2 (1.3)	12 (7.9) 6 (4.0) 6 (4.0) 2 (1.3) 2 (1.3) 4 (2.6) 4 (2.6)	5 (6.5) 3 (3.9) 2 (2.6) 0 0 3 (3.9) 2 (2.6)
HYPERGLYCEMIA All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	1 (0.7) 1 (0.7) 1 (0.7)	0 0 0	0 0 0 0	0 0 0 0	1 (1.3) 1 (1.3) 0 1 (1.3)
YYPERKALEMIA All Severity / Not Rel. Mild / Not Rel.	0 0 0	0 0 0	0 0 0	1 (0.7) 1 (0.7) 1 (0.7)	0 0 0
HYPERLIPEMIA All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	8 (5.4) 4 (2.7) 4 (2.7) 2 (1.3) 0 2 (1.3) 3 (2.0) 0 1 (0.7)	8 (5.2) 3 (1.9) 5 (3.2) 2 (1.3) 2 (1.3) 1 (0.6) 2 (1.3) 0 1 (0.6)	7 (4.5) 4 (2.5) 3 (1.9) 3 (1.9) 2 (1.3) 0 1 (0.6) 1 (0.6)	10 (6.6) 5 (3.3) 5 (3.3) 3 (2.0) 0 4 (2.6) 2 (1.3) 1 (0.7)	0 0 0 0 0 0
HYPOMAGNESEMIA All Severity / Not Rel.	0	0 0	1 (0.6) 1 (0.6)	0	0

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.
[2] - Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

Page

22

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS

By Severity And Drug Relationship

Body System [1] Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Severity / Drug Relationship [2] n=149 n=155 n=157 n=151 n = 770 0 0 0 Mild / Not Rel. 1 (0.6)PERIPHERAL EDEMA (2.7)(2.7)5 (3.2)5 (3.2) (2.5)(4.6)(5.2)/ Not Rel. All Severity (3.2)(4.0)(5.2)/ Related All Severity 0 1 (0.6)1 (0.7)0 Mild / Not Rel. 1 (0.7)(1.3)(2.5)(2.6)3 (3.9)Mild / Related 0 1 (0.6)(0.7)0 Moderate / Not Rel. 3 (2.0)2 (1.3)0 (1.3)1 (1.3)Severe / Not Rel. 1 (0.6)0 0 Ω SGOT INCREASED (0.6)(0.6)(2.6)0 All Severity / Not Rel. 0 0 0 1 (0.7)0 All Severity / Related 0 (0.6)(0.6)(2.0)0 / Not Rel. 0 (0.7)Moderate Ω 0 0 / Related Moderate 0 1 (0.6)0 (2.0)0 Severe / Related 0 0 1 (0.6)0 SGPT INCREASED 0 0 1 (0.6)1 (0.6)(2.6)All Severity / Not Rel. 0 0 (0.7)0 All Severity / Related 0 1 (0.6)1 (0.6)3 (2.0)0 / Not Rel. 0 Moderate 0 0 1 (0.7)0 Moderate / Related 0 (0.6)0 (2.0)0 0 Severe / Related 0 1 (0.6)0 0 0 (0.6)(0.6)(1.3)0 All Severity / Not Rel. 0 (0.6)0 0 / Related All Severity Ω Ω 1 (0.6)(1.3)0 / Not Rel. 0 (0.6)0 0 Mild / Related Ω 0 0 (0.7)0 Moderate / Related 0 0 1 (0.6)(0.7)0 WEIGHT GAIN (2.7)9 (5.8)12 (7.6)(3.3)3 (3.9)3 All Severity / Not Rel. (1.3)(1.9)3 (1.9)1 (0.7)(1.3)2 All Severity / Related (1.3)6 (3.9)9 (5.7)(2.6)(2.6)Mild / Not Rel. (1.3)3 (1.9)1 (0.6)(0.7)(1.3)Mild / Related (1.3)(1.3)6 (3.8)(1.3)2 (2.6)Moderate / Not Rel. (1.3)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

Page

23

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS

By Severity And Drug Relationship

Body System [1] Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Severity / Drug Relationship [2] n=149 n=155 n=157 n = 77Moderate / Related 0 3 (1.9)(1.9)(1.3)0 1 0 Severe / Related 0 (0.6)0 0 0 0 WEIGHT LOSS (1.3)0 0 All Severity / Not Rel. Λ 0 1 (0.6)0 0 All Severity / Related 0 1 (0.6)0 0 Moderate / Not Rel. 0 0 1 (0.6)0 Moderate / Related 0 0 1 (0.6)0 0 MUSCULOSKELETAL SYSTEM 36 (24.2)(30.3)40 (25.5)(19.9)19 (26.5)(22.3)(19.2)(22.1)All Severity / Not Rel. 32 (21.5)41 35 29 17 All Severity / Related (2.7)6 (3.9)(3.2)(0.7)(2.6)/ Not Rel. 15 (10.1) 13 (8.4)18 (11.5)13 (8.6)(9.1)3 Mild / Related (0.7)(1.9)(1.3)Ω / Not Rel. Moderate 12 (8.1)(13.5)12 (7.6)16 (10.6)10 (13.0)Moderate / Related (0.7)(1.9)(1.3)(0.7)2 (2.6)Severe / Not Rel. (3.4)(4.5)(3.2)Ω Λ / Related (1.3)Severe (0.6)0 0 ARTHRALGIA 18 (12.1)23 (14.8)19 (12.1)(8.6)9 (11.7)21 All Severity / Not Rel. 16 (10.7)(13.5)16 (10.2)12 (7.9)8 (10.4)All Severity / Related (1.3)(1.3)(1.9)(0.7)(1.3)Mild / Not Rel. (4.0)(5.2)(5.1)(2.0)(5.2)Mild / Related (0.6)1 (0.6)0 Moderate / Not Rel. (4.0)(4.5)(3.2)(6.0)(5.2)Moderate / Related (0.7)(0.6)(1.3)(0.7)(1.3)/ Not Rel. Severe (2.7)6 (3.9)(1.9)Ω Severe / Related (0.7)0 0 ARTHRITIS (1.3)(1.9)(1.3)(2.6)(2.6)All Severity / Not Rel. (1.3)(1.9)(1.3)(2.6)(2.6)0 Mild / Not Rel. (1.3)1 (0.6)(2.0)0 Moderate / Not Rel. Ω 3 (1.9)1 (0.6)(0.7)2 (2.6)0 ARTHROSIS 0 0 0 / Not Rel. All Severity Ω 0 2 (1.3)0 0 / Not Rel. 0 1 (0.6)0

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

Page 24

CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT AE4_SEV_DR NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

29SEP05 14:50

ody System [1]											
Adverse Event Severity / Drug	Relationship [2]		R 50 mg =149		R 100 mg =155		R 150 mg =157		R 200 mg =151		cebo 77
Moderate	/ Not Rel.	0		0		1	(0.6)	0		0	
BONE DISORDER All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	0 0 0		1 1 0 1	(0.6) (0.6) (0.6)	1 1 1 0	(0.6) (0.6) (0.6)	2 2 1 1	(1.3) (1.3) (0.7) (0.7)	0 0 0	
BURSITIS All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	1 1 1 0	(0.7) (0.7) (0.7)	0 0 0 0		2 2 2 0	(1.3) (1.3) (1.3)	1 1 0 1	(0.7) (0.7) (0.7)	0 0 0	
FIBROMYALGIA All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
GENERALIZED SPASM All Severity Mild	/ Not Rel. / Not Rel.	1 1 1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0	
JOINT DISORDER All Severity All Severity Mild Mild Moderate Moderate	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related	5 4 1 2 1 2 0	(3.4) (2.7) (0.7) (1.3) (0.7) (1.3)	3 3 0 0 0 3	(1.9) (1.9)	2 2 0 1 0 1	(1.3) (1.3) (0.6) (0.6)	3 2 1 2 0 0	(2.0) (1.3) (0.7) (1.3)	2 2 0 1 0 1 0	(2.6) (2.6) (1.3) (1.3)
LEG CRAMPS All Severity All Severity Mild Mild Moderate Moderate Severe Severe	/ Not Rel. / Related / Not Rel.	2 2 0 2 0 0 0	(1.3) (1.3) (1.3)	6 5 1 3 0 0 1 2	(3.9) (3.2) (0.6) (1.9) (0.6) (1.3)	5 3 2 2 1 1 0 0	(3.2) (1.9) (1.3) (1.3) (0.6) (0.6)	3 0 2 0 1 0 0	(2.0) (2.0) (1.3) (0.7)	3 3 0 2 0 1 0 0	(3.9) (3.9) (2.6) (1.3)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.
[2] - Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

CONFIDENTIAL Wyeth 427

Page 25

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationship [2]	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg D n=149 n=155 n=157	DVS SR 200 mg n=151	Placebo n= 77
MUSCLE CRAMP All Severity / Not Rel. All Severity / Related Mild / Not Rel. Moderate / Not Rel. Severe / Related	2 (1.3) 2 (1.3) 0 1 (0.7) 2 (1.3) 0 1 (0.7) 0 0 0 0 1 (0.6) 0 1 (0.7) 1 (0.6) 0 1 (0.7) 0 0	2 (1.3) 2 (1.3) 0 (0.7) 1 (0.7) 0 (0.7)	0 0 0 0 0
MUSCLE SPASMS All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Severe / Not Rel.	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	1 (0.7) 0 (0.7) 0 (0.7) 0 (0.7)	0 0 0 0 0
MUSCULOSKELETAL STIFFNESS All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	2 (1.3) 2 (1.3) 0 (0.7) 0 (0.7)	0 0 0 0 0 0
MYALGIA All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related	6 (4.0) 10 (6.5) 8 (5.1) 6 (4.0) 9 (5.8) 8 (5.1) 0 1 (0.6) 0 4 (2.7) 5 (3.2) 6 (3.8) 0 1 (0.6) 0 2 (1.3) 4 (2.6) 2 (1.3)	11 (7.3) 11 (7.3) 0 (4.0) 5 (3.3)	7 (9.1) 5 (6.5) 2 (2.6) 3 (3.9) 0 2 (2.6) 2 (2.6)
MYASTHENIA All Severity / Related Mild / Related Moderate / Related Severe / Related	0 3 (1.9) 1 (0.6) 0 3 (1.9) 1 (0.6) 0 2 (1.3) 0 0 1 (0.6) 0 0 1 (0.6)	0 0 0 0	0 0 0 0

Page

26

29SEP05 14:50 REPORT AE4 SEV DR CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Severity / Drug Relationship [2] n=149 n=155 n=157 OSTEOPOROSIS (1.3)(0.6)(2.6)All Severity / Not Rel. (1.3)1 (0.6)0 0 (1.3)All Severity / Related 0 0 0 0 (1.3)/ Not Rel. Mild (0.7)1 (0.6)0 0 (1.3)Mild / Related Λ 0 Ω 0 (1.3)Moderate / Not Rel. 1 (0.7)0 0 0 0 PLANTAR FASCIITIS 0 1 (0.6)0 0 All Severity / Not Rel. / Not Rel. 0 0 1 (0.6)0 0 Severe 0 0 1 (0.6)0 0 RHEUMATOID ARTHRITIS 0 1 (0.6)0 All Severity / Not Rel. 0 0 (0.6)0 0 0 0 Severe / Not Rel. (0.6)0 TENOSYNOVITIS 4 (2.7)(0.6)(0.6)(0.7)(1.3)(2.7)All Severity / Not Rel. 1 (0.6)1 (0.6)1 (0.7)1 (1.3)/ Not Rel. 0 0 Mild (1.3)0 0 Moderate / Not Rel. (1.3)(0.6)(0.6)(0.7)(1.3)(58.4)NERVOUS SYSTEM 87 107 (69.0)116 (73.9)120 (79.5)31 (40.3)All Severity / Not Rel. 20 (13.4)16 (10.3)10 (6.4)(9.3)(10.4)All Severity / Related 67 (45.0)91 (58.7)106 (67.5)106 (70.2)23 (29.9)Mild / Not Rel. (3.4)(4.5)(1.3)(2.6)(5.2)/ Related (16.1)27 (17.4)46 (29.3)(27.8)(13.0)Moderate / Not Rel. 11 (7.4)(4.5)(3.8)(5.3)(3.9)Moderate / Related 35 (23.5)43 (27.7)37 (23.6)42 (27.8)12 (15.6)Severe / Not Rel. (2.7)(1.3)(1.3)(1.3)(1.3)Severe / Related (5.4)21 (13.5)23 (14.6)22 (14.6)(1.3)ABNORMAL DREAMS (4.0)6 (3.9)(7.6)(5.3)(1.3)/ Not Rel. All Severity 0 (0.6)1 (0.6)(0.7)0 All Severity / Related (4.0)5 (3.2)11 (7.0)(4.6)(1.3)Mild / Not Rel. (0.6)1 (0.6)0 Mild / Related (2.7)(1.3)(4.5)2 (1.3)/ Not Rel. Moderate Ω 0 0 (0.7)0 Moderate / Related (1.3)(1.3)3 (1.9)(3.3)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

Page 27

Body System [1] Adverse Event			 3 50 ma		 3 100 ma		atment -		 R 200 mg	 pla	 acebo
	g Relationship [2]		=149		=155		=157		=151		77
Severe	/ Related	0		1	(0.6)	1	(0.6)	0		0	
ABNORMAL/CHANGED All Severity Mild	BEHAVIOR / Related / Related	1 1 1	(0.7) (0.7) (0.7)	1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
AGITATION All Severity All Severity Mild Mild Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Related / Related / Related	2 0 2 0 1 0	(1.3) (1.3) (0.7) (0.7)	1 0 1 0 0	(0.6) (0.6) (0.6)	3 0 3 0 1 2	(1.9) (1.9) (0.6) (1.3)	2 1 1 0 1 0	(1.3) (0.7) (0.7) (0.7) (0.7)	3 1 2 1 1 0 1	(3.9) (1.3) (2.6) (1.3) (1.3)
ANXIETY All Severity All Severity Mild Mild Moderate Moderate Severe Severe	/ Not Rel. / Related	13 7 6 2 2 3 3 2	(8.7) (4.7) (4.0) (1.3) (1.3) (2.0) (2.0) (1.3) (0.7)	10 2 8 1 2 1 4 0 2	(6.5) (1.3) (5.2) (0.6) (1.3) (0.6) (2.6) (1.3)	16 4 12 3 6 1 4 0 2	(10.2) (2.5) (7.6) (1.9) (3.8) (0.6) (2.5) (1.3)	12 4 8 3 4 1 4 0	(7.9) (2.6) (5.3) (2.0) (2.6) (0.7) (2.6)	3 0 3 0 0 0 3 0	(3.9) (3.9) (3.9)
APATHY All Severity Moderate	/ Related / Related	1 1 1	(0.7) (0.7) (0.7)	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
ATAXIA All Severity All Severity Moderate Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Related	0 0 0 0 0		4 1 3 1 2 1	(2.6) (0.6) (1.9) (0.6) (1.3) (0.6)	0 0 0 0 0		1 0 1 0 1	(0.7) (0.7) (0.7)	0 0 0 0	
BRAIN EDEMA All Severity	/ Not Rel.	0		0		0		1 1	(0.7) (0.7)	0	

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

By Severity And Drug Relationship

Page 28

Body System [1] Adverse Event Severity / Drug	g Relationship [2]		 R 50 mg :149			DVS SI	atment R 150 mg =157	DVS SI	R 200 mg =151	Pla n=	 acebo = 77
Mild	/ Not Rel.	0		0		0		1	(0.7)	0	
CARPAL TUNNEL SYI All Severity All Severity Mild Moderate Moderate	/ Not Rel.	0 0 0 0 0		1 0 0 1	(0.6) (0.6)	2 2 0 1 1 0	(1.3) (1.3) (0.6) (0.6)	3 0 1 2	(2.0) (2.0) (0.7) (1.3)	1 0 1 0 0	(1.3) (1.3) (1.3)
CERVICAL RADICULO All Severity Severe	DPATHY / Not Rel. / Not Rel.	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
CIRCUMORAL PAREST All Severity Mild Severe	PHESIA / Related / Related / Related	1 1 1 0	(0.7) (0.7) (0.7)	0 0 0 0		1 1 1 0	(0.6) (0.6) (0.6)	1 1 0 1	(0.7) (0.7) (0.7)	0 0 0	
CNS ANOMALY All Severity Mild	/ Not Rel. / Not Rel.	1 1 1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0	
CONFUSION All Severity All Severity Mild Mild Moderate Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related / Related / Related	2 1 1 0 0 1 1	(1.3) (0.7) (0.7) (0.7)	6 2 4 2 2 0 1	(3.9) (1.3) (2.6) (1.3) (1.3) (0.6) (0.6)	11 10 1 2 0 5 3	(7.0) (0.6) (6.4) (0.6) (1.3) (3.2) (1.9)	3 0 3 0 1 0 1	(2.0) (2.0) (0.7) (0.7) (0.7)	0 0 0 0 0 0 0 0	
DEPERSONALIZATION All Severity Mild Moderate Severe	N / Related / Related / Related / Related	1 1 0 0	(0.7) (0.7) (0.7)	3 3 1 1 1	(1.9) (1.9) (0.6) (0.6) (0.6)	0 0 0 0		1 1 0 0	(0.7) (0.7) (0.7)	0 0 0 0	

Page 29

29SEP05 14:50 REPORT AE4_SEV_DR CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

dy System [1] Adverse Event Severity / Drug Relationship [2]	DVS SR 50 mg n=149		DVS SR 100 mg I n=155		DVS SI		DVS S	R 200 mg =151	Placebo n= 77	
DEPRESSION All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Related Severe / Related	6 (4 3 (2 1 (0 3 (2 4 (2	6.0) 4.0) 2.0) 0.7) 2.0) 2.7)	9 3 6 1 2 3 0 2	(5.8) (1.9) (3.9) (0.6) (0.6) (1.3) (1.9)	8 0 8 0 4 0 3 0	(5.1) (5.1) (2.5) (1.9) (0.6)	7 2 5 0 2 2 2 0	(4.6) (1.3) (3.3) (1.3) (1.3) (1.3) (1.3)	4 4 0 2 0 2 0 0 0	(5.2) (5.2) (2.6) (2.6)
DIZZINESS All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Related Severe / Related	7 (4 26 (17 3 (2 13 (8 4 (2 10 (6	2.1) 4.7) 7.4) 2.0) 8.7) 2.7) 6.7)	51 12 39 5 17 6 14 1	(32.9) (7.7) (25.2) (3.2) (11.0) (3.9) (9.0) (0.6) (5.2)	49 11 38 7 21 3 13 1	(31.2) (7.0) (24.2) (4.5) (13.4) (1.9) (8.3) (0.6) (2.5)	51 4 47 4 23 0 21 0 3	(33.8) (2.6) (31.1) (2.6) (15.2) (13.9) (2.0)	6 0 6 0 3 0 3 0	(7.8) (7.8) (3.9) (3.9)
EMOTIONAL LABILITY All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	3 (2 7 (4 1 (0 3 (2 1 (0 1 (0	6.7) 2.0) 4.7) 0.7) 2.0) 0.7) 2.0) 0.7)	16 1 15 0 1 1 10 0 4	(10.3) (0.6) (9.7) (0.6) (0.6) (6.5) (2.6)	9 1 8 0 2 1 5 0	(5.7) (0.6) (5.1) (1.3) (0.6) (3.2) (0.6)	11 6 5 3 1 3 4 0	(7.3) (4.0) (3.3) (2.0) (0.7) (2.0) (2.6)	1 0 1 0 0 0 0	(1.3) (1.3) (1.3)
ENERGY INCREASED All Severity / Not Rel. All Severity / Related *Unknown / Not Rel. Moderate / Related	0 0 0 0		0 0 0 0		2 0 2 0 2	(1.3) (1.3) (1.3)	0 0 0 0		1 1 0 1 0	(1.3) (1.3) (1.3)
EUPHORIA	0		1	(0.6)	0		0		0	

Page 30

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug	Relationship [2]	DVS SI	R 50 mg =149	DVS SI	R 100 mg	DVS SI	atment R 150 mg =157	DVS SI	R 200 mg =151	Pla n=	 acebo = 77
All Severity Severe	/ Related / Related	0		1 1	(0.6) (0.6)	0		0		0	
FACIAL PARALYSIS All Severity Moderate	/ Not Rel. / Not Rel.	0 0 0		0 0 0			(0.6) (0.6) (0.6)	0 0 0		0 0 0	
FEELING DRUNK All Severity Moderate	/ Related / Related	1 1 1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0	
HALLUCINATIONS All Severity Mild	/ Related / Related	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
HOSTILITY All Severity All Severity Mild Mild Moderate Moderate Severe Severe	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related / Not Rel. / Related	12 1 11 2 0 7 0 2	(8.1) (0.7) (7.4) (0.7) (1.3) (4.7)	5 1 4 0 2 0 2 1 0	(3.2) (0.6) (2.6) (1.3) (1.3) (0.6)	12 3 9 0 5 3 3 0	(7.6) (1.9) (5.7) (3.2) (1.9) (1.9) (0.6)	5 2 3 0 2 0 1 2 0	(3.3) (1.3) (2.0) (1.3) (0.7) (1.3)	5 3 2 2 2 1 0 0	(6.5) (3.9) (2.6) (2.6) (2.6) (2.6) (1.3)
HYPERESTHESIA All Severity Moderate	/ Related / Related	1 1 1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0	
HYPERKINESIA All Severity All Severity Mild Moderate	/ Not Rel. / Related / Not Rel. / Related	2 1 1 1 1	(1.3) (0.7) (0.7) (0.7) (0.7)	0 0 0 0		1 0 1 0	(0.6) (0.6) (0.6)	0 0 0 0		0 0 0 0	
HYPERTONIA All Severity	/ Related	1 1	(0.7) (0.7)	0		0		2 2	(1.3) (1.3)	0	

Page

31

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS

By Severity And Drug Relationship

Body System [1] Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Severity / Drug Relationship [2] n=149 n=155 n=157 n = 770 Mild / Related 0 0 (1.3)0 0 0 0 Moderate / Related 1 (0.7)0 HYPESTHESIA (2.7)(3.2)(0.6)(1.3)(1.3)All Severity / Not Rel. (2.0)3 (1.9)1 (0.6)(1.3)0 All Severity / Related (0.7)(1.3)(1.3)2 / Not Rel. (2.0)(1.3)0 (0.7)0 / Related Mild 1 (0.7)(0.6)0 0 1 (1.3)/ Not Rel. / Related Moderate 0 1 (0.6)1 (0.6)1 (0.7)0 Severe 0 (0.6)0 0 HYPOKINESIA 0 0 0 1 (0.7)0 All Severity / Related 0 0 0 (0.7)0 0 0 0 (0.7)Severe / Related 0 HYPOTONIA (0.7)0 0 (0.7)0 All Severity / Not Rel. 0 0 0 1 (0.7)0 / Related All Severity 1 (0.7)0 0 0 0 Moderate / Not Rel. 0 0 (0.7)0 0 Moderate / Related (0.7)0 0 INSOMNIA 35 (23.5)38 (24.5)57 (36.3)52 (34.4)10 (13.0)All Severity / Not Rel. (5.4)(4.5)(4.5)(2.6)(2.6)/ Related 27 (20.0)(31.8)(31.8)All Severity (18.1)31 50 48 (10.4)/ Not Rel. (2.0)(3.9)(3.2)(0.7)(1.3)9 Mild / Related (4.0) (5.8)20 (12.7)23 (15.2)(2.6)Moderate / Not Rel. (2.7)(0.6)(1.3)(2.0)(1.3)16 Moderate / Related 17 (11.4)(10.3)21 (13.4)(11.3)(7.8)Severe / Not Rel. 1 (0.7) \cap (2.7)Severe / Related 6 (3.9)(5.7)8 (5.3)0 LIBIDO DECREASED (1.3)5 (3.2)(2.5)(5.3)(2.6)All Severity / Not Rel. 0 1 (0.6)1 (0.6)0 2 (2.6)All Severity / Related (1.3)4 (2.6)(1.9)8 (5.3)0 Mild / Not Rel. 0 0 2 (2.6)Mild / Related 1 (0.7)2 (1.3)2 (1.3)(1.3)0 Moderate / Not Rel. (0.6)1 (0.6)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

Page 32

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

dy System [1]		DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo										
Adverse Event Severity / Drug	Relationship [2]	DVS SI	R 50 mg =149		R 100 mg =155		R 150 mg =157		R 200 mg =151		cebo 77	
Moderate Severe	/ Related / Related	1 0	(0.7)	2 0	(1.3)	1 0	(0.6)	5 1	(3.3)	0		
LIBIDO INCREASED All Severity Mild	/ Related / Related	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		
MEMORY IMPAIRMENT All Severity All Severity Mild Mild Moderate Moderate	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related / Rot Rel.	1 0 1 0 1 0 0	(0.7) (0.7) (0.7)	2 1 1 0 1 1	(1.3) (0.6) (0.6) (0.6) (0.6)	3 0 3 0 2 0 1	(1.9) (1.9) (1.3) (0.6)	2 1 1 0 0 1	(1.3) (0.7) (0.7) (0.7)	1 0 1 0 0 0	(1.3) (1.3) (1.3)	
MOTION SICKNESS All Severity All Severity Moderate Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Not Rel.	1 1 0 1 0	(0.7) (0.7) (0.7)	2 1 1 0 1	(1.3) (0.6) (0.6) (0.6) (0.6)	0 0 0 0 0		0 0 0 0 0		0 0 0 0		
MOVEMENT DISORDER All Severity Moderate	/ Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0		
NERVE COMPRESSION All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	0 0 0		1 1 0 1	(0.6) (0.6) (0.6)	1 1 1 0	(0.6) (0.6) (0.6)	0 0 0		0 0 0		
NERVOUSNESS All Severity All Severity Mild Mild Moderate	/ Not Rel. / Related / Not Rel. / Related / Not Rel.	14 1 13 1 7 0	(9.4) (0.7) (8.7) (0.7) (4.7)	16 0 16 0 8	(10.3) (10.3) (5.2)	25 2 23 0 10 2	(15.9) (1.3) (14.6) (6.4) (1.3)	23 4 19 1 9 2	(15.2) (2.6) (12.6) (0.7) (6.0) (1.3)	4 1 3 1 2 0	(5.2) (1.3) (3.9) (1.3) (2.6)	

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

Page 33

ody System [1] Adverse Event	DVS SR 50 mg	DVS SR 100 mg	Treatment DVS SR 150 mg DVS	SR 200 mg	Placebo
Severity / Drug Relationship	2] n=149	n=155	n=157	n=151	n= 77
Moderate / Related Severe / Not Rel. Severe / Related	6 (4.0)	8 (5.2) 0	10 (6.4) 8 0 1 3 (1.9) 2	(0.7)	1 (1.3) 0 0
NEURALGIA All Severity / Not Rel. Moderate / Not Rel.	0 0 0	0 0 0	$egin{array}{cccc} 0 & & & 1 \\ 0 & & & 1 \\ 0 & & & 1 \\ \end{array}$		1 (1.3) 1 (1.3) 1 (1.3)
NEUROSIS All Severity / Related Moderate / Related	0 0 0	0 0 0	0 1 0 1 0 1	(0.7)	0 0 0
PARESTHESIA All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	1 (0.7) 0 (0.7) 1 (0.7) 0 (0.7) 0 0	5 (3.2) 9 (5.8) 3 (1.9)	6 (3.8) 5 0 3 6 (3.8) 2 0 3 4 (2.5) 2 0 0 1 (0.6) 0 1 (0.6) 0	(1.3) (2.0) (1.3)	0 0 0 0 0 0 0
PTOSIS All Severity / Not Rel. Moderate / Not Rel.	0 0 0	0 0 0	0 1 0 1 0 1	(0.7)	0 0 0
RESTLESS LEGS SYNDROME All Severity / Not Rel. All Severity / Related Mild / Related Moderate / Not Rel. Moderate / Related	0 0 0 0 0	2 (1.3) 0 (1.3) 1 (0.6) 0 (0.6)	1 (0.6) 1 1 (0.6) 0 0 1 0 0 1 (0.6) 0	(0.7)	0 0 0 0
SLEEP DISORDER All Severity / Not Rel. All Severity / Related Mild / Not Rel.	0 0 0 0	1 (0.6) 1 (0.6) 0 1 (0.6)	2 (1.3) 1 0 1 2 (1.3) 0 0 0	(0.7)	1 (1.3) 1 (1.3) 0

Page 34

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug			DVS SR 50 mg n=149		DVS SR 100 mg n=155			DVS S		Placebo n= 77	
Mild Moderate Moderate	/ Related / Not Rel. / Related	0 0 0		0 0 0		1 0 1	(0.6) (0.6)	0 1 0	(0.7)	0 1 0	(1.3)
SOMNOLENCE All Severity All Severity Mild Mild Moderate Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related / Related	8 2 6 1 5 1 1 0	(5.4) (1.3) (4.0) (0.7) (3.4) (0.7) (0.7)	29 27 2 15 0 9	(18.7) (1.3) (17.4) (1.3) (9.7) (5.8) (1.9)	32 6 26 5 12 1 10 4	(20.4) (3.8) (16.6) (3.2) (7.6) (0.6) (6.4) (2.5)	37 1 36 1 16 0 11 9	(24.5) (0.7) (23.8) (0.7) (10.6) (7.3) (6.0)	3 1 2 0 1 1 1	(3.9) (1.3) (2.6) (1.3) (1.3) (1.3)
SPEECH DISORDER All Severity All Severity Mild Moderate	/ Not Rel. / Related / Not Rel. / Related	0 0 0 0		0 0 0 0		1 1 0 1 0	(0.6) (0.6) (0.6)	1 0 1 0 1	(0.7) (0.7) (0.7)	0 0 0 0	
SUICIDAL IDEATION All Severity All Severity Severe Severe	/ Not Rel. / Related / Not Rel. / Related	1 1 0 1 0	(0.7) (0.7) (0.7)	1 0 1 0 1	(0.6) (0.6) (0.6)	0 0 0 0		0 0 0 0		0 0 0 0	
THINKING ABNORMAL All Severity All Severity Mild Moderate Moderate Severe	/ Not Rel. / Related / Related / Not Rel. / Related / Related	5 0 5 1 0 4	(3.4) (3.4) (0.7) (2.7)	6 1 5 1 4 0	(3.9) (0.6) (3.2) (0.6) (0.6) (2.6)	10 0 10 3 0 4 3	(6.4) (6.4) (1.9) (2.5) (1.9)	10 0 10 3 0 4 3	(6.6) (6.6) (2.0) (2.6) (2.0)	1 0 1 0 0 1	(1.3) (1.3) (1.3)
TREMOR All Severity All Severity Mild	/ Not Rel. / Related / Not Rel.	3 1 2 1	(2.0) (0.7) (1.3) (0.7)	7 1 6 1	(4.5) (0.6) (3.9) (0.6)	5 1 4 1	(3.2) (0.6) (2.5) (0.6)	12 0 12 0	(7.9) (7.9)	1 0 1 0	(1.3) (1.3)

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

By Severity And Drug Relationship

Page 35

Body System [1] Adverse Event Severity / Drug Relationship [2]	DVS SR 50 mg n=149	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo n=155 n=157 n=151 n= 77
Mild / Related Moderate / Related Severe / Related	1 (0.7) 1 (0.7) 0	
TRISMUS All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Related Severe / Related	2 (1.3) 0 (1.3) 0 (1.3) 0 (1.3)	1 (0.6) 0 0 0 0 0 1 (0.6) 2 (1.3) 3 (2.0) 0 1 (0.6) 0
TWITCHING All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related	2 (1.3) 1 (0.7) 1 (0.7) 0 0 1 (0.7) 1 (0.7)	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$
VERTIGO All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	5 (3.4) 5 (3.4) 0 (2.0) 0 (1.3)	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$
RESPIRATORY SYSTEM All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related	56 (37.6) 50 (33.6) 6 (4.0) 28 (18.8) 3 (2.0) 20 (13.4) 3 (2.0)	55 (35.5) 46 (29.3) 47 (31.1) 30 (39.0) 4 (2.6) 8 (5.1) 4 (2.6) 0 32 (20.6) 23 (14.6) 20 (13.2) 15 (19.5) 3 (1.9) 5 (3.2) 3 (2.0) 0 16 (10.3) 20 (12.7) 26 (17.2) 12 (15.6)

Page

36

CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS

By Severity And Drug Relationship

29SEP05 14:50

Body System [1] ----- Treatment Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Severity / Drug Relationship [2] n=149 n=155 n=157 n = 77Severe / Not Rel. (1.3)7 (4.5)3 (1.9)(0.7)3 (3.9)APNEA 0 0 0 1 (0.7) (0.7) 0 All Severity / Not Rel. 0 0 0 1 0 Mild / Not Rel. 0 0 0 1 (0.7)0 **ASTHMA** (0.7)1 (0.6)(0.6)0 / Not Rel. All Severity 1 (0.7)(0.6)1 (0.6)0 0 / Not Rel. / Not Rel. Mild 0 0 1 (0.6)0 0 Moderate 1 (0.7)0 0 0 0 (0.6)Severe / Not Rel. 0 1 0 0 0 BRONCHITIS (4.7)0 (3.3)(2.6)0 2 5 (3.3)(2.6)All Severity / Not Rel. (4.7)(1.3)/ Not Rel. Mild 1 (0.7)0 1 (0.6)0 0 Moderate / Not Rel. (3.4)0 (0.6)(3.3)(1.3)Ω Severe / Not Rel. (0.7)0 0 (1.3)COUGH INCREASED (10.1)(6.5)(3.8)(4.6)(7.8)12 10 5 All Severity / Not Rel. (8.1)(6.5)(3.2)(4.6)6 (7.8)/ Related All Severity 3 (2.0)0 1 (0.6)0 0 / Not Rel. (5.4)6 (3.9)4 (2.5)(3.3)(3.9)(1.3)Mild / Related 0 0 0 (2.7)Moderate / Not Rel. 2 (1.3)0 (1.3)2 (2.6)Moderate / Related (0.7)(0.6)Severe / Not Rel. (1.3)1 (0.6)0 (1.3)(1.3) (0.7) 0 DYSPNEA (1.3)(1.3)(4.5)2 All Severity / Not Rel. (1.3)5 (3.2)1 0 All Severity / Related (1.3)0 2 (1.3)1 (0.7)0 Mild / Not Rel. (0.6)(3.2)0 0 Mild / Related 1 (0.7)(1.3)1 (0.7)0 / Not Rel. Moderate Ω 0 0 1 (0.7)0 Moderate / Related 1 (0.7)0 0 0 0 Severe / Not Rel. 0 1 (0.6)0 0 0 EPISTAXIS 0 1 (0.6)4 (2.5)4 (2.6)(1.3)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

Page 37

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

ody System [1]						Trea	atment -				
Adverse Event Severity / Dru	g Relationship [2]		R 50 mg =149		R 100 mg =155		R 150 mg =157		R 200 mg =151		cebo 77
All Severity All Severity Mild Mild Moderate	/ Not Rel. / Related / Not Rel. / Related / Not Rel.	0 0 0 0		0 1 0 1 0	(0.6)	3 1 2 1 1	(1.9) (0.6) (1.3) (0.6) (0.6)	4 0 4 0	(2.6)	1 0 1 0	(1.3)
LARYNGISMUS All Severity All Severity Mild Mild	/ Not Rel. / Related / Not Rel. / Related	1 1 0 1	(0.7) (0.7) (0.7)	1 0 1 0 1	(0.6) (0.6) (0.6)	0 0 0 0		0 0 0 0		0 0 0 0	
LARYNGITIS All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	1 1 0 1	(0.7) (0.7) (0.7)	1 1 1 0	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
LUNG DISORDER All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	3 3 3 0	(2.0) (2.0) (2.0)	3 3 2 1	(1.9) (1.9) (1.3) (0.6)	2 2 2 0	(1.3) (1.3) (1.3)	1 1 0 1	(0.7) (0.7) (0.7)	1 1 1 0	(1.3) (1.3) (1.3)
NOSE DRYNESS All Severity Mild	/ Related / Related	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
PHARYNGITIS All Severity All Severity Mild Mild Moderate Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related / Not Rel.	10 10 0 3 0 6 0	(6.7) (6.7) (2.0) (4.0) (0.7)	11 11 0 7 0 3 0	(7.1) (7.1) (4.5) (1.9) (0.6)	14 12 2 7 1 5	(8.9) (7.6) (1.3) (4.5) (0.6) (3.2) (0.6)	14 14 0 4 0 9 0	(9.3) (9.3) (2.6) (6.0) (0.7)	5 5 0 3 0 2 0 0	(6.5) (6.5) (3.9) (2.6)
PNEUMONIA All Severity	/ Not Rel.	0		1	(0.6) (0.6)	2 2	(1.3) (1.3)	0		0	

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.
[2] - Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

CONFIDENTIAL 440 Wyeth

Page 38

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

dy System [1] Adverse Event Severity / Drug Rela	tionship [2]		R 50 mg =149	DVS S	R 100 mg =155	DVS SF		DVS S	R 200 mg =151		acebo = 77
	ot Rel. ot Rel.	0 0		0	(0.6)	1 1	(0.6) (0.6)	0		0	
	DING ot Rel. ot Rel.	1 1 1	(0.7) (0.7) (0.7)	1 1 1	(0.6) (0.6) (0.6)	0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
All Severity / R Mild / N Moderate / N	ot Rel. elated ot Rel. ot Rel. elated	10 10 0 8 2	(6.7) (6.7) (5.4) (1.3)	13 12 1 10 2	(8.4) (7.7) (0.6) (6.5) (1.3) (0.6)	7 7 0 5 2	(4.5) (4.5) (3.2) (1.3)	7 6 1 4 2	(4.6) (4.0) (0.7) (2.6) (1.3) (0.7)	7 7 0 4 3 0	(9.1) (9.1) (5.2) (3.9)
Mild / N Moderate / N	ot Rel. ot Rel. ot Rel. ot Rel.	3 3 1 2 0	(2.0) (2.0) (0.7) (1.3)	1 1 0 1 0	(0.6) (0.6) (0.6)	0 0 0 0		2 2 2 0 0	(1.3) (1.3) (1.3)	1 1 0 0 1	(1.3) (1.3)
All Severity / R Mild / N Moderate / N Moderate / R	ot Rel. elated ot Rel. ot Rel. elated ot Rel.	2 1 1 1 0 1	(1.3) (0.7) (0.7) (0.7) (0.7)	4 4 0 0 3 0 1	(2.6) (2.6) (1.9) (0.6)	0 0 0 0 0		3 0 2 1 0	(2.0) (2.0) (1.3) (0.7)	6 0 2 3 0	(7.8) (7.8) (2.6) (3.9) (1.3)
Mild / N Moderate / N	ot Rel. ot Rel. ot Rel. ot Rel.	12 12 7 4	(8.1) (8.1) (4.7) (2.7) (0.7)	19 19 3 12 4	(12.3) (12.3) (1.9) (7.7) (2.6)	10 10 3 6 1	(6.4) (6.4) (1.9) (3.8) (0.6)	18 18 9 9	(11.9) (11.9) (6.0) (6.0)	5 5 1 3 1	(6.5) (6.5) (1.3) (3.9) (1.3)
	CTION ot Rel. elated	18 18 0	(12.1) (12.1)	21 20 1	(13.5) (12.9) (0.6)	15 14 1	(9.6) (8.9) (0.6)	12 12 0	(7.9) (7.9)	11 11 0	(14.3) (14.3)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.
[2] - Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

CONFIDENTIAL Wyeth 441

Page 39

CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT AE4 SEV DR NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

29SEP05 14:50

Body System [1] Adverse Event Severity / Drug	Relationship [2]	DVS SR 50 mg n=149			DVS SR 100 mg n=155		Treatment - DVS SR 150 mg n=157		R 200 mg =151	Placebo n= 77	
Mild Mild Moderate Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Not Rel.	12 0 6 0	(8.1) (4.0)	15 0 4 1	(9.7) (2.6) (0.6) (0.6)	8 1 6 0	(5.1) (0.6) (3.8)	9 0 3 0	(6.0)	6 0 5 0	(7.8) (6.5)
VOICE ALTERATION All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
WHEEZING All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
YAWN All Severity All Severity Mild Moderate Moderate	/ Not Rel. / Related / Related / Not Rel. / Related	0 0 0 0 0		1 0 1 1 0 0	(0.6) (0.6) (0.6)	3 1 2 1 1	(1.9) (0.6) (1.3) (0.6) (0.6) (0.6)	2 0 2 2 0 0	(1.3) (1.3) (1.3)	0 0 0 0 0 0	
SKIN AND APPENDAGES All Severity All Severity Mild Mild Moderate Moderate Severe Severe	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related / Not Rel. / Related	30 18 12 8 4 10 6 0 2	(20.1) (12.1) (8.1) (5.4) (2.7) (6.7) (4.0) (1.3)	33 24 9 12 4 10 5 2	(21.3) (15.5) (5.8) (7.7) (2.6) (6.5) (3.2) (1.3)	29 18 11 13 5 3 4 2	(18.5) (11.5) (7.0) (8.3) (3.2) (1.9) (2.5) (1.3) (1.3)	25 15 10 7 6 4 4 4	(16.6) (9.9) (6.6) (4.6) (4.0) (2.6) (2.6) (2.6)	8 6 2 1 1 3 1 2 0	(10.4) (7.8) (2.6) (1.3) (1.3) (3.9) (1.3) (2.6)
ACNE All Severity All Severity Mild Mild Moderate	/ Not Rel. / Related / Not Rel. / Related / Not Rel.	2 2 0 1 0	(1.3) (1.3) (0.7)	1 0 1 0 1 0	(0.6) (0.6) (0.6)	2 1 1 1 1 0	(1.3) (0.6) (0.6) (0.6) (0.6)	1 1 0 0 0	(0.7) (0.7)	0 0 0 0 0 0	

Page

40

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

dy System [1] Adverse Event	DI/G G	 D 50 ma	D770 01			atment -	D070 01	 R 200 mg	Dla.	 cebo
Severity / Drug Relationship [2]		n=149		n=155		=157		=151		77
CONTACT DERMATITIS All Severity / Not Rel. All Severity / Related Mild / Not Rel. Moderate / Not Rel. Moderate / Related	1 1 0 0 1	(0.7) (0.7)	3 3 0 1 2 0	(1.9) (1.9) (0.6) (1.3)	2 2 0 2 0 0	(1.3) (1.3) (1.3)	2 1 1 1 0	(1.3) (0.7) (0.7) (0.7) (0.7)	0 0 0 0	
ERMATITIS ATOPIC All Severity / Not Rel. Moderate / Not Rel.	1 1 1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0	
ORY SKIN All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Related	2 1 1 1 0	(1.3) (0.7) (0.7) (0.7) (0.7)	2 1 1 1 0 1	(1.3) (0.6) (0.6) (0.6) (0.6)	3 2 1 2 1 0	(1.9) (1.3) (0.6) (1.3) (0.6)	1 0 1 0 0	(0.7) (0.7) (0.7)	0 0 0 0 0	
CRYTHEMA All Severity / Not Rel. Moderate / Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
EXFOLIATIVE DERMATITIS All Severity / Not Rel. Severe / Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
FUNGAL DERMATITIS All Severity / Not Rel. Moderate / Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		1 1 1	(1.3) (1.3) (1.3)
HERPES SIMPLEX All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel. Severe / Not Rel.	1 1 1 0 0	(0.7) (0.7) (0.7)	4 4 1 3 0	(2.6) (2.6) (0.6) (1.9)	3 3 2 0 1	(1.9) (1.9) (1.3) (0.6)	5 5 4 1 0	(3.3) (3.3) (2.6) (0.7)	0 0 0 0	
IERPES ZOSTER	2	(1.3)	2	(1.3)	1	(0.6)	0		0	

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

Page

41

Body System [1] Adverse Event Severity / Drug Relationship [2]	DVS SR 50 mg n=149	DVS SR 100 mg n=155	Treatment DVS SR 150 mg n=157	DVS SR 200 mg	Placebo n= 77
All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	2 (1.3) 0 (1.3)	2 (1.3) 2 (1.3) 0	1 (0.6) 0 (0.6)	0 0 0	0 0 0
IMPETIGO All Severity / Not Rel. Moderate / Not Rel.	0 0 0	0 0 0	0 0 0	1 (0.7) 1 (0.7) 1 (0.7)	0 0 0
MACULOPAPULAR RASH All Severity / Not Rel. Mild / Not Rel.	0 0 0	0 0 0	1 (0.6) 1 (0.6) 1 (0.6)	0 0 0	0 0 0
NAIL DISORDER All Severity / Related Mild / Related	1 (0.7) 1 (0.7) 1 (0.7)	0 0 0	0 0 0	0 0 0	0 0 0
NIGHT SWEATS All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	9 (6.0) 3 (2.0) 6 (4.0) 0 1 (0.7) 3 (2.0) 4 (2.7) 0 1 (0.7)	4 (2.6) 1 (0.6) 3 (1.9) 0 1 (0.6) 0 2 (1.3) 1 (0.6)	4 (2.5) 1 (0.6) 3 (1.9) 1 (0.6) 0 2 (1.3) 0 1 (0.6)	2 (1.3) 1 (0.7) 1 (0.7) 0 (0.7) 0 (0.7) 0 (0.7)	0 0 0 0 0 0 0
PRURITUS All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	6 (4.0) 4 (2.7) 2 (1.3) 1 (0.7) 1 (0.7) 3 (2.0) 1 (0.7) 0	6 (3.9) 4 (2.6) 2 (1.3) 2 (1.3) 2 (1.3) 1 (0.6) 0 (0.6)	6 (3.8) 4 (2.5) 2 (1.3) 4 (2.5) 1 (0.6) 0	0 0 0 0 0 0 0	0 0 0 0 0 0 0
PSORIASIS	0	0	1 (0.6)	0	0

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.
[2] - Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

CONFIDENTIAL Wyeth 444

Page

42

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

dy System [1] Adverse Event Severity / Drug Relationship [2]	DVS SI	R 50 mg =149	DVS SI	R 100 mg =155	DVS SI	atment - R 150 mg =157	DVS SI	R 200 mg =151		acebo = 77
All Severity / Not Rel. Moderate / Not Rel.	0		0		1 1	(0.6) (0.6)	0		0	
RASH All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel.	9 8 1 5 1 3	(6.0) (5.4) (0.7) (3.4) (0.7) (2.0)	4 4 0 4 0	(2.6) (2.6) (2.6)	4 3 1 3 0	(2.5) (1.9) (0.6) (1.9)	1 0 1 0 1	(0.7) (0.7) (0.7)	3 2 1 0 0 2	(3.9) (2.6) (1.3)
Moderate / Related	Ő	(2.0)	Ö		1	(0.6)	Ő		1	(1.3)
SEBORRHEA All Severity / Not Rel. Mild / Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
SEBORRHEIC KERATOSIS All Severity / Not Rel. Mild / Not Rel.	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
SKIN BENIGN NEOPLASM All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	1 1 1 0	(0.7) (0.7) (0.7)	2 2 1 1	(1.3) (1.3) (0.6) (0.6)	2 2 2 0	(1.3) (1.3) (1.3)	1 1 1 0	(0.7) (0.7) (0.7)	0 0 0	
SKIN CARCINOMA All Severity / Not Rel. Severe / Not Rel.	0 0 0		0 0 0		0 0 0		0 0 0		1 1 1	(1.3) (1.3) (1.3)
SKIN DISCOLORATION All Severity / Not Rel. Mild / Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
SKIN DISORDER All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related	1 0 1 0 1	(0.7) (0.7) (0.7)	1 1 0 1 0	(0.6) (0.6) (0.6)	1 1 0 1 0	(0.6) (0.6) (0.6)	0 0 0 0		2 1 1 1	(2.6) (1.3) (1.3) (1.3) (1.3)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.
[2] - Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

CONFIDENTIAL Wyeth 445

Page 43

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationship [2]	DVS SR 50 mg n=149	DVS SR 100 mg DVS SR 150 n=155 n=157	mg DVS SR 200 mg	Placebo n= 77
SKIN HYPERTROPHY All Severity / Not Rel. Mild / Not Rel.	1 (0.7) 1 (0.7) 1 (0.7)	0 0 0 0 0 0	0 0 0	0 0 0
SKIN MELANOMA All Severity / Not Rel. Moderate / Not Rel.	0 0 0	0 1 (0.6 0 1 (0.6 0 1 (0.6) O	0 0 0
SKIN ULCER All Severity / Not Rel. Moderate / Not Rel.	0 0 0	0 1 (0.6 0 1 (0.6 0 1 (0.6) Ö	0 0 0
SKIN WRINKLING All Severity / Not Rel. Mild / Not Rel.	0 0 0	0 1 (0.6 0 1 (0.6 0 1 (0.6) O	0 0 0
SUNBURN All Severity / Not Rel. Moderate / Not Rel.	0 0 0	1 (0.6) 0 1 (0.6) 0 1 (0.6) 0	0 0 0	0 0 0
SWEATING All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	4 (2.7) 1 (0.7) 3 (2.0) 0 1 (0.7) 1 (0.7) 1 (0.7) 0 (0.7)	6 (3.9) 4 (2.5 2 (1.3) 1 (0.6 4 (2.6) 3 (1.9 0 0 2 (1.3) 2 (1.3 2 (1.3) 0 0 2 (1.3) 1 (0.6 0 0 0) 3 (2.0)) 7 (4.6) 1 (0.7)) 4 (2.6) 0 3 (2.0)	0 0 0 0 0 0 0
URTICARIA All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel. Severe / Not Rel.	3 (2.0) 3 (2.0) 2 (1.3) 1 (0.7)	4 (2.6) 0 4 (2.6) 0 2 (1.3) 0 2 (1.3) 0	2 (1.3) 2 (1.3) 1 (0.7) 1 (0.7)	1 (1.3) 1 (1.3) 0 0 1 (1.3)
SPECIAL SENSES	19 (12.8)	39 (25.2) 43 (27.4) 44 (29.1)	6 (7.8)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.
[2] - Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

Page

44

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug I	DVS SR 50 mg n=149		DVS SR 100 mg I n=155		Treatment DVS SR 150 mg n=157					acebo = 77	
All Severity All Severity Mild Mild Moderate Moderate Severe Severe	/ Not Rel. / Related	10 9 9 6 0 3 1	(6.7) (6.0) (6.0) (4.0) (2.0) (0.7)	14 25 7 13 7 9 0	(9.0) (16.1) (4.5) (8.4) (4.5) (5.8)	13 30 7 14 5 15 1	(8.3) (19.1) (4.5) (8.9) (3.2) (9.6) (0.6) (0.6)	18 26 9 15 8 9	(11.9) (17.2) (6.0) (9.9) (5.3) (6.0) (0.7) (1.3)	4 2 2 1 2 1 0	(5.2) (2.6) (2.6) (1.3) (2.6) (1.3)
ABNORMAL VISION All Severity All Severity Mild Mild Moderate Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related / Related	6 2 4 2 4 0 0	(4.0) (1.3) (2.7) (1.3) (2.7)	13 3 10 2 7 1 2	(8.4) (1.9) (6.5) (1.3) (4.5) (0.6) (1.3) (0.6)	17 5 12 4 8 1 4	(10.8) (3.2) (7.6) (2.5) (5.1) (0.6) (2.5)	13 2 11 1 7 1 3 1	(8.6) (1.3) (7.3) (0.7) (4.6) (0.7) (2.0) (0.7)	1 0 1 0 1 0 0	(1.3) (1.3) (1.3)
CATARACT SPECIFIED All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	1 1 1 0	(0.7) (0.7) (0.7)	0 0 0		0 0 0		1 1 0 1	(0.7) (0.7) (0.7)	1 1 1 0	(1.3) (1.3) (1.3)
CONJUNCTIVITIS All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	0 0 0		3 3 2 1	(1.9) (1.9) (1.3) (0.6)	1 1 1 0	(0.6) (0.6) (0.6)	1 1 0 1	(0.7) (0.7) (0.7)	0 0 0	
CORNEAL LESION All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	0 0 0		0 0 0		1 1 1 0	(0.6) (0.6) (0.6)	1 1 0 1	(0.7) (0.7) (0.7)	0 0 0	
DRY EYES All Severity All Severity Mild	/ Not Rel. / Related / Related	0 0 0		1 1 0 0	(0.6) (0.6)	0 0 0		1 0 1 1	(0.7) (0.7) (0.7)	0 0 0	

Page

45

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationship [2]		DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS n=149 n=155 n=157				DVS SI					
Moderate	/ Not Rel.	0		 1	(0.6)					0	
EAR DISORDER All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel. / Not Rel.	1 1 1 0	(0.7) (0.7) (0.7)	2 2 2 2 0	(1.3) (1.3) (1.3)	2 2 1 1	(1.3) (1.3) (0.6) (0.6)	1 1 0 1	(0.7) (0.7) (0.7)	0 0 0	
EAR PAIN All Severity All Severity Mild Mild Moderate	/ Not Rel. / Related / Not Rel. / Related / Not Rel.	1 1 0 1 0	(0.7) (0.7) (0.7)	4 3 1 2 1 1	(2.6) (1.9) (0.6) (1.3) (0.6) (0.6)	3 2 1 1 1 1	(1.9) (1.3) (0.6) (0.6) (0.6) (0.6)	3 0 2 0 1	(2.0) (2.0) (1.3) (0.7)	1 0 0 0 1	(1.3) (1.3)
EYE DISORDER All Severity All Severity Mild Mild Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Related / Related / Not Rel.	0 0 0 0 0		2 1 1 1 0 0	(1.3) (0.6) (0.6) (0.6) (0.6)	3 2 1 1 0 1	(1.9) (1.3) (0.6) (0.6) (0.6)	1 0 1 0 0 0	(0.7) (0.7) (0.7)	0 0 0 0 0 0	
EYE PAIN All Severity All Severity Mild Mild Moderate	/ Not Rel. / Related / Not Rel. / Related / Related	1 1 0 1 0	(0.7) (0.7) (0.7)	1 0 1 0 0	(0.6) (0.6) (0.6)	1 0 1 0 0	(0.6) (0.6) (0.6)	4 3 1 3 1 0	(2.6) (2.0) (0.7) (2.0) (0.7)	0 0 0 0 0	
GLAUCOMA All Severity Mild	/ Not Rel. / Not Rel.	1 1 1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0	
HYPERACUSIS All Severity All Severity Mild	/ Not Rel. / Related / Not Rel.	1 0 1 0	(0.7) (0.7)	1 1 0 1	(0.6) (0.6)	1 0 1 0	(0.6) (0.6)	0 0 0		0 0 0	

Page 46

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Dru	g Relationship [2]	DVS SI	R 50 mg =149	DVS SI	R 100 mg	DVS SI	atment - R 150 mg =157	DVS SI	R 200 mg =151	Pla n=	 icebo = 77
Moderate	/ Related	1	(0.7)	0		1	(0.6)	0		0	
LACRIMATION DISO All Severity Mild	RDER / Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		0 0 0		1 1 1	(1.3) (1.3) (1.3)
MIOSIS All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
MYDRIASIS All Severity All Severity Mild Mild Moderate Severe		1 0 1 0 1 0	(0.7) (0.7) (0.7)	0	(2.6) (2.6) (0.6) (1.9)		(6.4) (0.6) (5.7) (0.6) (2.5) (3.2)	12 0 12 0 6 5	(7.9) (7.9) (4.0) (3.3) (0.7)	0 0 0 0 0	
OTITIS EXTERNA All Severity Mild	/ Not Rel. / Not Rel.	1 1 1	(0.7) (0.7) (0.7)	0 0 0		2 2 2	(1.3) (1.3) (1.3)	0 0 0		0 0 0	
OTITIS MEDIA All Severity Moderate Severe	/ Not Rel. / Not Rel. / Not Rel.	0 0 0		1 1 1 0	(0.6) (0.6) (0.6)	1 1 1 0	(0.6) (0.6) (0.6)	2 2 1 1	(1.3) (1.3) (0.7) (0.7)	0 0 0	
PAROSMIA All Severity All Severity Mild Moderate Moderate	/ Not Rel. / Related / Related / Not Rel. / Related	1 0 1 0 0 0	(0.7) (0.7) (0.7)	1 0 0 1 0	(0.6) (0.6)	0 0 0 0 0		1 0 1 1 0 0	(0.7) (0.7) (0.7)	0 0 0 0	
PHOTOPHOBIA All Severity All Severity	/ Not Rel. / Related	2 0 2	(1.3) (1.3)	1 0 1	(0.6) (0.6)	2 1 1	(1.3) (0.6) (0.6)	0 0 0		0 0 0	

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

Page 47

Body System [1] Adverse Event Severity / Drug Relationship [2]		DITC C	DITC CD EO ma		R 100 mg	DVS SI	R 150 mg	g DVS SR 200 mg n=151		Placebo n= 77	
Mild Mild Moderate	/ Not Rel. / Related / Related	0 1 1		0 1 0	(0.6)	1 0 1	(0.6)	0 0 0		0 0	
RETINAL DETACHMEN All Severity Severe	/ Not Rel.	1 1 1	(/	0 0 0		0 0 0		0 0 0		0 0 0	
TASTE PERVERSION All Severity All Severity Mild Mild Moderate Moderate		1 0 1 0 0 0	, ,	3 1 2 1 2 0 0	(1.9) (0.6) (1.3) (0.6) (1.3)	5 1 4 0 3 1	(3.2) (0.6) (2.5) (1.9) (0.6) (0.6)	3 0 3 0 2 0	(2.0) (2.0) (1.3) (0.7)	0 0 0 0 0	
TINNITUS All Severity All Severity Mild Mild Moderate Moderate Severe		5 2 3 2 2 0 1 0	(1.3) (2.0) (1.3) (1.3)	15 4 11 2 3 2 6 2	(9.7) (2.6) (7.1) (1.3) (1.9) (1.3) (3.9) (1.3)	9 1 8 1 2 0 5 1	(5.7) (0.6) (5.1) (0.6) (1.3) (3.2) (0.6)	8 5 3 5 1 0 2	(5.3) (3.3) (2.0) (3.3) (0.7) (1.3)	1 0 1 0 0 0 0	(1.3) (1.3) (1.3)
VESTIBULAR DISORD All Severity Moderate	/ Not Rel.	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	1 1 1	(0.7) (0.7) (0.7)	1 1 1	
VITREOUS DISORDER All Severity Mild Moderate		0 0 0		1 1 1 0	(0.6) (0.6) (0.6)	0 0 0		2 2 1 1	(1.3) (1.3) (0.7) (0.7)	0 0 0	
UROGENITAL SYSTEM All Severity All Severity		15	(12.1) (10.1) (2.0)	21	(16.8) (13.5) (3.2)	17	(15.9) (10.8) (5.1)	12	(13.2) (7.9) (5.3)	15 15 0	(19.5) (19.5)

Page

48

CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS

By Severity And Drug Relationship

29SEP05 14:50

Body System [1] Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Severity / Drug Relationship [2] n=149 n=155 n=157 n = 77Mild / Not Rel. (6.0)12 (7.7)10 (6.4)(5.3)11 (14.3)Mild / Related 2 (1.3)3 (1.9)3 (1.9)(2.6)0 (2.0) (2.0) / Not Rel. Moderate (2.7) (0.7) (4.5)(4.5)(3.9)/ Related Moderate 1 1 (0.6)(2.5)3 0 Severe / Not Rel. (1.3)1 (0.6)0 (0.7)1 (1.3)1 Severe / Related (0.6)1 (0.6)(0.7)0 Life Threatening / Not Rel. 0 1 (0.6)0 0 ABNORMAL EJACULATION/ORGASM 0 0 1 (0.6)0 0 All Severity / Related 0 0 (0.6)0 0 0 1 Severe / Related 0 (0.6)0 0 0 ALBUMINURIA 0 1 (0.6)0 0 All Severity / Not Rel. Ω 1 (0.6)0 0 Mild / Not Rel. 0 0 1 (0.6)0 0 0 ANORGASMIA Ω 0 (0.7)0 / Related 0 (0.7)All Severity 0 0 1 0 Mild / Related 0 0 (0.7)0 BREAST CYST (2.0)0 1 (0.6)0 (1.3)All Severity / Not Rel. (2.0)0 (0.6)0 (1.3)Mild / Not Rel. (1.3)0 1 (0.6)0 (1.3)Moderate / Not Rel. (0.7)0 0 0 0 0 0 0 BREAST DISORDER 1 (0.7)All Severity / Not Rel. (0.7)0 0 Ω 0 Moderate / Not Rel. (0.7)0 0 0 BREAST NEOPLASM (0.7)(1.3)0 0 (1.3)(0.7)All Severity / Not Rel. (0.6)0 0 (1.3)All Severity / Related 0 (0.6)0 0 0 / Not Rel. Mild Ω (0.6)0 0 (1.3)Mild / Related (0.6)0 0 0 Moderate / Not Rel. 1 (0.7)0 0 0 0 BREAST PAIN 3 (1.9)2 (1.3)(1.3)(5.2)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

By Severity And Drug Relationship

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS

Page

49

Body System [1] Adverse Event Severity / Drug Relationship	DVS SR 50 mg [2] n=149	DVS SR 100 mg	Treatment DVS SR 150 mg DVS SR 200 mg n=157 n=151	Placebo n= 77	
All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel.	0 0 0 0	3 (1.9) 0 3 (1.9) 0 0	2 (1.3) 1 (0.7) 0 1 (0.7) 2 (1.3) 0 0 1 (0.7) 0 1 (0.7)	4 (5.2) 0 2 (2.6) 0 2 (2.6)	
CERVICITIS All Severity / Not Rel. Mild / Not Rel.	0 0 0	1 (0.6) 1 (0.6) 1 (0.6)	0 0 0 0	0 0 0	
CERVIX DISORDER All Severity / Not Rel. Moderate / Not Rel.	0 0 0	1 (0.6) 1 (0.6) 1 (0.6)	0 0 0 0	0 0 0	
CERVIX NEOPLASM All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related	0 0 0 0	0 0 0 0	2 (1.3) 0 1 (0.6) 0 1 (0.6) 0 1 (0.6) 0 1 (0.6) 0	1 (1.3) 1 (1.3) 0 1 (1.3)	
CYSTITIS All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	1 (0.7) 1 (0.7) 1 (0.7)	3 (1.9) 3 (1.9) 2 (1.3) 1 (0.6)	2 (1.3) 1 (0.7) 2 (1.3) 1 (0.7) 1 (0.6) 0 1 (0.6) 1 (0.7)	1 (1.3) 1 (1.3) 1 (1.3)	
DYSURIA All Severity / Not Rel. Mild / Not Rel.	0 0 0	0 0 0	0 1 (0.7) 0 1 (0.7) 0 1 (0.7)	0 0 0	
FIBROCYSTIC BREAST All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	0 0 0 0	0 0 0	2 (1.3) 1 (0.7) 2 (1.3) 1 (0.7) 1 (0.6) 1 (0.7) 1 (0.6) 0	0 0 0 0	
HEMATURIA All Severity / Not Rel. Mild / Not Rel.	0 0 0	0 0 0	1 (0.6) 2 (1.3) 1 (0.6) 2 (1.3) 1 (0.6) 2 (1.3)	2 (2.6) 2 (2.6) 2 (2.6)	

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

Page 50

Body System [1] Adverse Event Severity / Drug Relationship [2]		DVS SI	DVS SR 50 mg n=149		R 100 mg	DVS SE	atment R 150 mg =157	DVS SI	R 200 mg =151	Placebo n= 77	
KIDNEY CALCULUS All Severity Mild Moderate Severe	/ Not Rel. / Not Rel. / Not Rel. / Not Rel.	1 1 0 1 0	(0.7) (0.7) (0.7)	0 0 0 0		2 2 0 1 1	(1.3) (1.3) (0.6) (0.6)	0 0 0 0		1 1 1 0	(1.3) (1.3) (1.3)
LEUKORRHEA All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	0 0 0		1 1 0 1	(0.6) (0.6)	1 1 1 0	(0.6) (0.6) (0.6)	1 1 1 0	(0.7) (0.7) (0.7)	0 0 0	
MASTITIS All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		0 0 0		1 1 1	(1.3) (1.3) (1.3)
	/ Not Rel. / Related / Not Rel. / Related	3 2 1 2 1	(2.0) (1.3) (0.7) (1.3) (0.7)	1 0 1 0 1	(0.6) (0.6) (0.6)	2 2 0 2 0	(1.3) (1.3) (1.3)	2 1 1 1 1	(1.3) (0.7) (0.7) (0.7) (0.7)	0 0 0 0	
OLIGURIA All Severity All Severity Mild Moderate	/ Not Rel. / Related / Related / Not Rel.	0 0 0 0		1 0 1 1 0	(0.6) (0.6) (0.6)	1 1 0 0 1	(0.6) (0.6)	0 0 0 0		0 0 0 0	
OVARIAN CARCINOMA All Severity Life Threatening	/ Not Rel. / Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
OVARIAN CYST All Severity Moderate	/ Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		0 0 0		1 1 1	(1.3) (1.3) (1.3)
PYELONEPHRITIS All Severity	/ Not Rel.	0		0		0		1 1	(0.7) (0.7)	1 1	(1.3) (1.3)

Page 51

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationship [2]		DVS SR 100 mc	DVS SR 150 mg DVS SR 200 mg n=157 n=151	
Mild / Not Rel. Moderate / Not Rel.	0	0	0 0 0 1 (0.7)	1 (1.3)
SEXUAL FUNCTION ABNORMAL All Severity / Related Mild / Related Moderate / Related	1 (0.7) 1 (0.7) 0 (0.7)	0	3 (1.9) 2 (1.3) 3 (1.9) 2 (1.3) 1 (0.6) 0 2 (1.3) 2 (1.3)	0 0 0
URINARY FREQUENCY All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Related	0 0 0 0 0	0 0 0 0	1 (0.6) 2 (1.3) 0 1 (0.7) 1 (0.6) 1 (0.7) 0 1 (0.7) 1 (0.6) 0 0 1 (0.7)	0 0 0 0 0
URINARY HESITATION All Severity / Related Severe / Related	0 0 0	0 0 0	0 1 (0.7) 0 1 (0.7) 0 1 (0.7)	0 0 0
URINARY INCONTINENCE All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	0 0 0	1 (0.6) 1 (0.6) 0 (0.6)	1 (0.6) 1 (0.7) 1 (0.6) 1 (0.7) 0 1 (0.6) 0	0 0 0
URINARY RETENTION All Severity / Not Rel. Mild / Not Rel.	0 0 0	1 (0.6) 1 (0.6) 1 (0.6)	0 0 0 0	0 0 0
URINARY TRACT DISORDER All Severity / Not Rel. Severe / Not Rel.	1 (0.7) 1 (0.7) 1 (0.7)	0 0 0	0 0 0 0	0 0 0
URINARY TRACT INFECTION All Severity / Not Rel. All Severity / Related Mild / Not Rel. Moderate / Not Rel.	6 (4.0) 6 (4.0) 0 3 (2.0) 2 (1.3)	0	6 (3.8) 2 (1.3) 5 (3.2) 2 (1.3) 1 (0.6) 0 2 (1.3) 1 (0.7) 3 (1.9) 0	2 (2.6) 2 (2.6) 0 1 (1.3) 1 (1.3)

Page

52

29SEP05 14:50 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4 SEV DR

- - NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS
By Severity And Drug Relationship

Body System [1] ------- Treatment ------Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Severity / Drug Relationship [2] n=149 n=155 n=157 n = 77Moderate / Related 0 (0.6)0 0 Severe / Not Rel. 1 (0.7)0 1 (0.7)0 0 0 0 URINARY URGENCY (0.7)0 All Severity / Not Rel. (0.7)0 0 0 0 Mild / Not Rel. (0.7)0 0 URINE ABNORMALITY 0 2 (1.3)0 1 (0.7)0 All Severity / Not Rel. / Related 0 1 (0.6)0 0 0 All Severity 0 (0.6)0 (0.7)0 Mild / Not Rel. 0 (0.6)0 0 0 Mild / Related 0 1 (0.6)(0.7)0 UTERINE FIBROIDS ENLARGED 0 0 0 0 1 (0.6)/ Not Rel. All Severity 0 0 1 (0.6)0 0 Mild / Not Rel. 0 0 (0.6)0 0 UTERINE HEMORRHAGE 0 0 1 (0.6)(1.3)0 All Severity / Not Rel. 0 (0.6)(0.6)0 0 All Severity / Related 0 1 (0.6)0 0 Mild / Not Rel. 0 0 1 (0.6)0 0 Moderate / Not Rel. 0 (0.6)0 0 0 0 Moderate / Related 0 1 (0.6)0 0 VAGINAL DRYNESS (1.9)(1.3)(0.7)(2.6)All Severity / Not Rel. 0 (1.3)0 (2.6)/ Related All Severity Ω (0.6)0 1 (0.7)0 Mild / Not Rel. 0 0 (0.7)(1.3)Moderate / Not Rel. 0 1 (0.6)0 0 Moderate / Related 0 0 0 (0.7)0 Severe / Not Rel. (0.6)0 (1.3)Severe / Related 0 (0.6)0 0 0 0 VAGINAL HEMORRHAGE (3.2)1 (0.6)(0.7)(2.6)2 All Severity / Not Rel. 0 5 (3.2)0 (0.7)(2.6)All Severity / Related Ω 0 1 (0.6)0 Λ / Not Rel. 5 (3.2)0 (0.7)(1.3)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

Page

53

29SEP05 14:50 REPORT AE4 SEV DR CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS
By Severity And Drug Relationship

Body System [1] Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Severity / Drug Relationship [2] n=149 n=155 n=157 n = 770 Moderate / Not Rel. 0 (1.3)0 Moderate / Related 0 (0.6)0 0 VAGINAL MONILIASIS 0 0 0 0 (0.6)/ Not Rel. All Severity Λ 1 (0.6)0 0 0 Mild / Not Rel. (0.6)0 0 VAGINITIS 1 (0.7)3 (1.9)1 (0.6)0 (1.3)All Severity / Not Rel. / Not Rel. 1 (0.7)3 (1.9)1 (0.6)0 (1.3)Mild 0 (1.3)1 (0.6)0 (1.3)Moderate / Not Rel. 1 (0.7)1 (0.6)0 0 0 VULVOVAGINAL DISORDER (1.3)0 0 All Severity / Not Rel. (0.7)1 (0.6)0 0 / Related All Severity 1 (0.7)0 0 0 0 Mild / Not Rel. (0.7)0 (0.6)0 0 Mild / Related 1 (0.7)0 0 0 0 TERMS NOT CLASSIFIABLE (0.7)(1.9)2 (1.3)(0.7)0 0 0 All Severity / Not Rel. 1 (0.6)0 / Related All Severity 1 (0.7)0 (1.3)1 (0.7)0 Mild / Not Rel. 0 (0.7)0 Mild / Related (0.7)0 0 (0.7)0 (0.6)Moderate / Not Rel. 0 0 1 0 0 Severe / Related (1.3)0 REACTION UNEVALUABLE (0.7)0 3 (1.9)(1.3)(0.7)Ω All Severity / Not Rel. (0.6)0 All Severity / Related (0.7)0 (1.3)(0.7)0 (0.7)Mild / Not Rel. 0 0 1 0 Mild / Related (0.7)(0.7)0 Moderate / Not Rel. 0 0 1 (0.6)0 0 2 Severe / Related 0 (1.3)0 0 ADVERSE EVENT ASSOC.W.MISC. FACTORS (2.7)(3.2)6 (3.8)(4.0)(9.1)/ Not Rel. All Severity (2.7)(3.2)6 (3.8)6 (4.0)(9.1)/ Not Rel. (1.3)(2.6)(2.5)(2.6)(3.9)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

29SEP05 14:50 REPORT AE4_SEV_DR CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 54

NUMBER (%) OF SUBJECTS REPORTING ADVERSE EVENTS By Severity And Drug Relationship

dy System [1] Adverse Event Severity / Dru	g Relationship [2]		R 50 mg =149		R 100 mg =155	DVS SF	atment R 150 mg =157	DVS SE			acebo = 77
Moderate	/ Not Rel.	2	(1.3)	1	(0.6)	2	(1.3)	2	(1.3)	4	(5.2)
ALLERGIC REACTIO	N OTHER THAN DRUG	4	(2.7)	3	(1.9)	2	(1.3)	4	(2.6)	3	(3.9)
All Severity	/ Not Rel.	4	(2.7)	3	(1.9)	2	(1.3)	4	(2.6)	3	(3.9)
Mild	/ Not Rel.	2	(1.3)	3	(1.9)	2	(1.3)	4	(2.6)	2	(2.6)
Moderate	/ Not Rel.	2	(1.3)	0		0		0		1	(1.3)
LOCAL REACTION T	O PROCEDURE	0		2	(1.3)	4	(2.5)	2	(1.3)	4	(5.2)
All Severity	/ Not Rel.	0		2	(1.3)	4	(2.5)	2	(1.3)	4	(5.2)
Mild	/ Not Rel.	0		1	(0.6)	2	(1.3)	0		1	(1.3)
Moderate	/ Not Rel.	0		1	(0.6)	2	(1.3)	2	(1.3)	3	(3.9)

ST 10-3: Number (%) of Subjects Reporting Posttherapy Adverse Events by Severity and Drug Relationship

100CT05 16:30 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 Page 1
REPORT AE4_SEV_DR_P

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS

By Severity And Drug Relationship

Body System [1]

Adverse Event

DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo

Adverse Event Severity / Drug Relationship [2]	DVS SR 50 n=149			R 100 mg =155		R 150 mg =157		R 200 mg =151		acebo = 77
ANY ADVERSE EVENT All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related Life Threatening / Not Rel.	51 (34) 69 (44) 19 (12) 26 (12) 32 (23) 8 (13) 11 (7)	4.2) 5.3) 2.8) 7.4) 5.4) L.5) 5.4) 7.4)	92 14 22 12 46 7	(81.3) (21.9) (59.4) (9.0) (14.2) (7.7) (29.7) (4.5) (15.5) (0.6)	13 45 6	(19.1) (8.3) (28.7)	22 13 55 5	(87.4) (21.2) (66.2) (9.3) (14.6) (8.6) (36.4) (33.3) (15.2)	5	(62.3) (37.7) (24.7) (15.6) (6.5) (16.9) (14.3) (5.2) (3.9)
BODY AS A WHOLE All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	20 (1) 14 (! 9 (! 14 (! 7 (! 1 (!	2.9) 9.5) 3.4) 9.4) 6.0) 9.4) 4.7) 0.7) 2.7)	39 12 11 8 23	(39.4) (14.2) (25.2) (7.7) (7.1) (5.2) (14.8) (1.3) (3.2)	7	(42.0) (15.3) (26.8) (9.6) (11.5) (4.5) (10.2) (1.3) (5.1)	43 13	(45.7) (17.2) (28.5) (8.6) (10.6) (8.6) (14.6) (3.3)	20 16 4 10 1 3 3	(26.0) (20.8) (5.2) (13.0) (1.3) (3.9) (3.9) (3.9)
ABDOMINAL PAIN All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	1 (0 1 (0 0 0 1 (0	1.3) 0.7) 0.7) 0.7)	5 3 2 1 1 1 1 0	(3.2) (1.9) (1.3) (0.6) (0.6) (0.6) (0.6) (0.6)	4 1 3 1 1 0 2 0 0	(2.5) (0.6) (1.9) (0.6) (0.6) (1.3)	2 0 2 0 0 0 0 2 0	(1.3) (1.3) (1.3)	1 0 1 0 0 0 0	(1.3) (1.3) (1.3)
ACCIDENTAL INJURY All Severity / Not Rel. All Severity / Related Mild / Not Rel. Moderate / Not Rel. Moderate / Related	3 (2 0 0	2.0) 2.0) L.3)	5 4 1 1 3 1	(3.2) (2.6) (0.6) (0.6) (1.9) (0.6)	1 0 1 0 0	(0.6) (0.6) (0.6)	5 0 2 3 0	(3.3) (3.3) (1.3) (2.0)	4 0 1 1 0	(5.2) (5.2) (1.3) (1.3)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

Page

2

100CT05 16:30 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4 SEV DR P

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS

By Severity And Drug Relationship

Body System [1] Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Severity / Drug Relationship [2] n=149 n=155 n=157 0 0 Severe / Not Rel. (0.7)0 2 (2.6)ALLERGIC REACTION 3 (2.0)(0.6)0 1 (0.7)0 (2.0)/ Not Rel. 1 All Severity (0.6)0 1 0 Mild / Not Rel. (1.3)1 (0.6)0 (0.7)0 (0.7)Moderate / Not Rel. 0 ASTHENIA 9 (6.0)21 (13.5)22 (14.0)19 (12.6)(5.2)All Severity / Not Rel. / Related 3 (2.0)(1.3)5 (3.2)(3.3)(1.3)All Severity (4.0) 19 (12.3)17 (10.8)(9.3)(3.9)(0.7)(0.6)Mild / Not Rel. 1 (1.9)(2.0)(1.3)Mild / Related (2.0)(4.5)(4.5)(5.3)(2.6)Moderate / Not Rel. (1.3)(0.6)(1.3)(1.3)0 5 Moderate / Related (2.0)11 (7.1)(3.8)(3.3)(1.3)Severe / Related (0.6)(2.5)(0.7)BACK PAIN (3.4)(2.6)(2.0)(3.9)/ Not Rel. (2.5)1 (0.7)3 All Severity (3.4)(2.6)(3.9)All Severity / Related (1.3)/ Not Rel. 3 Mild (1.3)(1.9)(1.3)1 (0.7)3 (3.9)/ Related 0 0 Mild 0 1 (0.7)0 Moderate / Not Rel. (2.0)(0.6)(1.3)0 Moderate / Related 0 0 (0.7)0 CHEST PAIN (1.3)(1.9)(1.3)(2.0)0 0 (1.3)All Severity / Not Rel. (1.3)(1.3)0 All Severity / Related Ω 3 (1.9)0 (0.7)0 / Not Rel. (0.7)0 (1.3)0 Mild / Related (1.3)0 (0.7)0 Moderate / Not Rel. (0.7)0 1 (0.6)0 Moderate / Related (0.6)0 Severe / Not Rel. 0 (0.6)0 0 (1.3)CHILLS (4.5)(1.9)6 (4.0)(1.3)3 All Severity / Not Rel. (0.7)(1.9)0 (1.3)All Severity / Related 1 (0.7)(2.6)3 (1.9)6 (4.0)0 / Not Rel. (0.7)(0.6)(1.3)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

Page

3

100CT05 16:30 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR_P

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS

By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug			DVS SR 50 mg n=149		R 100 mg =155	DVS SI		DVS S	R 200 mg	Placebo n= 77	
Mild Moderate Moderate Severe	/ Related / Not Rel. / Related / Related	0 0 0 1	(0.7)	1 2 1 2	(0.6) (1.3) (0.6) (1.3)	2 0 1 0	(1.3)	4 0 1 1	(2.6) (0.7) (0.7)	0 0 0	
CYST All Severity Mild	/ Not Rel. / Not Rel.	1 1 1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
FACE EDEMA All Severity Mild	/ Not Rel. / Not Rel.	1 1 1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0	
FEVER All Severity All Severity Mild Moderate	/ Not Rel. / Related / Related / Not Rel.	1 0 1 1 0	(0.7) (0.7) (0.7)	1 0 0 1	(0.6) (0.6)	0 0 0 0		0 0 0 0		0 0 0 0	
FLU SYNDROME All Severity All Severity Mild Moderate Severe Severe	/ Not Rel. / Related / Not Rel. / Not Rel. / Not Rel. / Related	1 0 1 0 0 0	(0.7) (0.7) (0.7)	1 1 0 1 0 0	(0.6) (0.6) (0.6)	2 2 0 1 0 1	(1.3) (1.3) (0.6) (0.6)	6 4 2 1 3 0 2	(4.0) (2.6) (1.3) (0.7) (2.0) (1.3)	1 0 0 0 0 1	(1.3) (1.3)
GENERALIZED EDEMA All Severity Moderate	/ Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
HEADACHE All Severity All Severity Mild Mild Moderate	/ Not Rel. / Related / Not Rel. / Related / Not Rel.	23 9 14 5 7 3	(6.0) (9.4)	27 5 22 4 8 1	(17.4) (3.2) (14.2) (2.6) (5.2) (0.6)	38 10 28 8 13 2	(24.2) (6.4) (17.8) (5.1) (8.3) (1.3)	9	(23.8) (6.0) (17.9) (4.0) (6.0) (2.0)	6 3 3 2 1 1	(7.8) (3.9) (3.9) (2.6) (1.3) (1.3)

100CT05 16:30 REPORT AE4_SEV_DR_P CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page

4

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationsh:		DVS SR 50 mg n=149		100 mg	DVS SR		DVS SR 200 mg		Placebo n= 77	
Moderate / Related Severe / Not Rel Severe / Related	. 1	(3.4) (0.7) (1.3)	11 0 3	(7.1) (1.9)	11 0 4	(7.0)	16 0 2	(10.6)	2 0 0	(2.6)
INFECTION All Severity / Not Rel Mild / Not Rel Moderate / Not Rel	. 3	(4.7) (4.7) (2.0) (2.7)	1 1 0 1	(0.6) (0.6) (0.6)	4 4 3 1	(2.5) (2.5) (1.9) (0.6)	2 2 1 1		3 3 1 2	(3.9) (3.9) (1.3) (2.6)
LAB TEST ABNORMAL All Severity / Not Rel All Severity / Related Mild / Related Moderate / Not Rel	1 1	(1.3) (0.7) (0.7) (0.7) (0.7)	0 0 0 0		0 0 0 0		0 0 0 0		0 0 0 0	
MALAISE All Severity / Not Rel All Severity / Related Mild / Not Rel Moderate / Not Rel Moderate / Related	. 0 . 0		1 0 1 0 0	(0.6) (0.6) (0.6)	1 1 0 0 1 0	(0.6) (0.6)	2 0 2 0 0 2	(1.3) (1.3) (1.3)	0 0 0 0	
MONILIASIS All Severity / Not Rel Mild / Not Rel			1 1 1	(0.6) (0.6) (0.6)	0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
NECK PAIN All Severity / Not Rel All Severity / Related Mild / Not Rel Mild / Related Moderate / Not Rel Moderate / Related	. 0 0 0 0	(0.7) (0.7)	0 0 0 0 0 0 0		2 1 1 1 0 0	(1.3) (0.6) (0.6) (0.6)	2 1 0 1 1 0	(1.3) (0.7) (0.7) (0.7) (0.7)	0 0 0 0 0	
PAIN All Severity / Not Rel All Severity / Related	. 2 1 1	(1.3) (0.7) (0.7)	4 2 2	(2.6) (1.3) (1.3)	6 5 1	(3.8) (3.2) (0.6)	4 4 0	(2.6) (2.6)	6 6 0	(7.8) (7.8)

100CT05 16:30 REPORT AE4_SEV_DR_P CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page

5

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationship [2]	DVS SR 50 mg n=149	DVS SR 100 mg n=155	Treatment DVS SR 150 mg DVS n=157	SR 200 mg n=151	Placebo n= 77
Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel.	1 (0.7) 0 0 1 (0.7)	1 (0.6) 1 (0.6) 0 1 (0.6) 1 (0.6)	0 1 (0.6) 1 (0.6)	4 (2.6) 0 0 0 0	4 (5.2) 0 1 (1.3) 0 1 (1.3)
PELVIC PAIN All Severity / Not Rel. Mild / Not Rel.	0 0 0	1 (0.6) 1 (0.6) 1 (0.6)	Ō	0 0 0	0 0 0
SARCOIDOSIS All Severity / Not Rel. Moderate / Not Rel.	0 0 0	0 0 0	0	1 (0.7) 1 (0.7) 1 (0.7)	0 0 0
WITHDRAWAL SYNDROME All Severity / Related Mild / Related Severe / Related	0 0 0 0	1 (0.6) 1 (0.6) 1 (0.6)	2 (1.3) 1 (0.6)	0 0 0 0	0 0 0
CARDIOVASCULAR SYSTEM All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related	18 (12.1) 7 (4.7) 11 (7.4) 4 (2.7) 5 (3.4)	28 (18.1) 10 (6.5) 18 (11.6) 6 (3.9) 7 (4.5)		0 (6.6)	6 (7.8) 1 (1.3) 5 (6.5) 0
Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related Life Threatening / Not Rel.	1 (0.7) 6 (4.0) 1 (0.7) 0	1 (0.6) 7 (4.5) 3 (1.9) 4 (2.6)	4 (2.5) 7 (4.5) 3 (1.9) 5 (3.2)	6 (4.0) 8 (5.3) 1 (0.7) 4 (2.6)	1 (1.3) 3 (3.9) 0 2 (2.6)
ARRHYTHMIA All Severity / Related Moderate / Related	0 0 0	0 0 0	Ō	0 0 0	1 (1.3) 1 (1.3) 1 (1.3)
CARDIOVASCULAR DISORDER All Severity / Not Rel. Severe / Not Rel.	0 0 0	0 0 0	1 (0.6)	0 0 0	0 0 0

Page

6

100CT05 16:30 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4 SEV DR P

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Severity / Drug Relationship [2] n=149 n=155 n=157 n=151 n = 770 0 CARDIOVASCULAR PHYSICAL FINDING 1 (0.7)0 0 / Not Rel. All Severity 1 (0.7)0 0 0 0 / Not Rel. Mild 1 (0.7)0 0 0 0 CORONARY ARTERY DISORDER Λ 0 Λ 1 (0.7)0 All Severity / Not Rel. 0 0 1 (0.7)0 / Not Rel. 0 0 0 1 (0.7)0 CORONARY OCCLUSION 0 1 (0.6)0 0 0 / Not Rel. All Severity 0 (0.6)0 0 0 / Not Rel. Severe 0 (0.6)0 0 0 HYPERTENSION (4.7)10 (6.4)(6.6)(2.6)4 (1.3)All Severity / Not Rel. (1.3)(2.6)8 (5.1)0 All Severity / Related 5 (3.4)4 (2.6)(1.3)8 (5.3)2 (2.6)Mild / Not Rel. (1.3)4 (2.6)(3.2)(0.7)0 Mild / Related (2.7)(1.9)(2.0)Ω / Not Rel. (1.9)(0.7)Moderate 3 0 Moderate / Related (0.7)(0.6)(0.6)(3.3)(1.3)1 0 Severe / Related 0 (0.6)1 (1.3)0 MIGRAINE 0 (0.6)(1.3)0 All Severity / Not Rel. 0 0 0 (0.7)0 / Related (0.7)All Severity 0 0 1 (0.6)1 0 / Related 0 (0.7)0 0 Moderate / Not Rel. 0 0 (0.7)0 Severe / Related Ω 0 (0.6)0 0 MYOCARDIAL INFARCT (0.7)0 (0.6)0 0 All Severity / Not Rel. 1 (0.7)0 1 (0.6)0 0 / Not Rel. (0.6)0 0 Life Threatening / Not Rel. 1 (0.7)0 0 0 0 PALPITATION (0.7)(1.3)0 (2.6)(1.3)All Severity / Not Rel. 0 0 (0.7)(1.3)All Severity / Related 1 (0.7)(1.3)0 3 (2.0)0 / Not Rel. 0 (0.7)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

100CT05 16:30 REPORT AE4_SEV_DR_P CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page

7

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationship [2]	DVS SR 50 m n=149	g DVS SR 100 m n=155	Treatment - g DVS SR 150 mg n=157	DVS SR 200 mg n=151	Placebo n= 77	
Mild / Related Moderate / Not Rel. Moderate / Related Severe / Related	0 0 1 0	2 (1.3) 0 0	0 0 0 0	2 (1.3) 0 0 1 (0.7)	0 1 (1.3) 0 0	
PERIPHERAL VASCULAR DISORDER All Severity / Not Rel. Mild / Not Rel.	1 (0.7 1 (0.7 1 (0.7) 0	0 0 0	0 0 0	0 0 0	
TACHYCARDIA All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Related	4 (2.7 1 (0.7 3 (2.0 1 (0.7 3 (2.0) 0) 3 (1.9)) 0	3 (1.9) 1 (0.6) 2 (1.3) 1 (0.6) 1 (0.6) 1 (0.6)	1 (0.7) 0 1 (0.7) 0 1 (0.7) 0 (0.7)	0 0 0 0 0	
VASODILATATION All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	7 (4.7 3 (2.0 4 (2.7 1 (0.7 0 1 (0.7 4 (2.7 1 (0.7	5 (3.2) 10 (6.5) 2 (1.3) 3 (1.9) 1 (0.6) 3 (1.9)	14 (8.9) 5 (3.2) 9 (5.7) 2 (1.3) 1 (0.6) 1 (0.6) 5 (3.2) 2 (1.3) 3 (1.9)	13 (8.6) 7 (4.6) 6 (4.0) 2 (1.3) 0 4 (2.6) 3 (2.0) 1 (0.7) 3 (2.0)	3 (3.9) 1 (1.3) 2 (2.6) 0 1 (1.3) 1 (1.3) 0 1 (1.3)	
DIGESTIVE SYSTEM All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	47 (31.5 17 (11.4 30 (20.1 9 (6.0 15 (10.1 7 (4.7 12 (8.1 1 (0.7 3 (2.0	10 (6.5) 56 (36.1) 5 (3.2) 19 (12.3) 5 (3.2) 23 (14.8) 0	72 (45.9) 12 (7.6) 60 (38.2) 7 (4.5) 31 (19.7) 5 (3.2) 19 (12.1) 0	76 (50.3) 9 (6.0) 67 (44.4) 7 (4.6) 21 (13.9) 2 (1.3) 39 (25.8) 0 7 (4.6)	10 (13.0) 2 (2.6) 8 (10.4) 2 (2.6) 4 (5.2) 0 (3.9) 0 (1.3)	
ABDOMINAL DISTENSION	2 (1.3) 0	0	1 (0.7)	1 (1.3)	

100CT05 16:30 REPORT AE4_SEV_DR_P CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

8

Page

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

ody System [1] Adverse Event Severity / Drug	g Relationship [2]		R 50 mg =149			DVS SF	atment R 150 mg =157	DVS SI	R 200 mg =151	Pla n=	
All Severity All Severity Moderate Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Related	1 1 1 1 0	(0.7) (0.7) (0.7) (0.7)	0 0 0 0		0 0 0 0		1 0 1 0 0	(0.7)	0 1 0 0	(1.3)
ANOREXIA All Severity Mild Moderate Severe	/ Related / Related / Related / Related	1 1 1 0 0	(0.7) (0.7) (0.7)	5 5 2 2 1	(3.2) (3.2) (1.3) (1.3) (0.6)	5 5 2 2 1	(3.2) (3.2) (1.3) (1.3) (0.6)	7 7 2 5 0	(4.6) (4.6) (1.3) (3.3)	0 0 0 0	
CHOLECYSTITIS All Severity Severe	/ Related / Related	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
CHOLELITHIASIS All Severity Severe	/ Related / Related	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
COLITIS All Severity Mild	/ Not Rel. / Not Rel.	1 1 1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0	
CONSTIPATION All Severity All Severity Mild Mild Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Related / Related / Related	6 1 5 1 2 2 1	(4.0) (0.7) (3.4) (0.7) (1.3) (1.3) (0.7)	10 0 10 0 4 5	(6.5) (6.5) (2.6) (3.2) (0.6)	9 2 7 2 3 3	(5.7) (1.3) (4.5) (1.3) (1.9) (1.9) (0.6)	10 3 7 3 2 3 2	(6.6) (2.0) (4.6) (2.0) (1.3) (2.0) (1.3)	2 0 2 0 0 1 1	(2.6) (2.6) (1.3) (1.3)
DIARRHEA All Severity All Severity Mild Mild	/ Not Rel. / Related / Not Rel. / Related	7 4 3 3 2	(4.7) (2.7) (2.0) (2.0) (1.3)	6 3 3 3 1	(3.9) (1.9) (1.9) (1.9) (0.6)	9 2 7 2 4	(5.7) (1.3) (4.5) (1.3) (2.5)	12 3 9 3 3	(7.9) (2.0) (6.0) (2.0) (2.0)	2 0 2 0 1	(2.6) (2.6) (1.3)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.
[2] - Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

100CT05 16:30 REPORT AE4_SEV_DR_P CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

9

Page

Body System [1] Adverse Event Severity / Drug Rela	tionship [2]		. 50 mg :149		 R 100 mg =155	DVS S	atment - R 150 mg =157	DVS S	 R 200 mg =151		 icebo = 77
Moderate / R	ot Rel. elated elated	1 1 0	(0.7) (0.7)	0 2 0	(1.3)	0 2 1	(1.3) (0.6)	0 6 0	(4.0)	0 1 0	(1.3)
All Severity / R Mild / R Moderate / N Moderate / R	ot Rel. elated elated ot Rel. elated elated	9 0 9 8 0 1	(6.0) (6.0) (5.4) (0.7)	16 1 15 8 1 6	(10.3) (0.6) (9.7) (5.2) (0.6) (3.9) (0.6)	16 0 16 14 0 2	(10.2) (10.2) (8.9) (1.3)	19 0 19 12 0 5	(12.6) (12.6) (7.9) (3.3) (1.3)	2 0 2 2 0 0	(2.6) (2.6) (2.6)
All Severity / R Mild / N Mild / R Moderate / N Moderate / R	fot Rel. elated ot Rel. elated ot Rel. elated ot Rel. elated ot Rel.	5 3 2 2 1 1 1 0	(3.4) (2.0) (1.3) (1.3) (0.7) (0.7) (0.7)	6 4 2 2 1 1 1	(3.9) (2.6) (1.3) (1.3) (0.6) (0.6) (0.6) (0.6)	6 3 2 1 1 2 0	(3.8) (1.9) (1.9) (1.3) (0.6) (0.6) (1.3)	3 1 2 0 1 1 1	(2.0) (0.7) (1.3) (0.7) (0.7) (0.7)	0 0 0 0 0 0 0 0 0	
	elated elated	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
All Severity / R Mild / N	ot Rel. elated ot Rel. elated	2 2 0 2 0	(1.3) (1.3) (1.3)	1 0 1 0 1	(0.6) (0.6) (0.6)	0 0 0 0		1 0 1 0 1	(0.7) (0.7) (0.7)	0 0 0 0	
	ot Rel. ot Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
ESOPHAGITIS All Severity / R	elated	1 1	(0.7) (0.7)	0		0		0		0	

100CT05 16:30 REPORT AE4_SEV_DR_P CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

Page 10

dy System [1] Adverse Event Severity / Drug Relationship [DVS S	R 50 mg =149	DVS SF		DVS SI	atment R 150 mg =157	DVS SI	R 200 mg =151		icebo = 77
Mild / Related	1	(0.7)	0		0		0		0	
GAMMA GLUTAMYL TRANSPEPTIDASE IN All Severity / Related Moderate / Related	ICREASED 0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
GASTRITIS All Severity / Not Rel. Mild / Not Rel.	0 0 0		0 0 0		0 0 0		0 0 0		1 1 1	(1.3) (1.3) (1.3)
GASTROENTERITIS All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	1 1 1 0	(0.7) (0.7) (0.7)	0 0 0		2 2 1 1	(1.3) (1.3) (0.6) (0.6)	0 0 0		0 0 0	
GASTROESOPHAGEAL REFLUX DISEASE All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related	1 1 0 0 0 1	(0.7) (0.7)	0 0 0 0 0		0 0 0 0 0 0		4 2 2 2 1 0 1	(2.6) (1.3) (1.3) (1.3) (0.7)	0 0 0 0 0	
GASTROINTESTINAL DISORDER All Severity / Not Rel. All Severity / Related Mild / Related Moderate / Not Rel.	0 0 0 0		1 1 0 0 1	(0.6) (0.6)	2 0 2 2 0	(1.3) (1.3) (1.3)	0 0 0 0		0 0 0 0	
GASTROINTESTINAL PHYSICAL FINDIN All Severity / Related Mild / Related	IG 1 1 1 1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0	
GINGIVITIS All Severity / Not Rel. Moderate / Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	

100CT05 16:30 REPORT AE4_SEV_DR_P

CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS

By Severity And Drug Relationship

Page 11

Body System [1] Adverse Event Severity / Drug Relationship [2]	DVS SR 50 mg n=149		Treatment - DVS SR 150 mg n=157	DVS SR 200 mg n=151	Placebo n= 77
GLOSSITIS All Severity / Not Rel. Mild / Not Rel.	0 0 0	0 0 0	0 0 0	0 0 0	1 (1.3) 1 (1.3) 1 (1.3)
HEPATITIS All Severity / Related Severe / Related	0 0 0	0 0 0	1 (0.6) 1 (0.6) 1 (0.6)	0 0 0	0 0 0
HIATAL HERNIA All Severity / Not Rel. Mild / Not Rel.	1 (0.7) 1 (0.7) 1 (0.7)	0 0 0	0 0 0	0 0 0	0 0 0
ILEUS All Severity / Not Rel. Severe / Not Rel.	0 0 0	0 0 0	1 (0.6) 1 (0.6) 1 (0.6)	0 0 0	0 0 0
INCREASED APPETITE All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Related	2 (1.3) 0 (1.3) 0 0 2 (1.3)	3 (1.9) 0 (1.9) 0 (0.6) 1 (0.6) 1 (0.6)	4 (2.5) 1 (0.6) 3 (1.9) 1 (0.6) 2 (1.3) 0 0 1 (0.6)	3 (2.0) 0 (2.0) 0 (1.3) 0 (0.7)	1 (1.3) 1 (1.3) 0 (1.3) 0 0 1 (1.3)
JAUNDICE All Severity / Related Mild / Related	0 0 0	0 0 0	1 (0.6) 1 (0.6) 1 (0.6)	0 0 0	0 0 0
LIVER FUNCTION TESTS ABNORMAL All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Severe / Related	3 (2.0) 1 (0.7) 2 (1.3) 1 (0.7) 1 (0.7) 1 (0.7)	1 (0.6) 0 (0.6) 0 (0.6) 0 (0.6)	1 (0.6) 0 1 (0.6) 0 1 (0.6) 0 (0.6)	0 0 0 0 0	0 0 0 0 0
NAUSEA	22 (14.8)	39 (25.2)	40 (25.5)	53 (35.1)	1 (1.3)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.
[2] - Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

100CT05 16:30 REPORT AE4_SEV_DR_P

CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS

By Severity And Drug Relationship

Page 12

Body System [1] Adverse Event Severity / Drug Relationship [2]	DVS SR	 R 50 mg =149	DVS SI		DVS SI	atment - R 150 mg =157	DVS S	 R 200 mg =151	Pla n=	 icebo : 77
All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	7 15 4 3 3 11 0	(4.7) (10.1) (2.7) (2.0) (2.0) (7.4) (0.7)	2 12 3 11 0	(3.2) (21.9) (1.3) (7.7) (1.9) (7.1)	3	(3.8) (21.7) (1.9) (10.2) (1.3) (8.9) (0.6) (2.5)	3 18 0	(2.0) (33.1) (2.0) (11.9) (19.2) (2.0)	0 1 0 1 0 0 0	(1.3)
NAUSEA AND VOMITING All Severity / Related Moderate / Related Severe / Related	0 0 0 0		1 1 0 1	(0.6) (0.6)	0 0 0		1 1 1 0	(0.7) (0.7) (0.7)	0 0 0	
PANCREAS DISORDER All Severity / Not Rel. Severe / Not Rel.	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
PANCREATITIS All Severity / Related Severe / Related	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
PEPTIC ULCER All Severity / Not Rel. Moderate / Not Rel.	1 1 1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0	
PERIODONTAL ABSCESS All Severity / Not Rel. Mild / Not Rel.	1 1 1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0	
RECTAL DISORDER All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel. Severe / Not Rel.	1 1 0 0	(0.7) (0.7)	0 0 0 0		2 2 1 1 0		0 0 0 0		0 0 0 0	
RECTAL HEMORRHAGE	0		0		1	(0.6)	0		0	

100CT05 16:30 REPORT AE4_SEV_DR_P CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 13

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug F	Relationship [2]		 50 mg 149		R 100 mg	DVS SF	tment R 150 mg =157	DVS S	 R 200 mg =151	Pla n=	
All Severity Moderate	/ Not Rel. / Not Rel.	0		0		1	(0.6) (0.6)	0		0	
	/ Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
STOOLS ABNORMAL All Severity Mild	/ Related / Related	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
	/ Not Rel. / Not Rel.	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related / Related	6 1 5 1 4 0 1	(4.0) (0.7) (3.4) (0.7) (2.7)	8 3 5 0 0 3 3 2	(5.2) (1.9) (3.2) (1.9) (1.9) (1.3)	5 0 5 0 0 0 4 1	(3.2) (3.2) (2.5) (0.6)	19 2 17 0 4 2 12	(12.6) (1.3) (11.3) (2.6) (1.3) (7.9) (0.7)	0 0 0 0 0 0 0 0 0	
	/ Not Rel. / Related / Not Rel. / Not Rel. / Related	3 2 1 2 0 1	(2.0) (1.3) (0.7) (1.3) (0.7)	2 2 0 2 0 0	(1.3) (1.3) (1.3)	2 2 0 1 1 0	(1.3) (1.3) (0.6) (0.6)	2 2 0 1 1 0	(1.3) (1.3) (0.7) (0.7)	2 2 0 2 0	(2.6) (2.6) (2.6)
DIABETES MELLITUS All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
GOITER All Severity	/ Not Rel.	1 1	(0.7) (0.7)	1 1	(0.6) (0.6)	0		0		1 1	(1.3) (1.3)

100CT05 16:30 REPORT AE4_SEV_DR_P CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 14

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug	Relationship [2]		R 50 mg =149		 R 100 mg =155	DVS SE	atment R 150 mg =157		R 200 mg =151		acebo = 77
Mild	/ Not Rel.	1	(0.7)	1	(0.6)	0		0		1	(1.3)
HYPERTHYROIDISM All Severity Moderate	/ Not Rel. / Not Rel.	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
HYPOTHYROIDISM All Severity All Severity Mild Moderate	/ Not Rel. / Related / Not Rel. / Related	1 0 1 0 1	(0.7) (0.7) (0.7)	1 1 0 1 0	(0.6) (0.6) (0.6)	0 0 0 0		0 0 0 0		0 0 0 0	
PARATHYROID DISOR All Severity Mild	DER / Not Rel. / Not Rel.	1 1 1	(0.7) (0.7) (0.7)	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
THYROID DISORDER All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		1 1 0 1	(0.7) (0.7) (0.7)	1 1 1 0	(1.3) (1.3) (1.3)
HEMIC AND LYMPHATIC All Severity All Severity Mild Mild Moderate Moderate	/ Not Rel.	1 0 1 0 0	(0.7) (0.7) (0.7)	7 3 4 3 3 0 1	(4.5) (1.9) (2.6) (1.9) (1.9) (0.6)	6 4 2 4 1 0	(3.8) (2.5) (1.3) (2.5) (0.6)	3 3 0 2 0 1	(2.0) (2.0) (1.3) (0.7)	1 0 1 0 0 0	(1.3) (1.3) (1.3)
ANEMIA All Severity Mild	/ Not Rel. / Not Rel.	1 1 1	(0.7) (0.7) (0.7)	1 1 1	(0.6) (0.6) (0.6)	2 2 2	(1.3) (1.3) (1.3)	0 0 0		0 0 0	
ECCHYMOSIS All Severity All Severity Mild	/ Not Rel. / Related / Not Rel.	0 0 0		3 0 3 0	(1.9) (1.9)	3 2 1 2	(1.9) (1.3) (0.6) (1.3)	2 2 0 1	(1.3) (1.3) (0.7)	0 0 0	

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.
[2] - Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

CONFIDENTIAL Wyeth 471

Page 15

100CT05 16:30 REPORT AE4_SEV_DR_P CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug	Relationship [2]	DVS SR 50	 0 mg I 9	OVS SE	R 100 mg =155	DVS SE		DVS S	R 200 mg	Pla n=	 icebo = 77
Mild Moderate Moderate	/ Related / Not Rel. / Related	0 0 0		2 0 1	(1.3)	1 0 0	(0.6)	0 1 0	(0.7)	0 0 0	
LEUKOCYTOSIS All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
LEUKOPENIA All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		0 0 0		1 1 1	(1.3) (1.3) (1.3)
NEUTROPENIA All Severity All Severity Mild Mild	/ Not Rel. / Related / Not Rel. / Related	0 0 0 0		2 1 1 1	(1.3) (0.6) (0.6) (0.6) (0.6)	0 0 0 0		0 0 0 0		0 0 0 0	
THROMBOCYTHEMIA All Severity Moderate	/ Related / Related	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
THROMBOCYTOPENIA All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
METABOLIC AND NUTRI All Severity All Severity Mild Mild Moderate Moderate Severe Severe	/ Not Rel.	8 (1 4 (2 3 (2 3 (2 4 (2	0.1) 4.7) 5.4) 2.7) 2.0) 2.0) 2.0) 2.7)	21 9 12 8 3 1 8 0	(13.5) (5.8) (7.7) (5.2) (1.9) (0.6) (5.2) (0.6)	26 12 14 8 8 4 5 0	(16.6) (7.6) (8.9) (5.1) (5.1) (2.5) (3.2) (0.6)	31 17 14 8 3 7 10 2	(20.5) (11.3) (9.3) (5.3) (2.0) (4.6) (6.6) (1.3) (0.7)	7 7 0 1 0 6 0 0	(9.1) (9.1) (1.3) (7.8)
ALKALINE PHOSPHAT	ASE INCREASED	0		0		1	(0.6)	1	(0.7)	0	

100CT05 16:30 REPORT AE4_SEV_DR_P CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

Page 16

Body System [1]						Trea	atment -				
Adverse Event Severity / Drug	Relationship [2]		R 50 mg =149		R 100 mg =155		R 150 mg =157		R 200 mg =151		acebo = 77
All Severity All Severity Mild Moderate	/ Not Rel. / Related / Related / Not Rel.	0 0 0 0		0 0 0 0		0 1 1 0	(0.6) (0.6)	1 0 0 1	(0.7)	0 0 0	
GLUCOSE TOLERANCE All Severity Mild	DECREASED / Not Rel. / Not Rel.	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
HYPERCHOLESTEREMI All Severity All Severity Mild Mild Moderate Moderate	/A / Not Rel. / Related	4 2 2 1 1 1	(2.7) (1.3) (1.3) (0.7) (0.7) (0.7) (0.7)	7 2 5 2 2 0 3	(4.5) (1.3) (3.2) (1.3) (1.3)	4 3 1 2 1 1 0	(2.5) (1.9) (0.6) (1.3) (0.6) (0.6)	12 6 6 2 2 4 4	(7.9) (4.0) (4.0) (1.3) (1.3) (2.6) (2.6)	5 5 0 0 5 0	(6.5) (6.5)
HYPERGLYCEMIA All Severity Mild	/ Not Rel. / Not Rel.	1 1 1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0	
HYPERKALEMIA All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
HYPERLIPEMIA All Severity All Severity Mild Mild Moderate Moderate Severe Severe	/ Not Rel. / Related	7 3 4 1 0 2 3 0	(4.7) (2.0) (2.7) (0.7) (1.3) (2.0) (0.7)	3 1 2 1 0 0 1	(1.9) (0.6) (1.3) (0.6) (0.6)	5 3 2 3 1 0 1 0	(3.2) (1.9) (1.3) (1.9) (0.6)	9 5 4 3 0 0 3 2 1	(6.0) (3.3) (2.6) (2.0) (2.0) (1.3) (0.7)	0 0 0 0 0 0 0 0 0	
PERIPHERAL EDEMA All Severity	/ Not Rel.	1 1	(0.7) (0.7)	3	(1.9) (1.9)	2 1	(1.3) (0.6)	4 3	(2.6) (2.0)	1 1	(1.3) (1.3)

Page 17

100CT05 16:30 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR_P

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Dru	g Relationship [2]		R 50 mg =149		R 100 mg =155	DVS S	atment - R 150 mg =157		 R 200 mg =151		 acebo = 77
All Severity Mild Mild Moderate	/ Related / Not Rel. / Related / Not Rel.	0 0 0 0 1	(0.7)	0 2 0 1	(1.3)	1 1 1 0	(0.6) (0.6) (0.6)	1 1 1 2	(0.7) (0.7) (0.7) (1.3)	0 0 0 1	(1.3)
SGOT INCREASED All Severity Moderate Severe	/ Related / Related / Related	0 0 0		1 1 1 0	(0.6) (0.6) (0.6)	1 1 0 1	(0.6) (0.6) (0.6)	1 1 1 0	(0.7) (0.7) (0.7)	0 0 0	
SGPT INCREASED All Severity Moderate Severe	/ Related / Related / Related	0 0 0		1 1 1 0	(0.6) (0.6) (0.6)	1 1 0 1	(0.6) (0.6)	1 1 1 0	(0.7) (0.7) (0.7)	0 0 0	
THIRST All Severity All Severity Mild Moderate	/ Not Rel. / Related / Not Rel. / Related	0 0 0 0		1 0 1 0	(0.6) (0.6) (0.6)	0 0 0 0		1 0 1 0 1	(0.7) (0.7) (0.7)	0 0 0 0	
WEIGHT GAIN All Severity All Severity Mild Mild Moderate Moderate	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related	3 1 2 1 2 0 0	(2.0) (0.7) (1.3) (0.7) (1.3)	7 3 4 3 1 0 3	(4.5) (1.9) (2.6) (1.9) (0.6)	11 3 8 1 5 2 3	(7.0) (1.9) (5.1) (0.6) (3.2) (1.3) (1.9)	3 1 2 1 1 0 1	(2.0) (0.7) (1.3) (0.7) (0.7)	1 0 1 0 0 0	(1.3) (1.3) (1.3)
WEIGHT LOSS All Severity All Severity Moderate Moderate	/ Not Rel. / Related / Not Rel. / Related	0 0 0 0		0 0 0 0		2 1 1 1	(1.3) (0.6) (0.6) (0.6) (0.6)	0 0 0 0		0 0 0 0	
MUSCULOSKELETAL SY All Severity	STEM / Not Rel.	21 19	(14.1) (12.8)	20 15	(12.9) (9.7)	20 17	(12.7) (10.8)	16 14	(10.6) (9.3)	8	(10.4) (10.4)

100CT05 16:30 REPORT AE4_SEV_DR_P CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 18

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

ody System [1] Adverse Event Severity / Drug Re	lationship [2]	DVS SI	R 50 mg =149	DVS SI	R 100 mg =155	DVS SE	atment R 150 mg =157	DVS SI	 R 200 mg =151		acebo 77
Mild / Mild / Moderate / Moderate / Severe /	Related Not Rel. Related Not Rel. Related Not Rel. Related	2 12 1 5 0 2	(1.3) (8.1) (0.7) (3.4) (1.3) (0.7)	5 5 3 9 2 1	(3.2) (3.2) (1.9) (5.8) (1.3) (0.6)	3 9 1 6 1 2	(1.9) (5.7) (0.6) (3.8) (0.6) (1.3) (0.6)	2 9 1 5 1 0	(1.3) (6.0) (0.7) (3.3) (0.7)	0 4 0 4 0 0	(5.2) (5.2)
All Severity / Mild / Moderate / Moderate / Severe /	Not Rel. Related Not Rel. Not Rel. Related Not Rel. Related	9 8 1 3 3 0 2	(6.0) (5.4) (0.7) (2.0) (2.0) (1.3) (0.7)	8 8 0 4 3 0 1	(5.2) (5.2) (2.6) (1.9) (0.6)	7 6 1 3 2 1 1 0	(4.5) (3.8) (0.6) (1.9) (1.3) (0.6) (0.6)	5 4 1 2 2 1 0	(3.3) (2.6) (0.7) (1.3) (1.3) (0.7)	1 0 0 1 0 0	(1.3) (1.3)
Mild /	Not Rel. Not Rel. Not Rel.	2 2 2 0	(1.3) (1.3) (1.3)	2 2 0 2	(1.3) (1.3) (1.3)	2 2 1 1	(1.3) (1.3) (0.6) (0.6)	3 3 2 1	(2.0) (2.0) (1.3) (0.7)	2 2 0 2	(2.6) (2.6)
Mild /	Not Rel. Not Rel. Not Rel.	0 0 0		0 0 0		2 2 1 1	(1.3) (1.3) (0.6) (0.6)	0 0 0		0 0 0	
Mild /	Not Rel. Not Rel. Not Rel.	0 0 0		1 1 0 1	(0.6) (0.6)	1 1 1 0	(0.6) (0.6) (0.6)	1 1 1 0	(0.7) (0.7) (0.7)	0 0 0	
	Not Rel. Not Rel.	1 1 1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0	
GENERALIZED SPASM		1	(0.7)	0		0		0		0	

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.
[2] - Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

100CT05 16:30 REPORT AE4_SEV_DR_P CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 19

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relation		2 50 mg 149		 100 mg 155				 . 200 mg 151		 acebo : 77
All Severity / Not I		(0.7) (0.7)	0		0		0		0	
JOINT DISORDER All Severity / Not I All Severity / Relat Mild / Not I Mild / Relat Moderate / Not I Moderate / Relat	ted 1 Rel. 1 ted 1 Rel. 0	(1.3) (0.7) (0.7) (0.7) (0.7)	1 0 0 0 0 1	(0.6) (0.6)	1 0 1 0 0 0	(0.6) (0.6) (0.6)	3 2 1 2 0 0	(2.0) (1.3) (0.7) (1.3)	0 0 0 0 0	
LEG CRAMPS All Severity / Not I All Severity / Relat Mild / Not I Mild / Relat Moderate / Not I Moderate / Relat Severe / Relat	ced 0 Rel. 1 ced 0 Rel. 0 Rel. 0 Ced 0	(0.7) (0.7) (0.7)	1 0 1 0 0 0 0 1	(0.6) (0.6)	4 2 2 1 1 1 0 1	(2.5) (1.3) (1.3) (0.6) (0.6) (0.6)	2 1 1 1 0 0	(1.3) (0.7) (0.7) (0.7) (0.7)	1 0 1 0 0 0 0	(1.3) (1.3) (1.3)
MUSCLE CRAMP All Severity / Not I Mild / Not I			0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
MUSCLE SPASMS All Severity / Not I All Severity / Relat Mild / Not I Mild / Relat	ced 0 Rel. 0		3 2 1 2 1	(1.9) (1.3) (0.6) (1.3) (0.6)	0 0 0 0		0 0 0 0		0 0 0 0	
MUSCULOSKELETAL STIFFNESS All Severity / Not I All Severity / Relat Mild / Not I Moderate / Not I Moderate / Relat	ted 1 Rel. 0 Rel. 0	(0.7) (0.7) (0.7)	0 0 0 0		3 2 1 1 1	(1.9) (1.3) (0.6) (0.6) (0.6) (0.6)	1 0 0 1 0	(0.7) (0.7) (0.7)	0 0 0 0 0	

100CT05 16:30 REPORT AE4 SEV DR P CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page

20

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] ------ Treatment ------Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Severity / Drug Relationship [2] n=149 n=155 n=157 n = 77MYALGIA (2.0)(1.9)(1.3)(2.0)(2.6)(2.0)2 (2.0)All Severity / Not Rel. 3 (1.3)2 (1.3)3 2 (2.6)All Severity / Related 0 (0.6)0 / Not Rel. 0 Mild (2.0)1 (0.6)2 (1.3)(2.6)Mild / Related Λ (0.6)0 \cap Moderate / Not Rel. 0 (1.3)1 (0.6)1 (0.7)0 MYASTHENIA 0 3 (1.9)1 (0.6)0 0 All Severity / Related 0 3 (1.9)1 (0.6)0 0 Mild / Related 0 (1.3)0 0 0 Moderate / Related 0 (0.6)0 0 0 Severe / Related (0.6)0 0 OSTEOPOROSIS 2 0 0 2 (1.3)1 (0.6)(2.6)All Severity / Not Rel. / Not Rel. (1.3)1 (0.6)0 0 (2.6)Mild (0.7)(0.6)0 0 (2.6)0 Moderate / Not Rel. 1 (0.7)0 0 0 RHEUMATOID ARTHRITIS 0 0 (0.6)0 0 0 All Severity / Not Rel. 0 1 (0.6)0 0 Severe / Not Rel. 0 0 1 (0.6)0 0 TENOSYNOVITIS (1.3)0 0 (0.7)(1.3)/ Not Rel. (1.3)All Severity 0 0 1 (0.7)1 (1.3)/ Not Rel. (0.7)0 Moderate / Not Rel. (0.7)0 (0.7)(1.3)NERVOUS SYSTEM 68 (45.6)(50.3)85 (54.1)(58.3)12 (15.6)All Severity / Not Rel. 18 (12.1)10 (6.5)9 (5.7)17 (11.3)(5.2)All Severity / Related 50 (33.6)68 (43.9)76 (48.4)71 (47.0)8 (10.4)(2.6)/ Not Rel. (4.0)(3.2)(7.9)(5.2)32 Mild / Related 18 (12.1) 18 (11.6)(20.4)25 (16.6)3 (3.9)Moderate / Not Rel. 9 (6.0)6 (3.9)3 (1.9)(2.6)Ω Moderate / Related 25 (16.8) 34 (21.9)29 (18.5)35 (23.2)(6.5)Severe / Not Rel. (2.0)(0.6)(0.7)0 / Related Severe (4.7)16 (10.3)15 (9.6)11 (7.3)0

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

100CT05 16:30 REPORT AE4_SEV_DR_P CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 21

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

dy System [1] Adverse Event Severity / Drug Relationship				 R 100 mg =155	DVS SE	atment R 150 mg =157		 R 200 mg =151		icebo 77
ABNORMAL DREAMS All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Related Severe / Related	0 5 0 4	(3.4) (3.4) (2.7) (0.7)	5 1 4 1 1 2 1	(3.2) (0.6) (2.6) (0.6) (0.6) (1.3) (0.6)	8 0 8 0 5 2	(5.1) (5.1) (3.2) (1.3) (0.6)	6 1 5 1 1 4 0	(4.0) (0.7) (3.3) (0.7) (0.7) (2.6)	1 0 1 0 1 0	(1.3) (1.3) (1.3)
ABNORMAL/CHANGED BEHAVIOR All Severity / Related Mild / Related	1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0	
AGITATION All Severity / Not Rel. All Severity / Related Mild / Not Rel. Moderate / Related Severe / Related	0 1 0 0	(0.7) (0.7) (0.7)	1 0 1 0 0	(0.6) (0.6) (0.6)	2 0 2 0 2 0	(1.3) (1.3) (1.3)	2 1 1 1 1 0	(1.3) (0.7) (0.7) (0.7) (0.7)	0 0 0 0	
ANXIETY All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	4 5 2 1 0 3 2	(6.0) (2.7) (3.4) (1.3) (0.7) (2.0) (1.3) (0.7)	9 1 8 1 2 0 4 0 2	(5.8) (0.6) (5.2) (0.6) (1.3) (2.6) (1.3)	10 3 7 2 4 1 3 0	(6.4) (1.9) (4.5) (1.3) (2.5) (0.6) (1.9)	10 4 6 3 3 1 3 0	(6.6) (2.6) (4.0) (2.0) (2.0) (0.7) (2.0)	1 0 1 0 0 0 0 1	(1.3) (1.3) (1.3)
APATHY All Severity / Related Moderate / Related	1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0	
ATAXIA All Severity / Not Rel. All Severity / Related Moderate / Not Rel.	0 0 0 0		4 1 3 1	(2.6) (0.6) (1.9) (0.6)	0 0 0		1 0 1 0	(0.7) (0.7)	0 0 0	

100CT05 16:30 REPORT AE4_SEV_DR_P CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

Page

22

Body System [1]	Treatment									
Adverse Event Severity / Drug Relationship [2]	DVS SR 50 mg n=149		DVS SR 150 mg n=157	DVS SR 200 mg n=151	Placebo n= 77					
Moderate / Related Severe / Related	0 0	2 (1.3) 1 (0.6)	0	1 (0.7)	0					
CARPAL TUNNEL SYNDROME All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel.	0 0 0 0 0	1 (0.6) 1 (0.6) 0 0 0 1 (0.6)	0 0 0 0 0	2 (1.3) 2 (1.3) 0 1 (0.7) 1 (0.7)	1 (1.3) 0 (1.3) 0 (1.3) 0 (1.3)					
CIRCUMORAL PARESTHESIA All Severity / Related Mild / Related	0 0 0	0 0 0	1 (0.6) 1 (0.6) 1 (0.6)	1 (0.7) 1 (0.7) 1 (0.7)	0 0 0					
CNS ANOMALY All Severity / Not Rel. Mild / Not Rel.	1 (0.7) 1 (0.7) 1 (0.7)	0 0 0	0 0 0	0 0 0	0 0 0					
CONFUSION All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Related	1 (0.7) 1 (0.7) 0 0 0 1 (0.7)	3 (1.9) 0 (1.9) 0 (0.6) 1 (0.6) 1 (0.6)	8 (5.1) 1 (0.6) 7 (4.5) 1 (0.6) 1 (0.6) 0 4 (2.5) 2 (1.3)	3 (2.0) 3 (2.0) 0 (0.7) 1 (0.7) 1 (0.7)	0 0 0 0 0 0					
DEPERSONALIZATION All Severity / Related Mild / Related Severe / Related	0 0 0	1 (0.6) 1 (0.6) 0 (0.6)	0 0 0 0	1 (0.7) 1 (0.7) 1 (0.7) 0	0 0 0 0					
DEPRESSION All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related	5 (3.4) 3 (2.0) 2 (1.3) 0 (1.3)	4 (2.6) 1 (0.6) 3 (1.9) 0	6 (3.8) 0 (3.8) 6 (3.8) 0 (1.9)	5 (3.3) 2 (1.3) 3 (2.0) 1 (0.7) 1 (0.7)	1 (1.3) 1 (1.3) 0 0					

Page 23

DVS SR Protocol 3151A2-315-US CSR-60178

100CT05 16:30 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR_P

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

ody System [1] Adverse Event Severity / Drug	Relationship [2]		DVS SR 50 mg n=149		DVS SR 100 mg n=155		Treatment - DVS SR 150 mg n=157		R 200 mg =151	Placebo n= 77	
Moderate Moderate Severe Severe	/ Not Rel. / Related / Not Rel. / Related	2 0 1 0	(1.3)	1 2 0 1	(0.6) (1.3) (0.6)	0 2 0 1	(1.3)	1 1 0 1	(0.7) (0.7) (0.7)	1 0 0 0	(1.3)
DIZZINESS All Severity All Severity Mild Mild Moderate Moderate Severe Severe	/ Not Rel. / Related	24 6 18 1 7 5 9 0 2	(16.1) (4.0) (12.1) (0.7) (4.7) (3.4) (6.0)	36 6 30 2 13 4 11 0 6	(23.2) (3.9) (19.4) (1.3) (8.4) (2.6) (7.1) (3.9)	34 6 28 2 15 3 9 1	(21.7) (3.8) (17.8) (1.3) (9.6) (1.9) (5.7) (0.6) (2.5)	31 4 27 4 12 0 14 0	(20.5) (2.6) (17.9) (2.6) (7.9) (9.3) (0.7)	1 0 1 0 1 0 0 0	(1.3) (1.3) (1.3)
EMOTIONAL LABILIT All Severity All Severity Mild Mild Moderate Moderate Severe Severe	/Y / Not Rel. / Related	9 3 6 1 2 1 3 1	(6.0) (2.0) (4.0) (0.7) (1.3) (0.7) (2.0) (0.7) (0.7)	16 1 15 0 1 1 10 0 4	(10.3) (0.6) (9.7) (0.6) (0.6) (6.5) (2.6)	9 1 8 0 2 1 5 0 1	(5.7) (0.6) (5.1) (1.3) (0.6) (3.2) (0.6)	10 5 5 3 1 2 4 0	(6.6) (3.3) (3.3) (2.0) (0.7) (1.3) (2.6)	0 0 0 0 0 0 0 0 0 0	
ENERGY INCREASED All Severity Moderate	/ Related / Related	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
EUPHORIA All Severity Severe	/ Related / Related	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
HALLUCINATIONS All Severity Mild	/ Related / Related	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	

100CT05 16:30 REPORT AE4_SEV_DR_P CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

Page 24

Body System [1] Adverse Event Severity / Drug Relationship [2]		DVS SR 50 mg n=149		DVS SR 100 mg n=155		Treatment - g DVS SR 150 mg n=157		DVS SR 200 mg n=151			 icebo = 77
HOSTILITY All Severity All Severity Mild Mild Moderate Moderate Severe Severe	/ Not Rel. / Related	11 0 11 0 2 0 7 0 2	(7.4) (7.4) (1.3) (4.7) (1.3)	5 1 4 0 2 0 2 1 0	(3.2) (0.6) (2.6) (1.3) (1.3) (0.6)	8 2 6 0 3 2 2 0	(5.1) (1.3) (3.8) (1.9) (1.3) (1.3) (0.6)	3 1 2 0 1 0 1 1	(2.0) (0.7) (1.3) (0.7) (0.7) (0.7)	2 1 1 1 1 0 0 0	(2.6) (1.3) (1.3) (1.3) (1.3)
HYPERESTHESIA All Severity Moderate	/ Related / Related	1 1 1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0	
HYPERKINESIA All Severity All Severity Mild Moderate	/ Not Rel. / Related / Not Rel. / Related	1 1 0 1 0	(0.7) (0.7) (0.7)	0 0 0 0		1 0 1 0	(0.6) (0.6) (0.6)	0 0 0 0		0 0 0 0	
HYPERTONIA All Severity Mild Moderate	/ Related / Related / Related	1 1 0 1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		2 2 2 0	(1.3) (1.3) (1.3)	0 0 0	
HYPESTHESIA All Severity All Severity Mild Mild Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related	2 1 1 1 1 0 0	(1.3) (0.7) (0.7) (0.7) (0.7)	1 0 1 0 0 0	(0.6) (0.6)	0 0 0 0 0		2 2 0 1 0	(1.3) (1.3) (0.7) (0.7)	0 0 0 0 0	
HYPOKINESIA All Severity Moderate	/ Related / Related	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	

Page 25

100CT05 16:30 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR_P

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

ody System [1] Adverse Event		DVS S	R 50 mg	DVS S	R 100 mg	DVS S	atment - R 150 mg	DVS S	R 200 mg	 Pla	acebo
Severity / Drug	Relationship [2]	n	=149	n	=155	n	=157	n	=151	n=	= 77
INSOMNIA All Severity All Severity Mild Mild Moderate Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related / Related	24 5 19 3 5 2 10 4	(2.0) (3.4) (1.3)	22 6 16 5 5 1 8	(14.2) (3.9) (10.3) (3.2) (3.2) (0.6) (5.2) (1.9)	31 6 25 6 9 0 12 4	(19.7) (3.8) (15.9) (3.8) (5.7) (7.6) (2.5)	27 5 22 2 11 3 9	(17.9) (3.3) (14.6) (1.3) (7.3) (2.0) (6.0) (1.3)	6 2 4 2 1 0 3	(7.8) (2.6) (5.2) (2.6) (1.3) (3.9)
LIBIDO DECREASED All Severity All Severity Mild Mild Moderate Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related / Related / Related	2 0 2 0 1 0 1	(1.3) (1.3) (0.7) (0.7)	5 1 4 0 2 1 2	(3.2) (0.6) (2.6) (1.3) (0.6) (1.3)	4 1 3 0 2 1 1 0	(2.5) (0.6) (1.9) (1.3) (0.6) (0.6)	7 0 7 0 2 0 4 1	(4.6) (4.6) (1.3) (2.6) (0.7)	1 0 1 0 0 0	(1.3) (1.3) (1.3)
	/ Not Rel. / Related / Not Rel. / Related / Related	1 0 1 0 1	(0.7) (0.7) (0.7)	1 0 1 0 1	(0.6) (0.6) (0.6)	3 0 3 0 2 1	(1.9) (1.9) (1.3) (0.6)	2 1 1 1 0 1	(1.3) (0.7) (0.7) (0.7)	0 0 0 0	
MOTION SICKNESS All Severity Moderate	/ Related / Related	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
MOVEMENT DISORDER All Severity Moderate	/ Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
NERVE COMPRESSION All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	

Page 26

100CT05 16:30 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR_P

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

Ody System [1] Adverse Event Severity / Drug Relationship [2]		DVS SR 50 mg n=149				Treatment DVS SR 150 mg n=157		DVS SR 200 mg n=151		Placebo n= 77	
NERVOUSNESS All Severity All Severity Mild Mild Moderate Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related / Related	9 0 9 0 4 0 5	(6.0) (6.0) (2.7) (3.4)	6 0 6 0 3 0 3	(3.9) (3.9) (1.9) (1.9)	13 2 11 0 3 2 7	(8.3) (1.3) (7.0) (1.9) (1.3) (4.5) (0.6)	14 2 12 1 5 1 6	(9.3) (1.3) (7.9) (0.7) (3.3) (0.7) (4.0) (0.7)	1 0 1 0 0 0 0	(1.3) (1.3) (1.3)
NEUROSIS All Severity Moderate	/ Related / Related	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
PARESTHESIA All Severity All Severity Mild Mild Moderate Moderate Severe Severe	/ Not Rel. / Related	1 0 1 0 1 0 0 0	(0.7) (0.7) (0.7)	10 3 7 1 3 1 2 1 2	(6.5) (1.9) (4.5) (0.6) (1.9) (0.6) (1.3) (0.6) (1.3)	3 0 3 0 1 0 1 0	(1.9) (1.9) (0.6) (0.6) (0.6)	2 2 0 2 0 0 0 0	(1.3) (1.3) (1.3)	0 0 0 0 0 0 0 0 0 0	
RESTLESS LEGS SYN All Severity Mild Moderate	NDROME / Related / Related / Related	0 0 0		2 2 1 1	(1.3) (1.3) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
SLEEP DISORDER All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
SOMNOLENCE All Severity All Severity Mild Mild	/ Not Rel. / Related / Not Rel. / Related	4 1 3 1 2	(2.7) (0.7) (2.0) (0.7) (1.3)	12 1 11 1 4	(7.7) (0.6) (7.1) (0.6) (2.6)	12 2 10 1 4	(7.6) (1.3) (6.4) (0.6) (2.5)	20 2 18 2 7	(13.2) (1.3) (11.9) (1.3) (4.6)	0 0 0 0	

100CT05 16:30 REPORT AE4_SEV_DR_P

CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS

By Severity And Drug Relationship

Page 27

Body System [1] Adverse Event Severity / Drug Relationship [2]		DVS SR 50 mg n=149		DVS SR 100 mg		DVS SR	tment 150 mg :157	DVS SI		Placebo n= 77
Moderate /	/ Not Rel. / Related / Related	0 1 0	(0.7)	0 5 2	(3.2) (1.3)	1 4 2	(0.6) (2.5) (1.3)	0 7 4		0 0 0
	/ Related / Related	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0
All Severity / Severe /	/ Not Rel. / Related / Not Rel. / Related	1 1 0 1 0	(0.7) (0.7) (0.7)	1 0 1 0 1	(0.6) (0.6) (0.6)	0 0 0 0		0 0 0 0		0 0 0 0
All Severity / Mild / Moderate /	/ Not Rel. / Related / Related / Not Rel. / Related / Related	3 0 3 0 0 3 0	(2.0) (2.0) (2.0)	5 1 4 1 1 3 0	(3.2) (0.6) (2.6) (0.6) (0.6) (1.9)	0	(5.1) (5.1) (1.3) (1.9) (1.9)	5 0 5 0 4 1		0 0 0 0 0 0
Mild / Moderate /	/ Related / Related / Related / Related	1 1 0 0	(0.7) (0.7) (0.7)	4 4 1 3 0	(2.6) (2.6) (0.6) (1.9)	1 1 0 0	(0.6) (0.6) (0.6)	7 7 3 3 1	(2.0)	0 0 0 0
Mild / Moderate /	/ Related / Related / Related / Related	0 0 0 0		1 1 0 1 0	(0.6) (0.6) (0.6)	2 2 1 0 1	(1.3) (1.3) (0.6) (0.6)	3 3 2 1 0	(2.0) (2.0) (1.3) (0.7)	0 0 0 0
	/ Not Rel. / Related	1 0 1	(0.7) (0.7)	0 0 0		1 0 1	(0.6) (0.6)	2 1 1	(1.3) (0.7) (0.7)	0 0 0

100CT05 16:30 REPORT AE4_SEV_DR_P CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 28

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug	Relationship [2]		 R 50 mg =149		R 100 mg =155	DVS S	atment - R 150 mg =157		 R 200 mg =151		acebo = 77
Mild Mild Moderate	/ Not Rel. / Related / Related	0 0 1	(0.7)	0 0 0		0 1 0	(0.6)	1 1 0	(0.7) (0.7)	0 0 0	
VERTIGO All Severity All Severity Mild Mild Moderate Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related / Related / Related	4 0 4 0 3 0 1 0	(2.7) (2.7) (2.0) (0.7)	1 0 0 0 1 0	(0.6) (0.6)	3 0 3 0 1 0 1	(1.9) (1.9) (0.6) (0.6) (0.6)	4 1 3 0 1 1 1	(2.6) (0.7) (2.0) (0.7) (0.7) (0.7) (0.7)	1 0 1 0 0 0	(1.3) (1.3) (1.3)
RESPIRATORY SYSTEM All Severity All Severity Mild Mild Moderate Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related / Not Rel.	15 13 2 7 1 6 1	(10.1) (8.7) (1.3) (4.7) (0.7) (4.0) (0.7)	16 14 2 10 1 2 1	(10.3) (9.0) (1.3) (6.5) (0.6) (1.3) (0.6) (1.3)	19 15 4 7 3 5 1	(12.1) (9.6) (2.5) (4.5) (1.9) (3.2) (0.6) (1.9)	16 16 0 10 0 5 0	(10.6) (10.6) (6.6) (3.3) (0.7)	7 7 0 3 0 2 0 2	(9.1) (9.1) (3.9) (2.6) (2.6)
APNEA All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
ASTHMA All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	1 1 0 1	(0.7) (0.7) (0.7)	0 0 0 0		1 1 1 0	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
BRONCHITIS All Severity Moderate	/ Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
COUGH INCREASED All Severity	/ Not Rel.	6 6	(4.0) (4.0)	0		1 1	(0.6) (0.6)	3	(2.0) (2.0)	2 2	(2.6) (2.6)

Page 29

100CT05 16:30 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR_P

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

dy System [1] Adverse Event Severity / Dru	g Relationship [2]		R 50 mg =149	DVS SE	R 100 mg	DVS SE	atment R 150 mg =157	DVS SI	R 200 mg =151	Pla n=	
Mild Moderate Severe	/ Not Rel. / Not Rel. / Not Rel.	4 2 0	(2.7) (1.3)	0 0 0		0 0 1	(0.6)	2 1 0	(1.3) (0.7)	1 0 1	(1.3) (1.3)
DYSPNEA All Severity All Severity Mild Mild Moderate	/ Not Rel. / Related / Not Rel. / Related / Related	2 0 2 0 1 1	(1.3) (1.3) (0.7) (0.7)	1 0 1 0	(0.6) (0.6) (0.6)	5 3 2 3 2 0	(3.2) (1.9) (1.3) (1.9) (1.3)	0 0 0 0 0		0 0 0 0	
EPISTAXIS All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	0 0 0		0 0 0		2 2 1 1	(1.3) (1.3) (0.6) (0.6)	2 2 2 0	(1.3) (1.3) (1.3)	0 0 0	
LARYNGISMUS All Severity Mild	/ Related / Related	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
LUNG DISORDER All Severity Moderate	/ Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
NOSE DRYNESS All Severity Mild	/ Related / Related	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
PHARYNGITIS All Severity Mild Moderate Severe	/ Not Rel. / Not Rel. / Not Rel. / Not Rel.	4 4 2 2 0	(2.7) (2.7) (1.3) (1.3)	2 2 1 1 0	(1.3) (1.3) (0.6) (0.6)	0 0 0 0		2 2 1 0 1	(1.3) (1.3) (0.7) (0.7)	0 0 0 0	
PNEUMONIA All Severity Severe	/ Not Rel. / Not Rel.	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	

Page 30

100CT05 16:30 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4 SEV DR P

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

ody System [1] Adverse Event Severity / Drug	Relationship [2]		R 50 mg =149		R 100 mg =155	DVS S	atment - R 150 mg =157	DVS SI	R 200 mg =151		cebo 77
PULMONARY PHYSICAL All Severity Mild	FINDING / Not Rel. / Not Rel.	1 1 1	(0.7) (0.7) (0.7)	0 0 0		0 0		0 0 0		0 0 0	
RHINITIS All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	0 0 0		3 3 3 0	(1.9) (1.9) (1.9)	3 3 1 2	(1.9) (1.9) (0.6) (1.3)	2 2 1 1	(1.3) (1.3) (0.7) (0.7)	2 2 1 1	(2.6) (2.6) (1.3) (1.3)
RHINITIS ALLERGIC All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	1 1 0 1	(0.7) (0.7) (0.7)	1 1 0 1	(0.6) (0.6) (0.6)	0 0 0 0		1 1 1 0	(0.7) (0.7) (0.7)	0 0 0	
SINUSITIS All Severity Mild Moderate Severe	/ Not Rel. / Not Rel. / Not Rel. / Not Rel.	1 1 1 0 0	(0.7) (0.7) (0.7)	2 2 0 0 2	(1.3) (1.3)	3 3 0 2 1	(1.9) (1.9) (1.3) (0.6)	2 2 2 0 0	(1.3) (1.3) (1.3)	3 3 1 1	(3.9) (3.9) (1.3) (1.3) (1.3)
UPPER RESPIRATORY All Severity All Severity Mild Moderate Moderate	INFECTION / Not Rel. / Related / Not Rel. / Not Rel. / Related	2 2 0 0 2 0	(1.3) (1.3)	7 6 1 5 1	(4.5) (3.9) (0.6) (3.2) (0.6) (0.6)	2 2 0 1 1 0	(1.3) (1.3) (0.6) (0.6)	5 5 0 3 2 0	(3.3) (3.3) (2.0) (1.3)	0 0 0 0	
YAWN All Severity Mild Moderate	/ Related / Related / Related	0 0 0		0 0 0		2 2 1 1	(1.3) (1.3) (0.6) (0.6)	0 0 0		0 0 0	
KIN AND APPENDAGES All Severity All Severity Mild Mild	/ Not Rel. / Related / Not Rel. / Related	16 6 10 3 3	(10.7) (4.0) (6.7) (2.0) (2.0)	8 4 4 3 2	(5.2) (2.6) (2.6) (1.9) (1.3)	17 8 9 5 4	(10.8) (5.1) (5.7) (3.2) (2.5)	15 8 7 5 5	(9.9) (5.3) (4.6) (3.3) (3.3)	3 2 1 0	(3.9) (2.6) (1.3)

100CT05 16:30 REPORT AE4_SEV_DR_P CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 31

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug	Relationship [2]	DVS SI	R 50 mg =149	DVS SF	R 100 mg	DVS SF	atment R 150 mg : =157	DVS SI	R 200 mg =151	Pla n=	 acebo = 77
Moderate Moderate Severe Severe	/ Not Rel. / Related / Not Rel. / Related	3 5 0 2	(2.0) (3.4) (1.3)	1 2 0 0	(0.6) (1.3)	2 3 1 2	(1.3) (1.9) (0.6) (1.3)	0 2 3 0	(1.3)	2 0 0 0	(2.6)
ACNE All Severity All Severity Mild Mild	/ Not Rel. / Related / Not Rel. / Related	0 0 0 0		1 0 1 0 1	(0.6) (0.6) (0.6)	1 0 1 0 1	(0.6) (0.6) (0.6)	1 1 0 1 0	(0.7) (0.7) (0.7)	0 0 0 0	
DERMATITIS ATOPIC All Severity Moderate		1 1 1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0	
DRY SKIN All Severity All Severity Mild Mild	/ Not Rel. / Related / Not Rel. / Related	0 0 0 0		1 1 0 1 0	(0.6) (0.6) (0.6)	2 1 1 1 1	(1.3) (0.6) (0.6) (0.6) (0.6)	0 0 0 0		0 0 0 0	
ERYTHEMA All Severity Moderate	/ Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
EXFOLIATIVE DERMAT All Severity Severe	/ Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
FUNGAL DERMATITIS All Severity Moderate	/ Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		0 0 0		1 1 1	(1.3) (1.3) (1.3)
HERPES SIMPLEX All Severity Mild Severe	/ Not Rel. / Not Rel. / Not Rel.	0 0 0		0 0 0		2 2 1 1	(1.3) (1.3) (0.6) (0.6)	0 0 0		0 0 0	

Page 32

100CT05 16:30 REPORT AE4_SEV_DR_P CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationship [2]	DVS SR 50 mg n=149	DVS SR 100 mg	Treatment DVS SR 150 mg DVS SR 200 mg n=157 n=151	Placebo n= 77
MACULOPAPULAR RASH All Severity / Not Rel. Mild / Not Rel.	0 0 0	0 0 0	1 (0.6) 0 1 (0.6) 0 1 (0.6) 0	0 0 0
NAIL DISORDER All Severity / Related Mild / Related	1 (0.7) 1 (0.7) 1 (0.7)	0 0 0	0 0 0 0	0 0 0
NIGHT SWEATS All Severity / Not Rel. All Severity / Related Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	8 (5.4) 2 (1.3) 6 (4.0) 1 (0.7) 2 (1.3) 4 (2.7) 0	2 (1.3) 0 (1.3) 1 (0.6) 0 (0.6)	3 (1.9) 2 (1.3) 0 1 (0.7) 3 (1.9) 1 (0.7) 0 0 0 2 (1.3) 0 0 1 (0.6)	0 0 0 0 0 0
PRURITUS All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Severe / Related	1 (0.7) 1 (0.7) 0 0 0 1 (0.7)	1 (0.6) 1 (0.6) 1 (0.6)	4 (2.5) 0 2 (1.3) 0 2 (1.3) 0 2 (1.3) 0 1 (0.6) 0	0 0 0 0 0
PSORIASIS All Severity / Not Rel. Moderate / Not Rel.	0 0 0	0 0 0	1 (0.6) 0 1 (0.6) 0 1 (0.6) 0	0 0 0
RASH All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel.	1 (0.7) 1 (0.7) 0 1 (0.7) 0	0 0 0 0 0	0 1 (0.7) 0 0 1 (0.7) 0 0 0 1 (0.7) 0 0 1 (0.7)	1 (1.3) 1 (1.3) 0 0 0 1 (1.3)
SEBORRHEA	0	0	0 1 (0.7)	0

100CT05 16:30 REPORT AE4_SEV_DR_P CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 33

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug	Relationship [2]	DVS SF n=		DVS SE	R 100 mg	DVS SI	atment R 150 mg =157	DVS SI	R 200 mg =151	Pla	 acebo = 77
All Severity Mild	/ Not Rel. / Not Rel.	0		0		0		1 1	(0.7) (0.7)	0	
SKIN BENIGN NEOPL All Severity Mild	ASM / Not Rel. / Not Rel.	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	1 1 1		0 0 0	
SKIN DISCOLORATION All Severity Mild	N / Not Rel. / Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
SKIN DISORDER All Severity All Severity Mild Mild	/ Not Rel. / Related / Not Rel. / Related	0 0 0 0		0 0 0 0		1 1 0 1 0	(0.6) (0.6) (0.6)	0 0 0 0		1 0 1 0 1	(1.3) (1.3) (1.3)
SKIN HYPERTROPHY All Severity Mild	/ Not Rel. / Not Rel.	1 1 1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0	
SKIN ULCER All Severity Moderate	/ Not Rel. / Not Rel.	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
SKIN WRINKLING All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
SWEATING All Severity All Severity Mild Mild Moderate Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related / Not Rel.	3 0 3 0 1 0 1	(2.0) (2.0) (0.7) (0.7)	3 1 2 0 1 1 1	(1.9) (0.6) (1.3) (0.6) (0.6) (0.6)	2 0 2 0 1 0 1 0	(1.3) (1.3) (0.6) (0.6)	7 2 5 1 3 0 2	(4.6) (1.3) (3.3) (0.7) (2.0) (1.3) (0.7)	0 0 0 0 0	

Page

34

100CT05 16:30 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT AE4_SEV_DR_P

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS

By Severity And Drug Relationship

Body System [1] Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Severity / Drug Relationship [2] n=149 n=155 n=157 n = 770 0 Severe / Related (0.7)0 URTICARIA 1 (0.7)0 0 0 0 All Severity / Not Rel. 1 0 0 0 0 Mild / Not Rel. (0.7)0 0 0 0 SPECIAL SENSES (6.0)26 (16.8)20 (12.7)(15.2)(1.3)(2.7)All Severity / Not Rel. 8 (5.2)5 (3.2)(4.6)0 / Related All Severity 5 (3.4)18 (11.6)15 (9.6)16 (10.6)(1.3)Mild / Not Rel. (2.7)(1.9)(1.9)(4.0)0 (3.2)(5.3)Mild / Related (2.0)(5.2)8 Ω Moderate / Not Rel. (3.2)1 (0.6)1 (0.7)0 Moderate / Related (1.3)(4.5)9 (5.7)(4.0)(1.3)0 Severe / Not Rel. 1 (0.6)0 Severe / Related 0 3 (1.9)(0.6)(1.3)0 ABNORMAL VISION (0.7)10 (6.5)(3.8)(5.3)0 / Not Rel. (1.3)(0.6)(0.7)All Severity 2 1 1 0 All Severity / Related (0.7)(5.2)(3.2)(4.6)0 Mild / Not Rel. (0.6)1 (0.6)0 0 5 Mild / Related 1 (0.7)(3.2)4 (2.5)3 (2.0)0 Moderate / Not Rel. (0.6)0 (0.7)0 Moderate / Related 0 2 (1.3)1 (0.6)(2.0)0 (0.7)Severe / Related 0 (0.6)0 0 0 0 CONJUNCTIVITIS (0.6)0 All Severity / Not Rel. Ω (0.6)0 Ω 0 Mild / Not Rel. 0 (0.6)0 0 0 DRY EYES (0.6)0 (0.7)0 All Severity / Not Rel. (0.6)0 0 All Severity / Related Ω 0 1 (0.7)0 / Related Mild Ω Ω 0 1 (0.7)Ω Moderate / Not Rel. (0.6)0 EAR PAIN (1.3)0 (0.7)0 All Severity / Not Rel. (0.6)0 (0.7)0

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

Page 35

100CT05 16:30 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR_P

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Dru	g Relationship [2]		 50 mg 149		 R 100 mg =155	DVS SI	atment - R 150 mg =157		 R 200 mg =151	Placebo n= 77
All Severity Mild Mild Moderate	/ Related / Not Rel. / Related / Not Rel.	0 0 0 0		1 0 1 1	(0.6) (0.6) (0.6)	0 0 0		0 1 0 0	(0.7)	0 0 0
EYE DISORDER All Severity Mild Severe	/ Not Rel. / Not Rel. / Not Rel.	0 0 0		1 1 1 0	(0.6) (0.6) (0.6)	1 1 0 1	(0.6) (0.6) (0.6)	1 1 1 0	(0.7) (0.7) (0.7)	0 0 0 0
EYE PAIN All Severity All Severity Mild Mild Moderate	/ Not Rel. / Related / Not Rel. / Related / Related	1 0 1 0	(0.7) (0.7) (0.7)	1 0 1 0 0	(0.6) (0.6)	0 0 0 0		2 1 1 1 0	(1.3) (0.7) (0.7) (0.7) (0.7)	0 0 0 0 0
GLAUCOMA All Severity Mild	/ Not Rel. / Not Rel.	1 1 1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0
HYPERACUSIS All Severity Moderate	/ Related / Related	1 1 1	(0.7) (0.7) (0.7)	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0
MYDRIASIS All Severity All Severity Mild Mild Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Related / Related	0 0 0 0 0		1 0 1 0 0	(0.6) (0.6) (0.6)	3 1 2 1 1 1 0	(1.9) (0.6) (1.3) (0.6) (0.6) (0.6)	7 0 7 0 3 3	(4.6) (4.6) (2.0) (2.0) (0.7)	0 0 0 0 0
OTITIS MEDIA All Severity Moderate	/ Not Rel. / Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0

Page 36

100CT05 16:30 REPORT AE4_SEV_DR_P CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationship [2]	DVS SR 50 mg n=149	g DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo n=155 n=157 n=77	
PAROSMIA All Severity / Not Rel. All Severity / Related Moderate / Not Rel. Moderate / Related	1 (0.7) 0 1 (0.7) 0 1 (0.7)	1 (0.6) 0 0 0 0 0 0 0 1 (0.6) 0 0	
PHOTOPHOBIA All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Related	2 (1.3) 0 (1.3) 0 (1.3) 0 (0.7) 1 (0.7)	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	
TASTE PERVERSION All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Related	0 0 0 0 0	1 (0.6) 1 (0.6) 1 (0.7) 0 1 (0.6) 0 0 0 0 0 1 (0.6) 1 (0.7) 0 1 (0.6) 0 0 0 0 0 0 1 (0.7) 0 0 0 0 0 0	
TINNITUS All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Related	4 (2.7) 2 (1.3) 2 (1.3) 2 (1.3) 1 (0.7) 0 (0.7)	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	
VESTIBULAR DISORDER All Severity / Not Rel. Moderate / Not Rel.	0 0 0	0 1 (0.6) 0 0 0 1 (0.6) 0 0 0 1 (0.6) 0	
VITREOUS DISORDER All Severity / Not Rel. Mild / Not Rel.	0 0 0	1 (0.6) 0 0 0 1 (0.6) 0 0 0 1 (0.6) 0 0	

Page 37

100CT05 16:30 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR_P

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationship [2]	DVS SR 50 mg n=149	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo n=155 n=157 n=151 n= 77
UROGENITAL SYSTEM All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related Life Threatening / Not Rel.	5 (3.4) 3 (2.0) 2 (1.3) 2 (1.3) 1 (0.7) 0 1 (0.7) 1 (0.7) 0	9 (5.8) 11 (7.0) 9 (6.0) 7 (9.1) 6 (3.9) 8 (5.1) 6 (4.0) 7 (9.1) 3 (1.9) 3 (1.9) 3 (2.0) 0 2 (1.3) 8 (5.1) 5 (3.3) 5 (6.5) 1 (0.6) 2 (1.3) 0 0 0 2 (1.3) 0 1 (0.7) 2 (2.6) 1 (0.6) 1 (0.6) 2 (1.3) 0 1 (0.6) 0 0 0 0 1 (0.6) 0 0 0 0
ALBUMINURIA All Severity / Not Rel. Mild / Not Rel.	0 0 0	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$
BREAST CYST All Severity / Not Rel. Mild / Not Rel.	1 (0.7) 1 (0.7) 1 (0.7)	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$
BREAST NEOPLASM All Severity / Related Mild / Related	0 0 0	1 (0.6) 0 0 0 1 (0.6) 0 0 0 1 (0.6) 0 0
BREAST PAIN All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	0 0 0	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$
CERVICITIS All Severity / Not Rel. Mild / Not Rel.	0 0 0	1 (0.6) 0 0 0 0 1 (0.6) 0 0 1 (0.6) 0 0 0
CERVIX DISORDER All Severity / Not Rel. Mild / Not Rel.	0 0 0	1 (0.6) 0 0 0 0 1 (0.6) 0 0 0 1 (0.6) 0 0 0
CERVIX NEOPLASM	0	0 1 (0.6) 0 1 (1.3)

100CT05 16:30 REPORT AE4_SEV_DR_P CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 38

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationship [2]	DVS SR 50 mg n=149	DVS SR 100 mg n=155	Treatment DVS SR 150 mg n=157	DVS SR 200 mg n=151	Placebo n= 77
All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related	0 0 0 0	0 0 0 0	0 1 (0.6) 0 1 (0.6)	0 0 0 0	1 (1.3) 0 1 (1.3)
CYSTITIS All Severity / Not Rel. Mild / Not Rel.	0	0	1 (0.6)	0	0
	0	0	1 (0.6)	0	0
	0	0	1 (0.6)	0	0
FIBROCYSTIC BREAST All Severity / Not Rel. Mild / Not Rel.	0	0	1 (0.6)	1 (0.7)	0
	0	0	1 (0.6)	1 (0.7)	0
	0	0	1 (0.6)	1 (0.7)	0
HEMATURIA All Severity / Not Rel. Mild / Not Rel.	0	0	1 (0.6)	2 (1.3)	1 (1.3)
	0	0	1 (0.6)	2 (1.3)	1 (1.3)
	0	0	1 (0.6)	2 (1.3)	1 (1.3)
KIDNEY CALCULUS All Severity / Not Rel. Mild / Not Rel.	0	0	0	0	1 (1.3)
	0	0	0	0	1 (1.3)
	0	0	0	0	1 (1.3)
LEUKORRHEA All Severity / Not Rel. Moderate / Not Rel.	0	1 (0.6)	0	0	0
	0	1 (0.6)	0	0	0
	0	1 (0.6)	0	0	0
OVARIAN CARCINOMA All Severity / Not Rel. Life Threatening / Not Rel.	0	1 (0.6)	0	0	0
	0	1 (0.6)	0	0	0
	0	1 (0.6)	0	0	0
PYELONEPHRITIS All Severity / Not Rel. Mild / Not Rel.	0	0	0	0	1 (1.3)
	0	0	0	0	1 (1.3)
	0	0	0	0	1 (1.3)
SEXUAL FUNCTION ABNORMAL All Severity / Related Mild / Related Moderate / Related	1 (0.7) 1 (0.7) 0 (0.7)	1 (0.6) 1 (0.6) 0 1 (0.6)	2 (1.3) 2 (1.3) 1 (0.6) 1 (0.6)	1 (0.7) 1 (0.7) 0 1 (0.7)	0 0 0

100CT05 16:30 REPORT AE4_SEV_DR_P CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

Page 39

dy System [1] Adverse Event Severity / Drug Relationship [2]	DVS SR 50 mg n=149	DVS SR 100 mg n=155	- Treatment DVS SR 150 mg : n=157	DVS SR 200 mg n=151	Placebo n= 77
URINARY FREQUENCY All Severity / Related Moderate / Related	0 0 0	0 0 0	0 0 0	1 (0.7) 1 (0.7) 1 (0.7)	0 0 0
URINARY HESITATION All Severity / Related Severe / Related	0 0 0	0 0 0	0 0 0	1 (0.7) 1 (0.7) 1 (0.7)	0 0 0
URINARY INCONTINENCE All Severity / Not Rel. Mild / Not Rel.	0 0 0	0 0 0	0 0 0	1 (0.7) 1 (0.7) 1 (0.7)	0 0 0
URINARY TRACT DISORDER All Severity / Not Rel. Severe / Not Rel.	1 (0.7) 1 (0.7) 1 (0.7)	0 0 0	0 0 0	0 0 0	0 0 0
URINARY TRACT INFECTION All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	0 0 0	1 (0.6) 1 (0.6) 0 1 (0.6)	1 (0.6) 1 (0.6) 1 (0.6)	0 0 0 0	1 (1.3) 1 (1.3) 1 (1.3)
URINE ABNORMALITY All Severity / Not Rel. Mild / Not Rel.	0 0 0	1 (0.6) 1 (0.6) 1 (0.6)	0 0 0	0 0 0	0 0 0
VAGINAL DRYNESS All Severity / Not Rel. All Severity / Related Mild / Not Rel. Moderate / Not Rel. Severe / Not Rel.	0 0 0 0 0	2 (1.3) 1 (0.6) 1 (0.6) 0 0 1 (0.6)	0 0 0 0 0	1 (0.7) 1 (0.7) 0 1 (0.7) 0	2 (2.6) 2 (2.6) 0 (1.3) 1 (1.3)
Severe / Related VAGINAL HEMORRHAGE All Severity / Not Rel. Mild / Not Rel.	0 0 0 0	1 (0.6) 1 (0.6) 1 (0.6) 1 (0.6)	0 0 0	0 0 0 0	0 1 (1.3) 1 (1.3) 1 (1.3)

100CT05 16:30 REPORT AE4 SEV DR P CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page

40

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] ----- Treatment -----Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Severity / Drug Relationship [2] n=149 n=155 n=157 n=151 n = 77VAGINITIS 0 (1.3)0 0 0 / Not Rel. 2 All Severity 0 (1.3)0 0 0 Mild / Not Rel. 0 (1.3)0 0 0 VULVOVAGINAL DISORDER (1.3)(0.6)0 Ω All Severity / Not Rel. (0.7)0 1 (0.6)0 0 All Severity / Related (0.7)0 0 0 0 Mild / Not Rel. 1 (0.7)0 1 (0.6)0 Ω Mild / Related 1 (0.7)0 0 0 0 TERMS NOT CLASSIFIABLE (0.7)(1.3)(0.7)0 All Severity / Related 1 (0.7)0 (1.3)1 (0.7)0 Mild / Related (0.7)(0.6)(0.7)0 0 1 Severe / Related (0.6)0 REACTION UNEVALUABLE (0.7)(1.3)(0.7)0 2 (0.7)All Severity / Related (0.7)0 (1.3)1 0 1 Mild / Related (0.7)(0.6)1 (0.7)0 Severe / Related 1 (0.6)0 0 ADVERSE EVENT ASSOC.W.MISC. FACTORS (1.3)0 (0.7)3 (3.9)/ Not Rel. All Severity (1.3)0 0 (0.7)(3.9)/ Not Rel. Mild (0.7)0 0 (0.7)(3.9)/ Not Rel. (0.7)Moderate 0 0 0 0 ALLERGIC REACTION OTHER THAN DRUG (1.3)1 (0.7)(1.3)/ Not Rel. All Severity (1.3)Ω Ω 1 (0.7)(1.3)Mild / Not Rel. (0.7)0 0 (0.7)(1.3)Moderate / Not Rel. 1 (0.7)0 0 0 0 LOCAL REACTION TO PROCEDURE (2.6)All Severity / Not Rel. 0 0 0 0 (2.6)Mild / Not Rel. Ω (2.6)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

ST 10-4: Number (%) of Subjects Reporting Treatment-Emergent Adverse Events

Page 1

29SEP05 14:53 REPORT AE5 TEAE CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

		Treatment									
Body System [1] Adverse Event	Overall P-Value *	DVS SR 50 mg n=149		DVS S n	DVS SR 100 mg n=155		R 150 mg =157	DVS S	R 200 mg =151	Placebo n= 77	
ANY ADVERSE EVENT	0.014*	134	(89.9)	146	(94.2)	149	(94.9)	147	(97.4)	67	(87.0)
BODY AS A WHOLE ABDOMINAL PAIN	0.749 0.036*	93 15	(62.4) (10.1)	101 5	(65.2) (3.2)	98 11	(62.4) (7.0)	87 4	(57.6) (2.6)	47 4	(61.0) (5.2)
ABSCESS ACCIDENTAL INJURY ACCIDENTAL OVERDOSE	0.468 0.244 0.485	0 11 0	(7.4)	0 16 1	(10.3) (0.6)	0 11 0	(7.0)	1 19 0	(0.7) (12.6)	0 11 0	(14.3)
ALLERGIC REACTION ASTHENIA	0.439 0.017*	4 11	(2.7) (7.4)	1 30	(0.6) (19.4)	2 27	(1.3) (17.2)	3 23	(2.0) (15.2)	0 7	(9.1)
BACK PAIN BODY ODOR	0.273 0.494	16 0	(10.7)	14	(9.0)	10	(6.4) (0.6)	9	(6.0)	10	(13.0)
CELLULITIS CHEST PAIN CHILLS	0.683 0.607 0.120	1 4 5	(0.7) (2.7) (3.4)	2 3 8	(1.3) (1.9) (5.2)	0 5 6	(3.2) (3.8)	2 3 11	(1.3) (2.0) (7.3)	1 0 0	(1.3)
CYST FACE EDEMA	0.403 0.515	4 5 2 2 2 6	(1.3)	0	(0.6)	0	(5.0)	1 2	(0.7) (1.3)	1 0	(1.3)
FEVER FLU SYNDROME	0.056 0.267	2 6	(1.3) (4.0)	1 15	(0.6) (9.7)	0	(5.7)	5 10	(3.3) (6.6)	0	(3.9)
GENERALIZED EDEMA HANGOVER EFFECT HEADACHE	0.818 0.093 0.549	1 0 48	(0.7)	1 0 43	(0.6) (27.7)	0 0 55	(35.0)	1 0 42	(0.7) (27.8)	0 1 26	(1.3) (33.8)
HEADACHE HEAT STROKE INFECTION	0.093	0 23	(15.4)	0 21	(13.5)	0 21	(13.4)	0 15	(9.9)	1 18	(1.3) (23.4)
INJECTION SITE HEMORRHAGE LAB TEST ABNORMAL	0.485 0.122	0 2 0	(1.3)	1	(0.6)	0	, ,	0	, ,	0	, ,
MALAISE MONILIASIS	0.306 0.637	0 1 5	(0.7)	3	(1.9) (0.6)	1	(0.6)	1 0 6	(0.7)	0 0 4	/F 0\
NECK PAIN OVERDOSE PAIN	0.284 0.494 0.130	0 16	(3.4)	1 0 15	(0.6) (9.7)	4 1 13	(2.5) (0.6) (8.3)	0 17	(4.0) (11.3)	0 15	(5.2) (19.5)
PELVIC PAIN PHOTOSENSITIVITY REACTION SARCOIDOSIS	0.122 0.485 0.468	2 0 0	(1.3)	0 1 0	(0.6)	0 0	(3.3)	0 0 1	(0.7)	0 0	(13.0)
CARDIOVASCULAR SYSTEM CARDIOVASCULAR PHYSICAL FINDING	0.141 0.458	13 1	(8.7) (0.7)	21	(13.5)	25 0	(15.9)	28	(18.5)	9	(11.7)
CORONARY ARTERY DISORDER	0.468	0		0		0		1	(0.7)	0	

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

Page

2

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Adverse Event	Overall P-Value *		R 50 mg =149		 R 100 mg =155	DVS S	atment - R 150 mg =157		 R 200 mg =151		acebo = 77
CORONARY OCCLUSION	0.468	0	(4.0)	0		0		1	(0.7)	0	(1 2)
HYPERTENSION MIGRAINE	0.255 0.676	6 1	(4.0) (0.7)	8	(5.2) (2.6)	10 4	(6.4) (2.5)	12 4	(7.9) (2.6)	1 1	(1.3) (1.3)
MYOCARDIAL INFARCT	0.642	1	(0.7)	0	, ,	1	(0.6)	0	, ,	0	, ,
PALPITATION	0.544	4	(2.7)	5	(3.2)	2	(1.3)	5	(3.3)	4	(5.2)
PERIPHERAL VASCULAR DISORDER SYNCOPE	0.627 0.494	1	(0.7)	0		0	(0.6)	1	(0.7)	0	
TACHYCARDIA	0.819	3	(2.0)	3	(1.9)	3	(1.9)	3	(2.0)	0	
VARICOSE VEIN	0.093	Õ	(2.0)	Ő	(1.5)	Õ	(1.5)	Ő	(2.0)	ĺ	(1.3)
VASODILATATION	0.556	2	(1.3)	2	(1.3)	6	(3.8)	4	(2.6)	2	(2.6)
DIGESTIVE SYSTEM	<0.001***	83	(55.7)	99	(63.9)	114	(72.6)	104	(68.9)	28	(36.4)
ABDOMINAL DISTENSION	0.013*	3	(2.0)	0		1	(0.6)	_ 1	(0.7)	4	(5.2)
ANOREXIA BLOOD IN STOOL	0.171 0.637	1	(4.7) (0.7)	9 1	(5.8) (0.6)	13	(8.3)	15 0	(9.9)	2	(2.6)
CHOLECYSTITIS	0.637	0	(0.7)	1	(0.6)	0		0		0	
CHOLELITHIASIS	0.465	0		2	(1.3)	0		0		0	
COLTTIS	0.108	3	(2.0)	0	(±•5)	0		1	(0.7)	0	
CONSTIPATION	0.266	16	(10.7)	27	(17.4)	25	(15.9)	27	(17.9)	8	(10.4)
DIARRHEA	0.482	17	(11.4)	12	(7.7)	9	(5.7)	14	(9.3)	6	(7.8)
DRY MOUTH	0.001**	18	(12.1)	33	(21.3)	31	(19.7)	35	(23.2)	3	(3.9)
DUODENITIS	0.494	0		0		1	(0.6)	0		0	
DYSPEPSIA	0.203	18	(12.1)	13	(8.4)	16	(10.2)	13	(8.6)	2	(2.6)
DYSPHAGIA	0.856	1	(0.7)	2	(1.3)	2	(1.3)	2	(1.3)	0	
ERUCTATION ESOPHAGEAL ULCER	0.846 0.485	2	(1.3)	1	(0.6) (0.6)	1	(0.6)	0	(0.7)	0	
ESOPHAGEAL OLCER ESOPHAGITIS	0.485	1	(0.7)	1	(0.6)	1	(0.6)	0		0	
FLATULENCE	0.941	1	(0.7)	1	(0.6)	1	(0.6)	2	(1.3)	1	(1.3)
GAMMA GLUTAMYL TRANSPEPTIDASE INCREASED	0.485	Ō	(0.7)	1	(0.6)	Ō	(0.0)	Õ	(1.5)	Ö	(1.0)
GASTRITIS	0.093	Ö		0	(- 0 0)	Ō		Ō		ĺ	(1.3)
GASTROENTERITIS	0.711	2	(1.3)	5	(3.2)	5	(3.2)	3	(2.0)	1	(1.3)
GASTROESOPHAGEAL REFLUX DISEASE	0.173		(2.0)	3	(1.9)	1	(0.6)	6	(4.0)	0	
GASTROINTESTINAL DISORDER	0.360	0		1	(0.6)	2	(1.3)	0		0	
GASTROINTESTINAL PHYSICAL FINDING	0.458	1	(0.7)	0	(0 6)	0		0		0	/1 01
GINGIVITIS	0.318	0 1	(0.7)	1	(0.6)	0		0		Ţ	(1.3)
GLOSSITIS HEMORRHAGIC GASTRITIS	0.637 0.494	0	(0.7)	1	(0.6)	0 1	(0.6)	0		0	

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.
Overall P-Value: P-value for Chi-Square.

3

Page

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

Body System [1] Adverse Event	Overall P-Value *		R 50 mg =149		R 100 mg =155	DVS S	atment - R 150 mg =157		R 200 mg =151		acebo = 77
HEPATITIS	0.494	0		0		1	(0.6)	0		0	
HIATAL HERNIA	0.642	ĺ	(0.7)	Ö		1	(0.6)	Ö		Ö	
INCREASED APPETITE	0.949	3	(2.0)	3	(1.9)	4	(2.5)	2	(1.3)	2	(2.6)
LIVER FUNCTION TESTS ABNORMAL	0.825	2	(1.3)	1	(0.6)	3	(1.9)	1	(0.7)	1	(1.3)
NAUSEA	<0.001***	41	(27.5)	60	(38.7)	75	(47.8)	68	(45.0)	5	(6.5)
NAUSEA AND VOMITING	0.594	0		1	(0.6)	1	(0.6)	2	(1.3)	0	
ORAL MONILIASIS	0.485	0		1	(0.6)	0		0		0	
PANCREATITIS	0.494	0		0		1	(0.6)	0		0	
PEPTIC ULCER	0.642	1	(0.7)	0		1	(0.6)	0		0	
PERIODONTAL ABSCESS	0.594	0		1	(0.6)	1	(0.6)	2	(1.3)	0	
PERIODONTITIS	0.642	1	(0.7)	0		1	(0.6)	-		-	
RECTAL DISORDER	0.708	1	(0.7)	0		2	(1.3)	1	(0.7)	1	(1.3)
RECTAL HEMORRHAGE	0.821	1	(0.7)	0		1	(0.6)	1	(0.7)	0	
STOOLS ABNORMAL	0.147	0		0		2	(1.3)	0		0	
TONGUE EDEMA	0.128	0		0		0		2 2	(1.3)	0	
TOOTH CARIES	0.688	1	(0.7)	0	44 01	1	(0.6)		(1.3)	1	(1.3)
ULCERATIVE STOMATITIS	0.141	0		2	(1.3)	0		0		0	
VOMITING	0.028*	8	(5.4)	11	(7.1)	11	(7.0)	17	(11.3)	0	
ENDOCRINE SYSTEM	0.625	2	(1.3)	1	(0.6)	1	(0.6)	3	(2.0)	2	(2.6)
DIABETES MELLITUS	0.643	0		1	(0.6)	0		3 1	(0.7)	0	
GOITER	0.312	0		0		0		1	(0.7)	1	(1.3)
HYPOTHYROIDISM	0.637	1	(0.7)	1	(0.6)	0		0		0	
PARATHYROID DISORDER	0.642	1	(0.7)	0		1	(0.6)	0		0	
THYROID DISORDER	0.312	0		0		0		1	(0.7)	1	(1.3)
HEMIC AND LYMPHATIC SYSTEM	0.233	2	(1.3)	7	(4.5)	6	(3.8)	5	(3.3)	0	
ANEMIA	0.658	0	(±•5)	1	(0.6)	1	(0.6)	0	(3.3)	0	
ECCHYMOSIS	0.341	1	(0.7)	4	(2.6)	5	(3.2)	3	(2.0)	ő	
GRANULOCYTOSIS	0.468	Ō	(0./	0	(2.0)	0	(0.2)	1	(0.7)	ő	
LEUKOCYTOSIS	0.468	Ŏ		Ŏ		Ŏ		ī	(0.7)	Ö	
LYMPHADENOPATHY	0.818	1	(0.7)	ĭ	(0.6)	Ö		1	(0.7)	0	
LYMPHOPENIA	0.468	Ō	(/	Ō	(/	Ŏ		ī	(0.7)	Ŏ	
NEUTROPENIA	0.485	0		1	(0.6)	0		0	, ,	0	
METABOLIC AND NUTRITIONAL	0.115	15	(10.1)	29	(18.7)	29	(18.5)	31	(20.5)	11	(14.3)
ALKALINE PHOSPHATASE INCREASED	0.333	0	(+0.+)	1	(0.6)	0	(=0.0)	2	(1.3)	0	(= 1.0)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.
Overall P-Value: P-value for Chi-Square.

Page

4

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

Body System [1] Adverse Event	Overall P-Value *		R 50 mg =149		R 100 mg =155	DVS S	atment - R 150 mg =157		R 200 mg =151		acebo = 77
DEHYDRATION	0.643	0		1	(0.6)	0		1	(0.7)	0	
GLUCOSE TOLERANCE DECREASED	0.494	0		0		1 5	(0.6)	0		0	
HYPERCHOLESTEREMIA	0.728	6	(4.0)	9	(5.8)	5	(3.2)	9	(6.0)	3	(3.9)
HYPERGLYCEMIA	0.093	0		0		0		0		1	(1.3)
HYPERLIPEMIA	0.162	5	(3.4)	8	(5.2)	4	(2.5)	9	(6.0)	0	
HYPOMAGNESEMIA	0.494	0		0		1	(0.6)	0		0	
PERIPHERAL EDEMA	0.651	3	(2.0)	4	(2.6)	4	(2.5)	3	(2.0)	4	(5.2)
SGOT INCREASED	0.032*	0		0		1	(0.6)	4	(2.6)	0	
SGPT INCREASED	0.103	0		1	(0.6)	1	(0.6)	4	(2.6)	0	
THIRST	0.335	0		0		1	(0.6)	2 5	(1.3)	0	
WEIGHT GAIN	0.243	4	(2.7)	9	(5.8)	12	(7.6)	5	(3.3)	3	(3.9)
WEIGHT LOSS	0.494	0		0		1	(0.6)	0		0	
MUSCULOSKELETAL SYSTEM	0.650	32	(21.5)	35	(22.6)	31	(19.7)	24	(15.9)	16	(20.8)
ARTHRALGIA	0.273	18	(12.1)	18	(11.6)	17	(10.8)	8	(5.3)	9	(11.7)
ARTHRITIS	0.793	2	(1.3)	1	(0.6)	1	(0.6)	3	(2.0)	1	(1.3)
ARTHROSIS	0.147	0	, , ,	0	(/	2	(1.3)	Ō	, ,	0	, , ,
BONE DISORDER	0.594	0		1	(0.6)	1	(0.6)	2	(1.3)	0	
BURSITIS	0.609	1	(0.7)	0	(/	2	(1.3)	1	(0.7)	Ô	
FIBROMYALGIA	0.468	0	, ,	0		0	, ,	1	(0.7)	0	
JOINT DISORDER	0.661	4	(2.7)	3	(1.9)	Ĩ	(0.6)	2	(1.3)	2	(2.6)
LEG CRAMPS	0.770	1	(0.7)	4	(2.6)	3	(1.9)	2	(2.0)	2	(2.6)
MUSCLE CRAMP	0.277	2	(1.3)	2	(1.3)	Õ	(1.5)	0	(2.0)	0	(2.0)
MUSCLE SPASMS	0.627	2	(1.3)	1	(0.6)	3	(1.9)	1	(0.7)	0	
MUSCULOSKELETAL STIFFNESS	0.127	$\bar{1}$	(0.7)	2	(1.3)	6	(3.8)	1 2	(1.3)	Ŏ	
MYALGIA	0.275	3	(2.0)	7	(4.5)	5	(3.2)	8	(5.3)	6	(7.8)
MYASTHENIA	0.485	Õ	(2.0)	i	(0.6)	Õ	(0.2)	Õ	(0.0)	Õ	(,,,,,,
OSTEOPOROSIS	0.147	2	(1.3)	1	(0.6)	0		0			(2.6)
PLANTAR FASCIITIS	0.494	0	(±.5)	Ō	(0.0)	ĭ	(0.6)	Ŏ		2	(2.0)
RHEUMATOID ARTHRITIS	0.494	0		Ö		1	(0.6)	Ö		Ö	
TENOSYNOVITIS	0.394	4	(2.7)	ĭ	(0.6)	1	(0.6)	ĭ	(0.7)	ĭ	(1.3)
IBNOOTNOVIIIO	0.331	-	(2.7)	_	(0.0)	_	(0.0)	_	(0.7)	-	(±•5)
NERVOUS SYSTEM	<0.001***	62	(41.6)	84	(54.2)	97	(61.8)	99	(65.6)	27	(35.1)
ABNORMAL DREAMS	0.217	4	(2.7)	2	(1.3)	5	(3.2)	7	(4.6)	0	
ABNORMAL/CHANGED BEHAVIOR	0.485	0	, ,	1	(0.6)	0	, ,	0	, ,	0	
AGITATION	0.083	1	(0.7)	0		3	(1.9)	1	(0.7)	3	(3.9)
ANXIETY	0.235	9	(6.0)	5	(3.2)	11	(7.0)	4	(2.6)	2	(2.6)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.
Overall P-Value: P-value for Chi-Square.

Page

5

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

ody System [1] Adverse Event	Overall P-Value *		R 50 mg =149		R 100 mg =155	DVS S	atment R 150 mg =157		R 200 mg =151		acebo = 77
APATHY	0.642	1	(0.7)	0		1	(0.6)	0		0	
ATAXIA	0.643	0	,	1	(0.6)	0	(/	1	(0.7)	0	
BRAIN EDEMA	0.468	0		0	, ,	0		ī	(0.7)	0	
CARPAL TUNNEL SYNDROME	0.696	0		1	(0.6)	2	(1.3)	2	(1.3)	1	(1.3)
CERVICAL RADICULOPATHY	0.494	0		0		1	(0.6)	0		0	
CIRCUMORAL PARESTHESIA	0.627	1	(0.7)	0		0		1	(0.7)	0	
CONFUSION	0.037*	1	(0.7)	4	(2.6)	8	(5.1)	2	(1.3)		
DEPERSONALIZATION	0.599	1	(0.7)	2	(1.3)	0		1	(0.7)	0	
DEPRESSION	0.840	6	(4.0)	6	(3.9)	3	(1.9)	5	(3.3)	3	(3.9)
DIZZINESS	<0.001***	17	(11.4)	30	(19.4)	29	(18.5)	41	(27.2)	6	(7.8)
EMOTIONAL LABILITY	0.607	1	(0.7)	2	(1.3)	1	(0.6)	0		0	
ENERGY INCREASED	0.147	0		0		2	(1.3)	0		0	
EUPHORIA	0.485	0		1	(0.6)	0		0		0	
FACIAL PARALYSIS	0.494	0		0		1	(0.6)	0		0	
FEELING DRUNK	0.458	1	(0.7)	0		0		0		0	
HOSTILITY	0.668	4	(2.7)	1	(0.6)	3	(1.9)	2	(1.3)	2	(2.6)
HYPERKINESIA	0.325	2	(1.3)	0		1	(0.6)	0		0	
HYPERTONIA	0.468	0		0		0		1 2	(0.7)	0	
HYPESTHESIA	0.442	4	(2.7)	5	(3.2)	1	(0.6)		(1.3)	1	(1.3)
HYPOKINESIA	0.468	0		0		0		1	(0.7)	0	
HYPOTONIA	0.627	1	(0.7)	0		0		1	(0.7)	0	
INSOMNIA	0.004**	23	(15.4)	27	(17.4)	43	(27.4)	39	(25.8)	8	(10.4)
LIBIDO DECREASED	0.206	2	(1.3)	5	(3.2)	3	(1.9)	8	(5.3)	1	(1.3)
LIBIDO INCREASED	0.494	0		0		1	(0.6)	0		0	
MEMORY IMPAIRMENT	0.744	0		2	(1.3)	2	(1.3)	2	(1.3)	1	(1.3)
MOTION SICKNESS	0.637	1	(0.7)	1	(0.6)	0		0		0	
MOVEMENT DISORDER	0.468	0		0		0		1	(0.7)	0	
NERVE COMPRESSION	0.494	0		0		1	(0.6)	0		0	
NERVOUSNESS	0.053	11	(7.4)	12	(7.7)	20	(12.7)	19	(12.6)	2	(2.6)
NEURALGIA	0.312	0		0		0		1	(0.7)	1	(1.3)
PARESTHESIA	0.046*	0		7	(4.5)	4	(2.5)	3	(2.0)	0	
PTOSIS	0.468	0		0		0		1	(0.7)	0	
RESTLESS LEGS SYNDROME	0.832	0		1	(0.6)	1	(0.6)	1	(0.7)	0	
SLEEP DISORDER	0.210	0		0		2	(1.3)	0		1	(1.3)
SOMNOLENCE	<0.001***	7	(4.7)	24	(15.5)	30	(19.1)	36	(23.8)	3	(3.9)
SPEECH DISORDER	0.648	0		0		1	(0.6)	1	(0.7)	0	
SUICIDAL IDEATION	0.458	1	(0.7)	0		0		0		0	

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.
Overall P-Value: P-value for Chi-Square.

Page

6

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

Body System [1] Adverse Event	Overall P-Value *		R 50 mg =149		R 100 mg =155	DVS S	atment - R 150 mg =157		R 200 mg =151		acebo = 77
THINKING ABNORMAL TREMOR TRISMUS TWITCHING	0.358 0.248 0.691 0.006**	3 2 2	(2.0) (1.3) (1.3) (0.7)	4 4 2 1	(2.6) (2.6) (1.3) (0.6)	8 4 1 1	(5.1) (2.5) (0.6) (0.6)	7 8 3 8	(4.6) (5.3) (2.0) (5.3)	1 1 0 1	(1.3) (1.3) (1.3)
VERTIGO	0.215	4	(2.7)	1	(0.6)	4	(2.5)	2	(1.3)	4	(5.2)
RESPIRATORY SYSTEM APNEA ASTHMA	0.107 0.468 0.828	52 0 1	(34.9)	46 0 1	(29.7) (0.6)	41 0 1	(26.1)	35 1 0	(23.2) (0.7)	28 0 0	(36.4)
BRONCHITIS COUGH INCREASED DYSPNEA	0.070 0.173 0.276	6 11 1	(4.0) (7.4) (0.7)	0 8 2	(5.2) (1.3)	1 5	(0.6) (3.2) (3.2)	4	(2.6) (2.0) (1.3)	2 5 0	(2.6) (6.5)
EPISTAXIS LARYNGISMUS LARYNGITIS	0.435 0.637 0.637	0 1 1	(0.7) (0.7)	1 1 1	(0.6) (0.6) (0.6)	5 3 0 0	(1.9)	2 3 0 0	(2.0)	1 0 0	(1.3)
LUNG DISORDER NOSE DRYNESS PHARYNGITIS	0.549 0.494 0.778	3 0 6	(2.0)	3 0 7	(1.9) (4.5)	2 1 11	(1.3) (0.6) (7.0)	0 0 8	(5.3)	1 0 5	(1.3) (6.5)
PNEUMONIA PULMONARY PHYSICAL FINDING RHINITIS RHINITIS ALLERGIC	0.658 0.643 0.500 0.478	0 0 8 3	(5.4) (2.0)	1 1 8 1	(0.6) (0.6) (5.2) (0.6)	1 0 5 0	(0.6)	0 1 5 2	(0.7) (3.3) (1.3)	0 0 6 1	(7.8) (1.3)
SINUS CONGESTION SINUSITIS UPPER RESPIRATORY INFECTION VOICE ALTERATION	0.002** 0.621 0.080 0.494	1 11 18 0	(0.7) (7.4) (12.1)	4 14 16 0	(2.6) (9.0) (10.3)	0 7 11 1	(4.5) (7.0) (0.6)	1 11 6 0	(0.7) (7.3) (4.0)	5 5 9	(6.5) (6.5) (11.7)
WHEEZING YAWN	0.485 0.354	0		1 1	(0.6) (0.6)	0 3	(1.9)	0 2	(1.3)	0	
SKIN AND APPENDAGES ACNE CONTACT DERMATITIS	0.471 0.823 0.721	24 2 1	(16.1) (1.3) (0.7)	28 1 3	(18.1) (0.6) (1.9)	22 2 2 0	(14.0) (1.3) (1.3)	22 1 2	(14.6) (0.7) (1.3)	7 0 0	(9.1)
DERMATITIS ATOPIC DRY SKIN FUNGAL DERMATITIS HERPES SIMPLEX	0.458 0.724 0.318 0.381	1 2 0 1	(0.7) (1.3) (0.7)	0 2 1 4	(1.3) (0.6) (2.6)	0 3 0 2	(1.9) (1.3)	0 1 0 4	(0.7) (2.6)	0 0 1 0	(1.3)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.
Overall P-Value: P-value for Chi-Square.

Page

7

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Adverse Event	Overall P-Value *		R 50 mg =149	DVS S		DVS S	atment R 150 mg =157	DVS S	R 200 mg =151	Pla n=	
IMPETIGO MACULOPAPULAR RASH NIGHT SWEATS PRURITUS PSORIASIS RASH SEBORRHEA SKIN BENIGN NEOPLASM SKIN CARCINOMA SKIN DISCOLORATION SKIN DISCOLORATION SKIN DISCORDER SKIN MELANOMA SKIN ULCER SKIN WEINKLING SUNBURN SWEATING URTICARIA	0.468 0.494 0.340 0.086 0.494 0.064 0.468 0.838 0.093 0.643 0.123 0.494 0.494 0.494 0.485 0.023*	0 0 2 5 0 9 0 1 0 0 0 0 0 2	(1.3) (3.4) (6.0) (0.7) (0.7)	0 0 3 4 4 0 3 3 0 2 0 0 1 1 1 0 0 0 0 1 4	(1.9) (2.6) (1.9) (1.3) (0.6) (0.6) (2.6) (1.9)	0 1 1 6 1 4 0 2 0 0 0 0 1 1 1	(0.6) (0.6) (3.8) (0.6) (2.5) (1.3) (0.6) (0.6) (0.6) (1.3)	1 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0	(0.7) (0.7) (0.7) (0.7) (0.7) (0.7)	0 0 0 0 0 2 0 0 1 0 2 0 0	(2.6) (1.3) (2.6)
SPECIAL SENSES ABNORMAL VISION CATARACT SPECIFIED CONJUNCTIVITIS CORNEAL LESION DRY EYES EAR DISORDER EAR PAIN EYE DISORDER EYE PAIN GLAUCOMA HYPERACUSIS LACRIMATION DISORDER MIOSIS MYDRIASIS OTITIS EXTERNA OTITIS MEDIA PAROSMIA PHOTOPHOBIA	0.001** 0.107 0.548 0.353 0.648 0.468 0.870 0.739 0.360 0.586 0.458 0.485 0.093 0.494 0.010** 0.353 0.335 0.643 0.658	13 5 1 0 0 0 1 1 0 0 0 1 1 0 0 0 0 1 1 0 0 0 0 0 0	(8.7) (3.4) (0.7) (0.7) (0.7) (0.7) (0.7) (0.7)	25 9 0 2 0 0 1 4 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 0 1 0 0 0 0 1 0 0 0 0 1 0 0 0 0 1 0	(16.1) (5.8) (1.3) (0.6) (2.6) (0.6) (0.6) (2.6)	35 14 0 1 1 1 0 2 3 3 2 1 0 0 0 1 1 1 0 0 2 3 2 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0	(22.3) (8.9) (0.6) (0.6) (1.3) (1.9) (1.3) (0.6) (6.4) (1.3) (0.6)	31 10 1 0 1 1 1 2 0 0 0 0 0 0 0 0 0	(20.5) (6.6) (0.7) (0.7) (0.7) (0.7) (1.3) (1.3)	5 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0	(6.5) (1.3) (1.3) (1.3)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.
Overall P-Value: P-value for Chi-Square.

8

Page

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

Body System [1] Adverse Event	Overall P-Value *		R 50 mg =149		R 100 mg =155	DVS S	atment - R 150 mg =157		R 200 mg =151		acebo = 77
RETINAL DETACHMENT	0.458	1	(0.7)	0		0		0		0	
TASTE PERVERSION	0.306	1 2	(0.7)	2 7	(1.3)	5	(3.2)	3	(2.0)	0	
TINNITUS	0.072 0.312	2	(1.3)	0	(4.5)	1	(0.6)	4	(2.6)	0 1	(1 2)
VESTIBULAR DISORDER VITREOUS DISORDER	0.128	0		0		0		1 2	(0.7) (1.3)	0	(1.3)
JROGENITAL SYSTEM	0.816	15	(10.1)	20	(12.9)	19	(12.1)	14	(9.3)	10	(13.0)
ABNORMAL EJACULATION/ORGASM	0.494	0		0		1	(0.6)	0		0	
ANORGASMIA	0.468	0	(1 0)	0		0		1	(0.7)	0	/1 0:
BREAST CYST BREAST DISORDER	0.186 0.458	2	(1.3) (0.7)	0		0		0		1	(1.3)
BREAST DISORDER BREAST NEOPLASM	0.438	1	(0.7)		(1.3)	0		0			(1.3)
BREAST PAIN	0.423	0	(0.7)	2	(1.3)	1	(0.6)	1	(0.7)	1 3	(3.9)
CERVICITIS	0.485	0		1	(0.6)	0	(0.0)	0	(0.7)	0	(3.3)
CERVIX DISORDER	0.485	Õ		ī	(0.6)	Õ		Ô		Õ	
CYSTITIS	0.948	1	(0.7)	2	(1.3)	1	(0.6)	1	(0.7)	1	(1.3)
DYSURIA	0.468	0	, ,	0	, ,	0	, ,	1	(0.7)	0	, ,
FIBROCYSTIC BREAST	0.494	0		0		1	(0.6)	0		0	
HEMATURIA	0.322	0		0		1	(0.6)	0		1	(1.3)
KIDNEY CALCULUS	0.353	1	(0.7)	0		2	(1.3)	0	= .	0	
LEUKORRHEA	0.648						(0.6)	1	(0.7)	0	(1 0)
MASTITIS METRORRHAGIA	0.093 0.688	0	(2.0)	0	(0.6)	0	(1.3)	0	(1.3)	1	(1.3)
OLIGURIA	0.658	0	(2.0)	1	(0.6)	2 1	(0.6)	2	(1.3)	0	
OVARIAN CYST	0.093	0		0	(0.0)	0	(0.0)	0		1	(1.3)
PYELONEPHRITIS	0.468	0		Õ		0			(0.7)	0	(±.5)
SEXUAL FUNCTION ABNORMAL	0.632	ĭ	(0.7)	ĭ	(0.6)	3 1	(1.9)	1 2	(1.3)	Ŏ	
URINARY FREQUENCY	0.648	0	, ,	0	, ,		(0.6)	1	(0.7)	0	
URINARY HESĨTATION	0.468	0		0		0		1	(0.7)	0	
URINARY INCONTINENCE	0.658	0		1	(0.6)	1	(0.6)	0		0	
URINARY RETENTION	0.485	0		1	(0.6)			0		0	
URINARY TRACT DISORDER	0.458	1 6	(0.7)	0	(1 0)	0	(2.2)	0	(0.7)	0	/1 2\
URINARY TRACT INFECTION URINARY URGENCY	0.318 0.458	b 1	(4.0)	3	(1.9)	5 0	(3.2)	1	(0.7)	1	(1.3)
URINARY URGENCY URINE ABNORMALITY	0.458	U T	(0.7)	2	(1.3)	0		1	(0.7)	0	
UTERINE HEMORRHAGE	0.360	0		1	(0.6)	2	(1.3)	0	(0.7)	0	
VAGINAL DRYNESS	0.165	0		3	(1.9)	0	(1.0)	2	(1.3)	2	(2.6)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.
Overall P-Value: P-value for Chi-Square.

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Page

9

----- Treatment ------Body System [1] Overall DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg $\,$ Adverse Event P-Value * n=149n=155 n=157 n=151 0 VAGINAL HEMORRHAGE 0.161 (2.6)(0.6)(0.7)(2.6)0 VAGINAL MONILIASIS 0.485 0 (0.6)0 0 0.322 0 0 0 VAGINITIS 1 (0.6)(1.3)0 0 TERMS NOT CLASSIFIABLE 0.356 0 (1.3)(0.7)REACTION UNEVALUABLE 0.356 0 0 (1.3)1 (0.7)0 ADVERSE EVENT ASSOC.W.MISC. FACTORS 0.129 (9.1)3 2 2 3 ALLERGIC REACTION OTHER THAN DRUG 0.644 4 (2.7)(1.9)(1.3)(1.3)(3.9)LOCAL REACTION TO PROCEDURE 0.063 (1.3)(2.5)(1.3)(5.2)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

Page 10

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

- NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Adverse Event	Overall P-Value *		ment Comparator 2					Pairwise P-Value *
ANY ADVERSE EVENT	0.014*	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	134/149 134/149 134/149 134/149	(89.9) (89.9) (89.9) (89.9)	146/155 149/157 147/151 67/ 77	(94.2) (94.9) (97.4) (87.0)	0.204 0.129 0.009** 0.509
		DVS SR 100 mg		146/155 146/155 146/155	(94.2) (94.2) (94.2)	149/157 147/151 67/ 77	(94.9) (97.4) (87.0)	0.808 0.257 0.076
		DVS SR 150 mg DVS SR 200 mg		149/157 149/157 149/157	(94.9) (94.9) (97.4)	147/151 67/ 77 67/ 77	(97.4) (87.0) (87.0)	0.379 0.040* 0.006**
BODY AS A WHOLE	0.749	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	93/149 93/149 93/149	(62.4) (62.4) (62.4)	101/155 98/157 87/151	(65.2) (62.4) (57.6)	0.635 1.000 0.412
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	93/149 101/155 101/155 101/155	(62.4) (65.2) (65.2) (65.2)	47/ 77 98/157 87/151 47/ 77	(61.0) (62.4) (57.6) (61.0)	0.885 0.639 0.197 0.564
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	98/157 98/157 87/151	(62.4) (62.4) (57.6)	87/151 47/ 77 47/ 77	(57.6) (61.0) (61.0)	0.417 0.886 0.671
ABDOMINAL PAIN	0.036*	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	15/149 15/149 15/149 15/149	(10.1) (10.1) (10.1) (10.1)	5/155 11/157 4/151 4/ 77	(3.2) (7.0) (2.6) (5.2)	0.020* 0.413 0.009** 0.312
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	5/155 5/155 5/155	(3.2) (3.2) (3.2)	11/157 4/151 4/ 77	(7.0) (2.6) (5.2)	0.198 1.000 0.484
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	11/157 11/157 11/157 4/151	(7.0) (7.0) (2.6)	4/151 4/ 77 4/ 77	(2.6) (5.2) (5.2)	0.111 0.779 0.448
ABSCESS	0.468	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg	0/149 0/155 0/157 1/151	(0.7)	1/151 1/151 1/151 0/ 77	(0.7) (0.7) (0.7)	1.000 0.493 0.490 1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

Page 11

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5_TEAE

- NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

ody System [1]	Overall	Treat	ment		Rat	io		Pairwise
Adverse Event	P-Value *	Comparator 1		Comparat	or 1	Comparat	or 2	P-Value
ACCIDENTAL INJURY	0.244	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	11/149 11/149 11/149 11/149	(7.4) (7.4) (7.4) (7.4)	16/155 11/157 19/151 11/ 77	(10.3) (7.0) (12.6) (14.3)	0.423 1.000 0.177 0.104
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	16/155 16/155 16/155	(10.3) (10.3) (10.3)	11/157 19/151 11/ 77	(7.0) (12.6) (14.3)	0.321 0.592 0.390
		DVS SR 150 mg	DVS SR 200 mg Placebo	11/157 11/157	(7.0) (7.0)	19/151 11/ 77	(12.6) (14.3)	0.124 0.094
		DVS SR 200 mg	Placebo	19/151	(12.6)	11/ 77	(14.3)	0.836
ACCIDENTAL OVERDOSE	0.485	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.497 1.000 1.000
ALLERGIC REACTION	0.439	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	4/149 4/149 4/149 4/149	(2.7) (2.7) (2.7) (2.7)	1/155 2/157 3/151 0/ 77	(0.6) (1.3) (2.0)	0.207 0.438 0.722 0.302
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	1/155 1/155 1/155	(0.6) (0.6)	2/157 3/151	(1.3) (2.0)	1.000 0.366
		DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	2/157 2/157	(0.6) (1.3) (1.3)	0/ 77 3/151 0/ 77	(2.0)	1.000 0.679 1.000
		DVS SR 200 mg	Placebo	3/151	(2.0)	0/ 77		0.553
ASTHENIA	0.017*	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	11/149 11/149 11/149	(7.4) (7.4) (7.4)	30/155 27/157 23/151	(19.4) (17.2) (15.2)	0.002** 0.010** 0.044*
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	11/149 30/155 30/155 30/155	(7.4) (19.4) (19.4) (19.4)	7/ 77 27/157 23/151 7/ 77	(9.1) (17.2) (15.2) (9.1)	0.796 0.662 0.367 0.056
		DVS SR 150 mg	DVS SR 200 mg Placebo	27/157 27/157	(17.2) (17.2)	23/151 7/ 77	(15.2) (9.1)	0.647 0.116
		DVS SR 200 mg	Placebo	23/151	(15.2)	7/ 77	(9.1)	0.220

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

Page 12

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Adverse Event	Overall P-Value *	Treat Comparator 1	ment Comparator 2	Comparat		io Comparat		Pairwise P-Value
BACK PAIN	0.273	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	16/149 16/149 16/149 16/149	(10.7) (10.7) (10.7) (10.7)	14/155 10/157 9/151 10/ 77	(9.0) (6.4) (6.0) (13.0)	0.702 0.219 0.149 0.662
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	14/155 14/155 14/155	(9.0) (9.0) (9.0)	10/157 9/151 10/ 77	(6.4) (6.0) (13.0)	0.403 0.387 0.366
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	10/157 10/157 9/151	(6.4) (6.4) (6.0)	9/151 10/ 77 10/ 77	(6.0) (13.0) (13.0)	1.000 0.133 0.080
BODY ODOR	0.494	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 1/157 1/157	(0.6) (0.6)	1/157 1/157 0/151 0/ 77	(0.6) (0.6)	1.000 1.000 1.000 1.000
CELLULITIS	0.683	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	2/155 0/157 2/151 1/ 77	(1.3) (1.3) (1.3)	1.000 0.487 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	2/155 2/155 2/155	(1.3) (1.3) (1.3)	0/157 2/151 1/ 77	(1.3) (1.3) (1.3)	0.246 1.000 1.000
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	0/157 0/157 2/151	(1.3)	2/151 1/ 77 1/ 77	(1.3) (1.3) (1.3)	0.240 0.329 1.000
CHEST PAIN	0.607	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	4/149 4/149 4/149	(2.7) (2.7) (2.7)	3/155 5/157 3/151	(1.9) (3.2) (2.0)	0.719 1.000 0.722
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	4/149 3/155 3/155 3/155	(2.7) (1.9) (1.9) (1.9)	0/ 77 5/157 3/151 0/ 77	(3.2) (2.0)	0.302 0.723 1.000 0.553
		DVS SR 150 mg	DVS SR 200 mg Placebo	5/157 5/157 5/157 3/151	(3.2) (3.2) (2.0)	3/151 0/ 77 0/ 77	(2.0)	0.723 0.175 0.553

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Page 13

Body System [1]	Overall P-Value *		ment					Pairwise
Adverse Event	r-value ^	Comparator 1	Comparator 2	Comparato) T. T	Comparato) L Z	P-Value
CHILLS	0.120	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg	5/149 5/149 5/149 5/149 8/155	(3.4) (3.4) (3.4) (3.4) (5.2)	8/155 6/157 11/151 0/ 77 6/157	(5.2) (3.8) (7.3)	0.574 1.000 0.198 0.169 0.597
		-	DVS SR 200 mg Placebo	8/155 8/155	(5.2) (5.2)	11/151 0/ 77	(7.3)	0.485 0.055
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	6/157 6/157 11/151	(3.8) (3.8) (7.3)	11/151 0/ 77 0/ 77	(7.3)	0.217 0.181 0.018*
CYST	0.403	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	2/149 2/149 2/149	(1.3) (1.3) (1.3)	0/155 0/157 1/151	(0.7)	0.239 0.236 0.621
		DVS SR 100 mg	Placebo DVS SR 200 mg Placebo	2/149 0/155 0/155	(1.3)	1/ 77 1/151 1/ 77	(1.3) (0.7) (1.3)	1.000 0.493 0.332
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	0/157 0/157 1/151	(0.7)	1/151 1/ 77 1/ 77	(0.7) (1.3) (1.3)	0.490 0.329 1.000
FACE EDEMA	0.515	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/149 2/149 2/149 2/149	(1.3) (1.3) (1.3) (1.3)	1/155 0/157 2/151 0/ 77	(0.6) (1.3)	0.616 0.236 1.000 0.549
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/155 1/155 1/155 1/155	(0.6) (0.6) (0.6)	0/157 2/151 0/ 77	(1.3)	0.497 0.619 1.000
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo	0/157 2/151	(1.3)	2/151 0/ 77	(1.3)	0.240
FEVER	0.056	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg	2/149 2/149	(1.3) (1.3)	1/155 0/157	(0.6)	0.616
		DVS SR 100 mg	DVS SR 200 mg Placebo DVS SR 150 mg	2/149 2/149 1/155 1/155	(1.3) (1.3) (0.6)	5/151 0/ 77 0/157 5/151	(3.3)	0.448 0.549 0.497 0.117

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 14

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

ody System [1] Adverse Event	Overall P-Value *	Treat Comparator 1	ment Comparator 2	Comparat		io Comparat		Pairwise P-Value *
FEVER	0.056	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo DVS SR 200 mg Placebo	1/155 0/157 5/151	(0.6)	0/ 77 5/151 0/ 77	(3.3)	1.000 0.027* 0.170
FLU SYNDROME	0.267	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg	6/149 6/149 6/149 6/149 15/155 15/155	(4.0) (4.0) (4.0) (4.0) (9.7) (9.7)	15/155 9/157 10/151 3/ 77 9/157 10/151	(9.7) (5.7) (6.6) (3.9) (5.7) (6.6)	0.069 0.600 0.442 1.000 0.209 0.405
		DVS SR 150 mg DVS SR 200 mg	Placebo DVS SR 200 mg Placebo Placebo	15/155 9/157 9/157 10/151	(9.7) (5.7) (5.7) (6.6)	3/ 77 10/151 3/ 77 3/ 77	(3.9) (6.6) (3.9) (3.9)	0.191 0.815 0.755 0.551
GENERALIZED EDEMA	0.818	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7) (0.6)	1/155 0/157 1/151 0/ 77 0/157	(0.6) (0.7)	1.000 0.487 1.000 1.000
		DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	1/155 1/155 1/155 0/157 1/151	(0.6) (0.6) (0.6)	1/151 0/ 77 1/151 0/ 77	(0.7) (0.7)	0.497 1.000 1.000 0.490 1.000
HANGOVER EFFECT	0.093	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/149 0/155 0/157 0/151		1/ 77 1/ 77 1/ 77 1/ 77	(1.3) (1.3) (1.3) (1.3)	0.341 0.332 0.329 0.338
HEADACHE	0.549	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg	48/149 48/149 48/149 48/149 43/155 43/155	(32.2) (32.2) (32.2) (32.2) (27.7) (27.7)	43/155 55/157 42/151 26/ 77 55/157 42/151	(27.7) (35.0) (27.8) (33.8) (35.0) (27.8)	0.453 0.630 0.450 0.881 0.181 1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Page 15

Body System [1] Adverse Event	Overall P-Value *		ment Comparator 2			io Comparat		Pairwise P-Value '
HEADACHE	0.549	DVS SR 150 mg	DVS SR 200 mg Placebo Placebo	55/157 55/157 42/151	(35.0) (35.0) (27.8)	42/151 26/ 77 26/ 77	(27.8) (33.8) (33.8)	0.180 0.885 0.362
HEAT STROKE	0.093	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/149 0/155 0/157 0/151		1/ 77 1/ 77 1/ 77 1/ 77	(1.3) (1.3) (1.3) (1.3)	0.341 0.332 0.329 0.338
INFECTION	0.095	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	23/149 23/149 23/149 21/155 21/155 21/155 21/157 21/157 15/151	(15.4) (15.4) (15.4) (15.4) (13.5) (13.5) (13.5) (13.4) (13.4) (9.9)	21/155 21/157 15/151 18/ 77 21/157 15/151 18/ 77 15/151 18/ 77 18/ 77	(13.5) (13.4) (9.9) (23.4) (13.4) (9.9) (23.4) (9.9) (23.4) (23.4)	0.745 0.628 0.168 0.149 1.000 0.377 0.065 0.379 0.063 0.009**
INJECTION SITE HEMORRHAGE	0.485	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.497 1.000 1.000
LAB TEST ABNORMAL	0.122	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/149 2/149 2/149 2/149	(1.3) (1.3) (1.3) (1.3)	0/155 0/157 0/151 0/ 77		0.239 0.236 0.246 0.549
MALAISE	0.306	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 200 mg Placebo	0/149 0/149 0/149 3/155 3/155 3/155 1/157	(1.9) (1.9) (1.9) (0.6)	3/155 1/157 1/151 1/157 1/151 0/ 77 1/151	(1.9) (0.6) (0.7) (0.6) (0.7)	0.248 1.000 1.000 0.369 0.623 0.553 1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 16

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5_TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Adverse Event	Overall P-Value *		ment Comparator 2	 Comparat		io Comparato		Pairwise P-Value *
MALAISE	0.306	DVS SR 150 mg DVS SR 200 mg	Placebo Placebo	1/157 1/151	(0.6) (0.7)	0/ 77 0/ 77		1.000
MONILIASIS	0.637	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149 1/155 1/155	(0.7) (0.7) (0.7) (0.7) (0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77 0/157 0/151 0/ 77	(0.6)	1.000 0.487 0.497 1.000 0.497 1.000 1.000
NECK PAIN	0.284	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	5/149 5/149 5/149 5/149 1/155 1/155 1/155 4/157 4/157 6/151	(3.4) (3.4) (3.4) (0.6) (0.6) (0.6) (2.5) (4.0)	1/155 4/157 6/151 4/ 77 4/157 6/151 4/ 77 6/151 4/ 77 4/ 77	(0.6) (2.5) (4.0) (5.2) (2.5) (4.0) (5.2) (4.0) (5.2) (5.2)	0.115 0.745 1.000 0.494 0.371 0.064 0.043* 0.535 0.444 0.737
OVERDOSE	0.494	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 1/157 1/157	(0.6) (0.6)	1/157 1/157 0/151 0/ 77	(0.6) (0.6)	1.000 1.000 1.000 1.000
PAIN	0.130	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo	16/149 16/149 16/149 15/155 15/155 15/155 13/157 13/157	(10.7) (10.7) (10.7) (10.7) (9.7) (9.7) (9.7) (8.3) (8.3) (11.3)	15/155 13/157 17/151 15/ 77 13/157 17/151 15/ 77 17/151 15/ 77	(9.7) (8.3) (11.3) (19.5) (8.3) (11.3) (19.5) (11.3) (19.5) (19.5)	0.850 0.559 1.000 0.101 0.696 0.711 0.060 0.444 0.018*

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Pairwise P-Value: Fisher's Exact Test P-value (2-Tail).

CONFIDENTIAL 513 Wyeth

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Page 17

Body System [1] Adverse Event	Overall P-Value *		cment Comparator 2	Rage Comparator 1		io Comparator 2		Pairwise P-Value *	
PELVIC PAIN	0.122	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/149 2/149 2/149 2/149	(1.3) (1.3) (1.3) (1.3)	0/155 0/157 0/151 0/ 77		0.239 0.236 0.246 0.549	
PHOTOSENSITIVITY REACTION	0.485	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.497 1.000 1.000	
SARCOIDOSIS	0.468	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/149 0/155 0/157 1/151	(0.7)	1/151 1/151 1/151 0/ 77	(0.7) (0.7) (0.7)	1.000 0.493 0.490 1.000	
CARDIOVASCULAR SYSTEM	0.141	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo	13/149 13/149 13/149 21/155 21/155 21/155 25/157 25/157 28/151	(8.7) (8.7) (8.7) (13.5) (13.5) (13.5) (15.9) (15.9) (15.9)	21/155 25/157 28/151 9/ 77 25/157 28/151 9/ 77 28/151 9/ 77 9/ 77	(13.5) (15.9) (18.5) (11.7) (15.9) (18.5) (11.7) (18.5) (11.7) (11.7)	0.206 0.059 0.018* 0.485 0.633 0.276 0.836 0.550 0.436 0.254	
CARDIOVASCULAR PHYSICAL FINDING	0.458	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	0/155 0/157 0/151 0/ 77		0.490 0.487 0.497 1.000	
CORONARY ARTERY DISORDER	0.468	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/149 0/155 0/157 1/151	(0.7)	1/151 1/151 1/151 0/ 77	(0.7) (0.7) (0.7)	1.000 0.493 0.490 1.000	
CORONARY OCCLUSION	0.468	DVS SR 50 mg	DVS SR 200 mg	0/149		1/151	(0.7)	1.000	

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Pairwise P-Value: Fisher's Exact Test P-value (2-Tail).

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Page 18

Body System [1] Adverse Event	Overall P-Value *	Treat Comparator 1	ment Comparator 2	Comparato		io Comparato	Pairwise P-Value *	
CORONARY OCCLUSION	0.468	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg Placebo	0/155 0/157 1/151	(0.7)	1/151 1/151 0/ 77	(0.7) (0.7)	0.493 0.490 1.000
HYPERTENSION	0.255	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	6/149 6/149 6/149 6/149 8/155 8/155 8/155 10/157 10/157	(4.0) (4.0) (4.0) (4.0) (5.2) (5.2) (5.2) (6.4) (6.4) (7.9)	8/155 10/157 12/151 1/ 77 10/157 12/151 1/ 77 12/151 1/ 77 1/ 77	(5.2) (6.4) (7.9) (1.3) (6.4) (7.9) (1.3) (7.9) (1.3) (1.3)	0.786 0.445 0.224 0.427 0.809 0.362 0.278 0.661 0.107 0.065
MIGRAINE	0.676	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	1/149 1/149 1/149 1/149 4/155 4/155 4/155 4/157 4/157 4/157	(0.7) (0.7) (0.7) (0.7) (2.6) (2.6) (2.6) (2.5) (2.5) (2.6)	4/155 4/157 4/151 1/ 77 4/157 4/151 1/ 77 4/151 1/ 77 1/ 77	(2.6) (2.5) (2.6) (1.3) (2.5) (2.6) (1.3) (2.6) (1.3) (1.3)	0.371 0.372 0.371 1.000 1.000 1.000 1.000 1.000 0.665
MYOCARDIAL INFARCT	0.642	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149 0/155 1/157	(0.7) (0.7) (0.7) (0.7) (0.6) (0.6)	0/155 1/157 0/151 0/ 77 1/157 0/151 0/ 77	(0.6)	0.490 1.000 0.497 1.000 1.000 1.000
PALPITATION	0.544	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	4/149 4/149 4/149	(2.7) (2.7) (2.7)	5/155 2/157 5/151	(3.2) (1.3) (3.3)	1.000 0.438 1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Page 19

Body System [1] Adverse Event	Overall P-Value *		cment Comparator 2			Comparator 2		Pairwise P-Value *	
PALPITATION	0.544	DVS SR 50 mg DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	4/149 5/155 5/155 5/155 2/157 2/157	(2.7) (3.2) (3.2) (3.2) (3.2) (1.3) (1.3)	4/ 77 2/157 5/151 4/ 77 5/151 4/ 77	(5.2) (1.3) (3.3) (5.2) (3.3) (5.2)	0.449 0.281 1.000 0.484 0.275 0.093	
		DVS SR 200 mg	Placebo	5/151	(3.3)	4/ 77	(5.2)	0.491	
PERIPHERAL VASCULAR DISORDER	0.627	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149 0/155 0/157 1/151	(0.7) (0.7) (0.7) (0.7)	0/155 0/157 1/151 0/ 77 1/151 1/151 0/ 77	(0.7) (0.7) (0.7)	0.490 0.487 1.000 1.000 0.493 0.490 1.000	
SYNCOPE	0.494	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 1/157 1/157	(0.6) (0.6)	1/157 1/157 0/151 0/ 77	(0.6) (0.6)	1.000 1.000 1.000 1.000	
TACHYCARDIA	0.819	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	3/149 3/149 3/149 3/149 3/155 3/155 3/155 3/157 3/157 3/157	(2.0) (2.0) (2.0) (2.0) (1.9) (1.9) (1.9) (1.9) (1.9) (2.0)	3/155 3/157 3/151 0/ 77 3/157 3/157 3/151 0/ 77 0/ 77	(1.9) (1.9) (2.0) (1.9) (2.0) (2.0)	1.000 1.000 1.000 0.553 1.000 1.000 0.553 1.000 0.553 0.553	
VARICOSE VEIN	0.093	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/149 0/155 0/157 0/151		1/ 77 1/ 77 1/ 77 1/ 77	(1.3) (1.3) (1.3) (1.3)	0.341 0.332 0.329 0.338	

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

Page 20

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT AE5_TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Adverse Event	Overall P-Value *	Treat Comparator 1	ment Comparator 2	 Comparat		io Comparat		Pairwise P-Value *
VASODILATATION	0.556	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/149 2/149 2/149 2/149	(1.3) (1.3) (1.3) (1.3)	2/155 6/157 4/151 2/ 77	(1.3) (3.8) (2.6) (2.6)	1.000 0.284 0.684 0.607
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	2/155 2/155 2/155 2/155	(1.3) (1.3) (1.3)	6/157 4/151 2/ 77	(3.8) (2.6) (2.6)	0.283 0.443 0.601
		DVS SR 150 mg	DVS SR 200 mg Placebo Placebo	6/157 6/157 4/151	(3.8) (3.8) (2.6)	4/151 2/ 77 2/ 77	(2.6) (2.6) (2.6)	0.750 1.000 1.000
DIGESTIVE SYSTEM	<0.001***	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	83/149 83/149 83/149	(55.7) (55.7) (55.7)	99/155 114/157 104/151	(63.9) (72.6) (68.9)	0.161 0.003** 0.023*
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	83/149 99/155 99/155 99/155	(55.7) (63.9) (63.9) (63.9)	28/ 77 114/157 104/151 28/ 77	(36.4) (72.6) (68.9) (36.4)	0.008** 0.114 0.398 <0.001***
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	114/157 114/157 104/151	(72.6) (72.6) (68.9)	104/151 28/ 77 28/ 77	(68.9) (36.4) (36.4)	0.531 <0.001*** <0.001***
ABDOMINAL DISTENSION	0.013*	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	3/149 3/149 3/149 3/149	(2.0) (2.0) (2.0) (2.0)	0/155 1/157 1/151 4/ 77	(0.6) (0.7) (5.2)	0.117 0.360 0.369 0.233
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	0/155 0/155 0/155	(2.0)	1/157 1/151 4/ 77	(0.6) (0.7) (5.2)	1.000 0.493 0.012*
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	1/157 1/157 1/151	(0.6) (0.6) (0.7)	1/151 4/ 77 4/ 77	(0.7) (5.2) (5.2)	1.000 0.041* 0.046*
ANOREXIA	0.171	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	7/149 7/149 7/149 7/149	(4.7) (4.7) (4.7) (4.7)	9/155 13/157 15/151 2/ 77	(5.8) (8.3) (9.9) (2.6)	0.799 0.250 0.120 0.722

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Page 21

Body System [1] Adverse Event	Overall P-Value *		cment Comparator 2			io Comparat		Pairwise P-Value *
ANOREXIA	0.171	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	9/155 9/155 9/155 13/157 13/157 15/151	(5.8) (5.8) (5.8) (8.3) (8.3) (9.9)	13/157 15/151 2/ 77 15/151 2/ 77 2/ 77	(8.3) (9.9) (2.6) (9.9) (2.6) (2.6)	0.508 0.206 0.345 0.693 0.153 0.061
BLOOD IN STOOL	0.637	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149 1/155 1/155	(0.7) (0.7) (0.7) (0.7) (0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77 0/157 0/151 0/ 77	(0.6)	1.000 0.487 0.497 1.000 0.497 1.000
CHOLECYSTITIS	0.485	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.497 1.000 1.000
CHOLELITHIASIS	0.141	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 2/155 2/155 2/155	(1.3) (1.3) (1.3)	2/155 0/157 0/151 0/ 77	(1.3)	0.499 0.246 0.498 1.000
COLITIS	0.108	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg DVS SR 200 mg Placebo	3/149 3/149 3/149 3/149 0/155 0/157 1/151	(2.0) (2.0) (2.0) (2.0) (2.7)	0/155 0/157 1/151 0/ 77 1/151 1/151 0/ 77	(0.7) (0.7) (0.7)	0.117 0.114 0.369 0.553 0.493 0.490 1.000
CONSTIPATION	0.266	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	16/149 16/149 16/149 16/149	(10.7) (10.7) (10.7) (10.7)	27/155 25/157 27/151 8/ 77	(17.4) (15.9) (17.9) (10.4)	0.102 0.240 0.099 1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Page 22

Body System [1] Adverse Event	Overall P-Value *	Treat Comparator 1	cment Comparator 2	 Comparat		cio Comparat		Pairwise P-Value *
CONSTIPATION	0.266	DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	27/155 27/155 27/155	(17.4) (17.4) (17.4)	25/157 27/151 8/ 77	(15.9) (17.9) (10.4)	0.763 1.000 0.178
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo	25/157 25/157 25/157 27/151	(15.9) (15.9) (17.9)	27/151 8/ 77 8/ 77	(17.9) (10.4)	0.652 0.319 0.175
DIARRHEA	0.482	DVS SR 200 mg	Placebo DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	17/149 17/149 17/149	(11.4) (11.4) (11.4)	12/155 9/157 14/151	(10.4) (7.7) (5.7) (9.3)	0.331 0.100 0.574
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	17/149 12/155 12/155 12/155	(11.4) (7.7) (7.7) (7.7)	6/ 77 9/157 14/151 6/ 77	(7.8) (5.7) (9.3) (7.8)	0.490 0.507 0.685 1.000
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	9/157 9/157 14/151	(5.7) (5.7) (9.3)	14/151 6/ 77 6/ 77	(9.3) (7.8) (7.8)	0.281 0.576 0.808
DRY MOUTH	0.001**	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	18/149 18/149 18/149 18/149	(12.1) (12.1) (12.1) (12.1)	33/155 31/157 35/151 3/ 77	(21.3) (19.7) (23.2) (3.9)	0.033* 0.086 0.015* 0.053
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	33/155 33/155 33/155	(21.3) (21.3) (21.3)	31/157 35/151 3/ 77	(19.7) (23.2) (3.9)	0.780 0.783 <0.001***
		DVS SR 150 mg	DVS SR 200 mg Placebo Placebo	31/157 31/157 31/157 35/151	(19.7) (19.7) (23.2)	35/151 3/ 77 3/ 77	(23.2) (3.9) (3.9)	0.490 <0.001*** <0.001***
DUODENITIS	0.494	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 1/157 1/157	(0.6)	1/157 1/157 0/151 0/ 77	(0.6)	1.000 1.000 1.000 1.000
DYSPEPSIA	0.203	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	18/149 18/149 18/149	(12.1) (12.1) (12.1)	13/155 16/157 13/151	(8.4) (10.2) (8.6)	0.345 0.716 0.348

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Page 23

Body System [1] Adverse Event	Overall P-Value *		ment Comparator 2			io Comparato		Pairwise P-Value *
DYSPEPSIA	0.203	DVS SR 50 mg DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	18/149 13/155 13/155 13/155	(12.1) (8.4) (8.4) (8.4)	2/ 77 16/157 13/151 2/ 77	(2.6) (10.2) (8.6) (2.6)	0.024* 0.697 1.000 0.153
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	16/157 16/157 13/151	(10.2) (10.2) (8.6)	13/151 2/ 77 2/ 77	(8.6) (2.6) (2.6)	0.699 0.064 0.097
DYSPHAGIA	0.856	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	2/155 2/157 2/151 0/ 77	(1.3) (1.3) (1.3)	1.000 1.000 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	2/155 2/155 2/155	(1.3) (1.3) (1.3)	2/157 2/151 0/ 77	(1.3) (1.3)	1.000 1.000 1.000
		DVS SR 150 mg DVS SR 200 mg	Placebo	2/157 2/157 2/151	(1.3) (1.3) (1.3)	2/151 0/ 77 0/ 77	(1.3)	1.000 1.000 0.551
ERUCTATION	0.846	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	2/149 2/149 2/149	(1.3) (1.3) (1.3)	1/155 1/157 1/151	(0.6) (0.6) (0.7)	0.616 0.614 0.621
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	2/149 1/155 1/155 1/155	(1.3) (0.6) (0.6) (0.6)	0/ 77 1/157 1/151 0/ 77	(0.6) (0.7)	0.549 1.000 1.000 1.000
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	1/157 1/157 1/151	(0.6) (0.6) (0.7)	1/151 0/ 77 0/ 77	(0.7)	1.000 1.000 1.000
ESOPHAGEAL ULCER	0.485	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.497 1.000 1.000
ESOPHAGITIS	0.642	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg	1/149 1/149	(0.7) (0.7)	0/155 1/157	(0.6)	0.490 1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 24

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

- NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Adverse Event	Overall P-Value *	Treat Comparator 1	ment Comparator 2			io Comparato		Pairwise P-Value *
ESOPHAGITIS	0.642	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	1/149 0/155 1/157	(0.7) (0.7) (0.6) (0.6)	0/151 0/ 77 1/157 0/151 0/ 77	(0.6)	0.497 1.000 1.000 1.000 1.000
FLATULENCE	0.941	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Placebo	1/149 1/149 1/149 1/155 1/155 1/155 1/157 1/157	(0.7) (0.7) (0.7) (0.7) (0.6) (0.6) (0.6) (0.6) (0.6) (1.3)	1/155 1/157 2/151 1/77 1/157 2/151 1/77 2/151 1/77 1/77	(0.6) (0.6) (1.3) (1.3) (0.6) (1.3) (1.3) (1.3) (1.3)	1.000 1.000 1.000 1.000 1.000 0.619 1.000 0.617 0.551 1.000
GAMMA GLUTAMYL TRANSPEPTIDASE INCREASED	0.485	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/155	(0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.497 1.000
GASTRITIS	0.093	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/149 0/155 0/157 0/151		1/ 77 1/ 77 1/ 77 1/ 77	(1.3) (1.3) (1.3) (1.3)	0.341 0.332 0.329 0.338
GASTROENTERITIS	0.711	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	2/149 2/149 2/149 5/155 5/155 5/155 5/157 5/157	(1.3) (1.3) (1.3) (1.3) (1.3) (3.2) (3.2) (3.2) (3.2) (3.2) (3.2) (2.0)	5/155 5/157 3/151 1/ 77 5/157 3/151 1/ 77 3/151 1/ 77 1/ 77	(3.2) (3.2) (2.0) (1.3) (3.2) (2.0) (1.3) (2.0) (1.3) (1.3)	0.448 0.449 1.000 1.000 0.723 0.666 0.723 0.667 1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 25

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

- NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Adverse Event	Overall P-Value *		ment Comparator 2			io Comparato		Pairwise P-Value *
GASTROESOPHAGEAL REFLUX DISEASE	0.173	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	3/149 3/149 3/149 3/149	(2.0) (2.0) (2.0) (2.0)	3/155 1/157 6/151 0/ 77	(1.9) (0.6) (4.0)	1.000 0.360 0.501 0.553
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	3/155 3/155 3/155	(1.9) (1.9) (1.9)	1/157 6/151 0/ 77	(0.6) (4.0)	0.369 0.331 0.553
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/157 1/157 1/157 6/151	(0.6) (0.6) (4.0)	6/151 0/ 77 0/ 77	(4.0)	0.063 1.000 0.099
CACEDOINEECHINAL DICODDED	0.360	3			(4.0)		(0, 6)	
GASTROINTESTINAL DISORDER	0.360	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	0/149 0/149 1/155 1/155	(0.6) (0.6)	1/155 2/157 2/157 0/151	(0.6) (1.3) (1.3)	1.000 0.499 1.000 1.000
		DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	1/155 2/157 2/157	(0.6) (1.3) (1.3)	0/ 77 0/151 0/ 77		1.000 0.499 1.000
GASTROINTESTINAL PHYSICAL FINDING	0.458	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	0/155 0/157 0/151 0/ 77		0.490 0.487 0.497 1.000
GINGIVITIS	0.318	DVS SR 50 mg	DVS SR 100 mg Placebo	0/149 0/149		1/155 1/ 77	(0.6) (1.3)	1.000 0.341
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/155 1/155 1/155	(0.6) (0.6) (0.6)	0/157 0/151 1/ 77	(1.3)	0.497 1.000 1.000
		DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo	0/157 0/151	(0.6)	1/ 77 1/ 77 1/ 77	(1.3) (1.3) (1.3)	0.329 0.338
GLOSSITIS	0.637	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.487 0.497 1.000
		DVS SR 100 mg	DVS SR 150 mg	1/155	(0.6)	0/157		0.497

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

Pairwise P-Value: Fisher's Exact Test P-value (2-Tail).

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Page 26

Body System [1] Adverse Event	Overall P-Value *		ment Comparator 2			io Comparato		Pairwise P-Value
GLOSSITIS	0.637	DVS SR 100 mg	DVS SR 200 mg Placebo	1/155 1/155	(0.6) (0.6)	0/151 0/ 77		1.000
HEMORRHAGIC GASTRITIS	0.494	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 1/157 1/157	(0.6) (0.6)	1/157 1/157 0/151 0/ 77	(0.6) (0.6)	1.000 1.000 1.000 1.000
HEPATITIS	0.494	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg		0/149 0/155 1/157 1/157	(0.6) (0.6)	1/157 1/157 0/151 0/ 77	(0.6) (0.6)	1.000 1.000 1.000 1.000
HIATAL HERNIA	0.642	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149 0/155 1/157	(0.7) (0.7) (0.7) (0.7) (0.6) (0.6)	0/155 1/157 0/151 0/ 77 1/157 0/151 0/ 77	(0.6)	0.490 1.000 0.497 1.000 1.000 1.000
INCREASED APPETITE	0.949	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg	3/149 3/149 3/149 3/155 3/155 3/155 4/157	(2.0) (2.0) (2.0) (2.0) (1.9) (1.9) (1.9) (2.5)	3/155 4/157 2/151 2/ 77 4/157 2/151 2/ 77 2/151	(1.9) (2.5) (1.3) (2.6) (2.5) (1.3) (2.6) (1.3)	1.000 1.000 0.683 1.000 1.000 1.000 0.685
		DVS SR 200 mg	Placebo	4/157 2/151	(2.5) (1.3)	2/77 2/77	(2.6) (2.6)	1.000
LIVER FUNCTION TESTS ABNORMAL	0.825	DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg	2/149 2/149 2/149 2/149 1/155	(1.3) (1.3) (1.3) (1.3) (0.6)	1/155 3/157 1/151 1/ 77 3/157	(0.6) (1.9) (0.7) (1.3) (1.9)	0.616 1.000 0.621 1.000 0.623

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 27

29SEP05 14:53 REPORT AE5 TEAE CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Adverse Event	Overall P-Value *		ment Comparator 2			io Comparat		Pairwise P-Value *
LIVER FUNCTION TESTS ABNORMAL	0.825	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	1/155 1/155 3/157 3/157 1/151	(0.6) (0.6) (1.9) (1.9) (0.7)	1/151 1/ 77 1/151 1/ 77 1/ 77	(0.7) (1.3) (0.7) (1.3) (1.3)	1.000 1.000 0.623 1.000 1.000
NAUSEA	<0.001***	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg	41/149 41/149 41/149 41/149 60/155 60/155	(27.5) (27.5) (27.5) (27.5) (27.5) (38.7) (38.7)	60/155 75/157 68/151 5/ 77 75/157 68/151	(38.7) (47.8) (45.0) (6.5) (47.8) (45.0)	0.040* <0.001*** 0.002** <0.001*** 0.111 0.297
		DVS SR 150 mg DVS SR 200 mg	Placebo DVS SR 200 mg Placebo Placebo	60/155 75/157 75/157 68/151	(38.7) (47.8) (47.8) (45.0)	5/ 77 68/151 5/ 77 5/ 77	(6.5) (45.0) (6.5) (6.5)	<0.001*** 0.649 <0.001*** <0.001***
NAUSEA AND VOMITING	0.594	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0/149 0/149 0/149 1/155 1/155 1/155 1/157	(0.6) (0.6) (0.6) (0.6) (0.6)	1/155 1/157 2/151 1/157 2/151 0/ 77 2/151 0/ 77	(0.6) (0.6) (1.3) (0.6) (1.3) (1.3)	1.000 1.000 0.498 1.000 0.619 1.000 0.617 1.000
ORAL MONILIASIS	0.485	DVS SR 200 mg DVS SR 50 mg DVS SR 100 mg	Placebo DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/151 0/149 1/155 1/155 1/155	(0.6) (0.6) (0.6)	0/ 77 1/155 0/157 0/151 0/ 77	(0.6)	0.551 1.000 0.497 1.000 1.000
PANCREATITIS	0.494	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 1/157 1/157	(0.6) (0.6)	1/157 1/157 0/151 0/ 77	(0.6) (0.6)	1.000 1.000 1.000 1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

Pairwise P-Value: Fisher's Exact Test P-value (2-Tail).

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Page 28

Body System [1] Adverse Event	Overall P-Value *	Treat Comparator 1		Comparato		io Comparato		Pairwise P-Value
PEPTIC ULCER	0.642	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg	1/149 1/149 1/149 1/149 0/155 1/157	(0.7) (0.7) (0.7) (0.7) (0.6)	0/155 1/157 0/151 0/ 77 1/157 0/151	(0.6)	0.490 1.000 0.497 1.000 1.000
PERIODONTAL ABSCESS	0.594	DVS SR 50 mg DVS SR 100 mg	Placebo DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/157 0/149 0/149 0/149 1/155 1/155	(0.6) (0.6) (0.6)	0/ 77 1/155 1/157 2/151 1/157 2/151 0/ 77	(0.6) (0.6) (1.3) (0.6) (1.3)	1.000 1.000 0.498 1.000 0.619 1.000
PERIODONTITIS	0.642	DVS SR 150 mg DVS SR 200 mg DVS SR 50 mg	DVS SR 200 mg Placebo Placebo DVS SR 100 mg DVS SR 150 mg	1/157 1/157 2/151 1/149 1/149	(0.6) (0.6) (1.3) (0.7) (0.7)	2/151 0/ 77 0/ 77 0/155 1/157	(1.3)	0.617 1.000 0.551 0.490 1.000
		DVS SR 100 mg DVS SR 150 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 0/155 1/157 1/157	(0.7) (0.7) (0.6) (0.6)	0/151 0/ 77 1/157 0/151 0/ 77	(0.6)	0.497 1.000 1.000 1.000
RECTAL DISORDER	0.708	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg	1/149 1/149 1/149 1/149 0/155 0/155	(0.7) (0.7) (0.7) (0.7)	0/155 2/157 1/151 1/ 77 2/157 1/151	(1.3) (0.7) (1.3) (1.3) (0.7)	0.490 1.000 1.000 1.000 0.498 0.493
		DVS SR 150 mg DVS SR 200 mg	Placebo DVS SR 200 mg Placebo Placebo	0/155 2/157 2/157 1/151	(1.3) (1.3) (0.7)	1/ 77 1/151 1/ 77 1/ 77	(1.3) (0.7) (1.3) (1.3)	0.332 1.000 1.000 1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 29

29SEP05 14:53 REPORT AE5 TEAE

CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

ody System [1]	Overall		ment					Pairwise
Adverse Event	P-Value *	Comparator 1	Comparator 2	Comparato	or 1	Comparato	or 2	P-Value
RECTAL HEMORRHAGE	0.821	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	0/155 1/157 1/151 0/ 77	(0.6) (0.7)	0.490 1.000 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg	0/155	(0.7)	1/157	(0.6) (0.7)	1.000
		DVS SR 150 mg	DVS SR 200 mg DVS SR 200 mg Placebo	0/155 1/157 1/157	(0.6) (0.6)	1/151 1/151 0/ 77	(0.7)	0.493 1.000 1.000
		DVS SR 200 mg	Placebo	1/151	(0.7)	0/ 77		1.000
STOOLS ABNORMAL	0.147	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 2/157 2/157	(1.3) (1.3)	2/157 2/157 0/151 0/ 77	(1.3) (1.3)	0.499 0.498 0.499 1.000
TONGUE EDEMA	0.128	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/149 0/155 0/157 2/151	(1.3)	2/151 2/151 2/151 0/ 77	(1.3) (1.3) (1.3)	0.498 0.243 0.240 0.551
TOOTH CARIES	0.688	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	0/155 1/157 2/151 1/ 77	(0.6) (1.3) (1.3)	0.490 1.000 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	0/155 0/155 0/155		1/157 2/151 1/ 77	(0.6) (1.3) (1.3)	1.000 0.243 0.332
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/157 1/157	(0.6) (0.6)	2/151 1/ 77	(1.3) (1.3)	0.617 0.551
		DVS SR 200 mg	Placebo	2/151	(1.3)	1/ 77	(1.3)	1.000
ULCERATIVE STOMATITIS	0.141	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 2/155 2/155 2/155	(1.3) (1.3) (1.3)	2/155 0/157 0/151 0/ 77	(1.3)	0.499 0.246 0.498 1.000
VOMITING	0.028*	DVS SR 50 mg	DVS SR 100 mg	8/149	(5.4)	11/155	(7.1)	0.638

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

Pairwise P-Value: Fisher's Exact Test P-value (2-Tail).

Page 30

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Adverse Event	Overall P-Value *	Treat Comparator 1		 Comparat			io Comparator 2	
VOMITING	0.028*	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	8/149 8/149 8/149 11/155 11/155 11/157 11/157	(5.4) (5.4) (5.4) (7.1) (7.1) (7.1)	11/157 17/151 0/ 77 11/157 17/151 0/ 77 17/151 0/ 77	(7.0) (11.3) (7.0) (11.3) (11.3)	0.639 0.093 0.054 1.000 0.237 0.018* 0.236 0.018*
		DVS SR 200 mg	Placebo Placebo	17/151	(7.0) (11.3)	0/ 77		<0.018^
ENDOCRINE SYSTEM	0.625	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/149 2/149 2/149 2/149	(1.3) (1.3) (1.3) (1.3)	1/155 1/157 3/151 2/ 77	(0.6) (0.6) (2.0) (2.6)	0.616 0.614 1.000 0.607
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/157 3/151 2/ 77	(0.6) (2.0) (2.6)	1.000 0.366 0.256
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	1/157 1/157 3/151	(0.6) (0.6) (2.0)	3/151 2/ 77 2/ 77	(2.0) (2.6) (2.6)	0.363 0.253 1.000
DIABETES MELLITUS	0.643	DVS SR 50 mg	DVS SR 100 mg	0/149 0/149		1/155 1/151	(0.6) (0.7)	1.000
		DVS SR 100 mg	DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/155 1/155 1/155	(0.6) (0.6) (0.6)	0/157 1/151 0/ 77	(0.7)	0.497 1.000 1.000
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo	0/157 1/151	(0.7)	1/151 0/ 77	(0.7)	0.490
GOITER	0.312	DVS SR 50 mg	DVS SR 200 mg Placebo	0/149 0/149		1/151 1/ 77	(0.7) (1.3)	1.000
		DVS SR 100 mg	DVS SR 200 mg Placebo	0/149 0/155 0/155		1/151 1/ 77	(0.7)	0.493
		DVS SR 150 mg	DVS SR 200 mg Placebo	0/157 0/157		1/151 1/ 77	(0.7) (1.3)	0.490 0.329
		DVS SR 200 mg	Placebo	1/151	(0.7)	1/ 77	(1.3)	1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

29SEP05 14:53 REPORT AE5 TEAE CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

NORDER (*) OF SODDECTS RETORITING TREATMENT EMERGENT ADVERGE EVENTS

Page 31

Body System [1] Adverse Event	Overall P-Value *		ment Comparator 2			io Comparato		Pairwise P-Value *
HYPOTHYROIDISM	0.637	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg	1/149 1/149 1/149 1/149 1/155 1/155	(0.7) (0.7) (0.7) (0.7) (0.6) (0.6)	1/155 0/157 0/151 0/ 77 0/157 0/157	(0.6)	1.000 0.487 0.497 1.000 0.497 1.000
PARATHYROID DISORDER	0.642	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	Placebo DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	1/155 1/149 1/149 1/149 1/149 0/155 1/157 1/157	(0.6) (0.7) (0.7) (0.7) (0.7) (0.6) (0.6)	0/77 0/155 1/157 0/151 0/77 1/157 0/151 0/77	(0.6)	1.000 0.490 1.000 0.497 1.000 1.000 1.000
THYROID DISORDER	0.312	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	0/149 0/149 0/155 0/155 0/157 0/157 1/151	(0.7)	1/151 1/ 77 1/151 1/ 77 1/151 1/ 77 1/ 77	(0.7) (1.3) (0.7) (1.3) (0.7) (1.3) (1.3)	1.000 0.341 0.493 0.332 0.490 0.329 1.000
HEMIC AND LYMPHATIC SYSTEM	0.233	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo	2/149 2/149 2/149 2/149 7/155 7/155 7/155 6/157 6/157 5/151	(1.3) (1.3) (1.3) (1.3) (4.5) (4.5) (4.5) (3.8) (3.8) (3.3)	7/155 6/157 5/151 0/ 77 6/157 5/151 0/ 77 5/151 0/ 77 0/ 77	(4.5) (3.8) (3.3) (3.8) (3.3) (3.3)	0.174 0.284 0.448 0.549 0.785 0.770 0.099 1.000 0.181 0.170
ANEMIA	0.658	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg	0/149 0/149		1/155 1/157	(0.6) (0.6)	1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Page 32

Body System [1] Adverse Event	Overall P-Value *	Treat Comparator 1	ment Comparator 2	Comparato		io Comparato		Pairwise P-Value
ANEMIA	0.658	DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	1/155 1/155 1/155 1/157	(0.6) (0.6) (0.6) (0.6)	1/157 0/151 0/ 77 0/151	(0.6)	1.000 1.000 1.000 1.000
ECCHYMOSIS	0.341	DVS SR 50 mg	Placebo DVS SR 100 mg	1/157	(0.6)	0/ 77 4/155	(2.6)	1.000
Zeemmoors	0.011	DVD DIC 30 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149	(0.7) (0.7) (0.7)	5/157 3/151 0/ 77	(3.2)	0.215 0.623 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	4/155 4/155 4/155	(2.6) (2.6) (2.6)	5/157 3/151 0/ 77	(3.2) (2.0)	1.000 1.000 0.305
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo	5/157 5/157 5/157 3/151	(3.2) (3.2) (2.0)	3/151 0/ 77 0/ 77	(2.0)	0.723 0.175 0.553
GRANULOCYTOSIS	0.468	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/149 0/155 0/157 1/151	(0.7)	1/151 1/151 1/151 0/ 77	(0.7) (0.7) (0.7)	1.000 0.493 0.490 1.000
LEUKOCYTOSIS	0.468	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/149 0/155 0/157 1/151	(0.7)	1/151 1/151 1/151 0/ 77	(0.7) (0.7) (0.7)	1.000 0.493 0.490 1.000
LYMPHADENOPATHY	0.818	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	1/155 0/157 1/151 0/ 77	(0.6) (0.7)	1.000 0.487 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/155 1/155 1/155 1/155	(0.7) (0.6) (0.6) (0.6)	0/157 1/151 0/ 77	(0.7)	0.497 1.000 1.000
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo	0/157 1/151	(0.7)	1/151 0/ 77	(0.7)	0.490 1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Page 33

Body System [1] Adverse Event	Overall P-Value *	Treat Comparator 1	comparator 2	 Comparat		io Comparat		Pairwise P-Value *
LYMPHOPENIA	0.468	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg		0/149 0/155 0/157 1/151	(0.7)	1/151 1/151 1/151 0/ 77	(0.7) (0.7) (0.7)	1.000 0.493 0.490 1.000
NEUTROPENIA	0.485	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.497 1.000
METABOLIC AND NUTRITIONAL	0.115	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	15/149 15/149 15/149 15/149 29/155 29/155 29/157 29/157 31/151	(10.1) (10.1) (10.1) (10.1) (18.7) (18.7) (18.7) (18.5) (18.5) (20.5)	29/155 29/157 31/151 11/ 77 29/157 31/151 11/ 77 31/151 11/ 77 11/ 77	(18.7) (18.5) (20.5) (14.3) (18.5) (20.5) (14.3) (20.5) (14.3) (14.3)	0.035* 0.050* 0.016* 0.382 1.000 0.774 0.464 0.668 0.466
ALKALINE PHOSPHATASE INCREASED	0.333	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo	0/149 0/149 1/155 1/155 1/155 0/157 2/151	(0.6) (0.6) (0.6) (1.3)	1/155 2/151 0/157 2/151 0/ 77 2/151 0/ 77	(0.6) (1.3) (1.3) (1.3)	1.000 0.498 0.497 0.619 1.000 0.240 0.551
DEHYDRATION	0.643	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg		0/149 0/149 1/155 1/155 1/155 0/157 1/151	(0.6) (0.6) (0.6) (0.7)	1/155 1/151 0/157 1/151 0/ 77 1/151 0/ 77	(0.6) (0.7) (0.7) (0.7)	1.000 1.000 0.497 1.000 1.000 0.490 1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 34

29SEP05 14:53 REPORT AE5 TEAE CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Adverse Event	Overall P-Value *		ment Comparator 2			io Comparato		Pairwise P-Value *
GLUCOSE TOLERANCE DECREASED	0.494	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 1/157 1/157	(0.6)	1/157 1/157 0/151 0/ 77	(0.6)	1.000 1.000 1.000 1.000
HYPERCHOLESTEREMIA	0.728	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	6/149 6/149 6/149 6/149 9/155 9/155 9/155 5/157 5/157 9/151	(4.0) (4.0) (4.0) (4.0) (5.8) (5.8) (5.8) (3.2) (3.2) (6.0)	9/155 5/157 9/151 3/ 77 5/157 9/151 3/ 77 9/151 3/ 77 3/ 77	(5.8) (3.2) (6.0) (3.9) (3.2) (6.0) (3.9) (6.0) (3.9) (3.9)	0.599 0.765 0.598 1.000 0.288 1.000 0.755 0.283 0.720 0.755
HYPERGLYCEMIA	0.093	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/149 0/155 0/157 0/151		1/ 77 1/ 77 1/ 77 1/ 77	(1.3) (1.3) (1.3) (1.3)	0.341 0.332 0.329 0.338
HYPERLIPEMIA	0.162	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	5/149 5/149 5/149 5/149 8/155 8/155 8/155 4/157 4/157 9/151	(3.4) (3.4) (3.4) (3.4) (5.2) (5.2) (5.2) (2.5) (2.5) (6.0)	8/155 4/157 9/151 0/ 77 4/157 9/151 0/ 77 9/151 0/ 77 0/ 77	(5.2) (2.5) (6.0) (2.5) (6.0) (6.0)	0.574 0.745 0.413 0.169 0.255 0.807 0.055 0.163 0.306 0.030*
HYPOMAGNESEMIA	0.494	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 1/157 1/157	(0.6) (0.6)	1/157 1/157 0/151 0/ 77	(0.6) (0.6)	1.000 1.000 1.000 1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Page 35

Body System [1] Adverse Event	Overall P-Value *	Treat Comparator 1	ment Comparator 2	Comparato		io Comparato		Pairwise P-Value
PERIPHERAL EDEMA	0.651	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	3/149 3/149 3/149 3/149	(2.0) (2.0) (2.0) (2.0)	4/155 4/157 3/151 4/ 77	(2.6) (2.5) (2.0) (5.2)	1.000 1.000 1.000 0.233
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	4/155 4/155 4/155	(2.6) (2.6) (2.6)	4/157 3/151 4/ 77	(2.5) (2.0) (5.2)	1.000 1.000 0.445
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	4/157 4/157 4/157 3/151	(2.5) (2.5) (2.5) (2.0)	3/151 4/ 77 4/ 77	(2.0) (5.2) (5.2)	1.000 0.444 0.230
SGOT INCREASED	0.032*	DVS SR 50 mg	DVS SR 150 mg	0/149		1/157	(0.6)	1.000
		DVS SR 100 mg	DVS SR 200 mg DVS SR 150 mg	0/149 0/155		4/151 1/157	(2.6) (0.6)	0.123 1.000
		DVS SR 150 mg		0/155 1/157	(0.6)	4/151 4/151	(2.6) (2.6)	0.058 0.207
		DVS SR 200 mg	Placebo Placebo	1/157 4/151	(0.6) (2.6)	0/ 77 0/ 77		1.000 0.303
SGPT INCREASED	0.103	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	0/149 0/149 0/149		1/155 1/157 4/151	(0.6) (0.6) (2.6)	1.000 1.000 0.123
		DVS SR 100 mg	DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/157 4/151 0/ 77	(0.6) (2.6)	1.000 0.210 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/157 1/157	(0.6) (0.6)	4/151 0/ 77	(2.6)	0.207
		DVS SR 200 mg	Placebo	4/151	(2.6)	0/ 77		0.303
THIRST	0.335	DVS SR 50 mg	DVS SR 150 mg DVS SR 200 mg	0/149 0/149		1/157 2/151	(0.6) (1.3)	1.000
		DVS SR 100 mg	DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg	0/155 0/155		1/157 2/151	(0.6) (1.3)	1.000
		DVS SR 150 mg	DVS SR 200 mg DVS SR 200 mg Placebo	1/157 1/157	(0.6) (0.6)	2/151 2/151 0/ 77	(1.3)	0.243 0.617 1.000
		DVS SR 200 mg		2/151	(1.3)	0/ 77		0.551

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Page 36

Body System [1] Adverse Event	Overall P-Value *	Treat Comparator 1	ment Comparator 2	 Comparat		io Comparat	Pairwise P-Value	
WEIGHT GAIN	0.243	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	4/149 4/149 4/149 4/149	(2.7) (2.7) (2.7) (2.7)	9/155 12/157 5/151 3/ 77	(5.8) (7.6) (3.3) (3.9)	0.258 0.071 1.000 0.692
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	9/155 9/155 9/155	(5.8) (5.8) (5.8)	12/157 5/151 3/ 77	(7.6) (3.3) (3.9)	0.652 0.413 0.755
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo	12/157 12/157 5/151	(7.6) (7.6) (3.3)	5/151 3/ 77 3/ 77	(3.3) (3.9) (3.9)	0.134 0.396 1.000
WEIGHT LOSS	0.494	DVS SR 50 mg	DVS SR 150 mg	0/149	(3.3)	1/157	(0.6)	1.000
	0,131		DVS SR 150 mg DVS SR 200 mg Placebo	0/155 1/157 1/157	(0.6) (0.6)	1/157 0/151 0/ 77	(0.6)	1.000 1.000 1.000
MUSCULOSKELETAL SYSTEM	0.650	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	32/149 32/149 32/149	(21.5) (21.5) (21.5)	35/155 31/157 24/151	(22.6) (19.7) (15.9)	0.890 0.778 0.238
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg	32/149 35/155 35/155	(21.5) (22.6) (22.6)	16/ 77 31/157 24/151	(20.8) (19.7) (15.9)	1.000 0.581 0.149
		DVS SR 150 mg	Placebo DVS SR 200 mg	35/155 31/157 31/157	(22.6) (19.7) (19.7)	16/ 77 24/151 16/ 77	(20.8) (15.9) (20.8)	0.867 0.457 0.863
		DVS SR 200 mg	Placebo Placebo	24/151	(15.9)	16/ 77	(20.8)	0.863
ARTHRALGIA	0.273	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	18/149 18/149 18/149	(12.1) (12.1) (12.1)	18/155 17/157 8/151	(11.6) (10.8) (5.3)	1.000 0.858 0.041*
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	18/149 18/155 18/155 18/155	(12.1) (11.6) (11.6) (11.6)	9/ 77 17/157 8/151 9/ 77	(11.7) (10.8) (5.3) (11.7)	1.000 0.859 0.064 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	17/157 17/157	(10.8) (10.8)	8/151 9/ 77	(5.3) (11.7)	0.095 0.828
		DVS SR 200 mg		8/151	(5.3)	9/ 77	(11.7)	0.109

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5_TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Page 37

ody System [1]	Overall	Treat	ment		Rat	io		Pairwise
Adverse Event	P-Value *		Comparator 2	Comparato		Comparato		P-Value
ARTHRITIS	0.793	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/149 2/149 2/149 2/149	(1.3) (1.3) (1.3) (1.3)	1/155 1/157 3/151 1/ 77	(0.6) (0.6) (2.0) (1.3)	0.616 0.614 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/157 3/151 1/ 77	(0.6) (2.0) (1.3)	1.000 0.366 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/157 1/157	(0.6) (0.6)	3/151 1/ 77	(2.0) (1.3)	0.363 0.551
		DVS SR 200 mg	Placebo	3/151	(2.0)	1/ 77	(1.3)	1.000
ARTHROSIS	0.147	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 2/157 2/157	(1.3) (1.3)	2/157 2/157 0/151 0/ 77	(1.3) (1.3)	0.499 0.498 0.499 1.000
BONE DISORDER	0.594	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	0/149 0/149 0/149		1/155 1/157 2/151	(0.6) (0.6) (1.3)	1.000 1.000 0.498
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/155 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/157 2/151 0/ 77	(0.6) (1.3)	1.000 0.619 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/157 1/157	(0.6) (0.6)	2/151 0/ 77	(1.3)	0.617 1.000
		DVS SR 200 mg	Placebo	2/151	(1.3)	0/ 77		0.551
BURSITIS	0.609	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	0/155 2/157 1/151 0/ 77	(1.3) (0.7)	0.490 1.000 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	0/155 0/155	. ,	2/157 1/151	(1.3) (0.7)	0.498 0.493
		DVS SR 150 mg	Placebo	2/157 2/157	(1.3) (1.3)	1/151 0/ 77	(0.7)	1.000
		DVS SR 200 mg	Placebo	1/151	(0.7)	0/ 77		1.000
FIBROMYALGIA	0.468	DVS SR 50 mg	DVS SR 200 mg	0/149		1/151	(0.7)	1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 38

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

- NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Adverse Event	Overall P-Value *	Treat Comparator 1	ment Comparator 2	Comparato		io Comparato		Pairwise P-Value *
FIBROMYALGIA	0.468	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg Placebo	0/155 0/157 1/151	(0.7)	1/151 1/151 0/ 77	(0.7)	0.493 0.490 1.000
JOINT DISORDER	0.661	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	4/149 4/149 4/149 4/149 3/155 3/155 3/155 1/157 1/157 2/151	(2.7) (2.7) (2.7) (2.7) (1.9) (1.9) (1.9) (0.6) (0.6) (1.3)	3/155 1/157 2/151 2/ 77 1/157 2/151 2/ 77 2/151 2/ 77 2/ 77	(1.9) (0.6) (1.3) (2.6) (0.6) (1.3) (2.6) (1.3) (2.6) (2.6)	0.719 0.204 0.446 1.000 0.369 1.000 1.000 0.617 0.253 0.605
LEG CRAMPS	0.770	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	1/149 1/149 1/149 1/149 4/155 4/155 4/155 3/157 3/157 3/151	(0.7) (0.7) (0.7) (0.7) (2.6) (2.6) (2.6) (1.9) (1.9) (2.0)	4/155 3/157 3/151 2/ 77 3/157 3/157 2/ 77 3/151 2/ 77 2/ 77	(2.6) (1.9) (2.0) (2.6) (1.9) (2.0) (2.6) (2.0) (2.6) (2.6)	0.371 0.623 0.623 0.268 0.722 1.000 1.000 0.665 1.000
MUSCLE CRAMP	0.277	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	2/149 2/149 2/149 2/149 2/155 2/155 2/155	(1.3) (1.3) (1.3) (1.3) (1.3) (1.3) (1.3)	2/155 0/157 0/151 0/ 77 0/157 0/151 0/ 77	(1.3)	1.000 0.236 0.246 0.549 0.246 0.498 1.000
MUSCLE SPASMS	0.627	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	2/149 2/149 2/149	(1.3) (1.3) (1.3)	1/155 3/157 1/151	(0.6) (1.9) (0.7)	0.616 1.000 0.621

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 39

29SEP05 14:53 REPORT AE5_TEAE CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

ody System [1] Adverse Event	Overall P-Value *		ment Comparator 2			io Comparato		Pairwise P-Value
MUSCLE SPASMS	0.627	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	2/149 1/155 1/155 1/155 3/157 3/157 1/151	(1.3) (0.6) (0.6) (0.6) (1.9) (1.9) (0.7)	0/ 77 3/157 1/151 0/ 77 1/151 0/ 77 0/ 77	(1.9) (0.7) (0.7)	0.549 0.623 1.000 1.000 0.623 0.553 1.000
MUSCULOSKELETAL STIFFNESS	0.127	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg	1/149 1/149 1/149 1/149 2/155	(0.7) (0.7) (0.7) (0.7) (0.7) (1.3)	2/155 6/157 2/151 0/ 77 6/157	(1.3) (3.8) (1.3)	1.000 0.122 1.000 1.000 0.283
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	2/155 2/155 6/157 6/157 2/151	(1.3) (1.3) (3.8) (3.8) (1.3)	2/151 0/ 77 2/151 0/ 77 0/ 77	(1.3)	1.000 1.000 0.283 0.181 0.551
MYALGIA	0.275	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg	3/149 3/149 3/149 3/149 7/155	(2.0) (2.0) (2.0) (2.0) (4.5)	7/155 5/157 8/151 6/ 77 5/157	(4.5) (3.2) (5.3) (7.8) (3.2)	0.337 0.724 0.218 0.065 0.572
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo	7/155 7/155 7/155 5/157 5/157 8/151	(4.5) (4.5) (3.2) (3.2) (5.3)	8/151 6/ 77 8/151 6/ 77 6/ 77	(5.3) (7.8) (5.3) (7.8) (7.8)	0.796 0.366 0.406 0.185 0.561
MYASTHENIA	0.485	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.497 1.000 1.000
OSTEOPOROSIS	0.147	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg	2/149 2/149	(1.3) (1.3)	1/155 0/157	(0.6)	0.616 0.236

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page

40

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

- NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Adverse Event	Overall P-Value *		cment Comparator 2			io Comparat		Pairwise P-Value *
OSTEOPOROSIS	0.147	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo Placebo Placebo	2/149 2/149 1/155 1/155 1/155 0/157 0/151	(1.3) (1.3) (0.6) (0.6) (0.6)	0/151 2/ 77 0/157 0/151 2/ 77 2/ 77	(2.6) (2.6) (2.6) (2.6)	0.246 0.607 0.497 1.000 0.256 0.107 0.113
PLANTAR FASCIITIS	0.494	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 1/157 1/157	(0.6) (0.6)	1/157 1/157 0/151 0/ 77	(0.6) (0.6)	1.000 1.000 1.000 1.000
RHEUMATOID ARTHRITIS	0.494	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 1/157 1/157	(0.6) (0.6)	1/157 1/157 0/151 0/ 77	(0.6) (0.6)	1.000 1.000 1.000 1.000
TENOSYNOVITIS	0.394	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	4/149 4/149 4/149 1/155 1/155 1/155 1/157 1/157 1/157	(2.7) (2.7) (2.7) (2.7) (0.6) (0.6) (0.6) (0.6) (0.6) (0.7)	1/155 1/157 1/151 1/ 77 1/157 1/151 1/ 77 1/151 1/ 77 1/ 77	(0.6) (0.6) (0.7) (1.3) (0.6) (0.7) (1.3) (0.7) (1.3) (1.3)	0.207 0.204 0.213 0.664 1.000 1.000 1.000 0.551 1.000
NERVOUS SYSTEM	<0.001***	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	62/149 62/149 62/149 62/149 84/155 84/155 84/155 97/157	(41.6) (41.6) (41.6) (41.6) (54.2) (54.2) (54.2) (61.8)	84/155 97/157 99/151 27/ 77 97/157 99/151 27/ 77 99/151	(54.2) (61.8) (65.6) (35.1) (61.8) (65.6) (35.1) (65.6)	0.030* <0.001*** <0.001*** 0.390 0.207 0.048* 0.008** 0.554

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5_TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Page 41

Body System [1] Adverse Event	Overall P-Value *	Treat Comparator 1	ment Comparator 2	 Comparat		io Comparat		Pairwise P-Value *
NERVOUS SYSTEM	<0.001***	DVS SR 150 mg DVS SR 200 mg	Placebo Placebo	97/157 99/151	(61.8) (65.6)	27/ 77 27/ 77	(35.1) (35.1)	<0.001*** <0.001***
ABNORMAL DREAMS	0.217	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	4/149 4/149 4/149	(2.7) (2.7) (2.7)	2/155 5/157 7/151	(1.3) (3.2) (4.6)	0.440 1.000 0.541
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	4/149 2/155 2/155 2/155	(2.7) (1.3) (1.3) (1.3)	0/ 77 5/157 7/151 0/ 77	(3.2) (4.6)	0.302 0.448 0.100 1.000
		DVS SR 150 mg DVS SR 200 mg		5/157 5/157 7/151	(3.2) (3.2) (4.6)	7/151 0/ 77 0/ 77	(4.6)	0.567 0.175 0.098
ABNORMAL/CHANGED BEHAVIOR	0.485	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.497 1.000 1.000
AGITATION	0.083	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	0/155 3/157 1/151 3/ 77	(1.9) (0.7) (3.9)	0.490 0.623 1.000 0.116
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	0/155 0/155 0/155	, ,	3/157 1/151 3/ 77	(1.9) (0.7) (3.9)	0.248 0.493 0.036*
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	3/157 3/157 1/151	(1.9) (1.9) (0.7)	1/151 3/ 77 3/ 77	(0.7) (3.9) (3.9)	0.623 0.398 0.113
ANXIETY	0.235	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	9/149 9/149 9/149	(6.0) (6.0) (6.0)	5/155 11/157 4/151	(3.2) (7.0) (2.6)	0.282 0.819 0.168
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	9/149 5/155 5/155 5/155	(6.0) (3.2) (3.2) (3.2)	2/ 77 11/157 4/151 2/ 77	(2.6) (7.0) (2.6) (2.6)	0.340 0.198 1.000 1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

Page 42

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

- NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Adverse Event	Overall P-Value *		ment Comparator 2			cio Comparato		Pairwise P-Value
ANXIETY	0.235	DVS SR 150 mg	DVS SR 200 mg Placebo Placebo	11/157 11/157 4/151	(7.0) (7.0) (2.6)	4/151 2/ 77 2/ 77	(2.6) (2.6) (2.6)	0.111 0.230 1.000
АРАТНУ	0.642	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149 0/155 1/157	(0.7) (0.7) (0.7) (0.7) (0.6) (0.6)	0/155 1/157 0/151 0/ 77 1/157 0/151 0/ 77	(0.6)	0.490 1.000 0.497 1.000 1.000 1.000
ATAXIA	0.643	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0/149 0/149 1/155 1/155 1/155 0/157 1/151	(0.6) (0.6) (0.6) (0.7)	1/155 1/151 0/157 1/151 0/ 77 1/151 0/ 77	(0.6) (0.7) (0.7) (0.7)	1.000 1.000 0.497 1.000 1.000 0.490 1.000
BRAIN EDEMA	0.468	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/149 0/155 0/157 1/151	(0.7)	1/151 1/151 1/151 0/ 77	(0.7) (0.7) (0.7)	1.000 0.493 0.490 1.000
CARPAL TUNNEL SYNDROME	0.696	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	0/149 0/149 0/149 0/149 1/155 1/155 1/155 2/157 2/157	(0.6) (0.6) (0.6) (1.3) (1.3) (1.3)	1/155 2/157 2/151 1/ 77 2/157 2/151 1/ 77 2/151 1/ 77 1/ 77	(0.6) (1.3) (1.3) (1.3) (1.3) (1.3) (1.3) (1.3) (1.3)	1.000 0.499 0.498 0.341 1.000 0.619 1.000 1.000
CERVICAL RADICULOPATHY	0.494	DVS SR 50 mg	DVS SR 150 mg	0/149	,	1/157	(0.6)	1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 43

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

- NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Adverse Event	Overall P-Value *	Treat Comparator 1	ment Comparator 2	Comparato		io Comparato		Pairwise P-Value *
CERVICAL RADICULOPATHY	0.494	DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo	0/155 1/157 1/157	(0.6)	1/157 0/151 0/ 77	(0.6)	1.000 1.000 1.000
CIRCUMORAL PARESTHESIA	0.627	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149 0/155 0/157 1/151	(0.7) (0.7) (0.7) (0.7)	0/155 0/157 1/151 0/ 77 1/151 1/151 0/ 77	(0.7) (0.7) (0.7)	0.490 0.487 1.000 1.000 0.493 0.490 1.000
CONFUSION	0.037*	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	1/149 1/149 1/149 1/149 4/155 4/155 4/155 8/157 8/157 2/151	(0.7) (0.7) (0.7) (0.7) (2.6) (2.6) (2.6) (5.1) (5.1) (1.3)	4/155 8/157 2/151 0/ 77 8/157 2/151 0/ 77 2/151 0/ 77 0/ 77	(2.6) (5.1) (1.3) (5.1) (1.3)	0.371 0.037* 1.000 1.000 0.378 0.685 0.305 0.104 0.055 0.551
DEPERSONALIZATION	0.599	DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149 2/155 2/155 2/155 0/157 1/151	(0.7) (0.7) (0.7) (0.7) (1.3) (1.3) (1.3)	2/155 0/157 1/151 0/ 77 0/157 1/151 0/ 77 1/151 0/ 77	(1.3) (0.7) (0.7) (0.7)	1.000 0.487 1.000 1.000 0.246 1.000 1.000 0.490 1.000
DEPRESSION	0.840	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	6/149 6/149 6/149 6/149	(4.0) (4.0) (4.0) (4.0)	6/155 3/157 5/151 3/ 77	(3.9) (1.9) (3.3) (3.9)	1.000 0.325 0.769 1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

- NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Page 44

Overall P-Value *	Treat Comparator 1	ment Comparator 2					Pairwise P-Value *
0.840	DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	6/155 6/155 6/155	(3.9) (3.9) (3.9)	3/157 5/151 3/ 77	(1.9) (3.3) (3.9)	0.334 1.000 1.000
	DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	3/157 3/157 5/151	(1.9) (1.9) (3.3)	5/151 3/ 77 3/ 77	(3.3) (3.9) (3.9)	0.495 0.398 1.000
<0.001***	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	17/149 17/149 17/149	(11.4) (11.4) (11.4)	30/155 29/157 41/151	(19.4) (18.5) (27.2)	0.059 0.109 <0.001*** 0.490
	DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	30/155 30/155	(19.4) (19.4)	29/157 41/151	(18.5) (27.2)	0.490 0.886 0.136 0.022*
	DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	29/157 29/157 41/151	(18.5) (18.5) (27.2)	41/151 6/ 77 6/ 77	(27.2) (7.8) (7.8)	0.078 0.033* <0.001***
0.607	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	1/149 1/149 1/149	(0.7) (0.7) (0.7)	2/155 1/157 0/151	(1.3) (0.6)	1.000 1.000 0.497
	DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	2/155 2/155 2/155 2/155	(1.3) (1.3) (1.3)	1/157 0/151 0/ 77	(0.6)	1.000 0.621 0.498 1.000
	DVS SR 150 mg	DVS SR 200 mg Placebo	1/157 1/157	(0.6) (0.6)	0/151 0/ 77		1.000
0.147	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 2/157 2/157	(1.3) (1.3)	2/157 2/157 0/151 0/ 77	(1.3) (1.3)	0.499 0.498 0.499 1.000
0.485	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.497 1.000 1.000
	0.840 <0.001*** 0.607	P-Value * Comparator 1 0.840 DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg <	P-Value * Comparator 1	P-Value * Comparator 1	P-Value * Comparator 1 Comparator 2 Comparator 1 0.840 DVS SR 100 mg DVS SR 200 mg 6/155 (3.9) Placebo 6/155 (3.9) Placebo 6/155 (3.9) DVS SR 200 mg 3/157 (1.9) Placebo 3/157 (1.9) Placebo 5/151 (3.3) OVS SR 200 mg DVS SR 200 mg 17/149 (11.4) DVS SR 200 mg 30/155 (19.4) DVS SR 200 mg 30/155 (19.4) DVS SR 200 mg 30/155 (19.4) DVS SR 200 mg 29/157 (18.5) Placebo 29/157 (18.5) Placebo 29/157 (18.5) DVS SR 200 mg Placebo 41/151 (27.2) 0.607 DVS SR 50 mg DVS SR 100 mg 1/149 (0.7) DVS SR 200 mg 1/155 (1.3) DVS SR 200 mg 1/155 (1.3) DVS SR 200 mg 1/157 (0.6) 0.147 DVS SR 50 mg DVS SR 150 mg 0/149 DVS SR 100 mg DVS SR 150 mg 0/155 (1.3) DVS SR 200 mg 2/157 (1.3) DVS SR 200 mg 1/155 (0.6) DVS SR 100 mg DVS SR 150 mg 0/149 DVS SR 100 mg DVS SR 150 mg 0/149 DVS SR 100 mg DVS SR 150 mg 1/155 (0.6) DVS SR 200 mg 1/155 (0.6)	P-Value * Comparator 1	P-Value * Comparator 1 Comparator 2 Comparator 1 Comparator 2

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 45

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

- NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Adverse Event	Overall P-Value *		ment Comparator 2			tio Comparator 2		Pairwise P-Value *	
FACIAL PARALYSIS	0.494	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 1/157 1/157	(0.6)	1/157 1/157 0/151 0/ 77	(0.6)	1.000 1.000 1.000 1.000	
FEELING DRUNK	0.458	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	0/155 0/157 0/151 0/ 77		0.490 0.487 0.497 1.000	
HOSTILITY	0.668	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg	4/149 4/149 4/149 4/149 1/155 1/155	(2.7) (2.7) (2.7) (2.7) (0.6) (0.6)	1/155 3/157 2/151 2/ 77 3/157 2/151	(0.6) (1.9) (1.3) (2.6) (1.9) (1.3)	0.207 0.717 0.446 1.000 0.623 0.619	
		DVS SR 150 mg DVS SR 200 mg	Placebo	1/155 3/157 3/157 2/151	(0.6) (1.9) (1.9) (1.3)	2/ 77 2/151 2/ 77 2/ 77	(2.6) (1.3) (2.6) (2.6)	0.256 1.000 0.665 0.605	
HYPERKINESIA	0.325	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	2/149 2/149 2/149 2/149 0/155 1/157 1/157	(1.3) (1.3) (1.3) (1.3) (0.6) (0.6)	0/155 1/157 0/151 0/ 77 1/157 0/151 0/ 77	(0.6)	0.239 0.614 0.246 0.549 1.000 1.000	
HYPERTONIA	0.468	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/149 0/155 0/157 1/151	(0.7)	1/151 1/151 1/151 0/ 77	(0.7) (0.7) (0.7)	1.000 0.493 0.490 1.000	
HYPESTHESIA	0.442	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	4/149 4/149 4/149	(2.7) (2.7) (2.7)	5/155 1/157 2/151	(3.2) (0.6) (1.3)	1.000 0.204 0.446	

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 46

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Adverse Event	Overall P-Value *		ment Comparator 2			io Comparat		Pairwise P-Value
HYPESTHESIA	0.442	DVS SR 50 mg DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	4/149 5/155 5/155 5/155 1/157 1/157	(2.7) (3.2) (3.2) (3.2) (3.2) (0.6) (0.6)	1/ 77 1/157 2/151 1/ 77 2/151 1/ 77	(1.3) (0.6) (1.3) (1.3) (1.3) (1.3)	0.664 0.120 0.448 0.666 0.617 0.551
		DVS SR 200 mg	Placebo	2/151	(1.3)	1/ 77	(1.3)	1.000
HYPOKINESIA	0.468	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/149 0/155 0/157 1/151	(0.7)	1/151 1/151 1/151 0/ 77	(0.7) (0.7) (0.7)	1.000 0.493 0.490 1.000
HYPOTONIA	0.627	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149 0/155 0/157 1/151	(0.7) (0.7) (0.7) (0.7)	0/155 0/157 1/151 0/ 77 1/151 1/151 0/ 77	(0.7) (0.7) (0.7)	0.490 0.487 1.000 1.000 0.493 0.490 1.000
INSOMNIA	0.004**	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg	23/149 23/149 23/149 23/149 27/155 27/155	(15.4) (15.4) (15.4) (15.4) (17.4) (17.4)	27/155 43/157 39/151 8/ 77 43/157 39/151	(17.4) (27.4) (25.8) (10.4) (27.4) (25.8)	0.647 0.012* 0.032* 0.415 0.042* 0.095
		DVS SR 150 mg DVS SR 200 mg	Placebo DVS SR 200 mg Placebo Placebo	27/155 43/157 43/157 39/151	(17.4) (27.4) (27.4) (25.8)	8/ 77 39/151 8/ 77 8/ 77	(10.4) (25.8) (10.4) (10.4)	0.178 0.797 0.004** 0.006**
LIBIDO DECREASED	0.206	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/149 2/149 2/149 2/149	(1.3) (1.3) (1.3) (1.3)	5/155 3/157 8/151 1/ 77	(3.2) (1.9) (5.3) (1.3)	0.448 1.000 0.104 1.000
		DVS SR 100 mg		5/155	(3.2)	3/157	(1.9)	0.500

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 47

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5_TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

0 mg DVS SR 200 mg Placebo 0 mg DVS SR 200 mg	5/155 (3.		or 2 	P-Value
Placebo 0 mg DVS SR 200 mg				
Placebo O mg Placebo	5/155 (3. 3/157 (1. 3/157 (1. 8/151 (5.	.2) 1/77 .9) 8/151 .9) 1/77	(5.3) (1.3) (5.3) (1.3) (1.3)	0.409 0.666 0.132 1.000 0.279
mg DVS SR 150 mg 0 mg DVS SR 150 mg 0 mg DVS SR 200 mg Placebo	0/149 0/155 1/157 (0. 1/157 (0.		(0.6) (0.6)	1.000 1.000 1.000 1.000
mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo O mg DVS SR 200 mg Placebo O mg Placebo	2/157 (1.	.3) 2/151 .3) 1/77 .3) 2/151 .3) 1/77	(1.3) (1.3) (1.3) (1.3) (1.3) (1.3) (1.3) (1.3) (1.3)	0.499 0.498 0.341 1.000 1.000 1.000 1.000
mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 (0. 1/149 (0. 1/149 (0. 1/155 (0. 1/155 (0.	.7) 0/157 .7) 0/151 .7) 0/77 .6) 0/157 .6) 0/151	(0.6)	1.000 0.487 0.497 1.000 0.497 1.000
mg DVS SR 200 mg 0 mg DVS SR 200 mg 0 mg DVS SR 200 mg 0 mg Placebo	0/149 0/155 0/157 1/151 (0.	1/151 1/151 1/151 .7) 0/ 77	(0.7) (0.7) (0.7)	1.000 0.493 0.490 1.000
		• . ,		
0	mg DVS SR 200 mg Placebo mg Placebo mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo mg DVS SR 200 mg Placebo mg DVS SR 200 mg Placebo mg DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg mg DVS SR 200 mg	mg DVS SR 200 mg 2/157 (1.77 Placebo 2/157 (1.77 mg Placebo 2/151 (1.77 mg DVS SR 100 mg 1/149 (0.77 DVS SR 200 mg 1/149 (0.77 Placebo 1/149 (0.77 mg DVS SR 200 mg 1/155 (0.77 DVS SR 200 mg 1/155 (0.77 Placebo 1/155 (0.77 mg DVS SR 200 mg 0/149 mg DVS SR 200 mg 0/155 mg DVS SR 200 mg 0/157	mg DVS SR 200 mg 2/157 (1.3) 2/151 Placebo 2/157 (1.3) 1/77 mg Placebo 2/151 (1.3) 1/77 mg DVS SR 100 mg 1/149 (0.7) 1/155 DVS SR 200 mg 1/149 (0.7) 0/157 DVS SR 200 mg 1/149 (0.7) 0/77 mg DVS SR 150 mg 1/155 (0.6) 0/157 DVS SR 200 mg 1/155 (0.6) 0/151 Placebo 1/155 (0.6) 0/151 mg DVS SR 200 mg 1/155 (0.6) 0/151 mg DVS SR 200 mg 0/155 1/151 mg DVS SR 200 mg 0/155 1/151 mg DVS SR 200 mg 0/157 1/151	mg DVS SR 200 mg 2/157 (1.3) 2/151 (1.3) Placebo 2/157 (1.3) 1/77 (1.3) mg Placebo 2/151 (1.3) 1/77 (1.3) mg Placebo 2/151 (1.3) 1/77 (1.3) mg DVS SR 100 mg 1/149 (0.7) 0/157 DVS SR 150 mg 1/149 (0.7) 0/157 Placebo 1/149 (0.7) 0/77 mg DVS SR 150 mg 1/155 (0.6) 0/157 DVS SR 200 mg 1/155 (0.6) 0/157 Placebo 1/155 (0.6) 0/77 mg DVS SR 200 mg 0/149 1/151 (0.7) mg DVS SR 200 mg 0/155 1/151 (0.7) mg DVS SR 200 mg 0/157 1/151 (0.7)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Page 48

Body System [1] Adverse Event	Overall P-Value *		ment Comparator 2			io Comparato		Pairwise P-Value *
NERVE COMPRESSION	0.494	DVS SR 150 mg	DVS SR 200 mg Placebo	1/157 1/157	(0.6) (0.6)	0/151 0/ 77		1.000
NERVOUSNESS	0.053	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	11/149 11/149 11/149	(7.4) (7.4) (7.4)	12/155 20/157 19/151	(7.7) (12.7) (12.6)	1.000 0.133 0.177
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	11/149 12/155 12/155 12/155	(7.4) (7.7) (7.7) (7.7)	2/ 77 20/157 19/151 2/ 77	(2.6) (12.7) (12.6) (2.6)	0.228 0.191 0.187 0.151
		DVS SR 150 mg	DVS SR 200 mg Placebo	20/157 20/157	(12.7) (12.7)	19/151 2/ 77	(12.6) (2.6)	1.000 0.015*
		DVS SR 200 mg	Placebo	19/151	(12.6)	2/ 77	(2.6)	0.014*
NEURALGIA	0.312	DVS SR 50 mg	DVS SR 200 mg Placebo	0/149 0/149		1/151 1/ 77	(0.7) (1.3)	1.000 0.341
		DVS SR 100 mg	DVS SR 200 mg Placebo	0/155 0/155		1/151 1/ 77	(0.7) (1.3)	0.493 0.332
		DVS SR 150 mg	DVS SR 200 mg Placebo	0/157 0/157		1/151 1/ 77	(0.7) (1.3)	0.490 0.329
		DVS SR 200 mg	Placebo	1/151	(0.7)	1/ 77	(1.3)	1.000
PARESTHESIA	0.046*	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg	0/149 0/149		7/155 4/157	(4.5) (2.5)	0.015* 0.123
		DVS SR 100 mg	DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg	0/149 7/155 7/155	(4.5) (4.5)	3/151 4/157 3/151	(2.0) (2.5) (2.0)	0.248 0.377 0.336
		DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	7/155 4/157 4/157	(4.5) (2.5) (2.5)	0/ 77 3/151 0/ 77	(2.0)	0.099 1.000 0.306
		DVS SR 200 mg	Placebo	3/151	(2.0)	0/ 77		0.553
PTOSIS	0.468	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/149 0/155 0/157 1/151	(0.7)	1/151 1/151 1/151 0/ 77	(0.7) (0.7) (0.7)	1.000 0.493 0.490 1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

Page 49

29SEP05 14:53 REPORT AE5 TEAE CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Adverse Event	Overall P-Value *		cment Comparator 2			io Comparat		Pairwise P-Value *
RESTLESS LEGS SYNDROME	0.832	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg	0/149 0/149 0/149 1/155	(0.6)	1/155 1/157 1/151 1/157	(0.6) (0.6) (0.7) (0.6)	1.000 1.000 1.000 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	1/155 1/155 1/157 1/157 1/151	(0.6) (0.6) (0.6) (0.6) (0.7)	1/151 0/ 77 1/151 0/ 77 0/ 77	(0.7)	1.000 1.000 1.000 1.000 1.000
SLEEP DISORDER	0.210	DVS SR 50 mg	DVS SR 150 mg Placebo	0/149 0/149 0/155	(017)	2/157 1/ 77 2/157	(1.3) (1.3) (1.3)	0.499 0.341 0.498
		DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo	0/155 0/155 2/157 2/157 0/151	(1.3) (1.3)	2/137 1/ 77 0/151 1/ 77 1/ 77	(1.3) (1.3) (1.3) (1.3)	0.498 0.332 0.499 1.000 0.338
SOMNOLENCE	<0.001***	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	7/149 7/149 7/149	(4.7) (4.7) (4.7)	24/155 30/157 36/151	(1.3) (15.5) (19.1) (23.8)	0.002** <0.001*** <0.001***
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	7/149 24/155 24/155 24/155	(4.7) (15.5) (15.5) (15.5)	3/ 77 30/157 36/151 3/ 77	(3.9) (19.1) (23.8) (3.9)	1.000 0.455 0.084 0.009**
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	30/157 30/157 36/151	(19.1) (19.1) (23.8)	36/151 3/ 77 3/ 77	(23.8) (3.9) (3.9)	0.333 0.001** <0.001***
SPEECH DISORDER	0.648	DVS SR 50 mg DVS SR 100 mg		0/149 0/149 0/155		1/157 1/151 1/157	(0.6) (0.7) (0.6)	1.000 1.000 1.000
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg Placebo Placebo	0/155 1/157 1/157 1/151	(0.6) (0.6) (0.7)	1/151 1/151 0/ 77 0/ 77	(0.7) (0.7)	0.493 1.000 1.000 1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5_TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Page 50

ody System [1]	Overall			Ratio				Pairwise	
Adverse Event	P-Value *	Comparator 1	Comparator 2	Comparato	or 1	Comparato	or 2	P-Value	
SUICIDAL IDEATION	0.458	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	0/155 0/157 0/151 0/ 77		0.490 0.487 0.497 1.000	
THINKING ABNORMAL	0.358	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	3/149 3/149 3/149 3/149	(2.0) (2.0) (2.0) (2.0)	4/155 8/157 7/151 1/ 77	(2.6) (5.1) (4.6) (1.3)	1.000 0.220 0.336 1.000	
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	4/155 4/155 4/155 4/155	(2.6) (2.6) (2.6)	8/157 7/151 1/ 77	(5.1) (4.6) (1.3)	0.378 0.374 1.000	
		DVS SR 150 mg	DVS SR 200 mg Placebo	8/157 8/157	(5.1) (5.1)	7/151 1/ 77	(4.6) (1.3)	1.000	
		DVS SR 200 mg	Placebo	7/151	(4.6)	1/ 77	(1.3)	0.272	
TREMOR	0.248	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/149 2/149 2/149 2/149	(1.3) (1.3) (1.3) (1.3)	4/155 4/157 8/151 1/ 77	(2.6) (2.5) (5.3) (1.3)	0.685 0.685 0.104 1.000	
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	4/155 4/155	(2.6) (2.6)	4/157 8/151	(2.5) (5.3)	1.000 0.252 1.000	
		DVS SR 150 mg	DVS SR 200 mg Placebo	4/155 4/157 4/157	(2.6) (2.5) (2.5)	1/ 77 8/151 1/ 77	(1.3) (5.3) (1.3)	0.249	
		DVS SR 200 mg	Placebo	8/151	(5.3)	1/ 77	(1.3)	0.279	
TRISMUS	0.691	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/149 2/149 2/149 2/149	(1.3) (1.3) (1.3) (1.3)	2/155 1/157 3/151 0/ 77	(1.3) (0.6) (2.0)	1.000 0.614 1.000 0.549	
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	2/149 2/155 2/155 2/155	(1.3) (1.3) (1.3) (1.3)	1/157 3/151 0/ 77	(0.6) (2.0)	0.621 0.681 1.000	
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/157 1/157	(0.6) (0.6)	3/151 0/ 77	(2.0)	0.363 1.000	
		DVS SR 200 mg		3/151	(2.0)	0/ 77		0.553	

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Page 51

Body System [1] Adverse Event	Overall P-Value *		ment Comparator 2	Comparat		io Comparat		Pairwise P-Value
TWITCHING	0.006**	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	1/155 1/157 8/151 1/ 77	(0.6) (0.6) (5.3) (1.3)	1.000 1.000 0.036* 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/157 8/151 1/ 77	(0.6) (5.3) (1.3)	1.000 0.018* 1.000
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	1/157 1/157 1/157 8/151	(0.6) (0.6) (5.3)	8/151 1/ 77 1/ 77	(5.3) (1.3) (1.3)	0.018* 0.551 0.279
VERTIGO	0.215	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	4/149 4/149 4/149	(2.7) (2.7) (2.7)	1/155 4/157 2/151	(0.6) (2.5) (1.3)	0.207 1.000 0.446
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	4/149 1/155 1/155 1/155	(2.7) (0.6) (0.6) (0.6)	4/ 77 4/157 2/151 4/ 77	(5.2) (2.5) (1.3) (5.2)	0.449 0.371 0.619 0.043*
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	4/157 4/157 2/151	(2.5) (2.5) (1.3)	2/151 4/ 77 4/ 77	(1.3) (5.2) (5.2)	0.685 0.444 0.183
RESPIRATORY SYSTEM	0.107	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	52/149 52/149 52/149 52/149	(34.9) (34.9) (34.9) (34.9)	46/155 41/157 35/151 28/ 77	(29.7) (26.1) (23.2) (36.4)	0.390 0.107 0.030* 0.884
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	46/155 46/155 46/155	(29.7) (29.7) (29.7)	41/157 35/151 28/ 77	(26.1) (23.2) (36.4)	0.529 0.243 0.370
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	41/157 41/157 41/157 35/151	(26.1) (26.1) (23.2)	35/151 28/ 77 28/ 77	(23.2) (36.4) (36.4)	0.598 0.127 0.042*
APNEA	0.468	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/149 0/155 0/157 1/151	(0.7)	1/151 1/151 1/151 0/ 77	(0.7) (0.7) (0.7)	1.000 0.493 0.490 1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Page 52

Body System [1] Adverse Event	Overall P-Value *	Treat Comparator 1		Comparato		cio Comparato		Pairwise P-Value
ASTHMA	0.828	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	1/155 1/157 0/151 0/ 77	(0.6) (0.6)	1.000 1.000 0.497 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/155 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/157 0/151 0/ 77	(0.6)	1.000 1.000 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/157 1/157	(0.6)	0/151 0/ 77		1.000
BRONCHITIS	0.070	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	6/149 6/149 6/149 6/149	(4.0) (4.0) (4.0) (4.0)	0/155 1/157 4/151 2/ 77	(0.6) (2.6) (2.6)	0.013* 0.061 0.540 0.719
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	0/155 0/155 0/155 0/155	(4.0)	1/157 4/151 2/ 77	(0.6) (2.6) (2.6)	1.000 0.058 0.109
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	1/157 1/157 4/151	(0.6) (0.6) (2.6)	4/151 2/ 77 2/ 77	(2.6) (2.6) (2.6)	0.207 0.253 1.000
COUGH INCREASED	0.173	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	11/149 11/149 11/149 11/149	(7.4) (7.4) (7.4)	8/155 5/157 3/151 5/ 77	(5.2) (3.2) (2.0) (6.5)	0.483 0.125 0.030* 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	8/155 8/155 8/155 8/155	(7.4) (5.2) (5.2) (5.2)	5/157 5/151 5/ 77	(3.2) (2.0) (6.5)	0.412 0.218 0.764
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	5/157 5/157 3/151	(3.2) (3.2) (2.0)	3/151 5/ 77 5/ 77	(2.0) (6.5) (6.5)	0.723 0.304 0.123
DYSPNEA	0.276	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	1/149 1/149 1/149	(0.7) (0.7) (0.7)	2/155 5/157 2/151	(1.3) (3.2) (1.3)	1.000 0.215 1.000
		DVS SR 100 mg	Placebo DVS SR 150 mg	1/149 2/155	(0.7) (1.3)	0/ 77 5/157	(3.2)	1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 53

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Adverse Event	Overall P-Value *	Treat Comparator 1	cment Comparator 2	Comparato		cio Comparato		Pairwise P-Value *
DYSPNEA	0.276	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	2/155 2/155 5/157 5/157 2/151	(1.3) (1.3) (3.2) (3.2) (1.3)	2/151 0/ 77 2/151 0/ 77 0/ 77	(1.3)	1.000 1.000 0.448 0.175 0.551
EPISTAXIS	0.435	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	0/149 0/149 0/149 0/149 1/155 1/155 1/155 3/157 3/157 3/151	(0.6) (0.6) (0.6) (1.9) (1.9) (2.0)	1/155 3/157 3/151 1/ 77 3/157 3/151 1/ 77 3/151 1/ 77 1/ 77	(0.6) (1.9) (2.0) (1.3) (1.9) (2.0) (1.3) (2.0) (1.3) (1.3)	1.000 0.248 0.248 0.341 0.623 0.366 1.000 1.000
LARYNGISMUS	0.637	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149 1/155 1/155	(0.7) (0.7) (0.7) (0.7) (0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77 0/157 0/151 0/ 77	(0.6)	1.000 0.487 0.497 1.000 0.497 1.000 1.000
LARYNGITIS	0.637	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149 1/155 1/155	(0.7) (0.7) (0.7) (0.7) (0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77 0/157 0/151 0/ 77	(0.6)	1.000 0.487 0.497 1.000 0.497 1.000 1.000
LUNG DISORDER	0.549	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	3/149 3/149 3/149 3/149	(2.0) (2.0) (2.0) (2.0)	3/155 2/157 0/151 1/ 77	(1.9) (1.3) (1.3)	1.000 0.678 0.121 1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 54

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Adverse Event	Overall P-Value *	Treat Comparator 1	cment Comparator 2	Comparato		cio Comparato		Pairwise P-Value *
LUNG DISORDER	0.549	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	3/155 3/155 3/155 3/155 2/157 2/157 0/151	(1.9) (1.9) (1.9) (1.3) (1.3)	2/157 0/151 1/ 77 0/151 1/ 77 1/ 77	(1.3) (1.3) (1.3) (1.3)	0.683 0.248 1.000 0.499 1.000 0.338
NOSE DRYNESS	0.494	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg		0/149 0/155 1/157 1/157	(0.6) (0.6)	1/157 1/157 0/151 0/ 77	(0.6) (0.6)	1.000 1.000 1.000 1.000
PHARYNGITIS	0.778	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	6/149 6/149 6/149 6/149 7/155 7/155 7/155 11/157 11/157 8/151	(4.0) (4.0) (4.0) (4.5) (4.5) (4.5) (7.0) (7.0) (5.3)	7/155 11/157 8/151 5/77 11/157 8/151 5/77 8/151 5/77 5/77	(4.5) (7.0) (5.3) (6.5) (7.0) (5.3) (6.5) (5.3) (6.5) (6.5)	1.000 0.321 0.786 0.516 0.468 0.796 0.539 0.638 1.000 0.766
PNEUMONIA	0.658	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0/149 0/149 1/155 1/155 1/155 1/157 1/157	(0.6) (0.6) (0.6) (0.6) (0.6)	1/155 1/157 1/157 0/151 0/ 77 0/151 0/ 77	(0.6) (0.6) (0.6)	1.000 1.000 1.000 1.000 1.000 1.000
PULMONARY PHYSICAL FINDING	0.643	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	0/149 0/149 1/155 1/155 1/155 0/157	(0.6) (0.6) (0.6)	1/155 1/151 0/157 1/151 0/ 77 1/151	(0.6) (0.7) (0.7) (0.7)	1.000 1.000 0.497 1.000 1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 55

29SEP05 14:53 REPORT AE5 TEAE CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Adverse Event	Overall P-Value *		cment Comparator 2			io Comparato		Pairwise P-Value
PULMONARY PHYSICAL FINDING	0.643	DVS SR 200 mg	Placebo	1/151	(0.7)	0/ 77		1.000
RHINITIS	0.500	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	8/149 8/149 8/149 8/149	(5.4) (5.4) (5.4) (5.4)	8/155 5/157 5/151 6/ 77	(5.2) (3.2) (3.3) (7.8)	1.000 0.404 0.411 0.562
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	8/155 8/155 8/155	(5.2) (5.2) (5.2)	5/157 5/151 6/ 77	(3.2) (3.3) (7.8)	0.412 0.573 0.559
		DVS SR 150 mg	DVS SR 200 mg	5/157	(3.2)	5/151 6/ 77	(3.3)	1.000 0.185
		DVS SR 200 mg	Placebo Placebo	5/157 5/151	(3.2) (3.3)	6/ 77	(7.8) (7.8)	0.189
RHINITIS ALLERGIC	0.478	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	3/149 3/149 3/149	(2.0) (2.0) (2.0)	1/155 0/157 2/151	(0.6) (1.3)	0.363 0.114 0.683
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	3/149 1/155 1/155 1/155	(2.0) (0.6) (0.6) (0.6)	1/ 77 0/157 2/151 1/ 77	(1.3) (1.3) (1.3)	1.000 0.497 0.619 1.000
		DVS SR 150 mg	DVS SR 200 mg	0/157	(0.0)	2/151	(1.3)	0.240
		DVS SR 200 mg	Placebo Placebo	0/157 2/151	(1.3)	1/ 77 1/ 77	(1.3) (1.3)	0.329 1.000
SINUS CONGESTION	0.002**	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg	1/149 1/149	(0.7) (0.7)	4/155 0/157	(2.6)	0.371
			DVS SR 200 mg Placebo	1/149 1/149	(0.7) (0.7)	1/151 5/ 77	(0.7) (6.5)	1.000 0.018*
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	4/155 4/155 4/155	(2.6) (2.6) (2.6)	0/157 1/151 5/ 77	(0.7) (6.5)	0.060 0.371 0.163
		DVS SR 150 mg	DVS SR 200 mg	0/157 0/157	(2.0)	1/151 5/ 77	(0.7)	0.490
		DVS SR 200 mg	Placebo Placebo	1/151	(0.7)	5/ 77	(6.5) (6.5)	0.018*
SINUSITIS	0.621	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg	11/149 11/149	(7.4) (7.4)	14/155 7/157	(9.0) (4.5)	0.679 0.335

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

Page

56

29SEP05 14:53 REPORT AE5 TEAE

CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Overall ----- Treatment ------ Pairwise Adverse Event P-Value * Comparator 1 Comparator 2 Comparator 1 Comparator 2 11/149 SINUSITIS 0.621 DVS SR 50 mg DVS SR 200 mg 11/151 1.000 Placebo 11/149 (7.4)5/ 77 (6.5)1.000 DVS SR 100 mg 7/157 DVS SR 150 mg 14/155 (9.0)(4.5)0.119 DVS SR 200 mg 14/155 (9.0)11/151 (7.3)0.678 5/ 77 11/151 (9.0)Placebo 14/155 (6.5) (7.3) 0.616 DVS SR 150 mg DVS SR 200 mg 7/157 (4.5)0.337 5/ 77 5/ 77 Placebo 7/157 (4.5)(6.5)0.536 DVS SR 200 mg Placebo 11/151 (7.3)(6.5)1.000 UPPER RESPIRATORY INFECTION 0.080 DVS SR 50 mg DVS SR 100 mg 18/149 (12.1)16/155 (10.3)0.717 (12.1) (12.1) DVS SR 150 mg 18/149 11/157 (7.0)0.171 DVS SR 200 mg 18/149 0.011* 6/151 9/ 77 11/157 18/149 (12.1)Placebo (11.7)1.000 (10.3)DVS SR 100 mg DVS SR 150 mg 16/155 (7.0)0.321 DVS SR 200 mg 16/155 (10.3)6/151 (4.0)9/ 77 Placebo 16/155 (10.3)(11.7)0.823 6/151 DVS SR 150 mg DVS SR 200 mg 11/157 (7.0) (7.0) (4.0)0.320 9/ 77 Placebo 11/157 (11.7)0.319 DVS SR 200 mg Placebo 9/ 77 6/151 (4.0)(11.7)0.044* VOICE ALTERATION 0.494 DVS SR 50 mg DVS SR 150 mg 0/149 1/157 (0.6) (0.6)1.000 DVS SR 100 mg DVS SR 150 mg 0/155 1/157 1.000 DVS SR 150 mg DVS SR 200 mg 1/157 (0.6)0/151 1.000 Placebo 1/157 (0.6)0/77 1.000 0/149 WHEEZING 0.485 DVS SR 50 mg DVS SR 100 mg 1/155 1.000 DVS SR 100 mg DVS SR 150 mg 1/155 (0.6)0/157 0.497 DVS SR 200 mg 1/155 (0.6)0/151 1.000 Placebo 1/155 (0.6)0/ 77 1.000 YAWN 0.354 DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg 0/149 1/155 (0.6)1.000 0/149 3/157 (1.9)0.248 DVS SR 200 mg 0/149 2/151 (1.3)0.498 DVS SR 100 mg DVS SR 150 mg 1/155 (0.6)3/157 (1.9)0.623 DVS SR 200 mg 1/155 (0.6)2/151 (1.3)0.619 Placebo 1/155 (0.6)0/77 1.000 DVS SR 150 mg DVS SR 200 mg 3/157 2/151 1.000

(1.9)

(1.3)

Pairwise P-Value: Fisher's Exact Test P-value (2-Tail).

CONFIDENTIAL 553 Wyeth

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Page 57

Body System [1] Adverse Event	Overall P-Value *		ment Comparator 2			io Comparat		Pairwise P-Value
YAWN	0.354	DVS SR 150 mg DVS SR 200 mg	Placebo Placebo	3/157 2/151	(1.9) (1.3)	0/ 77 0/ 77		0.553 0.551
SKIN AND APPENDAGES	0.471	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	24/149 24/149 24/149 24/149	(16.1) (16.1) (16.1) (16.1)	28/155 22/157 22/151 7/ 77	(18.1) (14.0) (14.6) (9.1)	0.761 0.634 0.750 0.160
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	28/155 28/155 28/155 28/155	(18.1) (18.1) (18.1) (18.1)	22/157 22/151 7/ 77	(14.0) (14.6) (9.1)	0.160 0.357 0.442 0.081
		DVS SR 150 mg	DVS SR 200 mg Placebo	22/157 22/157	(14.0) (14.0)	22/151 7/ 77	(14.6) (9.1)	1.000 0.398
		DVS SR 200 mg	Placebo	22/151	(14.6)	7/ 77	(9.1)	0.296
ACNE	0.823	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/149 2/149 2/149 2/149	(1.3) (1.3) (1.3) (1.3)	1/155 2/157 1/151 0/ 77	(0.6) (1.3) (0.7)	0.616 1.000 0.621 0.549
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/155 1/155 1/155	(0.6) (0.6) (0.6)	2/157 1/151 0/ 77	(1.3) (0.7)	1.000 1.000 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	2/157 2/157	(1.3) (1.3)	1/151 0/ 77	(0.7)	1.000
		DVS SR 200 mg		1/151	(0.7)	0/ 77		1.000
CONTACT DERMATITIS	0.721	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	3/155 2/157 2/151 0/ 77	(1.9) (1.3) (1.3)	0.623 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	3/155 3/155 3/155 3/155	(1.9) (1.9) (1.9)	2/157 2/151 0/ 77	(1.3) (1.3)	0.683 1.000 0.553
		DVS SR 150 mg	DVS SR 200 mg Placebo	2/157 2/157	(1.3) (1.3)	2/151 0/ 77	(1.3)	1.000
		DVS SR 200 mg	Placebo	2/151	(1.3)	0/ 77		0.551
DERMATITIS ATOPIC	0.458	DVS SR 50 mg	DVS SR 100 mg	1/149	(0.7)	0/155		0.490

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Page 58

Body System [1] Adverse Event	Overall P-Value *	Treat Comparator 1	ment Comparator 2	Comparato		cio Comparato		Pairwise P-Value
DERMATITIS ATOPIC	0.458	DVS SR 50 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149	(0.7) (0.7) (0.7)	0/157 0/151 0/ 77		0.487 0.497 1.000
DRY SKIN	0.724	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	2/149 2/149 2/149 2/149 2/155 2/155 2/155 3/157 3/157	(1.3) (1.3) (1.3) (1.3) (1.3) (1.3) (1.3) (1.9)	2/155 3/157 1/151 0/ 77 3/157 1/151 0/ 77 1/151 0/ 77	(1.3) (1.9) (0.7) (1.9) (0.7)	1.000 1.000 0.621 0.549 1.000 1.000 0.623 0.553
FUNGAL DERMATITIS	0.318	DVS SR 200 mg DVS SR 50 mg	Placebo Placebo DVS SR 100 mg	1/151 0/149	(1.9) (0.7)	0/ 77 1/155	(0.6) (1.3)	1.000
		DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo Placebo Placebo	0/149 1/155 1/155 1/155 0/157 0/151	(0.6) (0.6) (0.6)	1/ 77 0/157 0/151 1/ 77 1/ 77 1/ 77	(1.3) (1.3) (1.3) (1.3)	0.341 0.497 1.000 1.000 0.329 0.338
HERPES SIMPLEX	0.381	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	1/149 1/149 1/149 1/149 4/155 4/155 2/157	(0.7) (0.7) (0.7) (0.7) (2.6) (2.6) (2.6) (1.3)	4/155 2/157 4/151 0/ 77 2/157 4/151 0/ 77 4/151	(2.6) (1.3) (2.6) (1.3) (2.6) (2.6)	0.371 1.000 0.371 1.000 0.446 1.000 0.305 0.440
HERPES ZOSTER	0.532	DVS SR 200 mg DVS SR 50 mg	Placebo Placebo DVS SR 100 mg	2/157 4/151 2/149	(1.3) (2.6) (1.3)	0/ 77 0/ 77 0/ 77 2/155	(1.3)	1.000 0.303
HERLES ZOSIER	0.332	אוו אר שכ פאם mig	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	2/149 2/149 2/149	(1.3) (1.3) (1.3)	1/157 0/151	(0.6)	0.614

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

Page 59

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

- NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Adverse Event	Overall P-Value *	Treat Comparator 1	ment Comparator 2	Comparato		io Comparato		Pairwise P-Value
HERPES ZOSTER	0.532	DVS SR 50 mg DVS SR 100 mg	DVS SR 200 mg Placebo	2/149 2/155 2/155 2/155 2/155 1/157 1/157	(1.3) (1.3) (1.3) (1.3) (0.6) (0.6)	0/ 77 1/157 0/151 0/ 77 0/151 0/ 77	(0.6)	0.549 0.621 0.498 1.000 1.000
IMPETIGO	0.468	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg		0/149 0/155 0/157 1/151	(0.7)	1/151 1/151 1/151 0/ 77	(0.7) (0.7) (0.7)	1.000 0.493 0.490 1.000
MACULOPAPULAR RASH	0.494	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 1/157 1/157	(0.6) (0.6)	1/157 1/157 0/151 0/ 77	(0.6) (0.6)	1.000 1.000 1.000 1.000
NIGHT SWEATS	0.340	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	2/149 2/149 2/149 2/149 3/155 3/155 3/155 1/157 1/157	(1.3) (1.3) (1.3) (1.3) (1.9) (1.9) (1.9) (0.6) (0.6)	3/155 1/157 0/151 0/ 77 1/157 0/151 0/ 77 0/151 0/ 77	(1.9) (0.6) (0.6)	1.000 0.614 0.246 0.549 0.369 0.248 0.553 1.000
PRURITUS	0.086	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	5/149 5/149 5/149 5/149 4/155 4/155 6/157 6/157	(3.4) (3.4) (3.4) (3.4) (2.6) (2.6) (2.6) (2.8) (3.8)	4/155 6/157 0/151 0/ 77 6/157 0/151 0/ 77 0/151 0/ 77	(2.6) (3.8) (3.8)	0.746 1.000 0.029* 0.169 0.750 0.123 0.305 0.030*

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Page 60

Body System [1] Adverse Event	Overall P-Value *		ment Comparator 2			io Comparato		Pairwise P-Value *
PSORIASIS	0.494	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 1/157 1/157	(0.6) (0.6)	1/157 1/157 0/151 0/ 77	(0.6)	1.000 1.000 1.000 1.000
RASH	0.064	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo	9/149 9/149 9/149 9/149 3/155 3/155 3/155 4/157 4/157 1/151	(6.0) (6.0) (6.0) (6.0) (1.9) (1.9) (1.9) (2.5) (2.5) (0.7)	3/155 4/157 1/151 2/ 77 4/157 1/151 2/ 77 1/151 2/ 77 2/ 77	(1.9) (2.5) (0.7) (2.6) (2.5) (0.7) (2.6) (0.7) (2.6) (2.6)	0.081 0.161 0.010* 0.340 1.000 0.623 1.000 0.371 1.000 0.264
SEBORRHEA	0.468	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/149 0/155 0/157 1/151	(0.7)	1/151 1/151 1/151 0/ 77	(0.7) (0.7) (0.7)	1.000 0.493 0.490 1.000
SKIN BENIGN NEOPLASM	0.838	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo	1/149 1/149 1/149 1/149 2/155 2/155 2/155 2/157 2/157 1/151	(0.7) (0.7) (0.7) (0.7) (1.3) (1.3) (1.3) (1.3) (1.3) (0.7)	2/155 2/157 1/151 0/ 77 2/157 1/151 0/ 77 1/151 0/ 77 0/ 77	(1.3) (1.3) (0.7) (1.3) (0.7) (0.7)	1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
SKIN CARCINOMA	0.093	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/149 0/155 0/157 0/151		1/ 77 1/ 77 1/ 77 1/ 77	(1.3) (1.3) (1.3) (1.3)	0.341 0.332 0.329 0.338

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 61

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Adverse Event	Overall P-Value *		ment Comparator 2			io Comparato		Pairwise P-Value
SKIN DISCOLORATION	0.643	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0/149 0/149 1/155 1/155 1/155 0/157 1/151	(0.6) (0.6) (0.6) (0.7)	1/155 1/151 0/157 1/151 0/ 77 1/151 0/ 77	(0.6) (0.7) (0.7) (0.7)	1.000 1.000 0.497 1.000 1.000 0.490 1.000
SKIN DISORDER	0.123	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo Placebo Placebo	1/149 1/149 1/149 1/149 1/155 1/155 0/157 0/151	(0.7) (0.7) (0.7) (0.7) (0.6) (0.6) (0.6)	1/155 0/157 0/151 2/ 77 0/157 0/155 2/ 77 2/ 77 2/ 77	(0.6) (2.6) (2.6) (2.6) (2.6)	1.000 0.487 0.497 0.268 0.497 1.000 0.256 0.107 0.113
SKIN MELANOMA	0.494	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 1/157 1/157	(0.6) (0.6)	1/157 1/157 0/151 0/ 77	(0.6) (0.6)	1.000 1.000 1.000 1.000
SKIN ULCER	0.494	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 1/157 1/157	(0.6) (0.6)	1/157 1/157 0/151 0/ 77	(0.6) (0.6)	1.000 1.000 1.000 1.000
SKIN WRINKLING	0.494	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 1/157 1/157	(0.6) (0.6)	1/157 1/157 0/151 0/ 77	(0.6) (0.6)	1.000 1.000 1.000 1.000
SUNBURN	0.485	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.497 1.000 1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5_TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Page 62

Body System [1]	Overall	Treat	ment			io		Pairwise
Adverse Event	P-Value *	Comparator 1	Comparator 2	Comparat	or 1	Comparat	or 2	P-Value
SWEATING	0.023*	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/149 2/149 2/149 2/149	(1.3) (1.3) (1.3) (1.3)	4/155 2/157 9/151 0/ 77	(2.6) (1.3) (6.0)	0.685 1.000 0.061 0.549
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	4/155 4/155 4/155	(2.6) (2.6) (2.6)	2/157 9/151 0/ 77	(1.3) (6.0)	0.446 0.166 0.305
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	2/157 2/157 2/157 9/151	(1.3) (1.3) (6.0)	9/151 0/ 77 0/ 77	(6.0)	0.032* 1.000 0.030*
URTICARIA	0.536	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	3/149 3/149 3/149	(2.0) (2.0) (2.0)	3/155 0/157 2/151	(1.9) (1.3)	1.000 0.114 0.683
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	3/149 3/155 3/155 3/155	(2.0) (1.9) (1.9) (1.9)	1/ 77 0/157 2/151 1/ 77	(1.3) (1.3) (1.3)	1.000 0.121 1.000 1.000
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	0/157 0/157 2/151	(1.3)	2/151 1/ 77 1/ 77	(1.3) (1.3) (1.3)	0.240 0.329 1.000
PECIAL SENSES	0.001**	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	13/149 13/149 13/149 13/149	(8.7) (8.7) (8.7) (8.7)	25/155 35/157 31/151 5/ 77	(16.1) (22.3) (20.5) (6.5)	0.057 0.001*7 0.005*7 0.616
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	25/155 25/155 25/155	(16.1) (16.1) (16.1)	35/157 31/151 5/ 77	(22.3) (20.5) (6.5)	0.196 0.375 0.040*
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	35/157 35/157 35/157 31/151	(22.3) (22.3) (20.5)	31/151 5/ 77 5/ 77	(20.5) (6.5) (6.5)	0.782 0.003** 0.007**
ABNORMAL VISION	0.107	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	5/149 5/149 5/149 5/149	(3.4) (3.4) (3.4) (3.4)	9/155 14/157 10/151 1/ 77	(5.8) (8.9) (6.6) (1.3)	0.414 0.057 0.289 0.667

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 63

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5_TEAE

- NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

ody System [1] Adverse Event	Overall P-Value *		ment Comparator 2	Comparato		io Comparato		Pairwise P-Value
ABNORMAL VISION	0.107	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo	9/155 9/155 9/155 14/157 14/157 10/151	(5.8) (5.8) (5.8) (8.9) (8.9) (6.6)	14/157 10/151 1/ 77 10/151 1/ 77	(8.9) (6.6) (1.3) (6.6) (1.3) (1.3)	0.387 0.816 0.171 0.527 0.024* 0.104
CATARACT SPECIFIED	0.548	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	1/149 1/149 1/149 1/149 0/155	(0.7) (0.7) (0.7) (0.7)	0/155 0/157 1/151 1/ 77 1/151	(0.7) (1.3) (0.7)	0.490 0.487 1.000 1.000 0.493
		DVS SR 150 mg DVS SR 200 mg	Placebo DVS SR 200 mg Placebo Placebo	0/155 0/157 0/157 1/151	(0.7)	1/ 77 1/151 1/ 77 1/ 77	(1.3) (0.7) (1.3) (1.3)	0.332 0.490 0.329 1.000
CONJUNCTIVITIS	0.353	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 200 mg Placebo	0/149 0/149 2/155 2/155 2/155 1/157 1/157	(1.3) (1.3) (1.3) (0.6) (0.6)	2/155 1/157 1/157 0/151 0/ 77 0/151 0/ 77	(1.3) (0.6) (0.6)	0.499 1.000 0.621 0.498 1.000 1.000
CORNEAL LESION	0.648	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 200 mg Placebo Placebo	0/149 0/149 0/155 0/155 1/157 1/157 1/151	(0.6) (0.6) (0.7)	1/157 1/151 1/157 1/151 1/151 0/ 77 0/ 77	(0.6) (0.7) (0.6) (0.7) (0.7)	1.000 1.000 1.000 0.493 1.000 1.000
DRY EYES	0.468	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/149 0/155 0/157 1/151	(0.7)	1/151 1/151 1/151 0/ 77	(0.7) (0.7) (0.7)	1.000 0.493 0.490 1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5_TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Page 64

ody System [1]	Overall	Treat	ment	Ratio				Pairwise
Adverse Event	P-Value *		Comparator 2	Comparato	or 1	Comparato	or 2	P-Value
EAR DISORDER	0.870	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	1/155 2/157 1/151 0/ 77	(0.6) (1.3) (0.7)	1.000 1.000 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/155 1/155 1/155	(0.6) (0.6) (0.6)	2/157 1/151 0/ 77	(1.3) (0.7)	1.000 1.000 1.000
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	2/157 2/157 2/157 1/151	(1.3) (1.3) (1.3) (0.7)	1/151 0/ 77 0/ 77	(0.7)	1.000 1.000 1.000
EAR PAIN	0.739	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	1/149 1/149 1/149	(0.7) (0.7) (0.7)	4/155 3/157 2/151	(2.6) (1.9) (1.3)	0.371 0.623 1.000
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	1/149 4/155 4/155 4/155	(0.7) (2.6) (2.6) (2.6)	1/ 77 3/157 2/151 1/ 77	(1.3) (1.9) (1.3) (1.3)	1.000 0.722 0.685 1.000
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	3/157 3/157 2/151	(1.9) (1.9) (1.3)	2/151 1/ 77 1/ 77	(1.3) (1.3) (1.3)	1.000 1.000 1.000
EYE DISORDER	0.360	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	0/149 0/149 1/155	(0.6)	1/155 2/157 2/157	(0.6) (1.3) (1.3)	1.000 0.499 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo	1/155 1/155 2/157 2/157	(0.6) (0.6) (1.3) (1.3)	0/151 0/ 77 0/151 0/ 77		1.000 1.000 0.499 1.000
EYE PAIN	0.586	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7)	0/155 1/157 2/151 0/ 77	(0.6) (1.3)	0.490 1.000 1.000
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg	0/155 0/155	(0.7)	1/157 2/151 2/151	(0.6) (1.3)	1.000 1.000 0.243 0.617

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 65

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

- NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Adverse Event	Overall P-Value *		ment Comparator 2			io Comparato		Pairwise P-Value '
EYE PAIN	0.586	DVS SR 150 mg DVS SR 200 mg	Placebo Placebo	1/157 2/151	(0.6) (1.3)	0/ 77 0/ 77		1.000 0.551
GLAUCOMA	0.458	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	0/155 0/157 0/151 0/ 77		0.490 0.487 0.497 1.000
HYPERACUSIS	0.485	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.497 1.000 1.000
LACRIMATION DISORDER	0.093	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/149 0/155 0/157 0/151		1/ 77 1/ 77 1/ 77 1/ 77	(1.3) (1.3) (1.3) (1.3)	0.341 0.332 0.329 0.338
MIOSIS	0.494	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 1/157 1/157	(0.6) (0.6)	1/157 1/157 0/151 0/ 77	(0.6) (0.6)	1.000 1.000 1.000 1.000
MYDRIASIS	0.010**	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	1/149 1/149 1/149 1/149 4/155 4/155 4/155 10/157 10/157 9/151	(0.7) (0.7) (0.7) (0.7) (2.6) (2.6) (2.6) (6.4) (6.4) (6.0)	4/155 10/157 9/151 0/ 77 10/157 9/151 0/ 77 9/151 0/ 77	(2.6) (6.4) (6.0) (6.4) (6.0) (6.0)	0.371 0.011* 0.019* 1.000 0.170 0.166 0.305 1.000 0.033* 0.030*
OTITIS EXTERNA	0.353	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	1/149 1/149 1/149	(0.7) (0.7) (0.7)	0/155 2/157 0/151	(1.3)	0.490 1.000 0.497

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 66

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

- NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Adverse Event	Overall P-Value *		ment Comparator 2			cio Comparato		Pairwise P-Value *
OTITIS EXTERNA	0.353	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	1/149 0/155 2/157 2/157	(0.7) (1.3) (1.3)	0/ 77 2/157 0/151 0/ 77	(1.3)	1.000 0.498 0.499 1.000
OTITIS MEDIA	0.335	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 200 mg Placebo Placebo	0/149 0/149 0/155 0/155 1/157 1/157 2/151	(0.6) (0.6) (1.3)	1/157 2/151 1/157 2/151 2/151 0/ 77 0/ 77	(0.6) (1.3) (0.6) (1.3) (1.3)	1.000 0.498 1.000 0.243 0.617 1.000 0.551
PAROSMIA	0.643	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0/149 0/149 1/155 1/155 1/155 0/157 1/151	(0.6) (0.6) (0.6) (0.7)	1/155 1/151 0/157 1/151 0/ 77 1/151 0/ 77	(0.6) (0.7) (0.7) (0.7)	1.000 1.000 0.497 1.000 1.000 0.490 1.000
РНОТОРНОВІА	0.658	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0/149 0/149 1/155 1/155 1/155 1/157 1/157	(0.6) (0.6) (0.6) (0.6) (0.6)	1/155 1/157 1/157 0/151 0/ 77 0/151 0/ 77	(0.6) (0.6) (0.6)	1.000 1.000 1.000 1.000 1.000 1.000
RETINAL DETACHMENT	0.458	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	0/155 0/157 0/151 0/ 77		0.490 0.487 0.497 1.000
TASTE PERVERSION	0.306	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	1/149 1/149 1/149	(0.7) (0.7) (0.7)	2/155 5/157 3/151	(1.3) (3.2) (2.0)	1.000 0.215 0.623

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 67

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

- NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Adverse Event	Overall P-Value *		ment Comparator 2					Pairwise P-Value
TASTE PERVERSION	0.306	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	1/149 2/155 2/155 2/155 2/155 5/157 5/157 3/151	(0.7) (1.3) (1.3) (1.3) (3.2) (3.2)	0/ 77 5/157 3/151 0/ 77 3/151 0/ 77	(3.2) (2.0) (2.0)	1.000 0.448 0.681 1.000 0.723 0.175 0.553
TINNITUS	0.072	DVS SR 200 mg DVS SR 50 mg DVS SR 100 mg	Placebo DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	2/149 2/149 2/149 2/149 7/155 7/155	(2.0) (1.3) (1.3) (1.3) (1.3) (4.5) (4.5) (4.5)	7/155 1/157 4/151 0/ 77 1/157 4/151 0/ 77	(4.5) (0.6) (2.6) (0.6) (2.6)	0.174 0.614 0.684 0.549 0.036* 0.542 0.099
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	1/157 1/157 4/151	(0.6) (0.6) (2.6)	4/151 0/ 77 0/ 77	(2.6)	0.207 1.000 0.303
VESTIBULAR DISORDER	0.312	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	0/149 0/149 0/155 0/155 0/157 0/157 1/151	(0.7)	1/151 1/ 77 1/151 1/ 77 1/151 1/ 77 1/ 77	(0.7) (1.3) (0.7) (1.3) (0.7) (1.3) (1.3)	1.000 0.341 0.493 0.332 0.490 0.329 1.000
VITREOUS DISORDER	0.128	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/149 0/155 0/157 2/151	(1.3)	2/151 2/151 2/151 0/ 77	(1.3) (1.3) (1.3)	0.498 0.243 0.240 0.551
UROGENITAL SYSTEM	0.816	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg	15/149 15/149 15/149 15/149 20/155	(10.1) (10.1) (10.1) (10.1) (12.9)	20/155 19/157 14/151 10/ 77 19/157	(12.9) (12.1) (9.3) (13.0) (12.1)	0.476 0.591 0.847 0.509 0.865

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Page 68

Body System [1] Adverse Event	Overall P-Value *		ment Comparator 2			io Comparat		Pairwise P-Value
UROGENITAL SYSTEM	0.816	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	20/155 20/155 19/157 19/157 14/151	(12.9) (12.9) (12.1) (12.1) (9.3)	14/151 10/ 77 14/151 10/ 77 10/ 77	(9.3) (13.0) (9.3) (13.0) (13.0)	0.365 1.000 0.465 0.836 0.494
ABNORMAL EJACULATION/ORGASM	0.494		DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 1/157 1/157	(0.6) (0.6)	1/157 1/157 0/151 0/ 77	(0.6) (0.6)	1.000 1.000 1.000
ANORGASMIA	0.468	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/149 0/155 0/157 1/151	(0.7)	1/151 1/151 1/151 0/ 77	(0.7) (0.7) (0.7)	1.000 0.493 0.490 1.000
BREAST CYST	0.186	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo	2/149 2/149 2/149 2/149 0/155 0/157 0/151	(1.3) (1.3) (1.3) (1.3)	0/155 0/157 0/151 1/ 77 1/ 77 1/ 77 1/ 77	(1.3) (1.3) (1.3) (1.3)	0.239 0.236 0.246 1.000 0.332 0.329
BREAST DISORDER	0.458	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	0/155 0/157 0/151 0/ 77		0.490 0.487 0.497 1.000
BREAST NEOPLASM	0.425	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149 2/155 2/155 2/155 0/157	(0.7) (0.7) (0.7) (0.7) (1.3) (1.3) (1.3)	2/155 0/157 0/151 1/ 77 0/157 0/151 1/ 77	(1.3) (1.3) (1.3) (1.3)	1.000 0.487 0.497 1.000 0.246 0.498 1.000 0.329

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Page 69

Body System [1] Adverse Event	Overall P-Value *	Treat Comparator 1	ment Comparator 2		atio Comparator 2	Pairwise P-Value *
BREAST NEOPLASM	0.425	DVS SR 200 mg	Placebo	0/151	1/ 77 (1.3)	0.338
BREAST PAIN	0.082	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/149 0/149 0/149	3/155 (1.9) 1/157 (0.6) 1/151 (0.7) 3/77 (3.9)	0.248 1.000 1.000 0.039*
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	3/155 (1.9) 3/155 (1.9) 3/155 (1.9)	1/157 (0.6) 1/151 (0.7)	0.369 0.623 0.401
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/157 (0.6 1/157 (0.6	1/151 (0.7) 3/77 (3.9)	1.000 0.105
		DVS SR 200 mg	Placebo	1/151 (0.7)	3/ 77 (3.9)	0.113
CERVICITIS	0.485	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 1/155 (0.6 1/155 (0.6 1/155 (0.6	0/151	1.000 0.497 1.000 1.000
CERVIX DISORDER	0.485	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 1/155 (0.6 1/155 (0.6 1/155 (0.6	0/151	1.000 0.497 1.000 1.000
CYSTITIS	0.948	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	1/149 (0.7 1/149 (0.7 1/149 (0.7	1/157 (0.6) 1/151 (0.7)	1.000 1.000 1.000
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	1/149 (0.7) 2/155 (1.3) 2/155 (1.3) 2/155 (1.3)	1/157 (0.6) 1/151 (0.7)	1.000 0.621 1.000 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo Placebo	1/157 (0.6) 1/157 (0.6) 1/151 (0.7)	1/151 (0.7) 1/77 (1.3)	1.000 0.551 1.000
		3			,	
DYSURIA	0.468		DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg	0/149 0/155 0/157	1/151 (0.7) 1/151 (0.7) 1/151 (0.7)	1.000 0.493 0.490

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 70

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Adverse Event	Overall P-Value *		ment Comparator 2	Comparato		io Comparato		Pairwise P-Value
DYSURIA	0.468	DVS SR 200 mg	Placebo	1/151	(0.7)	0/ 77		1.000
FIBROCYSTIC BREAST	0.494	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 1/157 1/157	(0.6) (0.6)	1/157 1/157 0/151 0/ 77	(0.6) (0.6)	1.000 1.000 1.000 1.000
HEMATURIA	0.322	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg Placebo DVS SR 150 mg Placebo DVS SR 200 mg Placebo Placebo	0/149 0/149 0/155 0/155 1/157 1/157 0/151	(0.6) (0.6)	1/157 1/ 77 1/157 1/ 77 0/151 1/ 77 1/ 77	(0.6) (1.3) (0.6) (1.3) (1.3)	1.000 0.341 1.000 0.332 1.000 0.551 0.338
KIDNEY CALCULUS	0.353	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149 0/155 2/157 2/157	(0.7) (0.7) (0.7) (0.7) (1.3) (1.3)	0/155 2/157 0/151 0/ 77 2/157 0/151 0/ 77	(1.3)	0.490 1.000 0.497 1.000 0.498 0.499 1.000
LEUKORRHEA	0.648	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 200 mg Placebo Placebo	0/149 0/149 0/155 0/155 1/157 1/157	(0.6) (0.6) (0.7)	1/157 1/151 1/157 1/151 1/151 0/ 77 0/ 77	(0.6) (0.7) (0.6) (0.7) (0.7)	1.000 1.000 1.000 0.493 1.000 1.000
MASTITIS	0.093	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/149 0/155 0/157 0/151		1/ 77 1/ 77 1/ 77 1/ 77	(1.3) (1.3) (1.3) (1.3)	0.341 0.332 0.329 0.338
METRORRHAGIA	0.688	DVS SR 50 mg	DVS SR 100 mg	3/149	(2.0)	1/155	(0.6)	0.363

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 71

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

- NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Adverse Event	Overall P-Value *		cment Comparator 2			io Comparato		Pairwise P-Value *
METRORRHAGIA	0.688	DVS SR 50 mg	DVS SR 150 mg DVS SR 200 mg Placebo	3/149 3/149 3/149	(2.0) (2.0) (2.0)	2/157 2/151 0/ 77	(1.3) (1.3)	0.678 0.683 0.553
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/155 1/155 1/155 1/155	(0.6) (0.6) (0.6)	2/157 2/151 0/ 77	(1.3) (1.3)	1.000 0.619 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	2/157 2/157	(1.3) (1.3)	2/151 0/ 77	(1.3)	1.000
		DVS SR 200 mg	Placebo	2/151	(1.3)	0/ 77		0.551
OLIGURIA	0.658	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg	0/149 0/149		1/155 1/157	(0.6) (0.6)	1.000
		DVS SR 100 mg		1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/157 0/151 0/ 77	(0.6)	1.000 1.000 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/157 1/157	(0.6) (0.6)	0/151 0/ 77		1.000
OVARIAN CYST	0.093	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/149 0/155 0/157 0/151		1/ 77 1/ 77 1/ 77 1/ 77	(1.3) (1.3) (1.3) (1.3)	0.341 0.332 0.329 0.338
PYELONEPHRITIS	0.468	DVS SR 50 mg	DVS SR 200 mg	0/149		1/151	(0.7)	1.000
		DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg Placebo	0/155 0/157 1/151	(0.7)	1/151 1/151 0/ 77	(0.7) (0.7)	0.493 0.490 1.000
SEXUAL FUNCTION ABNORMAL	0.632	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	1/149 1/149 1/149	(0.7) (0.7) (0.7)	1/155 3/157 2/151	(0.6) (1.9) (1.3)	1.000 0.623 1.000
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg	1/149 1/155 1/155	(0.7) (0.6) (0.6)	0/ 77 3/157 2/151	(1.9) (1.3)	1.000 0.623 0.619
		DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	1/155 3/157 3/157	(0.6) (1.9) (1.9)	0/ 77 2/151 0/ 77	(1.3)	1.000 1.000 0.553

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

29SEP05 14:53 REPORT AE5_TEAE CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Page 72

ody System [1]	Overall		ment			io		Pairwise
Adverse Event	P-Value *		Comparator 2			Comparato		P-Value
SEXUAL FUNCTION ABNORMAL	0.632	DVS SR 200 mg	Placebo	2/151	(1.3)	0/ 77		0.551
URINARY FREQUENCY	0.648	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg	0/149 0/149 0/155 0/155 1/157 1/157	(0.6) (0.6) (0.7)	1/157 1/151 1/157 1/151 1/151 0/ 77 0/ 77	(0.6) (0.7) (0.6) (0.7) (0.7)	1.000 1.000 1.000 0.493 1.000 1.000
URINARY HESITATION	0.468	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/149 0/155 0/157 1/151	(0.7)	1/151 1/151 1/151 0/ 77	(0.7) (0.7) (0.7)	1.000 0.493 0.490 1.000
URINARY INCONTINENCE	0.658	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0/149 0/149 1/155 1/155 1/155 1/157 1/157	(0.6) (0.6) (0.6) (0.6) (0.6)	1/155 1/157 1/157 0/151 0/ 77 0/151 0/ 77	(0.6) (0.6) (0.6)	1.000 1.000 1.000 1.000 1.000 1.000
URINARY RETENTION	0.485	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.497 1.000 1.000
URINARY TRACT DISORDER	0.458	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	0/155 0/157 0/151 0/ 77		0.490 0.487 0.497 1.000
URINARY TRACT INFECTION	0.318	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	6/149 6/149 6/149 6/149	(4.0) (4.0) (4.0) (4.0)	3/155 5/157 1/151 1/ 77	(1.9) (3.2) (0.7) (1.3)	0.328 0.765 0.066 0.427

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 73

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Adverse Event	Overall P-Value *		ment Comparator 2			io Comparato		Pairwise P-Value
URINARY TRACT INFECTION	0.318	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	3/155 3/155 3/155 3/155 5/157 5/157 1/151	(1.9) (1.9) (1.9) (3.2) (3.2) (0.7)	5/157 1/151 1/ 77 1/151 1/ 77 1/ 77	(3.2) (0.7) (1.3) (0.7) (1.3) (1.3)	0.723 0.623 1.000 0.215 0.667 1.000
URINARY URGENCY	0.458	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	0/155 0/157 0/151 0/ 77		0.490 0.487 0.497 1.000
URINE ABNORMALITY	0.346	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0/149 0/149 2/155 2/155 2/155 0/157 1/151	(1.3) (1.3) (1.3) (0.7)	2/155 1/151 0/157 1/151 0/ 77 1/151 0/ 77	(1.3) (0.7) (0.7) (0.7)	0.499 1.000 0.246 1.000 1.000 0.490 1.000
UTERINE HEMORRHAGE	0.360	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0/149 0/149 1/155 1/155 1/155 2/157 2/157	(0.6) (0.6) (0.6) (1.3) (1.3)	1/155 2/157 2/157 0/151 0/ 77 0/151 0/ 77	(0.6) (1.3) (1.3)	1.000 0.499 1.000 1.000 1.000 0.499 1.000
VAGINAL DRYNESS	0.165	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo	0/149 0/149 0/149 3/155 3/155 3/155 0/157 0/157 2/151	(1.9) (1.9) (1.9)	3/155 2/151 2/ 77 0/157 2/151 2/ 77 2/151 2/ 77 2/ 77	(1.9) (1.3) (2.6) (1.3) (2.6) (1.3) (2.6) (2.6)	0.248 0.498 0.115 0.121 1.000 1.000 0.240 0.107 0.605

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

Page 74

29SEP05 14:53 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5 TEAE

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Adverse Event	Overall P-Value *		ment Comparator 2			io Comparato		Pairwise P-Value
VAGINAL HEMORRHAGE	0.161	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/149 0/149 0/149		4/155 1/157 1/151 2/ 77	(2.6) (0.6) (0.7) (2.6)	0.123 1.000 1.000 0.115
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	4/155 4/155 4/155	(2.6) (2.6) (2.6)	1/157 1/151 2/ 77	(0.6) (0.7) (2.6)	0.213 0.371 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/157 1/157	(0.6) (0.6)	1/151 2/ 77	(0.7) (2.6)	1.000 0.253
		DVS SR 200 mg	Placebo	1/151	(0.7)	2/ 77	(2.6)	0.264
VAGINAL MONILIASIS	0.485	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.497 1.000 1.000
VAGINITIS	0.322	DVS SR 50 mg	DVS SR 150 mg Placebo	0/149 0/149		1/157 1/ 77	(0.6) (1.3)	1.000
		DVS SR 100 mg	DVS SR 150 mg Placebo	0/155 0/155		1/157 1/ 77	(0.6)	1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/157 1/157	(0.6) (0.6)	0/151 1/ 77	(1.3)	1.000 0.551
		DVS SR 200 mg	Placebo	0/151	(0.6)	1/ 77	(1.3) (1.3)	0.338
ERMS NOT CLASSIFIABLE	0.356	DVS SR 50 mg	DVS SR 150 mg DVS SR 200 mg	0/149 0/149		2/157 1/151	(1.3) (0.7)	0.499
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	0/155 0/155		2/157 1/151	(1.3) (0.7)	0.498
		DVS SR 150 mg	DVS SR 200 mg	2/157	(1.3)	1/151	(0.7)	1.000
		DVS SR 200 mg	Placebo Placebo	2/157 1/151	(1.3) (0.7)	0/ 77 0/ 77		1.000
REACTION UNEVALUABLE	0.356	DVS SR 50 mg	DVS SR 150 mg DVS SR 200 mg	0/149 0/149		2/157 1/151	(1.3) (0.7)	0.499
		DVS SR 100 mg	DVS SR 200 mg DVS SR 200 mg	0/155 0/155		2/157 1/151	(1.3) (0.7)	0.498
		DVS SR 150 mg		2/157	(1.3)	1/151	(0.7)	1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

29SEP05 14:53 REPORT AE5 TEAE CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Page 75

Body System [1] Adverse Event	Overall P-Value *	Treat Comparator 1	cment Comparator 2	Comparato		cio Comparato		Pairwise P-Value
REACTION UNEVALUABLE	0.356	DVS SR 150 mg DVS SR 200 mg	Placebo Placebo	2/157 1/151	(1.3) (0.7)	0/ 77 0/ 77		1.000
ADVERSE EVENT ASSOC.W.MISC. FACTORS	0.129	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	4/149 4/149 4/149	(2.7) (2.7) (2.7)	5/155 6/157 4/151	(3.2) (3.8) (2.6)	1.000 0.751 1.000
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	4/149 5/155 5/155 5/155	(2.7) (3.2) (3.2) (3.2)	7/ 77 6/157 4/151 7/ 77	(9.1) (3.8) (2.6) (9.1)	0.048* 1.000 1.000 0.111
		DVS SR 150 mg	DVS SR 200 mg Placebo	6/157 6/157	(3.8)	4/151 7/ 77	(2.6) (9.1)	0.750 0.128
		DVS SR 200 mg	Placebo	4/151	(2.6)	7/ 77	(9.1)	0.047*
ALLERGIC REACTION OTHER THAN DRUG	0.644	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	4/149 4/149 4/149 4/149	(2.7) (2.7) (2.7) (2.7)	3/155 2/157 2/151 3/ 77	(1.9) (1.3) (1.3) (3.9)	0.719 0.438 0.446 0.692
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	3/155 3/155 3/155	(1.9) (1.9) (1.9)	2/157 2/151 3/ 77	(1.3) (1.3) (3.9)	0.683 1.000 0.401
		DVS SR 150 mg	DVS SR 200 mg Placebo	2/157 2/157	(1.3) (1.3)	2/151 3/ 77	(1.3)	1.000
		DVS SR 200 mg	Placebo	2/151	(1.3)	3/ 77	(3.9)	0.339
LOCAL REACTION TO PROCEDURE	0.063	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/149 0/149 0/149		2/155 4/157 2/151 4/ 77	(1.3) (2.5) (1.3) (5.2)	0.499 0.123 0.498 0.013*
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	2/155 2/155 2/155 2/155	(1.3) (1.3) (1.3)	4/157 2/151 4/ 77	(2.5) (1.3) (5.2)	0.684 1.000 0.096
		DVS SR 150 mg	DVS SR 200 mg Placebo	4/157 4/157	(2.5)	2/151 4/ 77	(1.3) (5.2)	0.685 0.444
		DVS SR 200 mg		2/151	(1.3)	4/ 77	(5.2)	0.183

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

ST 10-5: Number (%) of Subjects Reporting Treatment-Emergent Adverse Events by Severity and Drug Relationship

Adverse Event Severity / Drug Rela	tionship [2]		 R 50 mg =149		R 100 mg =155	DVS S	atment - R 150 mg =157		R 200 mg =151		acebo = 77
All Severity / R Mild / N Mild / R Moderate / N Moderate / R Severe / N	ot Rel. elated	61 19 21 36 32 17	(49.0) (40.9) (12.8) (14.1) (24.2) (21.5) (11.4) (5.4)	15	(94.2) (29.7) (64.5) (11.6) (16.1) (8.4) (31.0) (9.7) (17.4)	14 39		114 6 32 17 53 10	(97.4) (21.9) (75.5) (4.0) (21.2) (11.3) (35.1) (6.6) (19.2)	67 38 29 12 6 16 20 10 3	
All Severity / R Mild / N Mild / R Moderate / N Moderate / R Severe / N	ot Rel. elated ot Rel. elated ot Rel. elated ot Rel. elated ot Rel.	21 16 31	(38.9) (23.5) (14.1) (10.7) (20.8) (10.7)	23 22	(65.2) (36.8) (28.4) (16.8) (9.7) (14.8) (14.2) (5.2) (4.5)	98 49 49 20 19 18 17 11	(62.4) (31.2) (31.2) (12.7) (12.1) (11.5) (10.8) (7.0) (8.3)	44 16 18 18	(57.6) (28.5) (29.1) (10.6) (11.9) (11.9) (11.9) (6.0) (5.3)	47 37 10 11 2 21 7 5	(61.0) (48.1) (13.0) (14.3) (2.6) (27.3) (9.1) (6.5) (1.3)
All Severity / R Mild / N Mild / R Moderate / N Moderate / R Severe / N	ot Rel. elated ot Rel. elated ot Rel. elated ot Rel. elated ot Rel.	15 9 6 5 2 4 3 0	(2.7)	5 4 1 0 0 0 3 1	(0.6) (0.6)	2 5 0 2 1	(7.0) (1.9) (5.1) (1.3) (3.2) (1.3) (0.6) (0.6)	4 0 4 0 1 0 3 0	(2.6) (2.6) (0.7) (2.0)	4 4 0 3 0 1 0 0	(5.2) (5.2) (3.9) (1.3)
	ot Rel. ot Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
ACCIDENTAL INJURY All Severity / N	ot Rel.	11 11	(7.4) (7.4)		(10.3) (9.7)		(7.0) (7.0)		(12.6) (12.6)	11 11	(14.3) (14.3)

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

29SEP05 14:51 REPORT AE4 SEV DR T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page

2

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Severity / Drug Relationship [2] n=149 n=155 n=157 n = 77All Severity / Related 0 (0.6)0 Mild / Not Rel. (1.3)(4.5)5 (3.2)6 (4.0)4 (5.2)/ Not Rel. Moderate (4.7)6 (3.9)5 (3.2)12 (7.9)(5.2)/ Related Moderate 0 (0.6)0 / Not Rel. (1.3)2 (1.3)1 (0.6)1 (0.7)3 (3.9)Severe ACCIDENTAL OVERDOSE 0 (0.6)0 0 0 1 All Severity / Not Rel. 0 (0.6)0 0 Λ Mild / Not Rel. 0 1 (0.6)0 0 0 ALLERGIC REACTION (2.7)1 (0.6)(1.3)(2.0)0 All Severity / Not Rel. 2 (2.7)1 (0.6)(1.3)(2.0)0 / Not Rel. (1.3)(0.6)1 (0.6)(2.0)0 0 Moderate / Not Rel. (1.3)(0.6)0 ASTHENIA (7.4)30 (19.4)27 (17.2)(15.2)(9.1)5 All Severity / Not Rel. (1.3)(3.2)(2.5)(2.0)(5.2)All Severity / Related 25 (16.1)23 (14.6)(13.2)(3.9)(6.0)3 / Not Rel. (2.6)(1.9)(0.7)(5.2)Mild / Related (2.7)10 (6.5)11 (7.0)10 (6.6)1 (1.3)Moderate / Not Rel. (1.3)(0.6)1 (0.6)1 (0.7)0 9 Moderate / Related (3.4)13 (8.4)(3.2)(6.0)(2.6)Severe / Not Rel. Ω 0 0 (0.7)Ω (0.7)Severe / Related 0 (1.3)(4.5)0 9 BACK PAIN 16 (10.7)14 (9.0)10 (6.4)(6.0)10 (13.0)All Severity / Not Rel. 16 (10.7)14 (9.0)10 (6.4)(4.6)10 (13.0)All Severity / Related (1.3)Mild / Not Rel. 6 (4.0)9 (5.8)3 (1.9)3 (2.0)(7.8)(1.3)Mild / Related 0 0 0 Moderate / Not Rel. (6.0)(3.2)(3.2)(2.0)(5.2)Severe / Not Rel. (0.7)0 (1.3)(0.7)0 0 0 0 BODY ODOR 1 (0.6)0 All Severity / Related 0 0 1 (0.6)0 0 / Related Moderate 0 0 1 (0.6)0 0

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

29SEP05 14:51 REPORT AE4 SEV DR T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

By Severity And Drug Relationship

Page

3

Body System [1] Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Severity / Drug Relationship [2] n=149 n=155 n=157 n = 77CELLULITIS (0.7)(1.3)(1.3)(1.3)2 2 (1.3)All Severity / Not Rel. 1 (0.7)(1.3)0 1 (1.3)/ Not Rel. (0.7) (0.7) Mild 0 (0.6)0 0 / Not Rel. Moderate 1 (0.7)(0.6)0 1 (1.3)CHEST PAIN (2.7)(1.9)(3.2)(2.0)0 2 All Severity / Not Rel. (2.7)(1.3)(3.2)(2.0)0 All Severity / Related 0 (0.6)0 0 0 Mild / Not Rel. 3 (2.0)1 (0.6)1 (0.6)0 0 1 Moderate / Not Rel. (0.7)(0.6)(1.3)(1.3)0 Moderate / Related 0 (0.6)0 0 0 / Not Rel. Severe (1.3)(0.7)0 8 0 CHILLS (3.4)(5.2)6 (3.8)11 (7.3)All Severity / Not Rel. / Related 4 (2.6)3 (1.9)(1.3)0 All Severity (3.4)4 (2.6)(1.9)(6.0)0 Mild / Not Rel. (0.6)(1.9)(0.7)0 (2.0)Mild / Related 3 (1.3)1 (0.6)6 (4.0)0 Moderate / Not Rel. (1.3)(0.7)0 Moderate / Related (1.3)(0.6)(1.3)(0.7)0 / Not Rel. 0 Severe 0 (0.6)0 0 Severe / Related 0 (0.6)0 (1.3)0 0 0 CYST (1.3)1 (0.7)(1.3)All Severity / Not Rel. (1.3)0 0 (0.7)(1.3)0 0 Mild / Not Rel. (1.3)0 1 (0.7)Moderate / Not Rel. 0 0 Ω (1.3)FACE EDEMA (1.3)(0.6)0 (1.3)0 (0.7)All Severity / Not Rel. (1.3)(0.6)0 1 0 All Severity / Related 0 (0.7)0 Mild / Not Rel. 1 (0.7)0 0 0 0 Mild / Related Ω 0 0 1 (0.7)0 Moderate / Not Rel. (0.7)1 (0.6)0 0 Severe / Not Rel. 0 0 (0.7)0 FEVER (1.3)1 (0.6)0 (3.3)0

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

29SEP05 14:51 REPORT AE4 SEV DR T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page

4

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Severity / Drug Relationship [2] n=149 n=155 n=157 n = 77All Severity / Not Rel. (0.7)(0.6)(3.3)0 / Related 0 All Severity 1 (0.7)0 0 0 / Not Rel. (0.6)Mild 1 (0.7)1 0 (1.3)0 / Related 0 Mild (0.7)0 0 Moderate / Not Rel. 0 0 0 3 (2.0)0 FLU SYNDROME (4.0)15 (9.7)9 (6.6)All Severity / Not Rel. 6 (4.0)14 (9.0)8 (5.1)(4.6)3 (3.9)All Severity / Related 0 (0.6)1 (0.6)3 (2.0)0 Mild / Not Rel. (1.3)(4.5)(3.2)(1.3)(3.9)2 (1.3)Moderate / Not Rel. (2.0)6 (2.6)(2.6)Moderate / Related 1 (0.6)1 (0.6)0 Severe / Not Rel. (0.7)(0.6)(0.6)(0.7)0 0 0 (2.0)Severe / Related 0 GENERALIZED EDEMA (0.7)(0.6)0 (0.7)0 All Severity / Not Rel. 0 0 0 (0.7)0 All Severity / Related (0.7)1 1 (0.6)0 0 0 Mild / Related (0.7)(0.6)0 0 0 0 Moderate / Not Rel. 0 1 (0.7)0 0 0 HANGOVER EFFECT 0 0 (1.3)All Severity / Not Rel. 0 0 0 0 (1.3)Mild / Not Rel. 0 0 0 0 (1.3)HEADACHE (32.2)43 (27.7)55 (35.0)42 (27.8)26 (33.8)All Severity / Not Rel. 27 (18.1)20 (12.9)26 (16.6)16 (10.6)14 (18.2)21 23 All Severity / Related (14.1)(14.8)29 (18.5)26 (17.2)12 (15.6)Mild / Not Rel. 18 (12.1)8 (5.2)15 (9.6)(6.0)5 (6.5)(5.8) (7.0)(7.9)Mild / Related (5.4)11 12 (5.2)Moderate / Not Rel. (4.7)(5.8)5 (3.2)6 (4.0)(10.4)Moderate / Related 11 (7.4)11 (7.1)12 (7.6)11 (7.3)(9.1)/ Not Rel. Severe (1.3)3 (1.9)6 (3.8)(0.7)(1.3)Severe / Related (1.3)3 (1.9)(3.8)(2.0)(1.3)0 HEAT STROKE 0 0 0 (1.3)All Severity / Not Rel. 0 0 0 (1.3)

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

Page

5

29SEP05 14:51 REPORT AE4_SEV_DR_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

ody System [1] Adverse Event Severity / Drug	Relationship [2]		DVS SR 50 mg n=149		 R 100 mg =155	DVS S	atment - R 150 mg =157	DVS SI	R 200 mg =151	Placebo n= 77	
Mild	/ Not Rel.	0		0		0		0		1	(1.3)
INFECTION All Severity All Severity Mild Moderate Moderate Severe	/ Not Rel. / Related / Not Rel. / Not Rel. / Related / Not Rel.	23 23 0 10 12 0	(15.4) (15.4) (6.7) (8.1) (0.7)	21 21 0 13 8 0	(13.5) (13.5) (8.4) (5.2)	21 21 0 11 8 0 2	(13.4) (13.4) (7.0) (5.1) (1.3)	15 15 0 7 6 0 2	(9.9) (9.9) (4.6) (4.0) (1.3)	18 17 1 7 10 1	(23.4) (22.1) (1.3) (9.1) (13.0) (1.3)
INJECTION SITE HEN All Severity Mild	MORRHAGE / Not Rel. / Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
LAB TEST ABNORMAL All Severity All Severity Mild Moderate	/ Not Rel. / Related / Related / Not Rel.	2 1 1 1	(1.3) (0.7) (0.7) (0.7) (0.7)	0 0 0 0		0 0 0 0		0 0 0 0		0 0 0 0	
MALAISE All Severity All Severity Mild Mild Moderate Moderate	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related	0 0 0 0 0		3 1 2 1 2 0	(1.9) (0.6) (1.3) (0.6) (1.3)	1 0 0 0 1	(0.6) (0.6)	1 0 1 0 0 0	(0.7) (0.7) (0.7)	0 0 0 0 0	
MONILIASIS All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	1 1 0 1	(0.7) (0.7) (0.7)	1 1 1 0	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
NECK PAIN All Severity All Severity Mild	/ Not Rel. / Related / Not Rel.	5 5 0 4	(3.4) (3.4) (2.7)	1 1 0 1	(0.6) (0.6) (0.6)	4 2 2 1	(2.5) (1.3) (1.3) (0.6)	6 6 0 1	(4.0) (4.0) (0.7)	4 4 0 3	(5.2) (5.2) (3.9)

29SEP05 14:51 REPORT AE4_SEV_DR_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page

6

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationship [2]	DVS SR S			R 100 mg	DVS SF	atment - R 150 mg =157	DVS S	 R 200 mg =151		 acebo = 77
Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel.	0 1 0 0	(0.7)	0 0 0		1 0 1 1	(0.6) (0.6) (0.6)	0 4 0 1	(2.6) (0.7)	0 1 0 0	(1.3)
OVERDOSE All Severity / Not Rel. Severe / Not Rel.	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
PAIN All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel.	15 (1 7 0 7 1	10.7) 10.1) (0.7) (4.7) (4.7) (0.7) (0.7)	15 14 1 8 1 4 0 2	(9.7) (9.0) (0.6) (5.2) (0.6) (2.6) (1.3)	13 12 1 4 1 5 0	(8.3) (7.6) (0.6) (2.5) (0.6) (3.2) (1.9)	17 15 2 8 0 6 2	(11.3) (9.9) (1.3) (5.3) (4.0) (1.3) (0.7)	15 14 1 7 0 5 1 2	(19.5) (18.2) (1.3) (9.1) (6.5) (1.3) (2.6)
PELVIC PAIN All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	2 1	(1.3) (1.3) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0	
PHOTOSENSITIVITY REACTION All Severity / Not Rel. Mild / Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
SARCOIDOSIS All Severity / Not Rel. Moderate / Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
CARDIOVASCULAR SYSTEM All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel.	6 7 4 4	(8.7) (4.0) (4.7) (2.7) (2.7) (2.7)	21 6 15 4 8 2	(13.5) (3.9) (9.7) (2.6) (5.2) (1.3)	25 12 13 7 3 2	(15.9) (7.6) (8.3) (4.5) (1.9) (1.3)	28 8 20 3 10 3	(18.5) (5.3) (13.2) (2.0) (6.6) (2.0)	9 5 4 1 1 4	(11.7) (6.5) (5.2) (1.3) (1.3) (5.2)

29SEP05 14:51 REPORT AE4_SEV_DR_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page

7

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

dy System [1] Adverse Event Severity / Drug Relationship [2]	DVS SI	DVS SR 50 mg n=149		 R 100 mg =155	DVS SI	Treatment DVS SR 150 mg n=157		 R 200 mg =151	Placebo n= 77	
Moderate / Related Severe / Not Rel. Severe / Related Life Threatening / Not Rel.	3 0 0 1	(2.0)	5 0 2 0	(3.2)	5 3 5 0	(3.2) (1.9) (3.2)	9 2 1 0	(6.0) (1.3) (0.7)	2 0 1 0	(2.6)
CARDIOVASCULAR PHYSICAL FINDING All Severity / Not Rel. Mild / Not Rel.	1 1 1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0	
CORONARY ARTERY DISORDER All Severity / Not Rel. Moderate / Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
CORONARY OCCLUSION All Severity / Not Rel. Severe / Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
HYPERTENSION All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	6 2 4 2 2 2 0 2 0	(4.0) (1.3) (2.7) (1.3) (1.3) (1.3)	8 2 6 2 4 0 2 0	(5.2) (1.3) (3.9) (1.3) (2.6) (1.3)	10 5 5 4 3 0 1 1	(6.4) (3.2) (3.2) (2.5) (1.9) (0.6) (0.6) (0.6)	12 2 10 1 4 1 6 0	(7.9) (1.3) (6.6) (0.7) (2.6) (0.7) (4.0)	1 0 1 0 0 0 0 0	(1.3) (1.3)
MIGRAINE All Severity / Not Rel. All Severity / Related Mild / Not Rel. Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	1 1 0 0 1 0 0	(0.7) (0.7) (0.7)	4 2 2 1 1 1 0 1	(2.6) (1.3) (1.3) (0.6) (0.6) (0.6)	4 1 3 1 0 1 0 2	(2.5) (0.6) (1.9) (0.6) (0.6)	4 4 0 1 2 0 1 0	(2.6) (2.6) (0.7) (1.3) (0.7)	1 0 0 1 0 0	(1.3) (1.3)
MYOCARDIAL INFARCT	1	(0.7)	0		1	(0.6)	0		0	

8

Page

29SEP05 14:51 REPORT AE4_SEV_DR_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationship [2]	DVS SR 50 m n=149		Treatment	Placebo n= 77
All Severity / Not Rel. Severe / Not Rel. Life Threatening / Not Rel.	1 (0.7 0 1 (0.7	0	1 (0.6) 0 1 (0.6) 0 0 0	0 0 0
PALPITATION All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Related	4 (2.7 1 (0.7 3 (2.0 1 (0.7 2 (1.3 0 (0.7	1 (0.6) 4 (2.6) 0 4 (2.6) 1 (0.6)	2 (1.3) 5 (3.3) 0 (1.3) 0 (3.3) 2 (1.3) 0 (3.3) 2 (1.3) 0 (2.0) 0 0 1 (0.7) 0 1 (0.7)	4 (5.2) 3 (3.9) 1 (1.3) 1 (1.3) 0 2 (2.6) 1 (1.3)
PERIPHERAL VASCULAR DISORDER All Severity / Not Rel. All Severity / Related Mild / Not Rel. Moderate / Related	1 (0.7 1 (0.7 0 1 (0.7	0 0	0 1 (0.7) 0 0 1 (0.7) 0 0 1 (0.7) 0 0 1 (0.7)	0 0 0 0
SYNCOPE All Severity / Not Rel. Moderate / Not Rel.	0 0 0	0 0 0	1 (0.6) 0 1 (0.6) 0 1 (0.6) 0	0 0 0
TACHYCARDIA All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related	3 (2.0 1 (0.7 2 (1.3 1 (0.7 2 (1.3	0 3 (1.9) 0	3 (1.9) 3 (2.0) 2 (1.3) 1 (0.7) 1 (0.6) 2 (1.3) 2 (1.3) 0 0 2 (1.3) 0 1 (0.7) 1 (0.6) 0	0 0 0 0 0
VARICOSE VEIN All Severity / Not Rel. Moderate / Not Rel.	0 0 0	0 0 0	0 0 0 0	1 (1.3) 1 (1.3) 1 (1.3)
VASODILATATION All Severity / Not Rel.	2 (1.3 1 (0.7		6 (3.8) 4 (2.6) 2 (1.3) 1 (0.7)	2 (2.6) 0

29SEP05 14:51 REPORT AE4_SEV_DR_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

9

Page

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationship [2]		R 50 mg =149		 R 100 mg =155	DVS S	atment - R 150 mg =157		R 200 mg =151		 acebo = 77
All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	1 1 1 0 0 0	(0.7) (0.7) (0.7)	1 1 0 0 0 0 0	(0.6) (0.6)	4 0 0 1 2 1 2	(2.5) (0.6) (1.3) (0.6) (1.3)	3 1 1 0 2 0 0	(2.0) (0.7) (0.7) (1.3)	2 0 1 0 1 0	(2.6) (1.3) (1.3)
DIGESTIVE SYSTEM All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	83 32 51 15 32 11 16 6	(55.7) (21.5) (34.2) (10.1) (21.5) (7.4) (10.7) (4.0) (2.0)	99 18 81 8 37 6 30 4	(63.9) (11.6) (52.3) (5.2) (23.9) (3.9) (19.4) (2.6) (9.0)	114 24 90 9 41 11 35 4	(72.6) (15.3) (57.3) (5.7) (26.1) (7.0) (22.3) (2.5) (8.9)	104 16 88 6 35 8 44 2	(68.9) (10.6) (58.3) (4.0) (23.2) (5.3) (29.1) (1.3) (6.0)	28 7 21 6 9 1 11 0	(36.4) (9.1) (27.3) (7.8) (11.7) (1.3) (14.3)
ABDOMINAL DISTENSION All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Related	3 1 2 0 0 1 2 0	(2.0) (0.7) (1.3) (0.7) (1.3)	0 0 0 0 0		1 0 1 0 0 0	(0.6) (0.6) (0.6)	1 0 0 0 1 0	(0.7) (0.7)	4 1 3 0 1 1 1	(5.2) (1.3) (3.9) (1.3) (1.3) (1.3) (1.3)
ANOREXIA All Severity / Not Rel. All Severity / Related Mild / Related Moderate / Not Rel. Moderate / Related Severe / Related	7 0 7 7 0 0	(4.7) (4.7) (4.7)	9 1 8 4 1 2 2	(5.8) (0.6) (5.2) (2.6) (0.6) (1.3) (1.3)	13 0 13 7 0 5	(8.3) (8.3) (4.5) (3.2) (0.6)	15 0 15 9 0 5	(9.9) (9.9) (6.0) (3.3) (0.7)	2 0 2 1 0 1	(2.6) (2.6) (1.3) (1.3)
BLOOD IN STOOL All Severity / Not Rel.	1 1	(0.7) (0.7)	1 1	(0.6) (0.6)	0		0		0	

29SEP05 14:51 REPORT AE4_SEV_DR_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 10

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

dy System [1]	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo										
Adverse Event Severity / Drug R	elationship [2]	DVS S n	R 50 mg =149	DVS S	R 100 mg =155	DVS SR n=1		DVS S	R 200 mg =151		acebo = 77
Mild Moderate	/ Not Rel. / Not Rel.	1 0	(0.7)	0	(0.6)	0		0		0	
	/ Not Rel. / Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
	/ Not Rel. / Not Rel.	0 0 0		2 2 2	(1.3) (1.3) (1.3)	0 0 0		0 0 0		0 0 0	
Mild	/ Not Rel. / Not Rel. / Not Rel.	3 3 1 2	(2.0) (2.0) (0.7) (1.3)	0 0 0		0 0 0		1 1 1 0	(0.7) (0.7) (0.7)	0 0 0	
All Severity Mild Mild Moderate Moderate	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related / Related / Related	16 4 12 3 7 1 4	(10.7) (2.7) (8.1) (2.0) (4.7) (0.7) (2.7) (0.7)	27 3 24 2 12 1 10 2	(17.4) (1.9) (15.5) (1.3) (7.7) (0.6) (6.5) (1.3)	6	(15.9) (3.8) (12.1) (2.5) (7.0) (1.3) (3.2) (1.9)	27 5 22 3 9 2 10 3	(17.9) (3.3) (14.6) (2.0) (6.0) (1.3) (6.6) (2.0)	8 3 5 2 1 1 3	(10.4) (3.9) (6.5) (2.6) (1.3) (1.3) (3.9) (1.3)
All Severity Mild Mild Moderate Moderate Severe	/ Not Rel. / Related	17 11 6 4 4 3 2 4 0	(11.4) (7.4) (4.0) (2.7) (2.7) (2.0) (1.3) (2.7)	12 2 10 1 7 1 3 0	(7.7) (1.3) (6.5) (0.6) (4.5) (0.6) (1.9)	9 5 4 4 2 1 2 0	(5.7) (3.2) (2.5) (2.5) (1.3) (0.6) (1.3)	14 2 12 1 6 1 5 0	(9.3) (1.3) (7.9) (0.7) (4.0) (0.7) (3.3)	6 4 2 4 1 0 1 0	(7.8) (5.2) (2.6) (5.2) (1.3)
RY MOUTH All Severity	/ Not Rel.	18	(12.1)	33 4	(21.3) (2.6)	31 0	(19.7)	35 1	(23.2) (0.7)	3	(3.9)

29SEP05 14:51 REPORT AE4 SEV DR T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page

11

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

By Severity And Drug Relationship

Body System [1] Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Severity / Drug Relationship [2] n=149 n=155 n=157 n = 77All Severity / Related 18 (12.1)29 (18.7)31 (19.7)(22.5)(3.9)(0.7)Mild / Not Rel. 0 4 (2.6)0 0 (8.4)Mild / Related 13 (8.7)13 22 (14.0)23 (15.2)0 / Related Moderate (3.4)13 (8.4)8 (5.1)(6.0)(3.9)/ Related 0 3 (1.9)1 (0.6)2 (1.3)0 Severe 0 DUODENITIS 0 (0.6)0 0 All Severity / Not Rel. 0 1 (0.6)0 0 Mild / Not Rel. 0 0 1 (0.6)0 0 13 DYSPEPSIA 18 (12.1)(8.4)16 (10.2)13 (8.6)(2.6)All Severity / Not Rel. (6.0)(4.5)10 (6.4) (2.6)All Severity / Related (6.0)(3.9)(3.8)(6.0)(2.6)7 5 3 (2.0)Mild / Not Rel. (4.7)(3.2)(2.5)0 / Related Mild (4.0)(1.9)(1.9)6 (4.0)(2.6)Moderate / Not Rel. (1.3)(0.6)(3.2)(0.7)0 3 Moderate / Related (2.0)(1.9)(1.9)(2.0)0 Severe / Not Rel. (0.6)(0.6)0 2 DYSPHAGIA 1 (0.7)2 (1.3)(1.3)(1.3)0 0 2 All Severity / Not Rel. 0 (1.3)1 (0.7)0 All Severity / Related (0.7)(1.3)0 (0.7)0 Mild / Not Rel. 0 0 2 (1.3)1 (0.7)0 Mild / Related 1 (0.7)1 (0.6)0 0 0 Moderate / Related (0.6)0 (0.7)0 ERUCTATION (1.3)(0.6)1 (0.6)1 (0.7)0 All Severity / Not Rel. (1.3)(0.6)0 All Severity / Related 1 (0.6)0 (0.7)0 Mild / Not Rel. (1.3)0 1 (0.6)0 0 Moderate / Related 1 (0.6)1 (0.7)0 ESOPHAGEAL ULCER Ω 1 (0.6)0 0 0 1 All Severity / Not Rel. 0 (0.6)0 0 0 Moderate / Not Rel. 1 (0.6)0 0 0 ESOPHAGITIS (0.7)0 1 (0.6)0 0

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

29SEP05 14:51 REPORT AE4_SEV_DR_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 12

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

By Severity And Drug Relationship

dy System [1] Adverse Event Severity / Drug Relationship [2]	DVS SR 50 mg n=149			R 100 mg =155	DVS SF	atment - R 150 mg =157	DVS SR 200 mg n=151		Placebo n= 77	
All Severity / Not Rel. All Severity / Related Mild / Related Moderate / Not Rel.	0 1 1 0	(0.7) (0.7)	0 0 0 0		1 0 0 1	(0.6)	0 0 0 0		0 0 0 0	
FLATULENCE All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Related Severe / Related	1 0 1 0 1 0	(0.7) (0.7) (0.7)	1 0 1 0 0	(0.6) (0.6) (0.6)	1 0 1 0 0	(0.6) (0.6) (0.6)	2 0 2 0 1 0	(1.3) (1.3) (0.7) (0.7)	1 0 1 0 1 0 0	(1.3) (1.3) (1.3)
GAMMA GLUTAMYL TRANSPEPTIDASE INCREASED All Severity / Related Moderate / Related	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
GASTRITIS All Severity / Not Rel. Moderate / Not Rel.	0 0 0		0 0 0		0 0 0		0 0 0		1 1 1	(1.3) (1.3) (1.3)
GASTROENTERITIS All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel. Severe / Not Rel.	2 2 2 0 0	(1.3) (1.3) (1.3)	5 5 3 1 1	(3.2) (3.2) (1.9) (0.6) (0.6)	5 5 2 2 1	(3.2) (3.2) (1.3) (1.3) (0.6)	3 3 1 1 1	(2.0) (2.0) (0.7) (0.7) (0.7)	1 1 0 0	(1.3) (1.3) (1.3)
GASTROESOPHAGEAL REFLUX DISEASE All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Related	3 2 1 1 0 1 1 0	(2.0) (1.3) (0.7) (0.7) (0.7)	3 0 3 0 1 0 1	(1.9) (1.9) (0.6) (0.6) (0.6)	1 0 0 0 1 0	(0.6) (0.6)	6 3 3 1 0 2	(4.0) (2.0) (2.0) (2.0) (2.0) (0.7) (1.3)	0 0 0 0 0 0 0 0	
GASTROINTESTINAL DISORDER	0		1	(0.6)	2	(1.3)	0		0	

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.
[2] - Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

Page 13

29SEP05 14:51 REPORT AE4_SEV_DR_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationship [2]	DVS SR 50 mg n=149	DVS SR 100 mg n=155	Treatment g DVS SR 150 mg DVS SR 200 mg n=157 n=151	Placebo n= 77
All Severity / Not Rel. All Severity / Related Mild / Related Moderate / Not Rel.	0 0 0 0	1 (0.6) 0 0 1 (0.6)	1 (0.6) 0 1 (0.6) 0 1 (0.6) 0 1 (0.6) 0	0 0 0 0
GASTROINTESTINAL PHYSICAL FINDING All Severity / Related Mild / Related	1 (0.7) 1 (0.7) 1 (0.7)	0 0 0	0 0 0 0	0 0 0
GINGIVITIS All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	0 0 0 0	1 (0.6) 1 (0.6) 0 (0.6)	0 0 0 0 0 0 0 0	1 (1.3) 1 (1.3) 1 (1.3)
GLOSSITIS All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related	1 (0.7) 1 (0.7) 0 1 (0.7)	1 (0.6) 0 1 (0.6) 0 1 (0.6)	0 0 0 0 0 0 0 0 0 0 0	0 0 0 0
HEMORRHAGIC GASTRITIS All Severity / Not Rel. Moderate / Not Rel.	0 0 0	0 0 0	1 (0.6) 0 1 (0.6) 0 1 (0.6) 0	0 0 0
HEPATITIS All Severity / Related Severe / Related	0 0 0	0 0 0	1 (0.6) 0 1 (0.6) 0 1 (0.6) 0	0 0 0
HIATAL HERNIA All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	1 (0.7) 1 (0.7) 1 (0.7)	0 0 0 0	1 (0.6) 0 1 (0.6) 0 0 0 1 (0.6) 0	0 0 0
INCREASED APPETITE All Severity / Not Rel. All Severity / Related Mild / Not Rel.	3 (2.0) 3 (2.0) 0 1 (0.7)	3 (1.9) 0 3 (1.9)	4 (2.5) 2 (1.3) 2 (1.3) 0 2 (1.3) 2 (1.3) 1 (0.6) 0	2 (2.6) 0 2 (2.6)

29SEP05 14:51 REPORT AE4_SEV_DR_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 14

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

ody System [1] Adverse Event Severity / Drug Relationship [2		g DVS SR 100 mg n=155	Treatment - DVS SR 150 mg n=157	DVS SR 200 mg n=151	Placebo n= 77
Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	0 2 (1.3) 0 0	1 (0.6) 0 1 (0.6) 0 1 (0.6)	1 (0.6) 0 1 (0.6) 1 (0.6)	1 (0.7) 0 1 (0.7) 0 0	0 0 2 0 0
LIVER FUNCTION TESTS ABNORMAL All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Related	2 (1.3) 1 (0.7) 1 (0.7) 1 (0.7) 0 (0.7)	0 1 (0.6) 0 1 (0.6)	3 (1.9) 1 (0.6) 2 (1.3) 1 (0.6) 1 (0.6)	1 (0.7) 1 (0.7) 0 1 (0.7) 0	1 (1.3) 0 (1.3) 0 (1.3) 0 (1.3)
NAUSEA All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	41 (27.5) 10 (6.7) 31 (20.8) 4 (2.7) 18 (12.1) 5 (3.4) 11 (7.4) 1 (0.7) 2 (1.3)	4 (2.6) 56 (36.1) 3 (1.9) 31 (20.0) 0 16 (10.3) 1 (0.6)	75 (47.8) 10 (6.4) 65 (41.4) 6 (3.8) 35 (22.3) 2 (1.3) 22 (14.0) 2 (1.3) 8 (5.1)	68 (45.0) 4 (2.6) 64 (42.4) 1 (0.7) 33 (21.9) 3 (2.0) 26 (17.2) 0 5 (3.3)	5 (6.5) 1 (1.3) 4 (5.2) 1 (1.3) 3 (3.9) 0 1 (1.3) 0
NAUSEA AND VOMITING All Severity / Not Rel. All Severity / Related Mild / Related Moderate / Not Rel. Moderate / Related	0 0 0 0 0	1 (0.6) 0 1 (0.6) 1 (0.6) 0	1 (0.6) 1 (0.6) 0 0 1 (0.6)	2 (1.3) 0 (1.3) 0 (1.3) 0 0 (1.3)	0 0 0 0 0
ORAL MONILIASIS All Severity / Not Rel. Moderate / Not Rel.	0 0 0	1 (0.6) 1 (0.6) 1 (0.6)	0 0 0	0 0 0	0 0 0
PANCREATITIS All Severity / Related Severe / Related	0 0 0	0 0 0	1 (0.6) 1 (0.6) 1 (0.6)	0 0 0	0 0 0

29SEP05 14:51 REPORT AE4_SEV_DR_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 15

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

dy System [1] Adverse Event Severity / Drug Relationship [2]	DVS SR 50 mg n=149	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo n=155 n=157 n=151 n= 77
PEPTIC ULCER All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	1 (0.7) 1 (0.7) 0 1 (0.7)	0 1 (0.6) 0 0 0 1 (0.6) 0 0 0 1 (0.6) 0 0
PERIODONTAL ABSCESS All Severity / Not Rel. Moderate / Not Rel. Severe / Not Rel.	0 0 0 0	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
PERIODONTITIS All Severity / Not Rel. Moderate / Not Rel. Severe / Not Rel.	1 (0.7) 1 (0.7) 0 1 (0.7)	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$
RECTAL DISORDER All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel. Severe / Not Rel.	1 (0.7) 1 (0.7) 0 0 1 (0.7)	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$
RECTAL HEMORRHAGE All Severity / Not Rel. All Severity / Related Moderate / Not Rel. Moderate / Related	1 (0.7) 1 (0.7) 0 1 (0.7)	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$
STOOLS ABNORMAL All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related	0 0 0 0	0 2 (1.3) 0 0 0 1 (0.6) 0 0 0 1 (0.6) 0 0 0 1 (0.6) 0 0 0 1 (0.6) 0 0
TONGUE EDEMA All Severity / Not Rel. All Severity / Related Mild / Not Rel.	0 0 0	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$

Page 16

29SEP05 14:51 REPORT AE4_SEV_DR_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationship [2]							Treatment DVS SR 150 mg n=157		DVS SR 200 mg		 acebo = 77
Moderate	/ Related	0		0		0		1	(0.7)	0	
TOOTH CARIES All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	1 1 0 1	(0.7) (0.7) (0.7)	0 0 0		1 1 0 1	(0.6) (0.6) (0.6)	2 2 2 0	(1.3) (1.3) (1.3)	1 1 0 1	(1.3) (1.3) (1.3)
ULCERATIVE STOMATI All Severity Mild Moderate	ITIS / Not Rel. / Not Rel. / Not Rel.	0 0 0 0		2 2 1 1	(1.3) (1.3) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
VOMITING All Severity All Severity Mild Mild Moderate Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related / Related / Related	8 3 5 0 4 3 0 1	(5.4) (2.0) (3.4) (2.7) (2.0) (0.7)	11 4 7 1 1 3 6	(7.1) (2.6) (4.5) (0.6) (0.6) (1.9) (3.9)	11 4 7 2 4 2 2	(7.0) (2.5) (4.5) (1.3) (2.5) (1.3) (1.3) (0.6)	17 3 14 1 3 2 10	(11.3) (2.0) (9.3) (0.7) (2.0) (1.3) (6.6) (0.7)	0 0 0 0 0 0 0 0	
ENDOCRINE SYSTEM All Severity All Severity Mild Moderate Moderate	/ Not Rel. / Related / Not Rel. / Not Rel. / Related	2 1 1 0 1	(1.3) (0.7) (0.7) (0.7) (0.7)	1 1 0 1 0	(0.6) (0.6) (0.6)	1 0 1 0 0	(0.6) (0.6) (0.6)	3 3 0 2 1 0	(2.0) (2.0) (1.3) (0.7)	2 2 0 2 0	(2.6) (2.6) (2.6)
DIABETES MELLITUS All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
GOITER All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	1 1 1	(1.3) (1.3) (1.3)
HYPOTHYROIDISM		1	(0.7)	1	(0.6)	0		0		0	

Page 17

29SEP05 14:51 REPORT AE4_SEV_DR_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationship [2]		Treatment									
		DVS SR 50 mg n=149			DVS SR 100 mg n=155		DVS SR 150 mg n=157		DVS SR 200 mg n=151		acebo = 77
All Severity / F	Not Rel. Related Not Rel. Related	0 1 0 1	(0.7) (0.7)	1 0 1 0	(0.6)	0 0 0 0		0 0 0 0		0 0 0	
	Not Rel. Not Rel.	1 1 1	(0.7) (0.7) (0.7)	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
Mild / N	Not Rel. Not Rel. Not Rel.	0 0 0		0 0 0		0 0 0		1 1 0 1	(0.7) (0.7) (0.7)	1 1 1 0	(1.3) (1.3) (1.3)
All Severity / F Mild / Mild / F Moderate / N	FEM Not Rel. Related Not Rel. Related Not Rel. Related Rot Rel.	2 2 0 2 0 0 0	(1.3) (1.3) (1.3)	7 4 3 3 2 1 1	(4.5) (2.6) (1.9) (1.9) (1.3) (0.6) (0.6)	6 4 2 2 2 2 0	(3.8) (2.5) (1.3) (1.3) (1.3) (1.3)	5 5 0 3 0 2 0	(3.3) (3.3) (2.0) (1.3)	0 0 0 0 0	
	Not Rel. Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
All Severity / F Mild / Mild / F Moderate / N	Not Rel. Related Not Rel. Related Not Rel. Related	1 0 1 0 0 0	(0.7) (0.7) (0.7)	4 1 3 1 2 0 1	(2.6) (0.6) (1.9) (0.6) (1.3)	5 3 2 1 2 2 0	(3.2) (1.9) (1.3) (0.6) (1.3) (1.3)	3 0 2 0 1	(2.0) (2.0) (1.3) (0.7)	0 0 0 0 0	
	Not Rel. Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.
[2] - Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

29SEP05 14:51 REPORT AE4_SEV_DR_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 18

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Rel	lationship [2]		R 50 mg =149		 R 100 mg =155	DVS S	atment - R 150 mg =157		 R 200 mg =151		 icebo = 77
	Not Rel. Not Rel.	0 0 0		0 0 0		0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
Mild /	Not Rel. Not Rel. Not Rel.	1 1 1 0	(0.7) (0.7) (0.7)	1 1 0 1	(0.6) (0.6) (0.6)	0 0 0		1 1 1 0	(0.7) (0.7) (0.7)	0 0 0	
	Not Rel. Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
	Not Rel. Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
All Severity / Mild / Mild / Moderate / Moderate / Severe /	NAL Not Rel. Related	15 9 6 7 2 2 3 0	(10.1) (6.0) (4.0) (4.7) (1.3) (1.3) (2.0)	29 12 17 7 6 3 9 2	(18.7) (7.7) (11.0) (4.5) (3.9) (1.9) (5.8) (1.3) (1.3)	29 12 17 9 8 2 8 1	(18.5) (7.6) (10.8) (5.7) (5.1) (1.3) (5.1) (0.6) (0.6)	31 13 18 7 5 3 12 3	(20.5) (8.6) (11.9) (4.6) (3.3) (2.0) (7.9) (2.0) (0.7)	11 7 4 4 2 3 2 0 0	(14.3) (9.1) (5.2) (5.2) (2.6) (3.9) (2.6)
All Severity / Moderate /	INCREASED Not Rel. Related Not Rel. Related	0 0 0 0		1 0 1 0 1	(0.6) (0.6) (0.6)	0 0 0 0		2 1 1 1 1	(1.3) (0.7) (0.7) (0.7) (0.7)	0 0 0 0	
	Not Rel. Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	

29SEP05 14:51 REPORT AE4_SEV_DR_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 19

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationship [2]	DVS SR 50 mg n=149		DVS SR 100 mg		Treatment DVS SR 150 mg n=157		DVS SR 200 mg		Placebo n= 77	
GLUCOSE TOLERANCE DECREASED All Severity / Not Rel. Mild / Not Rel.	0 0 0		0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0	
HYPERCHOLESTEREMIA All Severity / Not Rel. All Severity / Related Mild / Not Rel.	6 (4. 2 (1. 4 (2. 1 (0.	3) 7) 7)	9363	(5.8) (1.9) (3.9) (1.9)	5 2 3 2	(3.2) (1.3) (1.9) (1.3)	9 3 6 1	(4.0) (0.7)	3 1 2 0	(3.9) (1.3) (2.6)
Mild / Related Moderate / Not Rel. Moderate / Related	3 (2. 1 (0. 1 (0.	7)	2 0 4	(1.3) (2.6)	1 0 2	(0.6) (1.3)	2 2 4		0 1 2	(1.3) (2.6)
HYPERGLYCEMIA All Severity / Not Rel. Moderate / Not Rel.	0 0 0		0 0 0		0 0 0		0 0 0		1 1 1	(1.3) (1.3) (1.3)
HYPERLIPEMIA All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related	5 (3. 2 (1. 3 (2. 2 (1. 0	3) 0) 3)	8 3 5 2 2 1 2	(5.2) (1.9) (3.2) (1.3) (1.3) (0.6) (1.3)	4 2 2 1 1 0	(2.5) (1.3) (1.3) (0.6) (0.6)	4 3 0 0	(3.3) (2.6) (2.0)	0 0 0 0 0	
Severe / Related Severe / Not Rel. Severe / Related	2 (1. 0 1 (0.	,	0 1	(0.6)	1 1 0	(0.6)	3 2 1	(1.3) (0.7)	0	
HYPOMAGNESEMIA All Severity / Not Rel. Mild / Not Rel.	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
PERIPHERAL EDEMA All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Severe / Not Rel.	3 (2. 3 (2. 0 (0. 0 (1.	0) 7)	4 4 0 1 0 2 1	(2.6) (2.6) (0.6) (1.3) (0.6)	4 3 1 3 1 0 0	(2.5) (1.9) (0.6) (1.9) (0.6)	3 2 1 2 1 0	(2.0) (1.3) (0.7) (1.3) (0.7)	4 4 0 3 0 1 0	(5.2) (5.2) (3.9) (1.3)

Page

20

29SEP05 14:51 REPORT AE4_SEV_DR_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationship [2]	DVS SR 50 mg n=149		Treatment DVS SR 150 mg DVS n=157		Placebo n= 77
SGOT INCREASED All Severity / Not Rel. All Severity / Related Moderate / Not Rel. Moderate / Related Severe / Related	0 0 0 0 0	0 0 0 0 0	0 1 (0.6) 0	4 (2.6) 1 (0.7) 3 (2.0) 1 (0.7) 3 (2.0)	0 0 0 0 0
SGPT INCREASED All Severity / Not Rel. All Severity / Related Moderate / Not Rel. Moderate / Related Severe / Related	0 0 0 0 0	1 (0.6) 0 (0.6) 1 (0.6) 0 (0.6)	0 1 (0.6) 0	4 (2.6) 1 (0.7) 3 (2.0) 1 (0.7) 3 (2.0)	0 0 0 0 0
THIRST All Severity / Related Mild / Related Moderate / Related	0 0 0	0 0 0 0	0	2 (1.3) 2 (1.3) 1 (0.7) 1 (0.7)	0 0 0
WEIGHT GAIN All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Related	4 (2.7) 3 (2.0) 1 (0.7) 3 (2.0) 1 (0.7) 0	9 (5.8) 3 (1.9) 6 (3.9) 3 (1.9) 2 (1.3) 0 3 (1.9) 1 (0.6)	3 (1.9) 9 (5.7) 1 (0.6) 6 (3.8) 2 (1.3) 3 (1.9)	5 (3.3) 1 (0.7) 4 (2.6) 1 (0.7) (1.3) 0 (1.3)	3 (3.9) 1 (1.3) 2 (2.6) 1 (1.3) 2 (2.6) 0 0
WEIGHT LOSS All Severity / Related Moderate / Related	0 0 0	0 0 0	1 (0.6))))	0 0 0
MUSCULOSKELETAL SYSTEM All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related	32 (21.5) 30 (20.1) 2 (1.3) 14 (9.4)	35 (22.6) 32 (20.6) 3 (1.9) 9 (5.8) 2 (1.3)	13 (8.3) 1	4 (15.9)	16 (20.8) 14 (18.2) 2 (2.6) 6 (7.8)

By Severity And Drug Relationship

Page

21

29SEP05 14:51 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT AE4_SEV_DR_T

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

Body System [1] Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Severity / Drug Relationship [2] n=149 n=155 n=157 n = 77Moderate / Not Rel. 11 (7.4)16 (10.3)10 (6.4)(9.3)(10.4)(0.6)Moderate / Related 1 (0.7)1 2 (1.3)0 2 (2.6)Severe / Not Rel. 5 (3.4)(4.5)5 (3.2)0 0 / Related 0 Severe (0.7)0 0 ARTHRALGIA (12.1)18 (11.6)17 (10.8)(5.3)(11.7)All Severity / Not Rel. 17 (11.4)16 (10.3)(8.9)(5.3)(10.4)All Severity / Related 1 (0.7)2 (1.3)3 (1.9)0 (1.3)Mild / Not Rel. 6 (4.0)4 (2.6)6 (3.8)1 (0.7)4 (5.2)Mild / Related 0 (0.6)1 (0.6)0 (4.7)Moderate / Not Rel. (3.9)(3.2)(4.6)4 (5.2)Moderate / Related 1 (0.7)(0.6)(1.3)(1.3)Severe / Not Rel. (2.7)(3.9)(1.9)0 ARTHRITIS (1.3) (1.3)1 (0.6)1 (0.6)(2.0) (2.0) (1.3)All Severity / Not Rel. (0.6)(0.6)(1.3)Mild / Not Rel. (1.3)0 (1.3)Ω / Not Rel. (0.7)Moderate 1 (0.6)1 (0.6)1 (1.3)0 0 2 0 ARTHROSIS (1.3)0 0 2 All Severity / Not Rel. 0 (1.3)0 0 Mild / Not Rel. 0 0 1 (0.6)0 0 Moderate / Not Rel. 0 0 1 (0.6)0 0 BONE DISORDER 0 (0.6)(0.6)(1.3)0 All Severity / Not Rel. 0 1 (0.6)1 (0.6)(1.3)0 / Not Rel. Mild Ω 0 (0.6)(0.7)0 Moderate / Not Rel. 0 (0.6)(0.7)0 BURSITIS (0.7)0 (1.3)1 (0.7)0 All Severity / Not Rel. (0.7)0 (1.3)(0.7)0 Mild / Not Rel. 1 (0.7)0 (1.3)0 0 Moderate / Not Rel. Ω 0 0 1 (0.7)0 0 0 FIBROMYALGIA 0 (0.7)0 / Not Rel. (0.7)All Severity Ω 0 0 1 0 / Not Rel. 0 (0.7)0

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

29SEP05 14:51 REPORT AE4_SEV_DR_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 22

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

dy System [1] Adverse Event Severity / Drug Relationship [2]	DVS SR 50 mg n=149	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo n=155 n=157 n=151 n= 77
JOINT DISORDER All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	4 (2.7) 4 (2.7) 2 (1.3) 2 (1.3)	3 (1.9) 1 (0.6) 2 (1.3) 2 (2.6) 3 (1.9) 1 (0.6) 2 (1.3) 2 (2.6) 0 0 2 (1.3) 1 (1.3) 3 (1.9) 1 (0.6) 0 1 (1.3)
LEG CRAMPS All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel. Severe / Not Rel.	1 (0.7) 1 (0.7) 1 (0.7) 0	4 (2.6) 3 (1.9) 3 (2.0) 2 (2.6) 4 (2.6) 3 (1.9) 3 (2.0) 2 (2.6) 2 (1.3) 2 (1.3) 2 (1.3) 2 (2.6) 0 1 (0.6) 1 (0.7) 0 2 (1.3) 0 0
MUSCLE CRAMP All Severity / Not Rel. All Severity / Related Mild / Not Rel. Moderate / Not Rel. Severe / Related	2 (1.3) 1 (0.7) 1 (0.7) 0 1 (0.7) 1 (0.7)	2 (1.3) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
MUSCLE SPASMS All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Severe / Not Rel.	2 (1.3) 2 (1.3) 0 1 (0.7) 0 1 (0.7)	1 (0.6) 3 (1.9) 1 (0.7) 0 1 (0.6) 3 (1.9) 0 0 0 1 (0.6) 3 (1.9) 0 0 1 (0.6) 3 (1.9) 0 0 0 0 1 (0.7) 0 0 0 0 0
MUSCULOSKELETAL STIFFNESS All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related	1 (0.7) 0 1 (0.7) 0 0 0 0 1 (0.7)	2 (1.3) 6 (3.8) 2 (1.3) 0 2 (1.3) 4 (2.5) 2 (1.3) 0 0 2 (1.3) 0 0 0 3 (1.9) 1 (0.7) 0 0 1 (0.6) 0 0 2 (1.3) 1 (0.6) 1 (0.7) 0 0 1 (0.6) 0
MYALGIA All Severity / Not Rel. All Severity / Related Mild / Not Rel.	3 (2.0) 3 (2.0) 0 3 (2.0)	7 (4.5) 5 (3.2) 8 (5.3) 6 (7.8) 6 (3.9) 5 (3.2) 8 (5.3) 4 (5.2) 1 (0.6) 0 0 2 (2.6) 4 (2.6) 4 (2.5) 3 (2.0) 2 (2.6)

Page 23

29SEP05 14:51 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR_T

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1]		Treatment		
Adverse Event Severity / Drug Relationship [2]		SR 100 mg DVS SR 150 mg n=155 n=157	DVS SR 200 mg n=151	Placebo n= 77
Mild / Related Moderate / Not Rel. Moderate / Related	0 1 0 2 0 0		0 5 (3.3) 0	0 2 (2.6) 2 (2.6)
MYASTHENIA All Severity / Related Mild / Related	$egin{array}{cccc} 0 & & & 1 \\ 0 & & & 1 \\ 0 & & & 1 \\ \end{array}$	1 (0.6) 0	0 0 0	0 0 0
OSTEOPOROSIS All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel.	2 (1.3) 1 2 (1.3) 1 0 0 0 1 (0.7) 1 0 0 1 (0.7) 0	1 (0.6) 0 0 0 1 (0.6) 0 0 0	0 0 0 0 0	2 (2.6) 1 (1.3) 1 (1.3) 1 (1.3) 1 (1.3)
PLANTAR FASCIITIS All Severity / Not Rel. Severe / Not Rel.	0 0 0 0 0 0	0 1 (0.6)	0 0 0	0 0 0
RHEUMATOID ARTHRITIS All Severity / Not Rel. Severe / Not Rel.	0 0 0 0 0 0	0 1 (0.6)	0 0 0	0 0 0
TENOSYNOVITIS All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	4 (2.7) 1 4 (2.7) 1 2 (1.3) 0 2 (1.3) 1	1 (0.6) 1 (0.6)	1 (0.7) 1 (0.7) 0 1 (0.7)	1 (1.3) 1 (1.3) 0 (1.3)
MERVOUS SYSTEM All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	62 (41.6) 84 16 (10.7) 18 46 (30.9) 66 4 (2.7) 10 21 (14.1) 22 10 (6.7) 6 21 (14.1) 32 2 (1.3) 2 4 (2.7) 12	8 (11.6) 15 (9.6) 6 (42.6) 82 (52.2) 0 (6.5) 6 (3.8) 2 (14.2) 35 (22.3) 6 (3.9) 7 (4.5) 2 (20.6) 29 (18.5) 2 (1.3) 2 (1.3)	99 (65.6) 8 (5.3) 91 (60.3) 2 (1.3) 43 (28.5) 5 (3.3) 28 (18.5) 1 (0.7) 20 (13.2)	27 (35.1) 8 (10.4) 19 (24.7) 4 (5.2) 7 (9.1) 3 (3.9) 11 (14.3) 1 (1.3)

29SEP05 14:51 REPORT AE4 SEV DR T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page

24

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Severity / Drug Relationship [2] n=149 n=155 n=157 n = 77ABNORMAL DREAMS (2.7)(1.3)(3.2)(4.6)0 1 All Severity / Not Rel. 0 (0.6)1 (0.6)(1.3)0 All Severity / Related (2.7)(0.6)(2.5)(3.3)0 / Not Rel. Mild 0 1 (0.6)(0.7)0 Mild / Related (1.3)1 (0.6)2 (1.3)2 (1.3)0 Moderate / Not Rel. (0.6)(0.7)0 Moderate / Related (1.3)0 (1.3)(2.0)0 ABNORMAL/CHANGED BEHAVIOR 0 1 (0.6)0 0 0 All Severity / Related 0 (0.6)0 0 0 Mild / Related 0 1 (0.6)0 0 0 AGITATION (0.7)0 (1.9)(0.7)(3.9)0 0 0 All Severity / Not Rel. (1.3)/ Related All Severity 1 (0.7)0 3 (1.9)1 (0.7)2 (2.6)/ Not Rel. 0 0 (1.3)Mild / Related (0.7)0 1 (0.6)0 (1.3)2 (0.7)Moderate / Related 0 0 (1.3)1 0 Severe / Related (1.3)ANXIETY (6.0)5 1 (3.2)11 (7.0)4 (2.6)(2.6)All Severity / Not Rel. (3.4)(0.6)(1.9)All Severity / Related (2.7)(2.6)8 (5.1)(2.6)(2.6)(0.7)Mild / Not Rel. (0.6)3 (1.9)0 / Related (1.3)(1.3)(2.5)(1.3)0 0 Moderate / Not Rel. (2.0)0 (0.6)Moderate / Related (1.3)1 (1.3)(1.3)(2.6)Severe / Not Rel. (0.7)Severe / Related (0.6)2 (1.3)0 0 APATHY (0.7)(0.6)0 0 All Severity / Related 1 (0.7)0 1 (0.6)0 0 Moderate / Related 1 (0.7)0 1 (0.6)0 0 ATAXIA 0 (0.6)0 (0.7)0 / Related (0.7)All Severity Ω (0.6)0 1 0 Moderate / Related (0.6)0 (0.7)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

29SEP05 14:51 REPORT AE4_SEV_DR_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship Page 25

dy System [1] Adverse Event Severity / Drug Relationship [2]	DVS SR 50 mg n=149	Treat DVS SR 100 mg DVS SR n=155 n=1	150 mg DVS SR 200 mg	Placebo n= 77	
BRAIN EDEMA All Severity / Not Rel. Mild / Not Rel.	0 0 0	0 0 0 0 0 0	1 (0.7) 1 (0.7) 1 (0.7)	0 0 0	
CARPAL TUNNEL SYNDROME All Severity / Not Rel. All Severity / Related Mild / Not Rel. Moderate / Not Rel. Moderate / Related	0 0 0 0 0	1 (0.6) 2 1 (0.6) 2 0 0 1 1 (0.6) 1	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	1 (1.3) 0 (1.3) 0 (1.3) 0 (1.3)	
CERVICAL RADICULOPATHY All Severity / Not Rel. Severe / Not Rel.	0 0 0	0 1 0 1 0 1	(0.6) 0 (0.6) 0 (0.6) 0	0 0 0	
CIRCUMORAL PARESTHESIA All Severity / Related Mild / Related Severe / Related	1 (0.7) 1 (0.7) 1 (0.7) 0	0 0 0 0 0 0 0 0	1 (0.7) 1 (0.7) 0 (0.7)	0 0 0 0	
CONFUSION All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Related Severe / Related	1 (0.7) 0 (0.7) 0 (0.7) 0 1 (0.7)	4 (2.6) 8 2 (1.3) 1 2 (1.3) 7 2 (1.3) 1 1 (0.6) 1 0 3 1 (0.6) 3	(5.1) 2 (1.3) (0.6) 0 (4.5) 2 (1.3) (0.6) 0 (0.6) 1 (0.7) (1.9) 0 (1.9) 1 (0.7)	0 0 0 0 0	
DEPERSONALIZATION All Severity / Related Mild / Related Moderate / Related	1 (0.7) 1 (0.7) 1 (0.7)	2 (1.3) 0 2 (1.3) 0 1 (0.6) 0 1 (0.6) 0	1 (0.7) 1 (0.7) 1 (0.7) 0	0 0 0 0	
DEPRESSION All Severity / Not Rel. All Severity / Related Mild / Not Rel.	6 (4.0) 5 (3.4) 1 (0.7) 1 (0.7)	6 (3.9) 3 3 (1.9) 0 3 (1.9) 3 1 (0.6) 0	(1.9) 5 (3.3) 2 (1.3) (1.9) 3 (2.0)	3 (3.9) 3 (3.9) 0 1 (1.3)	

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.
[2] - Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

29SEP05 14:51 REPORT AE4_SEV_DR_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 26

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug			 R 50 mg =149	DVS S		DVS S	R 150 mg	DVS S	 R 200 mg =151	Placebo n= 77	
Mild Moderate Moderate Severe Severe	/ Related / Not Rel. / Related / Not Rel. / Related	1 3 0 1 0	(0.7) (2.0) (0.7)	1 2 1 0 1	(0.6) (1.3) (0.6) (0.6)	1 0 1 0 1	(0.6) (0.6) (0.6)	1 2 2 0 0	(0.7) (1.3) (1.3)	0 2 0 0	(2.6)
	/ Not Rel. / Related	17 4 13 2 8 2 4 0	(11.4) (2.7) (8.7) (1.3) (5.4) (1.3) (2.7) (0.7)	30 7 23 4 13 2 8 1	(19.4) (4.5) (14.8) (2.6) (8.4) (1.3) (5.2) (0.6) (1.3)	29 8 21 6 11 7 1 3	(18.5) (5.1) (13.4) (3.8) (7.0) (0.6) (4.5) (0.6) (1.9)	3 21 0 14 0	(27.2) (2.0) (25.2) (2.0) (13.9) (9.3) (2.0)	6 1 5 1 2 0 3 0	(7.8) (1.3) (6.5) (1.3) (2.6) (3.9)
	/ Not Rel. / Related / Not Rel. / Related / Related	1 0 1 0 1	(0.7) (0.7) (0.7)	2 2 0 2 0	(1.3) (1.3) (1.3)	1 0 1 0 0	(0.6) (0.6)	0 0 0 0 0		0 0 0 0	
ENERGY INCREASED All Severity Moderate	/ Related / Related	0 0 0		0 0 0		2 2 2	(1.3) (1.3) (1.3)	0 0 0		0 0 0	
EUPHORIA All Severity Severe	/ Related / Related	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
FACIAL PARALYSIS All Severity Moderate	/ Not Rel. / Not Rel.	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
FEELING DRUNK All Severity	/ Related	1 1	(0.7) (0.7)	0		0		0		0	

29SEP05 14:51 REPORT AE4_SEV_DR_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 27

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

dy System [1] Adverse Event Severity / Drud	g Relationship [2]		DVS SR 50 mg n=149		 R 100 mg =155	DVS SI	atment R 150 mg =157		200 mg =151	Placebo n= 77	
Moderate	/ Related	1	(0.7)	0		0		0		0	
HOSTILITY All Severity All Severity Mild Moderate Moderate Severe	/ Not Rel. / Related / Related / Not Rel. / Related / Not Rel.	4 0 4 2 0 2	(2.7) (2.7) (1.3) (1.3)	1 0 1 1 0 0	(0.6) (0.6) (0.6)	3 1 2 1 1 1 0	(1.9) (0.6) (1.3) (0.6) (0.6) (0.6)	2 1 1 0 0	(1.3) (0.7) (0.7) (0.7)	2 1 1 1 0 0	(2.6) (1.3) (1.3) (1.3) (1.3)
YPERKINESIA All Severity All Severity Mild Moderate	/ Not Rel. / Related / Not Rel. / Related	2 1 1 1 1	(1.3) (0.7) (0.7) (0.7) (0.7)	0 0 0 0		1 0 1 0 1	(0.6) (0.6) (0.6)	0 0 0 0		0 0 0 0	
HYPERTONIA All Severity Mild	/ Related / Related	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
HYPESTHESIA All Severity All Severity Mild Mild Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related	4 3 1 3 1 0 0	(2.7) (2.0) (0.7) (2.0) (0.7)	5 3 2 2 1 1	(3.2) (1.9) (1.3) (1.3) (0.6) (0.6) (0.6)	1 0 0 0 1	(0.6) (0.6)	2 2 0 1 0 1 0	(1.3) (1.3) (0.7) (0.7)	1 0 1 0 1 0 0	(1.3) (1.3) (1.3)
HYPOKINESIA All Severity Severe	/ Related / Related	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
HYPOTONIA All Severity All Severity Moderate Moderate	/ Not Rel. / Related / Not Rel. / Related	1 0 1 0 1	(0.7) (0.7) (0.7)	0 0 0 0		0 0 0 0		1 1 0 1 0	(0.7) (0.7) (0.7)	0 0 0 0	

Page 28

29SEP05 14:51 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT AE4_SEV_DR_T NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationsh	DVS S ip [2] r		DVS S	R 100 mg	DVS SI	atment R 150 mg =157	DVS S	 R 200 mg =151	R 200 mg Placebo =151 n= 77	
INSOMNIA All Severity / Not Rel All Severity / Related Mild / Not Rel Mild / Related Moderate / Not Rel Moderate / Related Severe / Related Severe / Related	. 16 . 2 . 4 . 4 . 9	(1.3) (2.7) (2.7) (6.0)	27 3 24 3 8 0 11 0 5	(17.4) (1.9) (15.5) (1.9) (5.2) (7.1) (3.2)	2	(27.4) (1.9) (25.5) (1.3) (10.2) (0.6) (10.8) (4.5)	38 1 19 0	(25.8) (0.7) (25.2) (0.7) (12.6) (7.9) (4.6)	8 1 7 1 1 0 6 0	(10.4) (1.3) (9.1) (1.3) (1.3) (7.8)
LIBIDO DECREASED All Severity / Not Rel All Severity / Related Mild / Not Rel Mild / Related Moderate / Not Rel Moderate / Related Severe / Related	2 0 1 0 1	(1.3) (1.3) (0.7) (0.7)	5 1 4 0 2 1 2	(3.2) (0.6) (2.6) (1.3) (0.6) (1.3)	3 1 2 0 2 1 0	(1.9) (0.6) (1.3) (1.3) (0.6)	8 0 8 0 2 0 5	(5.3) (5.3) (1.3) (3.3) (0.7)	1 0 1 0 0 0	(1.3) (1.3) (1.3)
LIBIDO INCREASED All Severity / Related Mild / Related			0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
MEMORY IMPAIRMENT All Severity / Not Rel All Severity / Related Mild / Not Rel Mild / Related Moderate / Not Rel Moderate / Related	0 0 0		2 1 1 0 1 1 0	(1.3) (0.6) (0.6) (0.6) (0.6)	2 0 2 0 1 0	(1.3) (1.3) (0.6) (0.6)	2 1 1 0 0	(0.7) (0.7) (0.7)	1 0 1 0 0	(1.3) (1.3) (1.3)
MOTION SICKNESS All Severity / Not Rel Moderate / Not Rel Severe / Not Rel	. 1	(0.7) (0.7) (0.7)	1 1 0 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
MOVEMENT DISORDER	0		0		0		1	(0.7)	0	

29SEP05 14:51 REPORT AE4_SEV_DR_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 29

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationship [2]			DVS SR 50 mg n=149		DVS SR 100 mg n=155		atment - R 150 mg =157		 R 200 mg =151	Placebo n= 77	
	Not Rel. Not Rel.	0 0		0		0		1 1	(0.7) (0.7)	0	
	Not Rel. Not Rel.	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
All Severity / Mild / Mild / Moderate / Severe /	Not Rel. Related Not Rel. Related Not Rel. Related Not Rel. Related	11 10 16 0 4 0	(7.4) (0.7) (6.7) (0.7) (4.0) (2.7)	12 0 12 0 6 0 6	(7.7) (7.7) (3.9) (3.9)	20 0 20 0 9 0 8 0 3	(12.7) (12.7) (5.7) (5.1) (1.9)	19 3 16 1 8 1 6	(12.6) (2.0) (10.6) (0.7) (5.3) (0.7) (4.0) (0.7) (1.3)	2 0 2 0 2 0 0 0	(2.6) (2.6) (2.6)
	Not Rel. Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	1 1 1	(1.3) (1.3) (1.3)
All Severity / Mild / Mild / Moderate /	Not Rel. Related Not Rel. Related Related Related	0 0 0 0 0		7 3 4 3 2 1	(4.5) (1.9) (2.6) (1.9) (1.3) (0.6) (0.6)	4 0 4 0 3 1	(2.5) (2.5) (1.9) (0.6)	3 1 2 1 2 0 0	(2.0) (0.7) (1.3) (0.7) (1.3)	0 0 0 0 0	
	Not Rel. Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
All Severity /	ME Not Rel. Related Related	0 0 0		1 0 1 1	(0.6) (0.6) (0.6)	1 1 0 0	(0.6) (0.6)	1 0 1 0	(0.7) (0.7)	0 0 0	

Page

30

29SEP05 14:51 REPORT AE4_SEV_DR_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationship [2]			DVS SR 50 mg n=149			DVS S	atment R 150 mg =157	DVS S	R 200 mg =151		 icebo = 77
	/ Not Rel. / Related	0		0		1 0	(0.6)	0	(0.7)	0	
All Severity Mild Moderate	/ Not Rel. / Related / Related / Not Rel. / Related	0 0 0 0 0		0 0 0 0 0		2 0 2 1 0	(1.3) (1.3) (0.6) (0.6)	0 0 0 0 0		1 0 0 1	(1.3) (1.3)
All Severity Mild Mild Moderate Moderate	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related / Related	7 1 6 0 5 1 1	(4.7) (0.7) (4.0) (3.4) (0.7) (0.7)	24 2 22 2 12 0 7 3	(15.5) (1.3) (14.2) (1.3) (7.7) (4.5) (1.9)	30 5 25 4 12 1 9 4	(19.1) (3.2) (15.9) (2.5) (7.6) (0.6) (5.7) (2.5)	36 1 35 1 16 0 11 8	(23.8) (0.7) (23.2) (0.7) (10.6) (7.3) (5.3)	3 1 2 0 1 1 1	(3.9) (1.3) (2.6) (1.3) (1.3) (1.3)
All Severity Mild	/ Not Rel. / Related / Not Rel. / Related	0 0 0 0		0 0 0 0		1 1 0 1 0	(0.6) (0.6) (0.6)	1 0 1 0 1	(0.7) (0.7) (0.7)	0 0 0 0	
	/ Not Rel. / Not Rel.	1 1 1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0	
Mild Moderate	/ Related / Related / Related / Related	3 3 1 2 0	(2.0) (2.0) (0.7) (1.3)	4 4 1 3 0	(2.6) (2.6) (0.6) (1.9)	8 8 3 3 2	(5.1) (5.1) (1.9) (1.9) (1.3)	7 7 3 1 3	(4.6) (4.6) (2.0) (0.7) (2.0)	1 1 0 1	(1.3) (1.3) (1.3)
TREMOR All Severity	/ Not Rel.	2 1	(1.3) (0.7)	4 1	(2.6) (0.6)	4 1	(2.5) (0.6)	8 1	(5.3) (0.7)	1	(1.3)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.
[2] - Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

29SEP05 14:51 REPORT AE4_SEV_DR_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Page 31

Body System [1] Adverse Event Severity / Drug Relationship [2]	DVS SR 50 mg n=149	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo n=155 n=157 n=151 n= 77
All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Related	1 (0.7) 1 (0.7) 0 0 1 (0.7)	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$
TRISMUS All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Related	2 (1.3) 0 (1.3) 0 (1.3) 0 (1.3)	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
TWITCHING All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related	1 (0.7) 1 (0.7) 0 0 0 1 (0.7)	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$
VERTIGO All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	4 (2.7) 4 (2.7) 3 (2.0) 1 (0.7) 0	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$
RESPIRATORY SYSTEM All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related	52 (34.9) 48 (32.2) 4 (2.7) 28 (18.8) 2 (1.3)	46 (29.7) 41 (26.1) 35 (23.2) 28 (36.4) 42 (27.1) 33 (21.0) 31 (20.5) 28 (36.4) 4 (2.6) 8 (5.1) 4 (2.6) 0 24 (15.5) 15 (9.6) 12 (7.9) 14 (18.2) 3 (1.9) 5 (3.2) 3 (2.0) 0

Page 32

29SEP05 14:51 REPORT AE4_SEV_DR_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

dy System [1] Adverse Event			D E0	DV/C C1	. 100		atment -				 acebo
	g Relationship [2]		n=149		DVS SR 100 mg : n=155		n=157		=151	n= 77	
Moderate Moderate Severe	/ Not Rel. / Related / Not Rel.	19 2 1	(12.8) (1.3) (0.7)	12 1 6	(7.7) (0.6) (3.9)	17 3 1	(10.8) (1.9) (0.6)	19 1 0	(12.6) (0.7)	12 0 2	(15.6) (2.6)
APNEA All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
ASTHMA All Severity Mild Moderate Severe	/ Not Rel. / Not Rel. / Not Rel. / Not Rel.	1 1 0 1 0	(0.7) (0.7) (0.7)	1 1 0 0 1	(0.6) (0.6)	1 1 1 0 0	(0.6) (0.6) (0.6)	0 0 0 0		0 0 0 0	
BRONCHITIS All Severity Mild Moderate Severe	/ Not Rel. / Not Rel. / Not Rel. / Not Rel.	6 6 1 4 1	(4.0) (4.0) (0.7) (2.7) (0.7)	0 0 0 0		1 1 0 1 0	(0.6) (0.6) (0.6)	4 4 0 4 0	(2.6) (2.6) (2.6)	2 2 0 1 1	(2.6) (2.6) (1.3) (1.3)
COUGH INCREASED All Severity All Severity Mild Mild Moderate Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related / Not Rel.	11 8 3 5 2 3 1 0	(7.4) (5.4) (2.0) (3.4) (1.3) (2.0) (0.7)	8 8 0 5 0 1 0 2	(5.2) (5.2) (3.2) (0.6) (1.3)	5 4 1 3 0 0 1	(3.2) (2.5) (0.6) (1.9) (0.6) (0.6)	3 3 0 2 0 1 0	(2.0) (2.0) (1.3) (0.7)	5 0 3 0 2 0	(6.5) (6.5) (3.9) (2.6)
DYSPNEA All Severity All Severity Mild Mild Moderate Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related / Not Rel.	1 0 1 0 0 0 0	(0.7) (0.7)	2 2 0 1 0 0 0	(1.3) (1.3) (0.6)	5 3 2 3 2 0 0	(3.2) (1.9) (1.3) (1.9) (1.3)	2 1 1 0 1 1 0 0	(1.3) (0.7) (0.7) (0.7) (0.7)	0 0 0 0 0 0 0	

Page 33

29SEP05 14:51 REPORT AE4_SEV_DR_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

ody System [1] Adverse Event	Dig gp 50 ~~	DVC CD 100	Treatment g DVS SR 150 mg DVS SR 200 mg	r Placebo
Severity / Drug Relationship [2]	n=149	n=155	n=157 n=151	n= 77
EPISTAXIS All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel.	0 0 0 0 0	1 (0.6) 0 1 (0.6) 0 1 (0.6)	3 (1.9) 3 (2.0) 2 (1.3) 3 (2.0) 1 (0.6) 0 1 (0.6) 3 (2.0) 1 (0.6) 0	1 (1.3 1 (1.3 0 1 (1.3 0
LARYNGISMUS All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related	1 (0.7) 1 (0.7) 0 1 (0.7)	1 (0.6) 0 1 (0.6) 0 1 (0.6)	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 0 0 0
LARYNGITIS All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	1 (0.7) 1 (0.7) 0 1 (0.7)	1 (0.6) 1 (0.6) 1 (0.6) 0	0 0 0 0 0 0 0 0	0 0 0 0
LUNG DISORDER All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	3 (2.0) 3 (2.0) 3 (2.0)	3 (1.9) 3 (1.9) 2 (1.3) 1 (0.6)	2 (1.3) 0 2 (1.3) 0 2 (1.3) 0 0 0	1 (1.3 1 (1.3 1 (1.3
NOSE DRYNESS All Severity / Related Mild / Related	0 0 0	0 0 0	1 (0.6) 0 1 (0.6) 0 1 (0.6) 0	0 0 0
PHARYNGITIS All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel.	6 (4.0) 6 (4.0) 0 (2.0) 0 (2.0) 0 0	7 (4.5) 7 (4.5) 0 (4.5) 0 (1.9) 0 (1.9) 0 (0.6)	11 (7.0) 8 (5.3) 9 (5.7) 8 (5.3) 2 (1.3) 0 4 (2.5) 2 (1.3) 1 (0.6) 0 5 (3.2) 6 (4.0) 0 0	5 (6.5 5 (6.5 0 3 (3.9 0 2 (2.6
PNEUMONIA	0	1 (0.6)	1 (0.6) 0	0

Page

34

29SEP05 14:51 REPORT AE4_SEV_DR_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity /			DVS SR 50 mg n=149				R 150 mg	DVS SI		Placebo n= 77	
All Severit Moderate Severe	ty / Not Rel. / Not Rel. / Not Rel.	0 0 0		1 0 1	(0.6)	1 1 0	(0.6) (0.6)	0 0 0		0 0	
PULMONARY PHY All Severit Mild	YSICAL FINDING ty / Not Rel. / Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
RHINITIS All Severit All Severit Mild Moderate Moderate		8 8 0 6 2	(5.4) (5.4) (4.0) (1.3)	8 7 1 6 1	(5.2) (4.5) (0.6) (3.9) (0.6) (0.6)	5 5 0 4 1 0	(3.2) (3.2) (2.5) (0.6)	5 4 1 2 2 1	(3.3) (2.6) (0.7) (1.3) (1.3) (0.7)	6 6 0 3 3 0	(7.8) (7.8) (3.9) (3.9)
RHINITIS ALLI All Severit Mild Moderate Severe		3 3 1 2 0	(2.0) (2.0) (0.7) (1.3)	1 1 0 1 0	(0.6) (0.6) (0.6)	0 0 0 0		2 2 2 0 0	(1.3) (1.3) (1.3)	1 1 0 0 1	(1.3) (1.3)
SINUS CONGESS All Severit Mild Moderate Severe		1 1 1 0 0	(0.7) (0.7) (0.7)	4 4 0 3 1	(2.6) (2.6) (1.9) (0.6)	0 0 0 0		1 1 0 0	(0.7) (0.7) (0.7)	5 5 2 3 0	(6.5) (6.5) (2.6) (3.9)
SINUSITIS All Severit Mild Moderate Severe	ty / Not Rel. / Not Rel. / Not Rel. / Not Rel.	11 11 7 4 0	(7.4) (7.4) (4.7) (2.7)	14 14 3 8 3	(9.0) (9.0) (1.9) (5.2) (1.9)	7 7 2 5 0	(4.5) (4.5) (1.3) (3.2)	11 11 5 6 0	(7.3) (7.3) (3.3) (4.0)	5 5 1 3 1	
UPPER RESPIRA All Severia All Severia Mild		18 18 0 12	(12.1) (12.1) (8.1)	16 15 1 11	(10.3) (9.7) (0.6) (7.1)	11 10 1 5	(7.0) (6.4) (0.6) (3.2)	6 6 0 3	(4.0) (4.0) (2.0)	9 9 0 5	(11.7) (11.7) (6.5)

29SEP05 14:51 REPORT AE4_SEV_DR_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 35

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug			DVS SR 50 mg n=149		DVS SR 100 mg n=155		Treatment - DVS SR 150 mg n=157		 R 200 mg =151	Placebo n= 77	
Mild Moderate Moderate Severe	/ Related / Not Rel. / Related / Not Rel.	0 6 0	(4.0)	0 3 1 1	(1.9) (0.6) (0.6)	1 5 0	(0.6) (3.2)	0 3 0 0	(2.0)	0 4 0 0	(5.2)
VOICE ALTERATION All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
WHEEZING All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
YAWN All Severity All Severity Mild Moderate Moderate	/ Not Rel. / Related / Related / Not Rel. / Related	0 0 0 0 0		1 0 1 1 0 0	(0.6) (0.6) (0.6)	3 1 2 1 1	(1.9) (0.6) (1.3) (0.6) (0.6) (0.6)	2 0 2 2 0 0	(1.3) (1.3) (1.3)	0 0 0 0 0	
SKIN AND APPENDAGES All Severity All Severity Mild Mild Moderate Moderate Severe Severe	/ Not Rel. / Related	24 17 7 8 3 9 4 0	(16.1) (11.4) (4.7) (5.4) (2.0) (6.0) (2.7)	28 21 7 10 4 9 3 2	(18.1) (13.5) (4.5) (6.5) (2.6) (5.8) (1.9) (1.3)	22 16 6 12 4 3 1 1	(14.0) (10.2) (3.8) (7.6) (2.5) (1.9) (0.6) (0.6) (0.6)	22 14 8 8 5 4 3 2	(14.6) (9.3) (5.3) (5.3) (3.3) (2.6) (2.0) (1.3)	7 6 1 1 3 0 2 0	(9.1) (7.8) (1.3) (1.3) (1.3) (3.9) (2.6)
ACNE All Severity All Severity Mild Mild Moderate	/ Not Rel. / Related / Not Rel. / Related / Not Rel.	2 2 0 1 0 1	(1.3) (1.3) (0.7) (0.7)	1 0 1 0 1	(0.6) (0.6) (0.6)	2 1 1 1 1 0	(1.3) (0.6) (0.6) (0.6) (0.6)	1 1 0 0 0	(0.7) (0.7)	0 0 0 0	

Page 36

29SEP05 14:51 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR_T

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationship [2]	DVS SF	 R 50 mg =149	DVS SF	R 100 mg	DVS SE	atment R 150 mg =157	DVS SI	 R 200 mg =151	Pla n=	.cebo : 77
CONTACT DERMATITIS All Severity / Not Rel. All Severity / Related Mild / Not Rel. Moderate / Not Rel. Moderate / Related	1 1 0 0 1	(0.7) (0.7)	3 3 0 1 2	(1.9) (1.9) (0.6) (1.3)	2 2 0 2 0 0	(1.3) (1.3) (1.3)	2 1 1 1 0 1	(1.3) (0.7) (0.7) (0.7) (0.7)	0 0 0 0	
DERMATITIS ATOPIC All Severity / Not Rel. Moderate / Not Rel.	1 1 1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0	
DRY SKIN All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Related	2 1 1 1 1 0	(1.3) (0.7) (0.7) (0.7) (0.7)	2 1 1 1 0	(1.3) (0.6) (0.6) (0.6) (0.6)	3 2 1 2 1 0	(1.9) (1.3) (0.6) (1.3) (0.6)	1 0 1 0 0	(0.7) (0.7) (0.7)	0 0 0 0 0	
FUNGAL DERMATITIS All Severity / Not Rel. Moderate / Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		1 1 1	(1.3) (1.3) (1.3)
HERPES SIMPLEX All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	1 1 1 0	(0.7) (0.7) (0.7)	4 4 1 3	(2.6) (2.6) (0.6) (1.9)	2 2 2 0	(1.3) (1.3) (1.3)	4 4 3 1	(2.6) (2.6) (2.0) (0.7)	0 0 0	
HERPES ZOSTER All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	2 2 0 2	(1.3) (1.3) (1.3)	2 2 2 0	(1.3) (1.3) (1.3)	1 1 0 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
IMPETIGO All Severity / Not Rel. Moderate / Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
MACULOPAPULAR RASH	0		0		1	(0.6)	0		0	

Page 37

29SEP05 14:51 REPORT AE4_SEV_DR_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1]		Treatment									
Adverse Event Severity / Dru	g Relationship [2]		n=149		n=155		R 150 mg =157		R 200 mg =151		icebo = 77
All Severity Mild	/ Not Rel. / Not Rel.	0 0		0		1 1	(0.6)	0		0	
NIGHT SWEATS All Severity All Severity Mild Mild Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Related / Rot Rel.	2 0 2 0 0 2 0	(1.3) (1.3) (1.3)	3 1 2 0 1 1	(1.9) (0.6) (1.3) (0.6) (0.6) (0.6)	1 0 1 0 0	(0.6) (0.6) (0.6)	0 0 0 0 0		0 0 0 0 0	
PRURITUS All Severity All Severity Mild Mild Moderate Moderate Severe Severe	/ Not Rel. / Related	5 3 2 1 1 2 1 0	(3.4) (2.0) (1.3) (0.7) (0.7) (1.3) (0.7)	4 2 2 0 2 1 0 1	(2.6) (1.3) (1.3) (1.3) (0.6)	6 4 2 4 1 0 0 0	(3.8) (2.5) (1.3) (2.5) (0.6)	0 0 0 0 0 0		0 0 0 0 0 0 0 0 0 0	
PSORIASIS All Severity Moderate	/ Not Rel. / Not Rel.	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
RASH All Severity All Severity Mild Mild Moderate Moderate	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related	9 8 1 5 1 3 0	(6.0) (5.4) (0.7) (3.4) (0.7) (2.0)	3 0 3 0 0	(1.9) (1.9) (1.9)	4 3 1 3 0 0	(2.5) (1.9) (0.6) (1.9)	1 0 1 0 1 0	(0.7) (0.7) (0.7)	2 2 0 0 0 2	(2.6) (2.6)
SEBORRHEA All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	

Page

38

29SEP05 14:51 REPORT AE4_SEV_DR_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationship [2]	DVS SR 50 m n=149	g DVS SR 100 mc	Treatment g DVS SR 150 mg DVS SR 200 mg n=157 n=151	Placebo n= 77
SKIN BENIGN NEOPLASM All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	1 (0.7 1 (0.7 1 (0.7) 2 (1.3)	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	0 0 0
SKIN CARCINOMA All Severity / Not Rel. Severe / Not Rel.	0 0 0	0 0 0	0 0 0 0	1 (1.3) 1 (1.3) 1 (1.3)
SKIN DISCOLORATION All Severity / Not Rel. Mild / Not Rel.	0 0 0	1 (0.6) 1 (0.6) 1 (0.6)	0 1 (0.7) 0 1 (0.7) 0 1 (0.7)	0 0 0
SKIN DISORDER All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related	1 (0.7 0 1 (0.7 0 1 (0.7	1 (0.6) 0 1 (0.6)	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	2 (2.6) 1 (1.3) 1 (1.3) 1 (1.3) 1 (1.3)
SKIN MELANOMA All Severity / Not Rel. Moderate / Not Rel.	0 0 0	0 0 0	1 (0.6) 0 1 (0.6) 0 1 (0.6) 0	0 0 0
SKIN ULCER All Severity / Not Rel. Moderate / Not Rel.	0 0 0	0 0 0	1 (0.6) 0 1 (0.6) 0 1 (0.6) 0	0 0 0
SKIN WRINKLING All Severity / Not Rel. Mild / Not Rel.	0 0 0	0 0 0	1 (0.6) 0 1 (0.6) 0 1 (0.6) 0	0 0 0
SUNBURN All Severity / Not Rel. Moderate / Not Rel.	0 0 0	1 (0.6) 1 (0.6) 1 (0.6)	0 0 0 0	0 0 0
SWEATING All Severity / Not Rel.	2 (1.3 1 (0.7		2 (1.3) 9 (6.0) 1 (0.6) 3 (2.0)	0

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.
[2] - Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

Page 39

29SEP05 14:51 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT AE4_SEV_DR_T NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

By Severity And Drug Relationship

Body System [1]	Treatment									
Adverse Event Severity / Drug Relationship [2]		DVS SR 50 mg n=149		DVS SR 100 mg n=155		DVS SR 150 mg n=157		R 200 mg =151		cebo 77
All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel.	1 0 0 1 1 0	(0.7) (0.7) (0.7)	3 0 2 1 1 0	(1.9) (1.3) (0.6) (0.6)	1 0 1 0 0	(0.6) (0.6)	6 1 4 0 2 2	(4.0) (0.7) (2.6) (1.3) (1.3)	0 0 0 0	
URTICARIA All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel. Severe / Not Rel.	3 3 2 1 0	(2.0) (2.0) (1.3) (0.7)	3 3 1 2 0	(1.9) (1.9) (0.6) (1.3)	0 0 0 0		2 2 1 1 0	(1.3) (1.3) (0.7) (0.7)	1 0 0 1	(1.3) (1.3)
SPECIAL SENSES All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	13 9 4 8 3 0 1 1	(8.7) (6.0) (2.7) (5.4) (2.0) (0.7) (0.7)	25 9 16 5 9 4 7 0	(16.1) (5.8) (10.3) (3.2) (5.8) (2.6) (4.5)	35 12 23 7 12 4 11 1	(22.3) (7.6) (14.6) (4.5) (7.6) (2.5) (7.0) (0.6)	31 10 21 3 13 6 6	(20.5) (6.6) (13.9) (2.0) (8.6) (4.0) (4.0) (0.7) (1.3)	5 4 1 2 1 2 0 0	(6.5) (5.2) (1.3) (2.6) (1.3) (2.6)
ABNORMAL VISION All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Related	5 2 3 2 3 0 0	(3.4) (1.3) (2.0) (1.3) (2.0)	9 2 7 2 6 0 1 0	(5.8) (1.3) (4.5) (1.3) (3.9) (0.6)	14 4 10 3 6 1 4	(8.9) (2.5) (6.4) (1.9) (3.8) (0.6) (2.5)	10 1 9 1 6 0 2	(6.6) (0.7) (6.0) (0.7) (4.0) (1.3) (0.7)	1 0 1 0 1 0 0 0	(1.3) (1.3) (1.3)
CATARACT SPECIFIED All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	1 1 1 0	(0.7) (0.7) (0.7)	0 0 0		0 0 0		1 1 0 1	(0.7) (0.7) (0.7)	1 1 1 0	(1.3) (1.3) (1.3)

29SEP05 14:51 REPORT AE4_SEV_DR_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page

40

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1]			DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg						
Adverse Event Severity / Drug Relationship			100 mg 155		150 mg :157		1 200 mg :151		.cebo : 77
CONJUNCTIVITIS All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	0 0 0 0	2 2 1 1	(1.3) (1.3) (0.6) (0.6)	1 1 1 0	(0.6) (0.6) (0.6)	0 0 0		0 0 0 0	
CORNEAL LESION All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	0 0 0	0 0 0		1 1 1 0	(0.6) (0.6) (0.6)	1 1 0 1	(0.7) (0.7) (0.7)	0 0 0 0	
DRY EYES All Severity / Related Mild / Related	0 0 0	0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
EAR DISORDER All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	1 (0.7) 1 (0.7) 1 (0.7)	1 1 1 0	(0.6) (0.6) (0.6)	2 2 1 1	(1.3) (1.3) (0.6) (0.6)	1 1 0 1	(0.7) (0.7) (0.7)	0 0 0 0	
EAR PAIN All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel.	1 (0.7) 1 (0.7) 0 1 (0.7) 0	4 3 1 2 1	(2.6) (1.9) (0.6) (1.3) (0.6) (0.6)	3 2 1 1 1	(1.9) (1.3) (0.6) (0.6) (0.6) (0.6)	2 2 0 1 0 1	(1.3) (1.3) (0.7) (0.7)	1 1 0 0 0 1	(1.3) (1.3)
EYE DISORDER All Severity / Not Rel. All Severity / Related Mild / Related Moderate / Related Severe / Not Rel.	0 0 0 0 0	1 0 1 1 0 0	(0.6) (0.6) (0.6)	2 1 1 0 1 1	(1.3) (0.6) (0.6) (0.6) (0.6)	0 0 0 0		0 0 0 0 0	
EYE PAIN All Severity / Not Rel. Mild / Not Rel.	1 (0.7) 1 (0.7) 1 (0.7)	0 0 0		1 1 1	(0.6) (0.6) (0.6)	2 2 2	(1.3) (1.3) (1.3)	0 0 0	

Page

41

29SEP05 14:51 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR_T

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

dy System [1] Adverse Event Severity / Dru	g Relationship [2]		R 50 mg =149	DVS SI		DVS SI	atment R 150 mg =157	DVS SF	 R 200 mg =151	Placebo n= 77	
GLAUCOMA All Severity Mild	/ Not Rel. / Not Rel.	1 1 1	(0.7) (0.7) (0.7)	0 0		0 0 0		0 0		0 0 0	
HYPERACUSIS All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
LACRIMATION DISO All Severity Mild	RDER / Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		0 0 0		1 1 1	(1.3) (1.3) (1.3)
MIOSIS All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
MYDRIASIS All Severity All Severity Mild Mild Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Related / Related / Related	1 0 1 0 1 0	(0.7) (0.7) (0.7)	4 0 4 0 1 3	, ,	10 1 9 1 4 5	(6.4) (0.6) (5.7) (0.6) (2.5) (3.2)	9 0 9 0 4 4 1	(6.0) (6.0) (2.6) (2.6) (0.7)	0 0 0 0 0	
OTITIS EXTERNA All Severity Mild	/ Not Rel. / Not Rel.	1 1 1	(0.7) (0.7) (0.7)	0 0 0		2 2 2	(1.3) (1.3) (1.3)	0 0 0		0 0 0	
OTITIS MEDIA All Severity Moderate Severe	/ Not Rel. / Not Rel. / Not Rel.	0 0 0		0 0 0		1 1 1 0	(0.6) (0.6) (0.6)	2 2 1 1	(1.3) (1.3) (0.7) (0.7)	0 0 0	
PAROSMIA All Severity All Severity Mild	/ Not Rel. / Related / Related	0 0 0 0		1 1 0 0	(0.6) (0.6)	0 0 0		1 0 1 1	(0.7) (0.7) (0.7)	0 0 0	

Page

42

29SEP05 14:51 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT AE4_SEV_DR_T NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1]	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo										
Adverse Event Severity / Drug	Relationship [2]		R 50 mg =149	DVS SI	R 100 mg =155	DVS SI	R 150 mg =157		R 200 mg =151	Pl n	acebo = 77
Moderate	/ Not Rel.	0		1	(0.6)	0		0		0	
PHOTOPHOBIA All Severity All Severity Mild Mild	/ Not Rel. / Related / Not Rel. / Related	0 0 0 0		1 0 1 0 1	(0.6) (0.6) (0.6)	1 0 1 0	(0.6) (0.6) (0.6)	0 0 0 0		0 0 0 0	
RETINAL DETACHMENT All Severity Severe		1 1 1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0	
	/ Not Rel. / Related / Related / Not Rel. / Related	1 0 1 0 0	(0.7) (0.7) (0.7)	0	(1.3) (1.3) (1.3)	5 1 4 3 1 1	(3.2) (0.6) (2.5) (1.9) (0.6) (0.6)	3 0 3 2 0 1	(2.0) (2.0) (1.3) (0.7)	0 0 0 0 0	
	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related	2 1 1 1 1 0 0	(1.3) (0.7) (0.7) (0.7) (0.7)	3		1 0 1 0 0	(0.6) (0.6) (0.6)	4 2 2 2 1 0 1	(2.6) (1.3) (1.3) (1.3) (0.7)	0 0 0 0 0	
VESTIBULAR DISORDE All Severity Moderate	R / Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	1 1 1	(1.3) (1.3) (1.3)
VITREOUS DISORDER All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		2 2 1 1	(1.3) (1.3) (0.7) (0.7)	0 0 0	
UROGENITAL SYSTEM		15	(10.1)	20	(12.9)	19	(12.1)	14	(9.3)	10	(13.0)

Page

43

29SEP05 14:51 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT AE4_SEV_DR_T NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationship [2]	DVS SR 50 mg n=149	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo n=155 n=157 n=151 n= 77
All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	13 (8.7) 2 (1.3) 7 (4.7) 1 (0.7) 4 (2.7) 1 (0.7) 2 (1.3)	14 (9.0) 12 (7.6) 7 (4.6) 10 (13.0) 6 (3.9) 7 (4.5) 7 (4.6) 0 9 (5.8) 5 (3.2) 4 (2.6) 7 (9.1) 4 (2.6) 2 (1.3) 4 (2.6) 0 4 (2.6) 7 (4.5) 2 (1.3) 2 (2.6) 1 (0.6) 4 (2.5) 2 (1.3) 0 1 (0.6) 0 1 (0.7) 1 (1.3) 1 (0.6) 1 (0.6) 1 (0.7) 0
ABNORMAL EJACULATION/ORGASM All Severity / Related Severe / Related	0 0 0	0 1 (0.6) 0 0 0 1 (0.6) 0 0 0 1 (0.6) 0
ANORGASMIA All Severity / Related Mild / Related	0 0 0	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$
BREAST CYST All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	2 (1.3) 2 (1.3) 1 (0.7) 1 (0.7)	0 0 0 1 (1.3) 0 0 0 0 1 (1.3) 0 0 0 0 1 (1.3) 0 0 0 0
BREAST DISORDER All Severity / Not Rel. Moderate / Not Rel.	1 (0.7) 1 (0.7) 1 (0.7)	0 0 0 0 0 0 0 0 0 0 0 0
BREAST NEOPLASM All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel.	1 (0.7) 1 (0.7) 0 0 0 0 1 (0.7)	2 (1.3) 0 0 1 (1.3) 1 (0.6) 0 0 1 (1.3) 1 (0.6) 0 0 0 1 (0.6) 0 0 1 1 (0.6) 0 0 0 0 0 0
BREAST PAIN All Severity / Not Rel. All Severity / Related Mild / Not Rel.	0 0 0 0	3 (1.9) 1 (0.6) 1 (0.7) 3 (3.9) 3 (1.9) 1 (0.6) 0 3 (3.9) 0 0 1 (0.7) 0 3 (1.9) 1 (0.6) 0 2 (2.6)

29SEP05 14:51 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT AE4_SEV_DR_T

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

By Severity And Drug Relationship

Page

44

ly System [1] dverse Event Severity / Drug	Relationship [2]	DVS SR 50 mg n=149		DVS SR 100 mg n=155		DVS SR 150 mg		DVS SR 200 mg n=151		Placebo n= 77	
Mild Moderate	/ Related / Not Rel.	0		0		0		1 0	(0.7)	0	(1.3)
ERVICITIS All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
ERVIX DISORDER All Severity Moderate	/ Not Rel. / Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
YSTITIS All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	1 1 1 0	(0.7) (0.7) (0.7)	2 2 2 0	(1.3) (1.3) (1.3)	1 1 0 1	(0.6) (0.6) (0.6)	1 1 0 1	(0.7) (0.7) (0.7)	1 1 1 0	(1.3) (1.3) (1.3)
YSURIA All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
TIBROCYSTIC BREAST All Severity Moderate	/ Not Rel. / Not Rel.	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
EMATURIA All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		1 1 1	(1.3) (1.3) (1.3)
IDNEY CALCULUS All Severity Moderate Severe	/ Not Rel. / Not Rel. / Not Rel.	1 1 1 0	(0.7) (0.7) (0.7)	0 0 0		2 2 1 1	(1.3) (1.3) (0.6) (0.6)	0 0 0		0 0 0	
EUKORRHEA All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	1 1 1	(0.7) (0.7) (0.7)	0 0 0	

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.
[2] - Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

Page

45

29SEP05 14:51 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT AE4 SEV DR T NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS

By Severity And Drug Relationship Body System [1] Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg $\,$ Placebo Severity / Drug Relationship [2] n=149 n=155 n=157 0 0 0 0 1 (1.3) MASTITIS

All Severity Mild	/ Not Rel. / Not Rel.	0		0		0		0		1 1	(1.3) (1.3)
METRORRHAGIA All Severity All Severity Mild Mild	/ Not Rel. / Related / Not Rel. / Related	3 2 1 2 1	(2.0) (1.3) (0.7) (1.3) (0.7)	1 0 1 0	(0.6) (0.6) (0.6)	2 2 0 2 0	(1.3) (1.3) (1.3)	2 1 1 1 1	(1.3) (0.7) (0.7) (0.7) (0.7)	0 0 0 0	
OLIGURIA All Severity All Severity Mild Moderate	/ Not Rel. / Related / Related / Not Rel.	0 0 0 0		1 0 1 1 0	(0.6) (0.6) (0.6)	1 0 0 1	(0.6) (0.6)	0 0 0 0		0 0 0 0	
OVARIAN CYST All Severity Moderate	/ Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		0 0 0		1 1 1	(1.3) (1.3) (1.3)
PYELONEPHRITIS All Severity Moderate	/ Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
SEXUAL FUNCTION AB All Severity Mild Moderate		1 1 0 1	(0.7) (0.7) (0.7)	1 1 0 1	(0.6) (0.6) (0.6)	3 3 1 2	(1.9) (1.9) (0.6) (1.3)	2 2 0 2	(1.3) (1.3) (1.3)	0 0 0 0	
URINARY FREQUENCY All Severity All Severity Mild Mild	/ Not Rel. / Related / Not Rel. / Related	0 0 0 0		0 0 0 0		1 0 1 0 1	(0.6) (0.6) (0.6)	1 1 0 1 0	(0.7) (0.7) (0.7)	0 0 0 0	
URINARY HESITATION All Severity	/ Related	0		0		0		1	(0.7) (0.7)	0	

29SEP05 14:51 REPORT AE4_SEV_DR_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Page

46

Body System [1] Adverse Event Severity / Drug			DVS SR 50 mg n=149		DVS SR 100 mg		Treatment DVS SR 150 mg n=157		R 200 mg =151	Placebo n= 77	
Severe	/ Related	0		0		0		1	(0.7)	0	
URINARY INCONTINE All Severity Moderate	NCE / Not Rel. / Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	1 1 1		0 0 0		0 0 0	
URINARY RETENTION All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
URINARY TRACT DIS All Severity Severe		1 1 1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0	
URINARY TRACT INF All Severity All Severity Mild Moderate Moderate Severe	/ Not Rel.	6 0 3 2 0 1	(4.0) (4.0) (2.0) (1.3) (0.7)	3 0 2 1 0	(1.9) (1.9) (1.3) (0.6)	5 4 1 2 2 1 0	(3.2) (2.5) (0.6) (1.3) (1.3) (0.6)	1 0 0 0 0	(0.7) (0.7)	1 0 0 1 0	(1.3) (1.3) (1.3)
URINARY URGENCY All Severity Mild	/ Not Rel. / Not Rel.	1 1 1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0	
URINE ABNORMALITY All Severity All Severity Mild Mild	/ Not Rel. / Related / Not Rel. / Related	0 0 0 0		2 1 1 1 1	(1.3) (0.6) (0.6) (0.6) (0.6)	0 0 0 0		1 0 1 0 1	(0.7) (0.7) (0.7)	0 0 0 0	
UTERINE HEMORRHAGE All Severity All Severity Mild Moderate	E / Not Rel. / Related / Not Rel. / Not Rel. / Not Rel.	0 0 0 0		1 0 0 1	(0.6) (0.6)	2 1 1 1 0	(1.3) (0.6) (0.6) (0.6)	0 0 0 0		0 0 0 0	

29SEP05 14:51 REPORT AE4_SEV_DR_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Page

47

Body System [1] Adverse Event Severity / Drug Relationship [2]	DVS SR 50 mg n=149	DVS SR 100 mg DVS SR 150 mg Nn=155 n=157				DVS SR 200 mg n=151		Placebo n= 77	
Moderate / Related	0	0		1	(0.6)	0		0	
VAGINAL DRYNESS All Severity / Not Rel. All Severity / Related Mild / Not Rel. Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	0 0 0 0 0	3 2 1 0 1 0 1	(1.9) (1.3) (0.6) (0.6) (0.6) (0.6)	0 0 0 0 0		2 1 1 1 0 1 0	(1.3) (0.7) (0.7) (0.7) (0.7)	2 2 0 1 0 0 1	(2.6) (2.6) (1.3)
VAGINAL HEMORRHAGE All Severity / Not Rel. All Severity / Related Mild / Not Rel. Moderate / Not Rel. Moderate / Related VAGINAL MONILIASIS	0 0 0 0 0	4 4 0 4 0 0	(2.6) (2.6) (2.6)	1 0 1 0 0 1	(0.6) (0.6) (0.6)	1 0 1 0 0	(0.7) (0.7) (0.7)	2 2 0 1 1 0	(2.6) (2.6) (1.3) (1.3)
All Severity / Not Rel. Mild / Not Rel.	0	1 1	(0.6) (0.6)	0		0		0	
VAGINITIS All Severity / Not Rel. Mild / Not Rel.	0 0 0	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		1 1 1	(1.3) (1.3) (1.3)
FERMS NOT CLASSIFIABLE All Severity / Not Rel. All Severity / Related Mild / Not Rel. Moderate / Not Rel. Severe / Related	0 0 0 0 0	0 0 0 0		2 1 1 0 1 1	(1.3) (0.6) (0.6) (0.6) (0.6)	1 0 1 0 0	(0.7) (0.7) (0.7)	0 0 0 0	
REACTION UNEVALUABLE All Severity / Not Rel. All Severity / Related Mild / Not Rel.	0 0 0	0 0 0		2 1 1 0	(1.3) (0.6) (0.6)	1 1 0 1	(0.7) (0.7) (0.7)	0 0 0	

29SEP05 14:51 REPORT AE4 SEV DR T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship Page

48

Body System [1] Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Severity / Drug Relationship [2] n=149 n=155 n=157 n = 770 Moderate / Not Rel. 0 (0.6)0 0 Severe / Related 0 1 (0.6)0 0 ADVERSE EVENT ASSOC.W.MISC. FACTORS (2.7)(3.2)6 (3.8)(2.6)(9.1)All Severity / Not Rel. (2.7)5 (3.2)6 (3.8)(2.6)(9.1)Mild / Not Rel. (2.0)(2.6)(2.5)(1.3)3 (3.9)Moderate / Not Rel. (0.7)(0.6)(1.3)(1.3)(5.2)ALLERGIC REACTION OTHER THAN DRUG 4 (2.7) (2.7) (1.9)(1.3)(1.3)(3.9)3 All Severity / Not Rel. (1.9)(1.3)(1.3)(3.9)3 2 2 Mild / Not Rel. (2.0)(1.9)(1.3)(1.3)(2.6)Moderate / Not Rel. (0.7)(1.3)LOCAL REACTION TO PROCEDURE 0 2 (1.3)(2.5)(1.3)(5.2)/ Not Rel. All Severity 0 (1.3)4 (2.5)(1.3)(5.2)Mild / Not Rel. 0 (0.6)(1.3)(1.3)Moderate / Not Rel. 0 (0.6)(1.3)2 (1.3)(3.9)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

ST 10-6: Number (%) of Subjects Reporting Treatment-Emergent Adverse Events With Start Date During Week 1

130CT05 16:12 REPORT AE5_TEAE_WK1 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 1

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS WITH START DATE DURING WEEK 1

							atment -				
Body System [1] Adverse Event	Overall P-Value *		R 50 mg =149		R 100 mg =155		R 150 mg =157		R 200 mg =151		acebo = 77
ANY ADVERSE EVENT	<0.001***	71	(47.7)	113	(72.9)	115	(73.2)	119	(78.8)	30	(39.0)
BODY AS A WHOLE ABDOMINAL PAIN ACCIDENTAL INJURY ALLERGIC REACTION ASTHENIA BACK PAIN CHEST PAIN CHILLS FACE EDEMA FEVER	0.080 0.120 0.417 0.494 0.018* 0.336 0.485 0.117 0.627 0.637	33 5 0 0 9 1 0 3 1	(22.1) (3.4) (6.0) (0.7) (2.0) (0.7) (0.7)	51 1 0 0 21 1 1 6 0	(32.9) (0.6) (13.5) (0.6) (0.6) (3.9) (0.6)	42 6 1 16 0 0 4 0	(26.8) (3.8) (0.6) (0.6) (10.2) (2.5)	48 2 2 0 17 2 0 9	(31.8) (1.3) (1.3) (1.3) (1.3) (6.0) (0.7)	15 0 1 0 1 2 0 0 0	(19.5) (1.3) (1.3) (2.6)
FLU SYNDROME GENERALIZED EDEMA HEADACHE INFECTION MALAISE MONILIASIS	0.424 0.458 0.670 0.204 0.346 0.458	0 1 18 0 0	(0.7) (12.1) (0.7)	3 0 26 2 2	(1.9) (16.8) (1.3) (1.3)	2 0 28 0 0	(1.3)	2 0 22 0 1 0	(1.3) (14.6) (0.7)	0 0 11 1 0	(14.3) (1.3)
NECK PAIN PAIN	0.147 0.194	0 1	(0.7)	0 1	(0.6)	2	(1.3)	0 4	(2.6)	0 1	(1.3)
CARDIOVASCULAR SYSTEM HYPERTENSION MIGRAINE PALPITATION PERIPHERAL VASCULAR DISORDER TACHYCARDIA VASODILATATION	0.033* 0.594 0.485 0.224 0.468 0.345 0.356	2 0 0 2 0 0	(1.3)	7 1 1 3 0 3 0	(4.5) (0.6) (0.6) (1.9) (1.9)	4 1 0 0 0 1 2	(2.5) (0.6) (0.6) (1.3)	10 2 0 4 1 2	(6.6) (1.3) (2.6) (0.7) (1.3) (0.7)	0 0 0 0 0	
DIGESTIVE SYSTEM ABDOMINAL DISTENSION ANOREXIA CONSTIPATION DIARRHEA DRY MOUTH DYSPEPSIA	<0.001*** 0.458 0.234 0.277 0.472 <0.001*** 0.599	48 1 6 9 6 14 7	(32.2) (0.7) (4.0) (6.0) (4.0) (9.4) (4.7)	77 0 8 12 8 29 4	(49.7) (5.2) (7.7) (5.2) (18.7) (2.6)	84 0 12 9 5 24 5	(53.5) (7.6) (5.7) (3.2) (15.3) (3.2)	89 0 11 15 9 32 7	(58.9) (7.3) (9.9) (6.0) (21.2) (4.6)	7 0 1 2 1 0	(9.1) (1.3) (2.6) (1.3) (1.3)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

Page

2

130CT05 16:12 REPORT AE5 TEAE WK1 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS WITH START DATE DURING WEEK 1 $\,$

DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Body System [1] Overall Placebo Adverse Event P-Value * n=149 n=155 n=157 n=151 n = 770 DYSPHAGIA 0.823 (0.7)(1.3)(0.6)(1.3)ERUCTATION 0.828 1 (0.7)1 (0.6)1 (0.6)0 0 (0.6)FLATULENCE 0.417 0 0 1 (1.3)1 (1.3)GASTROENTERITIS 0.485 0 1 (0.6)0 0 Ω (0.7)GASTROESOPHAGEAL REFLUX DISEASE 0.326 1 0 0 2 (1.3)0 GASTROINTESTINAL PHYSICAL FINDING 0.458 1 (0.7)0 0 0 INCREASED APPETITE 0.799 (0.7)(0.6)0 (0.7)1 (1.3)0 NAUSEA <0.001*** 27 (18.1)52 (33.5)62 (39.5)63 (41.7)NAUSEA AND VOMITING 0.128 0 0 0 2 (1.3)0 PERIODONTITIS 0.494 0 0 (0.6)0 0 0 STOOLS ABNORMAL 0.494 0 0 (0.6)0 TONGUE EDEMA 0.128 0 0 0 2 (1.3)0 TOOTH CARIES 0.458 (0.7)0 0 VOMITING (3.4)(3.9)(2.5)0 0.064 6 11 (7.3)0 ENDOCRINE SYSTEM 0.485 0 (0.6)0 0 DIABETES MELLITUS 0.485 0 1 (0.6)0 0 0 METABOLIC AND NUTRITIONAL 0.540 0 (1.3)(0.6)(1.3)0 0.485 1 0 0 HYPERCHOLESTEREMIA 0 (0.6)0 PERIPHERAL EDEMA 0.485 0 1 (0.6)0 0 0 THIRST 0.335 0 0 (0.6)(1.3)0 0.568 3 5 MUSCULOSKELETAL SYSTEM (2.0)(1.9)(3.2)3 (2.0)(5.2)ARTHRALGIA 0.086 (1.9)(1.3)JOINT DISORDER 0 0.458 (0.7)0 0 0 LEG CRAMPS 0.003** 0 Ω Ω 0 2 (2.6)MUSCLE CRAMP 0.458 (0.7)0 0 0 0 MUSCULOSKELETAL STIFFNESS 0.356 0 (1.3)(0.7)0 (0.7)MYALGIA 0.510 3 (1.9)(1.3)1 (1.3)MYASTHENIA 0.485 (0.6)NERVOUS SYSTEM <0.001*** 34 (22.8)58 (37.4)74 (47.1)79 (52.3)13 (16.9)ABNORMAL DREAMS 0.326 1 (0.7)0 0 2 (1.3)0 AGITATION 0.227 0 0 3 (1.9)(0.7)1 ANXIETY 0.708 3 (2.0)3 (1.9)(3.8)(2.0)1 (1.3)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

 $^{^{\}star}$ - Statistical Significance at the .05, .01, .001 Levels is Denoted by * , ** , *** Respectively. Overall P-Value: P-value for Chi-Square.

Page

3

130CT05 16:12 REPORT AE5 TEAE WK1 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS WITH START DATE DURING WEEK 1

----- Treatment -----Overall DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Body System [1] Adverse Event P-Value * n = 770 ATAXIA 0.468 0 0 (0.7)0 CARPAL TUNNEL SYNDROME 0.494 0 0 1 (0.6)0 CONFUSION 0.374 (0.7)(0.6)(2.5)(1.3)(0.7)0 DEPERSONALIZATION 0.599 (0.7)(1.3)0 0 DEPRESSION 0.802 (0.7)1 (0.6)(0.7)1 (1.3)<0.001*** DIZZINESS (4.7)14 (9.0)17 (10.8)37 (24.5)(2.6)0.485 EUPHORIA 0 1 (0.6)0 0 (0.7)FEELING DRUNK 0.458 1 0 0 0 0 HOSTILITY 0.326 1 (0.7)0 0 (1.3)0 HYPERKINESIA 0.642 (0.7)0 (0.6)0 0 HYPERTONIA 0.468 0 (0.7)0 HYPESTHESIA 0.415 1 (0.6)0 (1.3)1 (1.3)HYPOTONIA 0.458 (0.7)0 0.006** (13.5)29 (18.5) 5 INSOMNIA 14 (9.4)21 32 (21.2)(6.5)LIBIDO DECREASED 0.410 1 (0.7)1 (0.6)1 (0.6)(2.6)1 (1.3)NERVOUSNESS 0.028* 10 (6.5)19 (12.1)16 (10.6)(2.6)PARESTHESIA 0.316 Ω 1 (0.6)(1.9)(0.7)RESTLESS LEGS SYNDROME 1 0.658 (0.6)(0.6)<0.001*** SOMNOLENCE (2.7)19 (12.3)(15.3)29 (19.2)0 Ω 0 SPEECH DISORDER 0.648 0 1 (0.6)1 (0.7)6 7 THINKING ABNORMAL 0.568 2 (1.3)3 (1.9)4 (2.5)(4.0)1 (1.3)(1.3)TREMOR 0.127 (0.7)3 (1.9)(4.6)(1.3)2 (1.3)TRISMUS 0.853 1 (0.7)(0.6)1 (0.6)0 0.023* (3.3)TWITCHING 0 (0.6)0 1 (1.3)VERTIGO 0.135 (2.0)(1.3)RESPIRATORY SYSTEM 0.346 (1.3)5 (3.2)8 (5.1)3 (2.0)3 (3.9)COUGH INCREASED 0.318 (0.6)0 (1.3)DYSPNEA 0.037* 3 (1.9)EPISTAXIS 0.417 0 0 (0.6)(1.3)1 (1.3)LARYNGISMUS 0.637 (0.7)(0.6)0 PHARYNGITIS 0.322 0 0 (0.6)0 1 (1.3)RHINITIS 0.485 Ω 1 (0.6)Ω Ω Ω SINUSITIS 0.642 (0.7)0 (0.6)0 UPPER RESPIRATORY INFECTION 0.617 0 (0.6)(1.3)(0.7)0 YAWN 0.658 0 (0.6)(0.6)0

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

 $^{^{\}star}$ - Statistical Significance at the .05, .01, .001 Levels is Denoted by * , ** , *** Respectively. Overall P-Value: P-value for Chi-Square.

Page

4

130CT05 16:12 REPORT AE5 TEAE WK1 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS WITH START DATE DURING WEEK 1

----- Treatment -----Overall DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Body System [1] Adverse Event P-Value * n=149 n=155 n=157 n= 77 SKIN AND APPENDAGES 0.842 (1.3)(2.6)(2.5)(1.3)(1.3)DRY SKIN 0.485 0 1 (0.6)0 0 0 (0.6)NIGHT SWEATS 0.494 0 0 0 PRURITUS 0.614 (0.7)1 (0.6)2 (1.3)0 0 RASH 0.658 Λ 1 (0.6)(0.6)Ω 0 SKIN DISORDER 0.093 0 1 (1.3)SWEATING 0.584 (0.7)(0.6)0 (1.3)SPECIAL SENSES 0.001** 6 (4.0)18 (11.6)23 (14.6)18 (11.9)1 (1.3)ABNORMAL VISION 0.106 4 (2.7)9 (5.8)11 (7.0)8 (5.3)0 0 EAR DISORDER 0.458 (0.7)Ω 0 0 EAR PAIN 0.658 1 (0.6)1 (0.6)0 EYE DISORDER 0.485 (0.6)0 0 LACRIMATION DISORDER 0.093 0 0 Ω 1 (1.3)MYDRIASIS 0.016* (0.7)4 (2.6)(5.7)(6.0)0 OTITIS MEDIA 0.494 (0.6)0 0 PHOTOPHOBIA 0.485 0 1 (0.6)0 0 0 (0.7)(1.3)3 (0.7)0 TASTE PERVERSION 0.641 (1.9)1 TINNITUS 0.340 (0.7)(1.9)(1.3)0 UROGENITAL SYSTEM 0.158 4 (2.6)(3.2)3 (2.0)0 ANORGASMIA 0.468 0 0 (0.7)0 METRORRHAGIA 0.494 0 0 1 (0.6)0 0 (0.6)(0.6)0 OLIGURIA 0.658 0 1 1 0 SEXUAL FUNCTION ABNORMAL 0.147 (1.3)0 0 URINARY FREQUENCY 0.494 0 0 (0.6)0 URINARY HESITATION 0.468 Ω Ω Ω (0.7)0 URINARY RETENTION 0.485 (0.6)0 URINE ABNORMALITY 0.643 Ω (0.6)0 (0.7)0 VAGINAL DRYNESS 0.485 0 (0.6)0 0 0 0 TERMS NOT CLASSIFIABLE 0.147 0 0 (1.3)0 REACTION UNEVALUABLE 0.147 0 0 (1.3)0 0 0 ADVERSE EVENT ASSOC.W.MISC. FACTORS 0.642 (0.7)(0.6)0 ALLERGIC REACTION OTHER THAN DRUG 0.642 (0.7)0 (0.6)0 0

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

 $^{^{\}star}$ - Statistical Significance at the .05, .01, .001 Levels is Denoted by * , ** , *** Respectively. Overall P-Value: P-value for Chi-Square.

13OCT05 16:12 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT AES_TEAE_WK1

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS WITH START DATE DURING WEEK 1 Page

5

Body System [1] Adverse Event	Overall P-Value *	Treat Comparator 1		Ratio Comparator 1 Comparator 2		Pairwise P-Value *		
ANY ADVERSE EVENT	<0.001***	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo	71/149 71/149 71/149 71/149 113/155 113/155 115/157 115/157 115/157	(47.7) (47.7) (47.7) (47.7) (72.9) (72.9) (72.9) (73.2) (73.2) (78.8)	113/155 115/157 119/151 30/ 77 115/157 119/151 30/ 77 119/151 30/ 77	(72.9) (73.2) (78.8) (39.0) (73.2) (78.8) (39.0) (78.8) (39.0) (39.0)	<pre><0.001*** <0.001*** <0.001*** 0.259 1.000 0.233 <0.001*** 0.287 <0.001*** <0.001***</pre>
BODY AS A WHOLE	0.080	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Placebo	33/149 33/149 33/149 51/155 51/155 51/155 42/157 42/157 48/151	(22.1) (22.1) (22.1) (22.1) (32.9) (32.9) (32.9) (26.8) (26.8) (31.8)	51/155 42/157 48/151 15/77 42/157 48/151 15/77 48/151 15/77 15/77	(32.9) (26.8) (31.8) (19.5) (26.8) (31.8) (19.5) (31.8) (19.5) (19.5)	0.040* 0.356 0.069 0.733 0.266 0.903 0.044* 0.381 0.259 0.060
ABDOMINAL PAIN	0.120	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	5/149 5/149 5/149 5/149 1/155 1/155 1/155 6/157 6/157 2/151	(3.4) (3.4) (3.4) (0.6) (0.6) (0.6) (3.8) (3.8) (1.3)	1/155 6/157 2/151 0/ 77 6/157 2/151 0/ 77 2/151 0/ 77 0/ 77	(0.6) (3.8) (1.3) (3.8) (1.3) (1.3)	0.115 1.000 0.281 0.169 0.121 0.619 1.000 0.283 0.181 0.551
ACCIDENTAL INJURY	0.417	DVS SR 50 mg	DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/149 0/149		1/157 2/151 1/ 77	(0.6) (1.3) (1.3)	1.000 0.498 0.341

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

130CT05 16:12 REPORT AE5_TEAE_WK1 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page

6

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS WITH START DATE DURING WEEK 1

Body System [1] Adverse Event	Overall P-Value *		ment Comparator 2		Ratio Comparator 1 Comparator 2		Pairwise P-Value *	
ACCIDENTAL INJURY	0.417	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	0/155 0/155 0/155 1/157 1/157 2/151	(0.6) (0.6) (1.3)	1/157 2/151 1/ 77 2/151 1/ 77 1/ 77	(0.6) (1.3) (1.3) (1.3) (1.3) (1.3)	1.000 0.243 0.332 0.617 0.551 1.000
ALLERGIC REACTION	0.494	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 1/157 1/157	(0.6) (0.6)	1/157 1/157 0/151 0/ 77	(0.6) (0.6)	1.000 1.000 1.000 1.000
ASTHENIA	0.018*	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	9/149 9/149 9/149 9/149 21/155 21/155 21/155 16/157 16/157 17/151	(6.0) (6.0) (6.0) (6.0) (13.5) (13.5) (13.5) (10.2) (10.2) (11.3)	21/155 16/157 17/151 1/ 77 16/157 17/151 1/ 77 17/151 1/ 77 1/ 77	(13.5) (10.2) (11.3) (10.2) (11.3) (10.2) (11.3) (1.3) (1.3) (1.3)	0.034* 0.214 0.150 0.170 0.386 0.605 0.002** 0.854 0.014* 0.008**
BACK PAIN	0.336	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	1/149 1/149 1/149 1/155 1/155 1/155 0/157 0/157 2/151	(0.7) (0.7) (0.7) (0.7) (0.6) (0.6) (0.6)	1/155 0/157 2/151 2/ 77 0/157 2/151 2/ 77 2/151 2/ 77 2/ 77	(0.6) (1.3) (2.6) (1.3) (2.6) (1.3) (2.6) (2.6)	1.000 0.487 1.000 0.268 0.497 0.619 0.256 0.240 0.107 0.605
CHEST PAIN	0.485	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg	0/149 1/155	(0.6)	1/155 0/157	(0.6)	1.000 0.497

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

130CT05 16:12 REPORT AE5_TEAE_WK1 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS WITH START DATE DURING WEEK 1 Page

7

Body System [1] Adverse Event	Overall P-Value *		ment Comparator 2					Pairwise P-Value *	
CHEST PAIN	0.485	DVS SR 100 mg	DVS SR 200 mg Placebo	1/155 1/155	(0.6) (0.6)	0/151 0/ 77		1.000	
CHILLS	0.117	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	3/149 3/149 3/149 3/149	(2.0) (2.0) (2.0) (2.0)	6/155 4/157 9/151 0/ 77	(3.9) (2.5) (6.0)	0.502 1.000 0.138 0.553	
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	6/155 6/155 6/155	(3.9) (3.9) (3.9)	4/157 9/151 0/ 77	(2.5) (6.0)	0.540 0.438 0.182	
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	4/157 4/157 9/151	(2.5) (2.5) (2.5) (6.0)	9/151 0/ 77 0/ 77	(6.0)	0.163 0.306 0.030*	
FACE EDEMA	0.627	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	0/155 0/157 1/151 0/ 77	(0.7)	0.490 0.487 1.000	
		DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg Placebo	0/155 0/157 1/151	(0.7)	1/151 1/151 0/ 77	(0.7) (0.7)	0.493 0.490 1.000	
FEVER	0.637	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.487 0.497 1.000	
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/155 1/155 1/155 1/155	(0.6) (0.6) (0.6)	0/157 0/151 0/ 77		0.497 1.000 1.000	
FLU SYNDROME	0.424	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	0/149 0/149 0/149		3/155 2/157 2/151	(1.9) (1.3) (1.3)	0.248 0.499 0.498	
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	3/155 3/155 3/155	(1.9) (1.9) (1.9)	2/157 2/151 0/ 77	(1.3) (1.3)	0.683 1.000 0.553	

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

8

Page

130CT05 16:12 REPORT AE5_TEAE_WK1 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Body System [1] Adverse Event	Overall P-Value *		ment Comparator 2		Ratio arator 1 Comparator 2		Pairwise P-Value *	
FLU SYNDROME	0.424	DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	2/157 2/157 2/151	(1.3) (1.3) (1.3)	2/151 0/ 77 0/ 77	(1.3)	1.000 1.000 0.551
GENERALIZED EDEMA	0.458	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	0/155 0/157 0/151 0/ 77		0.490 0.487 0.497 1.000
HEADACHE	0.670	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg	18/149 18/149 18/149 18/149 26/155	(12.1) (12.1) (12.1) (12.1) (16.8)	26/155 28/157 22/151 11/ 77 28/157	(16.8) (17.8) (14.6) (14.3) (17.8)	0.258 0.200 0.611 0.677 0.881
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	26/155 26/155 26/155 28/157 28/157 22/151	(16.8) (16.8) (17.8) (17.8) (14.6)	22/151 11/ 77 22/151 11/ 77 11/ 77	(14.6) (14.3) (14.6) (14.3) (14.3)	0.639 0.706 0.445 0.578 1.000
INFECTION	0.204	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo Placebo Placebo	0/149 0/149 2/155 2/155 2/155 0/157 0/151	(1.3) (1.3) (1.3)	2/155 1/ 77 0/157 0/151 1/ 77 1/ 77	(1.3) (1.3) (1.3) (1.3) (1.3)	0.499 0.341 0.246 0.498 1.000 0.329 0.338
MALAISE	0.346	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0/149 0/149 2/155 2/155 2/155 0/157 1/151	(1.3) (1.3) (1.3) (0.7)	2/155 1/151 0/157 1/151 0/ 77 1/151 0/ 77	(1.3) (0.7) (0.7) (0.7)	0.499 1.000 0.246 1.000 1.000 0.490 1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

9

Page

130CT05 16:12 REPORT AE5_TEAE_WK1 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS WITH START DATE DURING WEEK 1

Body System [1] Adverse Event	Overall P-Value *		ment Comparator 2			io Comparato		Pairwise P-Value *
MONILIASIS	0.458	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	0/155 0/157 0/151 0/ 77		0.490 0.487 0.497 1.000
NECK PAIN	0.147	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 2/157 2/157	(1.3) (1.3)	2/157 2/157 0/151 0/ 77	(1.3) (1.3)	0.499 0.498 0.499 1.000
PAIN	0.194	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	1/155 0/157 4/151 1/ 77	(0.6) (2.6) (1.3)	1.000 0.487 0.371 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/155 1/155 1/155 1/155 0/157	(0.6) (0.6) (0.6)	0/157 4/151 1/ 77	(2.6) (1.3)	0.497 0.210 1.000
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	0/157 0/157 4/151	(2.6)	4/151 1/ 77 1/ 77	(2.6) (1.3) (1.3)	0.057 0.329 0.665
CARDIOVASCULAR SYSTEM	0.033*	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/149 2/149 2/149 2/149	(1.3) (1.3) (1.3) (1.3)	7/155 4/157 10/151 0/ 77	(4.5) (2.5) (6.6)	0.174 0.685 0.035* 0.549
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	7/155 7/155 7/155 7/155	(4.5) (4.5) (4.5)	4/157 10/151 0/ 77	(2.5) (6.6)	0.377 0.463 0.099
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	4/157 4/157 10/151	(2.5) (2.5) (2.5) (6.6)	10/151 0/ 77 0/ 77	(6.6)	0.104 0.306 0.018*
HYPERTENSION	0.594	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	0/149 0/149 0/149		1/155 1/157 2/151	(0.6) (0.6) (1.3)	1.000 1.000 0.498
		DVS SR 100 mg	DVS SR 200 mg	1/155	(0.6)	1/157	(0.6)	1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

130CT05 16:12 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT AE5_TEAE_WK1

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS WITH START DATE DURING WEEK 1

Page 10

Body System [1] Adverse Event	Overall P-Value *		cment Comparator 2			cio Comparato		Pairwise P-Value *
HYPERTENSION	0.594	DVS SR 100 mg DVS SR 150 mg	DVS SR 200 mg Placebo DVS SR 200 mg	1/155 1/155 1/157	(0.6) (0.6) (0.6)	2/151 0/ 77 2/151	(1.3)	0.619 1.000 0.617
		DVS SR 200 mg	Placebo Placebo	1/157 2/151	(0.6) (1.3)	0/ 77 0/ 77		1.000 0.551
MIGRAINE	0.485	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.497 1.000
PALPITATION	0.224	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/149 2/149 2/149 2/149	(1.3) (1.3) (1.3) (1.3)	3/155 0/157 4/151 0/ 77	(1.9) (2.6)	1.000 0.236 0.684 0.549
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	3/155 3/155 3/155	(1.9) (1.9) (1.9)	0/157 4/151 0/ 77	(2.6)	0.121 0.720 0.553
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo	0/157 4/151	(2.6)	4/151 0/ 77	(2.6)	0.057 0.303
PERIPHERAL VASCULAR DISORDER	0.468	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/149 0/155 0/157 1/151	(0.7)	1/151 1/151 1/151 0/ 77	(0.7) (0.7) (0.7)	1.000 0.493 0.490 1.000
TACHYCARDIA	0.345	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg	0/149 0/149		3/155 1/157	(1.9) (0.6)	0.248
		DVS SR 100 mg	DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg	0/149 3/155 3/155	(1.9) (1.9)	2/151 1/157 2/151	(1.3) (0.6) (1.3)	0.498 0.369 1.000
		DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	3/155 1/157 1/157	(1.9) (0.6) (0.6)	0/ 77 2/151 0/ 77	(1.3)	0.553 0.617 1.000
		DVS SR 200 mg		2/151	(1.3)	0/ 77		0.551

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

130CT05 16:12 REPORT AE5_TEAE_WK1 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 11

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS
WITH START DATE DURING WEEK 1

Body System [1]	Overall	Treat	ment		Rat	io		Pairwise
Adverse Event	P-Value *	Comparator 1	Comparator 2	Comparate	or 1	Comparat	or 2	P-Value *
VASODILATATION	0.356	DVS SR 50 mg DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg	0/149 0/149 0/155		2/157 1/151 2/157	(1.3) (0.7) (1.3)	0.499 1.000 0.498
		DVS SR 150 mg	DVS SR 200 mg DVS SR 200 mg	0/155 2/157	(1.3)	1/151 1/151	(0.7) (0.7)	0.493 1.000
		DVS SR 200 mg	Placebo Placebo	2/157 1/151	(1.3) (0.7)	0/ 77 0/ 77		1.000
DIGESTIVE SYSTEM	<0.001***	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	48/149 48/149 48/149	(32.2) (32.2) (32.2)	77/155 84/157 89/151	(49.7) (53.5) (58.9)	0.002** <0.001*** <0.001**
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	48/149 77/155 77/155 77/155	(32.2) (49.7) (49.7) (49.7)	7/ 77 84/157 89/151 7/ 77	(9.1) (53.5) (58.9) (9.1)	<0.001*** 0.571 0.110 <0.001***
		DVS SR 150 mg	DVS SR 200 mg Placebo	84/157 84/157	(53.5) (53.5)	89/151 7/ 77	(58.9) (9.1)	0.359
		DVS SR 200 mg	Placebo	89/151	(58.9)	7/ 77	(9.1)	<0.001***
ABDOMINAL DISTENSION	0.458	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	0/155 0/157 0/151 0/ 77		0.490 0.487 0.497 1.000
ANOREXIA	0.234	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	6/149 6/149 6/149 6/149	(4.0) (4.0) (4.0) (4.0)	8/155 12/157 11/151 1/ 77	(5.2) (7.6) (7.3)	0.786 0.227 0.318 0.427
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	8/155 8/155 8/155	(5.2) (5.2) (5.2)	12/157 11/151 1/ 77	(1.3) (7.6) (7.3) (1.3)	0.427 0.489 0.485 0.278
		DVS SR 150 mg	DVS SR 200 mg Placebo	12/157 12/157	(7.6) (7.6)	11/151 1/ 77	(7.3) (1.3)	1.000
		DVS SR 200 mg	Placebo	11/151	(7.3)	1/ 77	(1.3)	0.064
CONSTIPATION	0.277	DVS SR 50 mg	DVS SR 100 mg	9/149	(6.0)	12/155	(7.7)	0.653

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

130CT05 16:12 REPORT AE5_TEAE_WK1 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 12

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS WITH START DATE DURING WEEK 1

Body System [1]	Overall	Treat	ment		Rat	io		Pairwise
Adverse Event	P-Value *	Comparator 1	Comparator 2	Comparat	or 1	Comparat	or 2	P-Value *
CONSTIPATION	0.277	DVS SR 50 mg	DVS SR 150 mg DVS SR 200 mg Placebo	9/149 9/149 9/149	(6.0) (6.0) (6.0)	9/157 15/151 2/ 77	(5.7) (9.9) (2.6)	1.000 0.287 0.340
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	12/155 12/155	(7.7) (7.7)	9/157 15/151	(5.7) (9.9)	0.507 0.549
		DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	12/155 9/157 9/157	(7.7) (5.7) (5.7)	2/ 77 15/151 2/ 77	(2.6) (9.9) (2.6)	0.151 0.204 0.348
		DVS SR 200 mg	Placebo	15/151	(9.9)	2/ 77	(2.6)	0.061
DIARRHEA	0.472	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	6/149 6/149 6/149 6/149	(4.0) (4.0) (4.0) (4.0)	8/155 5/157 9/151 1/ 77	(5.2) (3.2) (6.0) (1.3)	0.786 0.765 0.598 0.427
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	8/155 8/155 8/155	(5.2) (5.2) (5.2)	5/157 9/151 1/ 77	(3.2) (6.0) (1.3)	0.412 0.807 0.278
		DVS SR 150 mg	DVS SR 200 mg Placebo	5/157 5/157	(3.2) (3.2)	9/151 1/ 77	(6.0) (1.3)	0.283 0.667
		DVS SR 200 mg	Placebo	9/151	(6.0)	1/ 77	(1.3)	0.170
DRY MOUTH	<0.001***	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	14/149 14/149 14/149 14/149	(9.4) (9.4) (9.4) (9.4)	29/155 24/157 32/151 0/ 77	(18.7) (15.3) (21.2)	0.022* 0.123 0.006** 0.003**
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	29/155 29/155 29/155	(18.7) (18.7) (18.7)	24/157 32/151 0/ 77	(15.3) (21.2)	0.453 0.668 <0.001***
		DVS SR 150 mg	DVS SR 200 mg Placebo	24/157 24/157	(15.3) (15.3)	32/151 0/ 77	(21.2)	0.187 <0.001***
		DVS SR 200 mg	Placebo	32/151	(21.2)	0/ 77		<0.001***
DYSPEPSIA	0.599	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	7/149 7/149 7/149 7/149	(4.7) (4.7) (4.7) (4.7)	4/155 5/157 7/151 1/ 77	(2.6) (3.2) (4.6) (1.3)	0.371 0.565 1.000 0.270

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

130CT05 16:12 REPORT AE5_TEAE_WK1 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 13

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS WITH START DATE DURING WEEK 1

Body System [1]	Overall	Treat	ment		Rat	io		Pairwise
Adverse Event	P-Value *	Comparator 1	Comparator 2	Comparato	or 1	Comparato	or 2	P-Value *
DYSPEPSIA	0.599	DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	4/155 4/155 4/155	(2.6) (2.6) (2.6)	5/157 7/151 1/ 77	(3.2) (4.6) (1.3)	1.000 0.374 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	5/157 5/157	(3.2) (3.2)	7/151 1/ 77	(4.6) (1.3)	0.567 0.667
		DVS SR 200 mg	Placebo	7/151	(4.6)	1/ 77	(1.3)	0.272
DYSPHAGIA	0.823	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	2/155 1/157 2/151 0/ 77	(1.3) (0.6) (1.3)	1.000 1.000 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	2/155 2/155 2/155	(1.3) (1.3) (1.3)	1/157 2/151 0/ 77	(0.6) (1.3)	0.621 1.000 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/157 1/157	(0.6) (0.6)	2/151 0/ 77	(1.3)	0.617 1.000
		DVS SR 200 mg	Placebo	2/151	(1.3)	0/ 77		0.551
ERUCTATION	0.828	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	1/155 1/157 0/151 0/ 77	(0.6) (0.6)	1.000 1.000 0.497 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/155 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/157 0/151 0/ 77	(0.6)	1.000 1.000 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/157 1/157	(0.6) (0.6)	0/151 0/ 77		1.000
FLATULENCE	0.417	DVS SR 50 mg	DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/149 0/149		1/157 2/151 1/ 77	(0.6) (1.3) (1.3)	1.000 0.498 0.341
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	0/155 0/155 0/155 0/155		1/157 2/151 1/ 77	(0.6) (1.3) (1.3)	1.000 0.243 0.332
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/157 1/157	(0.6) (0.6)	2/151 1/ 77	(1.3) (1.3) (1.3)	0.552 0.617 0.551

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

Page 14

130CT05 16:12 REPORT AE5_TEAE_WK1 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS WITH START DATE DURING WEEK 1

Body System [1] Adverse Event	Overall P-Value *		cment Comparator 2			io Comparat		Pairwise P-Value *
FLATULENCE	0.417	DVS SR 200 mg	Placebo	2/151	(1.3)	1/ 77	(1.3)	1.000
GASTROENTERITIS	0.485	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.497 1.000 1.000
GASTROESOPHAGEAL REFLUX DISEASE	0.326	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149 0/155 0/157 2/151	(0.7) (0.7) (0.7) (0.7) (1.3)	0/155 0/157 2/151 0/ 77 2/151 2/151 0/ 77	(1.3) (1.3) (1.3)	0.490 0.487 1.000 1.000 0.243 0.240 0.551
GASTROINTESTINAL PHYSICAL FINDING	0.458	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	0/155 0/157 0/151 0/ 77		0.490 0.487 0.497 1.000
INCREASED APPETITE	0.799	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	1/149 1/149 1/149 1/155 1/155 1/155 0/157 0/157 1/151	(0.7) (0.7) (0.7) (0.7) (0.6) (0.6) (0.6)	1/155 0/157 1/151 1/ 77 0/157 1/151 1/ 77 1/151 1/ 77 1/ 77	(0.6) (0.7) (1.3) (0.7) (1.3) (0.7) (1.3) (1.3)	1.000 0.487 1.000 1.000 0.497 1.000 1.000 0.490 0.329 1.000
NAUSEA	<0.001***	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg	27/149 27/149 27/149 27/149 52/155	(18.1) (18.1) (18.1) (18.1) (33.5)	52/155 62/157 63/151 0/ 77 62/157	(33.5) (39.5) (41.7) (39.5)	0.003** <0.001*** <0.001*** <0.001*** 0.292

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

130CT05 16:12 REPORT AE5_TEAE_WK1 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 15

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS
WITH START DATE DURING WEEK 1

Body System [1]	Overall	Treat	ment		Rat	io		Pairwise
Adverse Event	P-Value *	Comparator 1	Comparator 2	Comparat	or 1	Comparat	or 2	P-Value *
NAUSEA	<0.001***	DVS SR 100 mg DVS SR 150 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo	52/155 52/155 62/157 62/157	(33.5) (33.5) (39.5) (39.5)	63/151 0/77 63/151 0/77	(41.7) (41.7)	0.157 <0.001*** 0.728 <0.001***
		DVS SR 200 mg	Placebo	63/151	(41.7)	0/ 77		<0.001***
NAUSEA AND VOMITING	0.128	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg		0/149 0/155 0/157 2/151	(1.3)	2/151 2/151 2/151 0/ 77	(1.3) (1.3) (1.3)	0.498 0.243 0.240 0.551
PERIODONTITIS	0.494	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 1/157 1/157	(0.6) (0.6)	1/157 1/157 0/151 0/ 77	(0.6) (0.6)	1.000 1.000 1.000 1.000
STOOLS ABNORMAL	0.494	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 1/157 1/157	(0.6) (0.6)	1/157 1/157 0/151 0/ 77	(0.6) (0.6)	1.000 1.000 1.000 1.000
TONGUE EDEMA	0.128	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/149 0/155 0/157 2/151	(1.3)	2/151 2/151 2/151 0/ 77	(1.3) (1.3) (1.3)	0.498 0.243 0.240 0.551
TOOTH CARIES	0.458	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	0/155 0/157 0/151 0/ 77		0.490 0.487 0.497 1.000
VOMITING	0.064	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	5/149 5/149 5/149 5/149	(3.4) (3.4) (3.4) (3.4)	6/155 4/157 11/151 0/ 77	(3.9) (2.5) (7.3)	1.000 0.745 0.198 0.169
		DVS SR 100 mg	DVS SR 150 mg	6/155	(3.9)	4/157	(2.5)	0.540

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

130CT05 16:12 REPORT AE5_TEAE_WK1 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 16

- - NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS
WITH START DATE DURING WEEK 1

Body System [1]	Overall		ment					Pairwise
Adverse Event	P-Value *	Comparator 1	Comparator 2	Comparato	or 1	Comparato	or 2	P-Value *
VOMITING	0.064	DVS SR 100 mg DVS SR 150 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo	6/155 6/155 4/157 4/157	(3.9) (3.9) (2.5) (2.5)	11/151 0/ 77 11/151 0/ 77	(7.3) (7.3)	0.220 0.182 0.065 0.306
		DVS SR 200 mg	Placebo	11/151	(7.3)	0/ 77		0.018*
ENDOCRINE SYSTEM	0.485	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.497 1.000 1.000
DIABETES MELLITUS	0.485	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.497 1.000 1.000
METABOLIC AND NUTRITIONAL	0.540	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo DVS SR 200 mg	0/149 0/149 0/149 2/155 2/155 2/155 1/157	(1.3) (1.3) (1.3) (0.6)	2/155 1/157 2/151 1/157 2/151 0/ 77 2/151	(1.3) (0.6) (1.3) (0.6) (1.3)	0.499 1.000 0.498 0.621 1.000 1.000
		DVS SR 200 mg	Placebo Placebo	1/157 2/151	(0.6) (1.3)	0/ 77 0/ 77	(2.0)	1.000 0.551
HYPERCHOLESTEREMIA	0.485	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.497 1.000 1.000
PERIPHERAL EDEMA	0.485	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.497 1.000 1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

130CT05 16:12 REPORT AE5_TEAE_WK1 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 17

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS WITH START DATE DURING WEEK 1

Body System [1]	Overall	Treat	ment		Rat	:io		Pairwise
Adverse Event	P-Value *	Comparator 1	Comparator 2	Comparato	or 1	Comparato	or 2	P-Value *
THIRST	0.335	DVS SR 50 mg DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg	0/149 0/149 0/155		1/157 2/151 1/157	(0.6) (1.3) (0.6)	1.000 0.498 1.000
		DVS SR 150 mg	DVS SR 200 mg DVS SR 200 mg	0/155 1/157	(0.6)	2/151 2/151	(1.3) (1.3)	0.243 0.617
		DVS SR 200 mg	Placebo Placebo	1/157 2/151	(0.6) (1.3)	0/ 77 0/ 77		1.000 0.551
MUSCULOSKELETAL SYSTEM	0.568	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	3/149 3/149 3/149	(2.0) (2.0) (2.0)	3/155 5/157 3/151	(1.9) (3.2) (2.0)	1.000 0.724 1.000 0.233
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	3/149 3/155 3/155 3/155	(2.0) (1.9) (1.9) (1.9)	4/ 77 5/157 3/151 4/ 77	(5.2) (3.2) (2.0) (5.2)	0.233 0.723 1.000 0.224
		DVS SR 150 mg	DVS SR 200 mg Placebo	5/157 5/157	(3.2)	3/151 4/ 77	(2.0) (5.2)	0.723 0.481
		DVS SR 200 mg	Placebo	3/151	(2.0)	4/ 77	(5.2)	0.230
ARTHRALGIA	0.086	DVS SR 50 mg	DVS SR 150 mg Placebo	0/149 0/149		3/157 1/ 77	(1.9) (1.3)	0.248
		DVS SR 100 mg	DVS SR 150 mg Placebo	0/155 0/155		3/157 1/ 77	(1.9) (1.3)	0.248
		DVS SR 150 mg	DVS SR 200 mg Placebo	3/157 3/157	(1.9) (1.9)	0/151 1/ 77	(1.3)	0.248
		DVS SR 200 mg	Placebo	0/151	(=::)	1/ 77	(1.3)	0.338
JOINT DISORDER	0.458	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	0/155 0/157 0/151 0/ 77		0.490 0.487 0.497 1.000
LEG CRAMPS	0.003**	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo	0/149 0/155 0/157 0/151		2/ 77 2/ 77 2/ 77 2/ 77	(2.6) (2.6) (2.6) (2.6)	0.115 0.109 0.107 0.113

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

130CT05 16:12 REPORT AE5_TEAE_WK1 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 18

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS WITH START DATE DURING WEEK 1

Body System [1] Adverse Event	Overall P-Value *	Treat Comparator 1	ment Comparator 2			io Comparat		Pairwise P-Value *
MUSCLE CRAMP	0.458	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	0/155 0/157 0/151 0/ 77		0.490 0.487 0.497 1.000
MUSCULOSKELETAL STIFFNESS	0.356	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 200 mg Placebo Placebo	0/149 0/149 0/155 0/155 2/157 2/157 1/151	(1.3) (1.3) (0.7)	2/157 1/151 2/157 1/151 1/151 0/ 77 0/ 77	(1.3) (0.7) (1.3) (0.7) (0.7)	0.499 1.000 0.498 0.493 1.000 1.000
MYALGIA	0.510	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	1/149 1/149 1/149 1/149 3/155 3/155 3/155 0/157 0/157 2/151	(0.7) (0.7) (0.7) (0.7) (1.9) (1.9) (1.9)	3/155 0/157 2/151 1/ 77 0/157 2/151 1/ 77 2/151 1/ 77 1/ 77	(1.9) (1.3) (1.3) (1.3) (1.3) (1.3) (1.3) (1.3)	0.623 0.487 1.000 1.000 0.121 1.000 1.000 0.240 0.329 1.000
MYASTHENIA	0.485	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.497 1.000 1.000
NERVOUS SYSTEM	<0.001***	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	34/149 34/149 34/149 34/149 58/155 58/155 58/155	(22.8) (22.8) (22.8) (22.8) (37.4) (37.4) (37.4)	58/155 74/157 79/151 13/ 77 74/157 79/151 13/ 77	(37.4) (47.1) (52.3) (16.9) (47.1) (52.3) (16.9)	0.006** <0.001*** <0.001*** 0.387 0.087 0.011* 0.001**

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

130CT05 16:12 REPORT AE5_TEAE_WK1 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 19

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS WITH START DATE DURING WEEK 1

Body System [1] Adverse Event	Overall P-Value *		ment Comparator 2					Pairwise P-Value *
NERVOUS SYSTEM	<0.001***	DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	74/157 74/157 79/151	(47.1) (47.1) (52.3)	79/151 13/ 77 13/ 77	(52.3) (16.9) (16.9)	0.425 <0.001***
ABNORMAL DREAMS	0.326	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg PVS SR 200 mg Placebo	1/149 1/149 1/149 1/149 0/155 0/157 2/151	(0.7) (0.7) (0.7) (0.7) (0.7)	0/155 0/157 2/151 0/ 77 2/151 2/151 0/ 77	(1.3) (1.3) (1.3)	0.490 0.487 1.000 1.000 0.243 0.240 0.551
AGITATION	0.227	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	0/149 0/149 0/149 0/155 0/155 0/155 3/157 3/157 1/151	(1.9) (1.9) (0.7)	3/157 1/151 1/ 77 3/157 1/151 1/ 77 1/151 1/ 77 1/ 77	(1.9) (0.7) (1.3) (1.9) (0.7) (1.3) (0.7) (1.3) (1.3)	0.248 1.000 0.341 0.248 0.493 0.332 0.623 1.000
ANXIETY	0.708	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	3/149 3/149 3/149 3/155 3/155 3/155 6/157 6/157 3/151	(2.0) (2.0) (2.0) (2.0) (1.9) (1.9) (1.9) (3.8) (3.8) (2.0)	3/155 6/157 3/151 1/ 77 6/157 3/151 1/ 77 3/151 1/ 77 1/ 77	(1.9) (3.8) (2.0) (1.3) (3.8) (2.0) (1.3) (2.0) (1.3) (1.3)	1.000 0.503 1.000 1.000 0.501 1.000 1.000 0.502 0.431 1.000
ATAXIA	0.468	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg	0/149 0/155 0/157		1/151 1/151 1/151	(0.7) (0.7) (0.7)	1.000 0.493 0.490

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

Page 20

130CT05 16:12 REPORT AE5_TEAE_WK1 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS WITH START DATE DURING WEEK 1

Body System [1] Adverse Event	Overall P-Value *		comparator 2					Pairwise P-Value *
ATAXIA	0.468	DVS SR 200 mg	Placebo	1/151	(0.7)	0/ 77		1.000
CARPAL TUNNEL SYNDROME	0.494	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 1/157 1/157	(0.6) (0.6)	1/157 1/157 0/151 0/ 77	(0.6) (0.6)	1.000 1.000 1.000 1.000
CONFUSION	0.374	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	1/149 1/149 1/149 1/149 1/155 1/155 1/155 4/157 4/157 2/151	(0.7) (0.7) (0.7) (0.7) (0.6) (0.6) (0.6) (2.5) (2.5) (1.3)	1/155 4/157 2/151 0/ 77 4/157 2/151 0/ 77 2/151 0/ 77 0/ 77	(0.6) (2.5) (1.3) (2.5) (1.3) (1.3)	1.000 0.372 1.000 1.000 0.371 0.619 1.000 0.685 0.306 0.551
DEPERSONALIZATION	0.599	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149 2/155 2/155 2/155 0/157 1/151	(0.7) (0.7) (0.7) (0.7) (1.3) (1.3) (1.3) (0.7)	2/155 0/157 1/151 0/ 77 0/157 1/151 0/ 77 1/151 0/ 77	(1.3) (0.7) (0.7) (0.7)	1.000 0.487 1.000 1.000 0.246 1.000 1.000 0.490 1.000
DEPRESSION	0.802	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	1/149 1/149 1/149 1/149 0/155 0/155 1/157	(0.7) (0.7) (0.7) (0.7)	0/155 1/157 1/151 1/ 77 1/157 1/151 1/ 77 1/151	(0.6) (0.7) (1.3) (0.6) (0.7) (1.3) (0.7)	0.490 1.000 1.000 1.000 1.000 0.493 0.332 1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

130CT05 16:12 REPORT AE5_TEAE_WK1 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 21

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS WITH START DATE DURING WEEK 1

Body System [1] Adverse Event	Overall P-Value *		ment Comparator 2			io Comparat		Pairwise P-Value *
DEPRESSION	0.802	DVS SR 150 mg DVS SR 200 mg	Placebo Placebo	1/157 1/151	(0.6) (0.7)	1/ 77 1/ 77	(1.3) (1.3)	0.551 1.000
DIZZINESS	<0.001***	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	7/149 7/149 7/149 7/149	(4.7) (4.7) (4.7) (4.7)	14/155 17/157 37/151 2/ 77	(9.0) (10.8) (24.5) (2.6)	0.175 0.056 <0.001*** 0.722
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	14/155 14/155 14/155	(9.0) (9.0) (9.0)	17/157 37/151 2/ 77	(10.8) (24.5) (2.6)	0.706 <0.001*** 0.097
		DVS SR 150 mg	DVS SR 200 mg Placebo	17/157 17/157	(10.8) (10.8)	37/151 2/ 77	(24.5)	0.002**
		DVS SR 200 mg	Placebo	37/151	(24.5)	2/ 77	(2.6)	<0.001***
EUPHORIA	0.485	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.497 1.000 1.000
FEELING DRUNK	0.458	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	0/155 0/157 0/151 0/ 77		0.490 0.487 0.497 1.000
HOSTILITY	0.326	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	0/155 0/157 2/151 0/ 77	(1.3)	0.490 0.487 1.000 1.000
		DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg Placebo	0/155 0/157 2/151	(1.3)	2/151 2/151 0/ 77	(1.3) (1.3)	0.243 0.240 0.551
HYPERKINESIA	0.642	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	0/155 1/157 0/151 0/ 77	(0.6)	0.490 1.000 0.497 1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 22

13OCT05 16:12 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE5_TEAE_WK1

- - NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS WITH START DATE DURING WEEK 1

Body System [1] Adverse Event	Overall P-Value *	Treat Comparator 1	ment Comparator 2			io Comparat		Pairwise P-Value *
HYPERKINESIA	0.642	DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo	0/155 1/157 1/157	(0.6) (0.6)	1/157 0/151 0/ 77	(0.6)	1.000 1.000 1.000
HYPERTONIA	0.468	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/149 0/155 0/157 1/151	(0.7)	1/151 1/151 1/151 0/ 77	(0.7) (0.7) (0.7)	1.000 0.493 0.490 1.000
HYPESTHESIA	0.415	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	0/149 0/149 0/149 1/155 1/155 1/155 0/157 0/157 2/151	(0.6) (0.6) (0.6) (1.3)	1/155 2/151 1/ 77 0/157 2/151 1/ 77 2/151 1/ 77 1/ 77	(0.6) (1.3) (1.3) (1.3) (1.3) (1.3) (1.3) (1.3)	1.000 0.498 0.341 0.497 0.619 1.000 0.240 0.329 1.000
HYPOTONIA	0.458	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	0/155 0/157 0/151 0/ 77		0.490 0.487 0.497 1.000
INSOMNIA	0.006**	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	21/155 21/155 29/157 29/157	(9.4) (9.4) (9.4) (9.4) (13.5) (13.5) (13.5) (18.5) (18.5) (21.2)	21/155 29/157 32/151 5/ 77 29/157 32/151 5/ 77 32/151 5/ 77 5/ 77	(13.5) (18.5) (21.2) (6.5) (18.5) (21.2) (6.5) (21.2) (6.5) (6.5)	0.285 0.032* 0.006** 0.615 0.281 0.096 0.126 0.570 0.017* 0.004**
LIBIDO DECREASED	0.410	DVS SR 50 mg	DVS SR 100 mg	1/149	(0.7)	1/155	(0.6)	1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

130CT05 16:12 REPORT AE5_TEAE_WK1 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 23

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS WITH START DATE DURING WEEK 1

Body System [1]	Overall	Treat	ment		Rat	io		Pairwise
Adverse Event	P-Value *	Comparator 1	Comparator 2	Comparat	or 1	Comparat	or 2	P-Value *
LIBIDO DECREASED	0.410	DVS SR 50 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149	(0.7) (0.7) (0.7)	1/157 4/151 1/ 77	(0.6) (2.6) (1.3)	1.000 0.371 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	1/155 1/155	(0.6) (0.6)	1/157 4/151	(0.6) (2.6)	1.000 0.210
		DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	1/155 1/157 1/157	(0.6) (0.6) (0.6)	1/ 77 4/151 1/ 77	(1.3) (2.6) (1.3)	1.000 0.207 0.551
		DVS SR 200 mg	Placebo	4/151	(2.6)	1/ 77	(1.3)	0.665
NERVOUSNESS	0.028*	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	7/149 7/149 7/149	(4.7) (4.7) (4.7)	10/155 19/157 16/151	(6.5) (12.1) (10.6)	0.620 0.024* 0.081
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	7/149 10/155 10/155 10/155	(4.7) (6.5) (6.5) (6.5)	2/ 77 19/157 16/151 2/ 77	(2.6) (12.1) (10.6) (2.6)	0.722 0.118 0.222 0.346
		DVS SR 150 mg	DVS SR 200 mg Placebo	19/157 19/157	(12.1) (12.1)	16/151 2/ 77	(10.6) (2.6)	0.722 0.015*
		DVS SR 200 mg	Placebo	16/151	(10.6)	2/ 77	(2.6)	0.038*
PARESTHESIA	0.316	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	0/149 0/149 0/149		1/155 3/157 1/151	(0.6) (1.9) (0.7)	1.000 0.248 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/155 1/155 1/155	(0.6) (0.6) (0.6)	3/157 1/151 0/ 77	(1.9) (0.7)	0.623 1.000 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	3/157 3/157	(1.9) (1.9)	1/151 0/ 77	(0.7)	0.623 0.553
		DVS SR 200 mg	Placebo	1/151	(0.7)	0/ 77		1.000
RESTLESS LEGS SYNDROME	0.658	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg	0/149 0/149		1/155 1/157	(0.6) (0.6)	1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/157 0/151 0/ 77	(0.6)	1.000 1.000 1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

130CT05 16:12 REPORT AE5_TEAE_WK1 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 24

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS WITH START DATE DURING WEEK 1

dy System [1]	Overall	Treat	ment	Ratio			Pairwise	
Adverse Event	P-Value *		Comparator 2					P-Value *
RESTLESS LEGS SYNDROME	0.658	DVS SR 150 mg	DVS SR 200 mg Placebo	1/157 1/157	(0.6) (0.6)	0/151 0/ 77		1.000
SOMNOLENCE	<0.001***	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	4/149 4/149 4/149 4/149	(2.7) (2.7) (2.7) (2.7)	19/155 24/157 29/151 0/ 77	(12.3) (15.3) (19.2)	0.002** <0.001*** <0.001*** 0.302
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	19/155 19/155	(12.3) (12.3) (12.3)	24/157 29/151 0/ 77	(15.3) (19.2)	0.512 0.116 <0.001***
		DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	19/155 24/157 24/157	(12.3) (15.3) (15.3)	29/151 0/ 77	(19.2)	0.370
		DVS SR 200 mg		29/151	(19.2)	0/ 77		<0.001***
SPEECH DISORDER	0.648	DVS SR 50 mg	DVS SR 150 mg DVS SR 200 mg	0/149 0/149		1/157 1/151	(0.6) (0.7)	1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	0/155 0/155		1/157 1/151	(0.6) (0.7)	1.000
		DVS SR 150 mg		1/157 1/157	(0.6) (0.6)	1/151	(0.7)	1.000
		DVS SR 200 mg		1/151	(0.7)	0/ 77		1.000
THINKING ABNORMAL	0.568	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/149 2/149 2/149 2/149	(1.3) (1.3) (1.3) (1.3)	3/155 4/157 6/151 1/ 77	(1.9) (2.5) (4.0) (1.3)	1.000 0.685 0.283 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	3/155 3/155 3/155 3/155	(1.9) (1.9) (1.9)	4/157 6/151 1/ 77	(2.5) (4.0) (1.3)	1.000 1.000 0.331 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	4/157 4/157	(2.5)	6/151 1/ 77	(4.0) (1.3)	0.535
		DVS SR 200 mg	Placebo	6/151	(4.0)	1/ 77	(1.3)	0.428
TREMOR	0.127	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	1/149 1/149 1/149	(0.7) (0.7) (0.7)	2/155 3/157 7/151	(1.3) (1.9) (4.6)	1.000 0.623 0.067

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

130CT05 16:12 REPORT AE5_TEAE_WK1 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 25

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS WITH START DATE DURING WEEK 1

Body System [1]	Overall	Treat	ment		Rat	io			
Adverse Event	P-Value *	Comparator 1	Comparator 2	Comparato	or 1	Comparato	or 2	P-Value *	
TREMOR	0.127	DVS SR 50 mg DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg	1/149 2/155 2/155	(0.7) (1.3) (1.3)	1/ 77 3/157 7/151	(1.3) (1.9) (4.6)	1.000 1.000 0.100	
		DVS SR 150 mg	Placebo DVS SR 200 mg	2/155 3/157	(1.3) (1.9)	1/ 77 7/151	(1.3) (4.6)	1.000 0.211	
		DVS SR 200 mg	Placebo Placebo	3/157 7/151	(1.9) (4.6)	1/ 77 1/ 77	(1.3) (1.3)	1.000 0.272	
TRISMUS	0.853	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	1/155 1/157 2/151 0/ 77	(0.6) (0.6) (1.3)	1.000 1.000 1.000 1.000	
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/155 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/157 2/151 0/ 77	(0.6) (1.3)	1.000 1.000 0.619 1.000	
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/157 1/157	(0.6) (0.6)	2/151 0/ 77	(1.3)	0.617	
		DVS SR 200 mg	Placebo	2/151	(1.3)	0/ 77		0.551	
TWITCHING	0.023*	DVS SR 50 mg	DVS SR 100 mg DVS SR 200 mg Placebo	0/149 0/149 0/149		1/155 5/151 1/ 77	(0.6) (3.3) (1.3)	1.000 0.060 0.341	
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/155 1/155 1/155 1/155	(0.6) (0.6) (0.6)	0/157 5/151 1/ 77	(3.3) (1.3)	0.497 0.117 1.000	
		DVS SR 150 mg	DVS SR 200 mg Placebo	0/157 0/157	(0.0)	5/151 1/ 77	(3.3)	0.027* 0.329	
		DVS SR 200 mg	Placebo	5/151	(3.3)	1/ 77	(1.3)	0.666	
VERTIGO	0.135	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	3/149 3/149 3/149 3/149	(2.0) (2.0) (2.0) (2.0)	0/155 0/157 2/151 0/ 77	(1.3)	0.117 0.114 0.683 0.553	
		DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg Placebo	0/155 0/157 2/151	(1.3)	2/151 2/151 0/ 77	(1.3) (1.3)	0.243 0.240 0.551	

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

130CT05 16:12 REPORT AE5_TEAE_WK1 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 26

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS WITH START DATE DURING WEEK 1

Body System [1] Overall Adverse Event P-Value RESPIRATORY SYSTEM 0.346		Comparator 2 DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg	2/149 2/149 2/149 2/149	(1.3) (1.3)	5/155 8/157	(3.2)	Pairwise P-Value *
RESPIRATORY SYSTEM 0.346	-	DVS SR 150 mg DVS SR 200 mg Placebo	2/149 2/149	(1.3)			0.448
	DVS SR 100 mg			(1.3)	3/151	(5.1) (2.0)	0.105 1.000
		DVS SR 200 mg Placebo	2/149 5/155 5/155 5/155	(1.3) (3.2) (3.2) (3.2)	3/ 77 8/157 3/151 3/ 77	(3.9) (5.1) (2.0) (3.9)	0.340 0.573 0.723 1.000
	DVS SR 150 mg	DVS SR 200 mg Placebo Placebo	8/157 8/157 3/151	(5.1) (5.1) (2.0)	3/151 3/ 77 3/ 77	(2.0) (3.9) (3.9)	0.219 1.000 0.408
COUGH INCREASED 0.318	DVS SR 50 mg	DVS SR 100 mg	0/149	(2.0)	1/155	(0.6)	1.000
COOGH INCREASED 0.310	DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg	0/149 1/155 1/155	(0.6) (0.6)	1/ 77 0/157 0/151	(1.3)	0.341 0.497 1.000
	DVS SR 150 mg DVS SR 200 mg	Placebo	1/155 0/157 0/151	(0.6)	1/ 77 1/ 77 1/ 77	(1.3) (1.3) (1.3)	1.000 0.329 0.338
DYSPNEA 0.037*	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg		0/149 0/155 3/157 3/157	(1.9) (1.9)	3/157 3/157 0/151 0/ 77	(1.9) (1.9)	0.248 0.248 0.248 0.553
EPISTAXIS 0.417	DVS SR 50 mg	DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/149 0/149		1/157 2/151 1/ 77	(0.6) (1.3) (1.3)	1.000 0.498 0.341
	DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	0/155 0/155 0/155 0/155		1/157 2/151 1/ 77	(0.6) (1.3) (1.3)	1.000 0.243 0.332
	DVS SR 150 mg		1/157 1/157	(0.6) (0.6)	2/151 1/ 77	(1.3) (1.3) (1.3)	0.332 0.617 0.551
	DVS SR 200 mg	Placebo	2/151	(1.3)	1/ 77	(1.3)	1.000
LARYNGISMUS 0.637	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg	1/149 1/149	(0.7) (0.7)	1/155 0/157	(0.6)	1.000 0.487

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

130CT05 16:12 REPORT AE5_TEAE_WK1 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 27

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS WITH START DATE DURING WEEK 1

Body System [1]	Overall	Treat	ment		Rat	:io		Pairwise
Adverse Event	P-Value *	Comparator 1	Comparator 2	Comparato	or 1	Comparato	r 2	P-Value *
LARYNGISMUS	0.637	DVS SR 50 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/155 1/155 1/155	(0.7) (0.7) (0.6) (0.6) (0.6)	0/151 0/ 77 0/157 0/151 0/ 77		0.497 1.000 0.497 1.000 1.000
PHARYNGITIS	0.322	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo	0/149 0/149 0/155 0/155 1/157 1/157 0/151	(0.6) (0.6)	1/157 1/77 1/157 1/77 0/151 1/77 1/77	(0.6) (1.3) (0.6) (1.3) (1.3)	1.000 0.341 1.000 0.332 1.000 0.551 0.338
RHINITIS	0.485	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.497 1.000 1.000
SINUSITIS	0.642	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149 0/155 1/157	(0.7) (0.7) (0.7) (0.7) (0.6) (0.6)	0/155 1/157 0/151 0/ 77 1/157 0/151 0/ 77	(0.6)	0.490 1.000 0.497 1.000 1.000 1.000
UPPER RESPIRATORY INFECTION	0.617	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0/149 0/149 0/149 1/155 1/155 1/155 2/157 2/157 1/151	(0.6) (0.6) (0.6) (1.3) (1.3) (0.7)	1/155 2/157 1/151 2/157 1/151 0/ 77 1/151 0/ 77	(0.6) (1.3) (0.7) (1.3) (0.7) (0.7)	1.000 0.499 1.000 1.000 1.000 1.000 1.000 1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

130CT05 16:12 REPORT AE5_TEAE_WK1 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 28

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS WITH START DATE DURING WEEK 1

Body System [1]	Overall	Treat	ment		Rat	io		Pairwise	
Adverse Event	P-Value *		Comparator 2			Comparato		P-Value *	
YAWN	0.658	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/149 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/155 1/157 1/157 0/151 0/ 77	(0.6) (0.6) (0.6)	1.000 1.000 1.000 1.000	
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/157 1/157	(0.6) (0.6)	0/151 0/ 77		1.000	
SKIN AND APPENDAGES	0.842	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/149 2/149 2/149 2/149	(1.3) (1.3) (1.3) (1.3)	4/155 4/157 2/151 1/ 77	(2.6) (2.5) (1.3) (1.3)	0.685 0.685 1.000 1.000	
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	4/155 4/155 4/155 4/155	(2.6) (2.6) (2.6)	4/157 2/151 1/ 77	(2.5) (1.3) (1.3)	1.000 1.000 0.685 1.000	
		DVS SR 150 mg	DVS SR 200 mg Placebo	4/157 4/157	(2.5) (2.5)	2/151 1/ 77	(1.3) (1.3)	0.685 1.000	
		DVS SR 200 mg	Placebo	2/151	(1.3)	1/ 77	(1.3)	1.000	
DRY SKIN	0.485	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.497 1.000 1.000	
NIGHT SWEATS	0.494	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 1/157 1/157	(0.6) (0.6)	1/157 1/157 0/151 0/ 77	(0.6) (0.6)	1.000 1.000 1.000 1.000	
PRURITUS	0.614	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	1/149 1/149 1/149	(0.7) (0.7) (0.7)	1/155 2/157 0/151	(0.6) (1.3)	1.000 1.000 0.497	
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/155 1/155 1/155	(0.7) (0.6) (0.6) (0.6)	0/ 77 2/157 0/151 0/ 77	(1.3)	1.000 1.000 1.000 1.000	

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

130CT05 16:12 REPORT AE5_TEAE_WK1 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 29

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS WITH START DATE DURING WEEK 1

Body System [1] Adverse Event	Overall P-Value *		cment Comparator 2					Pairwise P-Value *
PRURITUS	0.614	DVS SR 150 mg	DVS SR 200 mg Placebo	2/157 2/157	(1.3) (1.3)	0/151 0/ 77		0.499 1.000
RASH	0.658	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0/149 0/149 1/155 1/155 1/155 1/157 1/157	(0.6) (0.6) (0.6) (0.6) (0.6)	1/155 1/157 1/157 0/151 0/ 77 0/151 0/ 77	(0.6) (0.6) (0.6)	1.000 1.000 1.000 1.000 1.000 1.000
SKIN DISORDER	0.093	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/149 0/155 0/157 0/151		1/ 77 1/ 77 1/ 77 1/ 77	(1.3) (1.3) (1.3) (1.3)	0.341 0.332 0.329 0.338
SWEATING	0.584	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149 1/155 1/155 1/155 0/157 2/151	(0.7) (0.7) (0.7) (0.7) (0.6) (0.6) (0.6) (1.3)	1/155 0/157 2/151 0/ 77 0/157 2/151 0/ 77 2/151 0/ 77	(0.6) (1.3) (1.3) (1.3)	1.000 0.487 1.000 1.000 0.497 0.619 1.000 0.240 0.551
SPECIAL SENSES	0.001**	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	6/149 6/149 6/149 6/149 18/155 18/155 23/157 23/157 18/151	(4.0) (4.0) (4.0) (4.0) (11.6) (11.6) (14.6) (14.6) (11.9)	18/155 23/157 18/151 1/ 77 23/157 18/151 1/ 77 18/151 1/ 77	(11.6) (14.6) (11.9) (1.3) (14.6) (11.9) (1.3) (11.9) (1.3)	0.018* 0.002** 0.018* 0.427 0.503 1.000 0.005** 0.506 <0.001***

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

130CT05 16:12 REPORT AE5_TEAE_WK1 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 30

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS
WITH START DATE DURING WEEK 1

Overall	Treat		Pairwise				
P-Value *							P-Value *
0.106	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	4/149 4/149 4/149 4/149	(2.7) (2.7) (2.7) (2.7)	9/155 11/157 8/151 0/ 77	(5.8) (7.0) (5.3)	0.258 0.111 0.378 0.302
	DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	9/155	(5.8) (5.8) (5.8)	11/157 8/151 0/ 77	(7.0) (5.3)	0.818 1.000 0.031*
	DVS SR 150 mg	DVS SR 200 mg Placebo	11/157 11/157	(7.0) (7.0)	8/151 0/ 77	(5.3)	0.638 0.018* 0.054
0 458	3						0.490
0.430	DVD DIK 30 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149	(0.7) (0.7) (0.7)	0/157 0/151 0/ 77		0.487 0.497 1.000
0.658	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg	0/149 0/149		1/155 1/157	(0.6) (0.6)	1.000
	DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	1/155 1/155 1/155	(0.6) (0.6)	1/157 0/151	(0.6)	1.000 1.000 1.000
	DVS SR 150 mg		1/157 1/157 1/157	(0.6) (0.6)	0/151 0/ 77		1.000
0.485	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.497 1.000
0.093	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/149 0/155 0/157 0/151		1/ 77 1/ 77 1/ 77 1/ 77	(1.3) (1.3) (1.3) (1.3)	0.341 0.332 0.329 0.338
0.016*	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg	1/149 1/149	(0.7) (0.7)	4/155 9/157	(2.6) (5.7)	0.371 0.020*
	0.106 0.458 0.658	P-Value * Comparator 1 0.106 DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg 0.458 DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	P-Value * Comparator 1	P-Value * Comparator 1	P-Value * Comparator 1 Comparator 2 Comparator 1	P-Value * Comparator 1	P-Value * Comparator 1 Comparator 2 Comparator 1 Comparator 2

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.

130CT05 16:12 REPORT AE5_TEAE_WK1 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 31

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS WITH START DATE DURING WEEK 1

Body System [1]	Overall	Treat	ment		Pairwise			
Adverse Event	P-Value *	Comparator 1	Comparator 2	Comparato	or 1	Comparato	or 2	P-Value *
MYDRIASIS	0.016*	DVS SR 50 mg DVS SR 100 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 4/155 4/155 4/155	(0.7) (0.7) (2.6) (2.6) (2.6)	9/151 0/ 77 9/157 9/151 0/ 77	(6.0) (5.7) (6.0)	0.019* 1.000 0.257 0.166 0.305
		DVS SR 150 mg	DVS SR 200 mg Placebo	9/157 9/157	(5.7) (5.7)	9/151 0/ 77	(6.0)	1.000 0.032*
		DVS SR 200 mg	Placebo	9/151	(6.0)	0/ 77		0.030*
OTITIS MEDIA	0.494	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 1/157 1/157	(0.6) (0.6)	1/157 1/157 0/151 0/ 77	(0.6) (0.6)	1.000 1.000 1.000 1.000
РНОТОРНОВІА	0.485	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.497 1.000 1.000
TASTE PERVERSION	0.641	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg	1/149 1/149 1/149 1/149 2/155	(0.7) (0.7) (0.7) (0.7) (1.3)	2/155 3/157 1/151 0/ 77 3/157	(1.3) (1.9) (0.7) (1.9)	1.000 0.623 1.000 1.000
		DUG CD 150	DVS SR 200 mg Placebo	2/155 2/155 2/157	(1.3) (1.3)	1/151 0/ 77	(0.7)	1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	3/157 3/157	(1.9) (1.9)	1/151 0/ 77 0/ 77	(0.7)	0.623 0.553
		DVS SR 200 mg	Placebo	1/151	(0.7)			1.000
TINNITUS	0.340	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/149 1/149 1/149 1/149	(0.7) (0.7) (0.7) (0.7)	3/155 0/157 2/151 0/ 77	(1.9)	0.623 0.487 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	3/155 3/155	(1.9) (1.9)	0/157 2/151	(1.3)	0.121 1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

130CT05 16:12 REPORT AE5_TEAE_WK1 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 32

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS WITH START DATE DURING WEEK 1

Body System [1] Adverse Event	Overall P-Value *		ment Comparator 2					Pairwise P-Value *
TINNITUS	0.340	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo DVS SR 200 mg Placebo	3/155 0/157 2/151	(1.9)	0/ 77 2/151 0/ 77	(1.3)	0.553 0.240 0.551
UROGENITAL SYSTEM	0.158	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/149 0/149 4/155 4/155	(2.6) (2.6) (2.6)	4/155 5/157 3/151 5/157 3/151 0/ 77	(2.6) (3.2) (2.0) (3.2) (2.0)	0.123 0.061 0.248 1.000 1.000
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	5/157 5/157 3/151	(3.2) (3.2) (2.0)	3/151 0/ 77 0/ 77	(2.0)	0.723 0.175 0.553
ANORGASMIA	0.468	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/149 0/155 0/157 1/151	(0.7)	1/151 1/151 1/151 0/ 77	(0.7) (0.7) (0.7)	1.000 0.493 0.490 1.000
METRORRHAGIA	0.494	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 1/157 1/157	(0.6) (0.6)	1/157 1/157 0/151 0/ 77	(0.6) (0.6)	1.000 1.000 1.000 1.000
OLIGURIA	0.658	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0/149 0/149 1/155 1/155 1/155 1/157 1/157	(0.6) (0.6) (0.6) (0.6) (0.6)	1/155 1/157 1/157 0/151 0/ 77 0/151 0/ 77	(0.6) (0.6) (0.6)	1.000 1.000 1.000 1.000 1.000 1.000 1.000
SEXUAL FUNCTION ABNORMAL	0.147	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 2/157 2/157	(1.3) (1.3)	2/157 2/157 0/151 0/ 77	(1.3) (1.3)	0.499 0.498 0.499 1.000

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

130CT05 16:12 REPORT AE5_TEAE_WK1 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS WITH START DATE DURING WEEK 1 Page 33

Body System [1]	Overall	Treat	ment		Rat	io		Pairwise
Adverse Event	P-Value *	Comparator 1	Comparator 2	Comparato	r 1	Comparato	or 2	P-Value *
URINARY FREQUENCY	0.494	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 1/157 1/157	(0.6)	1/157 1/157 0/151 0/ 77	(0.6) (0.6)	1.000 1.000 1.000 1.000
URINARY HESITATION	0.468	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/149 0/155 0/157 1/151	(0.7)	1/151 1/151 1/151 0/ 77	(0.7) (0.7) (0.7)	1.000 0.493 0.490 1.000
URINARY RETENTION	0.485	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.497 1.000
URINE ABNORMALITY	0.643	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0/149 0/149 1/155 1/155 1/155 0/157 1/151	(0.6) (0.6) (0.6) (0.7)	1/155 1/151 0/157 1/151 0/ 77 1/151 0/ 77	(0.6) (0.7) (0.7) (0.7)	1.000 1.000 0.497 1.000 1.000 0.490 1.000
VAGINAL DRYNESS	0.485	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.497 1.000 1.000
TERMS NOT CLASSIFIABLE	0.147	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/155 2/157 2/157	(1.3) (1.3)	2/157 2/157 0/151 0/ 77	(1.3) (1.3)	0.499 0.498 0.499 1.000
REACTION UNEVALUABLE	0.147	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	0/149 0/155 2/157	(1.3)	2/157 2/157 0/151	(1.3) (1.3)	0.499 0.498 0.499

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Overall P-Value: P-value for Chi-Square.

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 34

13OCT05 16:12 CL REPORT AE5_TEAE_WK1

CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING TREATMENT EMERGENT ADVERSE EVENTS WITH START DATE DURING WEEK 1

Overall				Pairwise			
P-Value *	Comparator 1	Comparator 2	Comparato	or 1	Comparato	or 2	P-Value *
0.147	DVS SR 150 mg	Placebo	2/157	(1.3)	0/ 77		1.000
0.642	DVS SR 50 mg	DVS SR 100 mg	1/149	(0.7)	0/155		0.490
		DVS SR 150 mg	1/149	(0.7)	1/157	(0.6)	1.000
							0.497 1.000
	DVS SR 100 ma			(0.7)		(0.6)	1.000
				(0.6)		(0.0)	1.000
	DVD DIK 100 mg	Placebo	1/157	(0.6)	0/ 77		1.000
0.642	DVS SR 50 mg	DVS SR 100 mg	1/149	(0.7)	0/155		0.490
	-	DVS SR 150 mg	1/149	(0.7)	1/157	(0.6)	1.000
		DVS SR 200 mg		(0.7)			0.497
	100	Placebo		(0.7)			1.000
	_			(0 6)		(0.6)	1.000
	DVS SR 150 mg						1.000
	P-Value * 0.147 0.642	P-Value * Comparator 1 0.147 DVS SR 150 mg 0.642 DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	P-Value * Comparator 1 Comparator 2 0.147 DVS SR 150 mg Placebo 0.642 DVS SR 50 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 100 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo 0.642 DVS SR 50 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 100 mg DVS SR 100 mg DVS SR 200 mg Placebo DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 100 mg DVS SR 150 mg	P-Value * Comparator 1 Comparator 2 Comparator 2 0.147 DVS SR 150 mg Placebo 2/157 0.642 DVS SR 50 mg DVS SR 100 mg 1/149 DVS SR 200 mg 1/149 Placebo DVS SR 150 mg 0/155 DVS SR 150 mg DVS SR 200 mg 1/157 0.642 DVS SR 50 mg DVS SR 200 mg 1/157 0.642 DVS SR 50 mg DVS SR 100 mg 1/149 DVS SR 200 mg 1/149 DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg 0/155 DVS SR 150 mg DVS SR 200 mg 1/157	P-Value * Comparator 1 Comparator 2 Comparator 1 0.147 DVS SR 150 mg Placebo 2/157 (1.3) 0.642 DVS SR 50 mg DVS SR 100 mg 1/149 (0.7)	P-Value * Comparator 1 Comparator 2 Comparator 2 Comparator 1 Comparator 2 Comparator 1 Comparator 2 Comparat	P-Value * Comparator 1 Comparator 2 Comparator 1 Comparator 2 0.147 DVS SR 150 mg Placebo 2/157 (1.3) 0/77 0.642 DVS SR 50 mg DVS SR 150 mg 1/149 (0.7) 0/155 DVS SR 200 mg 1/149 (0.7) 1/157 (0.6) DVS SR 150 mg DVS SR 150 mg 0/155 DVS SR 150 mg DVS SR 200 mg 1/149 (0.7) 0/77 DVS SR 150 mg DVS SR 200 mg 1/157 (0.6) 0/151 Placebo 1/157 (0.6) 0/151 Placebo 1/157 (0.6) 0/77 0.642 DVS SR 50 mg DVS SR 100 mg 1/149 (0.7) 0/155 DVS SR 200 mg 1/149 (0.7) 0/155 DVS SR 200 mg 1/149 (0.7) 0/155 DVS SR 200 mg 1/149 (0.7) 0/151 Placebo 1/149 (0.7) 0/151 Placebo 1/149 (0.7) 0/151 DVS SR 150 mg DVS SR 150 mg 1/149 (0.7) 0/151 DVS SR 150 mg DVS SR 200 mg 1/149 (0.7) 0/151 DVS SR 150 mg DVS SR 150 mg 0/155 DVS SR 150 mg DVS SR 150 mg 1/149 (0.7) 0/151 DVS SR 150 mg DVS SR 200 mg 1/157 (0.6) 0/151

Overall P-Value: P-value for Chi-Square.

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

ST 10-7: Number (%) of Subjects Reporting Posttherapy-Emergent Adverse Events by Severity and Drug Relationship

100CT05 15:29 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4 SEV DR P T

Page 1

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1]							atment				
Adverse Event Severity / Drug	Relationship [2]		R 50 mg =149		R 100 mg =155		R 150 mg =157		R 200 mg =151		acebo = 77
All Severity Mild Mild Moderate Moderate	/ Not Rel. / Related	12 23		21 57 8 16 10	(5.2)	19 51 6 22 10	(3.8) (14.0) (6.4) (11.5)	74 28 46 15 10 10 27 3	(49.0) (18.5) (30.5) (9.9) (6.6) (6.6) (17.9) (2.0) (6.0)	12 12 10 6 1	(31.2) (15.6) (15.6) (13.0) (7.8) (1.3) (6.5) (1.3) (1.3)
All Severity Mild Mild Moderate Moderate	/ Not Rel. / Related	27 16 11 10 4 5 5	(18.1) (10.7) (7.4) (6.7) (2.7) (3.4) (3.4) (0.7) (1.3)	34 8 26 5 8 3 14 0 4	(21.9) (5.2) (16.8) (3.2) (5.2) (1.9) (9.0)	34 12 22 6 12 4 6 2	(7.6) (14.0) (3.8) (7.6)	41 16 25 11 9 5 15 0	(27.2) (10.6) (16.6) (7.3) (6.0) (3.3) (9.9) (0.7)	8 4 4 3 2 0 2 1 0	(10.4) (5.2) (5.2) (3.9) (2.6) (2.6) (1.3)
ABDOMINAL PAIN All Severity Mild Moderate	/ Related / Related / Related	0 0 0 0		2 2 1 1	(1.3) (1.3) (0.6) (0.6)	1 1 0 1	(0.6)	1 1 0 1	,	0 0 0	
ACCIDENTAL INJURY All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	0 0 0 0		0 0 0		0 0 0		2 2 1 1	(1.3) (1.3) (0.7) (0.7)	0 0 0	
ALLERGIC REACTION All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	3 3 2 1	(2.0) (2.0) (1.3) (0.7)	0 0 0 0		0 0 0 0		1 1 1 0	(0.7) (0.7) (0.7)	0 0 0	
ASTHENIA All Severity	/ Not Rel.	4	(2.7) (1.3)	9 1	(5.8) (0.6)	7 3	(4.5) (1.9)	11 3	(7.3) (2.0)	3	(3.9)

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

Page

2

100CT05 15:29 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4 SEV DR P T

- - - NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT EMERGENT ADVERSE EVENTS

By Severity And Drug Relationship

Body System [1] ----- Treatment Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo n=77Severity / Drug Relationship [2] n=149 n=155 n=157 n=151 All Severity / Related (1.3)(5.2)(2.5)(5.3)(3.9)Mild / Not Rel. (0.7)0 2 (1.3)(1.3)0 Mild / Related (0.7)(1.3)1 (0.6)5 (3.3)(2.6)(0.6)Moderate / Not Rel. (0.7)1 1 (0.6)(0.7)0 Moderate / Related (0.7)(3.2)2 (1.3)2 (1.3)1 (1.3)Severe / Related (0.6)1 (0.6)(0.7)0 BACK PAIN (0.7)1 (0.6)1 (0.6)2 (1.3)0 All Severity / Not Rel. 1 (0.7)1 (0.6)1 (0.6)0 0 All Severity / Related 0 0 2 (1.3)0 Mild / Not Rel. (0.7)(0.6)1 (0.6)0 0 Mild / Related 0 0 0 1 (0.7)0 Moderate / Related 0 0 0 (0.7)0 CHEST PAIN 0 (1.3)(1.3)3 (2.0) (1.3)0 All Severity / Not Rel. (1.3)0 All Severity / Related Ω (1.3)0 (0.7)0 / Not Rel. 0 2 0 Mild 0 0 (1.3)Mild / Related 0 (1.3)0 (0.7)0 0 0 0 0 Moderate / Not Rel. 1 (0.6)0 Severe / Not Rel. 0 0 1 (0.6)0 (1.3)(3.9)(1.3)3 (2.0)(1.3)(0.7)All Severity / Not Rel. 3 (1.9)0 0 1 (1.3)All Severity / Related (0.7)(1.9)(1.3)(2.0)Mild / Not Rel. (0.7)1 (0.6)0 0 1 (1.3)/ Related Mild Ω (0.6)1 (0.6)2 (1.3)0 Moderate / Not Rel. (1.3)0 0 Moderate / Related 0 (0.6)1 (0.6)(0.7)0 Severe / Related 1 (0.7)(0.6)0 0 0 0 0 0 FACE EDEMA (0.7)0 All Severity / Not Rel. (0.7)0 0 Ω 0 Mild / Not Rel. (0.7)0 0 0 FEVER (0.7)(0.6)0 0 0 All Severity / Not Rel. 0 (0.6)0 0 0

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

100CT05 15:29 REPORT AE4_SEV_DR_P_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

3

Page

Body System [1] Adverse Event Severity / Drug Relationship [2]		DVS SR 50 mg						DVS SR 200 mg		Placebo n= 77	
All Severity Mild Moderate	/ Related / Related / Not Rel.	1 1 0	(0.7) (0.7)	0 0 1	(0.6)	0 0 0		0 0		0 0 0	
FLU SYNDROME All Severity Mild Moderate Severe	/ Not Rel. / Not Rel. / Not Rel. / Not Rel.	1 1 0 0	(0.7) (0.7) (0.7)	0 0 0 0		2 2 1 0 1	(1.3) (1.3) (0.6) (0.6)	2 2 1 1 0	(1.3) (1.3) (0.7) (0.7)	1 0 0 1	(1.3) (1.3)
HEADACHE All Severity All Severity Mild Mild Moderate Moderate Severe Severe		14 5 9 2 3 2 5 1	(9.4) (3.4) (6.0) (1.3) (2.0) (1.3) (3.4) (0.7) (0.7)	20 3 17 2 5 1 9 0	(12.9) (1.9) (11.0) (1.3) (3.2) (0.6) (5.8) (1.9)	22 5 17 5 10 0 4 0 3	(14.0) (3.2) (10.8) (3.2) (6.4) (2.5) (1.9)	5 3 2 14 0	(16.6) (4.6) (11.9) (3.3) (2.0) (1.3) (9.3) (0.7)	2 0 2 0 1 0 1 0	(2.6) (2.6) (1.3) (1.3)
INFECTION All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	4 4 2 2	(2.7) (2.7) (1.3) (1.3)	0 0 0		2 2 1 1	(1.3) (1.3) (0.6) (0.6)	1 1 1 0	(0.7) (0.7) (0.7)	1 1 1 0	(1.3) (1.3) (1.3)
MALAISE All Severity All Severity Mild Moderate Moderate	/ Not Rel. / Related / Not Rel. / Not Rel. / Related	0 0 0 0 0		1 1 0 1 0	(0.6) (0.6) (0.6)	1 0 0 1 0	(0.6) (0.6)	1 0 1 0 0	(0.7) (0.7) (0.7)	0 0 0 0	
NECK PAIN All Severity Mild	/ Related / Related	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
PAIN		0		1	(0.6)	2	(1.3)	1	(0.7)	1	(1.3)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.
[2] - Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

Page

4

100CT05 15:29 REPORT AE4 SEV DR P T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT EMERGENT ADVERSE EVENTS

By Severity And Drug Relationship

Body System [1] Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo n=77Severity / Drug Relationship [2] n=149 n=155 n=157 n=151 All Severity / Not Rel. (0.6)(0.7)1 (1.3)All Severity / Related 0 1 (0.6)1 (0.6)0 0 Mild / Not Rel. 0 1 (0.6)(0.7)1 (1.3)Moderate / Related 0 1 (0.6)1 (0.6)0 0 PELVIC PAIN (0.6)0 0 0 All Severity / Not Rel. 0 1 (0.6)0 0 0 / Not Rel. Mild 0 1 (0.6)0 0 0 0 WITHDRAWAL SYNDROME (0.6)(1.3)0 2 (1.3)0 All Severity / Related 0 1 (0.6)0 Mild / Related 0 1 (0.6)1 (0.6)0 0 Severe / Related 0 (0.6)0 0 (10.6)CARDIOVASCULAR SYSTEM (6.0) (1.3)17 (11.0)12 (7.6)16 3 (3.9)All Severity / Not Rel. (3.2)4 (2.5)(4.6)All Severity / Related (4.7)12 (7.7)8 (5.1)9 (6.0)3 (3.9)/ Not Rel. 0 Mild (1.3)1 (0.6)(1.3)Mild / Related (2.6)(0.6)(1.3)0 1 1 1 0 Moderate / Not Rel. (0.7)(0.6)(0.6)(2.6)5 Moderate / Related 4 (2.7)4 (2.6)(3.2)4 (2.6)(2.6)Severe / Not Rel. (0.7)(1.3)(1.3)(0.7)0 Severe / Related 0 (2.6)2 (1.3)3 (2.0)1 (1.3)CORONARY OCCLUSION (0.6)0 0 0 / Not Rel. 0 All Severity 0 1 (0.6)0 0 Severe / Not Rel. Ω (0.6)0 Ω 0 HYPERTENSION (0.7)0 (1.3)(0.7)All Severity / Not Rel. 0 0 1 (0.6)1 0 All Severity / Related (0.7)0 (0.6)(0.7)1 (1.3)Mild / Related (0.7)0 0 0 0 Moderate / Not Rel. Ω Ω 1 (0.6)1 (0.7)0 Moderate / Related 1 (0.6)(0.7)1 (1.3)MIGRAINE 0 0 1 (0.6)2 (1.3)0 All Severity / Not Rel. 0 (0.7)0

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

Page

5

100CT05 15:29 REPORT AE4_SEV_DR_P_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationship [2]		DVS SR 100 mg DVS SR 150 n=155 n=157		Placebo n= 77	
All Severity / Related Mild / Related Moderate / Not Rel. Severe / Related	0 0 0	0 1 (0.6 0 0 0 0 1 (0.6	1 (0.7) 1 (0.7)	0 0 0 0	
MYOCARDIAL INFARCT All Severity / Not Rel. Severe / Not Rel.	0 0 0	0 1 (0.6 0 1 (0.6 0 1 (0.6	o ()	0 0 0	
PALPITATION All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related	0 0 0 0	1 (0.6) 0 0 0 1 (0.6) 0 0 0 1 (0.6) 0	1 (0.7) 1 (0.7) 0 1 (0.7)	0 0 0 0	
TACHYCARDIA All Severity / Related Mild / Related Moderate / Related	2 (1.3) 2 (1.3) 2 (1.3) 0	1 (0.6) 1 (0.6 1 (0.6) 1 (0.6 0 1 (0.6) 0	6) 1 (0.7)	0 0 0 0	
VASODILATATION All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	6 (4.0) 2 (1.3) 4 (2.7) 0 1 (0.7) 4 (2.7) 1 (0.7)	14 (9.0) 8 (5.1 4 (2.6) 2 (1.3 10 (6.5) 6 (3.8 2 (1.3) 1 (0.6 3 (1.9) 1 (0.6 1 (0.6) 1 (0.6 4 (2.6) 1 (0.6	3) 6 (4.0) 3) 6 (4.0) 6) 2 (1.3) 6) 0 3 (2.0) 5) 3 (2.0) 6) 1 (0.7)	2 (2.6) 0 (2.6) 0 0 1 (1.3) 1 (1.3)	
DIGESTIVE SYSTEM All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related	23 (15.4) 9 (6.0) 14 (9.4) 6 (4.0) 5 (3.4) 3 (2.0) 9 (6.0)	38 (24.5) 27 (17.2 10 (6.5) 6 (3.8 28 (18.1) 21 (13.4 5 (3.2) 4 (2.5 10 (6.5) 11 (7.0 5 (3.2) 2 (1.3 12 (7.7) 5 (3.2	3) 5 (3.3) 4) 27 (17.9) 5) 4 (2.6) 0) 10 (6.6) 3) 1 (0.7)	6 (7.8) 1 (1.3) 5 (6.5) 1 (1.3) 4 (5.2) 0	

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.
[2] - Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

Page

6

100CT05 15:29 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4 SEV DR P T

- - - NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT EMERGENT ADVERSE EVENTS

By Severity And Drug Relationship

Body System [1] ----- Treatment Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Severity / Drug Relationship [2] n=149 n=155 n=157 n=151 n = 77Severe / Related 0 (3.9)(3.2)(1.3)0 ANOREXIA 0 0 0 (1.3) (1.3)0 All Severity / Related 0 0 0 0 Moderate / Related 0 0 0 2 (1.3)0 0 CHOLECYSTITIS 0 0 0 All Severity / Related 0 0 1 (0.6)0 0 Severe / Related 0 0 1 (0.6)0 0 Ω 0 Ω CHOLELITHIASIS (0.6)All Severity / Related 0 0 1 (0.6)0 0 Severe / Related 0 0 (0.6)0 0 CONSTIPATION 0 0 1 (0.6)0 0 All Severity / Related 0 0 (0.6)0 0 Mild / Related 0 0 1 (0.6)0 0 DIARRHEA (4.0)(3.9)(3.2)(4.0)(2.6)3 (1.9)0 0 All Severity / Not Rel. (2.7)2 (1.3)All Severity / Related (1.3)3 (1.9)5 (3.2)4 (2.6)(2.6)Mild / Not Rel. (2.0)(1.9)0 (1.3)0 Mild / Related (1.3)(0.6)3 (1.9)0 (1.3)Moderate / Not Rel. (0.7)0 0 0 0 Moderate / Related (1.3)(0.6)(2.6)(1.3)Severe / Related 0 1 (0.6)0 0 DRY MOUTH (1.3)(1.3)(2.6)(2.6)2 All Severity / Related (1.3)(1.3)0 (2.6)(2.6)/ Related 2 (2.6)Mild (1.3)(1.3)0 2 (1.3)Moderate / Related 0 (0.7)Severe / Related 0 0 0 (0.7)0 0 DYSPEPSIA (3.2)(2.5)0 All Severity / Not Rel. 0 (1.9)1 (0.6)0 0 All Severity / Related (1.3)0 3 (1.9)0 0 / Not Rel. 0 (1.3)1 (0.6)0 0

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

Page

7

100CT05 15:29 REPORT AE4 SEV DR P T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] ----- Treatment Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Severity / Drug Relationship [2] n=149 n=155 n=157 n=151 n = 770 Mild / Related 1 (0.6)(0.6)0 0 Moderate / Not Rel. 0 1 (0.6)0 0 / Related Moderate 0 1 (0.6)(1.3)0 0 ERUCTATION (1.3)0 0 Ω Ω All Severity / Not Rel. (1.3)0 0 0 0 Mild / Not Rel. (1.3)0 0 0 0 GASTROENTERITIS (0.7)0 (1.3)0 0 All Severity / Not Rel. (0.7)0 (1.3)0 0 Mild / Not Rel. (0.7)0 1 (0.6)0 0 Moderate / Not Rel. 1 (0.6)0 0 GASTROINTESTINAL DISORDER 0 0 (0.6)0 0 1 All Severity / Related 0 0 1 (0.6)0 0 Mild / Related 0 0 1 (0.6)0 0 GLOSSITIS 0 0 0 0 1 (1.3)All Severity / Not Rel. 0 0 0 0 (1.3)0 Mild / Not Rel. 0 0 0 1 (1.3)ILEUS 0 (0.6)0 0 All Severity / Not Rel. 0 0 1 (0.6)0 0 / Not Rel. Severe 0 0 1 (0.6)0 0 0 INCREASED APPETITE 0 1 (0.6)2 (1.3)(0.7)All Severity / Not Rel. Ω Ω 1 (0.6)Ω 0 All Severity / Related 0 (0.6)1 (0.6)(0.7)0 Mild / Not Rel. 0 0 1 (0.6)0 0 Mild / Related 0 0 1 (0.6)1 (0.7)0 Moderate / Related (0.6)0 0 0 LIVER FUNCTION TESTS ABNORMAL (1.3)Ω 0 Ω Ω All Severity / Not Rel. (0.7)0 0 0 0 All Severity / Related (0.7)0 0 0 0 (0.7)Mild / Not Rel. 1 Ω 0 0 0 Moderate / Related 1 (0.7)0 0 0

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

100CT05 15:29 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4 SEV DR P T

- - - NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT EMERGENT ADVERSE EVENTS

By Severity And Drug Relationship

Page

8

Body System [1] ----- Treatment -----Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Severity / Drug Relationship [2] n=149 n=155 n=157 n=151 n = 77NAUSEA (9.4)(18.1)14 (8.9)(17.9)(1.3)All Severity / Not Rel. 5 (3.4)(2.6)3 (1.9)3 (2.0)0 All Severity / Related 9 (6.0)24 (15.5)11 (7.0)24 (15.9)1 (1.3)Mild / Not Rel. (1.3)(0.6)2 (1.3)3 (2.0)0 Mild / Related (0.7)10 (6.5)5 (3.2)11 (7.3)1 (1.3)Moderate / Not Rel. (2.0)3 (1.9)1 (0.6)0 Moderate / Related (5.4)9 (5.8)(2.5)12 (7.9)0 Severe / Related (3.2)(1.3)(0.7)0 0 0 0 NAUSEA AND VOMITING 0 (0.6)All Severity / Related 0 (0.6)0 0 0 Severe / Related 0 (0.6)0 0 0 PANCREAS DISORDER 0 0 0 0 1 (0.6)All Severity / Not Rel. 0 0 1 (0.6)0 0 Severe / Not Rel. 0 0 1 (0.6)0 0 PERIODONTAL ABSCESS 0 0 0 0 (0.7)All Severity / Not Rel. (0.7)0 0 0 0 Mild / Not Rel. (0.7)0 0 0 SIALADENITIS 0 0 (0.7)0 All Severity / Not Rel. 0 0 0 (0.7)0 / Not Rel. Moderate 0 0 0 1 (0.7)0 0 0 0 0 TOOTH CARIES 1 (0.6)All Severity / Not Rel. Ω Ω 1 (0.6)Ω Ω Moderate / Not Rel. 0 (0.6)0 0 VOMITING (3.4)(4.5)(2.5)12 (7.9)0 All Severity / Not Rel. (0.7)(1.9)(0.7)0 All Severity / Related (2.7)(2.6)4 (2.5)11 (7.3)0 Mild / Not Rel. (0.7)Ω Ω 0 Ω Mild / Related (2.0)0 0 3 (2.0)0 Moderate / Not Rel. (1.9)0 (0.7)0 Moderate / Related (0.7)(1.3)3 (1.9)8 (5.3)0 Severe / Related (1.3)1 (0.6)

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

9

Page

100CT05 15:29 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR_P_T

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1]						Trea	atment				
Adverse Event Severity / Drug	Relationship [2]	DVS SR 50 r n=149	ng		R 100 mg =155		R 150 mg =157		R 200 mg =151	Pla n=	acebo = 77
ENDOCRINE SYSTEM All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	0 0 0		1 1 1 0	(0.6) (0.6) (0.6)	1 1 0 1	(0.6) (0.6)	0 0 0		0 0 0	
GOITER All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
HYPERTHYROIDISM All Severity Moderate	/ Not Rel. / Not Rel.	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
HEMIC AND LYMPHATIC All Severity All Severity Mild Mild	/ Not Rel.	0 0 0 0		3 2 1 2 1	(1.9) (1.3) (0.6) (1.3) (0.6)	1 1 0 1 0	(0.6) (0.6) (0.6)	0 0 0 0		0 0 0 0	
ANEMIA All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
LEUKOCYTOSIS All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
NEUTROPENIA All Severity All Severity Mild Mild	/ Not Rel. / Related / Not Rel. / Related	0 0 0 0		2 1 1 1 1	(1.3) (0.6) (0.6) (0.6) (0.6)	0 0 0 0		0 0 0 0		0 0 0 0	
METABOLIC AND NUTRI All Severity All Severity Mild	TIONAL / Not Rel. / Related / Not Rel.	5 (3.4 3 (2.0 2 (1.3))	2 1 1 1	(1.3) (0.6) (0.6) (0.6)	3 2 1 2	(1.9) (1.3) (0.6) (1.3)	5 4 1 2		1 1 0 0	(1.3) (1.3)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.
[2] - Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

Page

10

100CT05 15:29 REPORT AE4_SEV_DR_P_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationship [2]				DVS SR 100 mg n=155		Treatment DVS SR 150 mg n=157			 R 200 mg =151	Placebo n= 77	
Mild Moderate Moderate	/ Related / Not Rel. / Related	1 3 1	(0.7) (2.0) (0.7)	0 0 1	(0.6)	1 0 0	(0.6)	0 2 1	(1.3)	0 1 0	(1.3)
HYPERCHOLESTEREMIA All Severity / Not Rel. All Severity / Related Mild / Related		1 1 0 0	(0.7) (0.7)	0 0 0		1 0 1 1	(0.6) (0.6) (0.6)	2 2 0 0	(1.3) (1.3)	1 1 0 0	(1.3) (1.3)
	/ Not Rel. / Not Rel. / Not Rel.	1 0 0 0	(0.7)	0 0 0		0 0 0		2 1 1 1	(1.3) (0.7) (0.7) (0.7)	1 0 0 0	(1.3)
HYPERLIPEMIA All Severity All Severity Mild	/ Not Rel. / Related / Not Rel. / Not Rel. / Related	3 2 1 0 2	(2.0) (1.3) (0.7) (1.3) (0.7)	0 0 0 0 0		2 2 0 2 0 0	(1.3) (1.3) (1.3)	1 0 1 0 0	(0.7) (0.7) (0.7)	0 0 0 0 0 0 0	
PERIPHERAL EDEMA All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	1 1 0 1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		1 1 1 0	(0.7) (0.7) (0.7)	0 0 0	
	/ Related / Related	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
	/ Not Rel. / Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
WEIGHT GAIN All Severity Mild	/ Related / Related	1 1 1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0	

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.
[2] - Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

Page 11

100CT05 15:29 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR_P_T

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1]						Trea	atment				
Adverse Event	Adverse Event Severity / Drug Relationship [2]				DVS SR 100 mg n=155		DVS SR 150 mg n=157		R 200 mg =151		acebo = 77
MUSCULOSKELETAL SYST All Severity All Severity Mild Mild Moderate Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related / Related	7 5 2 5 1 0 0	(4.7) (3.4) (1.3) (3.4) (0.7)	9 5 4 3 2 2 2	(5.8) (3.2) (2.6) (1.9) (1.3) (1.3) (1.3)	4 2 2 2 2 1 0 0 0	(2.5) (1.3) (1.3) (1.3) (0.6)	4 2 2 2 2 1 0 1	(2.6) (1.3) (1.3) (1.3) (0.7)	1 0 1 0 0 0	(1.3) (1.3) (1.3)
ARTHRALGIA All Severity All Severity Mild Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Related	1 0 1 0 0	(0.7) (0.7) (0.7)	3 0 3 0	(1.9) (1.9) (1.9)	0 0 0 0 0		1 0 1 0 1 0	(0.7) (0.7) (0.7)	0 0 0 0	
ARTHRITIS All Severity Moderate	/ Not Rel. / Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0	
GENERALIZED SPASM All Severity Mild	/ Not Rel. / Not Rel.	1 1 1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0	
JOINT DISORDER All Severity Mild Moderate	/ Related / Related / Related	1 1 1 0	(0.7) (0.7) (0.7)	0 0 0		0 0 0		1 1 0 1	(0.7) (0.7) (0.7)	0 0 0	
LEG CRAMPS All Severity All Severity Mild Mild Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Related / Related	1 0 1 0 0 0	(0.7) (0.7) (0.7)	1 0 1 0 0 1	(0.6) (0.6) (0.6)	2 0 2 0 1 0	(1.3) (1.3) (0.6) (0.6)	1 0 1 0 1 0	(0.7) (0.7) (0.7)	0 0 0 0 0 0 0	

Page

12

100CT05 15:29 REPORT AE4 SEV DR P T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Severity / Drug Relationship [2] n=149 n=155 n=157 n=151 n = 770 MUSCLE CRAMP 0 (0.7)0 (0.7)All Severity / Not Rel. 0 0 0 1 0 Mild / Not Rel. 0 0 0 (0.7)0 MUSCLE SPASMS (1.3)0 Λ Ω All Severity / Not Rel. 0 1 (0.6)0 0 0 All Severity / Related 0 1 (0.6)0 0 0 Mild / Not Rel. 0 1 (0.6)0 0 0 Mild / Related 0 1 (0.6)0 0 0 Ω 0 Ω MUSCULOSKELETAL STIFFNESS (0.6)All Severity / Not Rel. 0 0 1 (0.6)0 0 / Not Rel. 0 0 (0.6)0 0 MYALGIA (2.0) (2.0) 1 (0.6)1 (0.6)(0.7)1 (1.3)(1.3)All Severity / Not Rel. (0.6)(0.6)(0.7)1 Mild / Not Rel. (2.0)Ω 1 (0.6)(0.7)(1.3)/ Not Rel. Moderate 1 (0.6)0 0 0 0 MYASTHENIA 2 (1.3)1 (0.6)0 2 All Severity / Related 0 (1.3)1 (0.6)0 0 Mild / Related 0 (0.6)0 0 0 Moderate / Related 0 (0.6)0 0 0 Severe / Related 0 1 (0.6)0 0 NERVOUS SYSTEM (29.5)59 (38.1)45 (28.7)45 (29.8)7 (9.1)All Severity (2.5) / Not Rel. 11 (7.4)11 (7.1)4 10 (6.6)(2.6)All Severity / Related 33 (22.1)48 (31.0)41 (26.1)35 (23.2)(6.5)2 Mild / Not Rel. (1.3)(2.6)1 (0.6)(5.3)(2.6)(7.9)3 (3.9)Mild / Related (6.0)15 (9.7)21 (13.4)12 Moderate / Not Rel. (4.7)(4.5)(1.9)(0.7)20 (13.4) Moderate / Related 23 (14.8)14 (8.9)20 (13.2)2 (2.6)Severe / Not Rel. (1.3)0 0 (0.7)0 Severe / Related 4 (2.7)10 (6.5)6 (3.8)(2.0)0 ABNORMAL DREAMS (1.3)(3.2)(4.5)(2.6)1 (1.3)All Severity / Not Rel. 0 (0.6)0 (0.7)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

100CT05 15:29 REPORT AE4_SEV_DR_P_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Page 13

Body System [1] Adverse Event Severity / Drug Relationship [2]		DVS SR 100 mg DVS SR 150 mg DVS SR 20 n=155 n=157 n=15	
All Severity / Related Mild / Not Rel. Mild / Related Moderate / Related Severe / Related	2 (1.3) 0 2 (1.3) 0 0	1 (0.6) 0 1 (0.6) 1 (0.6) 5 (3.2) 1 (0.6)	2.0) 1 (1.3) 0.7) 0 0 0.7) 1 (1.3) 1.3) 0
ABNORMAL/CHANGED BEHAVIOR All Severity / Related Mild / Related	1 (0.7) 1 (0.7) 1 (0.7)	0 0 0 0 0 0 0 0	0 0 0
AGITATION All Severity / Not Rel. All Severity / Related Mild / Not Rel. Severe / Related	1 (0.7) 0 1 (0.7) 0 1 (0.7)	0 0 0	0.7) 0 0.7) 0 0.7) 0 0.7) 0
ANXIETY All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	4 (2.7) 2 (1.3) 2 (1.3) 1 (0.7) 0 1 (0.7) 1 (0.7) 1 (0.7)	1 (0.6) 1 (0.6) 4 (3.4) 4 (2.6) 5 (3.2) 4 (3.4) 1 (0.6) 0 3 (3.4) 2 (3.4) 1 (0.6) 1 (0.6) 1 (0.6)	5.3) 1 (1.3) 2.6) 0 2.6) 1 (1.3) 2.0) 0 1.3) 0 0,7) 0 1.3) 1 (1.3)
ATAXIA All Severity / Not Rel. All Severity / Related Moderate / Not Rel. Moderate / Related Severe / Related	0 0 0 0 0	3 (1.9) 0 0 1 (0.6) 0 0 2 (1.3) 0 0 1 (0.6) 0 0 1 (0.6) 0 0	0 0 0 0 0
CIRCUMORAL PARESTHESIA All Severity / Related Mild / Related	0 0 0		0.7) 0 0.7) 0 0.7) 0

Page

14

100CT05 15:29 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR_P_T

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationship [2]		DVS SR 100 mg DVS SR 150 mg n=155 n=157		Placebo n= 77
CONFUSION All Severity / Not Rel. All Severity / Related Mild / Related Moderate / Not Rel. Moderate / Related	1 (0.7) 1 (0.7) 0 0 1 (0.7)	0 0 0 (1.9) 2 (1.3) 3 (1.9) 1 (0.6) 1 (0.6)	1 (0.7) 0 1 (0.7) 0 0 1 (0.7)	0 0 0 0 0
DEPERSONALIZATION All Severity / Related Severe / Related	0 0 0	1 (0.6) 0 1 (0.6) 0 1 (0.6) 0	0 0 0	0 0 0
DEPRESSION All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Related	3 (2.0) 1 (0.7) 2 (1.3) 0 2 (1.3) 1 (0.7) 0	4 (2.6) 6 (3.8) 1 (0.6) 0 3 (1.9) 6 (3.8) 0 0 0 3 (1.9) 1 (0.6) 0 2 (1.3) 2 (1.3) 1 (0.6) 1 (0.6)	4 (2.6) 1 (0.7) 3 (2.0) 1 (0.7) 1 (0.7) 0 1 (0.7) 1 (0.7)	0 0 0 0 0 0
DIZZINESS All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Related	21 (14.1) 6 (4.0) 15 (10.1) 1 (0.7) 5 (3.4) 8 (5.4) 2 (1.3)	31 (20.0) 23 (14.6) 6 (3.9) 3 (1.9) 25 (16.1) 20 (12.7) 2 (1.3) 1 (0.6) 9 (5.8) 11 (7.0) 4 (2.6) 2 (1.3) 10 (6.5) 7 (4.5) 6 (3.9) 2 (1.3)	17 (11.3) 4 (2.6) 13 (8.6) 4 (2.6) 5 (3.3) 0 8 (5.3)	1 (1.3) 0 (1.3) 0 (1.3) 0 (1.3) 0 0
EMOTIONAL LABILITY All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel.	9 (6.0) 3 (2.0) 6 (4.0) 1 (0.7) 2 (1.3) 1 (0.7) 3 (2.0) 1 (0.7)	16 (10.3) 9 (5.7) 1 (0.6) 1 (0.6) 15 (9.7) 8 (5.1) 0 0 1 (0.6) 2 (1.3) 1 (0.6) 1 (0.6) 10 (6.5) 5 (3.2) 0	10 (6.6) 5 (3.3) 5 (3.3) 3 (2.0) 1 (0.7) 2 (1.3) 4 (2.6)	0 0 0 0 0 0

100CT05 15:29 REPORT AE4_SEV_DR_P_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Page 15

Body System [1] Adverse Event Severity / Drug Relationship [2]				DVS SR 100 mg n=155		Treatment DVS SR 150 mg n=157				Placebo n= 77	
Severe	/ Related	1	(0.7)	4	(2.6)	1	(0.6)	0		0	
HALLUCINATIONS All Severity Mild	/ Related / Related	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	
HOSTILITY All Severity All Severity Mild Mild Moderate Moderate Severe Severe	/ Not Rel. / Related / Not Rel.	9 0 9 0 1 0 6 0 2	(6.0) (6.0) (0.7) (4.0) (1.3)	4 1 3 0 1 0 2 1 0	(2.6) (0.6) (1.9) (0.6) (1.3) (0.6)	8 2 6 0 3 2 2 0	(5.1) (1.3) (3.8) (1.9) (1.3) (1.3) (0.6)	3 1 2 0 1 0 1 1 0	(2.0) (0.7) (1.3) (0.7) (0.7) (0.7)	2 1 1 1 0 0 0	(2.6) (1.3) (1.3) (1.3) (1.3)
HYPERESTHESIA All Severity Moderate	/ Related / Related	1 1 1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0	
HYPERTONIA All Severity Mild Moderate	/ Related / Related / Related	1 1 0 1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		1 1 1 0	(0.7) (0.7) (0.7)	0 0 0	
INSOMNIA All Severity All Severity Mild Mild Moderate Moderate Severe	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related / Related	12 2 10 2 2 0 7	(8.1) (1.3) (6.7) (1.3) (1.3) (4.7) (0.7)	12 4 8 3 2 1 5	(7.7) (2.6) (5.2) (1.9) (1.3) (0.6) (3.2) (0.6)	13 2 11 2 5 0 3 3	(8.3) (1.3) (7.0) (1.3) (3.2) (1.9) (1.9)	14 3 11 1 6 2 4	(9.3) (2.0) (7.3) (0.7) (4.0) (1.3) (2.6) (0.7)	2 1 1 1 0 0	(2.6) (1.3) (1.3) (1.3) (1.3)
MEMORY IMPAIRMENT All Severity Mild	/ Related / Related	1 1 1	(0.7) (0.7) (0.7)	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0	

Page 16

100CT05 15:29 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR_P_T

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationship [2]		DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo n=155 n=157 n=151 n= 77
MOTION SICKNESS All Severity / Related Moderate / Related	0 0 0	1 (0.6) 0 0 0 1 (0.6) 0 0 0 1 (0.6) 0 0
NERVOUSNESS All Severity / Not Rel. All Severity / Related Mild / Related Moderate / Not Rel. Moderate / Related	3 (2.0) 0 3 (2.0) 1 (0.7) 0 2 (1.3)	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$
NEUROSIS All Severity / Related Moderate / Related	0 0 0	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$
PARESTHESIA All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	1 (0.7) 0 (0.7) 0 (0.7) 0 (0.7) 0 0	2 (1.3) 0 2 (1.3) 0 5 (3.2) 2 (1.3) 0 0 0 0 2 (1.3) 0
RESTLESS LEGS SYNDROME All Severity / Related Moderate / Related	0 0 0	1 (0.6) 0 0 0 1 (0.6) 0 0 0 1 (0.6) 0 0
SLEEP DISORDER All Severity / Not Rel. Mild / Not Rel.	0 0 0	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
SOMNOLENCE All Severity / Not Rel. All Severity / Related Mild / Not Rel.	1 (0.7) 1 (0.7) 0 1 (0.7)	0 1 (0.6) 0 0 5 (3.2) 1 (0.6) 4 (2.6) 0

Page 17

100CT05 15:29 REPORT AE4_SEV_DR_P_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT EMERGENT ADVERSE EVENTS

By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationsh	DVS SR 50 mg	DVS SR 100 mg n=155		DVS SR 200 mg	Placebo n= 77
Mild / Related Moderate / Related Severe / Related	0 0 0	3 (1.9) 2 (1.3) 0	0 1 0 (0.6)	2 (1.3) 1 (0.7) 1 (0.7)	0 0 0
SUICIDAL IDEATION All Severity / Related Severe / Related	0 0 0	1 (0.6) 1 (0.6) 1 (0.6)	0 0 0	0 0 0	0 0 0
THINKING ABNORMAL All Severity / Not Rel All Severity / Related Moderate / Not Rel Moderate / Related Severe / Related	. 2 (1.3) 0 2 (1.3)	1 (0.6) 2 (1.3) 1 (0.6)	3 (1.9) 0 (1.9) 0 (1.3) 1 (0.6)	3 (2.0) 0 (2.0) 0 (2.0) 0 (2.0)	0 0 0 0 0
TREMOR All Severity / Related Mild / Related Moderate / Related		3 (1.9) 3 (1.9) 1 (0.6) 2 (1.3)	1 (0.6) 1 (0.6) 1 (0.6)	4 (2.6) 4 (2.6) 3 (2.0) 1 (0.7)	0 0 0 0
TRISMUS All Severity / Related Severe / Related	0 0 0	0 0 0	1 (0.6) 1 (0.6) 1 (0.6)	0 0 0	0 0 0
TWITCHING All Severity / Related Moderate / Related		0 0 0	0 0 0	0 0 0	0 0 0
VERTIGO All Severity / Not Rel All Severity / Related Mild / Related Moderate / Not Rel Moderate / Related	2 (1.3) 1 (0.7)	1 (0.6) 0 0 1 (0.6)	2 (1.3) 0 2 (1.3) 1 (0.6) 0 1 (0.6)	3 (2.0) 1 (0.7) 2 (1.3) 1 (0.7) 1 (0.7) 1 (0.7)	0 0 0 0 0
RESPIRATORY SYSTEM All Severity / Not Rel.	5 (3.4) 4 (2.7)	5 (3.2) 5 (3.2)	6 (3.8) 6 (3.8)	9 (6.0) 9 (6.0)	2 (2.6) 2 (2.6)

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More

Different Adverse Events In The Same Body System.
[2] - Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

Page 18

100CT05 15:29 REPORT AE4_SEV_DR_P_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event		DVS SI	 R 50 mg	DVS SE	 R 100 mg		atment - R 150 mg	DVS SI	 R 200 mg	 Plá	 acebo
Severity / Dru	Severity / Drug Relationship [2]		=149	n=	n=155		n=157		n=151		= 77
All Severity Mild Mild Moderate Severe	/ Related / Not Rel. / Related / Not Rel. / Not Rel.	1 2 1 2 0	(0.7) (1.3) (0.7) (1.3)	0 3 0 1 1	(1.9) (0.6) (0.6)	0 2 0 2 2 2	(1.3) (1.3) (1.3)	0 7 0 2 0	(4.6)	0 1 0 0	(1.3)
BRONCHITIS All Severity Moderate	/ Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
COUGH INCREASED All Severity Mild Moderate Severe	/ Not Rel. / Not Rel. / Not Rel. / Not Rel.	2 2 1 1 0	(1.3) (1.3) (0.7) (0.7)	0 0 0 0		0 0 0 0		1 1 0 0	(0.7) (0.7) (0.7)	1 0 0	(1.3) (1.3)
DYSPNEA All Severity All Severity Mild Mild	/ Not Rel. / Related / Not Rel. / Related	1 0 1 0 1	(0.7) (0.7) (0.7)	0 0 0 0		2 2 0 2 0	(1.3) (1.3) (1.3)	0 0 0 0		0 0 0 0	
EPISTAXIS All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		2 2 2	(1.3) (1.3) (1.3)	0 0 0	
LUNG DISORDER All Severity Moderate	/ Not Rel. / Not Rel.	0 0 0		0 0 0		0 0 0		1 1 1	(0.7) (0.7) (0.7)	0 0 0	
PHARYNGITIS All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	2 2 0 2	(1.3) (1.3) (1.3)	1 1 1 0	(0.6) (0.6) (0.6)	0 0 0 0		1 1 1 0	(0.7) (0.7) (0.7)	0 0 0	
PNEUMONIA All Severity	/ Not Rel.	0		0		1 1	(0.6) (0.6)	0		0	

Page

19

100CT05 15:29 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4_SEV_DR_P_T

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] Adverse Event Severity / Drug Relationship [2]	DVS SR 50 mg n=149	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Pla n=155 n=157 n=151 n=	 cebo 77
Severe / Not Rel.	0	0 1 (0.6) 0 0	
PULMONARY PHYSICAL FINDING All Severity / Not Rel. Mild / Not Rel.	1 (0.7) 1 (0.7) 1 (0.7)	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	
RHINITIS All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	0 0 0 0	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	(1.3) (1.3) (1.3)
SINUSITIS All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel. Severe / Not Rel.	0 0 0 0	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	
UPPER RESPIRATORY INFECTION All Severity / Not Rel. Mild / Not Rel. Moderate / Not Rel.	0 0 0 0	2 (1.3) 0 3 (2.0) 0 2 (1.3) 0 3 (2.0) 0 1 (0.6) 0 3 (2.0) 0 1 (0.6) 0	
SKIN AND APPENDAGES All Severity / Not Rel. All Severity / Related Mild / Not Rel. Mild / Related Moderate / Not Rel. Moderate / Related Severe / Not Rel. Severe / Related	12 (8.1) 5 (3.4) 7 (4.7) 2 (1.3) 3 (2.0) 3 (2.0) 2 (1.3) 0 2 (1.3)	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	
DERMATITIS ATOPIC All Severity / Not Rel. Moderate / Not Rel.	1 (0.7) 1 (0.7) 1 (0.7)	0 0 0 0 0 0 0 0 0 0 0 0	
HERPES SIMPLEX	0	0 1 (0.6) 0 0	

100CT05 15:29 REPORT AE4_SEV_DR_P_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Page

20

Body System [1] Adverse Event Severity / Drug			DVS SR 50 mg		DVS SR 100 mg		Treatment DVS SR 150 mg DV n=157		200 mg	Placebo n= 77
All Severity Severe	/ Not Rel. / Not Rel.	0		0		1	(0.6) (0.6)	0		0
NAIL DISORDER All Severity Mild	/ Related / Related		(0.7) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0
NIGHT SWEATS All Severity All Severity Mild Moderate Moderate Severe Severe	/ Not Rel. / Related / Related / Not Rel. / Related / Not Rel. / Related	2 4 1	(1.3)	1 0 1 0 0 1 0	(0.6) (0.6) (0.6)	3 0 3 0 0 2 0 1	(1.9) (1.9) (1.3) (0.6)	2 1 1 1 0 0 1	(1.3) (0.7) (0.7) (0.7)	0 0 0 0 0 0
PRURITUS All Severity Mild Moderate	/ Not Rel. / Not Rel. / Not Rel.	1 1 0 1	(0.7) (0.7) (0.7)	1 1 1 0	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0
RASH All Severity Mild	/ Not Rel. / Not Rel.	1 1 1		0 0 0		0 0 0		0 0 0		0 0 0
SKIN DISORDER All Severity Mild	/ Not Rel. / Not Rel.	0 0 0		0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0
SKIN HYPERTROPHY All Severity Mild	/ Not Rel. / Not Rel.		(0.7) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0
SWEATING All Severity All Severity Mild	/ Not Rel. / Related / Related	2 0 2 1		2 1 1 0	(1.3) (0.6) (0.6)	2 0 2 1	(1.3) (1.3) (0.6)	1 0 1 0	(0.7) (0.7)	0 0 0 0

Page

21

100CT05 15:29 REPORT AE4 SEV DR P T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1] ----- Treatment Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Severity / Drug Relationship [2] n=149 n=155 n=157 n=151 n = 770 Moderate / Not Rel. 1 (0.6)0 Moderate / Related 0 1 (0.6)1 (0.6)1 (0.7)0 Severe / Related (0.7)0 0 0 SPECIAL SENSES (4.0)(9.7)12 (7.6)12 (7.9)(1.3)All Severity / Not Rel. (0.7)(2.6)1 (0.6)6 (4.0)All Severity / Related (3.4)11 (7.1)11 (7.0)(4.0)(1.3)Mild / Not Rel. (0.7)1 (0.6)0 5 (3.3)0 Mild / Related 3 (2.0)(2.6) (1.9)3 (1.9)3 (2.0)0 Moderate / Not Rel. 3 (0.6)(0.7)0 7 3 Moderate / Related (1.3)(2.6)(4.5)(2.0)1 (1.3)Severe / Related (1.9)1 (0.6)0 ABNORMAL VISION (0.7)(2.6)2 (1.3)3 (2.0)All Severity / Not Rel. 0 (0.6)0 (0.7)0 All Severity / Related (0.7)3 (1.9)2 (1.3)(1.3)0 Mild / Related (0.7)1 (0.6)(1.3)1 (0.7)0 / Not Rel. (0.7)0 Moderate 0 1 (0.6)1 Moderate / Related 0 (0.6)0 (0.7)0 0 0 0 0 Severe / Related (0.6)0 DRY EYES (0.6)0 0 All Severity / Not Rel. 0 (0.6)0 0 0 / Not Rel. Moderate 0 1 (0.6)0 0 0 0 0 EYE DISORDER 0 1 (0.6)(0.7)All Severity / Not Rel. Ω (0.6)Ω (0.7)Ω Mild / Not Rel. 0 (0.6)0 (0.7)0 EYE PAIN (0.6)0 (1.3)0 All Severity / Not Rel. (0.7)0 All Severity / Related 0 1 (0.6)0 1 (0.7)0 Mild / Not Rel. Ω Ω Ω 1 (0.7)0 Mild / Related 0 0 (0.7)0 Moderate / Related 0 1 (0.6)0 0 0 HYPERACUSIS (0.7)0 1 (0.6)0 0

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

100CT05 15:29 REPORT AE4_SEV_DR_P_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Page

22

Body System [1] Adverse Event Severity / Drug R	Relationship [2]	DVS SI	R 50 mg =149		R 100 mg =155	DVS SE	atment R 150 mg =157		 R 200 mg =151	Placebo n= 77
All Severity Moderate	/ Related / Related	1 1	(0.7) (0.7)	0		1 1	(0.6) (0.6)	0		0
MYDRIASIS All Severity Mild Moderate	/ Related / Related / Related	0 0 0		0 0 0		0 0 0		3 3 2 1	(2.0) (2.0) (1.3) (0.7)	0 0 0
	/ Not Rel. / Not Rel.	0 0 0		1 1 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0		0 0 0
	/ Related / Related	1 1 1	(0.7) (0.7) (0.7)	0 0 0		0 0 0		0 0 0		0 0 0
Mild	/ Related / Related / Related	2 2 1 1	(1.3) (1.3) (0.7) (0.7)	0 0 0 0		1 1 0 1	(0.6) (0.6) (0.6)	0 0 0		0 0 0
All Severity Mild	/ Not Rel. / Related / Not Rel. / Related	0 0 0 0		1 1 0 1 0	(0.6) (0.6) (0.6)	1 0 1 0 1	(0.6) (0.6) (0.6)	0 0 0 0		0 0 0 0
All Severity Mild Mild Moderate Moderate	/ Not Rel. / Related / Not Rel. / Related / Not Rel. / Related / Related	3 1 2 1 1 0 1	(2.0) (0.7) (1.3) (0.7) (0.7)	9 1 8 0 3 1 3 2	(5.8) (0.6) (5.2) (1.9) (0.6) (1.9) (1.3)	8 0 8 0 2 0 5	(5.1) (5.1) (1.3) (3.2) (0.6)	4 3 1 3 0 0 1	(2.6) (2.0) (0.7) (2.0)	1 (1. 0 1 (1. 0 0 0 0 1 (1.
VESTIBULAR DISORDER	.	0		0		1	(0.6)	0		0

Page

23

100CT05 15:29 REPORT AE4 SEV DR P T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT EMERGENT ADVERSE EVENTS

By Severity And Drug Relationship

Body System [1] ----- Treatment -----Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Severity / Drug Relationship [2] n=149 n=155 n=157 n=151 n = 770 All Severity / Not Rel. 0 (0.6)0 0 Moderate / Not Rel. 0 0 1 (0.6)0 (0.6)0 0 0 VITREOUS DISORDER 1 All Severity / Not Rel. 0 (0.6)0 0 0 Mild / Not Rel. (0.6)0 0 UROGENITAL SYSTEM 3 (2.0)2 (1.3)(2.5)5 (3.3)3 (3.9)All Severity / Not Rel. (1.3)(1.3)3 (1.9)4 (2.6)3 (3.9)(0.7)All Severity / Related (0.7)(0.6)3 Mild / Not Rel. (1.3)(0.6)3 (1.9)(2.0)3 (3.9)Mild / Related (0.7)0 1 (0.6)0 Moderate / Not Rel. (0.6)0 (0.7)0 0 0 0 0 Moderate / Related (0.7)0 ALBUMINURIA 0 (0.6)0 All Severity / Not Rel. 0 0 1 (0.6)0 Ω / Not Rel. 0 0 Mild 0 0 1 (0.6)0 0 0 BREAST CYST (0.7)0 (0.7)0 All Severity / Not Rel. 0 0 0 Mild / Not Rel. (0.7)0 0 0 0 BREAST PAIN 0 1 (0.6)1 (0.7)All Severity / Not Rel. (0.6)(0.7)0 0 Mild / Not Rel. 0 0 1 (0.6)0 Moderate / Not Rel. Ω Ω Ω (0.7)0 CERVIX NEOPLASM 0 (0.6)0 (1.3)(1.3)All Severity / Not Rel. 0 0 0 0 1 All Severity / Related 0 (0.6)0 Mild / Not Rel. 0 0 0 0 1 (1.3)Mild / Related 0 0 1 (0.6)0 0 0 0 FIBROCYSTIC BREAST (0.6)(0.7)/ Not Rel. All Severity 0 Ω 1 (0.6)1 (0.7)0 / Not Rel. 0 1 (0.6)(0.7)0

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

Page

24

100CT05 15:29 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT AE4 SEV DR P T

- - - NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT EMERGENT ADVERSE EVENTS

By Severity And Drug Relationship

Body System [1] ----- Treatment -----Adverse Event DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Severity / Drug Relationship [2] n=149 n=155 n=157 n=151 n = 770 0 HEMATURIA 0 (0.7)0 (0.7)All Severity / Not Rel. 0 0 1 0 / Not Rel. Mild 0 0 0 (0.7)0 KIDNEY CALCULUS Ω 0 0 (1.3)All Severity / Not Rel. 0 0 0 0 1 (1.3)Mild / Not Rel. 0 0 0 0 1 (1.3)LEUKORRHEA 0 1 (0.6)0 0 0 All Severity / Not Rel. 0 (0.6)0 0 0 0 Moderate / Not Rel. 0 1 (0.6)0 0 PYELONEPHRITIS 0 0 0 (1.3)0 (1.3)All Severity / Not Rel. 0 0 Λ Mild / Not Rel. 0 0 0 0 1 (1.3)Ω 0 URINARY FREQUENCY (0.7)Ω All Severity / Related 0 (0.7)0 0 0 1 Moderate / Related 0 0 0 (0.7)0 0 0 0 URINARY INCONTINENCE 1 (0.7)0 All Severity / Not Rel. 0 0 0 (0.7)0 Mild / Not Rel. 0 0 0 1 (0.7)0 URINARY TRACT INFECTION 0 0 0 (1.3)All Severity / Not Rel. 0 0 0 0 1 (1.3)Mild / Not Rel. Ω Ω 0 Ω 1 (1.3)VAGINITIS (0.6)0 0 0 All Severity / Not Rel. 0 1 (0.6)0 0 0 Mild / Not Rel. (0.6)0 0 0 VULVOVAGINAL DISORDER (1.3)Ω Ω Ω Ω / Not Rel. All Severity (0.7)0 0 0 0 All Severity / Related (0.7)0 0 0 0 (0.7)Mild / Not Rel. Ω 0 Λ 0 Mild / Related (0.7)0

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.

^{[2] -} Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

Page

25

100CT05 15:29 REPORT AE4_SEV_DR_P_T CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

NUMBER (%) OF SUBJECTS REPORTING POST TREATMENT EMERGENT ADVERSE EVENTS By Severity And Drug Relationship

Body System [1]					Trea	tment			
Adverse Event Severity / Drug Relationship [2]		DVS SR 50 mg n=149		DVS SR 100 mg n=155	DVS SR 150 mg n=157				Placebo n= 77
FERMS NOT CLASSIFIABLE		1	(0.7)	0	1	(0.6)	1	(0.7)	0
All Severity / Rela		1	(0.7)	0	1	(0.6)	1	(0.7)	0
Mild / Rela Severe / Rela		0	(0.7)	0	1	(0.6)	0	(0.7)	0
REACTION UNEVALUABLE		1	(0.7)	0	1	(0.6)	1	(0.7)	0
All Severity / Rela	ated	1	(0.7)	0	1	(0.6)	1	(0.7)	0
Mild / Rela	ated	1	(0.7)	0	0		1	(0.7)	0
Severe / Rela	ated	0		0	1	(0.6)	0		0
ADVERSE EVENT ASSOC.W.MISC.	FACTORS	1	(0.7)	0	0		0		0
All Severity / Not	Rel.	1	(0.7)	0	0		0		0
Moderate / Not	Rel.	1	(0.7)	0	0		0		0
ALLERGIC REACTION OTHER T	THAN DRUG	1	(0.7)	0	0		0		0
All Severity / Not	Rel.	1	(0.7)	0	0		0		0
Moderate / Not	Rel.	1	(0.7)	0	0		0		0

NOTE: [1] - Body System Totals Are Not Necessarily The Sum Of The Individual Adverse Events Since A Subject May Report Two or More Different Adverse Events In The Same Body System.
[2] - Only The Adverse Events With The Worst Drug Relationship Within The Worst Severity (First Priority) Are Tabulated.

ST 10-8: Subject Narratives

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 1 REPORT NARR-INF SUBJECT NARRATIVE INFORMATION (Legend Page for Adverse Event Description) Column Label Column Description Abbreviation Description Text AE VERBATIM Adverse Event Verbatim BDY\SYS Body System Body as A Whole CV Cardiovascular System DΙ Digestive System Endocrine System Hemic and Lymphatic System ΕD $_{\rm HL}$ MN Metabolic and Nutritional MU Musculoskeletal System NE Nervous System Respiratory System Skin and Appendages Special Senses RE SA SS UR Urogenital System MC Adverse Event Assoc.W.Misc. Factors REL.\DAY Relative Day (Days) Τ\E Treatment Emergent Yes N or null Not ONSET\DATE AE Start Date STOP\DATE AE Stop Date DURA\TION AE Duration (days) SEV AE Severity LIF Life Threatening MIL Mild MOD Moderate SEV Severe OUT\COM Outcome of Adverse Event DTH Death PER Persisted RES Resolved ACTION Action Taken of Adverse Event Concomitant Medication D Discontinued Test Article Permanent ER Visit/No Tests or Procedures ER Visit/Tests or Procedures Ε ΕR Hospitalization None

2

Page

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

(Legend Page for Adverse Event Description)

Column Label	Column Description	Abbreviation	Description Text
RELA\TION\INV	Test Article(s) Relationshiby Investigator	O P PH R ST SU T U UT W WC Z DPOT DNOT PNOT POSS PROB	Other Action(s) Taken Primary Reason for Study Withdrawal Physical Therapy Reduced Test Article Dose Study Device Removed Surgical Procedure Temporarily Stopped Test Article Unscheduled Visit/No Test/Procedure Unscheduled Visit/Test/Procedure Withdrawn From Study Plan Wound Care Discontinued Test Article Permanently(secondary Reason) Definitely Definitely Not Probably Not Possibly Probably
S\A\E	Form 7443 Initiated	Y N or null	Yes Not
RELA\TION\MM	Test Article(s) Relationshiby Medical Monitor	ip DEFI DNOT PNOT POSS PROB	Definitely Definitely Not Probably Not Possible Probably
CASE\ID	Case ID for Serious AE		

a: Action Taken Of Adverse Event Code S=Specific Drug Therapy

Page

3

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-201-201009

INVESTIGATOR: 201, USA, 16584

TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 201009 , 53 Year old, Female, Black , 63.6 kg , 154.9 cm, 26.5 kg /M^2

THERAPY START DATE/STOP DATE : 17MAR04/ 13MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 15MAR05

NARRATIVE REASON : SERIOUS ADVERSE EVENT (SAE)

{CHEST PAIN}

RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM ID Chest pain (non-cardiac) BO Y 330 09FEB05 09FEB05 SEV RES S H O DNOT Y PNOT HQWYE355825MAR05

MEDICAL MONITOR COMMENTS :

Relevant Medical History: Gastroesophageal reflux disease (1999), overweight.

Relevant Prior Medications: none.

Relevant Concomitant Medications: aspirin, nitroglycerin, Toprol, Nexium.

Description of Event: The subject was admitted to the emergency room on 09 Feb 2005 with complaints of chest pain, shortness of breath, nausea, and fatigue. An ECG was performed, which was found to be normal. Cardiac enzymes and other laboratory parameters were normal, with the exception of mild anemia. Cardiac consultation indicated noncardiac chest pain. Because of the subject's maternal history of coronary artery disease, she had a thallium stress test with the following conclusions: small fixed inferior deficit probably secondary to artifact, no ischemia, ejection fraction of 64%, submaximal stress test.

Outcome: The subject was discharged on 09 Feb 2005 with no discharge summary because she was hospitalized for less than 24 hours. The event of chest pain was considered noncardiac in nature and both the investigator and medical monitor considered the event to be definitely not related to test article.

The subject continued test article and completed the study.

Page

4

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-201-201002

INVESTIGATOR : 201, USA, 16584

TREATMENT : Desvenlafaxine SR 200 mg
SUBJECT : 201002 , 50 Year old, Female, White , 71.2 kg , 157.5 cm, 28.7 kg /M^2

THERAPY START DATE/STOP DATE : 14JAN04/ 07DEC04

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 18JAN05

{BRAIN EDEMA}	NARRATIVE REASON :	: SI	ERIOUS	ADVER	SE EVENT	(SAE)							
AE VERBATIM	BDY SYS		REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT COM	ACTION	RELA TION INV	S A E	RELA TION MM	CASE ID
Cerebral edema	NE	Y	105	2	27APR04	28APR04	MIL	RES	НО	DNOT	Y	PNOT	HQWYE678503MAY0
{CHEST PAIN}	BDY SYS		REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT COM	ACTION	RELA TION INV	S A E	RELA TION MM	CASE ID
Chest pain	ВО	Y	94	1	16APR04	16APR04	MOD	RES	S O	PNOT		PNOT	HQWYE678503MAY0
Chest pain	ВО	Y	105	2	27APR04	28APR04	MIL	RES	0	DNOT	Y	PNOT	HQWYE678503MAY0
{FEVER}	BDY	Т	REL	DURA	ONSET	STOP		OUT		RELA TION	S A	RELA TION	CASE
AE VERBATIM	SYS	Ε	DAY	TION	DATE	DATE	SEV	COM	ACTION	INV	Ε	MM	ID
Fever Fever	B0 B0	Y Y	17 105	2	30JAN04 27APR04	31JAN04 28APR04	MOD MIL	RES RES	N S H	DNOT	Y	PNOT PNOT	HQWYE678503MAY04 HQWYE678503MAY04
{HEADACHE}										RELA	0	RELA	
AE VERBATIM	BDY SYS		REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT	ACTION	TION INV	S A E	TION MM	CASE ID
Headache Headache		N N	-1 105	2	13JAN04 27APR04	13JAN04 28APR04	SEV SEV	RES RES	N S H	DNOT	Y	PNOT PNOT	HQWYE678503MAY04 HQWYE678503MAY04
{INFECTION}										DELA	0	DELA	
AE VERBATIM	BDY SYS		REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT COM	ACTION	RELA TION INV	S A E	RELA TION MM	CASE ID

Page

5

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-201-201002

INVESTIGATOR : 201, USA, 16584

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 201002 , 50 Year old, Female, White , 71.2 kg , 157.5 cm, 28.7 kg /M^2

THERAPY START DATE/STOP DATE : 14JAN04/ 07DEC04

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 18JAN05

Bilateral mastoiditis,worsening	ВО	Y	105	29	27APR04	25MAY04	SEV	RES	S H O	DNOT	Y	PNOT	HQWYE678503MAY04
{NAUSEA}													
	BDY		REL	DURA	ONSET	STOP		OUT		RELA TION	S A	RELA TION	CASE
AE VERBATIM	SYS	Ε	DAY	TION	DATE	DATE	SEV	COM	ACTION	INV	Ε	MM	ID
Nausea	DI	Y	1	7	14JAN04	20JAN04	MIL	RES	N	PROB		PNOT	HQWYE678503MAY04
Nausea	DI	Y	105	2	27APR04	28APR04	MOD	RES	SH	DNOT	Y	PNOT	HQWYE678503MAY04
{NECK PAIN}													
(indoit filett)										RELA	S	RELA	
AE VERBATIM	BDY SYS		REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT	ACTION	TION INV	A E	TION MM	CASE ID
Neck pain	ВО	Y	14	·	27JAN04		MOD	PER	N	DNOT		PNOT	HQWYE678503MAY04
Neck pain Neck pain	BO BO	Y Y	14 105	44 2	27JAN04 27APR04	10MAR04 28APR04	MOD SEV	RES RES	N S H	DNOT DNOT	Y	PNOT PNOT	HQWYE678503MAY04 HQWYE678503MAY04
{VOMITING}													
	BDY	т	REL	DURA	ONSET	STOP		OUT		RELA TION	S	RELA TION	CASE
AE VERBATIM		_	DAY	TION	DATE	DATE	SEV	COM	ACTION	INV	E	MM	ID
Vomiting	DI	Y	105	2	27APR04	28APR04	MIL	RES	SH	DNOT	Y	PNOT	HQWYE678503MAY04

MEDICAL MONITOR COMMENTS :

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

Page 6

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR : 201, USA, 16584

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 201002 , 50 Year old, Female, White , 71.2 kg , 157.5 cm, 28.7 kg /M^2

THERAPY START DATE/STOP DATE : 14JAN04/ 07DEC04

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 18JAN05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Relevant Medical History: chronic bilateral ear infections (1998), cervical nerve damage (2002), smoking, overweight.

Relevant Prior Medication: Zyrtec.

Relevant Concomitant Medications: Zyrtec, Augmentin XR, Rocephin, Phenergan, cefotaxime, Flexeril, nitroglycerin, Toprol XL, Demerol, amoxicillin, lidocaine 1%, fentanyl, Diprivan, Marcaine, Decadron, Cleocin, Medrol, Lortab.

Description of Event: The subject has history of chronic bilateral ear infections. On 30 Mar 2004, she reported an episode of worsening bilateral ear infection, neck pain, and gum abscess with edema on right side of face. On 05 Apr 2004, gum abscess and edema continued, and the subject's laboratory evaluation indicated increased WBC count, decreased lymphocytes, and increased neutrophils. The subject was advised to seek treatment from her primary care physician. She was later admitted to the hospital on 27 Apr 2004 for fever, headache, nausea, vomiting, and neck and chest pain. Lumbar puncture was normal. Computed tomography scan showed severe bilateral cerebral edema. Magnetic resonance imaging study was normal. The subject's condition improved significantly with IV fluids, IV antibiotics, and pain control. Her final diagnosis was severe cephalgia, diffuse cerebral edema/meningismus, bilateral mastoiditis (subject's teeth were noted to be in poor condition).

Outcome: The subject was discharged on 28 Apr 2004 in good condition. The event was considered not related to test article by both the investigator and medical monitor. The subject continued test article and completed the study.

Page

7

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-202-201068

INVESTIGATOR : 202, USA, 15817

TREATMENT : Desvenlafaxine SR 100 mg

SUBJECT : 201068 , 69 Year old, Female, White , 71.8 kg , 160 cm, 28.0 kg /M^2

THERAPY START DATE/STOP DATE : 06FEB04/ 21DEC04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - CORONARY OCCLUSION)

STUDY COMPLETION DATE : 03JAN05

NARRATIVE REASON : SERIOUS ADVERSE EVENT (SAE)

{CORONARY OCCLUSION}

REPORT NARR-INF

BLOCKED CORONARY ARTERY

BDY T REL DURA ONSET STOP OUT TION A TION CASE
AE VERBATIM

BLOCKED CORONARY ARTERY

RELA S RELA
TION A TION CASE
DATE SEV COM ACTION INV E MM ID

RECA S RELA
TION A TION CASE
BLOCKED CORONARY ARTERY

RELA S RELA
TION A TION CASE
SYS E DAY TION DATE DATE SEV COM ACTION INV E MM ID

${\tt MEDICAL}$ MONITOR COMMENTS :

Relevant Medical History: overweight, hypertension-mild (since 1987), hyperlipidemia (since 2001).

Relevant Prior Medication: atenolol.

Relevant Concomitant Medications: Plavix, Lipitor, clopidogrel, Nexium, atenolol.

Description of Event: The subject was complaining about ongoing burning in the chest with modest levels of activity and was suspected to have unstable angina. She was admitted to the hospital for cardiac catheterization, which demonstrated a totally occluded circumflex vessel. She underwent a left circumflex to lateral circumflex angioplasty with stent. Follow-up with a stress echocardiogram was recommended to the subject.

Outcome: The subject was discharged on 23 Dec 2004. She discontinued participation in the study because of this event. She had follow-up with a cardiologist on 29 Mar 2005, 4 months after left circumflex stent deployment, at which time she was in good condition. Both investigator and medical monitor considered the event to be not related to test article.

CONFIDENTIAL 686 Wyeth

Page

8

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-202-201073

INVESTIGATOR: 202, USA, 15817

TREATMENT : Desvenlafaxine SR 100 mg

SUBJECT : 201073 , 49 Year old, Fémale, White , 81.4 kg , 166.4 cm, 29.4 kg /M^2

THERAPY START DATE/STOP DATE : 10FEB04/ 31JAN05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 21FEB05

NARRATIVE REASON : ADVERSE EVENTS OF SPECIAL INTEREST

{DEPRESSION}

BDY T REL DURA ONSET STOP OUT TION A TION CASE
AE VERBATIM

BDY T REL DURA ONSET STOP OUT TION A TION CASE
AE VERBATIM

Depressed

NE Y 21 6 01MAR04 06MAR04 SEV RES N POSS

MEDICAL MONITOR COMMENTS :

Relevant Medical History: The subject had no reported history of depression.

Relevant Prior Medications: none.

Relevant Concomitant Medication: none.

Description of Event: The subject was taking test article for 20 days before reporting an episode of depression that spontaneously resolved within 5 days. The episode was reported as severe and possibly related to test article.

Outcome: The subject had multiple events occurring in her life at the time the depression was reported. Depression was situational in nature. The subject completed the study. No further information is available.

CONFIDENTIAL 687 Wyeth

9

Page

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-202-201090

INVESTIGATOR : 202, USA, 15817

REPORT NARR-INF

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 201090 , 53 Year old, Fémale, Black , 75 kg , 165.1 cm, 27.5 kg /M 2

THERAPY START DATE/STOP DATE : 31MAR04/ 05APR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 06APR05

NARRATIVE REASON : CLINICALLY IMPORTANT LABORATORY VALUES

{PCI: TOTAL CHOLESTEROL}

Lab Test	Rel. Day (Days)	D.A.I	Test Date	Test Value (# => PCI)	Fasting (Y/N)	Range (Low)	Range (High)	Unit	Baseline Value
TOT.CHOL. /LIPID	-8	Screening/baseline	23MAR04	4.9651	Yes	0	5.1461	mmol/L	4.9651
TOT.CHOL. /LIPID	34	Week 4	03MAY04	6.4909	Yes	0	5.1461	mmol/L	4.9651
TOT.CHOL. /LIPID	57	Week 8	26MAY04	6.2064	Yes	0	5.1461	mmol/L	4.9651
TOT.CHOL. /LIPID	85	Week 12	23JUN04	8.1976 #	Yes	0	5.1461	mmol/L	4.9651
TOT.CHOL. /LIPID	183	Week 26	29SEP04	7.577	Yes	0	5.1461	mmol/L	4.9651
TOT.CHOL. /LIPID	247	Week 39	02DEC04	7.396	Yes	0	5.1461	mmol/L	4.9651
TOT.CHOL. /LIPID	275	Week 39	30DEC04	7.7321	Yes	0	5.1461	mmol/L	4.9651
TOT.CHOL. /LIPID	294	Week 39	18JAN05	6.6202	Yes	0	5.1461	mmol/L	4.9651
TOT.CHOL. /LIPID	328	Week 52	21FEB05	6.4391	Yes	0	5.1461	mmol/L	4.9651
TOT.CHOL. /LIPID	372	Week 52	06APR05	8.0166 #	Yes	0	5.1461	mmol/L	4.9651
TOT.CHOL. /LIPID	387	Follow-up	21APR05	6.9046	Yes	0	5.1461	mmol/L	4.9651

MEDICAL MONITOR COMMENTS :

Additional Relevant Lab Values:

Date	HDL	LDL	Triglycerides	
	(0.90-2.07 mmol/L)	(0-3.36 mmol/L)	(0.40-2.26 mmol/L)	
23Mar04 (Baseline) 03May04 (Week 4) 26May04 (Week 8) 23Jun04 (Week 12) 29Sep04 (Week 26) 02Dec04 (Week 39) 30Dec04 (Week 39)	1.60 1.60 1.89 1.73 1.71 2.12	2.82 4.37 4.03 5.84 5.20 4.86 5.38	2.74 2.59 1.45 3.15 3.31 2.07 1.99	

10

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 202, USA, 15817

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 201090 , 53 Year old, Female, Black , 75 kg , 165.1 cm, 27.5 kg /M^2

THERAPY START DATE/STOP DATE : 31MAR04/ 05APR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 06APR05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

18Jan05(Week 39)	1.78	4.40	2.25
21Feb05(Week 52)	1.65	4.47	1.53
06Apr05(Week 52)	1.55	5.66	4.06
21Apr05(Follow-up)	1.60	4.73	2.82

Relevant Medical History: overweight, hyperlipidemia (2002), hypertension (2000).

Relevant Prior Medication: Crestor.

Relevant Concomitant Medications: Crestor, Lipitor, niacin.

Outcome: The subject showed a progressive increase in total cholesterol levels from 4.9651 mmol/L at baseline to 8.1976 mmol/L at week 12 that was considered clinically important (increase >/= 1.97 mmol/L with value >/= 7.8 mmol/L). Total cholesterol value was still relatively high at week 26 and 39 before returning to 6.6202 mmol/L. At week 52, total cholesterol once again met criteria for clinical importance with a value of 8.0166 mmol/L. LDL cholesterol and triglycerides were also found to be elevated at week 12 and week 52.

Follow-up laboratory evaluations indicated that total cholesterol decreased. The subject completed the study. No further information is available.

Hypercholesterolemia was reported as an adverse event moderate in severity and definitely not related to test article.

Page 11

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-202-201066

INVESTIGATOR : 202, USA, 15817

TREATMENT : Placebo

SUBJECT : 201066 , 43 Year old, Female, White , 81.8 kg , 154.9 cm, 34.1 kg /M^2

THERAPY START DATE/STOP DATE : 10FEB04/ 31JAN05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 23FEB05

NARRATIVE REASON : CLINICALLY IMPORTANT LABORATORY VALUES

{PCI: TOTAL CHOLESTEROL}

Lab Test	Rel. Day (Days)	D.A.I	Test Date	Test Value (# => PCI)	Fasting (Y/N)	Range (Low)	Range (High)	Unit	Baseline Value
TOT.CHOL. /LIPID	-15	Screening/baseline	26JAN04	5.5082	Yes	0	5.1461	mmol/L	5.5082
TOT.CHOL. /LIPID	29	Week 4	09MAR04	5.353	No/Unkn			mmol/L	5.5082
TOT.CHOL. /LIPID	92	Week 12	11MAY04	5.0944	Yes	0	5.1461	mmol/L	5.5082
TOT.CHOL. /LIPID	190	Week 26	17AUG04	8.2235 #	Yes	0	5.1461	mmol/L	5.5082
TOT.CHOL. /LIPID	284	Week 39	19NOV04	3.0256	Yes	0	5.1461	mmol/L	5.5082
TOT.CHOL. /LIPID	358	Week 52	01FEB05	3.5945	No/Unkn			mmol/L	5.5082

MEDICAL MONITOR COMMENTS :

Additional Relevant Lab Values:

Date	HDL (0.90-2.07 mmol/L)	LDL (0-3.36 mmol/L)	Triglycerides (0.40-2.26 mmol/L)	
26Jan04 (Baseline)	1.19	3.65	3.41	
09Mar04 (Week 4)	1.29	2.99	5.30	
11May04 (Week 12)	1.27	3.39	2.17	
17Aug04 (Week 26)	1.37	5.69	5.77	
19Nov04 (Week 39)	0.90	1.34	3.83	
01Feb05 (Week 52)	1.16	1.63	3.98	

Relevant Medical History: obesity, hypothyroid (2001), diabetes type II-diet controlled.

Relevant Prior Medication: Synthroid

Relevant Concomitant Medications: Crestor, Synthroid.

CONFIDENTIAL 690 Wyeth

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

Page 12

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 202, USA, 15817

TREATMENT : Placebo

SUBJECT : 201066 , 43 Year old, Female, White , 81.8 kg , 154.9 cm, 34.1 kg /M^2

THERAPY START DATE/STOP DATE : 10FEB04/ 31JAN05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 23FEB05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Outcome: At week 26 of treatment, the subject had a total cholesterol value that was considered clinically important (increase >/= 1.97 mmol/L with value >/= 7.8 mmol/L). Triglycerides and LDL cholesterol values were also elevated at this time. At the following visits, the subject's total cholesterol returned to normal/baseline after taking Crestor.

The investigator did not report elevated cholesterol as an adverse event. The subject completed the study.

Page 13

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-203-201103

INVESTIGATOR : 203, USA, 5469

TREATMENT : Desvenlafaxine SR 100 mg

SUBJECT : 201103 , 45 Year old, Female, White , 76.8 kg , 154 cm, 32.4 kg /M^2

THERAPY START DATE/STOP DATE : 01MAR04/ 07DEC04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - HYPERLIPEMIA)

STUDY COMPLETION DATE : 13DEC04

NARRATIVE REASON: DISCONTINUATION DUE TO ADVERSE EVENT

{HYPERLIPEMIA}

AE VERBATIM	BDY T SYS E		DURA TION	ONSET DATE	STOP DATE	SEV	OUT COM	ACTION	RELA TION INV	S A E	RELA TION MM	CASE ID	
Hypertriglyceridemia	MN Y	29	247	29MAR04	30NOV04	MOD	RES	S	DNOT				 -
Hypertriglyceridemia	MN Y	276		01DEC04		SEV	PER	SP	POSS				

MEDICAL MONITOR COMMENTS:

Additional Relevant Lab Values:

Date	Total Cholesterol (0-5.15 mmol/L)	HDL (0.90-2.07 mmol/L)	LDL (0-3.36 mmol/L)	Triglycerides (0.40-2.26 mmol/L)	
19Feb04(Baseline)	5.07	0.62	2.82	3.58	
29Mar04(Week 4)	5.28	0.70	ND	5.63	
26Apr04 (Week 8)	4.37	0.62	ND	5.43	
25May04 (Week 12)	4.94	0.70	3.36	3.18	
02Sep04 (Week 26)	5.69	0.67	ND	5.33	
01Dec04(Week 39)	6.03	0.67	ND	6.27	
13Dec04 (Follow-up)	6.34	0.70	ND	7.20	
22Dec04 (Follow-up)	6.21	0.80	ND	7.41	

Relevant Medical History: obesity, hypertension-controlled.

Relevant Prior Medication: atenolol.

Relevant Concomitant Medication: Crestor.

Description of Event: The subject had elevated triglyceride levels beginning 29 Mar 2004. She took 10 mg of Crestor from

CONFIDENTIAL 692 Wyeth

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 14

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 203, USA, 5469

: Desvenlafaxine SR 100 mg

: 201103 , 45 Year old, Female, White , 76.8 kg , 154 cm, 32.4 kg /M^2

THERAPY START DATE/STOP DATE : 01MAR04/ 07DEC04

STUDY COMPLETION STATUS STUDY COMPLETION DATE : Discontinued (Adverse Event - HYPERLIPEMIA)

: 13DEC04

(continued from previous page)

MEDICAL MONITOR COMMENTS :

09 Apr 2004 to 09 Dec 2004 and the dose was increased to 20 mg beginning 10 Dec 2004. After taking Crestor, the subject had persistent elevated levels of triglycerides at subsequent visits.

Outcome: The subject discontinued from the study because of the adverse event of "hypertriglyceridemia" and her triglycerides remained elevated at follow-up. The investigator initially reported the adverse event hypertriglyceridemia to be moderate in severity and definitely not related to test article, but the report was later changed to severe and possibly related to test article at subject's last visit. The subject was scheduled to return for repeat laboratory evaluations, several times, but never returned.

Page

PNOT Y PNOT HQWYE409509APR04

15

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-203-201119

INVESTIGATOR: 203, USA, 5469

TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 201119 , 46 Year old, Female, White , 61.3 kg , 158.8 cm, 24.3 kg /M^2

RE N 50

THERAPY START DATE/STOP DATE : 11FEB04/ 29MAR04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - CHEST PAIN)

STUDY COMPLETION DATE : 06APR04

NARRATIVE REASON: SERIOUS ADVERSE EVENT (SAE) {CHEST PAIN} RELA S RELA CASE BDY T REL DURA ONSET STOP OUT TION A TION AE VERBATIM SYS E DAY DATE SEV COM ACTION INV Chest heaviness BO N 50 31MAR04 01APR04 SEV RES S H P O PNOT Y PNOT HQWYE409509APR04 {DYSPNEA} RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE INV E MM AE VERBATIM SYS E DAY TION DATE DATE COM ACTION

31MAR04

01APR04 MIL RES H

MEDICAL MONITOR COMMENTS :

Shortness of breath

Relevant Medical History: smoking, hypertension, borderline hyperlipidemia.

Relevant Prior Medications: none.

Relevant Concomitant Medications: nitroglycerin sublingual, nitroglycerin drip, Nitropaste, aspirin, morphine, metoprolol.

Description of Event: The subject missed 3 doses of test article before being admitted to the hospital on 31 Mar 2004 complaining of chest pain that was ongoing for the last 2 days, worse with activity, and relieved with rest. The morning of 31 Mar 2004, she had a sudden onset of chest pain in the left side with associated nausea, shortness of breath, light-headedness and diaphoresis, but no vomiting. The subject denied having any chest pain such as this in the past. She stated that it did not radiate in her arm, shoulder, or neck, but it did radiate straight through to her back. The subject stated she had a history of borderline high cholesterol and reported a family history positive for coronary artery disease; she is also a smoker. The patient described her pain as a "pile of bricks laying on my chest." A negative chest computed tomography study ruled out a pulmonary embolism, and myocardial infarction was subsequently ruled out by a negative stress echocardiogram and normal cardiac enzymes.

CONFIDENTIAL 694 Wyeth

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 16

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 203, USA, 5469

TREATMENT : Desvenlafaxine SR 150 mg

: 201119 , 46 Year old, Female, White , 61.3 kg , 158.8 cm, 24.3 kg /M^2

THERAPY START DATE/STOP DATE : 11FEB04/ 29MAR04

: Discontinued (Adverse Event - CHEST PAIN) STUDY COMPLETION STATUS STUDY COMPLETION DATE

: 06APR04

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Outcome: The subject was discharged from hospital 01 Apr 2004. Final diagnosis per emergency room physician was costochondritis and tobacco abuse. This event was considered not related to test article by both the investigator and medical monitor. The subject discontinued permanently from study because of this event.

Page 17

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-203-203514

INVESTIGATOR: 203, USA, 5469

TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 203514 , 48 Year old, Fémale, Black , 101.6 kg , 169.8 cm, 35.2 kg /M^2

THERAPY START DATE/STOP DATE : 25FEB04/ 17AUG04

STUDY COMPLETION STATUS : Discontinued (Unsatisfactory response - efficacy)

STUDY COMPLETION DATE : 23AUG04

NARRATIVE REASON : CLINICALLY IMPORTANT VITAL SIGNS {PCI: SYSTOLIC BLOOD PRESSURE}

Vital Sign	Position	Visit Date	D.A.I	Seq Num	Test Value (# => PCI)	Unit	Baseline Value
SYSTOLIC BP	Supine	25FEB04	Screening/baseline	1	130	mm Hq	139.25
SYSTOLIC BP	Supine	25FEB04	Screening/baseline	1	147	mm Hq	139.25
SYSTOLIC BP	Supine	25FEB04	Screening/baseline	3	130	mm Hq	139.25
SYSTOLIC BP	Supine	25FEB04	Screening/baseline	3	150	mm Hq	139.25
SYSTOLIC BP	Supine	24MAR04	Week 4	1	159	mm Hq	139.25
SYSTOLIC BP	Supine	24MAR04	Week 4	1	171 #	mm Hg	139.25
SYSTOLIC BP	Supine	24MAR04	Week 4	3	162	mm Hg	139.25
SYSTOLIC BP	Supine	24MAR04	Week 4	3	170 #	mm Hg	139.25
SYSTOLIC BP	Supine	26MAR04	Week 4	1	126	mm Hg	139.25
SYSTOLIC BP	Supine	26MAR04	Week 4	3	126	mm Hg	139.25
SYSTOLIC BP	Supine	23APR04	Week 8	1	154	mm Hg	139.25
SYSTOLIC BP	Supine	23APR04	Week 8	3	160	mm Hg	139.25
SYSTOLIC BP	Supine	26MAY04	Week 12	1	148	mm Hg	139.25
SYSTOLIC BP	Supine	26MAY04	Week 12	3	124	mm Hg	139.25
SYSTOLIC BP	Supine	18AUG04	Follow-up	1	125	mm Hg	139.25
SYSTOLIC BP	Supine	18AUG04	Follow-up	3	123	mm Hg	139.25

MEDICAL MONITOR COMMENTS :

Additional Relevant Vital Sign Values:

Date Supine Diastolic BP value

Date Supine Diastolic BP valu (mm Hg)

25Feb04(Baseline)	90 (Average of all screening/baseline values)
24Mar04(Week 4)	99
0.434 0.4 (57 1 4)	0.7

24Mar04 (Week 4) 97 24Mar04 (Week 4) 94

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 18

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 203, USA, 5469

TREATMENT : Desvenlafaxine SR 150 mg

: 203514 , 48 Year old, Female, Black , 101.6 kg , 169.8 cm, 35.2 kg /M^2

THERAPY START DATE/STOP DATE : 25FEB04/ 17AUG04

STUDY COMPLETION STATUS STUDY COMPLETION DATE : Discontinued (Unsatisfactory response - efficacy)

: 23AUG04

(continued from previous page)

MEDICAL MONITOR COMMENTS:

24Mar04(Week 4) 26Mar04 (Week 4) 83 26Mar04 (Week 4) 91 23Apr04(Week 8) 23Apr04 (Week 8) 93 26May04 (Week 12) 89 26May04 (Week 12) 83 18Aug04 (Week 26) 81 18Aug04 (Week 26) 82

Relevant Medical History: hypertension (since 2002), obesity.

Relevant Prior Medications: none.

Relevant Concomitant Medications: Accupril (quinapril hydrochloride), Dyazide.

Outcome: At week 4, the subject had 31.75 mm Hg and 30.75 mm Hg increases from baseline in systolic blood pressure that were considered clinically important (>/= 30 mm Hg from baseline with value >/= 160 mm Hg). She received Accupril on 25 Mar 2004 (and continued taking Accupril until 18 Aug 2004). At all subsequent visits, systolic blood pressure remained within normal range. Diastolic blood pressure also remained within normal range throughout the entire course of treatment. The subject also received Dyazide from 28 Apr 2004 to 18 Aug 2004.

The investigator reported the episode of hypertension as an adverse event moderate in severity and probably not related to test article. The subject discontinued from the study because of unsatisfactory response. No further information is available.

Page

19

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-203-201113

INVESTIGATOR: 203, USA, 5469

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 201113 , 52 Year old, Female, Black , 85.9 kg , 162.6 cm, 32.5 kg /M^2

THERAPY START DATE/STOP DATE : 19FEB04/ 25JAN05

STUDY COMPLETION STATUS : Discontinued (Subject Request Unrelated to Study)

STUDY COMPLETION DATE : 18FEB05

NARRATIVE REASON: ADVERSE EVENTS OF SPECIAL INTEREST

{CHEST PAIN}

BDY T REL DURA ONSET STOP OUT TION A TION CASE
AE VERBATIM

BO N 343 . 26JAN05 . MIL PER O POSS

MEDICAL MONITOR COMMENTS :

Relevant Medical History: past tobacco use, respiratory allergies (mild, 1971-continues), obesity.

Relevant Prior Medications: none.

Relevant Concomitant Medications: none.

Description of Event: The subject reported an episode of chest pain at her last visit. For 1 day before onset of the event, she did not take test article. The investigator reported the adverse event as mild in severity and possibly related to discontinuation of test article.

Outcome: The subject followed up with primary care physician. Chest x-ray study and ECG were performed and results were found to be normal. The chest pain was considered noncardiac in origin by the physician and was most likely related to acid reflux.

CONFIDENTIAL 698 Wyeth

Page

20

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-203-201125

INVESTIGATOR: 203, USA, 5469

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 201125 , 60 Year old, Female, White , 73.2 kg , 170.2 cm, 25.3 kg /M^2

THERAPY START DATE/STOP DATE : 28MAR04/ 05SEP04

STUDY COMPLETION STATUS : Discontinued (Unsatisfactory response - efficacy)

STUDY COMPLETION DATE : 24SEP04

NARRATIVE REASON: SERIOUS ADVERSE EVENT (SAE) {CORONARY ARTERY DISORDER} RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY DATE DATE SEV COM ACTION INV Coronary artery disease CV Y 27 23APR04 MOD PER S DNOT PNOT HQWYE677303MAY04 CV Y 27 Coronary artery disease 23APR04 MOD PER S H O DNOT Y PNOT HOWYE677303MAY04 {CORONARY OCCLUSION} RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM 23APR04 Blocked coronary arteries CV Y 27 24APR04 SEV RES H DNOT Y PNOT HQWYE677303MAY04

MEDICAL MONITOR COMMENTS :

Relevant Medical History: hypertension, overweight, hypothyroidism, hyperlipidemia, smoking.

Relevant Prior Medications: Synthroid, lisinopril.

Relevant Concomitant Medications: lisinopril, Plavix, Zocor, Lipitor, Toprol, Zetia, aspirin, nitroglycerin, heparin.

Description of Event: The subject contacted the site on 19 Apr 2004 to report onset of chest pain, shortness of breath, and weakness in her left arm since 16 Apr 2004. The investigator instructed her to contact her primary care physician immediately for evaluation or to go to the emergency room. On 20 Apr 2004 she saw her primary care physician, who referred her to a cardiologist. Given her history of hyperlipidemia, hypertension, and recent report of chest pain, the subject was scheduled for heart catheterization on 23 Apr 2004 to resolve the discrepancy between 2 previously negative stress tests (2001 and 15 Jul 03) and typical symptoms of angina. The heart catheterization revealed several blocked coronary arteries (70%-95% left anterior descending). Two (2) coronary artery stents were inserted on 23 Apr 2004 and the subject was hospitalized. No complications were reported.

CONFIDENTIAL 699 Wyeth

Page 21

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 203, USA, 5469

TREATMENT : Desvenlafaxine SR 200 mg

: 201125 , 60 Year old, Female, White , 73.2 kg , 170.2 cm, 25.3 kg /M^2

THERAPY START DATE/STOP DATE : 28MAR04/ 05SEP04

STUDY COMPLETION STATUS STUDY COMPLETION DATE : Discontinued (Unsatisfactory response - efficacy)

: 24SEP04

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Outcome: The subject was discharged 24 Apr 2004. Final diagnosis was coronary artery disease and stable angina. Both the investigator and medical monitor considered the event not related to test article because the coronary artery disease was probably preexisting.

Page

22

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-203-201147

INVESTIGATOR: 203, USA, 5469

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 201147 , 55 Year old, Female, White , 71.1 kg , 160.2 cm, 27.7 kg /M^2

THERAPY START DATE/STOP DATE : 10MAR04/ 29MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 20APR05

NARRATIVE REASON : ADVERSE EVENTS OF SPECIAL INTEREST

{CHEST PAIN}

BDY T REL DURA ONSET STOP OUT TION A TION CASE
AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM ID

Chest pain BO Y 274 1 08DEC04 08DEC04 MOD RES O PNOT

NARRATIVE REASON : CLINICALLY IMPORTANT LABORATORY VALUES

{PCI: TOTAL CHOLESTEROL}

Lab Test	Rel. Day (Days)	D.A.I	Test Date	Test Value (# => PCI)	Fasting (Y/N)	Range (Low)	Range (High)	Unit	Baseline Value
TOT.CHOL. /LIPID	-28	Screening/baseline	11FEB04	6.3357	Yes	0	5.1461	mmol/L	6.3357
TOT.CHOL. /LIPID	29	Week 4	07APR04	7.2667	Yes	0	5.1461	mmol/L	6.3357
TOT.CHOL. /LIPID	91	Week 12	08JUN04	7.396	Yes	0	5.1461	mmol/L	6.3357
TOT.CHOL. /LIPID	126	Week 26	13JUL04	6.6977	Yes	0	5.1461	mmol/L	6.3357
TOT.CHOL. /LIPID	176	Week 26	01SEP04	8.3528 #	Yes	0	5.1461	mmol/L	6.3357
TOT.CHOL. /LIPID	281	Week 39	15DEC04	5.6633	Yes	0	5.1461	mmol/L	6.3357
TOT.CHOL. /LIPID	407	Follow-up	20APR05	5.9219	Yes	0	5.1461	mmol/L	6.3357

MEDICAL MONITOR COMMENTS :

Additional Relevant Lab Values:

Date HDL LDL Triglycerides (0-3.36 mmol/L)(0.90-2.07 mmol/L)(0.40-2.26 mmol/L)2.42 11Feb04 (Baseline) 1.45 3.77 07Apr04 (Week 4) 1.55 4.94 1.68 2.75 08Jun04 (Week 12) 1.47 4.65 13Jul04 (Week 26) 2.28 ND ND

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 23

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 203, USA, 5469

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 201147 , 55 Year old, Female, White , 71.1 kg , 160.2 cm, 27.7 kg /M^2

THERAPY START DATE/STOP DATE : 10MAR04/ 29MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 20APR05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

01Sep04 (Week 26)	1.65	6.00	1.55
15Dec04(Week 39)	1.47	3.21	2.12
20Apr05(Follow-up)	1.42	3.31	2.61

Relevant Medical History: hypertension-mild, controlled (1996), overweight, heartburn/reflux/gastroesophageal reflux disease, asthma (1974).

Relevant Prior Medications: Cardizem, Prilosec.

Relevant Concomitant Medications: Cardizem, hydrochlorothiazide, Lotensin, Lipitor, Prilosec.

Description of Event: The subject showed a progressive increase in total cholesterol levels from 6.3357 mmol/L at baseline to 8.3528 mmol/L at week 26 that was considered clinically important (increase >/= 1.97 mmol/L with value >/= 7.8 mmol/L). LDL cholesterol and triglycerides were also found to be elevated at this time. At later visits the subject's total cholesterol returned to baseline levels after she took Lipitor. At week 39, the subject also reported an episode of chest pain, moderate in severity, which spontaneously resolved within 1 day.

Outcome: Hyperlipidemia was reported as an adverse event moderate in severity and possibly related to test article. Chest pain was found to be of noncardiac origin and was secondary to reflux the subject was having at time of event.

The subject completed the study.

Page 24

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION 315-203-203531

INVESTIGATOR: 203, USA, 5469

TREATMENT : Desvenlafaxine SR 50 mg

SUBJECT : 203531 , 55 Year old, Female, Black , 84.4 kg , 167.6 cm, 30.0 kg /M^2

THERAPY START DATE/STOP DATE : 25MAR04/ 16DEC04

STUDY COMPLETION STATUS : Discontinued (Unsatisfactory response - efficacy)

STUDY COMPLETION DATE : 17DEC04

NARRATIVE REASON: CLINICALLY IMPORTANT VITAL SIGNS {PCI: SYSTOLIC BLOOD PRESSURE}

Visit Seq Test Value

(ICI: BIBIODIC DECOD	INDOUND	Visit		Seq	Test Value		Baseline
Vital Sign	Position	Date	D.A.I	Num	(# => PCI)	Unit	Value
SYSTOLIC BP	Supine	17MAR04	Screening/baseline	1	149	mm Hg	130
SYSTOLIC BP	Supine	17MAR04	Screening/baseline	3	145	mm Hg	130
SYSTOLIC BP	Supine	25MAR04	Screening/baseline	1	112	mm Hg	130
SYSTOLIC BP	Supine	25MAR04	Screening/baseline	3	114	mm Hg	130
SYSTOLIC BP	Supine	27APR04	Week 4	1	152	mm Hg	130
SYSTOLIC BP	Supine	27APR04	Week 4	3	144	mm Hg	130
SYSTOLIC BP	Supine	09JUN04	Week 12	1	145	mm Hg	130
SYSTOLIC BP	Supine	09JUN04	Week 12	3	145	mm Hg	130
SYSTOLIC BP	Supine	15JUL04	Week 12	1	138	mm Hg	130
SYSTOLIC BP	Supine	15JUL04	Week 12	3	130	mm Hg	130
SYSTOLIC BP	Supine	17SEP04	Week 26	1	144	mm Hg	130
SYSTOLIC BP	Supine	17SEP04	Week 26	3	142	mm Hg	130
SYSTOLIC BP	Supine	17DEC04	Follow-up	1	173 #	mm Hg	130
SYSTOLIC BP	Supine	17DEC04	Follow-up	3	171 #	mm Hg	130
SYSTOLIC BP	Supine	30DEC04	Follow-up	1	160 #	mm Hg	130
SYSTOLIC BP	Supine	30DEC04	Follow-up	3	153	mm Hg	130

MEDICAL MONITOR COMMENTS :

Additional Relevant Vital Sign Values:

Visit Date Supine Diastolic Blood Pressure

(mm Hg)

25Mar04 (Baseline) 79 (Average of all screening/baseline values)

27Apr04 (Week 4) 89 27Apr04 (Week 4) 88

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 25

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 203, USA, 5469

TREATMENT : Desvenlafaxine SR 50 mg

: 203531 , 55 Year old, Female, Black , 84.4 kg , 167.6 cm, 30.0 kg /M^2

THERAPY START DATE/STOP DATE : 25MAR04/ 16DEC04

STUDY COMPLETION STATUS STUDY COMPLETION DATE : Discontinued (Unsatisfactory response - efficacy)

: 17DEC04

(continued from previous page)

MEDICAL MONITOR COMMENTS :

09Jun04	(Week		84
09Jun04	(Week	8)	87
15Jul04	(Week	12	70
15Jul04	(Week	12)	70
17Sep04	(Week	26)	82
17Sep04	(Week		86
17Dec04	(Week	39)	88
17Dec04	(Week	39)	86
30Dec04	(Follo	ow-up)	90
30Dec04	(Follo	w-up)	91

Relevant Medical History: hypertension (since 1989), heart palpitation, obesity, hypercholesterolemia.

Relevant Prior Medications: Norvasc, Lipitor.

Relevant Concomitant Medications: Norvasc, Tricor, Xenical, Lipitor.

Outcome: Hypertension was controlled at baseline and throughout 26 weeks of therapy. At week 39, the subject had a 43-mm Hg increase from baseline in systolic blood pressure that was considered clinically important (>/= 30 mm Hg from baseline with a value >/= 160 mm Hg). At follow-up visit, systolic blood pressure showed signs of returning to an acceptable range, with average systolic blood pressure below 160 mm of Hg. Diastolic blood pressure and heart rate remained normal throughout the course of treatment. The subject discontinued participation because of unsatisfactory response. No further information is available.

Page 26

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-204-201157

INVESTIGATOR: 204, USA, 15818

TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 201157 , 53 Year old, Female, White , 62.7 kg , 160 cm, 24.5 kg /M^2

THERAPY START DATE/STOP DATE : 23MAR04/ 15MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 16MAR05

NARRATIVE REASON: CLINICALLY IMPORTANT VITAL SIGNS

{PCI: ORTHOSTATIC HYPOTENSION}

Visit Date	D.A.I	Vital Sign	Position	Seq Num	Blood Pressure (mm Hg)	Orthostatic Change (mm Hg)
20SEP04	Week 26	DIASTOLIC BP	Supine	1	80	20
20SEP04	Week 26	DIASTOLIC BP	Supine	3	80	20
20SEP04	Week 26	DIASTOLIC BP	standing	4	60	20
20SEP04	Week 26	DIASTOLIC BP	standing	6	68	20
17DEC04	Week 39	DIASTOLIC BP	Supine	1	80	16
17DEC04	Week 39	DIASTOLIC BP	Supine	3	80	16
17DEC04	Week 39	DIASTOLIC BP	standing	4	64	16
17DEC04	Week 39	DIASTOLIC BP	standing	6	68	16

MEDICAL MONITOR COMMENTS :

Relevant Medical History: none.

Relevant Prior Medications: none.

Relevant Concomitant Medications: none.

Outcome: The subject had an episode of orthostatic hypotension, as measured by decreases of 20 mm Hg and 16 mm Hg in diastolic blood pressure from last supine to first standing at week 26 and week 39 of treatment, that was considered clinically important (decrease of >/= 15 mm Hg diastolic blood pressure from last supine to first standing). She did not report associated symptoms. At subsequent visits, blood pressure was normal, including measurements taken during postural changes.

The subject completed the study. The investigator did not report orthostatic hypotension as an adverse event.

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 27

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-204-201168

INVESTIGATOR: 204, USA, 15818

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 201168 , 52 Year old, Fémale, White , 50.5 kg , 154.9 cm, 21.0 kg /M^2

THERAPY START DATE/STOP DATE : 14APR04/ 11AUG04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - HYPERTENSION)

STUDY COMPLETION DATE : 20AUG04

NARRATIVE REASON : DISCONTINUATION DUE TO ADVERSE EVENT

{HYPERTENSION}

AE VERBATIM	BDY SYS		REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT	ACTION	TION INV	A E	TION MM	CASE ID	
Elevated Blood Pressure High blood pressure	CV	Y Y	28 62	31	11MAY04 14JUN04	10JUN04	MIL MOD	RES PER	N P	POSS POSS				_

MEDICAL MONITOR COMMENTS :

Additional Relevant Vital Sign Values:

Date Supine Blood Pressure Value

(mm Hg)

31Mar04-13Apr04(Baseline)	118/79 (Average of all screening/baseline values)
11May04 (Week 4)	138/90
11May04 (Week 4)	145/90
09Jun04 (Week 8)	140/90
09Jun04 (Week 8)	140/90
22Jul04 (Week 12)	124/84
22Jul04 (Week 12)	130/80
20Aug04 (Follow-up)	130/90
20Aug04 (Follow-up)	124/80
20Aug04 (Follow-up)	130/90

Relevant Medical History: none.

Relevant Prior Medications: none.

Relevant Concomitant Medications: none.

Page 28

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 204, USA, 15818

: Desvenlafaxine SR 200 mg

: 201168 , 52 Year old, Female, White , 50.5 kg , 154.9 cm, 21.0 kg /M^2

THERAPY START DATE/STOP DATE : 14APR04/ 11AUG04

STUDY COMPLETION STATUS STUDY COMPLETION DATE : Discontinued (Adverse Event - HYPERTENSION)

: 20AUG04

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Description of Event: The subject had a 27 mm Hg increase in systolic blood pressure beginning 11 May 2004. She did not receive any medication.

Outcome: The subject discontinued from the study because of the adverse event of hypertension. Her blood pressure remained relatively elevated at follow-up compared to baseline values. The investigator initially reported the adverse event as mild in severity and possibly related to test article, but the report was later changed to moderate in severity and still possibly related to test article at last visit and follow-up. No further information is available.

Page 29

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-204-201176

INVESTIGATOR : 204, USA, 15818

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 201176 , 54 Year old, Female, White , 71.3 kg , 175.3 cm, 23.2 kg /M^2

THERAPY START DATE/STOP DATE : 22APR04/ 16SEP04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - SGPT INCREASED)

STUDY COMPLETION DATE : 280CT04

NARRA {SGOT INCREASED}	TIVE REASON : S	ERIOUS	ADVER	SE EVENT	(SAE)							
AE VERBATIM	BDY T SYS E	REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT	ACTION	RELA TION INV	S A E	RELA TION MM	CASE ID
Elevated {SGPT and } SGOT Elevated {SGPT and } SGOT	MN Y MN Y	93 93	152	23JUL04 23JUL04	: 21DEC04	MOD MOD	PER RES	M	PROB PROB	Y Y	POSS	HQWYE6369070CT04 HQWYE6369070CT04
{SGPT INCREASED} AE VERBATIM	BDY T SYS E	REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT COM	ACTION	RELA TION INV	S A E	RELA TION MM	CASE ID
Elevated SGPT {and SGOT} Elevated SGPT {and SGOT}	MN Y MN Y	93 93	152	23JUL04 23JUL04	21DEC04	MOD MOD	PER RES	P W	PROB PROB	Y Y	POSS POSS	HQWYE6369070CT04 HQWYE6369070CT04
NARRATIVE {SGPT INCREASE}	REASON : DISCON	TINUAT	'ION DU	E TO ADVE	RSE EVENT	1						
	REASON: DISCON' BDY T SYS E	TINUAT REL DAY	DURA TION	E TO ADVE ONSET DATE	RSE EVENT STOP DATE	SEV	OUT COM	ACTION	RELA TION INV	S A E	RELA TION MM	CASE ID
{SGPT INCREASE}	BDY T	REL	DURA	ONSET	STOP			ACTION W W	TION	Ā	TION	
{SGPT INCREASE} AE VERBATIM Elevated {SGPT and } SGOT	BDY T SYS E MN Y	REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	COM	W	TION INV PROB PROB	A E Y Y	TION MM POSS POSS	ID HQWYE6369070CT04
{SGPT INCREASE} AE VERBATIM Elevated {SGPT and } SGOT Elevated {SGPT and } SGOT	BDY T SYS E MN Y	REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	COM	W	TION INV PROB	A E Y	TION MM POSS	ID HQWYE6369070CT04

CONFIDENTIAL 708 Wyeth

Page 30

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 204, USA, 15818

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 201176 , 54 Year old, Female, White , 71.3 kg , 175.3 cm, 23.2 kg /M^2

THERAPY START DATE/STOP DATE : 22APR04/ 16SEP04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - SGPT INCREASED) STUDY COMPLETION DATE : 280CT04

(continued from previous page)

Lab Test	Rel. Day (Days)	D.A.I	Test Date	<pre>Test Value (# => PCI)</pre>	Fasting (Y/N)	Range (Low)	Range (High)	Unit	Baseline Value
SGOT/AST	-36	Screening/baseline	17MAR04	25	Yes	0	42	mU/mL	25
SGOT/AST	37	Week 4	28MAY04	22	Yes	0	42	mU/mL	25
SGOT/AST	93	Week 12	23JUL04	224 #	Yes	0	42	mU/mL	25
SGOT/AST	107 152	Week 12	06AUG04	38 177	Yes	0	42	mU/mL	25
SGOT/AST		Week 26	20SEP04		Yes	0	42	mU/mL	25
SGOT/AST SGOT/AST	162 176	Follow-up Follow-up	30SEP04 140CT04	225 # 353 #	Yes Yes	0	42 42	mU/mL mU/mL	25 25
SGOT/AST SGOT/AST	189	Follow-up Follow-up	270CT04	333 # 33	Yes	0	42	mU/mL	25
SGOT/AST SGOT/AST	238	Follow-up Follow-up	15DEC04	25	Yes	0	42	mU/mL	25
Lab Test	Day (Days)	D.A.I	Test Date	Test Value (# => PCI)	Fasting (Y/N)	Range (Low)	Range (High)	Unit	Baselin Value
SGPT/ALT	-36	Screening/baseline	17MAR04	22	Yes	0	48	mU/mL	22
SGPT/ALT	37	Week 4	28MAY04	21	Yes	0	48	mU/mL	22 22
SGPT/ALT	93	Week 12	23JUL04	177	Yes	0	48	mU/mL	22
SGPT/ALT	107	Week 12	06AUG04	57	Yes	0	48	mU/mL	22
SGPT/ALT	152	Week 26	20SEP04	292 #	Yes	0	48	mU/mL	22
SGPT/ALT	162	Follow-up	30SEP04	348 #	Yes	0	48	mU/mL	22
SGPT/ALT	176	Follow-up	140CT04	423 #	Yes	0	48	mU/mL	22
SGPT/ALT SGPT/ALT	189 238	Follow-up	270CT04	53 17	Yes	0	48 48	mU/mL mU/mL	22 22
SGPT / A LT	238	Follow-up	15DEC04	⊥ /	Yes	U	40	IIIO/ML	22

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 31

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 204, USA, 15818

TREATMENT : Desvenlafaxine SR 200 mg

: 201176 , 54 Year old, Female, White , 71.3 kg , 175.3 cm, 23.2 kg /M^2

THERAPY START DATE/STOP DATE : 22APR04/ 16SEP04

STUDY COMPLETION STATUS STUDY COMPLETION DATE : Discontinued (Adverse Event - SGPT INCREASED)

: 280CT04

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Relevant Medical History: none.

Relevant Prior Medication: naproxen.

Relevant Concomitant Medications: naproxen, Phenergan.

Description of Event: At week 12, the subject had an increased AST/SGOT value that was considered clinically important (>/= 5x upper limit of normal). Repeat LFTs were drawn on 06 Aug 2004 and at this time, ALT/SGPT and AST/SGOT were within normal range. At following visits, LFTs increased again and the subject was withdrawn from the study.

Outcome: LFTs normalized after the subject discontinued test article. The event was reported as a serious adverse event (medically important) and considered possibly related to test article by both investigator and medical monitor. The subject's treatment was unblinded.

Page

32

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-204-201171

INVESTIGATOR : 204, USA, 15818

TREATMENT : Desvenlafaxine SR 50 mg

SUBJECT : 201171 , 53 Year old, Female, White , 63.6 kg , 162.6 cm, 24.1 kg /M^2

THERAPY START DATE/STOP DATE : 13APR04/ 05APR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 22APR05

NARRATIVE REASON : ADVERSE EVENTS OF SPECIAL INTEREST

{CHEST PAIN}

RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM Chest pain BO Y 308 61 14FEB05 15APR05 MOD RES S DNOT

MEDICAL MONITOR COMMENTS :

Relevant Medical History: hypertension (stopped September 2003), occasional heartburn.

Relevant Prior Medication: none.

Relevant Concomitant Medication: amoxicillin.

Description of Event: The subject reported an episode of chest pain that resolved within 60 days. The episode was reported as moderate in severity and definitely not related to test article. The subject also reported adverse events of cough, ear infection, and bronchitis during this same time period. She was given amoxicillin, which she took from 28 Feb 2005 to 15 Apr 2005.

Outcome: Per the investigator, it was noted that the chest pain was due to bronchitis and cough that subject had reported at the time of the event.

The subject completed the study.

CONFIDENTIAL 711 Wyeth

Page 33

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-205-201216

INVESTIGATOR: 205, USA, 17086

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 201216 , 55 Year old, Female, White , 62.1 kg , 166.7 cm, 22.3 kg /M^2

THERAPY START DATE/STOP DATE : 18FEB04/ 18FEB04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - HYPERTENSION)

STUDY COMPLETION DATE : 23FEB04

NARRATIVE REASON : DISCONTINUATION DUE TO ADVERSE EVENT

{HYPERTENSION}

BDY T REL DURA ONSET STOP OUT TION A TION CASE
AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM ID

Elevated blood pressure CV Y 1 2 18FEB04 MOD RES P PROB

MEDICAL MONITOR COMMENTS :

Additional Relevant Vital Sign Values:

Date Supine Blood Pressure Value

(mm Hg)

10-18Feb04 (Baseline) 115.5/70.5 (Average of all screening/baseline values)
23Feb04 (Week 4) 114/72
23Feb04 (Week 4) 112/74

Relevant Medical History: hypertension (2002), hypothyroidism (2001).

Relevant Prior Medications: atenolol, hydrochlorothiazide, Synthroid.

Relevant Concomitant Medications: atenolol, hydrochlorothiazide, Synthroid.

Description of Event: The subject discontinued from the study because of hypertension after 1 day of test article administration. At visits, her blood pressure readings were all within normal range. She reported that the increase in blood pressure occurred while she was at home.

Outcome: The investigator reported the adverse event as moderate in severity and probably related to test article.

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 34

REPORT NARR-INF

INVESTIGATOR: 205, USA, 17086

TREATMENT : Desvenlafaxine SR 200 mg
SUBJECT : 201216 , 55 Year old, Female, White , 62.1 kg , 166.7 cm, 22.3 kg /M^2

THERAPY START DATE/STOP DATE : 18FEB04/ 18FEB04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - HYPERTENSION) STUDY COMPLETION DATE : 23FEB04

(continued from previous page)

SUBJECT NARRATIVE INFORMATION

MEDICAL MONITOR COMMENTS :

No further information is available.

Page 35

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-206-201277

INVESTIGATOR: 206, USA, 5491

TREATMENT : Desvenlafaxine SR 100 mg

SUBJECT : 201277 , 58 Year old, Fémale, White , 61.4 kg , 158.8 cm, 24.3 kg /M^2

THERAPY START DATE/STOP DATE : 16MAR04/ 13MAY04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - LIVER FUNCTION TESTS ABNORMAL)

STUDY COMPLETION DATE : 07JUN04

NARRATIVE REASON: DISCONTINUATION DUE TO ADVERSE EVENT

{LIVER FUNCTION TESTS ABNORMAL}

	DDII	m	RET.	מפוזח	OMORE	amon.		OTTE		RELA	S	RELA	OR OF
AE VERBATIM	BDY	T	11111	TION	ONSET	STOP	CET	OUT	ACTION	TION	A	TION	CASE
AL VERBATIM	515	Ľ	DAY	TION	DATE	DATE	SEV	COM	ACTION	INV	Ľ	IAIIAI	ID
Elevated liver enzymes	DI	Y	56		10MAY04		MIL	PER	P	POSS			

MEDICAL MONITOR COMMENTS :

Additional Relevant Lab Values:

ALT (0-42 mU/ml)	AST (0-48 mU/ml)	Bilirubin (0-22.23 mcmol/L)
30	25	11.97
126	39	8.55
103	50	11.97
63	43	6.84
79	37	13.68
55	33	11.97
62	47	6.84
	(0-42 mU/ml) 30 126 103 63 79 55	(0-42 mU/ml) (0-48 mU/ml) 30 25 126 39 103 50 63 43 79 37 55 33

Relevant Medical History: none.

Relevant Prior Medications: none.

Relevant Concomitant Medications: none.

Description of Event: The subject had isolated elevated ALT/SGPT of 126 mU/mL on 12 Apr 2004 that was 3x the upper limit of normal. Repeat LFTs showed that ALT/SGPT improved, but was still elevated and above normal range. AST/SGOT remained within

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 36

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 206, USA, 5491

TREATMENT : Desvenlafaxine SR 100 mg

: 201277 , 58 Year old, Female, White , 61.4 kg , 158.8 cm, 24.3 kg /M^2

THERAPY START DATE/STOP DATE : 16MAR04/ 13MAY04

STUDY COMPLETION STATUS STUDY COMPLETION DATE : Discontinued (Adverse Event - LIVER FUNCTION TESTS ABNORMAL)

: 07JUN04

(continued from previous page)

MEDICAL MONITOR COMMENTS :

normal range. The subject stopped taking test article on 13 May 2004.

Outcome: The subject's ALT/SGPT remained slightly elevated at follow-up (<2x the upper limit of normal). The investigator reported elevated liver enzymes to be mild in severity and possibly related to test article. No further information regarding follow up is available.

Page

37

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-206-201293

INVESTIGATOR: 206, USA, 5491

TREATMENT : Desvenlafaxine SR 100 mg

SUBJECT : 201293 , 51 Year old, Female, White , 64.1 kg , 167.7 cm, 22.8 kg /M^2

THERAPY START DATE/STOP DATE : 12APR04/ 18APR04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - PALPITATION)

STUDY COMPLETION DATE : 19APR04

NARRATIVE REASON : ADVERSE EVENTS OF SPECIAL INTEREST

{CHEST PAIN}

REPORT NARR-INF

BDY T REL DURA ONSET STOP OUT TION A TION CASE
AE VERBATIM

BDY T REL DURA ONSET STOP OUT TION A TION CASE
SYS E DAY TION DATE DATE SEV COM ACTION INV E MM ID

Heavy feeling in chest

BO Y 4 . 15APR04 . MOD PER W POSS

MEDICAL MONITOR COMMENTS :

Relevant Medical History: mitral valve prolapse (1986).

Relevant Prior Medications: none.

Relevant Concomitant Medications: none.

Description of Event: The subject reported an episode of chest pain described as "heavy feeling in chest" on 15 Apr 2004. The episode was reported by the investigator as moderate in severity and possibly related to test article. The subject also reported adverse events of heart palpitations, difficulty swallowing, light-headedness and jaw pain during this same time period.

Outcome: The subject discontinued from the study because of the adverse event of heart palpitations after 6 days of test article. The episode of chest pain was persisting at last visit. The subject was lost to follow-up and had been contacted several times by the investigator, with no success. No further information is available.

CONFIDENTIAL 716 Wyeth

Page 38

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-206-201251

INVESTIGATOR: 206, USA, 5491

TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 201251 , 60 Year old, Female, White , 89.5 kg , 165 cm, 32.9 kg /M^2

THERAPY START DATE/STOP DATE : 17JAN04/ 17AUG04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - SGPT INCREASED)

STUDY COMPLETION DATE : 02SEP04

{SGOT INCREASED}	NARRATIVE REASON	: S	ERIOUS	ADVER	SE EVENT	(SAE)							
AE VERBATIM		Y T S E	REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT COM	ACTION	RELA TION INV	S A E	RELA TION MM	CASE ID
Elevated SGOT Elevated SGOT Elevated SGOT	MN MN	Y Y Y	182 182 182	· 229	16JUL04 16JUL04 16JUL04	01MAR05	SEV SEV SEV	PER PER RES	N W O	POSS POSS POSS	Y	POSS POSS POSS	HQWYE988313SEP04 HQWYE988313SEP04 HQWYE988313SEP04
{SGPT INCREASED} AE VERBATIM		Y T S E	REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT COM	ACTION	RELA TION INV	S A E	RELA TION MM	CASE ID
Elevated SGPT Elevated SGPT Elevated SGPT	MN MN MN	Y Y Y	182 182 182	· 229	16JUL04 16JUL04 16JUL04	01MAR05	SEV SEV SEV	PER PER RES	N P O	POSS POSS POSS	Y	POSS POSS POSS	HQWYE988313SEP04 HQWYE988313SEP04 HQWYE988313SEP04
{SGPT INCREASE}	NARRATIVE REASON : DI	SCON	TINUAT	ION DU	E TO ADVE	RSE EVENT							
AE VERBATIM		Y T S E	REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT COM	ACTION	RELA TION INV	S A E	RELA TION MM	CASE ID
Elevated SGOT Elevated SGOT Elevated SGOT	MN MN	Y Y Y	182 182 182	· 229	16JUL04 16JUL04 16JUL04	01MAR05	SEV SEV SEV	PER PER RES	N W O	POSS POSS POSS	Y	POSS POSS POSS	HQWYE988313SEP04 HQWYE988313SEP04 HQWYE988313SEP04
{SGOT INCREASE}													
AE VERBATIM		Y T S E	REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT COM	ACTION	RELA TION INV	S A E	RELA TION MM	CASE ID
Elevated SGPT	MN	Y	182	•	16JUL04	•	SEV	PER	N	POSS		POSS	HQWYE988313SEP04

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 39

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR : 206, USA, 5491
TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 201251 , 60 Year old, Female, White , 89.5 kg , 165 cm, 32.9 kg /M^2

THERAPY START DATE/STOP DATE : 17JAN04/ 17AUG04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - SGPT INCREASED) STUDY COMPLETION DATE : 02SEP04

(continued from previous page)

Elevated SGPT Elevated SGPT		MN Y 182 . MN Y 182 2	16JUL(29 16JUL(SEV PER SEV RES	P O	POSS POSS Y		E988313SEP04 E988313SEP04
NARF {PCI: SGOT/AST}	ATIVE REA	ASON : CLINICALLY IMPO	RTANT LABOR	RATORY VALUES	5				
Lab Test	Rel. Day (Days)	D.A.I	Test Date	Test Value (# => PCI)	Fasting (Y/N)	Range (Low)	Range (High)	Unit	Baseline Value
SGOT/AST SGOT/AST SGOT/AST SGOT/AST SGOT/AST SGOT/AST SGOT/AST	-9 28 84 182 192 202 230	Screening/baseline Week 4 Week 12 Week 26 Week 26 Week 26 Follow-up	08JAN04 13FEB04 09APR04 16JUL04 26JUL04 05AUG04 02SEP04	17 22 38 262 # 247 # 324 # 1052 #	Yes Yes Yes Yes Yes Yes	0 0 0 0 0	42 42 42 42 42 42 42 42	MU/ML MU/ML MU/ML MU/ML MU/ML MU/ML MU/ML	17 17 17 17 17 17 17
{PCI: SGOT/ALT} Lab Test	Rel. Day (Days)	D.A.I	Test Date	Test Value (# => PCI)	Fasting (Y/N)	Range (Low)	Range (High)	Unit	Baseline Value
SGPT/ALT SGPT/ALT SGPT/ALT SGPT/ALT SGPT/ALT SGPT/ALT SGPT/ALT	-9 28 84 182 192 202 230	Screening/baseline Week 4 Week 12 Week 26 Week 26 Week 26 Follow-up	08JAN04 13FEB04 09APR04 16JUL04 26JUL04 05AUG04 02SEP04	20 21 46 512 # 409 # 557 # 1212 #	Yes Yes Yes Yes Yes Yes	0 0 0 0 0	48 48 48 48 48 48 48	MU/ML MU/ML MU/ML MU/ML MU/ML MU/ML MU/ML MU/ML	20 20 20 20 20 20 20 20
{PCI: TOTAL BILIRUBIN}	Rel. Day (Days)	D.A.I	Test Date	Test Value (# => PCI)	Fasting (Y/N)	Range (Low)	Range (High)	Unit	Baseline Value
TOTAL BILIRUBIN	-9	Screening/baseline	08JAN04	18.81	Yes	0	22.23	mcmol/L	18.81

40

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 206, USA, 5491

TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 201251 , 60 Year old, Female, White , 89.5 kg , 165 cm, 32.9 kg /M^2

THERAPY START DATE/STOP DATE : 17JAN04/ 17AUG04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - SGPT INCREASED)

STUDY COMPLETION DATE : 02SEP04

(continued from previous page)

TOTAL BILIRUBIN TOTAL BILIRUBIN	28 84	Week 4 Week 12	13FEB04 09APR04	15.39 17.1	Yes Yes	0	22.23	mcmol/L mcmol/L	18.81 18.81
TOTAL BILIRUBIN	182	Week 26	16JUL04	18.81	Yes	0	22.23	mcmol/L	18.81
TOTAL BILIRUBIN	192	Week 26	26JUL04	17.1	Yes	0	22.23	mcmol/L	18.81
TOTAL BILIRUBIN	202	Week 26	05AUG04	18.81	Yes	0	22.23	mcmol/L	18.81
TOTAL BILIRUBIN	230	Follow-up	02SEP04	46.17 #	Yes	0	22.23	mcmol/L	18.81
TOTAL BILIRUBIN	242	Follow-up	14SEP04	275.31		Ω	22.23	mcmol/L	18.81

MEDICAL MONITOR COMMENTS :

Relevant Medical History: hepatitis (1971), obesity.

Relevant Prior Medication: Macrobid (since 2002).

Relevant Concomitant Medications: Macrobid, albuterol.

Description of Event: At week 26, the subject had an elevated ALT/SGPT of 512 mU/mL and AST/SGOT of 262 mU/mL that were considered clinically important (>/= 5x upper limit of normal). Two (2) consecutive repeat LFTs, drawn on 26 Jul 2004 and 05 Aug 2004, showed a progressive increase in LFTs (ALT/SGPT 557 mU/mL and AST/SGOT 324 mU/mL). At this time, it was decided that the subject stop taking test article. The increase in LFTs was considered medically important and reported as a serious adverse event.

After discontinuation of test article, LFTs continued to increase into the thousand range associated with elevated bilirubin, suggesting possible cholestasis component. A hepatitis panel drawn on 02 Sep 2004 and a liver ultrasound study performed on 10 Sep 2004 were normal.

On 14 Sep 2004, the subject started to develop jaundice with complaints of extreme fatigue, nausea, and vomiting. She was sent for gastrointestinal consultation and a computed tomography scan of the liver, chest radiography, and additional blood work were ordered. Based on the subject's medical history and test results, the increase in LFTs was considered possibly a drug hepatotoxicity either from test article or from Macrobid or from a combination of the 2 medications. Based on positivity of antinuclear antibodies (ANA) and anti-smooth muscle antibodies, an autoimmune hepatitis was also considered. Prednisone

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 41

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 206, USA, 5491

TREATMENT : Desvenlafaxine SR 150 mg

: 201251 , 60 Year old, Female, White , 89.5 kg , 165 cm, 32.9 kg /M^2

THERAPY START DATE/STOP DATE : 17JAN04/ 17AUG04

: Discontinued (Adverse Event - SGPT INCREASED)

STUDY COMPLETION STATUS STUDY COMPLETION DATE : 02SEP04

(continued from previous page)

MEDICAL MONITOR COMMENTS :

(40 mg) was prescribed on 27 Sep 2004, and the subject started feeling better. However, follow-up laboratory evaluation showed no improvement in liver enzymes, and the subject was consulted for the possibility of liver transplant on 07 Oct 2004.

On 04 Oct 2004, the subject's liver tests started to improve. She was closely monitored with weekly lab tests while continuing to take prednisone. On 09 Dec 2004, prednisone was decreased to 10 mg daily. On 04 Jan 2005, her liver tests continued to improve, and prednisone was decreased to 5 mg daily for the remaining 2 weeks, and then stopped.

During follow-up, the subject developed polycythemia of unclear etiology, which was evaluated by a hematologist. On 18 Feb 2005, a colonoscopy was performed because of hemoccult-positive stools from previous visits. The subject was found to have small internal hemorrhoids. An esophagogastroduodenoscopy was also performed on the same day; it demonstrated mild antral gastritis and a small hiatal hernia. The subject's hepatotoxicity continued to improve with normalization of her liver enzymes on 01 Mar 2005.

Outcome: The subject was never hospitalized, but the event was considered medically important and possibly related to test article by both the investigator and medical monitor. The medical monitor also considered the event possibly related to Macrobid. Final diagnosis was acute cholestatic hepatitis possibly related to test article, and/or to Macrobid, and/or of autoimmune origin.

Page

42

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-206-201271

INVESTIGATOR: 206, USA, 5491

TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 201271 , 55 Year old, Female, White , 73.6 kg , 158.6 cm, 29.3 kg /M^2

THERAPY START DATE/STOP DATE : 06MAR04/ 10JAN05

STUDY COMPLETION STATUS : Discontinued (Adverse Event - MYOCARDIAL INFARCT)

STUDY COMPLETION DATE : 21JAN05

NARRATIVE REASON : SERIOUS ADVERSE EVENT (SAE)

{MYOCARDIAL INFARCT}

RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY DATE SEV COM ACTION INV E MM Myocardial infarction CV Y 294 -5 24DEC04 28DEC04 SEV RES H P PNOT Y PNOT HOWYE663417JAN05

MEDICAL MONITOR COMMENTS :

Relevant Medical History: smoking, hypertension (1982), overweight, hyperlipidemia.

Relevant Prior Medication: lisinopril.

Relevant Concomitant Medications: lisinopril, metoprolol, aspirin, Crestor, Plavix, nitroglycerin, Imdur.

Description of Event: The subject was admitted to the hospital on 24 Dec 2004 for an episode of chest pain. Her CPKs and troponins were positive for acute myocardial infarction. The subject's initial ECG did show 1-mm ST segment depression in the inferior leads, which resolved with IV nitroglycerin therapy and beta-blocker. The subject was found to have elevated blood pressures (220/120 mm Hg). She was treated with labetalol and IV morphine sulfate. On 27 Dec 2004, the subject underwent a

successful percutaneous transluminal coronary angioplasty (PTCA) with implantation of 2 Cypher stents to the obtuse marginal coronary artery. On the following day, she was free from any significant chest pain and shortness of breath. Telemetry monitor showed sinus rhythm with no significant arrhythmias. The subject's blood pressure was stable and ranged between 108/55 mm Hg and 136/74 mm Hg.

Outcome: The subject was discharged from hospital 28 Dec 2004. Final diagnosis was acute myocardial infarction. The event was considered probably not related to test article by both the investigator and medical monitor and considered to be caused by the subject's medical history of hypertension, hyperlipidemia, and tobacco use. The subject discontinued from the study because of the adverse event.

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 43

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-206-201297

INVESTIGATOR: 206, USA, 5491

TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 201297 , 54 Year old, Female, White , 60.5 kg , 164.3 cm, 22.4 kg /M^2

THERAPY START DATE/STOP DATE : 23APR04/ 02FEB05

STUDY COMPLETION STATUS : Discontinued (Adverse Event - WEIGHT GAIN)

STUDY COMPLETION DATE : 02FEB05

NARRATIVE REASON: ADVERSE EVENTS OF SPECIAL INTEREST {CHEST PAIN} RELA S RELA CASE BDY T REL DURA ONSET STOP OUT TION A TION AE VERBATIM SYS E DAY TION DATE DATE COM ACTION INV E MM Chest pressure BO Y 135 04SEP04 04SEP04 MIL RES N PNOT Chest pressure BO Y 181 200CT04 200CT04 MIL RES N PNOT NARRATIVE REASON : CLINICALLY IMPORTANT VITAL SIGNS {PCI: SYSTOLIC BLOOD PRESSURE} Visit Seq Test Value Baseline Vital Sign Position Date D.A.I (# => PCI) Unit Value SYSTOLIC BP Supine 26MAR04 Screening/baseline 128 mm Hg SYSTOLIC BP Supine 26MAR04 Screening/baseline 122 mm Hg 128 Screening/baseline SYSTOLIC BP Supine 22APR04 130 mm Ha 128 SYSTOLIC BP Supine 22APR04 Screening/baseline 132 mm Hq 128 SYSTOLIC BP Supine 20MAY04 Week 4 144 mm Hq 128 SYSTOLIC BP Supine 20MAY04 Week 4 142 mm Ha 128 SYSTOLIC BP Supine 17JUN04 Week 8 140 mm Hq 128 17JUN04 SYSTOLIC BP Supine Week 8 138 mm Hq 128 SYSTOLIC BP Supine 14JUL04 Week 12 150 mm Ha 128 SYSTOLIC BP Supine 14JUL04 Week 12 148 mm Hq 128 Supine 280CT04 SYSTOLIC BP Week 26 162 # mm Hq 128 SYSTOLIC BP Supine 280CT04 Week 26 152 mm Hq 128 SYSTOLIC BP Supine 13JAN05 Week 39 124 mm Hq 128 130 128 SYSTOLIC BP Supine 13JAN05 Week 39 mm Hq SYSTOLIC BP Supine 02FEB05 Week 39 178 # mm Ha 128 SYSTOLIC BP Supine 02FEB05 Week 39 mm Hq {PCI: DIASTOLIC BLOOD PRESSURE} Visit Seq Test Value Baseline (# => PCI) Vital Sign Position Date D.A.I Num Unit Value DIASTOLIC BP Supine 26MAR04 Screening/baseline 90 mm Hq 82.5

CONFIDENTIAL 722 Wyeth

Page

44

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 206, USA, 5491

: Desvenlafaxine SR 150 mg

: 201297 , 54 Year old, Female, White , 60.5 kg , 164.3 cm, 22.4 kg /M^2

THERAPY START DATE/STOP DATE : 23APR04/ 02FEB05

STUDY COMPLETION STATUS STUDY COMPLETION DATE : Discontinued (Adverse Event - WEIGHT GAIN)

: 02FEB05

(continued from previous page)

DIASTOLIC BP	Supine	26MAR04	Screening/baseline	3	86	mm Hq	82.5
DIASTOLIC BP	Supine	22APR04	Screening/baseline	1	78	mm Hg	82.5
DIASTOLIC BP	Supine	22APR04	Screening/baseline	3	76	mm Hq	82.5
DIASTOLIC BP	Supine	20MAY04	Week 4	1	82	mm Hg	82.5
DIASTOLIC BP	Supine	20MAY04	Week 4	3	84	mm Hq	82.5
DIASTOLIC BP	Supine	17JUN04	Week 8	1	90	mm Hg	82.5
DIASTOLIC BP	Supine	17JUN04	Week 8	3	90	mm Hg	82.5
DIASTOLIC BP	Supine	14JUL04	Week 12	1	88	mm Hg	82.5
DIASTOLIC BP	Supine	14JUL04	Week 12	3	86	mm Hg	82.5
DIASTOLIC BP	Supine	280CT04	Week 26	1	86	mm Hg	82.5
DIASTOLIC BP	Supine	280CT04	Week 26	3	86	mm Hg	82.5
DIASTOLIC BP	Supine	13JAN05	Week 39	1	94	mm Hg	82.5
DIASTOLIC BP	Supine	13JAN05	Week 39	3	92	mm Hg	82.5
DIASTOLIC BP	Supine	02FEB05	Week 39	1	114 #	mm Hg	82.5
DIASTOLIC BP	Supine	02FEB05	Week 39	3	108 #	mm Hg	82.5

MEDICAL MONITOR COMMENTS :

Relevant Medical History: none.

Relevant Prior Medication: aspirin.

Relevant Concomitant Medication: spirin.

Description of Event: At week 26, the subject had a 34-mm Hg increase from baseline and 2 episodes at week 39 of 50-mm Hg and 53-mm Hg increases from baseline, in systolic blood pressure, as well as an increase from baseline of 31.5 mm Hg and 25.5 mm Hg in diastolic blood pressure (at week 39) that was considered clinically important (increase from baseline of systolic blood pressure >/= 30 mm Hg with a value >/= 160 mm Hg and/or increase from baseline of diastolic blood pressure >/= 20 mm Hg with a value >/= 100 mm Hg). At previous visits, both systolic and diastolic blood pressures remained within normal range. The subject did not receive any antihypertensive medication.

The subject also reported 2 episodes of chest pain described as "chest pressure," mild in severity, that spontaneously

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 45

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 206, USA, 5491

: Desvenlafaxine SR 150 mg

: 201297 , 54 Year old, Female, White , 60.5 kg , 164.3 cm, 22.4 kg /M^2

THERAPY START DATE/STOP DATE : 23APR04/ 02FEB05

STUDY COMPLETION STATUS STUDY COMPLETION DATE : Discontinued (Adverse Event - WEIGHT GAIN)

: 02FEB05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

resolved within 1 day.

Outcome: Hypertension was reported as an adverse event, mild in severity and possibly related to test article. The subject was referred by the investigator to follow-up with her primary care physician, but she was reluctant to go. The "chest pressure" was found to be noncardiac related and secondary to an anxiety attack. The subject discontinued from the study because of weight gain. No further information is available.

Page

46

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-206-201254

INVESTIGATOR: 206, USA, 5491

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 201254 , 52 Year old, Female, White , 64.1 kg , 158 cm, 25.7 kg /M^2

THERAPY START DATE/STOP DATE : 12FEB04/ 09MAY04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - HYPERTENSION)

STUDY COMPLETION DATE : 10MAY04

NARRATIVE REASON : DISCONTINUATION DUE TO ADVERSE EVENT

{HYPERTENSION}

BDY T REL DURA ONSET STOP OUT TION A TION CASE
AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM ID

Increase in blood pressure CV Y 30 88 12MAR04 07JUN04 MIL RES P POSS

NARRATIVE REASON : CLINICALLY IMPORTANT VITAL SIGNS

{PCI: SYSTOLIC BLOOD PRESSURE}

Visit Seq Test Value Baseline Vital Sign Position Date D.A.I Num (# => PCI) Unit Value Supine Screening/baseline 115.25 SYSTOLIC BP 15JAN04 mm Ha 115 SYSTOLIC BP Supine 15JAN04 Screening/baseline mm Ha 115.25 SYSTOLIC BP Supine 11FEB04 Screening/baseline 116 mm Hq 115.25 SYSTOLIC BP Supine 11FEB04 Screening/baseline 112 mm Ha 115.25 Supine SYSTOLIC BP 11MAR04 140 mm Hq 115.25 138 115.25 SYSTOLIC BP Supine 11MAR04 Week 4 mm Hq Supine SYSTOLIC BP 08APR04 Week 8 150 mm Ha 115.25 152 SYSTOLIC BP Supine 08APR04 Week 8 mm Hq 115.25 SYSTOLIC BP Supine 10MAY04 Follow-up 166 # mm Hq 115.25 SYSTOLIC BP Supine 10MAY04 Follow-up 164 # mm Ha 115.25 Follow-up SYSTOLIC BP Supine 07JUN04 127 mm Hq 115.25 07JUN04 Follow-up SYSTOLIC BP Supine mm Hq 115.25

 ${\tt MEDICAL}$ MONITOR COMMENTS :

Additional Relevant Vital Sign Values:

Date Supine Diastolic BP value (mm Hq)

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 47

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 206, USA, 5491

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 201254 , 52 Year old, Female, White , 64.1 kg , 158 cm, 25.7 kg /M^2

THERAPY START DATE/STOP DATE : 12FEB04/ 09MAY04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - HYPERTENSION)

STUDY COMPLETION DATE : 10MAY04

(continued from previous page)

MEDICAL MONITOR COMMENTS :

15Jan04-11Feb04 (Baseline) 71.5 (Average of all screening/baseline values) 11Mar04 (Week 4) 11Mar04 (Week 4) 82 08Apr04 (Week 8) 86 08Apr04 (Week 8) 86 10May04 (Week 12) 10May04 (Week 12) 92 07Jun04 (Follow-up) 84 07Jun04 (Follow-up) 82

Relevant Medical History: overweight, tachycardia (2002).

Relevant Prior Medication: Toprol.

Relevant Concomitant Medication: Toprol.

Description of Event: The subject had a progressive increase in blood pressure from baseline. At week 12, she had a 50.75-mm Hg and a 48.75-mm Hg increase in systolic blood pressure that were considered clinically important (increase from baseline of systolic blood pressure >/=30 mm Hg with a value >/=160 mm Hg). Diastolic blood pressure remained within normal range throughout the course of treatment.

Outcome: The subject discontinued from study because of hypertension. Her systolic blood pressure at follow-up visit was within normal range. Hypertension was reported as mild in severity and possibly related to test article.

No further information is available.

Page 48

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-206-201285

INVESTIGATOR: 206, USA, 5491

TREATMENT : Placebo

: 201285 , 73 Year old, Female, White , 65 kg , 161 cm, 25.1 kg /M^2 SUBJECT

THERAPY START DATE/STOP DATE : 20MAR04/ 23APR04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - INSOMNIA) STUDY COMPLETION DATE : 26APR04

NARRATIVE REASON : CLINICALLY IMPORTANT VITAL SIGNS (PCT - SYSTOTIC BLOOD PRESSURE)

(PCI: SISTULIC BI	TOOD LKESSOKE)	772 2 2 4		0	m+ 17-1		Danalina	
Vital Sign	Position	Visit Date	D.A.I	Seq Num	Test Value (# => PCI)	Unit	Baseline Value	
SYSTOLIC BP	Supine	04MAR04	Screening/baseline	1	130	mm Hq	139.5	
SYSTOLIC BP	Supine	04MAR04	Screening/baseline	3	130	mm Hq	139.5	
SYSTOLIC BP	Supine	19MAR04	Screening/baseline	1	148	mm Ha	139.5	
SYSTOLIC BP	Supine	19MAR04	Screening/baseline	3	150	mm Ha	139.5	
SYSTOLIC BP	Supine	16APR04	Week 4	1	160	mm Ha	139.5	
SYSTOLIC BP	Supine	16APR04	Week 4	3	170 #	mm Ha	139.5	
SYSTOLIC BP	Supine	26APR04	Follow-up	1	138	mm Ha	139.5	
SYSTOLIC BP	Supine	26APR04	Follow-up	3	140	mm Ha	139.5	

MEDICAL MONITOR COMMENTS :

Additional Relevant Vital Sign Values:

Supine Diastolic BP value

(mm Hg)

04-19Mar04(Baseline)	78	(Average	of	all	screening/baseline	values)
16Apr04(Week 4)	86	=			-	
16Apr04(Week 4)	88					
26Apr04(Follow-up)	84					
26Apr04(Follow-up)	86					

Relevant Medical History: overweight, hypothyroidism (since 2002).

Relevant Prior Medication: Levoxyl.

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 49

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 206, USA, 5491

TREATMENT : Placebo

: 201285 , 73 Year old, Female, White , 65 kg , 161 cm, 25.1 kg /M^2

THERAPY START DATE/STOP DATE : 20MAR04/ 23APR04

STUDY COMPLETION STATUS STUDY COMPLETION DATE : Discontinued (Adverse Event - INSOMNIA)

: 26APR04

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Relevant Concomitant Medication: Levoxyl.

Outcome: At week 4, the subject had a 30.5-mm Hg increase from baseline in systolic blood pressure that was considered clinically important (>= 30 mm Hg from baseline with value >/= 160 mm Hg). At the subsequent visit, systolic blood pressure remained within normal range. Diastolic blood pressure also remained within normal range throughout the course of treatment. The subject discontinued from the study because of insomnia. The investigator did not report the increase in systolic blood pressure as an adverse event.

Page

50

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-207-201303

INVESTIGATOR : 207, USA, 28890

TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 201303 , 49 Year old, Female, White , 60.9 kg , 165.5 cm, 22.2 kg /M^2

THERAPY START DATE/STOP DATE : 06JAN04/ 09JAN05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 10JAN05

NARRATIVE REASON: ADVERSE EVENTS OF SPECIAL INTEREST

{HOSTILITY}

AE VERBATIM	BDY SYS		REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT	ACTION	RELA TION INV	RELA TION MM	CASE ID
Aggressiveness Irritable	NE NE	N N	378 380	5	17JAN05 19JAN05	23JAN05	MOD MOD	PER RES		PNOT PNOT		

MEDICAL MONITOR COMMENTS :

Relevant Medical History: none.

Relevant Prior Medications: none.

Relevant Concomitant Medications: none.

Description of Event: The subject reported experiencing an episode of hostility, described as "aggressiveness" beginning 8 days after discontinuing test article, and persisting at follow-up. In addition, she also reported adverse event of feeling irritable, which spontaneously resolved in 5 days.

Outcome: The subject completed the study. The aggressiveness occurred after discontinuation of test article. No medication was administered. The investigator reported the adverse event as moderate in severity and probably not related to test article. No further information is available.

CONFIDENTIAL 729 Wyeth

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 51

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-207-201316

INVESTIGATOR: 207, USA, 28890

TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 201316 , 54 Year old, Female, White , 70.5 kg , 165.1 cm, 25.9 kg /M^2

THERAPY START DATE/STOP DATE : 24FEB04/ 18MAR04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - HYPERTENSION)

STUDY COMPLETION DATE : 23MAR04

NARRATIVE REASON : DISCONTINUATION DUE TO ADVERSE EVENT

{HYPERTENSION}

RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM Elevated blood pressure CV Y 5 28FEB04 20MAR04 SEV RES P POSS

MEDICAL MONITOR COMMENTS :

Additional Relevant Vital Sign Values:

Date Supine Blood Pressure Value (mm Hg)

(mm rig)

16-24Feb04 (Baseline) 116/81 (Average of all screening/baseline values)

23Mar04 (Week 4) 120/78 23Mar04 (Week 4) 118/76

Relevant Medical History: overweight, hypertension (since 1997).

Relevant Prior Medication: hydrochlorothiazide.

Relevant Concomitant Medication: hydrochlorothiazide.

Description of Event: The subject discontinued from the study because of elevated blood pressure. At visits, her blood pressure readings were all within normal range. She reported that the increase in blood pressure occurred while she was at home.

Page 52

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 207, USA, 28890

REPORT NARR-INF

: Desvenlafaxine SR 150 mg

: 201316 , 54 Year old, Female, White , 70.5 kg , 165.1 cm, 25.9 kg /M^2

THERAPY START DATE/STOP DATE : 24FEB04/ 18MAR04

STUDY COMPLETION STATUS STUDY COMPLETION DATE : Discontinued (Adverse Event - HYPERTENSION)

: 23MAR04

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Outcome: The subject discontinued from the study because of the adverse event of "elevated blood pressure." The investigator reported the adverse event as severe and possibly related to test article. The subject's blood pressure reading was within normal range at last visit, 5 days after last dose of test article. She refused to have a follow-up visit. No further information is available.

Page

53

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-207-201309

INVESTIGATOR: 207, USA, 28890

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 201309 , 50 Year old, Female, White , 81.4 kg , 157 cm, 33.0 kg /M^2

THERAPY START DATE/STOP DATE : 05FEB04/ 05FEB04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - HYPERTENSION)

STUDY COMPLETION DATE : 12FEB04

NARRATIVE REASON : DISCONTINUATION DUE TO ADVERSE EVENT

{HYPERTENSION}

RELA S RELA
BDY T REL DURA ONSET STOP OUT TION A TION CASE
AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM ID

Hypertension CV Y 2 3 06FEB04 MOD RES P PROB

MEDICAL MONITOR COMMENTS :

Additional Relevant Vital Sign Values:

Date Supine Blood Pressure Value

(mm Hq)

22Jan04-05Feb04 (Baseline) 127/85 (Average of all screening/baseline values)

12Feb04 (Week 4) 128/80 12Feb04 (Week 4) 130/78

Relevant Medical History: overweight, hyperlipemia (since 2002).

Relevant Prior Medication: atorvastatin.

Relevant Concomitant Medication: atorvastatin.

Description of Event: The subject discontinued from the study because of hypertension. After first dose of test article, she reported feeling dizzy and light-headed. The subject was a nurse and took her own blood pressure readings at home, at which time she reported an increase in blood pressure. At visits, her blood pressure readings were all within normal range.

Outcome: The subject discontinued from study because of hypertension. The investigator reported the adverse event as moderate

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 54

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 207, USA, 28890

TREATMENT : Desvenlafaxine SR 200 mg

: 201309 , 50 Year old, Female, White , 81.4 kg , 157 cm, 33.0 kg /M^2

THERAPY START DATE/STOP DATE : 05FEB04/ 05FEB04

: Discontinued (Adverse Event - HYPERTENSION) STUDY COMPLETION STATUS STUDY COMPLETION DATE

: 12FEB04

(continued from previous page)

MEDICAL MONITOR COMMENTS :

in severity and probably related to test article. The subject's blood pressure reading was within normal range at last visit, 7 days after last dose of test article.

Page 55

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-207-201313

INVESTIGATOR: 207, USA, 28890

TREATMENT : Desvenlafaxine SR 50 mg

SUBJECT : 201313 , 51 Year old, Female, White , 50.5 kg , 166.4 cm, 18.2 kg /M^2

THERAPY START DATE/STOP DATE : 11FEB04/ 09FEB05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 24FEB05

NARRATIVE REASON: ADVERSE EVENTS OF SPECIAL INTEREST

{OVERDOSE}
Comment

(not collected in database, but considered as reportable

overdose information)

MEDICAL MONITOR COMMENTS :

Relevant Medical History: none.

Relevant Prior Medications: none.

Relevant Concomitant Medications: none.

Description of Event: The subject elected to take double the amount of test article on 3 separate occasions (20 May 2004, 22 Jun 2004 and 28 Jun 2004) after missing a dose 1 day before each event. No associated symptoms were reported.

Outcome: The subject was not compliant with study medication schedule. Both investigator and medical monitor reported the event as non serious and not related to test article. No adverse event was reported for each event. The subject completed the study.

Page 56

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION 315-207-201317

INVESTIGATOR: 207, USA, 28890 TREATMENT : Placebo

: 201317 , 50 Year old, Female, White , 64.1 kg , 161.9 cm, 24.5 kg /M^2 SUBJECT

THERAPY START DATE/STOP DATE : 26MAR04/ 13OCT04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - INSOMNIA) STUDY COMPLETION DATE : 140CT04

NARRATIVE REASON : CLINICALLY IMPORTANT LABORATORY VALUES

{PCI: SGOT/AST}

Lab Test	Rel. Day (Days)	D.A.I	Test Date	Test Value (# => PCI)	Fasting (Y/N)	Range (Low)	Range (High)	Unit	Baseline Value
SGOT/AST	-8	Screening/baseline	18MAR04	28	Yes	0	42	mU/mL	28
SGOT/AST	33	Week 4	27APR04	219 #	Yes	0	42	mU/mL	28
SGOT/AST	36	Week 4	30APR04	61		0	42	mU/mL	28
SGOT/AST	62	Week 8	26MAY04	24		0	42	mU/mL	28
SGOT/AST	91	Week 12	24JUN04	24	Yes	0	42	mU/mL	28
SGOT/AST	203	Week 26	140CT04	23	Yes	0	42	mU/mL	28

MEDICAL MONITOR COMMENTS :

Additional Relevant Lab Values:

Date	ALT (0-48 mU/ml)	Total Bilirubin (0-22.23 mcmol/L)
18Mar04 (Baseline)	15	0.4
27Apr04(Week 4)	79	0.3
30Apr04 (Week 4)	49	ND
26May04 (Week 8)	11	ND
24Jun04 (Week 12)	14	0.4
140ct04 (Week 26)	12	0.6

Relevant Medical History: none.

Relevant Prior Medications: none.

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 57

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 207, USA, 28890

TREATMENT : Placebo

: 201317 , 50 Year old, Female, White , 64.1 kg , 161.9 cm, 24.5 kg /M^2

THERAPY START DATE/STOP DATE : 26MAR04/ 13OCT04

: Discontinued (Adverse Event - INSOMNIA) STUDY COMPLETION STATUS STUDY COMPLETION DATE

: 140CT04

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Relevant Concomitant Medications: none.

Outcome: At week 4 of treatment, the subject's AST/SGOT was elevated and considered clinically important (AST/SGOT = 5x upper limit of normal). On 30 Apr 2004, AST/SGOT had returned to values below 2x upper limit of normal (AST/SGOT = 1.4x upper limit of normal). At all following visits, her LFTs remained within normal range.

The investigator reported elevated liver function tests as moderate in severity and possibly related to test article. The subject discontinued from the study because of insomnia.

58

78.5

mm Hq

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-208-201359

INVESTIGATOR: 208, USA, 5125

TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 201359 , 47 Year old, Female, Black , 63.5 kg , 157.9 cm, 25.5 kg /M^2

THERAPY START DATE/STOP DATE : 22APR04/ 20OCT04

Supine

STUDY COMPLETION STATUS : Discontinued (Adverse Event - OVERDOSE)

STUDY COMPLETION DATE : 270CT04

NARRATIVE REASON : SERIOUS ADVERSE EVENT (SAE)

{OVERDOSE}

RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY TION DATE DATE COM ACTION INV E MM

Drug overdose BO Y 91 14 21JUL04 03AUG04 SEV RES P DNOT Y PNOT HQWYE488817NOV04

NARRATIVE REASON : CLINICALLY IMPORTANT VITAL SIGNS

270CT04

{PCI: DIASTOLIC BLOOD PRESSURE} Visit Seq Test Value Baseline Vital Sign Position Date D.A.I Num (# => PCI) Unit Value DIASTOLIC BP Supine 24MAR04 Screening/baseline mm Ha 78.5 DIASTOLIC BP Supine 24MAR04 Screening/baseline 78 mm Hq 78.5 DIASTOLIC BP 22APR04 Screening/baseline 78 mm Hq 78.5

Supine DIASTOLIC BP Supine 22APR04 Screening/baseline 80 mm Ha 78.5 DIASTOLIC BP Supine 17MAY04 78 mm Ha 78.5 DIASTOLIC BP Supine 17MAY04 Week 4 76 mm Hg 78.5 Supine DIASTOLIC BP 17JUN04 Week 8 88 mm Ha 78.5 78.5 DIASTOLIC BP Supine 17JUN04 Week 8 78 mm Hq DIASTOLIC BP Supine 21JUL04 Week 12 110 # mm Hq 78.5 DIASTOLIC BP Supine 21JUL04 Week 12 100 # mm Ha 78.5 DIASTOLIC BP Supine 270CT04 Follow-up mm Hq 78.5

Follow-up

SYSTOLIC BP

{PCI: ORTHOSTATIC HYPOTENSION}

Week 8

DIASTOLIC BP

17JUN04

Blood Orthostatic Visit Seq Pressure Change Date D.A.I Vital Sign Position Num (mm Hg) (mm Hq) 17JUN04 Week 8 SYSTOLIC BP Supine 3 122 30 17JUN04 Week 8 SYSTOLIC BP Supine

92

30

standing

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 59 REPORT NARR-INF SUBJECT NARRATIVE INFORMATION INVESTIGATOR: 208, USA, 5125 TREATMENT : Desvenlafaxine SR 150 mg : 201359 , 47 Year old, Female, Black , 63.5 kg , 157.9 cm, 25.5 kg /M^2 THERAPY START DATE/STOP DATE : 22APR04/ 20OCT04 STUDY COMPLETION STATUS : Discontinued (Adverse Event - OVERDOSE) STUDY COMPLETION DATE : 270CT04 (continued from previous page) 17JUN04 Week 8 SYSTOLIC BP standing 6 94 30 20 21JUL04 Week 12 DIASTOLIC BP Supine 110 Week 12 21JUL04 DIASTOLIC BP Supine 100 20 21JUL04 Week 12 DIASTOLIC BP standing 80 20 21JUL04 Week 12 DIASTOLIC BP standing 82 20 MEDICAL MONITOR COMMENTS : Additional Relevant Vital Sign Values: Date Supine Diastolic BP value (mm Hg) 24Mar04-22Apr04 (Baseline) 124 (Average of all screening/baseline values) 17May04 (Week 4) 130 17May04 (Week 4) 128 17Jun04 (Week 8) 122 122 17Jun04 (Week 8) 21Jul04 (Week 12) 130 128 21Jul04 (Week 12) 27Oct04 (Follow-up) 118 270ct04 (Follow-up) 118 Relevant Medical History: overweight. Relevant Prior Medications: none.

Description of Event: The subject elected to take double the amount of test article for 14 consecutive days from 21 Jul 2004

Relevant Concomitant Medications: none.

CONFIDENTIAL 738 Wyeth

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 60

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 208, USA, 5125

TREATMENT : Desvenlafaxine SR 150 mg

: 201359 , 47 Year old, Female, Black , 63.5 kg , 157.9 cm, 25.5 kg /M^2

THERAPY START DATE/STOP DATE : 22APR04/ 20OCT04

STUDY COMPLETION STATUS STUDY COMPLETION DATE : Discontinued (Adverse Event - OVERDOSE)

: 270CT04

(continued from previous page)

MEDICAL MONITOR COMMENTS :

to 03 Aug 2004. She took test article during the day and also in the evening for 2 weeks. No associated symptoms were reported.

At week 12 of treatment, the subject had 31.5-mm Hg and 21.5-mm Hg increases from baseline in diastolic blood pressure that were considered clinically important (>/= 20 mm Hg from baseline with value >/= 100 mm Hg). At all other visits, diastolic blood pressure remained within normal range. Systolic blood pressures were normal throughout the course of treatment. The investigator did not report increase in diastolic blood pressure as an adverse event.

At weeks 8 and 12 of treatment, the subject also experienced episodes of orthostatic hypotension, as measured by a decrease of 30 mm Hg systolic blood pressure from last supine to first standing, as well as a decrease of 20 mm Hg diastolic blood pressure from last supine to first standing. The subject did not report associated symptoms. The investigator did not report orthostatic hypotension as an adverse event.

Outcome: The subject discontinued from the study because of overdose. She was not compliant with study medication schedule. Both the investigator and medical monitor reported the adverse event as nonserious and not related to test article.

Page

61

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-208-201364

INVESTIGATOR : 208, USA, 5125

TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 201364 , 59 Year old, Female, White , 64 kg , 159.4 cm, 25.2 kg /M^2

THERAPY START DATE/STOP DATE : 06APR04/ 28MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 29MAR05

NARRATIVE REASON : CLINICALLY IMPORTANT VITAL SIGNS

{PCI: ORTHOSTATIC HYPOTENSION}

Visit Date	D.A.I	Vital Sign	Position	Seq Num	Blood Pressure (mm Hg)	Orthostatic Change (mm Hg)
27APR04	Week 4	DIASTOLIC BP	Supine	1	98	20
27APR04	Week 4	DIASTOLIC BP	Supine	3	98	20
27APR04	Week 4	DIASTOLIC BP	standing	4	78	20
27APR04	Week 4	DIASTOLIC BP	standing	6	78	20

MEDICAL MONITOR COMMENTS :

Relevant Medical History: overweight, hypertension (since 1993), mitral valve prolapse.

Relevant Prior Medication: lisinopril/hydrochlorothiazide.

Relevant Concomitant Medication: lisinopril/hydrochlorothiazide.

Outcome: The subject experienced an episode of orthostatic hypotension, as measured by a decrease of 20 mm Hg diastolic blood pressure from last supine to first standing at week 4 of treatment, that was considered clinically important (decrease of >/=15 mm Hg diastolic blood pressure from last supine to first standing). She did not report associated symptoms. At subsequent visits, blood pressure was normal, including during postural changes.

The subject completed the study. The investigator did not report orthostatic hypotension as an adverse event.

CONFIDENTIAL 740 Wyeth

Page

62

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-208-201372

INVESTIGATOR: 208, USA, 5125

REPORT NARR-INF

TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 201372 , 50 Year old, Fémale, Black , 80.1 kg , 162.2 cm, 30.4 kg /M 2

THERAPY START DATE/STOP DATE : 23APR04/ 18JUL04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - CARDIOVASCULAR DISORDER)

STUDY COMPLETION DATE : 12AUG04

NARRATIVE REASON: SERIOUS ADVERSE EVENT (SAE) {CARDIOVASCULAR DISORDER} RELA S RELA CASE BDY T REL DURA ONSET STOP OUT TION A TION AE VERBATIM SYS E DAY DATE SEV COM ACTION Coronary heart disease CV N -144 01DEC03 PER S H P PNOT Y PNOT HQWYE367822JUL04 Coronary heart disease CV N -144 . 01DEC03 SEV PER S W PNOT Y PNOT HOWYE367822JUL04 {MYOCARDIAL INFARCT} RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM Non ST elevation myocardial infarction CV N 93 24JUL04 SEV PER H O PNOT Y PNOT HQWYE367822JUL04

MEDICAL MONITOR COMMENTS :

Relevant Medical History: smoking, acid reflux, borderline hypertension, hypercholesterolemia, overweight, coronary heart disease (2003), history of chest pain, heart palpitations, and dyspnea for past 8 months.

Relevant Prior Medications: none.

Relevant Concomitant Medications: Zetia, Toprol, Norvasc, Aciphex.

Description of Event: In her medical history, the subject reported having chest pains, shortness of breath, heart palpitations, and nausea for the past 8 months, which she attributed to her acid reflux. She underwent an exercise stress echocardiograph study demonstrating ischemic electrocardiogram changes. However, there were no apparent echocardiographic abnormalities. Because the subject continued to have disabling anginal symptomatology, cardiac catheterization and possible coronary intervention were recommended. The subject underwent catheterization on 19 Jul 2004, which revealed the right coronary artery had a 99% artery blockage. She underwent percutaneous transluminal coronary angioplasty with placement of cypher stent into the distal right coronary artery. Her condition was stable and she was discharged 20 Jul 2004.

CONFIDENTIAL 741 Wyeth

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 63

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 208, USA, 5125

TREATMENT : Desvenlafaxine SR 150 mg

: 201372 , 50 Year old, Female, Black , 80.1 kg , 162.2 cm, 30.4 kg /M^2

THERAPY START DATE/STOP DATE : 23APR04/ 18JUL04

: Discontinued (Adverse Event - CARDIOVASCULAR DISORDER) STUDY COMPLETION STATUS STUDY COMPLETION DATE

: 12AUG04

(continued from previous page)

MEDICAL MONITOR COMMENTS :

The subject had a 2nd hospitalization on 24 Jul 2004 for complaints of sudden onset of chest pain/pressure, headache, dizziness, and light-headedness. Her first set of cardiac enzymes were negative and subsequently a small non-Q-wave myocardial infarction secondary to subacute stent thrombosis was ruled in. She was taken to the cardiac catheterization laboratory. Right coronary artery revealed total occlusion at the site of recent stent placement. The subject underwent PTCA and thrombectomy. Two (2) additional stents were deployed.

Outcome: The subject was discharged from 2nd hospitalization on 28 Jul 2004. Final diagnosis was non-ST elevation myocardial infarction secondary to thrombosis after stent placement. Both the investigator and medical monitor considered the event probably not related to test article.

Page

64

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-208-201361

INVESTIGATOR : 208, USA, 5125

TREATMENT : Desvenlafaxine SR 50 mg

SUBJECT : 201361 , 49 Year old, Female, White , 69.9 kg , 172.3 cm, 23.5 kg /M^2

THERAPY START DATE/STOP DATE : 07APR04/ 29MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 30MAR05

NARRATIVE REASON : ADVERSE EVENTS OF SPECIAL INTEREST

{CHEST PAIN}

REPORT NARR-INF

RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM 01FEB05 . Chest pain BO Y 301 MIL PER O PNOT

MEDICAL MONITOR COMMENTS :

Relevant Medical History: none.

Relevant Prior Medications: none.

Relevant Concomitant Medications: Ambien, Xanax, hydrochlorothiazide

Description of Event: The subject reported an episode of chest pain at her last visit. The episode was reported by the investigator as mild in severity and probably not related to test article.

Outcome: The subject followed up with primary care physician and was given ECG and stress test. Results for both tests were normal. Because the chest pain was occurring around the subject's breast area, and was most likely muscle related, it was suggested that she get a mammogram. Her mammogram was normal. The subject was reportedly continuing to have chest pain, but not as frequently.

The subject completed the study.

CONFIDENTIAL 743 Wyeth

Page

65

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-208-201374

INVESTIGATOR : 208, USA, 5125

TREATMENT : Desvenlafaxine SR 50 mg

SUBJECT : 201374 , 49 Year old, Female, Black , 58.7 kg , 152 cm, 25.4 kg /M^2

THERAPY START DATE/STOP DATE : 23APR04/ 31JAN05

STUDY COMPLETION STATUS : Discontinued (Adverse Event - DEPRESSION)

STUDY COMPLETION DATE : 01FEB05

NARRATIVE REASON: DISCONTINUATION DUE TO ADVERSE EVENT {DEPRESSION} RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM DATE SEV COM ACTION INV E MM 010CT04 . Depression NE Y 162 MOD PER S P PNOT NARRATIVE REASON : ADVERSE EVENTS OF SPECIAL INTEREST {DEPRESSION} RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE INV E MM AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION Depression NE Y 162 010CT04 . MOD PER S P PNOT

MEDICAL MONITOR COMMENTS :

Relevant Medical History: depression (since 2000), anxiety attacks (since 2000).

Relevant Prior Medications: none.

Relevant Concomitant Medication: Effexor.

Description of Event: The subject reported an episode of depression on 01 Oct 2004. The episode was reported as moderate in severity and probably not related to test article. The subject was given Effexor, which she began taking 17 Dec 2004 while she was still taking test article.

Outcome: The subject discontinued from the study because of depression. After the study she was being followed up by her primary care physician, and the subject was still taking Effexor at follow-up visit. Per the investigator, it was noted that she had started the study with a new job and the depression seemed to be situational because she was unhappy and began working more hours. The investigator did not think the depression would resolve soon because of the subject's unhappiness with her new employment. No further information is available.

CONFIDENTIAL 744 Wyeth

Page 66

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-208-201360

INVESTIGATOR: 208, USA, 5125

TREATMENT : Placebo

SUBJECT : 201360 , 57 Year old, Female, White , 48.1 kg , 154 cm, 20.3 kg /M^2

THERAPY START DATE/STOP DATE : 02APR04/ 17JAN05

STUDY COMPLETION STATUS : Discontinued (Adverse Event - HYPERTENSION)

STUDY COMPLETION DATE : 18JAN05

NARRATIVE REASON: DISCONTINUATION DUE TO ADVERSE EVENT

{HYPERTENSION}

BDY T REL DURA ONSET STOP OUT TION A TION CASE
AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM ID

Elevated blood pressure CV Y 22 . 23APR04 . SEV PER P PROB

NARRATIVE REASON : CLINICALLY IMPORTANT VITAL SIGNS

{PCI: SYSTOLIC BLOOD PRESSURE}

Vital Sign	Position	Visit Date	D.A.I	Seq Num	Test Value (# => PCI)	Unit	Baseline Value
SYSTOLIC BP	Supine	24MAR04	Screening/baseline	1	128	mm Hq	123.5
SYSTOLIC BP	Supine	24MAR04	Screening/baseline	3	126	mm Hg	123.5
SYSTOLIC BP	Supine	02APR04	Screening/baseline	1	118	mm Hg	123.5
SYSTOLIC BP	Supine	02APR04	Screening/baseline	3	122	mm Hg	123.5
SYSTOLIC BP	Supine	23APR04	Week 4	1	152	mm Hg	123.5
SYSTOLIC BP	Supine	23APR04	Week 4	3	158	mm Hg	123.5
SYSTOLIC BP	Supine	21MAY04	Week 8	1	140	mm Hg	123.5
SYSTOLIC BP	Supine	21MAY04	Week 8	3	146	mm Hg	123.5
SYSTOLIC BP	Supine	25JUN04	Week 12	1	134	mm Hg	123.5
SYSTOLIC BP	Supine	25JUN04	Week 12	3	132	mm Hg	123.5
SYSTOLIC BP	Supine	050CT04	Week 26	1	159	mm Hg	123.5
SYSTOLIC BP	Supine	050CT04	Week 26	3	159	mm Hg	123.5
SYSTOLIC BP	Supine	18JAN05	Follow-up	1	172 #	mm Hg	123.5
SYSTOLIC BP	Supine	18JAN05	Follow-up	3	168 #	mm Hg	123.5
SYSTOLIC BP	Supine	25JAN05	Follow-up	1	148	mm Hg	123.5
SYSTOLIC BP	Supine	25JAN05	Follow-up	3	148	mm Hg	123.5
SYSTOLIC BP	Supine	08FEB05	Follow-up	1	136	mm Hg	123.5
SYSTOLIC BP	Supine	08FEB05	Follow-up	3	142	mm Hg	123.5

{PCI: ORTHOSTATIC HYPOTENSION}

Orthostatic Blood Visit Seg Pressure Change Date D.A.I Vital Sign Position Num (mm Hq) (mm Hq) 23APR04 Week 4 SYSTOLIC BP Supine 152

Page 67

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 208, USA, 5125

TREATMENT : Placebo

: 201360 , 57 Year old, Female, White , 48.1 kg , 154 cm, 20.3 kg /M^2

THERAPY START DATE/STOP DATE : 02APR04/ 17JAN05

STUDY COMPLETION STATUS STUDY COMPLETION DATE : Discontinued (Adverse Event - HYPERTENSION)

: 18JAN05

(continued from previous page)

003.0004	77 1 4	avamet ta pp	<u> </u>	2	150	2.6
23APR04	Week 4	SYSTOLIC BP	Supine	3	158	36
23APR04	Week 4	SYSTOLIC BP	standing	4	122	36
23APR04	Week 4	SYSTOLIC BP	standing	6	130	36
050CT04	Week 26	SYSTOLIC BP	Supine	1	159	49
050CT04	Week 26	SYSTOLIC BP	Supine	3	159	49
050CT04	Week 26	SYSTOLIC BP	standing	4	110	49
05OCT04	Week 26	SYSTOLIC BP	standing	6	138	49
18JAN05	Follow-up	DIASTOLIC BP	Supine	ĭ	82	20
18JAN05	Follow-up	DIASTOLIC BP	Supine	3	84	20
18JAN05	Follow-up	DIASTOLIC BP	standing	4	64	20
18JAN05	Follow-up	DIASTOLIC BP	standing	6	66	20
18JAN05	Follow-up	SYSTOLIC BP	Supine	1	172	30
				2	168	
18JAN05	Follow-up	SYSTOLIC BP	Supine	3		30
18JAN05	Follow-up	SYSTOLIC BP	standing	4	138	30
18JAN05	Follow-up	SYSTOLIC BP	standing	6	128	30
25JAN05	Follow-up	SYSTOLIC BP	Supine	1	148	38
25JAN05	Follow-up	SYSTOLIC BP	Supine	3	148	38
25JAN05	Follow-up	SYSTOLIC BP	standing	4	110	38
25JAN05	Follow-up	SYSTOLIC BP	standing	6	120	38

MEDICAL MONITOR COMMENTS :

Relevant Medical History: hypothyroidism (since 1999/2000).

Relevant Prior Medication: Levoxyl.

Relevant Concomitant Medication: Levoxyl.

Description of Event: The subject's blood pressure increased from baseline beginning at week 4 while receiving treatment. However, blood pressure values remained within normal range up to week 26. At last visit, she had 48.5-mm Hg and 44.5-mm Hg increases from baseline in systolic blood pressure that were considered clinically important (increase of systolic blood pressure >/= 30 mm Hg from baseline with a value >/= 160 mm Hg). At follow-up,

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 68

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 208, USA, 5125

TREATMENT : Placebo

: 201360 , 57 Year old, Female, White , 48.1 kg , 154 cm, 20.3 kg /M^2

THERAPY START DATE/STOP DATE : 02APR04/ 17JAN05

STUDY COMPLETION STATUS STUDY COMPLETION DATE : Discontinued (Adverse Event - HYPERTENSION)

: 18JAN05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

the subject's blood pressure returned to normal ranges. No antihypertensive medication was administered.

The subject also experienced episodes of orthostatic hypotension, as measured by decreases of 36 mm Hg, 49 mm Hg, 20 mm Hg, 30 mm Hg, and 38 mm Hg diastolic blood pressure from last supine to first standing at weeks 4, 26, 39, and at follow-up that were considered clinically important (decrease of >/= 15 mm Hg diastolic blood pressure from last supine to first standing). Subject did not report associated symptoms. The investigator did not report orthostatic hypotension as an adverse event.

Outcome: The subject discontinued from the study because of increased blood pressure. The investigator reported hypertension as an adverse event and as being severe and probably related to test article. No further information is available.

Page 69

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-209-201437

INVESTIGATOR: 209, USA, 18921

TREATMENT : Desvenlafaxine SR 100 mg

SUBJECT : 201437 , 54 Year old, Female, White , 90.4 kg , 170 cm, 31.3 kg /M^2

THERAPY START DATE/STOP DATE : 02APR04/ 24OCT04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - SGPT INCREASED)

STUDY COMPLETION DATE : 260CT04

NARRATIVE REASON : DISCONTINUATION DUE TO ADVERSE EVENT

{SGOT INCREASE}

RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM Elevated ALAT(SGPT) 23SEP04 26OCT04 MOD RES P MN Y 175 34 POSS

MEDICAL MONITOR COMMENTS :

Additional Relevant Lab Values:

Date	ALT (0-48 mU/ml)	AST (0-48 mU/ml)	Total Bilirubin (0-22.23 mcmol/L)
19Mar04(Baseline)	40	21	6.84
30Apr04(Week 4)	62	31	8.55
28May04 (Week 8)	44	22	3.42
22Jun04(Week 12)	75	43	6.84
22Jul04(Week 12)	52	28	6.84
23Sep04(Week 26)	146	48	6.84
010ct04(Week 26)	110	49	6.84
210ct04(Week 26)	131	78	6.84
260ct04(Week 26)	79	31	6.84
05Nov04(Follow-up)	70	41	10.26
30Nov04(Follow-up)	4 4	23	6.84

Relevant Medical History: hepatitis B (since 1999), elevated liver enzymes (1999), overweight.

Relevant Prior Medications: none.

Page

70

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 209, USA, 18921

: Desvenlafaxine SR 100 mg

: 201437 , 54 Year old, Female, White , 90.4 kg , 170 cm, 31.3 kg /M^2

THERAPY START DATE/STOP DATE : 02APR04/ 24OCT04

: Discontinued (Adverse Event - SGPT INCREASED)

STUDY COMPLETION STATUS STUDY COMPLETION DATE : 260CT04

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Relevant Concomitant Medication: hydrochlorothiazide.

Outcome: The subject had a moderate increase in ALT/SGPT from baseline beginning 30 Apr 2004, which remained <2x upper limit of normal. On 23 Sep 2004, an increase in ALT/SGPT reached a value >3x upper limit of normal. The subject discontinued taking test article on 24 Oct 2004, and at subsequent visits repeat LFTs showed progressive return to normal values.

The investigator reported ALT/SGPT increase as moderate in severity and possibly related to test article. No further information is available.

Page

71

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-209-201422

INVESTIGATOR: 209, USA, 18921

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 201422 , 55 Year old, Fémale, White , 61 kg , 160 cm, 23.8 kg $/\mathrm{M}^2$

THERAPY START DATE/STOP DATE : 09MAR04/ 08MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 09MAR05

NARRATIVE REASON : ADVERSE EVENTS OF SPECIAL INTEREST

{DEPRESSION}

REPORT NARR-INF

RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM 12MAR05 . Depression NE N 369 SEV PER S DEFI

MEDICAL MONITOR COMMENTS :

Relevant Medical History: hypothyroidism (since 1985).

Relevant Prior Medication: Synthroid.

Relevant Concomitant Medications: Synthroid, Effexor.

Description of Event: The subject reported an episode of depression 4 days after last dose of test article, which spontaneously resolved within 18 days. The episode was reported by the investigator as severe and definitely related to discontinuation of test article.

Outcome: Effexor was given to the subject at follow-up visit to treat the depression. She was instructed to take 75 mg of Effexor for 7 days and then to take 37.5 mg for 5 days. Symptoms resolved on 30 Mar 2005.

CONFIDENTIAL 750 Wyeth

Page 72

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-210-201466

INVESTIGATOR: 210, USA, 26540

TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 201466 , 55 Year old, Fémale, White , 70.8 kg , 162.6 cm, 26.8 kg /M^2

THERAPY START DATE/STOP DATE : 13APR04/ 18JAN05

STUDY COMPLETION STATUS : Discontinued (Adverse Event - WEIGHT GAIN) STUDY COMPLETION DATE : 21JAN05

NARRATIVE REASON: CLINICALLY IMPORTANT LABORATORY VALUES {PCI: TRIGLYCERIDES} Rel. Tost Value Fasting Pange

Lab Test	Day (Days)	D.A.I	Test Date	Test Value (# => PCI)	(Y/N)	(Low)	Range (High)	Unit	Value Value
TRIGLYCERIDES /LIPID	-39	Screening/baseline	05MAR04	4.3805	Yes	0.3952	2.258	mmol/L	3.5281
TRIGLYCERIDES /LIPID	-18	Screening/baseline	26MAR04	2.6757	Yes	0.3952	2.258	mmol/L	3.5281
TRIGLYCERIDES /LIPID	30	Week 4	12MAY04	2.9241	Yes	0.3952	2.258	mmol/L	3.5281
TRIGLYCERIDES /LIPID	85	Week 12	06JUL04	3.2967	Yes	0.3952	2.258	mmol/L	3.5281
TRIGLYCERIDES /LIPID	192	Week 26	210CT04	8.0498 #	Yes	0.3952	2.258	mmol/L	3.5281
TRIGLYCERIDES /LIPID	221	Week 26	19NOV04	5.9273	Yes	0.3952	2.258	mmol/L	3.5281
TRIGLYCERIDES /LIPID	284	Week 39	21JAN05	3.816	Yes	0.3952	2.258	mmol/L	3.5281

{PCI: TOTAL CHOLESTEROL}

(ICI. IOIAL CHOLESIE	Rel.								
Lab Test	Day (Days)	D.A.I	Test Date	Test Value (# => PCI)	Fasting (Y/N)	Range (Low)	Range (High)	Unit	Baseline Value
TOT.CHOL. /LIPID	-39	Screening/baseline	05MAR04	8.4304	Yes	0	5.1461	mmol/L	6.9822
TOT.CHOL. /LIPID	-18	Screening/baseline	26MAR04	5.534	Yes	0	5.1461	mmol/L	6.9822
TOT.CHOL. /LIPID	30	Week 4	12MAY04	4.9393	Yes	0	5.1461	mmol/L	6.9822
TOT.CHOL. /LIPID	85	Week 12	06JUL04	5.0686	Yes	0	5.1461	mmol/L	6.9822
TOT.CHOL. /LIPID	192	Week 26	210CT04	9.6975 #	Yes	0	5.1461	mmol/L	6.9822
TOT.CHOL. /LIPID	221	Week 26	19NOV04	6.2323	Yes	0	5.1461	mmol/L	6.9822
TOT.CHOL. /LIPID	284	Week 39	21JAN05	5.172	Yes	0	5.1461	mmol/L	6.9822

MEDICAL MONITOR COMMENTS :

Additional Relevant Lab Values:

Date HDL LDL

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 73

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 210, USA, 26540

: Desvenlafaxine SR 150 mg

: 201466 , 55 Year old, Female, White , 70.8 kg , 162.6 cm, 26.8 kg /M^2

THERAPY START DATE/STOP DATE : 13APR04/ 18JAN05

STUDY COMPLETION STATUS STUDY COMPLETION DATE : Discontinued (Adverse Event - WEIGHT GAIN)

: 21JAN05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

	(0.90-2.07mol/L)	(0-3.36 mmol/L)
05Mar04(Baseline)	1.03	5.38
26Mar04(Baseline)	0.93	3.39
12May04 (Week 4)	0.93	2.66
06Jul04(Week 12)	0.80	2.77
210ct04 (Week 26)	1.11	ND
19Nov04 (Week 26)	0.93	ND
21Jan05 (Week 39)	0.83	2.59

Relevant Medical History: hyperlipidemia (since 2004), overweight.

Relevant Prior Medication: atorvastatin.

Relevant Concomitant Medication: atorvastatin.

Outcome: At week 26 of treatment, the subject had a single episode of both increased total cholesterol and triglycerides that was considered clinically important (increase >/= 1.97 mmol/L from baseline and value >/= 7.8 mmol/L for total cholesterol and a >/= 50% increase from baseline with a value >/= 7.9 mmol/L for triglycerides). Both total cholesterol and triglycerides returned to normal range at subsequent visits.

The subject discontinued from the study because of weight gain. The investigator did not report an increase in total cholesterol or triglycerides as an adverse event. The subject was being followed up by her primary care physician for her elevated cholesterol and triglycerides. No further information is available.

Page 74

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-213-201636

INVESTIGATOR: 213, USA, 4763

TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 201636 , 56 Year old, Female, White , 60.2 kg , 163.5 cm, 22.5 kg /M^2

THERAPY START DATE/STOP DATE : 13APR04/ 14MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 20APR05

{CHOLECYSTITIS}	NARRATIVE REAS	ON : S	ERIOUS	ADVER	SE EVENT	(SAE)							
AE VERBATIM		BDY T SYS E	REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT COM	ACTION	RELA TION INV	S A E	RELA TION MM	CASE ID
Cholecystitis		DI N	338	4	16MAR05	19MAR05	SEV	RES	Н	POSS	Y	PNOT	HQWYE428628MAR05
{ILEUS}										RELA	S	RELA	
AE VERBATIM		BDY T SYS E	REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT	ACTION	TION INV	A E	TION MM	CASE ID
Post-op ileus		DI N	341	17	19MAR05	04APR05	SEV	RES	Н	DNOT	Y	PNOT	HQWYE428628MAR05
{PANCREAS DISORDER}										DEI 7	C	DELA	
AE VERBATIM		BDY T SYS E	REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT COM	ACTION	RELA TION INV	S A E	RELA TION MM	CASE ID
Perforated pancreatic duct		DI N	341	10	19MAR05	28MAR05	SEV	RES	н о	DNOT	<u> </u>	PNOT	HOWYE428628MAR05

MEDICAL MONITOR COMMENTS :

Relevant Medical History: none.

Relevant Prior Medications: none.

Relevant Concomitant Medication:aspirin.

Description of Event: The subject complained of abdominal pain for 10 days before her hospitalization on 17 Mar 2005 for

CONFIDENTIAL 753 Wyeth

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

Page 75

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 213, USA, 4763

TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 201636 , 56 Year old, Female, White , 60.2 kg , 163.5 cm, 22.5 kg /M^2

THERAPY START DATE/STOP DATE : 13APR04/ 14MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 20APR05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

endoscopic retrograde cholangiopancreatography (ERCP), sphincterotomy, and stone removal from common bile duct. After discharge, she went to the emergency room on 19 Mar 2005 and was rehospitalized on 20 Mar 2005 because of pain. Laboratory studies indicated an elevation of bilirubin and liver enzymes, with normal amylase and white blood cell count. Radiography of abdomen showed some gastric distension and small bowel gas. The subject had postoperative ileus, probably edema at the sphincter of Oddi secondary to the ERCP. She was discharged on 25 Mar 2005 and less than 24 hours later re-admitted with unresolved symptoms of abdominal pain, increased serum bilirubin, bibasilar pneumonia, and a leak at the intrapancreatic distal common bile duct, as a result of perforation. Eight (8) liters of ascitic fluid contaminated with bile were aspirated. The common bile duct was opened and a T-tube was placed on 26 Mar 2005. Postoperative cholangiogram revealed no leaks. She was counseled to follow a no-fat diet.

Outcome: The subject recovered and was discharged on 04 Apr 2005. She completed the study. The investigator considered cholecystitis to be possibly related to test article, and the other adverse events, perforation of pancreatic duct and postoperative ileus, to be definitely not related to test article. Medical monitor considered cholecystitis and postoperative complications to be not related to test article.

Page 76

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-213-201638

INVESTIGATOR: 213, USA, 4763

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 201638 , 55 Year old, Female, White , 82.9 kg , 174 cm, 27.4 kg /M^2

THERAPY START DATE/STOP DATE : 17MAR04/ 20APR04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - HYPERLIPEMIA)

STUDY COMPLETION DATE : 28APR04

NARRATIVE REASON : DISCONTINUATION DUE TO ADVERSE EVENT

{HYPERLIPEMIA}

REPORT NARR-INF

AE VEDRATIM	BDY T	REL DAY	DURA	ONSET DATE	STOP DATE	SEV	OUT	л Стт ОМ	TION INV	A	TION	CASE	
Increased blood triglycerides	MNI V	20		1/1000/		OEV	DED	-D	DOGG		141141		 _
Increased blood triglycerides													

MEDICAL MONITOR COMMENTS :

Additional Relevant Lab Values:

Date	Total Cholesterol (0-5.15 mmol/L)	HDL Cholesterol (0.88-2.07 mmol/L)	LDL Cholesterol (0-3.36 mmol/L)	Triglycerides (0.40-2.26 mmol/L)
09Mar04 (Baseline)	7.50	0.83	5.48	2.59
14Apr04 (Week 4)	8.04	0.83	5.33	4.10
23Apr04 (Follow-up)	8.09	0.78	5.51	3.93

Relevant Medical History: hyperlipidemia, hypothyroidism, overweight, current smoking.

Relevant Prior Medications: Levoxyl, Zetia, Lopid.

Relevant Concomitant Medications: Levoxyl, Zetia, Lopid.

Outcome: The subject had uncontrolled hyperlipidemia at baseline. Total cholesterol and triglycerides increased during therapy reaching values of 8.04 mmol/L and 4.10 mmol/L, respectively. The subject was discontinued from the study because of uncontrolled hyperlipemia. The investigator reported the adverse event as severe, and possibly related to test article. No further information is available.

CONFIDENTIAL 755 Wyeth

Page 77

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-213-201642

INVESTIGATOR: 213, USA, 4763

REPORT NARR-INF

TREATMENT : Desvenlafaxine SR 200 mg

: 201642 , 56 Year old, Female, White , 81.4 kg , 159 cm, 32.2 kg /M^2

THERAPY START DATE/STOP DATE : 13APR04/ 16JUN04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - SEXUAL FUNCTION ABNORMAL) STUDY COMPLETION DATE : 07JUL04

NARRATIVE REASON: DISCONTINUATION DUE TO ADVERSE EVENT

{HYPERCHOLESTEROLEMIA}

									RELA	S	RELA	
	BDY T	REL	DURA	ONSET	STOP		OUT		TION	Α	TION	CASE
AE VERBATIM	SYS E	DAY	TION	DATE	DATE	SEV	COM	ACTION	INV	E	MM	ID
Increased cholesterol	MN Y	2.3		05MAY04		MTT	PER	M	POSS			

MEDICAL MONITOR COMMENTS:

Additional Relevant Lab Values:

Visit Date	Total Cholesterol (0-5.15 mmol/L)	HDL Cholesterol (0.88-2.07 mmol/L)	LDL Cholesterol (0-3.36 mmol/L)	Triglycerides (0.40-2.26 mmol/L)	
31Mar04 (Screening)	5.25	1.34	3.03	1.91	
05May04 (Week 4)	6.47	1.78	4.19	1.06	
07Jul04 (Follow up)	6.28	1.53	4.29	0.99	
16Aug04 (Follow up)	5.92	1.55	3.67	1.55	
14Sep04 (Follow up)	6.41	ND	ND	1.07	

Relevant Medical History: obesity.

Relevant Prior Medications: none.

Relevant Concomitant Medications: none.

Outcome: At week 4 of treatment, the subject discontinued from the study primarily because of sexual dysfunction. Secondary cause for discontinuation included increased cholesterol level. Although total cholesterol and LDL cholesterol levels increased above normal range, they remained below clinical importance (total cholesterol: >/= 1.97 mmol/L increase from baseline with a value >/= 7.8 mmol/L). Increased cholesterol persisted at follow-up visits. The investigator reported increased cholesterol levels mild in severity and possibly related to test article. No further information is available.

Page 78

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-213-201604

INVESTIGATOR: 213, USA, 4763

TREATMENT : Desvenlafaxine SR 50 mg

SUBJECT : 201604 , 55 Year old, Female, White , 75 kg , 169.6 cm, 26.1 kg /M^2

THERAPY START DATE/STOP DATE : 02MAR04/ 01MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 02MAR05

NARRATIVE REASON : CLINICALLY IMPORTANT ECG VALUES

{PCI: QT INTERVAL}

REPORT NARR-INF

Vital Sign	Rel. Day (Days)	D.A.I	Visit Date	Test Value (# => PCI)	Unit	Baseline Value	
QT INTRVL	-12	Screening/baseline	19FEB04	464	msec	464	
QT INTRVL	86	Week 12	26MAY04	484 #	msec	464	
QT INTRVL	366	Week 52	02MAR05	455	msec	464	

MEDICAL MONITOR COMMENTS :

·----

Additional Relevant ECG Values:

Visit Date	QTcB Interval (msec)	QTcF Interval (msec)	Heart Rate (bpm)
19FEB04 (Screening)	400	420	45
26MAY04 (Week 12)	394	421	41
02MAR05 (Week52)	411	426	49

Relevant Medical History: hypothyroidism.

Relevant Prior Medications: Celebrex, Synthroid.

Relevant Concomitant Medications: Celebrex, Synthroid.

Outcome: At week 12 of treatment, the subject had a 20-msec increase from baseline in QT interval with a value of 484 msec. At last visit, QT interval returned to normal ranges. All QTcB and QTcF intervals at all time points were normal (< 470 msec).

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

Page 79

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 213, USA, 4763

TREATMENT : Desvenlafaxine SR 50 mg

SUBJECT : 201604 , 55 Year old, Female, White , 75 kg , 169.6 cm, 26.1 kg /M^2

THERAPY START DATE/STOP DATE : 02MAR04/ 01MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 02MAR05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

The subject's physical examination and blood pressures were normal during the study. She completed the study. The investigator did not report the increase in QT interval as an adverse event.

Page

80

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-213-201614

INVESTIGATOR: 213, USA, 4763

TREATMENT : Desvenlafaxine SR 50 mg

SUBJECT : 201614 , 54 Year old, Female, White , 78 kg , 157 cm, 31.6 kg /M^2

THERAPY START DATE/STOP DATE : 25FEB04/ 22FEB05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 10MAR05

NARRATIVE REASON: ADVERSE EVENTS OF SPECIAL INTEREST

{DEPRESSION}

REPORT NARR-INF

RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM Depression NE Y 128 62 01JUL04 31AUG04 MOD RES N PNOT

MEDICAL MONITOR COMMENTS :

Relevant Medical History: The subject had no reported history of depression.

Relevant Prior Medications: none.

Relevant Concomitant Medications: none.

Outcome: On day 128 of treatment, the subject reported an episode of depression that was moderate in severity. The depressive episode resolved spontaneously within 60 days without any medication. The investigator stated that the subject was "emotionally labile and a lot was going on in her life." The subject completed the study. The investigator reported the adverse event as probably not related to test article.

CONFIDENTIAL 759 Wyeth

Page 81

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-213-201621

INVESTIGATOR: 213, USA, 4763

TREATMENT : Placebo

REPORT NARR-INF

SUBJECT : 201621 , 56 Year old, Female, White , 68.1 kg , 167 cm, 24.4 kg /M^2

THERAPY START DATE/STOP DATE : 03MAR04/ 01MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 02MAR05

NARRATIVE REASON : CLINICALLY IMPORTANT VITAL SIGNS

{PCI: ORTHOSTATIC HYPOTENSION}

Visit Date	D.A.I	Vital Sign	Position	Seq Num	Blood Pressure (mm Hg)	Orthostatic Change (mm Hg)
03MAR04	Screening/baseline	SYSTOLIC BP	Supine	1	140	32
03MAR04	Screening/baseline	SYSTOLIC BP	Supine	1	146	32
03MAR04	Screening/baseline	SYSTOLIC BP	Supine	3	130	32
03MAR04	Screening/baseline	SYSTOLIC BP	Supine	3	144	32
03MAR04	Screening/baseline	SYSTOLIC BP	standing	4	112	32
03MAR04	Screening/baseline	SYSTOLIC BP	standing	4	136	32
03MAR04	Screening/baseline	SYSTOLIC BP	standing	6	110	32
03MAR04	Screening/baseline	SYSTOLIC BP	standing	6	138	32
25MAR04	Week 4	DIASTOLIC BP	Supine	1	80	20
25MAR04	Week 4	DIASTOLIC BP	Supine	3	80	20
25MAR04	Week 4	DIASTOLIC BP	standing	4	60	20
25MAR04	Week 4	DIASTOLIC BP	standing	6	70	20

MEDICAL MONITOR COMMENTS :

Relevant Medical History: asthma.

Relevant Prior Medications: albuterol, Triprolidine + Pseudoephedrine.

Relevant Concomitant Medications: albuterol, Triprolidine + Pseudoephedrine.

Outcome: The subject experienced an episode of orthostatic systolic hypotension at baseline. At week 4 of treatment, she experienced an episode of orthostatic hypotension, as measured by a decrease of 20 mm Hg in diastolic blood pressure from last supine to first standing. The subject did not report associated symptoms. She was also receiving albuterol, which might have contributed to the orthostatic hypotension. At subsequent visits, blood pressure and heart rate remained within normal range, including measurements taken during postural changes. The subject completed the study. The investigator did not report orthostatic hypotension as an adverse event.

Page

82

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-215-201705

INVESTIGATOR: 215, USA, 28892

TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 201705 , 48 Year old, Female, White , 79.1 kg , 185 cm, 23.1 kg /M^2

THERAPY START DATE/STOP DATE : 18FEB04/ 16FEB05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 03MAR05

NARRATIVE REASON : ADVERSE EVENTS OF SPECIAL INTEREST

{CHEST PAIN}

REPORT NARR-INF

BDY T REL DURA ONSET STOP OUT TION A TION CASE
AE VERBATIM

BO Y 342 2 24JAN05 25JAN05 MOD RES S O DNOT

MEDICAL MONITOR COMMENTS :

Relevant Medical History: pacemaker (October 1998) because of arrhythmia, heart catheterization because of chest pain (09 Jan 2004).

Relevant Prior Medications: Percocet, Flexeril.

Relevant Concomitant Medications: Toprol, Medrol dosepak, Valium, Zelnorm, Duragesic patch.

Outcome: The subject reported an episode of chest pain, moderate in severity. The investigator stated that chest pain was cardiac in nature, associated with pacemaker malfunction. The subject recovered and completed the study. The investigator reported adverse event definitely not related to test article.

Page 83

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-215-201702

INVESTIGATOR: 215, USA, 28892

TREATMENT : Desvenlafaxine SR 50 mg

SUBJECT : 201702 , 53 Year old, Female, White , 60 kg , 160 cm, 23.4 kg /M^2

THERAPY START DATE/STOP DATE : 04MAR04/ 14SEP04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - HYPERTENSION)

STUDY COMPLETION DATE : 14SEP04

NARRATIVE REASON: DISCONTINUATION DUE TO ADVERSE EVENT

{HYPERTENSION}

REPORT NARR-INF

AE VERBATIM	BDY T SYS E		DURA TION	ONSET DATE	STOP DATE	SEV	OUT	ACTION	RELA TION INV	A	RELA TION MM	CASE ID	
High blood pressure	CV Y	175	23	25AUG04	16SEP04	MOD	RES	W	POSS				
Increased blood pressure	CV Y	175		25AUG04		MOD	PER	P	POSS				
Increased blood pressure	CV Y	175	23	25AUG04	16SEP04	MOD	RES	N	POSS				

MEDICAL MONITOR COMMENTS :

Additional Relevant Vital Sign Values:

Visit Date Supine Blood Pressure

(mm Hq)

25Feb04	(Baseline)	137/85	(Average	of	all	screening/baseline values)
25Aug04	(Week 26)	152/90				
25Aug04	(Week 26)	154/94				
14Sep04	(Week 39)	142/98				
14Sep04	(Week 39)	138/96				

Relevant Medical History: occasional migraine.

Relevant Prior Medications: Imitrex, Fioricet, Tylenol PM, prednisone, Sudafed.

Relevant Concomitant Medications: Imitrex, Fioricet, Tylenol PM, prednisone, Sudafed.

Outcome: Blood pressure was within normal range at baseline and up to week 26 of treatment. At week 26, the subject had a 17-mm Hg increase from baseline in systolic blood pressure.

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 84

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 215, USA, 28892

: Desvenlafaxine SR 50 mg

: 201702 , 53 Year old, Female, White , 60 kg , 160 cm, 23.4 kg /M^2

THERAPY START DATE/STOP DATE : 04MAR04/ 14SEP04

: Discontinued (Adverse Event - HYPERTENSION) STUDY COMPLETION STATUS STUDY COMPLETION DATE

: 14SEP04

(continued from previous page)

MEDICAL MONITOR COMMENTS :

At the following visit, systolic blood pressure remained within normal range. Diastolic blood pressure and heart rate remained normal throughout the entire course of treatment. The subject discontinued from the study because of increased blood pressure. The investigator reported the increase in blood pressure moderate in severity, possibly related to test article.

Page

85

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-216-201756

INVESTIGATOR: 216, USA, 9397

TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 201756 , 54 Year old, Female, White , 57.3 kg , 163.8 cm, 21.4 kg /M^2

THERAPY START DATE/STOP DATE : 11FEB04/ 07FEB05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 08FEB05

NARRATIVE REASON : ADVERSE EVENTS OF SPECIAL INTEREST

{DEPRESSION}

REPORT NARR-INF

RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM 11FEB05 . Dysphoria NE N 367 MOD PER S DEFI

MEDICAL MONITOR COMMENTS :

Relevant Medical History: no reported history of depression.

Relevant Prior Medications: none.

Relevant Concomitant Medications: none.

Outcome: The subject developed an episode of depression described as "dysphoria" 4 days after discontinuation of test article. The depressive episode was moderate in severity but required the prescription of an antidepressant, Effexor. The episode of depression resolved within 60 days. The subject completed the study. The investigator reported the adverse event as definitely related to discontinuation of test article.

CONFIDENTIAL 764 Wyeth

Page

86

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-216-201764

INVESTIGATOR: 216, USA, 9397

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 201764 , 51 Year old, Female, White , 74.1 kg , 162.6 cm, 28.0 kg /M^2

THERAPY START DATE/STOP DATE : 19FEB04/ 12MAY04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - THINKING ABNORMAL)

STUDY COMPLETION DATE : 27MAY04

NARRATIVE REASON: ADVERSE EVENTS OF SPECIAL INTEREST

{CHEST PAIN}

REPORT NARR-INF

BDY T REL DURA ONSET STOP OUT TION A TION CASE
AE VERBATIM

BO N 85 1 13MAY04 13MAY04 MIL RES N PNOT

MEDICAL MONITOR COMMENTS :

Relevant Medical History: occasional migraine, occasional indigestion, overweight.

Relevant Prior Medications: Tylenol PM, Exedrin migraine, ibuprofen, Tums.

Relevant Concomitant Medications: Exedrin migraine, ibuprofen, Tums.

Outcome: The subject experienced an episode of chest pain 1 day after discontinuation of test article. Chest pain was mild in severity and resolved within a day. The investigator reported that an ECG was performed that was normal and that the subject's chest pain was due to anxiety, as a result of events in personal life, and probably not related to test article. The subject discontinued from the study primarily because of "cognitive disturbance."

Page 87

3.8857 6.9388 mmol/L 8.7151

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-216-201767

INVESTIGATOR: 216, USA, 9397

GLUCOSE

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 201767 , 56 Year old, Female, Other , 75.5 kg , 160 cm, 29.5 kg /M^2

THERAPY START DATE/STOP DATE : 16MAR04/ 30MAR05

289

Week 39

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 31MAR05

{PCI: SYSTOLIC BLOO			: CLINICALLY II	MPORTANT V	ITAL SIGNS					
•	ĺ	Visit	D 7 T		Seq	Test Val		Basel		
Vital Sign	Position	Date	D.A.I		Num	(# => PC	I) Unit	Value		
SYSTOLIC BP	Supine	04MAR04	Screening/base	eline	1	152	mm Hq	136		
SYSTOLIC BP	Supine	04MAR04	Screening/base		3	150	mm Hg	136		
SYSTOLIC BP	Supine	16MAR04	Screening/base	eline	1	122	mm Hq	136		
SYSTOLIC BP	Supine	16MAR04	Screening/base	eline	3	120	mm Hq	136		
SYSTOLIC BP	Supine	13APR04	Week 4		1	180 #	mm Hq	136		
SYSTOLIC BP	Supine	13APR04	Week 4		3	180 #	mm Hg	136		
SYSTOLIC BP	Supine	11MAY04	Week 8		1	140	mm Hg	136		
SYSTOLIC BP	Supine	11MAY04	Week 8		3	150	mm Hg	136		
SYSTOLIC BP	Supine	08JUN04	Week 12		1	130	mm Hg	136		
SYSTOLIC BP	Supine	08JUN04	Week 12		3	132	mm Hg	136		
SYSTOLIC BP	Supine	14SEP04	Week 26		1	142	mm Hg	136		
SYSTOLIC BP	Supine	14SEP04	Week 26		3	142	mm Hg	136		
SYSTOLIC BP	Supine	29DEC04	Week 39		1	148	mm Hg	136		
SYSTOLIC BP	Supine	29DEC04	Week 39		3	150	mm Hg	136		
SYSTOLIC BP	Supine	31MAR05	Follow-up		1	138	mm Hg	136		
SYSTOLIC BP	Supine	31MAR05	Follow-up		3	130	mm Hg	136		
{PCI: GLUCOSE (FAST			CLINICALLY IMPO	RTANT LABOI	RATORY VALUES	S Fasting	Range	Range		Baseline
Lab Test	(Day	vs) D.A.I		Date	(# => PCI)	(Y/N)	(Low)	(High)	Unit	Value
TOD 1690	(Da)	, D.W.I		Date	(" -> 101)	(1/1/)	(HOW)	(111911)	OILL	value
GLUCOSE	-12	Screen	ning/baseline	04MAR04	8.7151	Yes	3.8857	6.9388	mmol/L	8.7151
GLUCOSE	29	Week 4		13APR04	8.9371	Yes	3.8857	6.9388	mmol/L	8.7151
GLUCOSE	45	Week 4	1	29APR04	11.2685	No/Unkn			mmol/L	8.7151
GLUCOSE	58	Week 8	3	12MAY04	7.3273	Yes	3.8857	6.9388	mmol/L	8.7151
GLUCOSE	85	Week 1	.2	08JUN04	6.8277	Yes	3.8857	6.9388	mmol/L	8.7151
GLUCOSE	183	Week 2	26	14SEP04	7.9379	Yes	3.8857	6.9388	mmol/L	8.7151

29DEC04 14.7102 # Yes

Page

8.7151

88

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

REPORT NARR-INF

GLUCOSE

INVESTIGATOR: 216, USA, 9397

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 201767 , 56 Year old, Female, Other , 75.5 kg , 160 cm, 29.5 kg /M^2

THERAPY START DATE/STOP DATE : 16MAR04/ 30MAR05

395

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 31MAR05

(continued from previous page)

GLUCOSE 381 Week 52 31MAR05 11.8236 # Yes 3.8857 6.9388 mmol/L 8.7151

14APR05 9.2147

Yes

3.8857

6.9388

mmol/L

MEDICAL MONITOR COMMENTS :

Relevant Medical History: hypertension (since 1999), type II diabetes (since 2003), overweight.

Relevant Prior Medications: Toprol XL, Norvasc, Avandia, Glucophage, Avalide.

Follow-up

Relevant Concomitant Medications: Toprol XL, Norvasc, Avandia, Glucophage, Avalide.

Outcome: At week 4 of treatment, the subject had a 44-mm Hg increase from baseline in systolic blood pressure that was considered clinically important (systolic blood pressure: >/= 30 mm from baseline with a value >/= 160 mm Hg). At subsequent visits, blood pressures returned to normal range. Heart rate remained normal throughout the entire course of treatment.

The subject also had a history of type II diabetes that was poorly controlled during the study (glucose values >/= 11.1 mmol/L at weeks 4, 39, and 52).

The subject completed the study. The investigator did not report the increase in blood pressure as an adverse event.

Page

89

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-216-201761

INVESTIGATOR: 216, USA, 9397

TREATMENT : Desvenlafaxine SR 50 mg

SUBJECT : 201761 , 56 Year old, Female, White , 70.9 kg , 160 cm, 27.7 kg /M^2

THERAPY START DATE/STOP DATE : 17FEB04/ 15MAR04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - DYSPEPSIA)

STUDY COMPLETION DATE : 16MAR04

NARRATIVE REASON: DISCONTINUATION DUE TO ADVERSE EVENT

{HOSTILITY}

REPORT NARR-INF

BDY T REL DURA ONSET STOP OUT TION A TION CASE
AE VERBATIM

NE Y 4 37 20FEB04 27MAR04 MIL RES W POSS

 ${\tt MEDICAL}$ MONITOR COMMENTS :

Relevant Medical History: hypertension, hypothyroidism.

Relevant Prior Medications: Diovan, Synthroid.

Relevant Concomitant Medications: Diovan, Synthroid.

Outcome: On day 4 of treatment, the subject experienced an episode of hostility described as "increased irritability", mild in Severity, which resolved within 30 days. She discontinued from the study because of this event (as well as vertigo) and did not receive any additional treatment. The investigator reported the adverse event to be possibly related to test article.

Page

90

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-217-201830

INVESTIGATOR: 217, USA, 7420

TREATMENT : Desvenlafaxine SR 100 mg

SUBJECT : 201830 , 52 Year old, Female, White , 64.1 kg , 152 cm, 27.7 kg /M^2

THERAPY START DATE/STOP DATE : 06APR04/ 06APR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 07APR05

NARRATIVE REASON : CLINICALLY IMPORTANT VITAL SIGNS

{PCI: DIASTOLIC BLOOD PRESSURE}

TT' had a C' am	Beet blee	Visit	D 7 T	Seq	Test Value	TT 1 to	Baseline
Vital Sign	Position	Date	D.A.I	Num	(# => PCI)	Unit	Value
DIASTOLIC BP	Supine	16MAR04	Screening/baseline	1	70	mm Hg	76.5
DIASTOLIC BP	Supine	16MAR04	Screening/baseline	3	7 4	mm Hg	76.5
DIASTOLIC BP	Supine	06APR04	Screening/baseline	1	82	mm Hg	76.5
DIASTOLIC BP	Supine	06APR04	Screening/baseline	3	80	mm Hg	76.5
DIASTOLIC BP	Supine	11MAY04	Week 4	1	84	mm Hg	76.5
DIASTOLIC BP	Supine	11MAY04	Week 4	3	84	mm Hg	76.5
DIASTOLIC BP	Supine	14JUN04	Week 8	1	84	mm Hg	76.5
DIASTOLIC BP	Supine	14JUN04	Week 8	3	84	mm Hg	76.5
DIASTOLIC BP	Supine	02JUL04	Week 12	1	92	mm Hg	76.5
DIASTOLIC BP	Supine	02JUL04	Week 12	3	100 #	mm Hg	76.5
DIASTOLIC BP	Supine	120CT04	Week 26	1	70	mm Hg	76.5
DIASTOLIC BP	Supine	120CT04	Week 26	3	72	mm Hg	76.5
DIASTOLIC BP	Supine	13JAN05	Week 39	1	90	mm Hg	76.5
DIASTOLIC BP	Supine	13JAN05	Week 39	3	84	mm Hg	76.5
DIASTOLIC BP	Supine	07APR05	Follow-up	1	72	mm Hg	76.5
DIASTOLIC BP	Supine	07APR05	Follow-up	3	76	mm Hg	76.5

MEDICAL MONITOR COMMENTS :

Additional Relevant Vital Sign Values:

Supine

Visit date Systolic Blood Pressure

(mm Hg)

16Mar04 (Baseline) 107 (Average of all screening/baseline values)
11May04 (Week 4) 120
11May04 (Week 4) 122

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 91

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 217, USA, 7420

TREATMENT : Desvenlafaxine SR 100 mg

SUBJECT : 201830 , 52 Year old, Female, White , 64.1 kg , 152 cm, 27.7 kg /M^2

THERAPY START DATE/STOP DATE : 06APR04/ 06APR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 07APR05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

14Jun04	(Week	8)	138
14Jun04	(Week	8)	128
02Jul04	(Week	12)	140
02Jul04	(Week	12)	140
120ct04	(Week	26)	100
120ct04	(Week	26)	112
13Jan05	(Week	39)	120
13Jan05	(Week	39)	120
07Apr05	(Week	52)	122
07Apr05	(Week	52)	122

Relevant Medical History: asthma.

Relevant Prior Medication: Ventolin.

Relevant Concomitant Medications: Ventolin, Zithromax.

Outcome: At week 12 of treatment, the subject had a 23.5-mm Hg increase from baseline in diastolic blood pressure that was considered clinically important (>/= 20 mm Hg from baseline with a value >/= 100 mm Hg).

At subsequent visits, diastolic blood pressure returned to within normal range. Systolic blood pressure and heart rate remained normal throughout the entire course of treatment. The subject completed the study. The investigator did not report the increase in diastolic blood pressure as an adverse event.

Page

92

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-217-201831

INVESTIGATOR : 217, USA, 7420

TREATMENT : Desvenlafaxine SR 100 mg

SUBJECT : 201831 , 39 Year old, Fémale, Black , 55.9 kg , 160 cm, 21.8 kg /M^2

THERAPY START DATE/STOP DATE : 31MAR04/ 07JAN05

STUDY COMPLETION STATUS : Discontinued (Subject Request Unrelated to Study)

STUDY COMPLETION DATE : 14FEB05

	RATIVE REASON	: S	ERIOUS	ADVER	SE EVENT	(SAE)							
{CHOLECYSTITIS} AE VERBATIM	BDY SYS		REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT COM	ACTION	RELA TION INV	S A E	RELA TION MM	CASE ID
Cholecystitis	DI	Y	199	3	150CT04	170CT04	SEV	RES	НО	DNOT	Y	PNOT	HQWYE267728DEC04
{CHOLELITHIASIS}										מ דום	S	חחת	
AE VERBATIM	BDY SYS		REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT COM	ACTION	RELA TION INV	A E	RELA TION MM	CASE ID
Gall stones Stones in gall-bladder (Gallsto	DI ones) DI	Y Y	108	94	16JUL04 16JUL04	170CT04	MOD MOD	RES PER	S H O S H O	DNOT	Y	PNOT	HQWYE408228SEP04

MEDICAL MONITOR COMMENTS :

Relevant Medical History: occasional constipation, renal lithiasis, hyperlipidemia.

Relevant Prior Medications: none.

Relevant Concomitant Medications: Zocor, Excedrin, Motrin, Vytorin, Darvocet, morphine.

Description of Event: The subject was first hospitalized on 20 Jul 2004 for cholelithiasis, and again on 15 Oct 2004 to undergo a laparoscopic cholecystectomy with a cholangiogram. Examination of abdomen revealed no gross abnormalities. Cholangiogram indicated good flow into duodenum with no evidence of common bile duct stones. Dissection of the gall bladder indicated the presence of stones, which were removed. The subject tolerated the operation without difficulty.

Outcome: The subject recovered from the operation and was discharged from the hospital on 19 Oct 2004. She discontinued from the study for unrelated causes. The investigator reported cholecystitis and gall stones to be definitely not related to test

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 93

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 217, USA, 7420

TREATMENT : Desvenlafaxine SR 100 mg

SUBJECT : 201831 , 39 Year old, Female, Black , 55.9 kg , 160 cm, 21.8 kg /M^2

THERAPY START DATE/STOP DATE : 31MAR04/ 07JAN05

STUDY COMPLETION STATUS : Discontinued (Subject Request Unrelated to Study) STUDY COMPLETION DATE : 14FEB05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

article. The medical monitor considered gall stones not related to test article.

Page

94

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-217-201819

INVESTIGATOR: 217, USA, 7420

REPORT NARR-INF

TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 201819 , 54 Year old, Female, White , 63.3 kg , 167.6 cm, 22.5 kg /M^2

THERAPY START DATE/STOP DATE : 16MAR04/ 14MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 14MAR05

NARRATIVE REASON : CLINICALLY IMPORTANT VITAL SIGNS {PCI: SUSTAINED HYPERTENSION}

Vital Sign	Position	Visit Date	Seq Num	D.A.I	<pre>Test Value (# => PCI)</pre>	Unit	Baseline Value
DIASTOLIC BP	Supine	25FEB04	1	Screening/baseline	82	mm Hg	75

DIASTOLIC BP	Supine	25FEB04	1	Screening/baseline	82	mm Hg	75	
DIASTOLIC BP	Supine	25FEB04	3	Screening/baseline	56	mm Hg	75	
DIASTOLIC BP	Supine	15MAR04	1	Screening/baseline	82	mm Hg	75	
DIASTOLIC BP	Supine	15MAR04	3	Screening/baseline	80	mm Hg	75	
DIASTOLIC BP	Supine	15APR04	1	Week 4	110	mm Hg	75	
DIASTOLIC BP	Supine	15APR04	3	Week 4	100 #	mm Hq	75	
DIASTOLIC BP	Supine	11MAY04	1	Week 8	82	mm Hq	75	
DIASTOLIC BP	Supine	11MAY04	3	Week 8	100 #	mm Hq	75	
DIASTOLIC BP	Supine	14JUN04	1	Week 12	80	mm Hg	75	
DIASTOLIC BP	Supine	14JUN04	3	Week 12	90 #	mm Hq	75	
DIASTOLIC BP	Supine	14SEP04	1	Week 26	80	mm Hq	75	
DIASTOLIC BP	Supine	14SEP04	3	Week 26	90 #	mm Hq	75	
DIASTOLIC BP	Supine	14DEC04	1	Week 39	100	mm Hq	75	
DIASTOLIC BP	Supine	14DEC04	3	Week 39	100 #	mm Hq	75	
DIASTOLIC BP	Supine	14MAR05	1	Week 52	100	mm Hq	75	
DIASTOLIC BP	Supine	14MAR05	3	Week 52	100 #	mm Hg	75	

MEDICAL MONITOR COMMENTS :

Additional Relevant Vital Sign Values:

Supine

Visit Date Systolic Blood Pressure (mm/Hg)

15Mar04 (Baseline) 138 (Average of all screening/baseline values)
15Apr04 (Week 4) 140

15Apr04 (Week 4) 140 15Apr04 (Week 4) 140

Page 95

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 217, USA, 7420

TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 201819 , 54 Year old, Female, White , 63.3 kg , 167.6 cm, 22.5 kg /M^2

THERAPY START DATE/STOP DATE : 16MAR04/ 14MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 14MAR05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

11May04	(Week	8)		132
11May04	(Week	8)		140
14Jun04	(Week	12)		124
14Jun04	(Week	12)		128
14Sep04	(Week	26)		130
14Sep04	(Week	26)		130
14Dec04	(Week	39)		150
14Dec04	(Week	39)		150
14Mar05	(Week	52)		140
14Mar05	(Week	52)		148
	11May04 14Jun04 14Jun04 14Sep04 14Sep04 14Dec04 14Dec04 14Mar05	11May04 (Week 14Jun04 (Week 14Jun04 (Week 14Sep04 (Week 14Sep04 (Week 14Dec04 (Week 14Dec04 (Week 14Mar05 (Week	11May04 (Week 8) 14Jun04 (Week 12) 14Jun04 (Week 12) 14Sep04 (Week 26) 14Sep04 (Week 26) 14Dec04 (Week 39) 14Dec04 (Week 39) 14Mar05 (Week 52)	11May04 (Week 8) 14Jun04 (Week 12) 14Jun04 (Week 12) 14Sep04 (Week 26) 14Sep04 (Week 26) 14Dec04 (Week 39) 14Dec04 (Week 39) 14Mar05 (Week 52)

Relevant Medical History: occasional sinus headaches, chronic cough.

Relevant Prior Medication: Zovirax.

Relevant Concomitant Medication: Zovirax.

Outcome: At weeks 8, 12, 26, 39, and 52 of treatment, the subject had sustained hypertension as defined by an increase from baseline in supine diastolic blood pressure of more than 10 mm Hg with a value greater than 90 mm Hg at 3 consecutive visits. Heart rate remained within normal range throughout the entire course of treatment. Physical examination and ECG performed at weeks 12 and 52 of treatment were normal. No antihypertensive medications were prescribed. The investigator did not report sustained hypertension as an adverse event. The subject completed the study. No further information is available.

Page 96

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-218-201884

INVESTIGATOR : 218, USA, 14714

TREATMENT : Desvenlafaxine SR 100 mg

SUBJECT : 201884 , 56 Year old, Female, White , 65.5 kg , 151 cm, 28.7 kg /M^2

THERAPY START DATE/STOP DATE : 26MAR04/ 20MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 21MAR05

NARRATIVE REASON : ADVERSE EVENTS OF SPECIAL INTEREST

{CHEST PAIN}

AE VERBATIM	BDY SYS		REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT	ACTION	RELA TION INV	S A E	RELA TION MM	CASE ID
Pressure in chest Pressure in chest	BO BO	Y Y	222 248	1	02NOV04 28NOV04	02NOV04 28NOV04	MIL MIL	RES RES	N N	PNOT PNOT			

MEDICAL MONITOR COMMENTS :

Relevant Medical History: high cholesterol, overweight.

Relevant Prior Medications: Zocor, Cholestyramine.

Relevant Concomitant Medications: Zocor, Sudafed, aspirin, Rolaids, antacids.

Outcome: During the course of the study, the subject experienced 2 episodes of chest pain described as "pressure in chest," mild in severity, which resolved the same day. The investigator reported that the adverse event was not cardiac in nature and counseled the subject to continue to consult with primary care physician on a regular basis. The subject experienced occasional heartburn at weeks 39 and 52 of treatment and was treated with Rolaids and antacids. She recovered and completed the study. No further information is available. The investigator reported that the adverse event was probably not related to test article.

Page 97

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-218-201873

INVESTIGATOR: 218, USA, 14714

TREATMENT : Desvenlafaxine SR 150 mg

: 201873 , 58 Year old, Female, White , 78.5 kg , 170.2 cm, 27.1 kg /M^2

THERAPY START DATE/STOP DATE : 04MAR04/ 02MAR05

: COMPLETED STUDY COMPLETION STATUS STUDY COMPLETION DATE : 03MAR05

NARRATIVE REASON : SERIOUS ADVERSE EVENT (SAE)

{RECTAL HEMORRHAGE}

REPORT NARR-INF

RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM ID

Increased bleeding from hemorrhoids DI N -1E3 1327 01JAN01 19AUG04 SEV RES H O DNOT Y PNOT HQWYE770802SEP04

MEDICAL MONITOR COMMENTS :

Relevant Medical History: increased bleeding from hemorrhoids.

Relevant Prior Medication: Lipitor.

Relevant Concomitant Medications: Lipitor, Aleve, Advil, Vicodin.

Description of Event: During week 26 of treatment, the subject underwent hemorrhoidectomy on 19 Aug 2004 to control increased bleeding from hemorrhoids. She recovered from the operation, and was discharged on 20 Aug 2004. Postoperative pain stopped on 20 Sep 2004 during week 28 of treatment.

Outcome: The subject recovered and completed the study. The investigator reported the adverse event as severe and definitely not related to test article. Medical monitor considered the adverse event not related to test article.

CONFIDENTIAL 776 Wyeth

Page 98

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-218-201877

INVESTIGATOR: 218, USA, 14714

TREATMENT : Desvenlafaxine SR 150 mg

: 201877 , 52 Year old, Fémale, White , 102.5 kg , 176.5 cm, 32.9 kg /M^2

THERAPY START DATE/STOP DATE : 10MAR04/ 01AUG04

: Discontinued (Adverse Event - HYPERTENSION) STUDY COMPLETION STATUS

STUDY COMPLETION DATE : 16AUG04

NARRATIVE REASON: DISCONTINUATION DUE TO ADVERSE EVENT

{HYPERTENSION}

RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM

02AUG04 10AUG04 MOD RES P High blood pressure CV N 146 9 POSS

MEDICAL MONITOR COMMENTS :

Additional Relevant Vital Sign Values:

Visit Date Supine Blood Pressure

(mm Hq)

03Mar04	(Baseline)	124/79	(Average	of	all	screening/baseline values)
31Mar04	(Week 4)	120/84	_			-
31Mar04	(Week 4)	128/84				
05May04	(Week 8)	140/80				
05May04	(Week 8)	136/84				
02Jun04	(Week 12)	134/88				
02Jun04	(Week 12)	142/94				
16Aug04	(Follow-up)	122/70				
16Aug04	(Follow-up)	124/82				

Relevant Medical History: obesity. Relevant Prior Medication: Excedrin.

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 99

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 218, USA, 14714

TREATMENT : Desvenlafaxine SR 150 mg

: 201877 , 52 Year old, Female, White , 102.5 kg , 176.5 cm, 32.9 kg /M^2

THERAPY START DATE/STOP DATE : 10MAR04/ 01AUG04

: Discontinued (Adverse Event - HYPERTENSION) STUDY COMPLETION STATUS STUDY COMPLETION DATE

: 16AUG04

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Relevant Concomitant Medications: Excedrin migraine, Tylenol, Tylenol cold, Tylenol PM, Tylenol sinus, Tylenol Extra Strength.

Outcome: On day 146 of treatment, the subject discontinued from the study because of hypertension. At all visits, systolic and diastolic blood pressure were within normal range. The investigator reported increase in blood pressure as an adverse event, possibly related to test article. No further information is available.

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-218-201866

INVESTIGATOR : 218, USA, 14714

TREATMENT : Desvenlafaxine SR 200 mg

: 201866 , 47 Year old, Female, White , 85.3 kg , 163 cm, 32.1 kg /M^2

THERAPY START DATE/STOP DATE : 12MAR04/ 13MAR05

: COMPLETED STUDY COMPLETION STATUS STUDY COMPLETION DATE : 14MAR05

NARRATIVE REASON: ADVERSE EVENTS OF SPECIAL INTEREST

{HOSTILITY}

AE VERBATIM	BDY SYS		REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT COM	ACTION	RELA TION INV	S A E	RELA TION MM	CASE ID	
Desire to hurt others (Feelings of anger)	NE	N	371	8	17MAR05	24MAR05	SEV	RES	S	DNOT				
Episodes of rage	NE	N	369	10	15MAR05	24MAR05	SEV	RES	S	DNOT				

MEDICAL MONITOR COMMENTS:

Relevant Medical History: none.

Relevant Prior Medications: none.

Relevant Concomitant Medications: none.

Outcome: Four (4) days after discontinuation of test article, the subject experienced an episode of hostility described as "desire to hurt others (feelings of anger)" and "episodes of rage." Other symptoms of mental distress, nervousness, uncontrollable crying, and erratic sleep patterns appeared along with hostility. The subject was prescribed Xanax and Activella. Hostility and associated symptoms resolved within 10 days. The investigator reported the adverse event as severe and definitely not related to test article.

CONFIDENTIAL

Page 100

Page 101

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-218-201875

INVESTIGATOR: 218, USA, 14714

REPORT NARR-INF

TREATMENT : Desvenlafaxine SR 200 mg

: 201875 , 51 Year old, Fémale, Black , 67.6 kg , 165.1 cm, 24.8 kg /M^2

Week 39

Week 39

Follow-up

THERAPY START DATE/STOP DATE : 08MAR04/ 03MAR05

: COMPLETED STUDY COMPLETION STATUS STUDY COMPLETION DATE : 04MAR05

NARRATIVE REASON : CLINICALLY IMPORTANT VITAL SIGNS (DCT. EVERATIC DIAAN DEFECTIOE)

PRESSURE;						
Position		D 7 T	Seq	Test Value	IIni+	Baseline Value
POSICION	Date	D.A.1	Nulli	(# -> PCI)	UIIIC	value
Supine	27FEB04	Screening/baseline	1	130	mm Hg	127
Supine	27FEB04	Screening/baseline	3	128	mm Hg	127
Supine	08MAR04	Screening/baseline	1	130	mm Hg	127
Supine	08MAR04	Screening/baseline	3	120	mm Hg	127
Supine	02APR04	Week 4	1	142	mm Hg	127
Supine	02APR04	Week 4	3	144	mm Hg	127
Supine	30APR04	Week 8	1	120	mm Hg	127
Supine	30APR04	Week 8	3	120	mm Hg	127
Supine	04JUN04	Week 12	1	150	mm Hg	127
Supine	04JUN04	Week 12	3	168 #	mm Hg	127
Supine	30AUG04	Week 26	1	118	mm Hg	127
Supine	30AUG04	Week 26	3	116	mm Hg	127
	Position Supine	Visit Position Date Supine 27FEB04 Supine 27FEB04 Supine 08MAR04 Supine 02APR04 Supine 02APR04 Supine 30APR04 Supine 30APR04 Supine 04JUN04 Supine 04JUN04 Supine 30AUG04	Visit Date D.A.I Supine 27FEB04 Screening/baseline Supine 27FEB04 Screening/baseline Supine 08MAR04 Screening/baseline Supine 08MAR04 Screening/baseline Supine 02APR04 Week 4 Supine 02APR04 Week 4 Supine 30APR04 Week 8 Supine 30APR04 Week 8 Supine 30APR04 Week 8 Supine 04JUN04 Week 12 Supine 04JUN04 Week 12 Supine 30AUG04 Week 26	Visit Seq Date D.A.I Num Supine 27FEB04 Screening/baseline 1 Supine 27FEB04 Screening/baseline 3 Supine 08MAR04 Screening/baseline 1 Supine 08MAR04 Screening/baseline 3 Supine 02APR04 Week 4 1 Supine 02APR04 Week 4 3 Supine 30APR04 Week 8 1 Supine 30APR04 Week 8 3 Supine 04JUN04 Week 12 1 Supine 30AUG04 Week 26 1	Visit Date D.A.I Seq Test Value Num (# => PCI)	Visit Date D.A.I Seq Test Value (# => PCI) Unit

mm Hq

mm Hq

mm Hq

mm Hq

127

127

127

127

112

112

122

124

MEDICAL MONITOR COMMENTS :

SYSTOLIC BP

SYSTOLIC BP

SYSTOLIC BP

SYSTOLIC BP

Additional Relevant Vital Sign Values:

Supine

Visit Date Diastolic Blood Pressure

(mm Hq)

Supine

Supine

Supine

Supine

27Feb04 (Baseline) 80 (Average of all screening/baseline values)

06DEC04

04MAR05

04MAR05 Follow-up

06DEC04

02Apr04 (Week 4)

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 102

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 218, USA, 14714

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 201875 , 51 Year old, Female, Black , 67.6 kg , 165.1 cm, 24.8 kg /M^2

THERAPY START DATE/STOP DATE : 08MAR04/ 03MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 04MAR05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

02Apr04 30Apr04 30Apr04 04Jun04	(Week (Week (Week (Week	8) 8) 12)	82 74 76 98
04Jun04	(Week	12)	98
30Aug04	(week		72
30Aug04	(week	26)	70
06Dec04	(Week	39)	68
06Dec04	(Week	39)	64
04Mar05	(Week	52)	80
04Mar05	(Week	52)	80

Relevant Medical History: open heart surgery (at age 5), hypertension (since 2001).

Relevant Prior Medications: lisinopril, Tylenol.

Relevant Concomitant Medications: lisinopril, Tylenol.

Outcome: At week 12 of treatment, the subject had a 41-mm Hg increase from baseline in systolic blood pressure that was considered clinically important (>/= 30 mm Hg from baseline with a value >/= 160 mm Hg). At subsequent visits, systolic blood pressure returned to within normal range. Diastolic blood pressure and heart rate remained normal throughout the entire course of treatment. The subject completed the study. The investigator did not report the increase in systolic blood pressure as an adverse event.

Page 103

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-218-201888

INVESTIGATOR : 218, USA, 14714

REPORT NARR-INF

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 201888 , 54 Year old, Female, White , 85.5 kg , 171.5 cm, 29.1 kg /M^2

THERAPY START DATE/STOP DATE : 01APR04/ 16NOV04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - HYPERCHOLESTEREMIA)

STUDY COMPLETION DATE : 09DEC04

NARRATIVE REASON : DISCONTINUATION DUE TO ADVERSE EVENT

{HYPERCHOLESTEROLEMIA}

AE VERBATIM	BDY SYS	E	REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT	ACTION	RELA TION INV	S A E	RELA TION MM	CASE ID
Increasing cholesterol	MN	Y	187	67	040CT04	09DEC04	MOD	RES	P 0	POSS			

MEDICAL MONITOR COMMENTS :

Additional Relevant Lab Values:

Visit date	Total Cholesterol (0-5.15 mmol/L)	HDL Cholesterol (0.88-2.07 mmol/L)	LDL Cholesterol (0-3.36 mmol/L)	Triglycerides (0.40-2.26 mmol/L)
25Mar04 (Baseline)	5.64	1.55	3.75	0.71
22Apr04 (Week 4)	6.44	1.71	4.32	0.88
29Jun04 (Week 12)	6.93	1.58	4.73	1.37
04Oct04 (Week 26)	7.01	1.50	4.76	1.61
09Dec04 (Follow-up)	6.34	1.60	4.22	1.11

Relevant Medical History: overweight.

Relevant Prior Medication: Vioxx.

Relevant Concomitant Medication: Vioxx.

Outcome: At week 26 of treatment, the subject showed progressive increase in total cholesterol levels from 5.64 mmol/L at baseline to 6.44 mmol/L at week 4, and to a maximum of 7.01 mmol/L at week 26 of treatment. HDL cholesterol and triglycerides remained within normal range. The subject discontinued from the study because of hypercholesterolemia. After discontinuation from treatment, total cholesterol showed trend towards return to baseline levels at follow-up visit.

CONFIDENTIAL 782 Wyeth

......

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 104

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 218, USA, 14714

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 201888 , 54 Year old, Female, White , 85.5 kg , 171.5 cm, 29.1 kg /M^2

THERAPY START DATE/STOP DATE : 01APR04/ 16NOV04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - HYPERCHOLESTEREMIA) STUDY COMPLETION DATE : 09DEC04

(continued from previous page)

MEDICAL MONITOR COMMENTS :

The investigator reported the adverse event as moderate in severity, possibly related to test article.

Page 105

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-218-201878

INVESTIGATOR: 218, USA, 14714

TREATMENT : Desvenlafaxine SR 50 mg

SUBJECT : 201878 , 50 Year old, Female, White , 70.8 kg , 167.6 cm, 25.2 kg /M^2

THERAPY START DATE/STOP DATE : 12MAR04/ 06MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 07MAR05

NARRATIVE REASON : CLINICALLY IMPORTANT VITAL SIGNS

{PCI: ORTHOSTATIC HYPOTENSION}

Visit Date	D.A.I	Vital Sign	Position	Seq Num	Blood Pressure (mm Hg)	Orthostatic Change (mm Hg)	
12APR04	Week 4	SYSTOLIC BP	Supine	1	136	30	-
12APR04	Week 4	SYSTOLIC BP	Supine	3	136	30	
12APR04	Week 4	SYSTOLIC BP	standing	4	106	30	
12APR04	Week 4	SYSTOLIC BP	standing	6	132	30	
29APR04	Week 8	SYSTOLIC BP	Supine	1	130	32	
29APR04	Week 8	SYSTOLIC BP	Supine	3	142	32	
29APR04	Week 8	SYSTOLIC BP	standing	4	110	32	
29APR04	Week 8	SYSTOLIC BP	standing	6	122	32	

MEDICAL MONITOR COMMENTS :

Relevant Medical History: history of migraine headaches (since age 12).

Relevant Prior Medications: none.

Relevant Concomitant Medications: none.

Outcome: At weeks 4 and 8 of treatment, the subject experienced an episode of orthostatic hypotension, as measured by decreases of 30 mm Hg and 32 mm Hg systolic blood pressure, respectively, from last supine to first standing, that was considered clinically important. She did not report associated symptoms. At subsequent visits, systolic blood pressure was normal, including measurements taken during postural changes. The subject completed the study. The investigator did not report orthostatic hypotension as an adverse event.

Page 106

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-218-201883

INVESTIGATOR: 218, USA, 14714

TREATMENT : Desvenlafaxine SR 50 mg

SUBJECT : 201883 , 56 Year old, Female, White , 62.6 kg , 157.5 cm, 25.2 kg /M^2

THERAPY START DATE/STOP DATE : 05APR04/ 30MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 31MAR05

NARRATIVE REASON : CLINICALLY IMPORTANT ECG VALUES

{PCI: QTCF INTERVAL}

Vital Sign	Rel. Day (Days)	D.A.I	Visit Date	Test Value (# => PCI)	Unit	Baseline Value	
QTCF INTRVL	-24	Screening/baseline	12MAR04	342	msec	342	
QTCF INTRVL	87	Week 12	30JUN04	395	msec	342	
QTCF INTRVL	361	Week 52	31MAR05	408 #	msec	342	

MEDICAL MONITOR COMMENTS :

Addition Delevent ECC Welves

Addition Relevant ECG Values:

Visit Date	QT (msec)	QTcB (msec)	Heart rate (beats/min)
12Mar04 (Baseli 30Jun04 (Week 1		345 409	63
31Mar05 (Week 5		415	67

Relevant Medical History: hypertension (2000), left anterior hemiblock and flat T-waves.

Relevant Prior Medications: Diovan, naproxen.

Relevant Concomitant Medications: Diovan, naproxen.

Outcome: At week 52 of treatment, the subject had an increase in QTcF interval greater than 60 msec from baseline (66 msec). She also had increases of 64 and 70 msec in QTcB interval at weeks 12 and 52 of treatment, respectively. However, all QT intervals at all time points remained below the upper limit (<470 msec). The subject's physical examination and blood pressures were normal during the study. She completed the study. The investigator did not report the increases in QTcF and QTcB intervals as adverse events. No further information is available.

Page 107

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-219-201910

INVESTIGATOR: 219, USA, 15808

TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 201910 , 50 Year old, Fémale, White , 60.9 kg , 156.2 cm, 25.0 kg /M^2

THERAPY START DATE/STOP DATE : 11MAR04/ 22DEC04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - HYPERLIPEMIA) STUDY COMPLETION DATE : 27DEC04

NARRATIVE REASON: DISCONTINUATION DUE TO ADVERSE EVENT

{HYPERLIPEMIA}

AE VERBATIM	BDY SYS		REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT	ACTION		A	RELA TION MM	CASE ID	
Worsening hyperlipidema hyperlipidemic	MN	Y	89	•	07JUN04	•	MOD	PER	M	POSS				
Worsening of pre-existing hyperlipidemic	MN	Y	89	•	07JUN04		MOD	PER	P	POSS				

hyperlipidemic NARRATIVE REASON : CLINICALLY IMPORTANT LABORATORY VALUES

{PCI: TRIGLYCERIDES}

Lab Test	Rel. Day (Days)	D.A.I	Test Date	Test Value (# => PCI)	Fasting (Y/N)	Range (Low)	Range (High)	Unit	Baseline Value
TRIGLYCERIDES /LIPID	-10	Screening/baseline	01MAR04	2.5854	Yes	0.3952	2.258	mmol/L	2.5854
TRIGLYCERIDES /LIPID	29	Week 4	08APR04	1.3209	Yes	0.3952	2.258	mmol/L	2.5854
TRIGLYCERIDES /LIPID	89	Week 12	07JUN04	3.3306	Yes	0.3952	2.258	mmol/L	2.5854
TRIGLYCERIDES /LIPID	118	Week 12	06JUL04	4.5725	Yes	0.3952	2.258	mmol/L	2.5854
TRIGLYCERIDES /LIPID	167	Week 26	24AUG04	1.6935	Yes	0.3952	2.258	mmol/L	2.5854
TRIGLYCERIDES /LIPID	188	Week 26	14SEP04	1.7274	Yes	0.3952	2.258	mmol/L	2.5854
TRIGLYCERIDES /LIPID	279	Week 39	14DEC04	9.8788 #	Yes	0.3952	2.258	mmol/L	2.5854
TRIGLYCERIDES /LIPID	292	Week 39	27DEC04	3.4547	Yes	0.3952	2.258	mmol/L	2.5854

MEDICAL MONITOR COMMENTS:

Relevant Medical History: hypothyroidism (2001), hyperlipidemia (2003), overweight.

CONFIDENTIAL Wyeth **786**

Page 108

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 219, USA, 15808

TREATMENT : Desvenlafaxine SR 150 mg

: 201910 , 50 Year old, Female, White , 60.9 kg , 156.2 cm, 25.0 kg /M^2

THERAPY START DATE/STOP DATE : 11MAR04/ 22DEC04

: Discontinued (Adverse Event - HYPERLIPEMIA) STUDY COMPLETION STATUS STUDY COMPLETION DATE

: 27DEC04

(continued from previous page)

MEDICAL MONITOR COMMENTS:

Additional Relevant Lab Values:

Visit Da	te	Total cholesterol (0-5.15 mmol/L)	HDL Cholesterol LDL (0.88-2.07 mmol/L)	Cholesterol (0-3.36 mmol/L)	
01Mar04	(Baseline)	6.96	1.42	4.34	
08Apr04	(Week 4)	6.80	1.34	4.86	
07Jun04	(Week 12)	8.71	1.50	5.69	
06Jul04	(Week 12)	8.33	ND	ND	
24Auq04	(Week 26)	6.08	1.60	3.70	
10Sep04	(Week 26)	4.97	ND	ND	
14Sep04	(Week 26)	5.09	1.42	2.87	
14Dec04	(Week 39)	8.79	1.14	ND	
27Dec04	(Week 39)	7.37	1.32	4.47	

Relevant Prior Medication: levothyroxine.

Relevant Concomitant Medications: levothyroxine, Crestor.

Outcome: The subject was not treated for known hyperlipidemia and had high total cholesterol, LDL cholesterol, and triglycerides at baseline. At week 39 of treatment, she discontinued from the study because of "worsening of preexisting" hyperlipidemia. Total cholesterol, LDL cholesterol, and triglycerides increased from baseline by 1.75 mmol/L, 1.35 mmol/L, and 0.75 mmol/L, respectively. The subject's lipid profile was brought under control by a prescription of Crestor. However, she discontinued taking Crestor on 30 Sep 2004 and total cholesterol and triglyceride levels returned to higher levels. Repeat lipid profile performed 2 weeks later showed a trend to return to baseline levels. The investigator reported the adverse event "worsening of hyperlipidemia" to be moderate in severity and possibly related to test article.

Page 109

RELA S RELA

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-219-201945

INVESTIGATOR: 219, USA, 15808

TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 201945 , 50 Year old, Female, White , 70 kg , 176.5 cm, 22.5 kg /M^2

THERAPY START DATE/STOP DATE : 05APR04/ 29MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 30MAR05

NARRATIVE REASON : ADVERSE EVENTS OF SPECIAL INTEREST

{DEPRESSION}

AE VERBATIM	BDY T REL SYS E DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT COM	ACTION		A	RELA TION MM	
"Sense of doom"	NE N 369	1	08APR05	08APR05	SEV	RES	S O	PROE	3		
Feeling of "impending doom" (after	NE Y 316	1	14FEB05	14FEB05	SEV	RES	N	PROB			
missing 3 days of test article)											

{THINKING ABNORMAL}

AE VERBATIM	BDY SYS		REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT	ACTION	TION	TION MM	CASE ID	
Decreased clarity of thinking	NE	N	369	1	08APR05	08APR05	SEV	RES	S O	PROB			
Decreased concentration ability	NE	Y	316	1	14FEB05	14FEB05	MOD	RES	N	PROB			
(after missing 3 days test article)													
Non suicidal preoccupation with being	NE	Y	316	1	14FEB05	14FEB05	MOD	RES	N	PROB			

Non suicidal preoccupation with dead (after 3 days missed test article)

artitle)

MEDICAL MONITOR COMMENTS :

Relevant Medical History: no reported history of depression.

Relevant Prior Medication: Flexeril.

Relevant Concomitant Medications: Flexeril, Sudafed, Valium, Xanax, Ambien.

Outcome: On day 316 of treatment, after missing test article for 3 days, the subject reported an episode of depression and abnormal thinking described as "decreased concentration and clarity of thinking," "feeling of impending doom," and

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 110

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 219, USA, 15808

: Desvenlafaxine SR 150 mg

: 201945 , 50 Year old, Female, White , 70 kg , 176.5 cm, 22.5 kg /M^2

THERAPY START DATE/STOP DATE : 05APR04/ 29MAR05

STUDY COMPLETION STATUS STUDY COMPLETION DATE : COMPLETED : 30MAR05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

"nonsuicidal preoccupation with being dead" that resolved spontaneously with the resumption of test article. At study completion and discontinuation of test article, the subject again reported crying spells, sleep disruption, sense of doom, and decreased clarity of thinking. The antidepressant medication, Effexor, was prescribed and symptoms resolved. The subject completed the study. The investigator reported the adverse events as severe in nature and probably related

to discontinuation of test article.

Page 111

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-220-201958

INVESTIGATOR : 220, USA, 592

TREATMENT : Desvenlafaxine SR 100 mg

SUBJECT : 201958 , 49 Year old, Female, Black , 71.7 kg , 180.4 cm, 22.0 kg /M^2

THERAPY START DATE/STOP DATE : 08MAR04/ 27MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 06APR05

NARRATIVE REASON : ADVERSE EVENTS OF SPECIAL INTEREST

{CHEST PAIN}

REPORT NARR-INF

BDY T REL DURA ONSET STOP OUT TION A TION CASE
AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM ID

Discomfort in chest BO N 397 1 08APR05 08APR05 MIL RES N POSS

MEDICAL MONITOR COMMENTS :

Relevant Medical History: chest pain of unknown etiology-negative tests (October 2003).

Relevant Prior Medications: none.

Relevant Concomitant Medications: none.

Outcome: After discontinuation of test article, the subject reported an episode of chest pain described as "discomfort in chest" as well as dizziness, nausea, light-headedness, fatigue, headache, and nervousness that resolved spontaneously within a day. The investigator reported the chest pain (as well as other adverse events) as possibly related to discontinuation of test article. The subject completed the study.

Page 112

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-225-202206

INVESTIGATOR : 225, USA, 19580

TREATMENT : Desvenlafaxine SR 150 mg SUBJECT : 202206, 62 Year old, Female, White, 52 kg, 158 cm, 20.8 kg/M^2

THERAPY START DATE/STOP DATE : 01APR04/ 10SEP04

STUDY COMPLETION STATUS : Discontinued (Subject Request Unrelated to Study) STUDY COMPLETION DATE : 110CT04

NARRATIVE REASON : CLINICALLY IMPORTANT VITAL SIGNS

{PCI: DIASTOLIC BLOC	D PRESSURE	}					
		Visit		Seq	Test Value		Baseline
Vital Sign	Position	Date	D.A.I	Num	(# => PCI)	Unit	Value
DIASTOLIC BP	Supine	09MAR04	Screening/baseline	1	86	mm Hg	86.5
DIASTOLIC BP	Supine	09MAR04	Screening/baseline	3	86	mm Hg	86.5
DIASTOLIC BP	Supine	01APR04	Screening/baseline	1	94	mm Hq	86.5
DIASTOLIC BP	Supine	01APR04	Screening/baseline	3	80	mm Hg	86.5
DIASTOLIC BP	Supine	04MAY04	Week 4	1	96	mm Hg	86.5
DIASTOLIC BP	Supine	04MAY04	Week 4	3	104	mm Hg	86.5
DIASTOLIC BP	Supine	01JUN04	Week 8	1	110 #	mm Hg	86.5
DIASTOLIC BP	Supine	01JUN04	Week 8	3	110 #	mm Hg	86.5
DIASTOLIC BP	Supine	23JUN04	Week 12	1	96	mm Ha	86.5
DIASTOLIC BP	Supine	23JUN04	Week 12	3	84	mm Ha	86.5
DIASTOLIC BP	Supine	110CT04	Follow-up	1	86	mm Ha	86.5
DIASTOLIC BP	Supine	110CT04	Follow-up	3	84	mm Hg	86.5

MEDICAL MONITOR COMMENTS :

Additional Relevant Vital Sign Values:

Supine

Visit Date Systolic Blood Pressure (mm Hq)

01Apr04 (Ba	seline)	150 (A	Average o	of all	screening/baseline	values)
04May04 (We		140 `	_		3.	,
04Mav04 (We		150				
01Jun04 (We		176				
01Jun04 (We	ek 8)	170				
23Jun04 (We	eek 12)	140				

Page 113

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 225, USA, 19580

: Desvenlafaxine SR 150 mg

: 202206 , 62 Year old, Female, White , 52 kg , 158 cm, 20.8 kg /M^2

THERAPY START DATE/STOP DATE : 01APR04/ 10SEP04

STUDY COMPLETION STATUS STUDY COMPLETION DATE : Discontinued (Subject Request Unrelated to Study)

: 110CT04

(continued from previous page)

MEDICAL MONITOR COMMENTS :

23Jun04	(Week 12)	136
110ct04	(Follow-up)	134
110ct04	(Follow-up)	138

Relevant Medical History: hypertension (1987), hypertension (1994).

Relevant Prior Medications: Lotrel, extra strength acetaminophen.

Relevant Concomitant Medications: Lotrel, clonidine.

Outcome: The subject had borderline elevated blood pressure at baseline. At week 8 of treatment, she had a 23.5-mm Hg increase from baseline in diastolic blood pressure that was considered clinically important (>/= 20 mm Hg from baseline with a value >/= 100 mm Hg). At subsequent visits, diastolic blood pressure returned to baseline values. The subject discontinued from the study at week 24 for reasons unrelated to study. The investigator did not report the increase in diastolic blood pressure as an adverse event.

Page 114

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-225-202218

INVESTIGATOR: 225, USA, 19580

TREATMENT : Desvenlafaxine SR 50 mg

SUBJECT : 202218 , 52 Year old, Female, White , 67 kg , 164 cm, 24.9 kg /M^2

THERAPY START DATE/STOP DATE : 12APR04/ 03APR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 04APR05

NARRATIVE REASON : ADVERSE EVENTS OF SPECIAL INTEREST

{DEPRESSION}

REPORT NARR-INF

RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM Depression NE Y 248 97 15DEC04 21MAR05 MIL RES N POSS

MEDICAL MONITOR COMMENTS :

Relevant Medical History: migraine headaches (1963), back pain (2003). No reported prior history of depression.

Relevant Prior Medications: none.

Relevant Concomitant Medications: none.

Outcome: At week 39 of treatment, the subject had an episode of depression, mild in severity, that resolved without treatment in 97 days. She reported that the episode of depression was related to events in personal life. The subject completed the study. The investigator reported the adverse event as possibly related to test article. No further information is available.

CONFIDENTIAL 793 Wyeth

Page 115

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-228-202368

INVESTIGATOR: 228, USA, 474

TREATMENT : Desvenlafaxine SR 100 mg

SUBJECT : 202368 , 56 Year old, Female, White , 84.4 kg , 169.2 cm, 29.5 kg /M^2

THERAPY START DATE/STOP DATE : 25FEB04/ 22FEB05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 24FEB05

NARRATIVE REASON : SERIOUS ADVERSE EVENT (SAE)

{CELLULITIS}

REPORT NARR-INF

BDY T REL DURA ONSET STOP OUT TION A TION CASE
AE VERBATIM

BDY T REL DURA ONSET STOP OUT TION A TION CASE
SYS E DAY TION DATE DATE SEV COM ACTION INV E MM ID

Cellulitis

BO Y 233 4 140CT04 170CT04 MIL RES S H DNOT Y PNOT HOWYE9295210CT04

MEDICAL MONITOR COMMENTS :

Relevant Medical History: joint pain, neck pain, kidney stones, back pain, knee pain, osteoarthritis.

Relevant Prior Medications: enteric aspirin, Celebrex, Midrin, propoxyphene.

Relevant Concomitant Medications: Tylenol, propoxyphene, cyclobenzaprine, hydrochlorothiazide, Advair, Astelin, spironolactone, dicloxacillin, Neurontin, Celebrex, cephalexin, Darvon-N, Keflex, ibuprofen, Lortab, Levaquin, meclizine, prednisolone.

Description of Event: The subject was admitted to hospital on 14 Oct 2004 for infection developed at the site of spinal cord stimulator battery replacement (for chronic pain control). She was administered intravenous antibiotics and remained afebrile. She was taking Darvocet-N 100 and Neurontin for pain control. Laboratory tests, complete blood count, and basic metabolic panel performed on 16 Oct 2004 were all normal. The subject was discharged on 17 Oct 2004 taking oral antibiotics. She was counseled to have spinal course stimulator battery removed, because of possible electrical leakage around battery. Bacterial infection resolved on 17 Oct 2004.

Outcome: The subject completed the study. The investigator reported the adverse event to be mild in severity and definitely not related to test article.

Page 116

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-228-202384

INVESTIGATOR : 228, USA, 474

TREATMENT : Desvenlafaxine SR 100 mg

SUBJECT : 202384 , 55 Year old, Fémale, Native American , 78.5 kg , 178 cm, 24.8 kg /M^2

THERAPY START DATE/STOP DATE : 09MAR04/ 03MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 04MAR05

NARRATIVE REASON: ADVERSE EVENTS OF SPECIAL INTEREST

{OVERDOSE}
Comment

(not collected in database, but considered as reportable

overdose information)

MEDICAL MONITOR COMMENTS :

Relevant Medical History: none.

Relevant Prior Medications: none.

Relevant Concomitant Medications: none.

Description of Event: The subject missed test article on study day 159 and elected to take double the quantity of tablets on study day 160. She did not report any associated symptoms. The investigator reported the event as an intentional overdose.

Outcome: Both investigator and medical monitor considered the event as nonserious. The subject completed the study.

Page 117

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-228-203682

INVESTIGATOR : 228, USA, 474

REPORT NARR-INF

TREATMENT : Desvenlafaxine SR 100 mg
SUBJECT : 203682 , 55 Year old, Female, Black , 74.3 kg , 155.8 cm, 30.6 kg /M^2

THERAPY START DATE/STOP DATE : 16MAR04/ 09MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 10MAR05

NARRATIVE REASON : CLINICALLY IMPORTANT VITAL SIGNS

{PCI: ORTHOSTATIC HYPOTENSION}

Visit Date	D.A.I	Vital Sign	Position	Seq Num	Blood Pressure (mm Hg)	Orthostatic Change (mm Hg)	
02MAR04	Screening/baseline	SYSTOLIC BP	Supine	1	160	31	
02MAR04	Screening/baseline	SYSTOLIC BP	Supine	3	170	31	
02MAR04	Screening/baseline	SYSTOLIC BP	standing	4	139	31	
02MAR04	Screening/baseline	SYSTOLIC BP	standing	6	132	31	
17MAY04	Week 8	SYSTOLIC BP	Supine	1	141	36	
17MAY04	Week 8	SYSTOLIC BP	Supine	3	143	36	
17MAY04	Week 8	SYSTOLIC BP	standing	4	107	36	
17MAY04	Week 8	SYSTOLIC BP	standing	6	119	36	

MEDICAL MONITOR COMMENTS :

Additional Relevant Vital Sign Values:

Visit Date	Position	Diastolic Blood Pressure (mm Hg)
02Mar04 (Baseline) 02Mar04 (Baseline) 02Mar04 (Baseline) 02Mar04 (Baseline) 17May04 (Week 8)	Standing Standing Supine Supine Standing Standing	84 90 80 94 69 77
17May04 (Week 8) 17May04 (Week 8)	Supine Supine	82 78

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

Page 118

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR : 228, USA, 474

TREATMENT : Desvenlafaxine SR 100 mg

SUBJECT : 203682 , 55 Year old, Female, Black , 74.3 kg , 155.8 cm, 30.6 kg /M^2

THERAPY START DATE/STOP DATE : 16MAR04/ 09MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 10MAR05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Relevant Medical History: hypercholesterolemia, hypertension, obesity.

Relevant Prior Medications: simvastatin, ramipril, Actifed, Percocet, ibuprofen.

Relevant Concomitant Medications: ramipril, ibuprofen, Zyrtec, Sudafed.

Outcome: At week 8 of treatment, the subject experienced an episode of orthostatic hypotension as measured by a decrease of 36 mm Hg in systolic blood pressure from last supine to first standing that was considered clinically important (decrease of >/= 30 mm Hg systolic blood pressure from last supine to first standing). She did not report any associated symptoms. At subsequent visits, blood pressure was normal, including measurements taken during postural changes. Postural hypotension was already present at baseline. The subject completed the study. The investigator did not report orthostatic hypotension as an adverse event.

Page 119

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-228-203701

INVESTIGATOR : 228, USA, 474

TREATMENT : Desvenlafaxine SR 100 mg

SUBJECT : 203701 , 56 Year old, Fémale, Other , 63.9 kg , 156.5 cm, 26.1 kg /M^2

THERAPY START DATE/STOP DATE : 26MAR04/ 17MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 18MAR05

NARRATIVE REASON : CLINICALLY IMPORTANT VITAL SIGNS

{PCI: SYSTOLIC BLOOD PRESSURE}

		Visit		Seq	Test Value		Baseline
Vital Sign	Position	Date	D.A.I	Num	(# => PCI)	Unit	Value
SYSTOLIC BP	Supine	16MAR04	Screening/baseline	1	122	mm Hg	116
SYSTOLIC BP	Supine	16MAR04	Screening/baseline	3	120	mm Hg	116
SYSTOLIC BP	Supine	26MAR04	Screening/baseline	1	110	mm Hg	116
SYSTOLIC BP	Supine	26MAR04	Screening/baseline	3	112	mm Hg	116
SYSTOLIC BP	Supine	23APR04	Week 4	1	122	mm Hg	116
SYSTOLIC BP	Supine	23APR04	Week 4	3	132	mm Hg	116
SYSTOLIC BP	Supine	25MAY04	Week 8	1	129	mm Hg	116
SYSTOLIC BP	Supine	25MAY04	Week 8	3	129	mm Hg	116
SYSTOLIC BP	Supine	21JUN04	Week 12	1	114	mm Hg	116
SYSTOLIC BP	Supine	21JUN04	Week 12	3	119	mm Hg	116
SYSTOLIC BP	Supine	20SEP04	Week 26	1	119	mm Hg	116
SYSTOLIC BP	Supine	20SEP04	Week 26	3	137	mm Hg	116
SYSTOLIC BP	Supine	17DEC04	Week 39	1	155	mm Hg	116
SYSTOLIC BP	Supine	17DEC04	Week 39	3	141	mm Hg	116
SYSTOLIC BP	Supine	03JAN05	Week 39	1	129	mm Hg	116
SYSTOLIC BP	Supine	03JAN05	Week 39	3	123	mm Hg	116
SYSTOLIC BP	Supine	18MAR05	Follow-up	1	162 #	mm Hg	116
SYSTOLIC BP	Supine	18MAR05	Follow-up	3	162 #	mm Hg	116

MEDICAL MONITOR COMMENTS :

Additional Relevant Vital Sign Values:

Supine

Visit Date Diastolic Blood Pressure

(mm Hq)

26Mar04 (Baseline) 76 (Average of all screening/baseline values)

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 120

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 228, USA, 474

TREATMENT : Desvenlafaxine SR 100 mg

SUBJECT : 203701 , 56 Year old, Female, Other , 63.9 kg , 156.5 cm, 26.1 kg /M^2

THERAPY START DATE/STOP DATE : 26MAR04/ 17MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 18MAR05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Relevant Medical History: hypercholesterolemia, hypertriglyceridemia, hypertension, overweight.

Relevant Prior Medication: diltiazem.

Relevant Concomitant Medication: diltiazem.

Outcome: At last visit, the subject had a 46-mm Hg increase from baseline in systolic blood pressure that was considered clinically important (>/= 30 mm Hg from baseline with a value >/= 160 mm Hg). At all previous visits, systolic blood pressure remained within normal range. Diastolic blood pressure and heart rate were normal throughout the entire course of treatment. The subject completed the study. The investigator did not report the increase in systolic blood pressure as an adverse event.

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

ION OF PROTOCOL 3151A2-315 Page 121

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-228-203716

INVESTIGATOR: 228, USA, 474

TREATMENT : Desvenlafaxine SR 100 mg

SUBJECT : 203716 , 78 Year old, Female, White , 84.3 kg , 156.9 cm, 34.2 kg /M^2

THERAPY START DATE/STOP DATE : 01APR04/ 22SEP04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - OVARIAN CARCINOMA)

STUDY COMPLETION DATE : 23SEP04

NARRATIVE REASON : SERIOUS ADVERSE EVENT (SAE)

{OVARIAN CARCINOMA}

cancer

RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM 250CT04 . Stage IV primary peritoneal ovarian UR N 208 LIF PER P DNOT Y PNOT HQWYE303107JUN05

MEDICAL MONITOR COMMENTS :

Relevant Medical History: fibroid tumors, hysterectomy, vaginal prolapse, obesity, hypertension.

Relevant Prior Medications: enteric aspirin, Ditropan, Lasix, Bextra, Lopressor, Ecotrin.

Relevant Concomitant Medications: enteric aspirin, Lopressor, Bextra, Ditropan, Advil.

Description of Event: The subject failed to return for her week 39 visit because she was hospitalized for diffuse abdominal pain for bloating, weight gain with anorexia, and vomiting. Exploratory laparotomy revealed a 5 cm x 6 cm solid mass associated with ascites, indicative of metastatic adenocarcinoma. Surgical procedures included ablation of tumor implants, bilateral salpingo-oophorectomy, total omentectomy, and rectosigmoid resection with end-to-end anastomosis. Hospital course was complicated by development of pneumothorax and bilateral malignant pleural effusions, which were drained. The subject was intubated twice for respiratory distress. She developed hematemesis and esophagoduodenogastroscopy (EGD) revealed grade III esophagitis. Chemotherapy was started on 03 Dec 2004. After chemotherapy, the subject developed urinary tract infection with Pseudomonas and was treated with antibiotics. After stabilization, she was transferred to LifeCare Hospital for management of medical issues and wound care. She was to undergo second round of chemotherapy on 27 Dec 2004 and was monitored for ascites and pleural effusions. The subject was counseled to have a computed tomography scan in 3 months for monitoring upper apical nodule in the lung. She was discharged from Lifecare Hospital on 07 Jan 2005. No further information is available.

Outcome: The investigator reported the serious adverse event to be life threatening and definitely not related to test article.

Page 122

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-228-202363

INVESTIGATOR: 228, USA, 474

TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 202363 , 56 Year old, Female, White , 99.6 kg , 171.5 cm, 33.9 kg /M^2

THERAPY START DATE/STOP DATE : 01MAR04/ 21FEB05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 22FEB05

NARRATIVE REASON : ADVERSE EVENTS OF SPECIAL INTEREST

{DEPRESSION}

REPORT NARR-INF

BDY T REL DURA ONSET STOP OUT TION A TION CASE
AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM ID

Depression NE N 361 13 24FEB05 08MAR05 MIL RES N DEFI

MEDICAL MONITOR COMMENTS :

Relevant Medical History: depression (01 Jan 1998-ongoing) with no antidepressant treatment.

Relevant Prior Medications: none.

Relevant Concomitant Medications: none.

Outcome: After completing 52 weeks of treatment, the subject reported depression as well as other withdrawal symptoms including headache, diarrhea, insomnia, recurrence of hot flashes, dizziness, and increased heart rate beginning 3 days after discontinuation of test article. Withdrawal symptoms resolved after the subject was given a prescription of Zoloft. The investigator, however, reported that ongoing depression could not be assessed because "her mother just passed away." The investigator reported the adverse event to be mild in severity and definitely related to discontinuation of test article.

CONFIDENTIAL 801 Wyeth

Page 123

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-228-202379

INVESTIGATOR : 228, USA, 474

TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 202379 , 63 Year old, Female, Other , 67.6 kg , 155.6 cm, 27.9 kg /M^2

THERAPY START DATE/STOP DATE : 05MAR04/ 27FEB05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 28FEB05

NARRATIVE REASON : SERIOUS ADVERSE EVENT (SAE)

{GASTROENTERITIS}

AE VERBATIM	BDY T SYS E	REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT COM	ACTION	RELA TION INV	A	TION	CASE ID
Gastroenteritis Gastroenteritis	DI N	375 19	2		15MAR05 26MAR04				DNOT	Y		HQWYE332702APR04 HOWYE332702APR04

MEDICAL MONITOR COMMENTS :

Relevant Medical History: hypothyroidism, hypertension, overweight.

Relevant Prior Medications: methotrexate, Synthroid, Vioxx, Ultracet.

Relevant Concomitant Medications: methotrexate, Synthroid, Vioxx, Ultracet, Protonix, ciprofloxacin, metoclopramide, prednisone, erythromycin.

Description of Event: At week 4 of treatment, the subject was admitted to hospital for substernal noncardiac chest pain, nausea, and vomiting. She underwent esophagogastroduodenoscopy (EGD) with biopsies. She had multiple gastric ulcers, likely from use of nonsteroidal antiinflammatory medications, and a large hiatal hernia. Laboratory tests including complete blood count with differential, and basic metabolic and lipid panels were normal. The subject was counseled to discontinue Vioxx, and was prescribed Protonix. She was asked to contact gastroenterologist 4 weeks later. The subject also had a cardiac catheterization and normal coronary angiography.

Outcome: The subject recovered from gastroenteritis and completed the study. The investigator reported the adverse events as mild in severity and definitely not related to test article. The medical monitor considered the adverse events to be not related to test article.

Page 124

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-228-203697

INVESTIGATOR: 228, USA, 474

TREATMENT : Desvenlafaxine SR 150 mg

: 203697 , 48 Year old, Fémale, White , 69.3 kg , 161.9 cm, 26.4 kg /M^2

THERAPY START DATE/STOP DATE : 30MAR04/ 19MAY04

: Discontinued (Adverse Event - HYPERTENSION) STUDY COMPLETION STATUS

STUDY COMPLETION DATE : 20MAY04

NARRATIVE REASON: DISCONTINUATION DUE TO ADVERSE EVENT

{HYPERTENSION}

REPORT NARR-INF

RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM High blood pressure-intermittent CV Y 47 15MAY04 03JUN04 MIL RES S P DNOT

MEDICAL MONITOR COMMENTS :

Additional Relevant Vital Sign Values:

Visit Date	Supine Systolic Blood Pressure (mm Hg)	Supine Diastolic Blood Pressure (mm Hg)
30Mar04 (Baseline)	125	80 (Average of all screening/baseline values)
26Apr04 (Week 4)	146	89
26Apr04 (Week 4)	139	91
20May04 (Week 8)	157	97
20May04 (Week 8)	156	96

Relevant Medical History: overweight.

Relevant Prior Medications: none.

Relevant Concomitant Medication: Tylenol PM.

Outcome: At week 8 of treatment, the subject experienced a 32-mm Hg increase from baseline in systolic blood pressure with a

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 125

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR : 228, USA, 474

TREATMENT : Desvenlafaxine SR 150 mg

: 203697 , 48 Year old, Female, White , 69.3 kg , 161.9 cm, 26.4 kg /M^2

THERAPY START DATE/STOP DATE : 30MAR04/ 19MAY04

: Discontinued (Adverse Event - HYPERTENSION) STUDY COMPLETION STATUS STUDY COMPLETION DATE

: 20MAY04

(continued from previous page)

MEDICAL MONITOR COMMENTS :

value that remained within normal range (<160 mm Hg). Diastolic blood pressure was also borderline at last visit (97 mm Hg). She discontinued from the study because of increased blood pressure.

The investigator reported the adverse event to be mild in severity and definitely not related to test article.

No further information is available.

Page 126

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-228-202357

INVESTIGATOR: 228, USA, 474

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 202357 , 48 Year old, Female, White , 80 kg , 168.9 cm, 28.0 kg /M^2

THERAPY START DATE/STOP DATE : 10MAR04/ 13MAR04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - INSOMNIA)

STUDY COMPLETION DATE : 26MAR04

NARRATIVE REASON : SERIOUS ADVERSE EVENT (SAE)

{MIGRAINE}

RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM Worsening migraine-left CV N -36 03FEB04 03FEB04 MOD RES S H O DNOT Y PNOT HQWYE462201MAR04

MEDICAL MONITOR COMMENTS :

Relevant Medical History: migraine headaches, hypertension, overweight.

Relevant Prior Medications: lisinopril, aspirin.

Relevant Concomitant Medication: aspirin.

Description of Event: During the screening period, the subject was hospitalized for new onset of numbness in the face and arm and for right eye scotoma. She developed numbing sensation in the left lip and face, which progressed to left arm down to finger tips. Laboratory tests including complete blood count, blood chemistry, and international normalized ratio were all within normal limits. Neurologic examination, MRI, and computed tomography scan of the head were normal. ECG was normal. Echocardiography showed mild concentric hypertrophy with trace mitral and tricuspid valve insufficiency with no thrombus. During hospitalization, the subject had no recurrence of symptoms. She was discharged on 05 Feb 2004.

Outcome: After recovery, the subject was randomly assigned, but she discontinued from the study after 4 days of test article administration, because of insomnia. The investigator reported the serious adverse event to be moderate in severity and definitely not related to test article. The medical monitor considered the serious adverse event to be not related to test article.

Page 127

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-228-202364

INVESTIGATOR : 228, USA, 474

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 202364 , 57 Year old, Female, White , 97.5 kg , 163.3 cm, 36.6 kg /M^2

THERAPY START DATE/STOP DATE : 27FEB04/ 24FEB05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 25FEB05

NARRATIVE REASON : SERIOUS ADVERSE EVENT (SAE)

{DEHYDRATION}

BDY T REL DURA ONSET STOP OUT TION A TION CASE
AE VERBATIM

BDY T REL DURA ONSET STOP OUT TION A TION CASE
SYS E DAY TION DATE DATE SEV COM ACTION INV E MM ID

Dehydration

MN Y 207 3 20SEP04 22SEP04 SEV RES H DNOT Y PNOT HOWYE783207DEC04

MEDICAL MONITOR COMMENTS :

Relevant Medical History: acid reflux, obesity, hypercholesterolemia.

Relevant Prior Medications: Nexium, Zocor.

Relevant Concomitant Medications: Nexium, Zocor, Drixoral, Advil, Aleve, Phenergan.

Description of Event: At week 26 of treatment, the subject was hospitalized for persistent nausea, vomiting, dehydration, and inability to tolerate oral intake. She experienced several episodes of emesis with no diarrhea, fever, or vertigo. During hospitalization, physical examination was normal and laboratory tests and complete blood count with differential were within normal range. Findings of computed tomography scan of abdomen were unremarkable. The subject was treated symptomatically with intravenous fluids and antiemetics, and discharged from hospital on 21 Sep 2004 with the final diagnosis of gastroenteritis.

Outcome: The subject recovered and completed the study. The investigator reported the serious adverse event to be severe and definitely not related to test article. The medical monitor considered the serious adverse event to be not related to test article.

Page 128

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-228-203715

INVESTIGATOR: 228, USA, 474

TREATMENT : Desvenlafaxine SR 50 mg

: 203715 , 50 Year old, Female, Black , 91.4 kg , 163.2 cm, 34.3 kg /M^2

THERAPY START DATE/STOP DATE : 07APR04/ 29MAR05

STUDY COMPLETION STATUS : COMPLETED : 30MAR05 STUDY COMPLETION DATE

NARRATIVE REASON : SERIOUS ADVERSE EVENT (SAE)

{CHEST PAIN}

REPORT NARR-INF

RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM ID Atypical chest pain BO Y 159 12SEP04 12SEP04 MIL RES H O DNOT Y PNOT HQWYE6342070CT04

MEDICAL MONITOR COMMENTS :

Relevant Medical History: acid reflux, obesity.

Relevant Prior Medications: Flonase, Clinoril, Zyrtec-D, Aciphex.

Relevant Concomitant Medications: Flonase, Clinoril, Zyrtec-D, Aciphex, atenolol, Lasix, aspirin.

Description of Event: At week 22 of treatment, the subject was hospitalized for an episode of chest pain preceded by a brief episode of palpitations. She remained hemodynamically stable throughout hospitalization. ECG was normal with no evidence of ischemia or infarct. Stress test revealed no ischemic changes, with normal recovery. The subject was counseled to follow up with family physician and start taking aspirin for heart protection and to check fasting lipid panel. She was discharged from hospital on 13 Sep 2004. Hospital procedures ruled out cardiac nature of chest pain.

Outcome: The subject recovered and completed the study. The investigator reported the serious adverse event to be mild in severity and definitely not related to test article. The medical monitor considered the serious adverse event to be not related to test article.

CONFIDENTIAL 807 Wyeth

Page 129

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-229-202421

INVESTIGATOR: 229, USA, 4403

TREATMENT : Desvenlafaxine SR 100 mg

UBJECT : 202421 , 58 Year old, Fémale, White , 61 kg , 164 cm, 22.7 kg /M^2

THERAPY START DATE/STOP DATE : 21APR04/ 24APR04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - TRISMUS)

STUDY COMPLETION DATE : 10MAY04

NARRATIVE REASON: ADVERSE EVENTS OF SPECIAL INTEREST

{CHEST PAIN}

REPORT NARR-INF

BDY T REL DURA ONSET STOP OUT TION A TION CASE
AE VERBATIM

BOY T REL DURA ONSET STOP OUT TION A TION CASE
AE VERBATIM

Chest pain with exertion

BO N 10 9 30APR04 08MAY04 MIL RES N POSS

${\tt MEDICAL}$ MONITOR COMMENTS :

Relevant Medical History: none.

Relevant Prior Medication: aspirin.

Relevant Concomitant Medication: aspirin.

Description of Event: The subject reported an episode of "chest pain with exertion," which started 6 days after last dose of test article (subject took only 2 doses of test article). This adverse event was mild in severity and considered by the investigator to be possibly related to test article. The subject also reported adverse events of anxiety, headaches, sore muscles, and insomnia during this same time period.

Outcome: Chest pain spontaneously resolved in 9 days. The subject was seen by primary care physician in June 2004; however, no tests or discontinuation of procedures were performed because the event had resolved at this time. The subject discontinued early from the study because of trismus. No further information is available.

CONFIDENTIAL 808 Wyeth

Page 130

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-229-202405

INVESTIGATOR: 229, USA, 4403

TREATMENT : Desvenlafaxine SR 50 mg

SUBJECT : 202405 , 54 Year old, $\tilde{\text{F}}$ emale, White , 51 kg , 152 cm, 22.1 kg $/\text{M}^2$

THERAPY START DATE/STOP DATE : 06APR04/ 07JUL04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - SOMNOLENCE)

STUDY COMPLETION DATE : 12JUL04

NARRATIVE REASON : SERIOUS ADVERSE EVENT (SAE)

{ACCIDENTAL INJURY}

RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM {Cellulitis from} cat scratch BO Y 52 23 27MAY04 18JUN04 MOD RES S H PNOT Y PNOT HOWYE174202JUN04

{CELLULITIS}

REPORT NARR-INF

RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM 27MAY04 18JUN04 MOD RES S H Cellulitis {from cat scratch} BO Y 52 23 PNOT Y PNOT HQWYE174202JUN04

MEDICAL MONITOR COMMENTS :

Relevant Medical History: none.

Relevant Prior Medication: baby aspirin.

Relevant Concomitant Medications: unknown antibiotic, Rocephin, Tetanus Toxoid, Unasyn.

Description of Event: The subject was admitted to the hospital on 28 May 2004 for evaluation of cellulitis on left hand. She complained about swelling, pain, and decreased range of motion in her left hand after being scratched several times while playing with her cat. An x-ray study was done, showing some soft-tissue swelling, and laboratory evaluation was also obtained. The subject was treated with a tetanus toxoid, and with antiobitics Rocephin and Unasyn IV. The subject was discharged to home on 30 May 2004. Cellulitis was reported to be completely resolved on 18 Jun 2004.

Outcome: The subject discontinued early from the study, at week 13, because of somnolence. The adverse event of cellulitis from cat scratch was considered moderate in severity and not related to test article by the investigator and medical monitor.

Page 131

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-229-202411

INVESTIGATOR : 229, USA, 4403

TREATMENT : Desvenlafaxine SR 50 mg

SUBJECT : 202411 , 53 Year old, Female, White , 80.5 kg , 165 cm, 29.6 kg /M^2

THERAPY START DATE/STOP DATE : 23APR04/ 30SEP04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - DEPRESSION)

STUDY COMPLETION DATE : 260CT04

{ANXIETY}	NARRATIVE REA	SON	: S	ERIOUS	ADVER	SE EVENT	(SAE)							
AE VERBATIM		BDY SYS		REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT COM	ACTION	RELA TION INV	S A E	RELA TION MM	CASE ID
Anxiety Anxiety		NE NE	Y Y	132 132	•	01SEP04 01SEP04		SEV SEV	PER PER	S H O S O	DNOT		PNOT	HQWYE7672140CT04 HQWYE7672140CT04
{SUICIDAL IDEATION}		BDY	m	REL	DURA	ONSET	STOP		OUT		RELA TION	S A	RELA TION	CASE
AE VERBATIM		SYS		DAY	TION	DATE	DATE	SEV	COM	ACTION	INV	E	MM	ID
Suicidal thoughts		NE	Y	161	5	30SEP04	040CT04	SEV	RES	SHO	DNOT	Y	PNOT	HQWYE7672140CT04
{DEPRESSION}		BDY	Т	REL	DURA	ONSET	STOP		OUT		RELA TION	S A	RELA TION	CASE
AE VERBATIM		SYS		DAY	TION	DATE	DATE	SEV	COM	ACTION	INV	Ε	MM	ID
Depression Depression		NE NE	Y Y	132 132	•	01SEP04 01SEP04	•	SEV SEV	PER PER	S H P O S O	DNOT DNOT	Y	PNOT PNOT	HQWYE7672140CT04 HQWYE7672140CT04
NA {DEPRESSION}	ARRATIVE REASON :	DIS	CON	TINUAT	ION DU	E TO ADVE	RSE EVENT							
AE VERBATIM		BDY SYS		REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT	ACTION	RELA TION INV	S A E	RELA TION MM	CASE ID
Depression Depression		NE NE	Y Y	132 132	:	01SEP04 01SEP04	•	SEV SEV	PER PER	S H P O S O	DNOT	Y	PNOT	HQWYE7672140CT04 HQWYE7672140CT04
MEDICAL MONITOR COMMENTS	S :													

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

Page 132

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 229, USA, 4403

TREATMENT : Desvenlafaxine SR 50 mg

SUBJECT : 202411 , 53 Year old, Female, White , 80.5 kg , 165 cm, 29.6 kg /M^2

THERAPY START DATE/STOP DATE : 23APR04/ 30SEP04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - DEPRESSION)

STUDY COMPLETION DATE : 260CT04

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Relevant Medical History: intermittent depression (30 years), intermittent anxiety (30 years), narcolepsy, alcohol dependence (alcohol free since 2002).

Relevant Prior Medication: Lexapro.

Relevant Concomitant Medications: Lexapro, Wellbutrin Xl.

Description of Event: The subject was admitted to the hospital on 30 Sep 2004 for a severe episode of depression, increased anxiety, and suicidal thoughts, which began 01 Sep 2004. At this time, it was discovered that the subject had an extensive history of depression, secondary to reported physical, emotional, and sexual abuse, alcoholism since age 15, past opioid use, and prior suicide attempt at age 19. (This information had not been previously disclosed to the investigator, before hospitalization). The subject had been followed by counselors and psychiatrists on and off, and had spent time in a rehabilitation facility approximately 15 years ago. At the time of admission, the subject complained of feeling depressed, with crying spells, feelings of hopelessness and worthlessness, poor sleep and appetite, and some suicidal thoughts without a specific plan. Her mood was depressed and she also presented with a constricted affect. While hospitalized, the subject attended Goals Group and depression classes, and her mood appeared to improve and stabilize. She was also treated with antidepressants Lexapro and Wellbutrin X1, and was discharged home with a friend on 04 Oct 2004.

Outcome: The subject was discontinued early from the study because of the adverse event of depression (last dose of test article was taken on 30 Sep 2004, date of hospital admission). The adverse events of depression, anxiety, and suicidal thoughts were reported to be severe, and definitely not related to test article, by the investigator and medical monitor. The suicidal thoughts resolved on 04 Oct 2004; however, the depression and anxiety were persisting at the end of the study, and the subject was taking Lexapro and Wellbutrin XI for treatment. No further information is available.

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-229-202419

Page 133

INVESTIGATOR: 229, USA, 4403

TREATMENT : Placebo

SUBJECT : 202419 , 53 Year old, Female, White , 81.5 kg , 175 cm, $26.6 \text{ kg} / \text{M}^2$

THERAPY START DATE/STOP DATE : 07APR04/ 05APR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 06APR05

(ACCIDENMAL INTUDY)	NARRATIVE REA	SON : S	ERIOUS	ADVER	SE EVENT	(SAE)							
{ACCIDENTAL INJURY} AE VERBATIM		BDY T SYS E	REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT COM	ACTION	RELA TION INV	S A E	RELA TION MM	CASE ID
Bulging lumbar disc Bulging lumbar disc Bulging lumbar disc		BO Y BO Y BO Y	29 29 29	· 71	05MAY04 05MAY04 05MAY04	: 14JUL04	MOD MOD MOD	PER PER RES	S S O S H O	PNOT PNOT PNOT	Y	PNOT PNOT PNOT	HQWYE5645060CT04 HQWYE5645060CT04 HQWYE5645060CT04
{CYST} AE VERBATIM		BDY T SYS E	REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT COM	ACTION	RELA TION INV	S A E	RELA TION MM	CASE ID
Cyst in lumbar area Cyst in lumbar area		BO Y BO Y	29 29	71	05MAY04 05MAY04	14JUL04	MOD MOD	PER RES	S S H O	PNOT PNOT	Y	PNOT PNOT	HQWYE5645060CT04 HQWYE5645060CT04
{PAIN} AE VERBATIM		BDY T	REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT COM	ACTION	RELA TION INV	S A E	RELA TION MM	CASE ID
Intractable leg pain		во у	13	100	19APR04	27JUL04	SEV	RES	SH	PNOT	Y	PNOT	HQWYE5645060CT04

MEDICAL MONITOR COMMENTS :

Relevant Medical History: arthritis small joints (at age 22).

Relevant Prior Medication: diclofenac.

CONFIDENTIAL 812 Wyeth

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

Page 134

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 229, USA, 4403

TREATMENT : Placebo

SUBJECT : 202419 , 53 Year old, Female, White , 81.5 kg , 175 cm, 26.6 kg /M^2

THERAPY START DATE/STOP DATE : 07APR04/ 05APR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 06APR05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Relevant Concomitant Medications: diclofenac, ibuprofen, Tylenol #3, Fioricet, Percocet, morphine.

Description of Event: The subject was admitted to the hospital on 14 Jul 2004 for surgical intervention for 1) degenerative disk disease of the lumbar spine (causing the adverse events of intractable low back pain and leg pain, which began 19 Apr 2004), 2) herniated nucleus pulposus, 3) large synovial cyst, L4-L5, 4) stenosis, and 5) bilateral sciatica. The physician discussed surgery as treatment after conservative treatment failed, and the subject underwent a lumbar decompression and cystectomy and fusion of L4-S1. She was discharged home on 16 Jul 2004 receiving Percocet for pain, and Keflex(subject did not report taking Keflex).

Outcome: The subject completed the study. The adverse events of bulging lumbar disc and cyst in lumbar area were considered to be moderate in severity and the intractable leg pain was considered to be severe; the investigator and medical monitor considered all of the above adverse events to be probably not related to test article.

Page 135

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-231-202503

INVESTIGATOR: 231, USA, 5070

REPORT NARR-INF

TREATMENT : Desvenlafaxine SR 100 mg

SUBJECT : 202503 , 53 Year old, Fémale, White , 78.6 kg , 171.5 cm, 26.7 kg /M^2

THERAPY START DATE/STOP DATE : 27FEB04/ 23NOV04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - HYPERCHOLESTEREMIA)

STUDY COMPLETION DATE : 15DEC04

NARRATIVE REASON : DISCONTINUATION DUE TO ADVERSE EVENT

{HYPERCHOLESTEROLEMIA}

AE VERBATIM	BDY SYS		REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT COM	ACTION	RELA TION INV	S A E	RELA TION MM	CASE ID	
Increased hypercholesterolemia	MN	Y	270	•	22NOV04	•	MOD	PER	Р	POSS				
{HYPERLIPEMIA}										RELA	S	RELA		
AE VERBATIM	BDY	_	REL	DURA	ONSET DATE	STOP	SEV	OUT	ACTION	TION	A E	TION	CASE	

AE VERBATIM

SYS E DAY TION DATE

DATE

SEV COM ACTION INV E MM ID

Elevated triglycerides

MN Y 270 24 22NOV04 15DEC04 MOD RES W POSS

MEDICAL MONITOR COMMENTS :

Additional Relevant Lab Values:

Date	Total Cholesterol (0-5.15 mmol/L)	Triglycerides (.40-2.26 mmol/L)
09Feb04 (Baseline)	7.49	2.04
29Mar04 (Week 4)	7.11	1.46
26May04 (Week 12)	8.09	1.46
23Aug04 (Week 26)	7.01	1.37
22Nov04 (Week 39)	8.84*	2.65
15Dec04 (Follow-up)	8.79*	1.36

^{*} indicates value of clinical importance

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 136

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 231, USA, 5070

: Desvenlafaxine SR 100 mg

: 202503 , 53 Year old, Female, White , 78.6 kg , 171.5 cm, 26.7 kg /M^2

THERAPY START DATE/STOP DATE : 27FEB04/ 23NOV04

STUDY COMPLETION STATUS STUDY COMPLETION DATE : Discontinued (Adverse Event - HYPERCHOLESTEREMIA)

: 15DEC04

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Relevant Medical History: hypercholesterolemia (2003), overweight.

Relevant Prior Medications: none.

Relevant Concomitant Medications: none.

Description of Event: This subject had a history of hypercholesterolemia since 2003, but was not receiving any treatment for this condition. The subject entered the study with elevated cholesterol levels, which remained elevated until discontinuation. At week 39, cholesterol and triglyceride values increased to 8.84 mmol/L and 2.65 mmol/L, respectively.

Outcome: The subject was withdrawn early from the study, at week 39 of treatment, because of increased hypercholesterolemia and elevated triglycerides. Laboratory evaluation was repeated at the follow-up visit, and triglycerides returned to within normal limits; however, cholesterol remained elevated. Both adverse events were considered by the investigator to be moderate in severity, and possibly related to test article. No further information or follow-up is available.

Page 137

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-231-202530

INVESTIGATOR: 231, USA, 5070

TREATMENT : Desvenlafaxine SR 100 mg

: 202530 , 52 Year old, Female, White , 67.5 kg , 175.9 cm, 21.8 kg /M^2

THERAPY START DATE/STOP DATE : 13APR04/ 12OCT04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - HYPERTENSION) STUDY COMPLETION DATE : 280CT04

{HYPERTENSION}	NARRATIVE	REASON :	DISCO	NTINUA	TION DU	E TO ADVE	RSE EVENT							
(IIII BRIBNOTON)											RELA	S	RELA	
AE VERBATIM			BDY T SYS E	REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT	ACTION	TION INV	A E	TION MM	CASE ID
Elevated BP			CV Y	60	•	11JUN04	•	MOD	PER	S P	POSS			
{DEPRESSION}	NARRATIV	E REASON	: ADVE	RSE EV	ENTS OF	SPECIAL	INTEREST							
(DELIKESSION)											RELA	S	RELA	
AE VERBATIM			BDY T SYS E	REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT	ACTION	TION INV	A E	TION	CASE ID
AL VERDALIM			212 F	DAI	IION	DAIL	DAIL	SEV	COM	ACTION	TIVV	Ŀ	IvIIvI	ID
Depressed			NE Y	35	46	17MAY04	01JUL04	MIL	RES	N	POSS			
1		VE REASON						1111	KED	IN	FOSS			
{PCI: SYSTOLIC BL		VE REASON Visit Date		NICALL				Tes	t Val	ue	I	Base Valu	eline ne	
{PCI: SYSTOLIC BL	LOOD PRESSURE }	Visit	D.A.	NICALL		TANT VITA	L SIGNS Seq	Tes	t Val => PC	ue	Į		ie	
{PCI: SYSTOLIC BL Vital Sign SYSTOLIC BP SYSTOLIC BP	Position Supine Supine Supine	Visit Date 30MAR04 30MAR04	D.A. Scree	NICALL I ening/ ening/	Y IMPOR baselin baselin	CTANT VITA	L SIGNS Seq	Tes (# 159	t Val => PC	ue I) Unit mm Ho mm Ho	3 - 3 - 1	Valu 156. 156.	. 5 . 5	
{PCI: SYSTOLIC BL Vital Sign SYSTOLIC BP SYSTOLIC BP SYSTOLIC BP SYSTOLIC BP	Position Supine Supine Supine Supine Supine	Visit Date 30MAR04 30MAR04 13APR04	D.A	NICALL I ening/ ening/ ening/	Y IMPOR baselin baselin baselin	TANT VITA	L SIGNS Seq Num 1 3 1	Tes (# 159 157 160	t Val => PC	ue I) Unit mm Ho mm Ho mm Ho	1	Valu 156. 156.	. 5 . 5	
{PCI: SYSTOLIC BL Vital Sign SYSTOLIC BP SYSTOLIC BP SYSTOLIC BP SYSTOLIC BP SYSTOLIC BP	Position Supine Supine Supine Supine Supine Supine	Visit Date 30MAR04 30MAR04 13APR04 13APR04	D.A. Scree Scree Scree Scree Scree	NICALL I ening/ ening/ ening/ ening/	Y IMPOR baselin baselin	TANT VITA	L SIGNS Seq Num	Tes (# 159 157 160 150	t Val => PC	ue I) Unit mm Ho mm Ho mm Ho	1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -	7alu 156. 156. 156.	.5 .5 .5	
{PCI: SYSTOLIC BL Vital Sign SYSTOLIC BP SYSTOLIC BP SYSTOLIC BP SYSTOLIC BP SYSTOLIC BP SYSTOLIC BP	Position Supine Supine Supine Supine Supine Supine Supine	Visit Date 30MAR04 30MAR04 13APR04 13APR04 14MAY04	D.A. Scree Scree Scree Week	NICALL I ening/i ening/i ening/i	Y IMPOR baselin baselin baselin	TANT VITA	SEQNS SEQNUM 1 3 1 3 1	Tes (# 159 157 160 150	t Val => PC	ue I) Unit mm Ho mm Ho mm Ho mm Ho	1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -	Valu 156. 156. 156. 156.	.5 .5 .5 .5	
{PCI: SYSTOLIC BL Vital Sign SYSTOLIC BP	Position Supine Supine Supine Supine Supine Supine Supine Supine Supine	Visit Date 30MAR04 30MAR04 13APR04 13APR04 14MAY04 14MAY04	D.A. Scree Scree Scree Scree Week Week	NICALL I ening/ ening/ ening/ ening/ 4 4	Y IMPOR baselin baselin baselin	TANT VITA	L SIGNS Seq Num 1 3 1	Tes (# 159 157 160 150 169 158	t Val	ue I) Unit mm Ho mm Ho mm Ho mm Ho mm Ho mm Ho	1	Valu 156. 156. 156. 156.	.5 .5 .5 .5	
{PCI: SYSTOLIC BL Vital Sign SYSTOLIC BP	Position Supine	Visit Date 30MAR04 30MAR04 13APR04 13APR04 14MAY04 14MAY04 11JUN04	D.A. Scree Scree Scree Scree Week Week Week	NICALL I ening/ ening/ ening/ ening/ 4 4 8	Y IMPOR baselin baselin baselin	TANT VITA	SEQNS SEQNOM 1 3 1 3 1 3 1	159 159 157 160 150 169 158	t Val=> PC	ue I) Unit mm Ho mm Ho mm Ho mm Ho mm Ho mm Ho		Valu 156. 156. 156. 156. 156.	.5 .5 .5 .5 .5 .5	
{PCI: SYSTOLIC BL Vital Sign SYSTOLIC BP	Position Supine	Visit Date 30MAR04 30MAR04 13APR04 13APR04 14MAY04 14MAY04 11JUN04	D.A. Scree Scree Scree Week Week Week Week	NICALL I ening/ ening/ ening/ ening/ 4 4 8 8	Y IMPOR baselin baselin baselin	TANT VITA	SEQNS SEQNUM 1 3 1 3 1	159 157 160 150 168 162 170	t Val => PC	ue I) Unit mm Ho		Valu 156. 156. 156. 156. 156. 156.	.5 .5 .5 .5 .5 .5	
{PCI: SYSTOLIC BL Vital Sign SYSTOLIC BP	Position Supine	Visit Date 30MAR04 30MAR04 13APR04 13APR04 14MAY04 11JUN04 11JUN04 08JUL04	D.A. Scree Scree Scree Week Week Week Week Week Week	NICALL Dening/ ening/ ening/ 4 4 8 8 12	Y IMPOR baselin baselin baselin	TANT VITA	SEQNS Seq Num 1 3 1 3 1 3 1 3 1 3 1	159 157 160 150 169 158 162 170	t Val	ue I) Unit mm H mm		Valu 156. 156. 156. 156. 156. 156.	.5 .5 .5 .5 .5 .5 .5	
{PCI: SYSTOLIC BL Vital Sign SYSTOLIC BP	Position Supine	Visit Date 30MAR04 30MAR04 13APR04 13APR04 14MAY04 11JUN04 11JUN04 08JUL04 08JUL04	Scree Scree Scree Scree Week Week Week Week Week	NICALL I ening/ ening/ ening/ ening/ 4 4 8 8 12 12	Y IMPOR baselin baselin baselin	TANT VITA	SEQNS SEQNOM 1 3 1 3 1 3 1	Tes (# 159 157 160 158 169 158 162 173 169	t Val	ue I) Unit mm Ho		Valu 156. 156. 156. 156. 156. 156. 156.	.5 .5 .5 .5 .5 .5 .5 .5	
{PCI: SYSTOLIC BL Vital Sign SYSTOLIC BP	Position Supine	Visit Date 30MAR04 13APR04 13APR04 14MAY04 11JUN04 11JUN04 08JUL04 08JUL04 08JUL04	Scree Scree Scree Scree Scree Week Week Week Week Week Follo	NICALL I ening/ ening/ ening/ 4 4 8 8 12 12 DW-up	Y IMPOR baselin baselin baselin	TANT VITA	Seq Num 1 3 1 3 1 3 1 3 1 3 1	159 157 160 158 162 170 173 169	t Val	ue I) Unit mm Ho		Valu 156. 156. 156. 156. 156. 156. 156.	5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	
{PCI: SYSTOLIC BL Vital Sign SYSTOLIC BP	Position Supine	Visit Date 30MAR04 30MAR04 13APR04 13APR04 14MAY04 11JUN04 11JUN04 08JUL04 08JUL04	Scree Scree Scree Scree Week Week Week Week Follo	NICALL I ening/ ening/ ening/ ening/ 4 4 8 8 12 12	Y IMPOR baselin baselin baselin	TANT VITA	SEQNS Seq Num 1 3 1 3 1 3 1 3 1 3 1	Tes (# 159 157 160 158 169 158 162 173 169	t Val	ue I) Unit mm Ho		Valu 156. 156. 156. 156. 156. 156. 156.	5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	

CONFIDENTIAL 816 Wyeth

Page 138

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 231, USA, 5070

TREATMENT : Desvenlafaxine SR 100 mg

: 202530 , 52 Year old, Female, White , 67.5 kg , 175.9 cm, 21.8 kg /M^2

THERAPY START DATE/STOP DATE : 13APR04/ 12OCT04

STUDY COMPLETION STATUS STUDY COMPLETION DATE : Discontinued (Adverse Event - HYPERTENSION)

: 280CT04

(continued from previous page)

NARRATIVE REASON : CLINICALLY IMPORTANT ECG VALUES

{PCI: QT INTERVAL}

Rel.

Day Visit Test Value Baseline Vital Sign (Days) D.A.I Date (# => PCI) Unit Value

30MAR04 QT INTRVL -14 Screening/baseline 460 msec 87 QT INTRVL Week 12 08JUL04 495 # msec 460

MEDICAL MONITOR COMMENTS :

Additional Relevant Vital Sign and ECG Values:

Date	Supine Diastolic BP value (mm Hg)	QTcF (msec)	QTcB (msec)	Heart Rate (beats/min)
30Mar04 (Baseline) 14May04 (Week 4)	95* 98	438	427	52
14May04 (Week 4) 11Jun04 (Week 8) 11Jun04 (Week 8)	97 104 108			
08Jul04 (Week 0) 08Jul04 (Week 12) 08Jul04 (Week 12)	88 98	440	416	44
130ct04 (Week 26) 130ct04 (Week 26)	95 96			
280ct04 (Follow-up 280ct04 (Follow-up				

^{*}Average of all screening/baseline values

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

TION OF PROTOCOL 3151A2-315 Page 139

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 231, USA, 5070

TREATMENT : Desvenlafaxine SR 100 mg

SUBJECT : 202530 , 52 Year old, Female, White , 67.5 kg , 175.9 cm, 21.8 kg /M^2

THERAPY START DATE/STOP DATE : 13APR04/ 12OCT04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - HYPERTENSION)

STUDY COMPLETION DATE : 280CT04

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Relevant Medical History: hypertension(2000), smoking, situational depression (2000), hypothyroidism.

Relevant Prior Medications: atenolol, Levoxyl.

Relevant Concomitant Medications: atenolol, Levoxyl, lisinopril, temazepam.

Outcome: The subject discontinued early from the study at week 26 because of increased blood pressure. This subject was hypertensive, receiving treatment (atenolol). Blood pressures were borderline at baseline (156.5/95 mm Hg). During study, blood pressure values had increased from baseline, reading absolute values of 170/98 mm Hg at week 12 and 173/95 mm Hg at week 26. Diastolic blood pressures were also elevated at this time.

The medical monitor requested that the site withdraw the subject from the study because of the persistent elevations in blood pressure. The subject was prescribed the medication lisinopril at week 6, in addition to atended. However, blood pressure values continued to increase despite antihypertensive therapy. Elevated blood pressure was reported by the investigator to be an adverse event, moderate in severity, and considered possibly related to test article. This adverse event was persisting at the end of the study, and no further information or follow-up is available.

In addition, at week 12 of treatment, the subject had a QT interval of 495 msec, that was considered clinically important (QT interval >/= 480 msec). QTcB and QTcF intervals at baseline and week 12 were normal (<470 msec). The subject's physical examinations were normal during the study; however, blood pressures were elevated throughout the study (as noted above). The investigator did not report the increase in QT interval as an adverse event. No additional information or follow-up is available.

Also, this subject reported an episode of depression, which began 17 May 2004. She does have a history of situational depression and was treated in the past for this condition, but did not receive any medication for depression during the study, and the adverse event resolved on its own by 01 Jul 2004. This adverse event was mild in severity, and considered possibly related to test article by the investigator.

Page 140

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-231-202507

INVESTIGATOR: 231, USA, 5070

TREATMENT : Desvenlafaxine SR 150 mg

: 202507 , 59 Year old, Female, White , 64.5 kg , 164 cm, 24.0 kg /M^2

THERAPY START DATE/STOP DATE : 09MAR04/ 04JAN05

STUDY COMPLETION STATUS : Discontinued (Other Event)

: 24JAN05 STUDY COMPLETION DATE

NARRATIVE REASON : SERIOUS ADVERSE EVENT (SAE)

{SKIN MELANOMA}

REPORT NARR-INF

RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM Melanoma-back SA Y 147 37 02AUG04 07SEP04 MOD RES S O PNOT Y PNOT HQWYE092516SEP04

MEDICAL MONITOR COMMENTS :

Relevant Medical History: none.

Relevant Prior Medications: none.

Relevant Concomitant Medications: none.

Description of Event: The subject was seen on 02 Aug 2004 by her dermatologist, for surgical excision of a malignant melanoma of the mid-back. Per the subject, moles were present before the start of the study. Pathology reports confirm the diagnosis of melanoma, and also confirm that this skin lesion was completely removed. Per the subject, no further treatment was necessary.

Outcome: This subject discontinued early from the study at week 43 of treatment. After going on vacation and forgetting to take her medications, she reported experiencing withdrawal symptoms, and did not wish to resume study medication. Melanoma-back was reported as an adverse event moderate in severity, and considered by the investigator and the medical monitor to be not related to test article.

CONFIDENTIAL 819 Wyeth

Page 141

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-231-202509

INVESTIGATOR : 231, USA, 5070

REPORT NARR-INF

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 202509 , 52 Year old, Female, White , 73.2 kg , 157 cm, 29.7 kg /M^2

THERAPY START DATE/STOP DATE : 03MAR04/ 22FEB05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 09MAR05

NARRATIVE REASON : CLINICALLY IMPORTANT VITAL SIGNS

{PCI: ORTHOSTATIC HYPOTENSION}

Visit Date	D.A.I	Vital Sign	Position	Seq Num	Blood Pressure (mm Hg)	Orthostatic Change (mm Hg)
05MAY04	Week 8	DIASTOLIC BP	Supine	1	94	32
05MAY04	Week 8	DIASTOLIC BP	Supine	3	92	32
05MAY04	Week 8	DIASTOLIC BP	standing	4	60	32
05MAY04	Week 8	DIASTOLIC BP	standing	6	72	32

MEDICAL MONITOR COMMENTS :

Relevant Medical History: hypercholesterolemia, overweight.

Relevant Prior Medications: Lipitor, baby aspirin.

Relevant Concomitant Medications: Lipitor, Crestor, baby aspirin.

Outcome: At week 8 of treatment, the subject had orthostatic hypotension, as measured by a decrease of 32 mm Hg diastolic blood pressure from last supine to first standing that was considered clinically important. The subject did not report any associated symptoms. Her blood pressure remained within normal limits at all subsequent visits, including measurements taken during postural changes. The subject completed the study. The investigator did not report orthostatic hypotension as an adverse event.

CONFIDENTIAL 820 Wyeth

Page 142

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-232-202566

INVESTIGATOR: 232, USA, 5058

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 202566 , 53 Year old, Fémale, Black , 82.5 kg , 168 cm, 29.2 kg /M^2

NARRATIVE REASON : CLINICALLY IMPORTANT VITAL SIGNS

THERAPY START DATE/STOP DATE : 24FEB04/ 28FEB05

: COMPLETED STUDY COMPLETION STATUS : 28FEB05 STUDY COMPLETION DATE

{PCI: SYSTOLIC BLOOD	PRESSURE }						
		Visit		Seq	Test Value		Baseline
Vital Sign	Position	Date	D.A.I	Num	(# => PCI)	Unit	Value
SYSTOLIC BP	Supine	09FEB04	Screening/baseline	1	150	mm Hq	146
SYSTOLIC BP	Supine	09FEB04	Screening/baseline	3	148	mm Hq	146
SYSTOLIC BP	Supine	24FEB04	Screening/baseline	1	144	mm Hq	146
SYSTOLIC BP	Supine	24FEB04	Screening/baseline	3	142	mm Hq	146
SYSTOLIC BP	Supine	23MAR04	Week 4	1	154	mm Hq	146
SYSTOLIC BP	Supine	23MAR04	Week 4	3	154	mm Hq	146
SYSTOLIC BP	Supine	20APR04	Week 8	1	112	mm Hq	146
SYSTOLIC BP	Supine	20APR04	Week 8	3	116	mm Hg	146
SYSTOLIC BP	Supine	18MAY04	Week 12	1	180 #	mm Hg	146
SYSTOLIC BP	Supine	18MAY04	Week 12	3	182 #	mm Hg	146
SYSTOLIC BP	Supine	24AUG04	Week 26	1	148	mm Hg	146
SYSTOLIC BP	Supine	24AUG04	Week 26	3	148	mm Hg	146
SYSTOLIC BP	Supine	30NOV04	Week 39	1	150	mm Hg	146
SYSTOLIC BP	Supine	30NOV04	Week 39	3	146	mm Hg	146
SYSTOLIC BP	Supine	28FEB05	Week 52	1	148	mm Hg	146
SYSTOLIC BP	Supine	28FEB05	Week 52	3	152	mm Hg	146

MEDICAL MONITOR COMMENTS :

20Apr04 (Week 8)

Additional Relevant Vital Sign Values:

Date Supine Diastolic BP value (mm Hq)

09-24Feb04 (Baseline) 89 (Average of all screening/baseline	values)
23Mar04 (Week 4) 88	,
23Mar04 (Week 4) 88	

CONFIDENTIAL 821 Wyeth

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

Page 143

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 232, USA, 5058

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 202566 , 53 Year old, Female, Black , 82.5 kg , 168 cm, 29.2 kg /M^2

THERAPY START DATE/STOP DATE : 24FEB04/ 28FEB05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 28FEB05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

20Anr04 (Week 8)

ZUAPTU4	(week	8)	ОО
18May04	(Week	12)	102
18May04	(Week	12)	102
24Aug04	(Week	26)	86
24Aug04	(Week	26)	90
20Nov04	(Week	39)	86
30Nov04	(Week	39)	90
28Feb05	(Week	52)	80
28Feb05	(Week	52)	90

Relevant Medical History: premature ventricular contractions (PVCs, 2001), overweight.

Relevant Prior Medication: Toprol.

Relevant Concomitant Medication: Toprol.

Outcome: At week 12 of treatment, the subject had a 34 to 36 mm Hg increase from baseline in systolic blood pressure that was considered clinically important (>/= 30 mm Hg from baseline with value >/= 160 mm Hg). At this time, the diastolic blood pressure was also increased, with a value of 102 mm Hg. At subsequent visits, systolic and diastolic blood pressures remained within normal range. Heart rate remained normal throughout the entire course of treatment. The subject completed the study. The investigator did not report the increase in systolic blood pressure as an adverse event.

Page 144

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-232-202553

INVESTIGATOR: 232, USA, 5058

TREATMENT : Placebo

SUBJECT : 202553 , 46 Year old, Female, White , 103.2 kg , 173.9 cm, 34.1 kg /M^2

THERAPY START DATE/STOP DATE : 25FEB04/ 20MAY04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - DEPRESSION)

STUDY COMPLETION DATE : 24MAY04

NARRATIVE REASON: DISCONTINUATION DUE TO ADVERSE EVENT {DEPRESSION} RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM 18MAY04 . Increased depression NE Y 84 MOD PER P PNOT NARRATIVE REASON : ADVERSE EVENTS OF SPECIAL INTEREST {DEPRESSION} RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM Increased depression 84 18MAY04 PER PNOT Increased depression NE Y 84 18MAY04 MOD PER W PNOT

MEDICAL MONITOR COMMENTS :

Relevant Medical History: depression (2002) treated with Paxil.

Relevant Prior Medication: Paxil.

Relevant Concomitant Medications: trazodone, Paxil (stopped during washout period).

Description of Event: The subject experienced an episode of depression described as "increased depression," which spontaneously resolved on 01 Jun 2004. She began taking Paxil on 21 May 2004 for treatment of this adverse event. After restarting Paxil, the subject was feeling better.

Outcome: The subject discontinued early from the study because of this adverse event of "increased depression." The investigator reported this adverse event as moderate in severity, and probably not related to test article.

CONFIDENTIAL 823 Wyeth

Page 145

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-233-202606

INVESTIGATOR: 233, USA, 17672

TREATMENT : Desvenlafaxine SR 100 mg SUBJECT : 202606 , 47 Year old, Female, White , 55 kg , 158.8 cm, 21.8 kg /M^2

THERAPY START DATE/STOP DATE : 21FEB04/ 15FEB05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 16FEB05

NARRATIVE REASON : CLINICALLY IMPORTANT LABORATORY VALUES

{PCI: TRIGLYCERIDES}

REPORT NARR-INF

Lab Test	Rel. Day (Days)	D.A.I	Test Date	Test Value (# => PCI)	Fasting (Y/N)	Range (Low)	Range (High)	Unit	Baseline Value
TRIGLYCERIDES /LIPID	-9	Screening/baseline	12FEB04	1.0951	Yes	0.3952	2.258	mmol/L	1.0951
TRIGLYCERIDES /LIPID	28	Week 4	19MAR04	2.9128	Yes	0.3952	2.258	mmol/L	1.0951
TRIGLYCERIDES /LIPID	38	Week 4	29MAR04	1.908	No/Unkn			mmol/L	1.0951
TRIGLYCERIDES /LIPID	87	Week 12	17MAY04	1.4113	Yes	0.3952	2.258	mmol/L	1.0951
TRIGLYCERIDES /LIPID	179	Week 26	17AUG04	8.4223 #	Yes	0.3952	2.258	mmol/L	1.0951
TRIGLYCERIDES /LIPID	223	Week 26	30SEP04	1.8516	Yes	0.3952	2.258	mmol/L	1.0951
TRIGLYCERIDES /LIPID	272	Week 39	18NOV04	1.1516	Yes	0.3952	2.258	mmol/L	1.0951
TRIGLYCERIDES /LIPID	362	Week 52	16FEB05	0.9597	Yes	0.3952	2.258	mmol/L	1.0951

MEDICAL MONITOR COMMENTS :

Additional Relevant Lab Values:

Date	Total Cholesterol (0-5.15 mmol/L)	HDL (.90-2.07mol/L)	LDL (0-3.36 mmol/L)
12FEB04 (Baseli 29MAR04 (week 4 19MAR04 (week 4 17MAY04 (week 1 17AUG04 (week 2 30SEP04 (week 2 18NOV04 (week 3) 6.70) 6.78 2) 6.54 6) 8.02 6) 6.41	1.81 1.78 1.76 1.81 1.50 1.81	4.53 3.59 4.14 4.09 6.41 3.75 3.75
16FEB05 (week 5	-,	1.86	3.75

CONFIDENTIAL 824 Wyeth

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

Page 146

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 233, USA, 17672

TREATMENT : Desvenlafaxine SR 100 mg

SUBJECT : 202606 , 47 Year old, Female, White , 55 kg , 158.8 cm, 21.8 kg /M^2

THERAPY START DATE/STOP DATE : 21FEB04/ 15FEB05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 16FEB05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Relevant Medical History: smoking (1 pack per day x 20 years).

Relevant Prior Medications: none.

Relevant Concomitant Medications: none.

Outcome: At week 26 of treatment, the subject had a single episode of increased triglycerides that was considered clinically important (>/= 50% increase from baseline with a value >/= 7.9 mmol/L). At this time, she also had an increase in total cholesterol and LDL cholesterol with values of 8.02 and 6.41 mmol/L, respectively. Laboratory evaluation was repeated approximately 5 weeks later, and triglycerides returned to within normal limits. The subject completed the study. The investigator did report hyperlipidemia as an adverse event, mild in severity, and definitely not related to test article.

Page 147

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-233-202613

INVESTIGATOR: 233, USA, 17672

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 202613 , 44 Year old, Female, White , 75 kg , 172.7 cm, 25.1 kg /M^2

THERAPY START DATE/STOP DATE : 04MAR04/ 28AUG04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - ASTHENIA)

STUDY COMPLETION DATE : 02SEP04

NARRATIVE REASON: ADVERSE EVENTS OF SPECIAL INTEREST

{CHEST PAIN}

REPORT NARR-INF

AE VERBATIM

BDY T REL DURA ONSET STOP OUT TION A TION CASE
SYS E DAY TION DATE DATE SEV COM ACTION INV E MM ID

Chest pain with deep inspiration

BO N 179 5 29AUG04 02SEP04 MIL RES N DNOT

MEDICAL MONITOR COMMENTS :

Relevant Medical History: hypercholesterolemia, overweight.

Relevant Prior Medications: none.

Relevant Concomitant Medications: none.

Description of Event: The subject reported an episode of chest pain described as "chest pain with deep inspiration," which started the day after last dose of test article. This adverse event was mild in severity, and considered definitely not related to test article by the investigator. The subject also reported adverse events of nausea and vomiting during the same time period.

Outcome: Chest pain spontaneously resolved in 5 days. Per the investigator, it was noted that the chest pain was due to intercostal muscle activity secondary to vomiting. The subject had discontinued early from the study because of bilateral arm weakness. No further information is available.

CONFIDENTIAL 826 Wyeth

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 148

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-233-202627

INVESTIGATOR: 233, USA, 17672

TREATMENT : Desvenlafaxine SR 50 mg

SUBJECT : 202627 , 71 Year old, Female, White , 58.1 kg , 165.1 cm, 21.3 kg /M^2

THERAPY START DATE/STOP DATE : 24MAR04/ 09JUN04

79

98

Week 12

Follow-up

STUDY COMPLETION STATUS : Discontinued (Adverse Event - LIVER FUNCTION TESTS ABNORMAL)

STUDY COMPLETION DATE : 11JUN04

NARRATIVE REASON: DISCONTINUATION DUE TO ADVERSE EVENT {LIVER FUNCTION TESTS ABNORMAL} RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM Elevated liver function tests DI N 10JUN04 MOD PER PΩ POSS Elevated liver functions DI N 79 20 10JUN04 29JUN04 MOD RES W O POSS NARRATIVE REASON: CLINICALLY IMPORTANT LABORATORY VALUES {PCI: SGOT/AST} Rel. Day Test Test Value Fasting Range Baseline Range Lab Test (Days) D.A.I Date (# => PCI) (Y/N)(Low) (High) Unit Value SGOT/AST Screening/baseline 11MAR04 40 Yes mU/mL 40 SGOT/AST 35 Week 4 27APR04 52 Yes 0 55 mU/mL 40 79 SGOT/AST Week 12 10JUN04 121 Yes 0 55 mU/mL 40 SGOT/AST 98 Follow-up 29JUN04 299 # 0 55 mU/mL 40 {PCI: SGOT/ALT} Rel. Day Test Test Value Fasting Range Range Baseline Lab Test (Days) D.A.I Date (# => PCI) (Y/N)(Low) (High) Unit Value SGPT/ALT Screening/baseline 11MAR04 mU/mL 35 0 34 SGPT/ALT Week 4 27APR04 46 Yes 48 mU/mL

MEDICAL MONITOR COMMENTS :

SGPT/ALT

SGPT/ALT

10JUN04

29JUN04

174

436 #

Yes

0

48

mU/mL

mU/mL

34

34

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

Page 149

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 233, USA, 17672

TREATMENT : Desvenlafaxine SR 50 mg

SUBJECT : 202627 , 71 Year old, Female, White , 58.1 kg , 165.1 cm, 21.3 kg /M^2

THERAPY START DATE/STOP DATE : 24MAR04/ 09JUN04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - LIVER FUNCTION TESTS ABNORMAL)

STUDY COMPLETION DATE : 11JUN04

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Additional Relevant Lab Values:

Date Total Bilirubin (0-22.23 mcmol/L)

(0-22.23 mcmol/L)

 11Mar04 (Baseline)
 8.55

 27Apr04 (Week 4)
 10.26

 10Jun04 (Week 12)
 8.55

 29Jun04 (Follow-up)
 6.84

Relevant Medical History: hypertension.

Relevant Prior Medications: Hyzaar, Zocor.

Relevant Concomitant Medications: Hyzaar, Zocor, Lotrel.

Outcome: At week 12 of treatment, the subject's ALT/SGPT and AST/SGOT were elevated (ALT/SGPT = 2.88 x upper limit of normal and AST/SGOT = 3.62 x upper limit of normal). The investigator instructed the subject to stop taking test article, and repeat LFTs were drawn on 29 Jun 2004. At this time, ALT/SGPT and AST/SGOT had further increased and were considered clinically important (ALT/SGPT = 9.08 x upper limit of normal and AST/SGOT = 7.12 x upper limit of normal). Bilirubin levels remained within the normal ranges. The investigator permanently withdrew the subject from the study, instructed her to stop taking the medication Zocor, and referred her to her primary care physician for follow-up. Since then, the subject has been lost to follow-up, and no further information regarding follow-up is available.

Page 150

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-233-202629

INVESTIGATOR: 233, USA, 17672

REPORT NARR-INF

TREATMENT : Desvenlafaxine SR 50 mg SUBJECT : 202629 , 55 Year old, Female, White , 89.1 kg , 162.6 cm, 33.7 kg /M^2

THERAPY START DATE/STOP DATE : 22MAR04/ 20MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 21MAR05

NARRATIVE REASON : CLINICALLY IMPORTANT VITAL SIGNS											
{PCI: SUSTAINED HYPE	PERTENSION }								- 1		
Vital Sign	Position	Visit Date	Seq Num	D.A.I			Test Val		Basel Value	ıne	
Vital Sign	POSICION	Date	Nulli	D.A.I			(# -/ PC	.I) UIIIL	value		
DIASTOLIC BP	Supine	12MAR04	1	Screening	/baseline		72	mm Hq	75.5		
DIASTOLIC BP	Supine	12MAR04	3	Screening	/baseline		80	mm Hq	75.5		
DIASTOLIC BP	Supine	22MAR04	1	Screening	/baseline		70	mm Hq	75.5		
DIASTOLIC BP	Supine	22MAR04	3	Screening	g/baseline		80	mm Hq	75.5		
DIASTOLIC BP	Supine	16APR04	1	Week 4			78	mm Hg	75.5		
DIASTOLIC BP	Supine	16APR04	3	Week 4			84	mm Hq	75.5		
DIASTOLIC BP	Supine	18MAY04	1	Week 8			90 #	mm Hq	75.5		
DIASTOLIC BP	Supine	18MAY04	3	Week 8			90 #	mm Ha	75.5		
DIASTOLIC BP	Supine	10JUN04	1	Week 12			90 #	mm Ha	75.5		
DIASTOLIC BP	Supine	10JUN04	3	Week 12			90 #	mm Hq	75.5		
DIASTOLIC BP	Supine	20SEP04	1	Week 26			90 #	mm Ha	75.5		
DIASTOLIC BP	Supine	20SEP04	3	Week 26			90 #	mm Ha	75.5		
DIASTOLIC BP	Supine	23DEC04	1	Week 39			80	mm Ha	75.5		
DIASTOLIC BP	Supine	23DEC04	3	Week 39			90 #	mm Ha	75.5		
DIASTOLIC BP	Supine	21MAR05	1	Follow-up)		82	mm Hq	75.5		
DIASTOLIC BP	Supine	21MAR05	3	Follow-up			80	mm Ha	75.5		
	<u>-</u>			-							
		REASON : 0	LINIC	ALLY IMPOR	RTANT LABOR	RATORY VALUES	5				
{PCI: TOTAL CHOLEST											
	Rel.	•									
	Day				Test	Test Value	Fasting	Range	Range		Baseline
Lab Test	(Day	ys) D.A.I			Date	(# => PCI)	(Y/N)	(Low)	(High)	Unit	Value
TOT.CHOL. /LIPID	-10	Screer	ing/h	aseline	12MAR04	5.4565	Yes	0	5.1461	mmol/L	5.4565
TOT.CHOL. /LIPID	26	Week 4		abcillic	16APR04	6.9563	Yes	Ö	5.1461	mmol/L	5.4565
TOT.CHOL. /LIPID	81	Week 1			10JUN04	7.8873 #	Yes	Ö	5.1461	mmol/L	5.4565
TOT.CHOL. /LIPID	183	Week 2			20SEP04	7.6028	Yes	0	5.1461	mmol/L	5.4565
TOT.CHOL. /LIPID	277	Week 3			23DEC04	6.3357	Yes	0	5.1461	mmol/L	5.4565
TOT.CHOL. /LIPID	365	Week 5			21MAR05	7.2925	Yes	0	5.1461	mmol/L	5.4565
TOT.CHOB. / HITTD	303	week s	_		2 11111100	1.2723	100	O	3.1401	пипот/ п	3.4303

MEDICAL MONITOR COMMENTS :

Page 151

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 233, USA, 17672

TREATMENT : Desvenlafaxine SR 50 mg

SUBJECT : 202629 , 55 Year old, Female, White , 89.1 kg , 162.6 cm, 33.7 kg /M^2

THERAPY START DATE/STOP DATE : 22MAR04/ 20MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 21MAR05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Additional Relevant Vital Sign and Lab Values:

Date S	Supine Systolic BP value (mm Hg)	Total Cholesterol (0-5.15 mmol/L)	HDL (.90-2.07mol/L)	LDL (0-3.36 mmol/L)
12-22Mar04 (Baseline		1.34	1.29	3.54
16Apr04 (Week 4)	132	2.69	1.11	4.60
16Apr04 (Week 4)	130			
18May04 (Week 8)	142			
18May04 (Week 8)	140			
10Jun04 (Week 12)	140	2.37	1.06	5.74
10Jun04 (Week 12)	142			
20Sep04 (Week 26)	140	2.15	1.19	5.43
20Sep04 (Week 26)	130			
23Dec04 (Week 39)	128	2.11	1.01	4.37
23Dec04 (Week 39)	127			
21Mar05 (Week 52)	132	2.62	1.06	5.04
21Mar05 (Week 52)	130			

^{*}Average of all screening/baseline values

Relevant Medical History: hypercholesterolemia, obesity.

Relevant Prior Medication: Lasix.

Relevant Concomitant Medication: Lasix.

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

Page 152

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 233, USA, 17672

TREATMENT : Desvenlafaxine SR 50 mg

SUBJECT : 202629 , 55 Year old, Female, White , 89.1 kg , 162.6 cm, 33.7 kg /M^2

THERAPY START DATE/STOP DATE : 22MAR04/ 20MAR05

STUDY COMPLETION STATUS : COMPLETED

STUDY COMPLETION DATE : 21MAR05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Outcome: At weeks 8 through 39 of treatment, the subject had sustained hypertension that was considered clinically important (increase of >/= 10 mm Hg supine diastolic blood pressure with value >/= 90 mm Hg at 3 consecutive visits). At last visit (week 52), diastolic blood pressures returned to within normal range. Systolic blood pressure remained within normal range throughout the study. The subject completed the study. The investigator did not report sustained hypertension as an adverse

Also, at week 12 of treatment, the subject had a single episode of an increased cholesterol that was considered clinically important (increase of >/= 1.97 mmol/L from baseline AND value >/= 7.8 mmol/L). At this time, the subject also had an increase in LDL cholesterol. She has a history of hypercholesterolemia, and cholesterol was elevated since baseline and remained elevated throughout the study. The investigator did report worsening hypercholesterolemia as an adverse event, moderate in severity, and possibly related to test article. The subject did not receive any treatment for hypercholesterolemia.

Page 153

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-234-203060

INVESTIGATOR: 234, USA, 28895

TREATMENT : Desvenlafaxine SR 100 mg

SUBJECT : 203060 , 53 Year old, Female, White , 70.9 kg , 157.5 cm, 28.6 kg /M^2

THERAPY START DATE/STOP DATE : 22APR04/ 16DEC04

STUDY COMPLETION STATUS : Discontinued (Unsatisfactory response - efficacy)

STUDY COMPLETION DATE : 03JAN05

NARRATIVE REASON: ADVERSE EVENTS OF SPECIAL INTEREST {DEPRESSION} RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY DATE DATE SEV COM ACTION INV E MM Depression NE N 241 25 18DEC04 11JAN05 SEV RES N POSS {SUICIDAL IDEATION} RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE E MM AE VERBATIM SYS E DAY TION DATE DATE COM ACTION INV Suicidal thoughts NE N 241 18DEC04 11JAN05 SEV RES N POSS

MEDICAL MONITOR COMMENTS :

Relevant Medical History: none.

Relevant Prior Medications: none.

Relevant Concomitant Medications: none.

Description of Event: The subject reported experiencing an episode of severe depression and suicidal thoughts beginning 2 days after discontinuing test article. In addition, she also reported adverse events of feeling emotional and irritable.

Outcome: The subject discontinued early from the study because of unsatisfactory response. The depression and suicidal thoughts occurred after discontinuation of test article, and gradually resolved on their own (no treatment) by the follow-up visit. The investigator reported the adverse events of depression and suicidal thoughts to be severe, and possibly related to discontinuation of test article.

CONFIDENTIAL 832 Wyeth

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 154

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-234-203063

INVESTIGATOR: 234, USA, 28895

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 203063 , 52 Year old, Female, White , 72.3 kg , 167.6 cm, 25.7 kg /M^2

THERAPY START DATE/STOP DATE : 08APR04/ 16NOV04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - HYPERTENSION)

STUDY COMPLETION DATE : 14DEC04

NARRATIVE REASON : DISCONTINUATION DUE TO ADVERSE EVENT

{HYPERTENSION}

RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM Increased blood pressure CV Y 27 225 04MAY04 14DEC04 MOD RES P POSS

 ${\tt MEDICAL\ MONITOR\ COMMENTS\ :}$

Additional Relevant Vital Sign Values:

Date Supine Blood Pressure (mm Hg)

25Mar-08Apr04 (Baseline) 126.5/78.5 (Average of all screening/baseline values) 04May04 (Week 4) 138/90

04May04 (Week 4) 04Jun04 (Week 8) 136/92 151/85 04Jun04 (Week 8) 145/89 01Jul04 (Week 12) 136/87 01Jul04 (Week 12) 140/86 120ct04 (Week 26) 134/92 120ct04 (Week 26) 140/96 14Dec04 (Follow-up) 124/86 14Dec04 (Follow-up) 126/84

Relevant Medical History: high cholesterol, high triglycerides, overweight.

Relevant Prior Medication: flaxseed oil.

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 155

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 234, USA, 28895

: Desvenlafaxine SR 200 mg

: 203063 , 52 Year old, Female, White , 72.3 kg , 167.6 cm, 25.7 kg /M^2

THERAPY START DATE/STOP DATE : 08APR04/ 16NOV04

STUDY COMPLETION STATUS STUDY COMPLETION DATE : Discontinued (Adverse Event - HYPERTENSION)

: 14DEC04

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Relevant Concomitant Medications: flaxseed oil, lovastatin.

Description of Event: The subject does not have a history of hypertension, but did enter the study with a history of high cholesterol and triglycerides. Blood pressure values at baseline were within normal limits. Beginning at week 4 of treatment, blood pressure values began to increase, and continued to increase at subsequent visits. However, none of the blood pressure values reported were considered clinically important and all measurements remained within normal limits.

Outcome: The investigator withdrew the subject early from the study because of increased blood pressure at week 31 of treatment. Blood pressure was re-checked at follow-up visit and had returned to baseline values. The investigator reported increased blood pressure as an adverse event moderate in severity, and possibly related to test article.

Page 156

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-235-202684

INVESTIGATOR: 235, USA, 5096

TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 202684 , 54 Year old, Female, White , 85.3 kg , 173.4 cm, 28.4 kg /M^2

THERAPY START DATE/STOP DATE : 15APR04/ 07JUL04

STUDY COMPLETION STATUS : Discontinued (Failed to Return)

STUDY COMPLETION DATE : 13JUL04

{CHEST PAIN}	NARRATIVE REASON	: S	ERIOUS	ADVER	SE EVENT	(SAE)							
AE VERBATIM		Y T S E	REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT	ACTION	RELA TION INV	S A E	RELA TION MM	CASE ID
Chest pain and pressure	ВО	Y	22	7	06MAY04	12MAY04	SEV	RES	S H	DNOT	Y	PNOT	HQWYE888513MAY0
{DUODENITIS}		ΥT	REL	DURA	ONSET	STOP		OUT		RELA TION	S A	RELA TION	CASE
AE VERBATIM		SE	DAY	TION	DATE	DATE	SEV	COM	ACTION	INV	Е	MM	ID
Duodenitis	DI	Y	22	6	06MAY04	11MAY04	MIL	RES	S 0	PNOT	Y	PNOT	HQWYE888513MAY0
{ESOPHAGITIS} AE VERBATIM		Y T S E	REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT COM	ACTION	RELA TION INV	S A E	RELA TION MM	CASE ID
Distal esophagitis	DI	Y	22	6	06MAY04	11MAY04	MOD	RES	S O	PNOT	Y	PNOT	HQWYE888513MAY0
{HEMORRHAGIC GASTRITIS} AE VERBATIM		Y T S E	REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT COM	ACTION	RELA TION INV	S A E	RELA TION MM	CASE ID
Gastritis with erosions	DI	Y	22	6	06MAY04	11MAY04	MOD	RES	S O	PNOT	Y	PNOT	HQWYE888513MAY0
{HIATAL HERNIA}		Y T S E	REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT	ACTION	RELA TION INV	S A E	RELA TION MM	CASE ID
Hiatal hernia	DI		22	6	06MAY04	11MAY04	MOD	RES		PNOT	Y	PNOT	HQWYE888513MAY0

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

ION OF PROTOCOL 3151A2-315 Page 157

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 235, USA, 5096

TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 202684 , 54 Year old, Female, White , 85.3 kg , 173.4 cm, 28.4 kg /M^2

THERAPY START DATE/STOP DATE : 15APR04/ 07JUL04

STUDY COMPLETION STATUS : Discontinued (Failed to Return)

STUDY COMPLETION DATE : 13JUL04

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Relevant Medical History: hypertension, elevated liver enzymes, chest pain-cardiac catheterization, possible cerebrovascular accident, overweight, smoking.

Relevant Prior Medications: aspirin, Plavix, atenolol.

Relevant Concomitant Medications: atenolol, Prevacid, Xanax, Nitrobid, magnesium sulfate, Fioricet, acetaminophen, Plavix, aspirin.

Description of Event: The subject was admitted to the hospital after complaints of chest pain and pressure. She was treated with nitroglycerin initially in the emergency room. A cardiac consultation and work-up were done; laboratory data were unremarkable except for low magnesium level (treated with magnesium sulfate), and cardiac enzymes were negative. ECGs ruled out myocardial infarction or any cardiac event, and showed only minor nonspecific ST-T changes. Chest radiography showed no active pulmonary pathology. A gastrointesinal consultation was also performed because of abnormal LFTs and the subject's complaints of heartburn and gastrointestinal symptoms for 1-2 weeks. An ultrasound study of the abdomen was negative. Also, a hepatitis panel was done and results were nonreactive.

An esophagogastroduodenoscopy (EGD) with biopsy was performed, which revealed moderate gastritis with multiple erosions. Distal esophagitis was also noted, as well as a small hiatal hernia and duodenitis. The subject's medications were adjusted (started taking Prevacid daily), and a low-salt, low-fat, low-cholesterol diet was recommended. The subject was discharged home 11 May 2004

Outcome: The subject discontinued early from the study after failing to return. The adverse events esophagitis and gastritis with erosions were considered by the investigator and medical monitor to be moderate in severity and probably not related to test article. Duodenitis was considered mild in severity and probably not related to test article, and the chest pain was considered severe and definitely not related to test article.

Page 158

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-235-202666

INVESTIGATOR: 235, USA, 5096

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 202666, 59 Year old, Female, White , 60.8 kg , 152.4 cm, 26.2 kg /M^2

THERAPY START DATE/STOP DATE : 31MAR04/ 29MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 30MAR05

NARRATIVE REASON : CLINICALLY IMPORTANT VITAL SIGNS {PCI: SYSTOLIC BLOOD PRESSURE} Seq Test Value Baseline Vital Sign Position Date D.A.I Num (# => PCI) Unit Value SYSTOLIC BP Supine 08MAR04 Screening/baseline 124 mm Hg 122.5 126 SYSTOLIC BP Supine 08MAR04 Screening/baseline mm Ha 122.5 SYSTOLIC BP Supine 31MAR04 Screening/baseline 122 mm Ha 122.5 118 SYSTOLIC BP Supine 31MAR04 Screening/baseline mm Hq 122.5 SYSTOLIC BP 122.5 Supine 28APR04 Week 4 122 mm Hq SYSTOLIC BP Supine 28APR04 Week 4 124 mm Ha 122.5 SYSTOLIC BP Supine 26MAY04 Week 8 112 mm Ha 122.5 SYSTOLIC BP Supine 26MAY04 Week 8 118 mm Hq 122.5 SYSTOLIC BP Supine 23JUN04 Week 12 108 mm Ha 122.5 $\bar{1}14$ 122.5 SYSTOLIC BP Supine 23JUN04 Week 12 mm Ha SYSTOLIC BP Supine 15SEP04 Week 26 118 mm Hq 122.5 SYSTOLIC BP Supine 15SEP04 Week 26 mm Ha 122.5 SYSTOLIC BP Supine 15DEC04 Week 39 136 mm Ha 122.5 140 SYSTOLIC BP Supine 15DEC04 Week 39 mm Hq 122.5 1 164 # 3 166 # SYSTOLIC BP Supine 30MAR05 Follow-up mm Hq 122.5 SYSTOLIC BP Supine 30MAR05 Follow-up mm Hq 122.5 {PCI: DIASTOLIC BLOOD PRESSURE} Visit Seq Test Value Baseline Vital Sign Position Date D.A.I Num (# => PCI) Unit Value 72 DIASTOLIC BP Supine 08MAR04 Screening/baseline mm Hg 08MAR04 Screening/baseline DIASTOLIC BP Supine 3 80 mm Ha 78 DIASTOLIC BP Supine 31MAR04 Screening/baseline 1 80 mm Hq 78 Supine 31MAR04 Screening/baseline 3 80 78 DIASTOLIC BP mm Hq 80 80 78 DIASTOLIC BP Supine 28APR04 Week 4 mm Ha 78 DIASTOLIC BP Supine 28APR04 Week 4 mm Hq 78 78 DIASTOLIC BP Supine 26MAY04 Week 8 mm Hg DIASTOLIC BP Supine 26MAY04 Week 8 mm Hq

CONFIDENTIAL 837 Wyeth

Page 159

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 235, USA, 5096

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 202666 , 59 Year old, Female, White , 60.8 kg , 152.4 cm, 26.2 kg /M^2

THERAPY START DATE/STOP DATE : 31MAR04/ 29MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 30MAR05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Relevant Medical History: overweight.

Relevant Prior Medications: none.

Relevant Concomitant Medications: none.

Outcome: At the subject's last visit (day after last dose of test article), she had 41.8- and 43.8-mm Hg increases from baseline in systolic blood pressure and a 22-mm Hg increase from baseline in diastolic blood pressure that were considered clinically important (systolic: >/= 30 mm Hg from baseline with value >/= 160 mm Hg, diastolic: >/= 20 mm Hg from baseline with value >/= 100 mm Hg). At all previous visits, diastolic and systolic blood pressures remained within normal range. The subject completed the study. The investigator reported hypertension as an adverse event, moderate in severity, and probably not related to test article. The subject was referred to primary care physician for follow-up. No further information is available.

Page 160

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-236-202711

INVESTIGATOR: 236, USA, 28896

TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 202711 , 54 Year old, Female, White , 60.4 kg , 167.9 cm, 21.4 kg /M^2

THERAPY START DATE/STOP DATE : 02MAR04/ 25MAY04

STUDY COMPLETION STATUS : Discontinued (Failed to Return)

STUDY COMPLETION DATE : 010CT04

NARRATIVE REASON : CLINICALLY IMPORTANT LABORATORY VALUES

{PCI: GLUCOSE (FASTING)}

Lab Test	Rel. Day (Days)	D.A.I	Test Date	Test Value (# => PCI)	Fasting (Y/N)	Range (Low)	Range (High)	Unit	Baseline Value
GLUCOSE	-18	Screening/baseline	13FEB04	6.1616	Yes	3.8857	6.9388	mmol/L	6.1616
GLUCOSE	29	Week 4	30MAR04	12.7118 #	Yes	3.8857	6.9388	mmol/L	6.1616
GLUCOSE	36	Week 4	06APR04	5.4955	Yes	3.8857	6.9388	mmol/L	6.1616
GLUCOSE	86	Week 12	26MAY04	4.4963	Yes	3.8857	6.9388	mmol/L	6.1616

MEDICAL MONITOR COMMENTS :

Relevant Medical History: type I diabetes (x 30 years), hyperlipidemia, hypothyroidism, coronary artery disease with stent Placement.

Relevant Prior Medications: Humalog, Zocor, Cardizem, Synthroid.

Relevant Concomitant Medications: Humalog, Zocor, Cardizem, Synthroid.

Outcome: At week 4 of treatment, the subject had a single episode of increased glucose that was considered clinically important (>/= 11.10 mmol/L). She was known to be a controlled diabetic, using an insulin pump. However, the subject did not give herself a bolus of insulin before her laboratory collection. Glucose evaluation was repeated approximately 1 week later, and results were within normal limits. The subject discontinued early from the study because of unsatisfactory response. The investigator did not report increased glucose as an adverse event.

CONFIDENTIAL 839 Wyeth

Page 161

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-236-202713

INVESTIGATOR: 236, USA, 28896

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 202713 , 59 Year old, Female, White , 89.4 kg , 164.2 cm, 33.2 kg /M^2

THERAPY START DATE/STOP DATE : 21APR04/ 04AUG04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - HYPERTENSION)

STUDY COMPLETION DATE : 11AUG04

NARRATIVE REASON : DISCONTINUATION DUE TO ADVERSE EVENT

{HYPERTENSION}

BDY T REL DURA ONSET STOP OUT TION CASE
AE VERBATIM

BDY T REL DURA ONSET STOP OUT TION A TION CASE
SYS E DAY TION DATE DATE SEV COM ACTION INV E MM ID

Elevated blood pressure

CV Y 96 24 25JUL04 17AUG04 MIL RES P POSS

 ${\tt MEDICAL\ MONITOR\ COMMENTS\ :}$

Additional Vital Sign Values:

Date Supine Blood Pressure

(mm Hg)

13Apr04-	29Apr04 (Baseline)	144/73	(Average	of	all	screening/baseline values)
25May04	(Week 4)	136/82	=			-
25May04	(Week 4)	134/84				
17Jun04	(Week 8)	150/76				
17Jun04	(Week 8)	148/76				
16Jul04	(Week 12)	136/76				
16Jul04	(Week 12)	132/74				
11Aug04	(Follow-up)	142/78				
11Auq04	(Follow-up)	140/78				

Relevant Medical History: hypertension(1999), hypercholesterolemia, obesity.

Relevant Prior Medications: Accupril, Lipitor.

Relevant Concomitant Medications: Accupril, Lipitor.

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 162

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 236, USA, 28896

TREATMENT : Desvenlafaxine SR 200 mg

: 202713 , 59 Year old, Female, White , 89.4 kg , 164.2 cm, 33.2 kg /M^2

THERAPY START DATE/STOP DATE : 21APR04/ 04AUG04

STUDY COMPLETION STATUS STUDY COMPLETION DATE : Discontinued (Adverse Event - HYPERTENSION)

: 11AUG04

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Description of Event: The subject had a history of hypertension and hypercholesterolemia, and was treated with the medications Accupril and Lipitor. Blood pressure values increased slightly from baseline during the study, but remained within normal range at study visits.

Outcome: The subject discontinued early from the study because of elevated blood pressure readings taken at home at week 39 of treatment. The investigator reported elevated blood pressure as an adverse event, mild in severity, and possibly related to test article.

Page 163

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-236-202706

INVESTIGATOR : 236, USA, 28896

TREATMENT : Desvenlafaxine SR 50 mg

SUBJECT : 202706 , 50 Year old, Female, White , 61.2 kg , 159.1 cm, 24.2 kg /M^2

THERAPY START DATE/STOP DATE : 31MAR04/ 27MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 28MAR05

NARRATIVE REASON : CLINICALLY IMPORTANT LABORATORY VALUES

{PCI: TOTAL CHOLESTEROL}

Lab Test	Rel. Day (Days)	D.A.I	Test Date	Test Value (# => PCI)	Fasting (Y/N)	Range (Low)	Range (High)	Unit	Baseline Value
TOT.CHOL. /LIPID	-22	Screening/baseline	09MAR04	5.6633	Yes	0	5.1461	mmol/L	5.6633
TOT.CHOL. /LIPID	21	Week 4	20APR04	6.0254	Yes	0	5.1461	mmol/L	5.6633
TOT.CHOL. /LIPID	48	Week 8	17MAY04	4.4479	Yes	0	5.1461	mmol/L	5.6633
TOT.CHOL. /LIPID	72	Week 8	10JUN04	5.1979	Yes	0	5.1461	mmol/L	5.6633
TOT.CHOL. /LIPID	189	Week 26	050CT04	4.8617	Yes	0	5.1461	mmol/L	5.6633
TOT.CHOL. /LIPID	210	Week 26	260CT04	6.465	No/Unkn			mmol/L	5.6633
TOT.CHOL. /LIPID	280	Week 39	04JAN05	7.8097 #	Yes	0	5.1461	mmol/L	5.6633
TOT.CHOL. /LIPID	363	Week 52	28MAR05	3.8273	Yes	0	5.1461	mmol/L	5.6633

MEDICAL MONITOR COMMENTS :

Additional Relevant Lab Values:

Date	HDL (.90-2.07mol/L)	LDL (0-3.36 mmol/L)	Triglycerides (.40-2.26 mmol/L)
09Mar04 (Baseline)	1.81	3.33	1.11
20Apr04 (Week 4)	1.71	3.75	1.24
17May04 (Week 8)	1.73	2.43	0.64
10Jun04 (Week 12)	1.71	3.08	0.93
050ct04 (Week 26)	1.55	2.51	1.75
260ct04 (Week 26)	1.83	4.24	0.85
04Jan05 (Week 39)	1.73	5.64	0.96
28Mar05 (Week 52)	1.66	1.88	0.64

Relevant Medical History: hypertension (2003).

CONFIDENTIAL 842 Wyeth

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

Page 164

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 236, USA, 28896

TREATMENT : Desvenlafaxine SR 50 mg

SUBJECT : 202706 , 50 Year old, Female, White , 61.2 kg , 159.1 cm, 24.2 kg /M^2

THERAPY START DATE/STOP DATE : 31MAR04/ 27MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 28MAR05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Relevant Prior Medications: triamterene hydrochlorothiazide.

Relevant Concomitant Medications: triamterene hydrochlorothiazide, Darvocet.

Description of Event: At week 39 of treatment, the subject had a single episode of increased cholesterol that was considered clinically important (increase >/= 1.97 mmol/L from baseline and value >/= 7.8 mmol/L). Cholesterol had been borderline elevated since baseline, and at subsequent visit was within normal limits.

Outcome: The subject completed the study. Hypercholesterolemia was reported as an adverse event, mild in severity, and considered by the investigator to be probably not related to test article.

Page 165

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-236-202704

INVESTIGATOR: 236, USA, 28896

TREATMENT : Placebo : 202704 , 52 Year old, Female, White , 75.6 kg , 153 cm, 32.3 kg $/M^2$

THERAPY START DATE/STOP DATE : 13APR04/ 10MAY04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - HYPERTENSION)

STUDY COMPLETION DATE : 11MAY04

NARRATIVE REASON: DISCONTINUATION DUE TO ADVERSE EVENT {HYPERTENSION} RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM DATE SEV COM ACTION INV E MM 11MAY04 26MAY04 MOD RES P Elevated BP CV N 29 16 POSS NARRATIVE REASON : CLINICALLY IMPORTANT VITAL SIGNS {PCI: SYSTOLIC BLOOD PRESSURE} Visit Seq Test Value Baseline Vital Sign Position Date D.A.I Num (# => PCI) Unit Value SYSTOLIC BP Supine 24MAR04 Screening/baseline mm Ha SYSTOLIC BP Supine 24MAR04 Screening/baseline 138 mm Ha 145 SYSTOLIC BP Supine 13APR04 Screening/baseline 152 mm Hq 145 SYSTOLIC BP Supine 13APR04 Screening/baseline 150 mm Ha 145 190 # SYSTOLIC BP Supine 11MAY04 Follow-up mm Hq 145 Supine SYSTOLIC BP 11MAY04 Follow-up 192 # mm Hq 145 SYSTOLIC BP Supine 26MAY04 Follow-up 160 mm Hq 145 SYSTOLIC BP Supine 26MAY04 Follow-up 158 mm Hq 145 {PCI: DIASTOLIC BLOOD PRESSURE} Visit Seq Test Value Baseline Vital Sign Position Date D.A.I (# => PCI) Unit Value DIASTOLIC BP Supine 24MAR04 Screening/baseline mm Hg DIASTOLIC BP Supine 24MAR04 Screening/baseline 70 mm Ha 75 DIASTOLIC BP Supine 13APR04 Screening/baseline 78 mm Hq 75 Supine 13APR04 Screening/baseline 75 DIASTOLIC BP 80 mm Hq DIASTOLIC BP Supine 11MAY04 Follow-up 102 # mm Ha 75 DIASTOLIC BP Supine 11MAY04 Follow-up 104 # mm Hq 75 75 DIASTOLIC BP Supine 26MAY04 Follow-up 92 mm Hq DIASTOLIC BP Supine 26MAY04 Follow-up mm Ha

CONFIDENTIAL 844 Wyeth

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 166

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 236, USA, 28896

TREATMENT : Placebo

: 202704 , 52 Year old, Female, White , 75.6 kg , 153 cm, 32.3 kg /M^2

THERAPY START DATE/STOP DATE : 13APR04/ 10MAY04

STUDY COMPLETION STATUS STUDY COMPLETION DATE : Discontinued (Adverse Event - HYPERTENSION)

: 11MAY04

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Relevant Medical History: obesity.

Relevant Prior Medications: none.

Relevant Concomitant Medications: none.

Description of Event: At week 4 of treatment, the subject had 45- and 47-mm Hg increases from baseline in systolic blood pressure and 27- and 29-mm Hg increases from baseline in diastolic blood pressure that were considered clinically important systolic: >/= 30 mm Hg from baseline and with value >/= 160 mm Hg, diastolic: >/= 20 mm Hg from baseline and with value >/= 100). At follow-up visit, blood pressures remained elevated.

Outcome: The subject discontinued early from the study because of elevated blood pressure. The investigator reported elevated blood pressure as an adverse event, mild in severity, and possibly related to test article. No further information is available.

Page 167

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-237-202764

INVESTIGATOR: 237, USA, 23432

TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 202764 , 56 Year old, Female, White , 61.8 kg , 162.6 cm, 23.4 kg /M^2

THERAPY START DATE/STOP DATE : 07APR04/ 06APR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 07APR05

NARRATIVE REASON : SERIOUS ADVERSE EVENT (SAE)

{CERVICAL RADICULOPATHY}

RELA S RELA CASE BDY T REL DURA ONSET STOP OUT TION A TION AE VERBATIM SYS E DAY DATE DATE SEV COM ACTION INV E MM Cervical spondylotic Radiculopathy c5-6 NE Y 212 04NOV04 15DEC04 SEV RES H O DNOT Y PNOT HQWYE586212JAN05

{NECK PAIN}

RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY TION DATE DATE COM ACTION INV E MM Neck pain BO Y 212 44 04NOV04 17DEC04 SEV RES H DNOT Y PNOT HQWYE586212JAN05

MEDICAL MONITOR COMMENTS :

Relevant Medical History: none.

Relevant Prior Medications: none.

Relevant Concomitant Medications: Aleve, Darvocet, Mobic, Valium, Celebrex, trazodone.

Description of Event: The subject was admitted to the hospital on 15 Dec 2004 for cervical spondylitic radiculopathy C5-6. She was involved in a motor vehicle accident on 03 Nov 2004, which triggered the onset of neck pain with radiation into her posterior right shoulder and right upper extremity, with weakness of the right upper extremity. Magnetic resonance imaging was performed, which confirmed spondylitic changes at C5-6 with some narrowing of the right neural foramen. The subject was treated with trazodone, Darvocet, and Valium for pain, and also underwent physical therapy, neither of which relieved her symptoms. Because of the persistent symptoms, and failure of conservative treatment, the subject agreed to undergo surgery (cervical discectomy with fusion at C5-6). The procedure was performed without complication, and the subject was discharged home on 16 Dec 2004.

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 168

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR : 237, USA, 23432
TREATMENT : Desvenlafaxine SR 150 mg

: 202764 , 56 Year old, Female, White , 61.8 kg , 162.6 cm, 23.4 kg /M^2

THERAPY START DATE/STOP DATE : 07APR04/ 06APR05

: COMPLETED STUDY COMPLETION STATUS STUDY COMPLETION DATE : 07APR05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Outcome: The subject completed the study. The adverse events of cervical spondylitic radiculopathy C5-6 and neck pain were considered severe by the investigator and medical monitor, and definitely not related to test article.

Page 169

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-237-202762

INVESTIGATOR: 237, USA, 23432

TREATMENT : Desvenlafaxine SR 50 mg

SUBJECT : 202762 , 53 Year old, Female, White , 76.3 kg , 165.1 cm, 28.0 kg /M^2

THERAPY START DATE/STOP DATE : 31MAR04/ 09AUG04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - MYOCARDIAL INFARCT)

STUDY COMPLETION DATE : 08SEP04

NARRATIVE REASON : SERIOUS ADVERSE EVENT (SAE)

{MYOCARDIAL INFARCT}

REPORT NARR-INF

BDY T REL DURA ONSET STOP OUT TION A TION CASE
AE VERBATIM

SYS E DAY TION DATE DATE SEV COM ACTION INV E MM ID

Acute myocardial infarction

CV Y 132 6 09AUG04 14AUG04 LIF RES S H P O PNOT Y PNOT HQWYE217212AUG04

MEDICAL MONITOR COMMENTS :

Relevant Medical History: hypercholesterolemia, overweight, smoking, family history of coronary artery disease.

Relevant Prior Medications: none.

Relevant Concomitant Medications: digoxin, Lasix, Zocor, aspirin, Lopressor, Indocin Sr, Darvocet.

Description of Event: The subject was admitted to the hospital on 09 Aug 2004 with severe chest pain. An ECG was done, which indicated that the subject had an acute inferior-posterior myocardial infarction. She was treated in the emergency room with aspirin, nitroglycerin, Retavase, and heparin. The subject immediately underwent cardiac catheterization, revealing severe and diffuse coronary artery disease, proximal occlusion of the right coronary artery, and moderate stenosis of the left coronary artery. Percutaneous transluminal coronary angioplasty and stenting of the right coronary artery were performed. The subject tolerated the procedure well, and had an uncomplicated recovery. She was discharged home on 19 Aug 2004 receiving the medications digoxin, Lasix, Zocor, aspirin, Lopressor, Indocin Sr, and Darvocet for pain.

Outcome: The subject was withdrawn early from the study because of myocardial infarction. This event was severe, and considered by the investigator and medical monitor to be probably not related to test article.

Page 170

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-237-202753

INVESTIGATOR: 237, USA, 23432

TREATMENT : Placebo

SUBJECT : 202753 , 52 Year old, Female, White , 76.1 kg , 160 cm, 29.7 kg /M^2

THERAPY START DATE/STOP DATE : 17MAR04/ 23MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 11APR05

NARRATIVE REASON : ADVERSE EVENTS OF SPECIAL INTEREST

{ARYTHMIA}

REPORT NARR-INF

AE VERBATIM

BDY T REL DURA ONSET STOP OUT TION A TION CASE
SYS E DAY TION DATE DATE SEV COM ACTION INV E MM ID

Arrhythmia, cardiac

CV N 391 . 11APR05 . MOD PER N POSS

 ${\tt MEDICAL}$ MONITOR COMMENTS :

Relevant Medical History: hypertension (2003), overweight.

Relevant Prior Medication: Toprol XL.

Relevant Concomitant Medication: Toprol XL.

Description of Event: Routine ECG performed at the subject's last visit had an overall evaluation of normal, but also showed premature ventricular contractions. No action was taken. ECGs at baseline and week 12 were also normal.

Outcome: The subject completed the study. The investigator reported this finding as an adverse event of "cardiac arrhythmia," moderate in severity, and possibly related to test article. No further information is available.

CONFIDENTIAL 849 Wyeth

Page 171

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-238-202831

INVESTIGATOR: 238, USA, 15449

TREATMENT : Desvenlafaxine SR 150 mg SUBJECT : 202831 , 53 Year old, Female, White , 61.8 kg , 157.4 cm, 24.9 kg /M^2

THERAPY START DATE/STOP DATE : 22MAR04/ 20MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 21MAR05 STUDY COMPLETION DATE

NARRATIVE REASON: CLINICALLY IMPORTANT LABORATORY VALUES

{PCI: TOTAL CHOLESTEROL}

Rel. Day Lab Test (Days)		D.A.I	Test Date	Test Value (# => PCI)	Fasting (Y/N)	Range (Low)	Range (High)	Unit	Baseline Value
TOT.CHOL. /LIPID	-11	Screening/baseline	11MAR04	4.6289	Yes	0	5.1461	mmol/L	4.6289
TOT.CHOL. /LIPID	29	Week 4	19APR04	7.5253	Yes	0	5.1461	mmol/L	4.6289
TOT.CHOL. /LIPID	57	Week 8	17MAY04	7.2408	Yes	0	5.1461	mmol/L	4.6289
TOT.CHOL. /LIPID	85	Week 12	14JUN04	7.8097 #	Yes	0	5.1461	mmol/L	4.6289
TOT.CHOL. /LIPID	186	Week 26	23SEP04	5.2754	Yes	0	5.1461	mmol/L	4.6289
TOT.CHOL. /LIPID	274	Week 39	20DEC04	5.353	Yes	0	5.1461	mmol/L	4.6289
TOT.CHOL. /LIPID	365	Week 52	21MAR05	4.8617	Yes	0	5.1461	mmol/L	4.6289

MEDICAL MONITOR COMMENTS :

Additional Relevant Lab Values:

Date	HDL (.90-2.07mol/L)	LDL (0-3.36 mmol/L)	Triglycerides (.40-2.26 mmol/L)
11Mar04 (Baseline)	1.40	2.48	1.61
19Apr04 (Week 4)	1.45	5.12	2.08
17May04 (Week 8)	ND	ND	2.13
14Jun04 (Week 12)	1.34	5.53	2.05
23Sep04 (Week 26)	1.32	3.18	1.68
20Dec04 (Week 39)	0.93	2.66	3.84
21Mar05 (Week 52)	1.14	3.10	1.35

Relevant Medical History: dyslipidemia (1999).

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 172

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 238, USA, 15449

TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 202831 , 53 Year old, Female, White , 61.8 kg , 157.4 cm, 24.9 kg /M^2

THERAPY START DATE/STOP DATE : 22MAR04/ 20MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 21MAR05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Relevant Prior Medication: Lipitor.

Relevant Concomitant Medication: Lipitor.

Outcome: At week 12 of treatment, the subject had a single episode of increased cholesterol that was considered clinically important (increase >/= 1.97 mmol/L and value >/= 7.8 mmol/L). At this time, she also had an increase in LDL cholesterol. Cholesterol returned to within normal limits at subsequent visits. The subject completed the study. The investigator did not report increased cholesterol as an adverse event.

Page 173

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-239-202859

INVESTIGATOR : 239, USA, 5485

TREATMENT : Desvenlafaxine SR 100 mg

SUBJECT : 202859 , 57 Year old, Female, White , 53.6 kg , 154.9 cm, 22.3 kg /M^2

THERAPY START DATE/STOP DATE : 23FEB04/ 06FEB05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 22FEB05

(DEDDECCTON)	NARRATIVE REASON	: ADVE	RSE EVE	ENTS OF	'SPECIAL	INTEREST							
{DEPRESSION} AE VERBATIM		BDY T SYS E	REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT COM	ACTION	RELA TION INV	S A E	RELA TION MM	CASE ID
Depression Sadness		NE Y NE N	135 352	4	06JUL04 08FEB05	09JUL04	MOD MOD	RES PER	S S	PNOT			
{URINARY RETENTION}										RELA	S	RELA	
AE VERBATIM		BDY T SYS E	REL DAY	DURA TION	ONSET DATE	STOP DATE	SEV	OUT COM	ACTION	TION INV	Ā E	TION MM	CASE ID
Urinary retention		UR Y	7	33	29FEB04	01APR04	MIL	RES	N	PNOT			

MEDICAL MONITOR COMMENTS :

Relevant Medical History: overactive bladder, urinary tract infection, polyps removed from bladder, trouble sleeping.

Relevant Prior Medications: none.

Relevant Concomitant Medication: Tylenol.

Description of Event: At week 19 of treatment, the subject reported a single episode of depression, mild in severity, for which she reported taking Tylenol. The event resolved in 4 days.

Also, the subject reported an episode of sadness, beginning 2 days after discontinuing test article. She was sent to her primary care physician for follow-up, and was prescribed Effexor on 15 Feb 2005 for treatment. As of 15 Jul 2005, it was reported that the subject was still under care of her primary care physician for ongoing depression and mood swings, but had shown some improvement, and was still taking Effexor.

CONFIDENTIAL 852 Wyeth

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

Page 174

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 239, USA, 5485

TREATMENT : Desvenlafaxine SR 100 mg

SUBJECT : 202859 , 57 Year old, Female, White , 53.6 kg , 154.9 cm, 22.3 kg /M^2

THERAPY START DATE/STOP DATE : 23FEB04/ 06FEB05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 22FEB05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

In addition, an episode of "urinary retention" was reported at week 1 of treatment. Although confirmed as urinary retention by the investigator, the episode was more likely to be "urinary hesitancy" because of the duration of the event (33 days). Besides, no catheterization was needed, and the episode resolved spontaneously.

Outcome: The subject completed the study. The investigator reported the adverse events of depression and sadness as moderate in severity, and probably not related to test article. The investigator reported "urinary retention" as mild in severity, and probably not related to test article.

Page 175

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-239-202869

INVESTIGATOR: 239, USA, 5485

TREATMENT : Desvenlafaxine SR 100 mg

SUBJECT : 202869 , 58 Year old, Female, Black , 63.6 kg , 161.3 cm, 24.4 kg /M^2

THERAPY START DATE/STOP DATE : 04MAR04/ 03MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 03MAR05

NARRATIVE REASON : SERIOUS ADVERSE EVENT (SAE)

{DYSPNEA}

RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY DATE DATE SEV COM ACTION INV E MM Shortness of breath RE Y 140 21,7111,04 23JUL04 SEV RES H PNOT Y PNOT HOWYE664530AUG04

MEDICAL MONITOR COMMENTS :

Relevant Medical History: shortness of breath, heart attack (2003), angina (1985), coronary artery disease, cardiac catheterization, heart murmur, hypertension, elevated cholesterol, heartburn, sinus congestion, respiratory allergies, depression(2004), anxiety(2003), trouble sleeping, smoking.

Relevant Prior Medications: Toprol, lisinopril, Lipitor, Vioxx, aspirin, Aleve.

Relevant Concomitant Medications: Toprol, lisinopril, Lipitor, Vioxx, aspirin, Aleve, gemfibrozil, losartan, Pravachol, Toprol XL, nitroglycerin, Protonix, Darvocet, Cozaar.

Description of Event: The subject was admitted to the hospital on 22 Jul 2004 with complaints of shortness of breath and chest pain without exertion that was unlike the chest pain she experienced in the past. Diffuse expiratory wheezing was noted upon auscultation of the lungs, but chest radiography was negative. Laboratory tests showed an elevation in white blood cell count. Myocardial infarction was ruled out after a series of ECGs, cardiac enzyme evaluation, and serial troponin evaluation. An exercise stress echocardiogram was negative. The subject was given Plavix and Lovenox upon admission, and continued on her home regimen of Toprol XL, hydrochlorothiazide, and Lipitor. The final diagnosis of this event was shortness of breath considered to be secondary to a respiratory virus. The subject was discharged home on 23 Jul 2004 taking the medications aspirin, nitroglycerin, Pravachol, losartan, and Toprol XL, and was advised to begin a low-fat, low-salt, and low-cholesterol diet.

Outcome: The subject completed the study. The adverse event shortness of breath was considered severe, and considered probably not related to test article by the investigator and medical monitor. The adverse event of chest pain was considered by the investigator and medical monitor to be moderate in severity, and probably not related to test article.

CONFIDENTIAL 854 Wyeth

Page 176

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-239-202882

INVESTIGATOR: 239, USA, 5485

TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 202882 , 55 Year old, Female, Black , 51.8 kg , 161 cm, 20.0 kg /M^2

THERAPY START DATE/STOP DATE : 01APR04/ 03JAN05

STUDY COMPLETION STATUS : Discontinued (Adverse Event - CHEST PAIN)

STUDY COMPLETION DATE : 14JAN05

NARRATIVE REASON : ADVERSE EVENTS OF SPECIAL INTEREST

{CHEST PAIN}

BDY T REL DURA ONSET STOP OUT TION A TION CASE
AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM ID

Chest pain BO N 279 1 04JAN05 04JAN05 MOD RES S P O PNOT

NARRATIVE REASON : CLINICALLY IMPORTANT VITAL SIGNS

{ PCI: SUSTAINED HYPERTENSION }

Vital Sign	Position	Visit Date	Seq Num	D.A.I	Test Value (# => PCI)	Unit	Baseline Value
3		00117704					
DIASTOLIC BP	Supine	09MAR04	Ţ	Screening/baseline	84	mm Hg	86
DIASTOLIC BP	Supine	09MAR04	3	Screening/baseline	88	mm Hg	86
DIASTOLIC BP	Supine	01APR04	1	Screening/baseline	84	mm Hg	86
DIASTOLIC BP	Supine	01APR04	3	Screening/baseline	88	mm Hg	86
DIASTOLIC BP	Supine	16APR04	1	Week 4	88	mm Hg	86
DIASTOLIC BP	Supine	16APR04	3	Week 4	86	mm Hg	86
DIASTOLIC BP	Supine	19MAY04	1	Week 8	106 #	mm Hg	86
DIASTOLIC BP	Supine	19MAY04	3	Week 8	96 #	mm Hg	86
DIASTOLIC BP	Supine	10JUN04	1	Week 8	98 #	mm Hg	86
DIASTOLIC BP	Supine	10JUN04	3	Week 8	96 #	mm Hg	86
DIASTOLIC BP	Supine	23SEP04	1	Week 26	100 #	mm Hg	86
DIASTOLIC BP	Supine	23SEP04	3	Week 26	96 #	mm Hg	86
DIASTOLIC BP	Supine	04JAN05	1	Follow-up	100 #	mm Hg	86
DIASTOLIC BP	Supine	04JAN05	3	Follow-up	100 #	mm Hg	86
DIASTOLIC BP	Supine	14JAN05	1	Follow-up	88	mm Hg	86
DIASTOLIC BP	Supine	14JAN05	3	Follow-up	88	mm Hg	86

MEDICAL MONITOR COMMENTS :

Additional Relevant Vital Sign Values:

Page 177

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 239, USA, 5485

TREATMENT : Desvenlafaxine SR 150 mg

: 202882 , 55 Year old, Female, Black , 51.8 kg , 161 cm, 20.0 kg /M^2

THERAPY START DATE/STOP DATE : 01APR04/ 03JAN05

STUDY COMPLETION STATUS STUDY COMPLETION DATE : Discontinued (Adverse Event - CHEST PAIN)

: 14JAN05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Date Supine Systolic Blood Pressure (mm Hg)

09Mar04-	01Apr04 (Baseline)	129.5	(Average	of	aIl	screening/baseline	values)
16Apr04	(Week 4)	124	_			-	
16Apr04	(Week 4)	126					
19May04	(Week 8)	156					
19May04	(Week 8)	140					
10Jun04	(Week 12)	146					
10Jun04	(Week 12)	130					
	(Week 26)	158					
23Sep04	(Week 26)	148					
04Jan05	(Week 39)	156					
	(Week 39)	160					
	(Follow-up)	126					
14Jan05	(Follow-up)	128					

Relevant Medical History: wheezing, coronary obstructive pulmonary disease (COPD), shortness of breath.

Relevant Prior Medication: albuterol.

Relevant Concomitant Medications: albuterol, Benicar HCT.

Outcome: From weeks 8 through 52 of treatment, the subject had sustained hypertension that was considered clinically important (increase of >/= 10 mm Hg supine diastolic blood pressure with value >/= 90 mm Hg at 3 consecutive visits). At last visit (day after last dose of test article), she had a 30.5-mm Hg increase from baseline in systolic blood pressure

Page 178

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 239, USA, 5485

TREATMENT : Desvenlafaxine SR 150 mg

: 202882 , 55 Year old, Female, Black , 51.8 kg , 161 cm, 20.0 kg /M^2

THERAPY START DATE/STOP DATE : 01APR04/ 03JAN05

STUDY COMPLETION STATUS STUDY COMPLETION DATE : Discontinued (Adverse Event - CHEST PAIN)

: 14JAN05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

that was considered clinically important (>/= 30 mm Hg from baseline with value >/= 160 mm Hg). At all prior visits, systolic blood pressure remained within normal range. At follow-up visit, both systolic and diastolic blood pressures returned to within normal range.

Also, the subject reported a single episode of chest pain, which began the day after she discontinued test article. This event spontaneously resolved in 1 day. ECG performed at this visit was normal.

The subject completed the study. The investigator did not report increased blood pressure or sustained hypertension as adverse events. Chest pain was reported as an adverse event, moderate in severity, and considered by the investigator to be probably not related to test article.

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-239-202874

INVESTIGATOR: 239, USA, 5485

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 202874 , 53 Year old, Female, White , 76.4 kg , 153.7 cm, 32.3 kg /M^2

THERAPY START DATE/STOP DATE : 18MAR04/ 09MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 10MAR05

NARRATIVE REASON : ADVERSE EVENTS OF SPECIAL INTEREST

{DEPRESSION}

REPORT NARR-INF

RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM Depressed NE N 360 12MAR05 MIL PER N PNOT Sadness NE Y 14 31MAR04 04APR04 MOD RES N POSS

MEDICAL MONITOR COMMENTS :

Relevant Medical History: hypothyroidism, trouble sleeping.

Relevant Prior Medication: Synthroid.

Relevant Concomitant Medication: Synthroid.

Description of Event: At week 2 of treatment, the subject reported a single episode of sadness, which spontaneously resolved in 5 days.

Also, the subject reported an episode of depression, beginning 3 days after discontinuing test article. She was referred to her primary care physician for follow-up. As of 15 Jul 2005, it was reported that the subject was still under care of her primary care physician for depression, but was not taking any medication for treatment of this condition.

Outcome: The subject completed the study. The investigator reported the adverse event of sadness as moderate in severity, and possibly related to test article. The investigator reported the episode of depression as mild in severity, and probably not related to test article.

Page 179

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

Page 180

315-239-202875

INVESTIGATOR: 239, USA, 5485

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 202875 , 52 Year old, Female, White , 74.5 kg , 165.1 cm, 27.3 kg /M^2

THERAPY START DATE/STOP DATE : 11MAR04/ 14JUL04

STUDY COMPLETION STATUS : Discontinued (Other Event)

STUDY COMPLETION DATE : 22JUL04

NARRATIVE REASON: ADVERSE EVENTS OF SPECIAL INTEREST

{DEPRESSION}

REPORT NARR-INF

BDY T REL DURA ONSET STOP OUT TION A TION CASE
AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM ID

Depression NE Y 83 . 01JUN04 . MOD PER S PNOT

MEDICAL MONITOR COMMENTS :

Relevant Medical History: depression (stopped 2002), insomnia.

Relevant Prior Medications: none.

Relevant Concomitant Medication: Effexor.

Description of Event: At week 11 of treatment, the subject reported an episode of depression, for which she was seen by her primary care physician, who prescribed Effexor treatment for her on 15 Jun 2004. The subject was withdrawn early from the study because of concomitant use of prohibited medication Effexor.

Outcome: As of 15 Jul 2005, it was reported that the subject was still under care of her primary care physician for depression, and the depression had improved since she started taking Effexor. The investigator reported the adverse event of depression as moderate in severity, and probably not related to test article.

CONFIDENTIAL 859 Wyeth

Page 181

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-239-202852

INVESTIGATOR: 239, USA, 5485

TREATMENT : Placebo

: 202852 , 43 Year old, Female, Black , 87.7 kg , 165.1 cm, 32.2 kg /M^2 SUBJECT

THERAPY START DATE/STOP DATE : 12JAN04/ 02JAN05

: COMPLETED STUDY COMPLETION STATUS : 25JAN05 STUDY COMPLETION DATE

NARRATIVE REASON : CLINICALLY IMPORTANT VITAL SIGNS

ital Sign	Position	Visit Date	D.A.I	Seq Num	Test Value (# => PCI)	Unit	Baseline Value
DIASTOLIC BP	Supine	10DEC03	Screening/baseline	1	68	mm Hg	80.5
IASTOLIC BP	Supine	10DEC03	Screening/baseline	3	72	mm Hq	80.5
IASTOLIC BP	Supine	12JAN04	Screening/baseline	1	90	mm Hq	80.5
IASTOLIC BP	Supine	12JAN04	Screening/baseline	3	92	mm Hq	80.5
IASTOLIC BP	Supine	03FEB04	Week 4	1	96	mm Hq	80.5
ASTOLIC BP	Supine	03FEB04	Week 4	3	92	mm Hq	80.5
IASTOLIC BP	Supine	25FEB04	Week 4	1	92	mm Hq	80.5
ASTOLIC BP	Supine	25FEB04	Week 4	3	88	mm Hq	80.5
ASTOLIC BP	Supine	30MAR04	Week 12	1	72	mm Hq	80.5
ASTOLIC BP	Supine	30MAR04	Week 12	3	72	mm Hq	80.5
IASTOLIC BP	Supine	29JUN04	Week 26	1	102 #	mm Hq	80.5
ASTOLIC BP	Supine	29JUN04	Week 26	3	96	mm Hq	80.5
IASTOLIC BP	Supine	060CT04	Week 39	1	58	mm Hq	80.5
IASTOLIC BP	Supine	060CT04	Week 39	3	58	mm Hq	80.5
IASTOLIC BP	Supine	03JAN05	Follow-up	ĺ	80	mm Hq	80.5
IASTOLIC BP	Supine	03JAN05	Follow-up	3	84	mm Hq	80.5

Lab Test	Rel. Day (Days)	D.A.I	Test Date	Test Value (# => PCI)	Fasting (Y/N)	Range (Low)	Range (High)	Unit	Baseline Value
GLUCOSE	-33	Screening/baseline	10DEC03	7.2163	Yes	3.8857	6.3837	mmol/L	7.2163
GLUCOSE	23	Week 4	03FEB04	8.5485	Yes	3.8857	6.3837	mmol/L	7.2163
GLUCOSE	79	Week 12	30MAR04	13.6 #	Yes	3.8857	6.3837	mmol/L	7.2163
GLUCOSE	114	Week 12	04MAY04	8.8261	Yes	3.8857	6.3837	mmol/L	7.2163
GLUCOSE	170	Week 26	29JUN04	7.9934	Yes	3.8857	6.3837	mmol/L	7.2163
GLUCOSE	269	Week 39	060CT04	10.4914	Yes	3.8857	6.3837	mmol/L	7.2163
GLUCOSE	358	Week 52	03JAN05	7.9934	Yes	3.8857	6.3837	mmol/L	7.2163

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

Page 182

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 239, USA, 5485

TREATMENT : Placebo

SUBJECT : 202852 , 43 Year old, Female, Black , 87.7 kg , 165.1 cm, 32.2 kg /M^2

THERAPY START DATE/STOP DATE : 12JAN04/ 02JAN05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 25JAN05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Additional Relevant Vital Sign Values:

Date Supine Systolic Blood Pressure (mm Hq)

10Dec03-12Ja	n04 (Baseline)	122	(Average	of	all	screening/baseline	values)
03Feb04 (Wee	k 4)	146				3	
03Feb04 (Wee	k 4)	146					
25Feb04 (Wee	k 8)	136					
25Feb04 (Wee	k 8)	128					
30Mar04 (Wee	k 12)	102					
30Mar04 (Wee	k 12)	106					
29Jun04 (Wee	ek 26)	158					
29Jun04 (Wee	k 26)	150					
060ct04 (Wee	ek 39)	100					
060ct04 (Wee	k 39)	100					
03Jan05 (Wee	ek 52)	120					
03Jan05 (Wee	ek 52)	120					

Relevant Medical History: hypertension, elevated cholesterol, type II diabetes, obesity.

Relevant Prior Medications: Glucophage, Lotensin, Diovan HCT, Metaglip.

Relevant Concomitant Medications: Glucophage, Lotensin, Diovan HCT, Metaglip, Lantus.

Outcome: At week 26 of treatment, the subject had a 21.5 mm-Hg increase from baseline in diastolic blood pressure that was considered clinically important (>/= 20 mm Hg from baseline with value >/= 100 mm Hg). At subsequent visits,

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

Page 183

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 239, USA, 5485

TREATMENT : Placebo

SUBJECT : 202852 , 43 Year old, Female, Black , 87.7 kg , 165.1 cm, 32.2 kg /M^2

THERAPY START DATE/STOP DATE : 12JAN04/ 02JAN05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 25JAN05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

diastolic blood pressures returned to normal range.

Also, at week 12 of treatment, the subject had a single episode of increased glucose that was considered clinically important (>/= 11.10 mmol/L). She was known to be a controlled diabetic, who reported that her blood sugars were within normal limits. Subsequent glucose values were also within normal limits.

The subject completed the study. The investigator did not report increased blood pressure as an adverse event. The investigator did report hyperglycemia as an adverse event, moderate in severity, and definitely not related to test article.

Page 184

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-240-202921

INVESTIGATOR: 240, USA, 28897

TREATMENT : Desvenlafaxine SR 100 mg SUBJECT : 202921 , 53 Year old, Female, Black , 81 kg , 158 cm, 32.4 kg /M^2

THERAPY START DATE/STOP DATE : 09MAR04/ 07MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 08MAR05

NARRATIVE REASON : CLINICALLY IMPORTANT VITAL SIGNS

AINED HYPERTENSIO

		Visit	Seq		Test Value		Baseline
Vital Sign	Position	Date	Num	D.A.I	(# => PCI)	Unit	Value
DIASTOLIC BP	Supine	17FEB04	1	Screening/baseline	76	mm Hq	77.5
			7				
DIASTOLIC BP	Supine	17FEB04	3	Screening/baseline	81	mm Hg	77.5
DIASTOLIC BP	Supine	09MAR04	1	Screening/baseline	78	mm Hg	77.5
DIASTOLIC BP	Supine	09MAR04	3	Screening/baseline	75	mm Hg	77.5
DIASTOLIC BP	Supine	08APR04	1	Week 4	83	mm Hg	77.5
DIASTOLIC BP	Supine	08APR04	3	Week 4	83	mm Hg	77.5
DIASTOLIC BP	Supine	06MAY04	1	Week 8	80	mm Hg	77.5
DIASTOLIC BP	Supine	06MAY04	3	Week 8	98	mm Hg	77.5
DIASTOLIC BP	Supine	27MAY04	1	Week 12	96 #	mm Hg	77.5
DIASTOLIC BP	Supine	27MAY04	3	Week 12	98	mm Hg	77.5
DIASTOLIC BP	Supine	31AUG04	1	Week 26	94 #	mm Hg	77.5
DIASTOLIC BP	Supine	31AUG04	3	Week 26	88	mm Hg	77.5
DIASTOLIC BP	Supine	30NOV04	1	Week 39	100 #	mm Hg	77.5
DIASTOLIC BP	Supine	30NOV04	3	Week 39	98	mm Hg	77.5
DIASTOLIC BP	Supine	08MAR05	1	Follow-up	90 #	mm Hg	77.5
DIASTOLIC BP	Supine	08MAR05	3	Follow-up	86	mm Hg	77.5

MEDICAL MONITOR COMMENTS :

Additional Relevant Lab Values:

Date Supine Systolic Blood Pressure

(mm Hq)

17Feb-09Mar04 (Baseline)	131.75 (Average of all screening/baseline values)
08Apr04 (Week 4)	134

08Apr04 (Week 4) 06May04 (Week 8) 133

Page 185

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 240, USA, 28897

TREATMENT : Desvenlafaxine SR 100 mg

SUBJECT : 202921 , 53 Year old, Female, Black , 81 kg , 158 cm, 32.4 kg /M^2

THERAPY START DATE/STOP DATE : 09MAR04/ 07MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 08MAR05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

06May04 (Week 8) 145 27May04 (Week 12) 27May04 (Week 12) 149 149 31Aug04 (Week 26) 149 31Aug04 (Week 26) 150 30Nov04 (Week 39) 155 30Nov04 (Week 39) 151 08Mar05 (Week 52) 138 08Mar05 (Week 52) 140

Relevant Medical History: mitral valve prolapse (1981), obesity.

Relevant Prior Medications: none.

Relevant Concomitant Medications: none.

Outcome: From weeks 12 through 52 of treatment, the subject's blood pressure measurements met clinical importance criteria for sustained hypertension (increase of >/= 10 mm Hg supine diastolic blood pressure with value >/= 90 mm Hg at 3 consecutive visits). In addition, at week 39 of treatment, she had a 22.5-mm Hg increase from baseline in diastolic blood pressure that was considered clinically important (>/= 20 mm Hg from baseline with value >/= 100 mm Hg).

The subject completed the study. The investigator did not report sustained hypertension as an adverse event. No further information is available.

Page 186

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-240-202906

INVESTIGATOR: 240, USA, 28897

REPORT NARR-INF

TREATMENT : Desvenlafaxine SR 50 mg

SUBJECT : 202906 , 56 Year old, Female, White , 77 kg , 165 cm, 28.3 kg /M^2

THERAPY START DATE/STOP DATE : 13FEB04/ 17FEB05

STUDY COMPLETION STATUS : COMPLETED : 18FEB05 STUDY COMPLETION DATE

NARRATIVE REASON : CLINICALLY IMPORTANT VITAL SIGNS

{PCI: SUSTAINED HYPERTENSION}

Vital Sign	Position	Visit Date	Seq Num	D.A.I	Test Value (# => PCI)	Unit	Baseline Value
3							
DIASTOLIC BP	Supine	10FEB04	1	Screening/baseline	.1.1	mm Hg	82.75
DIASTOLIC BP	Supine	10FEB04	3	Screening/baseline	78	mm Hg	82.75
DIASTOLIC BP	Supine	13FEB04	1	Screening/baseline	91	mm Hg	82.75
DIASTOLIC BP	Supine	13FEB04	3	Screening/baseline	85	mm Hg	82.75
DIASTOLIC BP	Supine	11MAR04	1	Week 4	80	mm Hg	82.75
DIASTOLIC BP	Supine	11MAR04	3	Week 4	84	mm Hg	82.75
DIASTOLIC BP	Supine	08APR04	1	Week 8	84	mm Hg	82.75
DIASTOLIC BP	Supine	08APR04	3	Week 8	89	mm Hg	82.75
DIASTOLIC BP	Supine	07MAY04	1	Week 12	88	mm Hg	82.75
DIASTOLIC BP	Supine	07MAY04	3	Week 12	88	mm Hg	82.75
DIASTOLIC BP	Supine	10AUG04	1	Week 26	91	mm Hg	82.75
DIASTOLIC BP	Supine	10AUG04	3	Week 26	93 #	mm Hg	82.75
DIASTOLIC BP	Supine	16NOV04	1	Week 39	99	mm Hg	82.75
DIASTOLIC BP	Supine	16NOV04	3	Week 39	100 #	mm Hq	82.75
DIASTOLIC BP	Supine	18FEB05	1	Follow-up	87	mm Hg	82.75
DIASTOLIC BP	Supine	18FEB05	3	Follow-up	97 #	mm Hg	82.75

MEDICAL MONITOR COMMENTS :

Additional Relevant Vital Sign Values:

Date Supine Systolic Blood Pressure (mm Hq)

19Jan04	(Baseline)	137
19Jan04	(Baseline)	134
13Feb04	(Baseline)	140
13Feb04	(Baseline)	158

Page 187

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 240, USA, 28897

TREATMENT : Desvenlafaxine SR 50 mg

SUBJECT : 202906 , 56 Year old, Female, White , 77 kg , 165 cm, 28.3 kg /M^2

THERAPY START DATE/STOP DATE : 13FEB04/ 17FEB05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 18FEB05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

11Mar04	(Week	4)	145
11Mar04	(Week	4)	143
08Apr04	(Week	8)	149
08Apr04	(Week	8)	145
07May04	(Week	12)	147
07Mav04	(Week	12)	143
10Auq04	(Week	26)	144
10Aug04	(Week	26)	148
16Nov04	(Week	39)	148
16Nov04	(Week	39)	152
18Feb05	(Week	52)	144
18Feb05	(Week	52)	151
		,	

Relevant Medical History: controlled hypertension.

Relevant Prior Medications: Cozaar, Diovan HCT.

Relevant Concomitant Medications: Cozaar, Diovan HCT.

Outcome: At weeks 26 through 52 of treatment, the subject's blood pressure measurements met clinical importance criteria for sustained hypertension (increase of >/=10 mm Hg supine diastolic blood pressure with value >/=90 mm Hg at 3 consecutive visits). No further information is available after week 52. The subject was known to be hypertensive, and took Cozaar and Diovan HCT for treatment of this condition.

The subject completed the study. The investigator reported increased blood pressure as an adverse event, mild to moderate in Severity, and probably related to test article.

Page 188

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-241-202960

INVESTIGATOR : 241, USA, 4780

TREATMENT : Desvenlafaxine SR 100 mg

SUBJECT : 202960 , 54 Year old, Female, White , 74.2 kg , 174 cm, 24.5 kg /M^2

THERAPY START DATE/STOP DATE : 02APR04/ 31MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 01APR05

NARRATIVE REASON : ADVERSE EVENTS OF SPECIAL INTEREST

{DEPRESSION}

REPORT NARR-INF

RELA S RELA BDY T REL DURA ONSET STOP OUT TION A TION CASE AE VERBATIM SYS E DAY TION DATE DATE SEV COM ACTION INV E MM Depression NE N 367 8 03APR05 10APR05 MOD RES S O POSS

MEDICAL MONITOR COMMENTS :

Relevant Medical History: none.

Relevant Prior Medications: none.

Relevant Concomitant Medications: none.

Description of Event: The subject reported an episode of depression, beginning 3 days after discontinuing test article. The subject also reported adverse events of headache, blurred vision, lack of concentration, lack of balance, seasickness, and shakiness during this time period. The subject saw her primary care physician on 04 Apr 2004 for follow-up, and was prescribed Prempro. The episode of depression resolved in 8 days.

Outcome: The subject completed the study. The investigator reported the adverse event of depression as moderate in severity, and possibly related to discontinuation of test article.

CONFIDENTIAL 867 Wyeth

Page 189

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-242-203020

INVESTIGATOR: 242, USA, 18225

TREATMENT : Desvenlafaxine SR 150 mg

SUBJECT : 203020 , 49 Year old, Female, White , 66.4 kg , 165 cm, 24.4 kg /M^2

THERAPY START DATE/STOP DATE : 12APR04/ 11APR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 12APR05

NARRATIVE REASON : ADVERSE EVENTS OF SPECIAL INTEREST

{CHEST PAIN}

REPORT NARR-INF

BDY T REL DURA ONSET STOP OUT TION A TION CASE
AE VERBATIM

BDY T REL DURA ONSET STOP OUT TION A TION CASE
SYS E DAY TION DATE DATE SEV COM ACTION INV E MM ID

Chest pain

BO Y 320 1 25FEB05 25FEB05 MOD RES SO PNOT

MEDICAL MONITOR COMMENTS :

Relevant Medical History: none.

Relevant Prior Medications: none.

Relevant Concomitant Medications: Phenergan, Valium, Toradol.

Description of Event: At week 45 of treatment, the subject reported an episode of chest pain, which resolved in 1 day. The subject also experienced vertigo, and was seen in the emergency room on 25 Feb 2005. A computed tomography scan, and ECG were performed, all with negative results. The subject was diagnosed with vertigo, and was treated with medications Phenergan, Valium, and Toradol, and sent home.

Outcome: The subject completed the study. The investigator reported chest pain as an adverse event moderate in severity, and probably not related to test article.

CONFIDENTIAL 868 Wyeth

Page 190

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-242-203008

INVESTIGATOR: 242, USA, 18225

TREATMENT : Desvenlafaxine SR 200 mg

SUBJECT : 203008 , 47 Year old, Female, White , 63.8 kg , 170.1 cm, 22.1 kg /M^2

THERAPY START DATE/STOP DATE : 02APR04/ 29SEP04

STUDY COMPLETION STATUS : Discontinued (Adverse Event - DRY MOUTH)

STUDY COMPLETION DATE : 010CT04

NARRATIVE REASON : SERIOUS ADVERSE EVENT (SAE)

{SARCOTDOSTS}

REPORT NARR-INF

AE VERBATIM	BDY T SYS E		DURA TION	ONSET DATE	STOP DATE	SEV	OUT COM	ACTION	RELA TION INV	A	TION	CASE ID
Sarcoidosis Sarcoidosis	BO Y BO Y	142 142	137	21AUG04 21AUG04	04JAN05		PER RES		PNOT PNOT	Y		HQWYE5454050CT04 HQWYE5454050CT04

MEDICAL MONITOR COMMENTS :

Relevant Medical History: joint aches.

Relevant Prior Medications: none.

Relevant Concomitant Medications: prednisone, acetaminophen, Aleve.

Description of Event: On 21 Aug 2004, the subject developed a fever for 1 day. On 27 Aug 2004, she experienced shortness of breath during exercise. On 10 Sep 2004, she developed a chronic fever, for which she was treated with acetaminophen and Aleve. She continued to experience shortness of breath, and the subject's husband noticed tachypnea while she was sleeping. The subject was seen by her primary care physician, and laboratory evaluation and chest radiography were done. Chest radiography revealed shading in 1 area. A chest computed tomography scan was performed on 29 Sep 2004, at which time the subject was diagnosed with sarcoidosis. She discontinued test article, and was referred to a pulmonary specialist for further evaluation. Pulmonary function tests were done, showing a minimal obstructive lung defect and mild decrease in diffusing capacity. Lung volumes were within normal limits. The subject started taking prednisone 40 mg on 09 Oct 2004 for treatment. Prednisone was discontinued on 04 Jan 2005, at which time the subject stated that she was considered fully recovered from the event, and that she had resumed her active lifestyle. She also stated that her physician considered the event to be related to inhaling of fumes or chemicals used for a new hot tub. This event of sarcoidosis was reported as being medically important.

Outcome: The subject discontinued early from the study because of sarcoidosis. This event was reported as moderate in severity, and was considered probably not related to test article by the investigator and medical monitor.

Page 191

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

315-242-203001

INVESTIGATOR: 242, USA, 18225

TREATMENT : Desvenlafaxine SR 50 mg

: 203001 , 45 Year old, Female, White , 91 kg , 175 cm, 29.7 kg /M^2

THERAPY START DATE/STOP DATE : 25MAR04/ 25MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 25MAR05

NARRATIVE REASON : CLINICALLY IMPORTANT VITAL SIGNS {PCI: SUSTAINED HYPERTENSION}

Vital Sign	Position	Visit Date	Seq Num	D.A.I	<pre>Test Value (# => PCI)</pre>	Unit	Baseline Value	
DIASTOLIC BP	Supine	18MAR04	1	Screening/baseline	72	mm Hg	77.5	
DIASTOLIC BP	Supine	18MAR04	3	Screening/baseline	76	mm Hg	77.5	
DIASTOLIC BP	Supine	25MAR04	1	Screening/baseline	82	mm Ha	77.5	
DIASTOLIC BP	Supine	25MAR04	3	Screening/baseline	80	mm Hq	77.5	
		0.60.4	-	, , ,				

DIASTOLIC BP Supine 26APR04 1 Week 4 mm Hq DIASTOLIC BP Supine 26APR04 3 Week 4 mm Ha 77.5 DIASTOLIC BP Supine 26MAY04 1 Week 8 76 mm Hq 77.5 76 DIASTOLIC BP Supine 26MAY04 3 Week 8 mm Hq 77.5 15JUN04 1 15JUN04 3 77.5 77.5 DIASTOLIC BP Supine Week 12 80 mm Ha DIASTOLIC BP Supine Week 12 80 mm Hq 77.5 DIASTOLIC BP Supine 23SEP04 1 Week 26 90 mm Hq 77.5 DIASTOLIC BP Supine 23SEP04 3 Week 26 90 # mm Hq DIASTOLIC BP Supine 23DEC04 1 Week 39 86 mm Hq 77.5 23DEC04 3 25MAR05 1 25MAR05 3 DIASTOLIC BP Supine Week 39 90 # mm Hq 77.5 DIASTOLIC BP Supine Week 52 90 mm Hq 77.5 90 # DIASTOLIC BP Supine Week 52 mm Hq 77.5

MEDICAL MONITOR COMMENTS :

26May04 (Week 8)

Relevant Additional Vital Sign Values:

Date Supine Systolic BP value

(mm Hq)

18-25Mar04(Baseline)	119.5	(Average	of al	l screening/baseline values)
26Apr04 (Week 4)	118			
26Apr04 (Week 4)	118			

130

Page 192

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

REPORT NARR-INF SUBJECT NARRATIVE INFORMATION

INVESTIGATOR: 242, USA, 18225

TREATMENT : Desvenlafaxine SR 50 mg

SUBJECT : 203001 , 45 Year old, Female, White , 91 kg , 175 cm, 29.7 kg /M^2

THERAPY START DATE/STOP DATE : 25MAR04/ 25MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 25MAR05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

26May04 (Week 8) 124 15Jun04 (Week 12) 15Jun04 (Week 12) 112 114 23Sep04 (Week 26) 138 23Sep04 (Week 26) 140 23Dec04 (Week 39) 23Dec04 (Week 39) 140 25Mar05 (Week 52) 160 # 25Mar05 (Week 52) 156

Relevant Medical History: hypothyroidism.

Relevant Prior Medications: Synthroid, Dyazide.

Relevant Concomitant Medications: Synthroid, Dyazide.

Outcome: From weeks 26 through 52 of treatment, the subject's blood pressure measurements met clinical importance criteria for sustained hypertension (increase of >/=10 mm Hg supine diastolic blood pressure with value >/=90 mm Hg at 3 consecutive visits). In addition, at last visit, she had a 35-mm Hg increase from baseline in systolic blood pressure that was considered clinically important (>/=30 mm Hg from baseline with value >/=160 mm Hg). At previous visits, systolic blood pressures were within normal range. No further information is available after week 52.

Thd subject completed the study. The investigator did not report increased blood pressure or sustained hypertension as adverse events.

Page 193

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315

SUBJECT NARRATIVE INFORMATION

315-243-203101

INVESTIGATOR : 243, USA, 473

REPORT NARR-INF

TREATMENT : Desvenlafaxine SR 100 mg

SUBJECT : 203101 , 50 Year old, Female, White , 70 kg , 156.3 cm, 28.7 kg /M^2

THERAPY START DATE/STOP DATE : 08MAR04/ 02MAR05

STUDY COMPLETION STATUS : COMPLETED STUDY COMPLETION DATE : 02MAR05

NARRATIVE REASON : CLINICALLY IMPORTANT LABORATORY VALUES

{PCI: TOTAL CHOLESTEROL}

Lab Test	Rel. Day (Days)	D.A.I	Test Date	Test Value (# => PCI)	Fasting (Y/N)	Range (Low)	Range (High)	Unit	Baseline Value
TOT.CHOL. /LIPID	-14	Screening/baseline	23FEB04	5.1979	Yes	0	5.1461	mmol/L	5.1979
TOT.CHOL. /LIPID	29	Week 4	05APR04	5.7409	Yes	0	5.1461	mmol/L	5.1979
TOT.CHOL. /LIPID	87	Week 12	02JUN04	6.4909	Yes	0	5.1461	mmol/L	5.1979
TOT.CHOL. /LIPID	192	Week 26	15SEP04	8.0683 #	Yes	0	5.1461	mmol/L	5.1979
TOT.CHOL. /LIPID	281	Week 39	13DEC04	5.172	Yes	0	5.1461	mmol/L	5.1979
TOT.CHOL. /LIPID	360	Week 52	02MAR05	6.2581	Yes	Ō	5.1461	mmol/L	5.1979

MEDICAL MONITOR COMMENTS :

Additional Relevant Lab Values:

Date	HDL (.90-2.07mol/L)	LDL (0-3.36 mmol/L)	Triglycerides (.40-2.26 mmol/L)
23Feb04 (Baseline)	1.19	3.44	1.22
05Apr04 (Week 4)	1.22	3.80	1.59
02Jun04 (Week 12)	1.29	4.29	1.95
15Sep04 (Week 26)	1.47	5.59	2.19
13Dec04 (Week 39)	1.24	3.26	1.48
02Mar05 (Week 52)	1.16	4.06	2.25

Relevant Medical History: none.

Relevant Prior Medications: none.

Relevant Concomitant Medication: Lipitor.

20DEC05 11:20 [DEV] CLINICAL INVESTIGATION OF PROTOCOL 3151A2-315 Page 194

REPORT NARR-INF

SUBJECT NARRATIVE INFORMATION

INVESTIGATOR : 243, USA, 473
TREATMENT : Desvenlafaxine SR 100 mg

: 203101 , 50 Year old, Female, White , 70 kg , 156.3 cm, 28.7 kg /M^2

THERAPY START DATE/STOP DATE : 08MAR04/ 02MAR05

STUDY COMPLETION STATUS STUDY COMPLETION DATE : COMPLETED : 02MAR05

(continued from previous page)

MEDICAL MONITOR COMMENTS :

Outcome: At week 26 of treatment, the subject had a single episode of increased cholesterol that was considered clinically important (increase >/= 1.97 mmol/L and value >/= 7.8 mmol/L). At this time, the subject also had an increase in LDL cholesterol. Cholesterol was slightly elevated since baseline, and though still slightly elevated, it greatly improved at subsequent visits with prescription of Lipitor. The subject completed the study. The investigator reported hyperlipidemia as an adverse event, mild in severity, and probably related to test article.

ST 10-9: Number (%) of Subjects With Laboratory Test Results of Potential Clinical Importance / Number Tested

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 Page 1

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Screening/baseline

Category Test+Units	Overall P-Value *	DVS SR 5	 50 mg	DVS SR 1	L00 mg	DVS SR	nent L50 mg	DVS SR 2	200 mg	Place	ebo
TOTAL	0.917	6/148	(4.1)	10/155	(6.5)	9/157	(5.7)	9/151	(6.0)	4/ 77	(5.2)
BLOOD CHEMISTRY POTASSIUM mmol/L HIGH URIC ACID mmol/L	0.839 0.457 0.457 0.362	1/148 1/148 1/148 0/148	(0.7) (0.7) (0.7)	2/155 0/154 0/154 1/155	(1.3)	2/157 0/157 0/157 2/157	(1.3)	1/151 0/151 0/151 0/151	(0.7)	0/ 77 0/ 76 0/ 76 0/ 77	
HIGH TOTAL BILIRUBIN mcmol/L HIGH	0.362 0.362 0.644 0.644	0/148 0/148 0/148		1/155 1/155 1/155	(0.6) (0.6) (0.6)	2/157 0/157 0/157	(1.3)	0/151 1/151 1/151	(0.7) (0.7)	0/ 77 0/ 77 0/ 77	
HEMATOLOGY HEMOGLOBIN g/L HIGH	0.335 0.486 0.486	0 /4 40		2/155 1/155 1/155	(1.3) (0.6) (0.6)	1/157 0/157 0/157	(0.6)	3/151 0/151 0/151	(2.0)	0/ 77 0/ 77 0/ 77	
HEMATOCRIT L/L HIGH WBC 10^9/L LOW PLATELET COUNT 10^9/L LOW	0.486 0.486 0.469 0.469 0.833 0.833 0.471	0/148 0/148 0/148 0/148 0/147		0/155 0/155 1/155 1/155 0/155 0/155	(0.6) (0.6)	0/157 0/157 1/157 1/157 0/157 0/157	(0.6) (0.6)	1/151 1/151 1/151 1/151 1/151 1/151	(0.7) (0.7) (0.7) (0.7) (0.7) (0.7)	0/ 77 0/ 77 0/ 77 0/ 77 0/ 76 0/ 76	
LIPID PROFILE TOT.CHOL. /LIPID mmol/L HIGH LDL CHOLESTEROL mmol/L	0.983 0.445 0.445 0.495	5/148 4/147 4/147 0/148	(3.4) (2.7) (2.7)	7/155 7/155 7/155 0/155	(4.5) (4.5) (4.5)	6/157 6/157 6/157 1/157	(3.8) (3.8) (3.8) (0.6)	5/151 5/151 5/151 0/151	(3.3) (3.3) (3.3)	3/ 77 0/ 77 0/ 77 0/ 77	(3.9)
INCREASE TRIGLYCERIDES /LIPID mmol/L HIGH	0.495 0.129 0.129	0/148 1/148 1/148	(0.7) (0.7)	0/155 1/155 1/155	(0.6) (0.6)	1/157 1/157 1/157	(0.6) (0.6) (0.6)	0/151 1/151 1/151	(0.7) (0.7)	0/ 77 3/ 77 3/ 77	(3.9) (3.9)
URINALYSIS URINE HEMOGLOBIN BLOOD POSITIVE	0.094 0.094 0.094	0/148 0/148 0/148		0/154 0/154 0/154		0/157 0/157 0/157		0/151 0/151 0/151		1/ 77 1/ 77 1/ 77	(1.3) (1.3) (1.3)

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.
Overall P-Value: P-value for Chi-Square.

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 2

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Screening/baseline

Category	Overall	Treatment			
Test+Units	P-Value *	TOTAL			
TOTAL	0.917	38/688	(5.5)		
BLOOD CHEMISTRY POTASSIUM mmol/L HIGH URIC ACID mmol/L HIGH TOTAL BILIRUBIN mcmol/L HIGH	0.839	6/688	(0.9)		
	0.457	1/686	(0.1)		
	0.457	1/686	(0.1)		
	0.362	3/688	(0.4)		
	0.362	3/688	(0.4)		
	0.644	2/688	(0.3)		
	0.644	2/688	(0.3)		
HEMATOLOGY HEMOGLOBIN g/L HIGH HEMATOCRIT L/L HIGH WBC 10^9/L LOW PLATELET COUNT 10^9/L LOW	0.335 0.486 0.486 0.469 0.469 0.833 0.833 0.471 0.471	6/688 1/688 1/688 1/688 1/688 3/688 3/688 1/686	(0.9) (0.1) (0.1) (0.1) (0.1) (0.4) (0.4) (0.1) (0.1)		
LIPID PROFILE TOT.CHOL. /LIPID mmol/L HIGH LDL CHOLESTEROL mmol/L INCREASE TRIGLYCERIDES /LIPID mmol/L HIGH	0.983 0.445 0.445 0.495 0.495 0.129	26/688 22/687 22/687 1/688 1/688 7/688 7/688	(3.8) (3.2) (3.2) (0.1) (0.1) (1.0) (1.0)		
URINALYSIS	0.094	1/687	(0.1)		
URINE HEMOGLOBIN BLOOD	0.094	1/687	(0.1)		
POSITIVE	0.094	1/687	(0.1)		

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

3

Page

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Category	Overall					Treatr	ment				
Test+Units	P-Value *	DVS SR 5	50 mg	DVS SR 1	L00 mg			DVS SR 2	200 mg	Place	ebo
TOTAL	0.569	6/142	(4.2)	9/139	(6.5)	8/132	(6.1)	4/125	(3.2)	6/ 76	(7.9)
BLOOD CHEMISTRY GLUCOSE mmol/L HIGH URIC ACID mmol/L HIGH SGOT/AST mU/mL HIGH	0.663 0.591 0.591 0.491 0.491 0.344 0.344	0/142 0/142 0/142 0/142 0/142 0/139 0/139		1/139 0/139 0/139 1/139 1/139 0/138	(0.7) (0.7) (0.7)	1/132 1/132 1/132 0/132 0/132 0/130 0/130	(0.8) (0.8) (0.8)	2/124 1/124 1/124 0/124 0/124 1/121	(1.6) (0.8) (0.8) (0.8)	1/ 76 0/ 76 0/ 76 0/ 76 0/ 76 1/ 76 1/ 76	(1.3) (1.3) (1.3)
HEMATOLOGY HEMOGLOBIN g/L HIGH LOW HEMATOCRIT L/L HIGH LOW WBC 10^9/L LOW	0.155 0.674 0.496 0.511 0.321 0.369 0.511 0.240	2/142 1/142 0/142 1/142 2/142 1/142 1/142 0/141 0/141	(1.4) (0.7) (0.7) (1.4) (0.7) (0.7)	4/139 1/139 1/139 0/139 2/139 2/139 0/139 2/138 2/138	(2.9) (0.7) (0.7) (1.4) (1.4) (1.4)	0/129 0/129 0/129 0/129 0/129 0/129 0/129 0/129 0/129		0/122 0/122 0/122 0/122 0/122 0/122 0/122 0/119 0/119		1/ 76 0/ 76 0/ 76 0/ 76 0/ 76 0/ 76 0/ 76 1/ 76	(1.3) (1.3) (1.3)
LIPID PROFILE TOT.CHOL. /LIPID mmol/L HIGH HDL CHOLESTEROL mmol/L DECREASE LDL CHOLESTEROL mmol/L INCREASE TRIGLYCERIDES /LIPID mmol/L HIGH	0.448 0.890 0.890 0.379 0.379 0.048* 0.048* 0.691	4/142 2/136 2/136 1/142 1/142 0/142 0/142 1/142	(2.8) (1.5) (1.5) (0.7) (0.7)	4/139 3/138 3/138 0/139 0/139 0/138 0/138 1/139 1/139	(2.9) (2.2) (2.2) (2.2)	7/132 4/132 4/132 0/132 0/132 1/132 1/132 2/132 2/132	(5.3) (3.0) (3.0) (0.8) (0.8) (1.5) (1.5)	2/124 2/119 2/119 0/124 0/124 0/124 1/124 1/124	(1.6) (1.7) (1.7) (1.7)	4/ 76 1/ 72 1/ 72 1/ 76 1/ 76 2/ 74 2/ 76 2/ 76	(5.3) (1.4) (1.4) (1.3) (1.3) (2.7) (2.7) (2.6) (2.6)

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

Page

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Category Test+Units	Overall P-Value *	Treatment TOTAL			
TOTAL	0.569	33/614	(5.4)		
BLOOD CHEMISTRY GLUCOSE mmol/L HIGH URIC ACID mmol/L HIGH SGOT/AST mU/mL HIGH	0.663 0.591 0.591 0.491 0.491 0.344 0.344	5/613 2/613 2/613 1/613 1/613 2/604 2/604			
HEMATOLOGY HEMOGLOBIN g/L HIGH LOW HEMATOCRIT L/L HIGH LOW WBC 10^9/L LOW	0.155 0.674 0.496 0.511 0.321 0.369 0.511 0.240 0.240	7/608 2/608 1/608 1/608 4/608 3/608 1/608 3/603 3/603	(1.2) (0.3) (0.2) (0.2) (0.7) (0.5) (0.2) (0.5) (0.5)		
LIPID PROFILE TOT.CHOL. /LIPID mmol/L HIGH HDL CHOLESTEROL mmol/L DECREASE LDL CHOLESTEROL mmol/L INCREASE TRIGLYCERIDES /LIPID mmol/L HIGH	0.448 0.890 0.890 0.379 0.379 0.048* 0.048* 0.691	21/613 12/597 12/597 2/613 2/613 3/610 3/610 7/613 7/613	(3.4) (2.0) (2.0) (0.3) (0.3) (0.5) (0.5) (1.1) (1.1)		

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

Page

5

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Category Test+Units	Overall P-Value *	DVS SR 50 mg	DVS SR 100 mg	Treatment DVS SR 150 mg	DVS SR 200 mg	Placebo
TOTAL	0.500	1/ 17 (5.9)	1/ 14 (7.1)	1/ 13 (7.7)	0/ 5	2/ 8 (25.0)
BLOOD CHEMISTRY	0.409	0/ 14	0/ 10	1/ 9 (11.1)	0/ 4	0/ 7
URIC ACID mmol/L	0.372	0/ 11	0/ 8	1/ 7 (14.3)	0/ 4	0/ 6
HIGH	0.372	0/ 11	0/ 8	1/ 7 (14.3)	0/ 4	0/ 6
HEMATOLOGY HEMOGLOBIN g/L LOW HEMATOCRIT L/L LOW	0.491 0.491 0.491 0.491 0.491	1/ 9 (11.1) 1/ 9 (11.1) 1/ 9 (11.1) 1/ 9 (11.1) 1/ 9 (11.1)	0/ 8 0/ 8 0/ 8 0/ 8 0/ 8	0/ 8 0/ 8 0/ 8 0/ 8 0/ 8		0/ 5 0/ 5 0/ 5 0/ 5 0/ 5
LIPID PROFILE	0.442	0/ 12	1/ 9 (11.1)	0/ 8	0/ 5	1/ 6 (16.7)
TRIGLYCERIDES /LIPID mmol/L	0.442	0/ 12	1/ 9 (11.1)	0/ 8	0/ 5	1/ 6 (16.7)
HIGH	0.442	0/ 12	1/ 9 (11.1)	0/ 8	0/ 5	1/ 6 (16.7)
URINALYSIS	0.157	0/ 7	0/ 7	0/ 6		1/ 4 (25.0)
URINE HEMOGLOBIN BLOOD	0.157	0/ 7	0/ 7	0/ 6		1/ 4 (25.0)
POSITIVE	0.157	0/ 7	0/ 7	0/ 6		1/ 4 (25.0)

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 6

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Category	Overall	Treatment
Test+Units	P-Value *	TOTAL
TOTAL	0.500	5/ 57 (8.8)
BLOOD CHEMISTRY	0.409	1/ 44 (2.3)
URIC ACID mmol/L	0.372	1/ 36 (2.8)
HIGH	0.372	1/ 36 (2.8)
HEMATOLOGY HEMOGLOBIN g/L LOW HEMATOCRIT L/L LOW	0.491 0.491 0.491 0.491 0.491	1/ 30 (3.3) 1/ 30 (3.3) 1/ 30 (3.3) 1/ 30 (3.3) 1/ 30 (3.3)
LIPID PROFILE	0.442	2/ 40 (5.0)
TRIGLYCERIDES /LIPID mmol/L	0.442	2/ 40 (5.0)
HIGH	0.442	2/ 40 (5.0)
URINALYSIS	0.157	1/ 24 (4.2)
URINE HEMOGLOBIN BLOOD	0.157	1/ 24 (4.2)
POSITIVE	0.157	1/ 24 (4.2)

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

Page

7

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Category Test+Units	Overall P-Value *							DVS SR 200 mg			
TOTAL	0.602	7/119	(5.9)	12/119	(10.1)	7/103	(6.8)	10/ 96	(10.4)	4/ 66	(6.1)
BLOOD CHEMISTRY POTASSIUM mmol/L HIGH GLUCOSE mmol/L HIGH URIC ACID mmol/L HIGH SGOT/AST mU/mL HIGH SGPT/ALT mU/mL HIGH	0.472 0.377 0.377 0.157 0.157 0.099 0.099 0.603 0.603 0.246 0.246	2/119 0/119 0/119 0/119 0/119 0/119 0/119 1/119 1/119 1/119	(0.8) (0.8) (0.8) (0.8) (0.8)	0/119 0/116 0/116 0/119 0/119 0/119 0/116 0/116 0/119 0/119		3/103 1/103 1/103 0/103 2/103 2/103 0/103 0/103 0/103	(2.9) (1.0) (1.0) (1.9) (1.9)	2/ 96 0/ 95 0/ 95 0/ 96 0/ 96 0/ 96 1/ 95 1/ 95 2/ 96 2/ 96	(1.1) (1.1) (1.1) (2.1) (2.1)	2/ 66 1/ 66 1/ 66 1/ 66 1/ 66 0/ 66 0/ 66 0/ 66 0/ 66 0/ 66	(3.0) (1.5) (1.5) (1.5) (1.5)
HEMATOLOGY HEMOGLOBIN g/L HIGH HEMATOCRIT L/L HIGH WBC 10^9/L HIGH LOW	0.142 0.518 0.518 0.518 0.518 0.362 0.379 0.171	0/118 0/118 0/118 0/118 0/118 0/116 0/116		3/118 1/118 1/118 1/118 1/118 2/118 0/118 2/118	(2.5) (0.8) (0.8) (0.8) (0.8) (1.7) (1.7)	0/102 0/102 0/102 0/102 0/102 0/102 0/102 0/102		1/ 96 0/ 96 0/ 96 0/ 96 0/ 96 1/ 95 1/ 95 0/ 95	(1.0) (1.1) (1.1)	0/ 66 0/ 66 0/ 66 0/ 66 0/ 66 0/ 63 0/ 63	
LIPID PROFILE TOT.CHOL. /LIPID mmol/L HIGH HDL CHOLESTEROL mmol/L DECREASE LDL CHOLESTEROL mmol/L INCREASE TRIGLYCERIDES /LIPID mmol/L HIGH	0.421 0.268 0.268 0.421 0.421 0.211 0.211 0.628 0.628	3/119 2/118 2/118 0/119 0/119 1/118 1/118 1/119 1/119	(2.5) (1.7) (1.7) (0.8) (0.8) (0.8) (0.8)	3/119 3/119 3/119 0/119 0/119 0/119 0/119 0/119	(2.5) (2.5) (2.5)	3/103 2/103 2/103 1/103 1/103 2/103 2/103 1/103 1/103	(2.9) (1.9) (1.9) (1.0) (1.0) (1.9) (1.9) (1.0)	6/ 96 5/ 96 5/ 96 0/ 96 0/ 96 3/ 96 0/ 96 0/ 96	(6.3) (5.2) (5.2) (3.1) (3.1)	1/ 66 0/ 65 0/ 65 0/ 66 0/ 66 0/ 65 1/ 66 1/ 66	(1.5) (1.5) (1.5)
URINALYSIS URINE PROTEIN ALBUMIN POSITIVE URINE ACETONE /KETONES POSITIVE	0.324 0.321 0.321 0.524 0.524	2/118 0/118 0/118 0/118 0/118	(1.7)	6/119 3/119 3/119 1/119 1/119	(5.0) (2.5) (2.5) (0.8) (0.8)	1/102 1/102 1/102 0/102 0/102	(1.0) (1.0) (1.0)	3/ 95 2/ 95 2/ 95 0/ 95 0/ 95	(3.2) (2.1) (2.1)	1/ 66 0/ 66 0/ 66 0/ 66 0/ 66	(1.5)

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 12

Category Test+Units	Overall P-Value *	Treatm	
TOTAL	0.602	40/503	(8.0)
BLOOD CHEMISTRY POTASSIUM mmol/L HIGH GLUCOSE mmol/L HIGH URIC ACID mmol/L HIGH SGOT/AST mU/mL HIGH SGPT/ALT mU/mL HIGH	0.472 0.377 0.377 0.157 0.157 0.099 0.099 0.603 0.603 0.246	9/503 2/499 2/499 1/503 1/503 2/503 2/503 2/499 2/499 3/503 3/503	(1.8) (0.4) (0.2) (0.2) (0.2) (0.4) (0.4) (0.4) (0.6) (0.6)
HEMATOLOGY HEMOGLOBIN g/L HIGH HEMATOCRIT L/L HIGH WBC 10^9/L HIGH LOW	0.142	4/500	(0.8)
	0.518	1/500	(0.2)
	0.518	1/500	(0.2)
	0.518	1/500	(0.2)
	0.518	1/500	(0.2)
	0.362	3/494	(0.6)
	0.379	1/494	(0.2)
	0.171	2/494	(0.4)
LIPID PROFILE TOT.CHOL. /LIPID mmol/L HIGH HDL CHOLESTEROL mmol/L DECREASE LDL CHOLESTEROL mmol/L INCREASE TRIGLYCERIDES /LIPID mmol/L HIGH	0.421	16/503	(3.2)
	0.268	12/501	(2.4)
	0.268	12/501	(2.4)
	0.421	1/503	(0.2)
	0.421	1/503	(0.2)
	0.211	6/501	(1.2)
	0.211	6/501	(1.2)
	0.628	3/503	(0.6)
	0.628	3/503	(0.6)
URINALYSIS URINE PROTEIN ALBUMIN POSITIVE URINE ACETONE /KETONES POSITIVE	0.324	13/500	(2.6)
	0.321	6/500	(1.2)
	0.321	6/500	(1.2)
	0.524	1/500	(0.2)
	0.524	1/500	(0.2)

8

Page

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 9

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Category Test+Units	Overall P-Value *	DVS SR 50 mg		DVS SR 100 mg			DVS SR 200 mg		Placebo	
URINE HEMOGLOBIN BLOOD POSITIVE	0.747	2/118 2/118	(1.7) (1.7)	2/119 2/119	(1.7)	0/102 0/102	2/ 95 2/ 95	(2.1)	1/ 66 1/ 66	(1.5) (1.5)

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 10

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Category	Overall	Treatment			
Test+Units	P-Value *	TOTAL			
URINE HEMOGLOBIN BLOOD	0.747	7/500	(1.4)		

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 11

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Category Test+Units	Overall P-Value *	DVS SR	50 mg	DVS SR	100 mg	DVS SR	ment 150 mg	DVS SR	200 mg	Place	ebo
TOTAL	0.514	14/101	(13.9)	14/112	(12.5)	13/ 91	(14.3)	14/ 83	(16.9)	4/ 59	(6.8)
BLOOD CHEMISTRY URIC ACID mmol/L HIGH SGOT/AST mU/mL HIGH SGPT/ALT mU/mL HIGH	0.790 0.874 0.874 0.532 0.532 0.514	1/101 1/101 1/101 0/100 0/100 0/101 0/101	(1.0) (1.0) (1.0)	2/112 1/112 1/112 0/112 0/112 1/112 1/112	(1.8) (0.9) (0.9) (0.9)	3/ 91 1/ 91 1/ 91 1/ 90 1/ 90 2/ 91 2/ 91	(3.3) (1.1) (1.1) (1.1) (1.1) (2.2) (2.2)	1/ 83 0/ 83 0/ 83 1/ 83 1/ 83 1/ 83	(1.2) (1.2) (1.2) (1.2) (1.2)	1/ 59 1/ 59 1/ 59 0/ 59 0/ 59 0/ 59 0/ 59	(1.7) (1.7) (1.7)
HEMATOLOGY HEMATOCRIT L/L HIGH	0.360 0.360 0.360	0/100 0/100 0/100		0/111 0/111 0/111		0/ 91 0/ 91 0/ 91		1/ 83 1/ 83 1/ 83	(1.2) (1.2) (1.2)	0/ 59 0/ 59 0/ 59	
LIPID PROFILE TOT.CHOL. /LIPID mmol/L HIGH HDL CHOLESTEROL mmol/L DECREASE LDL CHOLESTEROL mmol/L INCREASE TRIGLYCERIDES /LIPID mmol/L HIGH	0.158 0.462 0.462 0.336 0.336 0.015* 0.015* 0.625	9/101 2/100 2/100 2/101 2/101 1/101 1/101 4/101	(8.9) (2.0) (2.0) (2.0) (2.0) (1.0) (1.0) (4.0) (4.0)	7/112 6/108 6/108 0/112 0/112 2/111 2/111 3/112 3/112	(6.3) (5.6) (5.6) (1.8) (1.8) (2.7) (2.7)	5/ 91 3/ 91 3/ 91 1/ 91 1/ 91 0/ 89 0/ 89 2/ 91 2/ 91	(5.5) (3.3) (3.3) (1.1) (1.1)	10/ 83 5/ 83 5/ 83 0/ 83 0/ 83 6/ 83 3/ 83	(12.0) (6.0) (6.0) (7.2) (7.2) (3.6) (3.6)	1/ 59 1/ 58 1/ 58 0/ 59 0/ 59 1/ 59 0/ 59 0/ 59	(1.7) (1.7) (1.7) (1.7)
URINALYSIS URINE PROTEIN ALBUMIN POSITIVE URINE HEMOGLOBIN BLOOD POSITIVE	0.899 0.567 0.567 0.991 0.991	4/100 2/100 2/100 3/100 3/100	(4.0) (2.0) (2.0) (3.0) (3.0)	5/111 1/111 1/111 4/111 4/111	(4.5) (0.9) (0.9) (3.6) (3.6)	6/ 91 3/ 91 3/ 91 4/ 91 4/ 91	(6.6) (3.3) (3.3) (4.4) (4.4)	4/ 82 2/ 82 2/ 82 3/ 82 3/ 82	(4.9) (2.4) (2.4) (3.7) (3.7)	2/ 59 0/ 59 0/ 59 2/ 59 2/ 59	(3.4) (3.4) (3.4)

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

Page 12

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Category	Overall	Treatment			
Test+Units	P-Value *	TOTAL			
TOTAL	0.514	59/446	(13.2)		
BLOOD CHEMISTRY URIC ACID mmol/L HIGH SGOT/AST mU/mL HIGH SGPT/ALT mU/mL HIGH	0.790 0.874 0.874 0.532 0.532 0.514	8/446 4/446 4/446 2/444 2/444 4/446 4/446			
HEMATOLOGY	0.360	1/444	(0.2)		
HEMATOCRIT L/L	0.360	1/444	(0.2)		
HIGH	0.360	1/444	(0.2)		
LIPID PROFILE TOT.CHOL. /LIPID mmol/L HIGH HDL CHOLESTEROL mmol/L DECREASE LDL CHOLESTEROL mmol/L INCREASE TRIGLYCERIDES /LIPID mmol/L HIGH	0.158 0.462 0.462 0.336 0.336 0.015* 0.015* 0.625	32/446 17/440 17/440 3/446 3/446 10/443 12/446	(7.2) (3.9) (3.9) (0.7) (0.7) (2.3) (2.3) (2.7) (2.7)		
URINALYSIS URINE PROTEIN ALBUMIN POSITIVE URINE HEMOGLOBIN BLOOD POSITIVE	0.899	21/443	(4.7)		
	0.567	8/443	(1.8)		
	0.567	8/443	(1.8)		
	0.991	16/443	(3.6)		
	0.991	16/443	(3.6)		

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

Protocol 3151A2-315-US DVS SR CSR-60178

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 13

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Category Test+Units	Overall P-Value *	DVS SR	 50 mg	DVS SR	 100 mg	Treat	ment 150 mg	DVS SR	 200 mg	Plac	 ebo
TOTAL	0.993	13/ 94	(13.8)	14/ 94	(14.9)	12/ 83	(14.5)	10/ 70	(14.3)	6/ 50	(12.0)
BLOOD CHEMISTRY GLUCOSE mmol/L HIGH URIC ACID mmol/L HIGH SGOT/AST mU/mL HIGH	0.766 0.331 0.331 0.445 0.445 0.525	1/ 94 0/ 94 0/ 94 0/ 94 0/ 94 1/ 93 1/ 93	(1.1) (1.1) (1.1)	0/94		1/ 83	(1.2) (1.2) (1.2)	1/ 70 1/ 70 1/ 70 0/ 70 0/ 70 0/ 70 0/ 70	(1.4) (1.4) (1.4)	0/ 50 0/ 50 0/ 50 0/ 50 0/ 50 0/ 50 0/ 50	
HEMATOLOGY HEMOGLOBIN g/L HIGH WBC 10^9/L LOW	0.768 0.450 0.450 0.580 0.580	0/ 93 0/ 93 0/ 93 0/ 92 0/ 92		1/ 92 0/ 92 0/ 92 1/ 91 1/ 91	(1.1) (1.1) (1.1)	1/ 83 1/ 83 1/ 83 0/ 81 0/ 81	(1.2) (1.2) (1.2)	1/ 70 0/ 70 0/ 70 1/ 69 1/ 69	(1.4) (1.4) (1.4)	0/50 0/50 0/50 0/48 0/48	
LIPID PROFILE TOT.CHOL. /LIPID mmol/L HIGH HDL CHOLESTEROL mmol/L DECREASE LDL CHOLESTEROL mmol/L INCREASE TRIGLYCERIDES /LIPID mmol/L HIGH	0.711 0.560 0.560 0.547 0.547 0.800 0.800 0.843 0.843	6/ 94 4/ 93 4/ 93 0/ 94 0/ 94 1/ 94 1/ 94 2/ 94	(6.4) (4.3) (4.3) (1.1) (1.1) (2.1) (2.1)	4/ 94 3/ 93 3/ 93 0/ 94 1/ 93 1/ 93 1/ 94 1/ 94	(4.3) (3.2) (3.2) (1.1) (1.1) (1.1) (1.1)	8/ 83 5/ 81 5/ 81 1/ 83 1/ 83 0/ 83 0/ 83 3/ 83 3/ 83	(9.6) (6.2) (6.2) (1.2) (1.2) (3.6) (3.6)	5/ 70 1/ 70 1/ 70 1/ 70 1/ 70 1/ 70 1/ 70 2/ 70 2/ 70	(7.1) (1.4) (1.4) (1.4) (1.4) (1.4) (1.4) (2.9) (2.9)	3/ 50 1/ 49 1/ 49 1/ 50 1/ 50 0/ 50 0/ 50 1/ 50 1/ 50	(6.0) (2.0) (2.0) (2.0) (2.0) (2.0)
URINALYSIS URINE PROTEIN ALBUMIN POSITIVE URINE ACETONE /KETONES POSITIVE URINE HEMOGLOBIN BLOOD POSITIVE	0.596 0.355 0.355 0.047* 0.047* 0.385 0.385	6/ 93 1/ 93 1/ 93 0/ 93 0/ 93 5/ 93 5/ 93	(6.5) (1.1) (1.1) (5.4) (5.4)	9/ 93 5/ 93 5/ 93 3/ 93 2/ 93 2/ 93	(9.7) (5.4) (5.4) (3.2) (3.2) (2.2) (2.2)	3/ 83 2/ 83 2/ 83 0/ 83 0/ 83 1/ 83	(3.6) (2.4) (2.4) (1.2) (1.2)	6/ 70 4/ 70 4/ 70 0/ 70 0/ 70 4/ 70 4/ 70	(8.6) (5.7) (5.7) (5.7)	4/ 50 1/ 50 1/ 50 0/ 50 0/ 50 3/ 50 3/ 50	(8.0) (2.0) (2.0) (6.0)

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

Page 14

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Category Test+Units	Overall P-Value *	Treat	
TOTAL	0.993	55/391	(14.1)
BLOOD CHEMISTRY GLUCOSE mmol/L HIGH URIC ACID mmol/L HIGH SGOT/AST mU/mL HIGH	0.766 0.331 0.331 0.445 0.445 0.525	3/391 1/391 1/391 1/391 1/391 1/390 1/390	(0.3) (0.3) (0.3) (0.3)
HEMATOLOGY HEMOGLOBIN g/L HIGH WBC 10^9/L LOW	0.768 0.450 0.450 0.580 0.580	3/388 1/388 1/388 2/381 2/381	(0.3) (0.3) (0.5)
LIPID PROFILE TOT.CHOL. /LIPID mmol/L HIGH HDL CHOLESTEROL mmol/L DECREASE LDL CHOLESTEROL mmol/L INCREASE TRIGLYCERIDES /LIPID mmol/L HIGH	0.711 0.560 0.560 0.547 0.547 0.800 0.800 0.843 0.843	26/391 14/386 14/386 3/391 3/391 3/390 3/390 9/391 9/391	(3.6) (3.6) (0.8) (0.8) (0.8)
URINALYSIS URINE PROTEIN ALBUMIN POSITIVE URINE ACETONE /KETONES POSITIVE URINE HEMOGLOBIN BLOOD POSITIVE	0.596 0.355 0.355 0.047* 0.047* 0.385 0.385	28/389 13/389 13/389 3/389 3/389 15/389 15/389	(7.2) (3.3) (3.3) (0.8) (0.8) (3.9) (3.9)

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

Page 15

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Category Test+Units	Overall P-Value *	DVS SR	50 mg			Treat DVS SR			200 mg	Plac	ebo
TOTAL	0.603	9/ 86	(10.5)	8/ 85	(9.4)	10/ 70	(14.3)	11/ 64	(17.2)	5/ 47	(10.6)
BLOOD CHEMISTRY GLUCOSE mmol/L HIGH LOW CALCIUM mmol/L LOW SGOT/AST mU/mL HIGH	0.857 0.583 0.334 0.537 0.158 0.158 0.539 0.539	1/ 85 1/ 85 0/ 85 1/ 85 0/ 85 0/ 85 0/ 85 0/ 85	(1.2) (1.2) (1.2)	1/ 85 0/ 85 0/ 85 0/ 85 0/ 85 0/ 85 1/ 85 1/ 85	(1.2) (1.2) (1.2)	0/ 70 0/ 70 0/ 70 0/ 70 0/ 70 0/ 70 0/ 70 0/ 70		1/ 63 1/ 63 1/ 63 0/ 63 0/ 63 0/ 63 0/ 63	(1.6) (1.6) (1.6)	1/ 47 0/ 47 0/ 47 0/ 47 1/ 46 1/ 46 0/ 46 0/ 46	(2.1) (2.2) (2.2)
HEMATOLOGY HEMOGLOBIN g/L HIGH HEMATOCRIT L/L HIGH WBC 10^9/L LOW	0.048* 0.529 0.529 0.529 0.529 0.170 0.170	0/ 86 0/ 86 0/ 86 0/ 86 0/ 86 0/ 86		3/84 1/84 1/84 1/84 1/84 2/83 2/83	(3.6) (1.2) (1.2) (1.2) (1.2) (2.4) (2.4)	0/ 70 0/ 70 0/ 70 0/ 70 0/ 70 0/ 69 0/ 69		0/ 64 0/ 64 0/ 64 0/ 64 0/ 64 0/ 64 0/ 64		0/ 46 0/ 46 0/ 46 0/ 46 0/ 46 0/ 46 0/ 46	
LIPID PROFILE TOT.CHOL. /LIPID mmol/L HIGH HDL CHOLESTEROL mmol/L DECREASE LDL CHOLESTEROL mmol/L INCREASE TRIGLYCERIDES /LIPID mmol/L HIGH	0.095 0.335 0.335 0.404 0.404 0.204 0.204 0.509 0.509	4/ 85 2/ 83 2/ 83 0/ 85 0/ 85 2/ 85 0/ 85 0/ 85 0/ 85	(4.7) (2.4) (2.4) (2.4) (2.4)	1/ 85 1/ 84 1/ 84 0/ 85 0/ 85 1/ 85 1/ 85 0/ 85 0/ 85	(1.2) (1.2) (1.2) (1.2)	3/ 70 1/ 69 1/ 69 1/ 70 1/ 70 0/ 69 0/ 69 1/ 70 1/ 70	(4.3) (1.4) (1.4) (1.4) (1.4)	7/ 63 4/ 62 4/ 62 0/ 63 0/ 63 3/ 62 3/ 62 1/ 63 1/ 63	(11.1) (6.5) (6.5) (4.8) (4.8) (1.6) (1.6)	2/ 47 2/ 46 2/ 46 0/ 47 0/ 47 0/ 47 0/ 47 0/ 47 0/ 47	(4.3) (4.3) (4.3)
URINALYSIS URINE PROTEIN ALBUMIN POSITIVE URINE ACETONE /KETONES POSITIVE URINE HEMOGLOBIN BLOOD POSITIVE	0.709 0.754 0.754 0.861 0.861 0.397 0.397	4/ 86 2/ 86 2/ 86 1/ 86 1/ 86 1/ 86	(4.7) (2.3) (2.3) (1.2) (1.2) (1.2) (1.2)	5/ 83 1/ 83 1/ 83 1/ 83 1/ 83 3/ 83 3/ 83	(6.0) (1.2) (1.2) (1.2) (1.2) (3.6) (3.6)	7/ 69 3/ 69 3/ 69 0/ 69 0/ 69 5/ 69 5/ 69	(10.1) (4.3) (4.3) (7.2) (7.2)	4/ 64 1/ 64 1/ 64 1/ 64 1/ 64 2/ 64 2/ 64	(6.3) (1.6) (1.6) (1.6) (1.6) (3.1) (3.1)	4/ 47 1/ 47 1/ 47 1/ 47 1/ 47 2/ 47 2/ 47	(8.5) (2.1) (2.1) (2.1) (2.1) (4.3) (4.3)

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 16

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Category Test+Units	Overall P-Value *	Treat	
TOTAL	0.603	43/352	(12.2)
BLOOD CHEMISTRY GLUCOSE mmol/L HIGH LOW CALCIUM mmol/L LOW SGOT/AST mU/mL HIGH	0.857 0.583 0.334 0.537 0.158 0.158 0.539 0.539	4/350 2/350 1/350 1/350 1/349 1/349 1/349 1/349	(1.1) (0.6) (0.3) (0.3) (0.3) (0.3) (0.3) (0.3)
HEMATOLOGY HEMOGLOBIN g/L HIGH HEMATOCRIT L/L HIGH WBC 10^9/L LOW	0.048* 0.529 0.529 0.529 0.529 0.170	3/350 1/350 1/350 1/350 1/350 2/348 2/348	(0.9) (0.3) (0.3) (0.3) (0.3) (0.6) (0.6)
LIPID PROFILE TOT.CHOL. /LIPID mmol/L HIGH HDL CHOLESTEROL mmol/L DECREASE LDL CHOLESTEROL mmol/L INCREASE TRIGLYCERIDES /LIPID mmol/L HIGH	0.095 0.335 0.335 0.404 0.404 0.204 0.204 0.509 0.509	17/350 10/344 10/344 1/350 1/350 6/348 6/348 2/350 2/350	(4.9) (2.9) (2.9) (0.3) (0.3) (1.7) (1.7) (0.6) (0.6)
URINALYSIS URINE PROTEIN ALBUMIN POSITIVE URINE ACETONE /KETONES POSITIVE URINE HEMOGLOBIN BLOOD POSITIVE	0.709 0.754 0.754 0.861 0.861 0.397 0.397	24/349 8/349 8/349 4/349 4/349 13/349	(6.9) (2.3) (2.3) (1.1) (1.1) (3.7) (3.7)

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 17 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Follow-up

REPORT LAB5

Category	Overall						ment			
Test+Units	P-Value *	DVS SR	50 mg	DVS SR	100 mg	DVS SR	150 mg	DVS SR	200 mg	Placebo
TOTAL	0.179	6/ 36	(16.7)	12/ 41	(29.3)	7/ 47	(14.9)	8/ 47	(17.0)	0/ 11
BLOOD CHEMISTRY GLUCOSE mmol/L HIGH LOW TOTAL BILIRUBIN mcmol/L HIGH SGOT/AST mU/mL HIGH SGPT/ALT mU/mL HIGH	0.848 0.715 0.436 0.657 0.595 0.595 0.519 0.519 0.874	2/ 31 0/ 28 0/ 28 0/ 28 0/ 29 2/ 30 2/ 30 1/ 30 1/ 30	(6.5) (6.7) (6.7) (3.3) (3.3)	1/ 34 1/ 33 1/ 33 0/ 33 0/ 33 0/ 33 0/ 33 0/ 33 0/ 34 0/ 34	(2.9) (3.0) (3.0)	1/ 44 0/ 42 0/ 42 0/ 42 1/ 42 1/ 44 1/ 44 1/ 44	(2.4) (2.4) (2.4) (2.3) (2.3) (2.3) (2.3)	2/ 46 1/ 46 0/ 46 1/ 46 0/ 46 0/ 46 1/ 46 1/ 46 1/ 46 1/ 46	(4.3) (2.2) (2.2) (2.2) (2.2) (2.2) (2.2)	0/ 9 0/ 8 0/ 8 0/ 8 0/ 8 0/ 8 0/ 8 0/ 8 0/ 8
HEMATOLOGY HEMOGLOBIN g/L LOW HEMATOCRIT L/L LOW WBC 10^9/L HIGH LOW	0.242 0.639 0.639 0.278 0.278 0.047* 0.531 0.173	0/ 24 0/ 24 0/ 24 0/ 24 0/ 24 0/ 24 0/ 24 0/ 24		3/ 35 0/ 34 0/ 34 0/ 34 0/ 34 3/ 35 1/ 35 2/ 35	(8.6) (8.6) (2.9) (5.7)	2/ 41 1/ 41 1/ 41 2/ 41 2/ 41 0/ 41 0/ 41 0/ 41	(4.9) (2.4) (2.4) (4.9) (4.9)	0/ 38 0/ 38 0/ 38 0/ 38 0/ 38 0/ 38 0/ 38		0/ 7 0/ 7 0/ 7 0/ 7 0/ 7 0/ 7 0/ 7
LIPID PROFILE TOT.CHOL. /LIPID mmol/L HIGH HDL CHOLESTEROL mmol/L DECREASE LDL CHOLESTEROL mmol/L INCREASE TRIGLYCERIDES /LIPID mmol/L HIGH	0.383 0.540 0.540 0.416 0.416 0.525 0.525 0.160 0.160	3/ 28 1/ 24 1/ 24 1/ 28 1/ 28 1/ 28 1/ 28 1/ 28	(10.7) (4.2) (4.2) (3.6) (3.6) (3.6) (3.6) (3.6) (3.6)	6/ 33 2/ 29 2/ 29 0/ 33 0/ 33 1/ 32 1/ 32 4/ 33 4/ 33	(18.2) (6.9) (6.9) (3.1) (3.1) (12.1) (12.1)	4/ 43 2/ 40 2/ 40 2/ 42 2/ 42 0/ 42 0/ 42 0/ 43 0/ 43	(9.3) (5.0) (5.0) (4.8) (4.8)	3/ 47 0/ 43 0/ 43 0/ 46 0/ 46 0/ 44 0/ 44 3/ 47 3/ 47	(6.4) (6.4) (6.4)	0/ 9 0/ 7 0/ 7 0/ 8 0/ 8 0/ 8 0/ 8 0/ 9
URINALYSIS URINE PROTEIN ALBUMIN POSITIVE URINE ACETONE /KETONES POSITIVE URINE HEMOGLOBIN BLOOD	0.674 0.259 0.259 0.655 0.655 0.378	1/ 23 0/ 23 0/ 23 0/ 23 0/ 23 1/ 23	(4.3)	3/ 31 0/ 31 0/ 31 0/ 31 0/ 31 3/ 31	(9.7) (9.7)	1/ 40 0/ 40 0/ 40 1/ 40 1/ 40 0/ 40	(2.5) (2.5) (2.5)	3/ 38 2/ 38 2/ 38 0/ 38 0/ 38 2/ 38	(7.9) (5.3) (5.3)	0/ 5 0/ 5 0/ 5 0/ 5 0/ 5 0/ 5

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 18

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Follow-up

Category Test+Units	Overall P-Value *	Treat	
TOTAL	0.179	33/182	(18.1)
BLOOD CHEMISTRY GLUCOSE mmol/L HIGH LOW TOTAL BILIRUBIN mcmol/L HIGH SGOT/AST mU/mL HIGH SGPT/ALT mU/mL HIGH	0.848	6/164	(3.7)
	0.715	2/157	(1.3)
	0.436	1/157	(0.6)
	0.657	1/157	(0.6)
	0.595	1/158	(0.6)
	0.595	1/158	(0.6)
	0.519	4/161	(2.5)
	0.519	4/161	(2.5)
	0.874	3/162	(1.9)
	0.874	3/162	(1.9)
HEMATOLOGY HEMOGLOBIN g/L LOW HEMATOCRIT L/L LOW WBC 10^9/L HIGH LOW	0.242	5/145	(3.4)
	0.639	1/144	(0.7)
	0.639	1/144	(0.7)
	0.278	2/144	(1.4)
	0.278	2/144	(1.4)
	0.047*	3/145	(2.1)
	0.531	1/145	(0.7)
	0.173	2/145	(1.4)
LIPID PROFILE TOT.CHOL. /LIPID mmol/L HIGH HDL CHOLESTEROL mmol/L DECREASE LDL CHOLESTEROL mmol/L INCREASE TRIGLYCERIDES /LIPID mmol/L HIGH	0.383	16/160	(10.0)
	0.540	5/143	(3.5)
	0.540	5/143	(3.5)
	0.416	3/157	(1.9)
	0.416	3/157	(1.9)
	0.525	2/154	(1.3)
	0.525	2/154	(1.3)
	0.160	8/160	(5.0)
	0.160	8/160	(5.0)
URINALYSIS URINE PROTEIN ALBUMIN POSITIVE URINE ACETONE /KETONES POSITIVE URINE HEMOGLOBIN BLOOD	0.674	8/137	(5.8)
	0.259	2/137	(1.5)
	0.259	2/137	(1.5)
	0.655	1/137	(0.7)
	0.655	1/137	(0.7)
	0.378	6/137	(4.4)

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 19

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Follow-up

Category Test+Units	Overall P-Value *				DVS SR 200 mg		
POSITIVE	0.378	1/ 23 (4.3)	3/ 31 (9.7)	0/40	2/ 38 (5.3)	0/ 5	

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 20

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Follow-up

 $^{^{\}star}$ - Statistical Significance at the .05, .01, .001 Levels is Denoted by * , ** , ** Respectively. Overall P-Value: P-value for Chi-Square.

Page 21

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Screening/baseline

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Comparato		io Comparato		Pairwise P-Value *
TOTAL	0.917	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	6/148 6/148 6/148 6/148	(4.1) (4.1) (4.1) (4.1)	10/155 9/157 9/151 4/ 77	(6.5) (5.7) (6.0) (5.2)	0.444 0.600 0.598 0.739
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	10/155 10/155	(6.5) (6.5)	9/157 9/151	(5.7) (6.0)	0.817 1.000
		DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	10/155 9/157 9/157	(6.5) (5.7) (5.7)	4/ 77 9/151 4/ 77	(5.2) (6.0) (5.2)	1.000 1.000 1.000
		DVS SR 200 mg	Placebo	9/151	(6.0)	4/ 77	(5.2)	1.000
BLOOD CHEMISTRY	0.839	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/148 1/148 1/148 1/148	(0.7) (0.7) (0.7) (0.7)	2/155 2/157 1/151 0/ 77	(1.3) (1.3) (0.7)	1.000 1.000 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	2/155 2/155 2/155 2/155	(1.3) (1.3) (1.3)	2/157 1/151 0/ 77	(1.3) (0.7)	1.000 1.000 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	2/157 2/157	(1.3) (1.3)	1/151 0/ 77	(0.7)	1.000
		DVS SR 200 mg	Placebo	1/151	(0.7)	0/ 77		1.000
POTASSIUM mmol/L	0.457	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/148 1/148 1/148 1/148	(0.7) (0.7) (0.7) (0.7)	0/154 0/157 0/151 0/ 76		0.490 0.485 0.495 1.000
HIGH	0.457	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/148 1/148 1/148 1/148	(0.7) (0.7) (0.7) (0.7)	0/154 0/157 0/151 0/ 76		0.490 0.485 0.495 1.000
URIC ACID mmol/L	0.362	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/148 0/148 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/155 2/157 2/157 0/151 0/ 77	(0.6) (1.3) (1.3)	1.000 0.499 1.000 1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 22

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Screening/baseline

Category Test+Units	Overall P-Value *	Comparator 1	tment Comparator 2	Comparator 1	comparator 2	Pairwise P-Value *
URIC ACID mmol/L	0.362	DVS SR 150 mg	DVS SR 200 mg Placebo	2/157 (1.3) 2/157 (1.3)		0.499
HIGH	0.362	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0/148 0/148 1/155 (0.6) 1/155 (0.6) 1/155 (0.6) 2/157 (1.3) 2/157 (1.3)	0/151 0/ 77 0/151	1.000 0.499 1.000 1.000 1.000 0.499 1.000
TOTAL BILIRUBIN mcmol/L	0.644	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0/148 0/148 1/155 (0.6) 1/155 (0.6) 1/155 (0.6) 0/157 1/151 (0.7)	1/151 (0.7) 0/ 77 1/151 (0.7)	1.000 1.000 0.497 1.000 1.000 0.490 1.000
HIGH	0.644	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0/148 0/148 1/155 (0.6) 1/155 (0.6) 1/155 (0.6) 0/157 1/151 (0.7)	1/151 (0.7) 0/ 77 1/151 (0.7)	1.000 1.000 0.497 1.000 1.000 0.490 1.000
HEMATOLOGY	0.335	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	0/148 0/148 0/148 0/148 2/155 (1.3) 2/155 (1.3) 2/155 (1.3) 1/157 (0.6) 3/151 (2.0)	3/151 (2.0) 0/77 3/151 (2.0) 0/77	0.499 1.000 0.248 0.621 0.681 1.000 0.363 1.000 0.553

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 23

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Screening/baseline

Category Test+Units	Overall P-Value *	Trea Comparator 1	tment Comparator 2	Comparator		io Comparator		Pairwise P-Value *
HEMOGLOBIN g/L	0.486	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/155 ((0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.497 1.000 1.000
HIGH	0.486	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/155 ((0.6) (0.6) (0.6)	1/155 0/157 0/151 0/ 77	(0.6)	1.000 0.497 1.000
HEMATOCRIT L/L	0.469	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/148 0/155 0/157 1/151 ((0.7)	1/151 1/151 1/151 0/ 77	(0.7) (0.7) (0.7)	1.000 0.493 0.490 1.000
HIGH	0.469	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/148 0/155 0/157 1/151 ((0.7)	1/151 1/151 1/151 0/ 77	(0.7) (0.7) (0.7)	1.000 0.493 0.490 1.000
WBC 10^9/L	0.833	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	1/155 (1/155 (1/157 (1/157 ((0.6) (0.6) (0.6) (0.6) (0.6) (0.7)	1/155 1/157 1/151 1/157 1/155 1/155 0/ 77 1/151 0/ 77 0/ 77	(0.6) (0.6) (0.7) (0.6) (0.7) (0.7)	1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
LOW	0.833	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	1/155 (1/155 ((0.6) (0.6) (0.6) (0.6)	1/155 1/157 1/151 1/157 1/151 0/ 77 1/151	(0.6) (0.6) (0.7) (0.6) (0.7)	1.000 1.000 1.000 1.000 1.000 1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 24

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Screening/baseline

Category Test+Units	Overall P-Value *		tment Comparator 2	Comparator		cio Comparator 2	Pairwise P-Value *
LOW	0.833	DVS SR 150 mg DVS SR 200 mg	Placebo Placebo	1/157 1/151	(0.6) (0.7)	0/ 77 0/ 77	1.000
PLATELET COUNT 10^9/L	0.471	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/147 0/155 0/157 1/151	(0.7)	1/151 (0.7) 1/151 (0.7) 1/151 (0.7) 0/ 76	1.000 0.493 0.490 1.000
LOW	0.471	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/147 0/155 0/157 1/151	(0.7)	1/151 (0.7) 1/151 (0.7) 1/151 (0.7) 0/76	1.000 0.493 0.490 1.000
LIPID PROFILE	0.983	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	5/148 5/148 5/148 5/148 7/155 7/155 7/155 6/157 6/157 5/151	(3.4) (3.4) (3.4) (3.4) (4.5) (4.5) (4.5) (3.8) (3.8) (3.3)	7/155 (4.5) 6/157 (3.8) 5/151 (3.3) 3/ 77 (3.9) 6/157 (3.8) 5/151 (3.3) 3/ 77 (3.9) 5/151 (3.3) 3/ 77 (3.9) 3/ 77 (3.9)	0.771 1.000 1.000 1.000 0.785 0.770 1.000 1.000
TOT.CHOL. /LIPID mmol/L	0.445	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	4/147 4/147 4/147 4/147 7/155 7/155 7/155 6/157 6/157 5/151	(2.7) (2.7) (2.7) (2.7) (4.5) (4.5) (4.5) (3.8) (3.8) (3.3)	7/155 (4.5) 6/157 (3.8) 5/151 (3.3) 0/77 6/157 (3.8) 5/151 (3.3) 0/77 5/151 (3.3) 0/77 0/77	0.543 0.751 1.000 0.301 0.785 0.770 0.099 1.000 0.181 0.170
HIGH	0.445	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg	4/147 4/147	(2.7) (2.7)	7/155 (4.5) 6/157 (3.8)	0.543 0.751

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 25

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Screening/baseline

Category Test+Units	Overall P-Value *	Trea Comparator 1	tment Comparator 2	Comparato		io Comparato		Pairwise P-Value *
HIGH	0.445	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	4/147 4/147 7/155 7/155 7/155 6/157 6/157 5/151	(2.7) (2.7) (4.5) (4.5) (4.5) (3.8) (3.8) (3.3)	5/151 0/ 77 6/157 5/151 0/ 77 5/151 0/ 77 0/ 77	(3.3) (3.8) (3.3) (3.3)	1.000 0.301 0.785 0.770 0.099 1.000 0.181 0.170
LDL CHOLESTEROL mmol/L	0.495	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/148 0/155 1/157 1/157	(0.6) (0.6)	1/157 1/157 0/151 0/ 77	(0.6) (0.6)	1.000 1.000 1.000 1.000
INCREASE	0.495	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/148 0/155 1/157 1/157	(0.6) (0.6)	1/157 1/157 0/151 0/ 77	(0.6) (0.6)	1.000 1.000 1.000 1.000
TRIGLYCERIDES /LIPID mmol/L	0.129	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	1/148 1/148 1/148 1/148 1/155 1/155 1/155 1/157 1/157 1/157	(0.7) (0.7) (0.7) (0.7) (0.6) (0.6) (0.6) (0.6) (0.6) (0.7)	1/155 1/157 1/151 3/ 77 1/157 1/155 3/ 77 1/151 3/ 77 3/ 77	(0.6) (0.6) (0.7) (3.9) (0.6) (0.7) (3.9) (0.7) (3.9) (3.9)	1.000 1.000 1.000 0.117 1.000 1.000 0.108 1.000 0.105 0.113
HIGH	0.129	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	1/148 1/148 1/148 1/148 1/155 1/155	(0.7) (0.7) (0.7) (0.7) (0.6) (0.6) (0.6)	1/155 1/157 1/151 3/ 77 1/157 1/151 3/ 77	(0.6) (0.6) (0.7) (3.9) (0.6) (0.7) (3.9)	1.000 1.000 1.000 0.117 1.000 1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 26

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Screening/baseline

Category Test+Units	Overall P-Value *	i i e a cineri e		Comparato		Comparat	or 2	Pairwise P-Value *	
HIGH	0.129	DVS SR 150 mg	DVS SR 200 mg Placebo Placebo	1/157 1/157 1/151	(0.6) (0.6) (0.7)	1/151 3/ 77 3/ 77	(0.7) (3.9) (3.9)	1.000 0.105 0.113	
URINALYSIS	0.094	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/148 0/154 0/157 0/151		1/ 77 1/ 77 1/ 77 1/ 77	(1.3) (1.3) (1.3) (1.3)	0.342 0.333 0.329 0.338	
URINE HEMOGLOBIN BLOOD	0.094	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/148 0/154 0/157 0/151		1/ 77 1/ 77 1/ 77 1/ 77	(1.3) (1.3) (1.3) (1.3)	0.342 0.333 0.329 0.338	
POSITIVE	0.094	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/148 0/154 0/157 0/151		1/ 77 1/ 77 1/ 77 1/ 77	(1.3) (1.3) (1.3) (1.3)	0.342 0.333 0.329 0.338	

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 27

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 4

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Comparato		io Comparato		Pairwise P-Value *
TOTAL	0.569	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	6/142 6/142 6/142 6/142	(4.2) (4.2) (4.2) (4.2)	9/139 8/132 4/125 6/ 76	(6.5) (6.1) (3.2) (7.9)	0.438 0.587 0.754 0.350
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	9/139 9/139	(6.5) (6.5)	8/132 4/125	(6.1) (3.2)	1.000 0.264
		DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	9/139 8/132 8/132	(6.5) (6.1) (6.1)	6/ 76 4/125 6/ 76	(7.9) (3.2) (7.9)	0.781 0.378 0.775
		DVS SR 200 mg	Placebo	4/125	(3.2)	6/ 76	(7.9)	0.183
BLOOD CHEMISTRY	0.663	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/142 0/142 0/142 0/142		1/139 1/132 2/124 1/ 76	(0.7) (0.8) (1.6) (1.3)	0.495 0.482 0.216 0.349
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/139 1/139 1/139	(0.7) (0.7) (0.7)	1/132 2/124 1/ 76	(0.8) (1.6) (1.3)	1.000 0.603 1.000
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	1/132 1/132 2/124	(0.8) (0.8) (1.6)	2/124 1/ 76 1/ 76	(1.6) (1.3) (1.3)	0.612 1.000 1.000
		-			(1.0)			
GLUCOSE mmol/L	0.591	DVS SR 50 mg DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg	0/142 0/142 0/139		1/132 1/124 1/132	(0.8) (0.8) (0.8)	0.482 0.466 0.487
		DV3 3K 100 IIIg	DVS SR 200 mg	0/139		1/124	(0.8)	0.471
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/132 1/132	(0.8) (0.8)	1/124 0/ 76	(0.8)	1.000
		DVS SR 200 mg	Placebo	1/124	(0.8)	0/ 76		1.000
HIGH	0.591	DVS SR 50 mg	DVS SR 150 mg DVS SR 200 mg	0/142 0/142		1/132 1/124	(0.8) (0.8)	0.482 0.466
		DVS SR 100 mg	DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg	0/142 0/139 0/139		1/132 1/124	(0.8)	0.487 0.471
		DVS SR 150 mg	DVS SR 200 mg	1/132	(0.8)	1/124	(0.8)	1.000
		DVS SR 200 mg	Placebo Placebo	1/132 1/124	(0.8) (0.8)	0/ 76 0/ 76		1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 28

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 4

Category Test+Units	Overall P-Value *		tment Comparator 2	Comparator		io Comparato		Pairwise P-Value *
URIC ACID mmol/L	0.491	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/139 ((0.7) (0.7) (0.7)	1/139 0/132 0/124 0/ 76	(0.7)	0.495 1.000 1.000
HIGH	0.491	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/139 ((0.7) (0.7) (0.7)	1/139 0/132 0/124 0/ 76	(0.7)	0.495 1.000 1.000
SGOT/AST mU/mL	0.344	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	0/139 0/139 0/138 0/138 0/130 0/130 1/121 ((0.8)	1/121 1/ 76 1/121 1/ 76 1/121 1/ 76 1/ 76	(0.8) (1.3) (0.8) (1.3) (0.8) (1.3) (1.3)	0.465 0.353 0.467 0.355 0.482 0.369 1.000
HIGH	0.344	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	0/139 0/139 0/138 0/138 0/130 0/130 1/121 ((0.8)	1/121 1/ 76 1/121 1/ 76 1/121 1/ 76 1/ 76	(0.8) (1.3) (0.8) (1.3) (0.8) (1.3) (1.3)	0.465 0.353 0.467 0.355 0.482 0.369 1.000
HEMATOLOGY	0.155	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo Placebo Placebo	2/142 (2/142 (2/142 (4/139 (4/139 ((1.4) (1.4) (1.4) (1.4) (2.9) (2.9) (2.9)	4/139 0/129 0/122 1/ 76 0/129 0/122 1/ 76 1/ 76 1/ 76	(2.9) (1.3) (1.3) (1.3) (1.3)	0.444 0.499 0.501 1.000 0.123 0.125 0.658 0.371 0.384
HEMOGLOBIN g/L	0.674	DVS SR 50 mg	DVS SR 100 mg	1/142 ((0.7)	1/139	(0.7)	1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 29 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 4

REPORT LAB5

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Comparato		io Comparator		Pairwise P-Value
HEMOGLOBIN g/L	0.674	DVS SR 50 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	1/142 1/142 1/142 1/139 1/139 1/139	(0.7) (0.7) (0.7) (0.7) (0.7) (0.7)	0/129 0/122 0/ 76 0/129 0/122 0/ 76		1.000 1.000 1.000 1.000 1.000 1.000
HIGH	0.496	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/142 1/139 1/139 1/139	(0.7) (0.7) (0.7)	1/139 0/129 0/122 0/ 76	(0.7)	0.495 1.000 1.000
LOW	0.511	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/142 1/142 1/142 1/142	(0.7) (0.7) (0.7) (0.7)	0/139 0/129 0/122 0/ 76		1.000 1.000 1.000 1.000
HEMATOCRIT L/L	0.321	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg	2/142 2/142 2/142 2/142 2/139 2/139	(1.4) (1.4) (1.4) (1.4) (1.4) (1.4)	2/139 0/129 0/122 0/ 76 0/129 0/122	1.4)	1.000 0.499 0.501 0.544 0.499 0.500
			Placebo	2/139	(1.4)	0/ 76		0.541
HIGH	0.369	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/142 1/142 1/142 1/142	(0.7) (0.7) (0.7) (0.7)	2/139 0/129 0/122 0/ 76	1.4)	0.620 1.000 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	2/139 2/139 2/139 2/139	(1.4) (1.4) (1.4)	0/129 0/122 0/ 76		0.499 0.500 0.541
LOW	0.511	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/142 1/142 1/142 1/142	(0.7) (0.7) (0.7) (0.7)	0/139 0/129 0/122 0/ 76		1.000 1.000 1.000 1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 30

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 4

Category Test+Units	Overall P-Value *	Trea	tment 2	Comparato		Comparato		Pairwise P-Value *
WBC 10^9/L	0.240	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo Placebo Placebo	0/141 0/141 2/138 2/138 2/138 0/129 0/119	(1.4) (1.4) (1.4)	2/138 1/ 76 0/129 0/119 1/ 76 1/ 76	(1.4) (1.3) (1.3) (1.3) (1.3)	0.244 0.350 0.499 0.501 1.000 0.371 0.390
LOW	0.240	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo Placebo Placebo	0/141 0/141 2/138 2/138 2/138 0/129 0/119	(1.4) (1.4) (1.4)	2/138 1/ 76 0/129 0/119 1/ 76 1/ 76 1/ 76	(1.4) (1.3) (1.3) (1.3) (1.3)	0.244 0.350 0.499 0.501 1.000 0.371 0.390
LIPID PROFILE	0.448	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	4/142 4/142 4/142 4/142 4/139 4/139 7/132 7/132 2/124	(2.8) (2.8) (2.8) (2.8) (2.9) (2.9) (2.9) (5.3) (5.3) (1.6)	4/139 7/132 2/124 4/ 76 7/132 2/124 4/ 76 2/124 4/ 76 4/ 76	(2.9) (5.3) (1.6) (5.3) (5.3) (1.6) (5.3) (1.6) (5.3) (5.3)	1.000 0.364 0.688 0.454 0.367 0.687 0.457 0.174 1.000 0.203
TOT.CHOL. /LIPID mmol/L	0.890	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	2/136 2/136 2/136 2/136 3/138 3/138 3/138 4/132 4/132 2/119	(1.5) (1.5) (1.5) (1.5) (2.2) (2.2) (2.2) (3.0) (3.0) (1.7)	3/138 4/132 2/119 1/ 72 4/132 2/119 1/ 72 2/119 1/ 72 1/ 72	(2.2) (3.0) (1.7) (1.4) (3.0) (1.7) (1.4) (1.7) (1.4) (1.4)	1.000 0.442 1.000 1.000 0.718 1.000 1.000 0.686 0.658 1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 31

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 4

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Comparato		Comparato		Pairwise P-Value *
HIGH	0.890	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/136 2/136 2/136 2/136	(1.5) (1.5) (1.5) (1.5)	3/138 4/132 2/119 1/ 72	(2.2) (3.0) (1.7) (1.4)	1.000 0.442 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	3/138 3/138 3/138	(2.2) (2.2) (2.2)	4/132 2/119 1/ 72	(3.0) (1.7) (1.4)	0.718 1.000 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	4/132 4/132	(3.0)	2/119 1/ 72	(1.7) (1.4)	0.686 0.658
		DVS SR 200 mg	Placebo	2/119	(1.7)	1/ 72	(1.4)	1.000
HDL CHOLESTEROL mmol/L	0.379	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/142 1/142 1/142 1/142	(0.7) (0.7) (0.7) (0.7)	0/139 0/132 0/124 1/ 76	(1.3)	1.000 1.000 1.000 1.000
		DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo	0/139 0/132 0/124		1/ 76 1/ 76 1/ 76	(1.3) (1.3) (1.3)	0.353 0.365 0.380
DECREASE	0.379	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/142 1/142 1/142 1/142	(0.7) (0.7) (0.7) (0.7)	0/139 0/132 0/124 1/ 76	(1.3)	1.000 1.000 1.000 1.000
		DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo	0/139 0/132 0/124	(01/)	1/ 76 1/ 76 1/ 76	(1.3) (1.3) (1.3)	0.353 0.365 0.380
LDL CHOLESTEROL mmol/L	0.048*	DVS SR 50 mg	DVS SR 150 mg Placebo	0/142 0/142		1/132 2/ 74	(0.8) (2.7)	0.482 0.116
		DVS SR 100 mg	DVS SR 150 mg	0/138		1/132	(0.8)	0.489
		DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	0/138 1/132 1/132	(0.8) (0.8)	2/ 74 0/124 2/ 74	(2.7) (2.7)	0.121 1.000 0.293
		DVS SR 200 mg	Placebo	0/124		2/ 74	(2.7)	0.138
INCREASE	0.048*	DVS SR 50 mg	DVS SR 150 mg Placebo	0/142 0/142		1/132 2/ 74	(0.8) (2.7)	0.482 0.116

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 Page 32

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Comparator		cio Comparato		Pairwise P-Value *	
INCREASE	0.048*	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg Placebo DVS SR 200 mg Placebo Placebo	0/138 0/138 1/132 1/132 0/124	(0.8)	1/132 2/ 74 0/124 2/ 74 2/ 74	(0.8) (2.7) (2.7) (2.7)	0.489 0.121 1.000 0.293 0.138	
TRIGLYCERIDES /LIPID mmol/L	0.691	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/142 1/142 1/142 1/142	(0.7) (0.7) (0.7) (0.7)	1/139 2/132 1/124 2/ 76	(0.7) (1.5) (0.8) (2.6)	1.000 0.610 1.000 0.279	
		DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	1/139 1/139 1/139 2/132	(0.7) (0.7) (0.7) (1.5)	2/132 1/124 2/ 76 1/124	(1.5) (0.8) (2.6) (0.8)	0.614 1.000 0.286 1.000	
		DVS SR 200 mg	Placebo Placebo	2/132 1/124	(1.5) (0.8)	2/ 76 2/ 76	(2.6) (2.6)	0.624 0.559	
HIGH	0.691	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/142 1/142 1/142 1/142	(0.7) (0.7) (0.7) (0.7)	1/139 2/132 1/124 2/ 76	(0.7) (1.5) (0.8) (2.6)	1.000 0.610 1.000 0.279	
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/139 1/139 1/139	(0.7) (0.7) (0.7)	2/132 1/124 2/ 76	(1.5) (0.8) (2.6)	0.614 1.000 0.286	
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	2/132 2/132 1/124	(1.5) (1.5) (0.8)	1/124 2/ 76 2/ 76	(0.8) (2.6) (2.6)	1.000 0.624 0.559	

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square. Pairwise P-Value: Fisher's Exact Test P-value (2-Tail).

Page 33

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 8

Category Test+Units	Overall P-Value *		atment Comparator 2	Rat Comparator 1	Comparator 2	Pairwise P-Value '
TOTAL	0.500	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/ 17 (5.9) 1/ 17 (5.9) 1/ 17 (5.9) 1/ 17 (5.9)	1/ 14 (7.1) 1/ 13 (7.7) 0/ 5 2/ 8 (25.0)	1.000 1.000 1.000 0.231
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	1/ 14 (7.1) 1/ 14 (7.1)	1/ 13 (7.7) 0/ 5	1.000
		DVS SR 150 mg	Placebo DVS SR 200 mg	1/ 14 (7.1) 1/ 13 (7.7)	2/ 8 (25.0) 0/ 5	0.527 1.000
		DVS SR 200 mg	Placebo Placebo	1/ 13 (7.7) 0/ 5	2/ 8 (25.0) 2/ 8 (25.0)	0.531 0.487
BLOOD CHEMISTRY	0.409	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 14 0/ 10 1/ 9 (11.1) 1/ 9 (11.1)	1/ 9 (11.1) 1/ 9 (11.1) 0/ 4 0/ 7	0.391 0.474 1.000 1.000
URIC ACID mmol/L	0.372	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 11 0/ 8 1/ 7 (14.3) 1/ 7 (14.3)	1/ 7 (14.3) 1/ 7 (14.3) 0/ 4 0/ 6	0.389 0.467 1.000 1.000
HIGH	0.372	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 11 0/ 8 1/ 7 (14.3) 1/ 7 (14.3)	1/ 7 (14.3) 1/ 7 (14.3) 0/ 4 0/ 6	0.389 0.467 1.000
HEMATOLOGY	0.491	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg Placebo	1/ 9 (11.1) 1/ 9 (11.1) 1/ 9 (11.1)	0/ 8 0/ 8 0/ 5	1.000 1.000 1.000
HEMOGLOBIN g/L	0.491	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg Placebo	1/ 9 (11.1) 1/ 9 (11.1) 1/ 9 (11.1)	0/ 8 0/ 8 0/ 5	1.000 1.000 1.000
LOW	0.491	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg Placebo	1/ 9 (11.1) 1/ 9 (11.1) 1/ 9 (11.1)	0/ 8 0/ 8 0/ 5	1.000 1.000 1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 34

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 8

Category Test+Units	Overall P-Value *		tment Comparator 2		Comparator 2	Pairwise P-Value *
HEMATOCRIT L/L	0.491	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg Placebo	1/ 9 (11.1) 1/ 9 (11.1) 1/ 9 (11.1)	0/ 8 0/ 8 0/ 5	1.000 1.000 1.000
LOW	0.491	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg Placebo	1/ 9 (11.1) 1/ 9 (11.1) 1/ 9 (11.1)	0/ 8 0/ 8 0/ 5	1.000 1.000 1.000
LIPID PROFILE	0.442	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo Placebo Placebo	0/ 12 0/ 12 1/ 9 (11.1) 1/ 9 (11.1) 1/ 9 (11.1) 0/ 8 0/ 5	1/ 9 (11.1) 1/ 6 (16.7) 0/ 8 0/ 5 1/ 6 (16.7) 1/ 6 (16.7) 1/ 6 (16.7)	0.429 0.333 1.000 1.000 1.000 0.429 1.000
TRIGLYCERIDES /LIPID mmol/L	0.442	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo Placebo Placebo	0/ 12 0/ 12 1/ 9 (11.1) 1/ 9 (11.1) 1/ 9 (11.1) 0/ 8 0/ 5	1/ 9 (11.1) 1/ 6 (16.7) 0/ 8 0/ 5 1/ 6 (16.7) 1/ 6 (16.7) 1/ 6 (16.7)	0.429 0.333 1.000 1.000 1.000 0.429 1.000
HIGH	0.442	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo Placebo Placebo	0/ 12 0/ 12 1/ 9 (11.1) 1/ 9 (11.1) 1/ 9 (11.1) 0/ 8 0/ 5	1/ 9 (11.1) 1/ 6 (16.7) 0/ 8 0/ 5 1/ 6 (16.7) 1/ 6 (16.7) 1/ 6 (16.7)	0.429 0.333 1.000 1.000 1.000 0.429 1.000
URINALYSIS	0.157	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	Placebo Placebo Placebo	0/ 7 0/ 7 0/ 6	1/ 4 (25.0) 1/ 4 (25.0) 1/ 4 (25.0)	0.364 0.364 0.400
URINE HEMOGLOBIN BLOOD	0.157	DVS SR 50 mg	Placebo	0/ 7	1/ 4 (25.0)	0.364

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 Page 35

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 8

Category Test+Units	ry Overall Treatment nits P-Value * Comparator 1 Comparat			Ra Comparator 1	atio Comparator 2	Pairwise P-Value *
URINE HEMOGLOBIN BLOOD	0.157	DVS SR 100 mg DVS SR 150 mg	Placebo Placebo	0/ 7 0/ 6	1/ 4 (25.0) 1/ 4 (25.0)	0.364
POSITIVE	0.157	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	Placebo Placebo Placebo	0/ 7 0/ 7 0/ 6	1/ 4 (25.0) 1/ 4 (25.0) 1/ 4 (25.0)	0.364 0.364 0.400

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square. Pairwise P-Value: Fisher's Exact Test P-value (2-Tail).

Page 36

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 12

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Comparat		io Comparat		Pairwise P-Value *
TOTAL	0.602	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	7/119 7/119 7/119 7/119	(5.9) (5.9) (5.9) (5.9)	12/119 7/103 10/ 96 4/ 66	(10.1) (6.8) (10.4) (6.1)	0.339 0.790 0.309 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	12/119 12/119 12/119	(10.1) (10.1) (10.1)	7/103 10/ 96 4/ 66	(6.8) (10.4) (6.1)	0.474 1.000 0.423
		DVS SR 150 mg	DVS SR 200 mg Placebo	7/103 7/103	(6.8) (6.8)	10/ 96 4/ 66	(10.4) (6.1)	0.449
		DVS SR 200 mg	Placebo	10/ 96	(10.4)	4/ 66	(6.1)	0.403
BLOOD CHEMISTRY	0.472	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/119 2/119 2/119 2/119	(1.7) (1.7) (1.7) (1.7)	0/119 3/103 2/ 96 2/ 66	(2.9) (2.1) (3.0)	0.498 0.665 1.000 0.617
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	0/119 0/119 0/119	, ,	3/103 2/ 96 2/ 66	(2.9) (2.1) (3.0)	0.098 0.198 0.126
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	3/103 3/103 2/ 96	(2.9) (2.9) (2.1)	2/ 96 2/ 66 2/ 66	(2.1) (3.0) (3.0)	1.000 1.000 1.000
POTASSIUM mmol/L	0.377	DVS SR 50 mg	DVS SR 150 mg	0/119		1/103	(1.0)	0.464
		DVS SR 100 mg	Placebo DVS SR 150 mg Placebo	0/119 0/116 0/116		1/ 66 1/103 1/ 66	(1.5) (1.0) (1.5)	0.357 0.470 0.363
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/103 1/103	(1.0) (1.0)	0/ 95 1/ 66	(1.5)	1.000
		DVS SR 200 mg	Placebo	0/ 95	, , ,	1/ 66	(1.5)	0.410
HIGH 0.377	0.377	DVS SR 50 mg	DVS SR 150 mg Placebo	0/119 0/119		1/103 1/ 66	(1.0) (1.5)	0.464 0.357
		DVS SR 100 mg	DVS SR 150 mg Placebo	0/116 0/116		1/103 1/ 66	(1.0)	0.470
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/103 1/103	(1.0) (1.0)	0/ 95 1/ 66	(1.5)	1.000
		DVS SR 200 mg	Placebo	0/ 95	(/	1/ 66	(1.5)	0.410

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 37

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 12

Category Test+Units	Overall P-Value *	Trea Comparator 1	tment Comparator 2	Comparato		io Comparato		Pairwise P-Value *
GLUCOSE mmol/L	0.157	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/119 0/119 0/103 0/ 96		1/ 66 1/ 66 1/ 66 1/ 66	(1.5) (1.5) (1.5) (1.5)	0.357 0.357 0.391 0.407
HIGH	0.157	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/119 0/119 0/103 0/ 96		1/ 66 1/ 66 1/ 66 1/ 66	(1.5) (1.5) (1.5) (1.5)	0.357 0.357 0.391 0.407
URIC ACID mmol/L	0.099	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/119 0/119 2/103 2/103	(1.9) (1.9)	2/103 2/103 0/ 96 0/ 66	(1.9) (1.9)	0.214 0.214 0.498 0.521
HIGH	0.099	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/119 0/119 2/103 2/103	(1.9) (1.9)	2/103 2/103 0/ 96 0/ 66	(1.9) (1.9)	0.214 0.214 0.498 0.521
SGOT/AST mU/mL	0.603	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg DVS SR 200 mg Placebo	1/119 1/119 1/119 1/119 0/116 0/103 1/ 95	(0.8) (0.8) (0.8) (0.8) (1.1)	0/116 0/103 1/ 95 0/ 66 1/ 95 1/ 95 0/ 66	(1.1) (1.1) (1.1)	1.000 1.000 1.000 1.000 0.450 0.480 1.000
HIGH	0.603	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg DVS SR 200 mg Placebo	1/119 1/119 1/119 1/119 0/116 0/103 1/ 95	(0.8) (0.8) (0.8) (0.8) (1.1)	0/116 0/103 1/ 95 0/ 66 1/ 95 1/ 95 0/ 66	(1.1) (1.1) (1.1)	1.000 1.000 1.000 1.000 0.450 0.480 1.000
SGPT/ALT mU/mL	0.246	DVS SR 50 mg	DVS SR 100 mg	1/119	(0.8)	0/119		1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 38

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 12

Category Overal Test+Units P-Value		Trea	tment Comparator 2	Comparato		io Comparato		Pairwise P-Value '
SGPT/ALT mU/mL	0.246	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg DVS SR 200 mg Placebo	1/119 1/119 1/119 0/119 0/103 2/ 96	(0.8) (0.8) (0.8) (2.1)	0/103 2/ 96 0/ 66 2/ 96 2/ 96 0/ 66	(2.1) (2.1) (2.1)	1.000 0.587 1.000 0.198 0.231 0.514
HIGH	0.246	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg DVS SR 200 mg Placebo	1/119 1/119 1/119 1/119 0/119 0/103 2/ 96	(0.8) (0.8) (0.8) (0.8) (0.8)	0/119 0/103 2/ 96 0/ 66 2/ 96 2/ 96 0/ 66	(2.1) (2.1) (2.1)	1.000 1.000 0.587 1.000 0.198 0.231 0.514
HEMATOLOGY	0.142	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0/118 0/118 3/118 3/118 3/118 0/102 1/ 96	(2.5) (2.5) (2.5) (1.0)	3/118 1/ 96 0/102 1/ 96 0/ 66 1/ 96 0/ 66	(2.5) (1.0) (1.0) (1.0)	0.247 0.449 0.251 0.629 0.554 0.485 1.000
HEMOGLOBIN g/L	0.518	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/118 1/118 1/118 1/118	(0.8) (0.8) (0.8)	1/118 0/102 0/ 96 0/ 66	(0.8)	1.000 1.000 1.000 1.000
HIGH	0.518	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/118 1/118 1/118 1/118	(0.8) (0.8) (0.8)	1/118 0/102 0/ 96 0/ 66	(0.8)	1.000 1.000 1.000 1.000
HEMATOCRIT L/L	0.518	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/118 1/118 1/118 1/118	(0.8) (0.8) (0.8)	1/118 0/102 0/ 96 0/ 66	(0.8)	1.000 1.000 1.000 1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 39

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 12

Category Test+Units	Overall P-Value *	Trea Comparator 1	tment Comparator 2	Comparator 1	Ratio Comparator 2	Pairwise P-Value *
HIGH	0.518	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/118 1/118 (0. 1/118 (0. 1/118 (0.	8) 0/96	1.000 1.000 1.000 1.000
WBC 10^9/L	0.362	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0/116 0/116 2/118 (1. 2/118 (1. 2/118 (1. 0/102 1/95 (1.	7) 1/ 95 (1.1) 7) 0/ 63 1/ 95 (1.1)	0.498 0.450 0.500 1.000 0.544 0.482 1.000
HIGH	0.379	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/116 0/118 0/102 1/ 95 (1.	1/ 95 (1.1) 1/ 95 (1.1) 1/ 95 (1.1) 1) 0/ 63	0.450 0.446 0.482 1.000
LOW	0.171	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/116 2/118 (1. 2/118 (1. 2/118 (1.	7) 0/95	0.498 0.500 0.503 0.544
LIPID PROFILE	0.421	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	3/119 (2. 3/119 (2. 3/119 (2. 3/119 (2. 3/119 (2. 3/119 (2. 3/119 (2. 3/119 (2. 3/103 (2. 3/103 (2. 3/103 (2. 6/96 (6.	5) 3/103 (2.9) 5) 6/96 (6.3) 5) 1/66 (1.5) 5) 3/103 (2.9) 5) 6/96 (6.3) 5) 1/66 (1.5) 9) 6/96 (6.3) 9) 1/66 (1.5)	1.000 1.000 0.193 1.000 1.000 0.193 1.000 0.318 1.000
TOT.CHOL. /LIPID mmol/L	0.268	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	2/118 (1. 2/118 (1. 2/118 (1.	7) 3/119 (2.5) 7) 2/103 (1.9)	1.000 1.000 0.247

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page

40

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 12

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Comparato		io Comparator		Pairwise P-Value *
TOT.CHOL. /LIPID mmol/L	0.268	DVS SR 50 mg DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	2/118 3/119 3/119 3/119	(1.7) (2.5) (2.5) (2.5)		(1.9) (5.2)	0.539 1.000 0.471 0.553
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	2/103 2/103 5/ 96	(1.9) (1.9) (5.2)		(5.2)	0.266 0.523 0.082
HIGH	0.268	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/118 2/118 2/118 2/118	(1.7) (1.7) (1.7) (1.7)	2/103	(2.5) (1.9) (5.2)	1.000 1.000 0.247 0.539
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	3/119 3/119 3/119 2/103	(2.5) (2.5) (2.5) (2.5) (1.9)	2/103 5/ 96 0/ 65	(1.9) (5.2)	1.000 0.471 0.553 0.266
		DVS SR 200 mg	Placebo Placebo	2/103 5/ 96	(1.9) (5.2)	0/ 65 0/ 65	,	0.523 0.082
HDL CHOLESTEROL mmol/L	0.421	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/119 0/119 1/103 1/103	(1.0) (1.0)		(1.0) (1.0)	0.464 0.464 1.000 1.000
DECREASE	0.421	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/119 0/119 1/103 1/103	(1.0) (1.0)		(1.0) (1.0)	0.464 0.464 1.000 1.000
LDL CHOLESTEROL mmol/L	0.211	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/118 1/118 1/118 1/118	(0.8) (0.8) (0.8) (0.8)		(1.9) (3.1)	0.498 0.599 0.328 1.000
		DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/119 0/119 2/103 2/103	(1.9) (1.9)	3/ 96	(1.9) (3.1) (3.1)	0.214 0.087 0.674 0.523

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 41

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 12

Category Test+Units	Overall P-Value *	Trea Comparator 1	tment Comparator 2	Comparato		io Comparator 2	Pairwise P-Value *
LDL CHOLESTEROL mmol/L	0.211	DVS SR 200 mg	Placebo	3/ 96	(3.1)	0/ 65	0.273
INCREASE	0.211	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/118 1/118 1/118 1/118	(0.8) (0.8) (0.8) (0.8)	0/119 2/103 (1.9) 3/ 96 (3.1) 0/ 65	0.498 0.599 0.328 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	0/119 0/119	(0.0)	2/103 (1.9) 3/ 96 (3.1)	0.214
		DVS SR 150 mg	DVS SR 200 mg Placebo	2/103 2/103	(1.9) (1.9)	3/ 96 (3.1) 0/ 65	0.674 0.523
		DVS SR 200 mg	Placebo	3/ 96	(3.1)	0/ 65	0.273
TRIGLYCERIDES /LIPID mmol/L	0.628	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/119 1/119 1/119 1/119	(0.8) (0.8) (0.8) (0.8)	0/119 1/103 (1.0) 0/ 96 1/ 66 (1.5)	1.000 1.000 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg Placebo	0/119 0/119		1/103 (1.0) 1/66 (1.5)	0.464 0.357
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/103 1/103	(1.0) (1.0)	0/ 96 1/ 66 (1.5)	1.000
		DVS SR 200 mg	Placebo	0/ 96		1/ 66 (1.5)	0.407
HIGH	0.628	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/119 1/119 1/119 1/119	(0.8) (0.8) (0.8) (0.8)	0/119 1/103 (1.0) 0/ 96 1/ 66 (1.5)	1.000 1.000 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg Placebo	0/119 0/119	(0.0)	1/103 (1.0) 1/66 (1.5)	0.464
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/103 1/103	(1.0) (1.0)	0/ 96 1/ 66 (1.5)	1.000 1.000
		DVS SR 200 mg	Placebo	0/ 96		1/ 66 (1.5)	0.407
URINALYSIS	0.324	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/118 2/118 2/118 2/118	(1.7) (1.7) (1.7) (1.7)	6/119 (5.0) 1/102 (1.0) 3/ 95 (3.2) 1/ 66 (1.5)	0.281 1.000 0.658 1.000
		DVS SR 100 mg	DVS SR 150 mg	6/119	(5.0)	1/102 (1.0)	0.127

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 42

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 12

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Comparato		io Comparato		Pairwise P-Value *
URINALYSIS	0.324	DVS SR 100 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo	6/119 6/119 1/102 1/102	(5.0) (5.0) (1.0) (1.0)	3/ 95 1/ 66 3/ 95 1/ 66	(3.2) (1.5) (3.2) (1.5)	0.734 0.424 0.354 1.000
		DVS SR 200 mg	Placebo	3/ 95	(3.2)	1/ 66	(1.5)	0.645
URINE PROTEIN ALBUMIN	0.321	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	0/118 0/118 0/118		3/119 1/102 2/ 95	(2.5) (1.0) (2.1)	0.247 0.464 0.198
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	3/119 3/119 3/119	(2.5) (2.5) (2.5)	1/102 2/ 95 0/ 66	(1.0)	0.626 1.000 0.554
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	1/102 1/102 2/ 95	(1.0) (1.0) (2.1)	2/ 95 0/ 66 0/ 66	(2.1)	0.610 1.000 0.513
POSITIVE	0.321	DVS SR 50 mg	DVS SR 100 mg	0/118	(2.1)	3/119	(2.5)	0.247
10011111	0.321	DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/118 0/118 0/118 3/119 3/119 3/119	(2.5) (2.5) (2.5)	1/102 2/ 95 1/102 2/ 95 0/ 66	(1.0) (2.1) (1.0) (2.1)	0.464 0.198 0.626 1.000 0.554
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/102 1/102	(1.0) (1.0)	2/ 95 0/ 66	(2.1)	0.610
		DVS SR 200 mg	Placebo	2/ 95	(2.1)	0/ 66		0.513
URINE ACETONE /KETONES	0.524	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/118 1/119 1/119 1/119	(0.8) (0.8) (0.8)	1/119 0/102 0/ 95 0/ 66	(0.8)	1.000 1.000 1.000 1.000
POSITIVE	0.524	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/118 1/119 1/119 1/119	(0.8) (0.8) (0.8)	1/119 0/102 0/ 95 0/ 66	(0.8)	1.000 1.000 1.000 1.000
URINE HEMOGLOBIN BLOOD	0.747	DVS SR 50 mg	DVS SR 100 mg	2/118	(1.7)	2/119	(1.7)	1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 Page 43

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Category Test+Units	Overall P-Value *	Treatment Comparator 1 Comparator 2		Comparator 1 Comparato				
URINE HEMOGLOBIN BLOOD	0.747	DVS SR 50 mg	DVS SR 150 mg DVS SR 200 mg	2/118 2/118 2/118	(1.7) (1.7)	0/102 2/ 95 1/ 66	(2.1)	0.500
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg	2/119 2/119	(1.7) (1.7) (1.7)	0/102 2/ 95	(1.5) (2.1)	1.000 0.501 1.000
		DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	2/119 0/102 0/102	(1.7)	1/ 66 2/ 95 1/ 66	(1.5) (2.1) (1.5)	1.000 0.231 0.393
		DVS SR 200 mg	Placebo	2/ 95	(2.1)	1/ 66	(1.5)	1.000
POSITIVE	0.747	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/118 2/118 2/118 2/118	(1.7) (1.7) (1.7) (1.7)	2/119 0/102 2/ 95 1/ 66	(1.7) (2.1) (1.5)	1.000 0.500 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	2/119 2/119	(1.7) (1.7)	0/102 2/ 95	(2.1)	0.501 1.000
		DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	2/119 0/102 0/102	(1.7)	1/ 66 2/ 95 1/ 66	(1.5) (2.1) (1.5)	1.000 0.231 0.393
		DVS SR 200 mg	Placebo	2/ 95	(2.1)	1/ 66	(1.5)	1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square. Pairwise P-Value: Fisher's Exact Test P-value (2-Tail).

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 44

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 26

Category Test+Units	Overall P-Value *	Comparator 1	tment Comparator 2	Comparat		io Comparat		Pairwise P-Value *
TOTAL	0.514	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	14/101 14/101 14/101 14/101	(13.9) (13.9) (13.9) (13.9)	14/112 13/ 91 14/ 83 4/ 59	(12.5) (14.3) (16.9)	0.840 1.000 0.681 0.203
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	14/112 14/112	(12.5) (12.5)	13/ 91 14/ 83	(6.8) (14.3) (16.9)	0.836 0.415
		DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	14/112 13/ 91 13/ 91	(12.5) (14.3) (14.3)	4/ 59 14/ 83 4/ 59	(6.8) (16.9) (6.8)	0.303 0.679 0.194
		DVS SR 200 mg	Placebo	14/ 83	(16.9)	4/ 59	(6.8)	0.123
BLOOD CHEMISTRY	0.790	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	1/101 1/101 1/101	(1.0) (1.0) (1.0)	2/112 3/ 91 1/ 83	(1.8) (3.3) (1.2)	1.000 0.347 1.000
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	1/101 2/112 2/112 2/112	(1.0) (1.8) (1.8) (1.8)	1/ 59 3/ 91 1/ 83 1/ 59	(1.7) (3.3) (1.2) (1.7)	1.000 0.659 1.000 1.000
		DVS SR 150 mg	DVS SR 200 mg	3/ 91 3/ 91	(3.3)	1/ 83 1/ 59	(1.2)	0.622 1.000
		DVS SR 200 mg	Placebo Placebo	1/ 83	(3.3) (1.2)	1/ 59	(1.7) (1.7)	1.000
URIC ACID mmol/L	0.874	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/101 1/101 1/101 1/101	(1.0) (1.0) (1.0) (1.0)	1/112 1/ 91 0/ 83 1/ 59	(0.9) (1.1) (1.7)	1.000 1.000 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/112 1/112 1/112	(0.9) (0.9) (0.9)	1/ 91 0/ 83 1/ 59	(1.7) (1.1)	1.000 1.000 1.000
		DVS SR 150 mg	DVS SR 200 mg	1/ 91	(1.1)	0/83	, ,	1.000
		DVS SR 200 mg	Placebo Placebo	1/ 91 0/ 83	(1.1)	1/ 59 1/ 59	(1.7) (1.7)	1.000 0.415
HIGH	0.874	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/101 1/101 1/101 1/101	(1.0) (1.0) (1.0) (1.0)	1/112 1/ 91 0/ 83 1/ 59	(0.9) (1.1) (1.7)	1.000 1.000 1.000 1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 45

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 26

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Comparato		io Comparato		Pairwise P-Value *
HIGH	0.874	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	1/112 1/112 1/112 1/112 1/ 91 1/ 91 0/ 83	(0.9) (0.9) (0.9) (1.1) (1.1)	1/ 91 0/ 83 1/ 59 0/ 83 1/ 59 1/ 59	(1.1) (1.7) (1.7) (1.7)	1.000 1.000 1.000 1.000 1.000 0.415
SGOT/AST mU/mL	0.532	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 200 mg Placebo Placebo	0/100 0/100 0/112 0/112 1/ 90 1/ 90 1/ 83	(1.1) (1.1) (1.2)	1/ 90 1/ 83 1/ 90 1/ 83 1/ 83 0/ 59 0/ 59	(1.1) (1.2) (1.1) (1.2) (1.2)	0.474 0.454 0.446 0.426 1.000 1.000
HIGH	0.532	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 200 mg Placebo Placebo	0/100 0/100 0/112 0/112 1/ 90 1/ 90 1/ 83	(1.1) (1.1) (1.2)	1/ 90 1/ 83 1/ 90 1/ 83 1/ 83 0/ 59 0/ 59	(1.1) (1.2) (1.1) (1.2) (1.2)	0.474 0.454 0.446 0.426 1.000 1.000
SGPT/ALT mU/mL	0.514	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	0/101 0/101 0/101 1/112 1/112 1/112 2/ 91 2/ 91 1/ 83	(0.9) (0.9) (0.9) (0.9) (2.2) (2.2) (1.2)	1/112 2/ 91 1/ 83 2/ 91 1/ 83 0/ 59 1/ 83 0/ 59 0/ 59	(0.9) (2.2) (1.2) (2.2) (1.2) (1.2)	1.000 0.223 0.451 0.588 1.000 1.000 0.520 1.000
HIGH	0.514	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg	0/101 0/101 0/101 1/112	(0.9)	1/112 2/ 91 1/ 83 2/ 91	(0.9) (2.2) (1.2) (2.2)	1.000 0.223 0.451 0.588

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 46

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 26

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Comparat		io Comparato		Pairwise P-Value
HIGH	0.514	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	1/112 1/112 2/ 91 2/ 91 1/ 83	(0.9) (0.9) (2.2) (2.2) (1.2)	1/ 83 0/ 59 1/ 83 0/ 59 0/ 59	(1.2)	1.000 1.000 1.000 0.520 1.000
HEMATOLOGY	0.360	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/100 0/111 0/ 91 1/ 83	(1.2)	1/ 83 1/ 83 1/ 83 0/ 59	(1.2) (1.2) (1.2)	0.454 0.428 0.477 1.000
HEMATOCRIT L/L	0.360	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/100 0/111 0/ 91 1/ 83	(1.2)	1/ 83 1/ 83 1/ 83 0/ 59	(1.2) (1.2) (1.2)	0.454 0.428 0.477 1.000
HIGH	0.360	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/100 0/111 0/ 91 1/ 83	(1.2)	1/ 83 1/ 83 1/ 83 0/ 59	(1.2) (1.2) (1.2)	0.454 0.428 0.477 1.000
LIPID PROFILE	0.158	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	9/101 9/101 9/101 9/101 7/112 7/112 7/112 5/91 10/83	(8.9) (8.9) (8.9) (6.3) (6.3) (6.3) (5.5) (5.5) (12.0)	1/ 59 5/ 91	(6.3) (5.5) (12.0) (1.7) (5.5) (12.0) (1.7) (12.0) (1.7) (1.7)	0.604 0.416 0.627 0.093 1.000 0.201 0.265 0.176 0.404 0.026*
TOT.CHOL. /LIPID mmol/L	0.462	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg	2/100 2/100 2/100 2/100 6/108	(2.0) (2.0) (2.0) (2.0) (5.6)	6/108 3/ 91 5/ 83 1/ 58 3/ 91	(5.6) (3.3) (6.0) (1.7) (3.3)	0.282 0.670 0.248 1.000 0.513

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 47

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 26

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Comparato		io Comparato		Pairwise P-Value *
TOT.CHOL. /LIPID mmol/L	0.462	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	6/108 6/108 3/ 91 3/ 91 5/ 83	(5.6) (5.6) (3.3) (3.3) (6.0)	5/ 83 1/ 58 5/ 83 1/ 58 1/ 58	(6.0) (1.7) (6.0) (1.7) (1.7)	1.000 0.423 0.481 1.000 0.401
HIGH	0.462	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	2/100 2/100 2/100 2/100 6/108 6/108 6/108 3/ 91 3/ 91 5/ 83	(2.0) (2.0) (2.0) (2.0) (5.6) (5.6) (5.6) (3.3) (3.3) (6.0)	6/108 3/ 91 5/ 83 1/ 58 3/ 91 5/ 83 1/ 58 5/ 83 1/ 58 1/ 58	(5.6) (3.3) (6.0) (1.7) (3.3) (6.0) (1.7) (6.0) (1.7) (1.7)	0.282 0.670 0.248 1.000 0.513 1.000 0.423 0.481 1.000 0.401
HDL CHOLESTEROL mmol/L	0.336	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	2/101 2/101 2/101 2/101 0/112 1/ 91 1/ 91	(2.0) (2.0) (2.0) (2.0) (2.0) (1.1) (1.1)	0/112 1/ 91 0/ 83 0/ 59 1/ 91 0/ 83 0/ 59	(1.1)	0.224 1.000 0.502 0.532 0.448 1.000 1.000
DECREASE	0.336	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	2/101 2/101 2/101 2/101 0/112 1/ 91 1/ 91	(2.0) (2.0) (2.0) (2.0) (1.1) (1.1)	0/112 1/ 91 0/ 83 0/ 59 1/ 91 0/ 83 0/ 59	(1.1)	0.224 1.000 0.502 0.532 0.448 1.000 1.000
LDL CHOLESTEROL mmol/L	0.015*	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/101 1/101 1/101 1/101	(1.0) (1.0) (1.0) (1.0)	2/111 0/ 89 6/ 83 1/ 59	(1.8) (7.2) (1.7)	1.000 1.000 0.047* 1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 48

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 26

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Comparato		io Comparator 2	- Pairwise P-Value *
LDL CHOLESTEROL mmol/L	0.015*	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	2/111 2/111 2/111 0/ 89 0/ 89 6/ 83	(1.8) (1.8) (1.8) (7.2)	0/89 6/83 (7.2 1/59 (1.7 6/83 (7.2 1/59 (1.7 1/59 (1.7	1.000) 0.011*) 0.399
INCREASE	0.015*	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	1/101 1/101 1/101 1/101 2/111 2/111 2/111 0/ 89 0/ 89 6/ 83	(1.0) (1.0) (1.0) (1.0) (1.8) (1.8) (1.8) (7.2)	2/111 (1.8 0/89 6/83 (7.2 1/59 (1.7 0/89 6/83 (7.2 1/59 (1.7 6/83 (7.2 1/59 (1.7	1.000) 0.047*) 1.000 0.504) 0.076) 1.000) 0.011*) 0.399
TRIGLYCERIDES /LIPID mmol/L	0.625	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	4/101 4/101 4/101 4/101 3/112 3/112 3/112 2/ 91 2/ 91 3/ 83	(4.0) (4.0) (4.0) (4.0) (2.7) (2.7) (2.7) (2.2) (2.2) (3.6)	3/112 (2.7 2/91 (2.2 3/83 (3.6 0/59 2/91 (2.2 3/83 (3.6 0/59 3/83 (3.6 0/59 0/59 0/59	0.685 1.000 0.297 1.000 0.701 0.552
HIGH	0.625	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	4/101 4/101 4/101 4/101 3/112 3/112 2/ 91	(4.0) (4.0) (4.0) (4.0) (2.7) (2.7) (2.7) (2.2)	3/112 (2.7 2/ 91 (2.2 3/ 83 (3.6 0/ 59 2/ 91 (2.2 3/ 83 (3.6 0/ 59 3/ 83 (3.6	0.685 1.000 0.297 1.000 0.701 0.552

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 49

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 26

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Comparato		io Comparator 2	Pairwise P-Value *
HIGH	0.625	DVS SR 150 mg DVS SR 200 mg	Placebo Placebo	2/ 91 3/ 83	(2.2)	0/ 59 0/ 59	0.520 0.266
URINALYSIS	0.899	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	4/100 4/100 4/100 4/100	(4.0) (4.0) (4.0) (4.0)	5/111 (4.5) 6/ 91 (6.6) 4/ 82 (4.9) 2/ 59 (3.4)	0.523 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	5/111 5/111 5/111	(4.5) (4.5) (4.5)	6/ 91 (6.6) 4/ 82 (4.9) 2/ 59 (3.4)	0.548
		DVS SR 150 mg	DVS SR 200 mg Placebo	6/ 91 6/ 91	(6.6) (6.6)	4/ 82 (4.9) 2/ 59 (3.4)	0.750
		DVS SR 200 mg	Placebo	4/ 82	(4.9)	2/ 59 (3.4)	1.000
URINE PROTEIN ALBUMIN	0.567	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/100 2/100 2/100 2/100	(2.0) (2.0) (2.0) (2.0)	1/111 (0.9) 3/ 91 (3.3) 2/ 82 (2.4) 0/ 59	0.670
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	1/111 1/111 1/111	(0.9) (0.9)	3/ 91 (3.3) 2/ 82 (2.4) 0/ 59	0.329
		DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	3/ 91 3/ 91	(0.9) (3.3) (3.3)	0/ 59 2/ 82 (2.4) 0/ 59	
		DVS SR 200 mg	Placebo	2/ 82	(2.4)	0/ 59	0.510
POSITIVE	0.567	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/100 2/100 2/100 2/100	(2.0) (2.0) (2.0) (2.0)	1/111 (0.9) 3/ 91 (3.3) 2/ 82 (2.4) 0/ 59	0.670
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	1/111 1/111 1/111	(0.9)	3/ 91 (3.3) 2/ 82 (2.4) 0/ 59	0.329
		DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	3/ 91 3/ 91	(0.9) (3.3) (3.3)	2/ 82 (2.4) 0/ 59	
		DVS SR 200 mg	Placebo	2/ 82	(2.4)	0/ 59	0.510
URINE HEMOGLOBIN BLOOD	0.991	DVS SR 50 mg	DVS SR 100 mg	3/100	(3.0)	4/111 (3.6)	1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 50

NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 26

REPORT LAB5

Category Test+Units	Overall P-Value *	Trea	atment Comparator 2	Comparato		Comparato		Pairwise P-Value
URINE HEMOGLOBIN BLOOD	0.991	DVS SR 50 mg	DVS SR 150 mg DVS SR 200 mg Placebo	3/100 3/100 3/100	(3.0) (3.0) (3.0)	4/ 91 3/ 82 2/ 59	(4.4) (3.7) (3.4)	0.711 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	4/111 4/111 4/111	(3.6) (3.6) (3.6)	4/ 91 3/ 82 2/ 59	(4.4) (3.7) (3.4)	1.000 1.000 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	4/ 91 4/ 91 3/ 82	(4.4) (4.4) (3.7)	3/ 82 2/ 59 2/ 59	(3.7)	1.000
		DVS SR 200 mg	Placebo		, ,	,	(3.4)	1.000
POSITIVE	0.991	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	3/100 3/100 3/100 3/100	(3.0) (3.0) (3.0) (3.0)	4/111 4/ 91 3/ 82 2/ 59	(3.6) (4.4) (3.7) (3.4)	1.000 0.711 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	4/111 4/111 4/111	(3.6) (3.6) (3.6)	4/ 91 3/ 82 2/ 59	(4.4) (3.7) (3.4)	1.000 1.000 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	4/ 91 4/ 91	(4.4)	3/ 82 2/ 59	(3.7)	1.000
		DVS SR 200 mg	Placebo	3/ 82	(3.7)	2/ 59	(3.4)	1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square. Pairwise P-Value: Fisher's Exact Test P-value (2-Tail).

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

VESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 Page 51

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 39

Category	Overall	Trea	atment		Rat	io		Pairwise
Test+Units	P-Value *	Comparator 1	Comparator 2	Comparator	r 1	Comparat	or 2	P-Value '
TOTAL	0.993	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	13/ 94 13/ 94 13/ 94	(13.8) (13.8) (13.8) (13.8)	14/ 94 12/ 83 10/ 70 6/ 50	(14.9) (14.5) (14.3) (12.0)	1.000 1.000 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	14/ 94	(14.9) (14.9) (14.9)	12/ 83 10/ 70 6/ 50	(14.5) (14.3) (12.0)	1.000 1.000 0.801
		DVS SR 150 mg	DVS SR 200 mg Placebo	12/ 83 12/ 83	(14.5) (14.5) (14.5)	10/ 70 6/ 50	(14.3) (12.0)	1.000 0.797
		DVS SR 200 mg	Placebo	10/ 70	(14.3)	6/ 50	(12.0)	0.791
BLOOD CHEMISTRY	0.766	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/ 94 1/ 94 1/ 94 1/ 94	(1.1) (1.1) (1.1) (1.1)	0/ 94 1/ 83 1/ 70 0/ 50	(1.2) (1.4)	1.000 1.000 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	0/ 94 0/ 94		1/ 83 1/ 70	(1.2) (1.4)	0.469 0.427
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/ 83 1/ 83	(1.2) (1.2)	1/ 70 0/ 50	(1.4)	1.000
		DVS SR 200 mg	Placebo	1/ 70	(1.4)	0/50		1.000
GLUCOSE mmol/L	0.331	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/ 94 0/ 94 0/ 83 1/ 70	(1.4)	1/ 70 1/ 70 1/ 70 0/ 50	(1.4) (1.4) (1.4)	0.427 0.427 0.458 1.000
HIGH	0.331	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/ 94 0/ 94 0/ 83 1/ 70	(1.4)	1/ 70 1/ 70 1/ 70 0/ 50	(1.4) (1.4) (1.4)	0.427 0.427 0.458 1.000
URIC ACID mmol/L	0.445	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 94 0/ 94 1/ 83 1/ 83	(1.2) (1.2)	1/ 83 1/ 83 0/ 70 0/ 50	(1.2) (1.2)	0.469 0.469 1.000
HIGH	0.445	DVS SR 50 mg	DVS SR 150 mg	0/ 94		1/ 83	(1.2)	0.469

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 52

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 39

Category Test+Units	Overall P-Value *	Trea Comparator 1	tment 2	Ra Comparator 1	tio Comparator 2	Pairwise P-Value *
HIGH	0.445	DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo	0/ 94 1/ 83 (1.2) 1/ 83 (1.2)	1/ 83 (1.2) 0/ 70 0/ 50	0.469 1.000 1.000
SGOT/AST mU/mL	0.525	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/ 93 (1.1) 1/ 93 (1.1) 1/ 93 (1.1) 1/ 93 (1.1)	0/ 94 0/ 83 0/ 70 0/ 50	0.497 1.000 1.000
HIGH	0.525	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/ 93 (1.1) 1/ 93 (1.1) 1/ 93 (1.1) 1/ 93 (1.1)	0/ 94 0/ 83 0/ 70 0/ 50	0.497 1.000 1.000
HEMATOLOGY	0.768	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	0/ 93 0/ 93 0/ 93 1/ 92 (1.1) 1/ 92 (1.1) 1/ 83 (1.2) 1/ 83 (1.2) 1/ 70 (1.4)	1/ 92 (1.1) 1/ 83 (1.2) 1/ 70 (1.4) 1/ 83 (1.2) 1/ 70 (1.4) 0/ 50 1/ 70 (1.4) 0/ 50 0/ 50	0.497 0.472 0.429 1.000 1.000 1.000 1.000 1.000
HEMOGLOBIN g/L	0.450	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 93 0/ 92 1/ 83 (1.2) 1/ 83 (1.2)	1/ 83 (1.2) 1/ 83 (1.2) 0/ 70 0/ 50	0.472 0.474 1.000 1.000
HIGH	0.450	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 93 0/ 92 1/ 83 (1.2) 1/ 83 (1.2)	1/ 83 (1.2) 1/ 83 (1.2) 0/ 70 0/ 50	0.472 0.474 1.000 1.000
WBC 10^9/L	0.580	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg	0/ 92 0/ 92 1/ 91 (1.1)	1/ 91 (1.1) 1/ 69 (1.4) 0/ 81	0.497 0.429 1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 53

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 39

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	RacComparator 1	tio Comparator 2	Pairwise P-Value *
WBC 10^9/L	0.580	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo	1/ 91 (1.1) 1/ 91 (1.1) 0/ 81 1/ 69 (1.4)	1/69 (1.4) 0/48 1/69 (1.4) 0/48	1.000 1.000 0.460 1.000
LOW	0.580	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0/ 92 0/ 92 1/ 91 (1.1) 1/ 91 (1.1) 1/ 91 (1.1) 0/ 81 1/ 69 (1.4)	1/ 91 (1.1) 1/ 69 (1.4) 0/ 81 1/ 69 (1.4) 0/ 48 1/ 69 (1.4) 0/ 48	0.497 0.429 1.000 1.000 1.000 0.460 1.000
LIPID PROFILE	0.711	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Placebo	6/ 94 (6.4) 6/ 94 (6.4) 6/ 94 (6.4) 6/ 94 (6.4) 4/ 94 (4.3) 4/ 94 (4.3) 4/ 94 (4.3) 8/ 83 (9.6) 8/ 83 (9.6) 5/ 70 (7.1)	4/ 94 (4.3) 8/ 83 (9.6) 5/ 70 (7.1) 3/ 50 (6.0) 8/ 83 (9.6) 5/ 70 (7.1) 3/ 50 (6.0) 3/ 50 (6.0)	0.747 0.578 1.000 1.000 0.231 0.498 0.694 0.773 0.535 1.000
TOT.CHOL. /LIPID mmol/L	0.560	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	4/ 93 (4.3) 4/ 93 (4.3) 4/ 93 (4.3) 4/ 93 (4.3) 3/ 93 (3.2) 3/ 93 (3.2) 3/ 93 (3.2) 5/ 81 (6.2) 5/ 81 (6.2) 1/ 70 (1.4)	3/ 93 (3.2) 5/ 81 (6.2) 1/ 70 (1.4) 1/ 49 (2.0) 5/ 81 (6.2) 1/ 70 (1.4) 1/ 49 (2.0) 1/ 70 (1.4) 1/ 49 (2.0) 1/ 49 (2.0)	1.000 0.735 0.392 0.659 0.475 0.635 1.000 0.217 0.408 1.000
HIGH	0.560	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg	4/ 93 (4.3) 4/ 93 (4.3)	3/ 93 (3.2) 5/ 81 (6.2)	1.000 0.735

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 54

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 39

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Comparator		io Comparator 2	Pairwise P-Value '
HIGH	0.560	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	4/ 93 3/ 93 3/ 93 3/ 93 5/ 81 5/ 81	(4.3) (4.3) (3.2) (3.2) (3.2) (6.2) (6.2) (1.4)	1/ 70 (1. 1/ 49 (2. 5/ 81 (6. 1/ 70 (1. 1/ 49 (2. 1/ 70 (1. 1/ 49 (2. 1/ 49 (2.	0) 0.659 2) 0.475 4) 0.635 0) 1.000 4) 0.217 0) 0.408
HDL CHOLESTEROL mmol/L	0.547	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	1/ 83	(1.2) (1.2) (1.4)	1/ 83 (1. 1/ 70 (1. 1/ 50 (2. 1/ 83 (1. 1/ 70 (1. 1/ 50 (2. 1/ 70 (1. 1/ 50 (2. 1/ 50 (2.	4) 0.427 0) 0.347 2) 0.469 4) 0.427 0) 0.347 4) 1.000 0) 1.000
DECREASE	0.547	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	1/ 83	(1.2) (1.2) (1.4)	1/ 83 (1. 1/ 70 (1. 1/ 50 (2. 1/ 83 (1. 1/ 70 (1. 1/ 50 (2. 1/ 70 (1. 1/ 50 (2. 1/ 50 (2. 1/ 50 (2.	4) 0.427 0) 0.347 2) 0.469 4) 0.427 0) 0.347 4) 1.000 0) 1.000
LDL CHOLESTEROL mmol/L	0.800	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	1/ 94 1/ 94 1/ 94 1/ 93 1/ 93	(1.1) (1.1) (1.1) (1.1) (1.1) (1.1) (1.1)	1/ 93 (1. 0/ 83 1/ 70 (1. 0/ 50 0/ 83 1/ 70 (1. 0/ 50 1/ 70 (1.	1.000 1.000 1.000 1.000 4) 1.000 1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 Page 55

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 39

Category Test+Units	Overall P-Value *	Trea Comparator 1	tment Comparator 2	Comparator 1	Ratio Comparator 2	Pairwise P-Value *
LDL CHOLESTEROL mmol/L	0.800	DVS SR 200 mg	Placebo	1/ 70 (1.	4) 0/50	1.000
INCREASE	0.800	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	1/ 94 (1. 1/ 94 (1. 1/ 94 (1.	l) 0/83 l) 1/70 (1.4)	1.000 1.000 1.000
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	1/ 94 (1. 1/ 93 (1. 1/ 93 (1. 1/ 93 (1.	0/ 83 1) 1/ 70 (1.4)	1.000 1.000 1.000 1.000
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo	0/ 83 1/ 70 (1.	1/ 70 (1.4)	0.458 1.000
TRIGLYCERIDES /LIPID mmol/L	0.843	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/ 94 (2. 2/ 94 (2. 2/ 94 (2. 2/ 94 (2.	1) 3/83 (3.6) 1) 2/70 (2.9)	1.000 0.666 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/ 94 (1. 1/ 94 (1. 1/ 94 (1.	1) 3/83 (3.6) 1) 2/70 (2.9)	0.342 0.576 1.000
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	3/ 83 (3. 3/ 83 (3. 2/ 70 (2.	5) 2/70 (2.9) 5) 1/50 (2.0)	1.000 1.000 1.000
HIGH	0.843	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	2/ 94 (2. 2/ 94 (2. 2/ 94 (2.	1) 1/94 (1.1) 1) 3/83 (3.6) 1) 2/70 (2.9)	1.000 0.666 1.000
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	2/ 94 (2. 1/ 94 (1. 1/ 94 (1. 1/ 94 (1.	1) 3/83 (3.6) 1) 2/70 (2.9)	1.000 0.342 0.576 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	3/ 83 (3. 3/ 83 (3.	5) 2/70 (2.9) 5) 1/50 (2.0)	1.000
		DVS SR 200 mg	Placebo	2/ 70 (2.	9) 1/50 (2.0)	1.000
URINALYSIS	0.596	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	6/ 93 (6. 6/ 93 (6. 6/ 93 (6.	5) 3/83 (3.6)	0.592 0.503 0.764

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square. Pairwise P-Value: Fisher's Exact Test P-value (2-Tail).

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 56

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 39

Category Test+Units	Overall P-Value *		tment Comparator 2	Comparator		io Comparato		Pairwise P-Value *
URINALYSIS	0.596	DVS SR 50 mg DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	6/ 93 9/ 93 9/ 93 9/ 93 3/ 83	(6.5) (9.7) (9.7) (9.7) (9.7) (3.6)	4/ 50 3/ 83 6/ 70 4/ 50 6/ 70	(8.0) (3.6) (8.6) (8.0) (8.6)	0.740 0.140 1.000 1.000 0.302
		DVS SR 200 mg	Placebo Placebo	3/ 83 6/ 70	(3.6) (8.6)	4/ 50 4/ 50	(8.0) (8.0)	0.425 1.000
URINE PROTEIN ALBUMIN	0.355	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/ 93 1/ 93 1/ 93 1/ 93	(1.1) (1.1) (1.1) (1.1)	5/ 93 2/ 83 4/ 70 1/ 50	(5.4) (2.4) (5.7) (2.0)	0.211 0.602 0.166 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	5/ 93 5/ 93 5/ 93	(5.4) (5.4) (5.4)	2/ 83 4/ 70 1/ 50	(2.4) (5.7) (2.0)	0.449 1.000 0.665
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	2/ 83 2/ 83 4/ 70	(2.4) (2.4) (5.7)	4/ 70 1/ 50 1/ 50	(5.7) (2.0) (2.0)	0.413 1.000 0.400
POSITIVE	0.355	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	1/ 93 1/ 93 1/ 93	(1.1) (1.1) (1.1)	5/ 93 2/ 83 4/ 70	(5.4) (2.4) (5.7)	0.211 0.602 0.166
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	1/ 93 5/ 93 5/ 93 5/ 93	(1.1) (5.4) (5.4) (5.4)	1/ 50 2/ 83 4/ 70 1/ 50	(2.0) (2.4) (5.7) (2.0)	1.000 0.449 1.000 0.665
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	2/ 83 2/ 83 4/ 70	(2.4) (2.4) (5.7)	4/ 70 1/ 50 1/ 50	(5.7) (2.0) (2.0)	0.413 1.000 0.400
URINE ACETONE /KETONES	0.047*	DVS SR 50 mg	DVS SR 100 mg	0/ 93	, ,	3/ 93	(3.2)	0.246
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	3/ 93 3/ 93 3/ 93	(3.2) (3.2) (3.2)	0/ 83 0/ 70 0/ 50		0.248 0.260 0.552
POSITIVE	0.047*	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg	0/ 93 3/ 93	(3.2)	3/ 93 0/ 83	(3.2)	0.246 0.248

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 57

NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 39

REPORT LAB5

Category Test+Units	Overall P-Value *	Trea	atment Comparator 2	Comparator		tio Comparato		Pairwise P-Value '
POSITIVE	0.047*	DVS SR 100 mg	DVS SR 200 mg Placebo	3/ 93 3/ 93	(3.2)	0/ 70 0/ 50		0.260 0.552
URINE HEMOGLOBIN BLOOD	0.385	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	5/ 93	(5.4) (5.4) (5.4) (5.4)	2/ 93 1/ 83 4/ 70 3/ 50	(2.2) (1.2) (5.7) (6.0)	0.444 0.215 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	2/ 93 2/ 93 2/ 93	(2.2) (2.2) (2.2)	1/ 83 4/ 70 3/ 50	(1.2) (5.7) (6.0)	1.000 0.404 0.343
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo		(1.2) (1.2) (5.7)	4/ 70 3/ 50 3/ 50	(5.7) (6.0) (6.0)	0.179 0.149 1.000
		,		,	,		, ,	
POSITIVE	0.385	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	5/ 93 5/ 93 5/ 93 5/ 93	(5.4) (5.4) (5.4) (5.4)	2/ 93 1/ 83 4/ 70 3/ 50	(2.2) (1.2) (5.7) (6.0)	0.444 0.215 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	2/ 93 2/ 93 2/ 93	(2.2) (2.2) (2.2)	1/ 83 4/ 70 3/ 50	(1.2) (5.7) (6.0)	1.000 0.404 0.343
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/ 83	(1.2) (1.2)	4/ 70 3/ 50	(5.7) (6.0)	0.179 0.149
		DVS SR 200 mg	Placebo	4/ 70	(5.7)	3/ 50	(6.0)	1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square. Pairwise P-Value: Fisher's Exact Test P-value (2-Tail).

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 58

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 52

Category Test+Units	Overall P-Value *	Trea	atment Comparator 2	Comparat		io Comparat		Pairwise P-Value *
TOTAL	0.603	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	9/ 86 9/ 86 9/ 86 9/ 86	(10.5) (10.5) (10.5) (10.5)	8/ 85 10/ 70 11/ 64 5/ 47	(9.4) (14.3) (17.2) (10.6)	1.000 0.474 0.332 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	8/ 85 8/ 85 8/ 85	(9.4) (9.4) (9.4)	10/ 70 11/ 64 5/ 47	(14.3) (17.2) (10.6)	0.451 0.215 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	10/ 70 10/ 70	(14.3) (14.3)	11/ 64 5/ 47	(17.2) (10.6)	0.813 0.779
		DVS SR 200 mg	Placebo	11/ 64	(17.2)	5/ 47	(10.6)	0.418
BLOOD CHEMISTRY	0.857	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/ 85 1/ 85 1/ 85 1/ 85	(1.2) (1.2) (1.2) (1.2)	1/ 85 0/ 70 1/ 63 1/ 47	(1.2) (1.6) (2.1)	1.000 1.000 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/ 85 1/ 85 1/ 85	(1.2) (1.2) (1.2)	0/ 70 1/ 63 1/ 47	(1.6) (2.1)	1.000 1.000 1.000
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	0/ 70 0/ 70 1/ 63	(1.6)	1/ 63 1/ 47 1/ 47	(1.6) (2.1) (2.1)	0.474 0.402 1.000
GLUCOSE mmol/L	0.583	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/ 85 1/ 85 1/ 85 1/ 85	(1.2) (1.2) (1.2) (1.2)	0/ 85 0/ 70 1/ 63 0/ 47	(1.6)	1.000 1.000 1.000 1.000
		DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg Placebo	0/ 85 0/ 70 1/ 63	(1.6)	1/ 63 1/ 63 0/ 47	(1.6) (1.6)	0.426 0.474 1.000
HIGH	0.334	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/ 85 0/ 85 0/ 70 1/ 63	(1.6)	1/ 63 1/ 63 1/ 63 0/ 47	(1.6) (1.6) (1.6)	0.426 0.426 0.474 1.000
LOW	0.537	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg	1/ 85 1/ 85	(1.2) (1.2)	0/ 85 0/ 70		1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 59

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 52

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Ra Comparator 1	tio Comparator 2	Pairwise P-Value *
LOW	0.537	DVS SR 50 mg	DVS SR 200 mg Placebo	1/ 85 (1.2) 1/ 85 (1.2)	0/ 63 0/ 47	1.000
CALCIUM mmol/L	0.158	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/ 85 0/ 85 0/ 70 0/ 63	1/ 46 (2.2) 1/ 46 (2.2) 1/ 46 (2.2) 1/ 46 (2.2)	0.351 0.351 0.397 0.422
LOW	0.158	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/ 85 0/ 85 0/ 70 0/ 63	1/ 46 (2.2) 1/ 46 (2.2) 1/ 46 (2.2) 1/ 46 (2.2)	0.351 0.351 0.397 0.422
SGOT/AST mU/mL	0.539	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 85 1/ 85 (1.2) 1/ 85 (1.2) 1/ 85 (1.2)	0/63	1.000 1.000 1.000 1.000
HIGH	0.539	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 85 1/ 85 (1.2) 1/ 85 (1.2) 1/ 85 (1.2)	0/ 63	1.000 1.000 1.000 1.000
HEMATOLOGY	0.048*	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 86 3/ 84 (3.6) 3/ 84 (3.6) 3/ 84 (3.6)	0/64	0.118 0.251 0.259 0.552
HEMOGLOBIN g/L	0.529	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 86 1/ 84 (1.2) 1/ 84 (1.2) 1/ 84 (1.2)	0/ 64	0.494 1.000 1.000
HIGH	0.529	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 86 1/ 84 (1.2) 1/ 84 (1.2) 1/ 84 (1.2)	0/ 64	0.494 1.000 1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 60

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 52

Category Test+Units	Overall P-Value *		comparator 2	Comparator 1	atio Comparator 2	Pairwise P-Value *
HEMATOCRIT L/L	0.529	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 86 1/ 84 (1.2) 1/ 84 (1.2) 1/ 84 (1.2)	0/ 64	0.494 1.000 1.000
HIGH	0.529	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 86 1/ 84 (1.2) 1/ 84 (1.2) 1/ 84 (1.2)	0/ 64	0.494 1.000 1.000
WBC 10^9/L	0.170	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 86 2/ 83 (2.4) 2/ 83 (2.4) 2/ 83 (2.4)	0/64	0.240 0.501 0.505 0.538
LOW	0.170	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 86 2/ 83 (2.4) 2/ 83 (2.4) 2/ 83 (2.4)	0/ 64	0.240 0.501 0.505 0.538
LIPID PROFILE	0.095	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg	4/ 85 (4.7) 4/ 85 (4.7) 4/ 85 (4.7) 4/ 85 (4.7) 1/ 85 (1.2)	3/ 70 (4.3) 7/ 63 (11.1) 2/ 47 (4.3)	0.368 1.000 0.205 1.000 0.328
		DVS SR 150 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	1/ 85 (1.2) 1/ 85 (1.2) 3/ 70 (4.3) 3/ 70 (4.3) 7/ 63 (11.1)	7/ 63 (11.1) 2/ 47 (4.3) 7/ 63 (11.1) 2/ 47 (4.3)	0.011* 0.289 0.191 1.000 0.296
TOT.CHOL. /LIPID mmol/L	0.335	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	2/ 83 (2.4) 2/ 83 (2.4) 2/ 83 (2.4)	1/ 69 (1.4) 4/ 62 (6.5)	0.620 1.000 0.402
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg	2/ 83 (2.4) 1/ 84 (1.2) 1/ 84 (1.2)	1/ 69 (1.4)	0.616 1.000 0.163

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 61

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 52

Category Test+Units	Overall P-Value *		tment Comparator 2			Comparato		Pairwise P-Value *
TOT.CHOL. /LIPID mmol/L	0.335	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo DVS SR 200 mg Placebo Placebo	1/ 84 1/ 69 1/ 69 4/ 62	(1.2) (1.4) (1.4) (6.5)	2/ 46 4/ 62 2/ 46 2/ 46	(4.3) (6.5) (4.3) (4.3)	0.285 0.189 0.563 1.000
HIGH	0.335	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo	2/83 2/83 2/83 2/83 1/84 1/84 1/69 1/69	(2.4) (2.4) (2.4) (2.4) (1.2) (1.2) (1.2) (1.4) (1.4)	1/84 1/69 4/62 2/46 1/69 4/62 2/46 4/62 2/46	(1.2) (1.4) (6.5) (4.3) (1.4) (6.5) (4.3) (6.5) (4.3)	0.620 1.000 0.402 0.616 1.000 0.163 0.285 0.189 0.563
HDL CHOLESTEROL mmol/L	0.404	DVS SR 200 mg DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	Placebo DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	4/ 62 0/ 85 0/ 85 1/ 70 1/ 70	(1.4) (1.4)	2/ 46 1/ 70 1/ 70 0/ 63 0/ 47	(4.3) (1.4) (1.4)	1.000 0.452 0.452 1.000 1.000
DECREASE	0.404	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 85 0/ 85 1/ 70 1/ 70	(1.4) (1.4)	1/ 70 1/ 70 0/ 63 0/ 47	(1.4) (1.4)	0.452 0.452 1.000 1.000
LDL CHOLESTEROL mmol/L	0.204	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg	2/ 85 2/ 85 2/ 85 2/ 85 1/ 85 1/ 85	(2.4) (2.4) (2.4) (2.4) (1.2) (1.2)	1/ 85 0/ 69 3/ 62 0/ 47 0/ 69 3/ 62	(1.2) (4.8)	1.000 0.502 0.650 0.538 1.000 0.310
		DVS SR 150 mg DVS SR 200 mg	Placebo DVS SR 200 mg Placebo	1/ 85 0/ 69 3/ 62	(1.2) (1.2) (4.8)	0/ 47 3/ 62 0/ 47	(4.8)	1.000 0.103 0.257
INCREASE	0.204	DVS SR 50 mg	DVS SR 100 mg	2/ 85	(2.4)	1/ 85	(1.2)	1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 62

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 52

Category Test+Units	Overall P-Value *	Trea Comparator 1	tment Comparator 2	Ra Comparator 1		Pairwise P-Value *
INCREASE	0.204	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	2/ 85 (2.4) 2/ 85 (2.4) 2/ 85 (2.4) 1/ 85 (1.2) 1/ 85 (1.2) 1/ 85 (1.2) 0/ 69 3/ 62 (4.8)	0/ 69 3/ 62 (4.8) 0/ 47 0/ 69 3/ 62 (4.8) 0/ 47 3/ 62 (4.8) 0/ 47	0.502 0.650 0.538 1.000 0.310 1.000 0.103 0.257
TRIGLYCERIDES /LIPID mmol/L	0.509	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 200 mg Placebo Placebo	0/ 85 0/ 85 0/ 85 0/ 85 1/ 70 (1.4) 1/ 70 (1.4) 1/ 63 (1.6)	1/ 70 (1.4) 1/ 63 (1.6) 1/ 70 (1.4) 1/ 63 (1.6) 1/ 63 (1.6) 0/ 47 0/ 47	0.452 0.426 0.452 0.426 1.000 1.000
HIGH	0.509	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 200 mg Placebo Placebo	0/ 85 0/ 85 0/ 85 0/ 85 1/ 70 (1.4) 1/ 70 (1.4) 1/ 63 (1.6)	1/ 70 (1.4) 1/ 63 (1.6) 1/ 70 (1.4) 1/ 63 (1.6) 1/ 63 (1.6) 0/ 47 0/ 47	0.452 0.426 0.452 0.426 1.000 1.000
URINALYSIS	0.709	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	4/86 (4.7) 4/86 (4.7) 4/86 (4.7) 4/86 (4.7) 5/83 (6.0) 5/83 (6.0) 5/83 (6.0) 7/69 (10.1) 7/69 (10.1) 4/64 (6.3)	5/ 83 (6.0) 7/ 69 (10.1) 4/ 64 (6.3) 4/ 47 (8.5) 7/ 69 (10.1) 4/ 64 (6.3) 4/ 47 (8.5) 4/ 64 (6.3) 4/ 47 (8.5) 4/ 47 (8.5) 4/ 47 (8.5)	0.744 0.219 0.724 0.452 0.380 1.000 0.722 0.534 1.000 0.720
URINE PROTEIN ALBUMIN	0.754	DVS SR 50 mg	DVS SR 100 mg	2/ 86 (2.3)	,	1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 63

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 52

Category Test+Units	Overall P-Value *	Comparator 1	tment Comparator 2	Comparator 1		 omparato		Pairwise P-Value *
URINE PROTEIN ALBUMIN	0.754	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	2/ 86 (2 2/ 86 (2 1/ 83 (1 1/ 83 (1 1/ 83 (1 3/ 69 (4	2.3) 2.3) 2.3) 2.3) 2.2) 2.2) 3.2)	3/ 69 1/ 64 1/ 47 3/ 69 1/ 64 1/ 47 1/ 64 1/ 47	(4.3) (1.6) (2.1) (4.3) (1.6) (2.1) (1.6) (2.1)	0.656 1.000 1.000 0.330 1.000 1.000 0.620 0.646
		DVS SR 200 mg	Placebo		.6)	1/ 47	(2.1)	1.000
POSITIVE	0.754	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/ 86 (2 2/ 86 (2	2.3) 2.3) 2.3) 2.3)	1/ 83 3/ 69 1/ 64 1/ 47	(1.2) (4.3) (1.6) (2.1)	1.000 0.656 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/ 83 (1 1/ 83 (1 1/ 83 (1	.2)	3/ 69 1/ 64 1/ 47	(4.3) (1.6) (2.1)	0.330 1.000 1.000
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	3/ 69 (4	1.3) 1.3) 6)	1/ 64 1/ 47 1/ 47	(1.6) (2.1) (2.1)	0.620 0.646 1.000
URINE ACETONE /KETONES	0.861	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/ 86 (1 1/ 86 (1	2)	1/ 83 0/ 69 1/ 64 1/ 47	(1.2) (1.6) (2.1)	1.000 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/ 83 (1 1/ 83 (1	.2)	0/ 69 1/ 64 1/ 47	(1.6) (2.1)	1.000 1.000 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	0/ 69 0/ 69	•	1/ 64 1/ 47	(1.6) (2.1)	0.481 0.405
		DVS SR 200 mg	Placebo	1/ 64 (1	.6)	1/ 47	(2.1)	1.000
POSITIVE	0.861	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/ 86 (1 1/ 86 (1	.2)	1/ 83 0/ 69 1/ 64 1/ 47	(1.2) (1.6) (2.1)	1.000 1.000 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg	1/ 83 (1	.2)	0/ 69		1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 64

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 52

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Comparato		tio Comparator 2	- Pairwise P-Value *
POSITIVE	0.861	DVS SR 100 mg	DVS SR 200 mg Placebo	1/ 83 1/ 83	(1.2) (1.2)	1/ 64 (1.6 1/ 47 (2.1	
		DVS SR 150 mg	DVS SR 200 mg Placebo	0/ 69 0/ 69		1/ 64 (1.6 1/ 47 (2.1	
		DVS SR 200 mg	Placebo	1/ 64	(1.6)	1/ 47 (2.1	
URINE HEMOGLOBIN BLOOD	0.397	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/ 86 1/ 86 1/ 86 1/ 86	(1.2) (1.2) (1.2) (1.2)	3/83 (3.6 5/69 (7.2 2/64 (3.1 2/47 (4.3	0.089 0.576
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	3/ 83 3/ 83 3/ 83	(3.6) (3.6) (3.6)	5/ 69 (7.2 2/ 64 (3.1 2/ 47 (4.3	1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	5/ 69 5/ 69	(7.2) (7.2)	2/ 64 (3.1 2/ 47 (4.3	0.699
		DVS SR 200 mg	Placebo	2/ 64	(3.1)	2/ 47 (4.3	1.000
POSITIVE	0.397	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/ 86 1/ 86 1/ 86 1/ 86	(1.2) (1.2) (1.2) (1.2)	3/83 (3.6 5/69 (7.2 2/64 (3.1 2/47 (4.3	0.089 0.576
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	3/ 83 3/ 83 3/ 83	(3.6) (3.6) (3.6)	5/ 69 (7.2 2/ 64 (3.1 2/ 47 (4.3	0.469 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	5/ 69 5/ 69	(7.2) (7.2)	2/ 64 (3.1 2/ 47 (4.3	0.443 0.699
		DVS SR 200 mg	Placebo	2/ 64	(3.1)	2/47 (4.3	1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square. Pairwise P-Value: Fisher's Exact Test P-value (2-Tail).

Page 65

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Follow-up

Category Test+Units	Overall P-Value *	Comparator 1	atment Comparator 2	Comparato		io Comparat		Pairwise P-Value *
TOTAL	0.179	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	6/ 36 6/ 36 6/ 36 6/ 36	(16.7) (16.7) (16.7) (16.7)	12/ 41 7/ 47 8/ 47 0/ 11	(29.3) (14.9) (17.0)	0.281 1.000 1.000 0.312
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	12/ 41 12/ 41	(29.3) (29.3)	7/ 47 8/ 47 0/ 11	(14.9) (17.0)	0.124 0.207 0.050*
		DVS SR 150 mg	Placebo DVS SR 200 mg	12/ 41 7/ 47	(29.3) (14.9)	8/ 47	(17.0)	1.000
		DVS SR 200 mg	Placebo Placebo	7/ 47 8/ 47	(14.9) (17.0)	0/ 11 0/ 11		0.327 0.331
BLOOD CHEMISTRY	0.848	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	2/ 31 2/ 31 2/ 31	(6.5) (6.5) (6.5)	1/ 34 1/ 44 2/ 46 0/ 9	(2.9) (2.3) (4.3)	0.602 0.566 1.000 1.000
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	2/ 31 1/ 34 1/ 34 1/ 34	(6.5) (2.9) (2.9) (2.9)	1/ 44 2/ 46 0/ 9	(2.3) (4.3)	1.000 1.000 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/ 44	(2.3)	2/ 46 0/ 9	(4.3)	1.000
		DVS SR 200 mg	Placebo	2/ 46	(4.3)	0/ 9		1.000
GLUCOSE mmol/L	0.715	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg	0/ 28 0/ 28 1/ 33	(3.0)	1/ 33 1/ 46 0/ 42	(3.0) (2.2)	1.000 1.000 0.440
		DVS SIC 100 mg	DVS SR 130 mg DVS SR 200 mg Placebo	1/ 33 1/ 33	(3.0)	1/46	(2.2)	1.000
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo	0/ 42 1/ 46	(2.2)	1/ 46 0/ 8	(2.2)	1.000
HIGH	0.436	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 28 1/ 33 1/ 33 1/ 33	(3.0) (3.0) (3.0)	1/ 33 0/ 42 0/ 46 0/ 8	(3.0)	1.000 0.440 0.418 1.000
LOW	0.657	DVS SR 50 mg DVS SR 100 mg	DVS SR 200 mg DVS SR 200 mg	0/ 28 0/ 33		1/ 46 1/ 46	(2.2) (2.2)	1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 66

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Follow-up

Category Test+Units	Overall P-Value *	Trea Comparator 1	tment Comparator 2	Rat Comparator 1	Comparator 2	Pairwise P-Value *
LOW	0.657	DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo	0/ 42 1/ 46 (2.2)	1/ 46 (2.2) 0/ 8	1.000
TOTAL BILIRUBIN mcmol/L	0.595	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 29 0/ 33 1/ 42 (2.4) 1/ 42 (2.4)	1/ 42 (2.4) 1/ 42 (2.4) 0/ 46 0/ 8	1.000 1.000 0.477 1.000
HIGH	0.595	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 29 0/ 33 1/ 42 (2.4) 1/ 42 (2.4)	1/ 42 (2.4) 1/ 42 (2.4) 0/ 46 0/ 8	1.000 1.000 0.477 1.000
SGOT/AST mU/mL	0.519	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo Placebo	2/ 30 (6.7) 2/ 30 (6.7) 2/ 30 (6.7) 2/ 30 (6.7) 0/ 33 0/ 33 1/ 44 (2.3) 1/ 44 (2.3) 1/ 46 (2.2)	0/ 33 1/ 44 (2.3) 1/ 46 (2.2) 0/ 8 1/ 44 (2.3) 1/ 46 (2.2) 1/ 46 (2.2) 0/ 8 0/ 8	0.223 0.562 0.558 1.000 1.000 1.000 1.000
HIGH	0.519	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo Placebo	2/ 30 (6.7) 2/ 30 (6.7) 2/ 30 (6.7) 2/ 30 (6.7) 0/ 33 0/ 33 1/ 44 (2.3) 1/ 44 (2.3) 1/ 46 (2.2)	0/ 33 1/ 44 (2.3) 1/ 46 (2.2) 0/ 8 1/ 44 (2.3) 1/ 46 (2.2) 1/ 46 (2.2) 0/ 8 0/ 8	0.223 0.562 0.558 1.000 1.000 1.000 1.000 1.000
SGPT/ALT mU/mL	0.874	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/ 30 (3.3) 1/ 30 (3.3) 1/ 30 (3.3) 1/ 30 (3.3)	0/ 34 1/ 44 (2.3) 1/ 46 (2.2) 0/ 8	0.469 1.000 1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 67

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Follow-up

Category Test+Units	Overall P-Value *	Comparator 1	tment Comparator 2		atio Comparator 2	Pairwise P-Value *
SGPT/ALT mU/mL	0.874	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg DVS SR 200 mg Placebo Placebo	0/ 34 0/ 34 1/ 44 (2.3 1/ 44 (2.3) 0/8	1.000 1.000 1.000 1.000 1.000
HIGH	0.874	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg DVS SR 200 mg Placebo Placebo	1/ 30 (3.3 1/ 30 (3.3 1/ 30 (3.3 1/ 30 (3.3 0/ 34 0/ 34 1/ 44 (2.3 1/ 44 (2.3	1/ 44 (2.3) 1/ 46 (2.2) 0/ 8 1/ 44 (2.3) 1/ 46 (2.2) 1/ 46 (2.2) 1/ 46 (2.2)	0.469 1.000 1.000 1.000 1.000 1.000 1.000 1.000
HEMATOLOGY	0.242	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0/ 24 0/ 24 3/ 35 (8.6 3/ 35 (8.6 3/ 35 (8.6 2/ 41 (4.9 2/ 41 (4.9	0/38 0/7 0/38	0.264 0.527 0.657 0.105 1.000 0.494 1.000
HEMOGLOBIN g/L	0.639	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 24 0/ 34 1/ 41 (2.4 1/ 41 (2.4		1.000 1.000 1.000 1.000
LOW	0.639	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 24 0/ 34 1/ 41 (2.4 1/ 41 (2.4		1.000 1.000 1.000 1.000
HEMATOCRIT L/L	0.278	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	0/ 24 0/ 34 2/ 41 (4.9	2/ 41 (4.9) 2/ 41 (4.9) 0/ 38	0.527 0.498 0.494

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 68

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Follow-up

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Comparator 1	tio Comparator 2	Pairwise P-Value *
HEMATOCRIT L/L	0.278	DVS SR 150 mg	Placebo	2/ 41 (4.9)	0/ 7	1.000
LOW	0.278	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 24 0/ 34 2/ 41 (4.9) 2/ 41 (4.9)	2/ 41 (4.9) 2/ 41 (4.9) 0/ 38 0/ 7	0.527 0.498 0.494 1.000
WBC 10^9/L	0.047*	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 24 3/ 35 (8.6) 3/ 35 (8.6) 3/ 35 (8.6)	3/ 35 (8.6) 0/ 41 0/ 38 0/ 7	0.264 0.093 0.105 1.000
HIGH	0.531	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 24 1/ 35 (2.9) 1/ 35 (2.9) 1/ 35 (2.9)	1/ 35 0/ 41 0/ 38 0/ 7	1.000 0.461 0.479 1.000
LOW	0.173	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 24 2/ 35 (5.7) 2/ 35 (5.7) 2/ 35 (5.7)	2/ 35 (5.7) 0/ 41 0/ 38 0/ 7	0.509 0.209 0.226 1.000
LIPID PROFILE	0.383	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	3/ 28 (10.7) 3/ 28 (10.7) 3/ 28 (10.7) 3/ 28 (10.7) 6/ 33 (18.2) 6/ 33 (18.2) 6/ 33 (18.2) 4/ 43 (9.3) 4/ 43 (9.3) 3/ 47 (6.4)	6/ 33 (18.2) 4/ 43 (9.3) 3/ 47 (6.4) 0/ 9 4/ 43 (9.3) 3/ 47 (6.4) 0/ 9 3/ 47 (6.4) 0/ 9	0.488 1.000 0.665 0.562 0.315 0.151 0.312 0.705 1.000
TOT.CHOL. /LIPID mmol/L	0.540	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/ 24 (4.2) 1/ 24 (4.2) 1/ 24 (4.2) 1/ 24 (4.2)	2/ 29 (6.9) 2/ 40 (5.0) 0/ 43 0/ 7	1.000 1.000 0.358 1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 69

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Follow-up

Category Test+Units	Overall P-Value *		Comparator 2		atio Comparator 2	Pairwise P-Value '
TOT.CHOL. /LIPID mmol/L	0.540	DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	2/ 29 (6.9 2/ 29 (6.9 2/ 29 (6.9 2/ 40 (5.0 2/ 40 (5.0	0/43) 0/7) 0/43	1.000 0.159 1.000 0.229 1.000
HIGH	0.540	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo	1/ 24 (4.2 1/ 24 (4.2 1/ 24 (4.2 1/ 24 (4.2 2/ 29 (6.9 2/ 29 (6.9 2/ 29 (6.9 2/ 40 (5.0 2/ 40 (5.0	2/ 40 (5.0) 0/ 43 0/ 7) 2/ 40 (5.0) 0/ 43) 0/ 7) 0/ 43	1.000 1.000 0.358 1.000 1.000 0.159 1.000 0.229 1.000
HDL CHOLESTEROL mmol/L	0.416	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	1/ 28 (3.6 1/ 28 (3.6 1/ 28 (3.6 1/ 28 (3.6 0/ 33 2/ 42 (4.8 2/ 42 (4.8	2/ 42 (4.8) 0/ 46 0/ 8 2/ 42 (4.8) 0/ 46	0.459 1.000 0.378 1.000 0.501 0.225 1.000
DECREASE	0.416	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	1/ 28 (3.6 1/ 28 (3.6 1/ 28 (3.6 1/ 28 (3.6 0/ 33 2/ 42 (4.8 2/ 42 (4.8	2/ 42 (4.8) 0/ 46 0/ 8 2/ 42 (4.8) 0/ 46	0.459 1.000 0.378 1.000 0.501 0.225 1.000
LDL CHOLESTEROL mmol/L	0.525	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg	1/ 28 (3.6 1/ 28 (3.6 1/ 28 (3.6 1/ 28 (3.6 1/ 32 (3.1	0/42) 0/44) 0/8	1.000 0.400 0.389 1.000 0.432

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 70

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Follow-up

Category Test+Units	Overall P-Value *	Trea Comparator 1	tment Comparator 2	Comparator 1	comparator 2	Pairwise P-Value *
LDL CHOLESTEROL mmol/L	0.525	DVS SR 100 mg	DVS SR 200 mg Placebo	1/ 32 (3.1) 1/ 32 (3.1)	0 / 4 4 0 / 8	0.421
INCREASE	0.525	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/ 28 (3.6) 1/ 28 (3.6) 1/ 28 (3.6) 1/ 28 (3.6)	1/ 32 (3.1) 0/ 42 0/ 44 0/ 8	1.000 0.400 0.389 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/ 28 (3.6) 1/ 32 (3.1) 1/ 32 (3.1) 1/ 32 (3.1)	0/ 8 0/ 42 0/ 44 0/ 8	0.432 0.421 1.000
TRIGLYCERIDES /LIPID mmol/L	0.160	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/ 28 (3.6) 1/ 28 (3.6) 1/ 28 (3.6) 1/ 28 (3.6)	4/ 33 (12.1) 0/ 43 3/ 47 (6.4) 0/ 9	0.363 0.394 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	4/ 33 (12.1) 4/ 33 (12.1) 4/ 33 (12.1)	0/ 43 3/ 47 0/ 9	0.032* 0.439 0.561
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo	0/ 43 3/ 47 (6.4)	3/ 47 (6.4) 0/ 9	0.243 1.000
HIGH	0.160	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/ 28 (3.6) 1/ 28 (3.6) 1/ 28 (3.6) 1/ 28 (3.6)	4/ 33 (12.1) 0/ 43 3/ 47 (6.4) 0/ 9	0.363 0.394 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	4/ 33 (12.1) 4/ 33 (12.1) 4/ 33 (12.1)	0/ 43 3/ 47 0/ 9 (6.4)	0.032* 0.439 0.561
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo	0/ 43 3/ 47 (6.4)	3/ 47 (6.4) 0/ 9	0.243 1.000
URINALYSIS	0.674	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/ 23 (4.3) 1/ 23 (4.3) 1/ 23 (4.3) 1/ 23 (4.3)	3/ 31 (9.7) 1/ 40 (2.5) 3/ 38 (7.9) 0/ 5	0.628 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	3/ 31 (9.7) 3/ 31 (9.7)	1/ 40 (2.5) 3/ 38 (7.9)	0.311

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 71

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Follow-up

Category Test+Units	Overall P-Value *		tment Comparator 2	Comparato		cio Comparator 2	Pairwise P-Value *
URINALYSIS	0.674	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo DVS SR 200 mg Placebo Placebo	3/ 31 1/ 40 1/ 40 3/ 38	(9.7) (2.5) (2.5) (7.9)	0/ 5 3/ 38 (7.9) 0/ 5 0/ 5	1.000 0.352 1.000 1.000
URINE PROTEIN ALBUMIN	0.259	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/ 23 0/ 31 0/ 40 2/ 38	(5.3)	2/ 38 (5.3) 2/ 38 (5.3) 2/ 38 (5.3) 0/ 5	
POSITIVE	0.259	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/ 23 0/ 31 0/ 40 2/ 38	(5.3)	2/ 38 (5.3) 2/ 38 (5.3) 2/ 38 (5.3) 0/ 5	0.498
URINE ACETONE /KETONES	0.655	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 23 0/ 31 1/ 40 1/ 40	(2.5) (2.5)	1/ 40 (2.5) 1/ 40 (2.5) 0/ 38 0/ 5	
POSITIVE	0.655	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 23 0/ 31 1/ 40 1/ 40	(2.5) (2.5)	1/ 40 (2.5) 1/ 40 (2.5) 0/ 38 0/ 5	1.000 1.000 1.000 1.000
URINE HEMOGLOBIN BLOOD	0.378	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/ 23 1/ 23 1/ 23 1/ 23	(4.3) (4.3) (4.3) (4.3)	3/ 31 (9.7) 0/ 40 2/ 38 (5.3) 0/ 5	0.365 1.000 1.000
		DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	3/ 31 3/ 31 3/ 31 0/ 40 2/ 38	(9.7) (9.7) (9.7) (5.3)	0/ 40 2/ 38 (5.3) 0/ 5 2/ 38 (5.3) 0/ 5	1.000
POSITIVE	0.378	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg	1/ 23 1/ 23	(4.3) (4.3)	3/ 31 (9.7) 0/ 40	0.628 0.365

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 72

190CT05 13:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB5 NUMBER (%) OF SUBJECTS WITH LAB TEST RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Follow-up

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Comparato		cio Comparato		Pairwise P-Value *
POSITIVE	0.378	DVS SR 50 mg	DVS SR 200 mg Placebo	1/ 23 1/ 23	(4.3) (4.3)	2/ 38 0/ 5	(5.3)	1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	3/ 31 3/ 31	(9.7) (9.7)	0/ 40 2/ 38	(5.3)	0.079 0.651
		DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	3/ 31 0/ 40 2/ 38	(9.7) (5.3)	0/ 5 2/ 38 0/ 5	(5.3)	1.000 0.234 1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

ST 10-10: Descriptive Statistics and Analysis Within and Between Treatment Groups for Laboratory Tests

Page

1

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TES	ST: SODIUM	(mmol/L)	/ PART 1:	WITHIN	TREATMENT			
TREATMENT		OBSERVE	ID	BASELIN	IF.	CHANGE		ADJUSTED	[2]
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 50 mg	148			142.0	2.1				
Screening/baseline	148	142.0	2.1	142.0	2.1				
Week 4	141	140.5	2.6	142.0	2.1	-1.6***	2.8	-1.7***	0.2
Week 8	11	141.7	1.8	142.1	1.4	-0.4	2.2	-0.2	0.7
Week 12	118	141.7	2.1	142.0	2.1	-0.3	2.4 2.4 2.7	-0.4*	0.2
Week 26	100	142.3	2.2	142.0	2.0	0.3	2.4	0.2	0.2
Week 39	93	141.1	2.4	142.0	2.0	-0.9**	2.7	-1.1***	0.2
Week 52	84	141.7	2.0	142.1	1.9	-0.4	2.4	-0.5*	0.2
Final on-therapy	142	141.5	2.3 2.6	142.0	2.1	-0.5*	2.6	-0.7***	0.2
Follow-up	28	141.5	2.6	141.5	2.1	0.0	2.7	-0.4	0.4
DVS SR 100 mg	155			142.3	2.1				
Screening/baseline	155	142.3	2.1	142.3	2.1				
Week 4	139	140.3	2.4	142.3	2.1	-2.0***	2.9	-2.0***	0.2
Week 8	8	141.1	1.6	141.3 142.3 142.3	1.8	-0.1	2.0	-0.3	0.8
Week 12	119	141.8	2.2	142.3	2.1	-0.5*	2.7	-0.5*	0.2
Week 26	112	141.9	2.1	142.3	2.1 2.1 2.1	-0.3	2.6	-0.3	0.2
Week 39	94	141.0	2.4	142.5	2.1	-1.5***	2.6 2.7 2.4	-1.4***	0.2
Week 52	85	141.9	1.9 2.2 2.1	142.4	2.0	-0.5*	2.4	-0.4	0.2
Final on-therapy	140	141.5	2.2	142.3	2.0	-0.8**	2.9	-0.8***	0.2
Follow-up	33	141.7	2.1	141.8	2.5	-0.1	2.8	-0.4	0.4
DVS SR 150 mg	157			142.3	2.0				
Screening/baseline	157	142.3	2.0 2.1	142.3	2.0		0 5		
Week 4	132	140.6	2.1	142.3	2.0	-1.6***	2.5	-1.6***	0.2
Week 8	7	141.3	2.7	141.9	2.0	-0.6	2.4	-0.5	0.9
Week 12	103	141.5	2.2	142.3	2.2	-0.9**	2.6	-0.8***	0.2
Week 26	91	142.1	2.2	142.3	2.2	-0.2	2.7	-0.2	0.2
Week 39	83	141.0	2.4	142.3	2.3	-1.3***	2.7 2.7 2.4	-1.3***	0.2
Week 52	70	142.1	2.4	142.3	2.3	-0.2	2.4	-0.2 -0.6***	0.2
Final on-therapy	132	141.6	2.3	142.3	2.0	-0.7**	2.5		0.2
Follow-up	42	142.0	∠.⊥	142.8	1.9	-0.9*	2.3	-0.5	0.4
OVS SR 200 mg	151 151	1.40 4	2 1	142.4 142.4	2.1				
Screening/baseline Week 4	124	142.4 140.7	2.1 2.5	142.4	2.1 2.1	-1.8***	2.6	-1.7***	0.2
week 4	124	140./	2.5	142.5	∠.1	-1.0^^^	2.0	-1./^^^	0.2

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.
STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

2

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TES	T: SODIUM	(mmol/L)	/ PART 1:	WITHIN	TREATMENT			
TREATMENT		OBSERVE	D	BASELIN	E	CHANGE		ADJUSTED	[2]
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 200 mg (cont.)									
Week 8	4	140.3	3.7	142.3	1.3	-2.0	3.6	-1.8	1.1
Week 12	96	141.6	2.3	142.4	2.1	-0.8**	2.7	-0.7***	0.2
Week 26	83	142.3	2.2	142.3	2.2	0.0	2.6	0.1	0.2
Week 39	70	141.1	2.3	142.4	2.2	-1.3***	2.8 2.4	-1.2***	0.3
Week 52	63	141.6	2.4	142.2	2.1	-0.6	2.4	-0.6*	0.3
Final on-therapy	124	141.6	2.4	142.5	2.1	-0.8***	2.6	-0.7***	0.2
Follow-up	46	141.4	2.5	142.4	2.3	-1.0*	2.8	-0.8*	0.3
Placebo	77			142.2	1.9				
Screening/baseline	77	142.2	1.9	142.2	1.9				
Week 4	76	140.7	2.2	142.2	1.9	-1.5***	2.1	-1.5***	0.3
Week 8	6	141.2	3.4	141.2	2.1	0.0	1.9	-0.2	0.9
Week 12	66	141.8	2.0	142.2	1.8	-0.4	2.0	-0.4	0.3
Week 26	59	142.1	2.4	142.2	1.9	-0.1	2.3	-0.1	0.3
Week 39	50	141.5	2.0	142.1	1.9	-0.6	2.1	-0.7*	0.3
Week 52	47	141.7	2.2	142.0	1.9	-0.3	2.7	-0.5	0.3
Final on-therapy	77	141.6	2.2	142.2	1.9	-0.5	2.5	-0.6*	0.3
Follow-up	8	141.4	2.9	142.1	2.1	-0.8	3.4	-0.8	0.8

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.
STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.
STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

3

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST: SO	DIUM (mmol/L) / PA	ART 2: BETWEEN	TREATMENTS			
Data Analysis Interval [1]	OVERALL P-VALUE				STDERR OF DIFF. BET. ADJ. MEANS		
Week 4	0.643	DVS SR 50 mg I DVS SR 50 mg I DVS SR 50 mg I DVS SR 50 mg I DVS SR 100 mg I DVS SR 100 mg I DVS SR 100 mg I DVS SR 150 mg I DVS SR 150 mg I DVS SR 150 mg I DVS SR 150 mg I	DVS SR 200 mg Placebo DVS SR 150 mg Placebo Placebo DVS SR 200 mg	-0.1 -0.1 -0.2 -0.3 -0.5	0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3	0.379 0.728 0.846 0.511 0.226 0.296 0.164 0.885 0.721 0.633	
Week 8	0.807	DVS SR 50 mg I DVS SR 100 mg I DVS SR 100 mg I DVS SR 150 mg I DVS SR 200 mg I	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg	0.3 1.6 -0.0 0.2 1.5	1.1 1.3 1.2 1.2	0.946 0.791 0.245 0.986 0.854 0.296 0.940 0.377 0.807	
Week 12	0.652	DVS SR 50 mg I DVS SR 50 mg I	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg PVS SR 200 mg DVS SR 200 mg DVS SR 200 mg	0.0 0.3 0.3 -0.0 0.3 0.2 -0.1	0.3 0.3 0.3 0.3 0.3 0.3	0.868 0.234 0.325 0.980 0.300 0.406 0.868 0.858 0.296 0.383	
Week 26	0.517	DVS SR 50 mg I	DVS SR 100 mg	0.5	0.3	0.105	

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES. ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.

COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY).

STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

4

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

 	TEST: SOE	OIUM (mmol/L) /	PART 2: BETWEEN	TREATMENTS			
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1		DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE	
Week 26 (cont.)	0.517	DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 200 mg	-0.4 -0.2 -0.2 -0.1	0.3	0.263 0.749 0.406 0.665 0.224 0.587 0.449 0.876 0.602	
Week 39	0.599	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	0.2 0.1 -0.3 -0.1 -0.6 -0.1 -0.5	0.3 0.4 0.4 0.3 0.4 0.4 0.4	0.406 0.601 0.724 0.385 0.776 0.676 0.118 0.887 0.197 0.261	
Week 52	0.816	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg	-0.3 0.1 -0.0 -0.2 0.2 0.1 0.4	0.3 0.3 0.4 0.3 0.3 0.4	0.841 0.367 0.718 0.980 0.476 0.584 0.884 0.235 0.453 0.737	
Final on-therapy	0.988		DVS SR 100 mg DVS SR 150 mg	0.1	0.3 0.3	0.789 0.891	

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES. ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.

COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY).

STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

5

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST: SOI	TEST: SODIUM (mmol/L) / PART 2: BETWEEN TREATMENTS								
Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE				
Final on-therapy (cont.)	0.988	DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 200 mg	-0.0 -0.1 -0.1 -0.1 -0.2 0.0 -0.1	0.3 0.3 0.3 0.3 0.3 0.3 0.3	0.966 0.754 0.689 0.763 0.591 0.928 0.847 0.788				
Follow-up	0.882		DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-0.1 0.0 0.4 0.1 0.5 0.4 0.4 0.3	0.6 0.5 0.9 0.5 0.5 0.9	0.928 0.955 0.454 0.685 0.874 0.373 0.637 0.435 0.700 0.962				

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES. ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.

COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY).

STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

6

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST:	TEST: POTASSIUM (mmol/L) / PART 1: WITHIN TREATMENT								
FREATMENT		OBSERVI	ED	BASELIN	ΙE	CHANGE		ADJUSTED	[2]	
Data Analysis Interval [1]	[N] -	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR	
DVS SR 50 mg	148			4.55	0.44					
Screening/baseline	148	4.55	0.44	4.55	0.44					
Week 4	138	4.44	0.44	4.54	0.38 0.38	-0.10**	0.43	-0.07*	0.03	
Week 8	11	4.30	0.42	4.41	0.38	-0.11	0.40	-0.14	0.08	
Week 12	118	4.53	0.41	4.54	0.40	-0.01	0.41	0.02	0.03	
Week 26	99	4.50	0.40	4.51	0.40	-0.01	0.44	0.01	0.04	
Week 39	92	4.45	0.38	4.52	0.41	-0.07	0.47	-0.04	0.04	
Week 52	84	4.53	0.44	4.55	0.41	-0.02	0.49	0.02	0.04	
Final on-therapy	142	4.54	0.48	4.54	0.39	0.00	0.49	0.03	0.03	
Follow-up	29	4.43	0.52	4.60	0.59	-0.17	0.55	-0.09	0.08	
OVS SR 100 mg	154 154	4.48	0 41	4.48	0.41					
Screening/baseline Week 4	138	4.48	0.41	4.48 4.47	0.41	-0.11**	0.41	-0.12***	0.03	
Week 4 Week 8	138	4.36	0.37 0.19	4.47	0.41	-0.11^^	0.41	-0.12	0.03	
Week 12	116	4.45	0.39	4.50	0.42	-0.05	0.38	-0.04	0.03	
Week 26	112	4.45	0.41	4.50	0.42	-0.05	0.45	-0.04	0.04	
Week 39	94	4.40	0.38	4.48	0.43	-0.07	0.45	-0.08*	0.04	
Week 52	85	4.46	0.44	4.50	0.44	-0.04	0.49	-0.04	0.04	
Final on-therapy	140	4.44	0.41	4.48	0.41	-0.04	0.42	-0.04	0.03	
Follow-up	32	4.48	0.38	4.44	0.35	0.04	0.39	0.01	0.07	
DVS SR 150 mg	157			4.50	0.42					
Screening/baseline	157	4.50	0.42	4.50	0.42					
Week 4	130	4.43	0.42	4.48	0.39	-0.05	0.42	-0.05	0.03	
Week 8	7	4.37	0.31	4.49	0.38	-0.11	0.34	-0.10	0.10	
Week 12	103	4.46	0.42	4.47	0.40	-0.01	0.39	-0.02	0.04	
Week 26	90	4.41	0.39	4.49	0.41	-0.07	0.44	-0.07	0.04	
Week 39	83	4.38	0.38	4.49	0.41	-0.10*	0.42	-0.10*	0.04	
Week 52	70	4.49	0.34	4.49	0.42	0.00	0.40	0.00	0.05	
Final on-therapy Follow-up	131 42	4.48 4.46	0.36 0.40	4.48 4.52	0.39	0.00 -0.05	0.43 0.58	-0.00 -0.03	0.03	
DVS SR 200 mg	151	4.40	0.40	4.46	0.45	-0.03	0.30	-0.03	0.00	
Screening/baseline	151	4.46	0.45	4.46	0.45					
Week 4	121	4.42	0.43	4.46	0.43	-0.04	0.42	-0.05	0.03	
WCCh I	141	7.74	0.55	7.70	0.45	0.03	0.72	0.00	0.05	

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.
THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

7

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST:	POTASSIUM	(mmol/L)	/ PART 1	l: WITHIN	TREATMENT			
TREATMENT		OBSERVE		BASELI		CHANGE		ADJUSTE	
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 200 mg (cont.)									
Week 8	4	4.05	0.26	4.18	0.54	-0.13	0.41	-0.29*	0.14
Week 12	95	4.53	0.43	4.47	0.42	0.06	0.52	0.05	0.04
Week 26	83	4.50	0.44	4.46	0.43	0.05	0.53	0.03	0.04
Week 39	70	4.45	0.40	4.47	0.45	-0.02	0.52	-0.03	0.04
Week 52	63	4.44	0.43	4.44	0.44	0.00	0.50	-0.03	0.05
Final on-therapy	124	4.45	0.42	4.47	0.43	-0.02	0.51	-0.03	0.03
Follow-up	46	4.43	0.43	4.47	0.50	-0.04	0.54	-0.05	0.06
Placebo	76			4.40	0.39				
Screening/baseline	76	4.40	0.39	4.40	0.39				
Week 4	75	4.45	0.38	4.41	0.40	0.04	0.37	0.01	0.04
Week 8	6	4.45	0.15	4.42	0.33	0.03	0.23	0.01	0.11
Week 12	65	4.47	0.43	4.41	0.41	0.06	0.38	0.02	0.05
Week 26	58	4.44	0.41	4.42	0.41	0.02	0.39	-0.02	0.05
Week 39	49	4.37	0.33	4.41	0.42	-0.04	0.38	-0.09	0.05
Week 52	46	4.40	0.42	4.42	0.43	-0.02	0.36	-0.06	0.06
Final on-therapy	76	4.40	0.38	4.40	0.39	0.00	0.39	-0.05	0.04
Follow-up	8	4.23	0.31	4.24	0.15	-0.01	0.38	-0.19	0.14

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.
STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.
STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

8

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

,	TEST: POTA	SSIUM (mmol/L) /	PART 2: BETWEE	N TREATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1	COMPARED Comparator 2	DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 4	0.184	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0.05 -0.02 -0.01 -0.07 -0.07 -0.06 -0.12 0.01 -0.05 -0.06	0.04 0.04 0.04 0.05 0.04 0.04 0.05 0.04	0.250 0.638 0.768 0.159 0.109 0.159 0.018* 0.870 0.316 0.259
Week 8	0.514	DVS SR 50 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-0.07 -0.04 0.15 -0.15 0.03 0.22 -0.08 0.19 -0.11 -0.30	0.12 0.13 0.16 0.13 0.17 0.17 0.14 0.17 0.15 0.17	0.589 0.753 0.327 0.277 0.847 0.196 0.571 0.255 0.470 0.088
Week 12	0.340	DVS SR 50 mg DVS SR 50 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0.06 0.04 -0.03 -0.00 -0.02 -0.10 -0.07 -0.07 -0.04 0.03	0.05 0.05 0.05 0.06 0.05 0.05 0.06 0.05	0.180 0.424 0.513 0.969 0.619 0.055 0.243 0.163 0.472 0.601
Week 26	0.418	DVS SR 50 mg	DVS SR 100 mg	0.05	0.05	0.385

9

Page

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST: POTA	SSIUM (mmol/L) /	PART 2: BETWEE	N TREATMENTS			
Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE	
Week 26 (cont.)	0.418	DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	0.08 -0.03 0.02 0.03 -0.07 -0.02 -0.10 -0.05	0.06 0.06 0.06 0.05 0.05 0.06 0.06 0.06	0.164 0.651 0.690 0.558 0.197 0.740 0.076 0.417 0.436	
Week 39	0.711	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg	0.03 0.06 -0.01 0.04 0.02 -0.05 0.01 -0.07 -0.01 0.06	0.05 0.06 0.06 0.05 0.06 0.06 0.06	0.518 0.289 0.818 0.480 0.661 0.406 0.863 0.225 0.843 0.386	
Week 52	0.793	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg	0.02 0.05 0.08 -0.04 -0.01 0.02 0.03 0.06	0.06 0.06 0.07 0.06 0.06 0.07	0.342 0.762 0.474 0.273 0.547 0.873 0.762 0.684 0.422 0.672	
Final on-therapy	0.454		DVS SR 100 mg DVS SR 150 mg	0.07 0.04	0.05 0.05	0.111 0.439	

Page

10

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST: POTAS	SSIUM (mmol/L) /	PART 2: BETWEE	N TREATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED Comparator 2	DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	
Final on-therapy (cont.)	0.454	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	0.06 0.08 -0.04 -0.01 0.01 0.03 0.05 0.02	0.05 0.05 0.05 0.05 0.05 0.05 0.06	0.183 0.140 0.429 0.833 0.884 0.575 0.418 0.748
Follow-up	0.741	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	Placebo DVS SR 200 mg Placebo	-0.10 -0.06 -0.04 0.09 0.04 0.19 0.02 0.15	0.10 0.10 0.10 0.16 0.09 0.09 0.16 0.09 0.16	0.337 0.545 0.647 0.562 0.666 0.547 0.225 0.861 0.328 0.373

Page 11

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

	TEST	: CHLORIDE	(mmol/L) / PART 1	: WITHIN	TREATMENT			
TREATMENT		OBSERVED			E	CHANGE		ADJUSTED	[2]
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 50 mg	148			105.3	2.5				
Screening/baseline	148	105.3	2.5	105.3	2.5				
Week 4	141	104.7	2.8	105.3	2.5	-0.6**	2.6	-0.7***	0.2
Week 8	11	106.5	4.3	106.0	3.6	0.5	3.6	0.7	0.9
Week 12	118	105.0	2.9	105.4	2.6	-0.5	2.7	-0.5*	0.2
Week 26	100	105.5	2.7	105.5	2.5	-0.1	2.6	-0.0	0.2
Week 39	93	104.9	2.7	105.7	2.6	-0.8*	3.1	-0.7**	0.2
Week 52	84	105.2	2.5	105.9	2.4	-0.7**	2.5	-0.6*	0.2
Final on-therapy	142	105.0	2.6 2.7	105.3	2.5 2.5	-0.3	2.5	-0.4*	0.2
Follow-up	28	105.0	2.7	104.8	2.5	0.1	2.4	-0.1	0.4
DVS SR 100 mg	155			105.7	2.3				
Screening/baseline	155	105.7	2.3	105.7	2.3				
Week 4	139	104.2	2.8	105.7	2.3	-1.5***	2.9	-1.4***	0.2
Week 8	8	104.5	2.8	105.0	1.5	-0.5	2.4	-0.8	1.0
Week 12	119	104.9	2.5	105.8	2.3	-1.0***	2.4	-0.8***	0.2
Week 26	112	104.9	2.4	105.8	2.3	-0.9***	2.5	-0.8***	0.2
Week 39	94	104.4	2.6 2.3	105.8	2.4	-1.4***	2.9 2.7	-1.3***	0.2
Week 52	85	104.8	2.3	105.9	2.4	-1.1***		-1.0***	0.2
Final on-therapy	140	104.6	2.5	105.7	2.3	-1.2***	2.8	-1.0***	0.2
Follow-up	33	105.8	2.6	105.6	2.3	0.2	2.7	0.3	0.4
DVS SR 150 mg	157	405.0	0 5	105.2	2.5				
Screening/baseline	157	105.2	2.5	105.2	2.5	4 0	0 6		
Week 4	132	104.2	2.4	105.3	2.5	-1.0***	2.6	-1.1***	0.2
Week 8	100	104.6	2.9	106.3	2.1	-1.7	3.0	-1.4	1.1
Week 12 Week 26	103 91	104.5 105.1	2.5	105.2 105.2	2.5 2.5	-0.7** -0.0	2.3	-0.8*** -0.2	0.2
	83	103.1	2.5		2.5	-0.0	2.8	-0.2 -1.1***	0.2
Week 39 Week 52	83 70	104.3	2.7 2.5	105.3 105.2	2.6 2.7	-1.0^^	2.6	-0.6*	0.3
	132	104.7		105.2	2.7	-0.4	2.5	-0.6**	0.3
Final on-therapy Follow-up	42	104.7	2.5 2.5	105.3	2.5	-0.5^	2.5	-0.6	0.2
POIIOW-up DVS SR 200 mg	151	104.3	۷. ا	105.6	2.6	-0.4	۷. ر	-0.4	0.3
Screening/baseline	151	105.6	2.6	105.6	2.6				
Week 4	124	104.6	2.6	105.7	2.5	-1.2***	2.3	-1.0***	0.2
WCCK 1	147	104.0	2.0	100.7	۷. ۷	⊥•∠	۷. ۷	1.0	0.2

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.
THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 12

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

	TEST	: CHLORIDE	(mmol/L) / PART 1	: WITHIN	TREATMENT			
TREATMENT		OBSERVE	D	BASELIN	ſΕ	CHANGE		ADJUSTED	[2]
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 200 mg (cont.)									
Week 8	4	101.3	1.7	103.8	2.6	-2.5	3.3	-3.4*	1.5
Week 12	96	104.7	2.5	105.7	2.6	-1.1***	2.2	-1.0***	0.2
Week 26	83	105.1	2.5	105.8	2.7	-0.7**	2.0	-0.6*	0.2
Week 39	70	104.5	2.4	105.9	2.7	-1.4***	2.4	-1.2***	0.3
Week 52	63	104.9	3.1	105.9	2.7	-1.0**	2.6	-0.8**	0.3
Final on-therapy	124	104.8	2.7	105.7	2.5	-1.0***	2.5	-0.8***	0.2
Follow-up	46	104.7	2.7	105.4	2.5	-0.7	2.6	-0.7*	0.3
Placebo	77			105.2	2.4				
Screening/baseline	77	105.2	2.4	105.2	2.4				
Week 4	76	104.8	2.2	105.2	2.4	-0.4	2.5	-0.5*	0.3
Week 8	6	103.8	1.5	105.8	2.6	-2.0	2.9	-1.9	1.2
Week 12	66	105.0	2.6	105.1	2.3	-0.1	2.1	-0.3	0.3
Week 26	59	105.2	2.5	105.1	2.4	0.1	2.3	-0.1	0.3
Week 39	50	105.2	2.5	105.0	2.4	0.2	2.2	-0.2	0.3
Week 52	47	104.8	2.3	105.1	2.5	-0.3	2.8	-0.5	0.3
Final on-therapy	77	104.7	2.3	105.2	2.4	-0.5	2.7	-0.7*	0.3
Follow-up	8	104.6	2.4	105.1	2.4	-0.5	1.9	-0.6	0.8

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

13

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST: CHL	ORIDE (mmol/L) /	PART 2: BETWEE	N TREATMENTS			
Data Analysis Inte	rval [1] OVERALL		COMPARED Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE	
Week 4	0.048*	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	-0.1 -0.6	0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3	0.015* 0.139 0.278 0.571 0.354 0.199 0.009** 0.716 0.071 0.142	
Week 8	0.167	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Placebo	2.0 4.1 2.5 0.6 2.6 1.1 2.0 0.5	1.4 1.7 1.5 1.5 1.8 1.6	0.292 0.154 0.026* 0.091 0.700 0.151 0.488 0.284 0.753 0.428	
Week 12	0.213	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg	0.3 0.3 0.5 -0.2 -0.0 0.1 -0.5 -0.5	0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3	0.227 0.263 0.101 0.538 0.962 0.618 0.102 0.598 0.120 0.046*	
Week 26	0.078	DVS SR 50 mg	DVS SR 100 mg	0.7	0.3	0.013*	

Page

14

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST: CHL	ORIDE (mmol/L) /	PART 2: BETWEE	N TREATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1			STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 26 (cont.)	0.078	DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	0.1 0.5 0.1 -0.6 -0.2 -0.6 0.4 -0.1	0.3 0.3 0.4 0.3 0.3 0.3 0.3 0.4	0.642 0.092 0.802 0.053 0.531 0.063 0.229 0.875 0.220
Week 39	0.037*	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	0.4 0.5 -0.6 -0.2 -0.1 -1.2 0.1	0.4 0.4 0.4 0.4	0.082 0.242 0.188 0.166 0.607 0.770 0.005** 0.846 0.019* 0.015*
Week 52	0.732	DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg	0.4 0.0 0.3 -0.4 -0.1 -0.2 -0.1	0.3 0.4 0.4 0.4 0.4 0.4 0.4 0.4	0.251 0.915 0.474 0.952 0.326 0.731 0.304 0.5559 0.880 0.500
Final on-therapy	0.169		DVS SR 100 mg DVS SR 150 mg	0.7 0.3	0.3	0.014* 0.325

Page

15

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST: CHLO	DRIDE (mmol/L) /	PART 2: BETWEE	N TREATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1	COMPARED Comparator 2	DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Final on-therapy (cont.)	0.169	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	Placebo DVS SR 200 mg Placebo	0.4 0.3 -0.4 -0.2 -0.4 0.2 0.0	0.3 0.3 0.3 0.3 0.3 0.3 0.3	0.116 0.385 0.152 0.419 0.231 0.551 0.979 0.626
Follow-up	0.416	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo	0.6 0.5	0.6 0.5 0.9 0.5 0.5 0.9	0.525 0.562 0.281 0.579 0.190 0.065 0.328 0.581 0.834 0.922

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

Page 16

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST:	GLUCOSE	(mmol/L)	/ PART 1	: WITHIN	TREATMENT			
TREATMENT Data Analysis Interval [1]	[И] —	OBSERVE MEAN	EDSTD	BASELII	NESTD _	CHANGE	STD	ADJUSTED MEAN	[2] STDERR
DVS SR 50 mg Screening/baseline	2			6.41	1.45				
Screening/baseline	2	6.41	1.45	6.41	1.45				
DVS SR 150 mg	1			4.33					
Screening/baseline	1	4.33		4.33					

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

CONFIDENTIAL 961 Wyeth

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

 $^{[{\}tt N}]$ - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE. STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 17

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

	TEST: GLU	COSE, (FAS	STING) (m	mol/L) / 1	PART 1: W	ITHIN TREATN	MENT		
TREATMENT		OBSERVI	ED	BASELII	VE.	CHANGE	7.	ADJUSTEI	[2]
Data Analysis Interval	[1] [N] —	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERF
DVS SR 50 mg	147			5.20	0.63				
Screening/baseline	147	5.20	0.63	5.20	0.63				
Week 4	134	5.31	0.67	5.21 5.57	0.65	0.10	0.66	0.10*	0.04
Week 8	10	5.59	1.31	5.57	1.15	0.02	1.02	-0.03	0.21
Week 12	116	5.24 5.19	0.59	5.25 5.22 5.22 5.26	0.66	-0.02	0.66	-0.00	0.05
Week 26	99	5.19	0.55	5.22	0.71	-0.03	0.64	-0.02	0.05
Week 39	92 82	5.19 5.22	0.51	5.22	0.69	-0.03	0.57	-0.03	0.07
Week 52	120	5.22	0.99	5.26	0.71 0.64	-0.04 0.04	0.82 0.72	-0.03 0.04	0.07
Final on-therapy Follow-up	139 24	5.25 5.45	0.85 0.82	5.21 5.22	0.66	0.04	0.63	0.04	0.03
DVS SR 100 mg	155	3.43	0.02	5 26	0.54	0.23	0.05	0.25	0.10
Screening/baseline	155	5.26	0.54	5.26 5.26	0.54				
Week 4	138	5.25	0.56	5.27	0.53	-0.02	0.45	0.00	0.04
Week 8	8	5.25 5.54	0.50	5.27 5.65	0.84	-0.11	0.51	-0.14	0.24
Week 12	119	5.21 5.20	0.62	5.28 5.27	0.58	-0.07	0.52	-0.04	0.05
Week 26	108	5.20	0.64	5.27	0.59	-0.07	0.63	-0.05	0.05
Week 39	93	5.15	0.56	5.23 5.22	0.58	-0.08	0.63	-0.07	0.07
Week 52	84	5.17	0.63	5.22	0.57	-0.04	0.62	-0.04	0.07
Final on-therapy	139 29	5.25 5.55	0.62 0.94	5.28 5.34	0.55 0.58	-0.04 0.21	0.58 0.68	-0.01 0.24	0.05
Follow-up	29 157	3.33	0.94	5.34	0.58	0.21	0.68	0.24	0.14
DVS SR 150 mg Screening/baseline	157 157	5.13	0.58	5.13 5.13	0.58				
Week 4	132	5.26	0.66	5 18	0.59	0.08	0.56	0.07	0.04
Week 8	8	5.61	0.72	5.18 5.56	0.85	0.05	0.67	-0.01	0.24
Week 12	103	5.24	0.67	5.20	0.63	0.04	0.60	0.03	0.05
Week 26	91	5.37	0.79	5.17	0.62	0.20**	0.59	0.18**	0.06
Week 39	81	5.26	0.78	5.17	0.64	0.09	0.65	0.08	0.07
Week 52	69	5.25	0.59	5.18	0.63	0.07	0.54	0.06	0.08
Final on-therapy	132	5.24	0.64	5.18	0.59	0.06	0.61	0.06	0.05
Follow-up	39	5.27	0.66	5.03	0.61 0.61	0.24*	0.73	0.22	0.12
DVS SR 200 mg Screening/baseline	151 151	5.19	0.61	5.19 5.19	0.61				
Week 4	119	5.22	0.61	5.18	0.61	0.04	0.50	0.03	0.05
WCCh 1	117	0.22	0.01	0.10	0.01	0.01	0.00	0.00	0.00

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.
THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 18

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

	TEST:	GLUCOS	SE, (FAS	STING) (m	nol/L) / F	ART 1: W	ITHIN TREATM	ENT		
TREATMENT			OBSERVE	ED	BASELIN	ΙE	CHANGE		ADJUSTE	D [2]
Data Analysis Interval	[1] [[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 200 mg (cont.)										
Week 8		3	6.46	0.78	6.99	1.50	-0.54	0.74	-0.07	0.42
Week 12		96	5.17	0.50	5.19	0.62	-0.03	0.47	-0.04	0.05
Week 26		83	5.23	0.61	5.20	0.62	0.03	0.52	0.02	0.06
Week 39		70	5.24	1.29	5.23	0.66	0.01	0.88	0.01	0.08
Week 52		62	5.25	0.99	5.23	0.70	0.02	0.60	0.02	0.08
Final on-therapy	1	.20	5.25	0.79	5.18	0.61	0.07	0.53	0.06	0.05
Follow-up		42	5.38	1.14	5.27	0.74	0.11	0.86	0.12	0.11
Placebo		77			5.15	0.50				
Screening/baseline		77	5.15	0.50	5.15	0.50				
Week 4		72	5.23	0.62	5.16	0.50	0.07	0.48	0.06	0.06
Week 8		5	5.63	0.47	5.58	0.14	0.04	0.40	-0.00	0.30
Week 12		65	5.22	0.70	5.14	0.50	0.09	0.55	0.05	0.06
Week 26		58	5.13	0.64	5.15	0.49	-0.02	0.51	-0.04	0.07
Week 39		49	5.18	0.93	5.17	0.51	0.01	0.66	0.00	0.09
Week 52		46	5.20	0.66	5.19	0.53	0.01	0.45	0.00	0.09
Final on-therapy		77	5.21	0.61	5.15	0.50	0.06	0.45	0.04	0.07
Follow-up		7	5.28	0.72	5.06	0.54	0.22	0.65	0.20	0.28

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

19

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST:	GLUCOSE,	(FASTING) (mmol/L) / PART 2: BETWEEN TREATMENTS								
Data Analysis Interval	[1]	OVERALL P-VALUE	TREATMENTS Comparator 1			STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE				
Week 4		0.528	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0.10 0.03 0.07 0.05 -0.07 -0.02 -0.05 0.04 0.02	0.06 0.06 0.06 0.07 0.06 0.06 0.07 0.06	0.100 0.606 0.235 0.510 0.263 0.690 0.477 0.494 0.822 0.720				
Week 8		0.995	DVS SR 50 mg DVS SR 50 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0.10 -0.03 0.03 -0.03 -0.13 -0.07 -0.13 0.06 -0.00	0.32 0.32 0.48 0.37 0.33 0.48 0.38 0.49 0.38	0.746 0.937 0.945 0.939 0.702 0.886 0.731 0.905 0.994				
Week 12		0.640	DVS SR 50 mg DVS SR 50 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0.04 -0.03 0.04 -0.05 -0.08 -0.01 -0.10 0.07 -0.02 -0.09	0.07 0.07 0.07 0.08 0.07 0.07 0.08 0.07 0.08	0.522 0.611 0.604 0.494 0.258 0.930 0.220 0.322 0.813 0.269				
Week 26		0.020*	DVS SR 50 mg	DVS SR 100 mg	0.02	0.07	0.781				

Page

20

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST:	GLUCOSE,	(FASTING) (mmol	/L) / PART 2: B	BETWEEN TREAT	MENTS	
Data Analysis Interval	[1]	OVERALL P-VALUE	TREATMENTS Comparator 1			STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 26 (cont.)		0.020*	DVS SR 50 mg DVS SR 100 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-0.21 -0.05 0.02 -0.23 -0.07 -0.00 0.16 0.23 0.07	0.08 0.08 0.09 0.08 0.08 0.09 0.09	0.007** 0.538 0.826 0.003** 0.372 0.988 0.049* 0.011* 0.455
Week 39		0.615	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0.05 -0.11 -0.04 -0.03 -0.16 -0.09 -0.08 0.07 0.08	0.10 0.10 0.11 0.12 0.10 0.10 0.12 0.11 0.12 0.12	0.640 0.263 0.694 0.797 0.116 0.407 0.518 0.507 0.489 0.927
Week 52		0.850	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0.01 -0.09 -0.06 -0.03 -0.10 -0.07 -0.05 0.04 0.06 0.02	0.10 0.10 0.11 0.12 0.10 0.10 0.11 0.11	0.900 0.366 0.595 0.768 0.304 0.515 0.687 0.739 0.624 0.857
Final on-therapy		0.838	DVS SR 50 mg DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg	0.05 -0.02	0.07 0.07	0.457 0.792

Page

21

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

TEST:	GLUCOSE,	(FASTING) (mmol	/L) / PART 2: B	ETWEEN TREAT	MENTS	
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1	COMPARED Comparator 2	DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Final on-therapy (cont.)	0.838	DVS SR 100 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo Placebo Placebo	-0.02 -0.01 -0.07 -0.07 -0.06 -0.00 0.01	0.07 0.08 0.07 0.07 0.08 0.07 0.08 0.08	0.747 0.924 0.319 0.300 0.470 0.949 0.897 0.855
Follow-up	0.963	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	-0.00 0.02 0.11 0.04 0.02 0.11 0.04 0.09 0.02	0.20 0.19 0.19 0.32 0.18 0.18 0.31 0.17 0.30	0.993 0.923 0.553 0.911 0.911 0.523 0.904 0.573 0.955 0.800

Page 22

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

	T	EST: BUN	(mg/dL) /	PART 1: V	WITHIN TR	EATMENT				
TREATMENT		OBSERV	ED	BASELIN	NE	CHANG	E	ADJUSTE	D [2]	
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR	
DVS SR 50 mg	148			15.08	3.86					
Screening/baseline	148	15.08	3.86	15.08	3.86					
Week 4	141	15.13	3.73	15.22	3.86	-0.09	3.71	-0.16	0.27	
Week 8	11	14.91	3.18	16.18	2.75	-1.27	2.87	-1.24	1.17	
Week 12	118	15.67	3.94	15.17 15.39	4.03	0.50	3.71	0.40	0.31	
Week 26	100	15.31	3.80	15.39	3.93	-0.08	3.83	-0.14	0.35	
Week 39 Week 52	93 84	15.31 15.27	3.65 3.60	15.53 15.76	3.93 3.98	-0.22 -0.49	3.91 3.80	-0.22 -0.42	0.36 0.38	
Final on-therapy		15.14	3.70	15.76	3.85	-0.49	3.65	-0.42	0.29	
Follow-up	142 28	14.71	4.21	15.50	4.32	-0.79	4.29	-0.16	0.29	
DVS SR 100 mg	155	11./1	4.21	15.66	4.42	0.75	4.23	0.75	0.70	
Screening/baseline	155	15.66	4.42	15.66	4.42					
Week 4	139	15.31	4.67	15.85	4.47	-0.54*	3.15	-0.40	0.28	
Week 8	8	16.00	4.34	15.25	2.76	0.75	4.20	0.45	1.38	
Week 12	119	15.55	4.44	15.96 16.03	4.54	-0.41	3.49	-0.22	0.31	
Week 26	112	15.65	4.78	16.03	4.61	-0.38	4.42	-0.19	0.34	
Week 39	94	15.62	4.25	15.74 15.88	3.97	-0.13	3.63	-0.02	0.36	
Week 52	85	15.94	4.48	15.88	4.05	0.06	3.98	0.18	0.38	
Final on-therapy	140	15.99	4.46	15.87	4.46	0.11	4.06	0.30	0.30	
Follow-up	33	14.64	4.29	14.76	4.34 4.17	-0.12	3.43	-0.35	0.65	
DVS SR 150 mg Screening/baseline	157 157	15.71	4.17	15.71 15.71	4.17					
Week 4	132	15.48	4.44	15.71	4.23	-0.42	3.85	-0.26	0.28	
Week 8	7	14.86	7.20	13.43	3.95	1.43	4.72	0.48	1.55	
Week 12	103	16.01	4.34	16.03	4.09	-0.02	3.74	0.19	0.33	
Week 26	91	15.71	4.63	16.03 15.85	4.09 3.93	-0.13	3.53	-0.02	0.37	
Week 39	83	15.17	3.82	15.78	3.97	-0.61	3.88	-0.49	0.38	
Week 52	70	16.04	4.26	15.89	3.82	0.16	4.15	0.28	0.42	
Final on-therapy	132	15.80	4.30	15.91	4.23	-0.11	4.21	0.09	0.31	
Follow-up	42	15.83	5.02	16.21	4.76	-0.38	4.45	-0.10	0.58	
DVS SR 200 mg	151 151	15 17	2 07	15.17 15.17	3.97 3.97					
Screening/baseline Week 4	124	15.17 15.00	3.97 4.28	15.17	4.18	-0.23	3.44	-0.29	0.29	
Week 4	124	13.00	4.∠8	13.23	4.10	-0.23	3.44	-0.29	0.29	

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 23

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

	Т	EST: BUN	(mg/dL) /	PART 1: V	VITHIN TR	EATMENT			
TREATMENT Data Analysis Interval [1]	[N] -	OBSERVI MEAN	_	BASELIN MEAN	IE	CHANGE MEAN	STD -	ADJUSTE MEAN	D [2] STDERR
DVS SR 200 mg (cont.) Week 8	4	16.00	3.56	20.75	3.40	-4.75*	2.50	-3.09	2.13
Week 12	96	15.51	4.54	15.28	4.47	0.23	3.48	0.17	0.34
Week 26	83	15.75	4.47	15.48	4.51	0.27	3.34	0.24	0.39
Week 39	70	15.16	4.37	15.56	4.41	-0.40	4.31	-0.39	0.42
Week 52	63	15.51	4.58	15.46	4.37	0.05	3.79	-0.01	0.44
Final on-therapy	124	15.47	4.55	15.23	4.18	0.24	3.87	0.16	0.31
Follow-up	46	16.00	5.18	15.41	4.54	0.59	4.07	0.59	0.55
Placebo Screening/baseline	77 77	14.48	3.79	14.48 14.48	3.79 3.79				
Week 4	76	14.96	4.11	14.54	3.78	0.42	3.40	0.13	0.37
Week 8	6	17.67	2.58	17.00	5.40	0.67	5.32	0.99	1.59
Week 12	66	15.58	4.03	14.29	3.49	1.29*	3.98	0.87*	0.41
Week 26	59	14.81	4.06	14.58	3.80	0.24	4.11	-0.13	0.46
Week 39	50	14.58	3.96	14.68	3.73	-0.10	4.63	-0.53	0.49
Week 52	47	14.38	3.88	14.60	3.72	-0.21	3.43	-0.64	0.51
Final on-therapy	77	14.79	4.10	14.48	3.79	0.31	3.69	-0.09	0.40
Follow-up	8	17.38	3.70	13.50	4.41	3.88***	1.96	3.21*	1.32

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

24

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST:	BUN (mg/dL) / PA	RT 2: BETWEEN T	REATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	
Week 4	0.843	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	0.24 0.10 0.13 -0.29 -0.14 -0.11 -0.53 0.03 -0.39 -0.42	0.39 0.39 0.40 0.46 0.40 0.40 0.47 0.47	0.540 0.793 0.742 0.535 0.732 0.790 0.259 0.945 0.405 0.377
Week 8	0.497	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg	-1.69 -1.72 1.85 -2.23 -0.03 3.54 -0.54 3.57 -0.51 -4.08	1.94 2.42 1.97 2.03 2.59 2.11 2.80 2.26	0.356 0.383 0.451 0.266 0.989 0.183 0.800 0.213 0.822 0.127
Week 12	0.294	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg	0.63 0.21 0.23 -0.42 -0.40 -1.10 0.02 -0.68 -0.70	0.43 0.45 0.46 0.51 0.45 0.46 0.52 0.47 0.53	0.149 0.642 0.615 0.360 0.352 0.387 0.034* 0.965 0.200 0.190
Week 26	0.933	DVS SR 50 mg	DVS SR 100 mg	0.05	0.49	0.914

Page

25

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST:	BUN (mg/dL) / PA	RT 2: BETWEEN I	REATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 26 (cont.)	0.933	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg	-0.38 -0.01 -0.17 -0.43 -0.06 -0.26	0.54	0.813 0.470 0.990 0.727 0.400 0.916 0.631 0.848 0.538
Week 39	0.885	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	0.37 0.51	0.52 0.55 0.61 0.52 0.55 0.61 0.66	0.699 0.606 0.758 0.612 0.372 0.505 0.407 0.858 0.950 0.828
Week 52	0.524	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg	0.19 0.82 0.29	0.54 0.56 0.58 0.64 0.56 0.58 0.64 0.61	0.266 0.217 0.483 0.733 0.859 0.744 0.201 0.633 0.166 0.353
Final on-therapy	0.827		DVS SR 100 mg DVS SR 150 mg			0.262 0.545

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST:	BUN (mg/dL) / PA	RT 2: BETWEEN T	REATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1	COMPARED Comparator 2	DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Final on-therapy (cont.)	0.827	DVS SR 100 mg DVS SR 100 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	-0.32 -0.08 0.21 0.15 0.39 -0.07 0.18 0.25	0.43 0.50 0.43 0.43 0.50 0.44 0.51	0.454 0.879 0.619 0.735 0.432 0.882 0.720 0.628
Follow-up	0.082	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	-0.41 -0.65 -1.34 -3.97 -0.25 -0.94 -3.56 -0.69 -3.31 -2.62	0.96 0.91 0.89 1.50 0.87 0.85 1.47 0.79 1.44	0.671 0.473 0.134 0.009** 0.777 0.272 0.016* 0.387 0.023* 0.068

Page 26

Page 27

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

	TEST:	CREATININE	Ξ (mcmol/)	L) / PART	1: WITHIR	N TREATMENT			
TREATMENT		OBSERVI	₹D	BASELI	VE	CHANG:	F.	ADJUSTEI	[2]
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERF
DVS SR 50 mg	148			77.3	11.4				
Screening/baseline	148	77.3	11.4	77.3	11.4				
Week 4	141	78.7	11.6	77.3	11.5	1.4	11.4	1.1	0.8
Week 8	11	79.6	9.7	78.0	17.6	1.6	15.2	1.4	2.8
Week 12 Week 26	118 100	77.5 79.4	11.6 11.3	77.0 77.8	11.4	0.5 1.6	11.3	0.2 1.5	0.8
Week 39	93	78.8	10.2	77.2	11.9 11.9	1.6	11.4 9.5	1.5	0.9
Week 59 Week 52	84	79.1	9.5	77.5	11.9	1.7	10.6	1.5	0.9
Final on-therapy	142	79.1	11.0	77.2	11.5	1.9*	11.1	1.6*	0.7
Follow-up	28	76.7	11.3	76.1	10.3	0.6	9.3	0.3	1.7
DVS SR 100 mg	155			79.6	11.7				
Screening/baseline	155	79.6	11.7	79.6	11.7				
Week 4	139	80.6	13.9	79.9	11.6 12.0	0.7	8.7	1.2	0.8
Week 8	8	78.5	10.0	80.7	12.0	-2.2	6.3	-1.4	3.3
Week 12	119	79.3	11.1	80.0 80.2	11.7	-0.7	9.0 7.8	0.1	0.8
Week 26	112	80.0	11.1	80.2	11.8	-0.2	7.8	0.1 0.6 2.6**	0.8
Week 39 Week 52	94 85	81.7 81.2	12.7 11.1	79.7 80.3	11.6 11.1	2.1* 0.9	8.4 9.6	∠.b^^ 1.9*	0.9
Final on-therapy	140	81.3	12.7	80.1	11.7	1 2	9.1	1.9*	0.3
Follow-up	33	79.6	14.0	78.2	12.3	1.2 1.3	9.4	1.6	1.6
DVS SR 150 mg	157	, , , ,	11.0	77.8	11.1		J		-• \
Screening/baseline	157	77.8	11.1	77.8	11.1				
Week 4	132	79.9	10.8	78.3	11.1	1.6 1.3	9.6	1.7*	0.8
Week 8	7	80.8	18.0	79.6	14.4	1.3	10.7	1.7	3.6
Week 12	103	78.9	11.7	77.5	10.9	1.4	9.6	1.2 1.7	0.9
Week 26	91	79.0	11.1	76.9	10.7	2.0*	8.9	1.7	0.9
Week 39	83 70	77.4	10.3 9.9	76.5	10.6	1.0	8.5 8.0	0.6 1.2	1.0
Week 52 Final on-therapy		78.2 79.6		76.4	10.8	1.8	0.0	1 2	1.0
Final On-therapy Follow-up	132 42	79.6	10.6 12.2	78.3 78.1	11.1 11.2	1.3 1.1	8.8 9.6	1.3 1.2	1.4
VS SR 200 mg	151	10.1	14.4	77 3	11 2	± • ±	J. 0	± • ∠	±•-
Screening/baseline	151	77.3	11.2	77.3 77.3	11.2 11.2				
Week 4	124	78.7	11.4	76.6	11.3	2.1*	9.3	1.6	0.8

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.
THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES. $[{\tt N}]$ - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 28

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

	TEST:	CREATININE	C (mcmol/1)	L) / PART	1: WITHIN	N TREATMENT			
TREATMENT Data Analysis Interval [1]	[N]	OBSERVE MEAN	D_STD —	BASELII MEAN	NE	CHANGE MEAN	STD -	ADJUSTE MEAN	D [2] STDERR
DVS SR 200 mg (cont.)									
Week 8	4	81.8	4.4	81.8	8.5	0.0	7.2	1.3	4.7
Week 12	96	77.0	11.0	75.7	11.4	1.3	9.8	0.5	0.9
Week 26	83	77.7	11.7	75.2	11.9	2.6*	9.7	1.6	1.0
Week 39	70	77.2	13.5	75.3	12.2	1.9	9.9	1.2	1.0
Week 52	63	76.3	11.4	75.1	12.0	1.3	9.8	0.1	1.1
Final on-therapy	124	77.9	10.8	76.6	11.3	1.3	9.3	0.7	0.8
Follow-up	46	78.4	12.0	77.6	11.8	0.8	9.3	0.8	1.3
Placebo	77			78.6	12.0				
Screening/baseline	77	78.6	12.0	78.6	12.0				
Week 4	76	78.0	13.8	78.5	12.1	-0.5	10.2	-0.3	1.1
Week 8	6	79.6	15.8	73.7	12.1	5.9	7.2	3.9	3.9
Week 12	66	79.3	13.0	79.3	12.4	-0.0	9.6	0.5	1.1
Week 26	59	81.2	14.1	80.2	12.6	1.0	10.0	1.8	$\bar{1}.\bar{1}$
Week 39	50	79.6	15.5	80.4	13.4	-0.9	10.5	-0.1	1.2
Week 52	47	80.9	14.2	80.7	13.5	0.2	9.8	1.3	1.2
Final on-therapy	77	79.3	12.6	78.6	12.0	0.7	9.6	0.9	1.0
Follow-up	. 8	80.7	8.8	74.0	9.4	6.6	12.3	5.7	3.2
10110W WD	0	00.7	0.0	, 1.0	2.1	0.0	12.5	J . /	J.2

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

29

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST: CREAT	TININE (mcmol/L)	/ PART 2: BETWE	EN TREATMENT	S	
Data Analys	is Interval [1] OVERALL P-VALUE		COMPARED Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 4	0.610	DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	-0.4 1.6 0.0 2.0	1.3 1.2 1.3	0.916 0.640 0.670 0.263 0.718 0.748 0.228 0.973 0.134 0.147
Week 8	0.895	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg	-0.3 0.1 -2.5 -3.0 -2.7 -5.3 0.4 -2.2	4.4 4.6 5.5 4.8 4.9 5.8 5.2 5.9 5.3 6.2	0.541 0.947 0.992 0.600 0.540 0.648 0.315 0.951 0.675
Week 12	0.904	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg	$ \begin{array}{c} -1.1 \\ -0.4 \\ -0.4 \\ 0.7 \\ 0.7 \end{array} $	1.4 1.3 1.4	0.934 0.397 0.820 0.823 0.354 0.761 0.768 0.5559 0.613 0.984
Week 26	0.871	DVS SR 50 mg	DVS SR 100 mg	0.9	1.2	0.435

Page

30

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

Т	EST: CREAT	ININE (mcmol/L)	/ PART 2: BETWE	EN TREATMENT	S	
Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 26 (cont.)	0.871	DVS SR 50 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	-0.1 -0.3 -1.1	1.3 1.4 1.2 1.3 1.4 1.5	0.899 0.946 0.859 0.374 0.421 0.395 0.957 0.948 0.911
Week 39	0.406	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	-1.1 0.8 0.2 1.6 2.0 1.4 2.7 -0.6	1.3 1.4 1.5 1.3 1.4 1.5	0.380 0.518 0.862 0.290 0.135 0.326 0.072 0.665 0.622 0.395
Week 52	0.811	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	0.3 1.4 0.2 0.7 1.7 0.6 1.0	1.4 1.5 1.4 1.5 1.5	0.779 0.810 0.336 0.884 0.613 0.225 0.701 0.484 0.948 0.490
Final on-therapy	0.831		DVS SR 100 mg DVS SR 150 mg		1.0	0.771 0.798

Page 31

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

Т	EST: CREAT	ININE (mcmol/L)	/ PART 2: BETWE	EN TREATMENT	'S	
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1		DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Final on-therapy (cont.)	0.831	DVS SR 100 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo Placebo Placebo	0.8 0.7 0.6 1.1 1.0 0.6 0.5 -0.1	1.1 1.2 1.1 1.1 1.2 1.1 1.3	0.434 0.556 0.588 0.290 0.405 0.602 0.715 0.929
Follow-up	0.664	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	-1.3 -1.0 -0.6 -5.4 0.7 -4.1 0.4 -4.5	2.3 2.2 2.2 3.6 2.1 2.1 3.6 1.9 3.5	0.581 0.663 0.797 0.137 0.878 0.725 0.249 0.834 0.204 0.163

Page 32

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

	TEST	: CALCIUM	(mmol/L)	/ PART 1	: WITHIN	TREATMENT			
TREATMENT		OBSERV		BASELI		CHANGE		ADJUSTED	
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 50 mg	146			2.419	0.100				
Screening/baseline	146	2.419	0.100	2.419	0.100				
Week 4 Week 8	136 11	2.386 2.345	0.100 0.072	2.420 2.400	0.101 0.072	-0.034*** -0.054	0.090 0.103	-0.029*** -0.060*	0.007 0.024
Week 12	116	2.379	0.111	2.418	0.103	-0.039***	0.088	-0.036***	0.007
Week 26	97	2.383	0.098	2.417	0.102	-0.034***	0.095	-0.032***	0.008
Week 39	90	2.391	0.101	2.423	0.104	-0.031**	0.093	-0.027**	0.009
Week 52	82	2.400	0.107	2.419	0.108	-0.019*	0.072	-0.017	0.009
Final on-therapy	140	2.397	0.103	2.420	0.100	-0.023**	0.084	-0.019**	0.007
Follow-up	28	2.377	0.126	2.419	0.098	-0.043	0.114	-0.041*	0.017
DVS SR 100 mg	153	2 412	0 000	2.413	0.086				
Screening/baseline	153	2.413	0.086	2.413	0.086	0 000++	0 000	-0.022***	0 007
Week 4 Week 8	138 8	2.390 2.367	0.095 0.075	2.413 2.417	0.088	-0.023** -0.050	0.096 0.065	-0.022***	0.007 0.028
Week 12	115	2.360	0.073	2.417	0.086	-0.053***	0.086	-0.047	0.028
Week 26	111	2.388	0.089	2.413	0.085	-0.026**	0.092	-0.025***	0.007
Week 39	93	2.387	0.088	2.413	0.089	-0.026*	0.095	-0.027**	0.008
Week 52	84	2.388	0.087	2.414	0.090	-0.025*	0.101	-0.026**	0.009
Final on-therapy	139	2.391	0.094	2.413	0.088	-0.022**	0.096	-0.021**	0.007
Follow-up	32	2.400	0.101	2.409	0.088	-0.009	0.099	-0.013	0.016
DVS SR 150 mg	156			2.412	0.101				
Screening/baseline	156	2.412	0.101	2.412	0.101				
Week 4	129	2.389	0.096	2.408	0.101	-0.019*	0.088	-0.020**	0.007
Week 8	7	2.388	0.107	2.409	0.110	-0.021	0.082	-0.022	0.030
Week 12	102	2.363	0.098	2.407	0.106	-0.045***	0.101	-0.046***	0.008
Week 26	89	2.377	0.098	2.410	0.113	-0.033**	0.092	-0.035***	0.008
Week 39	82	2.398	0.075	2.407	0.090	-0.009	0.088	-0.013	0.009
Week 52	69	2.374	0.090	2.408	0.096	-0.034*	0.107	-0.037***	0.010
Final on-therapy	130	2.388	0.098	2.407	0.101	-0.019*	0.101	-0.021**	0.007
Follow-up	41	2.407	0.098	2.419	0.096	-0.012	0.094	-0.010	0.014
DVS SR 200 mg Screening/baseline	150 150	2.408	0.083	2.408	0.083				
Week 4	120	2.408	0.083	2.408	0.083	-0.017*	0.083	-0.020**	0.007
MCCV 4	120	2.500	0.077	4.404	0.001	0.01/	0.003	0.020	0.007

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 33

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

	TEST	: CALCIUM	(mmol/L)	/ PART 1:	WITHIN	TREATMENT			
TREATMENT		OBSERVI	ED	BASELIN	IE	CHANGE		ADJUSTED	[2]
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 200 mg (cont.)									
Week 8	4	2.364	0.094	2.501	0.087	-0.137*	0.075	-0.091*	0.042
Week 12	94	2.363	0.076	2.406	0.089	-0.043***	0.097	-0.046***	0.008
Week 26	82	2.371	0.065	2.405	0.083	-0.033**	0.090	-0.038***	0.009
Week 39	70	2.401	0.094	2.408	0.086	-0.007	0.102	-0.011	0.010
Week 52	63	2.364	0.082	2.407	0.086	-0.043***	0.093	-0.047***	0.010
Final on-therapy	123	2.376	0.081	2.405	0.086	-0.029***	0.090	-0.032***	0.007
Follow-up	46	2.401	0.081	2.422	0.085	-0.021	0.108	-0.017	0.013
Placebo	76			2.404	0.083				
Screening/baseline	76	2.404	0.083	2.404	0.083				
Week 4	75	2.394	0.083	2.405	0.084	-0.011	0.081	-0.013	0.009
Week 8	6	2.362	0.097	2.366	0.073	-0.004	0.094	-0.027	0.033
Week 12	65	2.399	0.079	2.409	0.085	-0.010	0.084	-0.011	0.010
Week 26	58	2.416	0.089	2.416	0.086	0.000	0.101	0.002	0.010
Week 39	49	2.421	0.099	2.425	0.085	-0.004	0.106	0.002	0.012
Week 52	46	2.413	0.104	2.427	0.086	-0.015	0.096	-0.008	0.012
Final on-therapy	76	2.407	0.095	2.404	0.083	0.003	0.093	-0.000	0.009
Follow-up	8	2.361	0.053	2.367	0.065	-0.006	0.071	-0.033	0.032

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

34

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST: CAL	CIUM (mmol/L) / I	PART 2: BETWEEN	TREATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1	COMPARED Comparator 2	DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 4	0.685	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-0.007 -0.009 -0.016 -0.002 -0.002 -0.009 0.000 -0.007	0.009 0.010 0.010 0.011 0.009 0.010 0.011 0.010 0.011	0.450 0.343 0.355 0.151 0.836 0.843 0.421 0.995 0.535 0.537
Week 8	0.663	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-0.013 -0.038 0.031 -0.033 -0.025 0.044 -0.020 0.069 0.005 -0.064	0.037 0.038 0.049 0.040 0.041 0.050 0.043 0.052 0.044	0.718 0.324 0.531 0.416 0.548 0.383 0.651 0.191 0.913 0.259
Week 12	0.013*	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg	Placebo DVS SR 200 mg Placebo	0.016 0.011 0.010 -0.024 -0.006 -0.007 -0.041 -0.001 -0.035 -0.034	0.010 0.011 0.011 0.012 0.011 0.011 0.012 0.011 0.012 0.013	0.113 0.320 0.371 0.046* 0.589 0.544 <0.001*** 0.939 0.005** 0.007**
Week 26	0.030*	DVS SR 50 mg	DVS SR 100 mg	-0.006	0.011	0.551

Page

35

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST: CAL	CIUM (mmol/L) /	PART 2: BETWEEN	TREATMENTS	·	
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1			STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 26 (cont.)	0.030*	DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0.003 0.006 -0.034 0.009 0.012 -0.027 0.003 -0.037 -0.040	0.011 0.012 0.013 0.011 0.011 0.013 0.012 0.013	0.795 0.608 0.010** 0.395 0.272 0.032* 0.800 0.006** 0.003**
Week 39	0.211	DVS SR 50 mg DVS SR 50 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-0.000 -0.014 -0.016 -0.029 -0.013 -0.016 -0.029 -0.003 -0.015 -0.013	0.012 0.012 0.013 0.014 0.012 0.013 0.014 0.013 0.015 0.015	0.977 0.276 0.211 0.046* 0.284 0.217 0.048* 0.839 0.299 0.407
Week 52	0.082	DVS SR 50 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0.009 0.020 0.030 -0.008 0.011 0.021 -0.017 0.010 -0.029 -0.038	0.013 0.013 0.014 0.015 0.013 0.014 0.015 0.014 0.016	0.484 0.132 0.030* 0.573 0.397 0.124 0.247 0.494 0.067 0.016*
Final on-therapy	0.126	DVS SR 50 mg DVS SR 50 mg		0.002 0.002	0.010 0.010	0.846 0.827

Page

36

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST: CALC	CIUM (mmol/L) /	PART 2: BETWEEN	TREATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1		DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Final on-therapy (cont.)	0.126	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg	Placebo DVS SR 200 mg	0.013 -0.019 0.000 0.011 -0.021 0.011 -0.021 -0.032	0.010	0.193 0.108 0.978 0.266 0.077 0.285 0.077 0.008**
Follow-up	0.657	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	-0.028 -0.031 -0.023 -0.008 -0.003 0.005 0.020 0.008 0.023	0.023 0.022 0.022 0.036 0.021 0.021 0.036 0.019 0.035	0.232 0.161 0.280 0.831 0.882 0.826 0.573 0.689 0.506 0.654

Page 37

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

	TEST:	TEST: PHOSPHORUS (mmol/L) / PART 1: WITHIN TREATMENT									
TREATMENT	OBSERVED			BASELI	NE	CHANGE		ADJUSTED	[2]		
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERF		
DVS SR 50 mg	148			1.258	0.147						
Screening/baseline	148 148	1.258	0.147	1.258 1.258	0.147						
Week 4	141	1.214	0.160	1.252 1.259	0.144	-0.039***	0.131	-0.041**	0.013		
Week 8	11	1.239	0.118	1.259	0.106	-0.021	0.139	-0.023	0.034		
Week 12	118	1.226	0.148	1.244 1.250	0.146	-0.018	0.124	-0.023*	0.011		
Week 26	100	1.229	0.159	1.250	0.138	-0.020	0.143	-0.022	0.013		
Week 39	93	1.215	0.149	1.246	0.138	-0.031*	0.138	-0.035**	0.014		
Week 52	84	1.239 1.227	0.162	1.243	0.136	-0.004 -0.025*	0.147	-0.009 -0.027*	0.014		
Final on-therapy Follow-up	142 28	1.222	0.164 0.193	1.251 1.305	0.144 0.183	-0.025^	0.140 0.116	-0.027^	0.011		
DVS SR 100 mg	155	1.222	0.100	1 263	0.129	0.003	0.110	0.075	0.023		
DVS SR 100 mg Screening/baseline	155	1.263	0.129	1.263 1.263	0.129						
Week 4	139	1.207	0.146	1.258	0.124	-0.051***	0.143	-0.051***	0.013		
Week 8	8	1.207	0.154	1.258 1.243	0.147	-0.036	0.149	-0.048	0.040		
Week 12		1.225	0.144	1.261 1.263	0.119	-0.036**	0.149	-0.032**	0.011		
Week 26	119 112	1.229	0.152	1.263	0.120	-0.034*	0.140	-0.029*	0.012		
Week 39	94 85	1.230	0.147	1.266	0.122	-0.036*	0.153	-0.030*	0.013		
Week 52		1.243	0.136	1.265	0.123	-0.022	0.127	-0.015	0.014		
Final on-therapy	140 33	1.241	0.138	1.257	0.124	-0.017	0.137	-0.016	0.011		
Follow-up		1.270	0.140	1.271	0.158	-0.001	0.159	-0.006	0.027		
DVS SR 150 mg	157	1 070	0 1 2 0	1.269	0.139						
Screening/baseline Week 4	157 132	1.270 1.231	0.139 0.151	1.269 1.264	0.139 0.136	-0.033*	0.162	-0.030*	0.013		
Week 4 Week 8	132	1.251	0.131	1.264	0.136	-0.033^	0.162	-0.030^	0.013		
Week 12	103	1.242	0.144	1.262	0.140	-0.020	0.159	-0.016	0.012		
Week 26	91	1.210	0.151	1.257	0.134	-0.047**	0.162	-0.045**	0.014		
Week 39	83	1.215	0.145	1.262	0.138	-0.047**	0.155	-0.043**	0.014		
Week 52	70	1.240	0.137	1.263	0.147	-0.023	0.159	-0.017	0.015		
Final on-therapy	132 42	1.240	0.141	1.264 1.296	0.136	-0.023	0.156	-0.020	0.011		
Follow-up		1.266	0.155	1.296	0.138	-0.030	0.169	-0.024	0.024		
DVS SR 200 mg	151			1.254 1.254	0.168						
Screening/baseline	151	1.254	0.168	1.254	0.168						
Week 4	124	1.238	0.228	1.251	0.174	-0.013	0.224	-0.015	0.014		

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.
THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 38

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

DVS SR 200 mg (cont.) Week 8		TEST:	PHOSPHORU	JS (mmol/	L) / PART	1: WITH	IN TREATMENT			
DVS SR 200 mg (cont.) Week 8	TREATMENT		OBSERVI	ED	BASELI	NE	CHANGE		ADJUSTE	D [2]
Week 8 4 1.243 0.107 1.251 0.127 -0.008 0.107 -0.015 0.05 Week 12 96 1.225 0.126 1.244 0.159 -0.019 0.147 -0.025 0.01 Week 26 83 1.215 0.139 1.234 0.156 -0.018 0.161 -0.029 0.01 Week 39 70 1.204 0.148 1.230 0.158 -0.026 0.146 -0.038* 0.01 Week 52 63 1.211 0.144 1.229 0.163 -0.017 0.149 -0.029 0.01 Final on-therapy 124 1.233 0.157 1.251 0.174 -0.018 0.150 -0.021 0.01 Follow-up 46 1.240 0.214 1.270 0.181 -0.030 0.206 -0.036 0.02 Placebo 77 1.262 0.129 1.262 0.129 0.129 0.008 0.136 0.009 0.01 Week 4 76 1.267 0.146 1.259 0.127 0.008 0.136 <td>Data Analysis Interval [1]</td> <td>[N]</td> <td>MEAN</td> <td>STD</td> <td>MEAN</td> <td>STD</td> <td>MEAN</td> <td>STD</td> <td>MEAN</td> <td>STDERR</td>	Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
Week 12 96 1.225 0.126 1.244 0.159 -0.019 0.147 -0.025 0.01 Week 26 83 1.215 0.139 1.234 0.156 -0.018 0.161 -0.029 0.01 Week 39 70 1.204 0.148 1.230 0.158 -0.026 0.146 -0.038* 0.01 Week 52 63 1.211 0.144 1.229 0.163 -0.017 0.149 -0.029 0.01 Final on-therapy 124 1.233 0.157 1.251 0.174 -0.018 0.150 -0.021 0.01 Follow-up 46 1.240 0.214 1.270 0.181 -0.030 0.206 -0.036 0.02 Placebo 77 1.262 0.129 1.262 0.129 0.126 0.129 0.026 -0.036 0.02 0.02 Week 4 76 1.267 0.146 1.259 0.127 0.008 0.136 0.009 0.01 <td>DVS SR 200 mg (cont.)</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	DVS SR 200 mg (cont.)									
Week 26 83 1.215 0.139 1.234 0.156 -0.018 0.161 -0.029 0.01 Week 39 70 1.204 0.148 1.230 0.158 -0.026 0.146 -0.038* 0.01 Week 52 63 1.211 0.144 1.229 0.163 -0.017 0.149 -0.029 0.01 Final on-therapy 124 1.233 0.157 1.251 0.174 -0.018 0.150 -0.021 0.01 Follow-up 46 1.240 0.214 1.270 0.181 -0.030 0.206 -0.036 0.02 Placebo 77 1.262 0.129 1.262 0.129 0.206 -0.036 0.02 Screening/baseline 77 1.262 0.129 1.262 0.129 0.127 0.008 0.136 0.009 0.01 Week 4 76 1.267 0.146 1.259 0.127 0.008 0.136 0.009 0.01 Week 12	Week 8	4	1.243	0.107	1.251	0.127	-0.008	0.107	-0.015	0.057
Week 39 70 1.204 0.148 1.230 0.158 -0.026 0.146 -0.038* 0.01 Week 52 63 1.211 0.144 1.229 0.163 -0.017 0.149 -0.029 0.01 Final on-therapy 124 1.233 0.157 1.251 0.174 -0.018 0.150 -0.021 0.01 Follow-up 46 1.240 0.214 1.270 0.181 -0.030 0.206 -0.036 0.02 Placebo 77 1.262 0.129 1.262 0.129 0.029 0.01 0.02										0.013
Week 52 63 1.211 0.144 1.229 0.163 -0.017 0.149 -0.029 0.01 Final on-therapy 124 1.233 0.157 1.251 0.174 -0.018 0.150 -0.021 0.01 Follow-up 46 1.240 0.214 1.270 0.181 -0.030 0.206 -0.036 0.02 Placebo 77 1.262 0.129 1.262 0.129 0.029 0.02 0.01 0.02 0.02 0.01 0.02 0.02 0.01 0.02 0.01										
Final on-therapy										0.016
Follow-up										
Placebo 77 Screening/baseline 77 1.262 0.129 Week 4 76 1.267 0.146 1.259 0.127 0.008 0.136 0.009 0.01 Week 8 6 1.259 0.132 1.302 0.117 -0.043 0.143 -0.020 0.04 Week 12 66 1.270 0.130 1.262 0.134 0.008 0.137 0.012 0.01 Week 26 59 1.248 0.125 1.265 0.128 -0.018 0.137 -0.012 0.01 Week 39 50 1.232 0.150 1.272 0.130 -0.040* 0.139 -0.032 0.01 Week 52 47 1.261 0.151 1.263 0.126 -0.002 0.160 0.003 0.01 Final on-therapy 77 1.273 0.147 1.262 0.129 0.0129 0.011 0.152 0.014										0.012
Screening/baseline 77 1.262 0.129 1.262 0.129 Week 4 76 1.267 0.146 1.259 0.127 0.008 0.136 0.009 0.01 Week 8 6 1.259 0.132 1.302 0.117 -0.043 0.143 -0.020 0.04 Week 12 66 1.270 0.130 1.262 0.134 0.008 0.137 0.012 0.01 Week 26 59 1.248 0.125 1.265 0.128 -0.018 0.137 -0.012 0.01 Week 39 50 1.232 0.150 1.272 0.130 -0.040* 0.139 -0.032 0.01 Week 52 47 1.261 0.151 1.263 0.126 -0.002 0.160 0.003 0.01 Final on-therapy 77 1.273 0.147 1.262 0.129 0.011 0.152 0.014 0.01			1.240	0.214			-0.030	0.206	-0.036	0.023
Week 4 76 1.267 0.146 1.259 0.127 0.008 0.136 0.009 0.01 Week 8 6 1.259 0.132 1.302 0.117 -0.043 0.143 -0.020 0.04 Week 12 66 1.270 0.130 1.262 0.134 0.008 0.137 0.012 0.01 Week 26 59 1.248 0.125 1.265 0.128 -0.018 0.137 -0.012 0.01 Week 39 50 1.232 0.150 1.272 0.130 -0.040* 0.139 -0.032 0.01 Week 52 47 1.261 0.151 1.263 0.126 -0.002 0.160 0.003 0.01 Final on-therapy 77 1.273 0.147 1.262 0.129 0.011 0.152 0.014 0.01			4 0 6 0							
Week 8 6 1.259 0.132 1.302 0.117 -0.043 0.143 -0.020 0.04 Week 12 66 1.270 0.130 1.262 0.134 0.008 0.137 0.012 0.01 Week 26 59 1.248 0.125 1.265 0.128 -0.018 0.137 -0.012 0.01 Week 39 50 1.232 0.150 1.272 0.130 -0.040* 0.139 -0.032 0.01 Week 52 47 1.261 0.151 1.263 0.126 -0.002 0.160 0.003 0.01 Final on-therapy 77 1.273 0.147 1.262 0.129 0.011 0.152 0.014 0.01								0 106		0 04 5
Week 12 66 1.270 0.130 1.262 0.134 0.008 0.137 0.012 0.01 Week 26 59 1.248 0.125 1.265 0.128 -0.018 0.137 -0.012 0.01 Week 39 50 1.232 0.150 1.272 0.130 -0.040* 0.139 -0.032 0.01 Week 52 47 1.261 0.151 1.263 0.126 -0.002 0.160 0.003 0.01 Final on-therapy 77 1.273 0.147 1.262 0.129 0.011 0.152 0.014 0.01										
Week 26 59 1.248 0.125 1.265 0.128 -0.018 0.137 -0.012 0.01 Week 39 50 1.232 0.150 1.272 0.130 -0.040* 0.139 -0.032 0.01 Week 52 47 1.261 0.151 1.263 0.126 -0.002 0.160 0.003 0.01 Final on-therapy 77 1.273 0.147 1.262 0.129 0.011 0.152 0.014 0.01										
Week 39 50 1.232 0.150 1.272 0.130 -0.040* 0.139 -0.032 0.01 Week 52 47 1.261 0.151 1.263 0.126 -0.002 0.160 0.003 0.01 Final on-therapy 77 1.273 0.147 1.262 0.129 0.011 0.152 0.014 0.01										
Week 52 47 1.261 0.151 1.263 0.126 -0.002 0.160 0.003 0.01 Final on-therapy 77 1.273 0.147 1.262 0.129 0.011 0.152 0.014 0.01										
Final on-therapy 77 1.273 0.147 1.262 0.129 0.011 0.152 0.014 0.01										
\mathbb{R}_{0}	Final on-therapy Follow-up	8	1.273	0.147	1.262	0.129	0.011	0.152	0.014	0.015

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

39

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST: PHOS	PHORUS (mmol/L)	/ PART 2: BETWE	EN TREATMENT	'S	
Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 4	0.050	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0.010 -0.011 -0.025 -0.050 -0.021 -0.035 -0.059 -0.014 -0.038 -0.024	0.018 0.018 0.019 0.021 0.018 0.019 0.021 0.019 0.022 0.022	0.584 0.540 0.171 0.021* 0.250 0.058 0.006** 0.451 0.077 0.271
Week 8	0.978	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg	DVS SR 200 mg Placebo	0.025 -0.009 -0.008 -0.003 -0.035 -0.033 -0.028 0.002 0.007	0.053 0.055 0.067 0.058 0.059 0.070 0.062 0.072 0.064 0.074	0.638 0.866 0.908 0.963 0.563 0.658 0.982 0.917 0.946
Week 12	0.204	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0.009 -0.007 0.001 -0.035 -0.016 -0.008 -0.044 0.008 -0.028 -0.027	0.016 0.017 0.017 0.019 0.017 0.017 0.019 0.018 0.019 0.020	0.561 0.674 0.931 0.065 0.325 0.642 0.019* 0.629 0.149 0.065
Week 26	0.619	DVS SR 50 mg	DVS SR 100 mg	0.007	0.018	0.703

Page

40

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST: PHOS	PHORUS (mmol/L) / PART 2: B	ETWEEN TREATMENT	?S	
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS COMPARED Comparator 1 Comparator		STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 26 (cont.)	0.619	DVS SR 50 mg DVS SR 150 DVS SR 50 mg DVS SR 200 DVS SR 50 mg Placebo DVS SR 100 mg DVS SR 150 DVS SR 100 mg DVS SR 200 DVS SR 100 mg Placebo DVS SR 150 mg DVS SR 200 DVS SR 150 mg DVS SR 200 DVS SR 150 mg Placebo DVS SR 200 mg Placebo	mg 0.006 -0.011 mg 0.016 mg -0.001 -0.018 mg -0.017 -0.034		0.234 0.755 0.617 0.395 0.966 0.402 0.407 0.128 0.451
Week 39	0.972	DVS SR 50 mg DVS SR 100 DVS SR 50 mg DVS SR 150 DVS SR 50 mg DVS SR 200 DVS SR 100 mg DVS SR 150 DVS SR 100 mg DVS SR 200 DVS SR 100 mg DVS SR 200 DVS SR 150 mg Placebo DVS SR 150 mg Placebo DVS SR 150 mg Placebo DVS SR 200 mg Placebo	mg 0.008 mg 0.003 -0.004 mg 0.013 mg 0.008 0.001 mg -0.005 -0.012	0.020 0.021 0.023 0.020 0.021 0.023	0.780 0.695 0.896 0.866 0.507 0.698 0.949 0.813 0.620 0.787
Week 52	0.752	DVS SR 50 mg DVS SR 100 DVS SR 50 mg DVS SR 150 DVS SR 50 mg DVS SR 200 DVS SR 50 mg DVS SR 150 DVS SR 100 mg DVS SR 150 DVS SR 100 mg DVS SR 200 DVS SR 100 mg DVS SR 200 DVS SR 150 mg DVS SR 200 DVS SR 150 mg DVS SR 200 DVS SR 150 mg Placebo DVS SR 200 mg Placebo	mg 0.008 mg 0.020 -0.012 mg 0.002 mg 0.014 -0.019 mg 0.012 -0.021	0.021 0.022 0.024 0.021 0.022	0.750 0.690 0.344 0.602 0.923 0.515 0.428 0.593 0.398 0.191
Final on-therapy	0.255	DVS SR 50 mg DVS SR 100 DVS SR 50 mg DVS SR 150		0.015 0.016	0.483 0.642

Page

41

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST: PHOS	PHORUS (mmol/L)	/ PART 2: BETWE	EN TREATMENT	'S	
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1	COMPARED Comparator 2	DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Final on-therapy (cont.)	0.255	DVS SR 100 mg DVS SR 100 mg	DVS SR 200 mg Placebo	-0.006 -0.041 0.004 0.004 -0.030 0.001 -0.034 -0.034	0.016 0.018 0.016 0.016 0.018 0.016 0.019 0.019	0.690 0.027* 0.821 0.780 0.104 0.955 0.072 0.068
Follow-up	0.423	DVS SR 100 mg DVS SR 100 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-0.067 -0.049 -0.037 -0.091 0.018 0.030 -0.024 0.012 -0.042 -0.054	0.040 0.037 0.037 0.062 0.036 0.035 0.061 0.033 0.059 0.059	0.093 0.193 0.316 0.141 0.617 0.397 0.686 0.719 0.476 0.358

Page

42

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

	TEST:	URIC ACI	D (mmol/L) / PART	1: WITHI	N TREATMENT			
TREATMENT		OBSERV	ED	BASELI	BASELINE			ADJUSTED	[2]
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	CHANGE MEAN	STD	MEAN	STDERF
DVS SR 50 mg	148			0.259	0.068				
Screening/baseline	148	0.259	0.068	0.259	0.068				
Week 4	141	0.253	0.064	0.260	0.069	-0.007*	0.041	-0.009**	0.003
Week 8	11	0.243	0.065	0.244	0.060	-0.001	0.044	-0.003	0.014
Week 12	118	0.256	0.063	0.258	0.067	-0.001	0.039	-0.003	0.004
Week 26	100	0.268	0.065	0.259	0.066	0.009*	0.045	0.008*	0.004
Week 39 Week 52	93 84	0.254 0.251	0.066 0.071	0.259 0.254	0.066 0.066	-0.006 -0.003	0.043	-0.006 -0.005	0.004
Final on-therapy	142	0.251	0.071	0.254	0.069	-0.003	0.042	-0.005	0.003
Follow-up	28	0.259	0.075	0.260	0.075	-0.000	0.029	-0.002	0.008
DVS SR 100 mg	155	0.233	0.075	0.264	0.067	0.001	0.023	0.002	0.000
Screening/baseline	155	0.264	0.067	0.264	0.067				
Week 4	139	0.255	0.067	0.265	0.068	-0.009*	0.049	-0.010**	0.003
Week 8	8	0.263	0.075	0.265	0.067	-0.001	0.025	-0.001	0.016
Week 12	119	0.261	0.059	0.265	0.065	-0.004	0.043	-0.004	0.004
Week 26	112	0.268	0.069	0.264	0.065	0.005	0.041	0.005	0.004
Week 39	94 85	0.249	0.057	0.256	0.057	-0.007	0.045	-0.008*	0.004
Week 52		0.247	0.061	0.259	0.064	-0.011**	0.037	-0.012**	0.005
Final on-therapy	140 33	0.261	0.066	0.265	0.067	-0.004	0.041	-0.004	0.004
Follow-up	33 157	0.283	0.084	0.273	0.083 0.071	0.010	0.037	0.011	0.007
DVS SR 150 mg Screening/baseline	157	0.272	0.071	0.271 0.271	0.071				
Week 4	132	0.263	0.064	0.271	0.071	-0.015***	0.036	-0.012***	0.003
Week 8	7	0.294	0.123	0.309	0.132	-0.015	0.071	-0.010	0.018
Week 12	103	0.275	0.070	0.276	0.070	-0.001	0.046	0.002	0.004
Week 26	91	0.277	0.070	0.271	0.066	0.006	0.040	0.007	0.004
Week 39	83	0.261	0.067	0.271	0.068	-0.011*	0.042	-0.008	0.004
Week 52	70	0.267	0.059	0.272	0.062	-0.006	0.053	-0.003	0.005
Final on-therapy	132 42	0.269	0.067	0.278	0.071	-0.009*	0.047	-0.007	0.004
Follow-up		0.263	0.068	0.268	0.081	-0.005	0.052	-0.005	0.00
DVS SR 200 mg	151	0.066	0 000	0.269	0.070				
Screening/baseline	151	0.269	0.070	0.269	0.070	0.01.4.5.5	0 040	0 0144	0 00
Week 4	124	0.253	0.061	0.267	0.069	-0.014***	0.042	-0.014***	0.003

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

43

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

	TEST:	URIC ACI	D (mmol/L)	/ PART	1: WITHIN	TREATMENT			
TREATMENT		OBSERV	ED	BASEL:	INE	CHANGE		ADJUSTED	[2]
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 200 mg (cont.)									
Week 8	4	0.254	0.095	0.298	0.081	-0.044	0.049	-0.040	0.023
Week 12	96	0.265	0.067	0.266	0.072	-0.001	0.042	-0.001	0.004
Week 26	83	0.263	0.067	0.265	0.075	-0.002	0.045	-0.002	0.004
Week 39	70	0.250	0.067	0.269	0.079	-0.019***	0.043	-0.017***	0.005
Week 52	63	0.269	0.075	0.273	0.079	-0.004	0.047	-0.002	0.005
Final on-therapy	124	0.265	0.070	0.267	0.069	-0.002	0.047	-0.002	0.004
Follow-up	46	0.269	0.078	0.266	0.075	0.003	0.049	0.003	0.006
Placebo	77			0.260	0.064				
Screening/baseline	77	0.260	0.064	0.260	0.064				
Week 4	76	0.269	0.063	0.260	0.064	0.009*	0.030	0.007	0.004
Week 8	6	0.236	0.069	0.226	0.043	0.010	0.034	0.005	0.019
Week 12	66	0.272	0.061	0.257	0.062	0.014**	0.036	0.013**	0.005
Week 26	59	0.273	0.071	0.254	0.065	0.019***	0.041	0.017**	0.005
Week 39	50	0.257	0.062	0.256	0.064	0.000	0.039	-0.001	0.006
Week 52	47	0.254	0.070	0.255	0.064	-0.002	0.040	-0.003	0.006
Final on-therapy	77	0.263	0.070	0.260	0.064	0.003	0.039	0.001	0.005
Follow-up	9	0.280	0.096	0.267	0.091	0.013	0.044	0.013	0.014

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

44

DVS SR Protocol 3151A2-315-US CSR-60178

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST: URIC	ACID (mmol/L) /	PART 2: BETWEE	N TREATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1	COMPARED Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 4	0.001**	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	Placebo DVS SR 200 mg Placebo	0.001 0.004 0.005 -0.016 0.003 0.004 -0.017 0.001 -0.020 -0.021	0.004 0.005 0.005 0.005 0.005 0.005 0.005 0.005	0.828 0.402 0.253 0.003** 0.533 0.353 0.002** 0.757 <0.001***
Week 8	0.637	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg		-0.002 0.007 0.037 -0.008 0.009 0.039 -0.007 0.030 -0.015 -0.046	0.022 0.023 0.028 0.024 0.024 0.029 0.025 0.025 0.027 0.031	0.945 0.766 0.186 0.725 0.729 0.183 0.789 0.305 0.575 0.148
Week 12	0.049*	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	Placebo DVS SR 200 mg	0.001 -0.005 -0.002 -0.016 -0.006 -0.003 -0.017 0.003 -0.011 -0.014	0.005 0.005 0.005 0.006 0.005 0.006 0.006 0.006	0.798 0.337 0.715 0.009** 0.226 0.543 0.004** 0.574 0.083 0.027*
Week 26	0.091	DVS SR 50 mg	DVS SR 100 mg	0.004	0.006	0.527

Page

45

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

TEST: URIC ACID (mmol/L) / PART 2: BETWEEN TREATMENTS										
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1		DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS					
Week 26 (cont.)	0.091	DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	0.001 0.010 -0.009 -0.003 0.007 -0.012 0.009 -0.010 -0.019	0.006 0.007 0.007 0.006 0.007 0.007 0.006 0.007	0.869 0.092 0.181 0.655 0.259 0.057 0.136 0.146				
Week 39	0.253	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	0.002 0.002 0.011 -0.005 0.000 0.009 -0.007 0.009 -0.007 -0.007	0.006 0.006 0.006 0.007 0.006 0.006 0.007 0.006	0.761 0.746 0.087 0.439 0.977 0.152 0.303 0.171 0.304 0.029*				
Week 52	0.553	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0.007 -0.002 -0.003 -0.009 -0.010 -0.009 -0.009 -0.000 0.001	0.006 0.007 0.007 0.008 0.007 0.008 0.007 0.008 0.007 0.008	0.275 0.796 0.627 0.769 0.194 0.135 0.223 0.821 0.952 0.885				
Final on-therapy	0.529		DVS SR 100 mg DVS SR 150 mg	-0.003 -0.001	0.005 0.005	0.548 0.894				

Page

46

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST: URIC	ACID (mmol/L) /	PART 2: BETWEE	N TREATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1	COMPARED Comparator 2	DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Final on-therapy (cont.)	0.529	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	Placebo DVS SR 200 mg	-0.006 -0.009 0.002 -0.003 -0.006 -0.005 -0.008 -0.003	0.005 0.006 0.005 0.005 0.006 0.005 0.006	0.261 0.136 0.648 0.588 0.327 0.330 0.176 0.617
Follow-up	0.465	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-0.013 0.003 -0.005 -0.015 0.016 0.008 -0.002 -0.008 -0.018	0.010	0.226 0.778 0.596 0.350 0.103 0.418 0.902 0.360 0.246 0.525

Page

47

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

TREATMENT Data Analysis Interval [1] [N] MEAN STD MEAN ST
Data Analysis Interval [1] [N] MEAN STD MEAN STD MEAN STD MEAN STDERR DVS SR 50 mg
Screening/baseline 148 8.98 3.77 8.98 3.77 Week 4 141 8.93 3.85 8.99 3.83 -0.06 2.78 -0.19 0.21 Week 8 12 9.69 6.37 10.55 3.78 -0.86 3.46 -0.69 0.28 Week 12 118 8.26 3.62 8.96 3.98 -0.70** 2.47 -0.91*** 0.24 Week 26 100 8.67 3.78 9.17 4.12 -0.50 2.67 -0.69** 0.26 Week 39 93 8.81 3.32 9.21 4.18 -0.40 3.19 -0.62* 0.29 Week 52 84 8.77 3.46 9.14 4.00 -0.37 2.75 -0.68* 0.27 Final on-therapy 142 8.71 3.23 8.97 3.82 -0.26 2.81 -0.43* 0.20 Follow-up 29 8.73 2.56 9.26 4.18 -0.53
Screening/baseline 148 8.98 3.77 8.98 3.77 Week 4 141 8.93 3.85 8.99 3.83 -0.06 2.78 -0.19 0.21 Week 8 12 9.69 6.37 10.55 3.78 -0.86 3.46 -0.69 0.98 Week 12 118 8.26 3.62 8.96 3.98 -0.70** 2.47 -0.91*** 0.24 Week 26 100 8.67 3.78 9.17 4.12 -0.50 2.67 -0.69** 0.26 Week 39 93 8.81 3.32 9.21 4.18 -0.40 3.19 -0.62* 0.29 Week 52 84 8.77 3.46 9.14 4.00 -0.37 2.75 -0.68* 0.27 Final on-therapy 142 8.71 3.23 8.97 3.82 -0.26 2.81 -0.43* 0.20 Follow-up 29 8.73 2.56 9.26 4.18 -0.53
Week 8 12 9.69 6.37 10.55 3.78 -0.86 3.46 -0.69 0.98 Week 12 118 8.26 3.62 8.96 3.98 -0.70** 2.47 -0.91*** 0.24 Week 26 100 8.67 3.78 9.17 4.12 -0.50 2.67 -0.91*** 0.26 Week 39 93 8.81 3.32 9.21 4.18 -0.40 3.19 -0.62* 0.29 Week 52 84 8.77 3.46 9.14 4.00 -0.37 2.75 -0.68* 0.27 Final on-therapy Follow-up 142 8.71 3.23 8.97 3.82 -0.26 2.81 -0.43* 0.20 DVS SR 100 mg 155 9.40 4.16
Week 12 118 8.26 3.62 8.96 3.98 -0.70** 2.47 -0.91*** 0.24 Week 26 100 8.67 3.78 9.17 4.12 -0.50 2.67 -0.69** 0.24 Week 39 93 8.81 3.32 9.21 4.18 -0.40 3.19 -0.62* 0.29 Week 52 84 8.77 3.46 9.14 4.00 -0.37 2.75 -0.68* 0.27 Final on-therapy 142 8.71 3.23 8.97 3.82 -0.26 2.81 -0.43* 0.20 Follow-up 29 8.73 2.56 9.26 4.18 -0.53 3.07 -0.63 3.83 DVS SR 100 mg 155 9.40 4.16
Week 26 100 8.67 3.78 9.17 4.12 -0.50 2.67 -0.69** 0.26 Week 39 93 8.81 3.32 9.21 4.18 -0.40 3.19 -0.62* 0.29 Week 52 84 8.77 3.46 9.14 4.00 -0.37 2.75 -0.68* 0.27 Final on-therapy Follow-up 142 8.71 3.23 8.97 3.82 -0.26 2.81 -0.43* 0.20 FOS SR 100 mg 155 9.40 4.16
Week 39 93 8.81 3.32 9.21 4.18 -0.40 3.19 -0.62* 0.29 Week 52 84 8.77 3.46 9.14 4.00 -0.37 2.75 -0.68* 0.27 Final on-therapy Follow-up 142 8.71 3.23 8.97 3.82 -0.26 2.81 -0.43* 0.20 PVS SR 100 mg 155 9.26 4.18 -0.53 3.07 -0.63 3.83
Week 52 84 8.77 3.46 9.14 4.00 -0.37 2.75 -0.68* 0.27 Final on-therapy 142 8.71 3.23 8.97 3.82 -0.26 2.81 -0.43* 0.20 Follow-up 29 8.73 2.56 9.26 4.18 -0.53 3.07 -0.63 3.83 DVS SR 100 mg 155 9.40 4.16
Final on-therapy 142 8.71 3.23 8.97 3.82 -0.26 2.81 -0.43* 0.20 Follow-up 29 8.73 2.56 9.26 4.18 -0.53 3.07 -0.63 3.83 DVS SR 100 mg 155 9.40 4.16
DVS SR 100 mg 155 9.40 4.16
DVS SR 100 mg 155 9.40 4.16
DVS 5K 100 mg 155 9.40 4.16
Screening/baseline 155 9.40 4.16 9.40 4.16 Week 4 139 8.87 3.72 9.40 4.26 -0.53* 2.98 -0.47* 0.22
Week 8 9 6.46 2.67 8.55 3.63 -2.09* 2.53 -2.51* 1.15
Week 12 119 8.71 3.40 9.58 4.42 -0.88*** 2.77 -0.79*** 0.24
Week 26 112 8.67 3.79 9.66 4.58 -0.99** 3.29 -0.94*** 0.25
Week 39 94 8.75 3.15 9.86 4.82 -1.11** 3.68 -0.96** 0.29
Week 52 85 8.63 3.08 9.92 4.92 -1.29** 3.55 -1.16*** 0.27
Final on-therapy 140 8.57 3.08 9.43 4.26 -0.86** 3.51 -0.76*** 0.21
Final on-therapy 140 8.57 3.08 9.43 4.26 -0.86** 3.51 -0.76*** 0.21 Follow-up 33 7.72 2.74 8.39 2.72 -0.67 2.53 -0.03 3.60
DVS SR 150 mg 157 9.62 3.57
Screening/baseline 157 9.60 3.58 9.62 3.57
Week 4 132 8.45 2.98 9.50 3.14 -1.05*** 2.77 -0.94*** 0.22
Week 8 7 8.31 2.69 8.55 1.40 -0.24 2.08 -0.66 1.30
Week 12 103 8.07 2.72 9.75 3.00 -1.68*** 2.51 -1.52*** 0.25
Week 26 91 8.36 2.80 9.75 3.05 -1.39*** 2.44 -1.30*** 0.28
Week 39 83 8.90 3.31 9.72 2.96 -0.82** 2.78 -0.75* 0.31 Week 52 70 8.18 2.90 9.84 2.98 -1.66*** 2.33 -1.57*** 0.30
Final on-therapy 132 8.19 2.85 9.50 3.14 -1.31*** 2.78 -1.18*** 0.21 Follow-up 42 14.54 41.31 9.57 3.74 4.97 39.84 4.61 3.19
DVS SR 200 mg 151 9.23 4.54
Screening/baseline 151 9.23 4.54 9.23 4.54
Week 4 124 7.54 2.36 9.10 4.65 -1.56*** 4.07 -1.63*** 0.23

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.
THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

Page

48

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

TEST: TOTAL BILIRUBIN (mcmol/L) / PART 1: WITHIN TREATMENT OBSERVED BASELINE CHANGE ADJUSTED [2] Data Analysis Interval [1] [N] MEAN MEAN MEAN MEAN STDERR DVS SR 200 mg (cont.) 8.14 7.03 -3.64* Week 8 8.98 3.53 13.68 -4.70 1.78 7.52 7.50 -1.85*** Week 12 2.52 9.37 5.10 4.67 -1.87*** 0.26 -2.07*** 2.60 -2.08*** Week 26 83 9.58 5.37 4.95 0.29 -1.94*** Week 39 9.50 5.75 -1.88** 70 7.62 2.60 5.31 0.34 -2.14** -2.08*** Week 52 63 7.65 2.71 9.80 5.99 5.35 0.31 -1.57*** -1.67*** Final on-therapy 124 7.53 2.33 9.10 4.65 4.11 0.22 Follow-up 46 8.44 9.03 3.01 -0.59 2.75 -0.50 3.04 9.39 Placebo 77 3.44 Screening/baseline 77 9.39 3.44 9.39 3.44 76 9.02 3.39 9.38 -0.36 -0.31 0.29 Week 4 3.46 2.74 3.59 -2.28 3.36 Week 8 6 7.98 3.36 10.26 -2.20 1.39 Week 12 66 9.59 4.55 9.43 3.50 0.16 3.51 0.17 0.32 59 9.65 9.71 Week 26 3.74 3.60 -0.06 2.91 0.02 0.34 4.72 Week 39 50 9.82 9.75 3.42 0.07 3.62 0.15 0.40 Week 52 47 9.61 3.43 9.90 3.38 -0.29 3.24 -0.17 0.36 77 9.39 Final on-therapy 9.08 3.33 3.44 -0.31 3.09 -0.24 0.28 0.91 -0.95 Follow-up 10.26 10.26 5.09 0.00 7.30

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

49

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

TEST: TOTAL BILIRUBIN (mcmol/L) / PART 2: BETWEEN TREATMENTS											
Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE					
Week 4	<0.001***	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 1200 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0.28 0.76 1.44 0.12 0.48 1.17 -0.16 0.69 -0.64 -1.33	0.30 0.31 0.31 0.36 0.31 0.31 0.36 0.32 0.37	0.359 0.015* <0.001*** 0.745 0.125 <0.001*** 0.657 0.031* 0.083 <0.001***					
Week 8	0.479	DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg	Placebo DVS SR 200 mg Placebo	1.81 -0.04 2.94 1.51 -1.85 1.13 -0.30 2.98 1.54 -1.44	1.53 1.64 2.01 1.70 1.71 2.17 1.81 2.26 1.91 2.25	0.244 0.983 0.154 0.381 0.289 0.606 0.868 0.196 0.424 0.528					
Week 12	<0.001***	DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-0.12 0.61 0.96 -1.08 -0.72 1.08 -0.96 0.35 -1.68 -2.04	0.33 0.35 0.35 0.40 0.35 0.35 0.39 0.36 0.41	0.729 0.080 0.007** 0.007** 0.037* 0.002** 0.015* 0.333 <0.001***					
Week 26	<0.001***	DVS SR 50 mg	DVS SR 100 mg	0.25	0.36	0.487					

Page

50

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST: TOTAL BI	LIRUBIN (mcmol/	L) / PART 2: BE	TWEEN TREATM	ENTS	
Data Analysis Interval	OVERALL [1] P-VALUE		COMPARED Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	
Week 26 (cont.)	<0.001***		DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo		0.39 0.43 0.37 0.38 0.42 0.40	0.112 <0.001*** 0.103 0.339 0.003** 0.024* 0.052 0.003** <0.001***
Week 39	0.002**		DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	-0.21 0.97 -1.11 1.18 -0.91	0.42 0.44 0.49 0.42 0.44 0.49 0.46 0.50	0.415 0.764 0.003** 0.116 0.623 0.029* 0.024* 0.010** 0.073 <0.001***
Neek 52	<0.001***	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg	1.40 -0.51 0.42 0.92 -0.98 0.51	0.40 0.42 0.45 0.40 0.41 0.45 0.43 0.47	0.215 0.028* <0.001*** 0.265 0.302 0.026* 0.030* 0.239 0.003** <0.001***
inal on-therapy	<0.001***		DVS SR 100 mg DVS SR 150 mg		0.29 0.29	0.255 0.011*

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

TEST: TOTAL BILIRUBIN (mcmol/L) / PART 2: BETWEEN TREATMENTS OVERALL TREATMENTS COMPARED DIFF. BET. STDERR OF DIFF. PAIRWISE Data Analysis Interval [1] P-VALUE Comparator 1 Comparator 2 ADJ. MEANS BET. ADJ. MEANS P-VALUE <0.001*** <0.001*** Final on-therapy (cont.) DVS SR 50 mg DVS SR 200 mg 1.23 0.30 DVS SR 50 mg Placebo -0.19 0.34 0.574 0.42 DVS SR 100 mg DVS SR 150 mg 0.29 0.159 DVS SR 100 mg DVS SR 200 mg 0.90 0.30 0.003** DVS SR 100 mg Placebo -0.52 0.34 0.129 DVS SR 150 mg DVS SR 200 mg 0.49 0.30 0.110 DVS SR 150 mg Placebo -0.94 0.35 0.007** <0.001*** DVS SR 200 mg Placebo -1.43 0.35 -0.59 Follow-up 0.762 DVS SR 50 mg DVS SR 100 mg 5.26 0.910 DVS SR 50 mg DVS SR 150 mg -5.23 0.295 4.98 DVS SR 50 mg DVS SR 200 mg -0.13 4.89 0.979 DVS SR 50 mg Placebo 0.33 8.24 0.968 DVS SR 100 mg DVS SR 150 mg 0.338 -4.64 4.82 0.47 DVS SR 100 mg DVS SR 200 mg 4.71 0.921 DVS SR 100 mg Placebo 0.92 8.17 DVS SR 150 mg DVS SR 200 mg 5.11 4.40 0.248 DVS SR 150 mg Placebo 7.95 0.486 5.56 DVS SR 200 mg Placebo 0.45 7.91 0.954

Page

51

Page 52

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

	TEST: TOTAL PROTEIN (g/L) / PART 1: WITHIN TREATMENT											
TREATMENT		OBSERVED		BASELIN	NE	CHANGE		ADJUSTED	[2]			
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERF			
DVS SR 50 mg	148			72.23	4.67			· · · · · · · · · · · · · · · · · · ·				
Screening/baseline	148	72.23	4.67	72.23	4.67							
Week 4	141	70.99	4.75	72.25	4.76	-1.26***	3.62	-1.17***	0.28			
Week 8	11	70.27	3.41	73.00	3.66	-2.73	5.12	-2.94**	1.02			
Week 12	118	69.84	4.59	71.56	4.61	-1.72***	3.55	-1.85***	0.30			
Week 26	100	70.43	4.75	71.46	4.50	-1.03**	3.49	-1.21***	0.34			
Week 39 Week 52	93 84	70.29 70.06	4.01 4.53	71.45 71.20	4.51 4.49	-1.16** -1.14**	3.81 3.55	-1.38*** -1.42***	0.34			
Final on-therapy	142	70.00	4.82	72.23	4.75	-1.25***	3.76	-1.16***	0.29			
Follow-up	29	69.79	3.89	72.23	3.42	-3.17***	4.28	-2.86***	0.62			
DVS SR 100 mg	155	03.73	0.03	72.03	3.88	0.11	1.20	2.00	0.02			
Screening/baseline	155	72.03	3.88	72.03	3.88							
Week 4	139	71.54	4.31	71.94 73.00	3.94	-0.40	3.81	-0.43	0.28			
Week 8	9	72.00	3.24	73.00	2.60	-1.00	2.12	-1.21	1.13			
Week 12	119	70.18	4.17	71.88	3.83	-1.71***	3.45	-1.72***	0.30			
Week 26	112	71.14	3.99	71.94	3.70	-0.79*	3.99	-0.78*	0.32			
Week 39 Week 52	94 85	70.73 70.32	4.05 3.67	72.09 72.14	3.75 3.90	-1.35** -1.82***	4.05 3.90	-1.27*** -1.72***	0.34			
Final on-therapy		70.32	4.38	71.93	3.90	-1.01**	4.23	-1.05***	0.29			
Follow-up	140 33	70.91	5.25	72.00	3.97	-1.33	4.38	-1.39*	0.58			
DVS SR 150 mg	157	70.07	0.20	71.88	4.37	1.00	1.50	1.00	0.00			
Screening/baseline	157	71.88	4.37	71.88 71.88	4.37							
Week 4	132	71.05	3.96	71.56	4.24	-0.51	3.90	-0.68*	0.29			
Week 8	7	71.43	5.41	73.29	5.88	-1.86	4.06	-1.91	1.27			
Week 12	103	70.14	4.58	71.70	4.40	-1.56***	3.76	-1.64***	0.32			
Week 26	91	70.36	3.78	71.57	3.98	-1.21**	3.50	-1.34***	0.35			
Week 39 Week 52	83 70	70.72 70.20	3.64 3.90	71.41 71.19	3.59 3.75	-0.69 -0.99*	3.29 3.54	-0.93** -1.27**	0.36			
Final on-therapy	132	70.20	3.90	71.19 71.56	4.24	-0.99^	3.65	-1.27^^	0.39			
Follow-up	42	70.62	4.00	71.56 72.12	4.79	-1.45**	3.16	-1.13	0.51			
DVS SR 200 mg	151	, 0 . 0 ,	1.00	72.27	4.24	1.10	3.10	1.10	0.01			
Screening/baseline	151	72.27	4.24	72.27 72.27	4.24							
Week 4	124	71.27	4.03	72.29	4.18	-1.02***	3.27	-0.91**	0.30			
WEER 4	124	/ ⊥ • ∠ /	4.03	14.43	4.10	-1.02 " " "	3.41	-U.9I.,	0.3			

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 53

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

	TEST:	TOTAL PRO	TEIN (g/	L) / PART	1: WITHI	N TREATMENT			
TREATMENT Data Analysis Interval [1]	[N] -	OBSERVE MEAN	ED	BASELIN MEAN	IE	CHANGE_ MEAN	STD -	ADJUSTED MEAN	[2] STDERR
Data Analysis interval [1]	[1/]	PILLAN	510	PILAN	SID	PILAN	SID	PHEAN	SIDERK
DVS SR 200 mg (cont.)									
Week 8	4	72.50	2.08	77.25	2.63	-4.75*	2.50	-2.60	1.79
Week 12	96	70.61	4.16	72.32	4.37	-1.71***	3.89	-1.56***	0.33
Week 26	83	71.16	4.19	72.48	4.42	-1.33**	4.24	-1.09**	0.37
Week 39	70	71.67	3.98	72.47	4.38	-0.80	3.58	-0.54	0.39
Week 52	63	70.87	4.14	72.70	4.44	-1.83***	3.93	-1.49***	0.42
Final on-therapy	124	70.68	4.05	72.29	4.18	-1.61***	3.84	-1.50***	0.31
Follow-up	46	71.39	3.79	72.22	3.95	-0.83	3.16	-0.80	0.49
Placebo	77			72.10	3.96				
Screening/baseline	77	72.10	3.96	72.10	3.96				
Week 4	76	71.01	4.04	72.09	3.98	-1.08*	4.06	-1.05**	0.38
Week 8	6	68.67	3.44	72.17	3.76	-3.50	4.18	-4.17**	1.39
Week 12	66	70.68	3.45	72.41	4.05	-1.73***	3.35	-1.55***	0.40
Week 26	59	70.93	3.84	72.27	3.89	-1.34**	3.27	-1.19**	0.44
Week 39	50	71.38	3.68	72.58	4.06	-1.20*	4.21	-0.89	0.46
Week 52	47	71.21	4.08	72.55	3.86	-1.34*	3.43	-1.06*	0.48
Final on-therapy	77	71.19	4.00	72.10	3.96	-0.91*	3.92	-0.87*	0.40
Follow-up	8	70.13	2.23	69.38	2.07	0.75	2.05	-0.28	1.18

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

54

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

TEST: TOTAL PROTEIN (g/L) / PART 2: BETWEEN TREATMENTS										
Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED Comparator 2			PAIRWISE P-VALUE				
Week 4	0.393	DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	-0.49 -0.26 -0.12 0.25 0.49 0.62 0.23 0.37	0.40 0.41 0.41 0.48 0.41 0.41 0.42 0.42 0.48 0.42	0.065 0.232 0.536 0.806 0.532 0.241 0.192 0.583 0.445 0.777				
Week 8	0.536	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	-1.03 -0.34 1.24 0.70 1.38 2.96 0.69 2.27	2.13 1.78 2.20	0.263 0.533 0.870 0.477 0.684 0.520 0.106 0.757 0.238 0.500				
Week 12	0.967	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-0.13 -0.21 -0.29 -0.30 -0.08 -0.16 -0.17 -0.08 -0.09	0.43 0.44 0.45 0.50 0.44 0.45 0.50 0.47 0.52 0.52	0.760 0.639 0.528 0.556 0.861 0.730 0.740 0.867 0.862 0.982				
Week 26	0.802	DVS SR 50 mg	DVS SR 100 mg	-0.43	0.46	0.355				

Page

55

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

TEST: TOTAL PROTEIN (g/L) / PART 2: BETWEEN TREATMENTS										
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1		DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE				
Week 26 (cont.)	0.802	DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	0.13 -0.12 -0.02 0.56 0.31 0.41 -0.25 -0.15	0.49 0.50 0.55 0.47 0.49 0.54 0.51 0.56	0.784 0.813 0.972 0.236 0.524 0.449 0.622 0.786 0.863				
Week 39	0.502	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg	DVS SR 200 mg Placebo	-0.45 -0.84	0.48 0.49 0.52 0.57 0.49 0.51 0.57 0.53 0.59 0.60	0.819 0.356 0.104 0.389 0.483 0.155 0.501 0.465 0.946 0.564				
Week 52	0.842	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	0.29 -0.15 0.07 -0.36 -0.44 -0.23 -0.65 0.22 -0.21	0.51 0.53 0.55 0.60 0.53 0.55 0.60 0.57 0.62 0.63	0.563 0.778 0.906 0.550 0.405 0.677 0.275 0.707 0.737 0.502				
Final on-therapy	0.761		DVS SR 100 mg DVS SR 150 mg	-0.11 -0.03	0.41 0.42	0.795 0.939				

Page

56

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

TEST: TOTAL PROTEIN (g/L) / PART 2: BETWEEN TREATMENTS										
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1	COMPARED Comparator 2	DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE				
Final on-therapy (cont.)	0.761	DVS SR 100 mg DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0.34 -0.28 0.08 0.45 -0.18 0.37 -0.25 -0.63	0.43 0.49 0.42 0.43 0.49 0.44 0.50	0.423 0.563 0.858 0.294 0.720 0.390 0.613 0.214				
Follow-up	0.098	DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-1.48 -1.40 -2.07 -2.58 0.07 -0.59 -1.10 -0.66 -1.18	0.84 0.80 0.79 1.34 0.77 0.75 1.31 0.71 1.29	0.082 0.081 0.009** 0.056 0.923 0.437 0.403 0.349 0.363 0.689				

Page 57

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

TEST: ALBUMIN (g/L) / PART 1: WITHIN TREATMENT										
TREATMENT		OBSERVED		BASELI	NE	CHANGE		ADJUSTED [2]		
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR	
DVS SR 50 mg	148			44.291	2.322					
DVS SR 50 mg Screening/baseline	148	44.291	2.322	44.291	2.322					
Week 4	141	43.872	2.378	44.340	2.366	-0.468*	2.183	-0.382*	0.160	
Week 8	11	44.091	2.386	44.636	2.014	-0.545	2.659	-0.596	0.647	
Week 12	118	43.458	2.159	44.288	2.471	-0.831***	2.001	-0.776***	0.164	
Week 26	100	42.770	2.282	44.210	2.405	-1.440***	2.157	-1.455***	0.212	
Week 39	93	42.710	2.500	44.151	2.449	-1.441***	2.513	-1.500***	0.221	
Week 52	84	42.988	2.496	43.976	2.454	-0.988***	2.027	-1.088***	0.225	
Final on-therapy	142	43.338	2.367	44.338	2.358	-1.000***	2.272	-0.916***	0.176	
Follow-up	29	42.793	2.226	45.103	1.915	-2.310***	2.634	-1.872***	0.478	
DVS SR 100 mg	155	44.181	2.179	44.181	2.179					
Screening/baseline Week 4	155 139	44.181	2.179	44.181 44.129	2.179	0.022	2.169	0.009	0.161	
Week 8	139	44.151	2.242	44.129	1.236	0.022	1.500	-0.117	0.161	
Week 12	119	43.563	2.150	44.210	2.239	-0.647***	2.057	-0.633***	0.163	
Week 26	112	43.205	2.298	44.304	2.155	-1.098***	2.780	-1.055***	0.200	
Week 39	94	43.213	2.323	44.383	2.205	-1.170***	2.426	-1.105***	0.219	
Week 52	85	43.212	2.455	44.376	2.225	-1.165***	2.426 2.251	-1.110***	0.223	
Final on-therapy	140	43.350	2.550	44.143	2.197	-0.793***	2.638	-0.801***	0.177	
Follow-up	33	43.030	2.845	43.697	1.794	-0.667	2.769	-0.840	0.441	
DVS SR 150 mg	157			44.268	2.280					
Screening/baseline	157	44.268	2.280	44.268	2.280					
Week 4	132	44.348	2.282	44.189	2.309	0.159	2.373	0.174	0.165	
Week 8	7	43.429	2.878	44.429	1.397	-1.000	2.000	-1.123	0.813	
Week 12	103	43.718	2.012	44.214	2.239	-0.495* -1.242***	2.081 2.287	-0.479**	0.175	
Week 26	91 83	43.055	2.354	44.297	2.219 2.215			-1.203***	0.222	
Week 39 Week 52	83 70	43.482 43.786	2.355 2.776	44.422 44.529	2.215	-0.940*** -0.743*	2.431 2.394	-0.854*** -0.629*	0.234	
Final on-therapy	132	43.700	2.776	44.189	2.301	-0.743*	2.198	-0.539**	0.240	
Follow-up	42	42.952	3.428	43.952	2.129	-1.000*	2.776	-1.062**	0.102	
DVS SR 200 mg	151	12.502	3.120	43.927	2.224	1.000	2.,,0	1.002	0.000	
Screening/baseline	151	43.927	2.224	43.927	2.224					
Week 4	124	43.863	2.217	43.976	2.199	-0.113	1.905	-0.198	0.171	

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 58

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

	TI	EST: ALBUM	IN (g/L)	/ PART 1:	WITHIN ?	TREATMENT			
TREATMENT		OBSERV	ΞD	BASELII	NE	CHANGE		ADJUSTED	[2]
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 200 mg (cont.)									
Week 8	4	44.000	3.367	46.000	2.160	-2.000	1.414	-1.580	1.098
Week 12	96	43.490	2.132	43.948	2.296	-0.458	2.401	-0.582**	0.182
Week 26	83	42.916	2.248	44.012	2.371	-1.096**	2.994	-1.234***	0.232
Week 39	70	43.043	2.343	43.900	2.366	-0.857**	2.267	-1.050***	0.255
Week 52	63	42.968	2.449	43.921	2.224	-0.952**	2.432	-1.074***	0.260
Final on-therapy	124	43.097	2.346	43.976	2.199	-0.879***	2.329	-0.965***	0.188
Follow-up	46	43.696	2.607	44.109	2.514	-0.413	2.688	-0.407	0.372
Placebo	77			44.104	2.081				
Screening/baseline	77	44.104	2.081	44.104	2.081				
Week 4	76	43.776	1.943	44.105	2.095	-0.329	2.187	-0.353	0.218
Week 8	6	42.833	1.602	45.167	2.714	-2.333	2.733	-2.201*	0.878
Week 12	66	43.894	1.832	44.242	1.969	-0.348	2.222	-0.317	0.219
Week 26	59	43.373	2.133	44.356	1.919	-0.983**	2.263	-0.907**	0.276
Week 39	50	43.800	2.268	44.480	1.843	-0.680	2.591	-0.563	0.301
Week 52	47	43.787	1.922	44.426	1.691	-0.638*	1.972	-0.565	0.300
Final on-therapy	77	43.597	2.123	44.104	2.081	-0.506*	2.174	-0.533*	0.239
Follow-up	8	42.875	1.126	42.750	2.121	0.125	1.727	-0.459	0.901

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

59

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST: A	LBUMIN (g/L) / P.	ART 2: BETWEEN	TREATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1	COMPARED Comparator 2	DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 4	0.100	DVS SR 100 mg DVS SR 100 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-0.391 -0.556 -0.185 -0.029 -0.166 0.206 0.362 0.372 0.527 0.155	0.227 0.230 0.234 0.270 0.231 0.235 0.271 0.238 0.273	0.086 0.016* 0.431 0.914 0.474 0.379 0.182 0.118 0.054 0.574
Week 8	0.427	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-0.479 0.526 0.983 1.605 1.005 1.462 2.084 0.457 1.078 0.621	0.964 1.037 1.280 1.092 1.080 1.324 1.138 1.379 1.201 1.393	0.623 0.615 0.448 0.152 0.359 0.278 0.077 0.743 0.376 0.659
Week 12	0.511	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg	DVS SR 200 mg Placebo	-0.143 -0.296 -0.194 -0.458 -0.154 -0.051 -0.316 0.102 -0.162 -0.264	0.231 0.240 0.245 0.274 0.240 0.244 0.273 0.253 0.281 0.285	0.538 0.218 0.429 0.095 0.521 0.834 0.249 0.685 0.565 0.354
Week 26	0.539	DVS SR 50 mg	DVS SR 100 mg	-0.400	0.291	0.170

Page

60

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST: A	LBUMIN (g/L) / PAI	RT 2: BETWEEN	TREATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	
Week 26 (cont.)	0.539	DVS SR 50 mg I DVS SR 50 mg I DVS SR 50 mg I DVS SR 100 mg I DVS SR 100 mg I DVS SR 100 mg I DVS SR 150 mg I DVS SR 150 mg I DVS SR 150 mg I DVS SR 200 mg I	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-0.252 -0.220 -0.548 0.148 0.180 -0.148 0.032 -0.296 -0.328	0.307 0.314 0.347 0.299 0.307 0.340 0.321 0.354	0.411 0.484 0.116 0.621 0.558 0.664 0.921 0.404 0.364
Week 39	0.114	DVS SR 50 mg I DVS SR 100 mg I DVS SR 100 mg I DVS SR 100 mg I DVS SR 150 mg I DVS SR 200 mg I	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-0.251 -0.055 -0.542 0.196 -0.291	0.321 0.337 0.373 0.320 0.337 0.372 0.346 0.381	0.205 0.045* 0.182 0.013* 0.434 0.870 0.146 0.571 0.445 0.218
Week 52	0.355	DVS SR 50 mg I DVS SR 50 mg I DVS SR 50 mg I DVS SR 50 mg I DVS SR 100 mg I DVS SR 100 mg I DVS SR 100 mg I DVS SR 150 mg I DVS SR 150 mg I DVS SR 150 mg I DVS SR 200 mg I	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-0.036 -0.545 0.445 -0.065	0.334 0.343 0.375 0.332 0.343 0.374 0.358	0.945 0.170 0.967 0.164 0.149 0.916 0.145 0.215 0.868 0.200
Final on-therapy	0.357	DVS SR 50 mg I		-0.115 -0.377	0.250 0.253	0.644 0.137

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

Page 61

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST: A	LBUMIN (g/L) / P	ART 2: BETWEEN	TREATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1		DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Final on-therapy (cont.)	0.357		DVS SR 200 mg	0.049 -0.383 -0.262 0.165 -0.268 0.426 -0.006 -0.433	0.258 0.297 0.254 0.258 0.297 0.262 0.300 0.304	0.848 0.197 0.304 0.524 0.368 0.104 0.983 0.155
Follow-up	0.189		DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-1.033 -0.810 -1.465 -1.413 0.222 -0.433 -0.380 -0.655 -0.603 0.052	0.656 0.619 0.606 1.032 0.588 0.577 0.999 0.539 0.980 0.975	0.118 0.193 0.017* 0.173 0.706 0.455 0.704 0.226 0.540 0.957

Page 62

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

	TEST	: SGOT/AS	T (mU/mL)	/ PART 1:	: WITHIN	FREATMENT			
TREATMENT		OBSERV	ED	BASELIN	VE.	CHANGE		ADJUSTED	[2]
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 50 mg Screening/baseline	146			21.9 21.9	7.2				
Screening/baseline	146	21.9	7.2	21.9	7.2				
Week 4	136	22.7	8.4	21.8	7.0 7.8 7.3 7.3	0.9	5.8	0.9	0.7
Week 8	12	24.7	9.6	24.1	7.8	0.6	3.1	-0.7	6.3
Week 12 Week 26	116 97	24.3 23.8	13.2 11.7	21.9 21.6	7.3	2.4** 2.1**	9.7 7.7	2.4***	0.7 1.8
Week 39	90	24.2	20.8	21.6	7.3 7.5	2.1^^	16.8	2.3*	1.1
Week 59 Week 52	82	22.9	8.3	21.9	6.1	1.7*	6.0	1.4	1.1
Final on-therapy	140	24.7	19.1	21.9	7.0	2.9*	15.5	2.9	1.5
Follow-up	30	37.4	58.2	25.4	10.2	12.0	52.9	12.2	15.8
DVS SR 100 mg	153			21.3 21.3	5.9				
Screening/baseline	153	21.3	5.9	21.3	5.9				
Week 4	138	22.0	5.8	21.6	6.1	0.5	5.2	0.4 2.1	0.7
Week 8	9	27.8	10.5	25.0	10.9	2.8	7.8	2.1	7.3
Week 12	115	23.4	6.8	21.3 21.5	6.2	2.1*** 1.2*	5.8 6.3	1.9**	0.7
Week 26 Week 39	111 93	22.7 21.9	7.2 8.3	21.5	6.1 6.5	0.7	5.8	1.0	1.7
Week 59 Week 52	84	23.0	14.8	21.2	5.8	1.9	14.7	1.6	1.1
Final on-therapy		23.2	12.9	21 5	6.1	1.7	12.2	1.7	1.5
Follow-up	139 33	21.3	7.3	21.5 21.0	6.7	0.3	5.8	0.2	15.0
DVS SR 150 mg	156			22.4	7.7				
Screening/baseline	156	22.4	7.7	22.4	7.7				
Week 4	129	23.3	8.1	22.5 33.5	8.1	0.8	7.2	0.9	0.8
Week 8	8	43.6	30.2	33.5	20.8	10.1	34.7	14.9	8.0
Week 12	102	24.7	9.8	23.2	8.6	1.5*	7.2	1.7* 4.8**	0.7
Week 26 Week 39	89 82	27.5 22.7	33.1 7.9	22.9 22.9	8.2 8.1	4.6	33.3	-0.2	1.9
Week 59 Week 52	82 69	23.7	12.9	22.9	8.4	-0.2 1.0	8.0 12.7	1.3	1.2
Final on-therapy	130	25.8	28.5	22 5	8.0	3.3	28.6	3.4*	1.6
Follow-up	43	47.0	157.1	22.5 22.5	6.3	24.4	157.9	24.4	13.1
DVS SR 200 mg	150			22.3	6.2				
Screening/baseline	150	22.3	6.2	22.3 22.3	6.2				
Week 4	120	22.7	16.8	21.9	6.3	0.8	15.5	0.8	0.8

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.
THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

63

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

	TEST:	SGOT/AST	[(mU/mL)	/ PART 1:	WITHIN 7	TREATMENT			
TREATMENT		OBSERVE	ED	BASELIN	E	CHANGI	Ξ	ADJUSTE	D [2]
Data Analysis Interval [1	.] [N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 200 mg (cont.)									
Week 8	4	46.3	52.9	23.8	8.7	22.5	55.0	21.0	10.9
Week 12	94	23.5	8.2	22.2	6.5	1.3	7.1	1.3	0.8
Week 26	82	24.4	17.9	22.0	6.2	2.3	17.4	2.3	1.9
Week 39	70	22.7	9.9	22.0	6.3	0.7	9.5	0.7	1.3
Week 52	63	21.8	6.4	22.3	5.9	-0.5	5.5	-0.3	1.3
Final on-therapy	123	23.0	15.5	21.9	6.3	1.1	14.9	1.1	1.6
Follow-up	46	22.6	6.4	23.2	7.1	-0.6	5.5	-0.6	12.6
Placebo	76			22.4	5.1				
Screening/baseline	76	22.4	5.1	22.4	5.1				
Week 4	75	22.6	6.5	22.3	5.2	0.3	6.5	0.4	1.0
Week 8	7	24.7	3.1	23.9	4.2	0.9	3.5	-0.6	8.3
Week 12	65	21.6	5.2	22.7	5.3	-1.1	5.6	-1.0	0.9
Week 26	58	22.5	4.5	22.9	5.5	-0.4	5.1	-0.2	2.3
Week 39	49	21.1	5.0	22.4	5.2	-1.4	5.8	-1.3	1.5
Week 52	46	23.3	7.9	22.5	5.2	0.7	7.0	1.0	1.5
Final on-therapy	76	22.9	6.5	22.4	5.1	0.5	6.4	0.5	2.0
Follow-up	8	19.8	2.4	20.1	3.7	-0.4	4.5	-0.5	30.4

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

64

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST: SGO	T/AST (MU/ML) / PART 2: BETWEE	N TREATMENTS	 	
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS COMPARED Comparator 1 Comparator 2	DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 4	0.972	DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg DVS SR 50 mg DVS SR 200 mg DVS SR 50 mg Placebo DVS SR 100 mg DVS SR 200 mg DVS SR 100 mg DVS SR 200 mg DVS SR 100 mg Placebo DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg Placebo DVS SR 200 mg Placebo	-0.1 0.1 0.5 -0.6 -0.5 -0.0	1.1 1.1 1.3 1.1 1.1 1.2 1.1 1.3 1.3	0.613 0.960 0.951 0.677 0.583 0.669 0.993 0.913 0.649 0.723
Week 8	0.301	DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg DVS SR 50 mg DVS SR 200 mg DVS SR 100 mg DVS SR 150 mg DVS SR 100 mg DVS SR 200 mg DVS SR 100 mg DVS SR 200 mg DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-15.6 -21.7 -0.1 -12.8 -18.9 2.7	9.6 10.4 12.6 10.4 10.9 13.1 11.0 13.7 11.7	0.773 0.140 0.093 0.990 0.247 0.158 0.810 0.660 0.192 0.123
Week 12	0.048*	DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg DVS SR 50 mg DVS SR 200 mg DVS SR 50 mg Placebo DVS SR 100 mg DVS SR 150 mg DVS SR 100 mg DVS SR 200 mg DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg Placebo DVS SR 200 mg Placebo	0.7 1.1 3.3 0.3 0.7 2.9	1.0 1.0 1.0 1.1 1.0 1.0 1.1 1.0 1.2	0.666 0.495 0.279 0.003** 0.792 0.501 0.010* 0.687 0.022* 0.058
Week 26	0.461	DVS SR 50 mg DVS SR 100 mg	1.0	2.4	0.694

Page

65

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST: SGO	T/AST (mU/mL) / PART 2: BETWEE	IN TREATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS COMPARED Comparator 1 Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 26 (cont.)	0.461	DVS SR 50 mg DVS SR 150 mg DVS SR 50 mg DVS SR 200 mg DVS SR 50 mg Placebo DVS SR 100 mg DVS SR 150 mg DVS SR 100 mg DVS SR 200 mg DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg Placebo DVS SR 200 mg Placebo	-0.3 2.2 3.8 -1.3 1.2 5.5 5.0	2.5 2.8 2.7 3.0	0.268 0.907 0.450 0.128 0.620 0.662 0.343 0.088 0.404
Week 39	0.335	DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg DVS SR 50 mg DVS SR 200 mg DVS SR 50 mg Placebo DVS SR 100 mg DVS SR 200 mg DVS SR 100 mg DVS SR 200 mg DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg Placebo DVS SR 150 mg Placebo DVS SR 150 mg Placebo DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg	1.6 3.7 9 0.8 9 -0.0 2.0 9 -0.9 1.2	1.7 1.9 1.6 1.7 1.8 1.7	0.280 0.119 0.329 0.049* 0.606 0.978 0.283 0.611 0.537 0.297
Week 52	0.801	DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg DVS SR 50 mg DVS SR 200 mg DVS SR 50 mg DVS SR 150 mg DVS SR 100 mg DVS SR 150 mg DVS SR 100 mg DVS SR 200 mg DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg Placebo DVS SR 200 mg Placebo	0.1 1.8 0.5 0.3 1.7 0.4	1.9 1.6 1.7 1.9 1.8	0.910 0.951 0.293 0.796 0.865 0.245 0.723 0.340 0.843 0.507
Final on-therapy	0.737	DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg		2.1 2.2	0.585 0.815

Page

66

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST: SGOT	T/AST (MU/ML) /	PART 2: BETWEEN	TREATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1		DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Final on-therapy (cont.)	0.737	DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 200 mg	1.8 2.3 -1.7 0.6 1.2 2.3 2.8 0.5	2.2 2.5 2.2 2.2 2.5 2.6 2.6	0.414 0.357 0.442 0.775 0.644 0.304 0.268 0.834
Follow-up	0.654	DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	12.0 -12.2 12.8 12.7 -24.3 0.7 0.7 25.0 -0.0	22.0 20.6 20.2 34.4 19.9 19.7 33.8 18.2 33.1	0.585 0.552 0.528 0.712 0.224 0.970 0.983 0.171 0.451 0.999

Page 67

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

	TEST	: SGPT/AI	T (mU/mL)	/ PART 1	: WITHIN	TREATMENT			
TREATMENT		OBSERV	'ED	BASELII	NE	CHANG	GE	ADJUSTE:	D [2]
Data Analysis Interval [1]	[N] _	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 50 mg	148			20.9	9.5				
Screening/baseline	148	20.9	9.5	20.9	9.5				
Week 4	141	21.2	10.9	20.9	9.1 12.3	0.3	6.8	0.1	0.8
Week 8	12	24.8	15.5	26.1	12.3	-1.3	5.8	-1.5	5.8
Week 12 Week 26	118 100	23.3 21.4	18.2 10.1	21.1 20.7	9.3 9.3	2.2	15.7 7.9	1.9 0.3	1.0 3.0
Week 39	93	22.2	11.2	20.7	9.5	1 5	9.3	1.0	0.9
Week 52	84	22.2	13.1	20.3	8.4	1.5 1.9	9.6	1.6	1.2
Final on-therapy	142	23.3	18.0	20.9	9.0	2.5	15.5	2.2	2.2
Follow-up	30	37.8	76.8	26.0	14.1	$1\overline{1.7}$	15.5 75.1	12.8	18.4
DVS SR 100 mg	155			20.2	8.9				
Screening/baseline	155	20.2	8.9	20.2	8.9				
Week 4	139	21.1 31.0	11.6	20.6	9.2 10.3	0.5	9.3	0.2	0.8
Week 8	9	31.0	15.6	24.4	10.3	6.6	10.7	5.9	6.8
Week 12	119 112	21.4 21.1	8.8	20.3	9.2 9.1	1.1 0.7	8.4 9.8	0.5 0.2	1.0 2.8
Week 26 Week 39	94	20.0	10.8 9.1	19.8	9.1	0.7	9.8 8.6	-0.7	
Week 59 Week 52	85	21.6	10.8	20.0	9.1 9.3	0.3 1.6	11.1	1.1	0.9 1.2
Final on-therapy	140	22.2	11.6	20.5	9 2	1.7	10.7	1.2	2.3
Follow-up	34	21.8	11.0	20.8	9.2 8.4	1.0	9.1	0.1	17.2
DVS SR 150 mg	157			22.8 22.8	12.1				
Screening/baseline	157	22.7	12.1	22.8	12.1 12.1				
Week 4	132	23.9 35.6	13.4	23.0 31.8	12.7 23.8	0.8 3.9	13.2 26.4	1.4 5.5	0.8
Week 8	8		19.4	31.8	23.8		26.4	5.5	7.3
Week 12	103	23.4	9.8	24.2 23.5	13.6	-0.8	_9.6	0.0	1.1
Week 26	91	29.0 21.8	57.2	23.5	13.4	5.5	57.2	6.3*	3.1
Week 39 Week 52	83 70	22.6	9.8 12.1	23.2 22.4	13.4 12.3	-1.5 0.2	11.7 13.6	-0.6 0.8	0.9 1.3
Final on-therapy	132	27.2	47.8	23.0	12.7	4.2	48.2	4.9*	2.3
Follow-up	44	48.5	179.7	21.8	8.3	26.7	179.9	26.2	15.1
DVS SR 200 mg	151	-3.0	= : 3 • /	22.4	10.6				10.1
Screening/baseline	151	22.4	10.6	22.4	10.6				
Week 4	124	21.7	10.2	21.8	10.0	-0.2	8.6	-0.1	0.8

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.
THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

68

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST:	SGPT/ALT	[(mU/mL)	/ PART 1:	: WITHIN	TREATMENT			
TREATMENT		OBSERVE	ED	BASELIN	JE	CHANGE		ADJUSTE	
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 200 mg (cont.)									
Week 8	4	46.3	55.2	29.0	4.1	17.3	52.6	18.0	10.1
Week 12	96	24.0	14.9	22.0	10.7	2.0	10.4	2.1	1.1
Week 26	83	25.0	31.0	22.1	11.0	2.9	30.4	3.2	3.2
Week 39	70	22.4	9.7	22.8	11.6	-0.3	9.6	0.3	1.0
Week 52	63	22.8	12.9	22.2	10.5	0.5	13.6	1.1	1.3
Final on-therapy	124	24.2	26.7	21.8	10.0	2.3	26.6	2.5	2.4
Follow-up	46	23.1	8.3	25.2	12.0	-2.1	9.3	-1.3	14.8
Placebo	77			21.2	10.8				
Screening/baseline	77	21.2	10.8	21.2	10.8				
Week 4	76	20.7	8.4	21.2	10.9	-0.5	9.6	-0.6	1.0
Week 8	7	25.7	11.9	22.7	8.1	3.0	4.8	1.8	7.7
Week 12	66	19.1	7.4	21.5	11.4	-2.3	11.2	-2.5	1.3
Week 26	59	18.9	6.4	21.6	12.0	-2.7	10.7	-2.7	3.8
Week 39	50	19.3	7.8	21.8	12.5	-2.5	12.4	-2.4*	1.2
Week 52	47	21.9	8.7	20.7	8.7	1.2	9.8	1.0	1.5
Final on-therapy	77	21.0	8.0	21.2	10.8	-0.2	11.2	-0.3	3.1
Follow-up	8	17.4	6.7	17.8	4.9	-0.4	4.1	-2.3	35.6

CONFIDENTIAL 1013 Wyeth

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

69

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST: SGPT/ALT (mU/mL) / PART 2: BETWEEN TREATMENTS										
Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS						
Week 4	0.576	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg	-1.3	1.1 1.1 1.3 1.1 1.1 1.3 1.1 1.3 1.3	0.968 0.253 0.862 0.579 0.272 0.832 0.557 0.201 0.131 0.693					
Week 8	0.568	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	-7.4 -7.0 -19.5 -3.3 0.4 -12.1 4.1 -12.5 3.7 16.2	8.9 9.3 11.7 9.7 10.0 12.2 10.2 12.4 10.7 12.8	0.415 0.460 0.105 0.736 0.969 0.328 0.691 0.320 0.732 0.213					
Week 12	0.057	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg Placebo	0.5 -1.6 3.0	1.5 1.5 1.7	0.317 0.193 0.918 0.008** 0.732 0.294 0.071 0.180 0.144 0.009**					
Week 26	0.372	DVS SR 50 mg	DVS SR 100 mg	0.1	4.1	0.985					

Page

70

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

TEST: SGPT/ALT (MU/ML) / PART 2: BETWEEN TREATMENTS													
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1			STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE							
Week 26 (cont.)	0.372	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg		4.3 4.4 4.9 4.2 4.3 4.8 4.5 4.9	0.157 0.509 0.540 0.142 0.487 0.543 0.479 0.068 0.243							
Week 39	0.186	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	-1.0 1.7	1.2 1.3 1.5 1.3 1.5 1.3 1.5 1.5	0.157 0.202 0.585 0.020* 0.924 0.445 0.247 0.511 0.225 0.081							
Week 52	0.995	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	0.7 0.5 0.5 0.3	1.6 1.7 1.8 1.9 1.7 1.8 1.9 2.0	0.801 0.671 0.797 0.783 0.852 0.980 0.950 0.881 0.920 0.970							
Final on-therapy	0.704		DVS SR 100 mg DVS SR 150 mg	1.0 -2.7	3.2 3.2	0.765 0.405							

Page

71

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST: SGPT	F/ALT (MU/ML) /	PART 2: BETWEEN	TREATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED Comparator 2	DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Final on-therapy (cont.)	0.704	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg	-0.3 2.5 -3.7 -1.3 1.5 2.4 5.2 2.8	3.3 3.8 3.3 3.3 3.8 3.4 3.9	0.928 0.513 0.263 0.705 0.687 0.473 0.178 0.474
Follow-up	0.698	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	Placebo DVS SR 200 mg Placebo	12.7 -13.4 14.1 15.1 -26.1 1.5 2.4 27.6 28.5 1.0	40.3	0.618 0.575 0.548 0.708 0.255 0.949 0.951 0.197 0.460 0.980

Page 72

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

	TEST: ALK. PHOS. (mU/mL) / PART 1: WITHIN TREATMENT								
TREATMENT		OBSERVI	ED	BASELII	NE	CHANGE		ADJUSTED	[2]
Data Analysis Interval [1]	[N] -	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 50 mg	148			82.5	24.5				
Screening/baseline	148	82.5	24.5	82.5	24.5				
Week 4	141	86.5	26.4	82.9	24.3	3.5***	10.7	3.6**	1.2
Week 8	12	96.3	31.0	91.9	26.8	4.3	21.5	4.0	4.4
Week 12	118	88.4	26.0	83.3	24.1	5.1*** 3.7**	12.2	5.1*** 3.9**	1.1
Week 26	100	87.0	26.4	83.3	24.8		12.6	3.9**	1.4
Week 39	93	89.2	27.6	84.6	24.9	4.6**	16.3	4.9**	1.5
Week 52	84	86.2	24.9	83.2	25.3	3.0	15.0	3.1*	1.5
Final on-therapy	142	87.1	25.5	83.3	24.5	3.8**	14.3	3.9***	1.2
Follow-up	30	83.0	23.0	79.9	21.6	3.1	14.4	2.6	3.1
DVS SR 100 mg	155			79.6	21.8				
Screening/baseline	155	79.6	21.8	79.6	21.8				
Week 4	139	85.6	23.0	80.2	22.1	5.4***	10.6	5.3***	1.2
Week 8	9	89.2	28.7	82.2	25.7	7.0*	8.3	7.2	5.1
Week 12	119	87.7	24.5	81.5	22.6 22.7	6.1***	11.0	6.1*** 6.3***	1.1
Week 26	112	87.7	24.4	81.4	22.7	6.3***	13.7	6.3***	1.3
Week 39	94	84.7	24.5	80.0	22.7	4.7**	14.6	4.3**	1.5
Week 52	85	87.2	26.5	80.4	23.4	6.9***	14.5	6.6***	1.5
Final on-therapy	140 34	87.3 85.1	25.0	80.2 80.9	22.0	7.0***	13.3	6.8***	1.2
Follow-up	157	83.1	22.8		20.2	4.2	13.1	3.8	2.9
DVS SR 150 mg Screening/baseline	157	82.7	23.6	82.6 82.6	23.7 23.7				
Week 4	132	88.0	30.3	80.8	21.4	7.2***	23.7	7.1***	1.3
Week 8	8	81.1	29.8	80.0	24.8	1.1	10.4	1.5	5.4
Week 12	103	87.9	21 8	79.4	20.5	8.6***	11.5	8.4***	1.2
Week 26	91	86.8	21.8 21.7	79.9	20.8	6.9***	14.1	6.6***	1.4
Week 39	83	87.5	21.1	80.1	21.3	7.4***	13.9	7.1***	1.6
Week 52	70	87.3	20.1	79.4	19.8	7.9***	14.0	7.4***	1.7
Final on-therapy	132	87.9	21.3	80.8	21.4	7.1***	14.0	6.9***	1.2
Follow-up	43	92.4	33.5	87.0	29.4	5.3	26.5	5.9*	2.6
DVS SR 200 mg	151			86.0	27.4			- · ·	
Screening/baseline	151	86.0	27.4	86.0	27.4				
Week 4	124	92.5	26.9	86.5	28.0	6.0***	10.7	6.3***	1.3

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.
THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 73

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST:	ALK. PHOS	\cdot (mU/mL)	/ PART 1	l: WITHIN	TREATMENT			
TREATMENT		OBSERVE		BASELII		CHANGE		ADJUSTED	
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 200 mg (cont.)									
Week 8	4	80.8	19.7	77.0	13.3	3.8	16.7	4.2	7.7
Week 12	96	96.3	29.9	86.8	29.0	9.4***	13.4	9.7***	1.2
Week 26	83	95.2	29.0	87.5	29.5	7.7***	16.6	8.4***	1.5
Week 39	70	97.1	27.3	88.8	29.4	8.3***	14.5	9.3***	1.7
Week 52	63	97.3	27.5	89.4	30.1	7.9***	14.5	9.0***	1.8
Final on-therapy	124	93.2	28.1	86.5	28.0	6.7***	15.1	7.2***	1.2
Follow-up	46	86.6	25.6	84.3	26.4	2.3	11.1	2.4	2.5
Placebo	77			80.3	23.4				
Screening/baseline	77	80.3	23.4	80.3	23.4				
Week 4	76	83.5	26.2	80.2	23.5	3.3**	10.1	3.2	1.7
Week 8	7	93.1	39.7	94.6	30.5	-1.4	11.1	-1.9	5.8
Week 12	66	81.8	22.5	79.6	22.3	2.2	9.8	2.0	1.4
Week 26	59	77.9	19.0	76.5	15.6	1.5	13.3	0.7	1.8
Week 39	50	79.7	20.3	77.0	15.8	2.7	15.0	1.8	2.1
Week 52	47	82.7	21.3	77.3	16.0	5.5*	15.4	4.7*	2.1
Final on-therapy	77	83.9	26.6	80.3	23.4	3.7*	13.9	3.4*	1.6
Follow-up	8	88.6	30.5	80.5	22.9	8.1	10.7	7.7	6.0

CONFIDENTIAL 1018 Wyeth

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

74

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

ī	TEST: ALK.	PHOS. (mU/mL) /	PART 2: BETWEE	N TREATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE				STDERR OF DIFF. BET. ADJ. MEANS	
Week 4	0.167	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	-3.6 -2.8 0.4 -1.9 -1.0 2.1	1.8	0.320 0.041* 0.121 0.844 0.288 0.560 0.303 0.649 0.055 0.134
Week 8	0.819	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	2.6 -0.2 5.9 5.8 3.0 9.1 -2.8 3.3	7.1 8.9 7.3 7.4 9.2 7.8 9.4	0.644 0.716 0.983 0.422 0.443 0.748 0.252 0.768 0.683 0.535
Week 12	<0.001***	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	-4.6 3.1 -2.3 -3.6 4.0 -1.3	1.6 1.8 1.6 1.6 1.7	0.531 0.041* 0.005** 0.086 0.147 0.025* 0.025* 0.425 <0.001***
Week 26	0.012*	DVS SR 50 mg	DVS SR 100 mg	-2.4	1.9	0.213

Page

75

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

7	TEST: ALK.	PHOS. (mU/mL) /	PART 2: BETWEE	N TREATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	
Week 26 (cont.)	0.012*	DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg	DVS SR 150 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	-4.5 3.2 -0.3 -2.2	2.0 2.3 1.9 2.0	0.176 0.027* 0.164 0.861 0.277 0.013* 0.382 0.011* 0.001**
Week 39	0.052	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	0.6 -2.1 -4.3 3.1 -2.8 -4.9 2.5 -2.2 5.2 7.4	2.1 2.2 2.3 2.6 2.2 2.3 2.5 2.4 2.6 2.7	0.776 0.329 0.060 0.228 0.209 0.033* 0.329 0.357 0.045* 0.006**
Week 52	0.114	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	-3.5 -4.3 -5.9 -1.6	2.2 2.3 2.4 2.6	0.115 0.062 0.014* 0.547 0.713 0.306 0.464 0.522 0.308 0.118
Final on-therapy	0.106	DVS SR 50 mg DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg	-2.9 -3.0	1.7 1.7	0.085 0.076

Page

76

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: BLOOD CHEMISTRY

	TEST: ALK.	PHOS. (mU/mL) /	PART 2: BETWEE	N TREATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1		DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Final on-therapy (cont.)	0.106	DVS SR 100 mg DVS SR 100 mg	DVS SR 200 mg Placebo	-3.3 0.5 -0.1 -0.4 3.3 -0.3 3.5 3.8	1.7 2.0 1.7 1.7 2.0 1.7 2.0	0.055 0.800 0.937 0.801 0.089 0.863 0.081 0.061
Follow-up	0.825	DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-1.3 -3.3 0.1 -5.1 -2.1 1.4 -3.9 3.5 -1.8	4.3 4.1 4.0 6.8 3.9 3.9 6.7 3.6 6.6	0.770 0.415 0.971 0.453 0.596 0.719 0.566 0.338 0.788

Page 77

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: ENDOCRINOLOGY

		TEST: FSH	(mU/mL)	/ PART 1:	WITHIN T	REATMENT			
TREATMENT		OBSERV	ED .	BASELI	NE	CHANG	GE	ADJUSTE	D [2]
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 50 mg	57			67.41	20.07				
Screening/baseline	57	67.41	20.07	67.41	20.07				
Week 4	1	61.60		75.90		-14.30		11 10	12.00
Final on-therapy	1 71	61.60		75.90	04 14	-14.30		-11.43	13.28
DVS SR 100 mg Screening/baseline	71	68.03	24.14	68.03 68.03	24.14 24.14				
Week 8	1	68.00	24.14	63.70	24.14	4.30		4.30	0.00
Week 39	1	50.00		64.90		-14.90		4.50	0.00
Final on-therapy	2	59.00	12.73	64.30	0.85	-5.30	13.58	-13.96	14.22
DVS SR 150 mg	2 73			67.31	20.41				
Screening/baseline	73	67.31	20.41	67.31	20.41				
Week 4	1	78.90		79.20		-0.30			
Week 12	1	45.10		93.50		-48.40		-48.40	0.00
Week 26	1	80.50		93.50		-13.00		-13.00	0.00
Final on-therapy	2	79.70	1.13	86.35	10.11	-6.65	8.98	6.60	19.07
DVS SR 200 mg	63	CO 15	05.00	69.15	25.08				
Screening/baseline Follow-up	63 1	69.15 115.40	25.08	69.15 127.50	25.08	-12.10			
Placebo	34	113.40		70.32	21.70	-12.10			
Screening/baseline	34	70.32	21.70	70.32	21.70				
Week 39	1	62.00	21.70	60.90	21.70	1.10			
Final on-therapy	1	62.00		60.90		1.10		-10.94	19.90
Follow-up	1	162.50		137.80		24.70			

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.
THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.
STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.
STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: ENDOCRINOLOGY

	TEST:	FSH (MU/ML) / PA	RT 2: BETWEEN T	REATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Final on-therapy	0.835	DVS SR 50 mg	DVS SR 150 mg Placebo DVS SR 150 mg Placebo	2.53 -18.04 -0.49 -20.56 -3.02 17.54	21.41 20.45 26.14 30.57 16.22 35.67	0.925 0.540 0.988 0.623 0.883 0.709

Page

78

Page 79

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

TEST: HEMOGLOBIN (g/L) / PART 1: WITHIN TREATMENT									
TREATMENT		OBSERV	ÆD.	BASELI	NE	CHANGE		ADJUSTED	[2]
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 50 mg	148			136.75	10.32				
Screening/baseline	148	136.75	10.32	136.75	10.32				
Week 4	141	135.59	10.64	136.92	10.23	-1.33**	5.54	-1.41**	0.49
Week 8	9	129.67	14.20	131.78	13.01	-2.11	6.45	-2.52	2.27
Week 12	117	136.03	9.96	137.62	10.10	-1.60**	6.17	-1.58**	0.54
Week 26	99	137.74	9.71	138.51	9.80	-0.77	6.98	-0.63	0.64
Week 39	92	137.83	10.07	137.67	10.54	0.15	7.55	0.08	0.67
Week 52	85	138.76	10.12	137.98	10.45	0.79	7.32	0.74	0.72
Final on-therapy	142	137.24	10.79	137.02	10.26	0.22	6.74	0.15	0.55
Follow-up	24	131.42	11.74	133.96	10.21	-2.54	6.13	-2.71	1.45
DVS SR 100 mg	155			137.67	8.87				
Screening/baseline	155	137.67	8.87	137.67	8.87				
Week 4	139	137.60	9.23	137.23	8.88	0.37	6.69	0.36	0.49
Week 8	8	135.75	8.58	139.25	7.67	-3.50	5.88	-3.09	2.40
Week 12	118	136.43	9.55	137.36	9.24	-0.92	6.16	-0.97	0.54
Week 26	111	138.04	9.44	137.95	9.02	0.09	7.00	0.08	0.61
Week 39	92	138.86	9.48	138.00	9.34	0.86	5.80	0.88	0.67
Week 52	84	137.76	9.17	138.13	8.91	-0.37	7.21	-0.37	0.73
Final on-therapy	140 34	137.47	9.46	137.33	8.92	0.14 -1.68	6.93 6.54	0.14 -1.75	0.55
Follow-up		133.53	10.36	135.21	8.50	-1.68	6.54	-1.75	1.21
DVS SR 150 mg	157 157	137.59	9.43	137.59 137.59	9.43 9.43				
Screening/baseline Week 4	129	138.03	9.43	137.65	9.43	0.38	5.98	0.45	0.51
Week 4 Week 8	129	136.25	10.70	138.13	10.70	-1.88	6.69	-1.59	2.37
Week 12	102	137.86	9.11	137.81	9.49	0.05	6.61	0.11	0.58
Week 12 Week 26	91	138.66	10.05	138.16	9.50	0.49	6.38	0.54	0.50
Week 39	83	140.01	9.91	138.08	9.77	1.93*	6.93	1.97**	0.71
Week 52	70	138.41	10.02	137.97	9.84	0.44	6.54	0.40	0.80
Final on-therapy	132	138.61	10.13	137.71	9.49	0.90	6.45	0.98	0.57
Follow-up	41	133.98	12.75	136.54	9.29	-2.56	8.59	-2.54*	1.10
DVS SR 200 mg	151	100.00	12.75	138.16	8.61	2.00	0.00	2.01	1.10
		100 16	0 (1		8.61				
Screening/baseline	151	138.16	8.61	138.16	8.01				

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.
THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.
STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.
STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

80

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

	TES:	r: HEMOGLO	BIN (g/L)) / PART 1	: WITHIN	TREATMENT			
TREATMENT		OBSERV	ED	BASELI	NE	CHANGE		ADJUSTED	[2]
Data Analysis Interval [1]] [N] ⁻	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 200 mg (cont.)									
Week 12	96	137.47	8.15	137.17	8.49	0.30	5.81	0.21	0.60
Week 26	83	137.93	8.80	137.39	8.60	0.54	6.42	0.38	0.70
Week 39	70	137.67	9.62	137.47	8.79	0.20	6.74	0.07	0.77
Week 52	64	137.39	9.13	137.91	8.91	-0.52	6.14	-0.58	0.83
Final on-therapy	124	136.90	8.62	137.65	8.33	-0.75	6.10	-0.69	0.59
Follow-up	38	138.92	9.27	139.53	8.54	-0.61	6.46	-0.36	1.16
Placebo	77			136.95	10.16				
Screening/baseline	77	136.95	10.16	136.95	10.16				
Week 4	76	134.59	9.47	137.04	10.20	-2.45**	6.88	-2.50***	0.67
Week 8	5	127.80	7.56	132.20	2.77	-4.40	7.83	-4.77	3.00
Week 12	66	136.61	9.97	137.95	9.99	-1.35	6.70	-1.26	0.72
Week 26	59	137.97	8.70	137.81	10.32	0.15	7.70	0.10	0.83
Week 39	50	139.92	6.73	138.64	9.91	1.28	8.55	1.49	0.91
Week 52	46	139.22	9.64	139.04	9.74	0.17	8.87	0.42	0.98
Final on-therapy	77	137.34	9.97	136.95	10.16	0.39	8.37	0.30	0.74
Follow-up	7	128.71	7.36	128.86	9.99	-0.14	5.18	-0.70	2.71

CONFIDENTIAL 1025 Wyeth

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

81

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

	TEST: HEMO	OGLOBIN (g/L) /	PART 2: BETWEEN	TREATMENTS			
Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS		
Week 4	<0.001***	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 200 mg	-1.86 -0.91 1.09 -0.09 0.86 2.86 0.95 2.95	0.72 0.83 0.74 0.84	0.011* 0.009** 0.208 0.189 0.899 0.234 <0.001*** 0.197 <0.001***	
Week 8	0.867	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg Placebo DVS SR 150 mg Placebo Placebo	0.57 -0.94 2.24 -1.50 1.68 3.18	3.33 3.70 3.32	0.868 0.781 0.550 0.655 0.671 0.418	
Week 12	0.105	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	-1.69 -1.80 -0.33	0.77 0.80 0.81 0.91 0.80 0.81 0.90 0.84 0.93	0.425 0.034* 0.027* 0.719 0.176 0.144 0.751 0.901 0.142 0.119	
Week 26	0.758	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg	-1.17 -1.01	0.89 0.93 0.95 1.05 0.91	0.423 0.208 0.289 0.485 0.610	

Page

82

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

	TEST: HEM	OGLOBIN (g/L) / PART 2: BETWEEN	N TREATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS COMPARED Comparator 1 Comparator 2	DIFF. BET. ADJ. MEANS		PAIRWISE P-VALUE
Week 26 (cont.)	0.758	DVS SR 100 mg DVS SR 100 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg DVS SR 200 mg Placebo DVS SR 200 mg DVS SR 200 mg	-0.03	0.93 1.03 0.97 1.07 1.09	0.744 0.979 0.871 0.685 0.800
Week 39	0.257	DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg DVS SR 50 mg DVS SR 200 mg DVS SR 100 mg DVS SR 150 mg DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-1.89 0.01 -1.41 -1.09 0.81 -0.61	0.95 0.98 1.02 1.13 0.98 1.02 1.13 1.05 1.16	0.401 0.053 0.992 0.216 0.264 0.428 0.593 0.070 0.674 0.236
Week 52	0.715	DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg DVS SR 50 mg DVS SR 200 mg DVS SR 100 mg DVS SR 150 mg DVS SR 100 mg DVS SR 200 mg DVS SR 100 mg Placebo DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg Placebo Placebo DVS SR 200 mg Placebo Placebo	0.35 1.32 0.32 -0.77 0.21 -0.79	1.03 1.08 1.10 1.22 1.08 1.11 1.22 1.15 1.27	0.278 0.748 0.232 0.793 0.477 0.851 0.517 0.398 0.984
Final on-therapy	0.380	DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg DVS SR 50 mg DVS SR 200 mg DVS SR 100 mg DVS SR 150 mg DVS SR 100 mg DVS SR 150 mg DVS SR 100 mg DVS SR 200 mg	-0.83 0.83 -0.16 -0.84	0.78 0.79 0.80 0.92 0.79 0.80	0.991 0.291 0.300 0.866 0.287 0.307

Page

83

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

	TEST: HEMO	OGLOBIN (g/L) /	PART 2: BETWEEN	TREATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED Comparator 2			PAIRWISE P-VALUE
Final on-therapy (cont.)	0.380	DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo	-0.16 1.66 0.68 -0.99	0.92 0.81 0.93 0.95	0.859 0.042* 0.468 0.297
Follow-up	0.637	DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-0.96 -0.17 -2.36 -2.01 0.78 -1.40 -1.06 -2.18 -1.84 0.34	1.88 1.82 1.88 3.05 1.64 1.69 2.96 1.60 2.93 2.98	0.611 0.924 0.211 0.510 0.633 0.410 0.722 0.175 0.531 0.909

Page 84

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

	TES	T: HEMATO	CRIT (L/L) / PART	1: WITHII	N TREATMENT			
TREATMENT		OBSER	VED	BASEL	TNE	CHANG	E.	ADJUSTE	D [2]
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 50 mg	148			0.41287	0.02925				
Screening/baseline		0.41287	0.02925	0.41287	0.02925				
Week 4	141	0.41066	0.03041	0.41329		-0.00263		-0.00288	0.00160
Week 8	9	0.39344	0.03910	0.39922		-0.00578		-0.00684	0.00629
Week 12	117	0.41046	0.02862	0.41566		-0.00520**		-0.00507**	0.00177
Week 26	99	0.41590	0.02921	0.41766		-0.00176		-0.00132	0.00203
Week 39	92	0.40911	0.02916	0.41511		-0.00600*		-0.00623**	0.00209
Week 52	85	0.41344	0.02950	0.41561		-0.00218		-0.00241	0.00222
Final on-therapy	142	0.41158	0.03067	0.41360		-0.00201		-0.00225	0.00173
Follow-up	24	0.39767	0.03322	0.40604		-0.00837	0.02040	-0.00891*	0.00438
DVS SR 100 mg	155	0 41 446	0 00500	0.41446	0.02533				
Screening/baseline	155	0.41446	0.02533	0.41446	0.02533	0 00041	0 00155	0 000174	0 00161
Week 4	139	0.41672	0.02737	0.41331	0.02549	0.00341		0.00317*	0.00161
Week 8	8	0.40713	0.02814	0.41763		-0.01050		-0.00968	0.00661
Week 12	118 111	0.41245 0.41546	0.02937 0.02627	0.41324 0.41458	0.02610	-0.00079 0.00088	0.02080	-0.00125 0.00044	0.00177
Week 26	92								
Week 39 Week 52	92 84	0.41110 0.41051	0.02815 0.02682	0.41432 0.41502		-0.00322 -0.00451	0.02040	-0.00372 -0.00493*	0.00209
Final on-therapy	140	0.41199	0.02808	0.41351		-0.00153		-0.00179	0.00223
Follow-up	34	0.41199	0.02993	0.41331	0.02331	-0.00133		-0.00179	0.00174
DVS SR 150 mg	157	0.40113	0.02333	0.41583	0.02420	0.00030	0.01000	0.00000	0.00500
Screening/baseline	157	0.41583	0.02694	0.41583	0.02694				
Week 4	129	0.41820	0.02915	0.41567	0.02712	0.00253	0 01913	0.00286	0.00167
Week 8	8	0.41050	0.03019	0.41913		-0.00863		-0.00765	0.00664
Week 12	102	0.41719	0.02738	0.41633	0.02681	0.00085	0.01964	0.00115	0.00190
Week 26	91	0.41921	0.02987	0.41720	0.02665	0.00201	0.02036	0.00232	0.00212
Week 39	83	0.41587	0.02803	0.41693		-0.00106		-0.00068	0.00220
Week 52	70	0.41454	0.02818	0.41643		-0.00189		-0.00186	0.00244
Final on-therapy	132	0.41659	0.02944	0.41599	0.02714	0.00060	0.02065	0.00100	0.00179
Follow-up	41	0.40468	0.03651	0.41388		-0.00920*		-0.00898**	0.00335
DVS SR 200 mg	151			0.41753	0.02693				
Screening/baseline	151	0.41753	0.02693	0.41753	0.02693				
Week 4	122	0.41561	0.02584	0.41643	0.02642	-0.00083	0.01960	-0.00032	0.00172

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 85

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

	TES	T: HEMATO	CRIT (L/L) / PART	1: WITHIN	TREATMENT			
TREATMENT		OBSER		BASEL		CHAN		ADJUSTED	
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 200 mg (cont.)									
Week 12	96	0.41632	0.02660	0.41575	0.02710	0.00057	0.01992	0.00073	0.00196
Week 26	83	0.41767	0.02973	0.41614	0.02777	0.00153	0.02254	0.00154	0.00221
Week 39	70	0.41014	0.02928	0.41669	0.02831	-0.00654*	0.02304	-0.00624**	0.00240
Week 52	64	0.41133	0.02841	0.41805	0.02851	-0.00672*	0.02069	-0.00619*	0.00256
Final on-therapy	124	0.41214	0.02702	0.41644	0.02627	-0.00431*	0.02115	-0.00378*	0.00185
Follow-up	38	0.41755	0.02985	0.42034	0.02786	-0.00279	0.02139	-0.00196	0.00352
Placebo	77			0.41213	0.02756				
Screening/baseline	77	0.41213	0.02756	0.41213	0.02756				
Week 4	76	0.40809	0.02601	0.41241	0.02764	-0.00432	0.02161	-0.00477*	0.00217
Week 8	5	0.38820	0.01920	0.40020	0.00835	-0.01200	0.01681	-0.01296	0.00834
Week 12	66	0.41359	0.02818	0.41474	0.02738	-0.00115	0.02161	-0.00124	0.00236
Week 26	59	0.41722	0.02386	0.41475	0.02817	0.00247	0.02325	0.00208	0.00263
Week 39	50	0.41496	0.01778	0.41668	0.02793	-0.00172	0.02530	-0.00142	0.00284
Week 52	46	0.41620	0.02685	0.41767	0.02653	-0.00148	0.02599	-0.00107	0.00302
Final on-therapy	77	0.41239	0.02675	0.41213	0.02756	0.00026	0.02555	-0.00037	0.00235
Follow-up	7	0.39071	0.01788	0.39000	0.02774	0.00071	0.01794	-0.00135	0.00822

CONFIDENTIAL 1030 Wyeth

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

86

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

	TEST: HEM	ATOCRIT (L/L) /	PART 2: BETWEEN	TREATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1		DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 4	0.005**	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	-0.00605 -0.00573 -0.00255 0.00190 0.00311 0.00349 0.00794 0.00763 0.00763	0.00227 0.00231 0.00235 0.00270 0.00232 0.00235 0.00270 0.00239 0.00274 0.00277	0.008** 0.013* 0.277 0.483 0.893 0.138 0.003** 0.185 0.006**
Week 8	0.938		DVS SR 100 mg DVS SR 150 mg Placebo DVS SR 150 mg Placebo Placebo	0.00284 0.00081 0.00612 -0.00203 0.00329 0.00532	0.00927 0.00932 0.01030 0.00923 0.01075 0.01080	0.762 0.932 0.558 0.828 0.762 0.627
Week 12	0.125	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	-0.00382 -0.00621 -0.00579 -0.00382 -0.00240 -0.00198 -0.00000 0.00042 0.00239 0.00197	0.00250 0.00260 0.00264 0.00295 0.00259 0.00264 0.00295 0.00273 0.00303 0.00306	0.128 0.017* 0.029* 0.196 0.356 0.454 0.999 0.877 0.430 0.521
Week 26	0.739	DVS SR 50 mg DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg	-0.00175 -0.00364 -0.00285 -0.00339 -0.00188	0.00279 0.00293 0.00300 0.00332 0.00285	0.530 0.215 0.343 0.307 0.510

Page

87

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

	TEST: HEM	ATOCRIT (L/L) / PART 2: BETWEEN	TREATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS COMPARED Comparator 1 Comparator 2	DIFF. BET. ADJ. MEANS		PAIRWISE P-VALUE
Week 26 (cont.)	0.739	DVS SR 100 mg DVS SR 200 mg DVS SR 100 mg Placebo DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg Placebo DVS SR 200 mg Placebo	-0.00110 -0.00164 0.00078 0.00024 -0.00054	0.00293 0.00325 0.00306 0.00337 0.00344	0.708 0.614 0.798 0.943 0.875
Week 39	0.278	DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg DVS SR 50 mg DVS SR 200 mg DVS SR 50 mg Placebo DVS SR 100 mg DVS SR 150 mg DVS SR 100 mg DVS SR 200 mg DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg Placebo DVS SR 150 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-0.00251 -0.00555 0.00001 -0.00481 -0.00304 0.00252 -0.00230 0.00556 0.00074 -0.00482	0.00296 0.00304 0.00318 0.00352 0.00304 0.00318 0.00352 0.00352 0.00359 0.00371	0.396 0.068 0.998 0.173 0.317 0.428 0.515 0.088 0.836 0.195
Week 52	0.583	DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg DVS SR 50 mg DVS SR 200 mg DVS SR 50 mg DVS SR 150 mg DVS SR 100 mg DVS SR 150 mg DVS SR 100 mg DVS SR 200 mg DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 200 mg Placebo	0.00252 -0.00055 0.00378 -0.00134 -0.00307 0.00126 -0.00386 0.00433 -0.00080 -0.00512	0.00315 0.00330 0.00339 0.00374 0.00331 0.00340 0.00375 0.00354 0.00388 0.00395	0.424 0.869 0.265 0.720 0.355 0.710 0.304 0.222 0.838 0.196
Final on-therapy	0.417	DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg DVS SR 50 mg DVS SR 200 mg DVS SR 50 mg Placebo DVS SR 100 mg DVS SR 150 mg DVS SR 100 mg DVS SR 200 mg	-0.00046 -0.00325 0.00154 -0.00188 -0.00279 0.00200	0.00245 0.00249 0.00253 0.00291 0.00250 0.00254	0.850 0.192 0.544 0.518 0.265 0.431

Page

88

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

	TEST: HEMA	ATOCRIT (L/L) /	PART 2: BETWEEN	TREATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1	COMPARED Comparator 2	DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Final on-therapy (cont.)	0.417	DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	Placebo	-0.00142 0.00478 0.00137 -0.00342	0.00292 0.00257 0.00295 0.00299	0.627 0.063 0.644 0.253
Follow-up	0.568	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Placebo	-0.00203 0.00007 -0.00695 -0.00756 0.00210 -0.00492 -0.00553 -0.00702 -0.00763	0.00571 0.00553 0.00566 0.00926 0.00498 0.00513 0.00896 0.00484 0.00890 0.00904	0.723 0.990 0.222 0.416 0.674 0.339 0.538 0.149 0.393

Page

89

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

	TE	ST: WBC (10^9/L) /	PART 1:	WITHIN TE	REATMENT			
TREATMENT		OBSERV	ED	BASELI	NE	CHANGI	7,	ADJUSTED	[2]
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 50 mg	148			6.294	1.784				
Screening/baseline	148	6.294	1.784	6.294	1.784				
Week 4	140	6.087	1.634	6.256	1.789	-0.169	1.284	-0.142	0.092
Week 8	9	5.756	1.407	6.033	1.683	-0.278	1.096	-0.270	0.278
Week 12	115	6.125	1.709	6.340 6.386	1.831 1.860	-0.215	1.335	-0.183	0.121
Week 26	99	6.054	1.930	6.386	1.860	-0.332*	1.368	-0.280*	0.118
Week 39 Week 52	91 85	6.104 6.076	1.646 1.794	6.393 6.386	1.858	-0.289* -0.309*	1.307 1.396	-0.225 -0.254	0.123 0.143
Final on-therapy		6.051	1.794	6.280	1.894 1.794	-0.229*	1.333	-0.254	0.143
Follow-up	142 24	6.258	1.640 1.345	6.246	2.169	0.012	1.578	0.047	0.109
DVS SR 100 mg	155	0.200	1.010	6.185	1.746	0.012	1.070	0.017	0.231
Screening/baseline	155	6.185	1.746	6.185	1.746				
Week 4	138	5.921	1.825	6.181	1.776	-0.260**	1.094	-0.251**	0.092
Week 8	8	4.713	1.825 1.341	6.181 4.762	1.180	-0.050	0.532	-0.361	0.315
Week 12	118	6.051	2.182	6.219	1.850	-0.169	1.329	-0.157	0.119
Week 26	107	5.768	2.032	6.021	1.744	-0.253*	1.248	-0.267*	0.113
Week 39	91	5.588	1.680	5.960	1.757	-0.373**	1.195 1.286	-0.408***	0.123
Week 52	83	5.796	2.188	6.117	1.924	-0.320*		-0.325*	0.145
Final on-therapy	140 35	5.989 6.031	2.072 1.870	6.170	1.766 1.771	-0.181 -0.037	1.376 1.200	-0.172 -0.051	0.110
Follow-up	157	0.031	1.8/0	6.069 6.148	1.745	-0.037	1.200	-0.051	0.193
DVS SR 150 mg Screening/baseline	157	6.148	1.745	6.148	1.745				
Week 4	129	5.966	1.804	6.180	1.745	-0.214*	1.046	-0.205*	0.095
Week 8	8	6.425	1.984	6.950	2.518	-0.525	1.161	-0.287	0.307
Week 12	102	5.936	1.737	6.153	1.801	-0.217	1.262	-0.216	0.128
Week 26	90	5.884	1.682	6.092	1.626	-0.208	1.213	-0.208	0.123
Week 39	81	5.857	1.956	6.189	1.800	-0.332**	1.132	-0.315*	0.130
Week 52	69	6.026	1.984	6.304	1.802	-0.278	1.632	-0.241	0.159
Final on-therapy	132	6.042	1.880	6.154	1.734	-0.111	1.486	-0.106	0.113
Follow-up	41	6.010	1.613	5.902	1.852	0.107	1.033	0.049	0.179
OVS SR 200 mg	151	C 11F	1 (00	6.115	1.689				
Screening/baseline Week 4	151 119	6.115 6.090	1.689 1.655	6.115 6.071	1.689 1.655	0.018	1.235	0.003	0.099
WEEK 4	119	0.090	1.033	0.0/1	1.033	0.018	1.233	0.003	0.099

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

90

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

	TF	ST: WBC (10^9/L) /	PART 1:	WITHIN TE	REATMENT			
			, ,						
TREATMENT		OBSERV	ΈD	BASELI	NE	CHANG		ADJUSTEI	
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 200 mg (cont.)									
Week 12	95	6.016	2.254	6.004	1.677	0.012	1.343	-0.013	0.133
Week 26	83	5.888	1.785	5.958	1.696	-0.070	1.112	-0.095	0.129
Week 39	69	5.970	1.962	5.933	1.760	0.036	1.372	-0.006	0.141
Week 52	64	5.928	1.859	5.852	1.627	0.030	1.261	0.013	0.165
Final on-therapy	123	5.926	1.643	6.046	1.652	-0.120	1.213	-0.144	0.117
	38	6.347	2.116	6.366	1.953	-0.120	1.213	0.049	0.117
Follow-up Placebo	30 77	0.347	2.110	5.910	1.808	-0.010	1.200	0.049	0.100
	77	E 010	1 000	5.910					
Screening/baseline	76	5.910	1.808		1.808	0 022	1 0 4 0	0 005	0 104
Week 4	/ 6	5.922	1.759	5.891	1.812	0.032	1.040	-0.025	0.124
Week 8	5	6.000	1.560	6.420	1.537	-0.420	0.661	-0.315	0.374
Week 12	63	5.871	1.988	5.903	1.889	-0.032	1.391	-0.074	0.163
Week 26	59	5.703	1.786	5.946	1.945	-0.242	0.975	-0.269	0.153
Week 39	48	6.002	2.011	6.017	2.039	-0.015	1.199	-0.037	0.169
Week 52	46	5.854	1.544	5.850	1.520	0.004	1.223	-0.059	0.195
Final on-therapy	77	5.891	1.874	5.910	1.808	-0.019	1.518	-0.079	0.148
Follow-up	7	5.843	1.679	5.843	1.094	0.000	1.261	-0.075	0.433

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

91

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

TEST: WBC (10^9/L) / PART 2: BETWEEN TREATMENTS									
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1	COMPARED Comparator 2	DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE			
Week 4	0.307	DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0.108 0.063 -0.145 -0.118 -0.046 -0.254 -0.226 -0.208 -0.180 0.028	0.130 0.132 0.135 0.155 0.133 0.136 0.155 0.138 0.157	0.405 0.636 0.283 0.448 0.730 0.062 0.145 0.132 0.251 0.861			
Week 8	0.997		DVS SR 150 mg Placebo	0.091 0.017 0.045 -0.074 -0.046 0.028	0.421 0.413 0.466 0.460 0.498 0.477	0.830 0.967 0.924 0.874 0.927 0.954			
Week 12	0.814	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-0.026 0.033 -0.170 -0.109 0.059 -0.144 -0.083 -0.203 -0.143 0.060	0.170 0.176 0.180 0.203 0.175 0.178 0.202 0.184 0.207 0.210	0.879 0.849 0.345 0.591 0.735 0.420 0.680 0.271 0.492 0.774			
Week 26	0.830	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg	DVS SR 200 mg	-0.013 -0.072 -0.185 -0.011 -0.058	0.164 0.171 0.175 0.193 0.167	0.935 0.675 0.290 0.956 0.728			

Page

92

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

	TEST: W	BC (10^9/L) / PA	RT 2: BETWEEN T	REATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1			STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 26 (cont.)	0.830	DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	Placebo DVS SR 200 mg Placebo	-0.172 0.003 -0.114 0.061 0.175	0.171 0.190 0.178 0.196 0.199	0.316 0.988 0.524 0.756 0.381
Week 39	0.177	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0.183 0.090 -0.219 -0.188 -0.093 -0.403 -0.371 -0.309 -0.278 0.032	0.174 0.179 0.188 0.209 0.179 0.187 0.209 0.192 0.214	0.293 0.615 0.244 0.371 0.603 0.032* 0.077 0.108 0.194 0.886
Week 52	0.541	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0.071 -0.013 -0.267 -0.194 -0.084 -0.338 -0.265 -0.254 -0.181 0.073	0.204 0.214 0.219 0.242 0.215 0.220 0.243 0.230 0.252	0.728 0.952 0.225 0.423 0.696 0.125 0.275 0.270 0.472 0.776
Final on-therapy	0.968	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg	-0.018 -0.084 -0.047 -0.112 -0.066 -0.028	0.155 0.157 0.160 0.184 0.158 0.161	0.906 0.593 0.771 0.545 0.677 0.860

Page

93

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

	TEST: W	BC (10^9/L) / PA	RT 2: BETWEEN T	TREATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED Comparator 2	DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Final on-therapy (cont.)	0.968	DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo	-0.093 0.037 -0.028 -0.065	0.185 0.163 0.187 0.189	0.613 0.819 0.883 0.731
Follow-up	0.993	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0.098 -0.001 -0.002 0.122 -0.099 -0.100 0.024 -0.000 0.124 0.124	0.303 0.295 0.298 0.492 0.263 0.269 0.474 0.259 0.468 0.471	0.748 0.996 0.995 0.804 0.707 0.711 0.959 0.999 0.792

Page

94

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

			120 (10)/	D) / III(I	.	IN TREATMENT			
TREATMENT		OBSERV	ED	BASELI	NE	CHANGE	1	ADJUSTED	[2]
Data Analysis Interval [1]	[N] -	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 50 mg	6			7.467	2.849				
Screening/baseline	6	7.467	2.849	7.467	2.849				
Week 4	2 2	7.590	2.192	8.255	1.464	-0.665	0.728	-0.420	0.783
Week 12	2	5.890	6.095	5.605	5.211	0.285	0.884	0.230	1.642
Week 26	4 2 2 5	7.153	3.978	6.788	3.360	0.365	0.758	0.556	0.693
Week 39	2	5.175	5.367	5.605	5.211	-0.430	0.156	-0.581	0.268
Week 52	2	8.230	1.428	8.390	0.467	-0.160	0.962	-0.380	0.756
Final on-therapy	5	6.754	3.171	7.042	2.965	-0.288	0.506	-0.336	0.885
DVS SR 100 mg	12	0 117	0 070	3.117	2.070				
Screening/baseline	12 6	3.117	2.070 2.822	3.117	2.070	0 045	0 5 6 4	0 155	0.442
Week 4 Week 8	1	3.417 1.620	2.822	3.462 1.550	2.434	-0.045 0.070	0.564	-0.155 0.070	0.442
Week 12	6	3.733	2.987	3 250	2.588	0.483	0.464	0.561	0.967
Week 12 Week 26	8	3.748	3.279	3.250 2.989	2.267	0.759	1.161	0.715	0.441
Week 39	4	3.425	2.968	3.095	2.694	0.330		0.311	0.165
Week 52	6	3.528	2.633	3.477	2.452	0.052	0.468 0.720	0.049	0.270
Final on-therapy		3.580	2.472	3.319	2.340	0.261	0.652	0.282	0.636
Follow-up	9 3	1.803	0.249	3.319 1.653	0.367	0.150	0.617	-2.166**	0.012
DVS SR 150 mg	10			3.786	3.443				
Screening/baseline	10	3.786	3.443	3.786 3.786	3.443				
Week 4	2 2	5.855	6.230	5.035	5.028	0.820	1.202	0.826	0.738
Week 12	2	5.460	5.487	5.035	5.028	0.425	0.460	0.402	1.637
Week 26	4 3	1.930	0.238	1.708	0.233	0.223	0.151	0.099	0.649
Week 39	3	2.047	0.099	1.710	0.286	0.337	0.318	0.390	0.195
Week 52	2 5 1 7	2.270	0.226	1.755	0.389	0.515	0.163	0.589	0.509
Final on-therapy	5	3.610	3.207	3.084	3.085	0.526**	0.176	0.551	0.850
Follow-up	1	8.870		8.590	2 505	0.280		9.601**	0.047
DVS SR 200 mg	7	E 470	2 505	5.479	3.585				
Screening/baseline Week 4	2	5.479 5.585	3.585 5.268	5.479 5.135	3.585 4.999	0.450	0.269	0.464	0.739
Week 12	4	7.510	7.320	5.318	4.291	2.193	4.070	2.154	1.161
Week 12 Week 26	3	1.780	0.056	1.713	0.179	0.067	0.138	-0.056	0.740
			0.000	± • / ± J	U • 1 / J	0.007	O • 1 3 0	0.000	0./10

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.
THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES. $[{\tt N}]$ - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

95

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

	TEST:	NEUTROPHI	LS (10^9/	L) / PART	1: WITH	IN TREATMEN	Γ		
TREATMENT		OBSERV	'ED	BASELI	NE	CHANG	ЭE	ADJUSTEI	D [2]
Data Analysis Interval [1] [N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 200 mg (cont.)									
Week 52	2	1.840	0.325	1.760	0.226	0.080	0.099	0.154	0.508
Final on-therapy	5	6.250	6.928	4.638	4.015	1.612	3.721	1.609	0.836
Follow-up	1	1.480		1.620		-0.140		-2.512**	0.013
Placebo	5			4.066	5.219				
Screening/baseline	5	4.066	5.219	4.066	5.219				
Week 4	3	4.513	4.915	5.543	6.803	-1.030	1.889	-0.986	0.605
Week 12	3	4.493	4.840	5.543	6.803	-1.050	1.978	-1.101	1.343
Week 26	2	5.435	5.084	7.345	8.549	-1.910	3.465	-1.685	0.948
Week 39	2	1.800	0.382	1.620	0.453	0.180	0.071	0.238	0.238
Week 52	2	1.760	0.339	1.620	0.453	0.140	0.113	0.220	0.515
Final on-therapy	3	4.183	4.204	5.543	6.803	-1.360	2.599	-1.380	1.086

CONFIDENTIAL 1040 Wyeth

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

96

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

	TEST: NEUTR	ROPHILS (10^9/L) / PART 2: BET	WEEN TREATMENT	TS .	
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS COMPARED Comparator 1 Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 4	0.407	DVS SR 50 mg DVS SR 100 m DVS SR 50 mg DVS SR 150 m DVS SR 50 mg DVS SR 200 m DVS SR 50 mg Placebo DVS SR 100 mg DVS SR 200 m DVS SR 100 mg DVS SR 200 m DVS SR 100 mg Placebo DVS SR 150 mg DVS SR 200 m DVS SR 150 mg DVS SR 200 m DVS SR 150 mg Placebo DVS SR 200 mg Placebo	9 -1.246 9 -0.884 0.566 9 -0.982 9 -0.619 0.831	0.756	0.783 0.276 0.431 0.577 0.284 0.491 0.301 0.736 0.090 0.163
Week 12	0.510	DVS SR 50 mg DVS SR 100 m DVS SR 50 mg DVS SR 150 m DVS SR 50 mg DVS SR 200 m DVS SR 100 mg DVS SR 150 m DVS SR 100 mg DVS SR 150 m DVS SR 100 mg DVS SR 200 m DVS SR 100 mg DVS SR 200 m DVS SR 150 mg DVS SR 200 m DVS SR 150 mg DVS SR 200 m DVS SR 150 mg DVS SR 200 m	g -0.172 g -1.924 1.332 g 0.158 g -1.593 1.662	1.922 2.315 2.004 2.112 1.908 1.526 1.672 2.004 2.113 1.767	0.867 0.942 0.358 0.541 0.935 0.319 0.342 0.401 0.492 0.093
Week 26	0.232	DVS SR 50 mg DVS SR 100 m DVS SR 50 mg DVS SR 150 m DVS SR 50 mg DVS SR 200 m DVS SR 50 mg Placebo DVS SR 100 mg DVS SR 200 m DVS SR 100 mg DVS SR 200 m DVS SR 100 mg Placebo DVS SR 150 mg Placebo DVS SR 150 mg Placebo	g 0.456 g 0.612 2.241 g 0.615 g 0.771 2.400	0.849 1.015 1.075 1.068 0.765 0.844 1.071 0.940 1.214 1.264	0.854 0.660 0.578 0.053 0.434 0.375 0.041* 0.871 0.162 0.217
Week 39	0.129	DVS SR 50 mg DVS SR 100 m	g -0.892	0.307	0.023*

Page

97

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

Т	EST: NEUTRO	OPHILS (10^9/L)	/ PART 2: BETWE	EN TREATMENT	S	
Data Analysis Interval [1]	OVERALL P-VALUE				STDERR OF DIFF. BET. ADJ. MEANS	
Week 39 (cont.)	0.129	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	-0.582 -0.819 -0.079 0.310 0.072 0.389	0.374 0.377 0.259 0.291 0.292 0.299	0.028* 0.163 0.066 0.768 0.322 0.811 0.235 0.627 0.493
Week 52	0.886	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	-0.968 -0.533 -0.599 -0.539 -0.104 -0.170 0.435	1.033 1.032 1.045 0.578 0.578 0.584	0.605 0.376 0.619 0.582 0.378 0.861 0.778 0.529 0.593 0.923
Final on-therapy	0.287	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	-0.887 -1.944 1.044 -0.269 -1.327 1.662 -1.057 1.931	1.264 1.213 1.375 1.043 1.053 1.271 1.195 1.393	0.589 0.491 0.124 0.456 0.799 0.222 0.205 0.386 0.180 0.040*
llow-up	0.005**	DVS SR 100 mg DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	-11.768 0.346	0.058 0.005	0.003** 0.009**

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

Page 98

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

TEST: NEUTROPHILS (10^9/L) / PART 2: BETWEEN TREATMENTS

Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1			STDERR OF DIFF. BET. ADJ. MEANS	
Follow-up (cont.)	0.005**	DVS SR 150 mg	DVS SR 200 mg	12.114	0.058	0.003**

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES. ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES. STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY). STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

CONFIDENTIAL 1043 Wyeth

Page

99

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

	ILDI.	птипостт	E9 (10 9/	T) / FALT	T: WIII.	IN TREATMENT			
TREATMENT		OBSERV	ED	BASELI	NE	CHANG	₹.	ADJUSTEI) [2]
Data Analysis Interval [1]	[N]	MEAN	STD -	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 50 mg	6			2.555 2.555	0.818				
Screening/baseline	6	2.555	0.818	2.555	0.818				
Week 4	2 2 4	3.010	1.230	3.205	0.983	-0.195	0.247	-0.059	0.341
Week 12	2	1.775	0.233	1.950	0.792	-0.175	0.559	-0.172	0.401
Week 26	4	2.425	1.003	2.528	1.037	-0.103	0.142	-0.087	0.245
Week 39	2	1.570	0.622	1.950	0.792	-0.380	0.170	-0.280**	0.077
Week 52	2 2 5	2.725	0.375	2.580 2.592	0.382	0.145*	0.007	0.173	0.376
Final on-therapy	5	2.482	1.012	2.592	0.909	-0.110	0.276	-0.103	0.256
DVS SR 100 mg	12	1 020	1 444	1.938 1.938	1.444				
Screening/baseline	12 6	1.938	1.444	1.938	1.444	-0.037	0 441	0 001	0 107
Week 4 Week 8	b 1	2.115 0.950	1.750	2.152 1.270	1.811	-0.037	0.441	-0.031 -0.320	0.187
Week 0 Week 12	1 6 8	2.095	1.895	2.210	1.766	-0.320	0.525	-0.320	0.000
Week 12 Week 26	0	1.773	1.895	1.766	1.236	0.006	0.323	0.008	0.234
Week 39	4	1.425	0.948	1 740	1.221	-0.315	0.324	-0.262**	0.133
Week 59 Week 52	4 6	2.000	1.507	1.740 1.935	1.406	0.065	0.312 0.620	0.072	0.033
Final on-therapy	9	2.193	1.844	2 1/10	1.627	0.046	0.560	0.048	0.186
Follow-up	9	1.070	0.246	2.148 1.323	0.249	-0.253	0.146	-0.304	0.191
DVS SR 150 mg	10	1.070	0.240	1 608	0.666	0.233	0.140	0.504	0.101
DVS SR 150 mg Screening/baseline	10	1.608	0.666	1.608 1.608	0.666				
Week 4	2	1.735	0.940	1 905	1.039	-0.170	0.099	-0.195	0.324
Week 12	2	1.630	0.778	1.905 1.905	1.039	-0.275	0.262	-0.277	0.401
Week 26	4	0.993	0.268	1.208	0.075	-0.215	0.197	-0.224	0.232
Week 39	2 2 4 3 2 5 1 7	0.970	0.173	1.217	0.090	-0.247*	0.085	-0.310**	0.062
Week 52	2	0.870	0.014	1.165	0.007	-0.295*	0.007	-0.313	0.362
Final on-therapy	5	1.222	0.550	1.494	0.644	-0.272**	0.126	-0.277	0.252
Follow-up	1	2.470		2.640		-0.170		0.022	0.612
Follow-up DVS SR 200 mg				2.640 2.016	0.902				
Screening/baseline	7	2.016	0.902	2.016	0.902				
Week 4	2	1.685	0.813	2.120	1.782	-0.435	0.969	-0.433	0.323
Week 12	4	1.578	0.537	1.888 1.193	1.085	-0.310	0.560	-0.314	0.283
Week 26	4 3 2	1.290	0.401	1.193	0.290	0.097	0.112	0.087	0.266
Week 39	2	1.040	0.269	1.095	0.332	-0.055	0.064	-0.146	0.076

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.
THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 100

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

	TEST:	LYMPHOCYT	ES (10^9/	L) / PART	1: WITH	IN TREATMENT	Γ		
TREATMENT		OBSERV	ED	BASELI	NE	CHANG	GE	ADJUSTEI	[2]
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 200 mg (cont.)									
Week 52	2	1.130	0.113	1.095	0.332	0.035	0.219	0.014	0.365
Final on-therapy	5	1.556	0.472	1.776	0.972	-0.220	0.536	-0.222	0.249
Follow-up	1	1.530		1.390		0.140		0.101	0.229
Placebo	5			1.412	0.242				
Screening/baseline	5	1.412	0.242	1.412	0.242				
Week 4	3	1.377	0.302	1.400	0.181	-0.023	0.339	-0.110	0.273
Week 12	3	1.497	0.687	1.400	0.181	0.097	0.722	0.044	0.333
Week 26	2	2.095	1.294	1.485	0.148	0.610	1.442	0.606	0.318
Week 39	2	1.105	0.219	1.410	0.255	-0.305	0.035	-0.325**	0.074
Week 52	2	1.135	0.120	1.410	0.255	-0.275	0.134	-0.285	0.355
Final on-therapy	3	1.760	1.086	1.400	0.181	0.360	1.104	0.354	0.325

CONFIDENTIAL 1045 Wyeth

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 101

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

Tì	EST: LYMPH	OCYTES (10^9/L) / PAR	RT 2: BETWEE	N TREATMENTS	5	
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS COMP			STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 4	0.863	DVS SR 50 mg DVS	SR 150 mg SR 200 mg Sebo SR 200 mg	-0.028 0.135 0.374 0.051 0.164 0.402 0.079 0.238 -0.084 -0.323	0.387 0.475 0.470 0.454 0.374 0.373 0.332 0.458 0.420 0.423	0.943 0.782 0.446 0.913 0.672 0.309 0.816 0.615 0.845 0.465
Week 12	0.924	DVS SR 50 mg DVS DVS SR 100 mg Plac DVS SR 150 mg DVS DVS SR 150 mg Plac DVS SR 150 mg Plac DVS SR 200 mg Plac	SR 150 mg SR 200 mg sebo SR 150 mg SR 200 mg sebo SR 200 mg	-0.086 0.105 0.141 -0.216 0.191 0.228 -0.130 0.037 -0.321 -0.357	0.464 0.566 0.491 0.522 0.464 0.368 0.413 0.491 0.521 0.437	0.856 0.857 0.779 0.687 0.689 0.549 0.759 0.942 0.551 0.431
Week 26	0.343	DVS SR 50 mg DVS DVS SR 50 mg DVS DVS SR 50 mg Plac	SR 200 mg cebo SR 150 mg SR 200 mg cebo SR 200 mg	-0.094 0.138 -0.174 -0.693 0.232 -0.079 -0.598 -0.311 -0.830 -0.519	0.289 0.354 0.378 0.408 0.283 0.311 0.356 0.342 0.390 0.411	0.749 0.703 0.652 0.110 0.425 0.802 0.114 0.378 0.050 0.226
Week 39	0.487	DVS SR 50 mg DVS	SR 100 mg	-0.018	0.091	0.849

Page 102

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

TI	EST: LYMPHO	OCYTES (10^9/L)	/ PART 2: BETWE	EN TREATMENT	S	
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1		DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	
Week 39 (cont.)	0.487	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	-0.116 0.064 -0.164 0.015	0.107 0.083 0.095 0.092	0.770 0.270 0.682 0.577 0.264 0.509 0.129 0.880 0.133
Week 52	0.814	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	0.058 0.357 -0.328 -0.028	0.548 0.530 0.423 0.427 0.414	0.815 0.397 0.779 0.412 0.389 0.896 0.413 0.529 0.956 0.566
Final on-therapy	0.534		DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	0.175 0.119 -0.456 0.325 0.270 -0.306 -0.055 -0.631	0.368 0.360 0.423 0.316 0.312 0.377	0.635 0.640 0.743 0.293 0.316 0.396 0.427 0.877 0.134 0.172
Follow-up	0.493		DVS SR 150 mg DVS SR 200 mg		0.768 0.230	0.744 0.328

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

Page 103

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

TEST: LYMPHOCYTES (10^9/L) / PART 2: BETWEEN TREATMENTS

Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1			STDERR OF DIFF. BET. ADJ. MEANS	
Follow-up (cont.)	0.493	DVS SR 150 mg	DVS SR 200 mg	-0.079	0.750	0.933

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.
ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.
ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.
STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.
COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY).
STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

CONFIDENTIAL 1048 Wyeth

Page 104

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

	TEST:	EOSINOPHI	LS (10^9/	L) / PART	IN TREATMENT				
TREATMENT		OBSERV	ED	BASELI	NE	CHANG	E	ADJUSTED	[2]
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 50 mg	6			0.248	0.116				
Screening/baseline	6	0.248	0.116	0.248	0.116				
Week 4	2 2 4 2 2 5	0.350	0.014	0.335	0.049	0.015	0.064	0.139*	0.057
Week 12	2	0.105	0.007	0.190	0.156	-0.085	0.148	-0.084*	0.038
Week 26	4	0.165	0.157	0.270	0.130	-0.105	0.148	-0.072	0.054
Week 39	2	0.080	0.042	0.190	0.156	-0.110	0.198	-0.092	0.068
Week 52	2	0.120	0.141	0.305	0.035	-0.185	0.177	-0.185	0.097
Final on-therapy	10	0.158	0.151	0.272	0.113	-0.114	0.157	-0.078	0.051
DVS SR 100 mg Screening/baseline	12 12	0.126	0.131	0.126 0.126	0.131 0.131				
Week 4	6	0.128	0.131	0.128	0.151	-0.052	0.168	-0.139**	0.034
Week 4 Week 8	1	0.010	0.031	0.040	0.136	-0.032	0.100	-0.139	0.000
Week 12	6	0.090	0.098	0.115	0.157	-0.025	0.067	-0.063*	0.024
Week 26	8	0.115	0.147	0.089	0.109	0.025	0.050	0.003	0.038
Week 39	4	0.090	0.024	0.070	0.036	0.020	0.042	-0.005	0.052
Week 52	6	0.153	0.178	0.103	0.122	0.050	0.105	0.050	0.052
Final on-therapy	9	0.142	0.158	0.127	0.152	0.016	0.109	-0.013	0.038
Follow-up	9 3	0.083	0.057	0.090	0.072	-0.007	0.015	-0.027*	0.001
DVS SR 150 mg	10			0.188	0.121				
Screening/baseline	10	0.188	0.121	0.188	0.121				
Week 4	2 2	0.300	0.028	0.395	0.064	-0.095	0.092	0.087	0.062
Week 12	2	0.080	0.071	0.395	0.064	-0.315*	0.007	-0.209***	0.046
Week 26	4	0.098	0.048	0.205	0.110	-0.108	0.131	-0.095	0.049
Week 39	4 3 2 5 1 7	0.170	0.200	0.200	0.135	-0.030	0.113	-0.008	0.057
Week 52	2	0.145	0.205	0.255	0.134	-0.110	0.071	-0.110	0.089
Final on-therapy	5	0.140	0.104	0.252	0.142	-0.112	0.129	-0.085	0.050
Follow-up DVS SR 200 mg	1	0.270		0.440	0 110	-0.170		-0.116*	0.003
DVS SK 200 mg		0 101	0 110	0.191	0.112				
Screening/baseline	7 2	0.191 0.140	0.112 0.170	0.191 0.135	0.112 0.120	0.005	0 040	0 000	0 054
Week 4 Week 12	4	0.140	0.170	0.135	0.120	-0.080	0.049	-0.066 -0.091**	0.054
Week 12 Week 26	3	0.088	0.078	0.168	0.079	-0.080	0.104	-0.091^^	0.027
Week 20 Week 39	2	0.050	0.013	0.100	0.093	0.005	0.110	-0.029	0.038
WCCK JJ	۷	0.050	0.014	0.043	0.007	0.000	0.007	0.023	0.073

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

Page 105

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

	TEST:	EOSINOPHI	LS (10 ⁹ /	L) / PART	1: WITH	IN TREATMENT			
TREATMENT Data Analysis Interval [1]	[N]	OBSERV	EDSTD _	BASELI MEAN	NESTD	CHANG	ESTD	ADJUSTEI	[2] STDERR
Data Anarysis interval [1]	[14]	MEAN	510	MEAN	510	PIEAN	310	PIEAN	SIDEM
DVS SR 200 mg (cont.)									
Week 52	2	0.050	0.028	0.045	0.007	0.005	0.021	0.005	0.093
Final on-therapy	5	0.080	0.066	0.142	0.089	-0.062	0.082	-0.084	0.049
Follow-up	1	0.020		0.210		-0.190		-0.185**	0.001
Placebo	5			0.162	0.112				
Screening/baseline	5	0.162	0.112	0.162	0.112				
Week 4	3	0.213	0.085	0.227	0.090	-0.013	0.153	0.005	0.043
Week 12	3	0.200	0.046	0.227	0.090	-0.027	0.047	-0.007	0.032
Week 26	2	0.300	0.028	0.270	0.071	0.030	0.042	0.063	0.073
Week 39	2	0.220	0.099	0.230	0.127	-0.010	0.028	0.023	0.072
Week 52	2	0.145	0.007	0.230	0.127	-0.085	0.134	-0.085	0.086
Final on-therapy	3	0.190	0.078	0.227	0.090	-0.037	0.127	-0.021	0.063

CONFIDENTIAL 1050 Wyeth

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 106

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

	TEST: EOSIN	OPHILS (10^9/L)	/ PART 2: BETWE	EN TREATMENT	'S	
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1			STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 4	0.036*	DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo		0.060	0.004** 0.507 0.034* 0.088 0.018* 0.257 0.030* 0.114 0.293 0.332
Week 12	0.039*	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Placebo	0.146 0.028 -0.056 -0.118 -0.202	0.060 0.047 0.050 0.056 0.035 0.041 0.055 0.054	0.645 0.062 0.891 0.147 0.025* 0.448 0.197 0.055 0.003**
Week 26	0.278	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 200 mg	0.023 0.002 -0.135 0.097 0.076 -0.061 -0.021 -0.158	0.070 0.083 0.084 0.065 0.066 0.087 0.078	0.318 0.748 0.983 0.130 0.155 0.267 0.494 0.790 0.084 0.176
Week 39	0.773	DVS SR 50 mg	DVS SR 100 mg	-0.087	0.090	0.365

Page 107

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

Т	EST: EOSING	OPHILS (10^9/L)	/ PART 2: BETWE	EN TREATMENT	'S	
Data Analysis Interval [1]	OVERALL P-VALUE				STDERR OF DIFF. BET. ADJ. MEANS	
Week 39 (cont.)		DVS SR 50 mg DVS SR 50 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	-0.063 -0.114	0.104 0.094	0.729
Week 52	0.418	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	-0.275 -0.190 -0.100 0.160	0.119 0.149 0.120 0.110	0.085 0.545 0.238 0.430 0.183 0.659 0.237 0.431 0.837 0.521
Final on-therapy	0.666	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	0.007 0.005 -0.057 0.072 0.071 0.008 -0.001 -0.064	0.069 0.073 0.080 0.065 0.061 0.075 0.072 0.080	0.333 0.922 0.941 0.481 0.277 0.257 0.915 0.984 0.429 0.446
Follow-up	0.010**	DVS SR 100 mg DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	0.089 0.158	0.004	0.029* 0.008**

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

Page 108

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

TEST: EOSINOPHILS (10^9/L) / PART 2: BETWEEN TREATMENTS

Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1			STDERR OF DIFF. BET. ADJ. MEANS	
Follow-up (cont.)	0.010**	DVS SR 150 mg	DVS SR 200 mg	0.069	0.003	0.028*

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.
ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.
ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.
STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.
COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY).
STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

CONFIDENTIAL 1053 Wyeth

Page 109

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

	TEST: MONOCYTES (10^9/L) / PART 1: WITHIN TREATMENT								
TREATMENT	OBSERVED			BASELI	NE	CHANG	Е	ADJUSTED	[2]
Data Analysis Interval [1]	[N] -	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 50 mg	6			0.442	0.169				
DVS SR 50 mg Screening/baseline	6	0.442	0.169	0.442	0.169				
Week 4	2	0.475	0.219	0.505	0.219	-0.030	0.000	-0.014	0.065
Week 12	2	0.355	0.092	0.325	0.035	0.030	0.057	0.030	0.074
Week 26	4 2 2 5	0.403	0.213	0.425	0.161	-0.023	0.055	0.003	0.050
Week 39	2	0.300	0.057	0.325	0.035	-0.025	0.021	-0.032	0.047
Week 52	2	0.530	0.014	0.345	0.064	0.185	0.049	0.220***	0.025
Final on-therapy	5	0.474	0.177	0.400	0.150	0.074	0.109	0.087	0.051
DVS SR 100 mg	12 12	0.264	0.143	0.264	0.143 0.143				
Screening/baseline Week 4	6	0.264	0.143	0.264 0.240	0.143	-0.023	0.032	-0.029	0.035
Week 4 Week 8	0 1	0.217	0.137	0.240	0.138	-0.023	0.032	-0.029	0.000
Week 12	6	0.210	0.139	0.230	0.127	-0.020	0.066	-0.020	0.044
Week 12 Week 26	8	0.203	0.144	0.270	0.168	-0.068	0.115	-0.076*	0.033
Week 39	4	0.198	0.181	0.238	0.145	-0.040	0.089	-0.040	0.031
Week 52	6	0.203	0.114	0.275	0.193	-0.072	0.085	-0.067**	0.014
Final on-therapy	9	0.212	0.146		0.161	-0.069	0.126	-0.075	0.037
Follow-up	3	0.260	0.115	0.281 0.257	0.075	0.003	0.040	0.018	0.004
VS SR 150 mg	10			0.294	0.157				
Screening/baseline	10	0.294	0.157	0.294	0.157				
Week 4	2	0.215	0.064	0.190	0.000	0.025	0.064	0.015	0.060
Week 12	2	0.265	0.035	0.190	0.000	0.075	0.035	0.077	0.080
Week 26	4	0.225	0.070	0.225	0.118	0.000	0.087	-0.018	0.048
Week 39	3	0.230	0.017	0.167	0.021	0.063*	0.015	0.069	0.039
Week 52	2 5	0.200	0.000	0.170	0.028	0.030	0.028	-0.010	0.026
Final on-therapy	5	0.236	0.041	0.218	0.103	0.018	0.070	0.001	0.052
Follow-up VS SR 200 mg	1 7	0.180		0.190 0.449	0.187	-0.010		0.040	0.008
Screening/baseline	7	0.449	0.187	0.449	0.187				
Week 4	2	0.449	0.304	0.449	0.107	0.075	0.078	0.077	0.057
Week 12	4	0.413	0.254	0.428	0.171	0.073	0.175	0.077	0.057
Week 26	3	0.210	0.089	0.280	0.156	-0.070	0.075	-0.076	0.054
Week 39	2.	0.190	0.028	0.190	0.014	0.000	0.042	0.004	0.045

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 110

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

	TEST:	MONOCYTE	S (10^9/I) / PART	1: WITHI	N TREATMENT			
TREATMENT Data Analysis Interval [1]	[N] OBSERVED STD		BASELI MEAN	NESTD	CHANGESTD		ADJUSTED [2] MEAN STDER		
DVS SR 200 mg (cont.)									
Week 52	2	0.220	0.057	0.190	0.014	0.030	0.071	-0.001	0.025
Final on-therapy	5	0.422	0.240	0.382	0.180	0.040	0.128	0.050	0.050
Follow-up	1	0.260		0.460		-0.200		-0.294*	0.012
Placebo	5			0.346	0.108				
Screening/baseline	5	0.346	0.108	0.346	0.108				
Week 4	3	0.210	0.061	0.380	0.121	-0.170	0.147	-0.164**	0.047
Week 12	3	0.293	0.112	0.380	0.121	-0.087*	0.025	-0.087	0.062
Week 26	2	0.400	0.212	0.435	0.106	-0.035	0.106	-0.007	0.068
Week 39	2	0.245	0.064	0.315	0.064	-0.070	0.000	-0.076	0.047
Week 52	2	0.245	0.078	0.315	0.064	-0.070	0.014	-0.048	0.025
Final on-therapy	3	0.347	0.184	0.380	0.121	-0.033	0.064	-0.024	0.064

CONFIDENTIAL 1055 Wyeth

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 111

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

	TEST: MONO	CYTES (10^9/L) /	PART 2: BETWEE	N TREATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1	COMPARED Comparator 2	DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	
Week 4	0.071	DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg	DVS SR 200 mg Placebo	0.015 -0.029 -0.091 0.150 -0.044 -0.107 0.135 -0.062 0.179 0.242	0.079 0.096 0.084 0.076 0.066 0.067 0.061 0.084 0.079	0.853 0.768 0.307 0.079 0.517 0.147 0.054 0.054 0.050 0.009**
Week 12	0.497	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 200 mg	0.036 -0.047 -0.001 0.117 -0.083 -0.037 0.081 0.046 0.164 0.119	0.086 0.109 0.093 0.096 0.087 0.076 0.078 0.106 0.105 0.080	0.683 0.676 0.990 0.247 0.364 0.635 0.318 0.675 0.146
Week 26	0.621	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg	DVS SR 200 mg Placebo	0.079 0.022 0.079 0.010 -0.058 0.000 -0.069 0.058 -0.011 -0.069	0.061 0.072 0.074 0.080 0.057 0.063 0.077 0.071 0.086 0.088	0.216 0.769 0.300 0.899 0.329 0.996 0.387 0.429 0.898
Week 39	0.281	DVS SR 50 mg	DVS SR 100 mg	0.008	0.057	0.892

Page 112

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

	TEST: MONOC	CYTES (10^9/L) /	PART 2: BETWEE	N TREATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1		DIFF. BET. ADJ. MEANS		PAIRWISE P-VALUE
Week 39 (cont.)	0.281	DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	-0.101 -0.036 0.044 -0.109 -0.044 0.036 0.065 0.145 0.080	0.067 0.069 0.061 0.049 0.054 0.056 0.056 0.065	0.173 0.617 0.493 0.063 0.444 0.537 0.282 0.062 0.275
Week 52	<0.001***	DVS SR 100 mg DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0.286 0.229 0.221 0.268 -0.057 -0.066 -0.019 -0.009 0.038 0.047	0.029 0.037 0.037 0.035 0.030 0.029 0.029 0.035 0.037 0.036	<pre><0.001*** <0.001*** <0.001*** <0.001*** 0.090 0.055 0.532 0.813 0.326 0.231</pre>
Final on-therapy	0.139	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0.162 0.086 0.037 0.111 -0.076 -0.126 -0.052 -0.049 0.025 0.074	0.064 0.075 0.070 0.081 0.062 0.063 0.075 0.074 0.084	0.019* 0.266 0.602 0.184 0.233 0.061 0.497 0.516 0.773 0.370
Follow-up	0.042*		DVS SR 150 mg DVS SR 200 mg	-0.022 0.312	0.008 0.013	0.215 0.027*

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

Page 113

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

TEST: MONOCYTES (10^9/L) / PART 2: BETWEEN TREATMENTS

Data Analysis Interval [1]	OVERALL P-VALUE				STDERR OF DIFF. BET. ADJ. MEANS	
Follow-up (cont.)	0.042*	DVS SR 150 mg	DVS SR 200 mg	0.335	0.017	0.033*

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.

COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY).

STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

CONFIDENTIAL 1058 Wyeth

Page 114

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

TREATMENT	OBSERVED			BASELINE			CHANGE		ADJUSTED [2]	
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR	
VS SR 50 mg	6			0.040	0.020					
Screening/baseline	6 2 2 4 2 2 5	0.040	0.020	0.040	0.020					
Week 4	2	0.025	0.021	0.050	0.000	-0.025	0.021	-0.006	0.011	
Week 12	2	0.025	0.007	0.035	0.021	-0.010	0.014	-0.002	0.009	
Week 26	4	0.023	0.015	0.043	0.015	-0.020	0.014	0.001	0.007	
Week 39	2	0.020	0.014	0.035	0.021	-0.015	0.007	-0.003	0.007	
Week 52	2	0.050	0.014	0.030	0.028	0.020	0.042	0.034**	0.009	
Final on-therapy	5	0.030	0.021	0.036	0.019	-0.006	0.034	0.007	0.007	
DVS SR 100 mg	12			0.015	0.012					
Screening/baseline	12	0.015	0.012	0.015	0.012					
Week 4	6 1 6 8	0.017	0.008	0.013	0.016	0.003	0.015	-0.002	0.005	
Week 8	1	0.000		0.020		-0.020		-0.020	0.000	
Week 12	6	0.017	0.018	0.018	0.013	-0.002	0.012	-0.004	0.005	
Week 26		0.014	0.007	0.013	0.012	0.001	0.011	-0.003	0.004	
Week 39	4	0.018	0.010	0.010	0.012	0.008	0.013	0.004	0.004	
Week 52	6	0.012	0.012	0.012	0.013	0.000	0.013	-0.003	0.005	
Final on-therapy	9	0.016	0.016	0.016	0.014	0.000	0.011	-0.004	0.005	
Follow-up		0.013	0.006	0.010	0.010	0.003	0.006	-0.001	0.003	
DVS SR 150 mg	10	0 010	0 010	0.019 0.019	0.012					
Screening/baseline	10	0.019	0.012	0.019	0.012		0 001	0 010		
Week 4	2	0.005	0.007	0.030	0.014	-0.025	0.021 0.014	-0.019	0.009	
Week 12		0.010	0.000	0.030	0.014	-0.020		-0.015	0.009	
Week 26 Week 39	4	0.010 0.013	0.008	0.013 0.017	0.010	-0.003 -0.003	0.010	-0.007 -0.003	0.005	
Week 59 Week 52	2 2 4 3 2 5	0.013	0.000	0.017	0.006	-0.003	0.006	-0.003	0.004	
	2	0.010	0.000	0.013	0.007	-0.003	0.007	-0.005	0.008	
Final on-therapy	1	0.010	0.000	0.018	0.013	-0.030	0.013	-0.010	0.008	
Follow-up DVS SR 200 mg	7	0.010		0.040	0.018	-0.030		-0.019	0.000	
Screening/baseline		0.026	0.018	0.026	0.018					
Week 4	7 2 4 3	0.020	0.018	0.020	0.018	0.000	0.000	-0.001	0.009	
Week 12	7	0.020	0.028	0.025	0.028	-0.013	0.015	-0.001	0.009	
Week 12 Week 26	3.	0.013	0.010	0.023	0.019	0.000	0.013	-0.011	0.006	
Week 39	2	0.010	0.000	0.010	0.010	0.005	0.010	-0.007	0.006	

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.
THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 115

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

	TEST:	BASOPHII	S (10^9/L) / PART	1: WITHI	N TREATMENT			
TREATMENT		OBSERV	ED	BASELI	NE	CHANGE	3	ADJUSTE	D [2]
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
VS SR 200 mg (cont.)									
Week 52	2	0.010	0.000	0.005	0.007	0.005	0.007	-0.004	0.009
Final on-therapy	5	0.014	0.005	0.022	0.018	-0.008	0.013	-0.007	0.006
Follow-up	1	0.010		0.020		-0.010		-0.009	0.004
Placebo	5			0.012	0.011				
Screening/baseline	5	0.012	0.011	0.012	0.011				
Week 4	3	0.020	0.000	0.013	0.015	0.007	0.015	0.001	0.007
Week 12	3	0.020	0.010	0.013	0.015	0.007	0.025	0.001	0.007
Week 26	2	0.020	0.014	0.015	0.021	0.005	0.035	0.002	0.007
Week 39	2	0.020	0.000	0.020	0.014	0.000	0.014	0.002	0.005
Week 52	2	0.010	0.014	0.020	0.014	-0.010***	0.000	-0.005	0.008
Final on-therapy	3	0.017	0.015	0.013	0.015	0.003	0.023	-0.003	0.008

CONFIDENTIAL 1060 Wyeth

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 116

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

	TEST: BASO	PHILS (10^9/L) /	PART 2: BETWEE	N TREATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1		DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 4	0.489	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-0.004 0.013 -0.005 -0.008 0.017 -0.001 -0.003 -0.018 -0.021 -0.002	0.013 0.013 0.014 0.014 0.011 0.010 0.008 0.012 0.012	0.744 0.335 0.707 0.592 0.132 0.920 0.704 0.166 0.107 0.840
Week 12	0.619	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0.003 0.013 0.009 -0.002 0.011 0.006 -0.005 -0.004 -0.016 -0.012	0.011 0.012 0.011 0.012 0.010 0.008 0.009 0.011 0.012 0.010	0.814 0.309 0.426 0.845 0.329 0.444 0.579 0.703 0.213 0.266
Week 26	0.760	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0.004 0.008 0.007 -0.002 0.004 0.003 -0.006 -0.000 -0.010 -0.009	0.008 0.009 0.010 0.010 0.006 0.007 0.008 0.007 0.008	0.631 0.396 0.455 0.857 0.536 0.616 0.456 0.958 0.270 0.315
Week 39	0.734	DVS SR 50 mg	DVS SR 100 mg	-0.007	0.008	0.444

Page 117

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

	TEST: BASO	PHILS (10^9/L) /	PART 2: BETWEE	N TREATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1	COMPARED Comparator 2	DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 39 (cont.)	0.734	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg		-0.000 -0.001 -0.006 0.007 0.006 0.001 -0.001 -0.005 -0.004	0.008 0.010 0.008 0.006 0.006 0.007 0.007	0.986 0.911 0.511 0.291 0.413 0.862 0.893 0.449 0.600
Week 52	0.053	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	0.037 0.039 0.038 0.039 0.002 0.001 0.002 -0.001 0.000 0.001	0.011 0.012 0.013 0.012 0.009 0.010 0.010 0.012 0.012	0.008** 0.013* 0.022* 0.011* 0.915 0.807 0.940 0.969 0.912
Final on-therapy	0.498	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	0.011 0.017 0.014 0.009 0.006 0.003 -0.002 -0.003 -0.007 -0.004	0.009 0.010 0.009 0.011 0.008 0.008 0.009 0.009 0.010	0.231 0.094 0.162 0.413 0.459 0.740 0.875 0.718 0.480 0.693
Follow-up	0.458		DVS SR 150 mg DVS SR 200 mg	0.018 0.008	0.010 0.006	0.314 0.373

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

Page 118

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

TEST: BASOPHILS (10^9/L) / PART 2: BETWEEN TREATMENTS

Data Analysis Interval [1]	OVERALL P-VALUE				STDERR OF DIFF. BET. ADJ. MEANS	
Follow-up (cont.)	0.458	DVS SR 150 mg	DVS SR 200 mg	-0.010	0.008	0.436

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.
ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.
ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.
STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.
COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY).
STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

CONFIDENTIAL 1063 Wyeth

Page 119

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

TEST: PLATELET COUNT (10^9/L) / PART 1: WITHIN TREATMENT										
TREATMENT		OBSERV	ΞD	BASELI	ΝE	CHANGE		ADJUSTED	[2]	
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR	
DVS SR 50 ma	147			264.9	58.7					
DVS SR 50 mg Screening/baseline	147	264.9	58.7	264.9	58.7					
Week 4	140	264.2	54.6	263.9	57.5	0.3	29.9 36.9	0.4	2.2	
Week 8	9	269.4	52.4	273.1	45.4	-3.7	36.9	-5.5	12.7	
Week 12	117	258.3	53.1	261.5 259.6	57.3 57.5	-3.2	30.5 31.6	-3.3 3.9	2.4	
Week 26	99	263.8	57.4	259.6	57.5	4.2	31.6	3.9	2.8	
Week 39 Week 52	92 85	275.7 275.0	55.6 62.1	265.5 264.4	58.1 58.4	10.2** 10.6*	32.1 37.8	10.5** 10.7**	3.4 3.6	
Final on-therapy	141	272.7	59.8	263.8	57.3	8.9**	34.7	9.0***	2.6	
Follow-up	24	248.9	51.6	247.3	62.9	1.5	27.2	0.8	6.2	
DVS SR 100 mg	155	210.5	01.0	256.3	55.7	1.0	27.2	0.0	0.2	
Screening/baseline	155	256.3	55.7	256.3	55.7					
Week 4	139	257.0	54.1	257.9	57.4	-1.0	24.4	-1.8	2.2	
Week 8	8	237.5	34.8	230.6	27.9	6.9	19.3	-6.2	15.3	
Week 12	117	254.9	54.6	260.4	60.5 61.8	-5.5*	26.2 30.8	-5.9* 4.2	2.4	
Week 26	111	264.8	62.6	260.4	61.8	4.4	30.8	4.2	2.6	
Week 39	92	265.1	60.2	257.3	62.0 61.9	7.8*	33.2	7.1* 9.1*	3.4 3.6	
Week 52	84	269.6	58.4	260.1	61.9	9.5**	28.0	9.1*	3.6	
Final on-therapy Follow-up	140 34	265.7 257.3	55.8 50.9	257.6 248.1	57.3 48.8	8.0** 9.2	28.7 28.7	7.2** 8.5	2.6 5.2	
DVS SR 150 mg	157	231.3	30.9	263.7	52.6	9.4	20.1	0.3	3.2	
Screening/baseline	157	263.7	52.6	263.7	52.6					
Week 4	129	261.1	48.9	262.1	52.3	-1.0	26.7	-1.2	2.3	
Week 8	8	284.3	62.4	262.1 321.1	70.5	-36.9	54.5	-26.0	14.8	
Week 12	102	253.1	48.3	258.9	53.3	-5.8*	27.7	-6.5*	2.5	
Week 26	90	262.0	52.2	260.4	53.3 51.7	1.6	27.7 27.3	1.4	2.9	
Week 39	83	272.7	60.8	260.4	52.2	12.3**	36.4 41.2	12.0***	3.6	
Week 52	70	276.9	51.7	262.8	54.0	14.1**	41.2	14.0***	3.9	
Final on-therapy	132	269.3	50.3	262.4	53.3	6.9*	37.6	6.8*	2.7	
Follow-up	41	268.8	73.7	266.1	59.2	2.7	38.2	3.8	4.7	
DVS SR 200 mg Screening/baseline	151 151	263.9	59.6	263.9 263.9	59.6 59.6					
Week 4	122	268.8	59.6	268.4	61.3	0.3	27.8	1.1	2.4	
WCCK I	144	200.0	33.0	200.7	01.5	0.5	21.0	±.• ±	4.4	

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.
THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES. [N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 120

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

TEST: PLATELET COUNT (10^9/L) / PART 1: WITHIN TREATMENT										
TREATMENT			OBSERVI	ED	BASELI	NE	CHANGE		ADJUSTED	[2]
Data Analysis Interval	[1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 200 mg (cont.)										
Week 12		96	257.5	50.9	264.2	54.2	-6.7*	28.6	-6.4*	2.6
Week 26		80	263.5	51.9	261.4	56.1	2.1	25.2	2.0	3.1
Week 39		70	271.4	61.6	261.5	55.7	9.9**	31.2	9.7*	3.9
Week 52		64	278.0	66.4	262.3	56.6	15.6***	24.6	15.4***	4.1
Final on-therapy		124	273.9	62.9	267.2	61.6	6.7*	28.6	7.3**	2.8
Follow-up		38	257.4	58.9	256.0	62.9	1.4	25.2	1.5	4.9
Placebo		76			267.3	56.9				
Screening/baseline		76	267.3	56.9	267.3	56.9				
Week 4		75	272.1	60.5	266.7	57.0	5.4	30.6	5.9	3.0
Week 8		5	280.0	54.5	305.8	38.1	-25.8	38.5	-19.0	17.4
Week 12		64	265.0	53.1	271.2	56.4	-6.3	25.2	-4.5	3.2
Week 26		58	272.5	50.3	271.9	54.2	0.6	26.4	2.0	3.6
Week 39		50	281.6	56.8	273.7	57.3	7.8	33.9	9.3*	4.6
Week 52		46	286.8	64.7	273.3	58.1	13.5**	34.0	14.7**	4.9
Final on-therapy		76	276.2	61.8	267.3	56.9	8.9*	30.8	9.5**	3.6
Follow-up		6	234.3	46.9	241.7	45.8	-7.3	24.0	-8.7	12.3

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 121

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

TEST: PLATELET COUNT (10^9/L) / PART 2: BETWEEN TREATMENTS										
Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE				
Week 4	0.311	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg	1.6 -0.7 -5.5 -0.6 -2.9 -7.7 -2.3 -7.1	3.8 3.3 3.8	0.494 0.626 0.827 0.142 0.854 0.380 0.042* 0.493 0.064 0.212				
Week 8	0.754	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg Placebo DVS SR 150 mg Placebo Placebo	20.5 13.5 19.8 12.8	19.5 19.8 21.7 23.4 24.4 21.7	0.971 0.310 0.540 0.405 0.605 0.749				
Week 12	0.880	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	3.0 1.2 0.6 0.5 -1.4 -0.1 -2.0	3.3 3.5 3.5 4.0 3.5 3.5 4.0 3.6 4.1	0.446 0.367 0.392 0.768 0.867 0.895 0.731 0.975 0.633 0.657				
Week 26	0.941	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg	-0.3 2.5 1.9 1.9 2.8	3.8 4.0 4.1 4.6 3.9	0.936 0.535 0.651 0.683 0.475				

Page 122

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

TE	ST: PLATEL	ET COUNT (10^9/L) / PART 2: BET	WEEN TREATME	NTS	
Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 26 (cont.)	0.941	DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	Placebo	2.2 2.2 -0.6 -0.6	4.0 4.5 4.2 4.7 4.8	0.590 0.628 0.884 0.893 0.998
Week 39	0.898	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg	DVS SR 100 mg	3.5 -1.4 0.8 1.2 -4.9 -2.7	4.8 4.9 5.2 5.7 4.9 5.2	0.469 0.772 0.875 0.833 0.319 0.605 0.692 0.672 0.652 0.947
Week 52	0.734	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 200 mg	-4.7 -4.1 -4.9 -6.4 -5.7 -1.5 -0.8	5.5 6.0 5.3 5.5 6.1	0.750 0.538 0.386 0.503 0.360 0.246 0.351 0.798 0.902 0.914
Final on-therapy	0.958		DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg	1.8 2.2 1.7 -0.5 0.4 -0.1	3.8	0.633 0.569 0.666 0.902 0.921 0.975

Page 123

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: HEMATOLOGY

TES	ST: PLATELI	ET COUNT (10^9/L) / PART 2: BET	WEEN TREATME	NTS	
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1		DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Final on-therapy (cont.)	0.958	DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo	-2.3 -0.5 -2.7 -2.2	4.5 3.9 4.5 4.6	0.601 0.899 0.548 0.628
Follow-up	0.687	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-7.7 -3.0 -0.7 9.4 4.7 7.0 17.1 2.2 12.4 10.2	8.0 7.8 7.9 13.7 7.0 7.1 13.3 6.8 13.2	0.339 0.702 0.925 0.494 0.502 0.329 0.201 0.742 0.349

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

Page 124

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: LIPID PROFILE

TEST: TOT.CHOL. /LIPID (mmol/L) / PART 1: WITHIN TREATMENT

TREATMENT		OBSERV		BASELI		CHANGE		ADJUSTEI	
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 50 mg Screening/baseline	2	5 400	0.007	5.482	0.987				
DVS SR 150 mg Screening/baseline Screening/baseline	1 1	5.482 5.948	0.987	5.482 5.948 5.948	0.987				

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

CONFIDENTIAL 1069 Wyeth

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 125

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

	TEST: TO	T.CHOL.	/LIPID,	(FASTING)	(mmol/L) / PART	1: WITHIN TR	EATMENT		
TREATMENT			OBSERVI		BASELII		CHANGE		ADJUSTED	
Data Analysis Inter	val [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
		1 4 7				1 000				
DVS SR 50 mg Screening/baseline		147 147	5.741	1.002	5.741 5.741	1.002				
Week 4		134	5.609	0.968	5.774	0.986	-0.165*	0.753	-0.177**	0.055
Week 8		10	5.345	0.690	5.741	0.799	-0.396	0.886	-0.532	0.276
Week 12		116	5.642	0.977	5.722	0.996	-0.080	0.725	-0.090	0.064
Week 26		99	5.689	0.942	5.687	0.949	0.003	0.696	-0.019	0.076
Week 39		92	5.738	0.954	5.707	0.965	0.031	0.772	0.017	0.080
Week 52		82	5.744 5.716	0.961 0.935	5.713 5.781	0.966 1.003	0.030 -0.064	0.788 0.894	0.025 -0.077	0.085 0.065
Final on-therapy Follow-up		139 24	5.881	1.004	5.948	0.981	-0.064	0.894	-0.077	0.065
DVS SR 100 mg		155	3.001	1.004	5.720	1.059	0.007	0.004	0.055	0.130
Screening/baseline		155	5.720	1.059	5.720	1.059				
Week 4		138	5.685	0.989 1.021	5.766	1.082	-0.082	0.649	-0.096	0.054
Week 8		9	5.977	1.021	6.382	1.018	-0.405	0.750	-0.090	0.298
Week 12		119	5.660	1.004	5.752 5.735	1.103	-0.091	0.785	-0.092	0.063
Week 26		108	5.760	1.048	5./35	1.100 1.092	0.024	0.877	0.020	0.073
Week 39 Week 52		93 84	5.631 5.793	1.021 0.859	5.653 5.650	1.092	-0.023 0.143	1.005 0.895	-0.058 0.110	0.080 0.084
Final on-therapy		139	5.869	0.999	5.769	1.079	0.100	0.838	0.083	0.065
Follow-up		29	5.634	1.330	5.759	1.316	-0.125	0.914	-0.181	0.144
DVS SR 150 mg		157			5.752 5.752	1.056				
Screening/baseline		157	5.752	1.056	5.752	1.056				
Week 4		132	5.801	0.995	5.758	1.038	0.043	0.721	0.025	0.055
Week 8		8	6.071	0.892	5.773	1.041	0.297	1.452	0.184	0.308
Week 12 Week 26		103 91	5.638 5.679	0.904 0.927	5.620 5.673	1.004	0.017 0.006	0.761 0.844	-0.028 -0.022	0.068 0.079
Week 39		81	5.821	1.024	5.716	1.048	0.105	0.764	0.022	0.085
Week 52		69	5.801	0.943	5.629	0.948	0.172	0.754	0.131	0.092
Final on-therapy		132	5.905	1.071	5.758 5.995	1.038	0.147*	0.727	0.126	0.067
Follow-up		40	5.592	1.010	5.995	1.257	-0.403**	0.879	-0.372**	0.122
DVS SR 200 mg		151	F 000	0.054	5.882 5.882	0.954				
Screening/baseline Week 4		151 119	5.882 5.914	0.954 0.903	5.882	0.954 0.911	0.027	0.630	0.046	0.058
WEEK 4		119	3.914	0.903	J.08/	0.911	0.027	0.630	0.046	0.030

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 126

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: LIPID PROFILE

TES	ST: TOT.CHOL.	/LIPID,	(FASTING)	(mmol/I	L) / PART	1: WITHIN TE	REATMENT		
TREATMENT		OBSERV	'ED	BASELI	INE	CHANGE	<u> </u>	ADJUSTE	D [2]
Data Analysis Interval	[1] [N] —	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 200 mg (cont.)									
Week 8	3	5.577	1.535	6.232	1.130	-0.655	2.013	-0.445	0.503
Week 12	96	5.918	1.014	5.805	0.909	0.113	0.910	0.131	0.071
Week 26	83	5.842	1.031	5.793	0.902	0.049	0.972	0.066	0.083
Week 39	70	5.727	0.869	5.796	0.941	-0.069	0.927	-0.048	0.092
Week 52	62	5.891	0.999	5.791	0.917	0.101	1.086	0.129	0.097
Final on-therapy	120	5.928	0.981	5.884	0.908	0.045	0.960	0.070	0.070
Follow-up	43	5.867	0.951	5.926	0.993	-0.060	0.914	-0.054	0.118
Placebo	77			5.952	0.854				
Screening/baseline	77	5.952	0.854	5.952	0.854				
Week 4	72	5.788	0.875	6.007	0.837	-0.219*	0.707	-0.167*	0.075
Week 8	5	5.141	0.640	5.596	1.315	-0.455	0.853	-0.694	0.392
Week 12	65	5.660	0.751	5.943	0.842	-0.282***	0.580	-0.218*	0.086
Week 26	58	5.649	0.859	5.920	0.841	-0.271**	0.764	-0.207*	0.099
Week 39	49	5.804	0.959	5.944	0.757	-0.140	0.753	-0.060	0.110
Week 52	46	5.996	0.935	5.939	0.813	0.057	0.779	0.149	0.113
Final on-therapy	77	5.854	0.925	5.952	0.854	-0.098	0.825	-0.047	0.088
Follow-up	7	5.885	0.471	5.855	0.694	0.030	0.633	0.009	0.292

CONFIDENTIAL 1071 Wyeth

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 127

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: LIPID PROFILE

TEST: TOT.CHOL. /LIPID, (FASTING) (mmol/L) / PART 2: BETWEEN TREATMENTS											
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1	COMPARED Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE					
Week 4	0.014*	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	-0.081 -0.203 -0.223 -0.010 -0.122 -0.142 0.071 -0.020 0.193 0.213	0.077 0.078 0.080 0.093 0.077 0.080 0.093 0.080 0.093	0.295 0.010** 0.006** 0.912 0.116 0.075 0.446 0.802 0.040* 0.026*					
Week 8	0.338		DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Placebo	-0.443 -0.716 -0.087 0.162 -0.273 0.355 0.604 0.629 0.878 0.249	0.411 0.412 0.577 0.476 0.432 0.579 0.499 0.592 0.496 0.642	0.291 0.093 0.881 0.737 0.532 0.544 0.236 0.297 0.087 0.701					
Week 12	0.024*	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	Placebo DVS SR 200 mg	0.002 -0.062 -0.221 0.127 -0.064 -0.223 0.126 -0.159 0.190 0.348	0.090 0.094 0.095 0.107 0.093 0.095 0.107 0.098 0.110	0.985 0.507 0.021* 0.236 0.493 0.019* 0.240 0.107 0.085 0.002**					
Week 26	0.297	DVS SR 50 mg	DVS SR 100 mg	-0.040	0.105	0.706					

Page 128

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: LIPID PROFILE

TEST: TOT	.CHOL. /LI	PID, (FASTING) (mmol/L) / PART	2: BETWEEN T	REATMENTS	
Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 26 (cont.)	0.297	DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	0.002 -0.086 0.187 0.042 -0.046 0.227 -0.088 0.185 0.273	0.110 0.112 0.125 0.108 0.110 0.123 0.115 0.127	0.984 0.446 0.136 0.697 0.676 0.066 0.443 0.147 0.035*
Week 39	0.672	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg	DVS SR 200 mg Placebo	0.075 -0.078 0.065 0.077 -0.152 -0.010 0.003 0.142 0.155 0.013	0.113 0.117 0.122 0.136 0.117 0.121 0.136 0.125 0.139 0.143	0.509 0.506 0.596 0.570 0.192 0.935 0.984 0.256 0.266 0.929
Week 52	0.882	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	Placebo DVS SR 150 mg DVS SR 200 mg	-0.019 -0.039 0.002 -0.019	0.119 0.125 0.129 0.142 0.125 0.125 0.129 0.141 0.134 0.147	0.476 0.401 0.423 0.382 0.870 0.886 0.783 0.989 0.899
Final on-therapy	0.169		DVS SR 100 mg DVS SR 150 mg	-0.160 -0.203	0.092 0.093	0.083 0.030*

Page 129

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: LIPID PROFILE

TEST: TOT.	.CHOL. /LI	PID, (FASTING) (mmol/L) / PART	2: BETWEEN T	REATMENTS	
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1	COMPARED Comparator 2	DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Final on-therapy (cont.)	0.169	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	Placebo DVS SR 200 mg Placebo	-0.147 -0.030 -0.043 0.013 0.130 0.056 0.173 0.117	0.096 0.109 0.093 0.096 0.109 0.097 0.110	0.125 0.782 0.646 0.894 0.235 0.566 0.118 0.297
Follow-up	0.333	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0.128 0.319 0.001 -0.062 0.191 -0.127 -0.190 -0.318 -0.381 -0.063	0.213 0.199 0.197 0.332 0.189 0.186 0.325 0.170 0.317	0.550 0.113 0.997 0.852 0.315 0.495 0.560 0.063 0.231 0.842

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

Page 130

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: LIPID PROFILE

	TEST:	HDL CHOLESTER	OL (mmol/L) / PART 1	: WITHIN	TREATMENT			
TREATMENT Data Analysis Interval [1	1] [N]	OBSERVED	STD	BASELINE MEAN		CHANGE	STD -	ADJUSTED MEAN	[2] ST DERR

DIIG CD E0	1		1 (0)
DVS SR 50 mg	Τ.		1.603
Screening/baseline	1	1.603	1.603
DVS SR 150 mg	1		1.526
Screening/baseline	1	1.526	1.526

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

CONFIDENTIAL 1075 Wyeth

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 131

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

TE	ST: HDL CH	OLESTEROL,	(FASTING)	(mmol/L) / PART	1: WITHIN TR	EATMENT		
TREATMENT		OBSERV		BASELI	NE	CHANGE		ADJUSTED	
Data Analysis Interval	[1] [N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
									
DVS SR 50 mg	147	1 600	0 440	1.690	0.449				
Screening/baseline	147	1.690	0.449	1.690	0.449	0 000	0 011	0 001	0.017
Week 4	134 9	1.677 1.635	0.450 0.249	1.710 1.678	0.457 0.223	-0.033 -0.043	0.211 0.180	-0.031 -0.042	0.017 0.070
Week 8 Week 12	116	1.633	0.249	1.678	0.223	-0.043	0.180	-0.042	0.070
Week 12 Week 26	99	1.647	0.438	1.688	0.466	-0.011	0.192	-0.010	0.021
Week 39	92	1.594	0.431	1.663	0.436	-0.068**	0.223	-0.070**	0.024
Week 52	82	1.553	0.384	1.639	0.405	-0.085***	0.199	-0.088***	0.025
Final on-therapy	139	1.628	0.429	1.697	0.456	-0.070***	0.240	-0.067***	0.020
Follow-up	24	1.604	0.478	1.697 1.778	0.432	-0.173**	0.234	-0.167**	0.053
DVS SR 100 mg	155			1.659 1.659	0.403				
Screening/baseline	155	1.659	0.403	1.659	0.403				
Week 4	138	1.682	0.421 0.589	1.683 1.645	0.411	-0.001	0.187	-0.002	0.017
Week 8	8	1.616		1.645	0.499	-0.029	0.207	-0.029	0.074
Week 12	119	1.644	0.446	1.670	0.425	-0.026	0.226	-0.027	0.020
Week 26	108	1.644	0.499	1.662	0.399	-0.018	0.317 0.299	-0.021	0.023
Week 39 Week 52	93 84	1.584 1.623	0.453 0.408	1.659 1.660	0.411	-0.075* -0.037	0.299	-0.076** -0.036	0.024 0.025
Final on-therapy	139	1.644	0.443	1 602	0.390	-0.037	0.242	-0.038	0.023
Follow-up	29	1.485	0.351	1.682 1.538	0.419	-0.054	0.199	-0.056	0.020
DVS SR 150 mg	157	1.100	0.001	1.724	0.444	0.001	0.100	0.000	0.019
Screening/baseline	157	1.724	0.444	1.724 1.724	0.444				
Week 4	132	1.720	0.477	1.699	0.445	0.021	0.186	0.022	0.017
Week 8	7	1.685	0.689	1.492	0.569	0.192*	0.183	0.188*	0.080
Week 12	103	1.729	0.501	1.703	0.460	0.026	0.256	0.028	0.022
Week 26	91	1.723	0.505	1.717	0.471	0.005	0.248	0.009	0.026
Week 39	81	1.671	0.504	1.714	0.483	-0.043	0.243	-0.038	0.026
Week 52	69	1.633	0.435	1.664	0.428	-0.031 -0.027	0.281	-0.029	0.027
Final on-therapy	132 39	1.673 1.723	0.450 0.535	1.699 1.844	0.445 0.471	-0.027 -0.121**	0.259 0.266	-0.024 -0.110*	0.020 0.043
Follow-up DVS SR 200 mg	151	1.723	0.555	1.622	0.471	-0.121""	0.200	-0.110~	0.043
Screening/baseline	151	1.622	0.415	1.622	0.415				
Week 4	119	1.641	0.459	1.634	0.416	0.007	0.216	0.003	0.018
		011							

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 132

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

TEST	: HDL CHO	LESTEROL,	(FASTING)	(mmol/L) / PART	1: WITHIN TR	REATMENT		
TREATMENT		OBSERV		BASELI		CHANGE		ADJUSTED	
Data Analysis Interval [1	L] [N] _	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVC CD 200 mg (cont)									
DVS SR 200 mg (cont.) Week 8	3	1.974	0.599	2.017	0.902	-0.043	0.367	-0.031	0.125
Week 12	96	1.627	0.414	1.604	0.395	0.023	0.214	0.016	0.023
Week 26	83	1.579	0.376	1.593	0.380	-0.014	0.223	-0.023	0.027
Week 39	70	1.553	0.378	1.581	0.376	-0.027	0.202	-0.039	0.028
Week 52	62	1.565	0.391	1.566	0.379	-0.002	0.230	-0.017	0.029
Final on-therapy	120	1.608	0.419	1.630	0.416	-0.023	0.224	-0.031	0.021
Follow-up	42	1.589	0.522	1.640	0.430	-0.050	0.315	-0.054	0.040
Placebo	77			1.713	0.434				
Screening/baseline	77	1.713	0.434	1.713	0.434				
Week 4	72	1.669	0.460	1.714	0.439	-0.045	0.209	-0.043	0.024
Week 8	5	1.459	0.494	1.490	0.506	-0.031	0.169	-0.035	0.094
Week 12	65	1.722	0.440	1.751	0.411	-0.029	0.246	-0.022	0.028
Week 26	58	1.737	0.403	1.796	0.400	-0.060*	0.187	-0.048	0.032
Week 39	49	1.649	0.385	1.783	0.396	-0.134***	0.166	-0.120***	0.033
Week 52	46	1.701	0.371	1.776	0.401	-0.075*	0.226	-0.053	0.034
Final on-therapy	77	1.665	0.445	1.713	0.434	-0.048	0.262	-0.044	0.027
Follow-up	-/	1.444	0.389	1.437	0.400	0.007	0.192	-0.011	0.100

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

IN - THE NOMBER OF SUBJECTS WITH MATCHING BASELINE.
STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.
STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 133

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: LIPID PROFILE

 TEST: HDI	CHOLESTER	ROL, (FASTING) (mmol/L) / PART	2: BETWEEN T	REATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE	
Week 4	0.110	DVS SR 100 mg DVS SR 100 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-0.030 -0.053 -0.035 0.012 -0.023 -0.005 0.042 0.019 0.065 0.047	0.024 0.024 0.025 0.029 0.024 0.025 0.029 0.025 0.029 0.030	0.219 0.030* 0.168 0.684 0.334 0.842 0.152 0.464 0.026* 0.118	
Week 8	0.224	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	-0.013 -0.230 -0.010 -0.006 -0.217 0.003 0.007 0.219 0.223 0.004	0.106 0.142 0.118 0.109 0.145	0.899 0.040* 0.943 0.957 0.957 0.985 0.956 0.156 0.080 0.981	
Week 12	0.324	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 200 mg Placebo DVS SR 200 mg	0.016 -0.038 -0.026 0.012 -0.055 -0.043 -0.004 0.012 0.050 0.038	0.030 0.031 0.034 0.030	0.573 0.203 0.394 0.727 0.068 0.164 0.900 0.701 0.153 0.286	
Week 26	0.606	DVS SR 50 mg	DVS SR 100 mg	-0.020	0.034	0.548	

Page 134

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: LIPID PROFILE

TEST: HDL CHOLESTEROL, (FASTING) (mmol/L) / PART 2: BETWEEN TREATMENTS										
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS COMPARED Comparator 1 Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE					
Week 26 (cont.)	0.606	DVS SR 50 mg DVS SR 150 mg DVS SR 50 mg DVS SR 200 mg DVS SR 50 mg Placebo DVS SR 100 mg DVS SR 150 mg DVS SR 100 mg DVS SR 200 mg DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg Placebo DVS SR 200 mg Placebo	-0.017 0.007 -0.029 0.003 0.028 0.032 0.057	0.035 0.036 0.040 0.035 0.036 0.040 0.037 0.041	0.160 0.631 0.856 0.397 0.935 0.487 0.385 0.164 0.556					
Week 39	0.294	DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg DVS SR 50 mg DVS SR 200 mg DVS SR 100 mg DVS SR 150 mg DVS SR 100 mg DVS SR 200 mg DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg Placebo DVS SR 150 mg Placebo DVS SR 200 mg Placebo	-0.031 0.051 -0.038 -0.037 0.044 0.001 0.082	0.034 0.035 0.037 0.041 0.035 0.037 0.041 0.038 0.042 0.044	0.844 0.372 0.408 0.221 0.278 0.312 0.288 0.978 0.052 0.064					
Week 52	0.357	DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg DVS SR 50 mg DVS SR 200 mg DVS SR 100 mg DVS SR 150 mg DVS SR 100 mg DVS SR 200 mg DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg Placebo DVS SR 150 mg Placebo DVS SR 200 mg Placebo	-0.059 -0.071 -0.035 -0.007 -0.019 0.017	0.035 0.037 0.038 0.042 0.037 0.038 0.042 0.040 0.043	0.141 0.113 0.065 0.409 0.851 0.679 0.768 0.576 0.420					
Final on-therapy	0.607	DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg		0.028 0.028	0.297 0.129					

Page 135

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: LIPID PROFILE

TEST: HDL	CHOLESTER	OL, (FASTING) (mmol/L) / PART	2: BETWEEN T	REATMENTS	
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1	COMPARED Comparator 2	DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Final on-therapy (cont.)	0.607	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo DVS SR 200 mg	-0.037 -0.024 -0.014 -0.008 0.005 0.006 0.019	0.029 0.033 0.028 0.029 0.033 0.030 0.034	0.208 0.473 0.625 0.797 0.871 0.828 0.565 0.706
Follow-up	0.434	DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-0.113 -0.156 0.045 -0.011 -0.053	0.067 0.113 0.066 0.063 0.110 0.059	0.164 0.402 0.095 0.172 0.493 0.868 0.628 0.346 0.367 0.689

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

Page 136

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: LIPID PROFILE

TEST: LDL CHOLESTEROL (mmol/L) / PART 1: WITHIN TREATMENT

Data Analysis Interval [1]	[N] -	MEAN	STD	MEAN	STD -	MEAN	STD -	MEAN	STDERR
DVS SR 50 mg Screening/baseline DVS SR 150 mg Screening/baseline	1 1 1 1	2.896		2.896 2.896 3.698 3.698					

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

CONFIDENTIAL 1081 Wyeth

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

IN - THE NOMBER OF SUBJECTS WITH MATCHING BASELINE.
STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.
STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 137

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

	TEST: I	LDL CHO	LESTEROL,	(FASTING)	(mmol/L) / PART	1: WITHIN T	REATMENT		
TREATMENT			OBSERV	ED	BASELI	NE	CHANG	E	ADJUSTED	[2]
Data Analysis Inter	rval [1]	[N] —	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERF
		1 47			2 400	0 010				
DVS SR 50 mg Screening/baseline		147 147	3.480	0.918	3.480 3.480	0.918 0.918				
Week 4		134	3.359	0.879	3.400	0.915	-0.127*	0.691	-0.141**	0.050
Week 8		9	3.057	0.369	3.486 3.359	0.776	-0.302	0.691	-0.458	0.231
Week 12		115	3.384	0.303	3 456	0.918	-0.072	0.633	-0.080	0.059
Week 26		99	3.387	0.918 0.869	3.456 3.432	0.823	-0.045	0.633 0.654	-0.060	0.070
Week 39		92	3.514	0.821	3.467	0.833	0.048	0.697	0.043	0.070
Week 52		82	3.554	0.811	3.488	0.833	0.065	0.667	0.068	0.073
Final on-therapy		139	3.480	0.832	3.504	0.922	-0.024	0.810	-0.036	0.057
Follow-up		24	3.628	0.960	3.504 3.654	0.974	-0.026	0.808	-0.004	0.143
DVS SR 100 mg Screening/baseline		155			3.496	0.935				
Screening/baseline		155	3.496	0.935	3.496	0.935				
Week 4		137	3.439	0.906	3.520 4.123	0.959 0.989	-0.081	0.560	-0.086	0.050
Week 8		7	3.683	0.862	4.123	0.989	-0.440	0.848	-0.076	0.270
Week 12		119	3.394	0.911	3.503 3.507	0.965	-0.110	0.682	-0.102	0.058
Week 26		107	3.470	0.904	3.507	0.962	-0.036	0.813	-0.025	0.06
Week 39		92	3.396	0.838	3.425	0.937	-0.028	0.904 0.745	-0.052	0.070
Week 52		84	3.569	0.754	3.430	0.905	0.139		0.117	0.072
Final on-therapy Follow-up		139 28	3.595 3.375	0.874 1.231	3.520 3.573	0.956 1.150	0.075 -0.199	0.718 0.805	0.069 -0.206	0.057
DVS SR 150 mg		157	3.373	1.231	3.175	0.965	-0.199	0.005	-0.200	0.132
Screening/baseline		157 157	3.435	0.965	3.435 3.435	0.965				
Week 4		132	3.479	0.892	3 467	0.968	0.012	0.685	-0.008	0.051
Week 8		7	3.517	0.854	3.467 3.565	1.092	-0.048	1.071	-0.064	0.259
Week 12		103	3.298	0.818	3.335	0.933	-0.037	0.713	-0.084	0.062
Week 26		89	3.296	0.883	3.351	0.969	-0.055	0.755	-0.098	0.074
Week 39		81	3.475	0.899	3.398	0.986	0.077	0.678	0.042	0.075
Week 52		68	3.541	0.889	3.380	0.896	0.161*	0.650	0.119	0.081
Final on-therapy		132	3.577	0.964	3.467 3.536	0.968	0.109	0.638	0.083	0.059
Follow-up		39	3.194	0.818	3.536	1.083	-0.342*	0.806	-0.363**	0.112
DVS SR 200 mg		151	0 606		3.636 3.636	0.879				
Screening/baseline		151	3.636	0.879	3.636	0.879	0 000	0 577	0 057	0 05
Week 4		119	3.663	0.863	3.633	0.839	0.030	0.577	0.057	0.05

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

 $^{[{\}tt N}]$ - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 138

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

TE	ST: LDL CH	OLESTEROL,	(FASTING)	(mmol/I	J) / PART	1: WITHIN T	REATMENT		
TREATMENT		OBSERV	ED	BASELI	NE	CHANG	E	ADJUSTE	D [2]
Data Analysis Interval	[1] [N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 200 mg (cont.)									
Week 8	3	3.207	1.216	3.474	0.570	-0.267	1.586	-0.345	0.396
Week 12	96	3.652	0.953	3.580	0.825	0.073	0.823	0.105	0.064
Week 26	83	3.616	0.968	3.574	0.789	0.041	0.876	0.077	0.076
Week 39	70	3.524	0.777	3.593	0.816	-0.069	0.832	-0.020	0.081
Week 52	61	3.650	0.906	3.581	0.806	0.070	0.971	0.110	0.085
Final on-therapy	120	3.648	0.895	3.633	0.836	0.015	0.829	0.050	0.061
Follow-up	40	3.574	0.914	3.606	0.952	-0.032	0.780	-0.028	0.110
Placebo	77			3.604	0.761				
Screening/baseline	77	3.604	0.761	3.604	0.761				
Week 4	70	3.462	0.796	3.636	0.744	-0.174*	0.656	-0.147*	0.070
Week 8	5	2.850	0.529	3.357	0.959	-0.507	0.698	-0.665*	0.308
Week 12	65	3.361	0.665	3.569	0.740	-0.207**	0.552	-0.179*	0.078
Week 26	58	3.339	0.823	3.531	0.742	-0.192*	0.633	-0.172	0.091
Week 39	49	3.563	0.845	3.574	0.682	-0.011	0.690	0.030	0.097
Week 52	46	3.672	0.800	3.591	0.702	0.082	0.666	0.125	0.098
Final on-therapy	76	3.546	0.824	3.608	0.765	-0.062	0.742	-0.036	0.077
Follow-up	7	3.713	0.525	3.720	0.783	-0.007	0.600	0.038	0.264

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.
STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.
STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 139

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: LIPID PROFILE

TEST: LDI	CHOLESTE	ROL, (FASTING) (mmol	l/L) / PART 2	2: BETWEEN T	REATMENTS	
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS COM	MPARED mparator 2	DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 4	0.039*	DVS SR 50 mg DVS DVS SR 50 mg DVS DVS SR 50 mg Pla	acebo S SR 200 mg acebo	-0.055 -0.133 -0.197 0.006 -0.078 -0.142 0.061 -0.064 0.139 0.203	0.071 0.072 0.074 0.086 0.071 0.073 0.086 0.074 0.086	0.438 0.063 0.008** 0.946 0.273 0.053 0.478 0.387 0.108 0.021*
Week 8	0.526	DVS SR 50 mg DVS DVS SR 50 mg DVS DVS SR 50 mg Plac DVS SR 100 mg DVS DVS SR 100 mg DVS DVS SR 100 mg Plac DVS SR 150 mg DVS DVS SR 150 mg DVS DVS SR 150 mg Plac	S SR 200 mg acebo S SR 200 mg	-0.382 -0.394 -0.113 0.207 -0.012 0.269 0.588 0.281 0.601 0.319	0.363 0.347 0.457 0.382 0.375 0.482 0.416 0.473 0.402 0.501	0.303 0.267 0.807 0.593 0.974 0.582 0.170 0.558 0.148 0.529
Week 12	0.048*	DVS SR 50 mg DVS DVS SR 50 mg DVS DVS SR 50 mg Pla DVS SR 100 mg DVS DVS SR 100 mg DVS DVS SR 100 mg DVS	acebo S SR 200 mg acebo	0.023 0.005 -0.184 0.099 -0.018 -0.207 0.077 -0.189 0.095 0.284	0.082 0.086 0.087 0.098 0.085 0.087 0.097 0.090 0.100	0.783 0.955 0.035* 0.310 0.834 0.017* 0.430 0.036* 0.345 0.005**
Week 26	0.274	DVS SR 50 mg DVS	S SR 100 mg	-0.035	0.097	0.719

Page 140

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: LIPID PROFILE

TEST: LDI	L CHOLESTE	ROL, (FASTING) (mmol/L) / PART	2: BETWEEN T	REATMENTS	
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1			STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 26 (cont.)	0.274	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0.038 -0.137 0.112 0.073 -0.102 0.147 -0.175 0.074 0.249	0.101 0.103 0.115 0.100 0.101 0.113 0.106 0.117 0.119	0.704 0.187 0.328 0.463 0.317 0.194 0.100 0.529 0.037*
Week 39	0.855	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0.094 0.001 0.063 0.013 -0.094 -0.032 -0.082 0.062 0.012 -0.050	0.100 0.103 0.107 0.119 0.103 0.107 0.120 0.110 0.122	0.345 0.995 0.560 0.916 0.364 0.768 0.495 0.576 0.922 0.692
Week 52	0.985	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	-0.050 -0.052 -0.042 -0.058 -0.002 0.008 -0.008 -0.008 -0.006 -0.016	0.103 0.109 0.112 0.122 0.108 0.112 0.122 0.117 0.127 0.127	0.629 0.634 0.707 0.636 0.984 0.946 0.947 0.934 0.962 0.904
Final on-therapy	0.483	DVS SR 50 mg DVS SR 50 mg		-0.105 -0.119	0.081 0.082	0.194 0.145

Page 141

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: LIPID PROFILE

TEST: LDI	CHOLESTER	ROL, (FASTING) (mmol/L) / PART	2: BETWEEN T	REATMENTS	
Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	
Final on-therapy (cont.)	0.483	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	0.000 -0.015 0.019 0.105 0.033 0.119	0.084 0.096	0.306 0.999 0.859 0.823 0.275 0.695 0.219 0.383
Follow-up	0.167	DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	0.359 0.024 -0.043 0.157 -0.178 -0.244 -0.335 -0.402	0.180 0.300 0.173 0.172 0.295	0.301 0.050* 0.895 0.888 0.366 0.303 0.409 0.035* 0.164 0.817

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

Page 142

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: LIPID PROFILE

	TEST: VL	DL CHOLESTE	ROL (mm	.ol/L) / PART	r 1: WI'	THIN TREATMENT			
TREATMENT Data Analysis Interval [1	.] [N] —	OBSERVED MEAN	STD	BASELINE MEAN	STD	CHANGE MEAN	STD -	ADJUSTED MEAN) [2] STDERR
DVS SR 50 mg Screening/baseline DVS SR 150 mg	1 1 1	0.285		0.285 0.285 0.725					
Screening/baseline	1	0.725		0.725					

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

CONFIDENTIAL 1087 Wyeth

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 143

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

TREATMENT Data Analysis Interval [1] [N] MEAN STD MEAN ST	[2] STDERR
Data Analysis Interval [1] [N] MEAN STD MEAN STD MEAN STD MEAN STD MEAN DVS SR 50 mg 147 0.572 0.296 Screening/baseline 147 0.572 0.296 0.572 0.296 Week 4 134 0.573 0.306 0.579 0.303 -0.005 0.217 -0.008 Week 8 9 0.495 0.096 0.601 0.137 -0.106 0.148 -0.131*	STDERF
Screening/baseline 147 0.572 0.296 0.572 0.296 Week 4 134 0.573 0.306 0.579 0.303 -0.005 0.217 -0.008 Week 8 9 0.495 0.096 0.601 0.137 -0.106 0.148 -0.131*	
Screening/baseline 147 0.572 0.296 0.572 0.296 Week 4 134 0.573 0.306 0.579 0.303 -0.005 0.217 -0.008 Week 8 9 0.495 0.096 0.601 0.137 -0.106 0.148 $-0.131*$	
Week 4 134 0.573 0.306 0.579 0.303 -0.005 0.217 -0.008 Week 8 9 0.495 0.096 0.601 0.137 -0.106 0.148 -0.131*	
Week 8 9 0.495 0.096 0.601 0.137 -0.106 0.148 -0.131*	
Week 8 9 0.495 0.096 0.601 0.137 -0.106 0.148 -0.131* Week 8 9 0.495 0.096 0.601 0.137 -0.106 0.148 -0.002	0.017
Waak 12 115 0.576 0.300 0.573 0.309 0.007 0.218 =0.002	0.064
Week 12 113 0.570 0.500 0.573 0.500 0.210 -0.002	0.020
Week 26 99 0.656 0.387 0.567 0.297 0.089*** 0.226 0.085***	0.023
Week 39 92 0.630 0.361 0.579 0.298 0.051* 0.246 0.048 Week 52 82 0.638 0.297 0.587 0.304 0.050* 0.218 0.050*	0.026
	0.024
Final on-therapy 139 0.610 0.291 0.581 0.301 0.029 0.227 0.025 Follow-up 24 0.650 0.313 0.517 0.237 0.133** 0.230 0.100	0.019
DVS SR 100 mg 155 0.566 0.313	0.052
DVS SR 100 mg 155 0.566 0.313 Screening/baseline 155 0.566 0.313 0.566 0.313	
Week 4 137 0.563 0.279 0.561 0.309 0.002 0.236 -0.006	0.017
Week 4 137 0.563 0.279 0.561 0.309 0.002 0.236 -0.006 Week 8 7 0.533 0.278 0.470 0.180 0.063 0.130 -0.008	0.074
Week 12 119 0.623 0.317 0.579 0.328 0.044* 0.225 0.040*	0.019
Week 12 119 0.623 0.317 0.579 0.328 0.044* 0.225 0.040* Week 26 107 0.638 0.319 0.564 0.313 0.074** 0.241 0.070**	0.022
Week 39 92 0.634 0.332 0.566 0.318 0.068* 0.272 0.061*	0.026
Week 52 84 0.602 0.296 0.561 0.298 0.041 0.260 0.031	0.024
Final on-therapy 139 0.624 0.302 0.568 0.320 0.055* 0.254 0.047*	0.019
Follow-up 28 0.731 0.423 0.640 0.357 0.091 0.260 0.097*	0.048
DVS SR 150 mg 157 0.594 0.305 Screening/baseline 157 0.594 0.305 0.594 0.305	
Screening/baseline 157 0.594 0.305 0.594 0.305	
Week 4 132 0.602 0.309 0.593 0.297 0.010 0.195 0.010	0.018
Week 8 7 0.703 0.245 0.881 0.492 -0.178 0.318 -0.105	0.074
Week 12 103 0.619 0.319 0.583 0.296 0.036 0.199 0.033 Week 26 89 0.625 0.296 0.584 0.305 0.042 0.251 0.041	0.021
Week 39 0.625 0.296 0.584 0.305 0.042 0.251 0.041 Week 39 81 0.676 0.339 0.605 0.321 0.071* 0.278 0.075**	0.028
Week 39 81 0.676 0.339 0.605 0.321 0.071* 0.278 0.075** Week 52 68 0.616 0.268 0.592 0.296 0.024 0.237 0.026	0.027
Final on-therapy 132 0.648 0.302 0.593 0.297 0.056** 0.241 0.055**	0.020
Follow-up 39 0.677 0.315 0.640 0.369 0.038 0.294 0.044	0.020
DVS SR 200 mg 151 0.626 0.335	0.010
Screening/baseline 151 0.626 0.335 0.626 0.335	
Week 4 119 0.611 0.334 0.621 0.333 -0.010 0.199 -0.002	0.019

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES. [N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 144

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: LIPID PROFILE

T	EST: VLDL CH	OLESTEROL,	(FASTING)	(mmol/I) / PART	1: WITHIN 7	REATMENT		
TREATMENT		OBSERV	ED	BASELI	NE	CHANC	SE.	ADJUSTEI	[2]
Data Analysis Interv	al [1] [N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 200 mg (cont.)									
Week 8	3	0.397	0.172	0.742	0.632	-0.345	0.472	-0.321**	0.110
Week 12	96	0.640	0.336	0.623	0.342	0.017	0.253	0.025	0.021
Week 26	83	0.648	0.361	0.626	0.352	0.022	0.280	0.031	0.026
Week 39	70	0.651	0.341	0.624	0.357	0.027	0.293	0.037	0.030
Week 52	61	0.647	0.289	0.627	0.346	0.020	0.300	0.035	0.028
Final on-therapy	120	0.652	0.344	0.621	0.331	0.031	0.279	0.040	0.021
Follow-up	40	0.625	0.308	0.632	0.332	-0.007	0.290	-0.003	0.040
Placebo	77			0.636	0.306				
Screening/baseline	77	0.636	0.306	0.636	0.306				
Week 4	70	0.615	0.294	0.618	0.272	-0.003	0.234	0.004	0.024
Week 8	5	0.834	0.635	0.751	0.581	0.083	0.112	0.110	0.085
Week 12	65	0.578	0.263	0.624	0.262	-0.046	0.233	-0.038	0.026
Week 26	58	0.574	0.239	0.593	0.238	-0.019	0.198	-0.017	0.030
Week 39	49	0.593	0.240	0.588	0.228	0.005	0.223	0.004	0.036
Week 52	46	0.624	0.273	0.574	0.232	0.050	0.210	0.045	0.032
Final on-therapy	76	0.636	0.300	0.626	0.294	0.010	0.208	0.020	0.026
Follow-up	7	0.729	0.334	0.699	0.359	0.030	0.232	0.056	0.095

CONFIDENTIAL 1089 Wyeth

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 145

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: LIPID PROFILE

TEST: VLDL	CHOLESTER	ROL, (FASTING) (mmol/L) / PART	2: BETWEEN T	REATMENTS	
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1		DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 4	0.952	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-0.002 -0.018 -0.006 -0.012 -0.016 -0.003 -0.010 0.013 0.006 -0.006	0.025 0.025 0.025 0.030 0.025 0.025 0.030 0.026 0.030 0.030	0.919 0.460 0.820 0.684 0.521 0.897 0.746 0.623 0.836 0.835
Week 8	0.042*	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-0.123 -0.026 0.190 -0.242 0.097 0.313 -0.118 0.216 -0.215 -0.431	0.096 0.099 0.127 0.107 0.109 0.133 0.114 0.132 0.112	0.212 0.792 0.148 0.033* 0.381 0.027* 0.311 0.113 0.066 0.005**
Week 12	0.112		DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-0.042 -0.035 -0.027 0.036 0.007 0.015 0.078 0.008 0.071 0.063	0.027 0.028 0.029 0.033 0.028 0.029 0.032 0.030 0.033	0.126 0.220 0.358 0.270 0.803 0.595 0.016* 0.781 0.033* 0.064
Week 26	0.077	DVS SR 50 mg	DVS SR 100 mg	0.016	0.032	0.629

Page 146

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: LIPID PROFILE

TEST: VLDI	L CHOLESTE	ROL, (FASTING) (mmol/L) / PAR	2: BETWEEN T	REATMENTS	
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS COMPARED Comparator 1 Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 26 (cont.)	0.077	DVS SR 50 mg DVS SR 150 mm DVS SR 50 mg DVS SR 200 mm DVS SR 50 mg Placebo DVS SR 100 mg DVS SR 150 mm DVS SR 100 mg DVS SR 200 mm DVS SR 100 mg DVS SR 200 mm DVS SR 150 mg DVS SR 200 mm DVS SR 150 mg DVS SR 200 mm DVS SR 150 mg DVS SR 200 mm DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0.054 0.102 0.028 0.038 0.087 0.010 0.059	0.034 0.035 0.038 0.033 0.034 0.038 0.035 0.039	0.197 0.121 0.008** 0.399 0.263 0.022* 0.778 0.135 0.222
Week 39	0.586	DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg DVS SR 50 mg DVS SR 200 mg DVS SR 50 mg Placebo DVS SR 100 mg DVS SR 200 mg DVS SR 100 mg DVS SR 200 mg DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg Placebo DVS SR 200 mg Placebo	-0.028 0.011 0.043 -0.015 0.024 0.056 0.038 0.071	0.037 0.038 0.040 0.044 0.038 0.040 0.044 0.041 0.045 0.046	0.724 0.467 0.790 0.327 0.699 0.553 0.203 0.348 0.117 0.482
Week 52	0.961	DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg DVS SR 50 mg DVS SR 200 mg DVS SR 50 mg DVS SR 150 mg DVS SR 100 mg DVS SR 150 mg DVS SR 100 mg DVS SR 200 mg DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg Placebo DVS SR 200 mg Placebo	0.025 0.015 0.005 0.005 0.004 -0.014 -0.009 -0.019		0.565 0.493 0.682 0.894 0.888 0.905 0.723 0.807 0.645 0.819
Final on-therapy	0.741	DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg		0.027 0.027	0.408 0.265

Page 147

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: LIPID PROFILE

TEST: VLDI	CHOLESTER	ROL, (FASTING) (mmol/L) / PART	2: BETWEEN T	REATMENTS	
Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED Comparator 2	DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	
Final on-therapy (cont.)	0.741	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	-0.015 0.005 -0.008 0.007 0.027 0.016 0.035 0.020	0.028 0.032 0.027 0.028 0.032 0.028 0.032 0.032	0.596 0.881 0.767 0.790 0.398 0.583 0.277 0.551
Follow-up	0.451	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	0.002 0.055 0.103 0.044 0.053 0.100 0.042 0.047 -0.011 -0.058	0.070 0.066 0.065 0.109 0.062 0.062 0.106 0.057 0.103	0.974 0.403 0.119 0.685 0.397 0.108 0.694 0.404 0.915 0.572

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

Page 148

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: LIPID PROFILE

	TEST:	TRI	GLYCERIDE	S /LIPID	(mmol/L)	/ PART 1:	WITHIN TREATM	ENT		
TREATMENT Data Analysis Interval	[1]	[N]	OBSER MEAN	VEDSTD	BASEL MEAN	INESTD	CHANGE_ MEAN	STD	ADJUSTED MEAN	[2] STDERR
DVS SR 50 mg Screening/baseline DVS SR 150 mg Screening/baseline		3 3 1	1.44137	0.77973	1.44137 1.44137 1.58060	0.77973 0.77973				
Screening/baseline		1	1.58060		1.58060					

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

CONFIDENTIAL 1093 Wyeth

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

 $^{[{\}tt N}]$ - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE. STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 149

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

TEST: TRIGLYCERIDES /LIPID, (FASTING) (mmol/L) / PART 1: WITHIN TREATMENT										
TREATMENT			OBSER	VED	BASEL	TNE	CHANG	Æ	ADJUSTED	[2]
Data Analysis Interva	1 [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 50 mg		147			1.23146	0.61055				
Screening/baseline		147 147	1.23146	0.61055	1.23146	0.61055				
Week 4		134	1.25125	0.66649	1.24587	0.62344	0.00539	0.46448	-0.00351	0.04050
Week 8		10	1.06352	0.19639	1.23060		-0.16708		-0.19997	0.18652
Week 12		116 99	1.28959	0.75005	1.24230	0.64135	0.04730	0.52542		0.04493
Week 26		99	1.43076	0.84204	1.23700	0.64790	0.19376***	0.49088	0.18584***	0.05604
Week 39		92 82	1.37383	0.78509	1.26302	0.64999	0.11081*		0.10391	0.06053
Week 52			1.39060	0.64973	1.28211	0.66179	0.10849*		0.10698	0.06235
Final on-therapy		139	1.32954	0.63621	1.25068	0.61873	0.07886	0.49076	0.06960	0.04821
Follow-up		24	1.41408	0.68428	1.12948	0.51409	0.28460*	0.49968	0.24668	0.14898
DVS SR 100 mg		155	1 22267	0.68109	1.23367	0.68109 0.68109				
Screening/baseline Week 4		138	1.23367 1.25721		1.23367 1.23904	0.68109	0.01817	0 5/160	0.00803	0.03992
Week 4 Week 8		130	1.61698	0.71180 1.52212	1.30336	0.89910	0.31362	0.54169 0.62508	0.29009	0.19526
Week 12		119	1.35870	0.68927		0.71306	0.09763*		0.09106*	0.04435
Week 26		108	1.42558	0.79078	1.24975	0.71490	0.17584**		0.17015**	0.05364
Week 39		93	1.44428	0.93925	1.25659	0.73000	0.18768**	0.68809	0.17925**	0.06021
Week 52		84	1.31515	0.64467	1.22121	0.64796	0.09395	0.56059	0.07450	0.06168
Final on-therapy			1.39095	0.80809	1.23800	0.69667	0.15294**	0.62325	0.14095**	0.04823
Follow-up		29	1.71842	1.33429	1.47237	0.86216	0.24604	0.85919	0.25893	0.13441
DVS SR 150 mg		157	1.29396		1.29396	0.66361				
Screening/baseline		157	1.29396	0.66361	1.29396	0.66361				
Week 4		132	1.31264	0.67393	1.29185	0.64539	0.02079	0.42372	0.02028	0.04078
Week 8		8	1.60036	0.54499	1.87274		-0.27238		-0.22271	0.21071
Week 12 Week 26		103 91	1.35535 1.44735	0.73749 0.86926	1.27226 1.29115	0.64313 0.67079	0.08309 0.15620*	0.46767 0.70752		0.04766
Week 26 Week 39		81	1.44733	0.86926	1.31703	0.67679	0.15620^	0.70752	0.15776^^	0.05842
Week 59		69	1.40438	0.78067	1.30473	0.65365	0.09965	0.63246	0.10479	0.06798
Final on-therapy		132	1.44350	0.75621	1.29185	0.64539	0.15165**	0.57890	0.15125**	0.04945
Follow-up		40	1.48662	0.68023	1.39233	0.79758	0.09429	0.64651	0.09531	0.11429
DVS SR 200 mg		151			1.36288	0.73014				
Screening/baseline		151 151	1.36288	0.73014	1.36288	0.73014				
Week 4		119	1.32729	0.72715	1.35101	0.72456	-0.02371	0.43044	-0.01345	0.04298

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

Page 150

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

TEST:	TRIGLYCE	CRIDES /LIE	PID, (FAST	ING) (mmo	1/L) / PA	RT 1: WITH	IN TREATMEN	IT	
TREATMENT		OBSEF	RVED	BASEL	INE	CHA	NGE	ADJUSTE	D [2]
Data Analysis Interval	[1] [N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 200 mg (cont.)									
Week 8	3	0.86557	0.37523	1.61823	1.37042	-0.75267	1.01788	-0.73572*	0.33654
Week 12	96		0.73104	1.35586	0.74440	0.03929	0.54854	0.05442	0.04941
Week 26	83	1.40948	0.78570	1.36147	0.76717	0.04802	0.60649	0.06190	0.06125
Week 39	70	1.42028	0.74383	1.35674	0.77696	0.06355	0.63699	0.07890	0.06943
Week 52	62	1.49921	0.95318	1.39231	0.78537	0.10690	0.80710	0.13783	0.07187
Final on-therapy	120	1.45275	0.89565	1.35170	0.72155	0.10105	0.69610	0.11352*	0.05190
Follow-up	43	1.56353	1.07028	1.44066	0.77343	0.12287	0.83323	0.13105	0.11032
Placebo	77	,		1.38487	0.66587				
Screening/baseline	77	1.38487	0.66587	1.38487	0.66587				
Week 4	72	1.44764	0.90566	1.40420	0.68105	0.04344	0.58063	0.06339	0.05531
Week 8	5	1.80642	1.38507	1.63028	1.25695	0.17614	0.25441	0.19464	0.26095
Week 12	65	1.26084	0.57128	1.35724	0.57114	-0.09640	0.50604	-0.08096	0.06003
Week 26	58	1.25280	0.52029	1.29252	0.51737	-0.03971	0.42300	-0.03791	0.07318
Week 39	4.9	1.29374	0.52434	1.28039	0.49583	0.01336	0.48518	0.01058	0.08292
Week 52	4 6	1.35702	0.59185	1.24927	0.50358	0.10775	0.45204	0.09656	0.08327
Final on-therapy	77	1.42856	0.76062	1.38487	0.66587	0.04369	0.48788	0.06330	0.06482
Follow-up	7	1.58704	0.73143	1.52416	0.78132	0.06289	0.49610	0.08344	0.27344

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

 $^{[{\}tt N}]$ - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 151

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: LIPID PROFILE

	TEST: TRIGLYCERIDES /LIPID, (FASTING) (mmol/L) / PART 2: BETWEEN TREATMENTS					
Data Analysi	OVERALL P-VALUE	TREATMENTS Comparator 1	COMPARED Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 4	0.843	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	-0.01154 -0.02378 0.00994 -0.06690 -0.01225 0.02148 -0.05536 0.03373 -0.04312 -0.07684	0.05683 0.05747 0.05910 0.06862 0.05707 0.05870 0.06828 0.05925 0.06872 0.06997	0.839 0.679 0.866 0.330 0.830 0.715 0.418 0.569 0.531 0.273
Week 8	0.078	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg		-0.49006 0.02274 0.53575 -0.39460 0.51280 1.02581 0.09545 0.51301 -0.41735 -0.93036	0.26768 0.28610 0.38595 0.32230 0.29057 0.38992 0.32700 0.39533 0.33315 0.42525	0.077 0.937 0.176 0.231 0.088 0.013* 0.772 0.205 0.220
Week 12	0.197	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	-0.05463 -0.04265 -0.01799 0.11738 0.01198 0.03664 0.17201 0.02466 0.16003 0.13538	0.06311 0.06549 0.06683 0.07503 0.06509 0.06642 0.07466 0.06867 0.07666	0.387 0.515 0.788 0.118 0.854 0.581 0.022* 0.720 0.037* 0.082
Week 26	0.086	DVS SR 50 mg	DVS SR 100 mg	0.01569	0.07754	0.840

Page 152

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: LIPID PROFILE

TEST: TRIGLY	CERIDES /	LIPID, (FASTING)	(mmol/L) / PAR	T 2: BETWEEN	TREATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED Comparator 2	DIFF. BET. ADJ. MEANS		PAIRWISE P-VALUE	
Week 26 (cont.)	0.086	DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 200 mg	0.02807 0.12394 0.22375 0.01238 0.10825 0.20806 0.09587 0.19568 0.09981	0.08096 0.08308 0.09218 0.07932 0.08147 0.09074 0.08463 0.09364 0.09541	0.729 0.136 0.016* 0.876 0.185 0.022* 0.258 0.037* 0.296	
Week 39	0.469	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	-0.07535 -0.05883 0.02501 0.09333 0.01652 0.10035 0.16867 0.08384 0.15215 0.06832	0.08535 0.08847 0.09215 0.10266 0.08826 0.09195 0.10247 0.09474 0.10506 0.10817	0.378 0.506 0.786 0.364 0.852 0.276 0.101 0.377 0.148 0.528	
Week 52	0.977	DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	0.03248 0.00219 -0.03085 0.01042 -0.03029 -0.06333 -0.02206 -0.03304 0.00823 0.04127	0.08770 0.09224 0.09516 0.10402 0.09182 0.09487 0.10357 0.09889 0.10750	0.711 0.981 0.746 0.920 0.742 0.505 0.831 0.739 0.939 0.708	
Final on-therapy	0.675	DVS SR 50 mg DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg	-0.07135 -0.08165	0.06815 0.06906	0.296 0.238	

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES. ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.

COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY).

STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 153

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: LIPID PROFILE

TEST: TRIGI	LYCERIDES /I	LIPID, (FASTING)	(mmol/L) / PAF	RT 2: BETWEEN	TREATMENTS	
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1	COMPARED Comparator 2	DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	
Final on-therapy (cont.)	0.675	DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg	DVS SR 200 mg Placebo	-0.04392 0.00630 -0.01030 0.02743 0.07765 0.03772 0.08794 0.05022	0.07088 0.08084 0.06907 0.07090 0.08087 0.07169 0.08153 0.08296	0.536 0.938 0.882 0.699 0.337 0.599 0.281 0.545
Follow-up	0.853	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0.11562 0.16324 0.16362 0.12787 0.17549 -0.03575	0.20137 0.18783 0.18588 0.31213 0.17641 0.17371 0.30443 0.15884 0.29634 0.29468	0.952 0.422 0.535 0.602 0.355 0.463 0.565 0.822 0.968 0.872

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES. ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.

COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY). STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 154

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: URINALYSIS

	TEST	: URINE	PH (N/A)	/ PART 1:	WITHIN T	REATMENT			
TREATMENT		OBSERVI	ED	BASELII	NE	CHANGE		ADJUSTED	[2]
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 50 ma	148			5.83	0.54				
DVS SR 50 mg Screening/baseline	148	5.83	0.54	5.83 5.83	0.54				
Week 4	139	5.92	0.57	5.83	0.53	0.09	0.56	0.08	0.05
Week 8	7	6.21	0.76	6.07	0.53	0.14	0.69	0.30	0.23
Week 12	117	5.91	0.60	5.83 5.82	0.53 0.52	0.07	0.67	0.05	0.05
Week 26	99	5.89	0.60	5.82	0.52	0.07	0.65	0.03	0.06
Week 39	92	5.87	0.55	5.81 5.84	0.55	0.06	0.56	0.03	0.06
Week 52	85	5.82	0.63	5.84	0.55	-0.02	0.63	-0.03	0.06
Final on-therapy	142 23	5.83 5.78	0.64 0.65	5.83 5.87	0.53 0.46	-0.00 -0.09	0.67 0.62	-0.02 -0.04	0.05 0.11
Follow-up	154	3.70	0.05	5.90	0.46	-0.09	0.62	-0.04	0.11
DVS SR 100 mg Screening/baseline	154	5.90	0.56	5.90	0.56				
Week 4	138	6 N1	0.62	5 93	0.55	0.08	0.60	0.12*	0.05
Week 8	7	6.01 5.93	0.45	5.93 5.86	0.69	0.07	0.79	0.07	0.22
Week 12	118	6.11	0.63	5.93	0.54	0.18**	0.60	0.22***	0.05
Week 26	110	6.01	0.61	5.93 5.93	0.55	0.09	0.75	0.12*	0.05
Week 39	92	5.99	0.67	5.92 5.89	0.55	0.07	0.65	0.10	0.06
Week 52	82	5.93	0.60	5.89	0.56	0.04	0.61	0.05	0.06
Final on-therapy	139 31	5.90	0.59	5.93	0.55	-0.03	0.62	0.02	0.05
Follow-up	31	5.77	0.62	5.68	0.54	0.10	0.55	0.04	0.10
DVS SR 150 mg	157 157			5.77 5.77	0.51				
Screening/baseline	157	5.77	0.51	5.77	0.51				
Week 4	131	5.95	0.58	5.74	0.51	0.20***	0.58	0.15**	0.05
Week 8	6	5.75	0.69	5.58	0.38	0.17	0.68	-0.02	0.25
Week 12 Week 26	102 91	5.96 5.87	0.64 0.62	5.77 5.82	0.53 0.51	0.19** 0.05	0.67 0.61	0.13* 0.01	0.06
Week 39	83	5.97	0.62	J.02 5 01	0.50	0.16*	0.65	0.13*	0.06
Week 59 Week 52	69	5.99	0.66	5.81 5.81	0.49	0.18*	0.69	0.15*	0.00
Final on-therapy	132	5.94	0.61	5.75	0.50	0.20***	0.67	0.13**	0.05
Follow-up	40	5.78	0.51	5.84	0.57	-0.06	0.63	-0.03	0.09
DVS SR 200 mg	151			5.82	0.49				2.03
Screening/baseline	151	5.82	0.49	5.82 5.82	0.49				
Week 4	122	5.96	0.65	5.83	0.50	0.13*	0.61	0.12*	0.05

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 155

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: URINALYSIS

	TEST	: URINE F	PH (N/A)	/ PART 1:	WITHIN I	REATMENT			
TREATMENT		OBSERVE		BASELIN		CHANGE		ADJUSTE	
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 200 mg (cont.)									
Week 12	95	5.92	0.57	5.85	0.52	0.07	0.65	0.06	0.06
Week 26	82	5.91	0.60	5.87	0.50	0.05	0.65	0.04	0.06
Week 39	70	5.94	0.63	5.89	0.51	0.05	0.61	0.06	0.07
Week 52	64	5.76	0.63	5.91	0.52	-0.16*	0.62	-0.13	0.07
Final on-therapy	124	5.81	0.61	5.83	0.50	-0.02	0.63	-0.04	0.05
Follow-up	38	5.89	0.57	5.72	0.41	0.17	0.62	0.14	0.09
Placebo	77			5.99	0.58				
Screening/baseline	77	5.99	0.58	5.99	0.58				
Week 4	75	5.91	0.61	6.01	0.58	-0.10	0.61	-0.03	0.06
Week 8	4	6.25	0.29	5.88	0.75	0.38	0.63	0.39	0.30
Week 12	66	5.83	0.55	5.98	0.59	-0.14	0.62	-0.08	0.07
Week 26	59	5.85	0.57	5.97	0.61	-0.12	0.66	-0.06	0.07
Week 39	50	5.78	0.65	5.90	0.60	-0.12	0.64	-0.10	0.08
Week 52	47	5.69	0.57	5.88	0.61	-0.19*	0.55	-0.18*	0.08
Final on-therapy	77	5.79	0.59	5.99	0.58	-0.20**	0.62	-0.12	0.06
Follow-up	5	6.10	0.65	6.10	0.22	0.00	0.61	0.18	0.24

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 156

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: URINALYSIS

	TEST: UR	INE PH (N/A) / PA	ART 2: BETWEEN	TREATMENTS		 :
Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED Comparator 2	DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 4	0.199	DVS SR 50 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-0.04 -0.07 -0.04 0.11 -0.03 -0.00 0.15 0.03 0.18 0.15	0.06 0.07 0.07 0.08 0.07 0.07 0.08 0.07 0.08 0.08	0.539 0.271 0.532 0.161 0.624 0.977 0.055 0.652 0.022* 0.058
Week 8	0.666	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg Placebo DVS SR 150 mg Placebo	0.22 0.32 -0.09 0.10 -0.32 -0.41	0.32 0.35 0.37 0.33 0.37	0.496 0.369 0.804 0.775 0.405 0.300
Week 12	0.011*	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-0.16 -0.08 -0.00 0.13 0.09 0.16 0.30 0.07 0.21	0.07 0.08 0.08 0.09 0.08 0.08 0.09 0.08	0.027* 0.316 0.959 0.128 0.255 0.040* <0.001*** 0.367 0.020* 0.131
Week 26	0.387	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	-0.09 0.02 -0.01 0.09 0.11	0.08 0.08 0.09 0.09 0.09	0.267 0.818 0.899 0.336 0.187

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES. ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.

COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY). STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 157

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: URINALYSIS

	TEST: UR	INE PH (N/A) / P.	ART 2: BETWEEN	TREATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1		DIFF. BET. ADJ. MEANS		PAIRWISE P-VALUE
Week 26 (cont.)	0.387	DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	Placebo DVS SR 200 mg Placebo	0.08 0.18 -0.03 0.07 0.10	0.08 0.09 0.09 0.10 0.10	0.355 0.053 0.731 0.455 0.299
Week 39	0.189	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-0.06 -0.10 -0.03 0.13 -0.04 0.03 0.20 0.07 0.23 0.17	0.08 0.08 0.09 0.10 0.08 0.09 0.10 0.09 0.10	0.445 0.243 0.717 0.171 0.673 0.727 0.044* 0.462 0.020* 0.107
Week 52	0.007**	DVS SR 50 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-0.09 -0.18 0.10 0.15 -0.10 0.19 0.24 0.29 0.34 0.05	0.09 0.09 0.09 0.10 0.09 0.09 0.10 0.11	0.328 0.044* 0.275 0.136 0.284 0.047* 0.021* 0.004** 0.002**
Final on-therapy	0.021*	DVS SR 50 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg	-0.03 -0.15 0.02 0.11 -0.12 0.05	0.07 0.07 0.07 0.08 0.07 0.07	0.610 0.028* 0.791 0.184 0.094 0.449

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES. ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.

COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY).

STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 158

04NOV05 15:24 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT LAB3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR LABORATORY TESTS

category name: URINALYSIS

	TEST: UR	INE PH (N/A) / F	PART 2: BETWEEN	TREATMENTS		
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1	COMPARED Comparator 2	DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Final on-therapy (cont.)	0.021*	DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	Placebo DVS SR 200 mg Placebo Placebo	0.14 0.17 0.26 0.09	0.08 0.07 0.08 0.08	0.079 0.017* 0.002** 0.284
Follow-up	0.605	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	-0.18 -0.22	0.15 0.14 0.14 0.27 0.13 0.13 0.26 0.12 0.26	0.616 0.964 0.224 0.420 0.598 0.445 0.593 0.171 0.416 0.874

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES. ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.

COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY).

STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

ST 10-11: Number (%) of Subjects With Vital Signs of Potential Clinical Importance

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 Page 1

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Screening/baseline

Category	Overall				Treati	ment				
Test+Units	P-Value *	DVS SR 50 mg	DVS SR 100 mg		DVS SR 150 mg		DVS SR 200 mg		Placebo	
TOTAL	0.046*	0/149	2/155	(1.3)	2/157	(1.3)	5/151	(3.3)	4/ 77	(5.2)
VITAL SIGNS WEIGHT kg DECREASE INCREASE	0.046* 0.356 0.494 0.648	0/149 0/149 0/149 0/149	2/155 0/155 0/155 0/155	(1.3)	2/157 2/157 1/157 1/157	(1.3) (1.3) (0.6) (0.6)	5/151 1/151 0/151 1/151	(3.3) (0.7) (0.7)	4/ 77 0/ 77 0/ 77 0/ 77	(5.2)
Postural BP Change SYSTOLIC BP mm Hg DECREASE Standing SYSTOLIC BP mm Hg DECREASE INCREASE Supine SYSTOLIC BP mm Hg	0.558 0.558 0.312 0.468 0.093 0.093	0/149 0/149 0/149 0/149 0/149 0/149	1/155 1/155 0/155 0/155 0/155 0/155	(0.6) (0.6)	0/157 0/157 0/157 0/157 0/157 0/157	(33.37)	1/151 1/151 1/151 1/151 0/151 0/151	(0.7) (0.7) (0.7) (0.7)	1/ 77 1/ 77 1/ 77 0/ 77 1/ 77	(1.3) (1.3) (1.3) (1.3) (1.3)
INCREASE Postural BP Change DIASTOLIC BP mm Hg DECREASE Standing DIASTOLIC BP mm Hg DECREASE Supine DIASTOLIC BP mm Hg DECREASE	0.093 0.124 0.124 0.093 0.093 0.093 0.312	0/149 0/149 0/149 0/149 0/149 0/149 0/149	0/155 1/155 1/155 0/155 0/155 0/155	(0.6) (0.6)	0/157 0/157 0/157 0/157 0/157 0/157 0/157		0/151 1/151 1/151 0/151 0/151 1/151	(0.7) (0.7) (0.7) (0.7)	1/ 77 2/ 77 2/ 77 1/ 77 1/ 77 1/ 77	(1.3) (2.6) (2.6) (1.3) (1.3) (1.3)

CONFIDENTIAL 1104 Wyeth

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

2

Page

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Screening/baseline

Category Test+Units	Overall P-Value *	Treatr	
TOTAL	0.046*	13/689	(1.9)
VITAL SIGNS WEIGHT kg DECREASE INCREASE POSTURAL BP Change SYSTOLIC BP mm Hg DECREASE Standing SYSTOLIC BP mm Hg DECREASE INCREASE SUPINE SYSTOLIC BP mm Hg INCREASE POSTURAL BP Change DIASTOLIC BP mm Hg DECREASE Standing DIASTOLIC BP mm Hg DECREASE Supine DIASTOLIC BP mm Hg DECREASE Supine DIASTOLIC BP mm Hg DECREASE Supine DIASTOLIC BP mm Hg DECREASE	0.046* 0.356 0.494 0.648 0.558 0.312 0.468 0.093 0.093 0.124 0.124 0.093 0.093 0.312 0.312	13/689 3/689 1/689 2/689 3/689 2/689 1/689 1/689 1/689 4/689 1/689 1/689 2/689	(1.9) (0.4) (0.1) (0.3) (0.4) (0.4) (0.3) (0.1) (0.1) (0.1) (0.6) (0.6) (0.6) (0.1) (0.3)

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 3

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Category	Overall	Treatment										
Test+Units	P-Value *	DVS SR	50 mg	DVS SR 1	L00 mg	DVS SR		DVS SR 2	200 mg	Place	ebo	
TOTAL	0.601	4/139	(2.9)	8/135	(5.9)	7/128	(5.5)	3/111	(2.7)	4/ 76	(5.3)	
VITAL SIGNS WEIGHT kg DECREASE INCREASE	0.601 0.523 0.151 0.800	4/139 3/138 2/138 1/138	(2.9) (2.2) (1.4) (0.7)	8/135 1/135 0/135 1/135	(5.9) (0.7) (0.7)	7/128 3/128 3/128 0/128	(5.5) (2.3) (2.3)	3/111 1/111 0/111 1/111	(2.7) (0.9) (0.9)	4/ 76 0/ 76 0/ 76 0/ 76	(5.3)	
Postural BP Change SYSTOLIC BP mm Hg DECREASE Standing SYSTOLIC BP mm Hg DECREASE	0.476 0.476 0.463 0.802	2/139 2/139 1/139 1/139	(1.4) (1.4) (0.7) (0.7)	1/135 1/135 2/135 1/135	(0.7) (0.7) (1.5) (0.7)	1/127 1/127 0/127 0/127	(0.8) (0.8)	0/111 0/111 2/111 1/111	(1.8) (0.9)	2/ 76 2/ 76 0/ 76 0/ 76	(2.6) (2.6)	
INCREASE Supine SYSTOLIC BP mm Hg DECREASE INCREASE	0.586 0.421 0.644 0.180	0/139 0/139 0/139 0/139		1/135 1/135 1/135 0/135	(0.7) (0.7) (0.7)	0/127 2/127 1/127 1/127	(1.6) (0.8) (0.8)	1/111 1/111 0/111 1/111	(0.9) (0.9) (0.9)	0/ 76 2/ 76 0/ 76 2/ 76	(2.6) (2.6)	
Postural BP Change DIASTOLIC BP mm Hg DECREASE Standing DIASTOLIC BP mm Hg INCREASE	0.451 0.451 0.358 0.358	0/139 0/139 0/139 0/139		1/135 1/135 1/135 2/135 2/135	(0.7) (0.7) (1.5) (1.5)	2/127 2/127 2/127 1/127 1/127	(1.6) (1.6) (0.8) (0.8)	0/111 0/111 0/111 0/111	(2.0)	1/ 76 1/ 76 0/ 76 0/ 76	(1.3) (1.3)	
Supine DIASTOLIC BP mm Hg INCREASE	0.380 0.380	0/139 0/139		0/135 0/135	(1.0)	1/127 1/127 1/127	(0.8)	0/111 0/111 0/111		1/ 76 1/ 76	(1.3) (1.3)	

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 4

Category Test+Units	Overall P-Value *	Treatm	
TOTAL	0.601	26/589	(4.4)
VITAL SIGNS	0.601	26/589	(4.4) (1.4)
WEIGHT kg	0.523	8/588	
DECREASE	0.151	3/588	(0.9)
INCREASE	0.800		(0.5)
Postural BP Change SYSTOLIC BP mm Hg	0.476	6/588	(1.0) (1.0)
DECREASE	0.476	6/588	
Standing SYSTOLIC BP mm Hg	0.463	3/588	(0.9)
DECREASE	0.802		(0.5)
INCREASE	0.586	2/588	(0.3)
Supine SYSTOLIC BP mm Hg	0.421	6/588	(1.0)
DECREASE	0.644	2/588	(0.3)
INCREASE	0.180	4/588	(0.7)
Postural BP Change DIASTOLIC BP mm Hg DECREASE	0.451	4/588	(0.7)
	0.451	4/588	(0.7)
Standing DIASTOLIC BP mm Hg	0.358	3/588	(0.5)
INCREASE	0.358	3/588	(0.5)
Supine DIASTOLIC BP mm Hg	0.380	2/588	(0.3)
INCREASE	0.380	2/588	(0.3)

Page

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

Page

5

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Category	Overall	Treatment										
Test+Units	P-Value *	DVS SR !	50 mg	DVS SR	100 mg	DVS SR		DVS SR 2	200 mg	Place	ebo	
TOTAL	0.140	1/124	(0.8)	7/125	(5.6)	9/114	(7.9)	6/ 97	(6.2)	4/ 71	(5.6)	
VITAL SIGNS WEIGHT kg DECREASE INCREASE POSTURAL BP Change SYSTOLIC BP mm Hg	0.140 0.341 0.509 0.542 0.844	1/124 0/124 0/124 0/124 1/124	(0.8)	7/125 2/125 2/125 0/125 1/125	(5.6) (1.6) (1.6) (0.8)	9/114 4/114 3/114 1/114 1/114	(7.9) (3.5) (2.6) (0.9) (0.9)	6/ 97 2/ 96 1/ 96 1/ 96 0/ 97	(6.2) (2.1) (1.0) (1.0)	4/ 71 1/ 71 1/ 71 0/ 71 0/ 71	(5.6) (1.4) (1.4)	
DECREASE Standing SYSTOLIC BP mm Hg DECREASE Supine SYSTOLIC BP mm Hg	0.844 0.577 0.577 0.601	1/124 0/124 0/124 0/124	(0.8)	1/125 0/125 0/125 1/125	(0.8)	1/114 1/114 1/114 0/114	(0.9) (0.9) (0.9)	0/ 97 1/ 97 1/ 97 1/ 97	(1.0) (1.0) (1.0)	0/ 71 1/ 71 1/ 71 1/ 71	(1.4) (1.4) (1.4)	
DECREASE INCREASE Postural BP Change DIASTOLIC BP mm Hg DECREASE Standing DIASTOLIC BP mm Hg	0.165 0.579 0.612 0.612 0.269	0/124 0/124 0/124 0/124 0/124		0/125 1/125 1/125 1/125 2/125	(0.8) (0.8) (0.8) (1.6)	0/114 0/114 1/114 1/114 0/114	(0.9) (0.9)	0/ 97 1/ 97 2/ 97 2/ 97 0/ 97	(1.0) (2.1) (2.1)	1/ 71 0/ 71 1/ 71 1/ 71 1/ 71	(1.4) (1.4) (1.4) (1.4)	
DECREASE INCREASE Supine DIASTOLIC BP mm Hg INCREASE Supine PULSE beats/min DECREASE	0.165 0.163 0.026* 0.026* 0.165 0.165	0/124 0/124 0/124 0/124 0/124 0/124		0/125 2/125 0/125 0/125 0/125 0/125	(1.6)	0/114 0/114 0/114 3/114 3/114 0/114	(2.6) (2.6)	0/ 97 0/ 97 0/ 97 0/ 97 0/ 97 0/ 97		1/ 71 0/ 71 0/ 71 0/ 71 0/ 71 1/ 71 1/ 71	(1.4) (1.4) (1.4) (1.4)	

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 8

Category Test+Units	Overall P-Value *	Treatm	
TOTAL	0.140	27/531	(5.1)
VITAL SIGNS	0.140	27/531	(5.1)
WEIGHT kg	0.341	9/530	(1.7)
DECREASE	0.509	7/530	(1.3)
INCREASE	0.542	2/530	(0.4)
Postural BP Change SYSTOLIC BP mm Hg	0.844	3/531	(0.6)
DECREASE	0.844	3/531	(0.6)
Standing SYSTOLIC BP mm Hg	0.577	3/531	(0.6)
DECREASE	0.577	3/531	(0.6)
Supine SYSTOLIC BP mm Hg	0.601	3/531	(0.6)
DECREASE	0.165		(0.2)
INCREASE	0.579		(0.4)
Postural BP Change DIASTOLIC BP mm Hg	0.612	5/531	(0.9)
DECREASE	0.612	5/531	(0.9)
Standing DIASTOLIC BP mm Hg	0.269	3/531	(0.6)
DECREASE	0.165	1/531	(0.2)
INCREASE	0.163	2/531	(0.4)
Supine DIASTOLIC BP mm Hg	0.026*	3/531	(0.6)
INCREASE	0.026*	3/531	(0.6)
Supine PULSE beats/min	0.165	1/531	(0.2)
DECREASE	0.165	1/531	(0.2)

Page

6

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

Protocol 3151A2-315-US DVS SR CSR-60178

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 7 REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Category Test+Units	Overall P-Value *	DVS SR !	 50 mg	DVS SR 1	 L00 mg	Treati DVS SR		DVS SR 2	 200 mg	Place	 ebo
TOTAL	0.842	4/117	(3.4)	8/118	(6.8)	5/101	(5.0)	5/ 96	(5.2)	3/ 64	(4.7)
VITAL SIGNS WEIGHT kg DECREASE INCREASE Standing SYSTOLIC BP mm Hg DECREASE INCREASE Supine SYSTOLIC BP mm Hg DECREASE INCREASE INCREASE	0.842 0.892 0.697 0.415 0.244 0.170 0.076 0.240 0.170 0.061	4/117 3/116 2/116 1/116 0/117 0/117 0/117 0/117	(3.4) (2.6) (1.7) (0.9)	8/118 5/118 5/118 0/118 2/118 2/118 0/118 2/118 0/118	(6.8) (4.2) (4.2) (1.7) (1.7) (1.7)	5/101 4/101 2/101 2/101 0/101 0/101 1/101 0/101 1/101	(5.0) (4.0) (2.0) (2.0) (1.0)	5/ 96 2/ 96 2/ 96 0/ 96 2/ 95 0/ 95 3/ 95 0/ 95	(5.2) (2.1) (2.1) (2.1) (2.1) (2.1) (3.2) (3.2)	3/ 64 2/ 64 1/ 64 1/ 64 0/ 64 0/ 64 0/ 64	(4.7) (3.1) (1.6) (1.6)
Postural BP Change DIASTOLIC BP mm Hg DECREASE Standing DIASTOLIC BP mm Hg INCREASE Supine DIASTOLIC BP mm Hg INCREASE Supine PULSE beats/min DECREASE	0.418 0.418 0.695 0.695 0.634 0.634 0.150	0/117 0/117 1/117 1/117 0/117 0/117 0/117 0/117	(0.9) (0.9)	0/118 0/118 1/118 1/118 1/118 1/118 0/118 0/118	(0.8) (0.8) (0.8) (0.8)	1/101 1/101 0/101 0/101 1/101 1/101 0/101 0/101	(1.0) (1.0) (1.0) (1.0)	0/ 95 0/ 95 0/ 95 0/ 95 0/ 95 0/ 95 0/ 95		0/ 64 0/ 64 0/ 64 0/ 64 0/ 64 1/ 64 1/ 64	(1.6) (1.6)

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

8

Page

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 12

Category Test+Units	Overall P-Value *	Treatm	
TOTAL	0.842	25/496	(5.0)
VITAL SIGNS WEIGHT kg DECREASE INCREASE Standing SYSTOLIC BP mm Hg DECREASE INCREASE SUPINE SYSTOLIC BP mm Hg DECREASE INCREASE INCREASE INCREASE POSTURAL BP Change DIASTOLIC BP mm Hg DECREASE Standing DIASTOLIC BP mm Hg INCREASE	0.842 0.892 0.697 0.415 0.244 0.170 0.076 0.240 0.170 0.061 0.418 0.418 0.695 0.695	12/495 4/495 4/495 2/495 2/495 6/495 4/495 1/495 1/495 2/495	(5.0) (3.2) (2.4) (0.8) (0.8) (0.4) (0.4) (0.4) (0.4) (0.8) (0.2) (0.2) (0.2) (0.4)
Supine DIASTOLIC BP mm Hg INCREASE Supine PULSE beats/min DECREASE	0.634 0.634 0.150 0.150	2/495 2/495 1/495 1/495	(0.4) (0.4) (0.2) (0.2)

CONFIDENTIAL 1111 Wyeth

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 9

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Overall				Treatment						
P-Value *	DVS SR :	50 mg	DVS SR	100 mg	DVS SR	150 mg	DVS SR	200 mg	Plac	ebo
0.617	9/102	(8.8)	16/111	(14.4)	11/ 89	(12.4)	11/ 81	(13.6)	10/ 59	(16.9)
0.617 0.447 0.819 0.477 0.064 0.257 0.257 0.616 0.502 0.409 0.624 0.624 0.385 0.385 0.385	9/102 6/101 4/101 2/101 0/102 0/102 2/102 2/102 1/102 1/102 1/102 1/102 0/102 0/102 0/102 0/102	(8.8) (5.9) (4.0) (2.0) (2.0) (1.0) (1.0) (1.0)	16/111 14/110 6/110 8/110 0/111 0/111 0/111 0/111 0/111 0/111 0/111 1/111 2/111 1/111	(14.4) (12.7) (5.5) (7.3) (1.8) (1.8) (0.9) (0.9)	11/89 11/89 5/89 6/89 0/89 0/89 0/89 1/89 1/89 1/89 1/89 0/89 0/89	(12.4) (12.4) (5.6) (6.7) (1.1) (1.1) (1.1) (1.1)	11/ 81 10/ 81 6/ 81 4/ 81 1/ 81 1/ 81 0/ 81 0/ 81 0/ 81 0/ 81 1/ 81 1/ 81	(13.6) (12.3) (7.4) (4.9) (1.2) (1.2) (1.2)	10/59 5/59 2/59 3/59 2/59 2/59 1/59 0/59 0/59 0/59 1/59 0/59 1/59	(16.9) (8.5) (3.4) (5.1) (3.4) (3.4) (1.7) (1.7) (1.7)
	P-Value * 0.617 0.617 0.447 0.819 0.477 0.064 0.064 0.257 0.257 0.616 0.502 0.409 0.624 0.624 0.385 0.385 0.440	P-Value * DVS SR 1 0.617 9/102 0.617 9/102 0.447 6/101 0.819 4/101 0.477 2/101 0.064 0/102 0.257 2/102 0.257 2/102 0.502 1/102 0.409 0/102 0.624 1/102 0.624 1/102 0.624 1/102 0.624 1/102 0.385 0/102 0.385 0/102 0.440 0/102 0.440 0/102 0.440 0/102 0.165 0/102	P-Value * DVS SR 50 mg 0.617 9/102 (8.8) 0.617 9/102 (8.8) 0.447 6/101 (5.9) 0.819 4/101 (4.0) 0.477 2/101 (2.0) 0.064 0/102 0.257 2/102 (2.0) 0.257 2/102 (2.0) 0.616 1/102 (1.0) 0.502 1/102 (1.0) 0.409 0/102 0.624 1/102 (1.0) 0.624 1/102 (1.0) 0.624 1/102 (1.0) 0.624 1/102 (1.0) 0.385 0/102 0.385 0/102 0.440 0/102 0.440 0/102 0.440 0/102 0.165 0/102	P-Value * DVS SR 50 mg DVS SR 0.617 9/102 (8.8) 16/111 0.617 9/102 (8.8) 16/111 0.447 6/101 (5.9) 14/110 0.819 4/101 (4.0) 6/110 0.477 2/101 (2.0) 8/110 0.064 0/102 0/111 0.257 2/102 (2.0) 0/111 0.257 2/102 (2.0) 0/111 0.257 2/102 (1.0) 0/111 0.502 1/102 (1.0) 0/111 0.502 1/102 (1.0) 0/111 0.409 0/102 0/111 0.409 0/102 0/111 0.624 1/102 (1.0) 0/111 0.624 1/102 (1.0) 0/111 0.385 0/102 1.01 0.385 0/102 2/111 0.385 0/102 2/111 0.385 0/102 1/111 0.440 0/102 1/111 0.440 0/102 1/111 0.440 0/102 0/110	P-Value * DVS SR 50 mg DVS SR 100 mg 0.617 9/102 (8.8) 16/111 (14.4) 0.617 9/102 (8.8) 16/111 (14.4) 0.447 6/101 (5.9) 14/110 (12.7) 0.819 4/101 (4.0) 6/110 (5.5) 0.477 2/101 (2.0) 8/110 (7.3) 0.064 0/102 0/111 0.257 2/102 (2.0) 0/111 0.257 2/102 (2.0) 0/111 0.257 2/102 (1.0) 0/111 0.502 1/102 (1.0) 0/111 0.502 1/102 (1.0) 0/111 0.409 0/102 0/111 0.409 0/102 0/111 0.624 1/102 (1.0) 0/111 0.624 1/102 (1.0) 0/111 0.624 1/102 (1.0) 0/111 0.385 0/102 2/111 (1.8) 0.385 0/102 2/111 (1.8) 0.385 0/102 1/111 (0.9) 0.440 0/102 1/111 (0.9) 0.440 0/102 1/111 (0.9) 0.440 0/102 0/110	P-Value * DVS SR 50 mg DVS SR 100 mg DVS SR 0.617 9/102 (8.8) 16/111 (14.4) 11/89 0.617 9/102 (8.8) 16/111 (14.4) 11/89 0.447 6/101 (5.9) 14/110 (12.7) 11/89 0.819 4/101 (4.0) 6/110 (5.5) 5/89 0.477 2/101 (2.0) 8/110 (7.3) 6/89 0.064 0/102 0/111 0/89 0.257 2/102 (2.0) 0/111 0/89 0.257 2/102 (2.0) 0/111 0/89 0.257 2/102 (2.0) 0/111 0/89 0.257 2/102 (1.0) 0/111 0/89 0.502 1/102 (1.0) 0/111 1/89 0.502 1/102 (1.0) 0/111 1/89 0.604 1/102 (1.0) 0/111 1/89 0.624 1/102 (1.0) 0/111 1/89 0.624 1/102 (1.0) 0/111 1/89 0.624 1/102 (1.0) 0/111 1/89 0.385 0/102 2/111 (1.8) 0/89 0.385 0/102 2/111 (1.8) 0/89 0.440 0/102 1/111 (0.9) 0/89 0.440 0/102 1/111 (0.9) 0/89 0.440 0/102 1/111 (0.9) 0/89 0.440 0/102 1/111 (0.9) 0/89 0.440 0/102 1/111 (0.9) 0/89	P-Value * DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg 0.617 9/102 (8.8) 16/111 (14.4) 11/89 (12.4) 0.617 9/102 (8.8) 16/111 (14.4) 11/89 (12.4) 0.447 6/101 (5.9) 14/110 (12.7) 11/89 (12.4) 0.819 4/101 (4.0) 6/110 (5.5) 5/89 (5.6) 0.477 2/101 (2.0) 8/110 (7.3) 6/89 (6.7) 0.064 0/102 0/111 0/89 0.257 2/102 (2.0) 0/111 0/89 0.257 2/102 (2.0) 0/111 0/89 0.257 2/102 (1.0) 0/111 1 1/89 (1.1) 0.502 1/102 (1.0) 0/111 1 1/89 (1.1) 0.502 1/102 (1.0) 0/111 1 1/89 (1.1) 0.624 1/102 (1.0) 0/111 1 1/89 (1.1) 0.624 1/102 (1.0) 0/111 1 1/89 (1.1) 0.624 1/102 (1.0) 0/111 1/89 (1.1) 0.624 1/102 (1.0) 0/111 1 1/89 (1.1) 0.624 1/102 (1.0) 0/111 1 1/89 (1.1) 0.385 0/102 2/111 (1.8) 0/89 0.385 0/102 2/111 (1.8) 0/89 0.440 0/102 1/111 (0.9) 0/89 0.440 0/102 1/111 (0.9) 0/89 0.440 0/102 0/100 0/110 0/89	P-Value * DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 0.617 9/102 (8.8) 16/111 (14.4) 11/ 89 (12.4) 11/ 81 0.617 9/102 (8.8) 16/111 (14.4) 11/ 89 (12.4) 11/ 81 0.447 6/101 (5.9) 14/110 (12.7) 11/ 89 (12.4) 10/ 81 0.819 4/101 (4.0) 6/110 (5.5) 5/ 89 (5.6) 6/ 81 0.477 2/101 (2.0) 8/110 (7.3) 6/ 89 (6.7) 4/ 81 0.064 0/102 0/111 0/ 89 1/81 0.257 2/102 (2.0) 0/111 0/ 89 0/ 81 0.257 2/102 (2.0) 0/111 0/ 89 0/ 81 0.257 2/102 (2.0) 0/111 0/ 89 0/ 81 0.502 1/102 (1.0) 0/111 1 1/89 (1.1) 0/ 81 0.502 1/102 (1.0) 0/111 1 1/89 (1.1) 0/ 81 0.409 0/102 0/111 1 1/89 (1.1) 0/ 81 0.624 1/102 (1.0) 0/111 1 1/89 (1.1) 0/ 81 0.624 1/102 (1.0) 0/111 1 1/89 (1.1) 0/ 81 0.624 1/102 (1.0) 0/111 1 1/89 (1.1) 0/ 81 0.624 1/102 (1.0) 0/111 1 1/89 (1.1) 0/ 81 0.385 0/102 2/111 (1.8) 0/ 89 1/81 0.385 0/102 2/111 (1.8) 0/ 89 1/81 0.385 0/102 2/111 (1.8) 0/ 89 1/81 0.440 0/102 1/111 (0.9) 0/ 89 0/ 81 0.440 0/102 1/111 (0.9) 0/ 89 0/ 81 0.440 0/102 1/111 (0.9) 0/ 89 0/ 81 0.165 0/102 0/110	P-Value * DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg 0.617 9/102 (8.8) 16/111 (14.4) 11/ 89 (12.4) 11/ 81 (13.6) 0.617 9/102 (8.8) 16/111 (14.4) 11/ 89 (12.4) 11/ 81 (13.6) 0.447 6/101 (5.9) 14/110 (12.7) 11/ 89 (12.4) 10/ 81 (12.3) 0.819 4/101 (4.0) 6/110 (5.5) 5/ 89 (5.6) 6/ 81 (7.4) 0.477 2/101 (2.0) 8/110 (7.3) 6/ 89 (6.7) 4/ 81 (4.9) 0.064 0/102 0/111 0/ 89 1/81 (1.2) 0.257 2/102 (2.0) 0/111 0/ 89 1/81 (1.2) 0.257 2/102 (2.0) 0/111 0/ 89 0/ 81 0.257 2/102 (2.0) 0/111 0/ 89 0/ 81 0.616 1/102 (1.0) 0/111 0/ 89 0/ 81 0.502 1/102 (1.0) 0/111 1/89 (1.1) 0/81 0.502 1/102 (1.0) 0/111 1/89 (1.1) 0/81 0.409 0/102 0/111 1/89 (1.1) 0/81 0.624 1/102 (1.0) 0/111 1/89 (1.1) 0/81 0.624 1/102 (1.0) 0/111 1/89 (1.1) 0/81 0.624 1/102 (1.0) 0/111 1/89 (1.1) 0/81 0.624 1/102 (1.0) 0/111 1/89 (1.1) 0/81 0.385 0/102 2/111 (1.8) 0/89 1/81 (1.2) 0.385 0/102 2/111 (1.8) 0/89 0/81 0.440 0/102 1/111 (0.9) 0/89 0/81 0.440 0/102 1/111 (0.9) 0/89 0/81 0.440 0/102 1/111 (0.9) 0/89 0/81 0.440 0/102 1/111 (0.9) 0/89 0/81	P-Value * DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Place 0.617 9/102 (8.8) 16/111 (14.4) 11/ 89 (12.4) 11/ 81 (13.6) 10/ 59 0.617 9/102 (8.8) 16/111 (14.4) 11/ 89 (12.4) 11/ 81 (13.6) 10/ 59 0.447 6/101 (5.9) 14/110 (12.7) 11/ 89 (12.4) 10/ 81 (12.3) 5/ 59 0.819 4/101 (4.0) 6/110 (5.5) 5/ 89 (5.6) 6/ 81 (7.4) 2/ 59 0.477 2/101 (2.0) 8/110 (7.3) 6/ 89 (6.7) 4/ 81 (4.9) 3/ 59 0.064 0/102 0/111 0/ 89 1/ 81 (1.2) 2/ 59 0.257 2/102 (2.0) 0/111 0/ 89 1/ 81 (1.2) 2/ 59 0.257 2/102 (2.0) 0/111 0/ 89 0/ 81 1/ 59 0.616 1/102 (1.0) 0/111 0/ 89 0/ 81 1/ 59 0.616 1/102 (1.0) 0/111 1/ 89 (1.1) 0/ 81 0/ 59 0.409 0/102 0/111 1/ 89 (1.1) 0/ 81 0/ 59 0.409 0/102 0/111 1/ 89 (1.1) 0/ 81 0/ 59 0.409 0/102 0/111 1/ 89 (1.1) 0/ 81 0/ 59 0.409 0/102 0/111 1/ 89 (1.1) 0/ 81 1/ 59 0.624 1/102 (1.0) 0/111 1/ 89 (1.1) 0/ 81 1/ 59 0.624 1/102 (1.0) 0/111 1/ 89 (1.1) 0/ 81 1/ 59 0.385 0/102 2/111 (1.8) 0/ 89 1/ 81 (1.2) 0/ 59 0.385 0/102 2/111 (1.8) 0/ 89 0/ 81 1/ 81 (1.2) 0/ 59 0.440 0/102 1/111 (0.9) 0/ 89 0/ 81 1/ 59 0.440 0/102 1/111 (0.9) 0/ 89 0/ 81 1/ 59 0.440 0/102 1/111 (0.9) 0/ 89 0/ 81 1/ 59 0.440 0/102 1/111 (0.9) 0/ 89 0/ 81 1/ 59 0.440 0/102 1/111 (0.9) 0/ 89 0/ 81 1/ 59 0.450 0/102 0/110 0/110 0/ 89 0/ 81 1/ 59

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 26

Category Test+Units	Overall P-Value *	Treati	
TOTAL	0.617	57/442	(12.9)
VITAL SIGNS WEIGHT kg DECREASE INCREASE	0.617 0.447 0.819 0.477	46/440 23/440	(10.5) (5.2)
Postural BP Change SYSTOLIC BP mm Hg DECREASE Standing SYSTOLIC BP mm Hg DECREASE	0.064 0.064 0.257 0.257	3/442 3/442 3/442	(0.7) (0.7) (0.7)
Supine SYSTOLIC BP mm Hg DECREASE INCREASE Postural BP Change DIASTOLIC BP mm Hg	0.616 0.502 0.409 0.624	2/442 1/442 1/442	(0.5)
DECREASE Standing DIASTOLIC BP mm Hg INCREASE	0.624 0.385 0.385	3/442 3/442 3/442	(0.7) (0.7) (0.7)
Supine DIASTOLIC BP mm Hg INCREASE Supine PULSE beats/min DECREASE	0.440 0.440 0.165 0.165		

Page 10

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

Page 11

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 39

Category Test+Units	Overall P-Value *	DVS SR	50 mg	DVS SR	100 mg	Treat DVS SR		DVS SR 2	 200 mg	Place	 ebo
TOTAL	0.007**	15/ 94	(16.0)	21/ 95	(22.1)	22/ 82	(26.8)	7/ 71	(9.9)	3/ 50	(6.0)
VITAL SIGNS WEIGHT kg DECREASE INCREASE INCREASE Postural BP Change SYSTOLIC BP mm Hg DECREASE Standing SYSTOLIC BP mm Hg DECREASE INCREASE Supine SYSTOLIC BP mm Hg DECREASE INCREASE INCREASE FOSTURAL BP Change DIASTOLIC BP mm Hg DECREASE Standing DIASTOLIC BP mm Hg INCREASE Supine DIASTOLIC BP mm Hg INCREASE Supine DIASTOLIC BP mm Hg INCREASE	0.007** 0.005** 0.591 0.015* 0.144 0.144 0.577 0.6647 0.651 0.064 0.107 0.431 0.624 0.624 0.292 0.292 0.310 0.310	15/ 94 12/ 93 5/ 93 7/ 93 0/ 94 1/ 94 1/ 94 1/ 94 1/ 94 1/ 94 1/ 94 1/ 94 1/ 94 0/ 94 0/ 94 0/ 94	(16.0) (12.9) (5.4) (7.5) (1.1) (1.1) (1.1) (1.1) (1.1) (1.1)	21/ 95 20/ 94 5/ 94 15/ 94 0/ 95 1/ 95 0/ 95 0/ 95 0/ 95 0/ 95 0/ 95 2/ 95 2/ 95 1/ 95	(22.1) (21.3) (5.3) (16.0) (1.1) (1.1) (2.1) (2.1) (2.1) (1.1)	22/ 82 20/ 80 6/ 80 14/ 80 0/ 82 2/ 82 1/ 82 1/ 82 2/ 82 2/ 82 1/ 82 2/ 82 2/ 82 2/ 82 2/ 82 2/ 82 2/ 82 2/ 82	(26.8) (25.0) (7.5) (17.5) (2.4) (1.2) (1.2) (1.2) (2.4) (2.4) (2.4) (2.4) (2.4) (2.4)	7/ 71 7/ 71 2/ 71 5/ 71 0/ 71 0/ 71 0/ 71 0/ 71 0/ 71 0/ 71 0/ 71 0/ 71 0/ 71	(9.9) (9.9) (2.8) (7.0)	3/ 50 2/ 50 1/ 50 1/ 50 1/ 50 0/ 50 0/ 50 0/ 50 1/ 50 0/ 50 1/ 50 0/ 50 1/ 50 0/ 50 0/ 50 0/ 50	(6.0) (4.0) (2.0) (2.0) (2.0) (2.0) (2.0) (2.0) (2.0) (2.0)

CONFIDENTIAL 1114 Wyeth

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 12

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Category Test+Units	Overall P-Value *	Treat	
TOTAL	0.007**	68/392	(17.3)
VITAL SIGNS WEIGHT kg DECREASE INCREASE Postural BP Change SYSTOLIC BP mm Hg DECREASE	0.007** 0.005** 0.591 0.015* 0.144	61/388 19/388 42/388 1/392	(17.3) (15.7) (4.9) (10.8) (0.3) (0.3)
Standing SYSTOLIC BP mm Hg DECREASE INCREASE Supine SYSTOLIC BP mm Hg DECREASE INCREASE	0.577 0.647 0.651 0.064 0.107 0.431	4/392 2/392 2/392 6/392 2/392	(1.0) (0.5) (0.5) (1.5) (0.5) (1.0)
Postural BP Change DIASTOLIC BP mm Hg DECREASE Standing DIASTOLIC BP mm Hg INCREASE Supine DIASTOLIC BP mm Hg INCREASE			(0.8) (0.8) (1.0) (1.0) (0.8) (0.8)

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

Page 13

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Category Test+Units	Overall P-Value *	DVS SR	 50 mg	DVS SR	 100 mg	Treat DVS SR		DVS SR	 200 mg	Plac	 ebo
TOTAL	0.207	16/ 82	(19.5)	24/ 84	(28.6)	15/ 69	(21.7)	13/ 65	(20.0)	5/ 46	(10.9)
VITAL SIGNS	0.207	16/ 82	(19.5)	24/ 84	(28.6)	15/ 69	(21.7)	13/ 65	(20.0)	5/ 46	(10.9)
WEIGHT kg	0.146	15/ 82	(18.3)	22/ 83	(26.5)	14/ 69	(20.3)	10/ 64	(15.6)	4/ 46	(8.7)
DECREASE	0.364	3/ 82	(3.7)	8/ 83	(9.6)	4/ 69	(5.8)	3/ 64	(4.7)	1/ 46	(2.2)
INCREASE	0.516	12/ 82	(14.6)	14/ 83	(16.9)	10/ 69	(14.5)	7/ 64	(10.9)	3/ 46	(6.5)
Standing SYSTOLIC BP mm Hg	0.350	2/ 82	(2.4)	0/84		0/ 69		1/ 65	(1.5)	0/46	
DECREASE	0.594	1/ 82	(1.2)	0/84		0/ 69		1/ 65	(1.5)	0/ 46	
INCREASE	0.520	1/ 82	(1.2)	0/84		0/ 69		0/ 65		0/46	
Supine SYSTOLIC BP mm Hg	0.486	1/ 82	(1.2)	1/84	(1.2)	0/ 69		2/ 65	(3.1)	0/ 46	
DECREASE	0.362	0/ 82		0/84		0/ 69		1/ 65	(1.5)	0/ 46	
INCREASE	0.815	1/ 82	(1.2)	1/ 84	(1.2)	0/ 69		1/ 65	(1.5)	0/46	
Postural BP Change DIASTOLIC BP mm Hg	0.631	0/ 82		1/84	(1.2)	1/ 69	(1.4)	0/ 65		1/ 46	(2.2)
DECREASE	0.631	0/ 82		1/ 84	(1.2)	1/ 69	(1.4)	0/ 65		1/ 46	(2.2)
Supine DIASTOLIC BP mm Hg	0.527	0/ 82		0/84		1/ 69	(1.4)	1/ 65	(1.5)	0/ 46	
INCREASE	0.527	0/ 82		0/84		1/ 69	(1.4)	1/ 65	(1.5)	0/46	

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 52

Category Test+Units	Overall P-Value *	Treat TOT	
TOTAL	0.207	73/346	(21.1)
VITAL SIGNS	0.207	73/346	(21.1)
WEIGHT kg	0.146	65/344	(18.9)
DECREASÉ	0.364	19/344	(5.5)
INCREASE	0.516	46/344	(13.4)
Standing SYSTOLIC BP mm Hg	0.350	3/346	(0.9)
DECREASE	0.594	2/346	(0.6)
INCREASE	0.520	1/346	(0.3)
Supine SYSTOLIC BP mm Hg	0.486	4/346	(1.2)
DECREASE	0.362	1/346	(0.3)
INCREASE	0.815	3/346	(0.9)
Postural BP Change DIASTOLIC BP mm Hg	0.631	3/346	(0.9)
DECREASE	0.631	3/346	(0.9)
Supine DIASTOLIC BP mm Hg	0.527	2/346	(0.6)
INCREASE	0.527	2/346	(0.6)

Page 14

CONFIDENTIAL 1117 Wyeth

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 15

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Follow-up

Category Test+Units	Overall P-Value *	DVS SR	50 mg	DVS SR	100 mg	Treat DVS SR		DVS SR 2	 200 mg	Plac	 ebo
TOTAL	0.333	5/ 32	(15.6)	7/ 39	(17.9)	8/ 59	(13.6)	3/ 60	(5.0)	2/ 15	(13.3)
VITAL SIGNS WEIGHT kg DECREASE INCREASE Postural BP Change SYSTOLIC BP mm Hg DECREASE	0.333 0.307 0.166 0.496 0.014* 0.014*	5/ 32 3/ 30 1/ 30 2/ 30 0/ 32 0/ 32	(15.6) (10.0) (3.3) (6.7)	7/ 39 5/ 38 2/ 38 3/ 38 0/ 38 0/ 38	(17.9) (13.2) (5.3) (7.9)	8/ 59 6/ 57 5/ 57 1/ 57 0/ 57 0/ 57	(13.6) (10.5) (8.8) (1.8)	3/ 60 2/ 58 0/ 58 2/ 58 0/ 60 0/ 60	(5.0) (3.4) (3.4)	2/ 15 0/ 14 0/ 14 0/ 14 1/ 15 1/ 15	(13.3) (6.7) (6.7)
Standing SYSTOLIC BP mm Hg DECREASE INCREASE Supine SYSTOLIC BP mm Hg INCREASE	0.746 0.839 0.069 0.723	1/ 32 1/ 32 0/ 32 1/ 32 1/ 32	(3.1) (3.1) (3.1) (3.1)	2/ 38 0/ 38 2/ 38 1/ 39 1/ 39	(5.3) (5.3) (2.6) (2.6)	1/ 57 1/ 57 0/ 57 1/ 58 1/ 58	(1.8) (1.8) (1.7) (1.7)	1/ 60 1/ 60 0/ 60 0/ 60 0/ 60	(1.7) (1.7)	0/ 15 0/ 15 0/ 15 0/ 15 0/ 15	(0.7)
POSTURAL BP Change DIASTOLIC BP mm Hg DECREASE Standing DIASTOLIC BP mm Hg DECREASE INCREASE Supine DIASTOLIC BP mm Hg INCREASE	0.723 0.160 0.160 0.720 0.635 0.426 0.373	0/ 32 0/ 32 1/ 32 0/ 32 1/ 32 0/ 32 0/ 32	(3.1)	1/ 39 0/ 38 0/ 38 1/ 38 0/ 38 1/ 39 1/ 39	(2.6) (2.6) (2.6) (2.6) (2.6)	1/ 58 1/ 57 1/ 57 1/ 57 1/ 57 0/ 57 0/ 58 0/ 58	(1.7) (1.8) (1.8) (1.8) (1.8)	0/ 60 0/ 60 0/ 60 0/ 60 0/ 60 0/ 60		0/ 15 1/ 15 1/ 15 0/ 15 0/ 15 0/ 15 0/ 15	(6.7) (6.7)

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Follow-up

Category Test+Units	Overall P-Value *	Treat TOT	
TOTAL	0.333	25/205	(12.2)
VITAL SIGNS WEIGHT kg DECREASE INCREASE POSTURAL BP Change SYSTOLIC BP mm Hg DECREASE Standing SYSTOLIC BP mm Hg DECREASE INCREASE INCREASE Supine SYSTOLIC BP mm Hg INCREASE POSTURAL BP Change DIASTOLIC BP mm Hg DECREASE Standing DIASTOLIC BP mm Hg DECREASE Standing DIASTOLIC BP mm Hg DECREASE Standing DIASTOLIC BP mm Hg	0.333 0.307 0.166 0.496 0.014* 0.014* 0.746 0.839 0.069 0.723 0.723 0.723 0.160 0.160 0.720 0.635 0.426	8/197 8/197 1/202 1/202 5/202 3/202 3/204 3/204 2/202 2/202 3/202	(8.1) (4.1) (4.1) (0.5) (0.5) (2.5) (1.5) (1.5) (1.5) (1.5) (1.5) (1.0) (1.5) (0.5) (0.5)

Page 16

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

Page 17

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Screening/baseline

Category Test+Units	Overall P-Value *	Trea Comparator 1	tment Comparator 2	Comparator		io Comparato		Pairwise P-Value *
TOTAL	0.046*	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	2/155 (2/155 (1.3) 1.3) 1.3) 1.3)	2/155 2/157 5/151 4/ 77 2/157 5/151 4/ 77 5/151	(1.3) (1.3) (3.3) (5.2) (1.3) (3.3) (5.2) (3.3)	0.499 0.499 0.060 0.013* 1.000 0.278 0.096 0.275
		DVS SR 200 mg	Placebo Placebo	2/157 (1.3)	4/ 77 4/ 77	(5.2) (5.2)	0.093 0.491
VITAL SIGNS	0.046*	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/149 0/149 0/149		2/155 2/157 5/151 4/ 77	(1.3) (1.3) (3.3) (5.2)	0.499 0.499 0.060 0.013*
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	2/155 (2/155 (2/155 (1.3) 1.3) 1.3)	2/157 5/151 4/ 77	(1.3) (3.3) (5.2)	1.000 0.278 0.096
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	2/157 (1.3) 1.3) 3.3)	5/151 4/ 77 4/ 77	(3.3) (5.2) (5.2)	0.275 0.093 0.491
WEIGHT kg	0.356	DVS SR 50 mg DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg	0/149 0/149 0/155		2/157 1/151 2/157	(1.3) (0.7) (1.3)	0.499 1.000 0.498
		DVS SR 150 mg	DVS SR 200 mg DVS SR 200 mg Placebo Placebo	2/157 (1.3) 1.3) 0.7)	1/151 1/151 0/ 77 0/ 77	(0.7) (0.7)	0.493 1.000 1.000 1.000
DECREASE	0.494	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo		0.6)	1/157 1/157 0/151 0/ 77	(0.6) (0.6)	1.000 1.000 1.000 1.000
INCREASE	0.648	DVS SR 50 mg	DVS SR 150 mg DVS SR 200 mg	0/149 0/149		1/157 1/151	(0.6) (0.7)	1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 18

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Screening/baseline

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Comparator		io Comparato		Pairwise P-Value *
INCREASE	0.648	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg DVS SR 200 mg Placebo Placebo	1/157	0.6) 0.6) 0.7)	1/157 1/151 1/151 0/ 77 0/ 77	(0.6) (0.7) (0.7)	1.000 0.493 1.000 1.000
Postural BP Change SYSTOLIC BP mm Hg	0.558	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	1/155 () 1/155 () 0/157 0/157	0.6) 0.6) 0.6)	1/155 1/151 1/ 77 0/157 1/151 1/ 77 1/151 1/ 77 1/ 77	(0.6) (0.7) (1.3) (0.7) (1.3) (0.7) (1.3) (1.3)	1.000 1.000 0.341 0.497 1.000 1.000 0.490 0.329 1.000
DECREASE	0.558	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	1/155 () 1/155 () 0/157 0/157	0.6) 0.6) 0.6)	1/155 1/151 1/ 77 0/157 1/151 1/ 77 1/151 1/ 77 1/ 77	(0.6) (0.7) (1.3) (0.7) (1.3) (0.7) (1.3) (1.3)	1.000 1.000 0.341 0.497 1.000 1.000 0.490 0.329 1.000
Standing SYSTOLIC BP mm Hg	0.312	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	0/149 0/149 0/155 0/155 0/157 0/157 1/151 ((0.7)	1/151 1/ 77 1/151 1/ 77 1/151 1/ 77 1/ 77	(0.7) (1.3) (0.7) (1.3) (0.7) (1.3) (1.3)	1.000 0.341 0.493 0.332 0.490 0.329 1.000
DECREASE	0.468	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg	0/149 0/155 0/157		1/151 1/151 1/151	(0.7) (0.7) (0.7)	1.000 0.493 0.490

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 19

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Screening/baseline

Category Test+Units	Overall P-Value *		tment Comparator 2			io Comparato		Pairwise P-Value *
DECREASE	0.468	DVS SR 200 mg	Placebo	1/151	(0.7)	0/ 77		1.000
INCREASE	0.093	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/149 0/155 0/157 0/151		1/ 77 1/ 77 1/ 77 1/ 77	(1.3) (1.3) (1.3) (1.3)	0.341 0.332 0.329 0.338
Supine SYSTOLIC BP mm Hg	0.093	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/149 0/155 0/157 0/151		1/ 77 1/ 77 1/ 77 1/ 77	(1.3) (1.3) (1.3) (1.3)	0.341 0.332 0.329 0.338
INCREASE	0.093	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/149 0/155 0/157 0/151		1/ 77 1/ 77 1/ 77 1/ 77	(1.3) (1.3) (1.3) (1.3)	0.341 0.332 0.329 0.338
Postural BP Change DIASTOLIC BP mm Hg	0.124	DVS SR 50 mg	DVS SR 100 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	0/149 0/149 0/149 1/155 1/155	(0.6) (0.6) (0.6)	1/155 1/151 2/ 77 0/157 1/151 2/ 77	(0.6) (0.7) (2.6) (0.7) (2.6)	1.000 1.000 0.115 0.497 1.000 0.256
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	0/157 0/157 1/151	(0.7)	1/151 2/ 77 2/ 77	(0.7) (2.6) (2.6)	0.490 0.107 0.264
DECREASE	0.124	DVS SR 50 mg	DVS SR 100 mg DVS SR 200 mg Placebo	0/149 0/149 0/149		1/155 1/151 2/ 77	(0.6) (0.7) (2.6)	1.000 1.000 0.115
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/155 1/155 1/155	(0.6) (0.6) (0.6)	0/157 1/151 2/ 77	(0.7) (2.6)	0.497 1.000 0.256
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	0/157 0/157 1/151	(0.7)	1/151 2/ 77 2/ 77	(0.7) (2.6) (2.6)	0.490 0.107 0.264

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 20 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Screening/baseline

REPORT VS5

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Comparator 1			Pairwise P-Value *
Standing DIASTOLIC BP mm Hg	0.093	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/149 0/155 0/157 0/151	1/ 77 1/ 77 1/ 77 1/ 77	(1.3) (1.3) (1.3) (1.3)	0.341 0.332 0.329 0.338
DECREASE	0.093	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/149 0/155 0/157 0/151	1/ 77 1/ 77 1/ 77 1/ 77	(1.3) (1.3) (1.3) (1.3)	0.341 0.332 0.329 0.338
Supine DIASTOLIC BP mm Hg	0.312	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	0/149 0/149 0/155 0/155 0/157 0/157 1/151 (0.	1/151 1/ 77 1/151 1/ 77 1/151 1/ 77 7) 1/ 77	(0.7) (1.3) (0.7) (1.3) (0.7) (1.3) (1.3)	1.000 0.341 0.493 0.332 0.490 0.329 1.000
DECREASE	0.312	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	0/149 0/149 0/155 0/155 0/157 0/157 1/151 (0.	1/151 1/ 77 1/151 1/ 77 1/151 1/ 77 7) 1/ 77	(0.7) (1.3) (0.7) (1.3) (0.7) (1.3) (1.3)	1.000 0.341 0.493 0.332 0.490 0.329 1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square. Pairwise P-Value: Fisher's Exact Test P-value (2-Tail).

CSR-60178

Page 21

DVS SR Protocol 3151A2-315-US

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Comparato		io Comparato		Pairwise P-Value *
TOTAL	0.601	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	4/139 4/139 4/139 4/139	(2.9) (2.9) (2.9) (2.9)	8/135 7/128 3/111 4/ 76	(5.9) (5.5) (2.7) (5.3)	0.250 0.362 1.000 0.457
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	8/135 8/135 8/135	(5.9) (5.9) (5.9)	7/128 3/111 4/ 76	(5.5) (5.5) (2.7) (5.3)	1.000 0.354 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	7/128 7/128	(5.5) (5.5)	3/111 4/ 76	(2.7) (5.3)	0.346
		DVS SR 200 mg	Placebo	3/111	(2.7)	4/ 76	(5.3)	0.445
VITAL SIGNS	0.601	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	4/139 4/139 4/139 4/139	(2.9) (2.9) (2.9) (2.9)	8/135 7/128 3/111 4/ 76	(5.9) (5.5) (2.7) (5.3)	0.250 0.362 1.000 0.457
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	8/135 8/135 8/135	(5.9) (5.9) (5.9)	7/128 3/111 4/ 76	(5.5) (2.7) (5.3)	1.000 0.354 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	7/128 7/128	(5.5) (5.5)	3/111 4/ 76	(2.7) (5.3)	0.346 1.000
		DVS SR 200 mg	Placebo	3/111	(2.7)	4/ 76	(5.3)	0.445
WEIGHT kg	0.523	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	3/138 3/138 3/138 3/138	(2.2) (2.2) (2.2) (2.2)	1/135 3/128 1/111 0/ 76	(0.7) (2.3) (0.9)	0.622 1.000 0.631 0.554
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/135 1/135 1/135	(0.7) (0.7) (0.7)	3/128 1/111 0/ 76	(2.3) (0.9)	0.359 1.000 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	3/128 3/128	(2.3) (2.3)	1/111 0/ 76	(0.9)	0.626 0.295
		DVS SR 200 mg	Placebo	1/111	(0.9)	0/ 76		1.000
DECREASE	0.151	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/138 2/138 2/138 2/138	(1.4) (1.4) (1.4) (1.4)	0/135 3/128 0/111 0/ 76	(2.3)	0.498 0.674 0.504 0.540

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square. Pairwise P-Value: Fisher's Exact Test P-value (2-Tail).

Page 22

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 4

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Comparato		io Comparato		Pairwise P-Value *
DECREASE	0.151	DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo	0/135 3/128 3/128	(2.3)	3/128 0/111 0/ 76	(2.3)	0.114 0.251 0.295
INCREASE	0.800	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/138 1/138 1/138 1/138	(0.7) (0.7) (0.7) (0.7)	1/135 0/128 1/111 0/ 76	(0.7) (0.9)	1.000 1.000 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/135 1/135 1/135	(0.7) (0.7) (0.7)	0/128 1/111 0/ 76	(0.9)	1.000 1.000 1.000
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo	0/128 1/111	(0.9)	1/111 0/ 76	(0.9)	0.464
Postural BP Change SYSTOLIC BP mm Hg	0.476	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/139 2/139 2/139 2/139	(1.4) (1.4) (1.4) (1.4)	1/135 1/127 0/111 2/ 76	(0.7) (0.8) (2.6)	1.000 1.000 0.504 0.615
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/135 1/135 1/135	(0.7) (0.7) (0.7)	1/127 0/111 2/ 76	(0.8)	1.000 1.000 0.295
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	1/127 1/127 0/111	(0.8)	0/111 2/ 76 2/ 76	(2.6) (2.6)	1.000 0.557 0.164
DECREASE	0.476	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/139 2/139 2/139 2/139	(1.4) (1.4) (1.4) (1.4)	1/135 1/127 0/111 2/ 76	(0.7) (0.8) (2.6)	1.000 1.000 0.504 0.615
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/135 1/135 1/135	(0.7) (0.7) (0.7)	1/127 0/111 2/ 76	(0.8)	1.000 1.000 0.295
		DVS SR 150 mg	DVS SR 200 mg Placebo Placebo	1/127 1/127 1/127 0/111	(0.8)	0/111 2/ 76 2/ 76	(2.6) (2.6)	1.000 0.557 0.164
Standing SYSTOLIC BP mm Hg	0.463	DVS SR 50 mg	DVS SR 100 mg	1/139	(0.7)	2/135	(1.5)	0.618

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 23

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 4

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	 Comparato				Pairwise P-Value
					L L	Comparato		
Standing SYSTOLIC BP mm Hg	0.463	DVS SR 50 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/139 1/139 1/139	(0.7) (0.7) (0.7)	0/127 2/111 0/ 76	(1.8)	1.000 0.586 1.000 0.499 1.000 0.515 1.000 1.000 1.000 1.000 1.000 0.466 1.000 0.466 1.000 0.466 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	2/135 2/135 2/135	(1.5) (1.5) (1.5)	0/127 2/111 0/ 76	(1.8)	1.000
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo	0/127 2/111	(1.8)	2/111 0/ 76	(1.8)	0.216
DECREASE	0.802	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg	1/139 1/139	(0.7) (0.7)	1/135 0/127	(0.7)	
			DVS SR 200 mg Placebo	1/139 1/139	(0.7)	1/111 0/ 76	(0.9)	1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	1/135 1/135	(0.7) (0.7)	0/127 1/111	(0.9)	
		DVS SR 150 mg	Placebo DVS SR 200 mg	1/135 0/127	(0.7)	0/ 76 1/111	(0.9)	0.466
		DVS SR 200 mg	Placebo	1/111	(0.9)	0/ 76		1.000
INCREASE	0.586	DVS SR 50 mg	DVS SR 100 mg DVS SR 200 mg	0/139 0/139		1/135 1/111	(0.7) (0.9)	
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	1/135 1/135	(0.7) (0.7)	0/127 1/111	(0.9)	1.000
		DVS SR 150 mg	Placebo DVS SR 200 mg	1/135 0/127	(0.7)	0/ 76 1/111	(0.9)	1.000
		DVS SR 200 mg	Placebo	1/111	(0.9)	0/76	(0.5)	
Supine SYSTOLIC BP mm Hg	0.421	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	0/139 0/139 0/139		1/135 2/127 1/111	(0.7) (1.6) (0.9)	0.493 0.227 0.444
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	0/139 1/135 1/135 1/135	(0.7) (0.7) (0.7)	2/ 76 2/127 1/111 2/ 76	(2.6) (1.6) (0.9) (2.6)	0.124 0.612 1.000 0.295
		DVS SR 150 mg	DVS SR 200 mg	2/127	(1.6)	1/111	(0.9)	1.000
		DVS SR 200 mg	Placebo Placebo	2/127 1/111	(1.6) (0.9)	2/ 76 2/ 76	(2.6) (2.6)	0.631 0.567

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 24

DVS SR Protocol 3151A2-315-US CSR-60178

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 4

Category Test+Units	Overall P-Value *	Trea	ntment Comparator 2	Comparato		io Comparato	Pairwise P-Value	
DECREASE	0.644	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0/139 0/139 1/135 1/135 1/135 1/127 1/127	(0.7) (0.7) (0.7) (0.8) (0.8)	1/135 1/127 1/127 0/111 0/ 76 0/111 0/ 76	(0.7) (0.8) (0.8)	0.493 0.477 1.000 1.000 1.000 1.000
INCREASE	0.180	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	0/139 0/139 0/139 0/135 0/135 0/135 1/127 1/127 1/111	(0.8) (0.8) (0.9)	1/127 1/111 2/ 76 1/127 1/111 2/ 76 1/111 2/ 76 2/ 76	(0.8) (0.9) (2.6) (0.8) (0.9) (2.6) (0.9) (2.6) (2.6)	0.477 0.444 0.124 0.485 0.451 0.129 1.000 0.557 0.567
Postural BP Change DIASTOLIC BP mm Hg	0.451	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	0/139 0/139 0/139 1/135 1/135 1/135 2/127 2/127 0/111	(0.7) (0.7) (0.7) (1.6) (1.6)	1/135 2/127 1/ 76 2/127 0/111 1/ 76 0/111 1/ 76 1/ 76	(0.7) (1.6) (1.3) (1.6) (1.3) (1.3)	0.493 0.227 0.353 0.612 1.000 0.500 1.000 0.406
DECREASE	0.451	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	0/139 0/139 0/139 1/135 1/135 1/135 2/127 2/127 0/111	(0.7) (0.7) (0.7) (1.6) (1.6)	1/135 2/127 1/ 76 2/127 0/111 1/ 76 0/111 1/ 76 1/ 76	(0.7) (1.6) (1.3) (1.6) (1.3) (1.3)	0.493 0.227 0.353 0.612 1.000 0.500 1.000 0.406

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 25

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 4

Category	Overall	Trea	tment		Rat	io		Pairwise
Test+Units	P-Value *	Comparator 1	Comparator 2	Comparato	or 1	Comparato	or 2	P-Value '
Standing DIASTOLIC BP mm Hg	0.358	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg	0/139 0/139		2/135 1/127	(1.5)	0.242
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	2/135 2/135 2/135	(1.5) (1.5) (1.5)	1/127 0/111 0/ 76	(0.8)	1.000 0.503 0.537
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/127 1/127	(0.8)	0/111 0/ 76		1.000
INCREASE	0.358	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg	0/139 0/139		2/135 1/127	(1.5) (0.8)	0.242 0.477
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	2/135 2/135 2/135	(1.5) (1.5) (1.5)	1/127 0/111 0/ 76	(0.8)	1.000 0.503 0.537
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/127 1/127	(0.8)	0/111 0/ 76		1.000
Supine DIASTOLIC BP mm Hg	0.380	DVS SR 50 mg	DVS SR 150 mg Placebo	0/139 0/139		1/127 1/ 76	(0.8) (1.3)	0.477 0.353
		DVS SR 100 mg	DVS SR 150 mg Placebo	0/135 0/135	(0.0)	1/127 1/ 76	(0.8) (1.3)	0.485 0.360
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	1/127 1/127 0/111	(0.8) (0.8)	0/111 1/ 76 1/ 76	(1.3) (1.3)	1.000 1.000 0.406
INCREASE	0.380	DVS SR 50 mg	DVS SR 150 mg	0/139		1/127	(0.8)	0.477
		DVS SR 100 mg	Placebo DVS SR 150 mg Placebo	0/139 0/135 0/135		1/ 76 1/127 1/ 76	(1.3) (0.8) (1.3)	0.353 0.485 0.360
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/127 1/127	(0.8) (0.8)	0/111 1/ 76	(1.3)	1.000
		DVS SR 200 mg	Placebo	0/111		1/ 76	(1.3)	0.406

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 Page 26

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Comparato		cio Comparato		Pairwise P-Value *
TOTAL	0.140	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/124 1/124 1/124 1/124	(0.8) (0.8) (0.8) (0.8)	7/125 9/114 6/ 97 4/ 71	(5.6) (7.9) (6.2) (5.6)	0.066 0.008** 0.045* 0.060
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	7/125 7/125 7/125 7/125	(5.6) (5.6) (5.6)	9/114 6/ 97 4/ 71	(7.9) (6.2) (5.6)	0.606 1.000 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	9/114 9/114	(7.9) (7.9)	6/ 97 4/ 71	(6.2) (5.6)	0.790 0.769
		DVS SR 200 mg	Placebo	6/ 97	(6.2)	4/ 71	(5.6)	1.000
VITAL SIGNS	0.140	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/124 1/124 1/124 1/124	(0.8) (0.8) (0.8)	7/125 9/114 6/ 97 4/ 71	(5.6) (7.9) (6.2) (5.6)	0.066 0.008** 0.045* 0.060
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	7/125 7/125 7/125 7/125	(5.6) (5.6) (5.6)	9/114 6/ 97 4/ 71	(7.9) (6.2) (5.6)	0.000 0.606 1.000 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	9/114 9/114	(7.9) (7.9)	6/ 97 4/ 71	(6.2) (5.6)	0.790 0.769
		DVS SR 200 mg	Placebo	6/ 97	(6.2)	4/ 71	(5.6)	1.000
WEIGHT kg	0.341	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/124 0/124 0/124 0/124		2/125 4/114 2/ 96 1/ 71	(1.6) (3.5) (2.1) (1.4)	0.498 0.051 0.189 0.364
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	2/125 2/125 2/125	(1.6) (1.6) (1.6)	4/114 2/ 96 1/ 71	(3.5) (2.1) (1.4)	0.429 1.000 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	4/114 4/114	(3.5) (3.5)	2/ 96 1/ 71	(2.1) (1.4)	0.690 0.651
		DVS SR 200 mg	Placebo	2/ 96	(2.1)	1/ 71	(1.4)	1.000
DECREASE	0.509	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/124 0/124 0/124 0/124		2/125 3/114 1/ 96 1/ 71	(1.6) (2.6) (1.0) (1.4)	0.498 0.108 0.436 0.364

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square. Pairwise P-Value: Fisher's Exact Test P-value (2-Tail).

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

5 Page 27

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 8

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Comparato		cio Comparato		Pairwise P-Value *
DECREASE	0.509	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	2/125 2/125 2/125 3/114 3/114 1/ 96	(1.6) (1.6) (1.6) (2.6) (2.6) (1.0)	3/114 1/ 96 1/ 71 1/ 96 1/ 71 1/ 71	(2.6) (1.0) (1.4) (1.0) (1.4) (1.4)	0.672 1.000 1.000 0.627 1.000 1.000
INCREASE	0.542	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 200 mg Placebo Placebo	0/124 0/124 0/125 0/125 1/114 1/114 1/ 96	(0.9) (0.9) (1.0)	1/114 1/ 96 1/114 1/ 96 1/ 96 0/ 71 0/ 71	(0.9) (1.0) (0.9) (1.0) (1.0)	0.479 0.436 0.477 0.434 1.000 1.000
Postural BP Change SYSTOLIC BP mm Hg	0.844	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	1/124 1/124 1/124 1/124 1/125 1/125 1/125 1/125 1/114 1/114	(0.8) (0.8) (0.8) (0.8) (0.8) (0.8) (0.9) (0.9)	1/125 1/114 0/ 97 0/ 71 1/114 0/ 97 0/ 71 0/ 97 0/ 71	(0.8) (0.9) (0.9)	1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
DECREASE	0.844	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	1/124 1/124 1/124 1/125 1/125 1/125 1/125 1/114 1/114	(0.8) (0.8) (0.8) (0.8) (0.8) (0.8) (0.8) (0.9) (0.9)	1/125 1/114 0/ 97 0/ 71 1/114 0/ 97 0/ 71 0/ 97 0/ 71	(0.8) (0.9) (0.9)	1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Standing SYSTOLIC BP mm Hg	0.577	DVS SR 50 mg	DVS SR 150 mg DVS SR 200 mg	0/124 0/124		1/114 1/ 97	(0.9) (1.0)	0.479 0.439

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 28

DVS SR Protocol 3151A2-315-US CSR-60178

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 8

Category Test+Units	Overall P-Value *		tment Comparator 2			cio Comparato		Pairwise P-Value *	
Standing SYSTOLIC BP mm Hg	0.577	DVS SR 50 mg DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	0/124 0/125 0/125 0/125		1/ 71 1/114 1/ 97 1/ 71	(1.4) (0.9) (1.0) (1.4)	0.364 0.477 0.437 0.362	
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	1/114 1/114 1/ 97	(0.9) (0.9) (1.0)	1/ 97 1/ 71 1/ 71	(1.0) (1.4) (1.4)	1.000 1.000 1.000	
DECREASE	0.577	DVS SR 50 mg	DVS SR 150 mg DVS SR 200 mg	0/124 0/124	. ,	1/114 1/ 97	(0.9) (1.0)	0.479 0.439	
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	0/124 0/125 0/125 0/125		1/ 71 1/114 1/ 97 1/ 71	(1.4) (0.9) (1.0) (1.4)	0.364 0.477 0.437 0.362	
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	1/114 1/114 1/ 97	(0.9) (0.9) (1.0)	1/ 71 1/ 97 1/ 71 1/ 71	(1.4) (1.0) (1.4) (1.4)	1.000 1.000 1.000	
Supine SYSTOLIC BP mm Hg	0.601	DVS SR 50 mg	DVS SR 100 mg	0/124 0/124	(1.0)	1/125 1/ 97	(0.8) (1.0)	1.000	
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg	0/124 1/125 1/125	(0.8) (0.8)	1/ 71 0/114 1/ 97	(1.4)	0.364 1.000 1.000	
		DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	1/125 0/114 0/114	(0.8)	1/ 71 1/ 97 1/ 71	(1.4) (1.0) (1.4)	1.000 0.460 0.384	
		DVS SR 200 mg	Placebo	1/ 97	(1.0)	1/ 71	(1.4)	1.000	
DECREASE	0.165	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/124 0/125 0/114 0/ 97		1/ 71 1/ 71 1/ 71 1/ 71	(1.4) (1.4) (1.4) (1.4)	0.364 0.362 0.384 0.423	
INCREASE	0.579	DVS SR 50 mg	DVS SR 100 mg	0/124		1/125	(0.8)	1.000	
		DVS SR 100 mg	DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg	0/124 1/125 1/125	(0.8) (0.8)	1/ 97 0/114 1/ 97	(1.0) (1.0)	0.439 1.000 1.000	

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 29 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 8

REPORT VS5

ategory	Overall	Trea	tment		Rat	io		Pairwise
Test+Units	P-Value *	Comparator 1	Comparator 2	Comparato	r 1	Comparato	or 2	P-Value
INCREASE	0.579	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo DVS SR 200 mg Placebo	1/125 0/114 1/ 97	(0.8)	0/ 71 1/ 97 0/ 71	(1.0)	1.000 0.460 1.000
Postural BP Change DIASTOLIC BP mm Hg	0.612	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/124 0/124 0/124 0/124		1/125 1/114 2/ 97 1/ 71	(0.8) (0.9) (2.1) (1.4)	1.000 0.479 0.192 0.364
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/125 1/125 1/125	(0.8) (0.8) (0.8)	1/114 2/ 97 1/ 71	(0.9) (2.1) (1.4)	1.000 0.582 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/114 1/114	(0.9) (0.9)	2/ 97 1/ 71	(2.1) (1.4)	0.595 1.000
		DVS SR 200 mg	Placebo	2/ 97	(2.1)	1/ 71	(1.4)	1.000
DECREASE	0.612	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg	0/124 0/124 0/124 0/124 1/125	(0.8)	1/125 1/114 2/ 97 1/ 71 1/114	(0.8) (0.9) (2.1) (1.4) (0.9)	1.000 0.479 0.192 0.364 1.000
			DVS SR 200 mg Placebo	1/125 1/125	(0.8) (0.8)	2/ 97 1/ 71	(2.1) (1.4)	0.582 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/114 1/114	(0.9) (0.9)	2/ 97 1/ 71	(2.1) (1.4)	0.595 1.000
		DVS SR 200 mg	Placebo	2/ 97	(2.1)	1/ 71	(1.4)	1.000
Standing DIASTOLIC BP mm Hg	0.269	DVS SR 50 mg	DVS SR 100 mg Placebo	0/124 0/124		2/125 1/ 71	(1.6) (1.4)	0.498 0.364
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	2/125 2/125 2/125	(1.6) (1.6) (1.6)	0/114 0/ 97 1/ 71	(1.4)	0.499 0.506 1.000
		DVS SR 150 mg DVS SR 200 mg	Placebo Placebo	0/114 0/ 97	(1.0)	1/ 71 1/ 71	(1.4) (1.4) (1.4)	0.384
DECREASE	0.165	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	Placebo Placebo Placebo	0/124 0/125 0/114		1/ 71 1/ 71 1/ 71	(1.4) (1.4) (1.4)	0.364 0.362 0.384

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 30

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 8

Category	Overall		atment			io		Pairwise
Test+Units	P-Value *	Comparator 1	Comparator 2	Comparator	1	Comparato	or 2	P-Value *
DECREASE	0.165	DVS SR 200 mg	Placebo	0/ 97		1/ 71	(1.4)	0.423
INCREASE	0.163	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/125	(1.6) (1.6) (1.6)	2/125 0/114 0/ 97 0/ 71	(1.6)	0.498 0.499 0.506 0.536
Supine DIASTOLIC BP mm Hg	0.026*	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo		(2.6) (2.6)	3/114 3/114 0/ 97 0/ 71	(2.6) (2.6)	0.108 0.107 0.251 0.287
INCREASE	0.026*	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo		(2.6) (2.6)	3/114 3/114 0/ 97 0/ 71	(2.6) (2.6)	0.108 0.107 0.251 0.287
Supine PULSE beats/min	0.165	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/124 0/125 0/114 0/ 97		1/ 71 1/ 71 1/ 71 1/ 71	(1.4) (1.4) (1.4) (1.4)	0.364 0.362 0.384 0.423
DECREASE	0.165	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/124 0/125 0/114 0/ 97		1/ 71 1/ 71 1/ 71 1/ 71	(1.4) (1.4) (1.4) (1.4)	0.364 0.362 0.384 0.423

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.
Pairwise P-Value: Fisher's Exact Test P-value (2-Tail).

CSR-60178

Page 31

DVS SR Protocol 3151A2-315-US

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 12

Category	Overall							
Test+Units	P-Value *	Comparator 1	Comparator 2	Comparato	or 1	Comparato	or 2	P-Value '
TOTAL	0.842	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	4/117 4/117 4/117 4/117	(3.4) (3.4) (3.4) (3.4)	8/118 5/101 5/ 96 3/ 64	(6.8) (5.0) (5.2) (4.7)	0.375 0.736 0.734 0.699
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	8/118 8/118 8/118	(6.8) (6.8) (6.8)	5/101 5/ 96 3/ 64	(5.0) (5.2) (4.7)	0.776 0.776 0.749
		DVS SR 150 mg	DVS SR 200 mg Placebo	5/101 5/101	(5.0) (5.0)	5/ 96 3/ 64	(5.2) (4.7)	1.000
		DVS SR 200 mg	Placebo	5/ 96	(5.2)	3/ 64	(4.7)	1.000
VITAL SIGNS	0.842	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	4/117 4/117 4/117 4/117	(3.4) (3.4) (3.4) (3.4)	8/118 5/101 5/ 96 3/ 64	(6.8) (5.0) (5.2) (4.7)	0.375 0.736 0.734 0.699
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	8/118 8/118 8/118	(6.8) (6.8) (6.8)	5/101 5/ 96 3/ 64	(5.0) (5.2) (4.7)	0.776 0.776 0.749
		DVS SR 150 mg	DVS SR 200 mg Placebo	5/101 5/101 5/ 96	(5.0) (5.0)	5/ 96 3/ 64 3/ 64	(5.2) (4.7)	1.000
		DVS SR 200 mg	Placebo		(5.2)		(4.7)	1.000
WEIGHT kg	0.892	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	3/116 3/116 3/116 3/116	(2.6) (2.6) (2.6) (2.6)	5/118 4/101 2/ 96 2/ 64	(4.2) (4.0) (2.1) (3.1)	0.722 0.707 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	5/118 5/118 5/118	(4.2) (4.2) (4.2)	4/101 2/ 96 2/ 64	(4.0) (2.1) (3.1)	1.000 0.463 1.000
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	4/101 4/101 2/ 96	(4.0) (4.0) (2.1)	2/ 96 2/ 64 2/ 64	(2.1) (3.1) (3.1)	0.683 1.000 1.000
DECREASE	0.697	DVS SR 50 mg	DVS SR 100 mg	2/116	(1.7)	5/118	(4.2)	0.446
DECKERGE	0.057	DVD DIX 30 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/116 2/116 2/116 2/116	(1.7) (1.7) (1.7) (1.7)	2/101 2/ 96 1/ 64	(2.0) (2.1) (1.6)	1.000 1.000 1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 32

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 12

ategory	Overall Treatment				Pairwise			
rest+Units	P-Value *	Comparator 1	Comparator 2	Comparato	or 1	Comparato	or 2	P-Value
DECREASE	0.697	DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	5/118 5/118 5/118	(4.2) (4.2) (4.2)	2/101 2/ 96 1/ 64	(2.0) (2.1) (1.6)	0.456 0.463 0.667
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	2/101 2/101 2/ 96	(2.0) (2.0) (2.1)	2/ 96 1/ 64 1/ 64	(2.1) (1.6) (1.6)	1.000 1.000 1.000
TMCDEACE	0.415	3					(1.0)	
INCREASE	0.415	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	1/116 1/116 1/116	(0.9) (0.9) (0.9)	0/118 2/101 0/ 96	(2.0)	0.496 0.599 1.000
		DVS SR 100 mg	Placebo DVS SR 150 mg Placebo	1/116 0/118 0/118	(0.9)	1/ 64 2/101 1/ 64	(1.6) (2.0) (1.6)	1.000 0.212 0.352
		DVS SR 150 mg	DVS SR 200 mg Placebo	2/101 2/101	(2.0) (2.0)	0/ 96 1/ 64	(1.6)	0.498
		DVS SR 200 mg	Placebo	0/96	(2.0)	1/ 64	(1.6)	0.400
Standing SYSTOLIC BP mm Hg	0.244	DVS SR 50 mg	DVS SR 100 mg DVS SR 200 mg	0/117 0/117		2/118 2/ 95	(1.7) (2.1)	0.498
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	2/118 2/118	(1.7) (1.7)	0/101 2/ 95	(2.1)	0.501
		DVS SR 150 mg DVS SR 200 mg	Placebo DVS SR 200 mg Placebo	2/118 0/101 2/ 95	(1.7) (2.1)	0/ 64 2/ 95 0/ 64	(2.1)	0.541 0.234 0.516
DECREASE	0.170	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/117 2/118 2/118 2/118	(1.7) (1.7) (1.7)	2/118 0/101 0/ 95 0/ 64	(1.7)	0.498 0.501 0.503 0.541
INCREASE	0.076	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/117 0/118 0/101 2/ 95	(2.1)	2/ 95 2/ 95 2/ 95 0/ 64	(2.1) (2.1) (2.1)	0.200 0.198 0.234 0.516
Supine SYSTOLIC BP mm Hg	0.240	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg	0/117 0/117		2/118 1/101	(1.7) (1.0)	0.498 0.463

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 33

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 12

Category Test+Units	Overall P-Value *		tment Comparator 2	Comparato		io Comparato		Pairwise P-Value * 0.088 1.000 0.658 0.541 0.356 1.000 0.274
Supine SYSTOLIC BP mm Hg	0.240	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	0/117 2/118 2/118 2/118 2/118 1/101 1/101 3/ 95	(1.7) (1.7) (1.7) (1.0) (1.0) (3.2)	3/ 95 1/101 3/ 95 0/ 64 3/ 95 0/ 64 0/ 64	(3.2) (1.0) (3.2) (3.2)	
DECREASE	0.170	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/117 2/118 2/118 2/118	(1.7) (1.7) (1.7)	2/118 0/101 0/ 95 0/ 64	(1.7)	0.498 0.501 0.503 0.541
INCREASE	0.061	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 200 mg Placebo Placebo	0/117 0/117 0/118 0/118 1/101 1/101 3/ 95	(1.0) (1.0) (3.2)	1/101 3/ 95 1/101 3/ 95 3/ 95 0/ 64 0/ 64	(1.0) (3.2) (1.0) (3.2) (3.2)	0.463 0.088 0.461 0.087 0.356 1.000 0.274
Postural BP Change DIASTOLIC BP mm Hg	0.418	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/117 0/118 1/101 1/101	(1.0) (1.0)	1/101 1/101 0/ 95 0/ 64	(1.0) (1.0)	0.463 0.461 1.000
DECREASE	0.418	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/117 0/118 1/101 1/101	(1.0) (1.0)	1/101 1/101 0/ 95 0/ 64	(1.0) (1.0)	0.463 0.461 1.000 1.000
Standing DIASTOLIC BP mm Hg	0.695	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg	1/117 1/117 1/117 1/117 1/118 1/118	(0.9) (0.9) (0.9) (0.9) (0.8) (0.8)	1/118 0/101 0/ 95 0/ 64 0/101 0/ 95	(0.8)	1.000 1.000 1.000 1.000 1.000 1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 34

DVS SR Protocol 3151A2-315-US CSR-60178

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 12

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2			cio Comparato		Pairwise P-Value *
Standing DIASTOLIC BP mm Hg	0.695	DVS SR 100 mg	Placebo	1/118	(0.8)	0/ 64		1.000
INCREASE	0.695	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	1/117 1/117 1/117 1/117 1/118 1/118 1/118	(0.9) (0.9) (0.9) (0.9) (0.8) (0.8) (0.8)	1/118 0/101 0/ 95 0/ 64 0/101 0/ 95 0/ 64	(0.8)	1.000 1.000 1.000 1.000 1.000 1.000 1.000
Supine DIASTOLIC BP mm Hg	0.634	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0/117 0/117 1/118 1/118 1/118 1/101 1/101	(0.8) (0.8) (0.8) (1.0) (1.0)	1/118 1/101 1/101 0/ 95 0/ 64 0/ 95 0/ 64	(0.8) (1.0) (1.0)	1.000 0.463 1.000 1.000 1.000 1.000
INCREASE	0.634	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0/117 0/117 1/118 1/118 1/118 1/101 1/101	(0.8) (0.8) (0.8) (1.0) (1.0)	1/118 1/101 1/101 0/ 95 0/ 64 0/ 95 0/ 64	(0.8) (1.0) (1.0)	1.000 0.463 1.000 1.000 1.000 1.000
Supine PULSE beats/min	0.150	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/117 0/118 0/101 0/ 95		1/ 64 1/ 64 1/ 64 1/ 64	(1.6) (1.6) (1.6) (1.6)	0.354 0.352 0.388 0.403
DECREASE	0.150	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/117 0/118 0/101 0/ 95		1/ 64 1/ 64 1/ 64 1/ 64	(1.6) (1.6) (1.6) (1.6)	0.354 0.352 0.388 0.403

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

CSR-60178

Page 35

DVS SR Protocol 3151A2-315-US

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 26

Category	Overall		tment					Pairwise
Test+Units	P-Value *	Comparator 1	Comparator 2	Comparat	or 1	Comparat	or 2	P-Value
TOTAL	0.617	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	9/102 9/102 9/102 9/102	(8.8) (8.8) (8.8) (8.8)	16/111 11/ 89 11/ 81 10/ 59	(14.4) (12.4) (13.6) (16.9)	0.287 0.482 0.346 0.135
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	16/111 16/111 16/111	(14.4) (14.4) (14.4)	11/ 89 11/ 81 10/ 59	(12.4) (13.6) (16.9)	0.835 1.000 0.661
		DVS SR 150 mg	DVS SR 200 mg Placebo	11/ 89 11/ 89	(12.4) (12.4)	11/ 81 10/ 59	(13.6) (16.9)	0.823 0.476
		DVS SR 200 mg	Placebo	11/ 81	(13.6)	10/ 59	(16.9)	0.636
VITAL SIGNS	0.617	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	9/102 9/102 9/102 9/102	(8.8) (8.8) (8.8) (8.8)	16/111 11/ 89 11/ 81 10/ 59	(14.4) (12.4) (13.6) (16.9)	0.287 0.482 0.346 0.135
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	16/111 16/111 16/111	(14.4) (14.4) (14.4)	11/ 89 11/ 81 10/ 59	(12.4) (13.6) (16.9)	0.133 0.835 1.000 0.661
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	11/ 89 11/ 89 11/ 81	(12.4) (12.4) (13.6)	11/ 81 10/ 59 10/ 59	(13.6) (16.9) (16.9)	0.823 0.476 0.636
	0.447	-			, ,		,	
WEIGHT kg	0.447	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	6/101 6/101 6/101 6/101	(5.9) (5.9) (5.9) (5.9)	14/110 11/ 89 10/ 81 5/ 59	(12.7) (12.4) (12.3) (8.5)	0.105 0.135 0.187 0.536
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	14/110 14/110 14/110	(12.7) (12.7) (12.7)	11/ 89 10/ 81 5/ 59	(12.4) (12.3) (8.5)	1.000 1.000 0.456
		DVS SR 150 mg	DVS SR 200 mg Placebo	11/ 89 11/ 89	(12.4) (12.4)	10/ 81 5/ 59	(12.3) (8.5)	1.000
		DVS SR 200 mg	Placebo	10/ 81	(12.3)	5/ 59	(8.5)	0.584
DECREASE	0.819	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	4/101 4/101 4/101 4/101	(4.0) (4.0) (4.0) (4.0)	6/110 5/ 89 6/ 81 2/ 59	(5.5) (5.6) (7.4) (3.4)	0.750 0.736 0.344 1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 36

DVS SR Protocol 3151A2-315-US CSR-60178

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 26

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2			Comparato		Pairwise P-Value
DECREASE	0.819	DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	6/110 6/110 6/110	(5.5) (5.5)	5/ 89 6/ 81	(5.6) (7.4)	1.000 0.764 0.715
		DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	5/ 89 5/ 89	(5.5) (5.6) (5.6)	2/ 59 6/ 81 2/ 59	(3.4) (7.4) (3.4)	0.715 0.759 0.703
		DVS SR 200 mg	Placebo	6/ 81	(7.4)	2/ 59	(3.4)	0.467
INCREASE	0.477	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/101 2/101 2/101 2/101	(2.0) (2.0) (2.0) (2.0)	8/110 6/ 89 4/ 81 3/ 59	(7.3) (6.7) (4.9) (5.1)	0.104 0.150 0.409 0.359
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	8/110 8/110 8/110	(7.3) (7.3) (7.3)	6/ 89 4/ 81 3/ 59	(6.7) (4.9) (5.1)	1.000 0.563 0.749
		DVS SR 150 mg	DVS SR 200 mg Placebo	6/ 89 6/ 89	(6.7) (6.7)	4/ 81 3/ 59	(4.9) (5.1)	0.749
		DVS SR 200 mg	Placebo	4/ 81	(4.9)	3/ 59	(5.1)	1.000
Postural BP Change SYSTOLIC BP mm Hg	0.064	DVS SR 50 mg	DVS SR 200 mg Placebo	0/102 0/102		1/ 81 2/ 59	(1.2) (3.4)	0.443 0.133
		DVS SR 100 mg	DVS SR 200 mg Placebo	0/111 0/111		1/ 81 2/ 59	(1.2) (3.4)	0.422 0.119
		DVS SR 150 mg	DVS SR 200 mg Placebo	0/ 89 0/ 89		1/ 81 2/ 59	(1.2) (3.4)	0.476 0.157
		DVS SR 200 mg	Placebo	1/ 81	(1.2)	2/ 59	(3.4)	0.573
DECREASE	0.064	DVS SR 50 mg	DVS SR 200 mg Placebo	0/102 0/102		1/ 81 2/ 59	(1.2) (3.4)	0.443 0.133
		DVS SR 100 mg	DVS SR 200 mg Placebo	0/111 0/111		1/ 81 2/ 59	(1.2) (3.4)	0.422 0.119
		DVS SR 150 mg	DVS SR 200 mg Placebo	0/ 89 0/ 89		1/ 81 2/ 59	(1.2)	0.476 0.157
		DVS SR 200 mg	Placebo	1/ 81	(1.2)	2/ 59	(3.4)	0.573
Standing SYSTOLIC BP mm Hg	0.257	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	2/102 2/102 2/102	(2.0) (2.0) (2.0)	0/111 0/ 89 0/ 81		0.228 0.500 0.504

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 37

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 26

Category	Overall		tment					Pairwise	
Test+Units	P-Value *	Comparator 1	Comparator 2	Comparato	or 1	Comparato	or 2	P-Value *	
Standing SYSTOLIC BP mm Hg	0.257	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	2/102 0/111 0/ 89 0/ 81	(2.0)	1/ 59 1/ 59 1/ 59 1/ 59	(1.7) (1.7) (1.7) (1.7)	1.000 0.347 0.399 0.421	
DECREASE	0.257	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Placebo Placebo Placebo	2/102 2/102 2/102 2/102 0/111 0/ 89 0/ 81	(2.0) (2.0) (2.0) (2.0)	0/111 0/ 89 0/ 81 1/ 59 1/ 59 1/ 59	(1.7) (1.7) (1.7) (1.7)	0.228 0.500 0.504 1.000 0.347 0.399 0.421	
Supine SYSTOLIC BP mm Hg	0.616	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	1/102 1/102 1/102 1/102 0/111 1/ 89 1/ 89	(1.0) (1.0) (1.0) (1.0) (1.1) (1.1)	0/111 1/89 0/81 0/59 1/89 0/81 0/59	(1.1)	0.479 1.000 1.000 1.000 0.445 1.000	
DECREASE	0.502	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/102 1/102 1/102 1/102	(1.0) (1.0) (1.0) (1.0)	0/111 0/ 89 0/ 81 0/ 59		0.479 1.000 1.000	
INCREASE	0.409	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/102 0/111 1/ 89 1/ 89	(1.1) (1.1)	1/ 89 1/ 89 0/ 81 0/ 59	(1.1) (1.1)	0.466 0.445 1.000 1.000	
Postural BP Change DIASTOLIC BP mm Hg	0.624	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg Placebo	1/102 1/102 1/102 1/102 0/111 0/111	(1.0) (1.0) (1.0) (1.0)	0/111 1/ 89 0/ 81 1/ 59 1/ 89 1/ 59	(1.1) (1.7) (1.1) (1.7)	0.479 1.000 1.000 1.000 0.445 0.347	

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 38

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 26

Category Test+Units	Overall P-Value *				Pairwise P-Value *			
Postural BP Change DIASTOLIC BP mm Hg	0.624	DVS SR 150 mg	DVS SR 200 mg Placebo Placebo	1/ 89 1/ 89 0/ 81	(1.1) (1.1)	0/ 81 1/ 59 1/ 59	(1.7) (1.7)	1.000 1.000 0.421
DECREASE	0.624	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	1/102 1/102 1/102 1/102 0/111 0/111 1/ 89 1/ 89 0/ 81	(1.0) (1.0) (1.0) (1.0) (1.1) (1.1)	0/111 1/ 89 0/ 81 1/ 59 1/ 89 1/ 59 0/ 81 1/ 59 1/ 59	(1.1) (1.7) (1.1) (1.7) (1.7) (1.7)	0.479 1.000 1.000 1.000 0.445 0.347 1.000 1.000
Standing DIASTOLIC BP mm Hg	0.385	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0/102 0/102 2/111 2/111 2/111 0/ 89 1/ 81	(1.8) (1.8) (1.8) (1.2)	2/111 1/81 0/89 1/81 0/59 1/81 0/59	(1.8) (1.2) (1.2) (1.2)	0.499 0.443 0.504 1.000 0.544 0.476 1.000
INCREASE	0.385	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0/102 0/102 2/111 2/111 2/111 0/ 89 1/ 81	(1.8) (1.8) (1.8) (1.2)	2/111 1/81 0/89 1/81 0/59 1/81 0/59	(1.8) (1.2) (1.2) (1.2)	0.499 0.443 0.504 1.000 0.544 0.476 1.000
Supine DIASTOLIC BP mm Hg	0.440	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo Placebo Placebo	0/102 0/102 1/111 1/111 1/111 0/ 89 0/ 81	(0.9) (0.9) (0.9)	1/111 1/59 0/89 0/81 1/59 1/59	(0.9) (1.7) (1.7) (1.7) (1.7)	1.000 0.366 1.000 1.000 1.000 0.399 0.421

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 39

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 26

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Comparato	Ratio omparator 1 Comparator 2			Pairwise P-Value *
INCREASE	0.440	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo Placebo	0/102 0/102 1/111 1/111 1/111 0/89	(0.9) (0.9) (0.9)	1/111 1/ 59 0/ 89 0/ 81 1/ 59 1/ 59	(0.9) (1.7) (1.7) (1.7)	1.000 0.366 1.000 1.000 1.000 0.399
Supine PULSE beats/min	0.165	DVS SR 200 mg DVS SR 50 mg DVS SR 100 mg	Placebo Placebo Placebo	0/ 81 0/102 0/110		1/ 59 1/ 59 1/ 59	(1.7) (1.7) (1.7)	0.421 0.366 0.349
DECREASE	0.165	DVS SR 150 mg DVS SR 200 mg DVS SR 50 mg DVS SR 100 mg	Placebo Placebo Placebo Placebo	0/89 0/81 0/102 0/110		1/ 59 1/ 59 1/ 59 1/ 59	(1.7) (1.7) (1.7) (1.7)	0.399 0.421 0.366 0.349
		DVS SR 150 mg DVS SR 200 mg	Placebo Placebo	0/ 89 0/ 81		1/ 59 1/ 59	(1.7) (1.7)	0.399

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.
Pairwise P-Value: Fisher's Exact Test P-value (2-Tail).

CSR-60178

40

Page

DVS SR Protocol 3151A2-315-US

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 39

Category	Overall	Trea	atment	Ra	tio	
Test+Units	P-Value *	Comparator 1	Comparator 2	Comparator 1	Comparator 2	P-Value *
TOTAL	0.007**	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg	15/ 94 (16.0) 15/ 94 (16.0) 15/ 94 (16.0) 15/ 94 (16.0) 21/ 95 (22.1) 21/ 95 (22.1)	21/ 95 (22.1) 22/ 82 (26.8) 7/ 71 (9.9) 3/ 50 (6.0) 22/ 82 (26.8) 7/ 71 (9.9)	0.355 0.096 0.355 0.113 0.487 0.058
		DVS SR 150 mg DVS SR 200 mg	Placebo DVS SR 200 mg Placebo Placebo	21/ 95 (22.1) 22/ 82 (26.8) 22/ 82 (26.8) 7/ 71 (9.9)	3/ 50 (6.0) 7/ 71 (9.9) 3/ 50 (6.0) 3/ 50 (6.0)	0.017* 0.012* 0.003** 0.521
VITAL SIGNS	0.007**	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	15/ 94 (16.0) 15/ 94 (16.0) 15/ 94 (16.0)	21/ 95 (22.1) 22/ 82 (26.8) 7/ 71 (9.9)	0.355 0.096 0.355
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	15/ 94 (16.0) 21/ 95 (22.1) 21/ 95 (22.1) 21/ 95 (22.1)	3/50 (6.0) 22/82 (26.8) 7/71 (9.9) 3/50 (6.0)	0.113 0.487 0.058 0.017*
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	22/ 82 (26.8) 22/ 82 (26.8) 7/ 71 (9.9)	7/ 71 (9.9) 3/ 50 (6.0) 3/ 50 (6.0)	0.012* 0.003** 0.521
WEIGHT kg	0.005**	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	12/ 93 (12.9) 12/ 93 (12.9) 12/ 93 (12.9) 12/ 93 (12.9)	20/ 94 (21.3) 20/ 80 (25.0) 7/ 71 (9.9) 2/ 50 (4.0)	0.174 0.050 0.628 0.138
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	20/ 94 (21.3) 20/ 94 (21.3) 20/ 94 (21.3)	20/ 80 (25.0) 7/ 71 (9.9) 2/ 50 (4.0)	0.591 0.057 0.006**
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	20/ 80 (25.0) 20/ 80 (25.0) 7/ 71 (9.9)	7/ 71 (9.9) 2/ 50 (4.0) 2/ 50 (4.0)	0.019* 0.002** 0.304
DECREASE	0.591	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	5/ 93 (5.4) 5/ 93 (5.4) 5/ 93 (5.4) 5/ 93 (5.4)	5/ 94 (5.3) 6/ 80 (7.5) 2/ 71 (2.8) 1/ 50 (2.0)	1.000 0.756 0.700 0.665

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 41

CSR-60178

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 39

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Comparato		tio Comparat		Pairwise P-Value *
DECREASE	0.591	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	5/ 94 5/ 94 5/ 94 6/ 80 6/ 80 2/ 71	(5.3) (5.3) (5.3) (7.5) (7.5) (2.8)	6/ 80 2/ 71 1/ 50 2/ 71 1/ 50 1/ 50	(7.5) (2.8) (2.0) (2.8) (2.0) (2.0)	0.756 0.700 0.665 0.283 0.249 1.000
INCREASE	0.015*	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	7/ 93 7/ 93 7/ 93 7/ 93 15/ 94 15/ 94 15/ 94 14/ 80 5/ 71	(7.5) (7.5) (7.5) (7.5) (16.0) (16.0) (16.0) (17.5) (17.5) (7.0)	15/ 94 14/ 80 5/ 71 1/ 50 14/ 80 5/ 71 1/ 50 1/ 50	(16.0) (17.5) (7.0) (2.0) (17.5) (7.0) (2.0) (7.0) (2.0) (2.0)	0.111 0.061 1.000 0.261 0.840 0.096 0.011* 0.083 0.009** 0.399
Postural BP Change SYSTOLIC BP mm Hg	0.144	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/ 94 0/ 95 0/ 82 0/ 71		1/ 50 1/ 50 1/ 50 1/ 50	(2.0) (2.0) (2.0) (2.0)	0.347 0.345 0.379 0.413
DECREASE	0.144	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/ 94 0/ 95 0/ 82 0/ 71		1/ 50 1/ 50 1/ 50 1/ 50	(2.0) (2.0) (2.0) (2.0)	0.347 0.345 0.379 0.413
Standing SYSTOLIC BP mm Hg	0.577	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/ 94 1/ 94 1/ 94 1/ 94 1/ 95 1/ 95 1/ 95 2/ 82 2/ 82	(1.1) (1.1) (1.1) (1.1) (1.1) (1.1) (1.1) (2.4) (2.4)	1/ 95 2/ 82 0/ 71 0/ 50 2/ 82 0/ 71 0/ 50 0/ 71 0/ 50	(1.1) (2.4) (2.4)	1.000 0.599 1.000 1.000 0.597 1.000 1.000 0.499 0.526

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 42

DVS SR Protocol 3151A2-315-US CSR-60178

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 39

Category Test+Units	Overall P-Value *	Trea	atment Comparator 2	Ra Comparator 1	tio Comparator 2	Pairwise P-Value *
DECREASE	0.647	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	1/ 94 (1.1) 1/ 94 (1.1) 1/ 94 (1.1) 1/ 94 (1.1) 0/ 95 1/ 82 (1.2) 1/ 82 (1.2)	0/ 95 1/ 82 (1.2) 0/ 71 0/ 50 1/ 82 (1.2) 0/ 71	0.497 1.000 1.000 1.000 0.463 1.000 1.000
INCREASE	0.651	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0/ 94 0/ 94 1/ 95 (1.1) 1/ 95 (1.1) 1/ 95 (1.1) 1/ 82 (1.2) 1/ 82 (1.2)	0/ 71 0/ 50 0/ 71	1.000 0.466 1.000 1.000 1.000 1.000
Supine SYSTOLIC BP mm Hg	0.064	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg Placebo DVS SR 200 mg Placebo Placebo	1/ 94 (1.1) 1/ 94 (1.1) 1/ 94 (1.1) 1/ 94 (1.1) 0/ 95 0/ 95 4/ 82 (4.9) 0/ 71		0.497 0.186 1.000 1.000 0.044* 0.345 0.124 0.649 0.413
DECREASE	0.107	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 94 0/ 95 2/ 82 (2.4) 2/ 82 (2.4)		0.216 0.213 0.499 0.526
INCREASE	0.431	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg Placebo	1/ 94 (1.1) 1/ 94 (1.1) 1/ 94 (1.1) 1/ 94 (1.1) 0/ 95 0/ 95	0/ 95 2/ 82 (2.4) 0/ 71 1/ 50 (2.0) 2/ 82 (2.4) 1/ 50 (2.0)	0.497 0.599 1.000 1.000 0.213 0.345

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 43

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 39

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	 Comparato		io Comparato		Pairwise P-Value
							,ı Z	
INCREASE	0.431	DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	2/ 82 2/ 82 0/ 71	(2.4) (2.4)	0/ 71 1/ 50 1/ 50	(2.0) (2.0)	0.499 1.000 0.413
Postural BP Change DIASTOLIC BP mm Hg	0.624	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/ 94 1/ 94 1/ 94 1/ 94	(1.1) (1.1) (1.1) (1.1)	0/ 95 1/ 82 0/ 71 1/ 50	(1.2)	0.497 1.000 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg Placebo	0/ 95 0/ 95	(1.1)	1/ 82 1/ 50	(1.2) (2.0)	0.463
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/ 82 1/ 82	(1.2) (1.2)	0/ 71 1/ 50	(2.0)	1.000
		DVS SR 200 mg	Placebo	0/ 71		1/ 50	(2.0)	0.413
DECREASE	0.624	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/ 94 1/ 94 1/ 94 1/ 94	(1.1) (1.1) (1.1) (1.1)	0/ 95 1/ 82 0/ 71 1/ 50	(1.2)	0.497 1.000 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg Placebo	0/ 95 0/ 95	(1.1)	1/ 82 1/ 50	(1.2)	0.463
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/ 82 1/ 82	(1.2) (1.2)	0/ 71 1/ 50	(2.0)	1.000
		DVS SR 200 mg	Placebo	0/ 71		1/ 50	(2.0)	0.413
Standing DIASTOLIC BP mm Hg	0.292	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg	0/ 94 0/ 94		2/ 95 2/ 82	(2.1) (2.4)	0.497 0.216
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	2/ 95 2/ 95 2/ 95	(2.1) (2.1) (2.1)	2/ 82 0/ 71 0/ 50	(2.4)	1.000 0.507 0.545
		DVS SR 150 mg	DVS SR 200 mg Placebo	2/ 93 2/ 82 2/ 82	(2.4) (2.4)	0/ 50 0/ 71 0/ 50		0.499
INCREASE	0.292	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg	0/ 94 0/ 94		2/ 95 2/ 82	(2.1) (2.4)	0.497 0.216
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	2/ 95 2/ 95 2/ 95	(2.1) (2.1) (2.1)	2/ 82 0/ 71 0/ 50	(2.4)	1.000 0.507 0.545

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 44

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 39

Overall P-Value *	Trea Comparator 1	tment Comparator 2	Comparator 1	Ratio Comparator 2	Pairwise P-Value	
0.292	DVS SR 150 mg	DVS SR 200 mg Placebo			0.499 0.526	
0.310	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	1/ 95 (1. 1/ 95 (1. 2/ 82 (2.	1) 0/71 1) 0/50 4) 0/71	1.000 0.216 0.597 1.000 1.000 0.499 0.526	
0.310	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/ 95 (1. 1/ 95 (1.	1) 0/71 1) 0/50	1.000 0.216 0.597 1.000 1.000 0.499	
	0.292 0.310	P-Value * Comparator 1 0.292 DVS SR 150 mg 0.310 DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg 0.310 DVS SR 50 mg	P-Value * Comparator 1	P-Value * Comparator 1	P-Value * Comparator 1	

Pairwise P-Value: Fisher's Exact Test P-value (2-Tail).

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

CSR-60178

Page 45

DVS SR Protocol 3151A2-315-US

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 52

Category	Overall		tment					Pairwise
Test+Units	P-Value *	Comparator 1	Comparator 2	Comparato	r 1	Comparat	or 2	P-Value '
TOTAL	0.207	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	16/ 82 16/ 82 16/ 82	(19.5) (19.5) (19.5) (19.5)	24/ 84 15/ 69 13/ 65 5/ 46	(28.6) (21.7) (20.0) (10.9)	0.205 0.840 1.000 0.320
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	24/ 84	(28.6) (28.6) (28.6)	15/ 69 13/ 65 5/ 46	(21.7) (20.0) (10.9)	0.358 0.256 0.027*
		DVS SR 150 mg	DVS SR 200 mg Placebo	15/ 69 15/ 69	(21.7) (21.7)	13/ 65 5/ 46	(20.0) (10.9)	0.835 0.208
		DVS SR 200 mg	Placebo	13/ 65	(20.0)	5/ 46	(10.9)	0.296
VITAL SIGNS	0.207	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	16/ 82 16/ 82	(19.5) (19.5) (19.5) (19.5)	24/ 84 15/ 69 13/ 65 5/ 46	(28.6) (21.7) (20.0) (10.9)	0.205 0.840 1.000 0.320
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	24/ 84 24/ 84	(28.6) (28.6) (28.6)	15/ 69 13/ 65 5/ 46	(21.7) (20.0) (10.9)	0.358 0.256 0.027*
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo Placebo	15/ 69 15/ 69	(21.7) (21.7) (20.0)	13/ 65 5/ 46 5/ 46	(20.0) (10.9) (10.9)	0.835 0.208 0.296
		_					, ,	
WEIGHT kg	0.146	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	15/ 82 15/ 82 15/ 82	(18.3) (18.3) (18.3) (18.3)	22/ 83 14/ 69 10/ 64 4/ 46	(26.5) (20.3) (15.6) (8.7)	0.263 0.837 0.825 0.197
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	22/ 83	(26.5) (26.5) (26.5)	14/ 69 10/ 64 4/ 46	(20.3) (15.6) (8.7)	0.445 0.158 0.021*
		DVS SR 150 mg	DVS SR 200 mg Placebo	14/ 69 14/ 69	(20.3) (20.3)	10/ 64	(15.6) (8.7)	0.508 0.119
		DVS SR 200 mg	Placebo	10/ 64	(15.6)	4/ 46	(8.7)	0.388
DECREASE	0.364	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	3/ 82 3/ 82 3/ 82 3/ 82	(3.7) (3.7) (3.7) (3.7)	8/ 83 4/ 69 3/ 64 1/ 46	(9.6) (5.8) (4.7) (2.2)	0.211 0.703 1.000 1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.
Pairwise P-Value: Fisher's Exact Test P-value (2-Tail).

CSR-60178

Page 46

DVS SR Protocol 3151A2-315-US

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 52

Category	Overall							Pairwise
Test+Units	P-Value *	Comparator 1	Comparator 2	Comparat	or 1	Comparat	or 2	P-Value
DECREASE	0.364	DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	8/ 83 8/ 83 8/ 83	(9.6) (9.6) (9.6)	4/ 69 3/ 64 1/ 46	(5.8) (4.7) (2.2)	0.548 0.349 0.157
		DVS SR 150 mg	DVS SR 200 mg Placebo	4/ 69 4/ 69	(5.8) (5.8)	3/ 64 1/ 46	(4.7) (2.2)	1.000 0.647
		DVS SR 200 mg	Placebo	3/ 64	(4.7)	1/ 46	(2.2)	0.639
INCREASE	0.516	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	12/ 82 12/ 82 12/ 82 12/ 82	(14.6) (14.6) (14.6) (14.6)	14/ 83 10/ 69 7/ 64 3/ 46	(16.9) (14.5) (10.9) (6.5)	0.831 1.000 0.623 0.253
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	14/ 83 14/ 83 14/ 83	(16.9) (16.9) (16.9)	10/ 69 7/ 64 3/ 46	(14.5) (10.9) (6.5)	0.824 0.350 0.111
		DVS SR 150 mg	DVS SR 200 mg Placebo	10/ 69 10/ 69	(14.5) (14.5)	7/ 64 3/ 46	(10.9) (6.5)	0.610 0.238
		DVS SR 200 mg	Placebo	7/ 64	(10.9)	3/ 46	(6.5)	0.516
Standing SYSTOLIC BP mm Hg	0.350	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/ 82 2/ 82 2/ 82 2/ 82	(2.4) (2.4) (2.4) (2.4)	0/ 84 0/ 69 1/ 65 0/ 46	(1.5)	0.242 0.500 1.000 0.536
		DVS SR 100 mg DVS SR 150 mg	DVS SR 200 mg DVS SR 200 mg	0/ 84 0/ 69	(2.1)	1/ 65 1/ 65	(1.5) (1.5)	0.436 0.485
		DVS SR 200 mg	Placebo	1/ 65	(1.5)	0/ 46	(1.5)	1.000
DECREASE	0.594	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	1/ 82 1/ 82 1/ 82	(1.2) (1.2) (1.2)	0/ 84 0/ 69 1/ 65	(1.5)	0.494 1.000 1.000
		DVS SR 100 mg	Placebo DVS SR 200 mg	1/ 82 0/ 84	(1.2)	0/ 46 1/ 65	(1.5)	1.000
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo	0/ 69 1/ 65	(1.5)	1/ 65 0/ 46	(1.5)	0.485
INCREASE	0.520	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	1/ 82 1/ 82 1/ 82	(1.2) (1.2) (1.2)	0/ 84 0/ 69 0/ 65		0.494 1.000 1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 47

DVS SR Protocol 3151A2-315-US CSR-60178

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 52

Category	Overall	Treatment			Rat	io		Pairwise
Test+Units	P-Value *	Comparator 1	Comparator 2	Comparato	or 1	Comparato	or 2	P-Value *
INCREASE	0.520	DVS SR 50 mg	Placebo	1/ 82	(1.2)	0/ 46		1.000
Supine SYSTOLIC BP mm Hg	0.486	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg	1/ 82 1/ 82 1/ 82 1/ 82 1/ 84	(1.2) (1.2) (1.2) (1.2) (1.2)	1/84 0/69 2/65 0/46 0/69	(1.2) (3.1)	1.000 1.000 0.584 1.000
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo	1/ 84 1/ 84 0/ 69 2/ 65	(1.2) (1.2) (3.1)	2/ 65 0/ 46 2/ 65 0/ 46	(3.1)	0.581 1.000 0.233 0.510
DECREASE	0.362	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/ 82 0/ 84 0/ 69 1/ 65	(1.5)	1/ 65 1/ 65 1/ 65 0/ 46	(1.5) (1.5) (1.5)	0.442 0.436 0.485 1.000
INCREASE	0.815	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/ 82 1/ 82 1/ 82 1/ 82	(1.2) (1.2) (1.2) (1.2)	1/ 84 0/ 69 1/ 65 0/ 46	(1.2) (1.5)	1.000 1.000 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/ 84 1/ 84 1/ 84	(1.2) (1.2) (1.2) (1.2)	0/ 69 1/ 65 0/ 46	(1.5)	1.000 1.000 1.000
		DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg Placebo	0/ 69 1/ 65	(1.5)	1/ 65 0/ 46	(1.5)	0.485 1.000
Postural BP Change DIASTOLIC BP mm Hg	0.631	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg Placebo	0/ 82 0/ 82 0/ 82		1/ 84 1/ 69 1/ 46	(1.2) (1.4) (2.2)	1.000 0.457 0.359
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/ 84 1/ 84 1/ 84	(1.2) (1.2) (1.2)	1/ 69 0/ 65 1/ 46	(1.4)	1.000 1.000 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/ 69 1/ 69 0/ 65	(1.4) (1.4)	0/ 65 1/ 46 1/ 46	(2.2) (2.2)	1.000 1.000 0.414

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 48

DVS SR Protocol 3151A2-315-US CSR-60178

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 52

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Comparato		cio Comparato		Pairwise P-Value *
DECREASE	0.631	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg Placebo	0/ 82 0/ 82 0/ 82		1/ 84 1/ 69 1/ 46	(1.2) (1.4) (2.2)	1.000 0.457 0.359
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/ 84 1/ 84 1/ 84	(1.2) (1.2) (1.2)	1/ 69 0/ 65 1/ 46	(2.2) (1.4)	1.000 1.000 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/ 69 1/ 69	(1.4) (1.4)	0/ 65 1/ 46	(2.2)	1.000
		DVS SR 200 mg	Placebo	0/ 65	(= /	1/ 46	(2.2)	0.414
Supine DIASTOLIC BP mm Hg	0.527	DVS SR 50 mg	DVS SR 150 mg DVS SR 200 mg	0/ 82 0/ 82		1/ 69 1/ 65	(1.4) (1.5)	0.457 0.442
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	0/ 84 0/ 84		1/ 69 1/ 65	(1.4) (1.5)	0.451 0.436
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/ 69 1/ 69	(1.4) (1.4)	1/ 65 0/ 46	(1.5)	1.000
		DVS SR 200 mg	Placebo	1/ 65	(1.5)	0/ 46		1.000
INCREASE	0.527	DVS SR 50 mg	DVS SR 150 mg DVS SR 200 mg	0/ 82 0/ 82		1/ 69 1/ 65	(1.4) (1.5)	0.457 0.442
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	0/ 84 0/ 84		1/ 69 1/ 65	(1.4) (1.5)	0.451 0.436
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/ 69 1/ 69	(1.4) (1.4)	1/ 65 0/ 46	(1.5)	1.000
		DVS SR 200 mg	Placebo	1/ 65	(1.5)	0/46		1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.
Pairwise P-Value: Fisher's Exact Test P-value (2-Tail).

CSR-60178

Page 49

DVS SR Protocol 3151A2-315-US

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Follow-up

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Rat Comparator 1	Comparator 2	Pairwise P-Value *
TOTAL	0.333	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	5/ 32 (15.6) 5/ 32 (15.6) 5/ 32 (15.6) 5/ 32 (15.6)	7/ 39 (17.9) 8/ 59 (13.6) 3/ 60 (5.0) 2/ 15 (13.3)	1.000 0.764 0.121 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	7/ 39 (17.9) 7/ 39 (17.9) 7/ 39 (17.9)	8/ 59 (13.6) 3/ 60 (5.0) 2/ 15 (13.3)	0.578 0.046* 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	8/ 59 (13.6) 8/ 59 (13.6)	3/ 60 (5.0) 2/ 15 (13.3)	0.125
		DVS SR 200 mg	Placebo	3/ 60 (5.0)	2/ 15 (13.3)	0.260
VITAL SIGNS	0.333	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	5/ 32 (15.6) 5/ 32 (15.6) 5/ 32 (15.6) 5/ 32 (15.6)	7/ 39 (17.9) 8/ 59 (13.6) 3/ 60 (5.0) 2/ 15 (13.3)	1.000 0.764 0.121 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	7/ 39 (17.9) 7/ 39 (17.9) 7/ 39 (17.9)	8/ 59 (13.6) 3/ 60 (5.0) 2/ 15 (13.3)	0.578 0.046* 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	8/ 59 (13.6) 8/ 59 (13.6)	3/ 60 (5.0) 2/ 15 (13.3)	0.125 1.000
		DVS SR 200 mg	Placebo	3/ 60 (5.0)	2/ 15 (13.3)	0.260
WEIGHT kg	0.307	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	3/ 30 (10.0) 3/ 30 (10.0) 3/ 30 (10.0) 3/ 30 (10.0)	5/ 38 (13.2) 6/ 57 (10.5) 2/ 58 (3.4) 0/ 14	1.000 1.000 0.332 0.540
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	5/ 38 (13.2) 5/ 38 (13.2) 5/ 38 (13.2)	6/ 57 (10.5) 2/ 58 (3.4) 0/ 14	0.750 0.109 0.307
		DVS SR 150 mg	DVS SR 200 mg Placebo	6/ 57 (10.5) 6/ 57 (10.5)	2/ 58 (3.4) 0/ 14	0.162 0.591
		DVS SR 200 mg	Placebo	2/ 58 (3.4)	0/ 14	1.000
DECREASE	0.166	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/ 30 (3.3) 1/ 30 (3.3) 1/ 30 (3.3) 1/ 30 (3.3)	2/ 38 (5.3) 5/ 57 (8.8) 0/ 58 0/ 14	1.000 0.660 0.341 1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 50

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Follow-up

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Comparator 1		cio Comparato		Pairwise P-Value *
DECREASE	0.166	DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	2/ 38 (5 2/ 38 (5 5/ 57 (8	.3) .3) .3) .8)	5/ 57 0/ 58 0/ 14 0/ 58 0/ 14	(8.8)	0.698 0.154 1.000 0.027* 0.575
INCREASE	0.496	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Placebo Placebo	2/ 30 (6 2/ 30 (6 2/ 30 (6 3/ 38 (7 3/ 38 (7 3/ 38 (7 1/ 57 (1 1/ 57 (1	.7) .7) .7) .9) .9) .9) .8)	3/ 38 1/ 57 2/ 58 0/ 14 1/ 57 2/ 58 0/ 14 2/ 58 0/ 14 0/ 14	(7.9) (1.8) (3.4) (1.8) (3.4) (3.4)	1.000 0.272 0.603 1.000 0.298 0.381 0.555 1.000 1.000
Postural BP Change SYSTOLIC BP mm Hg	0.014*	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/ 32 0/ 38 0/ 57 0/ 60		1/ 15 1/ 15 1/ 15 1/ 15	(6.7) (6.7) (6.7) (6.7)	0.319 0.283 0.208 0.200
DECREASE	0.014*	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/ 32 0/ 38 0/ 57 0/ 60		1/ 15 1/ 15 1/ 15 1/ 15	(6.7) (6.7) (6.7) (6.7)	0.319 0.283 0.208 0.200
Standing SYSTOLIC BP mm Hg	0.746	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	1/ 32 (3 1/ 32 (3 1/ 32 (3 2/ 38 (5 2/ 38 (5 2/ 38 (5 1/ 57 (1 1/ 57 (1	.1) .1) .1) .3) .3) .3) .8) .8)	2/ 38 1/ 57 1/ 60 0/ 15 1/ 57 1/ 60 0/ 15 1/ 60 0/ 15 0/ 15	(5.3) (1.8) (1.7) (1.8) (1.7) (1.7)	1.000 1.000 1.000 1.000 0.562 0.558 1.000 1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 51

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Follow-up

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Ra	tio Comparator 2	Pairwise P-Value *
		Comparator I				
DECREASE	0.839	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg	1/ 32 (3.1) 1/ 32 (3.1) 1/ 32 (3.1) 1/ 32 (3.1) 0/ 38 0/ 38	0/ 38 1/ 57 (1.8) 1/ 60 (1.7) 0/ 15 1/ 57 (1.8) 1/ 60 (1.7)	0.457 1.000 1.000 1.000 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/ 57 (1.8) 1/ 57 (1.8)	1/ 60 (1.7) 0/ 15	1.000
		DVS SR 200 mg	Placebo	1/ 60 (1.7)	0/ 15	1.000
INCREASE	0.069	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 32 2/ 38 (5.3) 2/ 38 (5.3) 2/ 38 (5.3)	2/ 38 (5.3) 0/ 57 0/ 60 0/ 15	0.496 0.157 0.148 1.000
Supine SYSTOLIC BP mm Hg	0.723	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg	1/ 32 (3.1) 1/ 32 (3.1) 1/ 32 (3.1) 1/ 32 (3.1) 1/ 39 (2.6)	1/ 39 (2.6) 1/ 58 (1.7) 0/ 60 0/ 15 1/ 58 (1.7)	1.000 1.000 0.348 1.000 1.000
		DVS SIC 100 mg	DVS SR 130 mg DVS SR 200 mg Placebo	1/ 39 (2.6) 1/ 39 (2.6) 1/ 39 (2.6)	0/ 60 0/ 15	0.394
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/ 58 (1.7) 1/ 58 (1.7)	0/ 60 0/ 15	0.492 1.000
INCREASE	0.723	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	1/ 32 (3.1) 1/ 32 (3.1) 1/ 32 (3.1)	1/ 39 (2.6) 1/ 58 (1.7) 0/ 60	1.000 1.000 0.348
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	1/ 32 (3.1) 1/ 39 (2.6) 1/ 39 (2.6) 1/ 39 (2.6)	0/ 15 1/ 58 (1.7) 0/ 60 0/ 15	1.000 1.000 0.394 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/ 58 (1.7) 1/ 58 (1.7)	0/ 60 0/ 15	0.492
Postural BP Change DIASTOLIC BP mm Hg	0.160	DVS SR 50 mg	DVS SR 150 mg Placebo	0/ 32 0/ 32	1/ 57 (1.8) 1/ 15 (6.7)	1.000 0.319

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 52

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT VS5 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Follow-up

Category Test+Units	Overall P-Value *		tment Comparator 2		comparator 2	Pairwise P-Value
Postural BP Change DIASTOLIC BP mm Hg	0.160	DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg Placebo DVS SR 200 mg Placebo	0/ 38 0/ 38 1/ 57 (1.8 1/ 57 (1.8)	1/ 15 (6.7)	1.000 0.283 0.487 0.376
DECREASE	0.160	DVS SR 200 mg DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo DVS SR 150 mg Placebo DVS SR 150 mg Placebo DVS SR 200 mg Placebo Placebo	0/ 60 0/ 32 0/ 32 0/ 38 0/ 38 1/ 57 (1.8 1/ 57 (1.8) 0/ 60		0.200 1.000 0.319 1.000 0.283 0.487 0.376 0.200
Standing DIASTOLIC BP mm Hg	0.720	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	1/ 32 (3.1 1/ 32 (3.1 1/ 32 (3.1 1/ 32 (3.1 1/ 38 (2.6 1/ 38 (2.6 1/ 38 (2.6 1/ 57 (1.8	1/ 57 (1.8) 0/ 60 0/ 15 1/ 57 (1.8) 0/ 60 0/ 15 0/ 60	1.000 1.000 0.348 1.000 1.000 0.388 1.000 0.487 1.000
DECREASE	0.635	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 32 0/ 38 1/ 57 (1.8 1/ 57 (1.8		1.000 1.000 0.487 1.000
INCREASE	0.426	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	1/ 32 (3.1 1/ 32 (3.1 1/ 32 (3.1 1/ 32 (3.1 1/ 38 (2.6 1/ 38 (2.6	0/ 57 0/ 60 0/ 15 0/ 57 0/ 60	1.000 0.360 0.348 1.000 0.400 0.388 1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

28NOV05 17:08 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 53 NUMBER (%) OF SUBJECTS WITH VITAL SIGNS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Follow-up

REPORT VS5

Category Test+Units	Overall P-Value *			Ratio Comparator 1 Comparator 2				Pairwise P-Value *	
Supine DIASTOLIC BP mm Hg	0.373	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 32 1/ 39 1/ 39 1/ 39	(2.6) (2.6) (2.6)	1/ 39 0/ 58 0/ 60 0/ 15	(2.6)	1.000 0.402 0.394 1.000	
INCREASE	0.373	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 32 1/ 39 1/ 39 1/ 39	(2.6) (2.6) (2.6)	1/ 39 0/ 58 0/ 60 0/ 15	(2.6)	1.000 0.402 0.394 1.000	

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.
Pairwise P-Value: Fisher's Exact Test P-value (2-Tail).

DVS SR CSR-60178 Protocol 3151A2-315-US

ST 10-12: Descriptive Statistics and Analysis Within and Between Treatment Groups for Vital Signs and Physical Characteristics

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 Page 1 REPORT VS3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

TEST: HEIGHT (cm) / PART 1: WITHIN TREATMENT										
TREATMENT		OBSERVED		BASELINE		CHANGE		ADJUSTED [2]		
Data Analysis Interval [1] [N] _	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR	
DVS SR 50 mg	149			163.0	6.6					
Screening/baseline	149	163.0	6.6	163.0	6.6					
DVS SR 100 mg	155			163.0	6.5					
Screening/baseline	155	163.0	6.5	163.0	6.5					
DVS SR 150 mg	157			163.9	7.0					
Screening/baseline	157	163.9	7.0	163.9	7.0					
DVS SR 200 mg	151			163.9	5.9					
Screening/baseline	151	163.9	5.9	163.9	5.9					
Placebo	77			163.2	7.1					
Screening/baseline	77	163.2	7.1	163.2	7.1					

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

CONFIDENTIAL 1157 Wyeth

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.
STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.
STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

2

TEST: WEIGHT (kg) / PART 1: WITHIN TREATMENT BASELINE CHANGE MEAN TREATMENT OBSERVED ADJUSTED [2] STD Data Analysis Interval [1] [N] MEAN STDERR DVS SR 50 mg 72.42 13.65 Screening/baseline 149
Week 4 138 72.43 13.65 72.42 13.65 72.03 72.72 72.85 -0.50*** -0.50*** 13.87 72.53 13.73 1.48 0.13 -0.24 -0.41* 72.96 73.25 -0.24 Week 8 124 14.20 14.00 13.72 1.59 0.16 116 2.09 Week 12 13.87 -0.40 0.21 0.33 101 73.13 Week 26 13.86 72.80 13.34 3.06 0.35 0.33 Week 39 0.79 74.25 14.61 73.46 13.19 4.76 0.82 0.46 1.92*** 1.92*** 74.08 72.76 Week 52 82 76.00 14.08 12.89 3.71 0.45 140 30 155 155 Final on-therapy 73.40 13.77 14.64 0.64 4.34 0.64 0.33 12.98 12.60 -0.33 Follow-up 67.32 13.38 67.65 3.15 -0.42 0.51 DVS SR 100 mg 71.81 12.61 12.29 71.81 71.81 12.60 Screening/baseline Week 4 135
Week 8 125
Week 12 118
Week 26 110
Week 39 94
Week 52 83
Final on-therapy 136
Follow-up 38
VS SR 150 mg 157
Screening/baseline 157
Week 4 128
Week 8 114
Week 26 89
Week 12 101
Week 26 89
Week 39 80
Week 52 69
Final on-therapy 128
Follow-up 57
VS SR 200 mg 151
Screening/baseline 155
Week 4 121
Week 8 90 -0.54*** Week 4 71.46 72.00 12.26 1.59 -0.55*** 72.26 72.58 72.00 -0.27 12.34 12.74 12.13 -0.26 1.85 -0.47* -0.47* 72.11 2.46 0.21 12.40 12.43 12.99 71.89 72.20 0.23 71.65 12.21 0.24 3.62 0.31 12.07 12.42 12.25 71.30 0.89 4.85 0.88 0.46 0.88 4.57 0.91* 4.25 71.97 71.09 0.88* 0.44 72.98 13.09 72.08 0.90** 0.33 12.77 72.51 72.09 3.36 71.64 13.03 DVS SR 150 mg 13.03 12.79 12.85 12.74 71.64 72.62 72.45 72.24 71.65 72.10 72.00 13.03 13.18 13.38 -0.52** 1.85 -0.52*** 0.14 -0.45* -0.45** 2.12 0.17 71.89 13.28 -0.35 2.51 -0.36 0.23 71.67 71.40 12.45 12.30 71.66 12.71 0.01 3.39 -0.00 0.35 1.02* 70.34 12.39 1.06 5.09 0.50 1.06* 4.11 0.53 3.92 -0.56 3.04 72.72 12.36 71.66 11.83 1.06* 0.48 72.62 73.15 13.00 13.18 0.53 0.35 68.61 13.88 69.17 14.64 -0.60 0.37 DVS SR 200 mg 72.49 12.03 72.51 72.99 12.03 72.49 12.03 -0.46** -0.44** 12.14 73.44 12.07 1.61 0.15 -0.19 Week 8 73.34 11.98 73.53 12.03 1.85 -0.18 0.19

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.
THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.
STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.
STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

3

TEST: WEIGHT (kg) / PART 1: WITHIN TREATMENT TREATMENT OBSERVED BASELINE CHANGE ADJUSTED [2] Data Analysis Interval [1] [N] STD MEAN STDERR DVS SR 200 mg (cont.) Week 12 73.15 11.96 73.44 12.00 -0.29 2.15 -0.28 0.23 Week 26 81 73.73 12.00 73.59 12.15 0.14 3.26 0.18 0.37 75.03 12.51 Week 39 71 12.58 74.11 0.92* 3.58 0.97 0.53 12.97 1.74*** 1.74*** Week 52 64 76.16 13.29 74.42 3.93 0.50 1.22*** 3.38 1.23*** Final on-therapy 111 74.66 12.40 73.44 12.07 0.37 Follow-up 58 72.99 11.42 72.41 11.17 0.58* 2.03 0.62 0.37 Placebo 77 71.59 13.15 77 71.59 71.59 13.15 Screening/baseline 13.15 71.60 71.76 Week 4 76 71.40 13.07 13.23 -0.20 1.16 -0.21 0.18 Week 8 71 71.64 13.12 13.24 -0.12 1.72 -0.14 0.22 71.61 12.40 71.96 12.51 -0.34 2.09 -0.36 Week 12 64 0.28 -0.11 Week 26 59 70.30 11.95 70.41 11.91 2.93 -0.150.43 Week 39 50 70.68 11.77 70.45 11.49 0.23 3.03 0.19 0.63 46 Week 52 71.00 10.97 70.51 10.78 0.49 3.44 0.48 0.59 Final on-therapy 76 71.73 13.30 71.60 13.23 0.13 2.98 0.12 0.45 Follow-up 14 73.14 18.59 73.56 18.52 -0.42 1.76 -0.34 0.74

CONFIDENTIAL 1159 Wyeth

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

4

TEST: WEIGHT (kg) / PART 2: BETWEEN TREATMENTS OVERALL TREATMENTS COMPARED DIFF. BET. STDERR OF DIFF. PAIRWISE Data Analysis Interval [1] P-VALUE Comparator 1 Comparator 2 ADJ. MEANS BET. ADJ. MEANS P-VALUE Week 4 0.633 DVS SR 50 mg DVS SR 100 mg 0.803 DVS SR 50 mg DVS SR 150 mg 0.02 0.19 0.934 0.786 DVS SR 50 mg DVS SR 200 mg -0.05 0.20 DVS SR 50 mg DVS SR 100 mg Placebo -0.29 0.23 0.200 DVS SR 150 mg -0.03 0.19 0.872 DVS SR 100 mg DVS SR 200 mg -0.10 0.20 0.613 DVS SR 100 mg Placebo -0.34 0.23 0.137 DVS SR 150 mg DVS SR 200 mg -0.07 0.20 0.729 DVS SR 150 mg Placebo -0.31 0.23 0.182 DVS SR 200 mg Placebo -0.23 0.23 0.319 DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg 0.777 0.03 0.23 0.901 Week 8 0.21 0.24 0.370 DVS SR 50 mg DVS SR 200 mg -0.06 0.25 0.811 DVS SR 50 mg Placebo -0.10 0.27 0.706 DVS SR 100 mg DVS SR 150 mg DVS SR 100 mg DVS SR 200 mg 0.18 0.24 0.438 -0.09 0.25 0.722 DVS SR 100 mg -0.13 0.27 Placebo 0.628 DVS SR 150 mg DVS SR 200 mg -0.27 0.25 0.283 DVS SR 150 mg Placebo -0.32 0.28 0.254 DVS SR 200 mg Placebo -0.04 0.880 0.29 DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg Week 12 0.982 0.07 0.30 0.807 0.31 -0.04 0.896 DVS SR 50 mg DVS SR 200 mg -0.12 0.31 0.701 DVS SR 50 mg Placebo DVS SR 100 mg DVS SR 150 mg -0.04 0.35 0.907 -0.11 0.713 0.31 DVS SR 100 mg DVS SR 200 mg -0.19 0.31 0.536 DVS SR 100 mg Placebo -0.11 0.35 0.746 DVS SR 150 mg DVS SR 200 mg -0.08 0.32 0.806 DVS SR 150 mg Placebo -0.00 0.36 0.998 DVS SR 200 mg Placebo 0.08 0.37 0.830 Week 26 0.890 DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg 0.12 0.45 0.783 0.35 0.460

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES. ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.

COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY).

STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

5

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1	COMPARED Comparator 2	DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 26 (cont.)	0.890	DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	0.50 0.23 0.05 0.38	0.54 0.47 0.48 0.53	0.722 0.352 0.627 0.918 0.477 0.724 0.786 0.561
Week 39	0.869	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	-0.19 -0.15 0.64 -0.14 -0.10	0.68 0.70 0.79 0.68 0.70	0.937 0.778 0.832 0.419 0.835 0.890 0.380 0.952 0.304 0.343
Week 52	0.229	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	0.18 1.44 -0.18 -0.87 0.39 -0.68 0.58	0.67 0.74 0.66 0.67 0.74 0.70	0.098 0.193 0.790 0.055 0.778 0.199 0.597 0.332 0.452 0.109
Final on-therapy	0.360	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0.11	0.48	0.578 0.816 0.234 0.350

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES. ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.

COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY). STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

6

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 Page REPORT VS3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

TEST: WEIGHT (kg) / PART 2: BETWEEN TREATMENTS										
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS COM			STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE				
Final on-therapy (cont.)	0.360	DVS SR 100 mg DVS DVS SR 100 mg DVS DVS SR 100 mg Pla DVS SR 150 mg DVS DVS SR 150 mg Pla DVS SR 150 mg Pla DVS SR 200 mg Pla	S SR 200 mg cebo S SR 200 mg cebo	0.37 -0.33 0.78 -0.70 0.41 1.11	0.48 0.50 0.56 0.51 0.57 0.58	0.438 0.509 0.162 0.166 0.470 0.056				
Follow-up	0.119	DVS SR 50 mg DVS DVS SR 100 mg DVS DVS SR 100 mg DVS DVS SR 100 mg DVS DVS SR 150 mg DVS DVS SR 150 mg DVS DVS SR 150 mg Pla DVS SR 200 mg Pla	S SR 150 mg S SR 200 mg ICebo S SR 150 mg S SR 200 mg ICebo S SR 200 mg	-0.87 0.18 -1.04 -0.08 1.06 -0.17 0.80 -1.23 -0.26 0.97	0.68 0.63 0.63 0.90 0.58 0.58 0.52 0.87	0.202 0.768 0.098 0.933 0.071 0.768 0.360 0.019* 0.753 0.244				

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES. ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.

COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY). STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

Page 7

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

TEST: BMI (Kg/m2) / PART 1: WITHIN TREATMENT														
TREATMENT	OBSERVED BASELINE CHAN		OBSERVED			BASELINE CHANGE ADJUSTED [2]								
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR					
DVS SR 50 mg	148			27.07	4.53									
Screening/baseline DVS SR 100 mg	148 155	27.07	4.53	27.07 26.95	4.53 4.70									
Screening/baseline DVS SR 150 mg	155 157	26.95	4.70	26.95 26.54	4.70 4.44									
Screening/baseline DVS SR 200 mg	157 151	26.54	4.44	26.54 26.94	4.44									
Screening/baseline Placebo	151	26.94	4.55	26.94 26.72	4.55 4.72									
Screening/baseline	77	26.72	4.72	26.72	4.72									

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

CONFIDENTIAL 1163 Wyeth

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

Page 8

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

TEST: SYSTOLIC BP, BP Cuff (mm Hg) / PART 1: WITHIN TREATMENT

TREATMENT		OBSERVED		BASELIN	E	CHANGE	<u> </u>	ADJUSTE	D [2]
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 100 mg	1	128.00		128.00					

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

CONFIDENTIAL 1164 Wyeth

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

9

Page

TEST: SYSTOLIC BP, BP Cuff (Standing) (mm Hg) / PART 1: WITHIN TREATMENT

TREATMENT		OBSERV	BASELI	INE	CHANC	GE.	ADJUSTE	D [2]	
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
 DVS SR 50 mg	149			118.78	11.40				
Screening/baseline	149	118.99	12.64	118.78	11.40				
Week 4	139	120.14	13.28	118.50	11.49	1.65*	8.90	1.14	0.90
Week 8	124	118.31	13.55	118.01	11.59	0.29	10.67	-0.49	1.05
Week 12	117	118.91	12.18	118.45	11.84	0.45	10.31	-0.29	1.07
Week 26	102	117.69	12.96	117.75	11.66	-0.07	10.47	-0.87	1.04
Week 39	94	120.67	13.52	117.80	11.39	2.87*	11.85	2.22	1.14
Week 52	82	119.06 119.81	13.45	118.11	11.36 11.45	0.95	11.73 11.14	0.24	1.24
Final on-therapy	140 32	118.63	13.99 14.03	118.50 119.66	10.57	1.31 -1.04	10.81	0.65 -1.03	1.00
Follow-up DVS SR 100 mg	155	118.63	14.03	120.59	12.35	-1.04	10.81	-1.03	1.90
Screening/baseline	155	120.95	14.40	120.59	12.35				
Week 4	135	120.27	14.87	121.06	12.73	-0.80	10.94	-0.64	0.91
Week 8	125	122.13	14.68	121.27	12.68	0.86	11.68	1.14	1.04
Week 12	118	120.00	15.14	121.07	13.04	-1.07	13.80	-0.81	1.07
Week 26	111	121.03	14.79	120.75	13.15	0.27	11.44	0.48	1.00
Week 39	95	121.72	13.82	120.17	12.70	1.54	12.24	1.62	1.13
Week 52	84	122.17	13.88	120.48	12.62	1.68	13.27	1.81	1.22
Final on-therapy	136	122.29	14.36	121.10	12.69	1.19	12.69	1.41	1.01
Follow-up	38	119.66	15.97	119.20	10.79	0.45	11.68	0.40	1.74
DVS SR 150 mg	157			120.12	10.23				
Screening/baseline	157	119.45	10.76	120.12	10.23	0.65	40.06	0 44	
Week 4	127	120.71	12.76	121.35	10.36	-0.65	12.36	-0.41	0.94
Week 8	114 101	123.18 121.47	14.07 13.42	121.51 121.19	10.32 10.69	1.66 0.28	12.88 12.27	2.03	1.09 1.15
Week 12 Week 26	89	121.47	11.38	121.19	10.69	0.28	10.69	1.45	1.13
Week 26 Week 39	82	123.18	14.63	121.99	10.05	1.57	13.29	2.09	1.12
Week 52	69	121.87	12.55	121.78	10.52	0.09	10.86	0.67	1.35
Final on-therapy	127	122.58	13.92	121.76	10.32	1.23	12.65	1.53	1.05
Follow-up	57	117.32	12.99	117.39	8.24	-0.08	10.48	-0.38	1.43
DVS SR 200 mg	151	117.02	12.00	119.93	11.57	0.00	10.10	0.00	1.10
Screening/baseline	151	119.03	12.16	119.93	11.57				
Week 4	111	120.35	13.91	120.04	11.46	0.31	11.75	0.20	1.00
Week 8	97	121.12	14.40	120.37	11.66	0.76	13.50	0.75	1.18

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.
THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.
ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:54 REPORT VS3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 10

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

TEST: SYSTOLIC BP, BP Cuff (Standing) (mm Hg) / PART 1: WITHIN TREATMENT											
TREATMENT		OBSERV	/ED	BASELI	NE	CHANG	E	ADJUSTE	D [2]		
Data Analysis Interval	[1] [N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR		
DVS SR 200 mg (cont.)											
Week 12	95	120.09	14.08	120.25	11.57	-0.16	14.11	-0.21	1.19		
Week 26	81	122.48	12.55	119.60	11.49	2.88*	12.10	2.70*	1.17		
Week 39	71	122.25	11.74	119.02	11.60	3.24**	8.55	2.96*	1.31		
Week 52	65	122.97	12.80	119.09	11.30	3.88**	11.65	3.51*	1.39		
Final on-therapy	111	122.56	14.07	120.04	11.46	2.52	13.67	2.38*	1.12		
Follow-up	60	121.37	13.72	120.70	12.10	0.66	10.63	0.81	1.39		
Placebo	77			122.26	12.64						
Screening/baseline	77	122.81	13.66	122.26	12.64						
Week 4	76	119.75	13.03	122.01	12.54	-2.26	10.74	-1.86	1.21		
Week 8	71	118.25	13.30	121.29	12.41	-3.04	13.05	-2.75*	1.38		
Week 12	64	118.31	13.32	121.64	12.34	-3.32*	10.88	-2.85*	1.45		
Week 26	59	117.76	12.43	121.13	10.80	-3.36*	11.35	-3.04*	1.37		
Week 39	50	119.58	13.77	122.06	10.97	-2.48	9.98	-1.83	1.56		
Week 52	46	122.07	14.33	122.02	11.20	0.04	11.07	0.72	1.65		
Final on-therapy	76	122.59	13.99	122.01	12.54	0.58	11.71	1.11	1.35		
Follow-up	15	126.67	15.19	124.68	12.41	1.98	10.51	2.67	2.80		

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

Page

11

TEST: SYSTOLIC BP, BP Cuff (Standing) (mm Hg) / PART 2: BETWEEN TREATMENTS DIFF. BET. STDERR OF DIFF. PAIRWISE OVERALL TREATMENTS COMPARED Data Analysis Interval [1] P-VALUE Comparator 1 Comparator 2 ADJ. MEANS BET. ADJ. MEANS P-VALUE Week 4 0.341 DVS SR 50 mg DVS SR 100 mg 0.164 DVS SR 50 mg DVS SR 150 mg 1.55 1.30 0.232 1.34 DVS SR 50 mg DVS SR 200 mg 0.94 0.485 DVS SR 50 mg DVS SR 100 mg Placebo 3.00 1.51 0.048* DVS SR 150 mg -0.23 1.30 0.862 DVS SR 100 mg DVS SR 200 mg -0.84 1.35 0.533 DVS SR 100 mg Placebo 1.22 1.51 0.421 DVS SR 150 mg DVS SR 200 mg -0.62 1.37 0.654 1.44 DVS SR 150 mg Placebo 1.53 0.345 DVS SR 200 mg Placebo 2.06 1.57 0.191 DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg 0.071 0.272 Week 8 -1.63 -2.52 1.52 0.098 DVS SR 50 mg DVS SR 200 mg -1.23 1.58 0.436 DVS SR 50 mg Placebo 1.74 2.26 0.195 -0.88 DVS SR 100 mg DVS SR 150 mg 1.51 0.558 DVS SR 100 mg 0.40 DVS SR 200 mg 0.800 DVS SR 100 mg Placebo 1.73 3.89 0.025* DVS SR 150 mg DVS SR 200 mg 1.28 1.61 0.426 DVS SR 150 mg Placebo 4.77 1.76 0.007** DVS SR 200 mg Placebo 3.49 1.82 0.056 Week 12 0.452 DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg 0.52 0.733 0.578 -0.88 1.58 DVS SR 50 mg DVS SR 200 mg 0.960 -0.08 1.60 DVS SR 50 mg Placebo DVS SR 100 mg DVS SR 150 mg 2.55 1.80 0.158 -1.40 1.57 0.374 DVS SR 100 mg DVS SR 200 mg -0.60 1.60 0.708 1.80 DVS SR 100 mg Placebo 2.03 0.258 DVS SR 150 mg DVS SR 200 mg 0.80 1.65 0.631 DVS SR 150 mg Placebo 3.43 1.85 0.064 DVS SR 200 mg Placebo 2.63 1.87 0.161 Week 26 0.015* DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg -1.35 1.45 0.351 -2.32 1.53 0.130

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES. ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.

COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY).

STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

12

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

Data Analysis Interval [1]	OVERALL P-VALUE	$\frac{\text{TREATMENTS}}{\text{Comparator 1}}$	COMPARED Comparator 2	DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 26 (cont.)	0.015*	DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	Placebo DVS SR 200 mg	4.49	1.72 1.49 1.53 1.69 1.61 1.76	0.023* 0.210 0.515 0.149 0.038* 0.441 0.011* 0.002**
Week 39	0.177	DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	-0.47 -1.34 3.45 -0.87 3.92	1.94 1.66 1.73 1.92 1.79	0.709 0.938 0.669 0.037* 0.778 0.438 0.074 0.626 0.048* 0.019*
Week 52	0.435	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	-0.44 -3.28 -0.48 1.14 -1.70 1.10 -2.84 -0.04	1.83 1.85 2.07 1.81 1.84 2.05	0.365 0.811 0.078 0.816 0.531 0.357 0.593 0.143 0.985 0.195
Final on-therapy	0.845	DVS SR 50 mg	DVS SR 200 mg	-0.76 -0.88 -1.73 -0.46	1.42 1.45 1.50 1.68	0.594 0.543 0.249 0.787

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES. ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.

COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY). STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

Page 13

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

TEST: SYSTO	OLIC BP, BI	P Cuff (Standing) (mm Hg) / PAR	T 2: BETWEEN	TREATMENTS	
Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Final on-therapy (cont.)	0.845	DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	-0.12 -0.97 0.30 -0.85 0.43 1.27	1.45 1.51 1.69 1.53 1.71	0.932 0.520 0.858 0.581 0.803 0.469
Follow-up	0.817	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	Placebo	-1.43 -0.65 -1.84 -3.71 0.78 -0.41 -2.27 -1.19 -3.05 -1.86	2.58 2.38 2.35 3.38 2.25 2.23 3.30 2.00 3.16 3.11	0.580 0.784 0.434 0.274 0.730 0.853 0.491 0.552 0.335 0.551

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

14

TEST: SYSTOLIC BP, BP Cuff (Supine) (mm Hg) / PART 1: WITHIN TREATMENT OBSERVED BASELINE CHANGE
MEAN STD MEAN STD MEAN CHANGE TREATMENT ADJUSTED [2] Data Analysis Interval [1] [N] MEAN STDERR DVS SR 50 mg 149 119.88 11.46 Screening/baseline 149 119.13 Week 4 139 121.17 12.49 119.88 11.46 1.34 1.13 -0.56 0.22 2.53* 1.23 1.62 0.55 139 121.17 124 120.44 117 119.24 13.47 119.83 11.49 10.62 0.67 0.95 12.90 12.33 119.30 119.79 11.69 11.75 11.71 0.17 -1.27

 Week 8
 124
 120.44

 Week 12
 117
 119.24

 Week 26
 102
 119.28

 Week 39
 94
 121.65

 Week 52
 82
 120.73

 Final on-therapy
 140
 121.41

 Follow-up
 32
 121.34

 DVS SR 100 mg
 155

 Screening/baseline
 155
 121.95

 Week 4
 135
 122.64

 Week 8
 125
 123.90

 Week 12
 118
 121.72

 Week 26
 111
 122.72

 Week 39
 95
 122.34

 Week 52
 84
 122.67

 Final on-therapy
 136
 122.76

 Follow-up
 39
 122.54

 DVS SR 150 mg
 157

 Screening/baseline
 157
 121.16

 Week 4
 127
 123.29

 Week 8
 114
 125.22

 Week 12
 101
 123.94

 Week 26
 89
 124.71

 Week 39
 82
 125.67

 Week 39
 8 Week 8 10.12 0.98 Week 12 9.51 1.02 12.81 119.06 -0.70 9.76 1.07 12.97 12.81 14.40 119.12 11.37 11.73 1.68 1.16 11.46 11.46 0.25 119.51 11.60 119.79 0.77 11.81 1.00 -0.11 0.88 10 -0.90 12. 0.52 11.0 57 10.87 60 11.95 2 11.58 10.39 120.80 122.45 11.05 12.30 13.97 0.36 1.73 DVS SR 100 mg 122.45 122.75 13.72 12.30 14.50 12.58 0.05 13.38 15.41 123.02 122.62 12.71 $\frac{1.16}{-0.74}$ 13.13 1.01 15.32 13.98 13.22 14.25 122.02 121.77 122.07 122.75 121.72 122.41 13.15 12.90 12.76 12.53 0.65 0.59 0.71 1.02 1.16 0.21 1.01 11.33 10.90 DVS SR 150 mg 12.30 13.21 14.36 12.87 122.41 123.71 123.95 123.65 10.90 11.19 11.14 11.34 12.60 12.63 12.01 11.64 13.67 10.83 12.99 10.03 -0.42 1.27 0.29 0.99 1.02 1.09 1.14 1.24 1.29 1.05 0.01 1.85 0.76 124.53 10.79 10.96 0.18 1.09 2.22 14.73 124.30 1.37 123.96 123.71 120.10 11.79 13.52 1.27 1.97 0.36 1.44 11.73 -2.42 10.99 9.18 -2.08 DVS SR 200 mg 121.24 11.38 12.11 121.24 11.38 14.25 121.40 11.57 1.70 11.64 1.47 1.06

13.52

97 123.71

Week 8

121.70

11.75

2.01

12.41

1.85

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE. STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

Page

15

TEST: SYSTOLIC BP, BP Cuff (Supine) (mm Hg) / PART 1: WITHIN TREATMENT TREATMENT OBSERVED BASELINE CHANGE ADJUSTED [2] Data Analysis Interval [1] [N] MEAN STDERR DVS SR 200 mg (cont.) Week 12 122.43 14.96 121.51 11.90 0.92 12.84 0.74 1.12 2.36 1.19 Week 26 81 122.91 12.69 120.55 11.75 11.81 1.94 122.92 123.71 11.60 Week 39 71 12.57 120.05 2.87* 9.34 2.32 1.33 2.96* Week 52 65 13.05 119.97 11.54 3.74* 12.85 1.32 1.98 Final on-therapy 111 123.66 13.44 121.40 11.57 2.26 13.08 1.12 Follow-up 60 122.53 12.27 122.28 11.01 0.26 9.56 0.40 1.27 Placebo 77 124.63 12.84 77 Screening/baseline 123.55 14.47 124.63 12.84 15.30 12.90 12.86 122.61 119.96 12.58 12.60 Week 4 76 124.30 -1.69 12.49 -1.11 -3.22* 1.29 Week 8 71 123.67 -3.71* 13.12 1.29 120.27 123.84 12.97 -3.58* -3.04* Week 12 64 10.89 1.37 Week 26 59 120.36 14.57 123.50 12.30 -3.14 13.21 -2.58 1.39 Week 39 50 120.56 14.26 124.59 12.24 -4.03* 13.48 -3.08 1.58 46 -2.39 -1.11 Week 52 122.43 12.18 124.82 12.64 11.62 1.58 76 124.38 15 127.80 0.82 Final on-therapy 14.89 124.30 12.58 0.08 13.71 1.36 Follow-up 13.36 126.62 11.98 1.18 9.22 2.26

CONFIDENTIAL 1171 Wyeth

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 Page 16 REPORT VS3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

	P-VALUE	Comparator 1	COMPARED Comparator 2	ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	P-VALUE
Week 4	0.609	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	0.63 0.67 -0.80 1.78 0.04 -1.43 1.15 -1.47 1.11 2.58	1.38 1.43 1.61 1.38 1.44 1.61	0.645 0.630 0.574 0.269 0.977 0.320 0.473 0.314 0.494 0.123
Week 8	0.017*	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-0.99 -1.68 -1.68 3.39 -0.70 -0.69 4.38 0.01 5.08 5.07	1.61 1.50 1.64	0.476 0.236 0.255 0.037* 0.620 0.638 0.007** 0.997 0.002** 0.003**
Week 12	0.159	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	-2.03 -2.01 1.77 -1.50 -1.48 2.30 0.03 3.81	1.49 1.51 1.71 1.48 1.51 1.70	0.711 0.174 0.185 0.300 0.312 0.328 0.176 0.987 0.030* 0.033*

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

Page

17

TEST: SYS	TOLIC BP,	BP Cuff (Supine)	(mm Hg) / PART	2: BETWEEN	TREATMENTS	
Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	
Week 26 (cont.)	0.107	DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 200 mg	-2.64 1.88 -0.44 -1.29 3.23 -0.85 3.67 4.52	1.56 1.72 1.65 1.80	0.098 0.286 0.771 0.409 0.062 0.608 0.042* 0.014*
Week 39	0.062	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	-0.55 -0.64	1.70 1.76 1.97 1.69 1.75 1.95	0.505 0.749 0.714 0.016* 0.334 0.324 0.062 0.957 0.008** 0.010**
Week 52	0.349	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 200 mg	-2.71 1.36 -0.56 -2.25 1.82 -1.69 2.38	1.75 1.77 1.98 1.73 1.76 1.96	0.781 0.560 0.126 0.493 0.746 0.202 0.354 0.362 0.242 0.050*
Final on-therapy	0.697	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0.56 -1.19 -1.21 -0.05		0.694 0.413 0.423 0.976

04NOV05 15:54 REPORT VS3

CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 18

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

TEST: SYSTOLIC BP, BP Cuff (Supine) (mm Hg) / PART 2: BETWEEN TREATMENTS DIFF. BET. STDERR OF DIFF. PAIRWISE OVERALL TREATMENTS COMPARED Data Analysis Interval [1] P-VALUE Comparator 1 Comparator 2 ADJ. MEANS BET. ADJ. MEANS P-VALUE 0.229 Final on-therapy (cont.) 0.697 DVS SR 100 mg DVS SR 150 mg -1.76DVS SR 100 mg DVS SR 200 mg -1.77 1.51 0.243 Placebo -0.61 1.69 DVS SR 100 mg 0.718 DVS SR 150 mg DVS SR 150 mg -0.01 DVS SR 200 mg 1.54 0.994 Placebo 1.14 1.71 0.505 DVS SR 200 mg Placebo 1.16 1.76 0.513 Follow-up 0.335 DVS SR 50 mg DVS SR 100 mg -0.47 2.34 0.842 DVS SR 50 mg DVS SR 150 mg 0.200 2.78 2.16 -0.03 -1.90 DVS SR 50 mg DVS SR 200 mg 2.15 0.988 DVS SR 50 mg Placebo 3.09 0.540 DVS SR 100 mg DVS SR 150 mg 3.25 2.03 0.112 DVS SR 100 mg DVS SR 200 mg 0.44 2.02 0.829 DVS SR 100 mg Placebo -1.43 3.00 0.634 DVS SR 150 mg DVS SR 200 mg -2.81 1.81 0.122 -4.68 DVS SR 150 mg Placebo 2.87 0.105 -1.86 2.84 DVS SR 200 mg Placebo 0.513

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

Page 19

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

TEST: DIASTOLIC BP, BP Cuff (mm Hg) / PART 1: WITHIN TREATMENT

TREATMENT		OBSERVEI)	BASELIN	E	CHANGE	Ξ.	ADJUSTE	D [2]
Data Analysis Interval [1] [N] _	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 100 mg	1			60.00				-	
Screening/baseline	1	60.00		60.00					

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

CONFIDENTIAL 1175 Wyeth

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

20

TEST: DIASTOLIC BP, BP Cuff (Standing) (mm Hg) / PART 1: WITHIN TREATMENT TREATMENT OBSERVED BASELINE CHANGE ADJUSTED [2] Data Analysis Interval [1] [N] MEAN MEAN STD STDERR DVS SR 50 mg 77.53 Screening/baseline 149 77.40 8.70 77.53 7.62 7.77 139 78.54 8.91 77.50 1.04* 6.12 1.02 0.61 76.65 78.19 9.97 Week 8 124 77.07 7.92 -0.43 7.55 -0.57 0.70 77.50 Week 12 117 8.21 7.87 0.69 6.28 0.65 0.68 7.10 Week 26 102 77.21 9.52 77.06 8.07 0.15 0.00 0.75 Week 39 77.94 8.53 77.14 8.09 0.80 7.95 0.71 0.77 Week 52 82 78.56 77.48 1.09 7.96 1.09 0.81 8.99 0.90 Final on-therapy 140 78.39 77.49 7.74 7.47 0.86 0.67 77.76 77.15 6.19 Follow-up 32 79.47 9.26 1.71 7.43 1.99 1.36 155 DVS SR 100 mg 7.04 155 76.33 8.64 77.15 7.04 Screening/baseline Week 4 135 78.04 9.50 77.44 7.26 0.60 7.40 0.56 0.61 1.22 Week 8 125 78.74 9.65 77.51 7.39 1.22 7.67 118 78.97 77.51 7.47 7.90 1.43* Week 12 9.86 1.46* 0.68 78.69 Week 26 111 9.40 77.53 7.56 1.16 7.79 1.17 0.72 Week 39 95 79.11 8.32 77.09 2.01* 7.75 1.90* 0.76 77.11 Week 52 78.39 9.01 7.13 1.28 8.51 1.12 0.80 136 78.68 77.50 7.27 1.13 Final on-therapy 9.55 1.17 8.12 0.68 Follow-up 38 78.87 76.57 7.27 8.58 157 7.15 DVS SR 150 mg 76.89 Screening/baseline 157 76.24 8.04 76.89 7.15 127 79.28 8.79 77.61 1.67* 8.02 1.67** 0.63 2.57*** 77.66 2.52** Week 8 114 80.18 8.18 7.14 8.15 0.73 78.92 77.34 7.26 Week 12 101 8.40 1.58 8.28 1.49* 0.74 Week 26 78.84 7.72 77.84 6.90 1.01 7.61 1.11 0.80 82 Week 39 78.49 10.05 77.45 6.77 1.04 9.75 1.07 0.82 Week 52 69 78.17 7.65 77.43 7.03 0.74 7.41 0.73 0.88 Final on-therapy 127 79.43 8.95 77.61 7.13 1.82* 9.07 1.82* 0.71 Follow-up 57 74.95 75.30 5.87 -0.358.01 -0.95 1.03 DVS SR 200 mg 151 77.48 7.57 Screening/baseline 151 76.89 77.48 7.57 Week 4 111 78.50 8.54 77.79 7.65 0.71 7.95 0.76 0.68

Week 8

78.61

78.04

7.72

0.57

9.01

0.74

0.79

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.
THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.
ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:54 REPORT VS3

Follow-up

CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 21

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

TEST: DIASTOLIC BP, BP Cuff (Standing) (mm Hg) / PART 1: WITHIN TREATMENT TREATMENT OBSERVED BASELINE CHANGE ADJUSTED [2] Data Analysis Interval [1] [N] MEAN STD STDERR DVS SR 200 mg (cont.) Week 12 78.62 8.64 77.94 7.81 0.69 8.95 0.82 0.76 Week 26 81 79.93 9.61 77.60 7.64 2.33* 8.89 2.36** 0.84 Week 39 71 79.07 7.86 77.21 7.60 1.86* 6.22 1.80* 0.88 77.30 7.50 2.91** Week 52 65 80.28 8.35 2.98** 7.88 0.91 79.61 77.79 Final on-therapy 111 9.23 7.65 1.83* 8.72 1.90* 0.76 Follow-up 60 78.38 9.10 77.74 7.41 0.65 8.40 0.92 1.00 Placebo 77 77.79 9.42 77 78.19 77.79 Screening/baseline 9.48 9.42 Week 4 76 77.50 9.89 77.67 9.42 -0.177.89 -0.15 0.82 Week 8 71 76.54 10.75 77.31 9.52 -0.78 8.84 -0.84 0.92 76.31 9.29 77.73 -1.42 -1.36 Week 12 64 9.58 8.81 0.93 Week 26 10.01 59 75.39 77.64 9.29 -2.258.95 -2.21* 0.99 Week 39 50 76.96 9.34 78.40 9.73 -1.44 7.86 -1.04 1.05 46 1.08 Week 52 78.52 7.95 78.32 10.01 0.21 9.29 0.60 Final on-therapy 76 78.30 9.27 77.67 9.42 0.63 9.84 0.66 0.91

79.62

8.63

2.18

6.71

3.13

2.00

6.68

15

81.80

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

Page

22

TEST: DIASTOLIC BP, BP Cuff (Standing) (mm Hg) / PART 2: BETWEEN TREATMENTS DIFF. BET. STDERR OF DIFF. PAIRWISE OVERALL TREATMENTS COMPARED Data Analysis Interval [1] P-VALUE Comparator 1 Comparator 2 ADJ. MEANS BET. ADJ. MEANS P-VALUE Week 4 0.480 DVS SR 50 mg DVS SR 100 mg 0.45 0.600 DVS SR 50 mg DVS SR 150 mg -0.66 0.88 0.452 0.780 DVS SR 50 mg DVS SR 200 mg 0.25 0.91 DVS SR 50 mg DVS SR 100 mg Placebo 1.16 1.02 0.253 DVS SR 150 mg -1.11 0.88 0.209 DVS SR 100 mg DVS SR 200 mg -0.20 0.91 0.828 DVS SR 100 mg Placebo 0.71 1.02 0.487 DVS SR 150 mg DVS SR 200 mg 0.91 0.93 0.326 1.82 1.03 DVS SR 150 mg Placebo 0.079 DVS SR 200 mg Placebo 0.91 1.06 0.392 DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg 0.011* 0.98 0.069 Week 8 -1.80 -3.14 1.01 0.002** DVS SR 50 mg DVS SR 200 mg -1.31 1.05 0.214 DVS SR 50 mg Placebo 0.27 1.16 0.815 DVS SR 100 mg DVS SR 150 mg DVS SR 100 mg DVS SR 200 mg -1.35 1.01 0.181 0.48 1.05 0.645 DVS SR 100 mg Placebo 2.07 1.15 0.074 DVS SR 150 mg DVS SR 200 mg 1.07 0.088 1.83 DVS SR 150 mg Placebo 3.41 1.17 0.004** DVS SR 200 mg Placebo 1.58 1.21 0.193 Week 12 0.127 DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg -0.77 0.97 0.424 -0.83 1.01 0.409 DVS SR 50 mg DVS SR 200 mg -0.16 0.874 1.02 DVS SR 50 mg Placebo DVS SR 100 mg DVS SR 150 mg 2.02 1.15 0.080 -0.06 1.00 0.953 1.02 1.15 DVS SR 100 mg DVS SR 200 mg 0.61 0.550 DVS SR 100 mg Placebo 2.79 0.016* DVS SR 150 mg DVS SR 200 mg 0.67 1.06 0.528 DVS SR 150 mg Placebo 2.85 1.18 0.016* DVS SR 200 mg Placebo 2.18 1.20 0.069 Week 26 0.008** DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg -1.17 1.04 0.263 -1.11 0.314

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

Page

23

TEST: DIASTOLIC BP, BP Cuff (Standing) (mm Hg) / PART 2: BETWEEN TREATMENTS OVERALL TREATMENTS COMPARED DIFF. BET. STDERR OF DIFF. PAIRWISE Data Analysis Interval [1] P-VALUE Comparator 1 Comparator 2 ADJ. MEANS BET. ADJ. MEANS P-VALUE 0.008** -2.36 Week 26 (cont.) DVS SR 50 mg DVS SR 200 mg 0.037* 2.21 DVS SR 50 mg Placebo 1.24 0.076 0.06 1.08 DVS SR 100 mg DVS SR 150 mg 0.958 DVS SR 100 mg DVS SR 200 mg -1.191.11 0.284 DVS SR 100 mg 3.38 Placebo 0.006** DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg Placebo -1.25 1.16 0.285 3.32 1.27 0.009** <0.001*** DVS SR 200 mg Placebo 4.56 1.30 Week 39 0.196 DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg -1.20 1.08 0.270 0.746 1.13 -0.36 DVS SR 50 mg DVS SR 200 mg -1.09 1.17 0.352 DVS SR 50 mg Placebo 1.74 1.31 0.182 DVS SR 100 mg DVS SR 150 mg 0.83 1.12 0.459 DVS SR 100 mg DVS SR 200 mg 0.11 1.17 0.928 2.94 Placebo DVS SR 100 mg 1.30 0.025* DVS SR 150 mg DVS SR 200 mg -0.73 0.547 DVS SR 150 mg Placebo 2.11 1.34 0.116 DVS SR 200 mg Placebo 1.38 2.84 0.040* -0.03 0.36 -1 81 0.979 Week 52 0.400 DVS SR 50 mg DVS SR 100 mg 1.14 DVS SR 50 mg DVS SR 150 mg 1.20 0.761 DVS SR 50 mg DVS SR 200 mg 1.22 0.138 DVS SR 50 mg Placebo 0.49 0.716 1.35 DVS SR 100 mg DVS SR 150 mg 0.39 1.19 0.741 DVS SR 100 mg DVS SR 200 mg -1.78 1.21 0.143 DVS SR 100 mg Placebo 0.52 1.35 0.698 DVS SR 150 mg DVS SR 200 mg -2.18 1.27 0.087 Placebo 1.40 DVS SR 150 mg 0.13 0.927 DVS SR 200 mg Placebo 2.31 1.42 0.104 Final on-therapy 0.707 DVS SR 50 mg DVS SR 100 mg -0.28 0.773 DVS SR 50 mg DVS SR 150 mg -0.96 0.98 0.324 DVS SR 50 mg DVS SR 200 mg -1.04 1.01 0.303 DVS SR 50 mg Placebo 0.20 0.862

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

Page

24

TEST. DIASTOLIC RP. RP Cuff (Standing) (mm Hg) / PART 2. RETWEEN TREATMENTS

1201. 21101	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Cull (Standing	, (119) / 1111		11(111111111111111111111111111111111111	
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1	COMPAREDComparator 2	DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Final on-therapy (cont.)	0.707	DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	-0.69 -0.77 0.47 -0.08 1.16 1.24	0.98 1.02 1.14 1.03 1.15	0.484 0.452 0.678 0.939 0.315 0.296
Follow-up	0.201	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	-0.16 2.94 1.07 -1.14 3.10 1.23 -0.97 -1.87 -4.08 -2.21	1.85 1.71 1.69 2.42 1.60 2.36 1.44 2.26 2.23	0.930 0.088 0.526 0.639 0.056 0.441 0.681 0.196 0.073

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

25

TEST: DIASTOLIC BP, BP Cuff (Supine) (mm Hg) / PART 1: WITHIN TREATMENT TREATMENT OBSERVED BASELINE CHANGE ADJUSTED [2] Data Analysis Interval [1] [N] MEAN STD STDERR DVS SR 50 mg 76.12 7.99 Screening/baseline 149 75.89 76.12 77.03 76.18 139 8.41 7.53 0.85 6.17 0.77 0.58 74.94 76.04 Week 8 124 8.65 75.64 7.56 -0.70 7.02 -0.95 0.65 -0.16 Week 12 117 7.69 76.11 7.46 -0.06 6.51 0.65 Week 26 102 76.64 8.49 75.79 7.68 0.84 6.77 0.69 0.69 Week 39 8.65 76.65 7.98 75.95 7.59 0.69 0.64 0.76 Week 52 77.17 8.07 75.99 7.73 1.18 7.31 1.16 0.74 Final on-therapy 140 77.03 8.35 76.15 7.51 0.88 7.05 0.75 0.62 Follow-up 32 77.78 7.46 76.41 5.74 1.38 5.65 1.47 1.14 155 DVS SR 100 mg 75.99 6.46 155 75.50 75.99 Screening/baseline 6.46 Week 4 135 77.76 8.39 76.28 6.62 1.49** 6.51 1.43* 0.59 Week 8 125 77.26 8.60 76.36 6.69 0.90 6.93 0.91 118 9.00 7.50 Week 12 77.42 76.27 6.80 1.14 1.11 0.64 77.36 Week 26 111 8.76 76.21 6.76 1.15 7.08 1.15 0.66 2.04** Week 39 78.01 95 7.96 75.86 6.44 2.15** 7.34 0.76 7.91 75.79 7.05 Week 52 76.82 6.42 1.03 0.92 0.73 136 77.17 76.33 0.78 Final on-therapy 8.46 6.63 0.84 6.93 0.63 Follow-up 39 76.90 75.47 6.86 157 DVS SR 150 mg 76.37 7.33 Screening/baseline 157 75.84 8.87 76.37 7.33 77.17 7.27 1.84** 127 78.80 8.07 1.63* 8.05 0.61 79.10 8.75 2.16** Week 8 114 1.85* 7.92 0.67 77.70 8.39 76.94 7.30 Week 12 101 0.76 7.90 0.99 0.70 77.93 Week 26 7.38 77.14 7.03 0.79 6.64 1.13 0.74 82 Week 39 78.01 9.15 76.62 6.95 1.39 8.93 1.68* 0.82 Week 52 69 78.81 6.98 76.42 7.03 2.39** 7.23 2.58** 0.80 7.27 Final on-therapy 127 79.13 8.45 77.17 1.97* 8.78 2.28*** 0.65 Follow-up 58 74.03 75.26 6.55 -1.22 7.76 -1.520.85 DVS SR 200 mg 151 76.25 7.51 Screening/baseline 151 75.09 76.25 7.51 Week 4 111 77.58 8.57 76.28 7.84 1.29 7.21 1.24 0.65

8.07

0.98

7.86

1.03

0.73

Week 8

77.45

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.
THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

Page 26

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

TEST: DIASTOLIC BP, BP Cuff (Supine) (mm Hg) / PART 1: WITHIN TREATMENT TREATMENT OBSERVED BASELINE CHANGE ADJUSTED [2] Data Analysis Interval [1] [N] MEAN STD STDERR DVS SR 200 mg (cont.) Week 12 77.46 8.23 76.30 8.11 1.17 7.74 1.15 0.72 7.74 Week 26 81 78.25 8.39 75.77 2.47** 8.42 2.31** 0.77 77.96 Week 39 71 7.55 75.37 7.42 2.59** 7.19 2.22* 0.88 3.62*** Week 52 65 79.34 8.30 75.46 7.31 3.88*** 7.74 0.83 7.84 2.25** Final on-therapy 111 78.53 8.29 76.28 8.29 2.17** 0.69 77.52 Follow-up 60 76.96 7.52 0.55 6.85 0.84 0.84 Placebo 77 76.36 8.10 77 Screening/baseline 76.45 8.65 76.36 8.10 Week 4 76 76.68 9.86 76.30 8.14 0.38 8.31 0.34 0.78 Week 8 71 75.38 9.55 75.93 8.19 -0.558.83 -0.69 0.85 75.42 8.70 -0.74 Week 12 64 76.05 8.42 -0.63 8.48 0.87 Week 26 -1.41 59 74.73 8.89 76.10 8.20 -1.378.96 0.91 Week 39 50 76.18 7.90 76.72 8.40 -0.549.71 -0.20 1.05 46 Week 52 77.26 6.95 76.72 8.71 0.54 8.44 0.87 0.98 77.88 Final on-therapy 76 8.61 76.30 8.14 1.58 9.35 1.51 0.84 Follow-up 15 82.40 5.41 77.37 6.74 5.03** 4.94 5.45** 1.67

CONFIDENTIAL 1182 Wyeth

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

27

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 Page REPORT VS3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1	COMPARED	DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	
Week 4	0.547	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	-1.08 -0.48 0.43 -0.41 0.19 1.10 0.60 1.51	0.84 0.87 0.97 0.84 0.87 0.98 0.99	0.419 0.199 0.584 0.658 0.627 0.826 0.262 0.497 0.128 0.373
Week 8	0.008**	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	-3.11 -1.97 -0.25 -1.25 -0.12 1.60 1.14 2.85	0.93 0.97 1.07 0.93 0.97 1.07 0.99	0.042* <0.001*** 0.043* 0.812 0.179 0.905 0.134 0.253 0.009** 0.126
Week 12	0.265	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo	-1.15 -1.30 0.59 0.12 -0.03 1.86 -0.16	0.95 0.96 1.09 0.95 0.96 1.08 1.00	0.164 0.228 0.178 0.590 0.896 0.973 0.088 0.876 0.121 0.095
Week 26	0.039*	DVS SR 50 mg DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg	-0.46 -0.44	0.95 1.01	0.632 0.663

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

Page

28

TEST: DIASTOLIC BP, BP Cuff (Supine) (mm Hg) / PART 2: BETWEEN TREATMENTS OVERALL TREATMENTS COMPARED DIFF. BET. STDERR OF DIFF. PAIRWISE Data Analysis Interval [1] P-VALUE Comparator 1 Comparator 2 ADJ. MEANS BET. ADJ. MEANS P-VALUE Week 26 (cont.) 0.039* DVS SR 50 mg DVS SR 200 mg -1.62 0.118 DVS SR 50 mg Placebo 2.10 1.14 0.065 DVS SR 100 mg DVS SR 150 mg 0.02 0.99 0.987 DVS SR 100 mg DVS SR 100 mg DVS SR 200 mg -1.16 1.02 0.253 Placebo 2.56 1.12 0.023* -1.18 DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg Placebo 1.07 0.271 2.54 1.17 0.030* DVS SR 200 mg Placebo 3.73 1.19 0.002** -1.41 -1.05 -1.59 Week 39 0.285 DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg 1.08 0.192 0.350 1.12 DVS SR 50 mg DVS SR 200 mg 0.173 1.16 DVS SR 50 mg Placebo 1.29 0.520 DVS SR 100 mg DVS SR 150 mg 0.36 1.11 0.747 DVS SR 100 mg DVS SR 200 mg -0.18 0.876 1.16 2.24 Placebo DVS SR 100 mg 1.29 0.084 DVS SR 150 mg DVS SR 200 mg 0.652 DVS SR 150 mg Placebo 1.33 0.157 2.42 DVS SR 200 mg Placebo 1.37 0.077 0.24 -1.41 -2.45 0.816 Week 52 0.066 DVS SR 50 mg DVS SR 100 mg 1.03 DVS SR 50 mg DVS SR 150 mg DVS SR 50 mg DVS SR 200 mg -1.41 1.09 0.195 -2.45 1.11 0.027* DVS SR 50 mg Placebo 0.30 1.23 0.809 DVS SR 100 mg DVS SR 150 mg -1.66 0.127 1.08 DVS SR 100 mg DVS SR 200 mg -2.70 1.10 0.015* DVS SR 100 mg Placebo 0.06 1.22 0.963 DVS SR 150 mg DVS SR 200 mg -1.04 1.15 0.367 DVS SR 150 mg Placebo DVS SR 200 mg Placebo Placebo 1.71 0.178 2.75 1.28 0.033* -0.04 -1.53 Final on-therapy 0.274 DVS SR 50 mg DVS SR 100 mg 0.968 DVS SR 50 mg DVS SR 150 mg 0.90 0.089 DVS SR 50 mg DVS SR 200 mg -1.43 0.93 0.125 DVS SR 50 mg Placebo -0.76 0.463

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

Page 29

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

TEST: DIAS	TOLIC BP, 1	BP Cuff (Supine)	(mm Hg) / PART	2: BETWEEN	TREATMENTS	
Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Final on-therapy (cont.)	0.274	DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	-1.49 -1.39 -0.73 0.10 0.76 0.66	0.90 0.93 1.05 0.95 1.06 1.09	0.098 0.137 0.486 0.913 0.471 0.544
Follow-up	0.005**	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	0.26 2.99 0.63 -3.99 2.72 0.37 -4.25 -2.36 -6.98 -4.62	1.55 1.43 1.42 2.03 1.34 1.34 1.97 1.20 1.88	0.864 0.038* 0.657 0.051 0.043* 0.784 0.032* 0.050 <0.001*** 0.014*

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

30

TEST: PULSE (Standing) (beats/min) / PART 1: WITHIN TREATMENT TREATMENT OBSERVED BASELINE CHANGE ADJUSTED [2] STD Data Analysis Interval [1] [N] MEAN MEAN STDERR DVS SR 50 mg 73.01 9.20 Screening/baseline 149 73.17 73.01 73.70 139 10.41 73.21 7.39 0.49 8.26 0.55 0.68 74.64 73.36 72.96 72.97 Week 8 124 10.20 1.68 9.53 1.63* 0.78 Week 12 117 10.05 0.39 9.28 0.41 0.77 Week 26 102 73.16 9.64 73.00 6.82 0.16 9.60 0.16 0.83 Week 39 72.41 8.94 73.12 -0.70 9.91 -0.66 0.90 Week 52 72.39 9.29 73.23 -0.84 9.25 -0.74 0.95 Final on-therapy 140 72.91 9.23 73.23 7.37 -0.32 8.47 -0.24 0.71 72.11 7.26 Follow-up 31 73.26 8.16 1.15 9.54 0.67 1.65 DVS SR 100 mg 155 73.03 8.20 155 73.43 8.98 73.03 8.20 Screening/baseline Week 4 135 73.37 9.31 72.31 7.76 1.06 8.18 0.83 0.69 2.15** 2.04** Week 8 125 74.94 10.27 72.80 7.75 9.15 118 72.91 72.40 Week 12 8.91 7.69 0.50 9.44 0.28 0.76 73.05 73.99 Week 26 110 8.61 73.08 7.99 -0.03 8.60 0.01 0.80 Week 39 73.17 95 9.12 9.65 0.89 0.89 74.65 73.42 Week 52 9.19 8.51 1.23 9.01 1.43 0.94 136 74.10 72.36 7.75 1.74* 1.45* Final on-therapy 9.14 8.57 0.72 5.29** Follow-up 38 78.84 73.55 7.80 9.94 5.38*** 157 72.66 7.76 DVS SR 150 mg 72.66 72.83 72.90 9.71 Screening/baseline 157 73.98 7.76 75.47 76.76 2.64*** 127 9.40 8.02 8.61 2.58*** 0.71 3.86*** 3.79*** Week 8 114 10.00 8.10 8.17 0.81 101 74.43 9.59 72.87 8.21 Week 12 1.56 8.84 1.53 0.82 Week 26 74.28 8.82 73.13 7.93 1.15 8.45 1.21 0.89 82 2.38* Week 39 75.44 10.33 73.06 8.10 9.78 2.39* 0.96 1.72 Week 52 69 74.43 9.03 72.72 7.81 9.16 1.56 1.03 127 3.05*** Final on-therapy 75.97 10.24 72.83 8.02 3.14*** 9.71 0.75 7.94 2.18 Follow-up 57 75.02 11.03 72.84 9.56 1.99 1.22 DVS SR 200 mg 151 73.88 8.04 Screening/baseline 151 74.42 73.88 8.04 2.17** 2.60*** Week 4 111 76.56 9.72 74.39 7.95 8.32 0.76 3.98*** 4.48*** Week 8 78.57 10.22 74.58 8.20 8.92 0.88

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

Page

31

TEST: PULSE (Standing) (beats/min) / PART 1: WITHIN TREATMENT TREATMENT OBSERVED BASELINE CHANGE ADJUSTED [2] Data Analysis Interval [1] [N] MEAN STD STD MEAN STDERR DVS SR 200 mg (cont.) 74.99 Week 12 9.49 74.12 8.11 0.87 8.10 1.36 0.85 Week 26 81 73.51 10.61 74.09 8.33 -0.59 9.44 -0.05 0.93 75.86 Week 39 71 9.77 74.02 8.18 1.84 9.44 2.37* 1.04 3.03** Week 52 65 76.52 11.03 73.97 8.41 2.55 10.92 1.07 74.39 7.95 Final on-therapy 111 75.85 10.09 1.46 9.85 2.05* 0.80 Follow-up 60 76.67 10.65 73.91 7.34 2.76* 8.95 2.99* 1.19 Placebo 77 72.28 7.12 77 7.12 Screening/baseline 72.18 8.38 72.28 Week 4 76 72.51 8.19 72.26 7.16 0.26 8.25 0.02 0.92 Week 8 71 72.61 9.31 72.23 7.18 0.37 9.27 0.08 1.03 70.58 72.21 Week 12 64 8.74 6.93 -1.63 8.11 -1.93 1.04 Week 26 -0.57 59 70.54 7.96 71.11 6.23 9.73 -1.48 1.09 Week 39 50 72.28 8.04 71.27 6.22 1.01 9.19 0.03 1.24 46 Week 52 72.80 7.64 71.12 6.27 1.68 8.38 0.72 1.27 Final on-therapy 76 73.16 8.29 72.26 7.16 0.90 8.72 0.56 0.97 2.91 Follow-up 15 77.00 12.50 74.60 7.94 2.40 11.87

CONFIDENTIAL 1187 Wyeth

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

Page

32

044*	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	-0.29 -2.03 -2.05 0.53 -1.75 -1.77 0.82	0.98 1.02 1.14	0.767 0.038* 0.044* 0.639
	DVS SR 150 mg DVS SR 200 mg		-0.02 2.57	1.14 1.04 1.16	0.077 0.085 0.474 0.983 0.027* 0.030*
006**	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-2.16 -2.85 1.55 -1.75 -2.43 1.96 -0.68 3.71	1.12 1.17 1.29 1.12 1.17 1.29 1.20	0.706 0.054 0.016* 0.229 0.119 0.039* 0.127 0.569 0.005** 0.001**
087	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	-1.12 -0.96 2.34 -1.25 -1.08 2.22 0.17	1.13 1.15 1.29 1.12 1.15 1.29 1.19	0.910 0.318 0.404 0.070 0.267 0.346 0.085 0.888 0.009**
(DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 50 mg DVS SR 150 mg DVS SR 50 mg DVS SR 200 mg DVS SR 50 mg Placebo DVS SR 100 mg DVS SR 200 mg DVS SR 100 mg DVS SR 200 mg DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg Placebo DVS SR 150 mg Placebo DVS SR 200 mg Placebo DVS SR 50 mg DVS SR 150 mg DVS SR 50 mg DVS SR 150 mg DVS SR 50 mg DVS SR 150 mg DVS SR 50 mg DVS SR 200 mg DVS SR 50 mg DVS SR 200 mg DVS SR 50 mg DVS SR 150 mg DVS SR 50 mg DVS SR 150 mg DVS SR 100 mg DVS SR 150 mg DVS SR 100 mg DVS SR 200 mg DVS SR 100 mg Placebo DVS SR 150 mg Placebo	DVS SR 50 mg DVS SR 150 mg —2.16 DVS SR 50 mg DVS SR 200 mg —2.85 DVS SR 50 mg Placebo DVS SR 100 mg DVS SR 200 mg —1.75 DVS SR 100 mg DVS SR 200 mg —2.43 DVS SR 100 mg DVS SR 200 mg —2.43 DVS SR 100 mg Placebo 1.96 DVS SR 150 mg DVS SR 200 mg —0.68 DVS SR 150 mg Placebo 3.71 DVS SR 200 mg Placebo 4.39 DVS SR 50 mg DVS SR 150 mg —1.12 DVS SR 50 mg DVS SR 200 mg —1.12 DVS SR 50 mg DVS SR 200 mg —0.96 DVS SR 50 mg DVS SR 200 mg —1.25 DVS SR 50 mg DVS SR 200 mg —1.25 DVS SR 100 mg DVS SR 150 mg —1.25 DVS SR 100 mg DVS SR 200 mg —1.08 DVS SR 100 mg DVS SR 200 mg —1.08 DVS SR 100 mg DVS SR 200 mg —1.08 DVS SR 150 mg Placebo 2.22 DVS SR 150 mg Placebo 3.46 DVS SR 200 mg Placebo 3.46 DVS SR 200 mg Placebo 3.30	DVS SR 50 mg DVS SR 150 mg -2.16 1.12 DVS SR 50 mg DVS SR 200 mg -2.85 1.17 DVS SR 50 mg Placebo 1.55 1.29 DVS SR 100 mg DVS SR 200 mg -2.43 1.17 DVS SR 100 mg DVS SR 200 mg -2.43 1.17 DVS SR 100 mg DVS SR 200 mg -2.43 1.17 DVS SR 150 mg DVS SR 200 mg -0.68 1.20 DVS SR 150 mg Placebo 3.71 1.31 DVS SR 200 mg Placebo 3.71 1.31 DVS SR 200 mg Placebo 4.39 1.36 DVS SR 50 mg DVS SR 150 mg -1.12 1.31 DVS SR 50 mg DVS SR 150 mg -1.12 1.13 DVS SR 50 mg DVS SR 200 mg -0.96 1.15 DVS SR 50 mg DVS SR 200 mg -1.12 1.13 DVS SR 50 mg DVS SR 200 mg -1.12 1.13 DVS SR 50 mg DVS SR 200 mg -1.12 1.15 DVS SR 100 mg DVS SR 150 mg -1.25 1.15 DVS SR 100 mg DVS SR 200 mg -1.25 1.12 DVS SR 100 mg DVS SR 200 mg -1.08 1.15 DVS SR 100 mg DVS SR 200 mg -1.08 1.15 DVS SR 100 mg DVS SR 200 mg -1.08 1.15 DVS SR 150 mg Placebo 2.22 1.29 DVS SR 150 mg Placebo 3.46 1.32 DVS SR 200 mg Placebo 3.46 1.32 DVS SR 200 mg Placebo 3.46 1.32 DVS SR 200 mg Placebo 3.340 1.34

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

Page

33

Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED		STDERR OF DIFF. BET. ADJ. MEANS	
Week 26 (cont.)	0.446	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0.21 1.64 -1.20 0.07 1.50 1.27 2.70 1.43	1.25 1.37 1.19 1.22 1.35 1.28 1.41	0.865 0.231 0.315 0.956 0.269 0.324 0.056 0.321
Week 39	0.098	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	-1.55 -3.05 -3.04 -0.69 -1.50 -1.49 0.86 0.01 2.36 2.34	1.27 1.32 1.37 1.53 1.31 1.37 1.53 1.41 1.57	0.222 0.021* 0.027* 0.650 0.254 0.277 0.576 0.994 0.134 0.148
Week 52	0.117	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-2.17 -2.30 -3.77 -1.46 -0.13 -1.60 0.71 -1.47 0.84 2.31	1.33 1.40 1.43 1.59 1.40 1.42 1.58 1.49 1.64	0.104 0.102 0.009** 0.359 0.927 0.261 0.653 0.324 0.608
Final on-therapy	0.022*	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	-1.68 -3.28 -2.28 -0.80	1.02 1.03 1.07 1.20	0.098 0.002** 0.034* 0.508

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

Page 34

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

TEST:	PULSE (St	anding) (beats/m	in) / PART 2: E	SETWEEN TREAT	MENTS	
Data Analysis Interval [1]	OVERALL P-VALUE				STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Final on-therapy (cont.)	0.022*	DVS SR 100 mg DVS SR 100 mg	DVS SR 200 mg Placebo	-1.60 -0.60 0.89 1.00 2.49 1.48	1.04 1.08 1.21 1.10 1.22 1.26	0.125 0.582 0.464 0.363 0.043* 0.240
Follow-up	0.277	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg	DVS SR 200 mg Placebo	-1.32 -2.32	2.22 2.05 2.03 2.89 1.90 2.80 1.70 2.67 2.65	0.035* 0.520 0.255 0.440 0.079 0.210 0.378 0.555 0.730 0.975

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

Page

35

TEST: PULSE (Supine) (beats/min) / PART 1: WITHIN TREATMENT

TREATMENT Data Analysis Interval [1] [1			TEST: PULSE (Supine) (beats/min) / PART 1: WITHIN TREATMENT												
	OBSERVED			BASELINE		CHANGE		ADJUSTED	[2]						
	N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR						
	49			68.83	7.62										
		69.54	8.37	68.83	7.62										
	39	69.28	8.78	68.87	7.54	0.41	7.23	0.48	0.59						
		70.17	7.76	68.57	7.41	1.60*	7.93	1.55*	0.68						
		69.28	9.44	68.78	7.40	0.50	8.46	0.62	0.71						
		68.86 68.47	8.35 7.98	68.68 68.85	7.20 6.95	0.18 -0.38	8.51 8.27	0.23 -0.35	0.72						
		68.73	8.49	68.86	7.11	-0.13	7.53	-0.12	0.81						
	40	69.59	8.95	68.87	7.51	0.71	7.67	0.79	0.65						
	32	67.38	6.01	68.69	7.23	-1.31	7.24	-1.57	1.35						
	55	07.50	0.01	68.18	7.18	1.01	, • 2 1	1.07	1.00						
Screening/baseline 15	55	68.92	8.05	68.18	7.18										
Week 4		68.76	8.50	67.74	7.16	1.01	7.32	0.68	0.60						
		70.67	8.40	68.07	7.04	2.60***	8.31	2.33***	0.68						
		68.59	8.28	67.81	7.21	0.78	9.01	0.43	0.70						
		68.46	7.93	68.20	7.28	0.26	7.90	0.07	0.69						
	95	69.06	8.35	68.29	7.59	0.77	8.94	0.50	0.79						
		70.99 70.17	7.42	68.63 67.78	7.75 7.15	2.36** 2.39***	8.13 8.22	2.25** 2.00**	0.80						
		73.29	8.08 8.08	68.89	6.46	4.39**	8.84	4.25***	0.66						
	57	13.29	0.00	68.79	7.77	4.39""	0.04	4.23	1.24						
	57	69.88	9.26	68.79	7.77										
	27	70.23	8.29	69.00	8.03	1.23	7.72	1.34*	0.62						
	14	72.54	8.94	69.00	8.09	3.53***	8.26	3.67***	0.71						
		70.44	8.50	68.83	8.08	1.60	8.28	1.74*	0.76						
		71.48	7.72	68.99	7.73	2.49**	8.04	2.69***	0.77						
		70.77	9.32	69.09	8.01	1.68	9.17	1.84*	0.86						
		70.97	8.68	68.79	7.52	2.18*	8.35	2.15*	0.89						
		71.76	9.71	69.00	8.03	2.77***	9.02	2.90***	0.68						
	57 51	70.91	9.46	69.44 69.59	7.79 6.83	1.47	9.85	1.61	1.01						
		70.22	7.99	69.59	6.83										
		71.30	8.07	69.72	6.90	1.58*	7.36	1.95**	0.66						
		72.63	9.39	69.83	7.05	2.80**	8.32	3.29***	0.77						

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.
THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.
ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

Page 36

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

TEST: PULSE (Supine) (beats/min) / PART 1: WITHIN TREATMENT TREATMENT OBSERVED BASELINE ADJUSTED [2] Data Analysis Interval [1] [N] MEAN STD STD STDERR DVS SR 200 mg (cont.) Week 12 71.00 8.33 69.35 6.80 1.65 8.16 2.04** 0.78 7.04 Week 26 81 69.75 8.61 69.51 0.24 7.76 0.69 0.81 71.58 8.05 Week 39 71 69.84 7.08 1.74 8.50 2.30* 0.92 Week 52 65 73.22 8.65 69.88 7.12 3.34** 8.86 3.84*** 0.91 3.02*** 2.58** Final on-therapy 111 72.30 8.56 69.72 6.90 8.56 0.73 2.17* Follow-up 60 71.72 8.12 69.55 6.25 6.99 2.36* 0.98 Placebo 77 68.03 77 68.03 Screening/baseline 68.56 7.50 6.14 Week 4 76 68.71 8.25 67.96 6.15 0.75 7.67 0.49 0.80 Week 8 71 67.62 8.89 67.93 6.20 -0.31 8.22 -0.64 0.90 7.23 67.79 -3.30*** 7.51 -3.67*** Week 12 64 64.48 6.12 0.96 Week 26 5.93 -1.82 59 65.46 7.87 67.28 7.96 -2.47** 0.95 Week 39 50 67.96 8.41 67.69 6.15 0.27 8.21 -0.32 1.10 Week 52 46 69.46 7.95 67.88 6.29 1.58 7.96 1.10 1.09 Final on-therapy 76 68.79 7.83 67.96 6.15 0.83 7.96 0.51 0.88 Follow-up 15 72.00 8.64 68.43 5.47 3.57 8.75 3.18 1.97

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

Page

37

TEST: PULSE (Supine) (beats/min) / PART 2: BETWEEN TREATMENTS OVERALL TREATMENTS COMPARED DIFF. BET. STDERR OF DIFF. PAIRWISE Comparator 1 Comparator 2 ADJ. MEANS BET. ADJ. MEANS P-VALUE Data Analysis Interval [1] P-VALUE Week 4 0.437 DVS SR 50 mg DVS SR 100 mg -0.20 0.810 DVS SR 50 mg DVS SR 150 mg -0.87 0.86 0.312 DVS SR 50 mg DVS SR 200 mg -1.47 0.89 0.099 DVS SR 50 mg DVS SR 100 mg Placebo -0.02 1.00 0.987 DVS SR 150 mg 0.86 -0.66 0.443 DVS SR 100 mg DVS SR 200 mg -1.26 0.90 0.160 DVS SR 100 mg Placebo 0.19 1.00 0.852 DVS SR 150 mg DVS SR 200 mg -0.60 0.91 0.508 DVS SR 150 mg Placebo 0.85 1.01 0.402 DVS SR 200 mg Placebo 1.45 1.04 0.164 DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg 0.002** -0.78 0.96 Week 8 -0.78 -2.12 -1.74 0.415 0.98 0.032* DVS SR 50 mg DVS SR 200 mg 1.03 0.091 DVS SR 50 mg Placebo 2.19 1.13 0.053 -1.33 DVS SR 100 mg DVS SR 150 mg 0.98 0.176 DVS SR 100 mg -0.96 DVS SR 200 mg 1.03 0.353 DVS SR 100 mg Placebo 2.97 1.13 0.009** DVS SR 150 mg DVS SR 200 mg 0.38 0.720 1.05 DVS SR 150 mg Placebo 4.30 1.15 <0.001*** DVS SR 200 mg Placebo 0.001** 3.93 1.19 DVS SR 50 mg DVS SR 100 mg
DVS SR 50 mg DVS SR 150 mg Week 12 <0.001*** 0.19 0.852 0.278 -1.13 1.04 DVS SR 50 mg DVS SR 200 mg -1.42 0.179 1.05 DVS SR 50 mg Placebo DVS SR 100 mg DVS SR 150 mg 4.28 1.19 <0.001*** -1.31 1.04 0.206 DVS SR 100 mg DVS SR 200 mg -1.61 1.05 0.128 1.19 DVS SR 100 mg Placebo 4.10 <0.001*** DVS SR 150 mg DVS SR 200 mg -0.29 1.09 0.788 DVS SR 150 mg Placebo 5.41 1.22 <0.001*** DVS SR 200 mg Placebo 5.70 1.24 <0.001*** Week 26 0.001** DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg 0.16 1.00 0.875 -2.46 1.05 0.020*

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

Page

38

Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1	COMPARED	DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 26 (cont.)	0.001**	DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	2.69 -2.62 -0.62 2.54 2.00 5.16	1.19 1.04 1.06 1.17 1.11 1.22	0.665 0.024* 0.012* 0.557 0.031* 0.074 <0.001***
Week 39	0.120	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo Placebo	-2.19 -2.65 -0.03 -1.34 -1.80 0.83 -0.46	1.17 1.22 1.36 1.17 1.22 1.35 1.26	0.450 0.062 0.030* 0.984 0.253 0.141 0.542 0.714 0.121 0.068
Week 52	0.024*	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg		-3.96 -1.23 0.10 -1.59 1.15 -1.69 1.05	1.20 1.22 1.36 1.20 1.22 1.35 1.27	0.038* 0.059 0.001** 0.367 0.932 0.194 0.395 0.186 0.455 0.055
Final on-therapy	0.044*	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	-1.20 -2.11 -2.23 0.28	0.94	0.195 0.026* 0.023* 0.799

04NOV05 15:54 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT VS3

Page 39

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR VITAL SIGNS AND PHYSICAL CHARACTERISTICS

Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Final on-therapy (cont.)	0.044*	DVS SR 100 mg DVS SR 100 mg	DVS SR 200 mg Placebo	-0.91 -1.03 1.48 -0.12 2.39 2.51	0.95 0.99 1.10 1.00 1.12 1.15	0.341 0.298 0.179 0.902 0.033* 0.029*
Follow-up	0.030*	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg		-5.82 -3.18 -3.93 -4.75 2.64 1.89 1.07 -0.75 -1.57 -0.82	1.83 1.68 1.67 2.38 1.60 1.58 2.32 1.41 2.21	0.002** 0.060 0.019* 0.048* 0.100 0.234 0.646 0.594 0.479 0.711

ST 10-13: Number (%) of Subjects With ECG Results of Potential Clinical Interest

170CT05 14:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 Page 1

REPORT ECG5 NUMBER (%) OF SUBJECTS WITH ECG RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Screening/baseline

Category	Overall						Treat	ment					
Test+Units	P-Value *	DVS SR	50 mg	DVS SR	100 mg	DVS SR		DVS SR	200 mg	Plac	ebo	TOT	AL
TOTAL	0.328	23/148	(15.5)	28/155	(18.1)	33/156	(21.2)	19/151	(12.6)	15/ 77	(19.5)	118/687	(17.2)
ECG OVERALL EVALUATION Not Normal HEART RATE beats/min DECREASE RHYTHM Not Sinus PR INTRVL msec HIGH QRS INTRVL msec HIGH QT INTRVL msec HIGH	0.328 0.560 0.560 0.487 0.487 0.832 0.832 0.805 0.805 0.352 0.352 0.811	23/148 17/148 17/148 0/148 0/148 7/148 7/148 5/148 5/148 0/148 0/148	(15.5) (11.5) (11.5) (4.7) (4.7) (4.7) (3.4) (3.4)	28/155 19/155 19/155 1/155 1/155 10/155 10/155 6/155 1/155 1/155 1/155	(18.1) (12.3) (12.3) (0.6) (0.6) (6.5) (6.5) (3.9) (0.6) (0.6) (0.6)	33/156 23/156 23/156 0/156 0/156 11/156 11/156 7/155 2/156 2/156 1/156	(21.2) (14.7) (14.7) (7.1) (7.1) (4.5) (4.5) (1.3) (1.3) (0.6) (0.6)	19/151 14/151 14/151 0/151 0/151 8/151 8/151 5/149 1/151 1/150 1/150	(12.6) (9.3) (9.3) (5.3) (5.3) (3.4) (0.7) (0.7) (0.7)	15/ 77 12/ 77 12/ 77 0/ 77 0/ 77 3/ 77 3/ 77 5/ 77 2/ 77 2/ 77 1/ 77	(19.5) (15.6) (15.6) (3.9) (3.9) (6.5) (6.5) (2.6) (2.6) (1.3) (1.3)	118/687 85/687 85/687 1/687 1/687 39/687 39/687 28/684 6/687 6/687 4/686	(17.2) (12.4) (12.4) (0.1) (0.1) (5.7) (5.7) (4.1) (4.1) (0.9) (0.9) (0.6)

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

170CT05 14:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 2

REPORT ECG5 NUMBER (%) OF SUBJECTS WITH ECG RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Category Test+Units	Overall	DVG GD E0			tment		
Test+Units	P-Value *	DVS SR 50 mg	DVS SR 100 mg	DVS SR 150 mg	DVS SR 200 mg	Placebo	TOTAL
TOTAL	0.042*	0/ 1	1/ 1 (100)	1/ 3 (33.3)	0/ 9	0/ 2	2/ 16 (12.5)
ECG OVERALL EVALUATION Not Normal RHYTHM	0.042* 0.328 0.328 0.003**	0/ 1 0/ 1 0/ 1 0/ 1	1/ 1 (100) 0/ 1 0/ 1 1/ 1 (100)	1/ 3 (33.3) 1/ 3 (33.3) 1/ 3 (33.3) 0/ 3	0/ 9 0/ 9 0/ 9 0/ 9	0/ 2 0/ 2 0/ 2 0/ 2	2/ 16 (12.5) 1/ 16 (6.3) 1/ 16 (6.3) 1/ 16 (6.3)
Not Sinus	0.003**	0/ 1	1/ 1 (100)	0/ 3	0/ 9	0/ 2	1/ 16 (6.3)

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

170CT05 14:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 3

REPORT ECG5 NUMBER (%) OF SUBJECTS WITH ECG RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Category Test+Units	Overall P-Value *	DVS SR 50 mg	DVS SR 100 mg	Treatment DVS SR 150 mg	Placebo	TOTAL
TOTAL	0.295	0/ 6	1/ 5 (20.0)	0/ 6	1/ 3 (33.3)	2/ 20 (10.0)
ECG OVERALL EVALUATION Not Normal PR INTRVL msec HIGH	0.295 0.295 0.295 0.368	0/ 6 0/ 6 0/ 6 0/ 6	1/ 5 (20.0) 1/ 5 (20.0) 1/ 5 (20.0) 1/ 5 (20.0) 1/ 5 (20.0)	0/ 6 0/ 6 0/ 6 0/ 6	1/ 3 (33.3) 1/ 3 (33.3) 1/ 3 (33.3) 0/ 3	2/ 20 (10.0) 2/ 20 (10.0) 2/ 20 (10.0) 1/ 20 (5.0) 1/ 20 (5.0)

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

Page

170CT05 14:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT ECG5 NUMBER (%) OF SUBJECTS WITH ECG RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Category Test+Units	Overall P-Value *	DVS SR	50 mg	DVS SR	 100 mg	DVS SR	Treat 150 mg	DVS SR 2	200 mg	Plac	ebo	TOT	 AL
TOTAL	0.065	16/119	(13.4)	20/119	(16.8)	15/100	(15.0)	9/ 95	(9.5)	17/ 65	(26.2)	77/498	(15.5)
ECG OVERALL EVALUATION Not Normal HEART RATE beats/min DECREASE RHYTHM Not Sinus PR INTRVL msec HIGH QRS INTRVL msec HIGH QTC INTRVL msec INCREASE QT INTRVL msec HIGH	0.065 0.163 0.163 0.156 0.156 0.665 0.393 0.393 0.393 0.825 0.413 0.413 0.697	16/119 11/119 11/119 0/117 0/117 4/119 4/119 3/117 3/117 0/117 1/117 1/117 1/117	(13.4) (9.2) (9.2) (3.4) (3.4) (2.6) (2.6) (0.9) (0.9) (0.9)	20/119 18/119 18/119 0/119 0/119 3/119 3/119 4/119 1/119 0/119 0/119 1/119	(16.8) (15.1) (15.1) (2.5) (2.5) (3.4) (3.4) (0.8) (0.8)	15/100 14/100 14/100 0/100 0/100 3/100 3/100 2/ 99 2/ 99 1/100 0/100 0/100 0/100	(15.0) (14.0) (14.0) (3.0) (3.0) (2.0) (2.0) (1.0) (1.0)	9/ 95 7/ 95 7/ 95 0/ 95 0/ 95 2/ 95 1/ 95 1/ 95 1/ 95 0/ 95 0/ 95	(9.5) (7.4) (7.4) (2.1) (2.1) (1.1) (1.1) (1.1)	17/ 65 12/ 65 12/ 65 1/ 65 1/ 65 4/ 65 4/ 65 1/ 65 1/ 65 1/ 65 0/ 65	(26.2) (18.5) (18.5) (1.5) (1.5) (6.2) (6.2) (6.2) (6.2) (1.5) (1.5) (1.5)	77/498 62/498 62/498 1/496 1/496 16/498 16/498 14/495 14/495 4/496 2/496 2/496 2/496	(15.5) (12.4) (12.4) (0.2) (0.2) (3.2) (3.2) (2.8) (0.8) (0.8) (0.4) (0.4) (0.4)

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

170CT05 14:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 5

REPORT ECG5 NUMBER (%) OF SUBJECTS WITH ECG RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Category Test+Units	Overall P-Value *	DVS SR 100 mg	DVS SR 150 mg	Treatment DVS SR 200 mg	Placebo	TOTAL
TOTAL	0.405	0/ 1	0/ 3	0/ 1	1/ 2 (50.0)	1/ 7 (14.3)
ECG OVERALL EVALUATION Not Normal	0.405 0.405 0.405	0/ 1 0/ 1 0/ 1	0/ 3 0/ 3 0/ 3	0/ 1 0/ 1 0/ 1	1/ 2 (50.0) 1/ 2 (50.0) 1/ 2 (50.0)	1/ 7 (14.3) 1/ 7 (14.3) 1/ 7 (14.3)

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

170CT05 14:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 6

REPORT ECG5 NUMBER (%) OF SUBJECTS WITH ECG RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Category Test+Units	Overall P-Value *	DVS SR	100 mg	Treatment DVS SR 150 mg	Т(OTAL
TOTAL	0.171	1/ 2	(50.0)	0/ 3	1/ 5	5 (20.0)
ECG OVERALL EVALUATION Not Normal	0.171 0.171 0.171	1/ 2 1/ 2 1/ 2		0/ 3 0/ 3 0/ 3	-/.	5 (20.0) 5 (20.0) 5 (20.0)

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

Page

7

170CT05 14:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT ECG5 NUMBER (%) OF SUBJECTS WITH ECG RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Category	Overall						Treat	ment					
Test+Units	P-Value *	DVS SR	50 mg	DVS SR	100 mg	DVS SR	150 mg		200 mg	Plac	ebo	TOT	AL
TOTAL	0.791	14/ 82	(17.1)	10/ 82	(12.2)	10/ 68	(14.7)	6/ 60	(10.0)	6/ 43	(14.0)	46/335	(13.7)
ECG OVERALL EVALUATION Not Normal RHYTHM Not Sinus PR INTRVL msec HIGH	0.791 0.713 0.713 0.877 0.877 0.486 0.486	14/ 82 10/ 82 10/ 82 2/ 82 2/ 82 3/ 82 3/ 82	(17.1) (12.2) (12.2) (2.4) (2.4) (3.7) (3.7)	10/ 82 8/ 82 8/ 82 1/ 82 1/ 82 2/ 82 2/ 82	(12.2) (9.8) (9.8) (1.2) (1.2) (2.4) (2.4)	10/ 68 9/ 68 9/ 68 1/ 68 1/ 67 1/ 67	(14.7) (13.2) (13.2) (1.5) (1.5) (1.5) (1.5)	6/ 60 4/ 60 4/ 60 1/ 60 1/ 60 1/ 60	(10.0) (6.7) (6.7) (1.7) (1.7) (1.7) (1.7)	6/ 43 6/ 43 6/ 43 0/ 43 0/ 43 3/ 43	(14.0) (14.0) (14.0) (14.0)	46/335 37/335 37/335 5/335 5/335 10/334 10/334	(13.7) (11.0) (11.0) (1.5) (1.5) (3.0) (3.0)
QRS INTRVL msec HIGH QTC INTRVL msec INCREASE QTCF INTRVL msec INCREASE	0.623 0.623 0.877 0.877 0.542 0.542	0/ 82 0/ 82 2/ 82 2/ 82 1/ 82 1/ 82	(2.4) (2.4) (1.2) (1.2)	1/ 82 1/ 82 1/ 82 1/ 82 0/ 82 0/ 82	(1.2) (1.2) (1.2) (1.2)	1/ 68 1/ 68 1/ 68 1/ 68 0/ 68 0/ 68	(1.5) (1.5) (1.5) (1.5)	0/ 60 0/ 60 1/ 60 1/ 60 0/ 60 0/ 60	(1.7) (1.7)	1/ 43 1/ 43 0/ 43 0/ 43 0/ 43 0/ 43	(2.3)	3/335 3/335 5/335 5/335 1/335 1/335	(0.9) (0.9) (1.5) (1.5) (0.3) (0.3)

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

8

Page

170CT05 14:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT ECG5 NUMBER (%) OF SUBJECTS WITH ECG RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Follow-up

Category Test+Units	Overall P-Value *	DVS SR	 50 ma	DVS SR	100 mg	DVS SR	Treat	ment	200 ma		lac	 ebo	то	 TAL
1050,011105	ı varac	DVD OIL	30 mg	DVO DI	100 1119	DVO DI	100 1119	DVD DIC .	200 1119	-	±uc	.000	10	11111
TOTAL	0.880	2/ 15	(13.3)	2/ 16	(12.5)	4/ 20	(20.0)	2/ 23	(8.7)	1/	7	(14.3)	11/ 81	(13.6)
ECG	0.880	2/ 15	(13.3)	2/ 16	(12.5)	4/ 20	(20.0)	2/ 23	(8.7)	1/	7	(14.3)	11/ 81	(13.6)
OVERALL EVALUATION	0.385	1/ 15	(6.7)	2/ 16	(12.5)	4/ 20	(20.0)	1/ 23	(4.3)	0/	7		8/ 81	(9.9)
Not Normal	0.385	1/ 15	(6.7)	2/ 16	(12.5)	4/ 20	(20.0)	1/ 23	(4.3)	0/	7		8/ 81	(9.9)
RHYTHM	0.635	0/ 15		0/ 16		0/ 20		1/ 23	(4.3)	0/	7		1/ 81	(1.2)
Not Sinus	0.635	0/ 15		0/ 16		0/ 20		1/ 23	(4.3)	0/	7		1/81	(1.2)
PR INTRVL msec	0.371	0/ 15		1/ 16	(6.3)	3/ 20	(15.0)	1/ 23	(4.3)	0/	7		5/ 81	(6.2)
HIGH	0.371	0/ 15		1/ 16	(6.3)	3/ 20	(15.0)	1/ 23	(4.3)	0/	7		5/ 81	(6.2)
QTC INTRVL msec	0.156	1/ 15	(6.7)	0/ 16	(,	0/ 20	, , , ,	0/ 23	,,	1/	7	(14.3)	2/ 81	(2.5)
INCREASE	0.156	1/ 15	(6.7)	0/ 16		0/ 20		0/ 23		1/	7	(14.3)	2/ 81	(2.5)

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

9

Page

170CT05 14:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT ECG5 NUMBER (%) OF SUBJECTS WITH ECG RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Screening/baseline

Category Test+Units	Overall P-Value *	Trea Comparator 1	tment Comparator 2	Comparator		io Comparat		Pairwise P-Value *
TOTAL	0.328	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	23/148 (23/148 ((15.5) (15.5) (15.5) (15.5)	28/155 33/156 19/151 15/ 77	(18.1) (21.2) (12.6) (19.5)	0.645 0.237 0.508 0.459
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	28/155 (28/155 ((18.1) (18.1)	33/156 19/151	(21.2) (12.6)	0.568 0.206
		DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	33/156 (33/156 ((18.1) (21.2) (21.2)	15/ 77 19/151 15/ 77	(19.5) (12.6) (19.5)	0.858 0.049* 0.864
		DVS SR 200 mg	Placebo	19/151 ((12.6)	15/ 77	(19.5)	0.174
ECG	0.328	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	23/148 (23/148 ((15.5) (15.5) (15.5)	28/155 33/156 19/151	(18.1) (21.2) (12.6)	0.645 0.237 0.508
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	28/155 (28/155 ((15.5) (18.1) (18.1) (18.1)	15/ 77 33/156 19/151 15/ 77	(19.5) (21.2) (12.6) (19.5)	0.459 0.568 0.206 0.858
		DVS SR 150 mg	DVS SR 200 mg Placebo	33/156 (33/156 ((21.2) (21.2)	19/151 15/ 77	(12.6) (19.5)	0.049* 0.864
		DVS SR 200 mg	Placebo	19/151 ((12.6)	15/ 77	(19.5)	0.174
OVERALL EVALUATION	0.560	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	17/148 (17/148 (17/148 ((11.5) (11.5) (11.5) (11.5)	19/155 23/156 14/151 12/ 77	(12.3) (14.7) (9.3) (15.6)	0.861 0.498 0.573 0.406
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	19/155 ((12.3) (12.3) (12.3)	23/156 14/151 12/ 77	(14.7) (9.3) (15.6)	0.619 0.463 0.540
		DVS SR 150 mg	DVS SR 200 mg Placebo	23/156 ((14.7) (14.7)	14/151 12/ 77	(9.3) (15.6)	0.162 0.848
		DVS SR 200 mg	Placebo	14/151	(9.3)	12/ 77	(15.6)	0.187
Not Normal	0.560	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	17/148 (17/148 ((11.5) (11.5) (11.5) (11.5)	19/155 23/156 14/151 12/ 77	(12.3) (14.7) (9.3) (15.6)	0.861 0.498 0.573 0.406

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Overall P-Value: P-value for Chi-Square.
Pairwise P-Value: Fisher's Exact Test P-value (2-Tail).

Page 10

170CT05 14:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT ECG5 NUMBER (%) OF SUBJECTS WITH ECG RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Screening/baseline

Category Test+Units	Overall P-Value *		tment Comparator 2			Comparat		Pairwise P-Value *
Not Normal	0.560	DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	19/155 19/155 19/155 23/156	(12.3) (12.3) (12.3) (12.3) (14.7)	23/156 14/151 12/ 77 14/151	(14.7) (9.3) (15.6) (9.3)	0.619 0.463 0.540 0.162
		DVS SR 200 mg	Placebo Placebo	23/156 14/151	(14.7) (9.3)	12/ 77 12/ 77	(15.6) (15.6)	0.848 0.187
HEART RATE beats/min	0.487	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/148 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/155 0/156 0/151 0/ 77	(0.6)	1.000 0.498 1.000
DECREASE	0.487	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/148 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/155 0/156 0/151 0/ 77	(0.6)	1.000 0.498 1.000 1.000
RHYTHM	0.832	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	7/148 7/148 7/148 7/148	(4.7) (4.7) (4.7)	10/155 11/156 8/151 3/ 77	(6.5) (7.1) (5.3)	0.621 0.470 1.000 1.000
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	10/155 10/155 10/155 10/155	(4.7) (6.5) (6.5) (6.5)	11/156 8/151 3/ 77	(3.9) (7.1) (5.3) (3.9)	1.000 1.000 0.809 0.552
		DVS SR 150 mg	DVS SR 200 mg Placebo	11/156 11/156	(7.1) (7.1)	8/151 3/ 77	(5.3) (3.9)	0.638
		DVS SR 200 mg	Placebo	8/151	(5.3)	3/ 77	(3.9)	0.754
Not Sinus	0.832	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	7/148 7/148 7/148 7/148	(4.7) (4.7) (4.7) (4.7)	10/155 11/156 8/151 3/ 77	(6.5) (7.1) (5.3) (3.9)	0.621 0.470 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	10/155 10/155 10/155	(6.5) (6.5) (6.5)	11/156 8/151 3/ 77	(7.1) (5.3) (3.9)	1.000 0.809 0.552
		DVS SR 150 mg	DVS SR 200 mg Placebo	11/156 11/156	(7.1) (7.1)	8/151 3/ 77	(5.3) (3.9)	0.638 0.398

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

170CT05 14:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 11

REPORT ECG5 NUMBER (%) OF SUBJECTS WITH ECG RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Screening/baseline

Category Test+Units	Overall P-Value *		tment Comparator 2			Comparato		Pairwise P-Value *
Not Sinus	0.832	DVS SR 200 mg	Placebo	8/151	(5.3)	3/ 77	(3.9)	0.754
PR INTRVL msec	0.805	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	5/148 5/148 5/148 5/148	(3.4) (3.4) (3.4) (3.4)	6/155 7/155 5/149 5/ 77	(3.9) (4.5) (3.4) (6.5)	1.000 0.771 1.000 0.316
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	6/155 6/155	(3.9) (3.9)	7/155 5/149	(4.5) (3.4)	1.000 1.000
		DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	6/155 7/155 7/155	(3.9) (4.5) (4.5)	5/ 77 5/149 5/ 77	(6.5) (3.4) (6.5)	0.513 0.770 0.539
		DVS SR 200 mg	Placebo	5/149	(3.4)	5/ 77	(6.5)	0.315
HIGH	0.805	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	5/148 5/148 5/148 5/148	(3.4) (3.4) (3.4) (3.4)	6/155 7/155 5/149 5/ 77	(3.9) (4.5) (3.4) (6.5)	1.000 0.771 1.000 0.316
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	6/155 6/155 6/155	(3.9) (3.9) (3.9)	7/155 5/149 5/ 77	(4.5) (3.4) (6.5)	1.000 1.000 0.513
		DVS SR 150 mg	DVS SR 200 mg Placebo	7/155 7/155	(4.5) (4.5)	5/149 5/ 77	(3.4) (6.5)	0.770 0.539
		DVS SR 200 mg	Placebo	5/149	(3.4)	5/ 77	(6.5)	0.315
QRS INTRVL msec	0.352	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/148 0/148 0/148 0/148		1/155 2/156 1/151 2/ 77	(0.6) (1.3) (0.7) (2.6)	1.000 0.499 1.000 0.116
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	1/155 1/155 1/155	(0.6) (0.6)	2/156 1/151 2/ 77	(1.3) (0.7)	1.000 1.000 0.256
		DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	2/156 2/156	(0.6) (1.3) (1.3)	1/151 2/ 77	(2.6) (0.7) (2.6)	1.000 0.601
		DVS SR 200 mg	Placebo	1/151	(0.7)	2/ 77	(2.6)	0.264
HIGH	0.352	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg	0/148 0/148		1/155 2/156	(0.6) (1.3)	1.000 0.499
							/	

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

170CT05 14:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 Page 12

REPORT ECG5 NUMBER (%) OF SUBJECTS WITH ECG RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Screening/baseline

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Comparato		io Comparato		Pairwise P-Value *
HIGH	0.352	DVS SR 50 mg	DVS SR 200 mg Placebo	0/148 0/148		1/151 2/ 77	(0.7)	1.000
		DVS SR 100 mg	DVS SR 150 mg	1/155 1/155	(0.6) (0.6)	2/156 1/151	(1.3) (0.7)	1.000
		DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	1/155 2/156 2/156	(0.6) (1.3) (1.3)	2/ 77 1/151 2/ 77	(2.6) (0.7) (2.6)	0.256 1.000 0.601
		DVS SR 200 mg	Placebo	1/151	(0.7)	2/ 77	(2.6)	0.264
QT INTRVL msec	0.811	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	0/148 0/148 0/148		1/155 1/156 1/150	(0.6) (0.6) (0.7)	1.000 1.000 1.000
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	0/148 1/155 1/155 1/155	(0.6) (0.6) (0.6)	1/ 77 1/156 1/150 1/ 77	(1.3) (0.6) (0.7) (1.3)	0.342 1.000 1.000 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/156 1/156	(0.6) (0.6)	1/150 1/ 77	(0.7)	1.000
		DVS SR 200 mg	Placebo	1/150	(0.7)	1/ 77	(1.3)	1.000
HIGH	0.811	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	0/148 0/148 0/148		1/155 1/156 1/150	(0.6) (0.6) (0.7)	1.000 1.000 1.000
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg	0/148 1/155 1/155	(0.6) (0.6)	1/ 77 1/156 1/150	(1.3) (0.6) (0.7)	0.342 1.000 1.000
		DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	1/155 1/156 1/156	(0.6) (0.6) (0.6)	1/ 77 1/150 1/ 77	(1.3) (0.7) (1.3)	1.000 1.000 0.553
		DVS SR 200 mg	Placebo	1/150	(0.7)	1/ 77	(1.3)	1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square. Pairwise P-Value: Fisher's Exact Test P-value (2-Tail).

170CT05 14:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 13

REPORT ECG5 NUMBER (%) OF SUBJECTS WITH ECG RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 4

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Rat Comparator 1	Comparator 2	Pairwise P-Value *
TOTAL	0.042*	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0/ 1 0/ 1 1/ 1 (100) 1/ 1 (100) 1/ 1 (100) 1/ 3 (33.3) 1/ 3 (33.3)	1/ 1 (100) 1/ 3 (33.3) 1/ 3 (33.3) 0/ 9 0/ 2 0/ 9 0/ 2	1.000 1.000 1.000 0.100 0.333 0.250 1.000
ECG	0.042*	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	0/ 1 0/ 1 1/ 1 (100) 1/ 1 (100) 1/ 1 (100) 1/ 3 (33.3) 1/ 3 (33.3)	1/ 1 (100) 1/ 3 (33.3) 1/ 3 (33.3) 0/ 9 0/ 2 0/ 9 0/ 2	1.000 1.000 1.000 0.100 0.333 0.250 1.000
OVERALL EVALUATION	0.328	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 1 0/ 1 1/ 3 (33.3) 1/ 3 (33.3)	1/ 3 (33.3) 1/ 3 (33.3) 0/ 9 0/ 2	1.000 1.000 0.250 1.000
Not Normal	0.328	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 1 0/ 1 1/ 3 (33.3) 1/ 3 (33.3)	1/ 3 (33.3) 1/ 3 (33.3) 0/ 9 0/ 2	1.000 1.000 0.250 1.000
RHYTHM	0.003**	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 1 1/ 1 (100) 1/ 1 (100) 1/ 1 (100)	1/ 1 (100) 0/ 3 0/ 9 0/ 2	1.000 0.250 0.100 0.333
Not Sinus	0.003**	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/ 1 1/ 1 (100) 1/ 1 (100) 1/ 1 (100)	1/ 1 (100) 0/ 3 0/ 9 0/ 2	1.000 0.250 0.100 0.333

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 14

170CT05 14:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT ECG5 NUMBER (%) OF SUBJECTS WITH ECG RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 8

Category Test+Units	Overall P-Value *		atment Comparator 2	Comparator 1		Pairwise P-Value *
TOTAL	0.295	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg Placebo DVS SR 150 mg Placebo Placebo	0/ 6 0/ 6 1/ 5 (20.0) 1/ 5 (20.0) 0/ 6	1/ 5 (20.0) 1/ 3 (33.3) 0/ 6 1/ 3 (33.3) 1/ 3 (33.3)	0.455 0.333 0.455 1.000 0.333
ECG	0.295	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg Placebo DVS SR 150 mg Placebo Placebo	0/ 6 0/ 6 1/ 5 (20.0) 1/ 5 (20.0) 0/ 6	1/ 5 (20.0) 1/ 3 (33.3) 0/ 6 1/ 3 (33.3) 1/ 3 (33.3)	0.455 0.333 0.455 1.000 0.333
OVERALL EVALUATION	0.295	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg Placebo DVS SR 150 mg Placebo Placebo	0/ 6 0/ 6 1/ 5 (20.0) 1/ 5 (20.0) 0/ 6	1/ 5 (20.0) 1/ 3 (33.3) 0/ 6 1/ 3 (33.3) 1/ 3 (33.3)	0.455 0.333 0.455 1.000 0.333
Not Normal	0.295	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 100 mg Placebo DVS SR 150 mg Placebo Placebo	0/ 6 0/ 6 1/ 5 (20.0) 1/ 5 (20.0) 0/ 6	1/ 5 (20.0) 1/ 3 (33.3) 0/ 6 1/ 3 (33.3) 1/ 3 (33.3)	0.455 0.333 0.455 1.000 0.333
PR INTRVL msec	0.368	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg Placebo	0/ 6 1/ 5 (20.0) 1/ 5 (20.0)	1/ 5 (20.0) 0/ 6 0/ 3	0.455 0.455 1.000
HIGH	0.368	DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg Placebo	0/ 6 1/ 5 (20.0) 1/ 5 (20.0)	1/ 5 (20.0) 0/ 6 0/ 3	0.455 0.455 1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

170CT05 14:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 15

REPORT ECG5 NUMBER (%) OF SUBJECTS WITH ECG RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 12

Category Test+Units	Overall P-Value *	Trea Comparator 1	tment Comparator 2	Comparator 1		nparato		Pairwise P-Value *
TOTAL	0.065	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	16/119 (13 16/119 (13 16/119 (13 16/119 (13	3.4) 15 3.4) 9	0/119 6/100 0/ 95	(16.8) (15.0) (9.5) (26.2)	0.588 0.846 0.400 0.044*
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	20/119 (16 20/119 (16	5.8) 15 5.8) 9	/100 / 95	(15.0) (9.5)	0.853 0.159
		DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	20/119 (16 15/100 (15 15/100 (15	5.0) 9 5.0) 17	65 9/ 95 1/ 65	(26.2) (9.5) (26.2)	0.177 0.280 0.106
		DVS SR 200 mg	Placebo	9/ 95 (9	0.5) 17	/ 65	(26.2)	0.008**
ECG	0.065	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	16/119 (13 16/119 (13 16/119 (13	3.4) 15 3.4) 9	0/119 5/100 9/ 95	(16.8) (15.0) (9.5)	0.588 0.846 0.400
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	16/119 (13 20/119 (16 20/119 (16 20/119 (16	5.8) 15 5.8) 9	7/ 65 5/100 9/ 95 7/ 65	(26.2) (15.0) (9.5) (26.2)	0.044* 0.853 0.159 0.177
		DVS SR 150 mg	DVS SR 200 mg	15/100 (15		95	(9.5)	0.280
		DVS SR 200 mg	Placebo Placebo	15/100 (15 9/ 95 (9		7/ 65 7/ 65	(26.2) (26.2)	0.106 0.008**
OVERALL EVALUATION	0.163	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	11/119 (9 11/119 (9).2) 14).2) 7	3/119 1/100 1/ 95 2/ 65	(15.1) (14.0) (7.4) (18.5)	0.234 0.293 0.805 0.101
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	18/119 (15 18/119 (15 18/119 (15	14 1.1) 14	1/100 7/ 95 2/ 65	(14.0) (7.4) (18.5)	0.850 0.090 0.677
		DVS SR 150 mg	DVS SR 200 mg	14/100 (14	1.0) 7	/ 95	(7.4)	0.168
		DVS SR 200 mg	Placebo Placebo	14/100 (14 7/ 95 (7		2/ 65 2/ 65	(18.5) (18.5)	0.514 0.046*
Not Normal	0.163	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	11/119 (9 11/119 (9).2) 14).2) 7	3/119 1/100 1/ 95 2/ 65	(15.1) (14.0) (7.4) (18.5)	0.234 0.293 0.805 0.101

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 16

170CT05 14:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT ECG5 NUMBER (%) OF SUBJECTS WITH ECG RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 12

Category Test+Units	Overall P-Value *	Trea Comparator 1	tment Comparator 2	Comparat		io Comparat		Pairwise P-Value *
Not Normal	0.163	DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	18/119 18/119 18/119	(15.1) (15.1) (15.1)	14/100 7/ 95 12/ 65	(14.0) (7.4) (18.5)	0.850 0.090 0.677
		DVS SR 150 mg	DVS SR 200 mg Placebo	14/100 14/100	(14.0) (14.0)	7/ 95 12/ 65	(7.4) (18.5)	0.168 0.514
		DVS SR 200 mg	Placebo	7/ 95	(7.4)	12/ 65	(18.5)	0.046*
HEART RATE beats/min	0.156	DVS SR 50 mg DVS SR 100 mg	Placebo Placebo	0/117 0/119		1/ 65 1/ 65	(1.5) (1.5)	0.357 0.353
		DVS SR 150 mg DVS SR 200 mg	Placebo Placebo	0/100 0/ 95		1/ 65 1/ 65	(1.5) (1.5)	0.394 0.406
DECREASE	0.156	DVS SR 50 mg DVS SR 100 mg	Placebo Placebo	0/117 0/119		1/ 65 1/ 65	(1.5) (1.5)	0.357 0.353
		DVS SR 150 mg DVS SR 200 mg	Placebo Placebo	0/100 0/ 95		1/ 65 1/ 65	(1.5) (1.5)	0.394 0.406
RHYTHM	0.665	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg	4/119 4/119	(3.4) (3.4)	3/119 3/100	(2.5) (3.0)	1.000
			DVS SR 200 mg Placebo	4/119 4/119	(3.4)	2/ 95 4/ 65	(2.1)	0.695 0.456
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	3/119 3/119	(2.5) (2.5)	3/100 2/ 95	(3.0) (2.1)	1.000
		DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	3/119 3/100 3/100	(2.5) (3.0) (3.0)	4/ 65 2/ 95 4/ 65	(6.2) (2.1) (6.2)	0.246 1.000 0.435
		DVS SR 200 mg	Placebo	2/ 95	(2.1)	4/ 65	(6.2)	0.225
Not Sinus	0.665	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg	4/119 4/119	(3.4) (3.4)	3/119 3/100	(2.5) (3.0)	1.000
			DVS SR 200 mg Placebo	4/119 4/119	(3.4)	2/ 95 4/ 65	(2.1) (6.2)	0.695 0.456
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	3/119 3/119	(2.5) (2.5)	3/100 2/ 95	(3.0) (2.1)	1.000
		DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	3/119 3/100 3/100	(2.5) (3.0) (3.0)	4/ 65 2/ 95 4/ 65	(6.2) (2.1) (6.2)	0.246 1.000 0.435

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 17

170CT05 14:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT ECG5 NUMBER (%) OF SUBJECTS WITH ECG RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 12

Category Test+Units	Overall P-Value *	Trea Comparator 1	tment Comparator 2	Comparato		Comparato		Pairwise P-Value *
Not Sinus	0.665	DVS SR 200 mg	Placebo	2/ 95	(2.1)	4/ 65	(6.2)	0.225
PR INTRVL msec	0.393	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	3/117 3/117 3/117 3/117	(2.6) (2.6) (2.6) (2.6)	4/119 2/ 99 1/ 95 4/ 65	(3.4) (2.0) (1.1) (6.2)	1.000 1.000 0.630 0.250
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	4/119 4/119	(3.4) (3.4)	2/ 99 1/ 95	(2.0) (1.1)	0.691 0.385
		DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	4/119 2/ 99 2/ 99	(3.4) (2.0) (2.0)	4/ 65 1/ 95 4/ 65	(6.2) (1.1) (6.2)	0.456 1.000 0.215
		DVS SR 200 mg	Placebo	1/ 95	(1.1)	4/ 65	(6.2)	0.159
HIGH	0.393	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	3/117 3/117 3/117 3/117	(2.6) (2.6) (2.6) (2.6)	4/119 2/ 99 1/ 95 4/ 65	(3.4) (2.0) (1.1) (6.2)	1.000 1.000 0.630 0.250
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	4/119 4/119 4/119	(3.4) (3.4) (3.4)	2/ 99 1/ 95 4/ 65	(2.0) (1.1) (6.2)	0.691 0.385 0.456
		DVS SR 150 mg	DVS SR 200 mg Placebo	2/ 99 2/ 99	(2.0)	1/ 95 4/ 65	(1.1) (6.2)	1.000
		DVS SR 200 mg	Placebo	1/ 95	(1.1)	4/ 65	(6.2)	0.159
QRS INTRVL msec	0.825	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	0/117 0/117 0/117 0/117		1/119 1/100 1/ 95 1/ 65	(0.8) (1.0) (1.1) (1.5)	1.000 0.461 0.448 0.357
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	1/119 1/119 1/119	(0.8) (0.8)	1/100 1/ 95	(1.0) (1.1)	1.000
		DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	1/119 1/100 1/100	(0.8) (1.0) (1.0)	1/ 65 1/ 95 1/ 65	(1.5) (1.1) (1.5)	1.000 1.000 1.000
		DVS SR 200 mg	Placebo	1/ 95	(1.0)	1/ 65	(1.5)	1.000
HIGH	0.825	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg	0/117 0/117		1/119 1/100	(0.8) (1.0)	1.000 0.461

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 18

170CT05 14:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT ECG5 NUMBER (%) OF SUBJECTS WITH ECG RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 12

Category Test+Units	Overall P-Value *	Trea	tment Comparator 2	Comparato		io Comparato		Pairwise P-Value *
HIGH	0.825	DVS SR 50 mg DVS SR 100 mg	DVS SR 200 mg Placebo DVS SR 150 mg	0/117 0/117 1/119	(0.8)	1/ 95 1/ 65 1/100	(1.1) (1.5) (1.0)	0.448 0.357 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo DVS SR 200 mg Placebo	1/119 1/119 1/100 1/100	(0.8) (0.8) (1.0) (1.0)	1/ 95 1/ 65 1/ 95 1/ 65	(1.1) (1.5) (1.1) (1.5)	1.000 1.000 1.000 1.000
		DVS SR 200 mg	Placebo	1/ 95	(1.0)	1/ 65	(1.5)	1.000
QTC INTRVL msec	0.413	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/117 1/117 1/117 1/117	(0.9) (0.9) (0.9) (0.9)	0/119 0/100 0/ 95 1/ 65	(1.5)	0.496 1.000 1.000 1.000
		DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo	0/119 0/100 0/ 95		1/ 65 1/ 65 1/ 65	(1.5) (1.5) (1.5)	0.353 0.394 0.406
INCREASE	0.413	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Placebo Placebo Placebo	1/117 1/117 1/117 1/117 0/119 0/100 0/ 95	(0.9) (0.9) (0.9) (0.9)	0/119 0/100 0/ 95 1/ 65 1/ 65 1/ 65 1/ 65	(1.5) (1.5) (1.5) (1.5)	0.496 1.000 1.000 1.000 0.353 0.394 0.406
QT INTRVL msec	0.697	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg	1/117 1/117 1/117 1/117 1/119	(0.9) (0.9) (0.9) (0.9) (0.8)	1/119 0/100 0/ 95 0/ 65 0/100	(0.8)	1.000 1.000 1.000 1.000
			DVS SR 200 mg Placebo	1/119 1/119	(0.8) (0.8)	0/ 95 0/ 65		1.000
HIGH	0.697	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/117 1/117 1/117 1/117	(0.9) (0.9) (0.9) (0.9)	1/119 0/100 0/ 95 0/ 65	(0.8)	1.000 1.000 1.000 1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

170CT05 14:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 Page 19

REPORT ECG5 NUMBER (%) OF SUBJECTS WITH ECG RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 12

Category Test+Units	Overall P-Value *			Ra Comparator 1	tio Comparator 2	Pairwise P-Value *
HIGH	0.697	DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	1/119 (0.8) 1/119 (0.8) 1/119 (0.8)	0/100 0/ 95 0/ 65	1.000

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square.

Pairwise P-Value: Fisher's Exact Test P-value (2-Tail).

Page 20

170CT05 14:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT ECG5 NUMBER (%) OF SUBJECTS WITH ECG RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 26

Category Test+Units	Overall P-Value *	Trea Comparator 1	tment Comparator 2	Comparator 1	Ratio Comparator 2	Pairwise P-Value *
TOTAL	0.405	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo	0/ 1 0/ 3 0/ 1	1/ 2 (50.0) 1/ 2 (50.0) 1/ 2 (50.0)	1.000 0.400 1.000
ECG	0.405	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo	0/ 1 0/ 3 0/ 1	1/ 2 (50.0) 1/ 2 (50.0) 1/ 2 (50.0)	1.000 0.400 1.000
OVERALL EVALUATION	0.405	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo	0/ 1 0/ 3 0/ 1	1/ 2 (50.0) 1/ 2 (50.0) 1/ 2 (50.0)	1.000 0.400 1.000
Not Normal	0.405	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo	0/ 1 0/ 3 0/ 1	1/ 2 (50.0) 1/ 2 (50.0) 1/ 2 (50.0)	1.000 0.400 1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square. Pairwise P-Value: Fisher's Exact Test P-value (2-Tail).

170CT05 14:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 Page 21

REPORT ECG5 NUMBER (%) OF SUBJECTS WITH ECG RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 39

Category Test+Units	Overall P-Value *		tment Comparator 2		Comparator 2	Pairwise P-Value *
TOTAL	0.171	DVS SR 100 mg	DVS SR 150 mg	1/ 2 (50.0)	0/ 3	0.400
ECG	0.171	DVS SR 100 mg	DVS SR 150 mg	1/ 2 (50.0)	0/ 3	0.400
OVERALL EVALUATION	0.171	DVS SR 100 mg	DVS SR 150 mg	1/ 2 (50.0)	0/ 3	0.400
Not Normal	0.171	DVS SR 100 mg	DVS SR 150 mg	1/ 2 (50.0)	0/ 3	0.400

* - Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square. Pairwise P-Value: Fisher's Exact Test P-value (2-Tail).

170CT05 14:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 22

REPORT ECG5 NUMBER (%) OF SUBJECTS WITH ECG RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 52

Category Test+Units	Overall P-Value *	Trea Comparator 1	tment Comparator 2	Ra Comparator 1	tio Comparator 2	Pairwise P-Value *
TOTAL	0.791	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	14/82 (17.1) 14/82 (17.1) 14/82 (17.1) 14/82 (17.1)	10/82 (12.2) 10/68 (14.7) 6/60 (10.0) 6/43 (14.0)	0.508 0.824 0.329 0.799
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	10/ 82 (12.2) 10/ 82 (12.2)	10/ 68 (14.7) 6/ 60 (10.0)	0.810 0.792
		DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	10/ 82 (12.2) 10/ 68 (14.7) 10/ 68 (14.7)	6/ 43 (14.0) 6/ 60 (10.0) 6/ 43 (14.0)	0.784 0.593 1.000
		DVS SR 200 mg	Placebo	6/ 60 (10.0)	6/ 43 (14.0)	0.550
ECG	0.791	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	14/ 82 (17.1) 14/ 82 (17.1) 14/ 82 (17.1)	10/ 82 (12.2) 10/ 68 (14.7) 6/ 60 (10.0)	0.508 0.824 0.329
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	14/ 82 (17.1) 10/ 82 (12.2) 10/ 82 (12.2) 10/ 82 (12.2)	6/ 43 (14.0) 10/ 68 (14.7) 6/ 60 (10.0) 6/ 43 (14.0)	0.799 0.810 0.792 0.784
		DVS SR 150 mg	DVS SR 200 mg	10/ 68 (14.7)	6/ 60 (10.0)	0.593
		DVS SR 200 mg	Placebo Placebo	10/ 68 (14.7) 6/ 60 (10.0)	6/ 43 (14.0) 6/ 43 (14.0)	1.000 0.550
OVERALL EVALUATION	0.713	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	10/82 (12.2) 10/82 (12.2) 10/82 (12.2) 10/82 (12.2)	8/82 (9.8) 9/68 (13.2) 4/60 (6.7) 6/43 (14.0)	0.803 1.000 0.395 0.784
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	8/ 82 (9.8) 8/ 82 (9.8) 8/ 82 (9.8)	9/ 68 (13.2) 4/ 60 (6.7) 6/ 43 (14.0)	0.607 0.560 0.554
		DVS SR 150 mg	DVS SR 200 mg	9/ 68 (13.2)	4/60 (6.7)	0.254
		DVS SR 200 mg	Placebo Placebo	9/ 68 (13.2) 4/ 60 (6.7)	6/ 43 (14.0) 6/ 43 (14.0)	1.000 0.313
Not Normal	0.713	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	10/82 (12.2) 10/82 (12.2) 10/82 (12.2) 10/82 (12.2)	8/82 (9.8) 9/68 (13.2) 4/60 (6.7) 6/43 (14.0)	0.803 1.000 0.395 0.784

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

170CT05 14:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 23

REPORT ECG5 NUMBER (%) OF SUBJECTS WITH ECG RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 52

Category Test+Units	Overall P-Value *		tment Comparator 2	Ra Comparator 1	tio Comparator 2	Pairwise P-Value *
Not Normal	0.713	DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	8/ 82 (9.8) 8/ 82 (9.8) 8/ 82 (9.8)	4/ 60 (6.7)	0.607 0.560 0.554
		DVS SR 150 mg	Placebo DVS SR 200 mg	9/ 68 (13.2)	4/60 (6.7)	0.254
		DVS SR 200 mg	Placebo Placebo	9/ 68 (13.2) 4/ 60 (6.7)		1.000 0.313
RHYTHM	0.877	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/82 (2.4) 2/82 (2.4) 2/82 (2.4) 2/82 (2.4)	1/ 68 (1.5) 1/ 60 (1.7)	1.000 1.000 1.000 0.545
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/ 82 (1.2) 1/ 82 (1.2) 1/ 82 (1.2)	1/ 68 (1.5) 1/ 60 (1.7)	1.000 1.000 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/ 68 (1.5) 1/ 68 (1.5)	1/ 60 (1.7)	1.000
		DVS SR 200 mg	Placebo	1/ 60 (1.7)		1.000
Not Sinus	0.877	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/ 82 (2.4) 2/ 82 (2.4) 2/ 82 (2.4) 2/ 82 (2.4)	1/ 68 (1.5) 1/ 60 (1.7)	1.000 1.000 1.000 0.545
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/ 82 (1.2) 1/ 82 (1.2) 1/ 82 (1.2)	1/ 68 (1.5) 1/ 60 (1.7)	1.000 1.000 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/ 68 (1.5) 1/ 68 (1.5)	1/ 60 (1.7)	1.000
		DVS SR 200 mg	Placebo	1/ 60 (1.7)		1.000
PR INTRVL msec	0.486	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	3/ 82 (3.7) 3/ 82 (3.7) 3/ 82 (3.7) 3/ 82 (3.7)	1/ 67 (1.5) 1/ 60 (1.7)	1.000 0.628 0.638 0.413
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	2/ 82 (2.4) 2/ 82 (2.4) 2/ 82 (2.4)	1/ 67 (1.5) 1/ 60 (1.7) 3/ 43 (7.0)	1.000 1.000 0.338
		DVS SR 150 mg	DVS SR 200 mg	1/ 67 (1.5)	1/ 60 (1.7)	1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

170CT05 14:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 24

REPORT ECG5 NUMBER (%) OF SUBJECTS WITH ECG RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 52

Category Test+Units	Overall P-Value *		tment Comparator 2			tio Comparator 2		Pairwise P-Value *
PR INTRVL msec	0.486	DVS SR 150 mg DVS SR 200 mg	Placebo Placebo	1/ 67 1/ 60	(1.5) (1.7)	3/ 43 3/ 43	(7.0) (7.0)	0.297
HIGH	0.486	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	3/ 82 3/ 82 3/ 82	(3.7) (3.7) (3.7)	2/ 82 1/ 67 1/ 60	(2.4) (1.5) (1.7)	1.000 0.628 0.638
		DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	3/ 82 2/ 82 2/ 82 2/ 82	(3.7) (2.4) (2.4) (2.4)	3/ 43 1/ 67 1/ 60 3/ 43	(7.0) (1.5) (1.7) (7.0)	0.413 1.000 1.000 0.338
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/ 67 1/ 67	(1.5) (1.5)	1/ 60 3/ 43	(1.7) (7.0)	1.000
		DVS SR 200 mg	Placebo	1/ 60	(1.7)	3/ 43	(7.0)	0.306
QRS INTRVL msec	0.623	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg Placebo	0/ 82 0/ 82 0/ 82		1/ 82 1/ 68 1/ 43	(1.2) (1.5) (2.3)	1.000 0.453 0.344
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	1/ 82 1/ 82	(1.2) (1.2)	1/ 68 0/ 60	(1.5)	1.000
		DVS SR 150 mg	Placebo DVS SR 200 mg	1/ 82 1/ 68	(1.2) (1.5)	1/ 43 0/ 60	(2.3)	1.000 1.000
		DVS SR 200 mg	Placebo Placebo	1/ 68 0/ 60	(1.5)	1/ 43 1/ 43	(2.3) (2.3)	1.000 0.417
HIGH	0.623	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg Placebo	0/ 82 0/ 82 0/ 82		1/ 82 1/ 68 1/ 43	(1.2) (1.5) (2.3)	1.000 0.453 0.344
		DVS SR 100 mg	DVS SR 150 mg	1/ 82 1/ 82	(1.2) (1.2)	1/ 68 0/ 60	(1.5)	1.000
		DVS SR 150 mg	Placebo DVS SR 200 mg	1/ 82 1/ 68	(1.2) (1.5)	1/ 43 0/ 60	(2.3)	1.000 1.000
		DVS SR 200 mg	Placebo Placebo	1/ 68 0/ 60	(1.5)	1/ 43 1/ 43	(2.3) (2.3)	1.000 0.417
QTC INTRVL msec	0.877	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	2/ 82 2/ 82 2/ 82	(2.4) (2.4) (2.4)	1/ 82 1/ 68 1/ 60	(1.2) (1.5) (1.7)	1.000 1.000 1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

170CT05 14:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 Page 25

REPORT ECG5 NUMBER (%) OF SUBJECTS WITH ECG RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Week 52

Category Test+Units			tment Comparator 2				tio Comparator 2	
QTC INTRVL msec	0.877	DVS SR 50 mg DVS SR 100 mg	Placebo DVS SR 150 mg DVS SR 200 mg Placebo	2/ 82 1/ 82 1/ 82 1/ 82	(2.4) (1.2) (1.2) (1.2)	0/ 43 1/ 68 1/ 60 0/ 43	(1.5) (1.7)	0.545 1.000 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/ 68 1/ 68	(1.5) (1.5)	1/ 60 0/ 43	(1.7)	1.000
		DVS SR 200 mg	Placebo	1/ 60	(1.7)	0/ 43		1.000
INCREASE	0.877	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/ 82 2/ 82 2/ 82 2/ 82	(2.4) (2.4) (2.4) (2.4)	1/ 82 1/ 68 1/ 60 0/ 43	(1.2) (1.5) (1.7)	1.000 1.000 1.000 0.545
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	1/ 82 1/ 82 1/ 82	(1.2) (1.2) (1.2)	1/ 68 1/ 60 0/ 43	(1.5) (1.7)	1.000 1.000 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	1/ 68 1/ 68	(1.5) (1.5)	1/ 60 0/ 43	(1.7)	1.000
		DVS SR 200 mg	Placebo	1/ 60	(1.7)	0/ 43		1.000
QTCF INTRVL msec	0.542	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/ 82 1/ 82 1/ 82 1/ 82	(1.2) (1.2) (1.2) (1.2)	0/ 82 0/ 68 0/ 60 0/ 43		1.000 1.000 1.000 1.000
INCREASE	0.542	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/ 82 1/ 82 1/ 82 1/ 82	(1.2) (1.2) (1.2) (1.2)	0/ 82 0/ 68 0/ 60 0/ 43		1.000 1.000 1.000 1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square. Pairwise P-Value: Fisher's Exact Test P-value (2-Tail).

170CT05 14:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page 26

REPORT ECG5 NUMBER (%) OF SUBJECTS WITH ECG RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Follow-up

Category Test+Units	Overall P-Value *	Trea Comparator 1	tment Comparator 2	Rat Comparator 1	Comparator 2	Pairwise P-Value *
TOTAL	0.880	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/ 15 (13.3) 2/ 15 (13.3) 2/ 15 (13.3) 2/ 15 (13.3)	2/ 16 (12.5) 4/ 20 (20.0) 2/ 23 (8.7) 1/ 7 (14.3)	1.000 0.680 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	2/ 16 (12.5) 2/ 16 (12.5)	4/ 20 (20.0) 2/ 23 (8.7)	0.672 1.000 1.000
		DVS SR 150 mg	Placebo DVS SR 200 mg Placebo	2/ 16 (12.5) 4/ 20 (20.0) 4/ 20 (20.0)	2/ 23 (8.7) 1/ 7 (14.3)	0.393 1.000
		DVS SR 200 mg	Placebo	2/ 23 (8.7)	1/ 7 (14.3)	1.000
ECG	0.880	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	2/ 15 (13.3) 2/ 15 (13.3) 2/ 15 (13.3) 2/ 15 (13.3)	2/ 16 (12.5) 4/ 20 (20.0) 2/ 23 (8.7) 1/ 7 (14.3)	1.000 0.680 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	2/ 15 (13.3) 2/ 16 (12.5) 2/ 16 (12.5) 2/ 16 (12.5)	1/ / (14.3) 4/ 20 (20.0) 2/ 23 (8.7) 1/ 7 (14.3)	1.000 0.672 1.000 1.000
		DVS SR 150 mg	DVS SR 200 mg	4/ 20 (20.0)	2/ 23 (8.7)	0.393
		DVS SR 200 mg	Placebo Placebo	4/ 20 (20.0) 2/ 23 (8.7)	1/ 7 (14.3) 1/ 7 (14.3)	1.000 1.000
OVERALL EVALUATION	0.385	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/ 15 (6.7) 1/ 15 (6.7) 1/ 15 (6.7) 1/ 15 (6.7)	2/ 16 (12.5) 4/ 20 (20.0) 1/ 23 (4.3) 0/ 7	1.000 0.365 1.000 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	2/ 16 (12.5) 2/ 16 (12.5) 2/ 16 (12.5)	4/ 20 (20.0) 1/ 23 (4.3) 0/ 7	0.672 0.557 1.000
		DVS SR 150 mg	DVS SR 200 mg	4/ 20 (20.0)	1/ 23 (4.3)	0.167
		DVS SR 200 mg	Placebo Placebo	4/ 20 (20.0) 1/ 23 (4.3)	0/ 7 0/ 7	0.545 1.000
Not Normal	0.385	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/ 15 (6.7) 1/ 15 (6.7) 1/ 15 (6.7) 1/ 15 (6.7)	2/ 16 (12.5) 4/ 20 (20.0) 1/ 23 (4.3) 0/ 7	1.000 0.365 1.000 1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 27

170CT05 14:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT ECG5 NUMBER (%) OF SUBJECTS WITH ECG RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Follow-up

Category Test+Units	Overall P-Value *	Trea Comparator 1	tment 2	Rat Comparator 1	Comparator 2	Pairwise P-Value *
Not Normal	0.385	DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo	2/ 16 (12.5) 2/ 16 (12.5) 2/ 16 (12.5)	4/ 20 (20.0) 1/ 23 (4.3) 0/ 7	0.672 0.557 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	4/ 20 (20.0) 4/ 20 (20.0)	1/ 23 (4.3) 0/ 7	0.167
		DVS SR 200 mg	Placebo	1/ 23 (4.3)	0/ 7	1.000
RHYTHM	0.635	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/ 15 0/ 16 0/ 20 1/ 23 (4.3)	1/ 23 (4.3) 1/ 23 (4.3) 1/ 23 (4.3) 0/ 7	1.000 1.000 1.000 1.000
Not Sinus	0.635	DVS SR 50 mg DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	DVS SR 200 mg DVS SR 200 mg DVS SR 200 mg Placebo	0/ 15 0/ 16 0/ 20 1/ 23 (4.3)	1/ 23 (4.3) 1/ 23 (4.3) 1/ 23 (4.3) 0/ 7	1.000 1.000 1.000 1.000
PR INTRVL msec	0.371	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	0/ 15 0/ 15 0/ 15	1/ 16 (6.3) 3/ 20 (15.0) 1/ 23 (4.3)	1.000 0.244 1.000
		DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg	1/ 16 (6.3) 1/ 16 (6.3)	3/ 20 (15.0) 1/ 23 (4.3)	0.613
		DVS SR 150 mg	Placebo DVS SR 200 mg	1/ 16 (6.3) 3/ 20 (15.0)	0/ 7 1/ 23 (4.3)	1.000
		DVS SR 200 mg	Placebo Placebo	3/ 20 (15.0) 1/ 23 (4.3)	0/ 7 0/ 7	0.545 1.000
HIGH	0.371	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	0/ 15 0/ 15 0/ 15	1/ 16 (6.3) 3/ 20 (15.0) 1/ 23 (4.3)	1.000 0.244 1.000
		DVS SR 100 mg	DVS SR 200 mg DVS SR 200 mg Placebo	1/ 16 (6.3) 1/ 16 (6.3) 1/ 16 (6.3)	3/ 20 (15.0) 1/ 23 (4.3) 0/ 7	0.613 1.000 1.000
		DVS SR 150 mg	DVS SR 200 mg Placebo	3/ 20 (15.0) 3/ 20 (15.0)	1/ 23 (4.3) 0/ 7	0.323
		DVS SR 200 mg	Placebo	1/ 23 (4.3)	0/ 7	1.000

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively.

Page 28

170CT05 14:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

REPORT ECG5 NUMBER (%) OF SUBJECTS WITH ECG RESULTS OF POTENTIAL CLINICAL IMPORTANCE / NO. TESTED

Data Analysis Interval: Follow-up

Category	Overall		tment		Ratio		
Test+Units	P-Value *	Comparator 1	Comparator 2	Comparator 1	Comparator 2	P-Value *	
QTC INTRVL msec	0.156	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	1/ 15 (6. 1/ 15 (6. 1/ 15 (6. 1/ 15 (6.	7) 0/20 7) 0/23	0.484 0.429 0.395 1.000	
		DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo Placebo	0/ 16 0/ 20 0/ 23	7) 1/ 7 (14.3) 1/ 7 (14.3) 1/ 7 (14.3) 1/ 7 (14.3)	0.304 0.259 0.233	
INCREASE	0.156	DVS SR 50 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo	1/ 15 (6. 1/ 15 (6. 1/ 15 (6. 1/ 15 (6.	7) 0/20 7) 0/23	0.484 0.429 0.395 1.000	
		DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg	Placebo Placebo Placebo	0/ 16 0/ 20 0/ 23	1/ 7 (14.3) 1/ 7 (14.3) 1/ 7 (14.3)	0.304 0.259 0.233	

^{* -} Statistical Significance at the .05, .01, .001 Levels is Denoted by *, **, *** Respectively. Overall P-Value: P-value for Chi-Square. Pairwise P-Value: Fisher's Exact Test P-value (2-Tail).

DVS SR CSR-60178 Protocol 3151A2-315-US

ST 10-14: Descriptive Statistics and Analysis Within and Between Treatment Groups for ECG Results

04NOV05 15:44 REPORT ECG3

CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

Page

1

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR ECG/EKG

TEST: HEART RATE, 12-Lead (beats/min) / PART 1: WITHIN TREATMENT									
TREATMENT		OBSERVED		BASELI	NE	CHANGE		ADJUSTED	[2]
Data Analysis Interval [1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 50 mg	148			63.57	9.73				
Screening/baseline	148	63.57	9.73	63.57	9.73				
Week 8	6	62.17	5.49	57.50	5.99	4.67	8.24	0.07	3.88
Week 12	116	63.47	9.18	63.61	9.74	-0.15	7.38	-0.07	0.61
Week 52	82	64.12	8.41	62.39	8.32	1.73*	7.07	1.25	0.78
Final on-therapy	123	64.11	8.61	63.30	9.63	0.80	7.39	0.79	0.64
Follow-up	15	65.80	10.07	61.13	8.69	4.67	10.38	3.86	2.24
DVS SR 100 mg	155			63.28	9.38				
Screening/baseline	155	63.28	9.38	63.28	9.38				
Week 4	1	47.00		45.00		2.00		0.90	8.45
Week 8	5	71.00	7.91	67.20	7.76	3.80	11.63	8.80	4.24
Week 12	119	64.46	8.14	62.94	9.29	1.52*	8.35	1.31*	0.60
Week 26	1	61.00		60.00		1.00		1.43	21.05
Week 39	2	84.00	11.31	66.00	8.49	18.00	2.83	18.00	6.29
Week 52	82	66.32	8.06	63.83	9.80	2.49**	8.39	2.70***	0.78
Final on-therapy	125	66.14	8.91	62.97	9.35	3.17***	8.14	3.01***	0.63
Follow-up	16	70.94	8.49	62.31	7.76	8.63**	8.95	8.15***	2.16
DVS SR 150 mg	156			63.35	9.59				
Screening/baseline	156	63.35	9.59	63.35	9.59				
Week 4	2	68.50	12.02	65.00	2.83	3.50	9.19	3.63	4.83
Week 8	6	69.83	11.34	64.00	8.02	5.83	14.25	7.66	3.63
Week 12	100	66.55	8.76	63.16	9.82	3.39***	7.51	3.28***	0.66
Week 26	3	72.33	15.28	55.00	6.08	17.33	14.84	16.14	14.93
Week 39	3	77.00	18.73	66.00	8.89	11.00	11.53	11.00	5.14
Week 52	68	68.01	8.92	63.96	9.25	4.06***	9.07	4.33***	0.85
Final on-therapy	109	68.17	9.73	63.20	9.57	4.96***	8.68	4.90***	0.68
Follow-up	20	71.95	12.52	67.10	10.28	4.85*	10.04	5.68**	1.95
DVS SR 200 mg	151			65.05	9.47				
Screening/baseline	151	65.05	9.47	65.05	9.47				
Week 4	9	65.89	9.27	63.22	6.74	2.67	6.18	2.69	2.26
Week 12	95	67.13	8.28	64.75	9.93	2.38**	7.93	2.93***	0.68
Week 26	1	61.00		63.00		-2.00		-0.59	23.30
Week 52	60	68.18	9.04	63.97	10.30	4.22***	8.24	4.50***	0.91
Final on-therapy	103	67.71	8.57	64.53	9.70	3.17***	8.09	3.68***	0.70

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.
[2] - ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

ŠTĀTISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:44 REPORT ECG3

Week 8

Week 12

Week 26

Week 52

Follow-up

Final on-therapy

CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

TEST: HEART RATE, 12-Lead (beats/min) / PART 1: WITHIN TREATMENT

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR ECG/EKG

59.33

62.49

64.00

62.77

62.54

64.29

8.29

8.03

8.27

12.74

TREATMENT OBSERVED BASELINE CHANGE ADJUSTED [2] Data Analysis Interval [1] [N] MEAN STD STD MEAN STD STDERR DVS SR 200 mg (cont.) 11.01 Follow-up 68.13 64.48 10.80 3.65* 6.49 3.77* 1.79 77 Placebo 62.82 8.13 62.82 72.50 Screening/baseline 77 8.13 62.82 8.13 Week 4 9.19 68.00 14.14 4.50 4.95 4.82 5.01 7.57 3.46

4.16

8.17

8.71

8.10

6.29

5.00

-0.86

-3.00

2.07

0.99

4.29

2.21

-1.26

-1.27

1.77

0.64

4.35

6.93

9.35

8.30

9.18

Page

5.15

0.82

24.48

1.07

0.84

3.25

2

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

3

65

43

71

64.33

61.63

61.00

64.84

63.52

68.57

CONFIDENTIAL 1225 Wyeth

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT ECG3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR ECG/EKG

Page

3

OVER					
Data Analysis Interval [1] P-VA	ALL TREATMENT LUE Comparator 1	COMPARED Comparator 2	DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 4 0.97	DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	-1.79 -3.92 0.94	8.81 10.55 5.32	0.791 0.843 0.719 0.863 0.866 0.706
Week 8 0.46	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg Placebo DVS SR 150 mg Placebo Placebo	-7.60 -2.15 1.13	5.47 6.24 5.42	0.175 0.185 0.736 0.837 0.354 0.407
Week 12 <0.00	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo Placebo	-1.96 -1.62 2.57 0.34 4.53	0.90 0.91 1.02 0.89 0.91 1.02 0.94 1.05	0.108 <0.001*** 0.001** 0.245 0.029* 0.075 0.012* 0.718 <0.001*** <0.001***
Week 26 0.92	DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	2.03 2.70 16.74	26.90 30.31 30.97 30.85 32.42 29.52	0.681 0.957 0.945 0.683 0.686 0.985
Week 39 0.48	0 DVS SR 100 mg	DVS SR 150 mg	7.00	8.13	0.480
Week 52 0.02	2* DVS SR 50 mg	DVS SR 100 mg	-1.45	1.10	0.187

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES. ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.

COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY). STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

4

DVS SR Protocol 3151A2-315-US CSR-60178

04NOV05 15:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT ECG3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR ECG/EKG

Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	
Week 52 (cont.)	0.022*	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-3.09 -3.25 -0.52 -1.63 -1.80 0.93 -0.16 2.56 2.73	1.15 1.20 1.32 1.15 1.19 1.32 1.24 1.37	0.008** 0.007** 0.694 0.158 0.134 0.482 0.896 0.062 0.053
Final on-therapy	<0.001***	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg	-2.22 -4.12 -2.89 0.14 -1.89 -0.67 2.37 1.22 4.26 3.04	0.94 1.05 0.97	0.014* <0.001*** 0.002** 0.891 0.041* 0.474 0.024* 0.209 <0.001*** 0.006**
Follow-up	0.560	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-4.28 -1.82 0.10 -0.48 2.46 4.38 3.80 1.92 1.34 -0.58	3.09 3.00 2.88 3.95 2.93 2.81 3.90 2.64 3.79	0.171 0.547 0.973 0.903 0.403 0.123 0.334 0.471 0.726 0.876

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES. ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.

COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY). STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

5

04NOV05 15:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT ECG3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR ECG/EKG

TEST: RR INTRVL, 12-Lead (msec) / PART 1: WITHIN TREATMENT CHANGE TREATMENT OBSERVED BASELINE ADJUSTED [2] STD MEAN Data Analysis Interval [1] [N] MEAN STD MEAN STDERR DVS SR 50 mg 966.1 141.4 148 141.4 Screening/baseline 966.1 966.1 141.4 6 971.0 87.3 1053.3 107.3 -82.3 139.8 -15.6 49.2 135.0 123.2 Week 12 116 966.1 965.0 979.5 138.3 1.2 107.5 -0.2 9.0 Week 52 -28.1* -22.2* 82 951.4 130.1 100.5 10.6 123 121.8 Final on-therapy 952.3 969.3 137.4 102.2 -16.8 8.9 Follow-up 15 929.4 1000.7 136.3 159.6 DVS SR 100 mg 155 971.8 149.0 Screening/baseline 155 971.8 149.0 971.8 149.0 1 5 Week 4 1268.0 1337.0 -69.0 -9.6 130.3 Week 8 854.4 96.1 906.4 100.4 -52.0 145.1 -119.5* 53.3 119 945.9 122.0 977.6 -31.7** -27.5** Week 12 150.5 132.1 8.9 1 -14.0 Week 26 981.0 995.0 -40.4 248.4 96.2 121.6 Week 39 719.0 922.0 -203.0 25.5 -203.2 -50.3*** 82 113.3 967.4 157.1 -49.9** 134.3 Week 52 917.5 10.6 125 -53.8*** Final on-therapy 923.9 130.1 977.6 152.0 126.4 -49.8*** 8.8 -123.4** -113.4*** Follow-up 16 981.0 137.5 129.4 28.2 147.9 DVS SR 150 mg 156 969.0 156 969.0 147.9 969.0 147.9 Screening/baseline 893.0 159.8 925.5 36.1 -32.5 123.7 -40.5 6 876.7 135.5 949.5 -72.8 173.0 -100.9* Week 8 116.8 46.0 122.8 971.9 -54.0*** -52.3*** Week 12 100 917.9 149.2 109.8 9.7 Week 26 853.0 174.6 1095.0 130.1 -242.0 203.4 -186.3 167.6 805.3 108.6 Week 39 180.5 918.7 116.1 -113.3 -113.2 63.0 -65.2*** 897.5 118.4 133.7 -59.3*** 125.4 Week 52 68 956.8 11.7 -72.0*** -71.4*** Final on-therapy 970.2 109 898.2 127.0 145.3 122.7 9.4 -77.2** Follow-up 20 857.4 149.1 915.9 146.1 -58.5 136.4 25.4 141.5 DVS SR 200 mg 151 942.9 942.9 Screening/baseline 151 141.5 942.9 141.5 927.3 -34.1 Week 4 116.0 961.4 94.8 78.4 -36.2 29.3 95 -40.8*** -48.9*** Week 12 908.4 117.2 949.2 150.7 112.9 10.0 40.0 -21.8 Week 26 992.0 952.0 264.3 -66.6*** -69.4*** Week 52 60 896.2 124.0 962.8 161.9 114.8 12.4 103 -49.7*** -57.6*** Final on-therapy 901.8 118.5 951.5 146.7 113.9 9.7

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.
THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:44 REPORT ECG3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR ECG/EKG

Page

6

TEST: RR INTRVL, 12-Lead (msec) / PART 1: WITHIN TREATMENT TREATMENT OBSERVED BASELINE ADJUSTED [2] Data Analysis Interval [1] [N] MEAN STD STD MEAN MEAN STDERR DVS SR 200 mg (cont.) Follow-up 903.0 150.2 956.7 163.8 -53.7* 102.7 -54.5* 23.4 77 Placebo 971.8 124.7 124.7 Screening/baseline 77 971.8 124.7 971.8 900.0 -68.0 -80.2 Week 4 832.0 100.4 183.8 83.4 64.8 23.5 Week 8 938.7 97.8 1018.7 75.3 -80.0* -44.9 64.9 Week 12 12.0 65 990.8 139.9 977.3 127.1 13.6 108.3 17.6 Week 26 983.0 931.0 52.0 -27.0 276.1 937.7 134.5 Week 52 43 111.0 973.9 132.2 -36.1 -33.2* 14.7 959.4 -13.4 Final on-therapy 71 129.5 976.2 125.3 -16.7 128.8 11.7 Follow-up 898.3 151.1 943.1 93.4 -44.9 101.3 -51.6 42.5

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

CONFIDENTIAL 1229 Wyeth

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

7

04NOV05 15:44 REPORT ECG3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR ECG/EKG

Data Analysis Interval [1]	TE
DVS SR 100 mg DVS SR 200 mg 26.6 136.0 0.849	Data Analysis Interval [1]
DVS SR 50 mg DVS SR 150 mg 85.4 69.7 0.239	Week 4
DVS SR 50 mg DVS SR 150 mg 52.1 13.2 <0.001***, DVS SR 50 mg DVS SR 200 mg 48.8 13.4 <0.001***, DVS SR 50 mg DVS SR 200 mg 48.8 13.4 <0.001***, DVS SR 50 mg Placebo -17.7 15.0 0.238 DVS SR 100 mg DVS SR 150 mg 24.7 13.2 0.061 DVS SR 100 mg DVS SR 200 mg 21.4 13.4 0.110 DVS SR 100 mg Placebo -45.1 15.0 0.003**	Week 8
DVS SR 150 mg DVS SR 200 mg -3.3 13.9 0.811 DVS SR 150 mg Placebo -69.9 15.5 <0.001*** DVS SR 200 mg Placebo -66.5 15.6 <0.001***	Week 12
Week 26 0.941 DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 200	Week 26
Week 39 0.462 DVS SR 100 mg DVS SR 150 mg -90.0 99.6 0.462	Week 39
Week 52 0.018* DVS SR 50 mg DVS SR 100 mg 28.0 15.0 0.063	Week 52

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES. ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.

COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY). STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:44 REPORT ECG3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR ECG/EKG

Page

8

TES	T: RR INTRV	L, 12-Lead (mse	c) / PART 2: BE	TWEEN TREATM	ENTS	
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1			STDERR OF DIFF. BET. ADJ. MEANS	
Week 52 (cont.)	0.018*	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg	DVS SR 200 mg Placebo	43.0 47.2 11.0 15.0 19.1 -17.1 4.2 -32.0 -36.2	15.8 16.3 18.1 15.8 16.3 18.1 17.0 18.7	0.007** 0.004** 0.544* 0.344 0.242 0.346 0.807 0.088
Final on-therapy	<0.001***	DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 200 mg	33.0 54.7 40.9 -3.3 21.6 7.9 -36.4 -13.8 -58.0 -44.2	12.5 13.0 13.2 14.7 12.9 13.1 14.7 13.6 15.0	0.009** <0.001*** 0.002** 0.820 0.095 0.550 0.013* 0.311 <0.001*** 0.004**
Follow-up	0.491	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg	DVS SR 200 mg Placebo	60.7 24.5 1.7 -1.2 -36.3 -59.0 -61.9 -22.7 -25.6 -2.9	40.4 39.1 37.5 51.7 38.1 36.7 51.0 34.6 49.4 48.5	0.137 0.534 0.963 0.982 0.345 0.112 0.229 0.513 0.606

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES. ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.

COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY).

STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

9

04NOV05 15:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT ECG3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR ECG/EKG

TEST: PR INTRVL, 12-Lead (msec) / PART 1: WITHIN TREATMENT OBSERVED____STD ADJUSTED [2] TREATMENT BASELINE Data Analysis Interval [1] [N] MEAN MEAN STDERR
 IVS SR 50 mg
 148

 Screening/baseline
 148

 Week 8
 6

 Week 12
 116

 Week 52
 82

 Final on-therapy
 123

 Follow-up
 15

 INS SR 100 mg
 155

 Screening/baseline
 155

 Week 4
 1

 Week 8
 5

 Instantant
 144.00

 Instantant
 156.61
 DVS SR 50 mg 148 156.05 20.07 156.05 20.07 22.10 151.00 23.28 0.50 6.72 1.50 6.66 -2.09 13.44 -1.63 13.57 -2.20 13.37 -2.73 13.69 21.76 21.41 157.14 158.16 -2.09 -1.63 -2.54* -2.32 20.90 1.22 21.77 1.58 21.45 20.90 -2.20 156.92 -2.68* 1.23 18.90 150.00 15.82 -4.56 DVS SR 100 mg 158.25 24.12 24.12 158.25 24.12 149.00 -5.00 -4.33 15.56 33.55
 Week 12
 119
 156.61

 Week 26
 1
 123.00

 Week 39
 2
 160.00

 Week 52
 82
 157.84

 Final on-therapy
 125
 156.88

 Follow-up
 16
 146.31

 VS SR 150 mg
 155

 Screening/baseline
 155
 160.27
 145.00 4.00 19.12 3.03 7.29 22.16 159.84 -3.24** -2.84* 24.14 12.82 1.21 119.00 4.00 -4.13 12.56 9.90 28.99 157.50 2.50 19.09 3.24 1.58 1.22 3.27 22.56 160.34 23.63 -2.50 -2.28 14.36 159.16 150.94 -1.95 21.79 24.05 -2.28 13.14 25.33 18.76 11.55 -6.14 7S SR 150 mg 155 Screening/baseline 155 160.37 160.37 27.44 DVS SR 150 mg 27.44 160.37 27.44 2 162.00 6 151.50 10.85 7.07 169.00 7.07 -7.00 0.00 -7.38 9.59 Week 8 149.33 22.21 2.17 21.65 2.62
 Week 8
 6
 151.50

 Week 12
 99
 156.71

 Week 26
 3
 167.00

 Week 39
 3
 159.00

 Week 52
 67
 156.18

 Final on-therapy
 108
 157.00

 Follow-up
 20
 161.20

 VS SR 200 mg
 149

 Screening/baseline
 149
 156.06

 Week 4
 8
 159.50

 Week 12
 93
 151.26
 -4.71* -3.82** 21.06 161.41 30.46 19.66 1.33 16.46 24.25 2.00 165.00 19.97 10.39 7.00 4.07 5.10 5.00 154.00 17.32 4.51 11.81 -6.66* -3.76 3.05 19.45 162.84 33.48 -5.40** 26.30 1.75 -2.84* 18.89 160.76 29.73 27.51 22.22 1.31 26.60 158.15 18.82 4.00 2.92 DVS SR 200 mg 156.06 20.34 20.34 21.80 156.06 163.38 15.59 -3.88 15.64 -3.96 5.32 93 151.26 16.91 155.70 -4.44** -5.34*** Week 12 20.11 1.37 -6.00 -4.60 Week 26 1 156.00 162.00 7.85 -4.20* Week 52 60 154.38 15.61 157.72 20.94 -3.33 16.63 1.85 Final on-therapy 101 153.10 16.66 156.31 19.84 -3.21* 15.79 -3.92** 1.36

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.
THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:44 REPORT ECG3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR ECG/EKG

TEST: PR INTRVL, 12-Lead (msec) / PART 1: WITHIN TREATMENT BASELINE TREATMENT OBSERVED ADJUSTED [2] Data Analysis Interval [1] [N] STD MEAN STD MEAN STDERR DVS SR 200 mg (cont.) Follow-up 157.18 13.36 160.95 19.82 -3.77 14.07 -1.86 2.80 Placebo 77 157.10 23.58 Screening/baseline 77 157.10 23.58 157.10 23.58 25.46 10.88 Week 4 165.00 154.50 16.26 10.50 9.19 10.86 Week 8 3 143.00 2.00 144.00 18.52 -1.00 19.52 -2.30 9.41 Week 12 65 161.02 24.11 158.65 24.49 2.37 14.53 2.39 1.63 Week 26 142.00 158.00 -16.00-15.487.69 2.19 Week 52 43 162.30 23.08 160.12 26.21 2.19 15.68 2.32 23.90 12.57 Final on-therapy 71 159.76 22.57 157.90 1.86 15.06 1.73 1.62 Follow-up 153.29 13.05 151.43 1.86 14.92 0.51 4.93

Page

10

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

CONFIDENTIAL 1233 Wyeth

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

11

04NOV05 15:44 REPORT ECG3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR ECG/EKG

TEST: PR INTRVL, 12-Lead (msec) / PART 2: BETWEEN TREATMENTS DIFF. BET. STDERR OF DIFF. PAIRWISE OVERALL TREATMENTS COMPARED Data Analysis Interval [1] P-VALUE Comparator 1 Comparator 2 ADJ. MEANS BET. ADJ. MEANS P-VALUE Week 4 0.638 DVS SR 100 mg DVS SR 150 mg 3.05 19.50 0.880 DVS SR 100 mg DVS SR 200 mg -0.37 16.58 0.983 18.42 DVS SR 100 mg Placebo -15.21 0.433 -3.42 DVS SR 150 mg DVS SR 200 mg 11.98 0.782 15.73 DVS SR 150 mg Placebo -18.26 0.279 DVS SR 200 mg Placebo -14.84 12.20 0.258 Week 8 0.971 DVS SR 50 mg DVS SR 100 mg -1.52 9.90 0.880 DVS SR 50 mg DVS SR 150 mg -1.12 9.39 0.907 DVS SR 50 mg Placebo 3.80 11.56 0.747 DVS SR 100 mg DVS SR 150 mg 0.41 9.87 0.968 DVS SR 100 mg Placebo 5.33 11.87 0.660 DVS SR 150 mg Placebo 4.92 11.53 0.676 Week 12 0.007** DVS SR 50 mg DVS SR 100 mg 0.30 1.72 0.859 DVS SR 50 mg DVS SR 150 mg 1.29 1.81 0.477 2.80 DVS SR 50 mg DVS SR 200 mg 1.83 0.127 DVS SR 50 mg Placebo -4.93 2.04 0.016* DVS SR 100 mg DVS SR 150 mg 0.98 1.79 0.585 DVS SR 100 mg DVS SR 200 mg 2.50 1.83 0.172 DVS SR 100 mg Placebo -5.23 2.03 0.010* DVS SR 150 mg DVS SR 200 mg 1.52 1.91 0.426 2.10 DVS SR 150 mg Placebo -6.21 0.003** DVS SR 200 mg Placebo <0.001*** -7.73 2.13 Week 26 0.509 DVS SR 100 mg DVS SR 150 mg -8.20 15.30 0.687 DVS SR 100 mg DVS SR 200 mg 0.46 15.92 0.982 Placebo DVS SR 100 mg 11.35 15.15 0.591 DVS SR 150 mg DVS SR 200 mg 8.67 8.89 0.508 DVS SR 150 mg Placebo 19.55 9.05 0.276 DVS SR 200 mg Placebo 10.89 10.89 0.500 Week 39 0.952 DVS SR 100 mg DVS SR 150 mg -1.26 18.75 0.952 Week 52 0.080 DVS SR 50 mg DVS SR 100 mg -0.04 2.24 0.986

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.

COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY).

STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 12

04NOV05 15:44 REPORT ECG3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR ECG/EKG

Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS COMPARED Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	
Week 52 (cont.)	0.080	DVS SR 50 mg DVS SR 150 mg DVS SR 50 mg DVS SR 200 mg DVS SR 50 mg Placebo DVS SR 100 mg DVS SR 150 mg DVS SR 100 mg DVS SR 200 mg DVS SR 100 mg Placebo DVS SR 150 mg Placebo DVS SR 150 mg Placebo DVS SR 200 mg Placebo DVS SR 200 mg Placebo	1.88 -4.63 3.12 1.92 -4.59 -1.20 -7.71	2.36 2.43 2.70 2.36 2.44 2.70 2.55 2.80 2.86	0.193 0.440 0.087 0.187 0.431 0.090 0.639 0.006**
Final on-therapy	0.094	DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg DVS SR 50 mg DVS SR 200 mg DVS SR 100 mg DVS SR 150 mg DVS SR 100 mg DVS SR 150 mg DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg Placebo DVS SR 200 mg Placebo	0.16 1.24 -4.41 0.89 1.97 -3.68	1.73 1.80 1.83 2.03 1.79 1.82 2.02 1.89 2.08	0.670 0.931 0.499 0.030* 0.618 0.279 0.070 0.567 0.028* 0.008**
Follow-up	0.177	DVS SR 50 mg DVS SR 100 mg DVS SR 50 mg DVS SR 150 mg DVS SR 50 mg DVS SR 200 mg DVS SR 100 mg DVS SR 150 mg DVS SR 100 mg DVS SR 200 mg DVS SR 100 mg DVS SR 200 mg DVS SR 150 mg DVS SR 200 mg DVS SR 150 mg Placebo DVS SR 150 mg Placebo	-8.56 -2.70 -5.08 -10.14 -4.27 -6.65	4.69 4.49 4.43 5.97 4.40 4.34 5.91 4.03 5.74	0.738 0.060 0.544 0.398 0.024* 0.328 0.264 0.150 0.546

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES. ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.

COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY).

STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

13

04NOV05 15:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT ECG3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR ECG/EKG

TEST: QRS INTRVL, 12-Lead (msec) / PART 1: WITHIN TREATMENT TREATMENT OBSERVED BASELINE ADJUSTED [2] Data Analysis Interval [1] [N] MEAN STD MEAN STD MEAN STDERR DVS SR 50 mg 82.09 82.09 Screening/baseline 148 6.74 82.09 6.74 8.24 2.55 Week 8 6 78.83 5.31 79.33 3.50 -0.50 -1.33 81.79 83.49 Week 12 116 6.63 81.96 6.82 -0.16 7.34 -0.33 0.64 Week 52 82 6.67 81.76 6.70 1.73* 7.39 1.39 0.74 Final on-therapy 123 83.10 6.50 81.82 6.68 1.28 7.27 0.95 0.62 Follow-up 15 82.27 83.47 6.56 -1.20 9.99 -0.41 1.80 DVS SR 100 mg 155 82.47 Screening/baseline 155 82.47 8.36 82.47 ĺ -3.00 -8.29 1.26 Week 4 73.00 76.00 5.83 5 Week 8 81.60 5.86 79.60 6.73 2.00 3.24 2.76 119 82.77 82.56 0.30 Week 12 9.25 8.56 0.21 8.77 0.63 Week 26 1 85.00 79.00 6.00 5.71 4.94 Week 39 85.00 81.00 11.31 5.66 3.91 4.86 82 9.34 Week 52 83.40 8.54 83.05 0.35 8.61 0.68 0.74 Final on-therapy 125 82.39 7.92 82.39 8.48 0.00 8.59 -0.02 0.61 Follow-up 16 83.69 83.00 8.02 0.69 9.86 1.74 82.63 DVS SR 150 mg 156 9.83 82.63 9.83 Screening/baseline 156 82.63 9.83 91.00 2.83 88.50 4.95 2.50 2.12 3.38 6 -0.16 Week 8 83.50 8.26 84.50 7.34 -1.00 6.07 2.55 Week 12 100 82.83 9.41 82.93 11.51 -0.10 8.45 0.15 0.69 Week 26 77.33 4.04 79.67 3.06 7.23 -2.333.51 -2.43 2.80 1.73 Week 39 83.33 10.02 81.67 1.67 6.11 3.97 84.75 82.43 2.33** Week 52 68 10.41 12.21 2.32* 8.14 0.81 Final on-therapy 109 84.38 9.60 83.06 11.19 1.31 9.07 1.66* 0.65 Follow-up 20 83.75 82.80 5.68 0.95 7.69 1.23 1.56 DVS SR 200 mg 151 81.68 8.18 81.68 85.33 Screening/baseline 151 8.18 81.68 8.18 Week 4 8.09 87.67 11.12 -2.33 8.06 -1.86 1.85 Week 12 95 80.78 8.21 81.56 8.48 -0.78 6.42 -1.11 0.71 Week 26 90.00 89.00 1.00 3.57 11.12 Week 52 60 82.32 6.10 81.67 9.76 0.65 8.80 0.27 0.87 Final on-therapy 103 81.76 6.54 82.16 8.86 -0.40 8.12 -0.54 0.67

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.
THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES. $[{\rm N}]$ - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:44 REPORT ECG3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR ECG/EKG

TEST: QRS INTRVL, 12-Lead (msec) / PART 1: WITHIN TREATMENT TREATMENT OBSERVED BASELINE ADJUSTED [2] Data Analysis Interval [1] [N] MEAN STD STD MEAN STD MEAN STDERR DVS SR 200 mg (cont.) Follow-up 82.87 7.85 81.65 6.52 1.22 8.05 0.63 1.45 77 Placebo 82.73 10.08 10.08 Screening/baseline 77 82.73 10.08 82.73 Week 4 91.00 2.83 86.00 4.24 5.00 1.41 4.65 3.91 10.69 Week 8 3 88.33 11.72 85.67 2.67 5.69 3.88 3.61 Week 12 65 84.48 10.44 82.86 10.58 1.62 8.37 1.83* 0.86 Week 26 81.00 73.00 8.00 6.00 9.16 Week 52 43 85.19 9.03 83.44 12.05 1.74 9.77 2.28* 1.02 Final on-therapy 71 85.38 9.36 82.93 10.39 2.45* 9.38 2.73*** 0.81 Follow-up 87.00 7.51 80.43 6.16 6.57* 5.03 5.05 2.64

Page

14

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.
STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.
STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

15

04NOV05 15:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT ECG3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR ECG/EKG

TEST: QRS INTRVL, 12-Lead (msec) / PART 2: BETWEEN TREATMENTS DIFF. BET. STDERR OF DIFF. PAIRWISE OVERALL TREATMENTS COMPARED Data Analysis Interval [1] P-VALUE Comparator 1 Comparator 2 ADJ. MEANS BET. ADJ. MEANS P-VALUE Week 4 0.238 DVS SR 100 mg DVS SR 150 mg -11.67 7.10 0.135 DVS SR 100 mg DVS SR 200 mg -6.42 6.16 0.325 6.99 DVS SR 100 mg Placebo -12.93 0.097 DVS SR 150 mg DVS SR 200 mg 5.24 4.32 0.256 DVS SR 150 mg Placebo -1.27 5.55 0.824 DVS SR 200 mg Placebo -6.51 4.33 0.167 Week 8 0.677 DVS SR 50 mg DVS SR 100 mg -2.59 0.493 -1.16 DVS SR 50 mg DVS SR 150 mg 3.69 0.757 DVS SR 50 mg Placebo 4.52 -5.20 0.268 DVS SR 100 mg DVS SR 150 mg 1.42 3.84 0.716 DVS SR 100 mg Placebo 0.581 -2.62 4.64 DVS SR 150 mg Placebo -4.04 4.30 0.362 Week 12 0.90 0.114 DVS SR 50 mg DVS SR 100 mg -0.63 0.487 DVS SR 50 mg DVS SR 150 mg -0.47 0.95 0.617 DVS SR 50 mg DVS SR 200 mg 0.78 0.96 0.414 DVS SR 50 mg Placebo -2.16 1.07 0.045* DVS SR 100 mg DVS SR 150 mg 0.16 0.94 0.868 DVS SR 100 mg DVS SR 200 mg 1.41 0.95 0.139 DVS SR 100 mg Placebo -1.53 1.07 0.152 DVS SR 150 mg DVS SR 200 mg 1.26 0.99 0.206 DVS SR 150 mg Placebo -1.69 1.10 0.127 DVS SR 200 mg Placebo -2.94 1.11 0.009** Week 26 0.562 DVS SR 100 mg DVS SR 150 mg 8.14 0.384 DVS SR 100 mg DVS SR 200 mg 2.14 13.05 0.896 Placebo DVS SR 100 mg -0.29 9.54 0.981 DVS SR 150 mg DVS SR 200 mg -6.00 11.78 0.700 DVS SR 150 mg Placebo -8.43 9.27 0.530 DVS SR 200 mg Placebo -2.43 19.07 0.919 Week 39 0.762 DVS SR 100 mg DVS SR 150 mg 2.18 6.28 0.762 Week 52 0.327 DVS SR 50 mg DVS SR 100 mg 1.05 0.499

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.

COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY).

STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

16

04NOV05 15:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT ECG3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR ECG/EKG

Data Analysis Interval [1]	OVERALL P-VALUE		COMPARED Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	
Week 52 (cont.)	0.327	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	-0.94 1.13 -0.88 -1.65 0.42 -1.59 2.07 0.06 -2.01	1.10 1.14 1.26 1.10 1.14 1.26 1.19 1.31	0.395 0.323 0.486 0.135 0.715 0.208 0.083 0.966 0.135
Final on-therapy	0.011*	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	0.96 -0.71 1.49 -1.78 -1.68 0.53 -2.74 2.21 -1.07	0.87 0.90 0.91 1.02 0.89 0.91 1.01 0.94 1.04	0.266 0.427 0.102 0.081 0.061 0.562 0.007** 0.019* 0.306 0.002**
Follow-up	0.553	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo	-1.53 -1.64 -1.04 -5.47 -0.11 0.49 -3.93 0.60 -3.82 -4.43	2.50 2.38 2.32 3.21 2.33 2.27 3.17 2.13 3.07 3.01	0.542 0.492 0.655 0.092 0.962 0.829 0.218 0.778 0.217 0.145

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES. ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.

COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY). STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 17

04NOV05 15:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT ECG3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR ECG/EKG

TEST: OTC INTRVL, 12-Lead (msec) / PART 1: WITHIN TREATMENT OBSERVED_____STD ADJUSTED [2] TREATMENT BASELINE Data Analysis Interval [1] [N] MEAN MEAN STDERR DVS SR 50 mg 148 406.31 21.27 Screening/baseline 148 406.31 Week 8 6 410.17 Week 12 116 402.99 21.27 406.31 21.27 148 400.31 6 410.17 116 402.99 82 406.91 123 404.89 15 408.27 21.59 399.17 12.34 11.00 32.59 7.01 8.65 18.73 19.22 19.78 27.74 21.63 19.86 404.92 402.54 21.45 22.21 Week 12 -1.93 -2.50 1.50 3.09 4.38* Week 52 1.92 21.11 Final on-therapy 20.62 404.46 -0.31 1.54 Follow-up 405.93 20.67 2.33 27.74 0.78 VS SR 100 mg 155 Screening/baseline 155 405.44 Week 4 1 402.00 Wook 8 5 415.40 DVS SR 100 mg 405.44 20.64 20.64 405.44 20.64 -15.00 417.00 -12.58 13.63 16.20 407.00 18.67 8.40 19.71 11.46 9.42 1.89 119 406.63 20.32 404.74 20.32 1.25 Week 12 17.82 1.48 1 426.00 2 458.00 Week 26 436.00 -10.00 42.34 26.56 7.07 22.43 2 458.00 82 410.33 21.92 28.99 Week 39 431.50 26.50 32.09 Week 52 62 710.82 Final on-therapy 125 410.82 16 416.19 404.21 20.18 6.12** 17.81 5.59** 1.92 404.93 5.89*** 8.75 22.19 20.14 18.47 5.35*** 1.52 21.91 407.44 18.96 23.23 7.81 4.78 156 408.56 21.55 DVS SR 150 mg 156 408.56 21.55 408.56 21.55 Screening/baseline 2 412.50 6 407.50 27.58 23.59 412.00 16.97 10.61 1.44 Week 8 408.83 19.44 -1.33 24.84 3.38 8.70 100 410.96 3 416.33 18.85 21.75 Week 12 409.14 1.82 18.81 3.10 1.62 28.10 27.62 21.66 3 416.33 3 405.00 11.27 15.18 Week 26 401.00 397.67 15.33 38.42 -44.49 24.22 12.50 Week 39 7.33 3.61 16.90 68 413.87 409.40 19.92 22.69 6.27** Week 52 4.47 2.12 5.00** 21.35 20.70 409.05 3.70 20.97 1.63 411.45 28.70 21.40 4.83 DVS SR 200 mg 405.25 20.18 20.18 10.23 405.25 20.18 409.50 14.46 -0.63 -0.43 4.76 94 407.28 2.30 Week 12 18.82 404.98 22.29 1.76 1.67 Week 26 1 433.00 466.00 -33.00 115.49 57.02 21.93 5.37* 19.31 Week 52 60 410.30 404.55 5.75* 19.78 2.24 Final on-therapy 102 408.49 18.18 405.33 21.75 3.16 18.67 2.80 1.69

CONFIDENTIAL 1240 Wyeth

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.
THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES. $[{\rm N}]$ - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:44 REPORT ECG3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR ECG/EKG

Page 18

TEST: QTC INTRVL, 12-Lead (msec) / PART 1: WITHIN TREATMENT										
TREATMENT			OBSERV	ED .	BASELI	NE	CHANG	E.	ADJUSTE	D [2]
Data Analysis Interval	[1]	[N]	MEAN	STD	MEAN	STD	MEAN	STD	MEAN	STDERR
DVS SR 200 mg (cont.)										
Follow-up		23	416.30	17.60	409.96	20.70	6.35*	13.16	6.42	3.99
Placebo		77			409.19	19.53				
Screening/baseline		77	409.19	19.53	409.19	19.53				
Week 4		2	418.50	33.23	399.00	24.04	19.50	9.19	16.58	9.89
Week 8		3	396.33	14.84	396.33	10.69	0.00	6.08	-6.54	12.30
Week 12		65	406.72	20.41	408.52	19.45	-1.80	20.60	-0.79	2.01
Week 26		1	384.00		413.00		-29.00		-50.36	20.11
Week 52		43	409.14	19.69	407.95	18.33	1.19	18.89	2.34	2.65
Final on-therapy		71	407.59	20.41	407.80	19.13	-0.21	18.53	0.53	2.02
Follow-up		7	413.43	30.41	418.00	23.61	-4.57	20.49	-1.25	7.27

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

CONFIDENTIAL 1241 Wyeth

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.
THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.
ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

19

04NOV05 15:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT ECG3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR ECG/EKG

TEST: QTC INTRVL, 12-Lead (msec) / PART 2: BETWEEN TREATMENTS						
Data Analysis Interval	OVERALL P-VALUE	TREATMENTS $\overline{\text{Com}}$ parator 1	COMPARED Comparator 2	DIFF. BET. ADJ. MEANS	STDERR OF DIFF. BET. ADJ. MEANS	PAIRWISE P-VALUE
Week 4	0.392		DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo		16.52 14.41 17.21 10.65 13.92 11.02	0.421 0.424 0.129 0.865 0.308 0.161
Week 8	0.699	DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg	DVS SR 100 mg DVS SR 150 mg Placebo DVS SR 150 mg Placebo Placebo	-4.45 3.63 13.55 8.08 18.01 9.92	12.46 14.82 12.68	0.735 0.775 0.375 0.533 0.268 0.527
Week 12	0.102	DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 100 mg DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	-1.85 -0.51 2.04 1.34 3.89	2.21 2.25 2.51 2.20 2.23 2.50 2.33 2.58	0.077 0.012* 0.059 0.498 0.401 0.819 0.415 0.566 0.132 0.329
Week 26	0.430	DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg Placebo Placebo	-73.14 92.71 -159.97	43.67 37.48 78.62	0.310 0.343 0.245 0.291 0.856 0.245
Week 39	0.482	DVS SR 100 mg	DVS SR 150 mg	28.48	33.30	0.482
Week 52	0.672	DVS SR 50 mg	DVS SR 100 mg	-2.50	2.72	0.359

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES. ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.

COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY). STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

20

04NOV05 15:44 REPORT ECG3

CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR ECG/EKG

	01700311	MDDA MMDNIMO	COMPARER	D.T.D.D. D.D.M.		DATDMIAD
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS Comparator 1			STDERR OF DIFF. BET. ADJ. MEANS	
Week 52 (cont.)	0.672	DVS SR 50 mg		-3.18	2.87	0.269
		DVS SR 50 mg DVS SR 50 mg	DVS SR 200 mg	-2.28 0.76	2.95 3.28	0.441 0.818
		DVS SR 100 mg	DVS SR 150 mg	-0.68	2.86	0.812
		DVS SR 100 mg DVS SR 100 mg		0.22 3.25	2.95 3.28	0.941 0.322
		DVS SR 100 mg		0.90	3.20	0.322
		DVS SR 150 mg		3.93	3.39	0.246
		DVS SR 200 mg	Placebo	3.03	3.48	0.384
Final on-therapy	0.042*	DVS SR 50 mg		-5.66	2.16	0.009**
		DVS SR 50 mg DVS SR 50 mg	DVS SR 150 mg DVS SR 200 mg	-5.30 -3.11	2.24 2.28	0.019* 0.173
		DVS SR 50 mg	Placebo	-0.84	2.54	0.741
		DVS SR 100 mg DVS SR 100 mg		0.36 2.55	2.23 2.27	0.873 0.262
		DVS SR 100 mg	Placebo	4.82	2.53	0.057
		DVS SR 150 mg DVS SR 150 mg		2.19 4.46	2.35 2.60	0.351 0.086
		DVS SR 200 mg		2.27	2.63	0.389
Follow-up	0.752		DVS SR 100 mg	-7.02	6.87	0.310
		DVS SR 50 mg		-4.04	6.55	0.539
		DVS SR 50 mg DVS SR 50 mg		-5.64 2.03	6.36 8.83	0.378 0.818
		DVS SR 100 mg	DVS SR 150 mg	2.98	6.42	0.644
		DVS SR 100 mg DVS SR 100 mg		1.39 9.06	6.23 8.72	0.825 0.302
		DVS SR 150 mg	DVS SR 200 mg	-1.59	5.85	0.786
		DVS SR 150 mg DVS SR 200 mg		6.08 7.67	8.42 8.29	0.473 0.358

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES. ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.

COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY).

STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 21

04NOV05 15:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT ECG3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR ECG/EKG

TEST: OTCF INTRVL, 12-Lead (msec) / PART 1: WITHIN TREATMENT TREATMENT OBSERVED BASELINE ADJUSTED [2] STD Data Analysis Interval [1] [N] MEAN MEAN STDERR DVS SR 50 mg 148 403.07 18.16 Screening/baseline 148 403.07 Week 8 6 407.83 Week 12 116 399.91 403.07 6 407.83 116 399.91 82 402.91 123 400.98 15 402.20 155 18.16 403.07 18.16 17.98 402.50 7.99 5.33 24.51 5.77 6.40 16.88 16.78 17.49 25.57 18.63 17.40 17.78 401.62 400.40 -2.30 1.77 18.42 -1.71 1.34 Week 52 19.47 1.73 Final on-therapy 401.49 18.06 -0.50 -1.17 1.35 Follow-up 25.35 405.20 19.50 -3.00 DVS SR 100 mg 402.25 18.98 75 SR 100 mg 155 Screening/baseline 155 402.25 Week 4 1 419 00 18.98 402.25 18.98 1 419.00 5 404.20 119 402.23 -2.03 3.62 Week 4 436.00 -17.00 13.25 14.89 11.78 Week 8 399.60 12.18 4.60 0.36 7.03 19.65 401.87 19.09 Week 12 14.93 -0.13 1.32 Week 26 1 2 424.00 436.00 -12.00 21.19 13.36 2 433.00 82 403.90 16.97 20.76 426.50 400.22 10.61 27.58 Week 39 6.50 25.01 1.73 1.34 24.17 Week 52 62 404.68 Final on-therapy 125 405.13 17.99 3.68* 15.77 2.86 402.05 405.31 19.00 17.80 20.67 2.63 15.85 2.20 20.07 18.72 -0.43 156 405.50 18.78 DVS SR 150 mg Screening/baseline 156 405.50 18.78 405.50 18.78 2 403.50 6 397.83 407.00 14.85 17.77 14.14 -3.50 0.71 -3.62 -5.25 7.76 Week 8 15.59 -6.67 404.50 11.27 6.46 16.56 14.18 12.06 100 404.50 Week 12 406.30 18.70 -1.80 17.20 -0.46 1.44 3 404.00 3 388.67 Week 26 407.00 10.15 -3.00 23.64 -34.70 10.63 391.67 9.29 -15.34 Week 39 -3.00 4.36 17.07 68 405.81 19.51 405.68 17.67 21.06 1.60 Week 52 0.13 1.91 Week 52 00 403.01
Final on-therapy 109 404.63
Follow-up 20 403.75
VS SR 200 mg 150
Screening/baseline 150 400.54
Week 4 8 405.63 17.56 406.12 18.29 -1.49 18.80 -0.17 1.44 -0.65 14.74 404.40 22.83 20.28 3.82 DVS SR 200 mg 400.54 17.81 400.54 17.81 17.81 9.36 407.63 14.61 -2.00 13.58 -1.79 3.88 94 400.22 Week 12 16.33 400.62 18.57 -0.39 -1.40 1.49 Week 26 1 432.00 462.00 -30.00 61.38 28.02 60 402.22 Week 52 18.15 400.98 17.79 1.23 16.45 0.73 2.02 Final on-therapy 102 400.95 16.67 401.17 18.33 -0.22 15.64 -1.02 1.48

CONFIDENTIAL 1244 Wyeth

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.
THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.
STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.
STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:44 REPORT ECG3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR ECG/EKG

Page

22

TEST: QTCF INTRVL, 12-Lead (msec) / PART 1: WITHIN TREATMENT TREATMENT OBSERVED BASELINE CHANGE ADJUSTED [2] Data Analysis Interval [1] [N] MEAN STD MEAN STD MEAN STDERR DVS SR 200 mg (cont.) Follow-up 408.35 20.81 405.74 20.71 2.61 12.61 2.54 3.56 77 406.57 Placebo 16.75 16.75 Screening/baseline 77 406.57 16.75 406.57 Week 4 405.50 23.33 391.50 10.61 14.00 12.73 5.81 8.76 9.64 397.33 -7.42 9.15 Week 8 3 392.00 8.50 -5.33 3.79 Week 12 65 405.40 18.21 406.28 16.71 -0.88 17.61 0.45 1.79 Week 26 383.00 408.00 -25.00-54.47 12.61 17.43 -1.21 Week 52 43 404.26 405.47 16.25 16.25 0.17 2.40 -0.31 Final on-therapy 71 404.14 17.34 405.51 16.38 -1.37 15.96 1.78 Follow-up 405.00 24.91 413.43 22.02 -8.43 18.60 -5.20 6.49

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

CONFIDENTIAL 1245 Wyeth

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

23

04NOV05 15:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT ECG3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR ECG/EKG

TEST: OTCF INTRVL, 12-Lead (msec) / PART 2: BETWEEN TREATMENTS OVERALL TREATMENTS COMPARED DIFF. BET. STDERR OF DIFF. PAIRWISE Data Analysis Interval [1] P-VALUE Comparator 1 Comparator 2 ADJ. MEANS BET. ADJ. MEANS P-VALUE Week 4 0.853 DVS SR 100 mg DVS SR 150 mg 1.59 15.38 0.920 DVS SR 100 mg DVS SR 200 mg -0.23 13.75 0.987 DVS SR 100 mg Placebo -7.84 17.68 0.669 DVS SR 150 mg DVS SR 150 mg -1.83 DVS SR 200 mg 8.68 0.839 Placebo -9.43 11.68 0.443 DVS SR 200 mg Placebo -7.61 9.62 0.452 Week 8 0.508 DVS SR 50 mg DVS SR 100 mg 2.15 9.53 0.824 DVS SR 50 mg DVS SR 150 mg 11.02 9.06 0.243 DVS SR 50 mg Placebo 13.20 11.20 0.257 DVS SR 100 mg DVS SR 150 mg 8.87 9.62 0.371 DVS SR 100 mg Placebo 11.04 0.350 11.46 DVS SR 150 mg Placebo 2.18 11.32 0.850 Week 12 0.699 DVS SR 50 mg DVS SR 100 mg -2.17 1.88 0.249 DVS SR 50 mg DVS SR 150 mg -1.83 1.97 0.352 -0.90 2.00 DVS SR 50 mg DVS SR 200 mg 0.653 DVS SR 50 mg Placebo -2.75 2.24 0.220 DVS SR 100 mg DVS SR 150 mg 0.33 1.96 0.864 DVS SR 100 mg DVS SR 200 mg 1.27 1.99 0.523 DVS SR 100 mg Placebo 0.795 -0.58 2.22 DVS SR 150 mg DVS SR 200 mg 0.93 2.08 0.653 DVS SR 150 mg Placebo -0.91 2.29 0.690 DVS SR 200 mg Placebo -1.85 2.33 0.428 Week 26 0.343 DVS SR 100 mg DVS SR 150 mg 55.90 0.235 DVS SR 100 mg DVS SR 200 mg -40.18 21.35 0.311 Placebo DVS SR 100 mg 75.66 22.39 0.183 DVS SR 150 mg DVS SR 200 mg -96.08 37.19 0.235 DVS SR 150 mg Placebo 19.76 10.75 0.317 DVS SR 200 mg Placebo 115.84 37.35 0.199 Week 39 0.402 DVS SR 100 mg DVS SR 150 mg 40.34 38.25 0.402 Week 52 0.897 DVS SR 50 mg DVS SR 100 mg -1.09 2.45 0.655

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.

COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY).

STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:44 REPORT ECG3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR ECG/EKG

Page

24

TEST: QTCF INTRVL, 12-Lead (msec) / PART 2: BETWEEN TREATMENTS							
Data Analysis Interval		ERALL /ALUE	TREATMENTS	COMPARED Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	
Week 52 (cont.)	0.8		DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	0.17 1.04 1.60 1.26 2.13 2.69 0.87 1.43 0.57	2.58 2.66 2.96 2.58 2.66 2.96 2.79 3.05 3.14	0.947 0.698 0.589 0.625 0.424 0.364 0.756 0.640 0.857
Final on-therapy	0.4		DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg			0.076 0.612 0.940 0.700 0.228 0.107 0.259 0.681 0.950 0.760
Follow-up	0.7		DVS SR 50 mg DVS SR 50 mg DVS SR 50 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 100 mg DVS SR 150 mg DVS SR 150 mg	DVS SR 150 mg DVS SR 200 mg Placebo DVS SR 200 mg	-2.86 -2.01 -5.84 1.90 0.85 -2.98 4.76 -3.83 3.91 7.74	5.83 5.67 7.85 5.73 5.56 7.78	0.642 0.732 0.306 0.809 0.882 0.594 0.542 0.465 0.606 0.299

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES. ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.

COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY). STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page 25

04NOV05 15:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT ECG3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR ECG/EKG

TEST: OT INTRVL, 12-Lead (msec) / PART 1: WITHIN TREATMENT OBSERVED STD ADJUSTED [2] TREATMENT Data Analysis Interval [1] [N] MEAN STDERR DVS SR 50 mg 148 397.53 26.10 Screening/baseline 148 397.53 Week 8 6 403.33 Week 12 116 394.34 26.10 397.53 26.10 16.54 409.50 11.98 -6.17 11.99 -4.81 7.03 116 394.34 82 395.45 123 393.56 15 391.27 25.67 23.89 395.91 26.00 -1.57 22.29 -2.25 1.80 -1.49 Week 52 -1.43 396.94 25.17 20.47 Final on-therapy 23.56 396.40 25.60 -2.84 21.44 -3.42 1.79 Follow-up 27.91 404.60 -13.33 33.00 -11.14 6.10 VS SR 100 mg 155 Screening/baseline 155 397.40 Week 4 1 455.00 Wook 8 5 383.40 DVS SR 100 mg 397.40 28.95 28.95 397.40 28.95 476.00 -21.00 26.13 20.98 385.80 397.89 -2.40 -3.88 21.66 10.38 19.45 7.69 119 394.29 27.92 -3.61 -3.51* Week 12 29.69 22.72 1.78 Week 26 1 2 422.00 435.00 -13.00 -8.95 11.80 2 387.50 82 391.83 31.82 26.34 Week 39
Week 52
Final on-therapy
Follow-up
16
384.38
156
176
400.02 12.73 -30.50 Week 39 418.00 19.09 -35.91 23.17 394.52 28.99 -2.70 24.61 -3.72 398.03 402.38 28.76 29.95 27.04 -4.60* 23.14 -4.50* 1.77 -16.72** 23.98 -18.00** 21.39 7S SR 150 mg 156 Screening/baseline 156 400.02 400.02 27.07 DVS SR 150 mg 27.07 400.02 27.07 387.00 379.83 2 8.49 396.50 9.19 -9.50 17.68 -14.80 Week 8 23.04 396.67 19.59 -16.83 -17.01* 16.87 6.34 23.90 15.89 18.01 25.24 392.27 381.33 -8.87*** -7.51*** Week 12 100 401.14 26.89 22.99 1.94 -36.67* Week 26 3 418.00 379.67 21.52 10.97 -38.69 6.71 359.67 14.73 Week 39 14.57 -20.00 -16.39 16.77 68 390.69 398.66 25.75 -7.97* 27.54 -7.13** Week 52 2.48 Week 52 00 390.05
Final on-therapy 109 389.50
Follow-up 20 382.05
VS SR 200 mg 150
Screening/baseline 150 391.95
Week 4 8 399.88 -11.26*** -10.02*** 24.27 400.76 26.14 25.04 1.90 -9.30 23.57 391.35 24.58 29.43 -12.58* 5.32 DVS SR 200 mg 391.95 26.77 26.77 15.35 391.95 26.77 -4.88 404.75 20.58 16.98 -4.74 4.64 94 386.89 22.46 392.74 -5.85** -7.76*** Week 12 26.34 2.01 -22.00 -11.16 Week 26 432.00 454.00 15.62 -8.47** 60 387.22 26.29 -7.55** Week 52 394.77 26.82 20.35 2.64 -6.78** -8.50*** Final on-therapy 102 386.90 24.33 393.69 26.05 20.38 1.97

CONFIDENTIAL 1248 Wyeth

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.
THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES. $[{\rm N}]$ - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

04NOV05 15:44 REPORT ECG3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR ECG/EKG

Page

26

TEST: QT INTRVL, 12-Lead (msec) / PART 1: WITHIN TREATMENT TREATMENT OBSERVED BASELINE ADJUSTED [2] Data Analysis Interval [1] [N] MEAN STD STD MEAN STDERR DVS SR 200 mg (cont.) Follow-up 394.13 36.56 398.87 34.71 -4.74 21.04 -4.91 4.91 77 22.74 Placebo 401.60 401.60 Screening/baseline 77 401.60 22.74 22.74 Week 4 380.50 6.36 376.00 15.56 4.50 21.92 -14.32 11.35 -15.67*** Week 8 3 383.33 12.06 399.00 11.53 0.58 -15.568.96 1.23 Week 12 65 403.29 26.02 402.06 22.97 20.08 2.95 2.41 Week 26 381.00 399.00 -18.00-26.82 14.24 395.02 Week 52 43 22.55 400.79 25.02 -5.77 24.94 -3.97 3.12 397.86 401.15 Final on-therapy 71 23.34 22.56 -3.30 23.38 -1.90 2.36 Follow-up 390.00 31.14 404.86 24.25 -14.8626.21 -12.55 8.92

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

CONFIDENTIAL 1249 Wyeth

^{[2] -} ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. THEIR STANDARD ERRORS ARE BASED ON THE POOLED DATA ACROSS ALL TREATMENTS.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

[[]N] - THE NUMBER OF SUBJECTS WITH MATCHING BASELINE.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY. STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

27

04NOV05 15:44 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315 REPORT ECG3

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR ECG/EKG

TEST: OT INTRVL, 12-Lead (msec) / PART 2: BETWEEN TREATMENTS OVERALL TREATMENTS COMPARED DIFF. BET. STDERR OF DIFF. PAIRWISE Data Analysis Interval [1] P-VALUE Comparator 1 Comparator 2 ADJ. MEANS BET. ADJ. MEANS P-VALUE Week 4 0.457 DVS SR 100 mg DVS SR 150 mg 24.29 0.130 DVS SR 100 mg DVS SR 200 mg 30.87 21.45 0.188 DVS SR 100 mg Placebo 40.46 27.98 0.186 DVS SR 150 mg DVS SR 200 mg -10.07 10.55 0.368 0.973 DVS SR 150 mg Placebo -0.48 13.95 DVS SR 200 mg Placebo 9.59 12.29 0.458 Week 8 0.411 DVS SR 50 mg DVS SR 100 mg -0.93 11.35 0.936 DVS SR 50 mg DVS SR 150 mg 12.20 9.59 0.223 DVS SR 50 mg Placebo 10.76 11.32 0.357 DVS SR 100 mg DVS SR 150 mg 13.13 9.83 0.202 DVS SR 100 mg Placebo 11.68 11.87 0.340 DVS SR 150 mg Placebo -1.45 10.98 0.897 Week 12 0.003** 2.53 DVS SR 50 mg DVS SR 100 mg 1.26 0.618 DVS SR 50 mg DVS SR 150 mg 5.26 2.65 0.048* 2.69 DVS SR 50 mg DVS SR 200 mg 5.51 0.041* DVS SR 50 mg Placebo -5.19 3.01 0.085 DVS SR 100 mg DVS SR 150 mg 4.00 2.63 0.129 DVS SR 100 mg DVS SR 200 mg 4.25 2.68 0.114 DVS SR 100 mg Placebo -6.46 2.99 0.031* DVS SR 150 mg DVS SR 200 mg 0.25 2.80 0.930 DVS SR 150 mg Placebo -10.46 3.09 <0.001*** DVS SR 200 mg Placebo -10.71 <0.001*** 3.14 Week 26 0.479 DVS SR 100 mg DVS SR 150 mg 29.74 14.19 0.283 DVS SR 100 mg DVS SR 200 mg 0.918 2.21 17.10 Placebo DVS SR 100 mg 17.87 20.39 0.542 -27.53 DVS SR 150 mg DVS SR 200 mg 18.29 0.373 DVS SR 150 mg Placebo -11.88 14.52 0.564 DVS SR 200 mg Placebo 15.66 25.38 0.648 Week 39 0.640 DVS SR 100 mg DVS SR 150 mg -19.52 35.76 0.640 Week 52 0.255 DVS SR 50 mg DVS SR 100 mg 2.30 3.19 0.472

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES.

ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL.

ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.

COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY).

STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

Page

28

04NOV05 15:44 REPORT ECG3 CLINICAL INVESTIGATION OF DVS-233 SR PROTOCOL 3151A2-315

DESCRIPTIVE STATISTICS AND ANALYSIS WITHIN AND BETWEEN TREATMENTS FOR ECG/EKG

TES'	T: QT INTR	VL, 12-Lead (msec) / PART 2:	BETWEEN TREATI	MENTS	
Data Analysis Interval [1]	OVERALL P-VALUE	TREATMENTS COMPARED Comparator 1 Comparator 2		STDERR OF DIFF. BET. ADJ. MEANS	
Week 52 (cont.)	0.255	DVS SR 50 mg DVS SR 150 m DVS SR 50 mg DVS SR 200 m DVS SR 50 mg Placebo DVS SR 100 mg DVS SR 150 m DVS SR 100 mg DVS SR 200 m DVS SR 150 mg Placebo DVS SR 150 mg Placebo DVS SR 150 mg Placebo DVS SR 200 mg Placebo	g 7.04 2.54 g 3.41 g 4.75 0.25 g 1.34 -3.16	3.35 3.47 3.85 3.35 3.47 3.85 3.62 3.98 4.09	0.089 0.043* 0.509 0.310 0.172 0.949 0.712 0.427 0.272
Final on-therapy	0.019*	DVS SR 50 mg DVS SR 100 m DVS SR 50 mg DVS SR 150 m DVS SR 50 mg DVS SR 200 m DVS SR 50 mg Placebo DVS SR 100 mg DVS SR 200 m DVS SR 100 mg DVS SR 200 m DVS SR 100 mg DVS SR 200 m DVS SR 150 mg DVS SR 200 m DVS SR 150 mg DVS SR 200 m DVS SR 150 mg Placebo DVS SR 200 mg Placebo	g 6.60 g 5.08 -1.52 g 5.52 g 4.00 -2.61 g -1.52 -8.13	2.52 2.61 2.66 2.96 2.65 2.95 2.74 3.03 3.08	0.668 0.012* 0.057 0.607 0.034* 0.132 0.377 0.579 0.007** 0.032*
Follow-up	0.628	DVS SR 50 mg DVS SR 100 m DVS SR 50 mg DVS SR 150 m DVS SR 50 mg DVS SR 200 m DVS SR 50 mg DVS SR 200 m DVS SR 100 mg DVS SR 150 m DVS SR 100 mg DVS SR 200 m DVS SR 150 mg DVS SR 200 m DVS SR 150 mg Placebo DVS SR 150 mg Placebo	g 1.44 g -6.23 1.42 g -4.14 g -11.81 -4.17	8.47 8.14 7.83 10.78 7.97 7.67 10.67 7.23 10.42 10.18	0.511 0.860 0.429 0.896 0.605 0.128 0.697 0.292 0.998 0.455

NOTE: [1] - ALL ANALYSES ARE DONE INDEPENDENTLY BY DATA ANALYSIS INTERVAL USING DATA WITH NON-MISSING BASELINE VALUES. ADJUSTED MEANS OF CHANGE ACCOUNT FOR UNBALANCE AMONG TREATMENTS WITH RESPECT TO ALL OTHER EFFECTS IN MODEL. ADJUSTED MEANS SHOULD BE INTERPRETED WITH CAUTION FOR SMALL SAMPLE SIZES.

STATISTICAL SIGNIFICANCE AT THE .05, .01, .001 LEVELS IS DENOTED BY *, **, *** RESPECTIVELY.

COMPARISONS BETWEEN TREATMENTS ARE BASED ON 1-WAY ANALYSIS OF COVARIANCE (UNADJUSTED FOR MULTIPLICITY).

STANDARD MODEL OF ANALYSIS: CHANGE = BASELINE TREATMENT.

ST 11-1: Summary Statistics for Subject Satisfaction Survey

Summary statistics for subject satisfaction DVS-233 SR protocol 315: final analysis (ITT) $\,$

14:23 Friday, October 14, 2005

p-value

1

Question number Character=01 Test Name=Ability to control hot flushes during the day

Treatment	Time slot	Category	-Number of subject N (%)	overall vs. p-value placebo
DVS SR 50 mg		Extremely dissatisfied Dissatisfied	9 7.44	0.006 0.381
		Neutral	28 23.14 47 38.84 24 19.83 5 6.10 12 14.63 6 7.32	
		Satisfied Extremely satisfied	4/ 38.84	•
	Week 52	Extremely dissatisfied	24 19.03 5 6.10	0.289 0.359
	Week 32	Dissatisfied	12 14.63	• • •
		Neutral	6 7.32	: :
		Satisfied	33 40.24	
		Extremely satisfied	6 7.32 33 40.24 26 31.71	
DVS SR 100 mg	Week 12	Extremely dissatisfied	4 3.28	. 0.001
		Dissatisfied	10 8.20	
		Neutral Satisfied	17 13.93	
		Satisfied	50 40.98	•
	Week 52	Extremely satisfied Extremely dissatisfied	41 33.61	. 0.055
	week 32	Dissatisfied	5 6 02	. 0.055
		Neutral	11 13.25	•
		Satisfied	33 39.76	: :
		Extremely satisfied	4 3.28 10 8.20 17 13.93 50 40.98 41 33.61 4 4.82 5 6.02 11 13.25 33 39.76 30 36.14	
DVS SR 150 mg	Week 12	Extremely dissatisfied	6 5.71 13 12.38 16 15.24 39 37.14	. 0.061
		Dissatisfied	13 12.38	
		Neutral	16 15.24	
		Satisfied	39 3/.14	•
	Week 52	Extremely satisfied Extremely dissatisfied	31 29.52	. 0.059
	week 32	Dissatisfied	2 2.86 7 10.00	. 0.039
		Neutral	7 10.00 9 12.86	
		Satisfied	25 35.71	: :
		Extremely satisfied	27 38.57	
DVS SR 200 mg	Week 12	Extremely dissatisfied	6 6.32	. 0.524
3		Dissatisfied	6 6.32 16 16.84	
		Neutral	19 20.00	
		Satisfied	33 34.74	
		Extremely satisfied	21 22.11	

Summary statistics for subject satisfaction DVS-233 SR protocol 315: final analysis (ITT)

14:23 Friday, October 14, 2005

2

Question number Character=01 Test Name=Ability to control hot flushes during the day

Treatment	Time slot	Category	-Number of	subject (%)	overall p-value	p-value vs. placebo
DVS SR 200 mg	Week 52	Extremely dissatisfied	2	3.17		0.266
		Dissatisfied	7	11.11		
		Neutral	12	19.05		
		Satisfied	22	34.92		
		Extremely satisfied	20	31.75	•	•
Placebo	Week 12	Extremely dissatisfied	4	5.97		
		Dissatisfied	15	22.39		
		Neutral	13	19.40		
		Satisfied	22	32.84		
		Extremely satisfied	13	19.40		
	Week 52	Extremely dissatisfied	2	4.35		
		Dissatisfied	9	19.57		
		Neutral	6	13.04		•
		Satisfied	19	41.30		
		Extremely satisfied	10	21.74		•

Summary statistics for subject satisfaction DVS-233 SR protocol 315: final analysis (ITT)

14:23 Friday, October 14, 2005

p-value

3

Question number Character=02 Test Name=Ability to control hot flushes during the night

Treatment	Time slot	Category	-Number of subject N (%)	overall vs. p-value placebo
DVS SR 50 mg	Week 12	Extremely dissatisfied Dissatisfied Neutral Satisfied	9 7.44 16 13.22 20 16.53 43 35.54	<0.001 0.106
	Week 52	Extremely satisfied Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied	33 27.27 7 8.54 10 12.20 13 15.85 25 30.49 27 32.93	0.058 0.861
DVS SR 100 mg	Week 12	Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied	2 1.64 9 7.38 14 11.48 35 28.69 62 50.82	<0.001 : : :
	Week 52	Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied	62 50.82 3 3.61 7 8.43 6 7.23 31 37.35 36 43.37	· · ·
DVS SR 150 mg	Week 12	Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied	6 5.71 9 8.57 15 14.29 39 37.14 36 34.29	
	Week 52	Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied	2 2.86 4 5.71 9 12.86 29 41.43 26 37.14	. 0.046
DVS SR 200 mg	Week 12	Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied	5 5.26 8 8.42 15 15.79 33 34.74 34 35.79	. 0.004

Summary statistics for subject satisfaction DVS-233 SR protocol 315: final analysis (ITT)

14:23 Friday, October 14, 2005

4

Question number Character=02 Test Name=Ability to control hot flushes during the night

Treatment	Time slot	Category	-Number of	subject (%)	overall p-value	p-value vs. placebo
DVS SR 200 mg	Week 52	Extremely dissatisfied	4	6.25		0.127
_		Dissatisfied	5	7.81	•	
		Neutral	7	10.94	•	
		Satisfied	20	31.25	•	
		Extremely satisfied	28	43.75	•	•
Placebo	Week 12	Extremely dissatisfied	6	8.96		
		Dissatisfied	15	22.39		
		Neutral	10	14.93		
		Satisfied	24	35.82		
		Extremely satisfied	12	17.91		
	Week 52	Extremely dissatisfied	0	0.00		
		Dissatisfied	12	26.09		
		Neutral	7	15.22		
		Satisfied	13	28.26		
		Extremely satisfied	14	30.43	•	•

Summary statistics for subject satisfaction DVS-233 SR protocol 315: final analysis (ITT)

5 14:23 Friday, October 14, 2005

p-value

CSR-60178

Question number Character=03 Test Name=Effect on quality of sleep

Treatment	Time slot	Category	-Number of subject N (%)	overall vs. p-value placebo
DVS SR 50 mg	Week 12 Week 52	Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied Extremely dissatisfied Dissatisfied Neutral Satisfied	9 7.50 11 9.17 30 25.00 38 31.67 32 26.67 5 6.10 11 13.41 16 19.51 33 40.24	0.026 0.590
DVS SR 100 mg	Week 12	Extremely satisfied Extremely dissatisfied Dissatisfied Neutral	17 20.73 4 3.28 6 4.92 29 23.77	. 0.003
	Week 52	Satisfied Extremely satisfied Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied	29 23.77 42 34.43 41 33.61 1 1.20 6 7.23 11 13.25 38 45.78 27 32.53	0.071
DVS SR 150 mg	Week 12	Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied	4 3.81 8 7.62 27 25.71 36 34.29 30 28.57	. 0.045
	Week 52	Extremely dissatisfied Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied	1 1.43 3 4.29 13 18.57 30 42.86 23 32.86	. 0.077
DVS SR 200 mg	Week 12	Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied	6 6.32 15 15.79 17 17.89 35 36.84 22 23.16	0.484

Summary statistics for subject satisfaction DVS-233 SR protocol 315: final analysis (ITT)

14:23 Friday, October 14, 2005

6

Question number Character=03 Test Name=Effect on quality of sleep

Treatment	Time slot	Category	-Number of	subject (%)	overall p-value	p-value vs. placebo
DVS SR 200 mg	Week 52	Extremely dissatisfied	2	3.13		0.430
3		Dissatisfied	6	9.38	•	•
		Neutral	14	21.88		
		Satisfied	20	31.25		
		Extremely satisfied	22	34.38	•	•
Placebo	Week 12	Extremely dissatisfied	4	5.97		
		Dissatisfied	11	16.42		
		Neutral	15	22.39		
		Satisfied	27	40.30		
		Extremely satisfied	10	14.93		
	Week 52	Extremely dissatisfied	1	2.17		
		Dissatisfied	8	17.39		
		Neutral	9	19.57		
		Satisfied	15	32.61		
		Extremely satisfied	13	28.26	•	•

Summary statistics for subject satisfaction DVS-233 SR protocol 315: final analysis (ITT)

14:23 Friday, October 14, 2005

7

Question number Character=04 Test Name=Effect on mood or emotions

Treatment	Time slot	Category	-Number of subject N (%)	
DVS SR 50 mg	Week 12 Week 52	Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied Extremely dissatisfied Dissatisfied Neutral Satisfied	1 0.83 6 4.96 33 27.27 50 41.32 31 25.62 2 2.44 6 7.32 12 14.63 35 42.68	0.008
DVS SR 100 mg	Week 12	Extremely satisfied Extremely dissatisfied	27 32.93 1 0.82	. 0.006
		Dissatisfied Neutral Satisfied Extremely satisfied	6 4.92 22 18.03 56 45.90 37 30.33	
	Week 52	Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied	1 1.20 1 1.20 15 18.07 34 40.96 32 38.55	. 0.215
DVS SR 150 mg	Week 12	Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied	1 0.95 2 1.90 24 22.86 39 37.14 39 37.14	0.002
	Week 52	Extremely dissatisfied Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied	0 0.00 2 2.86 13 18.57 27 38.57 28 40.00	0.194
DVS SR 200 mg	Week 12	Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied	2 2.11 6 6.32 24 25.26 42 44.21 21 22.11	. 0.277

Summary statistics for subject satisfaction DVS-233 SR protocol 315: final analysis (ITT)

14:23 Friday, October 14, 2005

8

Question number Character=04 Test Name=Effect on mood or emotions

Treatment	Time slot	Category	-Number of N	subject (%)	overall p-value	p-value vs. placebo
DVS SR 200 mg	Week 52	Extremely dissatisfied	1	1.56	•	0.656
		Dissatisfied	1	1.56		•
		Neutral	17	26.56	•	
		Satisfied	21	32.81	•	
		Extremely satisfied	24	37.50	•	•
Placebo	Week 12	Extremely dissatisfied	3	4.48		
		Dissatisfied	4	5.97	•	
		Neutral	21	31.34		
		Satisfied	27	40.30		
		Extremely satisfied	12	17.91		
	Week 52	Extremely dissatisfied	0	0.00		
		Dissatisfied	0	0.00		
		Neutral	15	32.61		
		Satisfied	18	39.13		
		Extremely satisfied	13	28.26		

Summary statistics for subject satisfaction DVS-233 SR protocol 315: final analysis (ITT)

14:23 Friday, October 14, 2005

CSR-60178

9

Question number Character=05 Test Name=Effect on interest in sex

Treatment	Time slot	Category	-Number of subject N (%)	p-value overall vs. p-value placebo
DVS SR 50 mg	Week 12 Week 52	Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied	7 6.09 16 13.91 60 52.17 26 22.61 6 5.22 3 3.70 11 13.58 35 43.21 22 27.16 10 12.35	0.420 0.548
DVS SR 100 mg	Week 12 Week 52	Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied	12 10.08 15 12.61 57 47.90 28 23.53 7 5.88 3 3.66 12 14.63 41 50.00 19 23.17 7 8.54	0.393
DVS SR 150 mg	Week 12 Week 52	Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied	7 6.80 12 11.65 56 54.37 22 21.36 6 5.83 3 4.29 10 14.29 31 44.29 17 24.29 9 12.86	0.596
DVS SR 200 mg	Week 12	Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied	18 19.78 9 9.89 35 38.46 25 27.47 4 4.40	0.104

Summary statistics for subject satisfaction DVS-233 SR protocol 315: final analysis (ITT)

14:23 Friday, October 14, 2005

10

Question number Character=05 Test Name=Effect on interest in sex

Treatment	Time slot	Category	-Number of N	subject	overall p-value	p-value vs. placebo
DVS SR 200 mg	Week 52	Extremely dissatisfied	7	11.11		0.433
		Dissatisfied	9	14.29		
		Neutral	19	30.16		
		Satisfied	21	33.33		
		Extremely satisfied	7	11.11	•	•
Placebo	Week 12	Extremely dissatisfied	5	7.81		
		Dissatisfied	6	9.38		
		Neutral	31	48.44		
		Satisfied	18	28.13		
		Extremely satisfied	4	6.25		
	Week 52	Extremely dissatisfied	2	4.44		
		Dissatisfied	5	11.11		
		Neutral	17	37.78		
		Satisfied	17	37.78		
		Extremely satisfied	4	8.89	•	•

Summary statistics for subject satisfaction DVS-233 SR protocol 315: final analysis (ITT)

14:23 Friday, October 14, 2005

p-value

11

Question number Character=06 Test Name=Effect on ability to concentrate

Treatment	Time slot	Category	-Number of N	subject (%)	overall p-value	vs. placebo
DVS SR 50 mg		Extremely dissatisfied Dissatisfied Neutral		0.83 5.79 37.19	0.249	
		Satisfied	50	41.32	•	•
		Extremely satisfied	18	41.32 14.88 0.00	. •	
	Week 52	Extremely dissatisfied	0	0.00	0.726	0.747
		Dissatisfied Neutral	19	8.54 23.17	•	•
		Satisfied			•	•
		Extremely satisfied	41 15	18.29		:
DVS SR 100 mg	Week 12	Extremely dissatisfied		1.65		0.300
		Dissatisfied	4	3.31	•	•
		Neutral Satisfied	31 59	25.62	•	•
		Extremely satisfied	25	48.76 20.66	•	•
	Week 52	Extremely dissatisfied	1	1.20		0.501
		Dissatisfied	1			
		Neutral	20	24.10		•
		Satisfied	43 18	51.81 21.69	•	•
		Extremely satisfied	18	21.09	•	•
DVS SR 150 mg	Week 12	Extremely dissatisfied		1.90		0.846
		Dissatisfied	6		•	•
		Neutral Satisfied	29 55	27.62 52.38	•	•
		Extremely satisfied	13	12.38	•	•
	Week 52	Extremely dissatisfied		0.00		0.474
		Dissatisfied	5	7.14	•	
		Neutral	12	17.14	•	•
		Satisfied	36 17	51.43	•	•
		Extremely satisfied	1 /	24.29	•	•
DVS SR 200 mg	Week 12	Extremely dissatisfied	3	3.16		0.411
		Dissatisfied	_ 6	6.32 28.42		•
		Neutral	27	28.42	•	•
		Satisfied Extremely satisfied	50 9	52.63 9.47	•	•
		excremeth sacratied	9	9.41	•	•

Summary statistics for subject satisfaction DVS-233 SR protocol 315: final analysis (ITT)

14:23 Friday, October 14, 2005

12

Question number Character=06 Test Name=Effect on ability to concentrate

Treatment	Time slot	Category	-Number of N	subject	overall p-value	p-value vs. placebo
DVS SR 200 mg	Week 52	Extremely dissatisfied	0	0.00		0.923
-		Dissatisfied	4	6.25		
		Neutral	16	25.00		
		Satisfied	32	50.00		
		Extremely satisfied	12	18.75	•	
Placebo	Week 12	Extremely dissatisfied	0	0.00		
		Dissatisfied	5	7.46		
		Neutral	21	31.34		
		Satisfied	30	44.78		
		Extremely satisfied	11	16.42		
	Week 52	Extremely dissatisfied	0	0.00		
		Dissatisfied	1	2.17		
		Neutral	10	21.74		
		Satisfied	31	67.39		
		Extremely satisfied	4	8.70	•	•

Summary statistics for subject satisfaction DVS-233 SR protocol 315: final analysis (ITT)

14:23 Friday, October 14, 2005

p-value

CSR-60178

13

Question number Character=07 Test Name=Tolerability to side effects

Treatment	Time slot	Category	-Number of N	subject (%)	overall p-value	vs. placebo
DVS SR 50 mg		Extremely dissatisfied Dissatisfied Neutral	0 3 20	2 48		0.950
	Week 52	Satisfied Extremely satisfied Extremely dissatisfied Dissatisfied Neutral Satisfied	6 7 40	7.32 8.54 48.78	0.700	•
100	1 10	Extremely satisfied	28	34.15	•	
DVS SR 100 mg	Week 12	Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied	2 5 23 54 38	18.85	· ·	0.562
	Week 52	Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied	2 1 11 34 35	2.41 1.20 13.25	:	0.655
DVS SR 150 mg	Week 12	Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied	1 9 16 51 27	0.96 8.65 15.38 49.04 25.96		0.253
	Week 52	Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied	0	0.00 11.43 5.71	•	0.244
DVS SR 200 mg	Week 12	Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied	1 12 15 41 26	12.63 15.79		0.131

Summary statistics for subject satisfaction DVS-233 SR protocol 315: final analysis (ITT)

14:23 Friday, October 14, 2005

14

Question number Character=07 Test Name=Tolerability to side effects

Treatment	Time eatment slot Category		-Number of	subject (%)	overall p-value	p-value vs. placebo	
DVS SR 200 mg	Week 52	Extremely dissatisfied	0	0.00		0.291	
_		Dissatisfied	3	4.69			
		Neutral	13	20.31			
		Satisfied	23	35.94			
		Extremely satisfied	25	39.06	•	•	
Placebo	Week 12	Extremely dissatisfied	3	4.48			
		Dissatisfied	0	0.00			
		Neutral	13	19.40			
		Satisfied	24	35.82			
		Extremely satisfied	27	40.30			
	Week 52	Extremely dissatisfied	0	0.00			
		Dissatisfied	0	0.00			
		Neutral	7	15.22		•	
		Satisfied	20	43.48			
		Extremely satisfied	19	41.30			

CSR-60178

15

Summary statistics for subject satisfaction DVS-233 SR protocol 315: final analysis (ITT)

14:23 Friday, October 14, 2005

Question number Character=08 Test Name=Overall satisfaction

Treatment	Time slot	Category	-Number of subject N $(\%)$	p-value overall vs. p-value placebo
DVS SR 50 mg	Week 12 Week 52	Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied Extremely dissatisfied Dissatisfied Neutral	6 4.96 14 11.57 18 14.88 56 46.28 27 22.31 5 6.10 10 12.20 6 7.32	0.008
		Satisfied Extremely satisfied	39 47.56 22 26.83	
DVS SR 100 mg	Week 12	Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied	2 1.64 8 6.56 15 12.30 48 39.34 49 40.16	. 0.007
	Week 52	Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied	3 3.61 5 6.02 3 3.61 42 50.60 30 36.14	. 0.171
DVS SR 150 mg	Week 12	Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied	3 2.86 7 6.67 13 12.38 49 46.67 33 31.43	. 0.061
	Week 52	Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied	1 1.43 10 14.29 3 4.29 31 44.29 25 35.71	0.480
DVS SR 200 mg	Week 12	Extremely dissatisfied Dissatisfied Neutral Satisfied Extremely satisfied	5 5.26 7 7.37 18 18.95 42 44.21 23 24.21	0.611

Summary statistics for subject satisfaction DVS-233 SR protocol 315: final analysis (ITT)

14:23 Friday, October 14, 2005

16

Question number Character=08 Test Name=Overall satisfaction

Treatment	Time tment slot Category		-Number of	subject (%)	overall p-value	p-value vs. placebo	
DVS SR 200 mg	Week 52	Extremely dissatisfied	2	3.13		0.830	
3		Dissatisfied	6	9.38	•	•	
		Neutral	10	15.63			
		Satisfied	25	39.06		•	
		Extremely satisfied	21	32.81	•	•	
Placebo	Week 12	Extremely dissatisfied	4	5.97			
		Dissatisfied	10	14.93			
		Neutral	8	11.94			
		Satisfied	28	41.79			
		Extremely satisfied	17	25.37			
	Week 52	Extremely dissatisfied	0	0.00			
		Dissatisfied	6	13.04			
		Neutral	8	17.39			
		Satisfied	19	41.30			
		Extremely satisfied	13	28.26	•	•	

ST 11-2: Summary Statistics for Sexual Function Questionnaire

Summary statistics for sexual function scores DVS-233 SR protocol 315: final analysis (ITT) $\,$

09:03 Wednesday, July 20, 2005

1

tests=Arousal

Treatment	Time No. of pairs		Baseline mean SD		Observed mean SD		Change from baseline mean SD	
DVS SR 50 mg	Screening/baseline Week 12	142 105	9.5 9.3	3.1 3.2	8.9	3.5	-0.4	2.9
DVS SR 100 mg	Screening/baseline Week 12	147 104	9.9 9.7	3.1 3.2	9.3	3.2	-0.4	3.0
DVS SR 150 mg	Screening/baseline Week 12	150 92	9.6 9.7	3.1 2.9	9.0	2.9	-0.7	2.6
DVS SR 200 mg	Screening/baseline Week 12	142 82	9.9 9.8	3.2 3.1	9.5	3.3	-0.3	2.9
Placebo	Screening/baseline Week 12	68 53	9.9 9.8	3.1 3.3	9.3	2.9	-0.5	3.0

Summary statistics for sexual function scores DVS-233 SR protocol 315: final analysis (ITT)

09:03 Wednesday, July 20, 2005

2

tests=Desire

Treatment	Time slot	No. of - pairs	mean S		Observed mean SD		Change from baseline mean SD	
DVS SR 50 mg	Screening/baseline Week 12	142 110	11.4 11.4	3.4 3.5	10.7	3.5	-0.6	2.9
DVS SR 100 mg	Screening/baseline Week 12	151 110	11.4 11.1	3.2 3.2	10.5	3.5	-0.6	3.0
DVS SR 150 mg	Screening/baseline Week 12	151 92	11.2 11.2	3.3 2.9	10.7	3.2	-0.5	2.7
DVS SR 200 mg	Screening/baseline Week 12	147 86	11.4 11.2	3.3 3.5	10.9	3.6	-0.3	3.0
Placebo	Screening/baseline Week 12	73 60	11.1 10.9	3.6 3.8	10.4	3.8	-0.5	3.0

Summary statistics for sexual function scores DVS-233 SR protocol 315: final analysis (ITT)

09:03 Wednesday, July 20, 2005

3

tests=Orgasm

Treatment	Time slot	No. of pairs							Change from mean S	
DVS SR 50 mg	Screening/baseline Week 12	109 76	5.8 5.9	2.8 2.8	5.3	2.6	-0.6	2.2		
DVS SR 100 mg	Screening/baseline Week 12	109 71	5.5 5.2	2.7	5.8	2.8	0.6	2.5		
DVS SR 150 mg	Screening/baseline Week 12	110 58	6.1 5.8	2.7	5.8	2.8	-0.1	2.2		
DVS SR 200 mg	Screening/baseline Week 12	109 56	5.4 5.2	2.6 2.5	5.9	3.1	0.8	3.3		
Placebo	Screening/baseline Week 12	46 32	6.1 5.9	3.1 2.9	5.9	3.0	0.0	1.9		

CSR-60178

4

Summary statistics for sexual function scores DVS-233 SR protocol 315: final analysis (ITT)

09:03 Wednesday, July 20, 2005

tests=Overall satisfaction

Treatment	Time slot	No. of - pairs	Basel: mean S		Observ mean		Change from mean	
DVS SR 50 mg	Screening/baseline Week 12	139 107	10.7 10.7	6.2 6.4	· 9.9	6.2	-0.8	5.5
DVS SR 100 mg	Screening/baseline Week 12	141 104	11.1 10.8	6.2 6.1	9.9	6.0	-1.0	5.7
DVS SR 150 mg	Screening/baseline Week 12	148 85	11.3 10.7	5.7 5.6	10.8	6.1	0.1	5.4
DVS SR 200 mg	Screening/baseline Week 12	141 82	11.1 10.5	5.9 6.0	11.1	6.9	0.6	6.1
Placebo	Screening/baseline Week 12	71 58	12.3 12.0	6.5 6.5	11.2	6.9	-0.8	5.4

Summary statistics for sexual function scores DVS-233 SR protocol 315: final analysis (ITT)

09:03 Wednesday, July 20, 2005

5

tests=Total severity score

Treatment	Time slot	No. of	Baseline mean SD	Observed mean SD	Change from baseline mean SD
DVS SR 50 mg	Screening/baseline Week 12	135 103	38.6 13.3 38.6 13.6		-2.1 11.5
DVS SR 100 mg	Screening/baseline Week 12	139 99	39.0 13.4 38.1 13.7	36.3 13.8	-1.8 12.2
DVS SR 150 mg	Screening/baseline Week 12	144 77	39.6 12.7 38.2 11.6	36.8 13.2	-1.4 11.0
DVS SR 200 mg	Screening/baseline Week 12	137 80	38.9 12.9 38.0 12.8	38.3 14.8	0.3 11.7
Placebo	Screening/baseline Week 12	63 51	40.2 13.6 39.6 13.9	37.8 14.7	-1.7 11.2

Protocol 3151A2-315-US

CSR-60178

6

Within and between group comparisons for sexual function scores DVS-233 SR protocol 315: final analysis (ITT)

09:03 Wednesday, July 20, 2005

tests=Arousal

Treatment	Time slot	No. of pairs	Adjusted cha	p-value nge vs. placebo	p-value within group
DVS SR 50 mg	Week 12	105	-0.54 0	.29 0.863	0.067
DVS SR 100 mg	Week 12	104	-0.56 0	.29 0.909	0.054
DVS SR 150 mg	Week 12	92	-0.94 0	.31 0.528	0.003
DVS SR 200 mg	Week 12	82	-0.44	.33 0.731	0.179
Placebo	Week 12	53	-0.62 0	.40 .	0.126

Protocol 3151A2-315-US

CSR-60178

7

Within and between group comparisons for sexual function scores DVS-233 SR protocol 315: final analysis (ITT)

09:03 Wednesday, July 20, 2005

tests=Desire

Treatment	Time slot	No. of pairs	Adjusted cha mean SE	p-value unge vs. placebo	p-value within group
DVS SR 50 mg	Week 12	110	-0.63	0.668	0.038
DVS SR 100 mg	Week 12	110	-0.54	0.30 0.811	0.074
DVS SR 150 mg	Week 12	92	-0.61	0.712	0.066
DVS SR 200 mg	Week 12	86	-0.30	0.799	0.376
Placebo	Week 12	60	-0.43	.39	0.271

Protocol 3151A2-315-US

CSR-60178

Within and between group comparisons for sexual function scores DVS-233 SR protocol 315: final analysis (ITT)

8 09:03 Wednesday, July 20, 2005

tests=Orgasm

Treatment	Time slot	No. of pairs	Adjusted mean	change SE	p-value vs. placebo	p-value within group
DVS SR 50 mg	Week 12	76	-0.54	0.31	0.309	0.081
DVS SR 100 mg	Week 12	71	0.69	0.32	0.225	0.031
DVS SR 150 mg	Week 12	58	-0.04	0.35	0.919	0.904
DVS SR 200 mg	Week 12	56	0.70	0.36	0.246	0.053
Placebo	Week 12	32	0.02	0.47		0.973

Protocol 3151A2-315-US

CSR-60178

9

Within and between group comparisons for sexual function scores DVS-233 SR protocol 315: final analysis (ITT)

09:03 Wednesday, July 20, 2005

tests=Overall satisfaction

Treatment	Time slot	No. of pairs	Adjusted mean	change SE	p-value vs. placebo	p-value within group	
DVS SR 50 mg	Week 12	107	-0.72	0.60	0.878	0.229	
DVS SR 100 mg	Week 12	104	-0.86	0.60	0.997	0.155	
DVS SR 150 mg	Week 12	85	0.10	0.67	0.329	0.885	
DVS SR 200 mg	Week 12	82	0.78	0.67	0.098	0.251	
Placebo	Week 12	58	-0.86	0.77		0.263	

Protocol 3151A2-315-US

CSR-60178

Within and between group comparisons for sexual function scores DVS-233 SR protocol 315: final analysis (ITT)

10 09:03 Wednesday, July 20, 2005

tests=Total severity score

Treatment	Time slot	No. of pairs	_	change SE	p-value vs. placebo	p-value within group	
DVS SR 50 mg	Week 12	103	-2.62	1.20	0.818	0.029	
DVS SR 100 mg	Week 12	99	-2.29	1.22	0.950	0.062	
DVS SR 150 mg	Week 12	77	-2.19	1.39	0.988	0.116	
DVS SR 200 mg	Week 12	80	-0.25	1.36	0.366	0.853	
Placebo	Week 12	51	-2.16	1.68	•	0.198	

ST 11-3: Summary Statistics for Quality of Life Scale

Summary statistics for quality of life scale (EQ VAS) DVS-233 SR protocol 315: final analysis (ITT)

09:03 Wednesday, July 20, 2005

1

Treatment	Time slot	No. of pairs	Basel mean	ine SD	Obser mean		Change from mean	
DVS SR 50 mg	Screening/baseline Week 4 Week 12	149 132 112	74.6 75.4 75.7	20.1 18.9 18.6	82.8 84.7	14.3 14.9	7.5 9.1	14.4 17.2
DVS SR 100 mg	Screening/baseline Week 4 Week 12	154 131 117	77.3 76.6 77.1	17.2 17.5 17.5	85.7 85.9	13.4 13.4	9.0 8.9	15.0 15.0
DVS SR 150 mg	Screening/baseline Week 4 Week 12	157 121 97	77.1 77.4 78.4	19.6 19.3 18.7	84.3 85.0	15.0 14.7	6.9 6.6	16.1 15.0
DVS SR 200 mg	Screening/baseline Week 4 Week 12	149 102 86	77.9 79.8 78.5	18.1 16.1 16.8	85.3 85.6	15.6 13.2	5.5 7.0	14.8 14.8
Placebo	Screening/baseline Week 4 Week 12	77 74 62	76.9 76.9 77.3	18.5 18.4 18.4	83.5 84.7	13.8 14.9	6.6 7.4	15.2 17.8

Protocol 3151A2-315-US

CSR-60178

2

Within and between group comparisons for quality of life scale (EQ VAS) DVS-233 SR protocol 315: final analysis (ITT)

09:03 Wednesday, July 20, 2005

Treatment	Time slot	No. of pairs	Adjusted mean		p-value vs. placebo	p-value within group
DVS SR 50 mg	Week 4	132	8.15	1.38	0.653	<0.001
	Week 12	112	9.79	1.60	0.386	<0.001
DVS SR 100 mg	Week 4	131	9.62	1.37	0.267	<0.001
	Week 12	117	9.35	1.54	0.484	<0.001
DVS SR 150 mg	Week 4	121	7.48	1.45	0.882	<0.001
	Week 12	97	7.09	1.71	0.854	<0.001
DVS SR 200 mg	Week 4	102	6.20	1.57	0.687	<0.001
	Week 12	86	7.87	1.82	0.914	<0.001
Placebo	Week 4 Week 12	74 62	7.15 7.58	1.80 2.10	:	<0.001 <0.001